<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33831349</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia.</ArticleTitle><Pagination><StartPage>1657</StartPage><EndPage>1674.e7</EndPage><MedlinePgn>1657-1674.e7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2021.03.024</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(21)00194-X</ELocationID><Abstract><AbstractText>The apolipoprotein E (APOE) gene is the strongest genetic risk factor for Alzheimer's disease and directly influences tauopathy and tau-mediated neurodegeneration. ApoE4 has strong deleterious effects on both parameters. In the brain, apoE is produced and secreted primarily by astrocytes and by activated microglia. The cell-specific role of each form of apoE in the setting of neurodegeneration has not been determined. We&#xa0;generated P301S Tau/Aldh1l1-CreERT2/apoE3<sup>flox/flox</sup> or Tau/Aldh1l1-CreERT2/apoE4<sup>flox/flox</sup> mice. At 5.5&#xa0;months of age, after the onset of tau pathology, we administered tamoxifen or vehicle and compared mice at 9.5&#xa0;months of age. Removing astrocytic APOE4 markedly reduced tau-mediated neurodegeneration and decreased phosphorylated tau (pTau) pathology. Single-nucleus RNA sequencing analysis revealed striking gene expression changes in all cell types, with astrocytic APOE4 removal decreasing disease-associated gene signatures in neurons, oligodendrocytes, astrocytes, and microglia. Removal of astrocytic APOE4 decreased tau-induced synaptic loss and microglial phagocytosis of synaptic elements, suggesting a key role for astrocytic apoE in synaptic degeneration.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer Disease, Research Center, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer Disease, Research Center, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gratuze</LastName><ForeName>Maud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer Disease, Research Center, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer Disease, Research Center, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer Disease, Research Center, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andhey</LastName><ForeName>Prabhakar Sairam</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manis</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer Disease, Research Center, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Zhuoran</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madore</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butovsky</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Evergrande Center for Immunologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artyomov</LastName><ForeName>Maxim</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer Disease, Research Center, Washington University, St. Louis, MO 63110, USA. Electronic address: ulrichjd@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer Disease, Research Center, Washington University, St. Louis, MO 63110, USA. Electronic address: holtzman@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS088137</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054672</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA091842</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG051812</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD021629</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell Rep Med. 2021 Jun 15;2(6):100316. doi: 10.1016/j.xcrm.2021.100316.</RefSource><PMID Version="1">34195681</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="Y">Phagocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOE</Keyword><Keyword MajorTopicYN="N">astrocyte</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>Declaration of interests D.M.H. is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. C2N Diagnostics has licensed certain anti-tau antibodies to AbbVie for therapeutic development. D.M.H. is on the scientific advisory board of Denali and consults for Genentech, Merck, and Cajal Neuroscience. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>8</Day><Hour>20</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33831349</ArticleId><ArticleId IdType="mid">NIHMS1687056</ArticleId><ArticleId IdType="pmc">PMC8141024</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2021.03.024</ArticleId><ArticleId IdType="pii">S0896-6273(21)00194-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Apicco DJ, Ash PEA, Maziuk B, LeBlang C, Medalla M, Al Abdullatif A, Ferragud A, Botelho E, Ballance HI, Dhawan U, et al. (2018). Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo. Nat. Neurosci 21, 72&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5745051</ArticleId><ArticleId IdType="pubmed">29273772</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Schindler C, Bruckner MK, Eschrich K, Bigl V, Zedlick D, and Marcova L (1997). Plastic neuronal remodeling is impaired in patients with Alzheimer&#x2019;s disease carrying apolipoprotein epsilon 4 allele. J. Neurosci 17, 516&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573225</ArticleId><ArticleId IdType="pubmed">8987775</ArticleId></ArticleIdList></Reference><Reference><Citation>Atagi Y, Liu C-C, Painter MM, Chen X-F, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, et al. (2015). Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J.Bio.Chem 290, 26043&#x2013;26050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646257</ArticleId><ArticleId IdType="pubmed">26374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B, Hales CM, Chen P-C, Gozal Y, Dammer EB, Fritz JJ, Wang X, Xia Q, Duong DM, Street C, et al. (2013). U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. USA 110, 16562&#x2013;16567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799305</ArticleId><ArticleId IdType="pubmed">24023061</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, et al. (2017). Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer&#x2019;s disease. Brain 140, 3286&#x2013;3300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, et al. (2012). Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047116</ArticleId><ArticleId IdType="pubmed">22622580</ArticleId></ArticleIdList></Reference><Reference><Citation>Brecht WJ, Harris FM, Chang S, Tesseur I, Yu G-Q, Xu Q, Dee Fish J, Wyss-Coray T, Buttini M, Mucke L, et al. (2004). Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice. J. Neurosci 24, 2527&#x2013;2534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729489</ArticleId><ArticleId IdType="pubmed">15014128</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussian TJ, Aziz A, Meyer CF, Swenson BL, van Deursen JM, and Baker DJ (2018). Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 562, 578&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206507</ArticleId><ArticleId IdType="pubmed">30232451</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E, and Satija R (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol 36, 411&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Cialic R, Krasemann S, Murugaiyan G, Fanek Z, Greco DJ, Wu PM, Doykan CE, Kiner O, et al. (2015). Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann. Neurol 77, 75&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432483</ArticleId><ArticleId IdType="pubmed">25381879</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, et al. (2014). Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat. Neurosci 17, 131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, et al. (2011). Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med 3, 89ra57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Durakoglugil MS, Xian X, and Herz J (2010). ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc. Natl. Acad. Sci. USA 107, 12011&#x2013;12016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900641</ArticleId><ArticleId IdType="pubmed">20547867</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejanovic B, Huntley MA, De Mazi&#xe8;re A, Meilandt WJ, Wu T, Srinivasan K, Jiang Z, Gandham V, Friedman BA, Ngu H, et al. (2018). Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies. Neuron 100, 1322&#x2013;1336.e1327.</Citation><ArticleIdList><ArticleId IdType="pubmed">30392797</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, Chen G, Shen T, Tran H, Nichols B, et al. (2017). Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med 9, eaag0481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792300</ArticleId><ArticleId IdType="pubmed">28123067</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond E, Pires G, MacMurray C, Askenazi M, Nayak S, Bourdon M, Safar J, Ueberheide B, and Wisniewski T (2020). Phosphorylated tau interactome in the human Alzheimer&#x2019;s disease brain. Brain 143, 2803&#x2013;2817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7526722</ArticleId><ArticleId IdType="pubmed">32812023</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Riemenschneider M, Strassner B, Grimmer T, Peller M, Knoll A, Wagenpfeil S, Minoshima S, Schwaiger M, and Kurz A (2005). Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology 64, 102&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642911</ArticleId></ArticleIdList></Reference><Reference><Citation>Geijselaers SLC, Aalten P, Ramakers I, De Deyn PP, Heijboer AC, Koek HL, OldeRikkert MGM, Papma JM, Reesink FE, Smits LL, et al. (2018). Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer&#x2019;s Disease. J. Alzheimers Dis 61, 309&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5734123</ArticleId><ArticleId IdType="pubmed">29154275</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze M, Leyns CE, Sauerbeck AD, St-Pierre MK, Xiong M, Kim N, Serrano JR, Tremblay ME, Kummer TT, Colonna M, et al. (2020). Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. J. Clin. Invest 130, 4954&#x2013;4968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456230</ArticleId><ArticleId IdType="pubmed">32544086</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N, McCabe C, Medina S, Varshavsky M, Kitsberg D, Dvir-Szternfeld R, Green G, Dionne D, Nguyen L, Marshall JL, et al. (2020). Disease-associated astrocytes in Alzheimer&#x2019;s disease and aging. Nat. Neurosci 23, 701&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9262034</ArticleId><ArticleId IdType="pubmed">32341542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafemeister C, and Satija R (2019). Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927181</ArticleId><ArticleId IdType="pubmed">31870423</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison IF, Ismail O, Machhada A, Colgan N, Ohene Y, Nahavandi P, Ahmed Z, Fisher A, Meftah S, Murray TK, et al. (2020). Impaired glymphatic function and clearance of tau in an Alzheimer&#x2019;s disease model. Brain 143, 2576&#x2013;2593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7447521</ArticleId><ArticleId IdType="pubmed">32705145</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, and Julius D (2006). The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat. Neurosci 9, 1512&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pubmed">17115040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, and Wellington CL (2004). Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain. J. Biol. Chem 279, 41197&#x2013;41207.</Citation><ArticleIdList><ArticleId IdType="pubmed">15269218</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Herz J, and Bu G (2012). Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med 2, a006312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3282491</ArticleId><ArticleId IdType="pubmed">22393530</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, et al. (2016). Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh Y-C, Guo C, Yalamanchili HK, Abreha M, Al-Ouran R, Li Y, Dammer EB, Lah JJ, Levey AI, Bennett DA, et al. (2019). Tau-Mediated Disruption of the Spliceosome Triggers Cryptic RNA Splicing and Neurodegeneration in Alzheimer&#x2019;s Disease. Cell Rep. 29, 301&#x2013;316.e310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919331</ArticleId><ArticleId IdType="pubmed">31597093</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh TV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, Roh J, Finn MB, Sullivan PM, Esparza TJ, et al. (2017). Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of beta-amyloidosis. Neuron 96, 1013&#x2013;1023 e1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5728673</ArticleId><ArticleId IdType="pubmed">29216448</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh TV, Wang C, Tran AC, Tabor GT, Mahan TE, Francis CM, Finn MB, Spellman R, Manis M, Tanzi RE, et al. (2019). Lack of hepatic apoE does not influence early Abeta deposition: observations from a new APOE knock-in model. Mol. Neurodegener 14, 37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6796484</ArticleId><ArticleId IdType="pubmed">31623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ECB, Dammer EB, Duong DM, Ping L, Zhou M, Yin L, Higginbotham LA, Guajardo A, White B, Troncoso JC, et al. (2020). Large-scale proteomic analysis of Alzheimer&#x2019;s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat. Med 26, 769&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405761</ArticleId><ArticleId IdType="pubmed">32284590</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. (2017). A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.e1217.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, et al. (2018). Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol 14, 577&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, and Sergushichev A (2021). Fast gene set enrichment analysis. bioRxiv, 060012; doi: 10.1101/060012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/060012</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O&#x2019;Loughlin E, Xu Y, Fanek Z, et al. (2017). The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581.e569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Visani AV, Baker SL, Brown JA, Bourakova V, Cha J, Chaudhary K, Edwards L, Iaccarino L, Janabi M, et al. (2020). Prospective longitudinal atrophy in Alzheimer&#x2019;s disease correlates with the intensity and topography of baseline tau-PET. Sci. Transl. Med 12, eaau5732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035952</ArticleId><ArticleId IdType="pubmed">31894103</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng K, Li E, Eser R, Piergies A, Sit R, Tan M, Neff N, Li SH, Rodriguez RD, Suemoto CK, et al. (2021). Molecular characterization of selectively vulnerable neurons in Alzheimer&#x2019;s disease. Nat. Neurosci 24, 276&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854528</ArticleId><ArticleId IdType="pubmed">33432193</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, Sullivan PM, and Holtzman DM (2015). Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathol. Commun 3, 70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641345</ArticleId><ArticleId IdType="pubmed">26556230</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvinchuk A, Wan Y-W, Swartzlander DB, Chen F, Cole A, Propson NE, Wang Q, Zhang B, Liu Z, and Zheng H (2018). Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer&#x2019;s Disease. Neuron 100, 1337&#x2013;1353.e1335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309202</ArticleId><ArticleId IdType="pubmed">30415998</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, and Bu G (2017). ApoE4 Accelerates Early Seeding of Amyloid Pathology. Neuron 96, 1024&#x2013;1032 e1023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948105</ArticleId><ArticleId IdType="pubmed">29216449</ArticleId></ArticleIdList></Reference><Reference><Citation>LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, and Binder LI (1995). Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc. Natl. Acad. Sci. USA 92, 10369&#x2013;10373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40798</ArticleId><ArticleId IdType="pubmed">7479786</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Fryatt G, Cleal M, Obst J, Pipi E, Monzon-Sandoval J, Ribe E, Winchester L, Webber C, Nevado A, et al. (2019). CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain 142, 3243&#x2013;3264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794948</ArticleId><ArticleId IdType="pubmed">31504240</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A, Kang YJ, Hasselmann J, Jairaman A, Sotelo A, Coburn M, Shabestari SK, Chadarevian JP, Fote G, Tu CH, et al. (2020). Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer&#x2019;s disease. Nat. Commun 11, 5370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7584603</ArticleId><ArticleId IdType="pubmed">33097708</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, Pachicano M, Joe E, Nelson AR, D&#x2019;Orazio LM, et al. (2020). APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature 581, 71&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7250000</ArticleId><ArticleId IdType="pubmed">32376954</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen JV, Thomassen M, M&#xf8;llg&#xe5;rd K, Noraberg J, and Jensen NA (2014). Zbtb20 Defines a Hippocampal Neuronal Identity Through Direct Repression of Genes That Control Projection Neuron Development in the Isocortex. Cereb. Cortex 24, 1216&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pubmed">23283686</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent AA, Lin K, van Lengerich B, Lianoglou S, Przybyla L, Davis SS, Llapashtica C, Wang J, Kim DJ, Xia D, et al. (2020). TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge. Neuron 105, 837&#x2013;854.e839.</Citation><ArticleIdList><ArticleId IdType="pubmed">31902528</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, et al. (2019). Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat. Neurosci 22, 191&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen C, Nolan AL, de Paula Fran&#xe7;a Resende E, Miller Z, Ehrenberg AJ, Gorno-Tempini ML, Rosen HJ, Kramer JH, Spina S, Rabinovici GD, et al. (2019). Alzheimer&#x2019;s disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation. Acta Neuropathol. 138, 597&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7012374</ArticleId><ArticleId IdType="pubmed">31250152</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitas RE, Boyles JK, Lee SH, Foss D, and Mahley RW (1987). Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 917, 148&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">3539206</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehfeld F, Maticzka D, Grosser S, Knauff P, Eravci M, Vida I, Backofen R, and Wulczyn FG (2018). The RNA-binding protein ARPP21 controls dendritic branching by functionally opposing the miRNA it hosts. Nat. Commun 9, 1235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964322</ArticleId><ArticleId IdType="pubmed">29581509</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio C, Wolfs L, Fattorelli N, Thrupp N, Voytyuk I, Schmidt I, Mancuso R, Chen W-T, Woodbury ME, Srivastava G, et al. (2019). The Major Risk Factors for Alzheimer&#x2019;s Disease: Age, Sex, and Genes Modulate the Microglia Response to A&#x3b2; Plaques. Cell Rep. 27, 1293&#x2013;1306.e1296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340153</ArticleId><ArticleId IdType="pubmed">31018141</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, and Holtzman DM (2018). Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol 18, 759&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425488</ArticleId><ArticleId IdType="pubmed">30140051</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Manis M, Long J, Wang K, Sullivan PM, Remolina Serrano J, Hoyle R, and Holtzman DM (2019). Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J. Exp. Med 216, 2546&#x2013;2561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, et al. (2017). ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan R, Lu TY, Chai H, Xu J, Huang BS, Golshani P, Coppola G, and Khakh BS (2016). New Transgenic Mouse Lines for Selectively Targeting Astrocytes and Studying Calcium Signals in Astrocyte Processes In Situ and In Vivo. Neuron 92, 1181&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5403514</ArticleId><ArticleId IdType="pubmed">27939582</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, et al. (2007). The Classical Complement Cascade Mediates CNS Synapse Elimination. Cell 131, 1164&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, and Roses AD (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, Hao Y, Stoeckius M, Smibert P, and Satija R (2019). Comprehensive Integration of Single-Cell Data. Cell 177, 1888&#x2013;1902 e1821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M, Thomas E, Kang MS, Lussier F, Tissot C, et al. (2020). Association of Apolipoprotein E epsilon4 With Medial Temporal Tau Independent of Amyloid-beta. JAMA Neurol. 77, 470&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990684</ArticleId><ArticleId IdType="pubmed">31860000</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Ulland TK, Mahan TE, Nystrom S, Nilsson KP, Song WM, Zhou Y, Reinartz M, Choi S, Jiang H, et al. (2018). ApoE facilitates the microglial response to amyloid plaque pathology. J. Exp. Med 215, 1047&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5881464</ArticleId><ArticleId IdType="pubmed">29483128</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, and Holtzman DM (2004). ABCA1 Is Required for Normal Central Nervous System ApoE Levels and for Lipidation of Astrocyte-secreted apoE. J. Biol. Chem 279, 40987&#x2013;40993.</Citation><ArticleIdList><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Weigand AJ, Thomas KR, Bangen KJ, Eglit GML, Delano-Wood L, Gilbert PE, Brickman AM, Bondi MW, and Alzheimer&#x2019;s Disease Neuroimaging I (2020). APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia. Alzheimers. Dement 17, 61&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">32886451</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, and Ivanov P (2019). Stress granules and neurodegeneration. Nat. Rev. Neurosci 20, 649&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6986315</ArticleId><ArticleId IdType="pubmed">31582840</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Zhang X, and Zhao L (2018). Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer&#x2019;s Disease Risk Reduction and Early Intervention. J. Neurosci 38, 6665&#x2013;6681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6067075</ArticleId><ArticleId IdType="pubmed">29967007</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Dejanovic B, Gandham VD, Gogineni A, Edmonds R, Schauer S, Srinivasan K, Huntley MA, Wang Y, Wang T-M, et al. (2019). Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy. Cell Rep. 28, 2111&#x2013;2123.e2116.</Citation><ArticleIdList><ArticleId IdType="pubmed">31433986</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, and Lee VM (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Young MD, and Behjati S (2020). SoupX removes ambient RNA contamination from droplet based single-cell RNA sequencing data. Gigascience 9, giaa151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7763177</ArticleId><ArticleId IdType="pubmed">33367645</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Davis MD, Martens YA, Shinohara M, Graff-Radford NR, Younkin SG, Wszolek ZK, Kanekiyo T, and Bu G (2017a). APOE epsilon4/epsilon4 diminishes neurotrophic function of human iPSC-derived astrocytes. Hum. Mol. Genet 26, 2690&#x2013;2700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886091</ArticleId><ArticleId IdType="pubmed">28444230</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Fu Y, Yamazaki Y, Ren Y, Davis MD, Liu C-C, Lu W, Wang X, Chen K, Cherukuri Y, et al. (2020). APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer&#x2019;s disease patient iPSC-derived cerebral organoids. Nat. Commun 11, 5540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7608683</ArticleId><ArticleId IdType="pubmed">33139712</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Liu C-C, Van Ingelgom AJ, Linares C, Kurti A, Knight JA, Heckman MG, Diehl NN, Shinohara M, Martens YA, et al. (2018). APOE &#x3b5;2 is associated with increased tau pathology in primary tauopathy. Nat. Commun 9, 4388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6197187</ArticleId><ArticleId IdType="pubmed">30348994</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Liu CC, Van Ingelgom AJ, Martens YA, Linares C, Knight JA, Painter MM, Sullivan PM, and Bu G (2017b). Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes. Neuron 96, 115&#x2013;129 e115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5621659</ArticleId><ArticleId IdType="pubmed">28957663</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, et al. (2020). Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med 26, 131&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV (2013). Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol. 70, 440&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4414030</ArticleId><ArticleId IdType="pubmed">23400708</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33831364</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Tackling neurodegenerative diseases with genomic engineering: A new stem cell initiative from the NIH.</ArticleTitle><Pagination><StartPage>1080</StartPage><EndPage>1083</EndPage><MedlinePgn>1080-1083</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2021.03.022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(21)00192-6</ELocationID><Abstract><AbstractText>The iPSC Neurodegenerative Disease Initiative (iNDI) is the largest-ever iPSC genome engineering project. iNDI will model more than 100 mutations associated with Alzheimer's disease and related dementias (ADRD) in isogenic iPSC lines. Resulting cell lines and phenotypic datasets will be broadly shared.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's Disease and Related Dementias, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skarnes</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's Disease and Related Dementias, National Institutes of Health, Bethesda, MD, USA; Lab of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's Disease and Related Dementias, National Institutes of Health, Bethesda, MD, USA; Lab of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA. Electronic address: cookson@mail.nih.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Center for Alzheimer's Disease and Related Dementias, National Institutes of Health, Bethesda, MD, USA; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. Electronic address: wardme@nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA AG000535</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005818" MajorTopicYN="N">Genetic Engineering</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057905" MajorTopicYN="Y">Stem Cell Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="Y">Stem Cell Transplantation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>8</Day><Hour>20</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33831364</ArticleId><ArticleId IdType="mid">NIHMS1790066</ArticleId><ArticleId IdType="pmc">PMC8985232</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2021.03.022</ArticleId><ArticleId IdType="pii">S0896-6273(21)00192-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, Yeromin AV, Scarfone VM, Marsh SE, Fimbres C, et al. (2017). iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases. Neuron 94, 278&#x2013;293.e9, 10.1016/j.neuron.2017.03.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.03.042</ArticleId><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch CM, Kao AW, Karydas A, Onanuga K, Martinez R, Argouarch A, Wang C, Huang C, Sohn PD, Bowles KR, et al.; Tau Consortium Stem Cell Group (2019). A Comprehensive Resource for Induced Pluripotent Stem Cells from Patients with Primary Tauopathies. Stem Cell Reports 13, 939&#x2013;955, 10.1016/j.stemcr.2019.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2019.09.006</ArticleId><ArticleId IdType="pmc">PMC6895712</ArticleId><ArticleId IdType="pubmed">31631020</ArticleId></ArticleIdList></Reference><Reference><Citation>Konttinen H, Cabral-da-Silva MEC, Ohtonen S, Wojciechowski S, Shakirzyanova A, Caligola S, Giugno R, Ishchenko Y, Hern&#xe1;ndez D, Fazaludeen MF, et al. (2019). PSEN1&#x394;E9, APPswe, and APOE4 Confer Disparate Phenotypes in Human iPSC-Derived Microglia. Stem Cell Reports 13, 669&#x2013;683, 10.1016/j.sterner.2019.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sterner.2019.08.004</ArticleId><ArticleId IdType="pmc">PMC6829767</ArticleId><ArticleId IdType="pubmed">31522977</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwart D, Gregg A, Scheckel C, Murphy EA, Paquet D, Duffield M, Fak J, Olsen O, Darnell RB, and Tessier-Lavigne M (2019). A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP &#x3b2;-CTFs, Not A&#x3b2;. Neuron 104, 256&#x2013;270.e5, 10.1016/j.neuron.2019.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.07.010</ArticleId><ArticleId IdType="pubmed">31416668</ArticleId></ArticleIdList></Reference><Reference><Citation>Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S, et al.; Parkinson Progression Marker Initiative (2011). The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol 95, 629&#x2013;635, 10.1016/j.pneurobio.2011.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2011.09.005</ArticleId><ArticleId IdType="pmc">PMC9014725</ArticleId><ArticleId IdType="pubmed">21930184</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J, Berry J, Svendsen C, Thompson L, Finkbeiner S, Van Eyk J, Fraenkel E, Cudkowicz M, Maragakis N, Sareen D, et al. (2020). Answer ALS: A Large-Scale Resource for Sporadic and Familial ALS Combining Clinical Data with Multi-Omics Data from Induced Pluripotent Cell Lines. Research Square, 10.21203/rs.3.rs-96858/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-96858/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Slanzi A, Iannoto G, Rossi B, Zenaro E, and Constantin G (2020). In vitro Models of Neurodegenerative Diseases. Front. Cell Dev. Biol 8, 328, 10.3389/fcell.2020.00328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00328</ArticleId><ArticleId IdType="pmc">PMC7247860</ArticleId><ArticleId IdType="pubmed">32528949</ArticleId></ArticleIdList></Reference><Reference><Citation>Streeter I, Harrison PW, Faulconbridge A, Flicek P, Parkinson H, and Clarke L; The HipSci Consortium (2017). The human-induced pluripotent stem cell initiative-data resources for cellular genetics. Nucleic Acids Res. 45 (D1), D691&#x2013;D697, 10.1093/nar/gkw928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw928</ArticleId><ArticleId IdType="pmc">PMC5210631</ArticleId><ArticleId IdType="pubmed">27733501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Ward ME, Chen R, Liu K, Tracy TE, Chen X, Xie M, Sohn PD, Ludwig C, Meyer-Franke A, et al. (2017). Scalable Production of iPSC-Derived Human Neurons to Identify Tau-Lowering Compounds by High-Content Screening. Stem Cell Reports 9, 1221&#x2013;1233, 10.1016/j.stemcr.2017.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.08.019</ArticleId><ArticleId IdType="pmc">PMC5639430</ArticleId><ArticleId IdType="pubmed">28966121</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong X, Chen M, Lim WA, Zhao D, and Qi LS (2016). CRISPR/Cas9 for Human Genome Engineering and Disease Research. Annu. Rev. Genomics Hum. Genet 17, 131&#x2013;154, 10.1146/annurev-genom-083115-022258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-genom-083115-022258</ArticleId><ArticleId IdType="pmc">PMC10216851</ArticleId><ArticleId IdType="pubmed">27216776</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33848474</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Tau aggregates are RNA-protein assemblies that mislocalize multiple nuclear speckle components.</ArticleTitle><Pagination><StartPage>1675</StartPage><EndPage>1691.e9</EndPage><MedlinePgn>1675-1691.e9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2021.03.026</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(21)00196-3</ELocationID><Abstract><AbstractText>Tau aggregates contribute to neurodegenerative diseases, including frontotemporal dementia and Alzheimer's disease (AD). Although RNA promotes tau aggregation in&#xa0;vitro, whether tau aggregates in cells contain RNA is unknown. We demonstrate, in cell culture and mouse brains, that cytosolic and nuclear tau aggregates contain RNA with enrichment for small nuclear RNAs (snRNAs) and small nucleolar RNAs (snoRNAs). Nuclear tau aggregates colocalize with and alter the composition, dynamics, and organization of nuclear speckles, membraneless organelles involved in pre-mRNA splicing. Moreover, several nuclear speckle components, including SRRM2, mislocalize to cytosolic tau aggregates in cells, mouse brains, and brains of individuals with AD, frontotemporal dementia (FTD), and corticobasal degeneration (CBD). Consistent with these alterations, we observe that the presence of tau aggregates is sufficient to alter pre-mRNA splicing. This work identifies tau alteration of nuclear speckles as a feature of tau aggregation that may contribute to the pathology of tau aggregates.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lester</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Colorado, Boulder, CO, USA; Medical Scientist Training Program, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ooi</LastName><ForeName>Felicia K</ForeName><Initials>FK</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakkar</LastName><ForeName>Nadine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayers</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA; Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woerman</LastName><ForeName>Amanda L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Biology and Institute for Applied Life Sciences, University of Massachusetts Amherst, Amherst, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wheeler</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Colorado, Boulder, CO, USA; Medical Scientist Training Program, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Department of Pathology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowser</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>George A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA; Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prusiner</LastName><ForeName>Stanley B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA; Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA; Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Roy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Colorado, Boulder, CO, USA; Howard Hughes Medical Institute, University of Colorado, Boulder, CO, USA. Electronic address: roy.parker@colorado.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 AG063468</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG002132</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM045443</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020537">RNA, Small Nucleolar</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C414618">SRRM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2021 May 19;109(10):1585-1587. doi: 10.1016/j.neuron.2021.04.022.</RefSource><PMID Version="1">34015263</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003600" MajorTopicYN="N">Cytosol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012326" MajorTopicYN="N">RNA Splicing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020537" MajorTopicYN="N">RNA, Small Nucleolar</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's Disease</Keyword><Keyword MajorTopicYN="N">Frontemporal Dementia</Keyword><Keyword MajorTopicYN="N">MAPT</Keyword><Keyword MajorTopicYN="N">Nuclear Speckles</Keyword><Keyword MajorTopicYN="N">RNA</Keyword><Keyword MajorTopicYN="N">RNA binding proteins</Keyword><Keyword MajorTopicYN="N">SRRM2</Keyword><Keyword MajorTopicYN="N">Splicing</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">snRNA</Keyword></KeywordList><CoiStatement>Declaration of interests R.P. is a founder and consultant for Faze Medicines. S.B.P. is a member of the Scientific Advisory Boards of ViewPoint Therapeutics and New Ventures Inc. and a member of the Supervisory Board of Priavoid, none of which have contributed financial or any other support to these studies.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33848474</ArticleId><ArticleId IdType="mid">NIHMS1694315</ArticleId><ArticleId IdType="pmc">PMC8141031</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2021.03.026</ArticleId><ArticleId IdType="pii">S0896-6273(21)00196-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, et al. (2002). Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci 22, 9340&#x2013;9351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambadipudi S, Biernat J, Riedel D, Mandelkow E, and Zweckstetter M (2017). Liquid-liquid phase separation of the microtubule-binding repeats of the Alzheimer-related protein Tau. Nat Commun 8, 275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5561136</ArticleId><ArticleId IdType="pubmed">28819146</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoyagi A, Condello C, St&#xf6;hr J, Yue W, Rivera BM, Lee JC, Woerman AL, Halliday G, Duinen S. van, Ingelsson M, et al. (2019). A&#x3b2; and tau prion-like activities decline with longevity in the Alzheimer&#x2019;s disease human brain. Science Translational Medicine 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6640844</ArticleId><ArticleId IdType="pubmed">31043574</ArticleId></ArticleIdList></Reference><Reference><Citation>Apicco DJ, Ash PEA, Maziuk B, LeBlang C, Medalla M, Abdullatif AA, Ferragud A, Botelho E, Ballance HI, Dhawan U, et al. (2018). Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo. Nat Neurosci 21, 72&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5745051</ArticleId><ArticleId IdType="pubmed">29273772</ArticleId></ArticleIdList></Reference><Reference><Citation>Apicco DJ, Zhang C, Maziuk B, Jiang L, Ballance HI, Boudeau S, Ung C, Li H, and Wolozin B (2019). Dysregulation of RNA Splicing in Tauopathies. Cell Rep 29, 4377&#x2013;4388.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6941411</ArticleId><ArticleId IdType="pubmed">31875547</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B, Hales CM, Chen P-C, Gozal Y, Dammer EB, Fritz JJ, Wang X, Xia Q, Duong DM, Street C, et al. (2013). U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer&#x2019;s disease. PNAS 110, 16562&#x2013;16567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799305</ArticleId><ArticleId IdType="pubmed">24023061</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengoa-Vergniory N, Velentza-Almpani E, Silva AM, Scott C, Vargas-Caballero M, Sastre M, Wade-Martins R, and Alegre-Abarrategui J (2021). Tau-proximity ligation assay reveals extensive previously undetected pathology prior to neurofibrillary tangles in preclinical Alzheimer&#x2019;s disease. Acta Neuropathologica Communications 9, 18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7844979</ArticleId><ArticleId IdType="pubmed">33509301</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg S, Kutra D, Kroeger T, Straehle CN, Kausler BX, Haubold C, Schiegg M, Ales J, Beier T, Rudy M, et al. (2019). ilastik: interactive machine learning for (bio)image analysis. Nature Methods 16, 1226&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pubmed">31570887</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger AM, Lohse M, and Usadel B (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114&#x2013;2120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4103590</ArticleId><ArticleId IdType="pubmed">24695404</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt R, L&#xe9;ger J, and Lee G (1995). Interaction of tau with the neural plasma membrane mediated by tau&#x2019;s amino-terminal projection domain. J. Cell Biol 131, 1327&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120645</ArticleId><ArticleId IdType="pubmed">8522593</ArticleId></ArticleIdList></Reference><Reference><Citation>Broccolini A, Engel WK, Alvarez RB, and Askanas V (2000). Paired helical filaments of inclusion-body myositis muscle contain RNA and survival motor neuron protein. Am. J. Pathol 156, 1151&#x2013;1155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876899</ArticleId><ArticleId IdType="pubmed">10751338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu&#xe9;e L, Bussi&#xe8;re T, Bu&#xe9;e-Scherrer V, Delacourte A, and Hof PR (2000). Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work. Brain Research Reviews 33, 95&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">10967355</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukar Maina M, Al-Hilaly YK, and Serpell LC (2016). Nuclear Tau and Its Potential Role in Alzheimer&#x2019;s Disease. Biomolecules 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4808803</ArticleId><ArticleId IdType="pubmed">26751496</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke JM, Moon SL, Matheny T, and Parker R (2019). RNase L Reprograms Translation by Widespread mRNA Turnover Escaped by Antiviral mRNAs. Mol. Cell 75, 1203&#x2013;1217.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6754297</ArticleId><ArticleId IdType="pubmed">31494035</ArticleId></ArticleIdList></Reference><Reference><Citation>Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, Campisi J, Yaswen P, Cooper PK, and Kaufman PD (2009). A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One 4, e6529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717805</ArticleId><ArticleId IdType="pubmed">19657394</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Kanai Y, Cowan NJ, and Hirokawa N (1992). Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature 360, 674&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">1465130</ArticleId></ArticleIdList></Reference><Reference><Citation>Criscione SW, Zhang Y, Thompson W, Sedivy JM, and Neretti N (2014). Transcriptional landscape of repetitive elements in normal and cancer human cells. BMC Genomics 15, 583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4122776</ArticleId><ArticleId IdType="pubmed">25012247</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaval B, and Doxsey SJ (2010). Pericentrin in cellular function and disease. J Cell Biol 188, 181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812529</ArticleId><ArticleId IdType="pubmed">19951897</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, Corjuc BT, Commins C, Dujardin S, Bannon RN, Corjuc D, Moore BD, Bennett RE, Jorfi M, Gonzales JA, et al. (2018). Tau reduction in the presence of amyloid-&#x3b2; prevents tau pathology and neuronal death in vivo. Brain 141, 2194&#x2013;2212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022692</ArticleId><ArticleId IdType="pubmed">29733334</ArticleId></ArticleIdList></Reference><Reference><Citation>Diner I, Nguyen T, and Seyfried NT (2017). Enrichment of Detergent-insoluble Protein Aggregates from Human Postmortem Brain. J Vis Exp</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5755167</ArticleId><ArticleId IdType="pubmed">29155708</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkel PD, Holden MR, Matin N, and Margittai M (2015). RNA Binds to Tau Fibrils and Sustains Template-Assisted Growth. Biochemistry 54, 4731&#x2013;4740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4526887</ArticleId><ArticleId IdType="pubmed">26177386</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras TR (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zhang W, Murzin AG, Murshudov G, Garringer HJ, Vidal R, Crowther RA, Ghetti B, Scheres SHW, and Goedert M (2018). Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature 561, 137&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, Zivanov J, Zhang W, Murzin AG, Garringer HJ, Vidal R, Crowther RA, Newell KL, Ghetti B, Goedert M, et al. (2019). Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 568, 420&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther RA, Ghetti B, Goedert M, and Scheres SHW (2017). Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Galganski L, Urbanek MO, and Krzyzosiak WJ (2017). Nuclear speckles: molecular organization, biological function and role in disease. Nucleic Acids Res 45, 10350&#x2013;10368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5737799</ArticleId><ArticleId IdType="pubmed">28977640</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe4;rtner U, Janke C, Holzer M, Vanmechelen E, and Arendt T (1998). Postmortem changes in the phosphorylation state of tau-protein in the rat brain. Neurobiol. Aging 19, 535&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">10192212</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaspar I, Wippich F, and Ephrussi A (2017). Enzymatic production of single-molecule FISH and RNA capture probes. RNA 23, 1582&#x2013;1591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5602115</ArticleId><ArticleId IdType="pubmed">28698239</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil L, Federico C, Pinedo F, Bruno F, Rebolledo AB, Montoya JJ, Olazabal IM, Ferrer I, and Saccone S (2017). Aging dependent effect of nuclear tau. Brain Research 1677, 129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">28974363</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Crino PB, Lee VM, Eberwine JH, and Trojanowski JQ (1997). Sequestration of RNA in Alzheimer&#x2019;s disease neurofibrillary tangles and senile plaques. Ann. Neurol 41, 200&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">9029069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg SD, Galvin JE, Chiu TS, Lee VM, Masliah E, and Trojanowski JQ (1998). RNA sequestration to pathological lesions of neurodegenerative diseases. Acta Neuropathol. 96, 487&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">9829812</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M (2005). Tau gene mutations and their effects. Movement Disorders 20, S45&#x2013;S52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16092090</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, and Spillantini MG (2000). Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer&#x2019;s disease. Biochim. Biophys. Acta 1502, 110&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">10899436</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Wischik CM, Crowther RA, Walker JE, and Klug A (1988). Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. U.S.A 85, 4051&#x2013;4055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280359</ArticleId><ArticleId IdType="pubmed">3131773</ArticleId></ArticleIdList></Reference><Reference><Citation>Grainger RJ, Barrass JD, Jacquier A, Rain J-C, and Beggs JD (2009). Physical and genetic interactions of yeast Cwc21p, an ortholog of human SRm300/SRRM2, suggest a role at the catalytic center of the spliceosome. RNA 15, 2161&#x2013;2173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779682</ArticleId><ArticleId IdType="pubmed">19854871</ArticleId></ArticleIdList></Reference><Reference><Citation>Graser S, Stierhof Y-D, Lavoie SB, Gassner OS, Lamla S, Le Clech M, and Nigg EA (2007). Cep164, a novel centriole appendage protein required for primary cilium formation. J Cell Biol 179, 321&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064767</ArticleId><ArticleId IdType="pubmed">17954613</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawardana CG, Mehrabian M, Wang X, Mueller I, Lubambo IB, Jonkman JEN, Wang H, and Schmitt-Ulms G (2015). The Human Tau Interactome: Binding to the Ribonucleoproteome, and Impaired Binding of the Proline-to-Leucine Mutant at Position 301 (P301L) to Chaperones and the Proteasome. Mol. Cell Proteomics 14, 3000&#x2013;3014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4638042</ArticleId><ArticleId IdType="pubmed">26269332</ArticleId></ArticleIdList></Reference><Reference><Citation>Guthrie CR, Greenup L, Leverenz JB, and Kraemer BC (2011). MSUT2 is a determinant of susceptibility to tau neurotoxicity. Hum Mol Genet 20, 1989&#x2013;1999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3080609</ArticleId><ArticleId IdType="pubmed">21355046</ArticleId></ArticleIdList></Reference><Reference><Citation>Hales CM, Dammer EB, Diner I, Yi H, Seyfried NT, Gearing M, Glass JD, Montine TJ, Levey AI, and Lah JJ (2014a). Aggregates of small nuclear ribonucleic acids (snRNAs) in Alzheimer&#x2019;s disease. Brain Pathol. 24, 344&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4096308</ArticleId><ArticleId IdType="pubmed">24571648</ArticleId></ArticleIdList></Reference><Reference><Citation>Hales CM, Seyfried NT, Dammer EB, Duong D, Yi H, Gearing M, Troncoso JC, Mufson EJ, Thambisetty M, Levey AI, et al. (2014b). U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer&#x2019;s disease due to autosomal dominant genetic mutations and trisomy 21. Mol Neurodegener 9, 15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022210</ArticleId><ArticleId IdType="pubmed">24773620</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, Cosio DMO, Farrell M, Quiroz YT, Mormino EC, et al. (2019). Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurol.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547132</ArticleId><ArticleId IdType="pubmed">31157827</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, Belaygorod L, Cairns NJ, Holtzman DM, and Diamond MI (2014). Proteopathic tau seeding predicts tauopathy in vivo. Proc. Natl. Acad. Sci. U.S.A 111, E4376&#x2013;4385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205609</ArticleId><ArticleId IdType="pubmed">25261551</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan L-L, et al. (2010). Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh Y-C, Guo C, Yalamanchili HK, Abreha M, Al-Ouran R, Li Y, Dammer EB, Lah JJ, Levey AI, Bennett DA, et al. (2019). Tau-Mediated Disruption of the Spliceosome Triggers Cryptic RNA Splicing and Neurodegeneration in Alzheimer&#x2019;s Disease. Cell Rep 29, 301&#x2013;316.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919331</ArticleId><ArticleId IdType="pubmed">31597093</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, Deerinck TJ, Ellisman MH, and Spector DL (1994). In vivo analysis of the stability and transport of nuclear poly(A)+ RNA. J. Cell Biol 126, 877&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120126</ArticleId><ArticleId IdType="pubmed">7519622</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilik &#x130;A, Malszycki M, L&#xfc;bke AK, Schade C, Meierhofer D, and Akta&#x15f; T (2020). SON and SRRM2 are essential for nuclear speckle formation. ELife 9, e60579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7671692</ArticleId><ArticleId IdType="pubmed">33095160</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L, Ash PEA, Maziuk BF, Ballance HI, Boudeau S, Abdullatif AA, Orlando M, Petrucelli L, Ikezu T, and Wolozin B (2019). TIA1 regulates the generation and response to toxic tau oligomers. Acta Neuropathol 137, 259&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377165</ArticleId><ArticleId IdType="pubmed">30465259</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson NR, Condello C, Guan S, Oehler A, Becker J, Gavidia M, Carlson GA, Giles K, and Prusiner SB (2017). Evidence for sortilin modulating regional accumulation of human tau prions in transgenic mice. PNAS 114, E11029&#x2013;E11036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5754811</ArticleId><ArticleId IdType="pubmed">29203673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampers T, Friedhoff P, Biernat J, Mandelkow EM, and Mandelkow E (1996). RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 399, 344&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">8985176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK, Sanders DW, Thomas TL, Ruchinskas AJ, Vaquer-Alicea J, Sharma AM, Miller TM, and Diamond MI (2016). Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo. Neuron 92, 796&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5392364</ArticleId><ArticleId IdType="pubmed">27974162</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong A, Matheny T, Jain S, Mitchell SF, Wheeler JR, and Parker R (2017). The Stress Granule Transcriptome Reveals Principles of mRNA Accumulation in Stress Granules. Molecular Cell 68, 808&#x2013;820.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5728175</ArticleId><ArticleId IdType="pubmed">29129640</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinsella RJ, K&#xe4;h&#xe4;ri A, Haider S, Zamora J, Proctor G, Spudich G, Almeida-King J, Staines D, Derwent P, Kerhornou A, et al. (2011). Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database (Oxford) 2011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170168</ArticleId><ArticleId IdType="pubmed">21785142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss T (2002). Small Nucleolar RNAs: An Abundant Group of Noncoding RNAs with Diverse Cellular Functions. Cell 109, 145&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">12007400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kota KP, Wagner SR, Huerta E, Underwood JM, and Nickerson JA (2008). Binding of ATP to UAP56 is necessary for mRNA export. Journal of Cell Science 121, 1526&#x2013;1537.</Citation><ArticleIdList><ArticleId IdType="pubmed">18411249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, Huelga SC, Clutario KM, Ling S-C, Liang TY, Mazur C, et al. (2012). Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat. Neurosci 15, 1488&#x2013;1497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586380</ArticleId><ArticleId IdType="pubmed">23023293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Newman ST, Gard DL, Band H, and Panchamoorthy G (1998). Tau interacts with src-family non-receptor tyrosine kinases. J. Cell. Sci 111 ( Pt 21), 3167&#x2013;3177.</Citation><ArticleIdList><ArticleId IdType="pubmed">9763511</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H-D, Funk CC, and Price ND (2020). iREAD: a tool for intron retention detection from RNA-seq data. BMC Genomics 21, 128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7006120</ArticleId><ArticleId IdType="pubmed">32028886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, and G&#xf6;tz J (2013). Profiling Murine Tau with 0N, 1N and 2N Isoform-Specific Antibodies in Brain and Peripheral Organs Reveals Distinct Subcellular Localization, with the 1N Isoform Being Enriched in the Nucleus. PLOS ONE 8, e84849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875548</ArticleId><ArticleId IdType="pubmed">24386422</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, and Anders S (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology 15, 550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Maj M, Gartner W, Ilhan A, Neziri D, Attems J, and Wagner L (2010). Expression of TAU in insulin-secreting cells and its interaction with the calcium-binding protein secretagogin. Journal of Endocrinology 205, 25&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">20061514</ArticleId></ArticleIdList></Reference><Reference><Citation>Maziuk BF, Apicco DJ, Cruz AL, Jiang L, Ash PEA, da Rocha EL, Zhang C, Yu WH, Leszyk J, Abisambra JF, et al. (2018). RNA binding proteins co-localize with small tau inclusions in tauopathy. Acta Neuropathol Commun 6, 71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6069705</ArticleId><ArticleId IdType="pubmed">30068389</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuin C, Goodman A, Chernyshev V, Kamentsky L, Cimini BA, Karhohs KW, Doan M, Ding L, Rafelski SM, Thirstrup D, et al. (2018). CellProfiler 3.0: Next-generation image processing for biology. PLOS Biology 16, e2005970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029841</ArticleId><ArticleId IdType="pubmed">29969450</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier S, Bell M, Lyons DN, Rodriguez-Rivera J, Ingram A, Fontaine SN, Mechas E, Chen J, Wolozin B, LeVine H, et al. (2016). Pathological Tau Promotes Neuronal Damage by Impairing Ribosomal Function and Decreasing Protein Synthesis. J. Neurosci 36, 1001&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4719006</ArticleId><ArticleId IdType="pubmed">26791227</ArticleId></ArticleIdList></Reference><Reference><Citation>Metuzals J, Robitaille Y, Houghton S, Gauthier S, and Leblanc R (1988). Paired helical filaments and the cytoplasmic-nuclear interface in Alzheimer&#x2019;s disease. J Neurocytol 17, 827&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">3230400</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalbano M, McAllen S, Puangmalai N, Sengupta U, Bhatt N, Johnson OD, Kharas MG, and Kayed R (2020). RNA-binding proteins Musashi and tau soluble aggregates initiate nuclear dysfunction. Nature Communications 11, 4305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7453003</ArticleId><ArticleId IdType="pubmed">32855391</ArticleId></ArticleIdList></Reference><Reference><Citation>Motameny S, Wolters S, N&#xfc;rnberg P, and Schumacher B (2010). Next Generation Sequencing of miRNAs &#x2013; Strategies, Resources and Methods. Genes (Basel) 1, 70&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960865</ArticleId><ArticleId IdType="pubmed">24710011</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr ME, Sullivan AC, and Frost B (2017). A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies. Trends Pharmacol Sci 38, 637&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5476494</ArticleId><ArticleId IdType="pubmed">28455089</ArticleId></ArticleIdList></Reference><Reference><Citation>Papasozomenos SC (1995). Nuclear tau immunoreactivity in presenile dementia with motor neuron disease: a case report. Clin Neuropathol 14, 100&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">7606894</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SA, Ahn SI, and Gallo J-M (2016). Tau mis-splicing in the pathogenesis of neurodegenerative disorders. BMB Rep 49, 405&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070727</ArticleId><ArticleId IdType="pubmed">27222125</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling S-C, Sun E, Wancewicz E, Mazur C, et al. (2011). Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nature Neuroscience 14, 459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Q D, Wr M, Q C, F L, and Jn K (2005). Ribosome dysfunction is an early event in Alzheimer&#x2019;s disease (J Neurosci).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725754</ArticleId><ArticleId IdType="pubmed">16207876</ArticleId></ArticleIdList></Reference><Reference><Citation>Rady RM, Zinkowski RP, and Binder LI (1995). Presence of tau in isolated nuclei from human brain. Neurobiology of Aging 16, 479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566354</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj T, Li YI, Wong G, Humphrey J, Wang M, Ramdhani S, Wang Y-C, Ng B, Gupta I, Haroutunian V, et al. (2018). Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer&#x2019;s disease susceptibility. Nat Genet 50, 1584&#x2013;1592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6354244</ArticleId><ArticleId IdType="pubmed">30297968</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswami M, Taylor JP, and Parker R (2013). Altered Ribostasis: RNA-Protein Granules in Degenerative Disorders. Cell 154, 727&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3811119</ArticleId><ArticleId IdType="pubmed">23953108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, et al. (2005). Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 25, 10637&#x2013;10647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725849</ArticleId><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>Rino J, Carvalho T, Braga J, Desterro JMP, L&#xfc;hrmann R, and Carmo-Fonseca M (2007). A Stochastic View of Spliceosome Assembly and Recycling in the Nucleus. PLoS Computational Biology 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2041977</ArticleId><ArticleId IdType="pubmed">17967051</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, et al. (2014). Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa-Maria I, Varghese M, Ksiezak-Reding H, Dzhun A, Wang J, and Pasinetti GM (2012). Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes. J. Biol. Chem 287, 20522&#x2013;20533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370237</ArticleId><ArticleId IdType="pubmed">22496370</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid-Burgk JL, H&#xf6;ning K, Ebert TS, and Hornung V (2016). CRISPaint allows modular base-specific gene tagging using a ligase-4-dependent mechanism. Nature Communications 7, 12338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4974478</ArticleId><ArticleId IdType="pubmed">27465542</ArticleId></ArticleIdList></Reference><Reference><Citation>Schr&#xf6;der HC, Bernd A, Zahn RK, and M&#xfc;ller WE (1984). Binding of polyribonucleotides and polydeoxyribonucleotides to bovine brain microtubule protein: age-dependent modulation via phosphorylation of high-molecular-weight microtubule-associated proteins and tau proteins. Mech. Ageing Dev 24, 101&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">6141331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulveda G, Antkowiak M, Brust-Mascher I, Mahe K, Ou T, Castro NM, Christensen LN, Cheung L, Jiang X, Yoon D, et al. (2018). Co-translational protein targeting facilitates centrosomal recruitment of PCNT during centrosome maturation in vertebrates. ELife 7, e34959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5976437</ArticleId><ArticleId IdType="pubmed">29708497</ArticleId></ArticleIdList></Reference><Reference><Citation>Siano G, Varisco M, Caiazza MC, Quercioli V, Mainardi M, Ippolito C, Cattaneo A, and Di Primio C (2019). Tau Modulates VGluT1 Expression. Journal of Molecular Biology 431, 873&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">30664870</ArticleId></ArticleIdList></Reference><Reference><Citation>Spector DL, and Lamond AI (2011). Nuclear Speckles. Cold Spring Harb Perspect Biol 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039535</ArticleId><ArticleId IdType="pubmed">20926517</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka H, Kondo K, Chen X, Homma H, Tagawa K, Kerever A, Aoki S, Saito T, Saido T, Muramatsu S-I, et al. (2018). The intellectual disability gene PQBP1 rescues Alzheimer&#x2019;s disease pathology. Mol Psychiatry 23, 2090&#x2013;2110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250680</ArticleId><ArticleId IdType="pubmed">30283027</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH, and Cleveland DW (2016). Decoding ALS: from genes to mechanism. Nature 539, 197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich G, Salvad&#xe8; A, Boersema P, Cal&#xec; T, Foglieni C, Sola M, Picotti P, Papin S, and Paganetti P (2018). Phosphorylation of nuclear Tau is modulated by distinct cellular pathways. Scientific Reports 8, 1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6286375</ArticleId><ArticleId IdType="pubmed">30531974</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderweyde T, Apicco DJ, Youmans-Kidder K, Ash PEA, Cook C, Lummertz da Rocha E, Jansen-West K, Frame AA, Citro A, Leszyk JD, et al. (2016). Interaction of tau with the RNA-Binding Protein TIA1 Regulates tau Pathophysiology and Toxicity. Cell Reports 15, 1455&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325702</ArticleId><ArticleId IdType="pubmed">27160897</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaquero-Garcia J, Barrera A, Gazzara MR, Gonz&#xe1;lez-Vallinas J, Lahens NF, Hogenesch JB, Lynch KW, and Barash Y (2016). A new view of transcriptome complexity and regulation through the lens of local splicing variations. ELife 5, e11752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4801060</ArticleId><ArticleId IdType="pubmed">26829591</ArticleId></ArticleIdList></Reference><Reference><Citation>Violet M, Delattre L, Tardivel M, Sultan A, Chauderlier A, Caillierez R, Talahari S, Nesslany F, Lefebvre B, Bonnefoy E, et al. (2014). A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions. Front Cell Neurosci 8, 84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3957276</ArticleId><ArticleId IdType="pubmed">24672431</ArticleId></ArticleIdList></Reference><Reference><Citation>Violet M, Chauderlier A, Delattre L, Tardivel M, Chouala MS, Sultan A, Marciniak E, Humez S, Binder L, Kayed R, et al. (2015). Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo. Neurobiol. Dis 82, 540&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">26385829</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner S, Chiosea S, Ivshina M, and Nickerson JA (2004). In vitro FRAP reveals the ATP-dependent nuclear mobilization of the exon junction complex protein SRm160. J Cell Biol 164, 843&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172284</ArticleId><ArticleId IdType="pubmed">15024032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Wang D, Zhao J, Qu M, Zhou X, He H, and He R (2006). The proline-rich domain and the microtubule binding domain of protein tau acting as RNA binding domains. Protein Pept. Lett 13, 679&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">17018010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S, Medalsy ID, Mandelkow E, and M&#xfc;ller DJ (2013). The fuzzy coat of pathological human Tau fibrils is a two-layered polyelectrolyte brush. Proc. Natl. Acad. Sci. U.S.A 110, E313&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3557036</ArticleId><ArticleId IdType="pubmed">23269837</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler JM, McMillan P, Strovas TJ, Liachko NF, Amlie-Wolf A, Kow RL, Klein RL, Szot P, Robinson L, Guthrie C, et al. (2019). Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain. Science Translational Medicine 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311111</ArticleId><ArticleId IdType="pubmed">31852801</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingett SW, and Andrews S (2018). FastQ Screen: A tool for multi-genome mapping and quality control. F1000Res 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6124377</ArticleId><ArticleId IdType="pubmed">30254741</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik CM, Novak M, Th&#xf8;gersen HC, Edwards PC, Runswick MJ, Jakes R, Walker JE, Milstein C, Roth M, and Klug A (1988). Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 85, 4506&#x2013;4510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280459</ArticleId><ArticleId IdType="pubmed">3132715</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman AL, Aoyagi A, Patel S, Kazmi SA, Lobach I, Grinberg LT, McKee AC, Seeley WW, Olson SH, and Prusiner SB (2016). Tau prions from Alzheimer&#x2019;s disease and chronic traumatic encephalopathy patients propagate in cultured cells. PNAS.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5167200</ArticleId><ArticleId IdType="pubmed">27911827</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Yao J, Wu DC, and Lambowitz AM (2019). Improved TGIRT-seq methods for comprehensive transcriptome profiling with decreased adapter dimer formation and bias correction. Scientific Reports 9, 1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6538698</ArticleId><ArticleId IdType="pubmed">31138886</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang S-M, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, and Lee VM-Y (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Kota KP, Alam SG, Nickerson JA, Dickinson RB, and Lele TP (2016). Coordinated dynamics of RNA splicing speckles in the nucleus. J Cell Physiol 231, 1269&#x2013;1275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4755833</ArticleId><ArticleId IdType="pubmed">26496460</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Tarutani A, Newell KL, Murzin AG, Matsubara T, Falcon B, Vidal R, Garringer HJ, Shi Y, Ikeuchi T, et al. (2020). Novel tau filament fold in corticobasal degeneration. Nature 1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Lin Y, Eschmann NA, Zhou H, Rauch JN, Hernandez I, Guzman E, Kosik KS, and Han S (2017). RNA stores tau reversibly in complex coacervates. PLoS Biol 15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5500003</ArticleId><ArticleId IdType="pubmed">28683104</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Yan C, Zhan X, Li L, Lei J, and Shi Y (2018). Structure of the human activated spliceosome in three conformational states. Cell Research 28, 307&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5835773</ArticleId><ArticleId IdType="pubmed">29360106</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimowska G, Shi J, Munguba G, Jackson MR, Alpatov R, Simmons MN, Shi Y, and Sugrue SP (2003). Pinin/DRS/memA Interacts with SRp75, SRm300 and SRrp130 in Corneal Epithelial Cells. Invest. Ophthalmol. Vis. Sci 44, 4715&#x2013;4723.</Citation><ArticleIdList><ArticleId IdType="pubmed">14578391</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33852843</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>13</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Dietary spermidine improves cognitive function.</ArticleTitle><Pagination><StartPage>108985</StartPage><MedlinePgn>108985</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2021.108985</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(21)00299-0</ELocationID><Abstract><AbstractText>Decreased cognitive performance is a hallmark of brain aging, but the underlying mechanisms and potential therapeutic avenues remain poorly understood. Recent studies have revealed health-protective and lifespan-extending effects of dietary spermidine, a natural autophagy-promoting polyamine. Here, we show that dietary spermidine passes the blood-brain barrier in mice and increases hippocampal eIF5A hypusination and mitochondrial function. Spermidine feeding in aged mice affects behavior in homecage environment tasks, improves spatial learning, and increases hippocampal respiratory competence. In a Drosophila aging model, spermidine boosts mitochondrial respiratory capacity, an effect that requires the autophagy regulator Atg7&#xa0;and the mitophagy mediators Parkin and Pink1. Neuron-specific Pink1 knockdown abolishes spermidine-induced improvement of olfactory associative learning. This suggests that the maintenance of mitochondrial and autophagic function is essential for enhanced cognition by spermidine feeding. Finally, we show large-scale prospective data linking higher dietary spermidine intake with a reduced risk for cognitive impairment in humans.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria; BioTechMed-Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofer</LastName><ForeName>Sebastian J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria; BioTechMed-Graz, 8010 Graz, Austria; Field of Excellence BioHealth, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmermann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria; Field of Excellence BioHealth, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pechlaner</LastName><ForeName>Raimund</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dammbrueck</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pendl</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcello</LastName><ForeName>G Mark</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Histology, University of Veterinary Medicine Budapest, 1078 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pogatschnigg</LastName><ForeName>Viktoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergmann</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gschiel</LastName><ForeName>Verena</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ristic</LastName><ForeName>Selena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tadic</LastName><ForeName>Jelena</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria; Field of Excellence BioHealth, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Keiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Veneto Institute of Molecular Medicine, 35129 Padova, Italy; Research Center for Child Mental Development, University of Fukui, 910-1193 Fukui, Japan; Department of Biology, University of Padova, 35121 Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Gesa</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging Molecular Biology and Biochemistry Medical University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farzi</LastName><ForeName>Aitak</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Otto Loewi Research Center (for Vascular Biology, Immunology and Inflammation), Division of Pharmacology, Medical University of Graz (MUG), 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xdc;&#xe7;al</LastName><ForeName>Muammer</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, RU Experimental Neurotraumatology, Medical University Graz, 8036 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xe4;fer</LastName><ForeName>Ute</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, RU Experimental Neurotraumatology, Medical University Graz, 8036 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poglitsch</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Royer</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mekis</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agreiter</LastName><ForeName>Marlene</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>T&#xf6;lle</LastName><ForeName>Regine C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Fribourg, Chemin du Mus&#xe9;e 10, 1700 Fribourg, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf3;tonyi</LastName><ForeName>P&#xe9;ter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Histology, University of Veterinary Medicine Budapest, 1078 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willeit</LastName><ForeName>Johann</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mairhofer</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Bruneck Hospital, 39031 Bruneck, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niederkofler</LastName><ForeName>Helga</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Bruneck Hospital, 39031 Bruneck, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallhuber</LastName><ForeName>Irmgard</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Bruneck Hospital, 39031 Bruneck, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rungger</LastName><ForeName>Gregorio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Bruneck Hospital, 39031 Bruneck, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tilg</LastName><ForeName>Herbert</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Defrancesco</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marksteiner</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy A, Hall State Hospital, 6060 Hall in Tirol, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinner</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>HEALTH-Institute for Biomedicine and Health Sciences, Joanneum Research Forschungsgesellschaft mbH, 8010 Graz, Austria; Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magnes</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>HEALTH-Institute for Biomedicine and Health Sciences, Joanneum Research Forschungsgesellschaft mbH, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pieber</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>BioTechMed-Graz, 8010 Graz, Austria; HEALTH-Institute for Biomedicine and Health Sciences, Joanneum Research Forschungsgesellschaft mbH, 8010 Graz, Austria; Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holzer</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Otto Loewi Research Center (for Vascular Biology, Immunology and Inflammation), Division of Pharmacology, Medical University of Graz (MUG), 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kroemer</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Equipe Labellis&#xe9;e par la Ligue Contre le Cancer, Universit&#xe9; Paris Descartes, Universit&#xe9; Paris Diderot, Universit&#xe9; Sorbonne Paris Cit&#xe9;, INSERM U1138, Centre de Recherche des Cordeliers, 75006 Paris, France; Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, 94 805 Villejuif, France; P&#xf4;le de Biologie, H&#xf4;pital Europ&#xe9;en Georges Pompidou, AP-HP, 75015 Paris, France; Suzhou Institute for Systems Biology, Chinese Academy of Sciences, 215123 Suzhou, China; Department of Women's and Children's Health, Karolinska University Hospital, 171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmona-Gutierrez</LastName><ForeName>Didac</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scorrano</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Veneto Institute of Molecular Medicine, 35129 Padova, Italy; Department of Biology, University of Padova, 35121 Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dengjel</LastName><ForeName>J&#xf6;rn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Fribourg, Chemin du Mus&#xe9;e 10, 1700 Fribourg, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madl</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>BioTechMed-Graz, 8010 Graz, Austria; Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging Molecular Biology and Biochemistry Medical University of Graz, 8010 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedej</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>BioTechMed-Graz, 8010 Graz, Austria; Department of Cardiology, Medical University of Graz, 8036 Graz, Austria; Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sigrist</LastName><ForeName>Stephan J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Institute of Biology/Genetics, Freie Universit&#xe4;t Berlin, 14195 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xe1;cz</LastName><ForeName>Bence</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Histology, University of Veterinary Medicine Budapest, 1078 Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiechl</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria; VASCage, Research Centre on Vascular Ageing and Stroke, 6020 Innsbruck, Austria. Electronic address: stefan.kiechl@i-med.ac.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenberg</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria; BioTechMed-Graz, 8010 Graz, Austria; Field of Excellence BioHealth, University of Graz, 8010 Graz, Austria. Electronic address: tobias.eisenberg@uni-graz.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madeo</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, 8010 Graz, Austria; BioTechMed-Graz, 8010 Graz, Austria; Field of Excellence BioHealth, University of Graz, 8010 Graz, Austria. Electronic address: frank.madeo@uni-graz.at.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>W 1226</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant><Grant><GrantID>I 3301</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant><Grant><GrantID>DOC 50</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant><Grant><GrantID>P 27893</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant><Grant><GrantID>P 31727</GrantID><Acronym>FWF_</Acronym><Agency>Austrian Science Fund FWF</Agency><Country>Austria</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="C111567">parkin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C433927">PTEN-induced putative kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 6.2.1.45</RegistryNumber><NameOfSubstance UI="C509349">ATG7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 6.2.1.45</RegistryNumber><NameOfSubstance UI="D000071193">Autophagy-Related Protein 7</NameOfSubstance></Chemical><Chemical><RegistryNumber>U87FK77H25</RegistryNumber><NameOfSubstance UI="D013095">Spermidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071193" MajorTopicYN="N">Autophagy-Related Protein 7</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010085" MajorTopicYN="N">Oxidative Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065852" MajorTopicYN="N">Spatial Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013095" MajorTopicYN="N">Spermidine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pink1</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">cognitive function</Keyword><Keyword MajorTopicYN="N">dietary spermidine</Keyword><Keyword MajorTopicYN="N">memory</Keyword><Keyword MajorTopicYN="N">mitochondria</Keyword><Keyword MajorTopicYN="N">mitophagy</Keyword></KeywordList><CoiStatement>Declaration of interests F.M., S.J.S., and D.C.-G. have equity interests in The Longevity Labs (TLL), a company founded in 2016 that develops natural food extracts. T.E. has equity interests in and conducts paid consultancies for TLL. G.K. holds research contracts with Bayer Healthcare, Genentech, GlaxoSmithKline, Institut M&#xe9;rieux, Kaleido Biosciences, Lytix Biopharma, NuCana, Oncolinx, PharmaMar, Samsara Therapeutics, SOTIO, and Tioma Therapeutics. G.K. is on the Board of Directors of the Bristol Myers Squibb Foundation France. G.K. is a scientific cofounder of everImmune, a biotech company that develops immunostimulatory bacteria, and Therafast Bio. F.M. and T.E. are inventors on a pending patent application related to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>14</Day><Hour>20</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33852843</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.108985</ArticleId><ArticleId IdType="pii">S2211-1247(21)00299-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33852845</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>13</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>eIF5A hypusination, boosted by dietary spermidine, protects from premature brain aging and mitochondrial dysfunction.</ArticleTitle><Pagination><StartPage>108941</StartPage><MedlinePgn>108941</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2021.108941</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(21)00255-2</ELocationID><Abstract><AbstractText>Mitochondrial function declines during brain aging and is suspected to play a key role in age-induced cognitive decline and neurodegeneration. Supplementing levels of spermidine, a body-endogenous metabolite, has been shown to promote mitochondrial respiration and delay aspects of brain aging. Spermidine serves as the amino-butyl group donor for the synthesis of hypusine (N<sup>&#x3b5;</sup>-[4-amino-2-hydroxybutyl]-lysine) at a specific lysine residue of the eukaryotic translation initiation factor 5A (eIF5A). Here, we show that in the Drosophila brain, hypusinated eIF5A levels decline with age but can be boosted by dietary spermidine. Several genetic regimes of attenuating eIF5A hypusination all similarly affect brain mitochondrial respiration resembling age-typical mitochondrial decay and also provoke a premature aging of locomotion and memory formation in adult Drosophilae. eIF5A hypusination, conserved through all eukaryotes as an obviously critical effector of spermidine, might thus be an important diagnostic and therapeutic avenue in aspects of brain aging provoked by mitochondrial decline.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>YongTian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Biology/Genetics, Freie Universit&#xe4;t Berlin, Berlin 14195, Germany; NeuroCure Cluster of Excellence, Charit&#xe9; Universit&#xe4;tmedizin Berlin, Berlin 10117, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piao</LastName><ForeName>Chengji</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Biology/Genetics, Freie Universit&#xe4;t Berlin, Berlin 14195, Germany; NeuroCure Cluster of Excellence, Charit&#xe9; Universit&#xe4;tmedizin Berlin, Berlin 10117, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beuschel</LastName><ForeName>Christine B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Institute for Biology/Genetics, Freie Universit&#xe4;t Berlin, Berlin 14195, Germany; NeuroCure Cluster of Excellence, Charit&#xe9; Universit&#xe4;tmedizin Berlin, Berlin 10117, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toppe</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Biology/Genetics, Freie Universit&#xe4;t Berlin, Berlin 14195, Germany; NeuroCure Cluster of Excellence, Charit&#xe9; Universit&#xe4;tmedizin Berlin, Berlin 10117, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kollipara</LastName><ForeName>Laxmikanth</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Leibniz-Institut f&#xfc;r Analytische Wissenschaften - ISAS - e.V., Dortmund 44139, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogdanow</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Chemical Biology, Leibniz-Forschungsinstitut f&#xfc;r Molekulare Pharmakologie (FMP), 13125 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maglione</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Biology/Genetics, Freie Universit&#xe4;t Berlin, Berlin 14195, Germany; NeuroCure Cluster of Excellence, Charit&#xe9; Universit&#xe4;tmedizin Berlin, Berlin 10117, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xfc;tzkendorf</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Biology/Genetics, Freie Universit&#xe4;t Berlin, Berlin 14195, Germany; NeuroCure Cluster of Excellence, Charit&#xe9; Universit&#xe4;tmedizin Berlin, Berlin 10117, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>See</LastName><ForeName>Jason Chun Kit</ForeName><Initials>JCK</Initials><AffiliationInfo><Affiliation>Institute for Biology/Genetics, Freie Universit&#xe4;t Berlin, Berlin 14195, Germany; NeuroCure Cluster of Excellence, Charit&#xe9; Universit&#xe4;tmedizin Berlin, Berlin 10117, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Biology/Genetics, Freie Universit&#xe4;t Berlin, Berlin 14195, Germany; NeuroCure Cluster of Excellence, Charit&#xe9; Universit&#xe4;tmedizin Berlin, Berlin 10117, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conrad</LastName><ForeName>Tim O F</ForeName><Initials>TOF</Initials><AffiliationInfo><Affiliation>Institute for Mathematics and Computer Sciences, Freie Universit&#xe4;t Berlin, Berlin 14195, Germany; Zuse Institute Berlin, Berlin 14195, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kintscher</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin 10117, Germany; Institute of Pharmacology, Center for Cardiovascular Research, Charit&#xe9; Universit&#xe4;tmedizin Berlin, Berlin 10115, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madeo</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biosciences, NAWI Graz, University of Graz, Graz, Austria; BioTechMed Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Chemical Biology, Leibniz-Forschungsinstitut f&#xfc;r Molekulare Pharmakologie (FMP), 13125 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sickmann</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Leibniz-Institut f&#xfc;r Analytische Wissenschaften - ISAS - e.V., Dortmund 44139, Germany; Department of Chemistry, College of Physical Sciences, University of Aberdeen, Aberdeen AB24 3FX, Scotland, UK; Medizinische Fakult&#xe4;t, Medizinische Proteom-Center (MPC), Ruhr-Universit&#xe4;t Bochum, Bochum 44801, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sigrist</LastName><ForeName>Stephan J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Institute for Biology/Genetics, Freie Universit&#xe4;t Berlin, Berlin 14195, Germany; NeuroCure Cluster of Excellence, Charit&#xe9; Universit&#xe4;tmedizin Berlin, Berlin 10117, Germany. Electronic address: stephan.sigrist@fu-berlin.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010448">Peptide Initiation Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3874VXF092</RegistryNumber><NameOfSubstance UI="C100028">hypusine</NameOfSubstance></Chemical><Chemical><RegistryNumber>K3Z4F929H6</RegistryNumber><NameOfSubstance UI="D008239">Lysine</NameOfSubstance></Chemical><Chemical><RegistryNumber>U87FK77H25</RegistryNumber><NameOfSubstance UI="D013095">Spermidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019588" MajorTopicYN="N">Aging, Premature</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019069" MajorTopicYN="N">Cell Respiration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008124" MajorTopicYN="N">Locomotion</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008239" MajorTopicYN="N">Lysine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010448" MajorTopicYN="N">Peptide Initiation Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="Y">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013095" MajorTopicYN="N">Spermidine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097574" MajorTopicYN="N">Eukaryotic Translation Initiation Factor 5A</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CG8005</Keyword><Keyword MajorTopicYN="N">brain aging</Keyword><Keyword MajorTopicYN="N">deoxyhypusine synthase</Keyword><Keyword MajorTopicYN="N">eIF5A</Keyword><Keyword MajorTopicYN="N">eIF5A hypusination</Keyword><Keyword MajorTopicYN="N">learning and memory</Keyword><Keyword MajorTopicYN="N">locomotion</Keyword><Keyword MajorTopicYN="N">longevity</Keyword><Keyword MajorTopicYN="N">mitochondrial respiration</Keyword><Keyword MajorTopicYN="N">spermidine</Keyword></KeywordList><CoiStatement>Declaration of interests F.M. and S.J.S. have equity interests in TLL (The Longevity Labs), a company founded in 2016 that develops natural food extracts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>14</Day><Hour>20</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33852845</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.108941</ArticleId><ArticleId IdType="pii">S2211-1247(21)00255-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33859405</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2916</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature immunology</Title><ISOAbbreviation>Nat Immunol</ISOAbbreviation></Journal><ArticleTitle>Microglia use TAM receptors to detect and engulf amyloid &#x3b2; plaques.</ArticleTitle><Pagination><StartPage>586</StartPage><EndPage>594</EndPage><MedlinePgn>586-594</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41590-021-00913-5</ELocationID><Abstract><AbstractText>Two microglial TAM receptor tyrosine kinases, Axl and Mer, have been linked to Alzheimer's disease, but their roles in disease have not been tested experimentally. We find that in Alzheimer's disease and its mouse models, induced expression of Axl and Mer in amyloid plaque-associated microglia was coupled to induced plaque decoration by the TAM ligand Gas6 and its co-ligand phosphatidylserine. In the APP/PS1 mouse model of Alzheimer's disease, genetic ablation of Axl and Mer resulted in microglia that were unable to normally detect, respond to, organize or phagocytose amyloid-&#x3b2; plaques. These major deficits notwithstanding, TAM-deficient APP/PS1 mice developed fewer dense-core plaques than APP/PS1 mice with normal microglia. Our findings reveal that the TAM system is an essential mediator of microglial recognition and engulfment of amyloid plaques and that TAM-driven microglial phagocytosis does not inhibit, but rather promotes, dense-core plaque development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Youtong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Molecular Neurobiology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biological Sciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Happonen</LastName><ForeName>Kaisa E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Molecular Neurobiology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burrola</LastName><ForeName>Patrick G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Molecular Neurobiology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Flow Cytometry Core, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hah</LastName><ForeName>Nasun</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Chapman Foundations Genomic Sequencing Core, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Razavi Newman Integrative Genomics and Bioinformatics Core, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nimmerjahn</LastName><ForeName>Axel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0875-7855</Identifier><AffiliationInfo><Affiliation>Waitt Advanced Biophotonics Center, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemke</LastName><ForeName>Greg</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5805-9855</Identifier><AffiliationInfo><Affiliation>Molecular Neurobiology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA. lemke@salk.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG060748</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA034388</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS108034</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 NS083038</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD023689</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS110688</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI101400</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS103522</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA014195</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Immunol</MedlineTA><NlmUniqueID>100941354</NlmUniqueID><ISSNLinking>1529-2908</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000705833">APP protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C580804">presenilin 1, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C097072">MERTK protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C490767">Mertk protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020794">Receptor Protein-Tyrosine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D000076202">c-Mer Tyrosine Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000094963">Axl Receptor Tyrosine Kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Immunol. 2021 May;22(5):543-544. doi: 10.1038/s41590-021-00918-0.</RefSource><PMID Version="1">33859407</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2021 Jun;17(6):328. doi: 10.1038/s41582-021-00513-9.</RefSource><PMID Version="1">33986528</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069416" MajorTopicYN="N">Intravital Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036641" MajorTopicYN="N">Microscopy, Fluorescence, Multiphoton</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081246" MajorTopicYN="N">RNA-Seq</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020794" MajorTopicYN="N">Receptor Protein-Tyrosine Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076202" MajorTopicYN="N">c-Mer Tyrosine Kinase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094963" MajorTopicYN="N">Axl Receptor Tyrosine Kinase</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33859405</ArticleId><ArticleId IdType="mid">NIHMS1680908</ArticleId><ArticleId IdType="pmc">PMC8102389</ArticleId><ArticleId IdType="doi">10.1038/s41590-021-00913-5</ArticleId><ArticleId IdType="pii">10.1038/s41590-021-00913-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lemke G Biology of the TAM receptors. Cold Spring Harbor Perspectives 5(11), 10.1101/cshperspect.a009076. (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a009076</ArticleId><ArticleId IdType="pmc">PMC3809585</ArticleId><ArticleId IdType="pubmed">24186067</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q &amp; Lemke G Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 293, 306&#x2013;311 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11452127</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemke G How macrophages deal with death. Nat Rev Immunol 19, 539&#x2013;549 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6733267</ArticleId><ArticleId IdType="pubmed">31019284</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott RS et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 411, 207&#x2013;211 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11346799</ArticleId></ArticleIdList></Reference><Reference><Citation>Zag&#xf3;rska A, Trav&#xe9;s PG, Lew ED, Dransfield I &amp; Lemke G Diversification of TAM receptor tyrosine kinase function. Nat Immunol 15, 920&#x2013;928 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4169336</ArticleId><ArticleId IdType="pubmed">25194421</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB &amp; Lemke G TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131, 1124&#x2013;1136 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18083102</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourgeaud L et al. TAM receptors regulate multiple features of microglial physiology. Nature 532, 240&#x2013;244 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5358512</ArticleId><ArticleId IdType="pubmed">27049947</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM &amp; Holtzman DM Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell 179, 312&#x2013;339 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>ImmGen C Open-source ImmGen: mononuclear phagocytes. Nat Immunol 17, 741 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27327993</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C &amp; Lemke G An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 6, 691&#x2013;704 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2025425</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290 e1217 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z et al. Immune hyperreactivity of Abeta plaque-associated microglia in Alzheimer&#x2019;s disease. Neurobiology of aging 55, 115&#x2013;122 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28434692</ArticleId></ArticleIdList></Reference><Reference><Citation>Lew ED et al. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. eLife 3:e03385 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206827</ArticleId><ArticleId IdType="pubmed">25265470</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N et al. CSF protein biomarkers predicting longitudinal reduction of CSF beta-amyloid42 in cognitively healthy elders. Translational psychiatry 3, e293 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756294</ArticleId><ArticleId IdType="pubmed">23962923</ArticleId></ArticleIdList></Reference><Reference><Citation>Sainaghi PP et al. Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimer&#x2019;s Disease. Journal of Alzheimer&#x2019;s disease : JAD 55, 59&#x2013;65 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27636849</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13, 159&#x2013;170 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL et al. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17, 157&#x2013;165 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mallory M, Mante M, Sisk A &amp; Masliaha E Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1&#x2013;42). J Neurosci Res 66, 573&#x2013;582 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11746377</ArticleId></ArticleIdList></Reference><Reference><Citation>Labzin LI, Heneka MT &amp; Latz E Innate Immunity and Neurodegeneration. Annu Rev Med 69, 437&#x2013;449 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29106805</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy ER et al. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J Clin Invest 130, 1912&#x2013;1930 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108898</ArticleId><ArticleId IdType="pubmed">31917687</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581 e569 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK &amp; Colonna M TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol 14, 667&#x2013;675 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30266932</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett ML et al. New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A 113, E1738&#x2013;1746 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4812770</ArticleId><ArticleId IdType="pubmed">26884166</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DK et al. Deep proteome profiling of the hippocampus in the 5XFAD mouse model reveals biological process alterations and a novel biomarker of Alzheimer&#x2019;s disease. Exp Mol Med 51, 1&#x2013;17 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6856180</ArticleId><ArticleId IdType="pubmed">31727875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YE, Chen J, Langen R &amp; Chan JR Monitoring apoptosis and neuronal degeneration by real-time detection of phosphatidylserine externalization using a polarity-sensitive indicator of viability and apoptosis. Nat Protoc 5, 1396&#x2013;1405 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4340478</ArticleId><ArticleId IdType="pubmed">20671723</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman BA et al. Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer&#x2019;s Disease Not Evident in Mouse Models. Cell Rep 22, 832&#x2013;847 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>Satija R, Farrell JA, Gennert D, Schier AF &amp; Regev A Spatial reconstruction of single-cell gene expression data. Nat Biotechnol 33, 495&#x2013;502 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4430369</ArticleId><ArticleId IdType="pubmed">25867923</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez H &amp; Pacheco R T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. J Neuroinflammation 11, 201 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4258012</ArticleId><ArticleId IdType="pubmed">25441979</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg E et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer&#x2019;s disease model. Nature communications 10, 3758 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6704256</ArticleId><ArticleId IdType="pubmed">31434879</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 398, 723&#x2013;728 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10227296</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 20, 4106&#x2013;4114 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 61, 797&#x2013;805 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F &amp; Helmchen F Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314&#x2013;1318 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A Two-photon imaging of microglia in the mouse cortex in vivo. Cold Spring Harb Protoc 2012 (2012) 10.1101/pdb.prot069294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/pdb.prot069294</ArticleId><ArticleId IdType="pubmed">22550299</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213, 667&#x2013;675 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Yuan P, Schain A &amp; Grutzendler J Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nature communications 6, 6176 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassiotis S et al. Lysosomal LAMP1 immunoreactivity exists in both diffuse and neuritic amyloid plaques in the human hippocampus. Eur J Neurosci 47, 1043&#x2013;1053 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29570886</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X et al. Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities. EMBO J 26, 2755&#x2013;2767 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888669</ArticleId><ArticleId IdType="pubmed">17476306</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM et al. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol 16, 30&#x2013;42 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7268202</ArticleId><ArticleId IdType="pubmed">31827267</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Suarez E, Liu TF, Kopelevich A &amp; Allen NJ Astrocyte-Secreted Chordin-like 1 Drives Synapse Maturation and Limits Plasticity by Increasing Synaptic GluA2 AMPA Receptors. Neuron 100, 1116&#x2013;1132 e1113 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6382071</ArticleId><ArticleId IdType="pubmed">30344043</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR et al. Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer&#x2019;s Disease. J Neurosci 37, 637&#x2013;647 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J Exp Med 212, 287&#x2013;295 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P et al. TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron 90, 724&#x2013;739 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Baik SH, Kang S, Son SM &amp; Mook-Jung I Microglia contributes to plaque growth by cell death due to uptake of amyloid beta in the brain of Alzheimer&#x2019;s disease mouse model. Glia 64, 2274&#x2013;2290 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27658617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosna J et al. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer&#x2019;s disease. Mol Neurodegener 13, 11 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5831225</ArticleId><ArticleId IdType="pubmed">29490706</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H et al. Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Abeta by microglia. Glia 60, 993&#x2013;1003 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325361</ArticleId><ArticleId IdType="pubmed">22438044</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X et al. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci U S A 106, 20324&#x2013;20329 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787156</ArticleId><ArticleId IdType="pubmed">19910533</ArticleId></ArticleIdList></Reference><Reference><Citation>Cambier CJ, Falkow S &amp; Ramakrishnan L Host evasion and exploitation schemes of Mycobacterium tuberculosis. Cell 159, 1497&#x2013;1509 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25525872</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza F, Lozupone M, Logroscino G &amp; Imbimbo BP A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol 15, 73&#x2013;88 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30610216</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutter-Paier B et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer&#x2019;s disease. Neuron 44, 227&#x2013;238 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15473963</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbimbo BP et al. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer&#x2019;s disease. Br J Pharmacol 156, 982&#x2013;993 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2697723</ArticleId><ArticleId IdType="pubmed">19239474</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888&#x2013;1902 e1821 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Bais AS &amp; Kostka D scds: computational annotation of doublets in single-cell RNA sequencing data. Bioinformatics 36, 1150&#x2013;1158 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7703774</ArticleId><ArticleId IdType="pubmed">31501871</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt SD, Mazzella MJ, Nixon RA &amp; Mathews PM Abeta measurement by enzyme-linked immunosorbent assay. Methods Mol Biol 849, 507&#x2013;527 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22528112</ArticleId></ArticleIdList></Reference><Reference><Citation>Tufail Y et al. Phosphatidylserine Exposure Controls Viral Innate Immune Responses by Microglia. Neuron 93, 574&#x2013;586 e578 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5600182</ArticleId><ArticleId IdType="pubmed">28111081</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenigsknecht-Talboo J et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci 28, 14156&#x2013;14164 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743894</ArticleId><ArticleId IdType="pubmed">19109498</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci 28, 4283&#x2013;4292 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernier LP et al. Nanoscale Surveillance of the Brain by Microglia via cAMP-Regulated Filopodia. Cell Rep 27, 2895&#x2013;2908 e2894 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31167136</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura T et al. Island cells control temporal association memory. Science 343, 896&#x2013;901 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5572219</ArticleId><ArticleId IdType="pubmed">24457215</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33871169</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease.</ArticleTitle><Pagination><StartPage>946</StartPage><EndPage>958</EndPage><MedlinePgn>946-958</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12345</ELocationID><Abstract><AbstractText>Proteome profile changes in Alzheimer's disease (AD) brains have been reported. However, it is unclear whether they represent a continuous process, or whether there is a sequential involvement of distinct proteins. To address this question, we used mass spectrometry. We analyzed soluble, dispersible, sodium dodecyl sulfate, and formic acid fractions of neocortex homogenates (mainly Brodmann area 17-19) from 18 pathologically diagnosed preclinical AD, 17 symptomatic AD, and 18 cases without signs of neurodegeneration. By doing so, we identified four groups of AD-related proteins being changed in levels in preclinical and symptomatic AD cases: early-responding, late-responding, gradually-changing, and fraction-shifting proteins. Gene ontology analysis of these proteins and all known AD-risk/causative genes identified vesicle endocytosis and the secretory pathway-related processes as an early-involved AD component. In conclusion, our findings suggest that subtle changes involving the secretory pathway and endocytosis precede severe proteome changes in symptomatic AD as part of the preclinical phase of AD. The respective early-responding proteins may also contribute to synaptic vesicle cycle alterations in symptomatic AD.</AbstractText><CopyrightInformation>&#xa9; 2021 the Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaohang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Department of Imaging and Pathology, KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leuven Brain Institute (LBI), KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsolis</LastName><ForeName>Konstantinos C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Bacteriology, Rega Institute, Department of Microbiology and Immunology, KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koper</LastName><ForeName>Marta J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Department of Imaging and Pathology, KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leuven Brain Institute (LBI), KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for the Research of Neurodegenerative Diseases, Department of Neurosciences, KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain and Disease Research, VIB, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ronisz</LastName><ForeName>Alicja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Department of Imaging and Pathology, KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leuven Brain Institute (LBI), KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ospitalieri</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Department of Imaging and Pathology, KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leuven Brain Institute (LBI), KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Arnim</LastName><ForeName>Christine A F</ForeName><Initials>CAF</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatrics, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandenberghe</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, UZ Leuven (University Hospitals Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tousseyn</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, UZ Leuven (University Hospitals Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheuerle</LastName><ForeName>Angelika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Pathology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Economou</LastName><ForeName>Anastassios</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Bacteriology, Rega Institute, Department of Microbiology and Immunology, KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carpentier</LastName><ForeName>Sebastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>BIOMED facility for SYstems BIOlogy based MAss spectrometry, KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar Rudolf</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-1036-1075</Identifier><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Department of Imaging and Pathology, KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leuven Brain Institute (LBI), KU Leuven (University of Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, UZ Leuven (University Hospitals Leuven), Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyloid beta peptide</Keyword><Keyword MajorTopicYN="N">human neocortex</Keyword><Keyword MajorTopicYN="N">label-free liquid chromatography tandem mass spectrometry</Keyword><Keyword MajorTopicYN="N">pathologically diagnosed preclinical Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">proteomics</Keyword><Keyword MajorTopicYN="N">symptomatic Alzheimer's disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>19</Day><Hour>8</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33871169</ArticleId><ArticleId IdType="doi">10.1002/alz.12345</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 2016;12:459-509.</Citation></Reference><Reference><Citation>Alzheimer A. &#xdc;ber eine eigenartige Erkrankung der Hirnrinde. Allg Zschr Psych. 1907;64:146-148.</Citation></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261:6084-6089.</Citation></Reference><Reference><Citation>Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245-4249.</Citation></Reference><Reference><Citation>Rijal Upadhaya A, Kosterin I, Kumar S, et&#xa0;al. Biochemical stages of amyloid &#x3b2;-peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically-preclinical Alzheimer's disease. Brain. 2014;137:887-903.</Citation></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A&#x3b2;-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791-1800.</Citation></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-259.</Citation></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathological process in Alzheimer's disease: age categories 1 year to 100 years. J Neuropathol Exp Neurol. 2011;70:960-969.</Citation></Reference><Reference><Citation>Hyman BT, Phelps CH, Beach TG, et&#xa0;al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8:1-13.</Citation></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, et&#xa0;al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755-766.</Citation></Reference><Reference><Citation>Drummond E, Nayak S, Pires G, Ueberheide B, Wisniewski T. Isolation of Amyloid Plaques and Neurofibrillary Tangles from Archived Alzheimer's Disease Tissue Using Laser-Capture Microdissection for Downstream Proteomics. Methods Mol Biol. 2018;1723:319-334.</Citation></Reference><Reference><Citation>Johnson ECB, Dammer EB, Duong DM, et&#xa0;al. Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med. 2020;26:769-780.</Citation></Reference><Reference><Citation>Donovan LE, Higginbotham L, Dammer EB, et&#xa0;al. Analysis of a membrane-enriched proteome from postmortem human brain tissue in Alzheimer's disease. Proteomics Clin Appl. 2012;6:201-211.</Citation></Reference><Reference><Citation>Hales CM, Dammer EB, Deng Q, et&#xa0;al. Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression. Proteomics. 2016;16:3042-3053.</Citation></Reference><Reference><Citation>Seyfried NT, Dammer EB, Swarup V, et&#xa0;al. A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer's sisease. Cell Syst. 2017;4:60-72 e4.</Citation></Reference><Reference><Citation>Hondius DC, van Nierop P, Li KW, et&#xa0;al. Profiling the human hippocampal proteome at all pathologic stages of Alzheimer's disease. Alzheimers Dement. 2016;12:654-668.</Citation></Reference><Reference><Citation>Mendonca CF, Kuras M, Nogueira FCS, et&#xa0;al. Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease. Neurobiol Dis. 2019;130:104509.</Citation></Reference><Reference><Citation>Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol. 1997;4:119-125.</Citation></Reference><Reference><Citation>Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem. 1997;272:22364-22372.</Citation></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, et&#xa0;al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486-489.</Citation></Reference><Reference><Citation>Lesne S, Koh MT, Kotilinek L, et&#xa0;al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352-357.</Citation></Reference><Reference><Citation>Habicht G, Haupt C, Friedrich RP, et&#xa0;al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc Natl Acad Sci U S A. 2007;104:19232-19237.</Citation></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, et&#xa0;al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837-842.</Citation></Reference><Reference><Citation>Rijal Upadhaya A, Capetillo-Zarate E, Kosterin I, et&#xa0;al. Dispersible amyloid &#x3b2;-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice. Neurobiol Aging. 2012;33:2641-2660.</Citation></Reference><Reference><Citation>Hung MC, Link W. Protein localization in disease and therapy. J Cell Sci. 2011;124:3381-3392.</Citation></Reference><Reference><Citation>Vendruscolo M, Knowles TP, Dobson CM. Protein solubility and protein homeostasis: a generic view of protein misfolding disorders. Cold Spring Harb Perspect Biol. 2011;3(12):a010454</Citation></Reference><Reference><Citation>Pace MC, Xu G, Fromholt S, et&#xa0;al. Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease. Acta Neuropathol. 2018;136:919-938.</Citation></Reference><Reference><Citation>Wesseling H, Mair W, Kumar M, et&#xa0;al. Tau PTM profiles identify patient heterogeneity and stages of Alzheimer's disease. Cell. 2020;183:1699-1713 e13.</Citation></Reference><Reference><Citation>Higginbotham L, Dammer EB, Duong DM, et&#xa0;al. Network analysis of a membrane-enriched brain proteome across stages of Alzheimer's. Dis Proteomes. 2019;7:30</Citation></Reference><Reference><Citation>McKetney J, Runde RM, Hebert AS, Salamat S, Roy S, Coon JJ. Proteomic atlas of the human brain in Alzheimer's disease. J Proteome Res. 2019;18:1380-1391.</Citation></Reference><Reference><Citation>Andreev VP, Petyuk VA, Brewer HM, et&#xa0;al. Label-free quantitative LC-MS proteomics of Alzheimer's disease and normally aged human brains. J Proteome Res. 2012;11:3053-3067.</Citation></Reference><Reference><Citation>Musunuri S, Wetterhall M, Ingelsson M, et&#xa0;al. Quantification of the brain proteome in Alzheimer's disease using multiplexed mass spectrometry. J Proteome Res. 2014;13:2056-2068.</Citation></Reference><Reference><Citation>Xu J, Patassini S, Rustogi N, et&#xa0;al. Regional protein expression in human Alzheimer's brain correlates with disease severity. Commun Biol. 2019;2:43.</Citation></Reference><Reference><Citation>Bai B, Wang X, Li Y, et&#xa0;al. Deep multilayer brain proteomics identifies molecular networks in Alzheimer's disease progression. Neuron. 2020;106:700.</Citation></Reference><Reference><Citation>Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ. 2006;2006:re1.</Citation></Reference><Reference><Citation>Hurtado DE, Molina-Porcel L, Iba M, et&#xa0;al. A{beta} accelerates the spatiotemporal progression of Tau Ppthology and augments Tau amyloidosis in an Alzheimer mouse model. Am J Pathol. 2010;177:1977-1988.</Citation></Reference><Reference><Citation>Hanseeuw BJ, Betensky RA, Jacobs HIL, et&#xa0;al. Association of amyloid and Tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76:915-924.</Citation></Reference><Reference><Citation>Hanseeuw BJ, Betensky RA, Mormino EC, et&#xa0;al. PET staging of amyloidosis using striatum. Alzheimers Dement. 2018;14:1281-1292.</Citation></Reference><Reference><Citation>Schwarz AJ, Yu P, Miller BB, et&#xa0;al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139:1539-1550.</Citation></Reference><Reference><Citation>Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol. 2017;134:187-205.</Citation></Reference><Reference><Citation>Drummond E, Nayak S, Faustin A, et&#xa0;al. Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer's disease. Acta Neuropathol. 2017;133:933-954.</Citation></Reference><Reference><Citation>Kamphuis W, Mamber C, Moeton M, et&#xa0;al. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One. 2012;7:e42823.</Citation></Reference><Reference><Citation>Challa AA, Stefanovic B. A novel role of vimentin filaments: binding and stabilization of collagen mRNAs. Mol Cell Biol. 2011;31:3773-3789.</Citation></Reference><Reference><Citation>Milton ID, Banner SJ, Ince PG, et&#xa0;al. Expression of the glial glutamate transporter EAAT2 in the human CNS: an immunohistochemical study. Brain Res Mol Brain Res. 1997;52:17-31.</Citation></Reference><Reference><Citation>Woltjer RL, Duerson K, Fullmer JM, et&#xa0;al. Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J Neuropathol Exp Neurol. 2010;69:667-676.</Citation></Reference><Reference><Citation>Garcia-Esparcia P, Diaz-Lucena D, Ainciburu M, et&#xa0;al. Glutamate transporter GLT1 expression in Alzheimer disease and dementia with Lewy bodies. Front Aging Neurosci. 2018;10:122.</Citation></Reference><Reference><Citation>Thal DR. Excitatory amino acid transporter EAAT-2 in tangle-bearing neurons in Alzheimer's disease. Brain Pathol. 2002;12:405-411.</Citation></Reference><Reference><Citation>Kowal J, Tkach M. Dendritic cell extracellular vesicles. Int Rev Cell Mol Biol. 2019;349:213-249.</Citation></Reference><Reference><Citation>McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987;79:195-200.</Citation></Reference><Reference><Citation>Gomes LA, Lopez-Sanmartin D, Tom&#xe9; SO, et&#xa0;al. Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation. Acta Neuropathol. 2021;141:173-192.</Citation></Reference><Reference><Citation>Pensalfini A, Kim S, Subbanna S, et&#xa0;al. Endosomal dysfunction induced by directly overactivating Rab5 recapitulates prodromal and neurodegenerative features of Alzheimer's disease. Cell Rep. 2020;33:108420.</Citation></Reference><Reference><Citation>Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 2011;121:171-181.</Citation></Reference><Reference><Citation>Rub U, Del Tredici K, Schultz C, Thal DR, Braak E, Braak H. The evolution of Alzheimer's disease-related cytoskeletal pathology in the human raphe nuclei. Neuropathol Appl Neurobiol. 2000;26:553-567.</Citation></Reference><Reference><Citation>Sassin I, Schultz C, Thal DR, et&#xa0;al. Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol. 2000;100:259-269.</Citation></Reference><Reference><Citation>Trinczek B, Ebneth A, Mandelkow EM, Mandelkow E. Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles. J Cell Sci. 1999;112(Pt 14):2355-2367.</Citation></Reference><Reference><Citation>Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol. 1998;143:777-794.</Citation></Reference><Reference><Citation>Alves RN, Iglesia RP, Prado MB, et&#xa0;al. A new take on prion protein dynamics in cellular trafficking. Int J Mol Sci. 2020;21.</Citation></Reference><Reference><Citation>Godsave SF, Peters PJ, Wille H. Subcellular distribution of the prion protein in sickness and in health. Virus Res. 2015;207:136-145.</Citation></Reference><Reference><Citation>Campana V, Sarnataro D, Zurzolo C. The highways and byways of prion protein trafficking. Trends Cell Biol. 2005;15:102-111.</Citation></Reference><Reference><Citation>Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457:1128-1132.</Citation></Reference><Reference><Citation>Gomes LA, Hipp SA, Rijal Upadhaya A, et&#xa0;al. Abeta-induced acceleration of Alzheimer-related tau-pathology spreading and its association with prion protein. Acta Neuropathol. 2019;138:913-941.</Citation></Reference><Reference><Citation>Corbett GT, Wang Z, Hong W, et&#xa0;al. PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathol. 2020;139:503-526.</Citation></Reference><Reference><Citation>Velayos JL, Irujo A, Cuadrado-Tejedor M, Paternain B, Moleres FJ, Ferrer V. The cellular prion protein and its role in Alzheimer disease. Prion. 2009;3:110-117.</Citation></Reference><Reference><Citation>Whitehouse IJ, Miners JS, Glennon EB, et&#xa0;al. Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-beta levels and Braak stage. PLoS One. 2013;8:e59554.</Citation></Reference><Reference><Citation>Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol. 1991;30:637-649.</Citation></Reference><Reference><Citation>Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol. 2003;62:1287-1301.</Citation></Reference><Reference><Citation>Thal DR, Del Tredici K, Ludolph AC, et&#xa0;al. Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response. Acta Neuropathol. 2011;122:577-589.</Citation></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et&#xa0;al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.</Citation></Reference><Reference><Citation>Morris JC, Heyman A, Mohs RC, et&#xa0;al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39:1159-1165.</Citation></Reference><Reference><Citation>Uhlen M, Fagerberg L, Hallstrom BM, et&#xa0;al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.</Citation></Reference><Reference><Citation>Cuyvers E, Sleegers K. Genetic variations underlying Alzheimer's disease: evidence from genome-wide association studies and beyond. Lancet Neurol. 2016;15:857-868.</Citation></Reference><Reference><Citation>de Rojas I, Moreno-Grau S, Tesi N, et&#xa0;al. Common variants in Alzheimer's disease: novel association of six genetic variants with AD and risk stratification by polygenic risk scores. medRxiv. 2020:19012021.</Citation></Reference><Reference><Citation>Fernandez-de Frutos M, Galan-Chilet I, Goedeke L, et&#xa0;al. MicroRNA 7 impairs insulin signaling and regulates Abeta levels through posttranscriptional regulation of the insulin receptor substrate 2, insulin receptor, insulin-degrading enzyme, and liver X receptor pathway. Mol Cell Biol. 2019;39:e00170-19.</Citation></Reference><Reference><Citation>Fukuda T, Naiki T, Saito M, Irie K. hnRNP K interacts with RNA binding motif protein 42 and functions in the maintenance of cellular ATP level during stress conditions. Genes Cells. 2009;14:113-128.</Citation></Reference><Reference><Citation>Pires G, McElligott S, Drusinsky S, et&#xa0;al. Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies. Acta Neuropathol Commun. 2019;7:195.</Citation></Reference><Reference><Citation>Fu H, Ge B, Chen D, et&#xa0;al. Phytanoyl-CoA 2-hydroxylase-interacting protein-like gene is a therapeutic target gene for glioblastoma multiforme. Med Sci Monit. 2019;25:2583-2590.</Citation></Reference><Reference><Citation>Rogaev EI, Sherrington R, Rogaeva EA, et&#xa0;al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995;376:775-778.</Citation></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, et&#xa0;al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754-760.</Citation></Reference><Reference><Citation>Chartier-Harlin MC, Crawford F, Houlden H, et&#xa0;al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature. 1991;353:844-846.</Citation></Reference><Reference><Citation>Goate A, Chartier-Harlin MC, Mullan M, et&#xa0;al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704-706.</Citation></Reference><Reference><Citation>St George-Hyslop P, Haines J, Rogaev E, et&#xa0;al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat Genet. 1992;2:330-334.</Citation></Reference><Reference><Citation>Szklarczyk D, Gable AL, Lyon D, et&#xa0;al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607-D613.</Citation></Reference><Reference><Citation>Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33904867</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>325</Volume><Issue>16</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>27</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Association Between Age at Diabetes Onset and Subsequent Risk of Dementia.</ArticleTitle><Pagination><StartPage>1640</StartPage><EndPage>1649</EndPage><MedlinePgn>1640-1649</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2021.4001</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Trends in type 2 diabetes show an increase in prevalence along with younger age of onset. While vascular complications of early-onset type 2 diabetes are known, the associations with dementia remains unclear.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether younger age at diabetes onset is more strongly associated with incidence of dementia.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Population-based study in the UK, the Whitehall II prospective cohort study, established in 1985-1988, with clinical examinations in 1991-1993, 1997-1999, 2002-2004, 2007-2009, 2012-2013, and 2015-2016, and linkage to electronic health records until March 2019. The date of final follow-up was March 31, 2019.</AbstractText><AbstractText Label="EXPOSURES">Type 2 diabetes, defined as a fasting blood glucose level greater than or equal to 126 mg/dL at clinical examination, physician-diagnosed type 2 diabetes, use of diabetes medication, or hospital record of diabetes between 1985 and 2019.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Incident dementia ascertained through linkage to electronic health records.</AbstractText><AbstractText Label="RESULTS">Among 10&#x202f;095 participants (67.3% men; aged 35-55 years in 1985-1988), a total of 1710 cases of diabetes and 639 cases of dementia were recorded over a median follow-up of 31.7 years. Dementia rates per 1000 person-years were 8.9 in participants without diabetes at age 70 years, and rates were 10.0 per 1000 person-years for participants with diabetes onset up to 5 years earlier, 13.0 for 6 to 10 years earlier, and 18.3 for more than 10 years earlier. In multivariable-adjusted analyses, compared with participants without diabetes at age 70, the hazard ratio (HR) of dementia in participants with diabetes onset more than 10 years earlier was 2.12 (95% CI, 1.50-3.00), 1.49 (95% CI, 0.95-2.32) for diabetes onset 6 to 10 years earlier, and 1.11 (95% CI, 0.70-1.76) for diabetes onset 5 years earlier or less; linear trend test (P&#x2009;&lt;&#x2009;.001) indicated a graded association between age at onset of type 2 diabetes and dementia. At age 70, every 5-year younger age at onset of type 2 diabetes was significantly associated with an HR of dementia of 1.24 (95% CI, 1.06-1.46) in analyses adjusted for sociodemographic factors, health behaviors, and health-related measures.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this longitudinal cohort study with a median follow-up of 31.7 years, younger age at onset of diabetes was significantly associated with higher risk of subsequent dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barbiellini Amidei</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Epidemiology of Ageing and Neurodegenerative Diseases, Universit&#xe9; de Paris, Inserm U1153, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fayosse</LastName><ForeName>Aurore</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Epidemiology of Ageing and Neurodegenerative Diseases, Universit&#xe9; de Paris, Inserm U1153, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumurgier</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Epidemiology of Ageing and Neurodegenerative Diseases, Universit&#xe9; de Paris, Inserm U1153, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cognitive Neurology Center, Lariboisi&#xe8;re - Fernand Widal Hospital, AP-HP, Universit&#xe9; de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado-Fragua</LastName><ForeName>Marcos D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Epidemiology of Ageing and Neurodegenerative Diseases, Universit&#xe9; de Paris, Inserm U1153, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabak</LastName><ForeName>Adam G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine and Oncology, Semmelweis University Faculty of Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health, Semmelweis University Faculty of Medicine, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Sloten</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Institute Maastricht (CARIM), Department of Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivim&#xe4;ki</LastName><ForeName>Mika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dugravot</LastName><ForeName>Aline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Epidemiology of Ageing and Neurodegenerative Diseases, Universit&#xe9; de Paris, Inserm U1153, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabia</LastName><ForeName>S&#xe9;verine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Epidemiology of Ageing and Neurodegenerative Diseases, Universit&#xe9; de Paris, Inserm U1153, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh-Manoux</LastName><ForeName>Archana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Epidemiology of Ageing and Neurodegenerative Diseases, Universit&#xe9; de Paris, Inserm U1153, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University College London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/R024227/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG056477</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/S011676/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG062553</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2021 Sep 7;326(9):871. doi: 10.1001/jama.2021.10485.</RefSource><PMID Version="1">34547088</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Tabak reported salary supported by grants from the UK Medical Research Council (MRC) (S011676) and NordForsk (the Nordic Research Programme on Health and Welfare, 75021) during the conduct of the study. Dr van Sloten reported grants from the Netherlands Organization for Scientific Research and the Netherlands Organization for Health Research and Development (VENI research grant 916.19.074) and the Dutch Heart Foundation (2018T025) outside the submitted work. Dr Kivimaki reported grants from the UK MRC (R024227; S011676), the National Institute on Aging (NIA), National Institutes of Health (NIH) (R01AG056477; RF1AG062553), NordForsk (70521), and the Academy of Finland (311492) during the conduct of the study. Dr Sabia reported a grant from the French National Research Agency (ANR-19-CE36-0004-01). Dr Singh-Manoux reported grants from NIH (R01AG056477; RF1AG062553), the UK MRC (R024227; S011676), and the British Heart Foundation (BHF) (RG/16/11/32334) during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>27</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33904867</ArticleId><ArticleId IdType="pmc">PMC8080220</ArticleId><ArticleId IdType="doi">10.1001/jama.2021.4001</ArticleId><ArticleId IdType="pii">2779197</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239-2251. doi:10.1016/S0140-6736(17)30058-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)30058-2</ArticleId><ArticleId IdType="pubmed">28190580</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarwar N, Gao P, Seshasai SR, et al. ; Emerging Risk Factors Collaboration . Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-2222. doi:10.1016/S0140-6736(10)60484-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)60484-9</ArticleId><ArticleId IdType="pmc">PMC2904878</ArticleId><ArticleId IdType="pubmed">20609967</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. ; Emerging Risk Factors Collaboration . Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-841. doi:10.1056/NEJMoa1008862</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1008862</ArticleId><ArticleId IdType="pmc">PMC4109980</ArticleId><ArticleId IdType="pubmed">21366474</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J. 2012;42(5):484-491. doi:10.1111/j.1445-5994.2012.02758.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1445-5994.2012.02758.x</ArticleId><ArticleId IdType="pubmed">22372522</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S, Peters SA, Woodward M, et al. . Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100&#x2009;000 cases of dementia. Diabetes Care. 2016;39(2):300-307. doi:10.2337/dc15-1588</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc15-1588</ArticleId><ArticleId IdType="pmc">PMC4722942</ArticleId><ArticleId IdType="pubmed">26681727</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Chen C, Hua S, et al. . An updated meta-analysis of cohort studies: diabetes and risk of alzheimer&#x2019;s disease. Diabetes Res Clin Pract. 2017;124:41-47. doi:10.1016/j.diabres.2016.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2016.10.024</ArticleId><ArticleId IdType="pubmed">28088029</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivim&#xe4;ki M, Singh-Manoux A, Pentti J, et al. ; IPD-Work consortium . Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis. BMJ. 2019;365:l1495. doi:10.1136/bmj.l1495</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l1495</ArticleId><ArticleId IdType="pmc">PMC6468884</ArticleId><ArticleId IdType="pubmed">30995986</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue M, Xu W, Ou YN, et al. . Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies. Ageing Res Rev. 2019;55:100944. doi:10.1016/j.arr.2019.100944</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2019.100944</ArticleId><ArticleId IdType="pubmed">31430566</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattar N, Rawshani A, Franz&#xe9;n S, et al. . Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation. 2019;139(19):2228-2237. doi:10.1161/CIRCULATIONAHA.118.037885</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.037885</ArticleId><ArticleId IdType="pubmed">30955347</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo X, Gao L, Guo L, et al. . Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol. 2016;4(2):115-124. doi:10.1016/S2213-8587(15)00508-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(15)00508-2</ArticleId><ArticleId IdType="pubmed">26704379</ArticleId></ArticleIdList></Reference><Reference><Citation>Tancredi M, Rosengren A, Svensson AM, et al. . Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720-1732. doi:10.1056/NEJMoa1504347</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1504347</ArticleId><ArticleId IdType="pubmed">26510021</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, Huntley J, Sommerlad A, et al. . Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30367-6</ArticleId><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopman RJ, Mainous AG III, Diaz VA, Geesey ME. Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med. 2005;3(1):60-63. doi:10.1370/afm.214</Citation><ArticleIdList><ArticleId IdType="doi">10.1370/afm.214</ArticleId><ArticleId IdType="pmc">PMC1466782</ArticleId><ArticleId IdType="pubmed">15671192</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmot MG, Smith GD, Stansfeld S, et al. . Health inequalities among British civil servants: the Whitehall II study. Lancet. 1991;337(8754):1387-1393. doi:10.1016/0140-6736(91)93068-K</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(91)93068-K</ArticleId><ArticleId IdType="pubmed">1674771</ArticleId></ArticleIdList></Reference><Reference><Citation>Tab&#xe1;k AG, Jokela M, Akbaraly TN, Brunner EJ, Kivim&#xe4;ki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215-2221. doi:10.1016/S0140-6736(09)60619-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)60619-X</ArticleId><ArticleId IdType="pmc">PMC2726723</ArticleId><ArticleId IdType="pubmed">19515410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindstr&#xf6;m J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26(3):725-731. doi:10.2337/diacare.26.3.725</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.26.3.725</ArticleId><ArticleId IdType="pubmed">12610029</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommerlad A, Perera G, Singh-Manoux A, Lewis G, Stewart R, Livingston G. Accuracy of general hospital dementia diagnoses in England: sensitivity, specificity, and predictors of diagnostic accuracy 2008-2016. Alzheimers Dement. 2018;14(7):933-943. doi:10.1016/j.jalz.2018.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.012</ArticleId><ArticleId IdType="pmc">PMC6057268</ArticleId><ArticleId IdType="pubmed">29703698</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson T, Ly A, Schnier C, et al. ; UK Biobank Neurodegenerative Outcomes Group and Dementias Platform UK . Identifying dementia cases with routinely collected health data: a systematic review. Alzheimers Dement. 2018;14(8):1038-1051. doi:10.1016/j.jalz.2018.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.016</ArticleId><ArticleId IdType="pmc">PMC6105076</ArticleId><ArticleId IdType="pubmed">29621480</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601-609. doi:10.1161/CIRCULATIONAHA.115.017719</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.017719</ArticleId><ArticleId IdType="pmc">PMC4741409</ArticleId><ArticleId IdType="pubmed">26858290</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170(2):244-256. doi:10.1093/aje/kwp107</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwp107</ArticleId><ArticleId IdType="pmc">PMC2732996</ArticleId><ArticleId IdType="pubmed">19494242</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell FE, Jr. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer; 2001. doi:10.1007/978-1-4757-3462-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4757-3462-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Standl E, Khunti K, Hansen TB, Schnell O. The global epidemics of diabetes in the 21st century: current situation and perspectives. Eur J Prev Cardiol. 2019;26(2_suppl):7-14. doi:10.1177/2047487319881021</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487319881021</ArticleId><ArticleId IdType="pubmed">31766915</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes UK . Facts and Stats. Revised October 2016. Accessed April 6, 2021.
https://diabetes-resources-production.s3-eu-west-1.amazonaws.com/diabetes-storage/migration/pdf/DiabetesUK_Facts_Stats_Oct16.pdf</Citation></Reference><Reference><Citation>Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes. 2009;58(1):71-77. doi:10.2337/db08-0586</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db08-0586</ArticleId><ArticleId IdType="pmc">PMC2606895</ArticleId><ArticleId IdType="pubmed">18952836</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawlings AM, Sharrett AR, Albert MS, et al. . The association of late-life diabetes status and hyperglycemia with incident mild cognitive impairment and dementia: the ARIC study. Diabetes Care. 2019;42(7):1248-1254. doi:10.2337/dc19-0120</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc19-0120</ArticleId><ArticleId IdType="pmc">PMC6609963</ArticleId><ArticleId IdType="pubmed">31221696</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawlings AM, Sharrett AR, Schneider AL, et al. . Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med. 2014;161(11):785-793. doi:10.7326/M14-0737</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-0737</ArticleId><ArticleId IdType="pmc">PMC4432464</ArticleId><ArticleId IdType="pubmed">25437406</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuligenga RH, Dugravot A, Tab&#xe1;k AG, et al. . Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study. Lancet Diabetes Endocrinol. 2014;2(3):228-235. doi:10.1016/S2213-8587(13)70192-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(13)70192-X</ArticleId><ArticleId IdType="pmc">PMC4274502</ArticleId><ArticleId IdType="pubmed">24622753</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Walker R, Hubbard RA, et al. . Glucose levels and risk of dementia. N Engl J Med. 2013;369(6):540-548. doi:10.1056/NEJMoa1215740</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1215740</ArticleId><ArticleId IdType="pmc">PMC3955123</ArticleId><ArticleId IdType="pubmed">23924004</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamed SA. Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications. Expert Rev Clin Pharmacol. 2017;10(4):409-428. doi:10.1080/17512433.2017.1293521</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17512433.2017.1293521</ArticleId><ArticleId IdType="pubmed">28276776</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Marseglia A, Shang Y, Dintica C, Patrone C, Xu W. Leisure activity and social integration mitigate the risk of dementia related to cardiometabolic diseases: a population-based longitudinal study. Alzheimers Dement. 2020;16(2):316-325. doi:10.1016/j.jalz.2019.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.09.003</ArticleId><ArticleId IdType="pubmed">31718906</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeri MS, Bendlin BB. The link between type 2 diabetes and dementia: from biomarkers to treatment. Lancet Diabetes Endocrinol. 2020;8(9):736-738. doi:10.1016/S2213-8587(20)30267-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(20)30267-9</ArticleId><ArticleId IdType="pubmed">32738930</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunnane SC, Trushina E, Morland C, et al. . Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;19(9):609-633. doi:10.1038/s41573-020-0072-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0072-x</ArticleId><ArticleId IdType="pmc">PMC7948516</ArticleId><ArticleId IdType="pubmed">32709961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellar D, Craft S. Brain insulin resistance in Alzheimer&#x2019;s disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 2020;19(9):758-766. doi:10.1016/S1474-4422(20)30231-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30231-3</ArticleId><ArticleId IdType="pmc">PMC9661919</ArticleId><ArticleId IdType="pubmed">32730766</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al. . Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018;14(3):168-181. doi:10.1038/nrneurol.2017.185</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.185</ArticleId><ArticleId IdType="pmc">PMC6098968</ArticleId><ArticleId IdType="pubmed">29377010</ArticleId></ArticleIdList></Reference><Reference><Citation>Willette AA, Bendlin BB, Starks EJ, et al. . Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. JAMA Neurol. 2015;72(9):1013-1020. doi:10.1001/jamaneurol.2015.0613</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.0613</ArticleId><ArticleId IdType="pmc">PMC4570876</ArticleId><ArticleId IdType="pubmed">26214150</ArticleId></ArticleIdList></Reference><Reference><Citation>van Sloten TT, Sedaghat S, Carnethon MR, Launer LJ, Stehouwer CDA. Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. Lancet Diabetes Endocrinol. 2020;8(4):325-336. doi:10.1016/S2213-8587(19)30405-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(19)30405-X</ArticleId><ArticleId IdType="pmc">PMC11044807</ArticleId><ArticleId IdType="pubmed">32135131</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Falvey CM, Hamilton N, et al. ; Health ABC Study . Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013;173(14):1300-1306. doi:10.1001/jamainternmed.2013.6176</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2013.6176</ArticleId><ArticleId IdType="pmc">PMC4041621</ArticleId><ArticleId IdType="pubmed">23753199</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan JM, Mele BS, Hogan DB, Leung AA. Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2018;6(1):e000563. doi:10.1136/bmjdrc-2018-000563</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjdrc-2018-000563</ArticleId><ArticleId IdType="pmc">PMC6254737</ArticleId><ArticleId IdType="pubmed">30487973</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman KJ, Gallacher JE, Hatch EE. Why representativeness should be avoided. Int J Epidemiol. 2013;42(4):1012-1014. doi:10.1093/ije/dys223</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dys223</ArticleId><ArticleId IdType="pmc">PMC3888189</ArticleId><ArticleId IdType="pubmed">24062287</ArticleId></ArticleIdList></Reference><Reference><Citation>Batty GD, Shipley M, Tab&#xe1;k A, et al. . Generalizability of occupational cohort study findings. Epidemiology. 2014;25(6):932-933. doi:10.1097/EDE.0000000000000184</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000000184</ArticleId><ArticleId IdType="pubmed">25265141</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33910058</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-9777</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>Cell stem cell</Title><ISOAbbreviation>Cell Stem Cell</ISOAbbreviation></Journal><ArticleTitle>Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer's patients.</ArticleTitle><Pagination><StartPage>1533</StartPage><EndPage>1548.e6</EndPage><MedlinePgn>1533-1548.e6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.stem.2021.04.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1934-5909(21)00161-2</ELocationID><Abstract><AbstractText>Sporadic Alzheimer's disease (AD) exclusively affects elderly people. Using direct conversion of AD patient fibroblasts into induced neurons (iNs), we generated an age-equivalent neuronal model. AD patient-derived iNs exhibit strong neuronal transcriptome signatures characterized by downregulation of mature neuronal properties and upregulation of immature and progenitor-like signaling pathways. Mapping iNs to longitudinal neuronal differentiation trajectory data demonstrated that AD iNs reflect a hypo-mature neuronal identity characterized by markers of stress, cell cycle, and de-differentiation. Epigenetic landscape profiling revealed an underlying aberrant neuronal state that shares similarities with malignant transformation and age-dependent epigenetic erosion. To probe for the involvement of aging, we generated rejuvenated iPSC-derived neurons that showed no significant disease-related transcriptome signatures, a feature that is consistent with epigenetic clock and brain ontogenesis mapping, which indicate that fibroblast-derived iNs more closely reflect old adult brain stages. Our findings identify AD-related neuronal changes as age-dependent cellular programs that impair neuronal identity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mertens</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, USA; Neural Aging Laboratory, Institute of Molecular Biology, CMBI, Leopold-Franzens-University Innsbruck, Tyrol, Austria. Electronic address: jerome.mertens@uibk.ac.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herdy</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, USA; Neural Aging Laboratory, Institute of Molecular Biology, CMBI, Leopold-Franzens-University Innsbruck, Tyrol, Austria; Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traxler</LastName><ForeName>Larissa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, USA; Neural Aging Laboratory, Institute of Molecular Biology, CMBI, Leopold-Franzens-University Innsbruck, Tyrol, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schafer</LastName><ForeName>Simon T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlachetzki</LastName><ForeName>Johannes C M</ForeName><Initials>JCM</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf6;hnke</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, USA; Neural Aging Laboratory, Institute of Molecular Biology, CMBI, Leopold-Franzens-University Innsbruck, Tyrol, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reid</LastName><ForeName>Dylan A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyungjun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zangwill</LastName><ForeName>Dina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Diana P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Ravi K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucciola</LastName><ForeName>Raffaella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou-Yang</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neural Aging Laboratory, Institute of Molecular Biology, CMBI, Leopold-Franzens-University Innsbruck, Tyrol, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karbacher</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neural Aging Laboratory, Institute of Molecular Biology, CMBI, Leopold-Franzens-University Innsbruck, Tyrol, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edenhofer</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Genomics, Stem Cells &amp; Regenerative Medicine, Institute of Molecular Biology, CMBI, Institute of Molecular Biology and CMBI, Leopold-Franzens-University Innsbruck, Tyrol, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Shani</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, USA; Sagol Department of Neurobiology, Faculty of Natural Sciences, University of Haifa, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horvath</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paquola</LastName><ForeName>Apua C M</ForeName><Initials>ACM</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, USA; Lieber Institute for Brain Development, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Christopher K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Shauna H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA; University of Minnesota, Twin Cities, Department of Neurology, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ku</LastName><ForeName>Manching</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sz&#xfc;cs</LastName><ForeName>Attila</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuronal Cell Biology Research Group, E&#xf6;tv&#xf6;s Lor&#xe1;nd University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lawrence S B</ForeName><Initials>LSB</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA; Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA, USA. Electronic address: gage@salk.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG056306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056511</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057706</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG056679</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA014195</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Stem Cell</MedlineTA><NlmUniqueID>101311472</NlmUniqueID><ISSNLinking>1875-9777</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">de-differentiation</Keyword><Keyword MajorTopicYN="N">induced neurons (iNs)</Keyword><Keyword MajorTopicYN="N">neuronal cell cycle re-entry</Keyword><Keyword MajorTopicYN="N">rejuvenation</Keyword></KeywordList><CoiStatement>Declaration of interests F.H.G. is an advisory board member of Cell Stem Cell.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>28</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33910058</ArticleId><ArticleId IdType="pmc">PMC8423435</ArticleId><ArticleId IdType="doi">10.1016/j.stem.2021.04.004</ArticleId><ArticleId IdType="pii">S1934-5909(21)00161-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen M., Carrasquillo M.M., Funk C., Heavner B.D., Zou F., Younkin C.S., Burgess J.D., Chai H.-S., Crook J., Eddy J.A. Human whole genome genotype and transcriptome data for Alzheimer&#x2019;s and other neurodegenerative diseases. Sci. Data. 2016;3:160089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association 2015 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2015;11:332&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">25984581</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreadis A. Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim. Biophys. Acta Bba - Mol Basis Dis. 2005;1739:91&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">15615629</ArticleId></ArticleIdList></Reference><Reference><Citation>Annese A., Manzari C., Lionetti C., Picardi E., Horner D.S., Chiara M., Caratozzolo M.F., Tullo A., Fosso B., Pesole G., D&#x2019;Erchia A.M. Whole transcriptome profiling of Late-Onset Alzheimer&#x2019;s Disease patients provides insights into the molecular changes involved in the disease. Sci. Rep. 2018;8:4282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5844946</ArticleId><ArticleId IdType="pubmed">29523845</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbab M., Baars S., Geijsen N. Modeling motor neuron disease: the matter of time. Trends Neurosci. 2014;37:642&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">25156326</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T. Cell cycle activation and aneuploid neurons in Alzheimer&#x2019;s disease. Mol. Neurobiol. 2012;46:125&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">22528601</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T., Holzer M., St&#xf6;be A., G&#xe4;rtner U., L&#xfc;th H.J., Br&#xfc;ckner M.K., Ueberham U. Activated mitogenic signaling induces a process of dedifferentiation in Alzheimer&#x2019;s disease that eventually results in cell death. Ann. N Y Acad. Sci. 2000;920:249&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193159</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayata P., Badimon A., Strasburger H.J., Duff M.K., Montgomery S.E., Loh Y.E., Ebert A., Pimenova A.A., Ramirez B.R., Chan A.T. Epigenetic regulation of brain region-specific microglia clearance activity. Nat. Neurosci. 2018;21:1049&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6090564</ArticleId><ArticleId IdType="pubmed">30038282</ArticleId></ArticleIdList></Reference><Reference><Citation>Benn S.C., Woolf C.J. Adult neuron survival strategies&#x2014;slamming on the brakes. Nat. Rev. Neurosci. 2004;5:686&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322527</ArticleId></ArticleIdList></Reference><Reference><Citation>Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., Joshi M.-B., Harpole D., Lancaster J.M., Berchuck A. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439:353&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16273092</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock E.M., Chen K.-C., Sharrow K., Herman J.P., Porter N.M., Foster T.C., Landfield P.W. Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J.&#xa0;Neurosci. 2003;23:3807&#x2013;3819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742177</ArticleId><ArticleId IdType="pubmed">12736351</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock E.M., Buechel H.M., Popovic J., Geddes J.W., Landfield P.W. Microarray analyses of laser-captured hippocampus reveal distinct gray and white matter signatures associated with incipient Alzheimer&#x2019;s disease. J.&#xa0;Chem. Neuroanat. 2011;42:118&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163806</ArticleId><ArticleId IdType="pubmed">21756998</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hnke L., Traxler L., Herdy J.R., Mertens J. Human neurons to model aging: a dish best served old. Drug Discov. Today Dis. Models. 2018;27:43&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6863511</ArticleId><ArticleId IdType="pubmed">31745399</ArticleId></ArticleIdList></Reference><Reference><Citation>Buenrostro J.D., Giresi P.G., Zaba L.C., Chang H.Y., Greenleaf W.J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods. 2013;10:1213&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959825</ArticleId><ArticleId IdType="pubmed">24097267</ArticleId></ArticleIdList></Reference><Reference><Citation>Busser J., Geldmacher D.S., Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer&#x2019;s disease brain. J.&#xa0;Neurosci. 1998;18:2801&#x2013;2807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792587</ArticleId><ArticleId IdType="pubmed">9525997</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldwell A.B., Liu Q., Schroth G.P., Galasko D.R., Yuan S.H., Wagner S.L., Subramaniam S. Dedifferentiation and neuronal repression define familial Alzheimer&#x2019;s disease. Sci. Adv. 2020;6:eaba5933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7673760</ArticleId><ArticleId IdType="pubmed">33188013</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow H.-M., Shi M., Cheng A., Gao Y., Chen G., Song X., So R.W.L., Zhang J., Herrup K. Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence. Nat. Neurosci. 2019;22:1806&#x2013;1819.</Citation><ArticleIdList><ArticleId IdType="pubmed">31636448</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman M. Axon degeneration mechanisms: commonality amid diversity. Nat. Rev. Neurosci. 2005;6:889&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">16224497</ArticleId></ArticleIdList></Reference><Reference><Citation>Contrepois K., Coudereau C., Benayoun B.A., Schuler N., Roux P.-F., Bischof O., Courbeyrette R., Carvalho C., Thuret J.-Y., Ma Z. Histone variant H2A.J accumulates in senescent cells and promotes inflammatory gene expression. Nat. Commun. 2017;8:14995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5436145</ArticleId><ArticleId IdType="pubmed">28489069</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordenonsi M., Zanconato F., Azzolin L., Forcato M., Rosato A., Frasson C., Inui M., Montagner M., Parenti A.R., Poletti A. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011;147:759&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">22078877</ArticleId></ArticleIdList></Reference><Reference><Citation>Currais A., Hortob&#xe1;gyi T., Soriano S. The neuronal cell cycle as a mechanism of pathogenesis in Alzheimer&#x2019;s disease. Aging (Albany NY) 2009;1:363&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806021</ArticleId><ArticleId IdType="pubmed">20157524</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B., Karran E. The cellular phase of Alzheimer&#x2019;s disease. Cell. 2016;164:603&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">26871627</ArticleId></ArticleIdList></Reference><Reference><Citation>Elobeid A., Libard S., Leino M., Popova S.N., Alafuzoff I. Altered proteins in the aging brain. J.&#xa0;Neuropathol. Exp. Neurol. 2016;75:316&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793886</ArticleId><ArticleId IdType="pubmed">26979082</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde T.E., DeKosky S.T., Galasko D. Alzheimer&#x2019;s disease: the right drug, the right time. Science. 2018;362:1250&#x2013;1251.</Citation><ArticleIdList><ArticleId IdType="pubmed">30545877</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A., Chew G., Ouyang J.F., Sun G., Choo X.Y., McLean C., Simmons R.K., Buckberry S., Vargas-Landin D.B., Poppe D. A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci. 2019;22:2087&#x2013;2097.</Citation><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu N., Tamada Y., Imai A., Palfalvi G., Kabeya Y., Shigenobu S., Ishikawa M., Angelis K.J., Chen C., Hasebe M. DNA damage triggers reprogramming of differentiated cells into stem cells in Physcomitrella. Nat. Plants. 2020;6:1098&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">32807952</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdy J., Schafer S., Kim Y., Ansari Z., Zangwill D., Ku M., Paquola A., Lee H., Mertens J., Gage F.H. Chemical modulation of transcriptionally enriched signaling pathways to optimize the conversion of fibroblasts into neurons. eLife. 2019;8:1502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524968</ArticleId><ArticleId IdType="pubmed">31099332</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrup K., Yang Y. Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? Nat. Rev. Neurosci. 2007;8:368&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">17453017</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath S., Oshima J., Martin G.M., Lu A.T., Quach A., Cohen H., Felton S., Matsuyama M., Lowe D., Kabacik S. Epigenetic clock for skin and blood cells applied to Hutchinson Gilford Progeria Syndrome and ex&#xa0;vivo studies. Aging (Albany NY) 2018;10:1758&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6075434</ArticleId><ArticleId IdType="pubmed">30048243</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath S. DNA methylation age of human tissues and cell types. Genome Biology. 2013;14:3156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4015143</ArticleId><ArticleId IdType="pubmed">24138928</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath S., Lu A.T., Cohen H., Raj K. Rapamycin retards epigenetic ageing of keratinocytes independently of its effects on replicative senescence, proliferation and differentiation. Aging (Albany NY) 2019;11:3238&#x2013;3249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6555449</ArticleId><ArticleId IdType="pubmed">31136303</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh C.J., Zhang B., Victor M.B., Dahiya S., Batista L.F., Horvath S., Yoo A.S. Maintenance of age in human neurons generated by microRNA-based neuronal conversion of fibroblasts. eLife. 2016;5:e18648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5067114</ArticleId><ArticleId IdType="pubmed">27644593</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel M.A., Yuan S.H., Bardy C., Reyna S.M., Mu Y., Herrera C., Hefferan M.P., Van Gorp S., Nazor K.L., Boscolo F.S. Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature. 2012;482:216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner L.M., G&#xf6;tz J. Amyloid-&#x3b2; and tau&#x2014;a toxic pas de deux in Alzheimer&#x2019;s disease. Nat. Rev. Neurosci. 2011;12:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21193853</ArticleId></ArticleIdList></Reference><Reference><Citation>Jopling C., Sleep E., Raya M., Mart&#xed; M., Raya A., Izpis&#xfa;a Belmonte J.C. Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. Nature. 2010;464:606&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846535</ArticleId><ArticleId IdType="pubmed">20336145</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang E., Wang X., Tippner-Hedges R., Ma H., Folmes C.D.L., Gutierrez N.M., Lee Y., Van Dyken C., Ahmed R., Li Y. Age-related accumulation of somatic mitochondrial DNA mutations in adult-derived human iPSCs. Cell Stem Cell. 2016;18:625&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">27151456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M., Park Y.-K., Kang T.-W., Lee S.-H., Rhee Y.-H., Park J.-L., Kim H.-J., Lee D., Lee D., Kim S.-Y., Kim Y.S. Dynamic changes in DNA methylation and hydroxymethylation when hES cells undergo differentiation toward a neuronal lineage. Hum. Mol. Genet. 2014;23:657&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">24087792</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Denli A.M., Wright R., Baul T.D., Clemenson G.D., Morcos A.S., Zhao C., Schafer S.T., Gage F.H., Kagalwala M.N. REST regulates non-cell-autonomous neuronal differentiation and maturation of neural progenitor cells via secretogranin II. J.&#xa0;Neurosci. 2015;35:14872&#x2013;14884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4635134</ArticleId><ArticleId IdType="pubmed">26538656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y., Zheng X., Ansari Z., Bunnell M.C., Herdy J.R., Traxler L., Lee H., Paquola A.C.M., Blithikioti C., Ku M. Mitochondrial aging defects emerge in directly reprogrammed human neurons due to their metabolic profile. Cell Rep. 2018;23:2550&#x2013;2558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6478017</ArticleId><ArticleId IdType="pubmed">29847787</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch P., Tamboli I.Y., Mertens J., Wunderlich P., Ladewig J., St&#xfc;ber K., Esselmann H., Wiltfang J., Br&#xfc;stle O., Walter J. Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of &#x3b3;-secretase activity in endogenous amyloid-&#x3b2; generation. Am. J. Pathol. 2012;180:2404&#x2013;2416.</Citation><ArticleIdList><ArticleId IdType="pubmed">22510327</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie R.M., Hyman B.T., Spires-Jones T.L. Alzheimer&#x2019;s disease: synapses gone cold. Mol. Neurodegener. 2011;6:63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3178498</ArticleId><ArticleId IdType="pubmed">21871088</ArticleId></ArticleIdList></Reference><Reference><Citation>Kole A.J., Annis R.P., Deshmukh M. Mature neurons: equipped for survival. Cell Death Dis. 2013;4:e689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3702294</ArticleId><ArticleId IdType="pubmed">23807218</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruman I.I., Wersto R.P., Cardozo-Pelaez F., Smilenov L., Chan S.L., Chrest F.J., Emokpae R., Jr., Gorospe M., Mattson M.P. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron. 2004;41:549&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">14980204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladewig J., Mertens J., Kesavan J., Doerr J., Poppe D., Glaue F., Herms S., Wernet P., K&#xf6;gler G., M&#xfc;ller F.-J. Small molecules enable highly efficient neuronal conversion of human fibroblasts. Nat. Methods. 2012;9:575&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">22484851</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M.-L., Zang T., Zou Y., Chang J.C., Gibson J.R., Huber K.M., Zhang C.-L. Small molecules enable neurogenin 2 to efficiently convert human fibroblasts into cholinergic neurons. Nat. Commun. 2013;4:2183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843951</ArticleId><ArticleId IdType="pubmed">23873306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Sardo V., Ferguson W., Erikson G.A., Topol E.J., Baldwin K.K., Torkamani A. Influence of donor age on induced pluripotent stem cells. Nat. Biotechnol. 2017;35:69&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505172</ArticleId><ArticleId IdType="pubmed">27941802</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T., Aron L., Zullo J., Pan Y., Kim H., Chen Y., Yang T.-H., Kim H.-M., Drake D., Liu X.S. REST and stress resistance in ageing and Alzheimer&#x2019;s disease. Nature. 2014;507:448&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4110979</ArticleId><ArticleId IdType="pubmed">24670762</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo C., Lancaster M.A., Castanon R., Nery J.R., Knoblich J.A., Ecker J.R. Cerebral organoids recapitulate epigenomic signatures of the human fetal brain. Cell Rep. 2016;17:3369&#x2013;3384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5495578</ArticleId><ArticleId IdType="pubmed">28009303</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo C., Lee Q.Y., Wapinski O., Castanon R., Nery J.R., Mall M., Kareta M.S., Cullen S.M., Goodell M.A., Chang H.Y. Global DNA methylation remodeling during direct reprogramming of fibroblasts to neurons. eLife. 2019;8:166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6333439</ArticleId><ArticleId IdType="pubmed">30644360</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Z., Wang H., Cai Y., Wang H., Niu K., Wu X., Ma H., Yang Y., Tong W., Liu F. Epigenetic drift of H3K27me3 in aging links glycolysis to healthy longevity in Drosophila. eLife. 2018;7:e35368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5991832</ArticleId><ArticleId IdType="pubmed">29809154</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinaro F., Haneklaus M., Zhang Z., Strano A., Evans L., Handfield L.-F., Ryan N.S., Fox N.C., Hemberg M., Ramanathan S. Molecular and cellular pathology of monogenic Alzheimer&#x2019;s disease at single cell resolution. bioRxiv. 2020 doi: 10.1101/2020.07.14.202317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.14.202317</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H., Davila-Velderrain J., Peng Z., Gao F., Mohammadi S., Young J.Z., Menon M., He L., Abdurrob F., Jiang X. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature. 2019;570:332&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M.P., Magnus T. Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 2006;7:278&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710114</ArticleId><ArticleId IdType="pubmed">16552414</ArticleId></ArticleIdList></Reference><Reference><Citation>McShea A., Wahl A.F., Smith M.A. Re-entry into the cell cycle: a mechanism for neurodegeneration in Alzheimer disease. Med. Hypotheses. 1999;52:525&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">10459833</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrell A.J., Stanger B.Z. Adult cell plasticity in&#xa0;vivo: de-differentiation and transdifferentiation are back in style. Nat. Rev. Mol. Cell Biol. 2016;17:413&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818993</ArticleId><ArticleId IdType="pubmed">26979497</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J., St&#xfc;ber K., Wunderlich P., Ladewig J., Kesavan J.C., Vandenberghe R., Vandenbulcke M., van Damme P., Walter J., Br&#xfc;stle O., Koch P. APP processing in human pluripotent stem cell-derived neurons is resistant to NSAID-based &#x3b3;-secretase modulation. Stem Cell Reports. 2013;1:491&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3871388</ArticleId><ArticleId IdType="pubmed">24371804</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J., St&#xfc;ber K., Poppe D., Doerr J., Ladewig J., Br&#xfc;stle O., Koch P. Embryonic stem cell-based modeling of tau pathology in human neurons. Am. J. Pathol. 2013;182:1769&#x2013;1779.</Citation><ArticleIdList><ArticleId IdType="pubmed">23499461</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J., Paquola A.C.M., Ku M., Hatch E., B&#xf6;hnke L., Ladjevardi S., McGrath S., Campbell B., Lee H., Herdy J.R. Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell. 2015;17:705&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5929130</ArticleId><ArticleId IdType="pubmed">26456686</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J., Wang Q.-W., Kim Y., Yu D.X., Pham S., Yang B., Zheng Y., Diffenderfer K.E., Zhang J., Soltani S., Pharmacogenomics of Bipolar Disorder Study Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature. 2015;527:95&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4742055</ArticleId><ArticleId IdType="pubmed">26524527</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J., Reid D., Lau S., Kim Y., Gage F.H. Aging in a dish: iPSC-derived and directly induced neurons for studying brain aging and age-related neurodegenerative diseases. Annu. Rev. Genet. 2018;52:271&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6415910</ArticleId><ArticleId IdType="pubmed">30208291</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K., Feldman H.M., Lu T., Drake D., Lim E.T., Ling K.-H., Bishop N.A., Pan Y., Seo J., Lin Y.-T. REST and neural gene network dysregulation in iPSC models of Alzheimer&#x2019;s disease. Cell Rep. 2019;26:1112&#x2013;1127.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6386196</ArticleId><ArticleId IdType="pubmed">30699343</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J.D., Ganat Y.M., Kishinevsky S., Bowman R.L., Liu B., Tu E.Y., Mandal P.K., Vera E., Shim J.-W., Kriks S. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell. 2013;13:691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4153390</ArticleId><ArticleId IdType="pubmed">24315443</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills J.D., Nalpathamkalam T., Jacobs H.I.L., Janitz C., Merico D., Hu P., Janitz M. RNA-Seq analysis of the parietal cortex in Alzheimer&#x2019;s disease reveals alternatively spliced isoforms related to lipid metabolism. Neurosci. Lett. 2013;536:90&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">23305720</ArticleId></ArticleIdList></Reference><Reference><Citation>Moehlmann T., Winkler E., Xia X., Edbauer D., Murrell J., Capell A., Kaether C., Zheng H., Ghetti B., Haass C., Steiner H. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc. Natl. Acad. Sci. U S A. 2002;99:8025&#x2013;8030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123014</ArticleId><ArticleId IdType="pubmed">12048239</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosch B., Morawski M., Mittag A., Lenz D., Tarnok A., Arendt T. Aneuploidy and DNA replication in the normal human brain and Alzheimer&#x2019;s disease. J.&#xa0;Neurosci. 2007;27:6859&#x2013;6867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672221</ArticleId><ArticleId IdType="pubmed">17596434</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z., Esiri M.M., Cato A.M., Smith A.D. Cell cycle markers in the hippocampus in Alzheimer&#x2019;s disease. Acta Neuropathol. 1997;94:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">9224524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocampo A., Reddy P., Martinez-Redondo P., Platero-Luengo A., Hatanaka F., Hishida T., Li M., Lam D., Kurita M., Beyret E. In&#xa0;vivo amelioration of age-associated hallmarks by partial reprogramming. Cell. 2016;167:1719&#x2013;1733.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5679279</ArticleId><ArticleId IdType="pubmed">27984723</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang Z.P., Yang N., Vierbuchen T., Ostermeier A., Fuentes D.R., Yang T.Q., Citri A., Sebastiano V., Marro S., S&#xfc;dhof T.C., Wernig M. Induction of human neuronal cells by defined transcription factors. Nature. 2011;476:220&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3159048</ArticleId><ArticleId IdType="pubmed">21617644</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson M., Chan D.N., Ha I., Case D., Cui Y., Van Handel B., Mikkola H.K., Lowry W.E. Defining the nature of human pluripotent stem cell progeny. Cell Res. 2012;22:178&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351932</ArticleId><ArticleId IdType="pubmed">21844894</ArticleId></ArticleIdList></Reference><Reference><Citation>Pistollato F., Ohayon E.L., Lam A., Langley G.R., Novak T.J., Pamies D., Perry G., Trushina E., Williams R.S.B., Roher A.E. Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities. Oncotarget. 2016;7:38999&#x2013;39016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5129909</ArticleId><ArticleId IdType="pubmed">27229915</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaisier S.B., Taschereau R., Wong J.A., Graeber T.G. Rank-rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures. Nucleic Acids Res. 2010;38:e169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2943622</ArticleId><ArticleId IdType="pubmed">20660011</ArticleId></ArticleIdList></Reference><Reference><Citation>Poplawski G.H.D., Kawaguchi R., Van Niekerk E., Lu P., Mehta N., Canete P., Lie R., Dragatsis I., Meves J.M., Zheng B. Injured adult neurons regress to an embryonic transcriptional growth state. Nature. 2020;581:77&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">32376949</ArticleId></ArticleIdList></Reference><Reference><Citation>Querfurth H.W., LaFerla F.M. Alzheimer&#x2019;s disease. N.&#xa0;Engl. J. Med. 2010;362:329&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107219</ArticleId></ArticleIdList></Reference><Reference><Citation>Renthal W., Tochitsky I., Yang L., Cheng Y.-C., Li E., Kawaguchi R., Geschwind D.H., Woolf C.J. Transcriptional reprogramming of distinct peripheral sensory neuron subtypes after axonal injury. Neuron. 2020;108:128&#x2013;144.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7590250</ArticleId><ArticleId IdType="pubmed">32810432</ArticleId></ArticleIdList></Reference><Reference><Citation>Riessland M., Kolisnyk B., Kim T.W., Cheng J., Ni J., Pearson J.A., Park E.J., Dam K., Acehan D., Ramos-Espiritu L.S. Loss of SATB1 induces p21-dependent cellular senescence in post-mitotic dopaminergic neurons. Cell Stem Cell. 2019;25:514&#x2013;530.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7493192</ArticleId><ArticleId IdType="pubmed">31543366</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders S.J., Campbell A.J., Cottrell J.R., Moller R.S., Wagner F.F., Auldridge A.L., Bernier R.A., Catterall W.A., Chung W.K., Empfield J.R. Progress in understanding and treating SCN2A-mediated disorders. Trends Neurosci. 2018;41:442&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015533</ArticleId><ArticleId IdType="pubmed">29691040</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh J.-I., Kawana N., Yamamoto Y. ChIP-seq data mining: remarkable differences in NRSF/REST target genes between human ESC and ESC-derived neurons. Bioinform. Biol. Insights. 2013;7:357&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855043</ArticleId><ArticleId IdType="pubmed">24324330</ArticleId></ArticleIdList></Reference><Reference><Citation>Saygin C., Matei D., Majeti R., Reizes O., Lathia J.D. Targeting cancer stemness in the clinic: from hype to hope. Cell Stem Cell. 2019;24:25&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30595497</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer S.T., Paquola A.C.M., Stern S., Gosselin D., Ku M., Pena M., Kuret T.J.M., Liyanage M., Mansour A.A., Jaeger B.N. Pathological priming causes developmental gene network heterochronicity in autistic subject-derived neurons. Nat. Neurosci. 2019;22:243&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402576</ArticleId><ArticleId IdType="pubmed">30617258</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P., Blennow K., Breteler M.M.B., de Strooper B., Frisoni G.B., Salloway S., Van der Flier W.M. Alzheimer&#x2019;s disease. Lancet. 2016;388:505&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma R., Kumar D., Jha N.K., Jha S.K., Ambasta R.K., Kumar P. Re-expression of cell cycle markers in aged neurons and muscles: whether cells should divide or die? Biochim. Biophys. Acta. 2017;1863:324&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">27639832</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith D.S., Leone G., DeGregori J., Ahmed M.N., Qumsiyeh M.B., Nevins J.R. Induction of DNA replication in adult rat neurons by deregulation of the retinoblastoma/E2F G1 cell cycle pathway. Cell Growth Differ. 2000;11:625&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">11149597</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein J.L., de la Torre-Ubieta L., Tian Y., Parikshak N.N., Hern&#xe1;ndez I.A., Marchetto M.C., Baker D.K., Lu D., Hinman C.R., Lowe J.K. A quantitative framework to evaluate modeling of cortical development by neural stem cells. Neuron. 2014;83:69&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4277209</ArticleId><ArticleId IdType="pubmed">24991955</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y., Liu M.-L., Zang T., Zhang C.-L. Direct reprogramming rather than iPSC-based reprogramming maintains aging hallmarks in human motor neurons. Front. Mol. Neurosci. 2017;10:359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5676779</ArticleId><ArticleId IdType="pubmed">29163034</ArticleId></ArticleIdList></Reference><Reference><Citation>Teschendorff A.E., West J., Beck S. Age-associated epigenetic drift: implications, and a case of epigenetic thrift? Hum. Mol. Genet. 2013;22(R1):R7&#x2013;R15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3782071</ArticleId><ArticleId IdType="pubmed">23918660</ArticleId></ArticleIdList></Reference><Reference><Citation>Traxler L., Edenhofer F., Mertens J. Next-generation disease modeling with direct conversion: a new path to old neurons. FEBS Lett. 2019;593:3316&#x2013;3337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6907729</ArticleId><ArticleId IdType="pubmed">31715002</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzahor E., Poss K.D. Cardiac regeneration strategies: staying young at heart. Science. 2017;356:1035&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5614484</ArticleId><ArticleId IdType="pubmed">28596337</ArticleId></ArticleIdList></Reference><Reference><Citation>Vadodaria K.C., Mertens J., Paquola A., Bardy C., Li X., Jappelli R., Fung L., Marchetto M.C., Hamm M., Gorris M. Generation of functional human serotonergic neurons from fibroblasts. Mol. Psychiatry. 2016;21:49&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">26503761</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Kant R., Langness V.F., Herrera C.M., Williams D.A., Fong L.K., Leestemaker Y., Steenvoorden E., Rynearson K.D., Brouwers J.F., Helms J.B. Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-&#x3b2; in iPSC-derived Alzheimer&#x2019;s disease neurons. Cell Stem Cell. 2019;24:363&#x2013;375.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6414424</ArticleId><ArticleId IdType="pubmed">30686764</ArticleId></ArticleIdList></Reference><Reference><Citation>Veitia R.A., Govindaraju D.R., Bottani S., Birchler J.A. Aging: somatic mutations, epigenetic drift and gene dosage imbalance. Trends Cell Biol. 2017;27:299&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">27939088</ArticleId></ArticleIdList></Reference><Reference><Citation>Victor M.B., Richner M., Hermanstyne T.O., Ransdell J.L., Sobieski C., Deng P.-Y., Klyachko V.A., Nerbonne J.M., Yoo A.S. Generation of human striatal neurons by microRNA-dependent direct conversion of fibroblasts. Neuron. 2014;84:311&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4223654</ArticleId><ArticleId IdType="pubmed">25374357</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilimas T., Mascarenhas J., Palomero T., Mandal M., Buonamici S., Meng F., Thompson B., Spaulding C., Macaroun S., Alegre M.-L. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat. Med. 2007;13:70&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">17173050</ArticleId></ArticleIdList></Reference><Reference><Citation>von Schimmelmann M., Feinberg P.A., Sullivan J.M., Ku S.M., Badimon A., Duff M.K., Wang Z., Lachmann A., Dewell S., Ma&#x2019;ayan A. Polycomb repressive complex 2 (PRC2) silences genes responsible for neurodegeneration. Nat. Neurosci. 2016;19:1321&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5088783</ArticleId><ArticleId IdType="pubmed">27526204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner I., Wang H., Weissert P.M., Straube W.L., Shevchenko A., Gentzel M., Brito G., Tazaki A., Oliveira C., Sugiura T. Serum proteases potentiate BMP-induced cell cycle re-entry of dedifferentiating muscle cells during newt limb regeneration. Dev. Cell. 2017;40:608&#x2013;617.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">28350991</ArticleId></ArticleIdList></Reference><Reference><Citation>Walton Chaska C., Zhang W., Pati&#xf1;o-Parrado I., Barrio-Alonso E., Garrido J.-J., Frade F.M. Primary neurons can enter M-phase. Scientific Reports. 2019;9:4594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6418114</ArticleId><ArticleId IdType="pubmed">30872646</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.-C., Oelze B., Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer&#x2019;s disease. PLoS ONE. 2008;3:e2698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2444024</ArticleId><ArticleId IdType="pubmed">18628954</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M.S. When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007;8:136&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796780</ArticleId><ArticleId IdType="pubmed">17268504</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff G., Young J.E., Martinez F.J., Buen F., Gore A., Kinaga J., Li Z., Yuan S.H., Zhang K., Goldstein L.S.B. The presenilin-1 &#x394;E9 mutation results in reduced &#x3b3;-secretase activity, but not total loss of PS1 function, in isogenic human stem cells. Cell Rep. 2013;5:974&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867011</ArticleId><ArticleId IdType="pubmed">24239350</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., Guo H., Chow N., Sallstrom J., Bell R.D., Deane R., Brooks A.I., Kanagala S., Rubio A., Sagare A. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat. Med. 2005;11:959&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pubmed">16116430</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Geldmacher D.S., Herrup K. DNA replication precedes neuronal cell death in Alzheimer&#x2019;s disease. J.&#xa0;Neurosci. 2001;21:2661&#x2013;2668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762514</ArticleId><ArticleId IdType="pubmed">11306619</ArticleId></ArticleIdList></Reference><Reference><Citation>Young J.E., Boulanger-Weill J., Williams D.A., Woodruff G., Buen F., Revilla A.C., Herrera C., Israel M.A., Yuan S.H., Edland S.D., Goldstein L.S. Elucidating molecular phenotypes caused by the SORL1 Alzheimer&#x2019;s disease genetic risk factor using human induced pluripotent stem cells. Cell Stem Cell. 2015;16:373&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4388804</ArticleId><ArticleId IdType="pubmed">25772071</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H., Mattsson N. Understanding the cause of sporadic Alzheimer&#x2019;s disease. Expert Rev. Neurother. 2014;14:621&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">24852227</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Moy W., Zhang H., Leites C., McGowan H., Shi J., Sanders A.R., Pang Z.P., Gejman P.V., Duan J. Open chromatin dynamics reveals stage-specific transcriptional networks in hiPSC-based neurodevelopmental model. Stem Cell Res. (Amst.) 2018;29:88&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6025752</ArticleId><ArticleId IdType="pubmed">29631039</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S.C., Widschwendter M., Teschendorff A.E. Epigenetic drift, epigenetic clocks and cancer risk. Epigenomics. 2016;8:705&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">27104983</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X., Boyer L., Jin M., Mertens J., Kim Y., Ma L., Ma L., Hamm M., Gage F.H., Hunter T. Metabolic reprogramming during neuronal differentiation from aerobic glycolysis to neuronal oxidative phosphorylation. eLife. 2016;5:859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4963198</ArticleId><ArticleId IdType="pubmed">27282387</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33911285</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>593</Volume><Issue>7858</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Meningeal lymphatics affect microglia responses and anti-A&#x3b2; immunotherapy.</ArticleTitle><Pagination><StartPage>255</StartPage><EndPage>260</EndPage><MedlinePgn>255-260</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-021-03489-0</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is the most prevalent cause of dementia<sup>1</sup>. Although there is no effective treatment for AD, passive immunotherapy with monoclonal antibodies against amyloid beta (A&#x3b2;) is a promising therapeutic strategy<sup>2,3</sup>. Meningeal lymphatic drainage has an important role in the accumulation of A&#x3b2; in the brain<sup>4</sup>, but it is not known whether modulation of meningeal lymphatic function can influence the outcome of immunotherapy in AD. Here we show that ablation of meningeal lymphatic vessels in 5xFAD mice (a mouse model of amyloid deposition that expresses five mutations found in familial AD) worsened the outcome of mice treated with anti-A&#x3b2; passive immunotherapy by exacerbating the deposition of A&#x3b2;, microgliosis, neurovascular dysfunction, and behavioural deficits. By contrast, therapeutic delivery of vascular endothelial growth factor C improved clearance of A&#x3b2; by monoclonal antibodies. Notably, there was a substantial overlap between the gene signature of microglia from 5xFAD mice with impaired meningeal lymphatic function and the transcriptional profile of activated microglia from the brains of individuals with AD. Overall, our data demonstrate that impaired meningeal lymphatic drainage exacerbates the microglial inflammatory response in AD and that enhancement of meningeal lymphatic function combined with immunotherapies could lead to better clinical outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Da Mesquita</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0786-5010</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA. damesquita@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. damesquita@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Papadopoulos</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Dykstra</LastName><ForeName>Taitea</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7756-809X</Identifier><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Brase</LastName><ForeName>Logan</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7175-3208</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farias</LastName><ForeName>Fabiana Geraldo</ForeName><Initials>FG</Initials><Identifier Source="ORCID">0000-0002-5215-7304</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wall</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kodira</LastName><ForeName>Chinnappa Dilip</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>PureTech Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lima</LastName><ForeName>Kalil Alves</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0002-9149-168X</Identifier><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herz</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6325-863X</Identifier><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louveau</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Dylan H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvador</LastName><ForeName>Andrea Francesca</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0002-9197-7575</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onengut-Gumuscu</LastName><ForeName>Suna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farber</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabhi</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milam</LastName><ForeName>Mary Grace</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smirnov</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rich</LastName><ForeName>Stephen S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0003-3872-7793</Identifier><AffiliationInfo><Affiliation>Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author><Author ValidYN="Y"><LastName>Benitez</LastName><ForeName>Bruno A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0002-2699-3878</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karch</LastName><ForeName>Celeste M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-6854-5547</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-3443-7716</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Indiana School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhatwal</LastName><ForeName>Jasmeer P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Department of Neurology, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harari</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-2635-6975</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kipnis</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3714-517X</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, University of Virginia, Charlottesville, VA, USA. kipnis@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St. Louis, St. Louis, MO, USA. kipnis@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA. kipnis@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Washington University in St. Louis, St. Louis, MO, USA. kipnis@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of Virginia, Charlottesville, VA, USA. kipnis@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG057777</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG034113</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS118146</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG057496</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057496</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG067764</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062734</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG034113</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034113</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042582">Vascular Endothelial Growth Factor C</NameOfSubstance></Chemical><Chemical><RegistryNumber>105J35OE21</RegistryNumber><NameOfSubstance UI="C000600266">aducanumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042601" MajorTopicYN="N">Lymphatic Vessels</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008578" MajorTopicYN="N">Meninges</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042582" MajorTopicYN="N">Vascular Endothelial Growth Factor C</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33911285</ArticleId><ArticleId IdType="mid">NIHMS1771973</ArticleId><ArticleId IdType="pmc">PMC8817786</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03489-0</ArticleId><ArticleId IdType="pii">10.1038/s41586-021-03489-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR Jr. et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement 14, 535&#x2013;562, doi:10.1016/j.jalz.2018.02.018 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG et al. Decreased clearance of CNS beta-amyloid in Alzheimer&#x2019;s disease. Science 330, 1774, doi:10.1126/science.1197623 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1197623</ArticleId><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarasoff-Conway JM et al. Clearance systems in the brain--implications for Alzheimer diseaser. Nat Rev Neurol 12, 248, doi:10.1038/nrneurol.2016.36 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.36</ArticleId><ArticleId IdType="pubmed">27020556</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney MD, Sagare AP &amp; Zlokovic BV Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 14, 133&#x2013;150, doi:10.1038/nrneurol.2017.188 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.188</ArticleId><ArticleId IdType="pmc">PMC5829048</ArticleId><ArticleId IdType="pubmed">29377008</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer&#x2019;s disease. Nature 560, 185&#x2013;191, doi:10.1038/s41586-018-0368-8 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0368-8</ArticleId><ArticleId IdType="pmc">PMC6085146</ArticleId><ArticleId IdType="pubmed">30046111</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S, Fu Z &amp; Kipnis J The Meningeal Lymphatic System: A New Player in Neurophysiology. Neuron 100, 375&#x2013;388, doi:10.1016/j.neuron.2018.09.022 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.09.022</ArticleId><ArticleId IdType="pmc">PMC6268162</ArticleId><ArticleId IdType="pubmed">30359603</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker S et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis 43, 575&#x2013;588, doi:10.3233/JAD-140741 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-140741</ArticleId><ArticleId IdType="pubmed">25096615</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastanenka KV et al. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. J Neurosci 36, 12549&#x2013;12558, doi:10.1523/JNEUROSCI.2080-16.2016 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2080-16.2016</ArticleId><ArticleId IdType="pmc">PMC5157102</ArticleId><ArticleId IdType="pubmed">27810931</ArticleId></ArticleIdList></Reference><Reference><Citation>Logovinsky V et al. Safety and tolerability of BAN2401--a clinical study in Alzheimer&#x2019;s disease with a protofibril selective Abeta antibody. Alzheimers Res Ther 8, 14, doi:10.1186/s13195-016-0181-2 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-016-0181-2</ArticleId><ArticleId IdType="pmc">PMC4822297</ArticleId><ArticleId IdType="pubmed">27048170</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J et al. Addendum: The antibody aducanumab reduces Abeta plaques in Alzheimer&#x2019;s disease. Nature 546, 564, doi:10.1038/nature22809 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22809</ArticleId><ArticleId IdType="pubmed">28640269</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard R &amp; Liu KY Questions EMERGE as Biogen claims aducanumab turnaround. Nat Rev Neurol, doi:10.1038/s41582-019-0295-9 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0295-9</ArticleId><ArticleId IdType="pubmed">31784690</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat Neurosci 21, 1380&#x2013;1391, doi:10.1038/s41593-018-0227-9 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0227-9</ArticleId><ArticleId IdType="pmc">PMC6214619</ArticleId><ArticleId IdType="pubmed">30224810</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustenhoven J et al. Functional characterization of the dural sinuses as a neuroimmune interface. Cell 184, 1000&#x2013;1016 e1027, doi:10.1016/j.cell.2020.12.040 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.040</ArticleId><ArticleId IdType="pmc">PMC8487654</ArticleId><ArticleId IdType="pubmed">33508229</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer&#x2019;s disease. Nature 505, 550&#x2013;554, doi:10.1038/nature12825 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12825</ArticleId><ArticleId IdType="pmc">PMC4050701</ArticleId><ArticleId IdType="pubmed">24336208</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki Y, Zhao N, Caulfield TR, Liu CC &amp; Bu G Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol 15, 501&#x2013;518, doi:10.1038/s41582-019-0228-7 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0228-7</ArticleId><ArticleId IdType="pmc">PMC7055192</ArticleId><ArticleId IdType="pubmed">31367008</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong M et al. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci Transl Med 13, doi:10.1126/scitranslmed.abd7522 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd7522</ArticleId><ArticleId IdType="pmc">PMC8128342</ArticleId><ArticleId IdType="pubmed">33597265</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi J Promising Results in 18-Month Analysis of Alzheimer Drug Candidate. JAMA 320, 965, doi:10.1001/jama.2018.13027 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.13027</ArticleId><ArticleId IdType="pubmed">30208438</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337&#x2013;341, doi:10.1038/nature14432 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14432</ArticleId><ArticleId IdType="pmc">PMC4506234</ArticleId><ArticleId IdType="pubmed">26030524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu JK et al. Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19, 1212&#x2013;1223, doi:10.1038/s41590-018-0232-x (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-018-0232-x</ArticleId><ArticleId IdType="pmc">PMC6317891</ArticleId><ArticleId IdType="pubmed">30323343</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L et al. Deep cervical lymph node ligation aggravates AD-like pathology of APP/PS1 mice. Brain Pathol 29, 176&#x2013;192, doi:10.1111/bpa.12656 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12656</ArticleId><ArticleId IdType="pmc">PMC8028636</ArticleId><ArticleId IdType="pubmed">30192999</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290 e1217, doi:10.1016/j.cell.2017.05.018 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581 e569, doi:10.1016/j.immuni.2017.08.008 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716, doi:10.1126/science.aad8373 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Montagne A et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature 581, 71&#x2013;76, doi:10.1038/s41586-020-2247-3 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2247-3</ArticleId><ArticleId IdType="pmc">PMC7250000</ArticleId><ArticleId IdType="pubmed">32376954</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanlandewijck M et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature 554, 475&#x2013;480, doi:10.1038/nature25739 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25739</ArticleId><ArticleId IdType="pubmed">29443965</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat Med 26, 131&#x2013;142, doi:10.1038/s41591-019-0695-9 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0695-9</ArticleId><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Nelson AR, Betsholtz C &amp; Zlokovic BV Establishment and Dysfunction of the Blood-Brain Barrier. Cell 163, 1064&#x2013;1078, doi:10.1016/j.cell.2015.10.067 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.10.067</ArticleId><ArticleId IdType="pmc">PMC4655822</ArticleId><ArticleId IdType="pubmed">26590417</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlmann RE et al. Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. Nat Neurosci, doi:10.1038/s41593-020-00737-w (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00737-w</ArticleId><ArticleId IdType="pmc">PMC7783656</ArticleId><ArticleId IdType="pubmed">33199898</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet 43, 436&#x2013;441, doi:10.1038/ng.801 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Buniello A et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res 47, D1005&#x2013;D1012, doi:10.1093/nar/gky1120 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1120</ArticleId><ArticleId IdType="pmc">PMC6323933</ArticleId><ArticleId IdType="pubmed">30445434</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science 261, 921&#x2013;923 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q et al. Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Mol Psychiatry 26, 309&#x2013;321, doi:10.1038/s41380-018-0246-7 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0246-7</ArticleId><ArticleId IdType="pmc">PMC6219464</ArticleId><ArticleId IdType="pubmed">30361487</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y et al. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer&#x2019;s disease risk. Sci Transl Med 11, doi:10.1126/scitranslmed.aau2291 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau2291</ArticleId><ArticleId IdType="pmc">PMC6697053</ArticleId><ArticleId IdType="pubmed">31413141</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y et al. Genome-wide association study identifies four novel loci associated with Alzheimer&#x2019;s endophenotypes and disease modifiers. Acta Neuropathol 133, 839&#x2013;856, doi:10.1007/s00401-017-1685-y (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1685-y</ArticleId><ArticleId IdType="pmc">PMC5613285</ArticleId><ArticleId IdType="pubmed">28247064</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KL et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer&#x2019;s disease. Nat Neurosci 20, 1052&#x2013;1061, doi:10.1038/nn.4587 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4587</ArticleId><ArticleId IdType="pmc">PMC5759334</ArticleId><ArticleId IdType="pubmed">28628103</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet 51, 414&#x2013;430, doi:10.1038/s41588-019-0358-2 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Del-Aguila JL et al. Assessment of the Genetic Architecture of Alzheimer&#x2019;s Disease Risk in Rate of Memory Decline. J Alzheimers Dis 62, 745&#x2013;756, doi:10.3233/JAD-170834 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170834</ArticleId><ArticleId IdType="pmc">PMC5989565</ArticleId><ArticleId IdType="pubmed">29480181</ArticleId></ArticleIdList></Reference><Reference><Citation>Merlini M et al. Fibrinogen Induces Microglia-Mediated Spine Elimination and Cognitive Impairment in an Alzheimer&#x2019;s Disease Model. Neuron 101, 1099&#x2013;1108 e1096, doi:10.1016/j.neuron.2019.01.014 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.01.014</ArticleId><ArticleId IdType="pmc">PMC6602536</ArticleId><ArticleId IdType="pubmed">30737131</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg EE et al. Eliminating microglia in Alzheimer&#x2019;s mice prevents neuronal loss without modulating amyloid-beta pathology. Brain 139, 1265&#x2013;1281, doi:10.1093/brain/aww016 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww016</ArticleId><ArticleId IdType="pmc">PMC5006229</ArticleId><ArticleId IdType="pubmed">26921617</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J Exp Med 216, 2546&#x2013;2561, doi:10.1084/jem.20190980 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190980</ArticleId><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinevez JY et al. TrackMate: An open and extensible platform for single-particle tracking. Methods 115, 80&#x2013;90, doi:10.1016/j.ymeth.2016.09.016 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2016.09.016</ArticleId><ArticleId IdType="pubmed">27713081</ArticleId></ArticleIdList></Reference><Reference><Citation>Finck R et al. Normalization of mass cytometry data with bead standards. Cytometry A 83, 483&#x2013;494, doi:10.1002/cyto.a.22271 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.22271</ArticleId><ArticleId IdType="pmc">PMC3688049</ArticleId><ArticleId IdType="pubmed">23512433</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine JH et al. Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. Cell 162, 184&#x2013;197, doi:10.1016/j.cell.2015.05.047 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.05.047</ArticleId><ArticleId IdType="pmc">PMC4508757</ArticleId><ArticleId IdType="pubmed">26095251</ArticleId></ArticleIdList></Reference><Reference><Citation>Patro R, Duggal G, Love MI, Irizarry RA &amp; Kingsford C Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 14, 417&#x2013;419, doi:10.1038/nmeth.4197 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4197</ArticleId><ArticleId IdType="pmc">PMC5600148</ArticleId><ArticleId IdType="pubmed">28263959</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrow J et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res 22, 1760&#x2013;1774, doi:10.1101/gr.135350.111 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.135350.111</ArticleId><ArticleId IdType="pmc">PMC3431492</ArticleId><ArticleId IdType="pubmed">22955987</ArticleId></ArticleIdList></Reference><Reference><Citation>Soneson C, Love MI &amp; Robinson MD Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4, 1521, doi:10.12688/f1000research.7563.2 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.7563.2</ArticleId><ArticleId IdType="pmc">PMC4712774</ArticleId><ArticleId IdType="pubmed">26925227</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W &amp; Anders S Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550, doi:10.1186/s13059-014-0550-8 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang LG, Han Y &amp; He QY clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284&#x2013;287, doi:10.1089/omi.2011.0118 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang LG, Yan GR &amp; He QY DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis. Bioinformatics 31, 608&#x2013;609, doi:10.1093/bioinformatics/btu684 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu684</ArticleId><ArticleId IdType="pubmed">25677125</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21, doi:10.1093/bioinformatics/bts635 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ &amp; Smyth GK edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139&#x2013;140, doi:10.1093/bioinformatics/btp616 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong G, Zhang W, Li H, Shen X &amp; Guo Z Separate enrichment analysis of pathways for up- and downregulated genes. J R Soc Interface 11, 20130950, doi:10.1098/rsif.2013.0950 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsif.2013.0950</ArticleId><ArticleId IdType="pmc">PMC3899863</ArticleId><ArticleId IdType="pubmed">24352673</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy DJ, Campbell KR, Lun AT &amp; Wills QF Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics 33, 1179&#x2013;1186, doi:10.1093/bioinformatics/btw777 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btw777</ArticleId><ArticleId IdType="pmc">PMC5408845</ArticleId><ArticleId IdType="pubmed">28088763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun AT, Bach K &amp; Marioni JC Pooling across cells to normalize single-cell RNA sequencing data with many zero counts. Genome Biol 17, 75, doi:10.1186/s13059-016-0947-7 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-016-0947-7</ArticleId><ArticleId IdType="pmc">PMC4848819</ArticleId><ArticleId IdType="pubmed">27122128</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888&#x2013;1902 e1821, doi:10.1016/j.cell.2019.05.031 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berge K et al. Observation weights unlock bulk RNA-seq tools for zero inflation and single-cell applications. Genome Biol 19, 24, doi:10.1186/s13059-018-1406-4 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-018-1406-4</ArticleId><ArticleId IdType="pmc">PMC6251479</ArticleId><ArticleId IdType="pubmed">29478411</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E &amp; Satija R Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36, 411&#x2013;420, doi:10.1038/nbt.4096 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4096</ArticleId><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Durinck S et al. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics 21, 3439&#x2013;3440, doi:10.1093/bioinformatics/bti525 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bti525</ArticleId><ArticleId IdType="pubmed">16082012</ArticleId></ArticleIdList></Reference><Reference><Citation>Durinck S, Spellman PT, Birney E &amp; Huber W Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc 4, 1184&#x2013;1191, doi:10.1038/nprot.2009.97 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2009.97</ArticleId><ArticleId IdType="pmc">PMC3159387</ArticleId><ArticleId IdType="pubmed">19617889</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw C, Sey NYA, Posthuma D &amp; Won H A response to Yurko et al: H-MAGMA, inheriting a shaky statistical foundation, yields excess false positives. bioRxiv, 2020.2009.2025.310722, doi:10.1101/2020.09.25.310722 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.25.310722</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337, doi:10.1038/s41586-019-1195-2 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis CS, Murrow LM &amp; Gartner ZJ DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst 8, 329&#x2013;337 e324, doi:10.1016/j.cels.2019.03.003 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2019.03.003</ArticleId><ArticleId IdType="pmc">PMC6853612</ArticleId><ArticleId IdType="pubmed">30954475</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafemeister C &amp; Satija R Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol 20, 296, doi:10.1186/s13059-019-1874-1 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1874-1</ArticleId><ArticleId IdType="pmc">PMC6927181</ArticleId><ArticleId IdType="pubmed">31870423</ArticleId></ArticleIdList></Reference><Reference><Citation>Del-Aguila JL et al. A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimers Res Ther 11, 71, doi:10.1186/s13195-019-0524-x (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0524-x</ArticleId><ArticleId IdType="pmc">PMC6689177</ArticleId><ArticleId IdType="pubmed">31399126</ArticleId></ArticleIdList></Reference><Reference><Citation>Pliner HA, Shendure J &amp; Trapnell C Supervised classification enables rapid annotation of cell atlases. Nat Methods 16, 983&#x2013;986, doi:10.1038/s41592-019-0535-3 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0535-3</ArticleId><ArticleId IdType="pmc">PMC6791524</ArticleId><ArticleId IdType="pubmed">31501545</ArticleId></ArticleIdList></Reference><Reference><Citation>Sul JH et al. Accurate and fast multiple-testing correction in eQTL studies. Am J Hum Genet 96, 857&#x2013;868, doi:10.1016/j.ajhg.2015.04.012 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2015.04.012</ArticleId><ArticleId IdType="pmc">PMC4457958</ArticleId><ArticleId IdType="pubmed">26027500</ArticleId></ArticleIdList></Reference><Reference><Citation>Duong D et al. Using genomic annotations increases statistical power to detect eGenes. Bioinformatics 32, i156&#x2013;i163, doi:10.1093/bioinformatics/btw272 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btw272</ArticleId><ArticleId IdType="pmc">PMC4908356</ArticleId><ArticleId IdType="pubmed">27307612</ArticleId></ArticleIdList></Reference><Reference><Citation>Darnell G, Duong D, Han B &amp; Eskin E Incorporating prior information into association studies. Bioinformatics 28, i147&#x2013;153, doi:10.1093/bioinformatics/bts235 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts235</ArticleId><ArticleId IdType="pmc">PMC3371867</ArticleId><ArticleId IdType="pubmed">22689754</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskin E Increasing power in association studies by using linkage disequilibrium structure and molecular function as prior information. Genome Res 18, 653&#x2013;660, doi:10.1101/gr.072785.107 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.072785.107</ArticleId><ArticleId IdType="pmc">PMC2279252</ArticleId><ArticleId IdType="pubmed">18353808</ArticleId></ArticleIdList></Reference><Reference><Citation>Nettleton D &amp; Doerge RW Accounting for variability in the use of permutation testing to detect quantitative trait loci. Biometrics 56, 52&#x2013;58, doi:10.1111/j.0006-341x.2000.00052.x (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0006-341x.2000.00052.x</ArticleId><ArticleId IdType="pubmed">10783776</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33927414</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Four distinct trajectories of tau deposition identified in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>871</StartPage><EndPage>881</EndPage><MedlinePgn>871-881</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-021-01309-6</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is characterized by the spread of tau pathology throughout the cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals, although recent work has demonstrated substantial variability in the population with AD. Using tau-positron emission tomography scans from 1,612 individuals, we identified 4 distinct spatiotemporal trajectories of tau pathology, ranging in prevalence from 18 to 33%. We replicated previously described limbic-predominant and medial temporal lobe-sparing patterns, while also discovering posterior and lateral temporal patterns resembling atypical clinical variants of AD. These 'subtypes' were stable during longitudinal follow-up and were replicated in a separate sample using a different radiotracer. The subtypes presented with distinct demographic and cognitive profiles and differing longitudinal outcomes. Additionally, network diffusion models implied that pathology originates and spreads through distinct corticolimbic networks in the different subtypes. Together, our results suggest that variation in tau pathology is common and systematic, perhaps warranting a re-examination of the notion of 'typical AD' and a revisiting of tau pathological staging.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Jacob W</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0001-6394-9940</Identifier><AffiliationInfo><Affiliation>Montreal Neurological Institute, McGill University, Montr&#xe9;al, Quebec, Canada. jacob.vogel@mail.mcgill.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Alexandra L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oxtoby</LastName><ForeName>Neil P</ForeName><Initials>NP</Initials><Identifier Source="ORCID">0000-0003-0203-3909</Identifier><AffiliationInfo><Affiliation>Centre for Medical Image Computing, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7147-0112</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strandberg</LastName><ForeName>Olof T</ForeName><Initials>OT</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Joie</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-2581-8100</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aksman</LastName><ForeName>Leon M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Centre for Medical Image Computing, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Physics and Biomedical Engineering, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grothe</LastName><ForeName>Michel J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-2600-9022</Identifier><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc&#xed;o/Consejo Superior de Investigaciones Cient&#xed;ficas/Universidad de Sevilla, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iturria-Medina</LastName><ForeName>Yasser</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9345-0347</Identifier><AffiliationInfo><Affiliation>Montreal Neurological Institute, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author><Author ValidYN="Y"><LastName>Pontecorvo</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-8419-7589</Identifier><AffiliationInfo><Affiliation>AVID Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devous</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-6871-0063</Identifier><AffiliationInfo><Affiliation>AVID Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><Identifier Source="ORCID">0000-0002-3626-4265</Identifier><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><Identifier Source="ORCID">0000-0003-2439-350X</Identifier><AffiliationInfo><Affiliation>Centre for Medical Image Computing, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyoo</LastName><ForeName>Chul Hyoung</ForeName><Initials>CH</Initials><Identifier Source="ORCID">0000-0003-2231-672X</Identifier><AffiliationInfo><Affiliation>Departments of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Alan C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0003-3841-6098</Identifier><AffiliationInfo><Affiliation>Montreal Neurological Institute, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8467-7286</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Lund, Sweden. oskar.hansson@med.lu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden. oskar.hansson@med.lu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K99 AG065501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/S03546X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>T32 MH019112</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/T027800/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062211" MajorTopicYN="N">Spatio-Temporal Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Enchi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sather</LastName><ForeName>Tamie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiminez</LastName><ForeName>Gus</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCArli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borowski</LastName><ForeName>Bret</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gunter</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senjem</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Chad</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landau</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Householder</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reinwald</LastName><ForeName>Lisa Taylor</ForeName><Initials>LT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figurski</LastName><ForeName>Michal</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelley</LastName><ForeName>Faber</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Sungeun</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nho</LastName><ForeName>Kwangsik</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Betty</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>Raina</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beccera</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teodoro</LastName><ForeName>Liberty</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Sara S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albers</LastName><ForeName>Colleen S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knopman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meyer</LastName><ForeName>Javier Villanueva</ForeName><Initials>JV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rountree</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dang</LastName><ForeName>Mimi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ances</LastName><ForeName>Beau</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leon</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliver</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geldmacher</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brockington</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsis</LastName><ForeName>Effie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greig</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Suffix>2nd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Kielb</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvin</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pogorelec</LastName><ForeName>Dana M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cerbone</LastName><ForeName>Brittany</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michel</LastName><ForeName>Christina A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Santi</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Terence Z</ForeName><Initials>TZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinha</LastName><ForeName>Partha</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oates</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrad</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>MaryAnn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bonnie S</ForeName><Initials>BS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makino</LastName><ForeName>Kelly M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAdams Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Womack</LastName><ForeName>Kyle</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathews</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quiceno</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arrastia</LastName><ForeName>Ramon Diaz</ForeName><Initials>RD</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Myron</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cook</LastName><ForeName>Kristen Martin</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tingus</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woo</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DHS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Radford</LastName><ForeName>Neill R Graff</ForeName><Initials>NRG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kendall</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>Brandy R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanovic</LastName><ForeName>Bojana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging Yuek Robin</ForeName><Initials>GYR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudge</LastName><ForeName>Benita</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Past</LastName><ForeName>Michele Assaly</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerwin</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marek Marsel</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipowski</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Joy L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>Barton</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan N</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>Christine M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sirrel</LastName><ForeName>Sherye A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budson</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Patricia Lynn</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolday</LastName><ForeName>Saba</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allard</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olichney</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capote</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adeli</LastName><ForeName>Anahita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kitzmiller</LastName><ForeName>Tamar J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Eben S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querfurth</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spicer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bachman</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finger</LastName><ForeName>Elizabether</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasternak</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rachinsky</LastName><ForeName>Irina</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomara</LastName><ForeName>Nunzio</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernando</LastName><ForeName>Raymundo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarrael</LastName><ForeName>Antero</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>Susan K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ponto</LastName><ForeName>Laura L Boles</ForeName><Initials>LLB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shim</LastName><ForeName>Hyungsub</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Karen Elizabeth</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Relkin</LastName><ForeName>Norman</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaing</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raudin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fargher</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>Balebail Ashok</ForeName><Initials>BA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33927414</ArticleId><ArticleId IdType="mid">NIHMS1760467</ArticleId><ArticleId IdType="pmc">PMC8686688</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01309-6</ArticleId><ArticleId IdType="pii">10.1038/s41591-021-01309-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hurd MD, Martorell P, Delavande A, Mullen KJ &amp; Langa KM Monetary Costs of Dementia in the United States. N. Engl. J. Med. 368, 1326&#x2013;1334 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959992</ArticleId><ArticleId IdType="pubmed">23550670</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I et al. Staging of Neurofibrillary Pathology in Alzheimer&#x2019;s Disease: A Study of the BrainNet Europe Consortium. Brain Pathol. 0, 080509082911413-??? (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659377</ArticleId><ArticleId IdType="pubmed">18371174</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT et al. National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 8, 1&#x2013;13 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3266529</ArticleId><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J &amp; Selkoe DJ The Amyloid Hypothesis of Alzheimer&#x2019;s Disease: Progress and Problems on the Road to Therapeutics. Science (80-. ). 297, 353&#x2013;356 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207&#x2013;216 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R et al. Prospective longitudinal atrophy in Alzheimer&#x2019;s disease correlates with the intensity and topography of baseline tau-PET. Sci. Transl. Med. 12, 1&#x2013;13 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035952</ArticleId><ArticleId IdType="pubmed">31894103</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer &#x2018; s disease. 1&#x2013;15 (2017) doi:10.1093/brain/awx243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx243</ArticleId><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;59 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H &amp; Tredici K Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389&#x2013;404 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M et al. PET Imaging of Tau Deposition in the Aging Human Brain. Neuron (2016) doi:10.1016/j.neuron.2016.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.01.028</ArticleId><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz AJ et al. Regional profiles of the candidate tau PET ligand 18 F-AV-1451 recapitulate key features of Braak histopathological stages. Brain aww023 (2016) doi:10.1093/brain/aww023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww023</ArticleId><ArticleId IdType="pubmed">26936940</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME et al. Neuropathologically defined subtypes of Alzheimer&#x2019;s disease with distinct clinical characteristics: A retrospective study. Lancet Neurol. 10, 785&#x2013;796 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer&#x2019;s disease: A case-control study. Lancet Neurol. 11, 868&#x2013;877 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490201</ArticleId><ArticleId IdType="pubmed">22951070</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira D, Nordberg A &amp; Westman E Biological subtypes of Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Neurology 0, under-review (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7238917</ArticleId><ArticleId IdType="pubmed">32047067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain 139, 1551&#x2013;1567 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Crutch SJ et al. Consensus classification of posterior cortical atrophy. Alzheimer&#x2019;s Dement. 13, 870&#x2013;884 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5788455</ArticleId><ArticleId IdType="pubmed">28259709</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML et al. Classification of primary progressive aphasia and its variants. Neurology 76, 1006&#x2013;1014 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R et al. The behavioural/dysexecutive variant of Alzheimer&#x2019;s disease: Clinical, neuroimaging and pathological features. Brain 138, 2732&#x2013;2749 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4623840</ArticleId><ArticleId IdType="pubmed">26141491</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond E et al. Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer&#x2019;s disease. Acta Neuropathol. 133, 933&#x2013;954 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5503748</ArticleId><ArticleId IdType="pubmed">28258398</ArticleId></ArticleIdList></Reference><Reference><Citation>Crist AM et al. Leveraging selective hippocampal vulnerability among Alzheimer&#x2019;s disease subtypes reveals a novel tau b i nding partner SERPINA 5. bioRxiv 2020.12.18.423469 (2020) doi:10.1101/2020.12.18.423469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.18.423469</ArticleId></ArticleIdList></Reference><Reference><Citation>Risacher SL et al. Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. Neurology 89, 2176&#x2013;2186 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5696639</ArticleId><ArticleId IdType="pubmed">29070667</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R et al. Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 16, 335&#x2013;344 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7012375</ArticleId><ArticleId IdType="pubmed">31672482</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AL et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nat. Commun. 9, 4273 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6189176</ArticleId><ArticleId IdType="pubmed">30323170</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong A et al. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer&#x2019;s disease: links to cognition, progression and biomarkers. Brain 140, 735&#x2013;747 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837514</ArticleId><ArticleId IdType="pubmed">28003242</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh Y et al. Anatomical heterogeneity of Alzheimer disease: based on cortical thickness on MRIs. Neurology 83, 1936&#x2013;44 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4248459</ArticleId><ArticleId IdType="pubmed">25344382</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam A et al. A highly predictive signature of cognition and brain atrophy for progression to Alzheimer&#x2019;s dementia. Gigascience 8, 1&#x2013;16 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6511068</ArticleId><ArticleId IdType="pubmed">31077314</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JW et al. Data-driven approaches for tau-PET imaging biomarkers in Alzheimer&#x2019;s disease. Hum. Brain Mapp. 40, 638&#x2013;651 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865737</ArticleId><ArticleId IdType="pubmed">30368979</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A et al. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease from Other Neurodegenerative Disorders. JAMA - Neurol. 1&#x2013;12 (2020) doi:10.1001/jamaneurol.2020.0989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0989</ArticleId><ArticleId IdType="pmc">PMC7215644</ArticleId><ArticleId IdType="pubmed">32391858</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JW et al. Spread of pathological tau proteins through communicating neurons in human Alzheimer&#x2019;s disease. Nat. Commun. 11, 2612 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251068</ArticleId><ArticleId IdType="pubmed">32457389</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall GA, Fairbanks LA, Tekin S, Vinters HV &amp; Cummings JL Early-onset Alzheimer&#x2019;s disease is associated with greater pathologic burden. J. Geriatr. Psychiatry Neurol. 20, 29&#x2013;33 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17341768</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL et al. The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 15, 675&#x2013;685 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6511453</ArticleId><ArticleId IdType="pubmed">30853465</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer&#x2019;s disease dementia. Brain 142, 1723&#x2013;1735 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536847</ArticleId><ArticleId IdType="pubmed">31009046</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR et al. Predicting future rates of tau accumulation on PET. Brain 143, 3136&#x2013;3150 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7586089</ArticleId><ArticleId IdType="pubmed">33094327</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R et al. Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tauand amyloid-PET. Neurology 10.1212/WNL.0000000000011270 (2020) doi:10.1212/wnl.0000000000011270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000011270</ArticleId><ArticleId IdType="pmc">PMC7884991</ArticleId><ArticleId IdType="pubmed">33262228</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S et al. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer&#x2019;s disease. Nat. Med. (2020) doi:10.1038/s41591-020-0938-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0938-9</ArticleId><ArticleId IdType="pmc">PMC7603860</ArticleId><ArticleId IdType="pubmed">32572268</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoyagi A et al. A&#x3b2; and tau prion-like activities decline with longevity in the Alzheimer&#x2019;s disease human brain. Sci. Transl. Med. 11, 1&#x2013;14 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6640844</ArticleId><ArticleId IdType="pubmed">31043574</ArticleId></ArticleIdList></Reference><Reference><Citation>Koedam ELGE et al. Early-Versus Late-Onset Alzheimer&#x2019;s Disease: More than Age Alone. J. Alzheimer&#x2019;s Dis. 19, 1401&#x2013;1408 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20061618</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun N, Mormino EC, Chen J, Sabuncu MR &amp; Yeo BTT Multi-modal latent factor exploration of atrophy, cognitive and tau heterogeneity in Alzheimer&#x2019;s disease. Neuroimage 201, (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31344486</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N et al. Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer&#x2019;s disease. Sci. Adv 6, eabd1327 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7695466</ArticleId><ArticleId IdType="pubmed">33246962</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukaetova-Ladinska EB et al. Regional Distribution of Paired Helical Filaments and Normal Tau Proteins in Aging and in Alzheimer&#x2019;s Disease with and without Occipital Lobe Involvement. Dement. Geriatr. Cogn. Disord. 3, 61&#x2013;69 (1992).</Citation></Reference><Reference><Citation>McKee AC et al. Visual Association Pathology in Preclinical Alzheimer Disease. J. Neuropathol. Exp. Neurol. 65, 621&#x2013;630 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16783172</ArticleId></ArticleIdList></Reference><Reference><Citation>Pikkarainen M, Kauppinen T &amp; Alafuzoff I Hyperphosphorylated Tau in the Occipital Cortex in Aged Non-demented Subjects. J. Neuropathol. Exp. Neurol. 68, 653&#x2013;660 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19458543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna Al-Shaikh F. S. et al. Selective Vulnerability of the Nucleus Basalis of Meynert among Neuropathologic Subtypes of Alzheimer Disease. JAMA Neurol. 32224, 225&#x2013;233 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6820048</ArticleId><ArticleId IdType="pubmed">31657834</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado A et al. The cholinergic system in subtypes of Alzheimer&#x2019;s disease: an in vivo longitudinal MRI study. Alzheimers. Res. Ther. 12, 51 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7203806</ArticleId><ArticleId IdType="pubmed">32375872</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogalski E, Johnson N, Weintraub S &amp; Mesulam M Increased Frequency of Learning Disability in Patients With Primary Progressive Aphasia and Their First-Degree Relatives. Arch. Neurol. 65, 1&#x2013;7 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892116</ArticleId><ArticleId IdType="pubmed">18268195</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA J. Am. Med. Assoc. 320, 1151&#x2013;1162 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233630</ArticleId><ArticleId IdType="pubmed">30326496</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ZA et al. Cortical developmental abnormalities in logopenic variant primary progressive aphasia with dyslexia. Brain Commun. 1&#x2013;8 (2019) doi:10.1093/braincomms/fcz027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcz027</ArticleId><ArticleId IdType="pmc">PMC7364264</ArticleId><ArticleId IdType="pubmed">32699834</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT Tau propagation, different tau phenotypes, and prion-like properties of tau. Neuron 82, 1189&#x2013;1190 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24945760</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z et al. Transmission of tauopathy strains is independent of their isoform composition. Nat. Commun. 11, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946697</ArticleId><ArticleId IdType="pubmed">31911587</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng K et al. Molecular characterization of selectively vulnerable neurons in Alzheimer&#x2019;s Disease. (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854528</ArticleId><ArticleId IdType="pubmed">33432193</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemoine L, Leuzy A, Chiotis K, Rodriguez-Vieitez E &amp; Nordberg A Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. Alzheimer&#x2019;s Dement. Diagnosis, Assess. Dis. Monit. 10, 232&#x2013;236 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5956931</ArticleId><ArticleId IdType="pubmed">29780868</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker SL, Harrison TM, Maa&#xdf; A, La Joie R &amp; Jagust W Effect of off-target binding on 18 F-Flortaucipir variability in healthy controls across the lifespan. J. Nucl. Med. jnumed.118.224113 (2019) doi:10.2967/jnumed.118.224113.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.118.224113</ArticleId><ArticleId IdType="pmc">PMC6785795</ArticleId><ArticleId IdType="pubmed">30877180</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R et al. Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948. Eur. J. Nucl. Med. Mol. Imaging 47, 342&#x2013;354 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6974501</ArticleId><ArticleId IdType="pubmed">31612245</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS et al. Positron Emission Tomography Imaging with [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol. 77, 829&#x2013;839 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186920</ArticleId><ArticleId IdType="pubmed">32338734</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimer&#x2019;s Dement. 16, 561&#x2013;571 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7067654</ArticleId><ArticleId IdType="pubmed">31784374</ArticleId></ArticleIdList></Reference><Reference><Citation>Soleimani-Meigooni DN et al. 18F-flortaucipir PET to autopsy comparisons in Alzheimer&#x2019;s disease and other neurodegenerative diseases. Brain 143, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7719031</ArticleId><ArticleId IdType="pubmed">33141172</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Wibom M, Pawlik D, Englund E &amp; Hansson O Correlation of in Vivo [ 18 F]Flortaucipir with Postmortem Alzheimer Disease Tau Pathology. JAMA Neurol 76, 310&#x2013;317 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439731</ArticleId><ArticleId IdType="pubmed">30508025</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Methods References</Title><Reference><Citation>Iturria-Medina Y, Sotero RC, Toussaint PJ &amp; Evans AC Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders. PLoS Comput. Biol. 10, (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4238950</ArticleId><ArticleId IdType="pubmed">25412207</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H et al. Predicted sequence of cortical tau and amyloid-&#x3b2; deposition in Alzheimer disease spectrum. Neurobiol. Aging 68, 76&#x2013;84 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29751288</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock C, Sikka S, Cheung B, Khanuja R, Ghosh SS, Yan C, Li Q, Lurie D, Vogelstein J, Burns R, S. C &amp; Mennes M, Kelly C, Di Martino A, F C. and M. M Towards Automated Analysis of Connectomes: The Configurable Pipeline for the Analysis of Connectomes (C-PAC). Front. Neuroinform. 7, (2013).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33932339</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>184</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>A cellular and spatial map of the choroid plexus across brain ventricles and ages.</ArticleTitle><Pagination><StartPage>3056</StartPage><EndPage>3074.e21</EndPage><MedlinePgn>3056-3074.e21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2021.04.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(21)00438-4</ELocationID><Abstract><AbstractText>The choroid plexus (ChP) in each brain ventricle produces cerebrospinal fluid (CSF) and forms the blood-CSF barrier. Here, we construct a single-cell and spatial atlas of each ChP in the developing, adult, and aged mouse brain. We delineate diverse cell types, subtypes, cell states, and expression programs in epithelial and mesenchymal cells across ages and ventricles. In the developing ChP, we predict a common progenitor pool for epithelial and neuronal cells, validated by lineage tracing. Epithelial and fibroblast cells show regionalized expression by ventricle, starting at embryonic stages and persisting with age, with a dramatic transcriptional shift with maturation, and a smaller shift in each aged cell type. With aging, epithelial cells upregulate host-defense programs, and resident macrophages upregulate interleukin-1&#x3b2; (IL-1&#x3b2;) signaling genes. Our atlas reveals cellular diversity, architecture and signaling across ventricles during development, maturation, and aging of the ChP-brain barrier.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dani</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herbst</LastName><ForeName>Rebecca H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCabe</LastName><ForeName>Cristin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Gilad S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Edmond and Lily Safra Center for Brain Sciences, Hebrew University of Jerusalem, Jerusalem 9190401, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Karol</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Experimental Biology, Faculty of Science, Masaryk University, Brno 611 37, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Joshua P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shipley</LastName><ForeName>Frederick B</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA; Graduate Program in Biophysics, Harvard University, Cambridge, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Ahram</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dionne</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Lan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodman</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riesenfeld</LastName><ForeName>Samantha J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prochazka</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Czech Centre for Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the CAS, Prague 142 20, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prochazkova</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Czech Centre for Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the CAS, Prague 142 20, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlacek</LastName><ForeName>Radislav</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Czech Centre for Phenogenomics and Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the CAS, Prague 142 20, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences and Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryja</LastName><ForeName>Vitezslav</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Experimental Biology, Faculty of Science, Masaryk University, Brno 611 37, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rozenblatt-Rosen</LastName><ForeName>Orit</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habib</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Edmond and Lily Safra Center for Brain Sciences, Hebrew University of Jerusalem, Jerusalem 9190401, Israel. Electronic address: naomi.habib@mail.huji.ac.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regev</LastName><ForeName>Aviv</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; Koch Institute of Integrative Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA. Electronic address: aviv.regev.sc@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehtinen</LastName><ForeName>Maria K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA; Graduate Program in Biophysics, Harvard University, Cambridge, MA 02115, USA. Electronic address: maria.lehtinen@childrens.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS088566</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL110852</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HD090255</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019070" MajorTopicYN="N">Cell Lineage</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002831" MajorTopicYN="N">Choroid Plexus</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="Y">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">brain barrier</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">choroid plexus</Keyword><Keyword MajorTopicYN="N">development</Keyword><Keyword MajorTopicYN="N">single-cell RNA sequencing</Keyword><Keyword MajorTopicYN="N">single-nucleus RNA sequencing</Keyword></KeywordList><CoiStatement>Declaration of interests A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and was an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics, and Asimov until July 31, 2020. A.R. has been an employee of Genentech since August 1, 2020. O.R.-R. is an employee of Genentech and co-inventor on patent applications filed by the Broad related to single cell genomics. R.H.H. has been an employee of Immunai since August 16, 2020. A.R., R.H.H., N.H., M.K.L., N.D., and A.J. are co-inventors on a provisional patent application filed by the Broad Institute relating to this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33932339</ArticleId><ArticleId IdType="mid">NIHMS1690857</ArticleId><ArticleId IdType="pmc">PMC8214809</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.04.003</ArticleId><ArticleId IdType="pii">S0092-8674(21)00438-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angerer P, Haghverdi L, B&#xfc;ttner M, Theis FJ, Marr C, and Buettner F (2016). Destiny: Diffusion maps for large-scale single-cell data in R. Bioinformatics 32, 1241&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pubmed">26668002</ArticleId></ArticleIdList></Reference><Reference><Citation>Awatramani R, Soriano P, Rodriguez C, Mai JJ, and Dymecki SM (2003). Cryptic boundaries in roof plate and choroid plexus identified by intersectional gene activation. Nat. Genet 35, 70&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">12923530</ArticleId></ArticleIdList></Reference><Reference><Citation>Awatramanil R, Soriano P, Rodriguez C, Mai JJ, and Dymecki SM (2003). Cryptic boundaries in roof plate and choroid plexus identified by intersectional gene activation. Nat. Genet 35, 70&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">12923530</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, Deczkowska A, David E, Castellano JM, Miller O, Kertser A, Berkutzki T, Barnett-Itzhaki Z, Bezalel D, Wyss-Coray T, et al. (2014). Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science (80-. ). 346, 89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869326</ArticleId><ArticleId IdType="pubmed">25147279</ArticleId></ArticleIdList></Reference><Reference><Citation>Becht E, McInnes L, Healy J, Dutertre CA, Kwok IWH, Ng LG, Ginhoux F, and Newell EW (2019). Dimensionality reduction for visualizing single-cell data using UMAP. Nat. Biotechnol 37, 38&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">30531897</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell SM, Schreiner CM, Wert SE, Mucenski ML, Scott WJ, and Whitsett JA (2008). R-spondin 2 is required for normal laryngeal-tracheal, lung and limb morphogenesis. Development 135, 1049&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">18256198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Zvi A, Lacoste B, Kur E, Andreone BJ, Mayshar Y, Yan H, and Gu C (2014). Mfsd2a is critical for the formation and function of the blood&#x2013;brain barrier. Nature 509, 507&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134871</ArticleId><ArticleId IdType="pubmed">24828040</ArticleId></ArticleIdList></Reference><Reference><Citation>Bielecki P, Riesenfeld SJ, Hutter JC, Torlai Triglia E, Kowalczyk MS, Ricardo-Gonzalez RR, Lian M, Amezcua Vesely MC, Kroehling L, Xu H, et al. (2021). Skin-resident innate lymphoid cells converge on a pathogenic effector state. Nature.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8336632</ArticleId><ArticleId IdType="pubmed">33536623</ArticleId></ArticleIdList></Reference><Reference><Citation>Blei D, Ng A, and Jordan M (2003). Latent Dirichlet Allocation.</Citation></Reference><Reference><Citation>van den Brink SC, Sage F, V&#xe9;rtesy &#xc1;, Spanjaard B, Peterson-Maduro J, Baron CS, Robin C, and van Oudenaarden A (2017). Single-cell sequencing reveals dissociation-induced gene expression in tissue subpopulations. Nat. Methods 14, 935&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">28960196</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks ER, and Wallingford JB (2014). Multiciliated Cells. Curr. Biol 24, R973&#x2013;R982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4441396</ArticleId><ArticleId IdType="pubmed">25291643</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K, Kaya T, Anastasina M, et al. (2020). Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science (80-. ). 370, eabd2985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857391</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JT, Lehtinen MK, and Sive H (2016). Zebrafish cerebrospinal fluid mediates cell survival through a retinoid signaling pathway. Dev. Neurobiol 76, 75&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4644717</ArticleId><ArticleId IdType="pubmed">25980532</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang P-T, and McMahon AP (1999). Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein. Nature 397, 617&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">10050855</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J, Shipley FB, Shannon ML, Alturkistani O, Dani N, Webb MD, Sugden AU, Andermann ML, and Lehtinen MK (2020). Inflammation of the Embryonic Choroid Plexus Barrier following Maternal Immune Activation. Dev. Cell 55(5), 617&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725967</ArticleId><ArticleId IdType="pubmed">33038331</ArticleId></ArticleIdList></Reference><Reference><Citation>Damkier HH, Brown PD, and Praetorius J (2013). Cerebrospinal Fluid Secretion by the Choroid Plexus. Physiol. Rev 93, 1847&#x2013;1892.</Citation><ArticleIdList><ArticleId IdType="pubmed">24137023</ArticleId></ArticleIdList></Reference><Reference><Citation>DeSisto J, O&#x2019;Rourke R, Jones HE, Pawlikowski B, Malek AD, Bonney S, Guimiot F, Jones KL, and Siegenthaler JA (2020). Single-Cell Transcriptomic Analyses of the Developing Meninges Reveal Meningeal Fibroblast Diversity and Function. Dev. Cell 54, 43&#x2013;59.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7769050</ArticleId><ArticleId IdType="pubmed">32634398</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey KK, Hsiao CJ, and Stephens M (2017). Visualizing the structure of RNA-seq expression data using grade of membership models. PLOS Genet. 13, e1006599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363805</ArticleId><ArticleId IdType="pubmed">28333934</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulken BW, Leeman DS, Boutet SC, Hebestreit K, and Brunet A (2017). Single-Cell Transcriptomic Analysis Defines Heterogeneity and Transcriptional Dynamics in the Adult Neural Stem Cell Lineage. Cell Rep. 18, 777&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5269583</ArticleId><ArticleId IdType="pubmed">28099854</ArticleId></ArticleIdList></Reference><Reference><Citation>Eden E, Lipson D, Yogev S, and Yakhini Z (2007). Discovering motifs in ranked lists of DNA sequences. PLoS Comput. Biol 3, 0508&#x2013;0522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1829477</ArticleId><ArticleId IdType="pubmed">17381235</ArticleId></ArticleIdList></Reference><Reference><Citation>Eden E, Navon R, Steinfeld I, Lipson D, and Yakhini Z (2009). GOrilla: A tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 10:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2644678</ArticleId><ArticleId IdType="pubmed">19192299</ArticleId></ArticleIdList></Reference><Reference><Citation>Efremova M, Vento-Tormo M, Teichmann SA, and Vento-Tormo R (2020). CellPhoneDB: inferring cell&#x2013;cell communication from combined expression of multi-subunit ligand&#x2013;receptor complexes. Nat. Protoc 15, 1484&#x2013;1506.</Citation><ArticleIdList><ArticleId IdType="pubmed">32103204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sejvar J, and Solomon T (2020). Neurological associations of COVID-19. Lancet Neurol. 19(9):767&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Fame RM, and Lehtinen MK (2020). Emergence and Developmental Roles of the Cerebrospinal Fluid System. Dev. Cell 52, 261&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">32049038</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, Slichter CK, Miller HW, McElrath MJ, Prlic M, et al. (2015). MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16, 278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming SJ, Marioni JC, and Babadi M (2019). CellBender remove-background: A deep generative model for unsupervised removal of background noise from scRNA-seq datasets. BioRxiv 791699.</Citation></Reference><Reference><Citation>Gaublomme JT, Li B, McCabe C, Knecht A, Yang Y, Drokhlyansky E, Van Wittenberghe N, Waldman J, Dionne D, Nguyen L, et al. (2019). Nuclei multiplexing with barcoded antibodies for single-nucleus genomics. Nat. Commun 10(1), 2907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6606589</ArticleId><ArticleId IdType="pubmed">31266958</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghersi-Egea J-F, Strazielle N, Catala M, Silva-Vargas V, Doetsch F, and Engelhardt B (2018). Molecular anatomy and functions of the choroidal blood-cerebrospinal fluid barrier in health and disease. Acta Neuropathol. 135, 337&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">29368213</ArticleId></ArticleIdList></Reference><Reference><Citation>Girvan M, and Newman MEJ (2002). Community structure in social and biological networks. Proc. Natl. Acad. Sci. U. S. A 99, 7821&#x2013;7826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122977</ArticleId><ArticleId IdType="pubmed">12060727</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N, Avraham-Davidi I, Basu A, Burks T, Shekhar K, Hofree M, Choudhury SR, Aguet F, Gelfand E, Ardlie K, et al. (2017). Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat. Methods 14, 955&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623139</ArticleId><ArticleId IdType="pubmed">28846088</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagan N, and Zervas M (2012). Wnt1 expression temporally allocates upper rhombic lip progenitors and defines their terminal cell fate in the cerebellum. Mol. Cell. Neurosci 49, 217&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351839</ArticleId><ArticleId IdType="pubmed">22173107</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghverdi L, B&#xfc;ttner M, Wolf FA, Buettner F, and Theis FJ (2016). Diffusion pseudotime robustly reconstructs lineage branching. Nat. Methods 13, 845&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">27571553</ArticleId></ArticleIdList></Reference><Reference><Citation>Haldar M, Kohyama M, So AY-L, KC W, Wu X, Brise&#xf1;o CG, Satpathy AT, Kretzer NM, Arase H, Rajasekaran NS, et al. (2014). Heme-Mediated SPI-C Induction Promotes Monocyte Differentiation into Iron-Recycling Macrophages. Cell 156, 1223&#x2013;1234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4010949</ArticleId><ArticleId IdType="pubmed">24630724</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TR, Dufort C, Dissing-Olesen L, Giera S, Young A, Wysoker A, Walker AJ, Gergits F, Segel M, Nemesh J, et al. (2019). Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. Immunity 50, 253&#x2013;271.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6655561</ArticleId><ArticleId IdType="pubmed">30471926</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrnberger L, Seitz R, Kuespert S, B&#xf6;sl MR, Fuchshofer R, and Tamm ER (2012). Lack of endothelial diaphragms in fenestrae and caveolae of mutant Plvap-deficient mice. Histochem. Cell Biol 138, 709&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">22782339</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hove H, Martens L, Scheyltjens I, De Vlaminck K, Rita Pombo Antunes A, De Prijck S, Vandamme N, De Schepper S, Van Isterdael G, Scott CL, et al. (2019). A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat. Neurosci 22(6):1021&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pubmed">31061494</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Ketova T, Fleming JT, Wang H, Dey SK, Litingtung Y, and Chiang C (2009). Sonic hedgehog signaling regulates a novel epithelial progenitor domain of the hindbrain choroid plexus. Development 136, 2535&#x2013;2543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709062</ArticleId><ArticleId IdType="pubmed">19570847</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudson AJ (1960). The development of the vascular pattern of the choroid plexus of the lateral ventricles. J. Comp. Neurol 115, 171&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">13716507</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter NL, and Dymecki SM (2007). Molecularly and temporally separable lineages form the hindbrain roof plate and contribute differentially to the choroid plexus. Development 134, 3449&#x2013;3460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2897145</ArticleId><ArticleId IdType="pubmed">17728348</ArticleId></ArticleIdList></Reference><Reference><Citation>Jord&#xe3;o MJC, Sankowski R, Brendecke SM, Sagar, Locatelli G, Tai Y-H, Tay TL, Schramm E, Armbruster S, Hagemeyer N, et al. (2019a). Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science 363, eaat7554.</Citation><ArticleIdList><ArticleId IdType="pubmed">30679343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser K, Gyllborg D, Proch&#xe1;zka J, Sala&#x161;ov&#xe1; A, Kompan&#xed;kov&#xe1; P, Molina FL, Laguna-Goya R, Radaszkiewicz T, Harno&#x161; J, Proch&#xe1;zkov&#xe1; M, et al. (2019). WNT5A is transported via lipoprotein particles in the cerebrospinal fluid to regulate hindbrain morphogenesis. Nat. Commun 10(1):1498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6445127</ArticleId><ArticleId IdType="pubmed">30940800</ArticleId></ArticleIdList></Reference><Reference><Citation>Kania A, and Klein R (2016). Mechanisms of ephrin-Eph signalling in development, physiology and disease. Nat. Rev. Mol. Cell Biol 17, 240&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">26790531</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimy JK, Zhang J, Kurland DB, Theriault BC, Duran D, Stokum JA, Furey CG, Zhou X, Mansuri MS, Montejo J, et al. (2017). Inflammation-dependent cerebrospinal fluid hypersecretion by the choroid plexus epithelium in posthemorrhagic hydrocephalus. Nat. Med 23, 997&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">28692063</ArticleId></ArticleIdList></Reference><Reference><Citation>Keep RF, and Jones HC (1990). A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat. Dev. Brain Res 56, 47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">2279331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinzel B, Pikiolek M, Orsini V, Sprunger J, Isken A, Zietzling S, Desplanches M, Dubost V, Breustedt D, Valdez R, et al. (2014). Functional roles of Lgr4 and Lgr5 in embryonic gut, kidney and skin development in mice. Dev. Biol 390, 181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">24680895</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohyama M, Ise W, Edelson BT, Wilker PR, Hildner K, Mejia C, Frazier WA, Murphy TL, and Murphy KM (2009). Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis. Nature 457, 318&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756102</ArticleId><ArticleId IdType="pubmed">19037245</ArticleId></ArticleIdList></Reference><Reference><Citation>Krausgruber T, Fortelny N, Fife-Gernedl V, Senekowitsch M, Schuster LC, Lercher A, Nemc A, Schmidl C, Rendeiro AF, Bergthaler A, et al. (2020). Structural cells are key regulators of organ-specific immune responses. Nature 583, 296&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610345</ArticleId><ArticleId IdType="pubmed">32612232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriegstein A, and Alvarez-Buylla A (2009). The glial nature of embryonic and adult neural stem cells. Annu. Rev. Neurosci 32, 149&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086722</ArticleId><ArticleId IdType="pubmed">19555289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, et al. (1997). Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390, 45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacar B, Linker SB, Jaeger BN, Krishnaswami S, Barron J, Kelder M, Parylak S, Paquola A, Venepally P, Novotny M, et al. (2016). Nuclear RNA-seq of single neurons reveals molecular signatures of activation. Nat. Commun 7:11022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4838832</ArticleId><ArticleId IdType="pubmed">27090946</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek JT, Johnson WE, Parker HS, Jaffe AE, and Storey JD (2012). The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307112</ArticleId><ArticleId IdType="pubmed">22257669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehtinen MK, Zappaterra MW, Chen X, Yang YJ, Hill AD, Lun M, Maynard T, Gonzalez D, Kim S, Ye P, et al. (2011). The Cerebrospinal Fluid Provides a Proliferative Niche for Neural Progenitor Cells. Neuron 69, 893&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3085909</ArticleId><ArticleId IdType="pubmed">21382550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, Brockway KS, Byrnes EJ, et al. (2007). Genome-wide atlas of gene expression in the adult mouse brain. Nature 445, 168&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">17151600</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis AE, Vasudevan HN, O&#x2019;Neill AK, Soriano P, and Bush JO (2013). The widely used Wnt1-Cre transgene causes developmental phenotypes by ectopic activation of Wnt signaling. Dev. Biol 379, 229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804302</ArticleId><ArticleId IdType="pubmed">23648512</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Cheng Z, Zhou L, Darmanis S, Neff NF, Okamoto J, Gulati G, Bennett ML, Sun LO, Clarke LE, et al. (2019). Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA Sequencing. Neuron 101, 207&#x2013;223.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336504</ArticleId><ArticleId IdType="pubmed">30606613</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Dziegielewska KM, VandeBerg JL, and Saunders NR (2010). Development of the lateral ventricular choroid plexus in a marsupial, Monodelphis domestica. Cerebrospinal Fluid Res. 7, 16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964622</ArticleId><ArticleId IdType="pubmed">20920364</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim HY, Lim SY, Tan CK, Thiam CH, Goh CC, Carbajo D, Chew SHS, See P, Chakarov S, Wang XN, et al. (2018). Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain Arterial Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell Collagen. Immunity 49, 326&#x2013;341.e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30054204</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindvall M, Edvinsson L, and Owman C (1978). Sympathetic nervous control of cerebrospinal fluid production from the choroid plexus. Science 201, 176&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">663649</ArticleId></ArticleIdList></Reference><Reference><Citation>Livet J, Weissman TA, Kang H, Draft RW, Lu J, Bennis RA, Sanes JR, and Lichtman JW (2007). Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. Nature 450, 56&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">17972876</ArticleId></ArticleIdList></Reference><Reference><Citation>Louvi A, and Wassef M (2000). Ectopic Engrailed 1 expression in the dorsal midline causes cell death, abnormal differentiation of circumventricular organs and errors in axonal pathfinding. Development 127, 4061&#x2013;4071.</Citation><ArticleIdList><ArticleId IdType="pubmed">10952903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun MP, Monuki ES, and Lehtinen MK (2015a). Development and functions of the choroid plexus&#x2013;cerebrospinal fluid system. Nat. Rev. Neurosci. 16, 445&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4629451</ArticleId><ArticleId IdType="pubmed">26174708</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun MP, Johnson MB, Broadbelt KG, Watanabe M, Kang YJ, Chau KF, Springel MW, Malesz A, Sousa AM, Pletikos M, et al. (2015b). Spatially heterogeneous choroid plexus transcriptomes encode positional identity and contribute to regional CSF production. J Neurosci 35, 4903&#x2013;4916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4389594</ArticleId><ArticleId IdType="pubmed">25810521</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Maaten L, and Hinton G (2008). Visualizing Data using t-SNE.</Citation></Reference><Reference><Citation>Mancini M, Greco A, Tedeschi E, Palma G, Ragucci M, Bruzzone MG, Coda ARD, Torino E, Scotti A, Zucca I, et al. (2015). Head and neck veins of the mouse. A magnetic resonance, micro computed tomography and high frequency color Doppler ultrasound study. PLoS One 10(6):e0129912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4466257</ArticleId><ArticleId IdType="pubmed">26067061</ArticleId></ArticleIdList></Reference><Reference><Citation>La Manno G, Soldatov R, Zeisel A, Braun E, Hochgerner H, Petukhov V, Lidschreiber K, Kastriti ME, L&#xf6;nnerberg P, Furlan A, et al. (2018). RNA velocity of single cells. Nature 560, 494&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6130801</ArticleId><ArticleId IdType="pubmed">30089906</ArticleId></ArticleIdList></Reference><Reference><Citation>Martik ML, and Bronner ME (2017). Regulatory Logic Underlying Diversification of the Neural Crest. Trends Genet. 33, 715&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610108</ArticleId><ArticleId IdType="pubmed">28851604</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew RS, Mullan H, Blusztajn JK, and Lehtinen MK (2016). Comment on &amp;quot;Multiple repressive mechanisms in the hippocampus during memory formation&amp;quot;. Science 353, 453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5026305</ArticleId><ArticleId IdType="pubmed">27482552</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazucanti CH, Liu QR, Lang D, Huang N, O&#x2019;Connell JF, Camandola S, and Egan JM (2019). Release of insulin produced by the choroids plexis is regulated by serotonergic signaling. JCI Insight 4(23):e131682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6962018</ArticleId><ArticleId IdType="pubmed">31647782</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis CS, Murrow LM, and Gartner ZJ (2019). DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst. 8, 329&#x2013;337.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6853612</ArticleId><ArticleId IdType="pubmed">30954475</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrak D, Levitin HM, Delgado AC, Crotet V, Yuan J, Chaker Z, Silva-Vargas V, Sims PA, and Doetsch F (2019). Single-Cell Analysis of Regional Differences in Adult V-SVZ Neural Stem Cell Lineages. Cell Rep. 26, 394&#x2013;406.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6368857</ArticleId><ArticleId IdType="pubmed">30625322</ArticleId></ArticleIdList></Reference><Reference><Citation>Montoro DT, Haber AL, Biton M, Vinarsky V, Lin B, Birket SE, Yuan F, Chen S, Leung HM, Villoria J, et al. (2018). A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. Nature 560, 319&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6295155</ArticleId><ArticleId IdType="pubmed">30069044</ArticleId></ArticleIdList></Reference><Reference><Citation>Muus C, Luecken M, Eraslan G, Waghray A, Heimberg G, Sikkema L, Kobayashi Y, Vaishnav ED, Subramanian A, Smilie C, et al. (2020). Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. BioRxiv 2020.04.19.049254.</Citation></Reference><Reference><Citation>Myung J, Schmal C, Hong S, Tsukizawa Y, Rose P, Zhang Y, Holtzman MJ, De Schutter E, Herzel H, Bordyugov G, et al. (2018). The choroid plexus is an important circadian clock component. Nat. Commun 9, 1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5852131</ArticleId><ArticleId IdType="pubmed">29540683</ArticleId></ArticleIdList></Reference><Reference><Citation>Par&#xe9; A, Mailhot B, L&#xe9;vesque SA, Juzwik C, Doss PMIA, L&#xe9;cuyer MA, Prat A, Rangachari M, Fournier A, and Lacroix S (2018). IL-1&#x3b2; enables CNS access to CCR2hi monocytes and the generation of pathogenic cells through GM-CSF released by CNS endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 115, E1194&#x2013;E1203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5819409</ArticleId><ArticleId IdType="pubmed">29358392</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini L, Albecka A, Mallery DL, Kellner MJ, Paul D, Carter AP, James LC, and Lancaster MA (2020a). SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids. Cell Stem Cell. 27(6):951&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7553118</ArticleId><ArticleId IdType="pubmed">33113348</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini L, Bonfio C, Chadwick J, Begum F, Skehel M, and Lancaster MA (2020b). Human CNS barrier-forming organoids with cerebrospinal fluid production. Science. 369(6500):eaaz5626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116154</ArticleId><ArticleId IdType="pubmed">32527923</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard JK, Stephens M, and Donnelly P (2000). Inference of Population Structure Using Multilocus Genotype Data. Genetics 155(2):945&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461096</ArticleId><ArticleId IdType="pubmed">10835412</ArticleId></ArticleIdList></Reference><Reference><Citation>Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli A, Lanzavecchia A, Engelhardt B, and Sallusto F (2009). C-C chemokine receptor 6&#x2013;regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol 10, 514&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">19305396</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A, Macosko EZ, Wysoker A, Goldman M, Krienen FM, de Rivera H, Bien E, Baum M, Bortolin L, Wang S, et al. (2018a). Molecular Diversity and Specializations among the Cells of the Adult Mouse Brain. Cell 174, 1015&#x2013;1030.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447408</ArticleId><ArticleId IdType="pubmed">30096299</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders NR, Dziegielewska KM, M&#xf8;llg&#xe5;rd K, and Habgood MD (2018b). Physiology and molecular biology of barrier mechanisms in the fetal and neonatal brain. J. Physiol 596, 5723&#x2013;5756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6265560</ArticleId><ArticleId IdType="pubmed">29774535</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiebinger G, Shu J, Tabaka M, Cleary B, Subramanian V, Solomon A, Gould J, Liu S, Lin S, Berube P, et al. (2019). Optimal-Transport Analysis of Single-Cell Gene Expression Identifies Developmental Trajectories in Reprogramming. Cell 176, 928&#x2013;943.e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402800</ArticleId><ArticleId IdType="pubmed">30712874</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, and Baruch K (2014). The resolution of neuroinflammation in neurodegeneration: Leukocyte recruitment via the choroid plexus. EMBO J. 33, 7&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3990679</ArticleId><ArticleId IdType="pubmed">24357543</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah PT, Stratton JA, Stykel MG, Abbasi S, Sharma S, Mayr KA, Koblinger K, Whelan PJ, and Biernaskie J (2018). Single-Cell Transcriptomics and Fate Mapping of Ependymal Cells Reveals an Absence of Neural Stem Cell Function. Cell 173, 1045&#x2013;1057.e9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29727663</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon ML, Fame RM, Chau KF, Dani N, Calicchio ML, G&#xe9;l&#xe9;oc GS, Lidov HGW, Alexandrescu S, and Lehtinen MK (2018). Mice Expressing Myc in Neural Precursors Develop Choroid Plexus and Ciliary Body Tumors. Am. J. Pathol 188, 1334&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5971223</ArticleId><ArticleId IdType="pubmed">29545198</ArticleId></ArticleIdList></Reference><Reference><Citation>Shechter R, Miller O, Yovel G, Rosenzweig N, London A, Ruckh J, Kim K-W, Klein E, Kalchenko V, Bendel P, et al. (2013). Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity 38, 555&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115271</ArticleId><ArticleId IdType="pubmed">23477737</ArticleId></ArticleIdList></Reference><Reference><Citation>Shipley FB, Dani N, Xu H, Deister C, Cui J, Head JP, Sadegh C, Fame RM, Shannon ML, Flores VI, et al. (2020). Tracking Calcium Dynamics and Immune Surveillance at the Choroid Plexus Blood-Cerebrospinal Fluid Interface. Neuron. 108(4):623&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7847245</ArticleId><ArticleId IdType="pubmed">32961128</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuangshoti S, and Netsky MG (1966). Histogenesis of choroid plexus in man. Am. J. Anat 118, 283&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">5915034</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Vargas V, Maldonado-Soto ARR, Mizrak D, Codega P, and Doetsch F (2016). Age-Dependent Niche Signals from the Choroid Plexus Regulate Adult Neural Stem Cells. Cell Stem Cell 19, 643&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">27452173</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M, Wang C, Cong L, Marjanovic ND, Kowalczyk MS, Zhang H, Nyman J, Sakuishi K, Kurtulus S, Gennert D, et al. (2016). A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells. Cell 166, 1500&#x2013;1511.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5019125</ArticleId><ArticleId IdType="pubmed">27610572</ArticleId></ArticleIdList></Reference><Reference><Citation>Snippert HJ, van der Flier LG, Sato T, van Es JH, van den Born M, Kroon-Veenboer C, Barker N, Klein AM, van Rheenen J, Simons BD, et al. (2010). Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 143, 134&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20887898</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong Y, Merino D, Nimmervoll B, Gupta K, Wang YD, Finkelstein D, Dalton J, Ellison DW, Ma X, Zhang J, et al. (2015). Cross-Species Genomics Identifies TAF12, NFYC, and RAD54L as Choroid Plexus Carcinoma Oncogenes. Cancer Cell 27, 712&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4458854</ArticleId><ArticleId IdType="pubmed">25965574</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanlandewijck M, He L, M&#xe4;e MA, Andrae J, Ando K, Del Gaudio F, Nahar K, Lebouvier T, Lavi&#xf1;a B, Gouveia L, et al. (2018). A molecular atlas of cell types and zonation in the brain vasculature. Nature 554, 475&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">29443965</ArticleId></ArticleIdList></Reference><Reference><Citation>Visel A, Thaller C, and Eichele G (2004). GenePaint.org: an atlas of gene expression patterns in the mouse embryo. Nucleic Acids Res. 32, D552&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308763</ArticleId><ArticleId IdType="pubmed">14681479</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Flanagan J, Su N, Wang L-C, Bui S, Nielson A, Wu X, Vo H-T, Ma X-J, and Luo Y (2012). RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J. Mol. Diagn 14, 22&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338343</ArticleId><ArticleId IdType="pubmed">22166544</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilting J, and Christ B (1989). An experimental and ultrastructural study on the development of the avian choroid plexus. Cell Tissue Res. 255, 487&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">2706656</ArticleId></ArticleIdList></Reference><Reference><Citation>Wingate RJT (2001). The rhombic lip and early cerebellar development. Curr. Opin. Neurobiol 11, 82&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">11179876</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, and Yang C (2020). Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain. Behav. Immun 87, 18&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146689</ArticleId><ArticleId IdType="pubmed">32240762</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Fame RM, Sadegh C, Sutin J, Naranjo C, Della Syau, Cui J, Shipley FB, Vernon A, Gao F, et al. (2021). Choroid plexus NKCC1 mediates cerebrospinal fluid clearance during mouse early postnatal development. Nat. Commun 12(1):447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7815709</ArticleId><ArticleId IdType="pubmed">33469018</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC, Kern F, Losada PM, Maat CA, Schmartz G, Fehlmann T, Schaum N, Lee DP, Calcuttawala K, Vest RT, et al. (2020). Broad transcriptional dysregulation of brain and choroid plexus cell types with COVID-19. BioRxiv 2020.10.22.349415.</Citation></Reference><Reference><Citation>Zhu L, Stein LR, Kim D, Ho K, Yu G-Q, Zhan L, Larsson TE, and Mucke L (2018). Klotho controls the brain-immune system interface in the choroid plexus. Proc. Natl. Acad. Sci. U. S. A 115, E11388&#x2013;E11396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6275534</ArticleId><ArticleId IdType="pubmed">30413620</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33958804</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>786</StartPage><EndPage>798</EndPage><MedlinePgn>786-798</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-021-00851-3</ELocationID><Abstract><AbstractText>Selective neurodegeneration is a critical causal factor in Alzheimer's disease (AD); however, the mechanisms that lead some neurons to perish, whereas others remain resilient, are unknown. We sought potential drivers of this selective vulnerability using single-nucleus RNA sequencing and discovered that ApoE expression level is a substantial driver of neuronal variability. Strikingly, neuronal expression of ApoE-which has a robust genetic linkage to AD-correlated strongly, on a cell-by-cell basis, with immune response pathways in neurons in the brains of wild-type mice, human ApoE knock-in mice and humans with or without AD. Elimination or over-expression of neuronal ApoE revealed a causal relationship among ApoE expression, neuronal MHC-I expression, tau pathology and neurodegeneration. Functional reduction of MHC-I ameliorated tau pathology in ApoE4-expressing primary neurons and in mouse hippocampi expressing pathological tau. These findings suggest a mechanism linking neuronal ApoE expression to MHC-I expression and, subsequently, to tau pathology and selective neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zalocusky</LastName><ForeName>Kelly A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0002-1895-2654</Identifier><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA. kzalocusky@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gladstone Center for Translational Advancement, San Francisco, CA, USA. kzalocusky@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. kzalocusky@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Najm</LastName><ForeName>Ramsey</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental and Stem Cell Biology Graduate Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taubes</LastName><ForeName>Alice L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Yanxia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gladstone Center for Translational Advancement, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Seo Yeon</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koutsodendris</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-2761-1480</Identifier><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental and Stem Cell Biology Graduate Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Maxine R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-1990-5099</Identifier><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Antara</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental and Stem Cell Biology Graduate Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bant</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amornkul</LastName><ForeName>Dah-Eun J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gladstone Center for Translational Advancement, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gladstone Center for Translational Advancement, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cisne-Thomson</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gladstone Center for Translational Advancement, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yadong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5871-4589</Identifier><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gladstone Center for Translational Advancement, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Developmental and Stem Cell Biology Graduate Program, University of California, San Francisco, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California, San Francisco, San Francisco, CA, USA. yadong.huang@gladstone.ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG055421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG048017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055682</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HD007470</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR028962</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2021 Jun;24(6):759-760. doi: 10.1038/s41593-021-00855-z.</RefSource><PMID Version="1">33958803</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="N">Gene Knock-In Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests Statement. Y.H. is a co-founder and scientific advisory board member of E-Scape Bio, Inc., GABAeron, Inc., and Mederon Bio, LLC. Other authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>7</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33958804</ArticleId><ArticleId IdType="mid">NIHMS1810043</ArticleId><ArticleId IdType="pmc">PMC9145692</ArticleId><ArticleId IdType="doi">10.1038/s41593-021-00851-3</ArticleId><ArticleId IdType="pii">10.1038/s41593-021-00851-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fu H, Hardy J &amp; Duff KE Selective vulnerability in neurodegenerative diseases. Nat. Neurosci 21, 1350&#x2013;1358 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6360529</ArticleId><ArticleId IdType="pubmed">30250262</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews-Zwilling Y et al. Apolipoprotein E4 causes age- and tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J. Neurosci 30, 13707&#x2013;13717 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988475</ArticleId><ArticleId IdType="pubmed">20943911</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y &amp; Mucke L Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204&#x2013;1222 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319071</ArticleId><ArticleId IdType="pubmed">22424230</ArticleId></ArticleIdList></Reference><Reference><Citation>Najm R, Jones EA &amp; Huang Y Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer&#x2019;s disease. Mol. Neurodegener 14&#x2013;24 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6558779</ArticleId><ArticleId IdType="pubmed">31186040</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. JAMA 278, 1349&#x2013;1356 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward A et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer&#x2019;s disease: A systematic review and meta-analysis. Neuroepidemiology 38, 1&#x2013;17 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22179327</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitas RE, Boyles JK, Lee SH, Foss D &amp; Mahley RW Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 917, 148&#x2013;161 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3539206</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat. Med 24, 647&#x2013;657 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948154</ArticleId><ArticleId IdType="pubmed">29632371</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu P-T et al. Specific regional transcription of apolipoprotein E in human brain neurons. Am. J. Pathol 154, 601&#x2013;611 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850012</ArticleId><ArticleId IdType="pubmed">10027417</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q et al. Profile and regulation of apolipoprotein E (apoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the apoE locus. J. Neurosci 26, 4985&#x2013;4994 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674234</ArticleId><ArticleId IdType="pubmed">16687490</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoferle J et al. Apolipoprotein E4 produced in GABAergic interneurons causes learning and memory deficits in mice. J. Neurosci 34, 14069&#x2013;14078 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4198545</ArticleId><ArticleId IdType="pubmed">25319703</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodbeck J et al. Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J. Biol. Chem 286, 17217&#x2013;17226 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3089564</ArticleId><ArticleId IdType="pubmed">21454574</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y-T et al. APOE4 Causes Widespread molecular and cellular alterations associated with Alzheimer&#x2019;s disease phenotypes in human iPSC-derived brain cell types. Neuron 98, 1141&#x2013;1154 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023751</ArticleId><ArticleId IdType="pubmed">29861287</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523&#x2013;527 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr AL et al. Neuronal apolipoprotein E4 expression results in proteome-wide alterations and compromises bioenergetic capacity by disrupting mitochondrial function. J. Alzheimers Dis 68, 991&#x2013;1011 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6481541</ArticleId><ArticleId IdType="pubmed">30883359</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Weisgraber KH &amp; Huang Y Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. USA 103, 5644&#x2013;5651 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1414631</ArticleId><ArticleId IdType="pubmed">16567625</ArticleId></ArticleIdList></Reference><Reference><Citation>Adelson JD et al. Neuroprotection from stroke in the absence of MHCI or PirB. Neuron 73, 1100&#x2013;1107 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314229</ArticleId><ArticleId IdType="pubmed">22445338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombeiro AL et al. MHC-I and PirB upregulation in the central and peripheral nervous system following sciatic nerve injury. PLoS One 11, e0161463 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995013</ArticleId><ArticleId IdType="pubmed">27551751</ArticleId></ArticleIdList></Reference><Reference><Citation>Corriveau RA, Huh GS &amp; Shatz CJ Regulation of Class I MHC gene expression in the developing and mature CNS by neural activity. Neuron 21, 505&#x2013;520 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9768838</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangold CA et al. CNS-wide sexually dimorphic induction of the major histocompatibility complex 1 pathway with aging. J. Gerontol. A. Biol. Sci. Med. Sci 72, 16&#x2013;29 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5155655</ArticleId><ArticleId IdType="pubmed">26786204</ArticleId></ArticleIdList></Reference><Reference><Citation>Starkey HDV et al. Neuroglial expression of the MHCI pathway and PirB receptor is upregulated in the hippocampus with advanced aging. J. Mol. Neurosci 48, 111&#x2013;126 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3414657</ArticleId><ArticleId IdType="pubmed">22562814</ArticleId></ArticleIdList></Reference><Reference><Citation>Datwani A et al. Classical MHCI molecules regulate retinogeniculate refinement and limit ocular dominance plasticity. Neuron 64, 463&#x2013;470 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787480</ArticleId><ArticleId IdType="pubmed">19945389</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H et al. Synapse elimination and learning rules co-regulated by MHC class I H2-Db. Nature 509, 195&#x2013;200 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4016165</ArticleId><ArticleId IdType="pubmed">24695230</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung L et al. Apolipoprotein E4 causes age- and sex-dependent impairments of hilar GABAergic interneurons and learning and memory deficits in mice. PLoS One 7, e53569 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534053</ArticleId><ArticleId IdType="pubmed">23300939</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci 34, 11929&#x2013;11947 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Cembrowski MS, Wang L, Sugino K, Shields BC &amp; Spruston N Hipposeq: a comprehensive RNA-seq database of gene expression in hippocampal principal neurons. eLife 5, e14997 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4846374</ArticleId><ArticleId IdType="pubmed">27113915</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A et al. Molecular diversity and specializations among the cells of the adult mouse brain. Cell 174, 1015&#x2013;1030 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447408</ArticleId><ArticleId IdType="pubmed">30096299</ArticleId></ArticleIdList></Reference><Reference><Citation>Lein ES et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445, 168&#x2013;176 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17151600</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dijk D et al. Recovering gene interactions from single-cell data using data diffusion. Cell 174, 716&#x2013;729 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6771278</ArticleId><ArticleId IdType="pubmed">29961576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M &amp; Goto S KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 28, 27&#x2013;30 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102409</ArticleId><ArticleId IdType="pubmed">10592173</ArticleId></ArticleIdList></Reference><Reference><Citation>Suberbielle E et al. Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-&#x3b2;. Nat. Neurosci 16, 613&#x2013;621 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637871</ArticleId><ArticleId IdType="pubmed">23525040</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerakis Y &amp; Hetz C A decay of the adaptive capacity of the unfolded protein response exacerbates Alzheimer&#x2019;s disease. Neurobiol. Aging 63, 162&#x2013;164 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29042130</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y &amp; Holtzman DM Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol 18, 759 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425488</ArticleId><ArticleId IdType="pubmed">30140051</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasic B et al. Shared and distinct transcriptomic cell types across neocortical areas. Nature 563, 72&#x2013;78 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6456269</ArticleId><ArticleId IdType="pubmed">30382198</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Darmanis S et al. A survey of human brain transcriptome diversity at the single cell level. Proc. Natl. Acad. Sci. USA 112, 7285&#x2013;7290 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4466750</ArticleId><ArticleId IdType="pubmed">26060301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtsuka M, Inoko H, Kulski JK &amp; Yoshimura S Major histocompatibility complex (Mhc) class Ib gene duplications, organization and expression patterns in mouse strain C57BL/6. BMC Genomics 9, 178 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2375909</ArticleId><ArticleId IdType="pubmed">18416856</ArticleId></ArticleIdList></Reference><Reference><Citation>Brecht WJ et al. Neuron-specific apolipoprotein E4 proteolysis is associated with increased Tau phosphorylation in brains of transgenic mice. J. Neurosci 24, 2527&#x2013;2534 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729489</ArticleId><ArticleId IdType="pubmed">15014128</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondrag&#xf3;n-Rodr&#xed;guez S, Perry G, Luna-Mu&#xf1;oz J, Acevedo-Aquino MC &amp; Williams S Phosphorylation of tau protein at sites Ser396&#x2013;404 is one of the earliest events in Alzheimer&#x2019;s disease and Down syndrome. Neuropathol. Appl. Neurobiol 40, 121&#x2013;135 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24033439</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H &amp; Braak E Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM-Y &amp; Trojanowski JQ Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nat. Rev. Neurosci 8, 663&#x2013;672 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Germain RN &amp; Margulies DH The biochemistry and cell biology of antigen processing and presentation. Ann. Rev. Immunol 11, 403&#x2013;450 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8476568</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen TH &amp; Leet DR Mechanism of class I assembly with &#x3b2;2 microglobulin and loading with peptide. in Advances in Immunology (ed. Dixon FJ) vol. 64 105&#x2013;137 (Academic Press, 1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9100981</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris FM et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer&#x2019;s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc. Natl. Acad. Sci. USA 100, 10966&#x2013;10971 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC196910</ArticleId><ArticleId IdType="pubmed">12939405</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesseur I et al. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am. J. Pathol 156, 951&#x2013;964 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1876840</ArticleId><ArticleId IdType="pubmed">10702411</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard CA, Butts DA &amp; Shatz CJ Regulation of CNS synapses by neuronal MHC class I. Proc. Natl. Acad. Sci. USA 104, 6828&#x2013;6833 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1871870</ArticleId><ArticleId IdType="pubmed">17420446</ArticleId></ArticleIdList></Reference><Reference><Citation>Gate D et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer&#x2019;s disease. Nature 577, 399&#x2013;404 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445078</ArticleId><ArticleId IdType="pubmed">31915375</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh GS et al. Functional requirement for class I MHC in CNS development and plasticity. Science 290, 2155&#x2013;2159 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2175035</ArticleId><ArticleId IdType="pubmed">11118151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T et al. Human LilrB2 is a &#x3b2;-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer&#x2019;s model. Science 341, 1399&#x2013;1404 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853120</ArticleId><ArticleId IdType="pubmed">24052308</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown GC &amp; Neher JJ Microglial phagocytosis of live neurons. Nat. Rev. Neurosci 15, 209&#x2013;216 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24646669</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamanaka H et al. Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. Hum. Mol. Genet 9, 353&#x2013;361 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10655544</ArticleId></ArticleIdList></Reference><Reference><Citation>Bien-Ly N, Gillespie AK, Walker D, Yoon SY &amp; Huang Y Reducing Human Apolipoprotein E levels attenuates age-dependent A&#x3b2; accumulation in mutant human amyloid precursor protein transgenic mice. J. Neurosci 32, 4803&#x2013;4811 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433173</ArticleId><ArticleId IdType="pubmed">22492035</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA et al. Religious orders study and rush memory and aging project. J. Alzheimers Dis 64, S161&#x2013;S189 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL et al. A multi-omic atlas of the human frontal cortex for aging and Alzheimer&#x2019;s disease research. Scientific Data 5, 180142 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>10x Genomics. Isolation of nuclei for single cell RNA sequencing - demonstrated protocol - sample prep - single cell gene expression - official 10x genomics support. Isolation of Nuclei for Single Cell RNA Sequencing
https://assets.ctfassets.net/an68im79xiti/6FhJX6yndYy0OwskGmMc8I/e2677be827e82cd954ecfb8b30278e5e/CG000124_SamplePrepDemonstratedProtocol_-_Nuclei_RevD.pdf (2018).</Citation></Reference><Reference><Citation>Allen Institute for Brain Science. Allen Cell Types Database Technical White Paper: Transcriptomics 1&#x2013;15 (2018).</Citation></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E &amp; Satija R Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888&#x2013;1902 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47:1&#x2013;13 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P et al. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res 13, 2498&#x2013;2504 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z et al. Comprehensive transcriptome analysis of neocortical layers in humans, chimpanzees and macaques. Nat. Neurosci 20, 886&#x2013;895 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28414332</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33980574</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>593</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eabb2639</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abb2639</ELocationID><Abstract><AbstractText>Tau has become an attractive alternative target for passive immunotherapy efforts for Alzheimer's disease (AD). The anatomical distribution and extent of tau pathology correlate with disease course and severity better than other disease markers to date. We describe here the generation, preclinical characterization, and phase 1 clinical characterization of semorinemab, a humanized anti-tau monoclonal antibody with an immunoglobulin G4 (igG4) isotype backbone. Semorinemab binds all six human tau isoforms and protects neurons against tau oligomer neurotoxicity in cocultures of neurons and microglia. In addition, when administered intraperitoneally once weekly for 13 weeks, murine versions of semorinemab reduced the accumulation of tau pathology in a transgenic mouse model of tauopathy, independent of antibody effector function status. Semorinemab also showed clear evidence of target engagement in vivo, with increases in systemic tau concentrations observed in tau transgenic mice, nonhuman primates, and humans. Higher concentrations of systemic tau were observed after dosing in AD participants compared to healthy control participants. No concerning safety signals were observed in the phase 1 clinical trial at single doses up to 16,800 mg and multiple doses totaling 33,600 mg in a month.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ayalon</LastName><ForeName>Gai</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-0872-9168</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seung-Hye</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0003-2328-9938</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adolfsson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-5875-9026</Identifier><AffiliationInfo><Affiliation>AC Immune SA, EPFL Innovation Park, Building B, CH-1015 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foo-Atkins</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Project Team Leadership, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atwal</LastName><ForeName>Jasvinder K</ForeName><Initials>JK</Initials><Identifier Source="ORCID">0000-0001-5995-478X</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blendstrup</LastName><ForeName>Mira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Early Clinical Development, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Booler</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Safety Assessment, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bravo</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6087-3733</Identifier><AffiliationInfo><Affiliation>Department of Safety Assessment, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendza</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunstein</LastName><ForeName>Flavia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Licensing and Early Development Safety, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Ruby</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Protein Chemistry, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandra</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couch</LastName><ForeName>Jessica A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Project Team Leadership, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Datwani</LastName><ForeName>Akash</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5293-2932</Identifier><AffiliationInfo><Affiliation>Department of Bioanalytical Sciences, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demeule</LastName><ForeName>Barth&#xe9;lemy</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-3009-2578</Identifier><AffiliationInfo><Affiliation>Department of Late Stage Pharmaceutical Development, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiCara</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Antibody Engineering, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erickson</LastName><ForeName>Rich</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Bioanalytical Sciences, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ernst</LastName><ForeName>James A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Protein Chemistry, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foreman</LastName><ForeName>Oded</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Dongping</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-3312-7326</Identifier><AffiliationInfo><Affiliation>Department of Biochemical and Cellular Pharmacology, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xf6;tzel</LastName><ForeName>Isidro</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-6910-7840</Identifier><AffiliationInfo><Affiliation>Department of Antibody Engineering, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keeley</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Project Team Leadership, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwok</LastName><ForeName>Michael C M</ForeName><Initials>MCM</Initials><Identifier Source="ORCID">0000-0003-2946-4629</Identifier><AffiliationInfo><Affiliation>Department of Protein Chemistry, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lafrance-Vanasse</LastName><ForeName>Julien</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8807-6277</Identifier><AffiliationInfo><Affiliation>Department of Protein Chemistry, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Han</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5641-2117</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yanmei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemical and Cellular Pharmacology, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luk</LastName><ForeName>Wilman</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-2627-4547</Identifier><AffiliationInfo><Affiliation>Department of Biochemical and Cellular Pharmacology, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manser</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9332-0975</Identifier><AffiliationInfo><Affiliation>Biostatistics, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muhs</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>AC Immune SA, EPFL Innovation Park, Building B, CH-1015 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngu</LastName><ForeName>Hai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfeifer</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>AC Immune SA, EPFL Innovation Park, Building B, CH-1015 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pihlgren</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5163-9539</Identifier><AffiliationInfo><Affiliation>AC Immune SA, EPFL Innovation Park, Building B, CH-1015 Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gautham K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Department of Safety Assessment, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scearce-Levie</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-0568-802X</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schauer</LastName><ForeName>Stephen P</ForeName><Initials>SP</Initials><Identifier Source="ORCID">0000-0001-6622-8719</Identifier><AffiliationInfo><Affiliation>Department of Biomarker Development, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>William B</ForeName><Initials>WB</Initials><Identifier Source="ORCID">0000-0002-6907-9031</Identifier><AffiliationInfo><Affiliation>Alliance for Multispecialty Research, University of Tennessee Medical Center, Knoxville, TN 37920, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solanoy</LastName><ForeName>Hilda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teng</LastName><ForeName>Edmond</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1375-857X</Identifier><AffiliationInfo><Affiliation>Department of Early Clinical Development, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wildsmith</LastName><ForeName>Kristin R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Biomarker Development, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bumbaca Yadav</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Preclinical and Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ying</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-8365-4303</Identifier><AffiliationInfo><Affiliation>Department of Bioanalytical Sciences, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuji</LastName><ForeName>Reina N</ForeName><Initials>RN</Initials><Identifier Source="ORCID">0000-0002-8294-5782</Identifier><AffiliationInfo><Affiliation>Department of Safety Assessment, Genentech Inc., San Francisco, CA 94080, USA. fuji.reina@gene.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerchner</LastName><ForeName>Geoffrey A</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0001-7674-0695</Identifier><AffiliationInfo><Affiliation>Department of Early Clinical Development, Genentech Inc., San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>13</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33980574</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abb2639</ArticleId><ArticleId IdType="pii">13/593/eabb2639</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34012113</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>594</Volume><Issue>7861</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>MIR-NATs repress MAPT translation and aid proteostasis in neurodegeneration.</ArticleTitle><Pagination><StartPage>117</StartPage><EndPage>123</EndPage><MedlinePgn>117-123</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-021-03556-6</ELocationID><Abstract><AbstractText>The human genome expresses thousands of natural antisense transcripts (NAT) that can regulate epigenetic state, transcription, RNA stability or translation of their overlapping genes<sup>1,2</sup>. Here we describe MAPT-AS1, a brain-enriched NAT that is conserved in primates and contains an embedded mammalian-wide interspersed repeat (MIR), which represses tau translation by competing for ribosomal RNA pairing with the MAPT mRNA internal ribosome entry site<sup>3</sup>. MAPT encodes tau, a neuronal intrinsically disordered protein (IDP) that stabilizes axonal microtubules. Hyperphosphorylated, aggregation-prone tau forms the hallmark inclusions of tauopathies<sup>4</sup>. Mutations in MAPT cause familial frontotemporal dementia, and common variations forming the MAPT H1 haplotype are a significant risk factor in many tauopathies<sup>5</sup> and Parkinson's disease. Notably, expression of MAPT-AS1 or minimal essential sequences from MAPT-AS1 (including MIR) reduces-whereas silencing MAPT-AS1 expression increases-neuronal tau levels, and correlate with tau pathology in human brain. Moreover, we identified many additional NATs with embedded MIRs (MIR-NATs), which are overrepresented at coding genes linked to neurodegeneration and/or encoding IDPs, and confirmed MIR-NAT-mediated translational control of one such gene, PLCG1. These results demonstrate a key role for MAPT-AS1 in tauopathies and reveal a potentially broad contribution of MIR-NATs to the tightly controlled translation of IDPs<sup>6</sup>, with particular relevance for proteostasis in neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simone</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7722-1093</Identifier><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK. r.simone@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK. r.simone@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Javad</LastName><ForeName>Faiza</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5215-6678</Identifier><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emmett</LastName><ForeName>Warren</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>UCL Genetics Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inivata Ltd, Babraham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilkins</LastName><ForeName>Oscar G</ForeName><Initials>OG</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Francis Crick Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Filipa Louren&#xe7;o</ForeName><Initials>FL</Initials><Identifier Source="ORCID">0000-0002-1710-9841</Identifier><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barahona-Torres</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-5289-4232</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zareba-Paslawska</LastName><ForeName>Justyna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6193-5908</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ehteramyan</LastName><ForeName>Mazdak</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuccotti</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cellular, Computational and Integrative Biology (CIBIO), Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modelska</LastName><ForeName>Angelika</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6544-1024</Identifier><AffiliationInfo><Affiliation>Department of Cellular, Computational and Integrative Biology (CIBIO), Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siva</LastName><ForeName>Kavitha</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cellular, Computational and Integrative Biology (CIBIO), Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Virdi</LastName><ForeName>Gurvir S</ForeName><Initials>GS</Initials><Identifier Source="ORCID">0000-0002-8942-0903</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Francis Crick Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Jamie S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-6954-9988</Identifier><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Francis Crick Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harley</LastName><ForeName>Jasmine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Francis Crick Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kay</LastName><ForeName>Victoria A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hondhamuni</LastName><ForeName>Geshanthi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trabzuni</LastName><ForeName>Daniah</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4826-9570</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryten</LastName><ForeName>Mina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9520-6957</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wray</LastName><ForeName>Selina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3062-7050</Identifier><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preza</LastName><ForeName>Elisavet</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kia</LastName><ForeName>Demis A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pittman</LastName><ForeName>Alan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8112-2987</Identifier><AffiliationInfo><Affiliation>Genetics Research Centre, Molecular and Clinical Sciences, St George's University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manzoni</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>UCL School of Pharmacy, Department of Pharmacology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lees</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, UCL, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Advanced Study, The Hong Kong University of Science and Technology, Hong Kong, SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denti</LastName><ForeName>Michela A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Cellular, Computational and Integrative Biology (CIBIO), Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quattrone</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cellular, Computational and Integrative Biology (CIBIO), Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patani</LastName><ForeName>Rickie</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3825-7675</Identifier><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Francis Crick Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svenningsson</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warner</LastName><ForeName>Thomas T</ForeName><Initials>TT</Initials><Identifier Source="ORCID">0000-0001-6195-6995</Identifier><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plagnol</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-5597-9215</Identifier><AffiliationInfo><Affiliation>UCL Genetics Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ule</LastName><ForeName>Jernej</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2452-4277</Identifier><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Francis Crick Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Chemistry, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Silva</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5052-5775</Identifier><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK. r.desilva@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK. r.desilva@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FC001002</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1001253</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-1307</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>202903/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/J004758/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N026004/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501542/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0501560</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K01417X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S006591/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K-1212</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N008324/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M02492X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067556">Internal Ribosome Entry Sites</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016372">RNA, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067556" MajorTopicYN="N">Internal Ribosome Entry Sites</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074702" MajorTopicYN="N">Proteostasis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016372" MajorTopicYN="N">RNA, Antisense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012270" MajorTopicYN="N">Ribosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing Interests</b>
. The authors (R.S. and R.dS.) declare the following competing interest: Patent WO2017199041A1</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34012113</ArticleId><ArticleId IdType="mid">EMS126982</ArticleId><ArticleId IdType="pmc">PMC7610982</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03556-6</ArticleId><ArticleId IdType="pii">10.1038/s41586-021-03556-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pelechano V, Steinmetz LM. Gene regulation by antisense transcription. Nat Rev Genet. 2013;14:880&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">24217315</ArticleId></ArticleIdList></Reference><Reference><Citation>Statello L, Guo C-J, Chen L-L, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22:96&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7754182</ArticleId><ArticleId IdType="pubmed">33353982</ArticleId></ArticleIdList></Reference><Reference><Citation>Veo BL, Krushel LA. Secondary RNA structure and nucleotide specificity contribute to internal initiation mediated by the human tau 5&#x2019; leader. RNA Biol. 2012;9:1344&#x2013;1360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3597575</ArticleId><ArticleId IdType="pubmed">22995835</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittman AM, et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet. 2005;42:837&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735957</ArticleId><ArticleId IdType="pubmed">15792962</ArticleId></ArticleIdList></Reference><Reference><Citation>Gsponer J, Futschik ME, Teichmann SA, Babu MM. Tight regulation of unstructured proteins: from transcript synthesis to protein degradation. Science. 2008;322:1365&#x2013;1368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803065</ArticleId><ArticleId IdType="pubmed">19039133</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchelli S, et al. Antisense Transcription in Loci Associated to Hereditary Neurodegenerative Diseases. Mol Neurobiol. 2019 doi: 10.1007/s12035-018-1465-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1465-2</ArticleId><ArticleId IdType="pmc">PMC6614138</ArticleId><ArticleId IdType="pubmed">30610612</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibley CR, et al. Recursive splicing in long vertebrate genes. Nature. 2015;521:371&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4471124</ArticleId><ArticleId IdType="pubmed">25970246</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JA, et al. Neuropathological and transcriptomic characteristics of the aged brain. Elife. 2017;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5679757</ArticleId><ArticleId IdType="pubmed">29120328</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis. 2018;64:S161&#x2013;S189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Coupland KG, et al. Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson&#x2019;s Disease. PLoS ONE. 2016;11:e0157924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4919105</ArticleId><ArticleId IdType="pubmed">27336847</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkouris M, et al. Long Non-coding RNAs Associated With Neurodegeneration-Linked Genes Are Reduced in Parkinson&#x2019;s Disease Patients. Front Cell Neurosci. 2019;13:58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6396023</ArticleId><ArticleId IdType="pubmed">30853899</ArticleId></ArticleIdList></Reference><Reference><Citation>Smit AF, Riggs AD. MIRs are classic, tRNA-derived SINEs that amplified before the mammalian radiation. Nucleic Acids Res. 1995;23:98&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC306635</ArticleId><ArticleId IdType="pubmed">7870595</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert N, Labuda D. CORE-SINEs: eukaryotic short interspersed retroposing elements with common sequence motifs. Proc Natl Acad Sci USA. 1999;96:2869&#x2013;2874.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15861</ArticleId><ArticleId IdType="pubmed">10077603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lander ES, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">11237011</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita T, Sobue K. Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway. J Biol Chem. 2009;284:27734&#x2013;27745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785701</ArticleId><ArticleId IdType="pubmed">19648118</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottley A, Phillips NM, Webb TE, Willis AE, Spriggs KA. eIF4A inhibition allows translational regulation of mRNAs encoding proteins involved in Alzheimer&#x2019;s disease. PLoS ONE. 2010;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946912</ArticleId><ArticleId IdType="pubmed">20927385</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauro VP, Edelman GM. The ribosome filter hypothesis. Proc Natl Acad Sci USA. 2002;99:12031&#x2013;12036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129393</ArticleId><ArticleId IdType="pubmed">12221294</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x2019;s disease. Nat Genet. 2014;46:989&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146673</ArticleId><ArticleId IdType="pubmed">25064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hon C-C, et al. An atlas of human long non-coding RNAs with accurate 5&#x2019; ends. Nature. 2017 doi: 10.1038/nature21374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21374</ArticleId><ArticleId IdType="pmc">PMC6857182</ArticleId><ArticleId IdType="pubmed">28241135</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapusta A, et al. Transposable elements are major contributors to the origin, diversification, and regulation of vertebrate long noncoding RNAs. PLoS Genet. 2013;9:e1003470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636048</ArticleId><ArticleId IdType="pubmed">23637635</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcik M. Internal Ribosome Entry Site-Mediated Translation in Neuronal Protein Synthesis. In: Sossin WS, editor. The Oxford Handbook of Neuronal Protein Synthesis. Oxford University Press; 2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordhb/9780190686307.013.9</ArticleId></ArticleIdList></Reference><Reference><Citation>Weingarten-Gabbay S, et al. Comparative genetics. Systematic discovery of cap-independent translation sequences in human and viral genomes. Science. 2016;351</Citation><ArticleIdList><ArticleId IdType="pubmed">26816383</ArticleId></ArticleIdList></Reference><Reference><Citation>Paek KY, et al. Translation initiation mediated by RNA looping. Proc Natl Acad Sci U S A. 2015;112:1041&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4313796</ArticleId><ArticleId IdType="pubmed">25583496</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature. 2019;570:332&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A, et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat Neurosci. 2019;22:2087&#x2013;2097.</Citation><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman BA, et al. Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer&#x2019;s Disease Not Evident in Mouse Models. Cell Rep. 2018;22:832&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomkins JE, et al. PINOT: an intuitive resource for integrating protein-protein interactions. Cell Commun Signal. 2020;18:92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7291677</ArticleId><ArticleId IdType="pubmed">32527260</ArticleId></ArticleIdList></Reference><Reference><Citation>Oates ME, et al. D2P2 database of disordered protein predictions. Nucleic Acids Res. 2013;41:D508&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531159</ArticleId><ArticleId IdType="pubmed">23203878</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciryam P, Tartaglia GG, Morimoto RI, Dobson CM, Vendruscolo M. Widespread aggregation and neurodegenerative diseases are associated with supersaturated proteins. Cell Rep. 2013;5:781&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883113</ArticleId><ArticleId IdType="pubmed">24183671</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards YJK, Lobley AE, Pentony MM, Jones DT. Insights into the regulation of intrinsically disordered proteins in the human proteome by analyzing sequence and gene expression data. Genome Biol. 2009;10:R50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2718516</ArticleId><ArticleId IdType="pubmed">19432952</ArticleId></ArticleIdList></Reference><Reference><Citation>Sposito T, et al. Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Hum Mol Genet. 2015;24:5260&#x2013;5269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4550814</ArticleId><ArticleId IdType="pubmed">26136155</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Kirwan P, Livesey FJ. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc. 2012;7:1836&#x2013;1846.</Citation><ArticleIdList><ArticleId IdType="pubmed">22976355</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall CE, et al. Progressive Motor Neuron Pathology and the Role of Astrocytes in a Human Stem Cell Model of VCP-Related ALS. Cell Rep. 2017;19:1739&#x2013;1749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5464993</ArticleId><ArticleId IdType="pubmed">28564594</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma M, Naldini L. Transduction of a gene expression cassette using advanced generation lentiviral vectors. Meth Enzymol. 2002;346:514&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">11883088</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutner RH, Zhang X-Y, Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc. 2009;4:495&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">19300443</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, F K. The mouse brain in stereotaxic coordinates. Academic; 2004.</Citation></Reference><Reference><Citation>Kopec AM, Rivera PD, Lacagnina MJ, Hanamsagar R, Bilbo SD. Optimized solubilization of TRIzol-precipitated protein permits Western blotting analysis to maximize data available from brain tissue. J Neurosci Methods. 2017;280:64&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5392113</ArticleId><ArticleId IdType="pubmed">28192129</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter CJ, Luo L. Splinkerette PCR for mapping transposable elements in Drosophila. PLoS ONE. 2010;5:e10168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854151</ArticleId><ArticleId IdType="pubmed">20405015</ArticleId></ArticleIdList></Reference><Reference><Citation>Trabzuni D, et al. Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. J Neurochem. 2011;119:275&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664422</ArticleId><ArticleId IdType="pubmed">21848658</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoneley M, Paulin FE, Le Quesne JP, Chappell SA, Willis AE. C-Myc 5&#x2019; untranslated region contains an internal ribosome entry segment. Oncogene. 1998;16:423&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">9467968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraushar ML, et al. Temporally defined neocortical translation and polysome assembly are determined by the RNA-binding protein Hu antigen R. Proc Natl Acad Sci USA. 2014;111:E3815&#x2013;3824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4246959</ArticleId><ArticleId IdType="pubmed">25157170</ArticleId></ArticleIdList></Reference><Reference><Citation>McGlincy NJ, Ingolia NT. Transcriptome-wide measurement of translation by ribosome profiling. Methods. 2017;126:112&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5582988</ArticleId><ArticleId IdType="pubmed">28579404</ArticleId></ArticleIdList></Reference><Reference><Citation>Adiconis X, et al. Comparative analysis of RNA sequencing methods for degraded or low-input samples. Nat Methods. 2013;10:623&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821180</ArticleId><ArticleId IdType="pubmed">23685885</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazquez L, et al. Exon Junction Complex Shapes the Transcriptome by Repressing Recursive Splicing. Mol Cell. 2018;72:496&#x2013;509.:e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6224609</ArticleId><ArticleId IdType="pubmed">30388411</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet j. 2011;17:10.</Citation></Reference><Reference><Citation>Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith T, Heger A, Sudbery I. UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy. Genome Res. 2017;27:491&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340976</ArticleId><ArticleId IdType="pubmed">28100584</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Moll P, Ante M, Seitz A, Reda T. QuantSeq 3&#x2019; mRNA sequencing for RNA quantification. Nat Methods. 2014;11 i-iii.</Citation></Reference><Reference><Citation>Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832824</ArticleId><ArticleId IdType="pubmed">20110278</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham H. Ggplot2: elegant graphics for data analysis. Springer; 2009.</Citation></Reference><Reference><Citation>Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32:1792&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC390337</ArticleId><ArticleId IdType="pubmed">15034147</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. Jalview Version 2--a multiple sequence alignment editor and analysis workbench. Bioinformatics. 2009;25:1189&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2672624</ArticleId><ArticleId IdType="pubmed">19151095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MF, Jungreis I, Kellis M. PhyloCSF: a comparative genomics method to distinguish protein coding and non-coding regions. Bioinformatics. 2011;27:i275&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117341</ArticleId><ArticleId IdType="pubmed">21685081</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovcharenko I, Nobrega MA, Loots GG, Stubbs L. ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes. Nucleic Acids Res. 2004;32:W280&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC441493</ArticleId><ArticleId IdType="pubmed">15215395</ArticleId></ArticleIdList></Reference><Reference><Citation>Plessy C, et al. Linking promoters to functional transcripts in small samples with nanoCAGE and CAGEscan. Nat Methods. 2010;7:528&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906222</ArticleId><ArticleId IdType="pubmed">20543846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lizio M, et al. Gateways to the FANTOM5 promoter level mammalian expression atlas. Genome Biol. 2015;16:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310165</ArticleId><ArticleId IdType="pubmed">25723102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenz R, et al. ViennaRNA Package 2.0. Algorithms Mol Biol. 2011;6:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319429</ArticleId><ArticleId IdType="pubmed">22115189</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15:R29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053721</ArticleId><ArticleId IdType="pubmed">24485249</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32:2847&#x2013;2849.</Citation><ArticleIdList><ArticleId IdType="pubmed">27207943</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen EY, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637064</ArticleId><ArticleId IdType="pubmed">23586463</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Duncan D, Shi Z, Zhang B. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013;41:W77&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692109</ArticleId><ArticleId IdType="pubmed">23703215</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498&#x2013;2504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia J, Benner MJ, Hancock REW. NetworkAnalyst--integrative approaches for protein-protein interaction network analysis and visual exploration. Nucleic Acids Res. 2014;42:W167&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086107</ArticleId><ArticleId IdType="pubmed">24861621</ArticleId></ArticleIdList></Reference><Reference><Citation>Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31:3555&#x2013;3557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626747</ArticleId><ArticleId IdType="pubmed">26139635</ArticleId></ArticleIdList></Reference><Reference><Citation>Luisier R, et al. Intron retention and nuclear loss of SFPQ are molecular hallmarks of ALS. Nat Commun. 2018;9 2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964114</ArticleId><ArticleId IdType="pubmed">29789581</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisarev AV, Kolupaeva VG, Yusupov MM, Hellen CUT, Pestova TV. Ribosomal position and contacts of mRNA in eukaryotic translation initiation complexes. EMBO J. 2008;27:1609&#x2013;1621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2426728</ArticleId><ArticleId IdType="pubmed">18464793</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34021136</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>21</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Transcriptional signature in microglia associated with A&#x3b2; plaque phagocytosis.</ArticleTitle><Pagination><StartPage>3015</StartPage><MedlinePgn>3015</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3015</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-021-23111-1</ELocationID><Abstract><AbstractText>The role of microglia cells in Alzheimer's disease (AD) is well recognized, however their molecular and functional diversity remain unclear. Here, we isolated amyloid plaque-containing (using labelling with methoxy-XO4, XO4<sup>+</sup>) and non-containing (XO4<sup>-</sup>) microglia from an AD mouse model. Transcriptomics analysis identified different transcriptional trajectories in ageing and AD mice. XO4<sup>+</sup> microglial transcriptomes demonstrated dysregulated expression of genes associated with late onset AD. We further showed that the transcriptional program associated with XO4<sup>+</sup> microglia from mice is present in a subset of human microglia isolated from brains of individuals with AD. XO4<sup>-</sup> microglia displayed transcriptional signatures associated with accelerated ageing and contained more intracellular post-synaptic material than XO4<sup>+</sup> microglia, despite reduced active synaptosome phagocytosis. We identified HIF1&#x3b1; as potentially regulating synaptosome phagocytosis in vitro using primary human microglia, and BV2 mouse microglial cells. Together, these findings provide insight into molecular mechanisms underpinning the functional diversity of microglia in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Grubman</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4408-4499</Identifier><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia. alexandra.grubman@monash.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia. alexandra.grubman@monash.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia. alexandra.grubman@monash.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Choo</LastName><ForeName>Xin Yi</ForeName><Initials>XY</Initials><Identifier Source="ORCID">0000-0002-1783-0102</Identifier><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, The University of Melbourne, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chew</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, 169857, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouyang</LastName><ForeName>John F</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0002-1239-1577</Identifier><AffiliationInfo><Affiliation>Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, 169857, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Guizhi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croft</LastName><ForeName>Nathan P</ForeName><Initials>NP</Initials><Identifier Source="ORCID">0000-0002-2128-5127</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossello</LastName><ForeName>Fernando J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ARC Center of Excellence in Plant Energy Biology, The University of Western Australia, Perth, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Harry Perkins Institute of Medical Research, Perth, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckberry</LastName><ForeName>Sam</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2388-6046</Identifier><AffiliationInfo><Affiliation>ARC Center of Excellence in Plant Energy Biology, The University of Western Australia, Perth, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Harry Perkins Institute of Medical Research, Perth, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landin</LastName><ForeName>Dulce Vargas</ForeName><Initials>DV</Initials><Identifier Source="ORCID">0000-0002-4773-9406</Identifier><AffiliationInfo><Affiliation>ARC Center of Excellence in Plant Energy Biology, The University of Western Australia, Perth, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Harry Perkins Institute of Medical Research, Perth, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pflueger</LastName><ForeName>Jahnvi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>ARC Center of Excellence in Plant Energy Biology, The University of Western Australia, Perth, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Harry Perkins Institute of Medical Research, Perth, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandekolk</LastName><ForeName>Teresa H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abay</LastName><ForeName>Zehra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yichen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaodong</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-9315-3406</Identifier><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larcombe</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haynes</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Catriona</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Victorian Brain Bank, Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Siew Yeen</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Physiology, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Trevor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>MHTP Medical Genomics Facility, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lister</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-6637-7239</Identifier><AffiliationInfo><Affiliation>ARC Center of Excellence in Plant Energy Biology, The University of Western Australia, Perth, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Harry Perkins Institute of Medical Research, Perth, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pouton</LastName><ForeName>Colin W</ForeName><Initials>CW</Initials><Identifier Source="ORCID">0000-0003-0224-3308</Identifier><AffiliationInfo><Affiliation>Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purcell</LastName><ForeName>Anthony W</ForeName><Initials>AW</Initials><Identifier Source="ORCID">0000-0003-0532-8331</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rackham</LastName><ForeName>Owen J L</ForeName><Initials>OJL</Initials><Identifier Source="ORCID">0000-0002-4390-0872</Identifier><AffiliationInfo><Affiliation>Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, 169857, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petretto</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2163-5921</Identifier><AffiliationInfo><Affiliation>Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, 169857, Singapore, Singapore. enrico.petretto@duke-nus.edu.sg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polo</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-2531-778X</Identifier><AffiliationInfo><Affiliation>Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia. jose.polo@monash.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia. jose.polo@monash.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, Australia. jose.polo@monash.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497443">Hif1a protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051795" MajorTopicYN="N">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>O.J.L.R. and J.M.P. are co-founders and shareholders of Mogrify Ltd. A.G. is presently an employee of Biogen. Biogen had no influence in the design or execution of this study. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>22</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34021136</ArticleId><ArticleId IdType="pmc">PMC8140091</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-23111-1</ArticleId><ArticleId IdType="pii">10.1038/s41467-021-23111-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. Nat. Rev. Immunol. 2018;18:225&#x2013;242. doi: 10.1038/nri.2017.125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.125</ArticleId><ArticleId IdType="pubmed">29151590</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A, Kanninen KM, Malm T. Multitasking microglia and Alzheimer&#x2019;s disease: diversity, tools and therapeutic targets. J. Mol. Neurosci. 2016;60:390&#x2013;404. doi: 10.1007/s12031-016-0825-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-016-0825-5</ArticleId><ArticleId IdType="pubmed">27660215</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli RC, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333:1456&#x2013;1458. doi: 10.1126/science.1202529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1202529</ArticleId><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer&#x2019;s disease and mild cognitive impairment. Neurobiol. Aging. 2006;27:1372&#x2013;1384. doi: 10.1016/j.neurobiolaging.2005.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.09.012</ArticleId><ArticleId IdType="pubmed">16289476</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, et al. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;367. doi: 10.1016/S1474-4422(13)70044-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70044-9</ArticleId><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat. Genet. 2011;43:429&#x2013;435. doi: 10.1038/ng.803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.803</ArticleId><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjoneska E, et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer&#x2019;s disease. Nature. 2015;518:365&#x2013;369. doi: 10.1038/nature14252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14252</ArticleId><ArticleId IdType="pmc">PMC4530583</ArticleId><ArticleId IdType="pubmed">25693568</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, et al. TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 2013;368:117&#x2013;127. doi: 10.1056/NEJMoa1211851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat. Genet. 2011;43:436&#x2013;441. doi: 10.1038/ng.801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell. 2013;153:707&#x2013;720. doi: 10.1016/j.cell.2013.03.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.03.030</ArticleId><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB, et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat. Biotechnol. 2018;36:70&#x2013;80. doi: 10.1038/nbt.4038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4038</ArticleId><ArticleId IdType="pmc">PMC5951394</ArticleId><ArticleId IdType="pubmed">29227469</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin D, et al. An environment-dependent transcriptional network specifies human microglia identity. Science. 2017;356:eaal3222. doi: 10.1126/science.aal3222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aal3222</ArticleId><ArticleId IdType="pmc">PMC5858585</ArticleId><ArticleId IdType="pubmed">28546318</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290.e17. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566&#x2013;581.e9. doi: 10.1016/j.immuni.2017.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer&#x2019;s disease. J. Neurosci. 2017;37:637&#x2013;647. doi: 10.1523/JNEUROSCI.2110-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2110-16.2016</ArticleId><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071. doi: 10.1016/j.cell.2015.01.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J. Exp. Med. 2015;212:287&#x2013;295. doi: 10.1084/jem.20142322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142322</ArticleId><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;92:252&#x2013;264. doi: 10.1016/j.neuron.2016.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.016</ArticleId><ArticleId IdType="pubmed">27710785</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 2016;213:667&#x2013;675. doi: 10.1084/jem.20151948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S-H, et al. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 2011;286:32713&#x2013;32722. doi: 10.1074/jbc.M111.254268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.254268</ArticleId><ArticleId IdType="pmc">PMC3173153</ArticleId><ArticleId IdType="pubmed">21771791</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann M, et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer&#x2019;s disease. Nat. Neurosci. 2010;13:411&#x2013;413. doi: 10.1038/nn.2511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2511</ArticleId><ArticleId IdType="pmc">PMC4072212</ArticleId><ArticleId IdType="pubmed">20305648</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabert K, et al. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat. Neurosci. 2016;19:504&#x2013;516. doi: 10.1038/nn.4222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4222</ArticleId><ArticleId IdType="pmc">PMC4768346</ArticleId><ArticleId IdType="pubmed">26780511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayata P, et al. Epigenetic regulation of brain region-specific microglia clearance activity. Nat. Neurosci. 2018;21:1049&#x2013;1060. doi: 10.1038/s41593-018-0192-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0192-3</ArticleId><ArticleId IdType="pmc">PMC6090564</ArticleId><ArticleId IdType="pubmed">30038282</ArticleId></ArticleIdList></Reference><Reference><Citation>De Biase LM, et al. Local cues establish and maintain region-specific phenotypes of basal ganglia microglia. Neuron. 2017;95:341&#x2013;356.e6. doi: 10.1016/j.neuron.2017.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.06.020</ArticleId><ArticleId IdType="pmc">PMC5754189</ArticleId><ArticleId IdType="pubmed">28689984</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, et al. NLRP3 is activated in Alzheimer&#x2019;s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674&#x2013;678. doi: 10.1038/nature11729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11729</ArticleId><ArticleId IdType="pmc">PMC3812809</ArticleId><ArticleId IdType="pubmed">23254930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131:1630&#x2013;1645. doi: 10.1093/brain/awn016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn016</ArticleId><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimshony T, et al. CEL-Seq2: sensitive highly-multiplexed single-cell RNA-Seq. Genome Biol. 2016;17:77. doi: 10.1186/s13059-016-0938-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-016-0938-8</ArticleId><ArticleId IdType="pmc">PMC4848782</ArticleId><ArticleId IdType="pubmed">27121950</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron. 2016;91:328&#x2013;340. doi: 10.1016/j.neuron.2016.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.06.015</ArticleId><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips MC. Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB Life. 2014;66:616&#x2013;623. doi: 10.1002/iub.1314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iub.1314</ArticleId><ArticleId IdType="pubmed">25328986</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, et al. The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci. 2013;16:1896&#x2013;1905. doi: 10.1038/nn.3554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3554</ArticleId><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SS, et al. Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. J. Exp. Med. 2018;215:2235&#x2013;2245. doi: 10.1084/jem.20180653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180653</ArticleId><ArticleId IdType="pmc">PMC6122978</ArticleId><ArticleId IdType="pubmed">30082275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamphuis W, Kooijman L, Schetters S, Orre M, Hol EM. Transcriptional profiling of CD11c-positive microglia accumulating around amyloid plaques in a mouse model for Alzheimer&#x2019;s disease. Biochim. Biophys. Acta. 2016;1862:1847&#x2013;1860. doi: 10.1016/j.bbadis.2016.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2016.07.007</ArticleId><ArticleId IdType="pubmed">27425031</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman BA, et al. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer&#x2019;s disease not evident in mouse models. Cell Rep. 2018;22:832&#x2013;847. doi: 10.1016/j.celrep.2017.12.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.12.066</ArticleId><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillet LC, et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol. Cell. Proteomics. 2012;11:O111.016717. doi: 10.1074/mcp.O111.016717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.O111.016717</ArticleId><ArticleId IdType="pmc">PMC3433915</ArticleId><ArticleId IdType="pubmed">22261725</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA. 1985;82:4245&#x2013;4249. doi: 10.1073/pnas.82.12.4245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.82.12.4245</ArticleId><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, et al. Temporal tracking of microglia activation in neurodegeneration at single-cell resolution. Cell Rep. 2017;21:366&#x2013;380. doi: 10.1016/j.celrep.2017.09.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.09.039</ArticleId><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel A, et al. Brain structure. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. Science. 2015;347:1138&#x2013;1142. doi: 10.1126/science.aaa1934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa1934</ArticleId><ArticleId IdType="pubmed">25700174</ArticleId></ArticleIdList></Reference><Reference><Citation>Haimon Z, et al. Re-evaluating microglia expression profiles using RiboTag and cell isolation strategies. Nat. Immunol. 2018;19:636&#x2013;644. doi: 10.1038/s41590-018-0110-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-018-0110-6</ArticleId><ArticleId IdType="pmc">PMC5986066</ArticleId><ArticleId IdType="pubmed">29777220</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M, et al. A transcriptomic atlas of aged human microglia. Nat. Commun. 2018;9:539. doi: 10.1038/s41467-018-02926-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-02926-5</ArticleId><ArticleId IdType="pmc">PMC5803269</ArticleId><ArticleId IdType="pubmed">29416036</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiselev VY, et al. SC3: consensus clustering of single-cell RNA-seq data. Nat. Methods. 2017;14:483&#x2013;486. doi: 10.1038/nmeth.4236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4236</ArticleId><ArticleId IdType="pmc">PMC5410170</ArticleId><ArticleId IdType="pubmed">28346451</ArticleId></ArticleIdList></Reference><Reference><Citation>Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat. Immunol. 2005;6:551&#x2013;557. doi: 10.1038/ni1206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1206</ArticleId><ArticleId IdType="pubmed">15908936</ArticleId></ArticleIdList></Reference><Reference><Citation>Angerer P, et al. destiny: Diffusion maps for large-scale single-cell data in R. Bioinformatics. 2016;32:1241&#x2013;1243. doi: 10.1093/bioinformatics/btv715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btv715</ArticleId><ArticleId IdType="pubmed">26668002</ArticleId></ArticleIdList></Reference><Reference><Citation>Street K, et al. Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics. 2018;19:477. doi: 10.1186/s12864-018-4772-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-018-4772-0</ArticleId><ArticleId IdType="pmc">PMC6007078</ArticleId><ArticleId IdType="pubmed">29914354</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng, K. T. [[5&#x2b9;-(4-Hydroxyphenyl)[2,2&#x2019;-Bithiophen]-5-yl]Methylene]-Propanedinitrile NIAD-4. Molecular Imaging and Contrast Agent Database (MICAD) https://www.ncbi.nlm.nih.gov/books/NBK23215/ (National Center for Biotechnology Information (US), 2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">20641418</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712&#x2013;716. doi: 10.1126/science.aad8373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad8373</ArticleId><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli RC, et al. TDP-43 depletion in microglia promotes amyloid clearance but also induces synapse loss. Neuron. 2017;95:297&#x2013;308.e6. doi: 10.1016/j.neuron.2017.05.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.05.037</ArticleId><ArticleId IdType="pmc">PMC5519492</ArticleId><ArticleId IdType="pubmed">28669544</ArticleId></ArticleIdList></Reference><Reference><Citation>Halle A, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 2008;9:857&#x2013;865. doi: 10.1038/ni.1636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1636</ArticleId><ArticleId IdType="pmc">PMC3101478</ArticleId><ArticleId IdType="pubmed">18604209</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, et al. Oligomeric amyloid &#x3b2; associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl Acad. Sci. USA. 2009;106:4012&#x2013;4017. doi: 10.1073/pnas.0811698106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0811698106</ArticleId><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Aibar S, et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods. 2017;14:1083&#x2013;1086. doi: 10.1038/nmeth.4463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4463</ArticleId><ArticleId IdType="pmc">PMC5937676</ArticleId><ArticleId IdType="pubmed">28991892</ArticleId></ArticleIdList></Reference><Reference><Citation>Sande BVde, et al. A scalable SCENIC workflow for single-cell gene regulatory network analysis. Nat. Protoc. 2020;15:2247&#x2013;2276. doi: 10.1038/s41596-020-0336-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-020-0336-2</ArticleId><ArticleId IdType="pubmed">32561888</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med. 2020;26:131&#x2013;142. doi: 10.1038/s41591-019-0695-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0695-9</ArticleId><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature. 2019;570:332&#x2013;337. doi: 10.1038/s41586-019-1195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A, et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci. 2019;22:2087&#x2013;2097. doi: 10.1038/s41593-019-0539-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0539-4</ArticleId><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng, K. et al. Molecular characterization of selectively vulnerable neurons in Alzheimer&#x2019;s disease. Nat. Neurosci.&#xa0;24, 276&#x2013;287 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854528</ArticleId><ArticleId IdType="pubmed">33432193</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xe4;mer A, Green J, Pollard J, Jr, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics. 2014;30:523&#x2013;530. doi: 10.1093/bioinformatics/btt703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt703</ArticleId><ArticleId IdType="pmc">PMC3928520</ArticleId><ArticleId IdType="pubmed">24336805</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke RM, et al. BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA. 2013;110:19567&#x2013;19572. doi: 10.1073/pnas.1319297110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1319297110</ArticleId><ArticleId IdType="pmc">PMC3845152</ArticleId><ArticleId IdType="pubmed">24218590</ArticleId></ArticleIdList></Reference><Reference><Citation>Esen N, Kielian T. Central role for MyD88 in the responses of microglia to pathogen-associated molecular patterns. J. Immunol. 2006;176:6802&#x2013;6811. doi: 10.4049/jimmunol.176.11.6802.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.11.6802</ArticleId><ArticleId IdType="pmc">PMC2440502</ArticleId><ArticleId IdType="pubmed">16709840</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, et al. mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia. J. Immunol. 2014;192:6009&#x2013;6019. doi: 10.4049/jimmunol.1303492.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1303492</ArticleId><ArticleId IdType="pmc">PMC4128178</ArticleId><ArticleId IdType="pubmed">24829408</ArticleId></ArticleIdList></Reference><Reference><Citation>Abud EM, et al. iPSC-derived human microglia-like cells to study neurological diseases. Neuron. 2017;94:278&#x2013;293.e9. doi: 10.1016/j.neuron.2017.03.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.03.042</ArticleId><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A, et al. A CX3CR1 reporter hESC line facilitates integrative analysis of in-vitro-derived microglia and improved microglia identity upon neuron-glia co-culture. Stem Cell Reports. 2020;14:1018&#x2013;1032. doi: 10.1016/j.stemcr.2020.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2020.04.007</ArticleId><ArticleId IdType="pmc">PMC7355140</ArticleId><ArticleId IdType="pubmed">32442534</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, et al. Disease-associated microglia: a universal immune sensor of neurodegeneration. Cell. 2018;173:1073&#x2013;1081. doi: 10.1016/j.cell.2018.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.05.003</ArticleId><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatro TF, et al. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat. Neurosci. 2017;20:1162&#x2013;1171. doi: 10.1038/nn.4597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4597</ArticleId><ArticleId IdType="pubmed">28671693</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos-Alonso A, et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer&#x2019;s-like pathology. Brain. 2016;139:891&#x2013;907. doi: 10.1093/brain/awv379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv379</ArticleId><ArticleId IdType="pmc">PMC4766375</ArticleId><ArticleId IdType="pubmed">26747862</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006;26:10129&#x2013;10140. doi: 10.1523/JNEUROSCI.1202-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendeln A-C, et al. Innate immune memory in the brain shapes neurological disease hallmarks. Nature. 2018;556:332&#x2013;338. doi: 10.1038/s41586-018-0023-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0023-4</ArticleId><ArticleId IdType="pmc">PMC6038912</ArticleId><ArticleId IdType="pubmed">29643512</ArticleId></ArticleIdList></Reference><Reference><Citation>Baik SH, et al. A breakdown in metabolic reprogramming causes microglia dysfunction in Alzheimer&#x2019;s disease. Cell Metab. 2019;30:493&#x2013;507.e6. doi: 10.1016/j.cmet.2019.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2019.06.005</ArticleId><ArticleId IdType="pubmed">31257151</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Condello C, Schain A, Harb R, Grutzendler J. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-&#x3b2; phagocytosis. J. Neurosci. 2010;30:17091&#x2013;17101. doi: 10.1523/JNEUROSCI.4403-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4403-10.2010</ArticleId><ArticleId IdType="pmc">PMC3077120</ArticleId><ArticleId IdType="pubmed">21159979</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellwig S, et al. Forebrain microglia from wild-type but not adult 5xFAD mice prevent amyloid-&#x3b2; plaque formation in organotypic hippocampal slice cultures. Sci. Rep. 2015;5:14624. doi: 10.1038/srep14624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep14624</ArticleId><ArticleId IdType="pmc">PMC4586757</ArticleId><ArticleId IdType="pubmed">26416689</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinenga G, G&#xf6;tz J. Scanning ultrasound removes amyloid-&#x3b2; and restores memory in an Alzheimer&#x2019;s disease mouse model. Sci. Transl. Med. 2015;7:278ra33. doi: 10.1126/scitranslmed.aaa2512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaa2512</ArticleId><ArticleId IdType="pubmed">25761889</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu AKY, et al. IL-33 ameliorates Alzheimer&#x2019;s disease-like pathology and cognitive decline. Proc. Natl Acad. Sci. USA. 2016;113:E2705&#x2013;E2713. doi: 10.1073/pnas.1604032113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1604032113</ArticleId><ArticleId IdType="pmc">PMC4868478</ArticleId><ArticleId IdType="pubmed">27091974</ArticleId></ArticleIdList></Reference><Reference><Citation>Boza-Serrano A, et al. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer&#x2019;s disease. Acta Neuropathol. 2019;138:251&#x2013;273. doi: 10.1007/s00401-019-02013-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02013-z</ArticleId><ArticleId IdType="pmc">PMC6660511</ArticleId><ArticleId IdType="pubmed">31006066</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J-E, et al. MyD88 deficiency ameliorates &#x3b2;-amyloidosis in an animal model of Alzheimer&#x2019;s disease. Am. J. Pathol. 2011;179:1095&#x2013;1103. doi: 10.1016/j.ajpath.2011.05.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2011.05.045</ArticleId><ArticleId IdType="pmc">PMC3157279</ArticleId><ArticleId IdType="pubmed">21763676</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaud J-P, Richard KL, Rivest S. MyD88-adaptor protein acts as a preventive mechanism for memory deficits in a mouse model of Alzheimer&#x2019;s disease. Mol. Neurodegener. 2011;6:5. doi: 10.1186/1750-1326-6-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-5</ArticleId><ArticleId IdType="pmc">PMC3030527</ArticleId><ArticleId IdType="pubmed">21235801</ArticleId></ArticleIdList></Reference><Reference><Citation>Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM. Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of A&#x3b2; uptake and degradation by astrocytes. J. Biol. Chem. 2012;287:13959&#x2013;13971. doi: 10.1074/jbc.M111.288746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.288746</ArticleId><ArticleId IdType="pmc">PMC3340151</ArticleId><ArticleId IdType="pubmed">22383525</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao H, et al. &#x391;-synuclein induces microglial cell migration through stimulating HIF-1&#x3b1; accumulation. J. Neurosci. Res. 2017;95:1809&#x2013;1817. doi: 10.1002/jnr.24012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.24012</ArticleId><ArticleId IdType="pubmed">28134982</ArticleId></ArticleIdList></Reference><Reference><Citation>Cougnoux A, et al. Unique molecular signature in mucolipidosis type IV microglia. J. Neuroinflammation. 2019;16:276. doi: 10.1186/s12974-019-1672-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1672-4</ArticleId><ArticleId IdType="pmc">PMC6935239</ArticleId><ArticleId IdType="pubmed">31883529</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 2013;4:385&#x2013;401. doi: 10.1016/j.celrep.2013.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.06.018</ArticleId><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Bader JM, et al. Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer&#x2019;s disease. Mol. Syst. Biol. 2020;16:e9356. doi: 10.15252/msb.20199356.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/msb.20199356</ArticleId><ArticleId IdType="pmc">PMC7266499</ArticleId><ArticleId IdType="pubmed">32485097</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathe G, et al. Quantitative proteomic profiling of cerebrospinal fluid to identify candidate biomarkers for Alzheimer&#x2019;s disease. Proteom. Clin. Appl. 2019;13:e1800105. doi: 10.1002/prca.201800105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prca.201800105</ArticleId><ArticleId IdType="pmc">PMC6639119</ArticleId><ArticleId IdType="pubmed">30578620</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona AE, Huang D, Sasse ME, Ransohoff RM. Isolation of murine microglial cells for RNA analysis or flow cytometry. Nat. Protoc. 2006;1:1947&#x2013;1951. doi: 10.1038/nprot.2006.327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.327</ArticleId><ArticleId IdType="pubmed">17487181</ArticleId></ArticleIdList></Reference><Reference><Citation>Amir E-AD, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat. Biotechnol. 2013;31:545&#x2013;552. doi: 10.1038/nbt.2594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2594</ArticleId><ArticleId IdType="pmc">PMC4076922</ArticleId><ArticleId IdType="pubmed">23685480</ArticleId></ArticleIdList></Reference><Reference><Citation>Girardot C, Scholtalbers J, Sauer S, Su S-Y, Furlong EEM. Je, a versatile suite to handle multiplexed NGS libraries with unique molecular identifiers. BMC Bioinformatics. 2016;17:419. doi: 10.1186/s12859-016-1284-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-016-1284-2</ArticleId><ArticleId IdType="pmc">PMC5055726</ArticleId><ArticleId IdType="pubmed">27717304</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmieder R, Edwards R. Quality control and preprocessing of metagenomic datasets. Bioinformatics. 2011;27:863&#x2013;864. doi: 10.1093/bioinformatics/btr026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btr026</ArticleId><ArticleId IdType="pmc">PMC3051327</ArticleId><ArticleId IdType="pubmed">21278185</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114&#x2013;2120. doi: 10.1093/bioinformatics/btu170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu170</ArticleId><ArticleId IdType="pmc">PMC4103590</ArticleId><ArticleId IdType="pubmed">24695404</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15&#x2013;21. doi: 10.1093/bioinformatics/bts635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923&#x2013;930. doi: 10.1093/bioinformatics/btt656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt656</ArticleId><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsyganov K, James Perry A, Kenneth Archer S, Powell D. RNAsik: a pipeline for complete and reproducible RNA-seq analysis that runs anywhere with speed and ease. J. Open Source Softw. 2018;3:583. doi: 10.21105/joss.00583.</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.00583</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimand J, et al. g:Profiler-a web server for functional interpretation of gene lists (2016 update) Nucleic Acids Res. 2016;44:W83&#x2013;W89. doi: 10.1093/nar/gkw199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw199</ArticleId><ArticleId IdType="pmc">PMC4987867</ArticleId><ArticleId IdType="pubmed">27098042</ArticleId></ArticleIdList></Reference><Reference><Citation>Rackham OJL, et al. A predictive computational framework for direct reprogramming between human cell types. Nat. Genet. 2016;48:331&#x2013;335. doi: 10.1038/ng.3487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3487</ArticleId><ArticleId IdType="pubmed">26780608</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, et al. limma Powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi: 10.1093/nar/gkv007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Boutros PC. VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinformatics. 2011;12:35. doi: 10.1186/1471-2105-12-35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-35</ArticleId><ArticleId IdType="pmc">PMC3041657</ArticleId><ArticleId IdType="pubmed">21269502</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284&#x2013;287. doi: 10.1089/omi.2011.0118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2011.0118</ArticleId><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson, M., Falcon, S., Pages, H. &amp; Li, N. org. Mm. eg. db: Genome Wide Annotation for Mouse (Bioconductor, 2015).</Citation></Reference><Reference><Citation>Zheng GXY, et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 2017;8:14049. doi: 10.1038/ncomms14049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms14049</ArticleId><ArticleId IdType="pmc">PMC5241818</ArticleId><ArticleId IdType="pubmed">28091601</ArticleId></ArticleIdList></Reference><Reference><Citation>Scialdone A, et al. Computational assignment of cell-cycle stage from single-cell transcriptome data. Methods. 2015;85:54&#x2013;61. doi: 10.1016/j.ymeth.2015.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2015.06.021</ArticleId><ArticleId IdType="pubmed">26142758</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy DJ, Campbell KR, Lun ATL, Wills QF. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics. 2017;33:1179&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408845</ArticleId><ArticleId IdType="pubmed">28088763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun ATL, McCarthy DJ, Marioni JC. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res. 2016;5:2122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5112579</ArticleId><ArticleId IdType="pubmed">27909575</ArticleId></ArticleIdList></Reference><Reference><Citation>Amezquita RA, et al. Orchestrating single-cell analysis with Bioconductor. Nat. Methods. 2020;17:137&#x2013;145. doi: 10.1038/s41592-019-0654-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0654-x</ArticleId><ArticleId IdType="pmc">PMC7358058</ArticleId><ArticleId IdType="pubmed">31792435</ArticleId></ArticleIdList></Reference><Reference><Citation>Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 2015;33:495&#x2013;502. doi: 10.1038/nbt.3192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3192</ArticleId><ArticleId IdType="pmc">PMC4430369</ArticleId><ArticleId IdType="pubmed">25867923</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews, T. S. &amp; Hemberg, M. M3Drop: dropout-based feature selection for scRNASeq. Bioinformatics35, 2865&#x2013;2867 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6691329</ArticleId><ArticleId IdType="pubmed">30590489</ArticleId></ArticleIdList></Reference><Reference><Citation>Scrucca L, Fop M, Murphy TB, Raftery AE. mclust 5: Clustering, classification and density estimation using Gaussian finite mixture models. R. J. 2016;8:289&#x2013;317. doi: 10.32614/RJ-2016-021.</Citation><ArticleIdList><ArticleId IdType="doi">10.32614/RJ-2016-021</ArticleId><ArticleId IdType="pmc">PMC5096736</ArticleId><ArticleId IdType="pubmed">27818791</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham, H. ggplot2. Wiley Interdisciplinary Reviews: Computational Statistics3, 180&#x2013;185 (2011).</Citation></Reference><Reference><Citation>Kolde, R. Pheatmap: Pretty Heatmaps. R package version 1 (2012).</Citation></Reference><Reference><Citation>Wickham H. Reshaping data with the reshape package. J. Stat. Softw. 2007;21:1&#x2013;20. doi: 10.18637/jss.v021.i12.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v021.i12</ArticleId></ArticleIdList></Reference><Reference><Citation>Categorical Scatter (Violin Point) Plots [R package ggbeeswarm version 0.6.0] (2017).</Citation></Reference><Reference><Citation>Csardi G, Nepusz T. The igraph software package for complex network research. Int. J. Complex Syst. 2006;1695:1&#x2013;9.</Citation></Reference><Reference><Citation>Read Excel Files [R package readxl version 1.3.1] (2019).</Citation></Reference><Reference><Citation>A Forward-Pipe Operator for R [R package magrittr version 2.0.1] (2020).</Citation></Reference><Reference><Citation>Wickham, H., Fran&#xe7;ois, R., Henry, L. &amp; M&#xfc;ller, K. dplyr: A grammar of data manipulation. Retrieved from https://CRAN.R-project.org/package=dplyr (2019a).</Citation></Reference><Reference><Citation>Neuwirth, E. ColorBrewer Palettes [R package RColorBrewer version 1.1-2]. (2014).</Citation></Reference><Reference><Citation>Bengtsson, H., Bengtsson, M. H. &amp; LazyLoad, T. Package &#x2018;R. utils&#x2019; (2020).</Citation></Reference><Reference><Citation>Slowikowski, K. Automatically Position Non-Overlapping Text Labels with &#x2018;ggplot2&#x2019; [R package ggrepel version 0.9.1] (2021).</Citation></Reference><Reference><Citation>Auguie, B. Miscellaneous Functions for &#x2018;Grid&#x2019; Graphics [R package gridExtra version 2.3] (2017).</Citation></Reference><Reference><Citation>Arnold, J. B. Extra Themes, Scales and Geoms for &#x2018;ggplot2&#x2019; [R package ggthemes version 4.2.4] (2021).</Citation></Reference><Reference><Citation>Douglas, B. &amp; Martin, M. Matrix: Sparse and Dense Matrix Classes and Methods [R package Matrix version 1.3-2] (2021).</Citation></Reference><Reference><Citation>Huber W. Orchestrating high-throughput genomic analysis with Bioconductor. Nat. Methods. 2015;12:115&#x2013;121. doi: 10.1038/nmeth.3252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3252</ArticleId><ArticleId IdType="pmc">PMC4509590</ArticleId><ArticleId IdType="pubmed">25633503</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengtsson, H. matrixStats: Functions that Apply to Rows and Columns of Matrices (and to Vectors) [R Package version 0.52. 2] (2017).</Citation></Reference><Reference><Citation>Wickham, H. scale: Scale Functions for Visualization [R package scales version 1.1.1] (2020).</Citation></Reference><Reference><Citation>Turner, S. annotables (Github). https://github.com/stephenturner/annotables (2019). Accessed on Jan 1, 2020.</Citation></Reference><Reference><Citation>Warnes, G. R. et al. gplots: Various R programming tools for plotting data.&#xa0;[R package version 2, no. 4] (2009).</Citation></Reference><Reference><Citation> Bolstad, B. preprocessCore: A collection of pre-processing functions. R package version 1.52.1, https://github.com/bmbolstad/preprocessCore (2021).</Citation></Reference><Reference><Citation>Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS ONE. 2010;5:e13984. doi: 10.1371/journal.pone.0013984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013984</ArticleId><ArticleId IdType="pmc">PMC2981572</ArticleId><ArticleId IdType="pubmed">21085593</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson, M. org. Hs. eg. db: Genome Wide Annotation for Human [R package version 3.2. 3] (Bioconductor, 2019).</Citation></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139&#x2013;140. doi: 10.1093/bioinformatics/btp616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell KR, Yau C. A descriptive marker gene approach to single-cell pseudotime inference. Bioinformatics. 2019;35:28&#x2013;35. doi: 10.1093/bioinformatics/bty498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty498</ArticleId><ArticleId IdType="pmc">PMC6298060</ArticleId><ArticleId IdType="pubmed">29939207</ArticleId></ArticleIdList></Reference><Reference><Citation>Bais AS, Kostka D. scds: Computational annotation of doublets in single cell RNA sequencing data. Bioinformatics. 2020;36:1150&#x2013;1158. doi: 10.1093/bioinformatics/btz698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz698</ArticleId><ArticleId IdType="pmc">PMC7703774</ArticleId><ArticleId IdType="pubmed">31501871</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang L-G, Yan G-R, He Q-Y. DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis. Bioinformatics. 2015;31:608&#x2013;609. doi: 10.1093/bioinformatics/btu684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu684</ArticleId><ArticleId IdType="pubmed">25677125</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie AT, et al. Brain cell type specific gene expression and co-expression network architectures. Sci. Rep. 2018;8:8868. doi: 10.1038/s41598-018-27293-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-27293-5</ArticleId><ArticleId IdType="pmc">PMC5995803</ArticleId><ArticleId IdType="pubmed">29892006</ArticleId></ArticleIdList></Reference><Reference><Citation>Durinck S, et al. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics. 2005;21:3439&#x2013;3440. doi: 10.1093/bioinformatics/bti525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bti525</ArticleId><ArticleId IdType="pubmed">16082012</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahlmann-Eltze, C. Significance Brackets for &#x2018;ggplot2&#x2019; [R package ggsignif version 0.6.0] (2019).</Citation></Reference><Reference><Citation>Kassambara, A. Pipe-Friendly Framework for Basic Statistical Tests [R package rstatix version 0.6.0] (2020).</Citation></Reference><Reference><Citation>Kassambara, A. &#x2018;ggplot2&#x2019; Based Publication Ready Plots [R package ggpubr version 0.4.0] (2020).</Citation></Reference><Reference><Citation>Langfelder P, Horvath S. Fast R functions for robust correlations and hierarchical clustering. J. Stat. Softw. 2012;46:i11. doi: 10.18637/jss.v046.i11.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v046.i11</ArticleId><ArticleId IdType="pmc">PMC3465711</ArticleId><ArticleId IdType="pubmed">23050260</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nat. Genet. 2017;49:708&#x2013;718. doi: 10.1038/ng.3818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3818</ArticleId><ArticleId IdType="pubmed">28319088</ArticleId></ArticleIdList></Reference><Reference><Citation>Escher C, et al. Using iRT, a normalized retention time for more targeted measurement of peptides. Proteomics. 2012;12:1111&#x2013;1121. doi: 10.1002/pmic.201100463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.201100463</ArticleId><ArticleId IdType="pmc">PMC3918884</ArticleId><ArticleId IdType="pubmed">22577012</ArticleId></ArticleIdList></Reference><Reference><Citation>Illing PT, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012;486:554&#x2013;558. doi: 10.1038/nature11147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11147</ArticleId><ArticleId IdType="pubmed">22722860</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLean B, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010;26:966&#x2013;968. doi: 10.1093/bioinformatics/btq054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq054</ArticleId><ArticleId IdType="pmc">PMC2844992</ArticleId><ArticleId IdType="pubmed">20147306</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogolla N, Galimberti I, DePaola V, Caroni P. Preparation of organotypic hippocampal slice cultures for long-term live imaging. Nat. Protoc. 2006;1:1165&#x2013;1171. doi: 10.1038/nprot.2006.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.168</ArticleId><ArticleId IdType="pubmed">17406399</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlen CJ, et al. Diverse requirements for microglial survival, specification, and function revealed by defined-medium cultures. Neuron. 2017;94:759&#x2013;773.e8. doi: 10.1016/j.neuron.2017.04.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.04.043</ArticleId><ArticleId IdType="pmc">PMC5523817</ArticleId><ArticleId IdType="pubmed">28521131</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A, et al. Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol. Neurodegener. 2018;13:67. doi: 10.1186/s13024-018-0297-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0297-x</ArticleId><ArticleId IdType="pmc">PMC6303871</ArticleId><ArticleId IdType="pubmed">30577865</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb C, Wolock S, Klein AM. SPRING: a kinetic interface for visualizing high dimensional single-cell expression data. Bioinformatics. 2018;34:1246&#x2013;1248. doi: 10.1093/bioinformatics/btx792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btx792</ArticleId><ArticleId IdType="pmc">PMC6030950</ArticleId><ArticleId IdType="pubmed">29228172</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewey, M. Meta-Analysis of Significance Values [R package metap version 1.4] (2020).</Citation></Reference><Reference><Citation>Lehrman EK, et al. CD47 protects synapses from excess microglia-mediated pruning during development. Neuron. 2018;100:120&#x2013;134.e6. doi: 10.1016/j.neuron.2018.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.09.017</ArticleId><ArticleId IdType="pmc">PMC6314207</ArticleId><ArticleId IdType="pubmed">30308165</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34020948</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>21</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Aging-associated deficit in CCR7 is linked to worsened glymphatic function, cognition, neuroinflammation, and &#x3b2;-amyloid pathology.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eabe4601</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abe4601</ELocationID><Abstract><AbstractText>Aging leads to a progressive deterioration of meningeal lymphatics and peripheral immunity, which may accelerate cognitive decline. We hypothesized that an age-related reduction in C-C chemokine receptor type 7 (CCR7)-dependent egress of immune cells through the lymphatic vasculature mediates some aspects of brain aging and potentially exacerbates cognitive decline and Alzheimer's disease-like brain &#x3b2;-amyloid (A&#x3b2;) pathology. We report a reduction in CCR7 expression by meningeal T cells in old mice that is linked to increased effector and regulatory T cells. Hematopoietic CCR7 deficiency mimicked the aging-associated changes in meningeal T cells and led to reduced glymphatic influx and cognitive impairment. Deletion of CCR7 in 5xFAD transgenic mice resulted in deleterious neurovascular and microglial activation, along with increased A&#x3b2; deposition in the brain. Treating old mice with anti-CD25 antibodies alleviated the exacerbated meningeal regulatory T cell response and improved cognitive function, highlighting the therapeutic potential of modulating meningeal immunity to fine-tune brain function in aging and in neurodegenerative diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Da Mesquita</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0786-5010</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA. damesquita@mayo.edu kipnis@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herz</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wall</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dykstra</LastName><ForeName>Taitea</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lima</LastName><ForeName>Kalil Alves</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0002-9149-168X</Identifier><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norris</LastName><ForeName>Geoffrey T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Department of Immunology, University of Washington, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabhi</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7681-2150</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7600-9499</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kipnis</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3714-517X</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Brain Immunology and Glia (BIG), University of Virginia, Charlottesville, VA, USA. damesquita@mayo.edu kipnis@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Brain Immunology and Glia (BIG), Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG034113</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG034113</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057496</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>22</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34020948</ArticleId><ArticleId IdType="pmc">PMC8139596</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abe4601</ArticleId><ArticleId IdType="pii">7/21/eabe4601</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Erkkinen M. G., Kim M. O., Geschwind M. D., Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb. Perspect. Biol. 10, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5880171</ArticleId><ArticleId IdType="pubmed">28716886</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R., Abdalla N., Kawas C. H., Corrada M. M., Forecasting the prevalence of preclinical and clinical Alzheimer&#x2019;s disease in the United States. Alzheimers Dement. 14, 121&#x2013;129 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5803316</ArticleId><ArticleId IdType="pubmed">29233480</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C. R. Jr., Bennett D. A., Blennow K., Carrillo M. C., Dunn B., Haeberlein S. B., Holtzman D. M., Jagust W., Jessen F., Karlawish J., Liu E., Molinuevo J. L., Montine T., Phelps C., Rankin K. P., Rowe C. C., Scheltens P., Siemers E., Snyder H. M., Sperling R.; Contributors , NIA-AA research framework: Toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M., Mangialasche F., Ngandu T., Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat. Rev. Neurol. 14, 653&#x2013;666 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30291317</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza F., Lozupone M., Logroscino G., Imbimbo B. P., A critical appraisal of amyloid-&#x3b2;-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 15, 73&#x2013;88 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30610216</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj A. C., Jun G., Beecham G. W., Wang L. S., Vardarajan B. N., Buros J., Gallins P. J., Buxbaum J. D., Jarvik G. P., Crane P. K., Larson E. B., Bird T. D., Boeve B. F., Graff-Radford N. R., De Jager P. L., Evans D., Schneider J. A., Carrasquillo M. M., Ertekin-Taner N., Younkin S. G., Cruchaga C., Kauwe J. S., Nowotny P., Kramer P., Hardy J., Huentelman M. J., Myers A. J., Barmada M. M., Demirci F. Y., Baldwin C. T., Green R. C., Rogaeva E., George-Hyslop P. S., Arnold S. E., Barber R., Beach T., Bigio E. H., Bowen J. D., Boxer A., Burke J. R., Cairns N. J., Carlson C. S., Carney R. M., Carroll S. L., Chui H. C., Clark D. G., Corneveaux J., Cotman C. W., Cummings J. L., DeCarli C., DeKosky S. T., Diaz-Arrastia R., Dick M., Dickson D. W., Ellis W. G., Faber K. M., Fallon K. B., Farlow M. R., Ferris S., Frosch M. P., Galasko D. R., Ganguli M., Gearing M., Geschwind D. H., Ghetti B., Gilbert J. R., Gilman S., Giordani B., Glass J. D., Growdon J. H., Hamilton R. L., Harrell L. E., Head E., Honig L. S., Hulette C. M., Hyman B. T., Jicha G. A., Jin L. W., Johnson N., Karlawish J., Karydas A., Kaye J. A., Kim R., Koo E. H., Kowall N. W., Lah J. J., Levey A. I., Lieberman A. P., Lopez O. L., Mack W. J., Marson D. C., Martiniuk F., Mash D. C., Masliah E., McCormick W. C., McCurry S. M., McDavid A. N., McKee A. C., Mesulam M., Miller B. L., Miller C. A., Miller J. W., Parisi J. E., Perl D. P., Peskind E., Petersen R. C., Poon W. W., Quinn J. F., Rajbhandary R. A., Raskind M., Reisberg B., Ringman J. M., Roberson E. D., Rosenberg R. N., Sano M., Schneider L. S., Seeley W., Shelanski M. L., Slifer M. A., Smith C. D., Sonnen J. A., Spina S., Stern R. A., Tanzi R. E., Trojanowski J. Q., Troncoso J. C., Van Deerlin V. M., Vinters H. V., Vonsattel J. P., Weintraub S., Welsh-Bohmer K. A., Williamson J., Woltjer R. L., Cantwell L. B., Dombroski B. A., Beekly D., Lunetta K. L., Martin E. R., Kamboh M. I., Saykin A. J., Reiman E. M., Bennett D. A., Morris J. C., Montine T. J., Goate A. M., Blacker D., Tsuang D. W., Hakonarson H., Kukull W. A., Foroud T. M., Haines J. L., Mayeux R., Pericak-Vance M. A., Farrer L. A., Schellenberg G. D., Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat. Genet. 43, 436&#x2013;441 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J. S., Younkin S., Hazrati L., Collinge J., Pocock J., Lashley T., Williams J., Lambert J. C., Amouyel P., Goate A., Rademakers R., Morgan K., Powell J., St George-Hyslop P., Singleton A., Hardy J.; Alzheimer Genetic Analysis Group , TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 368, 117&#x2013;127 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K., Rosenzweig N., Kertser A., Deczkowska A., Sharif A. M., Spinrad A., Tsitsou-Kampeli A., Sarel A., Cahalon L., Schwartz M., Breaking immune tolerance by targeting Foxp3+ regulatory T cells mitigates Alzheimer&#x2019;s disease pathology. Nat. Commun. 6, 7967 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4557123</ArticleId><ArticleId IdType="pubmed">26284939</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Cella M., Mallinson K., Ulrich J. D., Young K. L., Robinette M. L., Gilfillan S., Krishnan G. M., Sudhakar S., Zinselmeyer B. H., Holtzman D. M., Cirrito J. R., Colonna M., TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K., Deczkowska A., Rosenzweig N., Tsitsou-Kampeli A., Sharif A. M., Matcovitch-Natan O., Kertser A., David E., Amit I., Schwartz M., PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer&#x2019;s disease. Nat. Med. 22, 135&#x2013;137 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26779813</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T. K., David E., Baruch K., Lara-Astaiso D., Toth B., Itzkovitz S., Colonna M., Schwartz M., Amit I., A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S., Madore C., Cialic R., Baufeld C., Calcagno N., El Fatimy R., Beckers L., O&#x2019;Loughlin E., Xu Y., Fanek Z., Greco D. J., Smith S. T., Tweet G., Humulock Z., Zrzavy T., Conde-Sanroman P., Gacias M., Weng Z., Chen H., Tjon E., Mazaheri F., Hartmann K., Madi A., Ulrich J. D., Glatzel M., Worthmann A., Heeren J., Budnik B., Lemere C., Ikezu T., Heppner F. L., Litvak V., Holtzman D. M., Lassmann H., Weiner H. L., Ochando J., Haass C., Butovsky O., The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566&#x2013;581.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Holtzman D. M., Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol. 18, 759&#x2013;772 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425488</ArticleId><ArticleId IdType="pubmed">30140051</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrdjen D., Pavlovic A., Hartmann F. J., Schreiner B., Utz S. G., Leung B. P., Lelios I., Heppner F. L., Kipnis J., Merkler D., Greter M., Becher B., High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity 48, 599 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29562204</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Manis M., Long J., Wang K., Sullivan P. M., Remolina Serrano J., Hoyle R., Holtzman D. M., Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J. Exp. Med. 216, 2546&#x2013;2561 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano A. J., Gadani S. P., Kipnis J., How and why do T cells and their derived cytokines affect the injured and healthy brain? Nat. Rev. Neurosci. 18, 375&#x2013;384 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5823005</ArticleId><ArticleId IdType="pubmed">28446786</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S., Fu Z., Kipnis J., The meningeal lymphatic system: A new player in neurophysiology. Neuron 100, 375&#x2013;388 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6268162</ArticleId><ArticleId IdType="pubmed">30359603</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves de Lima K., Rustenhoven J., Kipnis J., Meningeal immunity and its function in maintenance of the central nervous system in health and disease. Annu. Rev. Immunol. 38, 597&#x2013;620 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32340575</ArticleId></ArticleIdList></Reference><Reference><Citation>Derecki N. C., Cardani A. N., Yang C. H., Quinnies K. M., Crihfield A., Lynch K. R., Kipnis J., Regulation of learning and memory by meningeal immunity: A key role for IL-4. J. Exp. Med. 207, 1067&#x2013;1080 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867291</ArticleId><ArticleId IdType="pubmed">20439540</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh J. T., Hendrix S., Boato F., Smirnov I., Zheng J., Lukens J. R., Gadani S., Hechler D., Golz G., Rosenberger K., Kammertons T., Vogt J., Vogelaar C., Siffrin V., Radjavi A., Fernandez-Castaneda A., Gaultier A., Gold R., Kanneganti T. D., Nitsch R., Zipp F., Kipnis J., MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4. J. Clin. Invest. 125, 699&#x2013;714 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4319416</ArticleId><ArticleId IdType="pubmed">25607842</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadani S. P., Smirnov I., Smith A. T., Overall C. C., Kipnis J., Characterization of meningeal type 2 innate lymphocytes and their response to CNS injury. J. Exp. Med. 214, 285&#x2013;296 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5294864</ArticleId><ArticleId IdType="pubmed">27994070</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano A. J., Xu Y., Tustison N. J., Marsh R. L., Baker W., Smirnov I., Overall C. C., Gadani S. P., Turner S. D., Weng Z., Peerzade S. N., Chen H., Lee K. S., Scott M. M., Beenhakker M. P., Litvak V., Kipnis J., Unexpected role of interferon-&#x3b3; in regulating neuronal connectivity and social behaviour. Nature 535, 425&#x2013;429 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961620</ArticleId><ArticleId IdType="pubmed">27409813</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A., Herz J., Alme M. N., Salvador A. F., Dong M. Q., Viar K. E., Herod S. G., Knopp J., Setliff J. C., Lupi A. L., Da Mesquita S., Frost E. L., Gaultier A., Harris T. H., Cao R., Hu S., Lukens J. R., Smirnov I., Overall C. C., Oliver G., Kipnis J., CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat. Neurosci. 21, 1380&#x2013;1391 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6214619</ArticleId><ArticleId IdType="pubmed">30224810</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogelaar C. F., Mandal S., Lerch S., Birkner K., Birkenstock J., Buhler U., Schnatz A., Raine C. S., Bittner S., Vogt J., Kipnis J., Nitsch R., Zipp F., Fast direct neuronal signaling via the IL-4 receptor as therapeutic target in neuroinflammation. Sci. Transl. Med. 10, eaao2304 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29491183</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves de Lima K., Rustenhoven J., Da Mesquita S., Wall M., Salvador A., Smirnov I., Cebinelli G. M., Mamuladze T., Baker W., Papadopoulos Z., Lopes B., Cao W., Xie X., Herz J., Kipnis J., Meningeal &#x3b3;&#x3b4; T cells regulate anxiety-like behavior via IL-17a signaling in neurons. Nat. Immunol. 21, 1421&#x2013;1429 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8496952</ArticleId><ArticleId IdType="pubmed">32929273</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A., Smirnov I., Keyes T. J., Eccles J. D., Rouhani S. J., Peske J. D., Derecki N. C., Castle D., Mandell J. W., Lee K. S., Harris T. H., Kipnis J., Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337&#x2013;341 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4506234</ArticleId><ArticleId IdType="pubmed">26030524</ArticleId></ArticleIdList></Reference><Reference><Citation>Aspelund A., Antila S., Proulx S. T., Karlsen T. V., Karaman S., Detmar M., Wiig H., Alitalo K., A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212, 991&#x2013;999 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493418</ArticleId><ArticleId IdType="pubmed">26077718</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S., Louveau A., Vaccari A., Smirnov I., Cornelison R. C., Kingsmore K. M., Contarino C., Onengut-Gumuscu S., Farber E., Raper D., Viar K. E., Powell R. D., Baker W., Dabhi N., Bai R., Cao R., Hu S., Rich S. S., Munson J. M., Lopes M. B., Overall C. C., Acton S. T., Kipnis J., Functional aspects of meningeal lymphatics in ageing and Alzheimer&#x2019;s disease. Nature 560, 185&#x2013;191 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6085146</ArticleId><ArticleId IdType="pubmed">30046111</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw A. C., Goldstein D. R., Montgomery R. R., Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 13, 875&#x2013;887 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4096436</ArticleId><ArticleId IdType="pubmed">24157572</ArticleId></ArticleIdList></Reference><Reference><Citation>Goronzy J. J., Weyand C. M., Mechanisms underlying T cell ageing. Nat. Rev. Immunol. 19, 573&#x2013;583 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7584388</ArticleId><ArticleId IdType="pubmed">31186548</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh S. E., Abud E. M., Lakatos A., Karimzadeh A., Yeung S. T., Davtyan H., Fote G. M., Lau L., Weinger J. G., Lane T. E., Inlay M. A., Poon W. W., Blurton-Jones M., The adaptive immune system restrains Alzheimer&#x2019;s disease pathogenesis by modulating microglial function. Proc. Natl. Acad. Sci. U.S.A. 113, E1316&#x2013;E1325 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780638</ArticleId><ArticleId IdType="pubmed">26884167</ArticleId></ArticleIdList></Reference><Reference><Citation>Spani C., Suter T., Derungs R., Ferretti M. T., Welt T., Wirth F., Gericke C., Nitsch R. M., Kulic L., Reduced &#x3b2;-amyloid pathology in an APP transgenic mouse model of Alzheimer&#x2019;s disease lacking functional B and T cells. Acta Neuropathol. Commun. 3, 71 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4642668</ArticleId><ArticleId IdType="pubmed">26558367</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A., Da Mesquita S., Kipnis J., Lymphatics in neurological disorders: A neuro-lympho-vascular component of multiple sclerosis and Alzheimer&#x2019;s disease? Neuron 91, 957&#x2013;973 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5019121</ArticleId><ArticleId IdType="pubmed">27608759</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustenhoven J., Drieu A., Mamuladze T., Alves de Lima K., Dykstra T., Wall M., Papadopoulos Z., Kanamori M., Salvador A. F., Baker W., Lemieux M., Da Mesquita S., Cugurra A., Fitzpatrick J., Sviben S., Kossina R., Bayguinov P., Townsend R., Smirnov I., Lopes M. B., Herz J., Kipnis J., Functional characterization of the dural sinuses as a neuroimmune interface. Cell 184, 1000&#x2013;1016.e27 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8487654</ArticleId><ArticleId IdType="pubmed">33508229</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S., Dominguez A. L., Lustgarten J., High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J. Immunol. 177, 8348&#x2013;8355 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17142731</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipnis J., Cohen H., Cardon M., Ziv Y., Schwartz M., T cell deficiency leads to cognitive dysfunction: Implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc. Natl. Acad. Sci. U.S.A. 101, 8180&#x2013;8185 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419577</ArticleId><ArticleId IdType="pubmed">15141078</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaehne E. J., Baune B. T., Effects of chemokine receptor signalling on cognition-like, emotion-like and sociability behaviours of CCR6 and CCR7 knockout mice. Behav. Brain Res. 261, 31&#x2013;39 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24333375</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestre H., Hablitz L. M., Xavier A. L., Feng W., Zou W., Pu T., Monai H., Murlidharan G., Castellanos Rivera R. M., Simon M. J., Pike M. M., Pla V., Du T., Kress B. T., Wang X., Plog B. A., Thrane A. S., Lundgaard I., Abe Y., Yasui M., Thomas J. H., Xiao M., Hirase H., Asokan A., Iliff J. J., Nedergaard M., Aquaporin-4-dependent glymphatic solute transport in the rodent brain. eLife 7, e40070 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6307855</ArticleId><ArticleId IdType="pubmed">30561329</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff J. J., Wang M., Liao Y., Plogg B. A., Peng W., Gundersen G. A., Benveniste H., Vates G. E., Deane R., Goldman S. A., Nagelhus E. A., Nedergaard M., A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#x3b2;. Sci. Transl. Med. 4, 147ra111 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot-Sestier M. V., Doty K. R., Gate D., Rodriguez J. Jr., Leung B. P., Rezai-Zadeh K., Town T., Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 85, 534&#x2013;548 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352138</ArticleId><ArticleId IdType="pubmed">25619654</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarty P., Li A., Ceballos-Diaz C., Eddy J. A., Funk C. C., Moore B., DiNunno N., Rosario A. M., Cruz P. E., Verbeeck C., Sacino A., Nix S., Janus C., Price N. D., Das P., Golde T. E., IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85, 519&#x2013;533 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4320003</ArticleId><ArticleId IdType="pubmed">25619653</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaeser S. A., Herzig M. C., Coomaraswamy J., Kilger E., Selenica M. L., Winkler D. T., Staufenbiel M., Levy E., Grubb A., Jucker M., Cystatin C modulates cerebral beta-amyloidosis. Nat. Genet. 39, 1437&#x2013;1439 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18026102</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoka V., Turk V., Turk B., Lysosomal cathepsins and their regulation in aging and neurodegeneration. Ageing Res. Rev. 32, 22&#x2013;37 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27125852</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierksma A., Lu A., Mancuso R., Fattorelli N., Thrupp N., Salta E., Zoco J., Blum D., Buee L., De Strooper B., Fiers M., Novel Alzheimer risk genes determine the microglia response to amyloid-&#x3b2; but not to TAU pathology. EMBO Mol. Med. 12, e10606 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7059012</ArticleId><ArticleId IdType="pubmed">31951107</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M., Calabrese E., Marventano I., Piancone F., Gatti A., Calvo M. G., Nemni R., Clerici M., PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimer&#x2019;s disease. J. Alzheimers Dis. 21, 927&#x2013;938 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20634592</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K., Deczkowska A., David E., Castellano J. M., Miller O., Kertser A., Berkutzki T., Barnett-Itzhaki Z., Bezalel D., Wyss-Coray T., Amit I., Schwartz M., Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346, 89&#x2013;93 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869326</ArticleId><ArticleId IdType="pubmed">25147279</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenzweig N., Dvir-Szternfeld R., Tsitsou-Kampeli A., Keren-Shaul H., Ben-Yehuda H., Weill-Raynal P., Cahalon L., Kertser A., Baruch K., Amit I., Weiner A., Schwartz M., PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat. Commun. 10, 465 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6349941</ArticleId><ArticleId IdType="pubmed">30692527</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz Hernandez J. C., Bracko O., Kersbergen C. J., Muse V., Haft-Javaherian M., Berg M., Park L., Vinarcsik L. K., Ivasyk I., Rivera D. A., Kang Y., Cortes-Canteli M., Peyrounette M., Doyeux V., Smith A., Zhou J., Otte G., Beverly J. D., Davenport E., Davit Y., Lin C. P., Strickland S., Iadecola C., Lorthois S., Nishimura N., Schaffer C. B., Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer&#x2019;s disease mouse models. Nat. Neurosci. 22, 413&#x2013;420 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508667</ArticleId><ArticleId IdType="pubmed">30742116</ArticleId></ArticleIdList></Reference><Reference><Citation>Herisson F., Frodermann V., Courties G., Rohde D., Sun Y., Vandoorne K., Wojtkiewicz G. R., Masson G. S., Vinegoni C., Kim J., Kim D. E., Weissleder R., Swirski F. K., Moskowitz M. A., Nahrendorf M., Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration. Nat. Neurosci. 21, 1209&#x2013;1217 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6148759</ArticleId><ArticleId IdType="pubmed">30150661</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai R., Pan C., Ghasemigharagoz A., Todorov M. I., Forstera B., Zhao S., Bhatia H. S., Parra-Damas A., Mrowka L., Theodorou D., Rempfler M., Xavier A. L. R., Kress B. T., Benakis C., Steinke H., Liebscher S., Bechmann I., Liesz A., Menze B., Kerschensteiner M., Nedergaard M., Erturk A., Panoptic imaging of transparent mice reveals whole-body neuronal projections and skull-meninges connections. Nat. Neurosci. 22, 317&#x2013;327 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494982</ArticleId><ArticleId IdType="pubmed">30598527</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasciuto E., Burton O. T., Roca C. P., Lagou V., Rajan W. D., Theys T., Mancuso R., Tito R. Y., Kouser L., Callaerts-Vegh Z., de la Fuente A. G., Prezzemolo T., Mascali L. G., Brajic A., Whyte C. E., Yshii L., Martinez-Muriana A., Naughton M., Young A., Moudra A., Lemaitre P., Poovathingal S., Raes J., De Strooper B., Fitzgerald D. C., Dooley J., Liston A., Microglia require CD4 T cells to complete the fetal-to-adult transition. Cell 182, 625&#x2013;640.e24 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427333</ArticleId><ArticleId IdType="pubmed">32702313</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N., McCabe C., Medina S., Varshavsky M., Kitsberg D., Dvir-Szternfeld R., Green G., Dionne D., Nguyen L., Marshall J. L., Chen F., Zhang F., Kaplan T., Regev A., Schwartz M., Disease-associated astrocytes in Alzheimer&#x2019;s disease and aging. Nat. Neurosci. 23, 701&#x2013;706 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9262034</ArticleId><ArticleId IdType="pubmed">32341542</ArticleId></ArticleIdList></Reference><Reference><Citation>Finck R., Simonds E. F., Jager A., Krishnaswamy S., Sachs K., Fantl W., Pe&#x2019;er D., Nolan G. P., Bendall S. C., Normalization of mass cytometry data with bead standards. Cytometry A 83, 483&#x2013;494 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3688049</ArticleId><ArticleId IdType="pubmed">23512433</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine J. H., Simonds E. F., Bendall S. C., Davis K. L., Amir E. D., Tadmor M. D., Litvin O., Fienberg H. G., Jager A., Zunder E. R., Finck R., Gedman A. L., Radtke I., Downing J. R., Pe&#x2019;er D., Nolan G. P., Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162, 184&#x2013;197 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4508757</ArticleId><ArticleId IdType="pubmed">26095251</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gassen S., Callebaut B., Van Helden M. J., Lambrecht B. N., Demeester P., Dhaene T., Saeys Y., FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87, 636&#x2013;645 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25573116</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy D. J., Campbell K. R., Lun A. T., Wills Q. F., Scater: Pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics 33, 1179&#x2013;1186 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408845</ArticleId><ArticleId IdType="pubmed">28088763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun A. T., Bach K., Marioni J. C., Pooling across cells to normalize single-cell RNA sequencing data with many zero counts. Genome Biol. 17, 75 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4848819</ArticleId><ArticleId IdType="pubmed">27122128</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T., Butler A., Hoffman P., Hafemeister C., Papalexi E., Mauck W. M. III, Hao Y., Stoeckius M., Smibert P., Satija R., Comprehensive integration of single-cell data. Cell 177, 1888&#x2013;1902.e21 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>S. E. Marsh, T. Kamath, A. J. Walker, L. Dissing-Olesen, T. R. Hammond, A. M. H. Young, A. Abdulraouf, N. Nadaf, C. Dufort, S. Murphy, V. Kozareva, C. Vanderburg, S. Hong, H. Bulstrode, P. J. Hutchinson, D. J. Gaffney, R. J. M. Franklin, E. Z. Macosko, B. Stevens, Single cell sequencing reveals glial specific responses to tissue processing &amp; enzymatic dissociation in mice and humans. bioRxiv 2020.12.03.408542 [Preprint]. 3 December 2020. 10.1101/2020.12.03.408542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.03.408542</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berge K., Perraudeau F., Soneson C., Love M. I., Risso D., Vert J. P., Robinson M. D., Dudoit S., Clement L., Observation weights unlock bulk RNA-seq tools for zero inflation and single-cell applications. Genome Biol. 19, 24 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251479</ArticleId><ArticleId IdType="pubmed">29478411</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson M. D., McCarthy D. J., Smyth G. K., edgeR: A bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139&#x2013;140 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong G., Zhang W., Li H., Shen X., Guo Z., Separate enrichment analysis of pathways for up- and downregulated genes. J. R. Soc. Interface 11, 20130950 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3899863</ArticleId><ArticleId IdType="pubmed">24352673</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G., Wang L. G., Han Y., He Q. Y., clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 16, 284&#x2013;287 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G., Wang L. G., Yan G. R., He Q. Y., DOSE: An R/bioconductor package for disease ontology semantic and enrichment analysis. Bioinformatics 31, 608&#x2013;609 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25677125</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34032364</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging.</ArticleTitle><Pagination><StartPage>88</StartPage><EndPage>102</EndPage><MedlinePgn>88-102</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12369</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Blood proteins are emerging as candidate biomarkers for Alzheimer's disease (AD). We systematically profiled the plasma proteome to identify novel AD blood biomarkers and develop a high-performance, blood-based test for AD.</AbstractText><AbstractText Label="METHODS">We quantified 1160 plasma proteins in a Hong Kong Chinese cohort by high-throughput proximity extension assay and validated the results in an independent cohort. In subgroup analyses, plasma biomarkers for amyloid, tau, phosphorylated tau, and neurodegeneration were used as endophenotypes of AD.</AbstractText><AbstractText Label="RESULTS">We identified 429 proteins that were dysregulated in AD plasma. We selected 19 "hub proteins" representative of the AD plasma protein profile, which formed the basis of a scoring system that accurately classified clinical AD (area under the curve &#xa0;=&#xa0;0.9690-0.9816) and associated endophenotypes. Moreover, specific hub proteins exhibit disease stage-dependent dysregulation, which can delineate AD stages.</AbstractText><AbstractText Label="DISCUSSION">This study comprehensively profiled the AD plasma proteome and serves as a foundation for a high-performance, blood-based test for clinical AD screening and staging.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Alzheimer's &amp; Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yuanbing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiaopu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ip</LastName><ForeName>Fanny C</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Nicole C H</ForeName><Initials>NCH</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Kit</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Ronnie M N</ForeName><Initials>RMN</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Estella P S</ForeName><Initials>EPS</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Bonnie W Y</ForeName><Initials>BWY</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Andrew L T</ForeName><Initials>ALT</Initials><AffiliationInfo><Affiliation>Divisions of Neurology and Geriatrics, Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Vincent C T</ForeName><Initials>VCT</Initials><AffiliationInfo><Affiliation>Gerald Choa Neuroscience Centre, Lui Che Woo Institute of Innovative Medicine, Therese Pei Fong Chow Research Centre for Prevention of Dementia, Division of Neurology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwok</LastName><ForeName>Timothy C Y</ForeName><Initials>TCY</Initials><AffiliationInfo><Affiliation>Therese Pei Fong Chow Research Centre for Prevention of Dementia, Division of Geriatrics, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Kin Y</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Amy K Y</ForeName><Initials>AKY</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ip</LastName><ForeName>Nancy Y</ForeName><Initials>NY</Initials><Identifier Source="ORCID">0000-0002-2763-8907</Identifier><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development; Shenzhen-Hong Kong Institute of Brain Science, HKUST Shenzhen Research Institute, Shenzhen, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L501542/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1001253</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-1307</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/J004758/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K01417X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058068" MajorTopicYN="N">Endophenotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006723" MajorTopicYN="N" Type="Geographic">Hong Kong</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="Y">Mass Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">biomarker panel</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">disease staging</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">plasma proteome</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>H.Z. has served on scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx; has given lectures in symposia sponsored by Fujirebio, AlzeCure, and Biogen; and is a cofounder of Brain Biomarker Solutions (BBS) of Gothenburg AB, which is part of the GU Ventures Incubator Program (outside submitted work). All other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>25</Day><Hour>8</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34032364</ArticleId><ArticleId IdType="pmc">PMC9292367</ArticleId><ArticleId IdType="doi">10.1002/alz.12369</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et&#xa0;al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2010;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia. 2011;7:263&#x2010;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack Jr CR, Bennett DA, Blennow K, et&#xa0;al. NIA&#x2010;AA research framework: toward a biological definition of Alzheimer's disease. Alzheimer's &amp; Dementia. 2018;14:535&#x2010;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinuevo JL, Ayton S, Batrla R, et&#xa0;al. Current state of Alzheimer's fluid biomarkers. Acta Neuropathol (Berl). 2018;136:821&#x2010;853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280827</ArticleId><ArticleId IdType="pubmed">30488277</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, Kaneko N, Villemagne VL, et&#xa0;al. High performance plasma amyloid&#x2010;&#x3b2; biomarkers for Alzheimer's disease. Nature. 2018;554:249.</Citation><ArticleIdList><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O, Schultz SA, Apel A, et&#xa0;al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019;25:277&#x2010;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Pascoal TA, Ashton NJ, et&#xa0;al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. The Lancet Neurology. 2020;19:422&#x2010;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, et&#xa0;al. Discriminative accuracy of plasma Phospho&#x2010;tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772&#x2010;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Zetterberg H, Reiman EM, et&#xa0;al. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross&#x2010;sectional and longitudinal cohort study. Lancet Neurol. 2020;19:513&#x2010;521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7417082</ArticleId><ArticleId IdType="pubmed">32470423</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Berron D, Smith R, et&#xa0;al. Associations of Plasma Phospho&#x2010;Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7653537</ArticleId><ArticleId IdType="pubmed">33165506</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Benedet AL, Ashton NJ, et&#xa0;al. Diagnostic performance and prediction of clinical progression of plasma phospho&#x2010;tau181 in the Alzheimer's Disease Neuroimaging Initiative. Mol Psychiatry. 2020:1&#x2010;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">33106600</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et&#xa0;al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging&#x2010;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia. 2011;7:280&#x2010;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Doecke JD, Laws SM, Faux NG, et&#xa0;al. Blood&#x2010;based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol. 2012;69:1318&#x2010;1325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6287606</ArticleId><ArticleId IdType="pubmed">22801742</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Z, Yin J, Yuan H, et&#xa0;al. Blood&#x2010;derived plasma protein biomarkers for Alzheimer's disease in Han Chinese. Frontiers Aging Neurosci. 2018;10:414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6305130</ArticleId><ArticleId IdType="pubmed">30618720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S, Britschgi M, Herbert C, et&#xa0;al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007;13:1359&#x2010;1362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Bryant SE, Xiao G, Barber R, et&#xa0;al. A serum protein&#x2013;based algorithm for the detection of Alzheimer disease. Arch Neurol. 2010;67:1077&#x2010;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069805</ArticleId><ArticleId IdType="pubmed">20837851</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattlecker M, Kiddle SJ, Newhouse S, et&#xa0;al. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer's &amp; Dementia. 2014;10:724&#x2010;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">24768341</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelan CD, Mattsson N, Nagle MW, et&#xa0;al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease. Acta Neuropathologica Communications. 2019;7:1&#x2010;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836495</ArticleId><ArticleId IdType="pubmed">31694701</ArticleId></ArticleIdList></Reference><Reference><Citation>Assarsson E, Lundberg M, Holmquist G, et&#xa0;al. Homogenous 96&#x2010;plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3995906</ArticleId><ArticleId IdType="pubmed">24755770</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold L, Ayers D, Bertino J, et&#xa0;al. Aptamer&#x2010;based multiplexed proteomic technology for biomarker discovery. Nature Precedings. 2010:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000457</ArticleId><ArticleId IdType="pubmed">21165148</ArticleId></ArticleIdList></Reference><Reference><Citation>Egerstedt A, Berntsson J, Smith ML, et&#xa0;al. Profiling of the plasma proteome across different stages of human heart failure. Nat Commun. 2019;10:1&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6925199</ArticleId><ArticleId IdType="pubmed">31862877</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehallier B, Gate D, Schaum N, et&#xa0;al. Undulating changes in human plasma proteome profiles across the lifespan. Nat Med. 2019;25:1843&#x2010;1850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7062043</ArticleId><ArticleId IdType="pubmed">31806903</ArticleId></ArticleIdList></Reference><Reference><Citation>Association AP . Diagnostic and statistical manual of mental disorders (DSM&#x2010;5&#xae;): American Psychiatric Pub; 2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">24413388</ArticleId></ArticleIdList></Reference><Reference><Citation>Pangman VC, Sloan J, Guse L. An examination of psychometric properties of the mini&#x2010;mental state examination and the standardized mini&#x2010;mental state examination: implications for clinical practice. Appl Nurs Res. 2000;13:209&#x2010;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">11078787</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, B&#xe9;dirian V, et&#xa0;al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695&#x2010;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et&#xa0;al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2010;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia. 2011;7:270&#x2010;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615629</ArticleId><ArticleId IdType="pubmed">19033363</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44.</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens JH, Stunnenberg HG. BLUEPRINT: mapping human blood cell epigenomes. Haematologica;. 2013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3789449</ArticleId><ArticleId IdType="pubmed">24091925</ArticleId></ArticleIdList></Reference><Reference><Citation>Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32&#x2010;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15405679</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong ER, DeLong DM, Clarke&#x2010;Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988:837&#x2010;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW, Eijkemans MJ, Harrell Jr FE, Habbema JDF. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med. 2000;19:1059&#x2010;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">10790680</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74:557&#x2010;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Palmqvist S, et&#xa0;al. Plasma &#x3b2;&#x2010;amyloid in Alzheimer's disease and vascular disease. Sci Rep. 2016;6:1&#x2010;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4886210</ArticleId><ArticleId IdType="pubmed">27241045</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n J, Ashton NJ, Blennow K, Zetterberg H. An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. Curr Opin Neurobiol. 2020;61:29&#x2010;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">31838254</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiddle SJ, Sattlecker M, Proitsi P, et&#xa0;al. Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. Journal of Alzheimer's Disease. 2014;38:515&#x2010;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">24121966</ArticleId></ArticleIdList></Reference><Reference><Citation>del Mar Hernandez M, Esteban M, Szabo P, Boada M, Unzeta M. Human plasma semicarbazide sensitive amine oxidase (SSAO), &#x3b2;&#x2010;amyloid protein and aging. Neurosci Lett. 2005;384:183&#x2010;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">15894424</ArticleId></ArticleIdList></Reference><Reference><Citation>Stieler JT, Lederer C, Bru&#xc8;ckner MK, et&#xa0;al. Impairment of mitogenic activation of peripheral blood lymphocytes in Alzheimer's disease. Neuroreport. 2001;12:3969&#x2010;3972.</Citation><ArticleIdList><ArticleId IdType="pubmed">11742221</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares HD, Potter WZ, Pickering E, et&#xa0;al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol. 2012;69:1310&#x2010;1317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683865</ArticleId><ArticleId IdType="pubmed">22801723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Holtzman DM, Fagan AM, et&#xa0;al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 2012;79:897&#x2010;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3425844</ArticleId><ArticleId IdType="pubmed">22855860</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler P, Akuffo EL, Bodnar WM, et&#xa0;al. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium&#x2010;derived factor: two novel biomarkers of Alzheimer's disease in human plasma. PROTEOMICS&#x2013;Clinical Applications. 2008;2:467&#x2010;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">21136851</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh VK. Studies of neuroimmune markers in Alzheimer's disease. Mol Neurobiol. 1994;9:73.</Citation><ArticleIdList><ArticleId IdType="pubmed">7534089</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang S, Lee JH, Sohn BK, et&#xa0;al. Suppression of AIMP1 protects cognition in Alzheimer's disease model mice 3xTg&#x2010;AD. Neuroreport. 2017;28:82&#x2010;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">27906773</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Q, Polom K, Williams C, et&#xa0;al. A targeted proteomics approach reveals a serum protein signature as diagnostic biomarker for resectable gastric cancer. EBioMedicine. 2019;44:322&#x2010;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6606959</ArticleId><ArticleId IdType="pubmed">31151932</ArticleId></ArticleIdList></Reference><Reference><Citation>Shad KF, Aghazadeh Y, Ahmad S, Kress B. Peripheral markers of Alzheimer's disease: surveillance of white blood cells. Synapse. 2013;67:541&#x2010;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">23404438</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RH, Brightling CE, McKenna S, et&#xa0;al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet North Am Ed. 2002;360:1715&#x2010;1721.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480423</ArticleId></ArticleIdList></Reference><Reference><Citation>Group AC. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560&#x2010;2572.</Citation><ArticleIdList><ArticleId IdType="pubmed">18539916</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang TJ, Gona P, Larson MG, et&#xa0;al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631&#x2010;2639.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182988</ArticleId></ArticleIdList></Reference><Reference><Citation>Jerrard&#x2010;Dunne P, Evans A, McGovern R, et&#xa0;al. Ethnic differences in markers of thrombophilia: implications for the investigation of ischemic stroke in multiethnic populations: the South London Ethnicity and Stroke Study. Stroke. 2003;34:1821&#x2010;1826.</Citation><ArticleIdList><ArticleId IdType="pubmed">12843341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ujcic&#x2010;Voortman JK, Baan CA, Verhoeff AP, Krol A, Seidell JC. Ethnic differences in systemic inflammation: an investigation of C&#x2010;reactive protein levels among Moroccan, Turkish and Dutch groups in the Netherlands. Atherosclerosis. 2011;218:511&#x2010;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">21788019</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto Y, Conroy SM, Ollberding NJ, et&#xa0;al. Ethnic differences in serum adipokine and C&#x2010;reactive protein levels: the multiethnic cohort. Int J Obes. 2014;38:1416&#x2010;1422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4247246</ArticleId><ArticleId IdType="pubmed">24522245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganz P, Heidecker B, Hveem K, et&#xa0;al. Development and validation of a protein&#x2010;based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. 2016;315:2532&#x2010;2541.</Citation><ArticleIdList><ArticleId IdType="pubmed">27327800</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef H, Czupalla CJ, Lee D, et&#xa0;al. Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1. Nat Med. 2019;25:988&#x2010;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6642642</ArticleId><ArticleId IdType="pubmed">31086348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Xu Y, Zhuo R, et&#xa0;al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model. Nat Commun. 2019;10:1&#x2010;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6433910</ArticleId><ArticleId IdType="pubmed">30911003</ArticleId></ArticleIdList></Reference><Reference><Citation>Religa P, Cao R, Religa D, et&#xa0;al. VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival. Sci Rep. 2013;3:2053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690383</ArticleId><ArticleId IdType="pubmed">23792494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira D, Verhagen C, Hern&#xe1;ndez&#x2010;Cabrera JA, et&#xa0;al. Distinct subtypes of Alzheimer's disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications. Sci Rep. 2017;7:46263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5394684</ArticleId><ArticleId IdType="pubmed">28417965</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J&#x2010;Y, Na HK, Kim S, et&#xa0;al. Robust identification of Alzheimer's disease subtypes based on cortical atrophy patterns. Sci Rep. 2017;7:1&#x2010;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5343676</ArticleId><ArticleId IdType="pubmed">28276464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira D, Pereira JB, Volpe G, Westman E. Subtypes of Alzheimer's disease display distinct network abnormalities extending beyond their pattern of brain atrophy. Frontiers in Neurology. 2019;10:524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547836</ArticleId><ArticleId IdType="pubmed">31191430</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun BB, Maranville JC, Peters JE, et&#xa0;al. Genomic atlas of the human plasma proteome. Nature. 2018;558:73&#x2010;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697541</ArticleId><ArticleId IdType="pubmed">29875488</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta&#x2010;analysis. Arch Gen Psychiatry. 1998;55:809&#x2010;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">9736007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63:287&#x2010;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M, Carrasquillo MM, Funk C, et&#xa0;al. Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. Scientific Data. 2016;3:160089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058336</ArticleId><ArticleId IdType="pubmed">27727239</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Gaiteri C, Bodea L&#x2010;G, et&#xa0;al. Integrated systems approach identifies genetic nodes and networks in late&#x2010;onset Alzheimer's disease. Cell. 2013;153:707&#x2010;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C&#x2010;W, Tsai M&#x2010;H, Chen N&#x2010;C, et&#xa0;al. Clinical significance of circulating vascular cell adhesion molecule&#x2010;1 to white matter disintegrity in Alzheimer's dementia. Thromb Haemost. 2015;114:1230&#x2010;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">26289958</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazarian A, Arbeev KG, Yashkin AP, Kulminski AM. Genetic heterogeneity of Alzheimer's disease in subjects with and without hypertension. GeroScience. 2019;41:137&#x2010;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6544706</ArticleId><ArticleId IdType="pubmed">31055733</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson EC, Dammer EB, Duong DM, et&#xa0;al. Large&#x2010;scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med. 2020;26:769&#x2010;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405761</ArticleId><ArticleId IdType="pubmed">32284590</ArticleId></ArticleIdList></Reference><Reference><Citation>Berchtold NC, Coleman PD, Cribbs DH, Rogers J, Gillen DL, Cotman CW. Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease. Neurobiol Aging. 2013;34:1653&#x2010;1661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022280</ArticleId><ArticleId IdType="pubmed">23273601</ArticleId></ArticleIdList></Reference><Reference><Citation>Naughton BJ, Duncan FJ, Murrey DA, et&#xa0;al. Blood genome&#x2010;wide transcriptional profiles reflect broad molecular impairments and strong blood&#x2010;brain links in Alzheimer's disease. J Alzheimer's Dis. 2015;43:93&#x2010;108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5777140</ArticleId><ArticleId IdType="pubmed">25079797</ArticleId></ArticleIdList></Reference><Reference><Citation>Konki M, Malonzo M, Karlsson IK, et&#xa0;al. Peripheral blood DNA methylation differences in twin pairs discordant for Alzheimer's disease. Clinical Epigenetics. 2019;11:130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6721173</ArticleId><ArticleId IdType="pubmed">31477183</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34031605</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.</ArticleTitle><Pagination><StartPage>1034</StartPage><EndPage>1042</EndPage><MedlinePgn>1034-1042</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-021-01348-z</ELocationID><Abstract><AbstractText>A combination of plasma phospho-tau (P-tau) and other accessible biomarkers might provide accurate prediction about the risk of developing Alzheimer's disease (AD) dementia. We examined this in participants with subjective cognitive decline and mild cognitive impairment from the BioFINDER (n&#x2009;=&#x2009;340) and Alzheimer's Disease Neuroimaging Initiative (ADNI) (n&#x2009;=&#x2009;543) studies. Plasma P-tau, plasma A&#x3b2;42/A&#x3b2;40, plasma neurofilament light, APOE genotype, brief cognitive tests and an AD-specific magnetic resonance imaging measure were examined using progression to AD as outcome. Within 4 years, plasma P-tau217 predicted AD accurately (area under the curve (AUC) = 0.83) in BioFINDER. Combining plasma P-tau217, memory, executive function and APOE produced higher accuracy (AUC = 0.91, P&#x2009;&lt;&#x2009;0.001). In ADNI, this model had similar AUC (0.90) using plasma P-tau181 instead of P-tau217. The model was implemented online for prediction of the individual probability of progressing to AD. Within 2 and 6 years, similar models had AUCs of 0.90-0.91 in both cohorts. Using cerebrospinal fluid P-tau, A&#x3b2;42/A&#x3b2;40 and neurofilament light instead of plasma biomarkers did not improve the accuracy significantly. The clinical predictions by memory clinic physicians had significantly lower accuracy (4-year AUC = 0.71). In summary, plasma P-tau, in combination with brief cognitive tests and APOE genotyping, might greatly improve the diagnostic prediction of AD and facilitate recruitment for AD trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9267-1930</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden. sebastian.palmqvist@med.lu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden. sebastian.palmqvist@med.lu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tideman</LastName><ForeName>Pontus</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cullen</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3930-4354</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1890-4193</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author><Author ValidYN="Y"><LastName>Dage</LastName><ForeName>Jeffery L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-2192-1699</Identifier><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stomrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2869-8378</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson-Carlgren</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8467-7286</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden. oskar.hansson@med.lu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden. oskar.hansson@med.lu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000612345">ApoE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34031605</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01348-z</ArticleId><ArticleId IdType="pii">10.1038/s41591-021-01348-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Palmqvist, S. et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid &#x3b2;-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 71, 1282&#x2013;1289 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25155658</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.1358</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze, S. et al. CSF A&#x3b2;42/A&#x3b2;40 and A&#x3b2;42/A&#x3b2;38 ratios: better diagnostic markers of Alzheimer disease. Ann. Clin. Transl. Neurol. 3, 154&#x2013;165 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27042676</ArticleId><ArticleId IdType="pmc">4774260</ArticleId><ArticleId IdType="doi">10.1002/acn3.274</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelemy, N. R. et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer&#x2019;s disease and PET amyloid-positive patient identification. Alzheimers Res. Ther. 12, 26 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32183883</ArticleId><ArticleId IdType="pmc">7079453</ArticleId><ArticleId IdType="doi">10.1186/s13195-020-00596-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson, N. et al. A&#x3b2; deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer&#x2019;s disease. Sci. Adv. 6, eaaz2387 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2387</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren, N. et al. The implications of different approaches to define AT(N) in Alzheimer disease. Neurology 94, e2233&#x2013;e2244 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32398359</ArticleId><ArticleId IdType="pmc">7357296</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000009485</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J. &amp; Hansson, O. Staging &#x3b2;-amyloid pathology with amyloid positron emission tomography. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2019.2214 (2019).</Citation></Reference><Reference><Citation>Rabinovici, G. D. et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA 321, 1286&#x2013;1294 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30938796</ArticleId><ArticleId IdType="pmc">6450276</ArticleId><ArticleId IdType="doi">10.1001/jama.2019.2000</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy, A. et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 77, 955&#x2013;965 (2020).</Citation></Reference><Reference><Citation>Ossenkoppele, R. et al. Discriminative accuracy of [<sup>18</sup>F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151&#x2013;1162 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30326496</ArticleId><ArticleId IdType="pmc">6233630</ArticleId><ArticleId IdType="doi">10.1001/jama.2018.12917</ArticleId></ArticleIdList></Reference><Reference><Citation>Gisslen, M. et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3, 135&#x2013;140 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26870824</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2015.11.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische, O. et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer&#x2019;s disease. Nat. Med. 25, 277&#x2013;283 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30664784</ArticleId><ArticleId IdType="pmc">6367005</ArticleId><ArticleId IdType="doi">10.1038/s41591-018-0304-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist, S. et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related &#x3b2;-amyloid status. JAMA Neurol. 76, 1060&#x2013;1069 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31233127</ArticleId><ArticleId IdType="pmc">6593637</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.1632</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler, S. E. et al. High-precision plasma &#x3b2;-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 93, e1647&#x2013;e1659 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31371569</ArticleId><ArticleId IdType="pmc">6946467</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000008081</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze, S. et al. Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat. Med. 26, 379&#x2013;386 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32123385</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer&#x2019;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422&#x2013;433 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32333900</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(20)30071-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772&#x2013;781 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32722745</ArticleId><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen, N. C. et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat. Aging 1, 114&#x2013;123 (2021).</Citation></Reference><Reference><Citation>Jack, C. R. Jr. et al. Defining imaging biomarker cut points for brain aging and Alzheimer&#x2019;s disease. Alzheimers Dement. 13, 205&#x2013;216 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27697430</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2016.08.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham, K. P. &amp; Anderson, D. R. Multimodel inference: understanding AIC and BIC in model selection. Soc. Methods Res. https://doi.org/10.1177/0049124104268644 (2004).</Citation></Reference><Reference><Citation>Olofsen, E. &amp; Dahan, A. Using Akaike&#x2019;s information theoretic criterion in mixed-effects modeling of pharmacokinetic data: a simulation study. F1000Research 2, 71 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">26673949</ArticleId><ArticleId IdType="doi">10.12688/f1000research.2-71.v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo, J. B. et al. Factors affecting A&#x3b2; plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 122, 401&#x2013;413 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21805181</ArticleId><ArticleId IdType="pmc">3299300</ArticleId><ArticleId IdType="doi">10.1007/s00401-011-0861-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovod, V. et al. Amyloid &#x3b2; concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 13, 841&#x2013;849 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28734653</ArticleId><ArticleId IdType="pmc">5567785</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2017.06.2266</ArticleId></ArticleIdList></Reference><Reference><Citation>Borland, E. et al. The Montreal Cognitive Assessment: normative data from a large Swedish population-based cohort. J. Alzheimers Dis. 59, 893&#x2013;901 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28697562</ArticleId><ArticleId IdType="pmc">5545909</ArticleId><ArticleId IdType="doi">10.3233/JAD-170203</ArticleId></ArticleIdList></Reference><Reference><Citation>Borland, E., Stomrud, E., van Westen, D., Hansson, O. &amp; Palmqvist, S. The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. Alzheimers Res. Ther. 12, 30 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32209137</ArticleId><ArticleId IdType="pmc">7093968</ArticleId><ArticleId IdType="doi">10.1186/s13195-020-00592-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrazzuoli, F. et al. Brief cognitive tests used in primary care cannot accurately differentiate mild cognitive impairment from subjective cognitive decline. J. Alzheimers Dis. 75, 1191&#x2013;1201 (2020).</Citation></Reference><Reference><Citation>Barthelemy, N. R., Horie, K., Sato, C. &amp; Bateman, R. J. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer&#x2019;s disease. J. Exp. Med. 217, e20200861 (2020).</Citation></Reference><Reference><Citation>Karikari, T. K. et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer&#x2019;s Disease Neuroimaging Initiative. Mol. Psychiatry 26, 429&#x2013;442 (2020).</Citation></Reference><Reference><Citation>Mattsson-Carlgren, N. et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer&#x2019;s disease. Brain 143, 3234&#x2013;3241 (2020).</Citation></Reference><Reference><Citation>Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14, 989&#x2013;997 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29626426</ArticleId><ArticleId IdType="pmc">6097897</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2018.02.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist, S. et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer&#x2019;s disease. EMBO Mol. Med. 11, e11170 (2019).</Citation></Reference><Reference><Citation>Insel, P. S. et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology 93, e322&#x2013;e333 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31289148</ArticleId><ArticleId IdType="pmc">6669933</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000007831</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist, S. et al. Accurate risk estimation of &#x3b2;-amyloid positivity to identify prodromal Alzheimer&#x2019;s disease: cross-validation study of practical algorithms. Alzheimers Dement. 15, 194&#x2013;204 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30365928</ArticleId><ArticleId IdType="pmc">6374284</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2018.08.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp, K. V., Rentz, D. M., Orlovsky, I., Sperling, R. A. &amp; Mormino, E. C. Optimizing the preclinical Alzheimer&#x2019;s cognitive composite with semantic processing: the PACC5. Alzheimers Dement. 3, 668&#x2013;677 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2017.10.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924&#x2013;1938 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25988462</ArticleId><ArticleId IdType="pmc">4486209</ArticleId><ArticleId IdType="doi">10.1001/jama.2015.4668</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheyer, O. et al. Female sex and Alzheimer&#x2019;s risk: the menopause connection. J. Prev. Alzheimers Dis. 5, 225&#x2013;230 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30298180</ArticleId><ArticleId IdType="pmc">6198681</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack, C. R. Jr. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29653606</ArticleId><ArticleId IdType="pmc">5958625</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183&#x2013;194 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2796.2004.01388.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts, R. O. et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30, 58&#x2013;69 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18259084</ArticleId><ArticleId IdType="pmc">2821441</ArticleId><ArticleId IdType="doi">10.1159/000115751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gothlin, M., Eckerstrom, M., Rolstad, S., Wallin, A. &amp; Nordlund, A. Prognostic accuracy of mild cognitive impairment subtypes at different cut-off levels. Dement. Geriatr. Cogn. Disord. 43, 330&#x2013;341 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28591751</ArticleId><ArticleId IdType="doi">10.1159/000477341</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato, C. et al. Tau kinetics in neurons and the human central nervous system. Neuron 97, 1284&#x2013;1298 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29566794</ArticleId><ArticleId IdType="pmc">6137722</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2018.02.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopponen, M., Raiha, I., Isoaho, R., Vahlberg, T. &amp; Kivela, S. L. Diagnosing cognitive impairment and dementia in primary health care&#x2014;a more active approach is needed. Age Ageing 32, 606&#x2013;612 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14600001</ArticleId><ArticleId IdType="doi">10.1093/ageing/afg097</ArticleId></ArticleIdList></Reference><Reference><Citation>Valcour, V. G., Masaki, K. H., Curb, J. D. &amp; Blanchette, P. L. The detection of dementia in the primary care setting. Arch. Intern. Med. 160, 2964&#x2013;2968 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11041904</ArticleId><ArticleId IdType="doi">10.1001/archinte.160.19.2964</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc5;strand, R., Rolstad, S. &amp; Wallin, A. Cognitive Impairment Questionnaire (CIMP-QUEST): reported topographic symptoms in MCI and dementia. Acta Neurol. Scand. 121, 384&#x2013;391 (2009).</Citation></Reference><Reference><Citation>Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H. Jr., Chance, J. M. &amp; Filos, S. Measurement of functional activities in older adults in the community. J. Gerontol. 37, 323&#x2013;329 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">7069156</ArticleId><ArticleId IdType="doi">10.1093/geronj/37.3.323</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen, W. G., Mohs, R. C. &amp; Davis, K. L. A new rating scale for Alzheimer&#x2019;s disease. Am. J. Psychiatry 141, 1356&#x2013;1364 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId><ArticleId IdType="doi">10.1176/ajp.141.11.1356</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman, K. I. Clock-drawing: is it the ideal cognitive screening test? Int J. Geriatr. Psychiatry 15, 548&#x2013;561 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10861923</ArticleId><ArticleId IdType="doi">10.1002/1099-1166(200006)15:6&lt;548::AID-GPS242&gt;3.0.CO;2-U</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist, S. et al. Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer&#x2019;s disease in mild cognitive impairment: six-year follow-up study. PLoS ONE 7, e38639 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22761691</ArticleId><ArticleId IdType="pmc">3382225</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0038639</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson-Carlgren, N., Palmqvist, S., Blennow, K. &amp; Hansson, O. Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nat. Commun. 11, 6252 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33288742</ArticleId><ArticleId IdType="pmc">7721731</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-19957-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson, O. et al. CSF biomarkers of Alzheimer&#x2019;s disease concord with amyloid-&#x3b2; PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 14, 1470&#x2013;1481 (2018).</Citation></Reference><Reference><Citation>Palmqvist, S. et al. Earliest accumulation of &#x3b2;-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat. Commun. 8, 1214 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29089479</ArticleId><ArticleId IdType="pmc">5663717</ArticleId><ArticleId IdType="doi">10.1038/s41467-017-01150-x</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 7, 263&#x2013;269 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21514250</ArticleId><ArticleId IdType="pmc">3312024</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen, P. S., Petersen, R. C., Donohue, M. &amp; Weiner, M. W. &amp; Alzheimer&#x2019;s Disease Neuroimaging Initiative. Alzheimer&#x2019;s Disease Neuroimaging Initiative 2 Clinical Core: progress and plans. Alzheimers Dement. 11, 734&#x2013;739 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26194309</ArticleId><ArticleId IdType="pmc">4643840</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2015.05.005</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann, G. et al. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology 34, 939&#x2013;944 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId><ArticleId IdType="doi">10.1212/WNL.34.7.939</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau, S. M. et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 72, 578&#x2013;586 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23109153</ArticleId><ArticleId IdType="pmc">3786871</ArticleId><ArticleId IdType="doi">10.1002/ana.23650</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34039738</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>595</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>26</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaba7394</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aba7394</ELocationID><Abstract><AbstractText>Accumulation of pathological tau in synapses has been identified as an early event in Alzheimer's disease (AD) and correlates with cognitive decline in patients with AD. Tau is a cytosolic axonal protein, but under disease conditions, tau accumulates in postsynaptic compartments and presynaptic terminals, due to missorting within neurons, transsynaptic transfer between neurons, or a failure of clearance pathways. Using subcellular fractionation of brain tissue from rTg4510 tau transgenic mice with tauopathy and human postmortem brain tissue from patients with AD, we found accumulation of seed-competent tau predominantly in postsynaptic compartments. Tau-mediated toxicity in postsynaptic compartments was exacerbated by impaired proteasome activity detected by measuring lysine-48 polyubiquitination of proteins targeted for proteasomal degradation. To combat the accumulation of tau and proteasome impairment in the postsynaptic compartments of rTg4510 mouse brain, we stimulated the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1R) with its ligand PACAP administered intracerebroventricularly to rTg4510 mice. We observed enhanced synaptic proteasome activity and reduced total tau in postsynaptic compartments in mouse brain after PACAP treatment. The clearance of tau from postsynaptic compartments correlated with attenuated tauopathy and improved cognitive performance of rTg4510 transgenic mice on two behavioral tests. These results suggest that activating PAC1R could prevent accumulation of aggregate-prone tau and indicate a potential therapeutic approach for AD and other tauopathies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schaler</LastName><ForeName>Ari W</ForeName><Initials>AW</Initials><Identifier Source="ORCID">0000-0003-2504-220X</Identifier><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Runyan</LastName><ForeName>Avery M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-2710-6334</Identifier><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clelland</LastName><ForeName>Catherine L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sydney</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fowler</LastName><ForeName>Stephanie L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0001-6693-9959</Identifier><AffiliationInfo><Affiliation>U.K. Dementia Research Institute, University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueroa</LastName><ForeName>Helen Y</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shioda</LastName><ForeName>Seiji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Innovative Drug Discovery, Global Research Center for Innovative Life Science, Hoshi University, Tokyo 142-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santa-Maria</LastName><ForeName>Ismael</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2801-5020</Identifier><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials><Identifier Source="ORCID">0000-0002-6177-868X</Identifier><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>U.K. Dementia Research Institute, University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myeku</LastName><ForeName>Natura</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-6404-7954</Identifier><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA. nm2631@cumc.columbia.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>L30 AG074191</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095922</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG070075</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG055694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG064244</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051237">Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051237" MajorTopicYN="N">Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="Y">Tauopathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="Y">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>5</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34039738</ArticleId><ArticleId IdType="mid">NIHMS1787604</ArticleId><ArticleId IdType="pmc">PMC8988215</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aba7394</ArticleId><ArticleId IdType="pii">13/595/eaba7394</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen MK et al., Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA neurology 75, 1215&#x2013;1224 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233853</ArticleId><ArticleId IdType="pubmed">30014145</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia C et al., Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. JAMA neurology 74, 427&#x2013;436 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5470368</ArticleId><ArticleId IdType="pubmed">28241163</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Nievas BG et al., Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain 136, 2510&#x2013;2526 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722351</ArticleId><ArticleId IdType="pubmed">23824488</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thai DR, Ghebremedhin E, Del Tredici K, Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70, 960&#x2013;969 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR et al., Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067&#x2013;1081 (2010)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Cope TE et al., Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy. Brain 141, 550&#x2013;567 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837359</ArticleId><ArticleId IdType="pubmed">29293892</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R et al., Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med 12, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035952</ArticleId><ArticleId IdType="pubmed">31894103</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai HC et al., The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol 181, 1426&#x2013;1435 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463637</ArticleId><ArticleId IdType="pubmed">22867711</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen LD, Ziv NE, Recent insights on principles of synaptic protein degradation. F1000Res 6, 675 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5461898</ArticleId><ArticleId IdType="pubmed">28620464</ArticleId></ArticleIdList></Reference><Reference><Citation>Felsenberg J, Dombrowski V, Eisenhardt D, A role of protein degradation in memory consolidation after initial learning and extinction learning in the honeybee (Apis mellifera). Learn Mem 19, 470&#x2013;477 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22988289</ArticleId></ArticleIdList></Reference><Reference><Citation>Balaji V, Kaniyappan S, Mandelkow E, Wang Y, Mandelkow EM, Pathological missorting of endogenous MAPT/Tau in neurons caused by failure of protein degradation systems. Autophagy 14, 2139&#x2013;2154 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6984766</ArticleId><ArticleId IdType="pubmed">30145931</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller JN, Hanni KB, Markesbery WR, Impaired proteasome function in Alzheimer's disease. J Neurochem 75, 436&#x2013;439 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10854289</ArticleId></ArticleIdList></Reference><Reference><Citation>Myeku N et al., Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med 22, 46&#x2013;53 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4787271</ArticleId><ArticleId IdType="pubmed">26692334</ArticleId></ArticleIdList></Reference><Reference><Citation>Thibaudeau TA, Anderson RT, Smith DM, A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers. Nat Commun 9, 1097 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5854577</ArticleId><ArticleId IdType="pubmed">29545515</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaler AW, Myeku N, Cilostazol, a phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline. Transl Res 193, 31&#x2013;41 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10075247</ArticleId><ArticleId IdType="pubmed">29232559</ArticleId></ArticleIdList></Reference><Reference><Citation>VerPlank JJS, Lokireddy S, Zhao J, Goldberg AL, 26S Proteasomes are rapidly activated by diverse hormones and physiological states that raise cAMP and cause Rpn6 phosphorylation. Proc Natl Acad Sci U S A, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410790</ArticleId><ArticleId IdType="pubmed">30782827</ArticleId></ArticleIdList></Reference><Reference><Citation>VerPlank JJS, Tyrkalska SD, Fleming A, Rubinsztein DC, Goldberg AL, cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases. Proc Natl Acad Sci U S A 117, 14220&#x2013;14230 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7321992</ArticleId><ArticleId IdType="pubmed">32513741</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X et al., Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis. Nat Cell Biol 18, 202&#x2013;212 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4844191</ArticleId><ArticleId IdType="pubmed">26655835</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaudry D et al., Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61, 283&#x2013;357 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19805477</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirabayashi T, Nakamachi T, Shioda S, Discovery of PACAP and its receptors in the brain. J Headache Pain 19, 28 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884755</ArticleId><ArticleId IdType="pubmed">29619773</ArticleId></ArticleIdList></Reference><Reference><Citation>Shioda S et al., Pleiotropic functions of PACAP in the CNS: neuroprotection and neurodevelopment. Ann N Y Acad Sci 1070, 550&#x2013;560 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16888224</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain 138, 2814&#x2013;2833 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26283673</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW, Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 27, 457&#x2013;464 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wilde MC, Overk CR, Sijben JW, Masliah E, Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability. Alzheimers Dement 12, 633&#x2013;644 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058345</ArticleId><ArticleId IdType="pubmed">26776762</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1, 213&#x2013;216 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1669710</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A et al., Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685&#x2013;697 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A et al., Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. Brain 140, 3286&#x2013;3300 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW et al., Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271&#x2013;1288 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokireddy S, Kukushkin NV, Goldberg AL, cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. Proc Natl Acad Sci U S A 112, E7176&#x2013;7185 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702992</ArticleId><ArticleId IdType="pubmed">26669444</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman JL et al., Widespread tau seeding activity at early Braak stages. Acta Neuropathol 133, 91&#x2013;100 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833300</ArticleId><ArticleId IdType="pubmed">27878366</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL et al., Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain. Front Neurosci 12, 267 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5928393</ArticleId><ArticleId IdType="pubmed">29740275</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser AS, Attwood MM, Rask-Andersen M, Schioth HB, Gloriam DE, Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6882681</ArticleId><ArticleId IdType="pubmed">29075003</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennissen FJ, Anglada-Huguet M, Sydow A, Mandelkow E, Mandelkow EM, Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau DeltaK280. Proc Natl Acad Sci U S A 113, 11597&#x2013;11602 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5068267</ArticleId><ArticleId IdType="pubmed">27671637</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M, Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci U S A 106, 16877&#x2013;16882 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743726</ArticleId><ArticleId IdType="pubmed">19805389</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Maderdrut JL, Lertora JJ, Batuman V, Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study. Peptides 28, 1891&#x2013;1895 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17582655</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtaki H et al., Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc Natl Acad Sci U S A 103, 7488&#x2013;7493 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1464366</ArticleId><ArticleId IdType="pubmed">16651528</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamache J et al., Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice. Nat Commun 10, 2479 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554306</ArticleId><ArticleId IdType="pubmed">31171783</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D et al., Tau local structure shields an amyloid-forming motif and controls aggregation propensity. Nat Commun 10, 2493 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6555816</ArticleId><ArticleId IdType="pubmed">31175300</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL et al., Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice. J Exp Med 213, 2635&#x2013;2654 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5110027</ArticleId><ArticleId IdType="pubmed">27810929</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin etal S., Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease. Nat Med 26, 1256&#x2013;1263 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603860</ArticleId><ArticleId IdType="pubmed">32572268</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A, Targeted protein degraders crowd into the clinic. Nat Rev Drug Discov 20, 247&#x2013;250 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33737725</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X et al., UBLCP1 is a 26S proteasome phosphatase that regulates nuclear proteasome activity. Proc Natl Acad Sci U S A 108, 18649&#x2013;18654 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219150</ArticleId><ArticleId IdType="pubmed">21949367</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34040151</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Low-intensity ultrasound restores long-term potentiation and memory in senescent mice through pleiotropic mechanisms including NMDAR signaling.</ArticleTitle><Pagination><StartPage>6975</StartPage><EndPage>6991</EndPage><MedlinePgn>6975-6991</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-021-01129-7</ELocationID><Abstract><AbstractText>Advanced physiological aging is associated with impaired cognitive performance and the inability to induce long-term potentiation (LTP), an electrophysiological correlate of memory. Here, we demonstrate in the physiologically aged, senescent mouse brain that scanning ultrasound combined with microbubbles (SUS<sup>+MB</sup>), by transiently opening the blood-brain barrier, fully restores LTP induction in the dentate gyrus of the hippocampus. Intriguingly, SUS treatment without microbubbles (SUS<sup>only</sup>), i.e., without the uptake of blood-borne factors, proved even more effective, not only restoring LTP, but also ameliorating the spatial learning deficits of the aged mice. This functional improvement is accompanied by an altered milieu of the aged hippocampus, including a lower density of perineuronal nets, increased neurogenesis, and synaptic signaling, which collectively results in improved spatial learning. We therefore conclude that therapeutic ultrasound is a non-invasive, pleiotropic modality that may enhance cognition in elderly&#xa0;humans.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Blackmore</LastName><ForeName>Daniel G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Turpin</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palliyaguru</LastName><ForeName>Tishila</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Harrison T</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chicoteau</LastName><ForeName>Antony</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8220-6982</Identifier><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelekanos</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Nghia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Jae</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6716-5681</Identifier><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Robert K P</ForeName><Initials>RKP</Initials><Identifier Source="ORCID">0000-0003-3414-2448</Identifier><AffiliationInfo><Affiliation>Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sah</LastName><ForeName>Pankaj</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Center for Neuroscience and Neural Engineering, and Department of Biology, Southern University of Science and Technology, Shenzhen, Guangdong Province, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartlett</LastName><ForeName>Perry F</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Center for Neuroscience and Neural Engineering, and Department of Biology, Southern University of Science and Technology, Shenzhen, Guangdong Province, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;tz</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8501-7896</Identifier><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia. j.goetz@uq.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="Y">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="Y">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34040151</ArticleId><ArticleId IdType="pmc">PMC8760044</ArticleId><ArticleId IdType="doi">10.1038/s41380-021-01129-7</ArticleId><ArticleId IdType="pii">10.1038/s41380-021-01129-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836174</ArticleId><ArticleId IdType="pubmed">23746838</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackmore DG, Turpin F, Mohamed AZ, Zong F, Pandit R, Pelekanos M, et al. Multimodal analysis of aged wild-type mice exposed to repeated scanning ultrasound treatments demonstrates long-term safety. Theranostics. 2018;8:6233&#x2013;47..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6299703</ArticleId><ArticleId IdType="pubmed">30613294</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinenga G, G&#xf6;tz J. Scanning ultrasound removes amyloid-beta and restores memory in an Alzheimer&#x2019;s disease mouse model. Sci Tran Med. 2015;7:278ra33.</Citation><ArticleIdList><ArticleId IdType="pubmed">25761889</ArticleId></ArticleIdList></Reference><Reference><Citation>Nisbet RM, Van der Jeugd A, Leinenga G, Evans HT, Janowicz PW, G&#xf6;tz J. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model. Brain. 2017;140:1220&#x2013;30..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5405237</ArticleId><ArticleId IdType="pubmed">28379300</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinenga G, Langton C, Nisbet R, G&#xf6;tz J. Ultrasound treatment of neurological diseases&#x2014;current and emerging applications. Nat Rev Neurol. 2016;12:161&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">26891768</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandit R, Koh WK, Sullivan RKP, Palliyaguru T, Parton RG, G&#xf6;tz J. Role for caveolin-mediated transcytosis in facilitating transport of large cargoes into the brain via ultrasound. J Control Release. 2020;327:667&#x2013;75..</Citation><ArticleIdList><ArticleId IdType="pubmed">32918963</ArticleId></ArticleIdList></Reference><Reference><Citation>Turturro A, Duffy P, Hass B, Kodell R, Hart R. Survival characteristics and age-adjusted disease incidences in C57BL/6 mice fed a commonly used cereal-based diet modulated by dietary restriction. J Gerontol A Biol Sci Med Sci. 2002;57:B379&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">12403793</ArticleId></ArticleIdList></Reference><Reference><Citation>Benice TS, Rizk A, Kohama S, Pfankuch T, Raber J. Sex-differences in age-related cognitive decline in C57BL/6J mice associated with increased brain microtubule-associated protein 2 and synaptophysin immunoreactivity. Neuroscience. 2006;137:413&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330151</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H, Shubert T, Zhao C, Gage FH. Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci. 2005;25:8680&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360197</ArticleId><ArticleId IdType="pubmed">16177036</ArticleId></ArticleIdList></Reference><Reference><Citation>Seip R, Chin CT, Hall CS, Raju BI, Ghanem A, Tiemann K. Targeted ultrasound-mediated delivery of nanoparticles: on the development of a new HIFU-based therapy and imaging device. IEEE Trans Biomed Eng. 2010;57:61&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">19695986</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, G&#xf6;tz J. Somatodendritic accumulation of Tau in Alzheimer&#x2019;s disease is promoted by Fyn-mediated local protein translation. EMBO J. 2017;36:3120&#x2013;38..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666608</ArticleId><ArticleId IdType="pubmed">28864542</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans HT, Benetatos J, van Roijen M, Bodea LG, G&#xf6;tz J. Decreased synthesis of ribosomal proteins in tauopathy revealed by non-canonical amino acid labelling. EMBO J. 2019;38:e101174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6600635</ArticleId><ArticleId IdType="pubmed">31268600</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics. 2020;36:2628&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7178415</ArticleId><ArticleId IdType="pubmed">31882993</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman PS, Elias WJ, Ghanouni P, Gwinn R, Lipsman N, Schwartz M, et al. Neurological adverse event profile of magnetic resonance imaging-guided focused ultrasound thalamotomy for essential tremor. Mov Disord. 2018;33:843&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29701263</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandit R, Leinenga G, G&#xf6;tz J. Repeated ultrasound treatment of tau transgenic mice clears neuronal tau by autophagy and improves behavioral functions. Theranostics. 2019;9:3754&#x2013;67..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6587352</ArticleId><ArticleId IdType="pubmed">31281511</ArticleId></ArticleIdList></Reference><Reference><Citation>Refinetti R. The circadian rhythm of body temperature. Front Biosci (Landmark Ed) 2010;15:564&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">20036834</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarmolenko PS, Moon EJ, Landon C, Manzoor A, Hochman DW, Viglianti BL, et al. Thresholds for thermal damage to normal tissues: an update. Int J Hyperth. 2011;27:320&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3609720</ArticleId><ArticleId IdType="pubmed">21591897</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatch RJ, Leinenga G, G&#xf6;tz J. Scanning ultrasound (SUS) causes no changes to neuronal excitability and prevents age-related reductions in hippocampal CA1 dendritic structure in wild-type mice. PLoS One. 2016;11:e0164278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5058555</ArticleId><ArticleId IdType="pubmed">27727310</ArticleId></ArticleIdList></Reference><Reference><Citation>Malenka RC. The long-term potential of LTP. Nat Rev Neurosci. 2003;4:923&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">14595403</ArticleId></ArticleIdList></Reference><Reference><Citation>Froc DJ, Eadie B, Li AM, Wodtke K, Tse M, Christie BR. Reduced synaptic plasticity in the lateral perforant path input to the dentate gyrus of aged C57BL/6 mice. J Neurophysiol. 2003;90:32&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12634277</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll RA. A brief history of long-term potentiation. Neuron. 2017;93:281&#x2013;90..</Citation><ArticleIdList><ArticleId IdType="pubmed">28103477</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge S, Yang CH, Hsu KS, Ming GL, Song H. A critical period for enhanced synaptic plasticity in newly generated neurons of the adult brain. Neuron. 2007;54:559&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040308</ArticleId><ArticleId IdType="pubmed">17521569</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster KA, McLaughlin N, Edbauer D, Phillips M, Bolton A, Constantine-Paton M, et al. Distinct roles of NR2A and NR2B cytoplasmic tails in long-term potentiation. J Neurosci. 2010;30:2676&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840640</ArticleId><ArticleId IdType="pubmed">20164351</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer KU, Schulman H. CaM kinase: still inspiring at 40. Neuron. 2019;103:380&#x2013;94..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6688632</ArticleId><ArticleId IdType="pubmed">31394063</ArticleId></ArticleIdList></Reference><Reference><Citation>Philpot BD, Cho KK, Bear MF. Obligatory role of NR2A for metaplasticity in visual cortex. Neuron. 2007;53:495&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847797</ArticleId><ArticleId IdType="pubmed">17296552</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Matsliah SI, Seroussi Y, Rosenblum K, Barkai E. Persistent ERK activation maintains learning-induced long-lasting modulation of synaptic connectivity. Learn Mem. 2008;15:756&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">18832562</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirbhoy PS, Farris S, Steward O. Synaptic activation of ribosomal protein S6 phosphorylation occurs locally in activated dendritic domains. Learn Mem. 2016;23:255&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4880148</ArticleId><ArticleId IdType="pubmed">27194793</ArticleId></ArticleIdList></Reference><Reference><Citation>Conquet F, Bashir ZI, Davies CH, Daniel H, Ferraguti F, Bordi F, et al. Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature. 1994;372:237&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969468</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui TJ, Tari PK, Connor SA, Zhang P, Dobie FA, She K, et al. An LRRTM4-HSPG complex mediates excitatory synapse development on dentate gyrus granule cells. Neuron. 2013;79:680&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">23911104</ArticleId></ArticleIdList></Reference><Reference><Citation>Fawcett JW, Oohashi T, Pizzorusso T. The roles of perineuronal nets and the perinodal extracellular matrix in neuronal function. Nat Rev Neurosci. 2019;20:451&#x2013;65..</Citation><ArticleIdList><ArticleId IdType="pubmed">31263252</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Cacquevel M, Saksida LM, Bussey TJ, Schneider BL, Aebischer P, et al. Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology. Exp Neurol. 2015;265:48&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4353684</ArticleId><ArticleId IdType="pubmed">25483398</ArticleId></ArticleIdList></Reference><Reference><Citation>Su W, Matsumoto S, Sorg B, Sherman LS. Distinct roles for hyaluronan in neural stem cell niches and perineuronal nets. Matrix Biol. 2019;78-79:272&#x2013;83..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6068007</ArticleId><ArticleId IdType="pubmed">29408010</ArticleId></ArticleIdList></Reference><Reference><Citation>Vukovic J, Borlikova GG, Ruitenberg MJ, Robinson GJ, Sullivan RK, Walker TL, et al. Immature doublecortin-positive hippocampal neurons are important for learning but not for remembering. J Neurosci. 2013;33:6603&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619068</ArticleId><ArticleId IdType="pubmed">23575857</ArticleId></ArticleIdList></Reference><Reference><Citation>Clelland CD, Choi M, Romberg C, Clemenson GD, Jr., Fragniere A, Tyers P, et al. A functional role for adult hippocampal neurogenesis in spatial pattern separation. Science. 2009;325:210&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2997634</ArticleId><ArticleId IdType="pubmed">19590004</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci. 1996;16:2027&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578509</ArticleId><ArticleId IdType="pubmed">8604047</ArticleId></ArticleIdList></Reference><Reference><Citation>Couillard-Despres S, Winner B, Schaubeck S, Aigner R, Vroemen M, Weidner N, et al. Doublecortin expression levels in adult brain reflect neurogenesis. Eur J Neurosci. 2005;21:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">15654838</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooney SJ, Shah K, Yeung S, Burgess A, Aubert I, Hynynen K. Focused ultrasound-induced neurogenesis requires an increase in blood-brain barrier permeability. PLoS One. 2016;11:e0159892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961388</ArticleId><ArticleId IdType="pubmed">27459643</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J, Kong C, Lee J, Choi BY, Sim J, Koh CS, et al. Focused ultrasound-induced blood-brain barrier opening improves adult hippocampal neurogenesis and cognitive function in a cholinergic degeneration dementia rat model. Alzheimer&#x2019;s Res Ther. 2019;11:110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6933667</ArticleId><ArticleId IdType="pubmed">31881998</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarcelli T, Jordao JF, O&#x2019;Reilly MA, Ellens N, Hynynen K, Aubert I. Stimulation of hippocampal neurogenesis by transcranial focused ultrasound and microbubbles in adult mice. Brain Stimul. 2014;7:304&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4103630</ArticleId><ArticleId IdType="pubmed">24629831</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh SJ, Lee JM, Kim HB, Lee J, Han S, Bae JY, et al. Ultrasonic neuromodulation via astrocytic TRPA1. Curr Biol. 2019;29:3386&#x2013;401.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31588000</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta S, Sengupta P. Men and mice: relating their ages. Life Sci. 2016;152:244&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26596563</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyler WJ, Lani SW, Hwang GM. Ultrasonic modulation of neural circuit activity. Curr Opin Neurobiol. 2018;50:222&#x2013;31..</Citation><ArticleIdList><ArticleId IdType="pubmed">29674264</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam MJ, Kitamura T, Saitoh Y, Ohkawa N, Kondo T, Inokuchi K. Adult neurogenesis conserves hippocampal memory capacity. J Neurosci. 2018;38:6854&#x2013;63..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6596118</ArticleId><ArticleId IdType="pubmed">29986876</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng W, Aimone JB, Gage FH. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nat Rev Neurosci. 2010;11:339&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886712</ArticleId><ArticleId IdType="pubmed">20354534</ArticleId></ArticleIdList></Reference><Reference><Citation>Senkov O, Andjus P, Radenovic L, Soriano E, Dityatev A. Neural ECM molecules in synaptic plasticity, learning, and memory. Prog Brain Res. 2014;214:53&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">25410353</ArticleId></ArticleIdList></Reference><Reference><Citation>Romberg C, Yang S, Melani R, Andrews MR, Horner AE, Spillantini MG, et al. Depletion of perineuronal nets enhances recognition memory and long-term depression in the perirhinal cortex. J Neurosci. 2013;33:7057&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3655688</ArticleId><ArticleId IdType="pubmed">23595763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsman N, Meng Y, Bethune AJ, Huang Y, Lam B, Masellis M, et al. Blood-brain barrier opening in Alzheimer&#x2019;s disease using MR-guided focused ultrasound. Nat Commun. 2018;9:2336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6060168</ArticleId><ArticleId IdType="pubmed">30046032</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouget P, Frey S, Ahnine H, Attali D, Claron J, Constans C, et al. Neuronavigated repetitive transcranial ultrasound stimulation induces long-lasting and reversible effects on oculomotor performance in non-human primates. Front Physiol. 2020;11:1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7466663</ArticleId><ArticleId IdType="pubmed">32973560</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanguinetti JL, Hameroff S, Smith EE, Sato T, Daft CMW, Tyler WJ, et al. Transcranial focused ultrasound to the right prefrontal cortex improves mood and alters functional connectivity in humans. Front Hum Neurosci. 2020;14:52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7058635</ArticleId><ArticleId IdType="pubmed">32184714</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinker ST, Preiswerk F, White PJ, Mariano TY, McDannold NJ, Bubrick EJ. Focused ultrasound platform for investigating therapeutic neuromodulation across the human hippocampus. Ultrasound Med Biol. 2020;46:1270&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7239323</ArticleId><ArticleId IdType="pubmed">32088061</ArticleId></ArticleIdList></Reference><Reference><Citation>Downs ME, Lee SA, Yang G, Kim S, Wang Q, Konofagou EE. Non-invasive peripheral nerve stimulation via focused ultrasound in vivo. Phys Med Biol. 2018;63:035011.</Citation><ArticleIdList><ArticleId IdType="pubmed">29214985</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson B, Hamani C, Rabin JS, Goubran M, Meng Y, Huang Y, et al. Magnetic resonance-guided focused ultrasound capsulotomy for refractory obsessive compulsive disorder and major depressive disorder: clinical and imaging results from two phase I trials. Mol Psychiatry. 2020;25:1946&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">32404942</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV, Cooke SF. Long-term potentiation and long-term depression: a clinical perspective. Clinics (Sao Paulo) 2011;66:3&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3118435</ArticleId><ArticleId IdType="pubmed">21779718</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34092791</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1548-7105</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature methods</Title><ISOAbbreviation>Nat Methods</ISOAbbreviation></Journal><ArticleTitle>L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma.</ArticleTitle><Pagination><StartPage>631</StartPage><EndPage>634</EndPage><MedlinePgn>631-634</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41592-021-01174-8</ELocationID><Abstract><AbstractText>L1CAM is a transmembrane protein expressed on neurons that was presumed to be found on neuron-derived extracellular vesicles (NDEVs) in human biofluids. We developed a panel of single-molecule array assays to evaluate the use of L1CAM for NDEV isolation. We demonstrate that L1CAM is not associated with extracellular vesicles in human plasma or cerebrospinal fluid and therefore recommend against its use as a marker in NDEV isolation protocols.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Norman</LastName><ForeName>Maia</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9654-4904</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ter-Ovanesyan</LastName><ForeName>Dmitry</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trieu</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazarovits</LastName><ForeName>Roey</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowal</LastName><ForeName>Emma J K</ForeName><Initials>EJK</Initials><AffiliationInfo><Affiliation>Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ju Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen-Plotkin</LastName><ForeName>Alice S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regev</LastName><ForeName>Aviv</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Church</LastName><ForeName>George M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walt</LastName><ForeName>David R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-5524-7348</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. dwalt@bwh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA. dwalt@bwh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA. dwalt@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS082265</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>RM1 HG008525</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS115139</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG062418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072979</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Methods</MedlineTA><NlmUniqueID>101215604</NlmUniqueID><ISSNLinking>1548-7091</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000633764">L1CAM protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039842">Neural Cell Adhesion Molecule L1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002498" MajorTopicYN="N">Centrifugation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002850" MajorTopicYN="N">Chromatography, Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067128" MajorTopicYN="N">Extracellular Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039842" MajorTopicYN="N">Neural Cell Adhesion Molecule L1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. D.R.W. is a founder and equity holder of Quanterix. A.R. is an SAB member of Thermo Fisher Scientific, Neogene Therapeutics, Asimov and Syros Pharmaceuticals. A.R. is a cofounder of and equity holder in Celsius Therapeutics and an equity holder in Immunitas. From 1 August 2020, A.R. is an employee of Genentech. G.M.C. is a founder, consultant or advisory board member to companies listed here: http://arep.med.harvard.edu/gmc/tech.html. These companies had no influence over any aspect of this research. We have filed intellectual property on methods for EV analysis and isolation. M.N., D.T.-O. and D.R.W. filed a provisional patent for the measurement of EVs using single-molecule arrays as described in this study. Additionally, D.T.-O., E.J.K.K., A.R. and G.M.C. filed intellectual property relating to the identification and use of new candidate markers for NDEV isolation.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>7</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34092791</ArticleId><ArticleId IdType="mid">NIHMS1792094</ArticleId><ArticleId IdType="pmc">PMC9075416</ArticleId><ArticleId IdType="doi">10.1038/s41592-021-01174-8</ArticleId><ArticleId IdType="pii">10.1038/s41592-021-01174-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Raposo G &amp; Stoorvogel W Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol 200, 373&#x2013;383 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575529</ArticleId><ArticleId IdType="pubmed">23420871</ArticleId></ArticleIdList></Reference><Reference><Citation>Hlavin ML &amp; Lemmon V Molecular structure and functional testing of human L1CAM: an interspecies comparison. Genomics 11, 416&#x2013;423 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1769655</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiolini F et al. A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing. eLife 8, e44305 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6398979</ArticleId><ArticleId IdType="pubmed">30829570</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissin DM et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol 28, 595&#x2013;599 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919230</ArticleId><ArticleId IdType="pubmed">20495550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobb RJ et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J. Extracell. Vesicles 4, 27031 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4507751</ArticleId><ArticleId IdType="pubmed">26194179</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechtersheimer S et al.. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J. Cell Biol 155, 661&#x2013;673 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2198870</ArticleId><ArticleId IdType="pubmed">11706054</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L et al. The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. J. Biol. Chem 287, 25927&#x2013;25940 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406677</ArticleId><ArticleId IdType="pubmed">22692213</ArticleId></ArticleIdList></Reference><Reference><Citation>Carithers LJ et al. A novel approach to high-quality postmortem tissue procurement: the GTEx project. Biopreserv. Biobank 13, 311&#x2013;319 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4675181</ArticleId><ArticleId IdType="pubmed">26484571</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M et al. Plasma exosomal &#x3b1;-synuclein is likely CNS-derived and increased in Parkinson&#x2019;s disease. Acta Neuropathol 128, 639&#x2013;650 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201967</ArticleId><ArticleId IdType="pubmed">24997849</ArticleId></ArticleIdList></Reference><Reference><Citation>Thery C et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7, 1535750 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6322352</ArticleId><ArticleId IdType="pubmed">30637094</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG et al. Extracellular vesicles in neurodegenerative disease&#x2014;pathogenesis to biomarkers. Nat. Rev. Neurol 12, 346&#x2013;357 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27174238</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M, Sheng L, Stewart T, Zabetian CP &amp; Zhang J New windows into the brain: central nervous system-derived extracellular vesicles in blood. Prog. Neurobiol 175, 96&#x2013;106 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6546433</ArticleId><ArticleId IdType="pubmed">30685501</ArticleId></ArticleIdList></Reference><Reference><Citation>Shevchenko A, Wilm M, Vorm O &amp; Mann M Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal. Chem 68, 850&#x2013;858 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8779443</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J &amp; Gygi SP Proteomics: the move to mixtures. J. Mass Spectrom 36, 1083&#x2013;1091 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11747101</ArticleId></ArticleIdList></Reference><Reference><Citation>Eng JK, McCormack AL &amp; Yates JR An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass Spectrom 5, 976&#x2013;989 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">24226387</ArticleId></ArticleIdList></Reference><Reference><Citation>Busskamp V et al. Rapid neurogenesis through transcriptional activation in human stem cells. Mol. Syst. Biol 10, 760 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299601</ArticleId><ArticleId IdType="pubmed">25403753</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorvaldsdottir H, Robinson JT &amp; Mesirov JP Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinform 14, 178&#x2013;192 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3603213</ArticleId><ArticleId IdType="pubmed">22517427</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34107254</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Replicative senescence dictates the emergence of disease-associated microglia and contributes to A&#x3b2; pathology.</ArticleTitle><Pagination><StartPage>109228</StartPage><MedlinePgn>109228</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">109228</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2021.109228</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(21)00579-9</ELocationID><Abstract><AbstractText>The sustained proliferation of microglia is a key hallmark of Alzheimer's disease (AD), accelerating its progression. Here, we aim to understand the long-term impact of the early and prolonged microglial proliferation observed in AD, hypothesizing that extensive and repeated cycling would engender a distinct transcriptional and phenotypic trajectory. We show that the early and sustained microglial proliferation seen in an AD-like model promotes replicative senescence, characterized by increased &#x3b2;gal activity, a senescence-associated transcriptional signature, and telomere shortening, correlating with the appearance of disease-associated microglia (DAM) and senescent microglial profiles in human post-mortem AD cases. The prevention of early microglial proliferation hinders the development of senescence and DAM, impairing the accumulation of A&#x3b2;, as well as associated neuritic and synaptic damage. Overall, our results indicate that excessive microglial proliferation leads to the generation of senescent DAM, which contributes to early A&#x3b2; pathology in AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yanling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fryatt</LastName><ForeName>Gemma L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghorbani</LastName><ForeName>Mohammadmersad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obst</LastName><ForeName>Juliane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menassa</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin-Estebane</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muntslag</LastName><ForeName>Tim A O</ForeName><Initials>TAO</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olmos-Alonso</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerrero-Carrasco</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cragg</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Nicola</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Biological Sciences, University of Southampton, Southampton General Hospital, Southampton, UK. Electronic address: d.gomez-nicola@soton.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>24721</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/P024572/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016922" MajorTopicYN="N">Cellular Senescence</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APP/PS1</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">CSF1R</Keyword><Keyword MajorTopicYN="N">disease-associated microglia (DAM)</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>9</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34107254</ArticleId><ArticleId IdType="pmc">PMC8206957</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.109228</ArticleId><ArticleId IdType="pii">S2211-1247(21)00579-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alliot F., Godin I., Pessac B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res. Dev. Brain Res. 1999;117:145&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">10567732</ArticleId></ArticleIdList></Reference><Reference><Citation>Askew K., Gomez-Nicola D. A story of birth and death: insights into the formation and dynamics of the microglial population. Brain Behav. Immun. 2018;69:9&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28341583</ArticleId></ArticleIdList></Reference><Reference><Citation>Askew K., Li K., Olmos-Alonso A., Garcia-Moreno F., Liang Y., Richardson P., Tipton T., Chapman M.A., Riecken K., Beccari S. Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain. Cell Rep. 2017;18:391&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5263237</ArticleId><ArticleId IdType="pubmed">28076784</ArticleId></ArticleIdList></Reference><Reference><Citation>Bisht K., Sharma K.P., Lecours C., S&#xe1;nchez M.G., El Hajj H., Milior G., Olmos-Alonso A., G&#xf3;mez-Nicola D., Luheshi G., Valli&#xe8;res L. Dark microglia: a new phenotype predominantly associated with pathological states. Glia. 2016;64:826&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4949554</ArticleId><ArticleId IdType="pubmed">26847266</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussian T.J., Aziz A., Meyer C.F., Swenson B.L., van Deursen J.M., Baker D.J. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature. 2018;562:578&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206507</ArticleId><ArticleId IdType="pubmed">30232451</ArticleId></ArticleIdList></Reference><Reference><Citation>Carnero A. Markers of cellular senescence. Methods Mol. Biol. 2013;965:63&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">23296651</ArticleId></ArticleIdList></Reference><Reference><Citation>Casella G., Munk R., Kim K.M., Piao Y., De S., Abdelmohsen K., Gorospe M. Transcriptome signature of cellular senescence. Nucleic Acids Res. 2019;47:7294&#x2013;7305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6698740</ArticleId><ArticleId IdType="pubmed">31251810</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton E.L., Mancuso R., Nielsen T.T., Mizielinska S., Holmes H., Powell N., Norona F., Larsen J.O., Milioto C., Wilson K.M., FReJA Early microgliosis precedes neuronal loss and behavioural impairment in mice with a frontotemporal dementia-causing CHMP2B mutation. Hum. Mol. Genet. 2017;26:873&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409096</ArticleId><ArticleId IdType="pubmed">28093491</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C., Yuan P., Schain A., Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar A&#x3b2;42 hotspots around plaques. Nat. Commun. 2015;6:6176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagher N.N., Najafi A.R., Kayala K.M., Elmore M.R., White T.E., Medeiros R., West B.L., Green K.N. Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. J.&#xa0;Neuroinflammation. 2015;12:139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522109</ArticleId><ArticleId IdType="pubmed">26232154</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O. A biomarker that identifies senescent human cells in culture and in aging skin in&#xa0;vivo. Proc. Natl. Acad. Sci. USA. 1995;92:9363&#x2013;9367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40985</ArticleId><ArticleId IdType="pubmed">7568133</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A., Davis C.A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T.R. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G., McDavid A., Yajima M., Deng J., Gersuk V., Shalek A.K., Slichter C.K., Miller H.W., McElrath M.J., Prlic M. MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 2015;16:278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanary B.E., Streit W.J. Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes. Glia. 2004;45:75&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">14648548</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanary B.E., Sammons N.W., Nguyen C., Walker D., Streit W.J. Evidence that aging and amyloid promote microglial cell senescence. Rejuvenation Res. 2007;10:61&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">17378753</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy S.A., Yang F., Irrizarry M., Hyman B., Saido T.C., Hsiao K., Cole G.M. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 1998;152:307&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858113</ArticleId><ArticleId IdType="pubmed">9422548</ArticleId></ArticleIdList></Reference><Reference><Citation>Fridman A.L., Tainsky M.A. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene. 2008;27:5975&#x2013;5987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843241</ArticleId><ArticleId IdType="pubmed">18711403</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., Mehler M.F., Conway S.J., Ng L.G., Stanley E.R. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann T., Zeller N., Raasch J., Kierdorf K., Frenzel K., Ketscher L., Basters A., Staszewski O., Brendecke S.M., Spiess A. USP18 lack in microglia causes destructive interferonopathy of the mouse brain. EMBO J. 2015;34:1612&#x2013;1629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4475397</ArticleId><ArticleId IdType="pubmed">25896511</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Nicola D., Fransen N.L., Suzzi S., Perry V.H. Regulation of microglial proliferation during chronic neurodegeneration. J.&#xa0;Neurosci. 2013;33:2481&#x2013;2493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619184</ArticleId><ArticleId IdType="pubmed">23392676</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayflick L. The Limited in&#xa0;Vitro Lifetime of Human Diploid Cell Strains. Exp. Cell Res. 1965;37:614&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">14315085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Segura A., de Jong T.V., Melov S., Guryev V., Campisi J., Demaria M. Unmasking Transcriptional Heterogeneity in Senescent Cells. Curr. Biol. 2017;27:2652&#x2013;2660.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5788810</ArticleId><ArticleId IdType="pubmed">28844647</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y., Ibata I., Ito D., Ohsawa K., Kohsaka S. A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem. Biophys. Res. Commun. 1996;224:855&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">8713135</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in&#xa0;vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004;13:159&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamminga L.M., Bystrykh L.V., de Boer A., Houwer S., Douma J., Weersing E., Dontje B., de Haan G. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood. 2006;107:2170&#x2013;2179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895717</ArticleId><ArticleId IdType="pubmed">16293602</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T.K., David E., Baruch K., Lara-Astaiso D., Toth B. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell. 2017;169:1276&#x2013;1290.e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A.M., Babcock A.A., Saeed H., Myhre C.L., Kassem M., Finsen B. Telomere dysfunction reduces microglial numbers without fully inducing an aging phenotype. Neurobiol. Aging. 2015;36:2164&#x2013;2175.</Citation><ArticleIdList><ArticleId IdType="pubmed">25892207</ArticleId></ArticleIdList></Reference><Reference><Citation>Kracht L., Borggrewe M., Eskandar S., Brouwer N., Chuva de Sousa Lopes S.M., Laman J.D., Scherjon S.A., Prins J.R., Kooistra S.M., Eggen B.J.L. Human fetal microglia acquire homeostatic immune-sensing properties early in development. Science. 2020;369:530&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">32732419</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S., Madore C., Cialic R., Baufeld C., Calcagno N., El Fatimy R., Beckers L., O&#x2019;Loughlin E., Xu Y., Fanek Z. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity. 2017;47:566&#x2013;581.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B.Y., Han J.A., Im J.S., Morrone A., Johung K., Goodwin E.C., Kleijer W.J., DiMaio D., Hwang E.S. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell. 2006;5:187&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">16626397</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y., Smyth G.K., Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Limbad C., Oron T.R., Alimirah F., Davalos A.R., Tracy T.E., Gan L., Desprez P.Y., Campisi J. Astrocyte senescence promotes glutamate toxicity in cortical neurons. PLoS ONE. 2020;15:e0227887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6964973</ArticleId><ArticleId IdType="pubmed">31945125</ArticleId></ArticleIdList></Reference><Reference><Citation>Love M.I., Huber W., Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., Fryatt G., Cleal M., Obst J., Pipi E., Monz&#xf3;n-Sandoval J., Ribe E., Winchester L., Webber C., Nevado A., NIMA Consortium CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain. 2019;142:3243&#x2013;3264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794948</ArticleId><ArticleId IdType="pubmed">31504240</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Estebane M., Gomez-Nicola D. Targeting Microglial Population Dynamics in Alzheimer&#x2019;s Disease: Are We Ready for a Potential Impact on Immune Function? Front. Cell Neurosci. 2020;14:149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289918</ArticleId><ArticleId IdType="pubmed">32581720</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Muriana A., Mancuso R., Francos-Quijorna I., Olmos-Alonso A., Osta R., Perry V.H., Navarro X., Gomez-Nicola D., L&#xf3;pez-Vales R. CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves. Sci. Rep. 2016;6:25663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4865981</ArticleId><ArticleId IdType="pubmed">27174644</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H., Adaikkan C., Gao F., Young J.Z., Manet E., Hemberg M., De Jager P.L., Ransohoff R.M., Regev A., Tsai L.H. Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell Rep. 2017;21:366&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., Puigserver P., Carlsson E., Ridderstr&#xe5;le M., Laurila E. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003;34:267&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808457</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikodemova M., Kimyon R.S., De I., Small A.L., Collier L.S., Watters J.J. Microglial numbers attain adult levels after undergoing a rapid decrease in cell number in the third postnatal week. J.&#xa0;Neuroimmunol. 2015;278:280&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297717</ArticleId><ArticleId IdType="pubmed">25468773</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmos-Alonso A., Schetters S.T., Sri S., Askew K., Mancuso R., Vargas-Caballero M., Holscher C., Perry V.H., Gomez-Nicola D. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer&#x2019;s-like pathology. Brain. 2016;139:891&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4766375</ArticleId><ArticleId IdType="pubmed">26747862</ArticleId></ArticleIdList></Reference><Reference><Citation>Picelli S., Bj&#xf6;rklund A.K., Faridani O.R., Sagasser S., Winberg G., Sandberg R. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat. Methods. 2013;10:1096&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">24056875</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj D.D., Moser J., van der Pol S.M., van Os R.P., Holtman I.R., Brouwer N., Oeseburg H., Schaafsma W., Wesseling E.M., den Dunnen W. Enhanced microglial pro-inflammatory response to lipopolysaccharide correlates with brain infiltration and blood-brain barrier dysregulation in a mouse model of telomere shortening. Aging Cell. 2015;14:1003&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4693462</ArticleId><ArticleId IdType="pubmed">26238505</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawji K.S., Mishra M.K., Michaels N.J., Rivest S., Stys P.K., Yong V.W. Immunosenescence of microglia and macrophages: impact on the ageing central nervous system. Brain. 2016;139:653&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839598</ArticleId><ArticleId IdType="pubmed">26912633</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasmono R.T., Oceandy D., Pollard J.W., Tong W., Pavli P., Wainwright B.J., Ostrowski M.C., Himes S.R., Hume D.A. A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood. 2003;101:1155&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pubmed">12393599</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaerzadeh F., Phan L., Miller D., Dacquel M., Hachmeister W., Hansen C., Bechtle A., Tu D., Martcheva M., Foster T.C. Microglia senescence occurs in both substantia nigra and ventral tegmental area. Glia. 2020;68:2228&#x2013;2245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8356201</ArticleId><ArticleId IdType="pubmed">32275335</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon E., Obst J., Gomez-Nicola D. The Evolving Dialogue of Microglia and Neurons in Alzheimer&#x2019;s Disease: Microglia as Necessary Transducers of Pathology. Neuroscience. 2019;405:24&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">29427657</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosna J., Philipp S., Albay R., 3rd, Reyes-Ruiz J.M., Baglietto-Vargas D., LaFerla F.M., Glabe C.G. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer&#x2019;s disease. Mol. Neurodegener. 2018;13:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5831225</ArticleId><ArticleId IdType="pubmed">29490706</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg E.E., Lee R.J., Najafi A.R., Rice R.A., Elmore M.R., Blurton-Jones M., West B.L., Green K.N. Eliminating microglia in Alzheimer&#x2019;s mice prevents neuronal loss without modulating amyloid-&#x3b2; pathology. Brain. 2016;139:1265&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006229</ArticleId><ArticleId IdType="pubmed">26921617</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg E., Severson P.L., Hohsfield L.A., Crapser J., Zhang J., Burton E.A., Zhang Y., Spevak W., Lin J., Phan N.Y. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer&#x2019;s disease model. Nat. Commun. 2019;10:3758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6704256</ArticleId><ArticleId IdType="pubmed">31434879</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit W.J., Khoshbouei H., Bechmann I. Dystrophic microglia in late-onset Alzheimer&#x2019;s disease. Glia. 2020;68:845&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">31922322</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 2005;102:15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hove H., Martens L., Scheyltjens I., De Vlaminck K., Pombo Antunes A.R., De Prijck S., Vandamme N., De Schepper S., Van Isterdael G., Scott C.L. A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat. Neurosci. 2019;22:1021&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pubmed">31061494</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Cella M., Mallinson K., Ulrich J.D., Young K.L., Robinette M.L., Gilfillan S., Krishnan G.M., Sudhakar S., Zinselmeyer B.H. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Kishimoto Y., Grammatikakis I., Gottimukkala K., Cutler R.G., Zhang S., Abdelmohsen K., Bohr V.A., Misra Sen J., Gorospe M., Mattson M.P. Senolytic therapy alleviates A&#x3b2;-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer&#x2019;s disease model. Nat. Neurosci. 2019;22:719&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605052</ArticleId><ArticleId IdType="pubmed">30936558</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34103486</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>A&#x3b2; receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers.</ArticleTitle><Pagination><StartPage>3451</StartPage><MedlinePgn>3451</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3451</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-021-23507-z</ELocationID><Abstract><AbstractText>Several cell-surface receptors for neurotoxic forms of amyloid-&#x3b2; (A&#x3b2;) have been described, but their molecular interactions with A&#x3b2; assemblies and their relative contributions to mediating Alzheimer's disease pathology have remained uncertain. Here, we used super-resolution microscopy to directly visualize A&#x3b2;-receptor interactions at the nanometer scale. We report that one documented A&#x3b2; receptor, PrP<sup>C</sup>, specifically inhibits the polymerization of A&#x3b2; fibrils by binding to the rapidly growing end of each fibril, thereby blocking polarized elongation at that end. PrP<sup>C</sup> binds neurotoxic oligomers and protofibrils in a similar fashion, suggesting that it may recognize a common, end-specific, structural motif on all of these assemblies. Finally, two other A&#x3b2; receptors, Fc&#x3b3;RIIb and LilrB2, affect A&#x3b2; fibril growth in a manner similar to PrP<sup>C</sup>. Our results suggest that receptors may trap A&#x3b2; oligomers and protofibrils on the neuronal surface by binding to a common molecular determinant on these assemblies, thereby initiating a neurotoxic signal.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Ladan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0002-6985-5790</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA. daharris@bu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS065244</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG070709</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR029237</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002147">Calmodulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C080571">Fc gamma receptor IIB</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017452">Receptors, IgG</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>2390-54-7</RegistryNumber><NameOfSubstance UI="C009462">thioflavin T</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002147" MajorTopicYN="N">Calmodulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009498" MajorTopicYN="N">Neurotoxins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058105" MajorTopicYN="N">Polymerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="Y">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017452" MajorTopicYN="N">Receptors, IgG</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>9</Day><Hour>5</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34103486</ArticleId><ArticleId IdType="pmc">PMC8187732</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-23507-z</ArticleId><ArticleId IdType="pii">10.1038/s41467-021-23507-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR, Jr., et al. NIA-AA Research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 2018;14:535&#x2013;562. doi: 10.1016/j.jalz.2018.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179:312&#x2013;339. doi: 10.1016/j.cell.2019.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.09.001</ArticleId><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe, D. J. Alzheimer&#x2019;s disease. Cold Spring Harb. Perspect. Biol. 3, 10.1101/cshperspect.a004457 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119915</ArticleId><ArticleId IdType="pubmed">21576255</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011;1:a006189. doi: 10.1101/cshperspect.a006189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006189</ArticleId><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat. Med. 2008;14:837&#x2013;842. doi: 10.1038/nm1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A beta oligomers&#x2014;a decade of discovery. J. Neurochem. 2007;101:1172&#x2013;1184. doi: 10.1111/j.1471-4159.2006.04426.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04426.x</ArticleId><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. A&#x3b2; oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer&#x2019;s disease. J. Neurosci. 2007;27:796&#x2013;807. doi: 10.1523/JNEUROSCI.3501-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3501-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, L. M. &amp; Strittmatter, S. M. Binding sites for amyloid-beta oligomers and synaptic toxicity. Cold Spring Harbor Perspect. Med.7, 10.1101/cshperspect.a024075 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5411685</ArticleId><ArticleId IdType="pubmed">27940601</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith LM, Kostylev MA, Lee S, Strittmatter SM. Systematic and standardized comparison of reported amyloid-&#x3b2; receptors for sufficiency, affinity, and Alzheimer&#x2019;s disease relevance. J. Biol. Chem. 2019;294:6042&#x2013;6053. doi: 10.1074/jbc.RA118.006252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.006252</ArticleId><ArticleId IdType="pmc">PMC6463724</ArticleId><ArticleId IdType="pubmed">30787106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457:1128&#x2013;1132. doi: 10.1038/nature07761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07761</ArticleId><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam TI, et al. FcgammaRIIb mediates amyloid-beta neurotoxicity and memory impairment in Alzheimer&#x2019;s disease. J. Clin. Investig. 2013;123:2791&#x2013;2802. doi: 10.1172/JCI66827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI66827</ArticleId><ArticleId IdType="pmc">PMC3696552</ArticleId><ArticleId IdType="pubmed">23921129</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T, et al. Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer&#x2019;s model. Science. 2013;341:1399&#x2013;1404. doi: 10.1126/science.1242077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1242077</ArticleId><ArticleId IdType="pmc">PMC3853120</ArticleId><ArticleId IdType="pubmed">24052308</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse M, et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature. 2011;469:47&#x2013;52. doi: 10.1038/nature09635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09635</ArticleId><ArticleId IdType="pmc">PMC3030448</ArticleId><ArticleId IdType="pubmed">21113149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, et al. Amyloid beta peptides block new synapse assembly by nogo receptor-mediated inhibition of T-type calcium channels. Neuron. 2017;96:355&#x2013;372.e356. doi: 10.1016/j.neuron.2017.09.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.09.041</ArticleId><ArticleId IdType="pmc">PMC6101033</ArticleId><ArticleId IdType="pubmed">29024660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse M, et al. Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J. Neurosci. 2011;31:10427&#x2013;10431. doi: 10.1523/JNEUROSCI.1459-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1459-11.2011</ArticleId><ArticleId IdType="pmc">PMC3314063</ArticleId><ArticleId IdType="pubmed">21775587</ArticleId></ArticleIdList></Reference><Reference><Citation>Balducci C, et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc. Natl Acad. Sci. USA. 2010;107:2295&#x2013;2300. doi: 10.1073/pnas.0911829107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0911829107</ArticleId><ArticleId IdType="pmc">PMC2836680</ArticleId><ArticleId IdType="pubmed">20133875</ArticleId></ArticleIdList></Reference><Reference><Citation>Calella AM, et al. Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol. Med. 2010;2:306&#x2013;314. doi: 10.1002/emmm.201000082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201000082</ArticleId><ArticleId IdType="pmc">PMC2962809</ArticleId><ArticleId IdType="pubmed">20665634</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels HW, Nguyen LN, Nabavi S, Malinow R. The prion protein as a receptor for amyloid-beta. Nature. 2010;466:E4-5. doi: 10.1038/nature09217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09217</ArticleId><ArticleId IdType="pmc">PMC3057871</ArticleId><ArticleId IdType="pubmed">20703260</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Yadav SP, Surewicz WK. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. J. Biol. Chem. 2010;285:26377&#x2013;26383. doi: 10.1074/jbc.M110.145516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.145516</ArticleId><ArticleId IdType="pmc">PMC2924066</ArticleId><ArticleId IdType="pubmed">20576610</ArticleId></ArticleIdList></Reference><Reference><Citation>Fluharty BR, et al. An N-terminal fragment of the prion protein binds to amyloid-beta oligomers and inhibits their neurotoxicity in vivo. J. Biol. Chem. 2013;288:7857&#x2013;7866. doi: 10.1074/jbc.M112.423954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.423954</ArticleId><ArticleId IdType="pmc">PMC3597823</ArticleId><ArticleId IdType="pubmed">23362282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll AJ, et al. Amyloid-beta nanotubes are associated with prion protein-dependent synaptotoxicity. Nat. Commun. 2013;4:2416. doi: 10.1038/ncomms3416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3416</ArticleId><ArticleId IdType="pmc">PMC3908552</ArticleId><ArticleId IdType="pubmed">24022506</ArticleId></ArticleIdList></Reference><Reference><Citation>Bove-Fenderson E, Urano R, Straub JE, Harris DA. Cellular prion protein targets amyloid-beta fibril ends via its C-terminal domain to prevent elongation. J. Biol. Chem. 2017;292:16858&#x2013;16871. doi: 10.1074/jbc.M117.789990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.789990</ArticleId><ArticleId IdType="pmc">PMC5641888</ArticleId><ArticleId IdType="pubmed">28842494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganzinger KA, et al. Single-molecule imaging reveals that small amyloid-beta1-42 oligomers interact with the cellular prion protein (PrP(C)) Chembiochem. 2014;15:2515&#x2013;2521. doi: 10.1002/cbic.201402377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.201402377</ArticleId><ArticleId IdType="pmc">PMC4371635</ArticleId><ArticleId IdType="pubmed">25294384</ArticleId></ArticleIdList></Reference><Reference><Citation>Freir DB, et al. Interaction between prion protein and toxic amyloid &#x3b2; assemblies can be therapeutically targeted at multiple sites. Nat. Commun. 2011;2:336. doi: 10.1038/ncomms1341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms1341</ArticleId><ArticleId IdType="pmc">PMC3156817</ArticleId><ArticleId IdType="pubmed">21654636</ArticleId></ArticleIdList></Reference><Reference><Citation>Um JW, et al. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 2012;15:1227&#x2013;1235. doi: 10.1038/nn.3178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3178</ArticleId><ArticleId IdType="pmc">PMC3431439</ArticleId><ArticleId IdType="pubmed">22820466</ArticleId></ArticleIdList></Reference><Reference><Citation>Um JW, et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron. 2013;79:887&#x2013;902. doi: 10.1016/j.neuron.2013.06.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.06.036</ArticleId><ArticleId IdType="pmc">PMC3768018</ArticleId><ArticleId IdType="pubmed">24012003</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas LT, Strittmatter SM. Oligomers of amyloid beta prevent physiological activation of the cellular prion protein-metabotropic glutamate receptor 5 complex by glutamate in Alzheimer disease. J. Biol. Chem. 2016;291:17112&#x2013;17121. doi: 10.1074/jbc.M116.720664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.720664</ArticleId><ArticleId IdType="pmc">PMC5016115</ArticleId><ArticleId IdType="pubmed">27325698</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas LT, Kostylev MA, Strittmatter SM. Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5) J. Biol. Chem. 2014;289:28460&#x2013;28477. doi: 10.1074/jbc.M114.584342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.584342</ArticleId><ArticleId IdType="pmc">PMC4192497</ArticleId><ArticleId IdType="pubmed">25148681</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimbel DA, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci. 2010;30:6367&#x2013;6374. doi: 10.1523/JNEUROSCI.0395-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0395-10.2010</ArticleId><ArticleId IdType="pmc">PMC3323924</ArticleId><ArticleId IdType="pubmed">20445063</ArticleId></ArticleIdList></Reference><Reference><Citation>Salazar SV, et al. Conditional deletion of prnp rescues behavioral and synaptic deficits after disease onset in transgenic alzheimer&#x2019;s disease. J. Neurosci. 2017;37:9207&#x2013;9221. doi: 10.1523/JNEUROSCI.0722-17.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0722-17.2017</ArticleId><ArticleId IdType="pmc">PMC5607466</ArticleId><ArticleId IdType="pubmed">28842420</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunther EC, et al. Rescue of transgenic Alzheimer&#x2019;s pathophysiology by polymeric cellular prion protein antagonists. Cell Rep. 2019;26:145&#x2013;158.e148. doi: 10.1016/j.celrep.2018.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.12.021</ArticleId><ArticleId IdType="pmc">PMC6358723</ArticleId><ArticleId IdType="pubmed">30605671</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, et al. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer&#x2019;s disease model mouse. BMC Neurosci. 2010;11:130. doi: 10.1186/1471-2202-11-130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-11-130</ArticleId><ArticleId IdType="pmc">PMC2964735</ArticleId><ArticleId IdType="pubmed">20946660</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dyck, C. H. et al. Effect of AZD0530 on cerebral metabolic decline in Alzheimer Disease: a randomized clinical trial. JAMA Neurol.10.1001/jamaneurol.2019.2050 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6646979</ArticleId><ArticleId IdType="pubmed">31329216</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SI, et al. Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl Acad. Sci. USA. 2013;110:9758&#x2013;9763. doi: 10.1073/pnas.1218402110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1218402110</ArticleId><ArticleId IdType="pmc">PMC3683769</ArticleId><ArticleId IdType="pubmed">23703910</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio P, et al. Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation. Nat. Commun. 2016;7:10948. doi: 10.1038/ncomms10948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10948</ArticleId><ArticleId IdType="pmc">PMC4820785</ArticleId><ArticleId IdType="pubmed">27009901</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SI, Vendruscolo M, Dobson CM, Knowles TP. From macroscopic measurements to microscopic mechanisms of protein aggregation. J. Mol. Biol. 2012;421:160&#x2013;171. doi: 10.1016/j.jmb.2012.02.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2012.02.031</ArticleId><ArticleId IdType="pubmed">22406275</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeg M, et al. Clusterin binds to Abeta1-42 oligomers with high affinity and interferes with peptide aggregation by inhibiting primary and secondary nucleation. J. Biol. Chem. 2016;291:6958&#x2013;6966. doi: 10.1074/jbc.M115.689539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.689539</ArticleId><ArticleId IdType="pmc">PMC4807280</ArticleId><ArticleId IdType="pubmed">26884339</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SIA, et al. A molecular chaperone breaks the catalytic cycle that generates toxic Abeta oligomers. Nat. Struct. Mol. Biol. 2015;22:207&#x2013;213. doi: 10.1038/nsmb.2971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2971</ArticleId><ArticleId IdType="pmc">PMC4595974</ArticleId><ArticleId IdType="pubmed">25686087</ArticleId></ArticleIdList></Reference><Reference><Citation>Habchi J, et al. Systematic development of small molecules to inhibit specific microscopic steps of Abeta42 aggregation in Alzheimer&#x2019;s disease. Proc. Natl Acad. Sci. USA. 2017;114:E200&#x2013;E208. doi: 10.1073/pnas.1615613114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1615613114</ArticleId><ArticleId IdType="pmc">PMC5240708</ArticleId><ArticleId IdType="pubmed">28011763</ArticleId></ArticleIdList></Reference><Reference><Citation>Munke A, et al. Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication. Proc. Natl Acad. Sci. USA. 2017;114:6444&#x2013;6449. doi: 10.1073/pnas.1700407114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1700407114</ArticleId><ArticleId IdType="pmc">PMC5488933</ArticleId><ArticleId IdType="pubmed">28584111</ArticleId></ArticleIdList></Reference><Reference><Citation>Rust MJ, Bates M, Zhuang X. Sub-diffraction-limit imaging by stochastic optical reconstruction microscopy (STORM) Nat. methods. 2006;3:793&#x2013;795. doi: 10.1038/nmeth929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth929</ArticleId><ArticleId IdType="pmc">PMC2700296</ArticleId><ArticleId IdType="pubmed">16896339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kner P, Chhun BB, Griffis ER, Winoto L, Gustafsson MG. Super-resolution video microscopy of live cells by structured illumination. Nat. methods. 2009;6:339&#x2013;342. doi: 10.1038/nmeth.1324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1324</ArticleId><ArticleId IdType="pmc">PMC2895555</ArticleId><ArticleId IdType="pubmed">19404253</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstrand E, Boland B, Walsh DM, Linse S. Amyloid beta-protein aggregation produces highly reproducible kinetic data and occurs by a two-phase process. ACS Chem. Neurosci. 2010;1:13&#x2013;18. doi: 10.1021/cn900015v.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn900015v</ArticleId><ArticleId IdType="pmc">PMC3368626</ArticleId><ArticleId IdType="pubmed">22778803</ArticleId></ArticleIdList></Reference><Reference><Citation>Young LJ, Kaminski Schierle GS, Kaminski CF. Imaging Abeta(1-42) fibril elongation reveals strongly polarised growth and growth incompetent states. Phys. Chem. Chem. Phys. 2017;19:27987&#x2013;27996. doi: 10.1039/C7CP03412A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C7CP03412A</ArticleId><ArticleId IdType="pmc">PMC7612976</ArticleId><ArticleId IdType="pubmed">29026905</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinotsi D, et al. Direct observation of heterogeneous amyloid fibril growth kinetics via two-color super-resolution microscopy. Nano Lett. 2014;14:339&#x2013;345. doi: 10.1021/nl4041093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/nl4041093</ArticleId><ArticleId IdType="pmc">PMC3901574</ArticleId><ArticleId IdType="pubmed">24303845</ArticleId></ArticleIdList></Reference><Reference><Citation>DePace AH, Weissman JS. Origins and kinetic consequences of diversity in Sup35 yeast prion fibers. Nat. Struct. Biol. 2002;9:389&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">11938354</ArticleId></ArticleIdList></Reference><Reference><Citation>Ban T, et al. Direct observation of Abeta amyloid fibril growth and inhibition. J. Mol. Biol. 2004;344:757&#x2013;767. doi: 10.1016/j.jmb.2004.09.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2004.09.078</ArticleId><ArticleId IdType="pubmed">15533443</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA. 1998;95:6448&#x2013;6453. doi: 10.1073/pnas.95.11.6448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.11.6448</ArticleId><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Nuallain B, et al. Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J. Neurosci.: Off. J. Soc. Neurosci. 2010;30:14411&#x2013;14419. doi: 10.1523/JNEUROSCI.3537-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3537-10.2010</ArticleId><ArticleId IdType="pmc">PMC2987723</ArticleId><ArticleId IdType="pubmed">20980598</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll AJ, et al. Amyloid-&#x3b2; nanotubes are associated with prion protein-dependent synaptotoxicity. Nat. Commun. 2013;4:2416. doi: 10.1038/ncomms3416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3416</ArticleId><ArticleId IdType="pmc">PMC3908552</ArticleId><ArticleId IdType="pubmed">24022506</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang C, Imberdis T, Garza MC, Wille H, Harris DA. A Neuronal Culture System to Detect Prion Synaptotoxicity. PLoS Pathog. 2016;12:e1005623. doi: 10.1371/journal.ppat.1005623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005623</ArticleId><ArticleId IdType="pmc">PMC4881977</ArticleId><ArticleId IdType="pubmed">27227882</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang C, et al. Prions activate a p38 MAPK synaptotoxic signaling pathway. PLoS Pathog. 2018;14:e1007283. doi: 10.1371/journal.ppat.1007283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007283</ArticleId><ArticleId IdType="pmc">PMC6147624</ArticleId><ArticleId IdType="pubmed">30235355</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam, T. I. et al. FcgammaRIIb-SHIP2 axis links Abeta to tau pathology by disrupting phosphoinositide metabolism in Alzheimer&#x2019;s disease model. eLife 5, 10.7554/eLife.18691 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5106215</ArticleId><ArticleId IdType="pubmed">27834631</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard NR, Smith KG. B cell inhibitory receptors and autoimmunity. Immunology. 2003;108:263&#x2013;273. doi: 10.1046/j.1365-2567.2003.01592.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2567.2003.01592.x</ArticleId><ArticleId IdType="pmc">PMC1782894</ArticleId><ArticleId IdType="pubmed">12603592</ArticleId></ArticleIdList></Reference><Reference><Citation>Syken J, Grandpre T, Kanold PO, Shatz CJ. PirB restricts ocular-dominance plasticity in visual cortex. Science. 2006;313:1795&#x2013;1800. doi: 10.1126/science.1128232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1128232</ArticleId><ArticleId IdType="pubmed">16917027</ArticleId></ArticleIdList></Reference><Reference><Citation>Gremer L, et al. Fibril structure of amyloid-beta(1-42) by cryo-electron microscopy. Science. 2017;358:116&#x2013;119. doi: 10.1126/science.aao2825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aao2825</ArticleId><ArticleId IdType="pmc">PMC6080689</ArticleId><ArticleId IdType="pubmed">28882996</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollmer M, et al. Cryo-EM structure and polymorphism of Abeta amyloid fibrils purified from Alzheimer&#x2019;s brain tissue. Nat. Commun. 2019;10:4760. doi: 10.1038/s41467-019-12683-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12683-8</ArticleId><ArticleId IdType="pmc">PMC6820800</ArticleId><ArticleId IdType="pubmed">31664019</ArticleId></ArticleIdList></Reference><Reference><Citation>Luhrs T, et al. 3D structure of Alzheimer&#x2019;s amyloid-&#x3b2;(1-42) fibrils. Proc. Natl Acad. Sci. USA. 2005;102:17342&#x2013;17347. doi: 10.1073/pnas.0506723102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0506723102</ArticleId><ArticleId IdType="pmc">PMC1297669</ArticleId><ArticleId IdType="pubmed">16293696</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;nig, A. S. et al. Structural details of amyloid &#x3b2; oligomers in complex with human prion protein as revealed by solid-state MAS NMR spectroscopy. The Journal of biological chemistry296, 100499, 10.1016/j.jbc.2021.100499 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8042448</ArticleId><ArticleId IdType="pubmed">33667547</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang W, Yau WM, Luo Y, Mattson MP, Tycko R. Antiparallel &#x3b2;-sheet architecture in Iowa-mutant &#x3b2;-amyloid fibrils. Proc. Natl Acad. Sci. USA. 2012;109:4443&#x2013;4448. doi: 10.1073/pnas.1111305109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1111305109</ArticleId><ArticleId IdType="pmc">PMC3311365</ArticleId><ArticleId IdType="pubmed">22403062</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycko, R. Molecular structure of aggregated amyloid-&#x3b2;: insights from solid-state nuclear magnetic resonance. Cold Spring Harbor Perspect. Med. 6, 10.1101/cshperspect.a024083 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968170</ArticleId><ArticleId IdType="pubmed">27481836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kheterpal I, Chen M, Cook KD, Wetzel R. Structural differences in Abeta amyloid protofibrils and fibrils mapped by hydrogen exchange&#x2014;mass spectrometry with on-line proteolytic fragmentation. J. Mol. Biol. 2006;361:785&#x2013;795. doi: 10.1016/j.jmb.2006.06.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2006.06.066</ArticleId><ArticleId IdType="pubmed">16875699</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheidt HA, Morgado I, Huster D. Solid-state NMR reveals a close structural relationship between amyloid-&#x3b2; protofibrils and oligomers. J. Biol. Chem. 2012;287:22822&#x2013;22826. doi: 10.1074/jbc.M112.367474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.367474</ArticleId><ArticleId IdType="pmc">PMC3391088</ArticleId><ArticleId IdType="pubmed">22589542</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, et al. Out-of-register parallel &#x3b2;-sheets and antiparallel &#x3b2;-sheets coexist in 150-kDa oligomers formed by amyloid-&#x3b2;(1-42) J. Mol. Biol. 2020;432:4388&#x2013;4407. doi: 10.1016/j.jmb.2020.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2020.05.018</ArticleId><ArticleId IdType="pmc">PMC7387221</ArticleId><ArticleId IdType="pubmed">32470558</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosener NS, et al. A d-enantiomeric peptide interferes with heteroassociation of amyloid-beta oligomers and prion protein. J. Biol. Chem. 2018;293:15748&#x2013;15764. doi: 10.1074/jbc.RA118.003116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.003116</ArticleId><ArticleId IdType="pmc">PMC6187637</ArticleId><ArticleId IdType="pubmed">30131337</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieznanski K, Choi JK, Chen S, Surewicz K, Surewicz WK. Soluble prion protein inhibits amyloid &#x3b2; (A&#x3b2;) fibrillization and toxicity. J. Biol. Chem. 2012;287:33104&#x2013;33108. doi: 10.1074/jbc.C112.400614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C112.400614</ArticleId><ArticleId IdType="pmc">PMC3460415</ArticleId><ArticleId IdType="pubmed">22915585</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieznanski K, Surewicz K, Chen S, Nieznanska H, Surewicz WK. Interaction between prion protein and Abeta amyloid fibrils revisited. ACS Chem. Neurosci. 2014;5:340&#x2013;345. doi: 10.1021/cn500019c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn500019c</ArticleId><ArticleId IdType="pmc">PMC4030797</ArticleId><ArticleId IdType="pubmed">24669873</ArticleId></ArticleIdList></Reference><Reference><Citation>Younan ND, Sarell CJ, Davies P, Brown DR, Viles JH. The cellular prion protein traps Alzheimer&#x2019;s A&#x3b2; in an oligomeric form and disassembles amyloid fibers. FASEB J. 2013;27:1847&#x2013;1858. doi: 10.1096/fj.12-222588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.12-222588</ArticleId><ArticleId IdType="pmc">PMC3767752</ArticleId><ArticleId IdType="pubmed">23335053</ArticleId></ArticleIdList></Reference><Reference><Citation>Younan ND, Chen KF, Rose RS, Crowther DC, Viles JH. Prion protein stabilizes amyloid-beta (Abeta) oligomers and enhances Abeta neurotoxicity in a Drosophila model of Alzheimer&#x2019;s disease. J. Biol. Chem. 2018;293:13090&#x2013;13099. doi: 10.1074/jbc.RA118.003319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.003319</ArticleId><ArticleId IdType="pmc">PMC6109938</ArticleId><ArticleId IdType="pubmed">29887525</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu LQ, et al. Influence of specific HSP70 domains on fibril formation of the yeast prion protein Ure2. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2013;368:20110410. doi: 10.1098/rstb.2011.0410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2011.0410</ArticleId><ArticleId IdType="pmc">PMC3638396</ArticleId><ArticleId IdType="pubmed">23530260</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosawa F, Kasai M. A theory of linear and helical aggregations of macromolecules. J. Mol. Biol. 1962;4:10&#x2013;21. doi: 10.1016/S0022-2836(62)80112-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2836(62)80112-0</ArticleId><ArticleId IdType="pubmed">14482095</ArticleId></ArticleIdList></Reference><Reference><Citation>Ban T, Hamada D, Hasegawa K, Naiki H, Goto Y. Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence. J. Biol. Chem. 2003;278:16462&#x2013;16465. doi: 10.1074/jbc.C300049200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C300049200</ArticleId><ArticleId IdType="pubmed">12646572</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, et al. Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-beta clearance and aggregation in Alzheimer&#x2019;s disease. Sci. Transl. Med. 2016;8:332ra344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5512541</ArticleId><ArticleId IdType="pubmed">27030596</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostylev MA, et al. Liquid and hydrogel phases of PrP(C) linked to conformation shifts and triggered by Alzheimer&#x2019;s amyloid-&#x3b2; oligomers. Mol. Cell. 2018;72:426&#x2013;443.e412. doi: 10.1016/j.molcel.2018.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.10.009</ArticleId><ArticleId IdType="pmc">PMC6226277</ArticleId><ArticleId IdType="pubmed">30401430</ArticleId></ArticleIdList></Reference><Reference><Citation>Arndt JW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta. Sci. Rep. 2018;8:6412. doi: 10.1038/s41598-018-24501-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-24501-0</ArticleId><ArticleId IdType="pmc">PMC5913127</ArticleId><ArticleId IdType="pubmed">29686315</ArticleId></ArticleIdList></Reference><Reference><Citation>Ondrejcak T, et al. Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo. J. Neurosci. 2018;38:10595&#x2013;10606. doi: 10.1523/JNEUROSCI.1700-18.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1700-18.2018</ArticleId><ArticleId IdType="pmc">PMC6290298</ArticleId><ArticleId IdType="pubmed">30355631</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira DG, et al. &#x3b1;-Synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B. Nat. Neurosci. 2017;20:1569&#x2013;1579. doi: 10.1038/nn.4648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4648</ArticleId><ArticleId IdType="pubmed">28945221</ArticleId></ArticleIdList></Reference><Reference><Citation>Aulic S, et al. &#x3b1;-Synuclein amyloids hijack prion protein to gain cell entry, facilitate cell-to-cell spreading and block prion replication. Sci. Rep. 2017;7:10050. doi: 10.1038/s41598-017-10236-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-10236-x</ArticleId><ArticleId IdType="pmc">PMC5577263</ArticleId><ArticleId IdType="pubmed">28855681</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett GT, et al. PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathol. 2020;139:503&#x2013;526. doi: 10.1007/s00401-019-02114-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02114-9</ArticleId><ArticleId IdType="pmc">PMC7035229</ArticleId><ArticleId IdType="pubmed">31853635</ArticleId></ArticleIdList></Reference><Reference><Citation>Dohler F, et al. High molecular mass assemblies of amyloid-&#x3b2; oligomers bind prion protein in patients with Alzheimer&#x2019;s disease. Brain. 2014;137:873&#x2013;886. doi: 10.1093/brain/awt375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt375</ArticleId><ArticleId IdType="pubmed">24519981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostylev MA, et al. Prion-protein-interacting amyloid-&#x3b2; oligomers of high molecular weight are tightly correlated with memory impairment in multiple Alzheimer mouse models. J. Biol. Chem. 2015;290:17415&#x2013;17438. doi: 10.1074/jbc.M115.643577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.643577</ArticleId><ArticleId IdType="pmc">PMC4498078</ArticleId><ArticleId IdType="pubmed">26018073</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson M, et al. The complex PrP(c)-Fyn couples human oligomeric A&#x3b2; with pathological tau changes in Alzheimer&#x2019;s disease. J. Neurosci. 2012;32:16857&#x2013;16871a. doi: 10.1523/JNEUROSCI.1858-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1858-12.2012</ArticleId><ArticleId IdType="pmc">PMC3568961</ArticleId><ArticleId IdType="pubmed">23175838</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott-McKean JJ, et al. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Abeta oligomers: Implications for novel therapeutic strategy in Alzheimer&#x2019;s disease. Neurobiol. Dis. 2016;91:124&#x2013;131. doi: 10.1016/j.nbd.2016.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.03.001</ArticleId><ArticleId IdType="pmc">PMC4860038</ArticleId><ArticleId IdType="pubmed">26949218</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, DeKosky ST, Galasko D. Alzheimer&#x2019;s disease: the right drug, the right time. Science. 2018;362:1250&#x2013;1251. doi: 10.1126/science.aau0437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aau0437</ArticleId><ArticleId IdType="pubmed">30545877</ArticleId></ArticleIdList></Reference><Reference><Citation>Barry AE, et al. Alzheimer&#x2019;s disease brain-derived amyloid-&#x3b2;-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J. Neurosci. 2011;31:7259&#x2013;7263. doi: 10.1523/JNEUROSCI.6500-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6500-10.2011</ArticleId><ArticleId IdType="pmc">PMC6622598</ArticleId><ArticleId IdType="pubmed">21593310</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL. Abeta toxicity in Alzheimer&#x2019;s disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochemistry Int. 2002;41:345&#x2013;352. doi: 10.1016/S0197-0186(02)00050-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-0186(02)00050-5</ArticleId><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jungbauer L, Yu C, LaDu MJ. Preparing synthetic Abeta in different aggregation states. Methods Mol. Biol. 2011;670:13&#x2013;32. doi: 10.1007/978-1-60761-744-0_2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-60761-744-0_2</ArticleId><ArticleId IdType="pmc">PMC3752843</ArticleId><ArticleId IdType="pubmed">20967580</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaech S, Banker G. Culturing hippocampal neurons. Nat. Protoc. 2006;1:2406&#x2013;2415. doi: 10.1038/nprot.2006.356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.356</ArticleId><ArticleId IdType="pubmed">17406484</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34083450</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>373</Volume><Issue>6553</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Heterogeneity of meningeal B cells reveals a lymphopoietic niche at the CNS borders.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eabf9277</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.abf9277</ELocationID><Abstract><AbstractText>The meninges contain adaptive immune cells that provide immunosurveillance of the central nervous system (CNS). These cells are thought to derive from the systemic circulation. Through single-cell analyses, confocal imaging, bone marrow chimeras, and parabiosis experiments, we show that meningeal B cells derive locally from the calvaria, which harbors a bone marrow niche for hematopoiesis. B cells reach the meninges from the calvaria through specialized vascular connections. This calvarial-meningeal path of B cell development may provide the CNS with a constant supply of B cells educated by CNS antigens. Conversely, we show that a subset of antigen-experienced B cells that populate the meninges in aging mice are blood-borne. These results identify a private source for meningeal B cells, which may help maintain immune privilege within the CNS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Brioschi</LastName><ForeName>Simone</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3849-3926</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Wei-Le</ForeName><Initials>WL</Initials><Identifier Source="ORCID">0000-0002-6984-4514</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Peng</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-0301-2985</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Meng</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3453-7805</Identifier><AffiliationInfo><Affiliation>Interdepartmental Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT 06511, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shchukina</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Zev J</ForeName><Initials>ZJ</Initials><Identifier Source="ORCID">0000-0002-6234-7005</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bando</LastName><ForeName>Jennifer K</ForeName><Initials>JK</Initials><Identifier Source="ORCID">0000-0002-1331-7424</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaeger</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-2875-8297</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czepielewski</LastName><ForeName>Rafael S</ForeName><Initials>RS</Initials><Identifier Source="ORCID">0000-0002-2475-3838</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swain</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0683-368X</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mogilenko</LastName><ForeName>Denis A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-5427-5243</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beatty</LastName><ForeName>Wandy L</ForeName><Initials>WL</Initials><Identifier Source="ORCID">0000-0003-0715-7361</Identifier><AffiliationInfo><Affiliation>Department of Molecular Microbiology, Center for Infectious Disease Research, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayguinov</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Washington University Center for Cellular Imaging, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzpatrick</LastName><ForeName>James A J</ForeName><Initials>JAJ</Initials><Identifier Source="ORCID">0000-0002-7907-3602</Identifier><AffiliationInfo><Affiliation>Washington University Center for Cellular Imaging, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Cell Biology and Physiology and Neuroscience, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Washington University in Saint Louis, Saint Louis, MO 63130, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuettpelz</LastName><ForeName>Laura G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fronick</LastName><ForeName>Catrina C</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0002-2766-9551</Identifier><AffiliationInfo><Affiliation>McDonnell Genome Institute, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smirnov</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kipnis</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3714-517X</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapiro</LastName><ForeName>Virginia S</ForeName><Initials>VS</Initials><Identifier Source="ORCID">0000-0001-9978-341X</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Gregory F</ForeName><Initials>GF</Initials><Identifier Source="ORCID">0000-0003-3588-0637</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Washington University in Saint Louis, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilfillan</LastName><ForeName>Susan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1672-0996</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cella</LastName><ForeName>Marina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1230-1313</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artyomov</LastName><ForeName>Maxim N</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0000-0002-1133-4212</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinstein</LastName><ForeName>Steven H</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0003-4957-1544</Identifier><AffiliationInfo><Affiliation>Interdepartmental Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT 06511, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5222-4987</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA. mcolonna@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F30 DK127540</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR073752</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DK077653</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI104739</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059082</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG051485</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 DK118110</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2021 Aug;596(7870):38-40. doi: 10.1038/d41586-021-01962-4.</RefSource><PMID Version="1">34285399</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2021 Jul 23;373(6553):396-397. doi: 10.1126/science.abj8183.</RefSource><PMID Version="1">34437108</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016175" MajorTopicYN="N">B-Lymphocyte Subsets</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001854" MajorTopicYN="N">Bone Marrow Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004388" MajorTopicYN="N">Dura Mater</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073860" MajorTopicYN="N">Immune Privilege</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038041" MajorTopicYN="Y">Lymphopoiesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008578" MajorTopicYN="N">Meninges</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010950" MajorTopicYN="N">Plasma Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012886" MajorTopicYN="N">Skull</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> All authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34083450</ArticleId><ArticleId IdType="mid">NIHMS1737162</ArticleId><ArticleId IdType="pmc">PMC8448524</ArticleId><ArticleId IdType="doi">10.1126/science.abf9277</ArticleId><ArticleId IdType="pii">science.abf9277</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alves de Lima K, Rustenhoven J, Kipnis J, Meningeal Immunity and Its Function in Maintenance of the Central Nervous System in Health and Disease. Annu. Rev. Immunol (2020), doi:10.1146/annurev-immunol-102319-103410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-102319-103410</ArticleId><ArticleId IdType="pubmed">32340575</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt B, Vajkoczy P, Weller RO, The movers and shapers in immune privilege of the CNS. Nat. Immunol (2017), , doi:10.1038/ni.3666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3666</ArticleId><ArticleId IdType="pubmed">28092374</ArticleId></ArticleIdList></Reference><Reference><Citation>Rua R, McGavern DB, Advances in Meningeal Immunity. Trends Mol. Med (2018), , doi:10.1016/j.molmed.2018.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2018.04.003</ArticleId><ArticleId IdType="pmc">PMC6044730</ArticleId><ArticleId IdType="pubmed">29731353</ArticleId></ArticleIdList></Reference><Reference><Citation>Herisson F, et al., Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration. Nat. Neurosci (2018), doi:10.1038/s41593-018-0213-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0213-2</ArticleId><ArticleId IdType="pmc">PMC6148759</ArticleId><ArticleId IdType="pubmed">30150661</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai R, et al., Panoptic imaging of transparent mice reveals whole-body neuronal projections and skull&#x2013;meninges connections. Nat. Neurosci (2019), doi:10.1038/s41593-018-0301-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0301-3</ArticleId><ArticleId IdType="pmc">PMC6494982</ArticleId><ArticleId IdType="pubmed">30598527</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao H, et al., Leukaemia hijacks a neural mechanism to invade the central nervous system. Nature (2018), doi:10.1038/s41586-018-0342-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0342-5</ArticleId><ArticleId IdType="pmc">PMC10257142</ArticleId><ArticleId IdType="pubmed">30022166</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, et al., A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell. 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Mundt S, Mrdjen D, Utz SG, Greter M, Schreiner B, Becher B, Conventional DCs sample and present myelin antigens in the healthy CNS and allow parenchymal T cell entry to initiate neuroinflammation. Sci. Immunol (2019), doi:10.1126/sciimmunol.aau8380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aau8380</ArticleId><ArticleId IdType="pubmed">30679199</ArticleId></ArticleIdList></Reference><Reference><Citation>Rickert RC, Roes J, Rajewsky K, B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. (1997), doi:10.1093/nar/25.6.1317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/25.6.1317</ArticleId><ArticleId IdType="pmc">PMC146582</ArticleId><ArticleId IdType="pubmed">9092650</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A, et al., CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat. Neurosci (2018), , doi:10.1038/s41593-018-0227-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0227-9</ArticleId><ArticleId IdType="pmc">PMC6214619</ArticleId><ArticleId IdType="pubmed">30224810</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn JH, et al., Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid. Nature (2019), doi:10.1038/s41586-019-1419-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1419-5</ArticleId><ArticleId IdType="pubmed">31341278</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung JW, Mrazek MD, Yang Y, Herzenberg LA, Herzenberg LA, Phenotypically distinct B cell development pathways map to the three B cell lineages in the mouse. Proc. Natl. Acad. Sci. U. S. A (2006), doi:10.1073/pnas.0511305103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0511305103</ArticleId><ArticleId IdType="pmc">PMC1458871</ArticleId><ArticleId IdType="pubmed">16606838</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K, Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J. Exp. Med (1991), doi:10.1084/jem.173.5.1213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.173.5.1213</ArticleId><ArticleId IdType="pmc">PMC2118850</ArticleId><ArticleId IdType="pubmed">1827140</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwata N, Igarashi H, Ohmura T, Aizawa S, Sakaguchi N, Cutting edge: absence of expression of RAG1 in peritoneal B-1 cells detected by knocking into RAG1 locus with green fluorescent protein gene. J. Immunol (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10586023</ArticleId></ArticleIdList></Reference><Reference><Citation>DeSisto J, et al., Single-Cell Transcriptomic Analyses of the Developing Meninges Reveal Meningeal Fibroblast Diversity and Function. Dev. Cell (2020), doi:10.1016/j.devcel.2020.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2020.06.009</ArticleId><ArticleId IdType="pmc">PMC7769050</ArticleId><ArticleId IdType="pubmed">32634398</ArticleId></ArticleIdList></Reference><Reference><Citation>Schena F, et al., Dependence of Immunoglobulin Class Switch Recombination in B Cells on Vesicular Release of ATP and CD73 Ectonucleotidase Activity. Cell Rep. (2013), doi:10.1016/j.celrep.2013.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.05.022</ArticleId><ArticleId IdType="pubmed">23770243</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustenhoven J, et al., Functional characterization of the dural sinuses as a neuroimmune interface. Cell. 184, 1000&#x2013;1016.e27 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8487654</ArticleId><ArticleId IdType="pubmed">33508229</ArticleId></ArticleIdList></Reference><Reference><Citation>Almanzar N, et al., A single-cell transcriptomic atlas characterizes ageing tissues in the mouse. Nature (2020), doi:10.1038/s41586-020-2496-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2496-1</ArticleId><ArticleId IdType="pmc">PMC8240505</ArticleId><ArticleId IdType="pubmed">32669714</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogilenko DA, et al., Comprehensive Profiling of an Aging Immune System Reveals Clonal GZMK+ CD8+ T Cells as Conserved Hallmark of Inflammaging. Immunity (2021), doi:10.1016/j.immuni.2020.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.11.005</ArticleId><ArticleId IdType="pubmed">33271118</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick Z, et al., Gut-educated IgA plasma cells defend the meningeal venous sinuses. Nature (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7748383</ArticleId><ArticleId IdType="pubmed">33149302</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann T, et al., Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat. Immunol 17, 797&#x2013;805 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968048</ArticleId><ArticleId IdType="pubmed">27135602</ArticleId></ArticleIdList></Reference><Reference><Citation>Jord&#xe3;o MJC, et al., Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science (80-. ). (2019), doi:10.1126/science.aat7554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat7554</ArticleId><ArticleId IdType="pubmed">30679343</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hove H, et al., A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat. Neurosci (2019), doi:10.1038/s41593-019-0393-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0393-4</ArticleId><ArticleId IdType="pubmed">31061494</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrdjen D, et al., High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells Reveals Distinct Myeloid Subsets in Health, Aging, and Disease. Immunity. 48, 380&#x2013;395.e6 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29426702</ArticleId></ArticleIdList></Reference><Reference><Citation>Fistonich C, et al., Cell circuits between B cell progenitors and IL-7+mesenchymal progenitor cells control B cell development. J. Exp. Med (2018), doi:10.1084/JEM.20180778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/JEM.20180778</ArticleId><ArticleId IdType="pmc">PMC6170173</ArticleId><ArticleId IdType="pubmed">30158115</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie Y, Waite J, Brewer F, Sunshine MJ, Littman DR, Zou YR, The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J. Exp. Med (2004), doi:10.1084/jem.20041185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041185</ArticleId><ArticleId IdType="pmc">PMC2211858</ArticleId><ArticleId IdType="pubmed">15520246</ArticleId></ArticleIdList></Reference><Reference><Citation>Zikherman J, Parameswaran R, Weiss A, Endogenous antigen tunes the responsiveness of naive B cells but not T cells. Nature. 489, 160&#x2013;164 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3438375</ArticleId><ArticleId IdType="pubmed">22902503</ArticleId></ArticleIdList></Reference><Reference><Citation>Litzenburger T, et al., B lymphocytes producing demyelinating autoantibodies: Development and function in gene-targeted transgenic mice. J. Exp. Med 188, 169&#x2013;180 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2525547</ArticleId><ArticleId IdType="pubmed">9653093</ArticleId></ArticleIdList></Reference><Reference><Citation>Cugurra JKA, Mamuladze T, Rustenhoven J, Dykstra T, Beroshvili G, Greenberg ZJ, Baker W, Papadopoulos Z, Drieu A, Blackburn S, Kanamori M, Brioschi S, Herz J, Schuettpelz LG, Colonna M, Smirnov I, Skull and vertebral bone marrow are myeloid reservoirs for the meninges and CNS parenchyma. Science. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863069</ArticleId><ArticleId IdType="pubmed">34083447</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancro MP, Age-Associated B Cells. Annu. Rev. Immunol (2020), doi:10.1146/annurev-immunol-092419-031130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-092419-031130</ArticleId><ArticleId IdType="pubmed">31986068</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubtsov AV, et al., Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity. Blood (2011), doi:10.1182/blood-2011-01-331462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-01-331462</ArticleId><ArticleId IdType="pmc">PMC3152497</ArticleId><ArticleId IdType="pubmed">21543762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y, O&#x2019;Neill P, Naradikian MS, Scholz JL, Cancro MP, A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood (2011), doi:10.1182/blood-2011-01-330530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-01-330530</ArticleId><ArticleId IdType="pmc">PMC3152496</ArticleId><ArticleId IdType="pubmed">21562046</ArticleId></ArticleIdList></Reference><Reference><Citation>Manni M, et al., Regulation of age-associated B cells by IRF5 in systemic autoimmunity. Nat. Immunol (2018), doi:10.1038/s41590-018-0056-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-018-0056-8</ArticleId><ArticleId IdType="pmc">PMC6095139</ArticleId><ArticleId IdType="pubmed">29483597</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas OL, et al., Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10. Cell (2019), doi:10.1016/j.cell.2018.11.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.11.035</ArticleId><ArticleId IdType="pmc">PMC6903689</ArticleId><ArticleId IdType="pubmed">30612739</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser SL, et al., B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med (2008), doi:10.1056/NEJMoa0706383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0706383</ArticleId><ArticleId IdType="pubmed">18272891</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser SL, et al., Ofatumumab versus Teriflunomide in Multiple Sclerosis. N. Engl. J. Med (2020), doi:10.1056/nejmoa1917246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1917246</ArticleId><ArticleId IdType="pubmed">32757523</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al., TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med 213, 667&#x2013;75 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Metscher BD, MicroCT for developmental biology: A versatile tool for high-contrast 3D imaging at histological resolutions. Dev. Dyn (2009), doi:10.1002/dvdy.21857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dvdy.21857</ArticleId><ArticleId IdType="pubmed">19235724</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, et al., Comprehensive Integration of Single-Cell Data. Cell (2019), doi:10.1016/j.cell.2019.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.031</ArticleId><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafemeister C, Satija R, Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. (2019), doi:10.1186/s13059-019-1874-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1874-1</ArticleId><ArticleId IdType="pmc">PMC6927181</ArticleId><ArticleId IdType="pubmed">31870423</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G, et al., MAST: A flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. (2015), doi:10.1186/s13059-015-0844-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-015-0844-5</ArticleId><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Le T, et al., BBrowser : Making single-cell data easily accessible (2020), doi:10.1101/2020.12.11.414136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.11.414136</ArticleId></ArticleIdList></Reference><Reference><Citation>Angerer P, Haghverdi L, B&#xfc;ttner M, Theis FJ, Marr C, Buettner F, Destiny: Diffusion maps for large-scale single-cell data in R. Bioinformatics (2016), doi:10.1093/bioinformatics/btv715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btv715</ArticleId><ArticleId IdType="pubmed">26668002</ArticleId></ArticleIdList></Reference><Reference><Citation>Street K, et al., Slingshot: Cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics (2018), doi:10.1186/s12864-018-4772-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-018-4772-0</ArticleId><ArticleId IdType="pmc">PMC6007078</ArticleId><ArticleId IdType="pubmed">29914354</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, et al., Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun (2019), doi:10.1038/s41467-019-09234-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09234-6</ArticleId><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Browaeys R, Saelens W, Saeys Y, NicheNet: modeling intercellular communication by linking ligands to target genes. Nat. Methods 17, 159&#x2013;162 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31819264</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta NT, Vander Heiden JA, Uduman M, Gadala-Maria D, Yaari G, Kleinstein SH, Change-O: A toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. Bioinformatics (2015), doi:10.1093/bioinformatics/btv359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btv359</ArticleId><ArticleId IdType="pmc">PMC4793929</ArticleId><ArticleId IdType="pubmed">26069265</ArticleId></ArticleIdList></Reference><Reference><Citation>Vander Heiden JA, et al., pRESTO : a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires. 30, 1930&#x2013;1932 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4071206</ArticleId><ArticleId IdType="pubmed">24618469</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsoussi WB, et al., A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. J. Immunol 205, 915&#x2013;922 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566074</ArticleId><ArticleId IdType="pubmed">32591393</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta NT, Adams KD, Briggs AW, Timberlake SC, Vigneault F, Kleinstein SH, Hierarchical Clustering Can Identify B Cell Clones with High Confidence in Ig Repertoire Sequencing Data. J. Immunol 198, 2489&#x2013;2499 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340603</ArticleId><ArticleId IdType="pubmed">28179494</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou JQ, Kleinstein SH, Cutting Edge: Ig H Chains Are Sufficient to Determine Most B Cell Clonal Relationships. J. Immunol 203, 1687&#x2013;1692 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865802</ArticleId><ArticleId IdType="pubmed">31484734</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34083447</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>373</Volume><Issue>6553</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eabf7844</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.abf7844</ELocationID><Abstract><AbstractText>The meninges are a membranous structure enveloping the central nervous system (CNS) that host a rich repertoire of immune cells mediating CNS immune surveillance. Here, we report that the mouse meninges contain a pool of monocytes and neutrophils supplied not from the blood but by adjacent skull and vertebral bone marrow. Under pathological conditions, including spinal cord injury and neuroinflammation, CNS-infiltrating myeloid cells can originate from brain borders and display transcriptional signatures distinct from their blood-derived counterparts. Thus, CNS borders are populated by myeloid cells from adjacent bone marrow niches, strategically placed to supply innate immune cells under homeostatic and pathological conditions. These findings call for a reinterpretation of immune-cell infiltration into the CNS during injury and autoimmunity and may inform future therapeutic approaches that harness meningeal immune cells.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Cugurra</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7636-4869</Identifier><AffiliationInfo><Affiliation>Gutenberg Research Fellowship Group of Neuroimmunology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Mamuladze</LastName><ForeName>Tornike</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7088-3967</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rustenhoven</LastName><ForeName>Justin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9376-7424</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dykstra</LastName><ForeName>Taitea</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-7756-809X</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beroshvili</LastName><ForeName>Giorgi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Zev J</ForeName><Initials>ZJ</Initials><Identifier Source="ORCID">0000-0002-6234-7005</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadopoulos</LastName><ForeName>Zach</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-5681-1388</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drieu</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6237-4719</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackburn</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanamori</LastName><ForeName>Mitsuhiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brioschi</LastName><ForeName>Simone</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3849-3926</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herz</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuettpelz</LastName><ForeName>Laura G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5222-4987</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smirnov</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kipnis</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3714-517X</Identifier><AffiliationInfo><Affiliation>Gutenberg Research Fellowship Group of Neuroimmunology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. kipnis@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP1 AT010416</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034113</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG034113</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057496</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2021 Aug;596(7870):38-40. doi: 10.1038/d41586-021-01962-4.</RefSource><PMID Version="1">34285399</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001853" MajorTopicYN="N">Bone Marrow</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001854" MajorTopicYN="N">Bone Marrow Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002493" MajorTopicYN="N">Central Nervous System Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004388" MajorTopicYN="N">Dura Mater</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004681" MajorTopicYN="N">Encephalomyelitis, Autoimmune, Experimental</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008578" MajorTopicYN="N">Meninges</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012886" MajorTopicYN="N">Skull</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013119" MajorTopicYN="N">Spinal Cord Injuries</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013131" MajorTopicYN="N">Spine</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> JK is a member of a scientific advisory group for PureTech Health.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34083447</ArticleId><ArticleId IdType="mid">NIHMS1777452</ArticleId><ArticleId IdType="pmc">PMC8863069</ArticleId><ArticleId IdType="doi">10.1126/science.abf7844</ArticleId><ArticleId IdType="pii">science.abf7844</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bassler K, Schulte-Schrepping J, Warnat-Herresthal S, Aschenbrenner AC, Schultze JL, The Myeloid Cell Compartment-Cell by Cell. Annu. Rev. Immunol 37, 269&#x2013;293 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30649988</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilliams M, Mildner A, Yona S, Developmental and functional heterogeneity of monocytes. Immunity 49, 595&#x2013;613 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30332628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng LG, Ostuni R, Hidalgo A, Heterogeneity of neutrophils. Nat. Rev. Immunol 19, 255&#x2013;265 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30816340</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon S, Pl&#xfc;ddemann A, Tissue macrophages: heterogeneity and functions. BMC Biol 15, 53 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5492929</ArticleId><ArticleId IdType="pubmed">28662662</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F et al., Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841&#x2013;845 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K et al., Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat. Neurosci 16, 273&#x2013;280 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23334579</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz C et al., A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336, 86&#x2013;90 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22442384</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilliams M, Scott CL, Does niche competition determine the origin of tissue-resident macrophages? Nat. Rev. Immunol 17, 451&#x2013;460 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28461703</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FMV, Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci 10, 1538&#x2013;1543 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18026097</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore MRP et al., Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82, 380&#x2013;397 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronk JC et al., Peripherally derived macrophages can engraft the brain independent of irradiation and maintain an identity distinct from microglia. J. Exp. Med 215, 1627&#x2013;1647 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5987928</ArticleId><ArticleId IdType="pubmed">29643186</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett FC et al., A combination of ontogeny and CNS environment establishes microglial identity. Neuron 98, 1170&#x2013;1183.e8 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023731</ArticleId><ArticleId IdType="pubmed">29861285</ArticleId></ArticleIdList></Reference><Reference><Citation>Herz J, Filiano AJ, Smith A, Yogev N, Kipnis J, Myeloid cells in the central nervous system. Immunity 46, 943&#x2013;956 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657250</ArticleId><ArticleId IdType="pubmed">28636961</ArticleId></ArticleIdList></Reference><Reference><Citation>Jord&#xe3;o MJC et al., Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science 363 (2019), doi:10.1126/science.aat7554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aat7554</ArticleId><ArticleId IdType="pubmed">30679343</ArticleId></ArticleIdList></Reference><Reference><Citation>Mundt S et al., Conventional DCs sample and present myelin antigens in the healthy CNS and allow parenchymal T cell entry to initiate neuroinflammation. Sci. Immunol 4 (2019), doi:10.1126/sciimmunol.aau8380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aau8380</ArticleId><ArticleId IdType="pubmed">30679199</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrdjen D et al., High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells Reveals Distinct Myeloid Subsets in Health, Aging, and Disease. Immunity 48, 380&#x2013;395.e6 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29426702</ArticleId></ArticleIdList></Reference><Reference><Citation>Utz SG et al., Early Fate Defines Microglia and Non-parenchymal Brain Macrophage Development. Cell 181, 557&#x2013;573.e18 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32259484</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hove H et al., A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat. Neurosci 22, 1021&#x2013;1035 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31061494</ArticleId></ArticleIdList></Reference><Reference><Citation>Korin B et al., High-dimensional, single-cell characterization of the brain&#x2019;s immune compartment. Nat. Neurosci 20, 1300&#x2013;1309 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28758994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajami B et al., Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models. Nat. Neurosci 21, 541&#x2013;551 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629134</ArticleId><ArticleId IdType="pubmed">29507414</ArticleId></ArticleIdList></Reference><Reference><Citation>Herisson F et al., Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration. Nat. Neurosci 21, 1209&#x2013;1217 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6148759</ArticleId><ArticleId IdType="pubmed">30150661</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao H et al., Leukaemia hijacks a neural mechanism to invade the central nervous system. Nature 560, 55&#x2013;60 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10257142</ArticleId><ArticleId IdType="pubmed">30022166</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai R et al., Panoptic imaging of transparent mice reveals whole-body neuronal projections and skull-meninges connections. Nat. Neurosci 22, 317&#x2013;327 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494982</ArticleId><ArticleId IdType="pubmed">30598527</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustenhoven J et al., Functional characterization of the dural sinuses as a neuroimmune interface. Cell 184, 1000&#x2013;1016.e27 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8487654</ArticleId><ArticleId IdType="pubmed">33508229</ArticleId></ArticleIdList></Reference><Reference><Citation>Brioschi S et al., Heterogeneity of meningeal B lymphocytes reveals a novel niche for B cell ontogeny at the CNS borders. Science</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8448524</ArticleId><ArticleId IdType="pubmed">34083450</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowotschin S, Hadjantonakis A-K, Use of KikGR a photoconvertible green-to-red fluorescent protein for cell labeling and lineage analysis in ES cells and mouse embryos. BMC Dev. Biol 9, 49 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2872819</ArticleId><ArticleId IdType="pubmed">19740427</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo MV, Latour LL, McGavern DB, Distinct myeloid cell subsets promote meningeal remodeling and vascular repair after mild traumatic brain injury. Nat. Immunol 19, 442&#x2013;452 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426637</ArticleId><ArticleId IdType="pubmed">29662169</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M et al., Cranial suture regeneration mitigates skull and neurocognitive defects in craniosynostosis. Cell 184, 243&#x2013;256.e18 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7891303</ArticleId><ArticleId IdType="pubmed">33417861</ArticleId></ArticleIdList></Reference><Reference><Citation>Randolph GJ, Emigration of monocyte-derived cells to lymph nodes during resolution of inflammation and its failure in atherosclerosis. Curr Opin Lipidol 19, 462&#x2013;468 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2652166</ArticleId><ArticleId IdType="pubmed">18769227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastorakos P, McGavern D, The anatomy and immunology of vasculature in the central nervous system. Sci. Immunol 4 (2019), doi:10.1126/sciimmunol.aav0492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aav0492</ArticleId><ArticleId IdType="pmc">PMC6816468</ArticleId><ArticleId IdType="pubmed">31300479</ArticleId></ArticleIdList></Reference><Reference><Citation>Giladi A et al., Cxcl10+ monocytes define a pathogenic subset in the central nervous system during autoimmune neuroinflammation. Nat. Immunol 21, 525&#x2013;534 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32313246</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner CA, Roqu&#xe9; PJ, Goverman JM, Pathogenic T cell cytokines in multiple sclerosis. J. Exp. Med 217 (2020), doi:10.1084/jem.20190460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190460</ArticleId><ArticleId IdType="pmc">PMC7037255</ArticleId><ArticleId IdType="pubmed">31611252</ArticleId></ArticleIdList></Reference><Reference><Citation>Shechter R et al., Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity 38, 555&#x2013;569 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115271</ArticleId><ArticleId IdType="pubmed">23477737</ArticleId></ArticleIdList></Reference><Reference><Citation>Bovetti S et al., Blood vessels form a scaffold for neuroblast migration in the adult olfactory bulb. J. Neurosci 27, 5976&#x2013;5980 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672264</ArticleId><ArticleId IdType="pubmed">17537968</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuddapah VA, Robel S, Watkins S, Sontheimer H, A neurocentric perspective on glioma invasion. Nat. Rev. Neurosci 15, 455&#x2013;465 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5304245</ArticleId><ArticleId IdType="pubmed">24946761</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauveau A et al., Visualization of T Cell Migration in the Spleen Reveals a Network of Perivascular Pathways that Guide Entry into T Zones. Immunity 52, 794&#x2013;807.e7 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237890</ArticleId><ArticleId IdType="pubmed">32298648</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth TL et al., Transcranial amelioration of inflammation and cell death after brain injury. Nature 505, 223&#x2013;228 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3930079</ArticleId><ArticleId IdType="pubmed">24317693</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun ATL, Bach K, Marioni JC, Pooling across cells to normalize single-cell RNA sequencing data with many zero counts. Genome Biol 17, 75 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4848819</ArticleId><ArticleId IdType="pubmed">27122128</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berge K et al., Observation weights unlock bulk RNA-seq tools for zero inflation and single-cell applications. Genome Biol 19, 24 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251479</ArticleId><ArticleId IdType="pubmed">29478411</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139&#x2013;140 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong G, Zhang W, Li H, Shen X, Guo Z, Separate enrichment analysis of pathways for up- and downregulated genes. J. R. Soc. Interface 11, 20130950 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3899863</ArticleId><ArticleId IdType="pubmed">24352673</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G, Wang L-G, Han Y, He Q-Y, clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284&#x2013;287 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3339379</ArticleId><ArticleId IdType="pubmed">22455463</ArticleId></ArticleIdList></Reference><Reference><Citation>Baccin C et al., Combined single-cell and spatial transcriptomics reveal the molecular, cellular and spatial bone marrow niche organization. Nat. Cell Biol 22, 38&#x2013;48 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610809</ArticleId><ArticleId IdType="pubmed">31871321</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A et al., CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat. Neurosci 21, 1380&#x2013;1391 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6214619</ArticleId><ArticleId IdType="pubmed">30224810</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S et al., Functional aspects of meningeal lymphatics in ageing and Alzheimer&#x2019;s disease. Nature 560, 185&#x2013;191 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6085146</ArticleId><ArticleId IdType="pubmed">30046111</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Mesquita S et al., Meningeal lymphatics affect microglia responses and anti-A&#x3b2; immunotherapy. Nature (2021), doi:10.1038/s41586-021-03489-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03489-0</ArticleId><ArticleId IdType="pmc">PMC8817786</ArticleId><ArticleId IdType="pubmed">33911285</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34133945</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>14</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>21</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>C9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation.</ArticleTitle><Pagination><StartPage>2275</StartPage><EndPage>2291.e8</EndPage><MedlinePgn>2275-2291.e8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2021.05.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(21)00373-1</ELocationID><Abstract><AbstractText>C9orf72 repeat expansions cause inherited amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD) and result in both loss of C9orf72 protein expression and production of potentially toxic RNA and dipeptide repeat proteins. In addition to ALS/FTD, C9orf72 repeat expansions have been reported in a broad array of neurodegenerative syndromes, including Alzheimer's disease. Here we show that C9orf72 deficiency promotes a change in the homeostatic signature in microglia and a transition to an inflammatory state characterized by an enhanced type I IFN signature. Furthermore, C9orf72-depleted microglia trigger age-dependent neuronal defects, in particular enhanced cortical synaptic pruning, leading to altered learning and memory behaviors in mice. Interestingly, C9orf72-deficient microglia promote enhanced synapse loss and neuronal deficits in a mouse model of amyloid accumulation while paradoxically improving plaque clearance. These findings suggest that altered microglial function due to decreased C9orf72 expression directly contributes to neurodegeneration in repeat expansion carriers independent of gain-of-function toxicities.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lall</LastName><ForeName>Deepti</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Neural Science and Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA; Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorenzini</LastName><ForeName>Ileana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Barrow Neurological Institute, 350 W. Thomas Road, Phoenix, AZ 85013, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mota</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Center for Neural Science and Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA; Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Shaughn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Neural Science and Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA; Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahan</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davtyan</LastName><ForeName>Hayk</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, Sue &amp; Bill Gross Stem Cell Research Center, 3200 Gross Hall, 845 Health Sciences Road, University of California, Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rexach</LastName><ForeName>Jessica E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muhammad</LastName><ForeName>A K M Ghulam</ForeName><Initials>AKMG</Initials><AffiliationInfo><Affiliation>Center for Neural Science and Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA; Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelest</LastName><ForeName>Oksana</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landeros</LastName><ForeName>Jesse</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Neural Science and Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA; Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vazquez</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Neural Science and Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA; Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Junwon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Barrow Neurological Institute, 350 W. Thomas Road, Phoenix, AZ 85013, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaffari</LastName><ForeName>Layla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Barrow Neurological Institute, 350 W. Thomas Road, Phoenix, AZ 85013, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Rourke</LastName><ForeName>Jacqueline Gire</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Center for Neural Science and Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA; Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Program in Neurogenetics, Department of Neurology, Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blurton-Jones</LastName><ForeName>Mathew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, Sue &amp; Bill Gross Stem Cell Research Center, 3200 Gross Hall, 845 Health Sciences Road, University of California, Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sattler</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Barrow Neurological Institute, 350 W. Thomas Road, Phoenix, AZ 85013, USA. Electronic address: rita.sattler@barrowneuro.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baloh</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Center for Neural Science and Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA; Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA; Department of Neurology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA. Electronic address: robert.baloh@csmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS105916</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061895</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG055524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS097545</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS085207</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 NS065723</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2021 Jul 21;109(14):2203-2204. doi: 10.1016/j.neuron.2021.06.031.</RefSource><PMID Version="1">34293287</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword></KeywordList><CoiStatement>Declaration of interests R.H.B. is employed by Roche Pharmaceuticals. D.M.H. is listed as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics, LLC. C2N Diagnostics, LLC, has licensed certain anti-tau antibodies to AbbVie for therapeutic development. D.M.H. is on the scientific advisory board of Denali and consults for Genentech, Merck, and Cajal Neurosciences. D.M.H. and J.D.U. are listed as inventors on a provisional patent from Washington University on TREM2 antibodies. R.S. is on the scientific advisory board of Spinogenix Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>16</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34133945</ArticleId><ArticleId IdType="mid">NIHMS1708667</ArticleId><ArticleId IdType="pmc">PMC8298293</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2021.05.020</ArticleId><ArticleId IdType="pii">S0896-6273(21)00373-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>ABO-RADY M, KALMBACH N, PAL A, SCHLUDI C, JANOSCH A, RICHTER T, FREITAG P, BICKLE M, KAHLERT AK, PETRI S, STEFANOV S, GLASS H, STAEGE S, JUST W, BHATNAGAR R, EDBAUER D, HERMANN A, WEGNER F &amp; STERNECKERT JL 2020. Knocking out C9ORF72 Exacerbates Axonal Trafficking Defects Associated with Hexanucleotide Repeat Expansion and Reduces Levels of Heat Shock Proteins. Stem Cell Reports, 14, 390&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7066330</ArticleId><ArticleId IdType="pubmed">32084385</ArticleId></ArticleIdList></Reference><Reference><Citation>AFGAN E, BAKER D, BATUT B, VAN DEN BEEK M, BOUVIER D, CECH M, CHILTON J, CLEMENTS D, CORAOR N, GRUNING BA, GUERLER A, HILLMAN-JACKSON J, HILTEMANN S, JALILI V, RASCHE H, SORANZO N, GOECKS J, TAYLOR J, NEKRUTENKO A &amp; BLANKENBERG D 2018. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res, 46, W537&#x2013;W544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6030816</ArticleId><ArticleId IdType="pubmed">29790989</ArticleId></ArticleIdList></Reference><Reference><Citation>ALMEIDA S &amp; GAO FB 2016. Lost &amp; found: C9ORF72 and the autophagy pathway in ALS/FTD. EMBO J, 35, 1251&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910530</ArticleId><ArticleId IdType="pubmed">27154207</ArticleId></ArticleIdList></Reference><Reference><Citation>ATANASIO A, DECMAN V, WHITE D, RAMOS M, IKIZ B, LEE HC, SIAO CJ, BRYDGES S, LAROSA E, BAI Y, FURY W, BURFEIND P, ZAMFIROVA R, WARSHAW G, ORENGO J, OYEJIDE A, FRALISH M, AUERBACH W, POUEYMIROU W, FREUDENBERG J, GONG G, ZAMBROWICZ B, VALENZUELA D, YANCOPOULOS G, MURPHY A, THURSTON G &amp; LAI KM 2016. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci Rep, 6, 23204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>AW E, ZHANG Y &amp; CARROLL M 2020. Microglial responses to peripheral type 1 interferon. J Neuroinflammation, 17, 340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7659169</ArticleId><ArticleId IdType="pubmed">33183319</ArticleId></ArticleIdList></Reference><Reference><Citation>BAKER M, MACKENZIE IR, PICKERING-BROWN SM, GASS J, RADEMAKERS R, LINDHOLM C, SNOWDEN J, ADAMSON J, SADOVNICK AD, ROLLINSON S, CANNON A, DWOSH E, NEARY D, MELQUIST S, RICHARDSON A, DICKSON D, BERGER Z, ERIKSEN J, ROBINSON T, ZEHR C, DICKEY CA, CROOK R, MCGOWAN E, MANN D, BOEVE B, FELDMAN H &amp; HUTTON M 2006. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 442, 916&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>BARUCH K, ROSENZWEIG N, KERTSER A, DECZKOWSKA A, SHARIF AM, SPINRAD A, TSITSOU-KAMPELI A, SAREL A, CAHALON L &amp; SCHWARTZ M 2015. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer&#x2019;s disease pathology. Nat Commun, 6, 7967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4557123</ArticleId><ArticleId IdType="pubmed">26284939</ArticleId></ArticleIdList></Reference><Reference><Citation>BLANKENBERG D, GORDON A, VON KUSTER G, CORAOR N, TAYLOR J, NEKRUTENKO A &amp; GALAXY T 2010. Manipulation of FASTQ data with Galaxy. Bioinformatics, 26, 1783&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2894519</ArticleId><ArticleId IdType="pubmed">20562416</ArticleId></ArticleIdList></Reference><Reference><Citation>BOIVIN M, PFISTER V, GAUCHEROT A, RUFFENACH F, NEGRONI L, SELLIER C &amp; CHARLET-BERGUERAND N 2020. Reduced autophagy upon C9ORF72 loss synergizes with dipeptide repeat protein toxicity in G4C2 repeat expansion disorders. EMBO J, 39, e100574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7024836</ArticleId><ArticleId IdType="pubmed">31930538</ArticleId></ArticleIdList></Reference><Reference><Citation>BRENNER D, SIEVERDING K, BRUNO C, LUNINGSCHROR P, BUCK E, MUNGWA S, FISCHER L, BROCKMANN SJ, ULMER J, BLIEDERHAUSER C, PHILIBERT CE, SATOH T, AKIRA S, BOILLEE S, MAYER B, SENDTNER M, LUDOLPH AC, DANZER KM, LOBSIGER CS, FREISCHMIDT A &amp; WEISHAUPT JH 2019. Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. J Exp Med, 216, 267&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6363427</ArticleId><ArticleId IdType="pubmed">30635357</ArticleId></ArticleIdList></Reference><Reference><Citation>BRETTSCHNEIDER J, TOLEDO JB, VAN DEERLIN VM, ELMAN L, MCCLUSKEY L, LEE VM &amp; TROJANOWSKI JQ 2012. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One, 7, e39216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>BROUWERS N, NUYTEMANS K, VAN DER ZEE J, GIJSELINCK I, ENGELBORGHS S, THEUNS J, KUMAR-SINGH S, PICKUT BA, PALS P, DERMAUT B, BOGAERTS V, DE POOTER T, SERNEELS S, VAN DEN BROECK M, CUIJT I, MATTHEIJSSENS M, PEETERS K, SCIOT R, MARTIN JJ, CRAS P, SANTENS P, VANDENBERGHE R, DE DEYN PP, CRUTS M, VAN BROECKHOVEN C &amp; SLEEGERS K 2007. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol, 64, 1436&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17923627</ArticleId></ArticleIdList></Reference><Reference><Citation>BROUWERS N, SLEEGERS K, ENGELBORGHS S, MAURER-STROH S, GIJSELINCK I, VAN DER ZEE J, PICKUT BA, VAN DEN BROECK M, MATTHEIJSSENS M, PEETERS K, SCHYMKOWITZ J, ROUSSEAU F, MARTIN JJ, CRUTS M, DE DEYN PP &amp; VAN BROECKHOVEN C 2008. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology, 71, 656&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">18565828</ArticleId></ArticleIdList></Reference><Reference><Citation>BURBERRY A, SUZUKI N, WANG JY, MOCCIA R, MORDES DA, STEWART MH, SUZUKI-UEMATSU S, GHOSH S, SINGH A, MERKLE FT, KOSZKA K, LI QZ, ZON L, ROSSI DJ, TROWBRIDGE JJ, NOTARANGELO LD &amp; EGGAN K 2016. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med, 8, 347ra93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>BURBERRY A, WELLS MF, LIMONE F, COUTO A, SMITH KS, KEANEY J, GILLET G, VAN GASTEL N, WANG JY, PIETILAINEN O, QIAN M, EGGAN P, CANTRELL C, MOK J, KADIU I, SCADDEN DT &amp; EGGAN K 2020. C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature, 582, 89&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7416879</ArticleId><ArticleId IdType="pubmed">32483373</ArticleId></ArticleIdList></Reference><Reference><Citation>CACACE R, VAN CAUWENBERGHE C, BETTENS K, GIJSELINCK I, VAN DER ZEE J, ENGELBORGHS S, VANDENBULCKE M, VAN DONGEN J, BAUMER V, DILLEN L, MATTHEIJSSENS M, PEETERS K, CRUTS M, VANDENBERGHE R, DE DEYN PP, VAN BROECKHOVEN C &amp; SLEEGERS K 2013. C9orf72 G4C2 repeat expansions in Alzheimer&#x2019;s disease and mild cognitive impairment. Neurobiol Aging, 34, 1712 e1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23352322</ArticleId></ArticleIdList></Reference><Reference><Citation>CRUTS M, GIJSELINCK I, VAN DER ZEE J, ENGELBORGHS S, WILS H, PIRICI D, RADEMAKERS R, VANDENBERGHE R, DERMAUT B, MARTIN JJ, VAN DUIJN C, PEETERS K, SCIOT R, SANTENS P, DE POOTER T, MATTHEIJSSENS M, VAN DEN BROECK M, CUIJT I, VENNEKENS K, DE DEYN PP, KUMAR-SINGH S &amp; VAN BROECKHOVEN C 2006. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature, 442, 920&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>DAVIES VJ, HOLLINS AJ, PIECHOTA MJ, YIP W, DAVIES JR, WHITE KE, NICOLS PP, BOULTON ME &amp; VOTRUBA M 2007. Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function. Hum Mol Genet, 16, 1307&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">17428816</ArticleId></ArticleIdList></Reference><Reference><Citation>DAVTYAN H, MKRTICHYAN M, MOVSESYAN N, PETRUSHINA I, MAMIKONYAN G, CRIBBS DH, AGADJANYAN MG &amp; GHOCHIKYAN A 2010. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther, 17, 261&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2820600</ArticleId><ArticleId IdType="pubmed">19865176</ArticleId></ArticleIdList></Reference><Reference><Citation>DAVTYAN H, PETRUSHINA I &amp; GHOCHIKYAN A 2014. Immunotherapy for Alzheimer&#x2019;s disease: DNA- and protein-based epitope vaccines. Methods Mol Biol, 1143, 259&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">24715293</ArticleId></ArticleIdList></Reference><Reference><Citation>DEJESUS-HERNANDEZ M, FINCH NA, WANG X, GENDRON TF, BIENIEK KF, HECKMAN MG, VASILEVICH A, MURRAY ME, ROUSSEAU L, WEESNER R, LUCIDO A, PARSONS M, CHEW J, JOSEPHS KA, PARISI JE, KNOPMAN DS, PETERSEN RC, BOEVE BF, GRAFF-RADFORD NR, DE BOER J, ASMANN YW, PETRUCELLI L, BOYLAN KB, DICKSON DW, VAN BLITTERSWIJK M &amp; RADEMAKERS R 2017. In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathol, 134, 255&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5508036</ArticleId><ArticleId IdType="pubmed">28508101</ArticleId></ArticleIdList></Reference><Reference><Citation>DEJESUS-HERNANDEZ M, MACKENZIE IR, BOEVE BF, BOXER AL, BAKER M, RUTHERFORD NJ, NICHOLSON AM, FINCH NA, FLYNN H, ADAMSON J, KOURI N, WOJTAS A, SENGDY P, HSIUNG GY, KARYDAS A, SEELEY WW, JOSEPHS KA, COPPOLA G, GESCHWIND DH, WSZOLEK ZK, FELDMAN H, KNOPMAN DS, PETERSEN RC, MILLER BL, DICKSON DW, BOYLAN KB, GRAFF-RADFORD NR &amp; RADEMAKERS R 2011. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron, 72, 245&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>EIMER WA &amp; VASSAR R 2013. Neuron loss in the 5XFAD mouse model of Alzheimer&#x2019;s disease correlates with intraneuronal Abeta42 accumulation and Caspase-3 activation. Mol Neurodegener, 8, 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552866</ArticleId><ArticleId IdType="pubmed">23316765</ArticleId></ArticleIdList></Reference><Reference><Citation>FARG MA, SUNDARAMOORTHY V, SULTANA JM, YANG S, ATKINSON RAK, LEVINA V, HALLORAN MA, GLEESON PA, BLAIR IP, SOO KY, KING AE &amp; ATKIN JD 2017. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum Mol Genet, 26, 4093&#x2013;4094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886132</ArticleId><ArticleId IdType="pubmed">28973528</ArticleId></ArticleIdList></Reference><Reference><Citation>FILIANO AJ, MARTENS LH, YOUNG AH, WARMUS BA, ZHOU P, DIAZ-RAMIREZ G, JIAO J, ZHANG Z, HUANG EJ, GAO FB, FARESE RV JR. &amp; ROBERSON ED 2013. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci, 33, 5352&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740510</ArticleId><ArticleId IdType="pubmed">23516300</ArticleId></ArticleIdList></Reference><Reference><Citation>FILIKCI Z, GUSTAFSSON MAK, HENRIKSEN OM, MARNER L &amp; HOGH P 2020. C9ORF72 hexanucleotide repeat expansion with Alzheimer&#x2019;s disease-like clinical phenotype: A case report with results from neuropsychology, CSF, FDG-PET, and PiB-PET. Clin Case Rep, 8, 3416&#x2013;3420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7752426</ArticleId><ArticleId IdType="pubmed">33363944</ArticleId></ArticleIdList></Reference><Reference><Citation>FINCH N, BAKER M, CROOK R, SWANSON K, KUNTZ K, SURTEES R, BISCEGLIO G, ROVELET-LECRUX A, BOEVE B, PETERSEN RC, DICKSON DW, YOUNKIN SG, DERAMECOURT V, CROOK J, GRAFF-RADFORD NR &amp; RADEMAKERS R 2009. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain, 132, 583&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664450</ArticleId><ArticleId IdType="pubmed">19158106</ArticleId></ArticleIdList></Reference><Reference><Citation>FOMIN V, RICHARD P, HOQUE M, LI C, GU Z, FISSORE-O&#x2019;LEARY M, TIAN B, PRIVES C &amp; MANLEY JL 2018. The C9ORF72 Gene, Implicated in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, Encodes a Protein That Functions in Control of Endothelin and Glutamate Signaling. Mol Cell Biol, 38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206455</ArticleId><ArticleId IdType="pubmed">30150298</ArticleId></ArticleIdList></Reference><Reference><Citation>FONSECA MI, CHU SH, HERNANDEZ MX, FANG MJ, MODARRESI L, SELVAN P, MACGREGOR GR &amp; TENNER AJ 2017. Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain. J Neuroinflammation, 14, 48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340039</ArticleId><ArticleId IdType="pubmed">28264694</ArticleId></ArticleIdList></Reference><Reference><Citation>FREISCHMIDT A, WIELAND T, RICHTER B, RUF W, SCHAEFFER V, MULLER K, MARROQUIN N, NORDIN F, HUBERS A, WEYDT P, PINTO S, PRESS R, MILLECAMPS S, MOLKO N, BERNARD E, DESNUELLE C, SORIANI MH, DORST J, GRAF E, NORDSTROM U, FEILER MS, PUTZ S, BOECKERS TM, MEYER T, WINKLER AS, WINKELMAN J, DE CARVALHO M, THAL DR, OTTO M, BRANNSTROM T, VOLK AE, KURSULA P, DANZER KM, LICHTNER P, DIKIC I, MEITINGER T, LUDOLPH AC, STROM TM, ANDERSEN PM &amp; WEISHAUPT JH 2015. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci, 18, 631&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>FRIEDMAN BA, SRINIVASAN K, AYALON G, MEILANDT WJ, LIN H, HUNTLEY MA, CAO Y, LEE SH, HADDICK PCG, NGU H, MODRUSAN Z, LARSON JL, KAMINKER JS, VAN DER BRUG MP &amp; HANSEN DV 2018. Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer&#x2019;s Disease Not Evident in Mouse Models. Cell Rep, 22, 832&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>GENDRON TF, BIENIEK KF, ZHANG YJ, JANSEN-WEST K, ASH PE, CAULFIELD T, DAUGHRITY L, DUNMORE JH, CASTANEDES-CASEY M, CHEW J, COSIO DM, VAN BLITTERSWIJK M, LEE WC, RADEMAKERS R, BOYLAN KB, DICKSON DW &amp; PETRUCELLI L 2013. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol, 126, 829&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>GHIDONI R, BENUSSI L, GLIONNA M, FRANZONI M &amp; BINETTI G 2008. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology, 71, 1235&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18768919</ArticleId></ArticleIdList></Reference><Reference><Citation>GITLER AD &amp; TSUIJI H 2016. There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS. Brain Res, 1647, 19&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003651</ArticleId><ArticleId IdType="pubmed">27059391</ArticleId></ArticleIdList></Reference><Reference><Citation>HAMMOND TR, DUFORT C, DISSING-OLESEN L, GIERA S, YOUNG A, WYSOKER A, WALKER AJ, GERGITS F, SEGEL M, NEMESH J, MARSH SE, SAUNDERS A, MACOSKO E, GINHOUX F, CHEN J, FRANKLIN RJM, PIAO X, MCCARROLL SA &amp; STEVENS B 2019. Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. Immunity, 50, 253&#x2013;271 e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6655561</ArticleId><ArticleId IdType="pubmed">30471926</ArticleId></ArticleIdList></Reference><Reference><Citation>HARMS M, BENITEZ BA, CAIRNS N, COOPER B, COOPER P, MAYO K, CARRELL D, FABER K, WILLIAMSON J, BIRD T, DIAZ-ARRASTIA R, FOROUD TM, BOEVE BF, GRAFF-RADFORD NR, MAYEUX R, CHAKRAVERTY S, GOATE AM, CRUCHAGA C &amp; CONSORTIUM N-LNFS 2013. C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. JAMA Neurol, 70, 736&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681841</ArticleId><ArticleId IdType="pubmed">23588422</ArticleId></ArticleIdList></Reference><Reference><Citation>HENEKA MT, CARSON MJ, EL KHOURY J, LANDRETH GE, BROSSERON F, FEINSTEIN DL, JACOBS AH, WYSS-CORAY T, VITORICA J, RANSOHOFF RM, HERRUP K, FRAUTSCHY SA, FINSEN B, BROWN GC, VERKHRATSKY A, YAMANAKA K, KOISTINAHO J, LATZ E, HALLE A, PETZOLD GC, TOWN T, MORGAN D, SHINOHARA ML, PERRY VH, HOLMES C, BAZAN NG, BROOKS DJ, HUNOT S, JOSEPH B, DEIGENDESCH N, GARASCHUK O, BODDEKE E, DINARELLO CA, BREITNER JC, COLE GM, GOLENBOCK DT &amp; KUMMER MP 2015. Neuroinflammation in Alzheimer&#x2019;s disease. Lancet Neurol, 14, 388&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909703</ArticleId><ArticleId IdType="pubmed">25792098</ArticleId></ArticleIdList></Reference><Reference><Citation>HENSMAN MOSS DJ, POULTER M, BECK J, HEHIR J, POLKE JM, CAMPBELL T, ADAMSON G, MUDANOHWO E, MCCOLGAN P, HAWORTH A, WILD EJ, SWEENEY MG, HOULDEN H, MEAD S &amp; TABRIZI SJ 2014. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology, 82, 292&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929197</ArticleId><ArticleId IdType="pubmed">24363131</ArticleId></ArticleIdList></Reference><Reference><Citation>HO WY, TAI YK, CHANG JC, LIANG J, TYAN SH, CHEN S, GUAN JL, ZHOU H, SHEN HM, KOO E &amp; LING SC 2019. The ALS-FTD-linked gene product, C9orf72, regulates neuronal morphogenesis via autophagy. Autophagy, 15, 827&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6526867</ArticleId><ArticleId IdType="pubmed">30669939</ArticleId></ArticleIdList></Reference><Reference><Citation>HONG S, BEJA-GLASSER VF, NFONOYIM BM, FROUIN A, LI S, RAMAKRISHNAN S, MERRY KM, SHI Q, ROSENTHAL A, BARRES BA, LEMERE CA, SELKOE DJ &amp; STEVENS B 2016. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science, 352, 712&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>JACKSON JL, FINCH NA, BAKER MC, KACHERGUS JM, DEJESUS-HERNANDEZ M, PEREIRA K, CHRISTOPHER E, PRUDENCIO M, HECKMAN MG, THOMPSON EA, DICKSON DW, SHAH J, OSKARSSON B, PETRUCELLI L, RADEMAKERS R &amp; VAN BLITTERSWIJK M 2020. Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers. Mol Neurodegener, 15, 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6993399</ArticleId><ArticleId IdType="pubmed">32000838</ArticleId></ArticleIdList></Reference><Reference><Citation>KEREN-SHAUL H, SPINRAD A, WEINER A, MATCOVITCH-NATAN O, DVIR-SZTERNFELD R, ULLAND TK, DAVID E, BARUCH K, LARA-ASTAISO D, TOTH B, ITZKOVITZ S, COLONNA M, SCHWARTZ M &amp; AMIT I 2017. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell, 169, 1276&#x2013;1290 e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>KIM D, PERTEA G, TRAPNELL C, PIMENTEL H, KELLEY R &amp; SALZBERG SL 2013. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol, 14, R36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053844</ArticleId><ArticleId IdType="pubmed">23618408</ArticleId></ArticleIdList></Reference><Reference><Citation>KOPPERS M, BLOKHUIS AM, WESTENENG HJ, TERPSTRA ML, ZUNDEL CA, VIEIRA DE SA R, SCHELLEVIS RD, WAITE AJ, BLAKE DJ, VELDINK JH, VAN DEN BERG LH &amp; PASTERKAMP RJ 2015. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann Neurol, 78, 426&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4744979</ArticleId><ArticleId IdType="pubmed">26044557</ArticleId></ArticleIdList></Reference><Reference><Citation>KRASEMANN S, MADORE C, CIALIC R, BAUFELD C, CALCAGNO N, EL FATIMY R, BECKERS L, O&#x2019;LOUGHLIN E, XU Y, FANEK Z, GRECO DJ, SMITH ST, TWEET G, HUMULOCK Z, ZRZAVY T, CONDE-SANROMAN P, GACIAS M, WENG Z, CHEN H, TJON E, MAZAHERI F, HARTMANN K, MADI A, ULRICH JD, GLATZEL M, WORTHMANN A, HEEREN J, BUDNIK B, LEMERE C, IKEZU T, HEPPNER FL, LITVAK V, HOLTZMAN DM, LASSMANN H, WEINER HL, OCHANDO J, HAASS C &amp; BUTOVSKY O 2017. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity, 47, 566&#x2013;581 e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>LANGFELDER P &amp; HORVATH S 2008. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics, 9, 559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>LANGFELDER P, LUO R, OLDHAM MC &amp; HORVATH S 2011. Is my network module preserved and reproducible? PLoS Comput Biol, 7, e1001057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024255</ArticleId><ArticleId IdType="pubmed">21283776</ArticleId></ArticleIdList></Reference><Reference><Citation>LANGSETH AJ, KIM J, UGOLINO JE, SHAH Y, HWANG HY, WANG J, BERGLES DE &amp; BROWN SP 2017. Cell-type specific differences in promoter activity of the ALS-linked C9orf72 mouse ortholog. Sci Rep, 7, 5685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5515847</ArticleId><ArticleId IdType="pubmed">28720882</ArticleId></ArticleIdList></Reference><Reference><Citation>LEE CYD, DAGGETT A, GU X, JIANG LL, LANGFELDER P, LI X, WANG N, ZHAO Y, PARK CS, COOPER Y, FERANDO I, MODY I, COPPOLA G, XU H &amp; YANG XW 2018. Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer&#x2019;s Disease Models. Neuron, 97, 1032&#x2013;1048 e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927822</ArticleId><ArticleId IdType="pubmed">29518357</ArticleId></ArticleIdList></Reference><Reference><Citation>LINDQUIST SG, DUNO M, BATBAYLI M, PUSCHMANN A, BRAENDGAARD H, MARDOSIENE S, SVENSTRUP K, PINBORG LH, VESTERGAARD K, HJERMIND LE, STOKHOLM J, ANDERSEN BB, JOHANNSEN P &amp; NIELSEN JE 2013. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. Clin Genet, 83, 279&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">22650353</ArticleId></ArticleIdList></Reference><Reference><Citation>LUI H, ZHANG J, MAKINSON SR, CAHILL MK, KELLEY KW, HUANG HY, SHANG Y, OLDHAM MC, MARTENS LH, GAO F, COPPOLA G, SLOAN SA, HSIEH CL, KIM CC, BIGIO EH, WEINTRAUB S, MESULAM MM, RADEMAKERS R, MACKENZIE IR, SEELEY WW, KARYDAS A, MILLER BL, BORRONI B, GHIDONI R, FARESE RV JR., PAZ JT, BARRES BA &amp; HUANG EJ 2016. Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Cell, 165, 921&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>MACKENZIE IR, ARZBERGER T, KREMMER E, TROOST D, LORENZL S, MORI K, WENG SM, HAASS C, KRETZSCHMAR HA, EDBAUER D &amp; NEUMANN M 2013. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol, 126, 859&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">24096617</ArticleId></ArticleIdList></Reference><Reference><Citation>MAJOUNIE E, ABRAMZON Y, RENTON AE, PERRY R, BASSETT SS, PLETNIKOVA O, TRONCOSO JC, HARDY J, SINGLETON AB &amp; TRAYNOR BJ 2012. Repeat expansion in C9ORF72 in Alzheimer&#x2019;s disease. N Engl J Med, 366, 283&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3513272</ArticleId><ArticleId IdType="pubmed">22216764</ArticleId></ArticleIdList></Reference><Reference><Citation>MARCHBANK NJ, CRAIG JE, LEEK JP, TOOHEY M, CHURCHILL AJ, MARKHAM AF, MACKEY DA, TOOMES C &amp; INGLEHEARN CF 2002. Deletion of the OPA1 gene in a dominant optic atrophy family: evidence that haploinsufficiency is the cause of disease. J Med Genet, 39, e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735190</ArticleId><ArticleId IdType="pubmed">12161614</ArticleId></ArticleIdList></Reference><Reference><Citation>MARSH SE, ABUD EM, LAKATOS A, KARIMZADEH A, YEUNG ST, DAVTYAN H, FOTE GM, LAU L, WEINGER JG, LANE TE, INLAY MA, POON WW &amp; BLURTON-JONES M 2016. The adaptive immune system restrains Alzheimer&#x2019;s disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A, 113, E1316&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780638</ArticleId><ArticleId IdType="pubmed">26884167</ArticleId></ArticleIdList></Reference><Reference><Citation>MATHYS H, ADAIKKAN C, GAO F, YOUNG JZ, MANET E, HEMBERG M, DE JAGER PL, RANSOHOFF RM, REGEV A &amp; TSAI LH 2017. Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell Rep, 21, 366&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642107</ArticleId><ArticleId IdType="pubmed">29020624</ArticleId></ArticleIdList></Reference><Reference><Citation>MCCAULEY ME, O&#x2019;ROURKE JG, YANEZ A, MARKMAN JL, HO R, WANG X, CHEN S, LALL D, JIN M, MUHAMMAD A, BELL S, LANDEROS J, VALENCIA V, HARMS M, ARDITI M, JEFFERIES C &amp; BALOH RH 2020. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature, 585, 96&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484469</ArticleId><ArticleId IdType="pubmed">32814898</ArticleId></ArticleIdList></Reference><Reference><Citation>MINAMI SS, MIN SW, KRABBE G, WANG C, ZHOU Y, ASGAROV R, LI Y, MARTENS LH, ELIA LP, WARD ME, MUCKE L, FARESE RV JR. &amp; GAN L 2014. Progranulin protects against amyloid beta deposition and toxicity in Alzheimer&#x2019;s disease mouse models. Nat Med, 20, 1157&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4196723</ArticleId><ArticleId IdType="pubmed">25261995</ArticleId></ArticleIdList></Reference><Reference><Citation>MIZIELINSKA S, LASHLEY T, NORONA FE, CLAYTON EL, RIDLER CE, FRATTA P &amp; ISAACS AM 2013. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol, 126, 845&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830745</ArticleId><ArticleId IdType="pubmed">24170096</ArticleId></ArticleIdList></Reference><Reference><Citation>MRDJEN D, PAVLOVIC A, HARTMANN FJ, SCHREINER B, UTZ SG, LEUNG BP, LELIOS I, HEPPNER FL, KIPNIS J, MERKLER D, GRETER M &amp; BECHER B 2018. High-Dimensional Single-Cell Mapping of Central Nervous System Immune Cells Reveals Distinct Myeloid Subsets in Health, Aging, and Disease. Immunity, 48, 599.</Citation><ArticleIdList><ArticleId IdType="pubmed">29562204</ArticleId></ArticleIdList></Reference><Reference><Citation>NASSIF M, WOEHLBIER U &amp; MANQUE PA 2017. The Enigmatic Role of C9ORF72 in Autophagy. Front Neurosci, 11, 442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5541066</ArticleId><ArticleId IdType="pubmed">28824365</ArticleId></ArticleIdList></Reference><Reference><Citation>NUYTEMANS K, BADEMCI G, KOHLI MM, BEECHAM GW, WANG L, YOUNG JI, NAHAB F, MARTIN ER, GILBERT JR, BENATAR M, HAINES JL, SCOTT WK, ZUCHNER S, PERICAK-VANCE MA &amp; VANCE JM 2013. C9ORF72 intermediate repeat copies are a significant risk factor for Parkinson disease. Ann Hum Genet, 77, 351&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3815478</ArticleId><ArticleId IdType="pubmed">23845100</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;ROURKE JG, BOGDANIK L, YANEZ A, LALL D, WOLF AJ, MUHAMMAD AK, HO R, CARMONA S, VIT JP, ZARROW J, KIM KJ, BELL S, HARMS MB, MILLER TM, DANGLER CA, UNDERHILL DM, GOODRIDGE HS, LUTZ CM &amp; BALOH RH 2016. C9orf72 is required for proper macrophage and microglial function in mice. Science, 351, 1324&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>PAOLICELLI RC, JAWAID A, HENSTRIDGE CM, VALERI A, MERLINI M, ROBINSON JL, LEE EB, ROSE J, APPEL S, LEE VM, TROJANOWSKI JQ, SPIRES-JONES T, SCHULZ PE &amp; RAJENDRAN L 2017. TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss. Neuron, 95, 297&#x2013;308 e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5519492</ArticleId><ArticleId IdType="pubmed">28669544</ArticleId></ArticleIdList></Reference><Reference><Citation>PETKAU TL, NEAL SJ, MILNERWOOD A, MEW A, HILL AM, ORBAN P, GREGG J, LU G, FELDMAN HH, MACKENZIE IR, RAYMOND LA &amp; LEAVITT BR 2012. Synaptic dysfunction in progranulin-deficient mice. Neurobiol Dis, 45, 711&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">22062772</ArticleId></ArticleIdList></Reference><Reference><Citation>RENTON AE, MAJOUNIE E, WAITE A, SIMON-SANCHEZ J, ROLLINSON S, GIBBS JR, SCHYMICK JC, LAAKSOVIRTA H, VAN SWIETEN JC, MYLLYKANGAS L, KALIMO H, PAETAU A, ABRAMZON Y, REMES AM, KAGANOVICH A, SCHOLZ SW, DUCKWORTH J, DING J, HARMER DW, HERNANDEZ DG, JOHNSON JO, MOK K, RYTEN M, TRABZUNI D, GUERREIRO RJ, ORRELL RW, NEAL J, MURRAY A, PEARSON J, JANSEN IE, SONDERVAN D, SEELAAR H, BLAKE D, YOUNG K, HALLIWELL N, CALLISTER JB, TOULSON G, RICHARDSON A, GERHARD A, SNOWDEN J, MANN D, NEARY D, NALLS MA, PEURALINNA T, JANSSON L, ISOVIITA VM, KAIVORINNE AL, HOLTTA-VUORI M, IKONEN E, SULKAVA R, BENATAR M, WUU J, CHIO A, RESTAGNO G, BORGHERO G, SABATELLI M, CONSORTIUM I, HECKERMAN D, ROGAEVA E, ZINMAN L, ROTHSTEIN JD, SENDTNER M, DREPPER C, EICHLER EE, ALKAN C, ABDULLAEV Z, PACK SD, DUTRA A, PAK E, HARDY J, SINGLETON A, WILLIAMS NM, HEUTINK P, PICKERING-BROWN S, MORRIS HR, TIENARI PJ &amp; TRAYNOR BJ 2011. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron, 72, 257&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>REXACH J, SWARUP V, CHANG T &amp; GESCHWIND D 2019. Dementia risk genes engage gene networks poised to tune the immune response towards chronic inflammatory states. bioRxiv, 597542.</Citation></Reference><Reference><Citation>REXACH JE, POLIOUDAKIS D, YIN A, SWARUP V, CHANG TS, NGUYEN T, SARKAR A, CHEN L, HUANG J, LIN LC, SEELEY W, TROJANOWSKI JQ, MALHOTRA D &amp; GESCHWIND DH 2020. Tau Pathology Drives Dementia Risk-Associated Gene Networks toward Chronic Inflammatory States and Immunosuppression. Cell Rep, 33, 108398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7842189</ArticleId><ArticleId IdType="pubmed">33207193</ArticleId></ArticleIdList></Reference><Reference><Citation>RIZZU P, BLAUWENDRAAT C, HEETVELD S, LYNES EM, CASTILLO-LIZARDO M, DHINGRA A, PYZ E, HOBERT M, SYNOFZIK M, SIMON-SANCHEZ J, FRANCESCATTO M &amp; HEUTINK P 2016. C9orf72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced in C9orf72, MAPT and GRN mutation carriers. Acta Neuropathol Commun, 4, 37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832459</ArticleId><ArticleId IdType="pubmed">27079381</ArticleId></ArticleIdList></Reference><Reference><Citation>ROY ER, WANG B, WAN YW, CHIU G, COLE A, YIN Z, PROPSON NE, XU Y, JANKOWSKY JL, LIU Z, LEE VM, TROJANOWSKI JQ, GINSBERG SD, BUTOVSKY O, ZHENG H &amp; CAO W 2020. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J Clin Invest, 130, 1912&#x2013;1930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108898</ArticleId><ArticleId IdType="pubmed">31917687</ArticleId></ArticleIdList></Reference><Reference><Citation>SABERI S, STAUFFER JE, JIANG J, GARCIA SD, TAYLOR AE, SCHULTE D, OHKUBO T, SCHLOFFMAN CL, MALDONADO M, BAUGHN M, RODRIGUEZ MJ, PIZZO D, CLEVELAND D &amp; RAVITS J 2018. Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. Acta Neuropathol, 135, 459&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935138</ArticleId><ArticleId IdType="pubmed">29196813</ArticleId></ArticleIdList></Reference><Reference><Citation>SALA FRIGERIO C, WOLFS L, FATTORELLI N, THRUPP N, VOYTYUK I, SCHMIDT I, MANCUSO R, CHEN WT, WOODBURY ME, SRIVASTAVA G, MOLLER T, HUDRY E, DAS S, SAIDO T, KARRAN E, HYMAN B, PERRY VH, FIERS M &amp; DE STROOPER B 2019. The Major Risk Factors for Alzheimer&#x2019;s Disease: Age, Sex, and Genes Modulate the Microglia Response to Abeta Plaques. Cell Rep, 27, 1293&#x2013;1306 e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340153</ArticleId><ArticleId IdType="pubmed">31018141</ArticleId></ArticleIdList></Reference><Reference><Citation>SCHAFER DP, LEHRMAN EK, KAUTZMAN AG, KOYAMA R, MARDINLY AR, YAMASAKI R, RANSOHOFF RM, GREENBERG ME, BARRES BA &amp; STEVENS B 2012. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron, 74, 691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>SNOWDEN JS, ROLLINSON S, LAFON C, HARRIS J, THOMPSON J, RICHARDSON AM, JONES M, GERHARD A, NEARY D, MANN DM &amp; PICKERING-BROWN S 2012. Psychosis, C9ORF72 and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry, 83, 1031&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">22832738</ArticleId></ArticleIdList></Reference><Reference><Citation>STEPHAN AH, MADISON DV, MATEOS JM, FRASER DA, LOVELETT EA, COUTELLIER L, KIM L, TSAI HH, HUANG EJ, ROWITCH DH, BERNS DS, TENNER AJ, SHAMLOO M &amp; BARRES BA 2013. A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci, 33, 13460&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742932</ArticleId><ArticleId IdType="pubmed">23946404</ArticleId></ArticleIdList></Reference><Reference><Citation>STEVENS B, ALLEN NJ, VAZQUEZ LE, HOWELL GR, CHRISTOPHERSON KS, NOURI N, MICHEVA KD, MEHALOW AK, HUBERMAN AD, STAFFORD B, SHER A, LITKE AM, LAMBRIS JD, SMITH SJ, JOHN SW &amp; BARRES BA 2007. The classical complement cascade mediates CNS synapse elimination. Cell, 131, 1164&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>SUDRIA-LOPEZ E, KOPPERS M, DE WIT M, VAN DER MEER C, WESTENENG HJ, ZUNDEL CA, YOUSSEF SA, HARKEMA L, DE BRUIN A, VELDINK JH, VAN DEN BERG LH &amp; PASTERKAMP RJ 2016. Full ablation of C9orf72 in mice causes immune system-related pathology and neoplastic events but no motor neuron defects. Acta Neuropathol, 132, 145&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4911370</ArticleId><ArticleId IdType="pubmed">27206760</ArticleId></ArticleIdList></Reference><Reference><Citation>SUZUKI N, MAROOF AM, MERKLE FT, KOSZKA K, INTOH A, ARMSTRONG I, MOCCIA R, DAVIS-DUSENBERY BN &amp; EGGAN K 2013. The mouse C9ORF72 ortholog is enriched in neurons known to degenerate in ALS and FTD. Nat Neurosci, 16, 1725&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397902</ArticleId><ArticleId IdType="pubmed">24185425</ArticleId></ArticleIdList></Reference><Reference><Citation>TAKAHASHI H, KLEIN ZA, BHAGAT SM, KAUFMAN AC, KOSTYLEV MA, IKEZU T, STRITTMATTER SM &amp; ALZHEIMER&#x2019;S DISEASE NEUROIMAGING I 2017. Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network. Acta Neuropathol, 133, 785&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391267</ArticleId><ArticleId IdType="pubmed">28070672</ArticleId></ArticleIdList></Reference><Reference><Citation>TAYLOR JP, BROWN RH JR. &amp; CLEVELAND DW 2016. Decoding ALS: from genes to mechanism. Nature, 539, 197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>ULLAND TK &amp; COLONNA M 2018. TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol, 14, 667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">30266932</ArticleId></ArticleIdList></Reference><Reference><Citation>ULRICH JD, FINN MB, WANG Y, SHEN A, MAHAN TE, JIANG H, STEWART FR, PICCIO L, COLONNA M &amp; HOLTZMAN DM 2014. Altered microglial response to Abeta plaques in APPPS1&#x2013;21 mice heterozygous for TREM2. Mol Neurodegener, 9, 20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>VAN MOSSEVELDE S, VAN DER ZEE J, CRUTS M &amp; VAN BROECKHOVEN C 2017. Relationship between C9orf72 repeat size and clinical phenotype. Curr Opin Genet Dev, 44, 117&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">28319737</ArticleId></ArticleIdList></Reference><Reference><Citation>VIODE A, FOURNIER C, CAMUZAT A, FENAILLE F, NEURO CEBBB, LATOUCHE M, ELAHI F, LE BER I, JUNOT C, LAMARI F, ANQUETIL V &amp; BECHER F 2018. New Antibody-Free Mass Spectrometry-Based Quantification Reveals That C9ORF72 Long Protein Isoform Is Reduced in the Frontal Cortex of Hexanucleotide-Repeat Expansion Carriers. Front Neurosci, 12, 589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6122177</ArticleId><ArticleId IdType="pubmed">30210275</ArticleId></ArticleIdList></Reference><Reference><Citation>WANG Y, CELLA M, MALLINSON K, ULRICH JD, YOUNG KL, ROBINETTE ML, GILFILLAN S, KRISHNAN GM, SUDHAKAR S, ZINSELMEYER BH, HOLTZMAN DM, CIRRITO JR &amp; COLONNA M 2015. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell, 160, 1061&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>WHITE MA, KIM E, DUFFY A, ADALBERT R, PHILLIPS BU, PETERS OM, STEPHENSON J, YANG S, MASSENZIO F, LIN Z, ANDREWS S, SEGONDS-PICHON A, METTERVILLE J, SAKSIDA LM, MEAD R, RIBCHESTER RR, BARHOMI Y, SERRE T, COLEMAN MP, FALLON JR, BUSSEY TJ, BROWN RH JR. &amp; SREEDHARAN J 2018. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci, 21, 552&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>WHITELAW BS 2018. Microglia-mediated synaptic elimination in neuronal development and disease. J Neurophysiol, 119, 1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866459</ArticleId><ArticleId IdType="pubmed">28835520</ArticleId></ArticleIdList></Reference><Reference><Citation>WILLIAMS PA, MORGAN JE &amp; VOTRUBA M 2011. Mouse models of dominant optic atrophy: what do they tell us about the pathophysiology of visual loss? Vision Res, 51, 229&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">20801145</ArticleId></ArticleIdList></Reference><Reference><Citation>XIAO S, MCKEEVER PM, LAU A &amp; ROBERTSON J 2019. Synaptic localization of C9orf72 regulates post-synaptic glutamate receptor 1 levels. Acta Neuropathol Commun, 7, 161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813971</ArticleId><ArticleId IdType="pubmed">31651360</ArticleId></ArticleIdList></Reference><Reference><Citation>YIN F, DUMONT M, BANERJEE R, MA Y, LI H, LIN MT, BEAL MF, NATHAN C, THOMAS B &amp; DING A 2010. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J, 24, 4639&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992364</ArticleId><ArticleId IdType="pubmed">20667979</ArticleId></ArticleIdList></Reference><Reference><Citation>ZHANG J, VELMESHEV D, HASHIMOTO K, HUANG YH, HOFMANN JW, SHI X, CHEN J, LEIDAL AM, DISHART JG, CAHILL MK, KELLEY KW, LIDDELOW SA, SEELEY WW, MILLER BL, WALTHER TC, FARESE RV JR., TAYLOR JP, ULLIAN EM, HUANG B, DEBNATH J, WITTMANN T, KRIEGSTEIN AR &amp; HUANG EJ 2020. Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency. Nature, 588, 459&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746606</ArticleId><ArticleId IdType="pubmed">32866962</ArticleId></ArticleIdList></Reference><Reference><Citation>ZHANG Y, CHEN K, SLOAN SA, BENNETT ML, SCHOLZE AR, O&#x2019;KEEFFE S, PHATNANI HP, GUARNIERI P, CANEDA C, RUDERISCH N, DENG S, LIDDELOW SA, ZHANG C, DANEMAN R, MANIATIS T, BARRES BA &amp; WU JQ 2014. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci, 34, 11929&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>ZHU Q, JIANG J, GENDRON TF, MCALONIS-DOWNES M, JIANG L, TAYLOR A, DIAZ GARCIA S, GHOSH DASTIDAR S, RODRIGUEZ MJ, KING P, ZHANG Y, LA SPADA AR, XU H, PETRUCELLI L, RAVITS J, DA CRUZ S, LAGIER-TOURENNE C &amp; CLEVELAND DW 2020. Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nat Neurosci.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384305</ArticleId><ArticleId IdType="pubmed">32284607</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34134980</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>25</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Following spatial A&#x3b2; aggregation dynamics in evolving Alzheimer's disease pathology by imaging stable isotope labeling kinetics.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eabg4855</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abg4855</ELocationID><Abstract><AbstractText>&#x3b2;-Amyloid (A&#x3b2;) plaque formation is the major pathological hallmark of Alzheimer's disease (AD) and constitutes a potentially critical, early inducer driving AD pathogenesis as it precedes other pathological events and cognitive symptoms by decades. It is therefore critical to understand how A&#x3b2; pathology is initiated and where and when distinct A&#x3b2; species aggregate. Here, we used metabolic isotope labeling in <i>APP<sup>NL-G-F</sup></i> knock-in mice together with mass spectrometry imaging to monitor the earliest seeds of A&#x3b2; deposition through ongoing plaque development. This allowed visualizing A&#x3b2; aggregation dynamics within single plaques across different brain regions. We show that formation of structurally distinct plaques is associated with differential A&#x3b2; peptide deposition. Specifically, A&#x3b2;1-42 is forming an initial core structure followed by radial outgrowth and late secretion and deposition of A&#x3b2;1-38. These data describe a detailed picture of the earliest events of precipitating amyloid pathology at scales not previously possible.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Michno</LastName><ForeName>Wojciech</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-3096-3604</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology, and Pharmacology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stringer</LastName><ForeName>Katie M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0003-1616-2437</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology, and Pharmacology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enzlein</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1789-4090</Identifier><AffiliationInfo><Affiliation>Center for Mass Spectrometry and Optical Spectroscopy, Mannheim University of Applied Sciences, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passarelli</LastName><ForeName>Melissa K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0003-2466-1439</Identifier><AffiliationInfo><Affiliation>Laboratory of Biological Geochemistry, Ecole Polytechnique F&#xe9;d&#xe9;rale de Lausanne (EPFL), Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry and Biochemistry, Concordia University, Montr&#xe9;al, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escrig</LastName><ForeName>Stephane</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7525-4000</Identifier><AffiliationInfo><Affiliation>Laboratory of Biological Geochemistry, Ecole Polytechnique F&#xe9;d&#xe9;rale de Lausanne (EPFL), Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitanova</LastName><ForeName>Karina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8800-4150</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology, and Pharmacology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Jack</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6049-4020</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology, and Pharmacology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1890-4193</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3930-4354</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meibom</LastName><ForeName>Anders</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4542-2819</Identifier><AffiliationInfo><Affiliation>Laboratory of Biological Geochemistry, Ecole Polytechnique F&#xe9;d&#xe9;rale de Lausanne (EPFL), Lausanne, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Advanced Surface Analysis, Institute of Earth Sciences, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hopf</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0802-6451</Identifier><AffiliationInfo><Affiliation>Center for Mass Spectrometry and Optical Spectroscopy, Mannheim University of Applied Sciences, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Frances A</ForeName><Initials>FA</Initials><Identifier Source="ORCID">0000-0001-8515-9077</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology, and Pharmacology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanrieder</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6059-198X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden. jh@gu.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/S005145/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007553" MajorTopicYN="N">Isotope Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>17</Day><Hour>5</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34134980</ArticleId><ArticleId IdType="pmc">PMC8208724</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abg4855</ArticleId><ArticleId IdType="pii">7/25/eabg4855</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blennow K., de Leon M. J., Zetterberg H., Alzheimer&#x2019;s disease. Lancet 368, 387&#x2013;403 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A., Frosch M. P., Masliah E., Hyman B. T., Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P., Blennow K., Breteler M. M. B., de Strooper B., Frisoni G. B., Salloway S., van der Flier W. M., Alzheimer&#x2019;s disease. Lancet 388, 505&#x2013;517 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E., Neuropathological staging of Alzheimer related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal D. R., Capetillo-Zarate E., Del Tredici K., Braak H., The development of amyloid beta protein deposits in the aged brain. Sci. Aging Knowledge Environ. 2006, re1 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16525193</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal D. R., R&#xfc;b U., Orantes M., Braak H., Phases of A&#x3b2;-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791&#x2013;1800 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong R. A., &#x3b2;-Amyloid plaques: Stages in life history or independent origin? Dement. Geriatr. Cogn. Disord. 9, 227&#x2013;238 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9681645</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings D. M., Liu W., Portelius E., Bayram S., Yasvoina M., Ho S. H., Smits H., Ali S. S., Steinberg R., Pegasiou C. M., James O. T., Matarin M., Richardson J. C., Zetterberg H., Blennow K., Hardy J. A., Salih D. A., Edwards F. A., First effects of rising amyloid-&#x3b2; in transgenic mouse brain: Synaptic transmission and gene expression. Brain 138, 1992&#x2013;2004 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4572488</ArticleId><ArticleId IdType="pubmed">25981962</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermark G. T., Johnson K. H., Westermark P., Staining methods for identification of amyloid in tissue. Methods Enzymol. 309, 3&#x2013;25 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10507013</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlred L., Michno W., Kaya I., Sj&#xf6;vall P., Syv&#xe4;nen S., Hanrieder J., Probing amyloid-&#x3b2; pathology in transgenic Alzheimer&#x2019;s disease (tgArcSwe) mice using MALDI imaging mass spectrometry. J. Neurochem. 138, 469&#x2013;478 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27115712</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong S. E., Blagoev B., Kratchmarova I., Kristensen D. B., Steen H., Pandey A., Mann M., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1, 376&#x2013;386 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12118079</ArticleId></ArticleIdList></Reference><Reference><Citation>Westman-Brinkmalm A., Abramsson A., Pannee J., Gang C., Gustavsson M. K., von Otter M., Blennow K., Brinkmalm G., Heumann H., Zetterberg H., SILAC zebrafish for quantitative analysis of protein turnover and tissue regeneration. J. Proteomics 75, 425&#x2013;434 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21890006</ArticleId></ArticleIdList></Reference><Reference><Citation>McClatchy D. B., Dong M. Q., Wu C. C., Venable J. D., Yates J. R. III, 15N metabolic labeling of mammalian tissue with slow protein turnover. J. Proteome Res. 6, 2005&#x2013;2010 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527585</ArticleId><ArticleId IdType="pubmed">17375949</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman R. J., Munsell L. Y., Morris J. C., Swarm R., Yarasheski K. E., Holtzman D. M., Human amyloid-&#x3b2; synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12, 856&#x2013;861 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Hark T. J., Rao N. R., Castillon C., Basta T., Smukowski S., Bao H., Upadhyay A., Bomba-Warczak E., Nomura T., O&#x2019;Toole E. T., Morgan G. P., Ali L., Saito T., Guillermier C., Saido T. C., Steinhauser M. L., Stowell M. H. B., Chapman E. R., Contractor A., Savas J. N., Pulse-chase proteomics of the App knockin mouse models of Alzheimer&#x2019;s disease reveals that synaptic dysfunction originates in presynaptic terminals. Cell Syst. 12, 141&#x2013;158.e9 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7897324</ArticleId><ArticleId IdType="pubmed">33326751</ArticleId></ArticleIdList></Reference><Reference><Citation>Savas J. N., Wang Y. Z., DeNardo L. A., Martinez-Bartolome S., McClatchy D. B., Hark T. J., Shanks N. F., Cozzolino K. A., Lavall&#xe9;e-Adam M., Smukowski S. N., Park S. K., Kelly J. W., Koo E. H., Nakagawa T., Masliah E., Ghosh A., Yates J. R. III, Amyloid accumulation drives proteome-wide alterations in mouse models of Alzheimer&#x2019;s disease-like pathology. Cell Rep. 21, 2614&#x2013;2627 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5726791</ArticleId><ArticleId IdType="pubmed">29186695</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson R. W., Gabelle A., Lucey B. P., Barth&#xe9;lemy N. R., Leckey C. A., Hirtz C., Lehmann S., Sato C., Patterson B. W., West T., Yarasheski K., Rohrer J. D., Wildburger N. C., Schott J. M., Karch C. M., Wray S., Miller T. M., Elbert D. L., Zetterberg H., Fox N. C., Bateman R. J., SILK studies&#x2014;Capturing the turnover of proteins linked to neurodegenerative diseases. Nat. Rev. Neurol. 15, 419&#x2013;427 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6876864</ArticleId><ArticleId IdType="pubmed">31222062</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman R. J., Siemers E. R., Mawuenyega K. G., Wen G., Browning K. R., Sigurdson W. C., Yarasheski K. E., Friedrich S. W., DeMattos R. B., May P. C., Paul S. M., Holtzman D. M., A &#x3b3;-secretase inhibitor decreases amyloid-&#x3b2; production in the central nervous system. Ann. Neurol. 66, 48&#x2013;54 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730994</ArticleId><ArticleId IdType="pubmed">19360898</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega K. G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J. C., Yarasheski K. E., Bateman R. J., Decreased clearance of CNS &#x3b2;-amyloid in Alzheimer&#x2019;s disease. Science 330, 1774 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Potter R., Sigurdson W., Santacruz A., Shih S., Ju Y. E., Kasten T., Morris J. C., Mintun M., Duntley S., Bateman R. J., Effects of age and amyloid deposition on A&#x3b2; dynamics in the human central nervous system. Arch. Neurol. 69, 51&#x2013;58 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254706</ArticleId><ArticleId IdType="pubmed">21911660</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R., Patterson B. W., Elbert D. L., Ovod V., Kasten T., Sigurdson W., Mawuenyega K., Blazey T., Goate A., Chott R., Yarasheski K. E., Holtzman D. M., Morris J. C., Benzinger T. L. S., Bateman R. J., Increased in vivo amyloid-&#x3b2;42 production, exchange, and loss in presenilin mutation carriers. Sci. Transl. Med. 5, 189ra77 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B. W., Elbert D. L., Mawuenyega K. G., Kasten T., Ovod V., Ma S., Xiong C., Chott R., Yarasheski K., Sigurdson W., Zhang L., Goate A., Benzinger T., Morris J. C., Holtzman D., Bateman R. J., Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann. Neurol. 78, 439&#x2013;453 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4546566</ArticleId><ArticleId IdType="pubmed">26040676</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanrieder J., Phan N. T. N., Kurczy M. E., Ewing A. G., Imaging mass spectrometry in neuroscience. ACS Chem. Nerosci. 4, 666&#x2013;679 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656743</ArticleId><ArticleId IdType="pubmed">23530951</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinhauser M. L., Bailey A. P., Senyo S. E., Guillermier C., Perlstein T. S., Gould A. P., Lee R. T., Lechene C. P., Multi-isotope imaging mass spectrometry quantifies stem cell division and metabolism. Nature 481, 516&#x2013;519 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3267887</ArticleId><ArticleId IdType="pubmed">22246326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildburger N. C., Gyngard F., Guillermier C., Patterson B. W., Elbert D., Mawuenyega K. G., Schneider T., Green K., Roth R., Schmidt R. E., Cairns N. J., Benzinger T. L. S., Steinhauser M. L., Bateman R. J., Amyloid-&#x3b2; plaques in clinical Alzheimer&#x2019;s disease brain incorporate stable isotope tracer in vivo and exhibit nanoscale heterogeneity. Front. Neurol. 9, 169 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5874304</ArticleId><ArticleId IdType="pubmed">29623063</ArticleId></ArticleIdList></Reference><Reference><Citation>Arts M., Soons Z., Ellis S. R., Pierzchalski K. A., Balluff B., Eijkel G. B., Dubois L. J., Lieuwes N. G., Agten S. M., Hackeng T. M., van&#x2005;Loon L. J. C., Heeren R. M. A., Olde Damink S. W. M., Detection of localized hepatocellular amino acid kinetics by using mass spectrometry imaging of stable isotopes. Angew. Chem. Int. Ed. Engl. 56, 7146&#x2013;7150 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6099435</ArticleId><ArticleId IdType="pubmed">28493648</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis S. R., Hall E., Panchal M., Flinders B., Madsen J., Koster G., Heeren R. M. A., Clark H. W., Postle A. D., Mass spectrometry imaging of phosphatidylcholine metabolism in lungs administered with therapeutic surfactants and isotopic tracers. J. Lipid Res. 62, 100023 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7961103</ArticleId><ArticleId IdType="pubmed">33453219</ArticleId></ArticleIdList></Reference><Reference><Citation>Enzlein T., Cordes J., Munteanu B., Michno W., Serneels L., de Strooper B., Hanrieder J., Wolf I., Ch&#xe1;vez-Guti&#xe9;rrez L., Hopf C., Computational analysis of Alzheimer amyloid plaque composition in 2D- and elastically reconstructed 3D-MALDI MS images. Anal. Chem. 92, 14484&#x2013;14493 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33138378</ArticleId></ArticleIdList></Reference><Reference><Citation>Michno W., Nystr&#xf6;m S., Wehrli P., Lashley T., Brinkmalm G., Guerard L., Syv&#xe4;nen S., Sehlin D., Kaya I., Brinet D., Nilsson K. P. R., Hammarstr&#xf6;m P., Blennow K., Zetterberg H., Hanrieder J., Pyroglutamation of amyloid-&#x3b2;x-42 (A&#x3b2;x-42) followed by A&#x3b2;1&#x2013;40 deposition underlies plaque polymorphism in progressing Alzheimer&#x2019;s disease pathology. J. Biol. Chem. 294, 6719&#x2013;6732 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6497931</ArticleId><ArticleId IdType="pubmed">30814252</ArticleId></ArticleIdList></Reference><Reference><Citation>Michno W., Wehrli P. M., Blennow K., Zetterberg H., Hanrieder J., Molecular imaging mass spectrometry for probing protein dynamics in neurodegenerative disease pathology. J. Neurochem. 151, 488&#x2013;506 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30040875</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T., Matsuba Y., Mihira N., Takano J., Nilsson P., Itohara S., Iwata N., Saido T. C., Single App knock-in mouse models of Alzheimer&#x2019;s disease. Nat. Neurosci. 17, 661&#x2013;663 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgold S., Bittner T., Dorostkar M. M., Kieser D., Fuhrmann M., Mitteregger G., Kretzschmar H., Schmidt B., Herms J., In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks. Acta Neuropathol. 121, 327&#x2013;335 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038220</ArticleId><ArticleId IdType="pubmed">21136067</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C., Schain A., Grutzendler J., Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. Sci. Rep. 1, 19 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3216507</ArticleId><ArticleId IdType="pubmed">22355538</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingstedt T., &#xc5;slund A., Simon R. A., Johansson L. B. G., Mason J. J., Nystr&#xf6;m S., Hammarstr&#xf6;m P., Nilsson K. P. R., Synthesis of a library of oligothiophenes and their utilization as fluorescent ligands for spectral assignment of protein aggregates. Org. Biomol. Chem. 9, 8356&#x2013;8370 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3326384</ArticleId><ArticleId IdType="pubmed">22051883</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslund A., Sigurdson C. J., Klingstedt T., Grathwohl S., Bolmont T., Dickstein D. L., Glimsdal E., Prokop S., Lindgren M., Konradsson P., Holtzman D. M., Hof P. R., Heppner F. L., Gandy S., Jucker M., Aguzzi A., Hammarstr&#xf6;m P., Nilsson K. P. R., Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. ACS Chem. Biol. 4, 673&#x2013;684 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886514</ArticleId><ArticleId IdType="pubmed">19624097</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson T. C., Vickers J. C., The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer&#x2019;s disease. Neuroscience 105, 99&#x2013;107 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11483304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda S., Allsop D., Glenner G. G., Morphology and distribution of plaque and related deposits in the brains of Alzheimer&#x2019;s disease and control cases. An immunohistochemical study using amyloid beta-protein antibody. Lab. Invest. 60, 113&#x2013;122 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2642985</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson D. W., Crystal H. A., Mattiace L. A., Masur D. M., Blau A. D., Davies P., Yen S. H., Aronson M. K., Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol. Aging 13, 179&#x2013;189 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1311804</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T., Saido T. C., Mann D. M., Lee V. M., Trojanowski J. Q., Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am. J. Pathol. 149, 1823&#x2013;1830 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865366</ArticleId><ArticleId IdType="pubmed">8952519</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijal Upadhaya A., Kosterin I., Kumar S., von Arnim C. A. F., Yamaguchi H., F&#xe4;ndrich M., Walter J., Thal D. R., Biochemical stages of amyloid-&#x3b2; peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer&#x2019;s disease. Brain 137, 887&#x2013;903 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24519982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord A., Kalimo H., Eckman C., Zhang X.-Q., Lannfelt L., Nilsson L. N. G., The Arctic Alzheimer mutation facilitates early intraneuronal A&#x3b2; aggregation and senile plaque formation in transgenic mice. Neurobiol. Aging 27, 67&#x2013;77 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16298242</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord A., Philipson O., Klingstedt T., Westermark G., Hammarstr&#xf6;m P., Nilsson K. P. R., Nilsson L. N. G., Observations in APP bitransgenic mice suggest that diffuse and compact plaques form via independent processes in Alzheimer&#x2019;s disease. Am. J. Pathol. 178, 2286&#x2013;2298 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3081149</ArticleId><ArticleId IdType="pubmed">21514441</ArticleId></ArticleIdList></Reference><Reference><Citation>Latif-Hernandez A., Sabanov V., Ahmed T., Craessaerts K., Saito T., Saido T., Balschun D., The two faces of synaptic failure in AppNL-G-F knock-in mice. Alzheimers Res. Ther. 12, 100 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445922</ArticleId><ArticleId IdType="pubmed">32838792</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y., Visualization of A&#x3b2;42(43) and A&#x3b2;40 in senile plaques with end-specific A&#x3b2; monoclonals: Evidence that an initially deposited species is A&#x3b2; 42(43). Neuron 13, 45&#x2013;53 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere C. A., Blusztajn J. K., Yamaguchi H., Wisniewski T., Saido T. C., Selkoe D. J., Sequence of deposition of heterogeneous amyloid &#x3b2;-peptides and APO E in Down syndrome: Implications for initial events in amyloid plaque formation. Neurobiol. Dis. 3, 16&#x2013;32 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">9173910</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M., Spires-Jones T. L., Prada C., Garcia-Alloza M., de Calignon A., Rozkalne A., Koenigsknecht-Talboo J., Holtzman D. M., Bacskai B. J., Hyman B. T., Rapid appearance and local toxicity of amyloid-&#x3b2; plaques in a mouse model of Alzheimer&#x2019;s disease. Nature 451, 720&#x2013;724 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T., Haiss F., Eicke D., Radde R., Mathis C. A., Klunk W. E., Kohsaka S., Jucker M., Calhoun M. E., Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J. Neurosci. 28, 4283&#x2013;4292 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk W. E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D. P., Bergstr&#xf6;m M., Savitcheva I., Huang G. F., Estrada S., Aus&#xe9;n B., Debnath M. L., Barletta J., Price J. C., Sandell J., Lopresti B. J., Wall A., Koivisto P., Antoni G., Mathis C. A., L&#xe5;ngstr&#xf6;m B., Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306&#x2013;319 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic M. D., Klunk W. E., Abrahamson E. E., Mathis C. A., Price J. C., Tsopelas N. D., Lopresti B. J., Ziolko S., Bi W., Paljug W. R., Debnath M. L., Hope C. E., Isanski B. A., Hamilton R. L., DeKosky S. T., Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain 131, 1630&#x2013;1645 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.-E., Han P.-L., An update of animal models of Alzheimer disease with a reevaluation of plaque depositions. Exp. Neurobiol. 22, 84&#x2013;95 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3699678</ArticleId><ArticleId IdType="pubmed">23833557</ArticleId></ArticleIdList></Reference><Reference><Citation>Philipson O., Lord A., Gumucio A., O&#x2019;Callaghan P., Lannfelt L., Nilsson L. N. G., Animal models of amyloid-&#x3b2;-related pathologies in Alzheimer&#x2019;s disease. FEBS J. 277, 1389&#x2013;1409 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20136653</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao L., McClatchy D. B., Park S. K., Xu T., Lu B., Yates J. R. III, Quantitative analysis of brain nuclear phosphoproteins identifies developmentally regulated phosphorylation events. J. Proteome Res. 7, 4743&#x2013;4755 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659596</ArticleId><ArticleId IdType="pubmed">18823140</ArticleId></ArticleIdList></Reference><Reference><Citation>Contat C., Ancey P. B., Zangger N., Sabatino S., Pascual J., Escrig S., Jensen L., Goepfert C., Lanz B., Lepore M., Gruetter R., Rossier A., Berezowska S., Neppl C., Zlobec I., Clerc-Rosset S., Knott G. W., Rathmell J. C., Abel E. D., Meibom A., Meylan E., Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth. eLife 9, e53618 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7311173</ArticleId><ArticleId IdType="pubmed">32571479</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegenast-Braun B. M., Skodras A., Bayraktar G., Mahler J., Fritschi S. K., Klingstedt T., Mason J. J., Hammarstr&#xf6;m P., Nilsson K. P. R., Liebig C., Jucker M., Spectral discrimination of cerebral amyloid lesions after peripheral application of luminescent conjugated oligothiophenes. Am. J. Pathol. 181, 1953&#x2013;1960 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23041059</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen J., Mahler J., Beschorner N., Kaeser S. A., H&#xe4;sler L. M., Baumann F., Nystr&#xf6;m S., Portelius E., Blennow K., Lashley T., Fox N. C., Sepulveda-Falla D., Glatzel M., Oblak A. L., Ghetti B., Nilsson K. P. R., Hammarstr&#xf6;m P., Staufenbiel M., Walker L. C., Jucker M., Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U.S.A. 114, 13018&#x2013;13023 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5724274</ArticleId><ArticleId IdType="pubmed">29158413</ArticleId></ArticleIdList></Reference><Reference><Citation>Guardia-Laguarta C., Pera M., Clarim&#xf3;n J., Molinuevo J. L., S&#xe0;nchez-Valle R., Llad&#xf3; A., Coma M., G&#xf3;mez-Isla T., Blesa R., Ferrer I., Lle&#xf3; A., Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation. J. Neuropathol. Exp. Neurol. 69, 53&#x2013;59 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20010303</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E., Bogdanovic N., Gustavsson M. K., Volkmann I., Brinkmalm G., Zetterberg H., Winblad B., Blennow K., Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer&#x2019;s disease. Acta Neuropathol. 120, 185&#x2013;193 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568930</ArticleId><ArticleId IdType="pubmed">20419305</ArticleId></ArticleIdList></Reference><Reference><Citation>Nystr&#xf6;m S., Psonka-Antonczyk K. M., Ellingsen P. G., Johansson L. B. G., Reitan N., Handrick S., Prokop S., Heppner F. L., Wegenast-Braun B. M., Jucker M., Lindgren M., Stokke B. T., Hammarstr&#xf6;m P., Nilsson K. P. R., Evidence for age-dependent in vivo conformational rearrangement within A&#x3b2; amyloid deposits. ACS Chem. Biol. 8, 1128&#x2013;1133 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23521783</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E., Tran A. J., Andreasson U., Persson R., Brinkmalm G., Zetterberg H., Blennow K., Westman-Brinkmalm A., Characterization of amyloid &#x3b2; peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J. Proteome Res. 6, 4433&#x2013;4439 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17927230</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannee J., Portelius E., Minthon L., Gobom J., Andreasson U., Zetterberg H., Hansson O., Blennow K., Reference measurement procedure for CSF amyloid beta (A&#x3b2;)1&#x2013;42 and the CSF A&#x3b2;1&#x2013;42/A&#x3b2;1&#x2013;40 ratio - a cross-validation study against amyloid PET. J. Neurochem. 139, 651&#x2013;658 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27579672</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanrieder J., Ljungdahl A., F&#xe4;lth M., Mammo S. E., Bergquist J., Andersson M., L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry. Mol. Cell. Proteomics 10, M111.009308 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205869</ArticleId><ArticleId IdType="pubmed">21737418</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmalm G., Portelius E., &#xd6;hrfelt A., Mattsson N., Persson R., Gustavsson M. K., Vite C. H., Gobom J., M&#xe5;nsson J. E., Nilsson J., Halim A., Larson G., R&#xfc;etschi U., Zetterberg H., Blennow K., Brinkmalm A., An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid &#x3b2; and amyloid precursor protein in human and cat cerebrospinal fluid. J. Mass Spectrom. 47, 591&#x2013;603 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22576872</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34153974</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>595</Volume><Issue>7868</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Dysregulation of brain and choroid plexus cell types in severe COVID-19.</ArticleTitle><Pagination><StartPage>565</StartPage><EndPage>571</EndPage><MedlinePgn>565-571</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-021-03710-0</ELocationID><Abstract><AbstractText>Although SARS-CoV-2 primarily targets the respiratory system, patients with and survivors of COVID-19 can suffer neurological symptoms<sup>1-3</sup>. However, an unbiased understanding of the cellular and molecular processes that are affected in the brains of patients with COVID-19 is missing. Here we profile 65,309&#xa0;single-nucleus transcriptomes from 30&#xa0;frontal cortex and choroid plexus samples across 14&#xa0;control individuals (including 1&#xa0;patient with terminal influenza) and 8&#xa0;patients with COVID-19. Although our systematic analysis yields no molecular traces of SARS-CoV-2 in the brain, we observe broad cellular perturbations indicating that barrier cells of the choroid plexus sense and relay peripheral inflammation into the brain and show that peripheral T cells infiltrate the parenchyma. We discover microglia and astrocyte subpopulations associated with COVID-19 that share features with pathological cell states that have previously been reported in human neurodegenerative disease<sup>4-6</sup>. Synaptic signalling of upper-layer excitatory neurons-which are evolutionarily expanded in humans<sup>7</sup> and linked to cognitive function<sup>8</sup>-is preferentially affected in COVID-19. Across cell types, perturbations associated with COVID-19 overlap with those found in chronic brain disorders and reside in genetic variants associated with cognition, schizophrenia and depression. Our findings and public dataset provide a molecular framework to understand current observations of COVID-19-related neurological disease, and any such disease that may emerge at a later date.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-6756-4746</Identifier><AffiliationInfo><Affiliation>Department of Bioengineering, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ChEM-H, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kern</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-8223-3750</Identifier><AffiliationInfo><Affiliation>Chair for Clinical Bioinformatics, Saarland University, Saarbr&#xfc;cken, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Losada</LastName><ForeName>Patricia M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agam</LastName><ForeName>Maayan R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maat</LastName><ForeName>Christina A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmartz</LastName><ForeName>Georges P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Chair for Clinical Bioinformatics, Saarland University, Saarbr&#xfc;cken, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fehlmann</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1967-2918</Identifier><AffiliationInfo><Affiliation>Chair for Clinical Bioinformatics, Saarland University, Saarbr&#xfc;cken, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Julian A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Institute for Neuropathology, Saarland University Hospital and Medical Faculty of Saarland University, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaum</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Davis P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calcuttawala</LastName><ForeName>Kruti</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vest</LastName><ForeName>Ryan T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berdnik</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Nannan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hahn</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gate</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0481-9657</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McNerney</LastName><ForeName>M Windy</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Channappa</LastName><ForeName>Divya</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cobos</LastName><ForeName>Inma</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludwig</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Saarland University, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulz-Schaeffer</LastName><ForeName>Walter J</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0001-5886-2322</Identifier><AffiliationInfo><Affiliation>Institute for Neuropathology, Saarland University Hospital and Medical Faculty of Saarland University, Homburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5361-0895</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. andreas.keller@ccb.uni-saarland.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chair for Clinical Bioinformatics, Saarland University, Saarbr&#xfc;cken, Germany. andreas.keller@ccb.uni-saarland.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5893-0831</Identifier><AffiliationInfo><Affiliation>ChEM-H, Stanford University, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA. twc@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG047126</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2021 Aug;17(8):461. doi: 10.1038/s41582-021-00536-2.</RefSource><PMID Version="1">34234324</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2021 Oct;598(7882):E4. doi: 10.1038/s41586-021-04080-3.</RefSource><PMID Version="1">34625744</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002831" MajorTopicYN="N">Choroid Plexus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>21</Day><Hour>20</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34153974</ArticleId><ArticleId IdType="mid">NIHMS1730334</ArticleId><ArticleId IdType="pmc">PMC8400927</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03710-0</ArticleId><ArticleId IdType="pii">10.1038/s41586-021-03710-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mao L et al.Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 77, 683&#x2013;690 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X et al.Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med 8, 475&#x2013;481 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J et al.Neurologic features in severe SARS-CoV-2 infection. N. Engl. J. Med 382, 2268&#x2013;2270 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179967</ArticleId><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al.A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al.Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala Frigerio C et al.The major risk factors for Alzheimer&#x2019;s disease: age, sex, and genes modulate the microglia response to A&#x3b2; plaques. Cell Rep. 27, 1293&#x2013;1306 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340153</ArticleId><ArticleId IdType="pubmed">31018141</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidon A et al.Dendritic action potentials and computation in human layer 2/3 cortical neurons. Science 367, 83&#x2013;87 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31896716</ArticleId></ArticleIdList></Reference><Reference><Citation>Velmeshev D et al.Single-cell genomics identifies cell type-specific molecular changes in autism. Science 364, 685&#x2013;689 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7678724</ArticleId><ArticleId IdType="pubmed">31097668</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J et al.Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 19, 919&#x2013;929 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Varatharaj A et al.Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 7, 875&#x2013;882 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7316461</ArticleId><ArticleId IdType="pubmed">32593341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellul MA et al.Neurological associations of COVID-19. Lancet Neurol. 19, 767&#x2013;783 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-S&#xe1;nchez CM et al.Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology 95, e1060&#x2013;e1070 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7668545</ArticleId><ArticleId IdType="pubmed">32482845</ArticleId></ArticleIdList></Reference><Reference><Citation>Liotta EM et al.Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann. Clin. Transl. Neurol 7, 2221&#x2013;2230 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7664279</ArticleId><ArticleId IdType="pubmed">33016619</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. The prevalence of long COVID symptoms and COVID-19 complications, Office for National Statistics, https://www.ons.gov.uk/news/statementsandletters/theprevalenceoflongcovidsymptomsandcovid19complications (2020).</Citation></Reference><Reference><Citation>Carf&#xec; A, Bernabei R &amp; Landi F Persistent symptoms in patients after acute COVID-19. J. Am. Med. Assoc 324, 603&#x2013;605 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Anrather J &amp; Kamel H Effects of COVID-19 on the nervous system. Cell 183, 16&#x2013;27 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437501</ArticleId><ArticleId IdType="pubmed">32882182</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri L et al.Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370, 856&#x2013;860 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857391</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J et al.Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci 24, 168&#x2013;175 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E et al.Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med 218, e20202135 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob F et al.Human pluripotent stem cell-derived neural cells and brain organoids reveal SARS-CoV-2 neurotropism predominates in choroid plexus epithelium. Cell Stem Cell 27, 937&#x2013;950 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7505550</ArticleId><ArticleId IdType="pubmed">33010822</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini L et al.SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids. Cell Stem Cell 27, 951&#x2013;961 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7553118</ArticleId><ArticleId IdType="pubmed">33113348</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani N et al.A cellular and spatial map of the choroid plexus across brain ventricles and ages. Cell 184, 3056&#x2013;3074 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8214809</ArticleId><ArticleId IdType="pubmed">33932339</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC et al.A human brain vascular atlas reveals diverse cell mediators of Alzheimer&#x2019;s disease risk. Preprint at 10.1101/2021.04.26.441262 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.26.441262</ArticleId><ArticleId IdType="pmc">PMC9635042</ArticleId><ArticleId IdType="pubmed">35165441</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB et al.Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat. Biotechnol 36, 70&#x2013;80 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5951394</ArticleId><ArticleId IdType="pubmed">29227469</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A et al.A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci 22, 2087&#x2013;2097 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;kel S et al.Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature 566, 543&#x2013;547 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6544546</ArticleId><ArticleId IdType="pubmed">30747918</ArticleId></ArticleIdList></Reference><Reference><Citation>Dachet F et al.Selective time-dependent changes in activity and cell-specific gene expression in human postmortem brain. Sci. Rep 11, 6078 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7988150</ArticleId><ArticleId IdType="pubmed">33758256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CC, Zhong G, Huang IC &amp; Farzan M IFITM-family proteins: the cell&#x2019;s first line of antiviral defense. Annu. Rev. Virol 1, 261&#x2013;283 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4295558</ArticleId><ArticleId IdType="pubmed">25599080</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachim MY et al.Interferon-induced transmembrane protein (IFITM3) is upregulated explicitly in SARS-CoV-2 infected lung epithelial cells. Front. Immunol 11, 1372 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301886</ArticleId><ArticleId IdType="pubmed">32595654</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockx B et al.Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368, 1012&#x2013;1015 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164679</ArticleId><ArticleId IdType="pubmed">32303590</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K et al.Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346, 89&#x2013;93 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869326</ArticleId><ArticleId IdType="pubmed">25147279</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S et al.Inference and analysis of cell-cell communication using CellChat. Nat. Commun 12, 1088 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7889871</ArticleId><ArticleId IdType="pubmed">33597522</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S et al.Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Erny D &amp; Hagemeyer N Ontogeny and homeostasis of CNS myeloid cells. Nat. Immunol 18, 385&#x2013;392 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28323268</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulken BW et al.Single-cell analysis reveals T cell infiltration in old neurogenic niches. Nature 571, 205&#x2013;210 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111535</ArticleId><ArticleId IdType="pubmed">31270459</ArticleId></ArticleIdList></Reference><Reference><Citation>Tr&#xf6;scher AR et al.Microglial nodules provide the environment for pathogenic T cells in human encephalitis. Acta Neuropathol. 137, 619&#x2013;635 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426829</ArticleId><ArticleId IdType="pubmed">30663001</ArticleId></ArticleIdList></Reference><Reference><Citation>Safaiyan S et al.White matter aging drives microglial diversity. Neuron 109, 1100&#x2013;1117 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33606969</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Amin P &amp; Ofengeim D Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat. Rev. Neurosci 20, 19&#x2013;33 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6342007</ArticleId><ArticleId IdType="pubmed">30467385</ArticleId></ArticleIdList></Reference><Reference><Citation>Matute-Blanch C et al.Chitinase 3-like 1 is neurotoxic in primary cultured neurons. Sci. Rep 10, 7118 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188887</ArticleId><ArticleId IdType="pubmed">32346016</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay R, Lee S &amp; Rudy B GABAergic interneurons in the neocortex: from cellular properties to circuits. Neuron 91, 260&#x2013;292 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4980915</ArticleId><ArticleId IdType="pubmed">27477017</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen CCH &amp; Crochet S Synaptic computation and sensory processing in neocortical layer 2/3. Neuron 78, 28&#x2013;48 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23583106</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Dalahmah O et al.Single-nucleus RNA-seq identifies Huntington disease astrocyte states. Acta Neuropathol. Commun 8, 19 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7029580</ArticleId><ArticleId IdType="pubmed">32070434</ArticleId></ArticleIdList></Reference><Reference><Citation>Buniello A et al.The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005&#x2013;D1012 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323933</ArticleId><ArticleId IdType="pubmed">30445434</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseini S et al.Long-term neuroinflammation induced by influenza a virus infection and the impact on hippocampal neuron morphology and function. J. Neurosci 38, 3060&#x2013;3080 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6596076</ArticleId><ArticleId IdType="pubmed">29487124</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleidi M &amp; Isacson O Viral and inflammatory triggers of neurodegenerative diseases. Sci. Transl. Med 4, 121ps3 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3982831</ArticleId><ArticleId IdType="pubmed">22344685</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y et al.Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med 26, 131&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Swiech L et al.In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol 33, 102&#x2013;106 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4492112</ArticleId><ArticleId IdType="pubmed">25326897</ArticleId></ArticleIdList></Reference><Reference><Citation>Corces MR et al.An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat. Methods 14, 959&#x2013;962 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623106</ArticleId><ArticleId IdType="pubmed">28846090</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong S et al.A single-cell RNA-seq survey of the developmental landscape of the human prefrontal cortex. Nature 555, 524&#x2013;528 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29539641</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes L, Healy J, Saul N &amp; Gro&#xdf;berger L UMAP: uniform manifold approximation and projection. J. Open Source Softw 3, 861 (2018).</Citation></Reference><Reference><Citation>Young MD &amp; Behjati S SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data. Gigascience 9, giaa151 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7763177</ArticleId><ArticleId IdType="pubmed">33367645</ArticleId></ArticleIdList></Reference><Reference><Citation>Satija R, Farrell JA, Gennert D, Schier AF &amp; Regev A Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol 33, 495&#x2013;502 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4430369</ArticleId><ArticleId IdType="pubmed">25867923</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis CS, Murrow LM &amp; Gartner ZJ DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6853612</ArticleId><ArticleId IdType="pubmed">30954475</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafemeister C &amp; Satija R Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 296 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927181</ArticleId><ArticleId IdType="pubmed">31870423</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G et al.MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol. 16, 278 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Soneson C &amp; Robinson MD Bias, robustness and scalability in single-cell differential expression analysis. Nat. Methods 15, 255&#x2013;261 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29481549</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Li B, Nelson CE &amp; Nabavi S Comparative analysis of differential gene expression analysis tools for single-cell RNA sequencing data. BMC Bioinformatics 20, 40 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6339299</ArticleId><ArticleId IdType="pubmed">30658573</ArticleId></ArticleIdList></Reference><Reference><Citation>Mou T, Deng W, Gu F, Pawitan Y &amp; Vu TN Reproducibility of methods to detect differentially expressed genes from single-cell RNA sequencing. Front. Genet 10, 1331 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6979262</ArticleId><ArticleId IdType="pubmed">32010190</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Molin A, Baruzzo G &amp; Di Camillo B Single-cell RNA-sequencing: assessment of differential expression analysis methods. Front. Genet 8, 62 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5440469</ArticleId><ArticleId IdType="pubmed">28588607</ArticleId></ArticleIdList></Reference><Reference><Citation>Ximerakis M et al.Single-cell transcriptomic profiling of the aging mouse brain. Nat. Neurosci 22, 1696&#x2013;1708 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31551601</ArticleId></ArticleIdList></Reference><Reference><Citation>The Tabula Muris Consortium. A single-cell transcriptomic atlas characterizes ageing tissues in the mouse. Nature 583, 590&#x2013;595 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8240505</ArticleId><ArticleId IdType="pubmed">32669714</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AC et al.Physiological blood&#x2013;brain transport is impaired with age by a shift in transcytosis. Nature 583, 425&#x2013;430 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8331074</ArticleId><ArticleId IdType="pubmed">32612231</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MB et al.Brain endothelial cells are exquisite sensors of age-related circulatory cues. Cell Rep. 30, 4418&#x2013;4432 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292569</ArticleId><ArticleId IdType="pubmed">32234477</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk AJ et al.A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med 26, 1070&#x2013;1076 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382903</ArticleId><ArticleId IdType="pubmed">32514174</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu G et al.The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing. Cell Discov. 6, 73 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7574992</ArticleId><ArticleId IdType="pubmed">33101705</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte-Schrepping J et al.Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell 182, 1419&#x2013;1440 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405822</ArticleId><ArticleId IdType="pubmed">32810438</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C et al.Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nat. Commun 11, 3924 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7413381</ArticleId><ArticleId IdType="pubmed">32764665</ArticleId></ArticleIdList></Reference><Reference><Citation>Meckiff BJ et al.Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19. Cell 183, 1340&#x2013;1353 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534589</ArticleId><ArticleId IdType="pubmed">33096020</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS et al.Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci. Immunol 5, eabd1554 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402635</ArticleId><ArticleId IdType="pubmed">32651212</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y et al.Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19. Cell 183, 1479&#x2013;1495 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598382</ArticleId><ArticleId IdType="pubmed">33171100</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen EY et al.Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637064</ArticleId><ArticleId IdType="pubmed">23586463</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y et al.Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun 10, 1523 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstner N et al.GeneTrail 3: advanced high-throughput enrichment analysis. Nucleic Acids Res. 48, W515&#x2013;W520 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319559</ArticleId><ArticleId IdType="pubmed">32379325</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowell HL et al.muscat detects subpopulation-specific state transitions from multi-sample multi-condition single-cell transcriptomics data. Nat. Commun 11, 6077 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7705760</ArticleId><ArticleId IdType="pubmed">33257685</ArticleId></ArticleIdList></Reference><Reference><Citation>Law CW, Chen Y, Shi W &amp; Smyth GK voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053721</ArticleId><ArticleId IdType="pubmed">24485249</ArticleId></ArticleIdList></Reference><Reference><Citation>Spandidos A, Wang X, Wang H &amp; Seed B PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification. Nucleic Acids Res. 38, D792&#x2013;D799 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808898</ArticleId><ArticleId IdType="pubmed">19906719</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C et al.The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol 32, 381&#x2013;386 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4122333</ArticleId><ArticleId IdType="pubmed">24658644</ArticleId></ArticleIdList></Reference><Reference><Citation>Bost P et al.Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell 181, 1475&#x2013;1488 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7205692</ArticleId><ArticleId IdType="pubmed">32479746</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasumizu Y, Hara A, Sakaguchi S &amp; Ohkura N VIRTUS: a pipeline for comprehensive virus analysis from conventional RNA-seq data. Bioinformatics btaa859 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745649</ArticleId><ArticleId IdType="pubmed">33017003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Song L, Breitwieser FP &amp; Salzberg SL Centrifuge: rapid and sensitive classification of metagenomic sequences. Genome Res. 26, 1721&#x2013;1729 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5131823</ArticleId><ArticleId IdType="pubmed">27852649</ArticleId></ArticleIdList></Reference><Reference><Citation>Stano M, Beke G &amp; Klucar L viruSITE-integrated database for viral genomics. Database 2016, baw162 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5199161</ArticleId><ArticleId IdType="pubmed">28025349</ArticleId></ArticleIdList></Reference><Reference><Citation>Wauters E et al.Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. Cell Res. 31, 272&#x2013;290 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8027624</ArticleId><ArticleId IdType="pubmed">33473155</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy DJ, Campbell KR, Lun ATL &amp; Wills QF Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics 33, 1179&#x2013;1186 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408845</ArticleId><ArticleId IdType="pubmed">28088763</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths JA, Richard AC, Bach K, Lun ATL &amp; Marioni JC Detection and removal of barcode swapping in single-cell RNA-seq data. Nat. Commun 9, 2667 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039488</ArticleId><ArticleId IdType="pubmed">29991676</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun ATL et al.EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data. Genome Biol. 20, 63 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6431044</ArticleId><ArticleId IdType="pubmed">30902100</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Z, Eils R &amp; Schlesner M Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847&#x2013;2849 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27207943</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham H et al.Welcome to the Tidyverse. J. Open Source Softw 4, 1686 (2019). 10.21105/joss.01686.</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.01686</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan X, Han X, Li Q, Yang QW &amp; Wang J Modulators of microglial activation and polarization after intracerebral haemorrhage. Nat. Rev. Neurol 13, 420&#x2013;433 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5575938</ArticleId><ArticleId IdType="pubmed">28524175</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34157306</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>15</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms.</ArticleTitle><Pagination><StartPage>2413</StartPage><EndPage>2426.e7</EndPage><MedlinePgn>2413-2426.e7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2021.05.034</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(21)00413-X</ELocationID><Abstract><AbstractText>APOE is the strongest genetic risk factor for late-onset Alzheimer's disease. ApoE exacerbates tau-associated neurodegeneration by driving microglial activation. However, how apoE regulates microglial activation and whether targeting apoE is therapeutically beneficial in tauopathy is unclear. Here, we show that overexpressing an apoE metabolic receptor, LDLR (low-density lipoprotein receptor), in P301S tauopathy mice markedly reduces brain apoE and ameliorates tau pathology and neurodegeneration. LDLR overexpression (OX) in microglia cell-autonomously downregulates microglial Apoe expression and is associated with suppressed microglial activation as in apoE-deficient microglia. ApoE deficiency and LDLR OX strongly drive microglial immunometabolism toward enhanced catabolism over anabolism, whereas LDLR-overexpressing microglia also uniquely upregulate specific ion channels and neurotransmitter receptors upon activation. ApoE-deficient and LDLR-overexpressing mice harbor enlarged pools of oligodendrocyte progenitor cells (OPCs) and show greater preservation of myelin integrity under neurodegenerative conditions. They also show less reactive astrocyte activation in the setting of tauopathy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andhey</LastName><ForeName>Prabhakar Sairam</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ising</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn and German Center for Neurodegenerative Diseases (DZNE), Bonn 53127, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kairuo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snipes</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyer</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawson</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manis</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Javier Remolina</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benitez</LastName><ForeName>Bruno A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artyomov</LastName><ForeName>Maxim</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital of Bonn and German Center for Neurodegenerative Diseases (DZNE), Bonn 53127, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA. Electronic address: ulrichj@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA. Electronic address: holtzman@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS090934</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS118146</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2021 Aug 4;109(15):2363-2365. doi: 10.1016/j.neuron.2021.07.013.</RefSource><PMID Version="1">34352209</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="N">Receptors, LDL</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ApoE</Keyword><Keyword MajorTopicYN="N">LDLR</Keyword><Keyword MajorTopicYN="N">OPC</Keyword><Keyword MajorTopicYN="N">metabolism</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">myelin</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>Declaration of interests D.M.H. and C.I. are listed as inventors on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. C2N Diagnostics has licensed certain anti-tau antibodies to AbbVie for therapeutic development. D.M.H. is on the scientific advisory board of Denali and consults for Genentech, Merck, and Cajal Neurosciences.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>20</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34157306</ArticleId><ArticleId IdType="mid">NIHMS1712133</ArticleId><ArticleId IdType="pmc">PMC8349883</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2021.05.034</ArticleId><ArticleId IdType="pii">S0896-6273(21)00413-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, et al. (1997). Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 17, 263&#x2013;264. 10.1038/ng1197-263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1197-263</ArticleId><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Haim L, Carrillo-de Sauvage MA, Ceyzeriat K, and Escartin C (2015). Elusive roles for reactive astrocytes in neurodegenerative diseases. Front Cell Neurosci 9, 278. 10.3389/fncel.2015.00278.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00278</ArticleId><ArticleId IdType="pmc">PMC4522610</ArticleId><ArticleId IdType="pubmed">26283915</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez BA, and Sands MS (2017). Primary fibroblasts from CSP&#x3b1; mutation carriers recapitulate hallmarks of the adult onset neuronal ceroid lipofuscinosis. Sci Rep 7, 6332. 10.1038/s41598-017-06710-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-06710-1</ArticleId><ArticleId IdType="pmc">PMC5524943</ArticleId><ArticleId IdType="pubmed">28740222</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitsky T, Regard J, Copeland NG, Jenkins NA, Sisodia SS, and Price DL (1996). A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genetic Analysis: Biomolecular Engineering 13, 159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">9117892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bories GFP, and Leitinger N (2017). Macrophage metabolism in atherosclerosis. FEBS Lett 591, 3042&#x2013;3060. 10.1002/1873-3468.12786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.12786</ArticleId><ArticleId IdType="pubmed">28796886</ArticleId></ArticleIdList></Reference><Reference><Citation>Boucsein C, Kettenmann H, and Nolte C (2000). Electrophysiological properties of microglial cells in normal and pathologic rat brain slices. Eur J Neurosci 12, 2049&#x2013;2058. 10.1046/j.1460-9568.2000.00100.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.2000.00100.x</ArticleId><ArticleId IdType="pubmed">10886344</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyles JK, Pitas RE, Wilson E, Mahley RW, and Taylor JM (1985). Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 76, 1501&#x2013;1513. 10.1172/jci112130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci112130</ArticleId><ArticleId IdType="pmc">PMC424114</ArticleId><ArticleId IdType="pubmed">3932467</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu G (2009). Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nature reviews. Neuroscience 10, 333&#x2013;344. 10.1038/nrn2620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2620</ArticleId><ArticleId IdType="pmc">PMC2908393</ArticleId><ArticleId IdType="pubmed">19339974</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E, and Satija R (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36, 411&#x2013;420. 10.1038/nbt.4096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4096</ArticleId><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Coetzee WA, Amarillo Y, Chiu J, Chow A, Lau D, McCormack T, Moreno H, Nadal MS, Ozaita A, Pountney D, et al. (1999). Molecular diversity of K+ channels. Ann N Y Acad Sci 868, 233&#x2013;285. 10.1111/j.1749-6632.1999.tb11293.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1999.tb11293.x</ArticleId><ArticleId IdType="pubmed">10414301</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Lucente J, Nguyen HM, Wulff H, Jin LW, and Maezawa I (2018). The voltage-gated potassium channel Kv1.3 is required for microglial pro-inflammatory activation in vivo. Glia 66, 1881&#x2013;1895. 10.1002/glia.23457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23457</ArticleId><ArticleId IdType="pmc">PMC6185766</ArticleId><ArticleId IdType="pubmed">30043400</ArticleId></ArticleIdList></Reference><Reference><Citation>Domercq M, Vazquez-Villoldo N, and Matute C (2013). Neurotransmitter signaling in the pathophysiology of microglia. Front Cell Neurosci 7, 49. 10.3389/fncel.2013.00049.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00049</ArticleId><ArticleId IdType="pmc">PMC3630369</ArticleId><ArticleId IdType="pubmed">23626522</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, and Julius D (2006). The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci 9, 1512&#x2013;1519. 10.1038/nn1805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1805</ArticleId><ArticleId IdType="pubmed">17115040</ArticleId></ArticleIdList></Reference><Reference><Citation>Heeren J, Beisiegel U, and Grewal T (2006). Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol 26, 442&#x2013;448. 10.1161/01.atv.0000201282.64751.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.atv.0000201282.64751.47</ArticleId><ArticleId IdType="pubmed">16373604</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, and Paul SM (2000). Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 97, 2892&#x2013;2897. 10.1073/pnas.050004797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.050004797</ArticleId><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Herz J, and Bu G (2012). Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor perspectives in medicine 2. 10.1101/cshperspect.a006312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006312</ArticleId><ArticleId IdType="pmc">PMC3282491</ArticleId><ArticleId IdType="pubmed">22393530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi S, Herz J, Maeda N, Goldstein JL, and Brown MS (1994). The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci U S A 91, 4431&#x2013;4435. 10.1073/pnas.91.10.4431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.10.4431</ArticleId><ArticleId IdType="pmc">PMC43799</ArticleId><ArticleId IdType="pubmed">8183926</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo P, Attwell D, and Madry C (2019). Ion Channels and Receptors as Determinants of Microglial Function. Trends Neurosci 42, 278&#x2013;292. 10.1016/j.tins.2018.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2018.12.007</ArticleId><ArticleId IdType="pubmed">30678990</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, and Holtzman DM (2009). Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 64, 632&#x2013;644. 10.1016/j.neuron.2009.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.11.013</ArticleId><ArticleId IdType="pmc">PMC2787195</ArticleId><ArticleId IdType="pubmed">20005821</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Eltorai AEM, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, and Holtzman DM (2012). Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of A&#x3b2; amyloidosis. The Journal of experimental medicine 209, 2149&#x2013;2156. 10.1084/jem.20121274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20121274</ArticleId><ArticleId IdType="pmc">PMC3501350</ArticleId><ArticleId IdType="pubmed">23129750</ArticleId></ArticleIdList></Reference><Reference><Citation>Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K, Tsuda M, Joshi BV, Jacobson KA, Kohsaka S, and Inoue K (2007). UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 446, 1091&#x2013;1095. 10.1038/nature05704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05704</ArticleId><ArticleId IdType="pmc">PMC3464483</ArticleId><ArticleId IdType="pubmed">17410128</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z, et al. (2017). The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581.e569. 10.1016/j.immuni.2017.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn SA, van Landeghem FK, Zacharias R, Farber K, Rappert A, Pavlovic S, Hoffmann A, Nolte C, and Kettenmann H (2004). Microglia express GABA(B) receptors to modulate interleukin release. Mol Cell Neurosci 25, 312&#x2013;322. 10.1016/j.mcn.2003.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2003.10.023</ArticleId><ArticleId IdType="pubmed">15019947</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, and Holtzman DM (2017). TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci U S A 114, 11524&#x2013;11529. 10.1073/pnas.1710311114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1710311114</ArticleId><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="pubmed">29073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, Sullivan PM, and Holtzman DM (2015). Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta neuropathologica communications 3, 70&#x2013;70. 10.1186/s40478-015-0250-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0250-y</ArticleId><ArticleId IdType="pmc">PMC4641345</ArticleId><ArticleId IdType="pubmed">26556230</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487. 10.1038/nature21029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, and Bu G (2007). Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56, 66&#x2013;78. 10.1016/j.neuron.2007.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.08.008</ArticleId><ArticleId IdType="pmc">PMC2045076</ArticleId><ArticleId IdType="pubmed">17920016</ArticleId></ArticleIdList></Reference><Reference><Citation>LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, and Binder LI (1995). Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proceedings of the National Academy of Sciences of the United States of America 92, 10369&#x2013;10373. 10.1073/pnas.92.22.10369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.22.10369</ArticleId><ArticleId IdType="pmc">PMC40798</ArticleId><ArticleId IdType="pubmed">7479786</ArticleId></ArticleIdList></Reference><Reference><Citation>Madry C, Kyrargyri V, Arancibia-Carcamo IL, Jolivet R, Kohsaka S, Bryan RM, and Attwell D (2018). Microglial Ramification, Surveillance, and Interleukin-1beta Release Are Regulated by the Two-Pore Domain K(+) Channel THIK-1. Neuron 97, 299&#x2013;312.e296. 10.1016/j.neuron.2017.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.12.002</ArticleId><ArticleId IdType="pmc">PMC5783715</ArticleId><ArticleId IdType="pubmed">29290552</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Fryatt G, Cleal M, Obst J, Pipi E, Monzon-Sandoval J, Ribe E, Winchester L, Webber C, Nevado A, et al. (2019). CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain 142, 3243&#x2013;3264. 10.1093/brain/awz241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz241</ArticleId><ArticleId IdType="pmc">PMC6794948</ArticleId><ArticleId IdType="pubmed">31504240</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurrob F, Jiang X, et al. (2019). Single-cell transcriptomic analysis of Alzheimer's disease. Nature 570, 332&#x2013;337. 10.1038/s41586-019-1195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy AJ, Akhtari M, Tolani S, Pagler T, Bijl N, Kuo CL, Wang M, Sanson M, Abramowicz S, Welch C, et al. (2011). ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest 121, 4138&#x2013;4149. 10.1172/jci57559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci57559</ArticleId><ArticleId IdType="pmc">PMC3195472</ArticleId><ArticleId IdType="pubmed">21968112</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HM, Grossinger EM, Horiuchi M, Davis KW, Jin LW, Maezawa I, and Wulff H (2017). Differential Kv1.3, KCa3.1, and Kir2.1 expression in "classically" and "alternatively" activated microglia. Glia 65, 106&#x2013;121. 10.1002/glia.23078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23078</ArticleId><ArticleId IdType="pmc">PMC5113690</ArticleId><ArticleId IdType="pubmed">27696527</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama A, Komitova M, Suzuki R, and Zhu X (2009). Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. Nat Rev Neurosci 10, 9&#x2013;22. 10.1038/nrn2495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2495</ArticleId><ArticleId IdType="pubmed">19096367</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohsawa K, Irino Y, Nakamura Y, Akazawa C, Inoue K, and Kohsaka S (2007). Involvement of P2X4 and P2Y12 receptors in ATP-induced microglial chemotaxis. Glia 55, 604&#x2013;616. 10.1002/glia.20489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20489</ArticleId><ArticleId IdType="pubmed">17299767</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp A, Gmeiner B, and Huttinger M (2006). Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. Biochimie 88, 473&#x2013;483. 10.1016/j.biochi.2005.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2005.10.007</ArticleId><ArticleId IdType="pubmed">16376010</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE, Leshuk C, Hernandez I, Wegmann S, Hyman BT, et al. (2020). LRP1 is a master regulator of tau uptake and spread. Nature 580, 381&#x2013;385. 10.1038/s41586-020-2156-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2156-5</ArticleId><ArticleId IdType="pmc">PMC7687380</ArticleId><ArticleId IdType="pubmed">32296178</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, and Roses AD (1993). Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 90, 9649&#x2013;9653. 10.1073/pnas.90.20.9649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.20.9649</ArticleId><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, and Holtzman DM (2018). Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol 18, 759&#x2013;772. 10.1038/s41577-018-0051-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-018-0051-1</ArticleId><ArticleId IdType="pmc">PMC6425488</ArticleId><ArticleId IdType="pubmed">30140051</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Manis M, Long J, Wang K, Sullivan PM, Remolina Serrano J, Hoyle R, and Holtzman DM (2019). Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J Exp Med. 10.1084/jem.20190980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20190980</ArticleId><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, et al. (2017). ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523&#x2013;527. 10.1038/nature24016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>TCW J, Liang S, Qian L, Pipalia N, Chao M, Shi Y, Bertelsen SE, Kapoor M, Marcora E, et al. (2019). Cholesterol and matrisome pathways dysregulated in human APOE &#x3b5;4 glia. bioRxiv.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9340815</ArticleId><ArticleId IdType="pubmed">35750033</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchihara T, Duyckaerts C, He Y, Kobayashi K, Seilhean D, Amouyel P, and Hauw JJ (1995). ApoE immunoreactivity and microglial cells in Alzheimer's disease brain. Neurosci Lett 195, 5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7478253</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, et al. (2017). TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Cell 170, 649&#x2013;663.e613. 10.1016/j.cell.2017.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.07.023</ArticleId><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Xiong M, Gratuze M, Bao X, Shi Y, Andhey PS, Manis M, Schroeder C, Yin Z, Madore C, et al. (2021). Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron. 10.1016/j.neuron.2021.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.03.024</ArticleId><ArticleId IdType="pmc">PMC8141024</ArticleId><ArticleId IdType="pubmed">33831349</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendt S, Maricos M, Vana N, Meyer N, Guneykaya D, Semtner M, and Kettenmann H (2017). Changes in phagocytosis and potassium channel activity in microglia of 5xFAD mice indicate alterations in purinergic signaling in a mouse model of Alzheimer's disease. Neurobiol Aging 58, 41&#x2013;53. 10.1016/j.neurobiolaging.2017.05.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.05.027</ArticleId><ArticleId IdType="pubmed">28697378</ArticleId></ArticleIdList></Reference><Reference><Citation>William Rebeck G, Reiter JS, Strickland DK, and Hyman BT (1993). Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron 11, 575&#x2013;580. 10.1016/0896-6273(93)90070-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(93)90070-8</ArticleId><ArticleId IdType="pubmed">8398148</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW, and Huang Y (2006). Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci 26, 4985&#x2013;4994. 10.1523/jneurosci.5476-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.5476-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674234</ArticleId><ArticleId IdType="pubmed">16687490</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CP, Gilley JA, Zhang G, and Kernie SG (2011). ApoE is required for maintenance of the dentate gyrus neural progenitor pool. Development 138, 4351&#x2013;4362. 10.1242/dev.065540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.065540</ArticleId><ArticleId IdType="pmc">PMC3177307</ArticleId><ArticleId IdType="pubmed">21880781</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel A, Mu&#xf1;oz-Manchado AB, Codeluppi S, L&#xf6;nnerberg P, La Manno G, Jur&#xe9;us A, Marques S, Munguba H, He L, Betsholtz C, et al. (2015). Brain structure. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. Science 347, 1138&#x2013;1142. 10.1126/science.aaa1934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa1934</ArticleId><ArticleId IdType="pubmed">25700174</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, Holtzman DM, and Bu G (2006). Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal A??42 accumulation in amyloid model mice. Journal of Biological Chemistry 281, 36180&#x2013;36186. 10.1074/jbc.M604436200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M604436200</ArticleId><ArticleId IdType="pubmed">17012232</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, et al. (2020). Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nat Med 26, 131&#x2013;142. 10.1038/s41591-019-0695-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0695-9</ArticleId><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34155411</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1187</StartPage><EndPage>1196</EndPage><MedlinePgn>1187-1196</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-021-01369-8</ELocationID><Abstract><AbstractText>Dominantly inherited Alzheimer's disease (DIAD) causes predictable biological changes decades before the onset of clinical symptoms, enabling testing of interventions in the asymptomatic and symptomatic stages to delay or slow disease progression. We conducted a randomized, placebo-controlled, multi-arm trial of gantenerumab or solanezumab in participants with DIAD across asymptomatic and symptomatic disease stages. Mutation carriers were assigned 3:1 to either drug or placebo and received treatment for 4-7 years. The primary outcome was a cognitive end point; secondary outcomes included clinical, cognitive, imaging and fluid biomarker measures. Fifty-two participants carrying a mutation were assigned to receive gantenerumab, 52 solanezumab and 40 placebo. Both drugs engaged their A&#x3b2; targets but neither demonstrated a beneficial effect on cognitive measures compared to controls. The solanezumab-treated group showed a greater cognitive decline on some measures and did not show benefits on downstream biomarkers. Gantenerumab significantly reduced amyloid plaques, cerebrospinal fluid total tau, and phospho-tau181 and attenuated increases of neurofilament light chain. Amyloid-related imaging abnormalities edema was observed in 19.2% (3 out of 11 were mildly symptomatic) of the gantenerumab group, 2.5% of the placebo group and 0% of the solanezumab group. Gantenerumab and solanezumab did not slow cognitive decline in symptomatic DIAD. The asymptomatic groups showed no cognitive decline; symptomatic participants had declined before reaching the target doses.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2631-0942</Identifier><AffiliationInfo><Affiliation>Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-6764-3866</Identifier><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clifford</LastName><ForeName>David B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guoqiao</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llibre-Guerra</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0002-2137-7750</Identifier><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hitchcock</LastName><ForeName>Janice M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Hitchcock Regulatory Consulting, Inc, Fishers, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santacruz</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-4110-6472</Identifier><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aschenbrenner</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><Identifier Source="ORCID">0000-0002-8114-0552</Identifier><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-2109-2955</Identifier><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coalier</LastName><ForeName>Kelley A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-0576-2472</Identifier><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-3443-7716</Identifier><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snider</LastName><ForeName>B Joy</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mummery</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6739-0803</Identifier><AffiliationInfo><Affiliation>University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Surti</LastName><ForeName>G Mustafa</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannequin</LastName><ForeName>Didier</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallon</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berman</LastName><ForeName>Sarah B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Emory University Medical Center, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimenez-Velazquez</LastName><ForeName>Ivonne Z</ForeName><Initials>IZ</Initials><AffiliationInfo><Affiliation>University of Puerto Rico School of Medicine, San Juan, Puerto Rico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials><Identifier Source="ORCID">0000-0002-1810-9763</Identifier><AffiliationInfo><Affiliation>University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0002-9703-2265</Identifier><AffiliationInfo><Affiliation>Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Valle</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7750-896X</Identifier><AffiliationInfo><Affiliation>Hospital Cl&#xed;nic i Provincial de Barcelona, August Pi i Sunyer Biomedical Research Institute-Universitat de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>William S</ForeName><Initials>WS</Initials><Identifier Source="ORCID">0000-0001-8603-4233</Identifier><AffiliationInfo><Affiliation>Neuroscience Research Australia, University of New South Wales Medicine, Randwick, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>McGill Center for Studies in Aging, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>University of California San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brosch</LastName><ForeName>Jared R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek Robin</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jayadev</LastName><ForeName>Suman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Washington School of Medicine, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Formaglio</LastName><ForeName>Mait&#xe9;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospices Civils de Lyon, Lyons, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masellis</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarnette</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Australian Alzheimer's Research Foundation, University of Western Australia, Perth, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pariente</LastName><ForeName>J&#xe9;r&#xe9;mie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Toulouse, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neurological Institute, Salpetriere University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9880-9788</Identifier><AffiliationInfo><Affiliation>Centre Hospitalier R&#xe9;gional Universitaire de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0001-7916-622X</Identifier><AffiliationInfo><Affiliation>Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0003-0555-4654</Identifier><AffiliationInfo><Affiliation>University of Rhode Island, Kingston, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Keck School of Medicine, University of Southern California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials><Identifier Source="ORCID">0000-0003-1686-4965</Identifier><AffiliationInfo><Affiliation>University of California San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>Scott M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Berry Consultants, LLC, Austin, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wendelberger</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-4426-9602</Identifier><AffiliationInfo><Affiliation>Berry Consultants, LLC, Austin, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Scott W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holdridge</LastName><ForeName>Karen C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaari</LastName><ForeName>Roy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baudler</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmar</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontoura</LastName><ForeName>Paulo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giacobino</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerchner</LastName><ForeName>Geoffrey A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-7729-1702</Identifier><AffiliationInfo><Affiliation>Washington University School of Medicine, St. Louis, MO, USA. batemanr@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network&#x2013;Trials Unit</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG046179, R01AG053267-S1</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)</Agency><Country/></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046179</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053267</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG042791</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)</Agency><Country/></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG042791</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066508</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19AG032438</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)</Agency><Country/></Grant><Grant><GrantID>S10 OD025214</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG042791-S1</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>4DF060P933</RegistryNumber><NameOfSubstance UI="C571128">gantenerumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>5D6PWO0333</RegistryNumber><NameOfSubstance UI="C550616">solanezumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Formaglio</LastName><ForeName>Mait&#xe9;</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mills</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pariente</LastName><ForeName>J&#xe9;r&#xe9;mie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34155411</ArticleId><ArticleId IdType="mid">NIHMS1790300</ArticleId><ArticleId IdType="pmc">PMC8988051</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01369-8</ArticleId><ArticleId IdType="pii">10.1038/s41591-021-01369-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR Jr. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement 14, 535&#x2013;562 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E &amp; Del Tredici K Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol 70, 960&#x2013;969 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ et al. Autosomal-dominant Alzheimer&#x2019;s disease: a review and proposal for the prevention of Alzheimer&#x2019;s disease. Alzheimers Res. Ther 3, 1 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83, 253&#x2013;260 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC et al. Developing an international network for Alzheimer&#x2019;s research: the Dominantly Inherited Alzheimer Network. Clin. Investig. (Lond.) 2, 975&#x2013;984 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3489185</ArticleId><ArticleId IdType="pubmed">23139856</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N. Engl. J. Med 367, 795&#x2013;804 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>McDade E et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 91, e1295&#x2013;e1306 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6177272</ArticleId><ArticleId IdType="pubmed">30217935</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer&#x2019;s disease: a longitudinal study. Lancet Neurol 17, 241&#x2013;250 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5816717</ArticleId><ArticleId IdType="pubmed">29397305</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J et al. The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature 537, 50&#x2013;56 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D &#x3b2;-secretase inhibitors for Alzheimer&#x2019;s disease: heading in the wrong direction? Lancet Neurol 18, 624&#x2013;626 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31202466</ArticleId></ArticleIdList></Reference><Reference><Citation>Henley D et al. Preliminary results of a trial of atabecestat in preclinical Alzheimer&#x2019;s disease. N. Engl. J. Med 380, 1483&#x2013;1485 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30970197</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF et al. Randomized trial of verubecestat for prodromal Alzheimer&#x2019;s disease. N. Engl. J. Med 380, 1408&#x2013;1420 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776078</ArticleId><ArticleId IdType="pubmed">30970186</ArticleId></ArticleIdList></Reference><Reference><Citation>Karran E &amp; De Strooper B The amyloid cascade hypothesis: are we poised for success or failure? J. Neurochem 139, 237&#x2013;252 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27255958</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Morstorf T &amp; Zhong K Alzheimer&#x2019;s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res. Ther 6, 37 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4095696</ArticleId><ArticleId IdType="pubmed">25024750</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulder KL et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res. Ther 5, 48 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978584</ArticleId><ArticleId IdType="pubmed">24131566</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills SM et al. Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial. Rev. Neurol. (Paris) 169, 737&#x2013;743 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880800</ArticleId><ArticleId IdType="pubmed">24016464</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ et al. The DIAN-TU Next Generation Alzheimer&#x2019;s prevention trial: adaptive design and disease progression model. Alzheimers Dement 13, 8&#x2013;19 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5218895</ArticleId><ArticleId IdType="pubmed">27583651</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412&#x2013;2414 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J et al. Reducing patient burden in clinical trials through the use of historical controls: appropriate selection of historical data to minimize risk of bias. Ther. Innov. Regul. Sci 54, 850&#x2013;860 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32557308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G et al. A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer&#x2019;s disease. Stat. Med 37, 3047&#x2013;3055 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105413</ArticleId><ArticleId IdType="pubmed">29761523</ArticleId></ArticleIdList></Reference><Reference><Citation>Viele K et al. Use of historical control data for assessing treatment effects in clinical trials. Pharm. Stat 13, 41&#x2013;54 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951812</ArticleId><ArticleId IdType="pubmed">23913901</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L et al. Mild senile dementia of the Alzheimer type: 2. longitudinal assessment. Ann. Neurol 23, 477&#x2013;484 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3389756</ArticleId></ArticleIdList></Reference><Reference><Citation>Breines E The functional assessment scale as an instrument for measuring changes in levels of function of nursing home residents following occupational therapy. Can. J. Occup. Ther 55, 135&#x2013;140 (1988).</Citation></Reference><Reference><Citation>Fitzmaurice GM, Laird NM &amp; Ware JH Applied Longitudinal Analysis (John Wiley &amp; Sons, 2012).</Citation></Reference><Reference><Citation>Siemers ER et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer&#x2019;s disease patients. Alzheimers Dement 12, 110&#x2013;120 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26238576</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig LS et al. Trial of solanezumab for mild dementia due to Alzheimer&#x2019;s disease. N. Engl. J. Med 378, 321&#x2013;330 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29365294</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J et al. Drug development in Alzheimer&#x2019;s disease: the path to 2025. Alzheimers Res. Ther 8, 39 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5028936</ArticleId><ArticleId IdType="pubmed">27646601</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J Lessons learned from Alzheimer disease: clinical trials with negative outcomes. Clin. Transl. Sci 11, 147&#x2013;152 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866992</ArticleId><ArticleId IdType="pubmed">28767185</ArticleId></ArticleIdList></Reference><Reference><Citation>McDade E &amp; Bateman RJ Stop Alzheimer&#x2019;s before it starts. Nature 547, 153&#x2013;155 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28703214</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y et al. Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. Neuroimage Clin 19, 406&#x2013;416 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6051499</ArticleId><ArticleId IdType="pubmed">30035025</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG et al. Imaging and cerebrospinal fluid biomarkers in early preclinical Alzheimer disease. Ann. Neurol 80, 379&#x2013;387 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016232</ArticleId><ArticleId IdType="pubmed">27398953</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein G et al. Thirty-six-month amyloid positron emission tomography results show continued reduction in amyloid burden with subcutaneous gantenerumab. J. Prev. Alzheimers Dis 8, 3&#x2013;6 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33336218</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd C, McCann H &amp; Halliday GM Variations in the neuropathology of familial Alzheimer&#x2019;s disease. Acta Neuropathol 118, 37&#x2013;52 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19306098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM et al. Neuropathology of autosomal dominant Alzheimer disease in the national Alzheimer coordinating center database. J. Neuropathol. Exp. Neurol 75, 284&#x2013;290 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4934612</ArticleId><ArticleId IdType="pubmed">26888304</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA et al. Tau PET in autosomal dominant Alzheimer&#x2019;s disease: relationship with cognition, dementia and other biomarkers. Brain 142, 1063&#x2013;1076 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439328</ArticleId><ArticleId IdType="pubmed">30753379</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA et al. Donanemab in early Alzheimer&#x2019;s disease. N. Engl. J. Med 384, 1691&#x2013;1704 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeberlein SB et al. Emerge and Engage topline results: phase 3 studies of aducanumab in early Alzheimer&#x2019;s disease. Alzheimers Dement 16, e047259 (2020).</Citation></Reference><Reference><Citation>Schuck EL et al. Population pharmacokinetic/pharmacodynamic analyses of BAN2401 in patients with early Alzheimer&#x2019;s disease: correlation of BAN2401 exposure, pet standard uptake value ratio, and cognitive outcomes. Alzheimers Dement 15, P1582&#x2013;P1583 (2019).</Citation></Reference><Reference><Citation>Woodcock J &amp; LaVange LM Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med 377, 62&#x2013;70 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28679092</ArticleId></ArticleIdList></Reference><Reference><Citation>Taves DR Minimization: a new method of assigning patients to treatment and control groups. Clin. Pharmacol. Ther 15, 443&#x2013;453 (1974).</Citation><ArticleIdList><ArticleId IdType="pubmed">4597226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer&#x2019;s disease. Alzheimers Res. Ther 9, 95 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5723032</ArticleId><ArticleId IdType="pubmed">29221491</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D WMS-R: Wechsler Memory Scale&#x2013;Revised: manual (Psychological Corporation, 1987).</Citation></Reference><Reference><Citation>Wechsler D Wechsler Adult Intelligence Scale&#x2013;Revised (Psychological Corporation, 1981).</Citation></Reference><Reference><Citation>Lim YY et al. A method for cross-cultural adaptation of a verbal memory assessment. Behav. Res. Methods 41, 1190&#x2013;1200 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19897828</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson TAC et al. Sensitivity and test&#x2013;retest reliability of the International Shopping List Test in assessing verbal learning and memory in mild Alzheimer&#x2019;s disease. Arch. Clin. Neuropsychol 26, 412&#x2013;424 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21613302</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE &amp; McHugh PR &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res 12, 189&#x2013;198 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R et al. Amyloid-related imaging abnormalities in patients with Alzheimer&#x2019;s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11, 241&#x2013;249 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063417</ArticleId><ArticleId IdType="pubmed">22305802</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B FreeSurfer. Neuroimage 62, 774&#x2013;781 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685476</ArticleId><ArticleId IdType="pubmed">22248573</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B et al. Automatically parcellating the human cerebral cortex. Cereb. Cortex 14, 11&#x2013;22 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14654453</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage 23, 724&#x2013;738 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15488422</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y et al. Partial volume correction in quantitative amyloid imaging. Neuroimage 107, 55&#x2013;64 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y &amp; Correction AC for partial volume effects in PET: principle and validation. J. Nucl. Med 39, 904&#x2013;911 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow M et al. Safety and biomarker effects of solanezumab in patients with Alzheimer&#x2019;s disease. Alzheimers Dement 8, 261&#x2013;271 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22672770</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert CP &amp; Casella G Monte Carlo Statistical Methods (Springer, 2004).</Citation></Reference><Reference><Citation>Weninger S et al. Collaboration for Alzheimer&#x2019;s prevention: principles to guide data and sample sharing in preclinical Alzheimer&#x2019;s disease trials. Alzheimers Dement 12, 631&#x2013;632 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111162</ArticleId><ArticleId IdType="pubmed">27157073</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34210891</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>373</Volume><Issue>6554</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>30</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>A fast link between face perception and memory in the temporal pole.</ArticleTitle><Pagination><StartPage>581</StartPage><EndPage>585</EndPage><MedlinePgn>581-585</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.abi6671</ELocationID><Abstract><AbstractText>The question of how the brain recognizes the faces of familiar individuals has been important throughout the history of neuroscience. Cells linking visual processing to person memory have been proposed but not found. Here, we report the discovery of such cells through recordings from an area in the macaque temporal pole identified with functional magnetic resonance imaging. These cells responded to faces that were personally familiar. They responded nonlinearly to stepwise changes in face visibility and detail and holistically to face parts, reflecting key signatures of familiar face recognition. They discriminated between familiar identities, as fast as a general face identity area. The discovery of these cells establishes a new pathway for the fast recognition of familiar individuals.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Landi</LastName><ForeName>Sofia M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0002-8443-5639</Identifier><AffiliationInfo><Affiliation>Laboratory of Neural Systems, The Rockefeller University, New York, NY, USA. slandi@uw.edu wfreiwald@rockefeller.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Biophysics, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viswanathan</LastName><ForeName>Pooja</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6992-0134</Identifier><AffiliationInfo><Affiliation>Laboratory of Neural Systems, The Rockefeller University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Nash Family Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serene</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8976-8435</Identifier><AffiliationInfo><Affiliation>Laboratory of Neural Systems, The Rockefeller University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freiwald</LastName><ForeName>Winrich A</ForeName><Initials>WA</Initials><Identifier Source="ORCID">0000-0001-8456-5030</Identifier><AffiliationInfo><Affiliation>Laboratory of Neural Systems, The Rockefeller University, New York, NY, USA. slandi@uw.edu wfreiwald@rockefeller.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Brains, Minds &amp; Machines, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>figshare</DataBankName><AccessionNumberList><AccessionNumber>10. 6084/m9.figshare.14642619</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 EY021594</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH105397</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS110901</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005145" MajorTopicYN="N">Face</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000066499" MajorTopicYN="Y">Facial Recognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> Authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>2</Day><Hour>5</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34210891</ArticleId><ArticleId IdType="mid">NIHMS1754117</ArticleId><ArticleId IdType="pmc">PMC8645414</ArticleId><ArticleId IdType="doi">10.1126/science.abi6671</ArticleId><ArticleId IdType="pii">science.abi6671</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Freiwald WA, Tsao DY, Science. 330, 845&#x2013;851 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181095</ArticleId><ArticleId IdType="pubmed">21051642</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross CG, Neuroscientist. 8, 512&#x2013;518 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12374433</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce V, Young A, Br. J. Psychol. 77, 305&#x2013;327 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3756376</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrett DI, Hietanen JK, Oram MW, Benson PJ, Philos. Trans. R. Soc. Lond. B Biol. Sci. 335, 23&#x2013;30 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1348133</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanwisher N, McDermott J, Chun MM, The Journal of neuroscience : the official journal of the Society for Neuroscience. 17, 4302&#x2013;4311 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573547</ArticleId><ArticleId IdType="pubmed">9151747</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroga RQ, Reddy L, Kreiman G, Koch C, Fried I, Nature. 435, 1102&#x2013;1107 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15973409</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura K, Matsumoto K, Mikami A, Kubota K, Journal of Neurophysiology. 71, 1206&#x2013;1221 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8201413</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson IR, Plotzker A, Ezzyat Y, Brain. 130, 1718&#x2013;1731 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17392317</ArticleId></ArticleIdList></Reference><Reference><Citation>Landi SM, Freiwald WA, Science. 357, 591&#x2013;595 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5612776</ArticleId><ArticleId IdType="pubmed">28798130</ArticleId></ArticleIdList></Reference><Reference><Citation>Barry DN, Maguire EA, Trends Cogn Sci (Regul Ed). 23, 635&#x2013;636 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31270021</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L, Tsao DY, Cell. 169, 1013&#x2013;1028.e14 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8088389</ArticleId><ArticleId IdType="pubmed">28575666</ArticleId></ArticleIdList></Reference><Reference><Citation>Gobbini MI et al., PLoS ONE. 8, e66620 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3689778</ArticleId><ArticleId IdType="pubmed">23805248</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha P, Balas B, Ostrovsky Y, Russell R, Proc. IEEE. 94, 1948&#x2013;1962 (2006).</Citation></Reference><Reference><Citation>Ramon M, Vizioli L, Liu-Shuang J, Rossion B, Proc Natl Acad Sci USA. 112, E4835&#x2013;44 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4568242</ArticleId><ArticleId IdType="pubmed">26283361</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews TJ, Davies-Thompson J, Kingstone A, Young AW, J. Neurosci. 30, 3544&#x2013;3552 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839485</ArticleId><ArticleId IdType="pubmed">20203214</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis HD, Shepherd JW, Davies GM, Perception. 8, 431&#x2013;439 (1979).</Citation><ArticleIdList><ArticleId IdType="pubmed">503774</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AW, Hay DC, McWeeny KH, Flude BM, Ellis AW, Perception. 14, 737&#x2013;746 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">3837875</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher C, Freiwald WA, Proc Natl Acad Sci USA. 112, 14717&#x2013;14722 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664356</ArticleId><ArticleId IdType="pubmed">26464511</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton AM, Jenkins R, Hancock PJB, White D, Cogn. Psychol. 51, 256&#x2013;284 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16198327</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandford A, Burton AM, Cognition. 132, 262&#x2013;268 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24853629</ArticleId></ArticleIdList></Reference><Reference><Citation>Gobbini MI, Haxby JV, Neuropsychologia. 45, 32&#x2013;41 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">16797608</ArticleId></ArticleIdList></Reference><Reference><Citation>Natu V, O&#x2019;Toole AJ, Br. J. Psychol. 102, 726&#x2013;747 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21988381</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyano KW et al., Curr. Biol. 31, 1&#x2013;12.e5 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7855058</ArticleId><ArticleId IdType="pubmed">33065012</ArticleId></ArticleIdList></Reference><Reference><Citation>Konorski J, Chicago: University of Chicago Press. (1967).</Citation></Reference><Reference><Citation>Xiang JZ, Brown MW, Neuropharmacology. 37, 657&#x2013;676 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9705004</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman DJ, Riesenhuber M, Poggio T, Miller EK, Cereb. Cortex. 16, 1631&#x2013;1644 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16400159</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer T, Olson CR, Proc Natl Acad Sci USA. 108, 19401&#x2013;19406 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3228439</ArticleId><ArticleId IdType="pubmed">22084090</ArticleId></ArticleIdList></Reference><Reference><Citation>Woloszyn L, Sheinberg DL, Neuron. 74, 193&#x2013;205 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329224</ArticleId><ArticleId IdType="pubmed">22500640</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwiedrzik CM, Freiwald WA, Neuron. 96, 89&#x2013;97.e4 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5757317</ArticleId><ArticleId IdType="pubmed">28957679</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoville WB, Milner B, J. Neurol. Neurosurg. Psychiatr. 20, 11&#x2013;21 (1957).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC497229</ArticleId><ArticleId IdType="pubmed">13406589</ArticleId></ArticleIdList></Reference><Reference><Citation>Sliwa J, Freiwald WA, Science. 356, 745&#x2013;749 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5540642</ArticleId><ArticleId IdType="pubmed">28522533</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobs K, Isik L, Pantazis D, Kanwisher N, Nat. Commun. 10, 1258 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425020</ArticleId><ArticleId IdType="pubmed">30890707</ArticleId></ArticleIdList></Reference><Reference><Citation>Visconti di Oleggio Castello M., Gobbini MI, PLoS ONE. 10, e0136548 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4549263</ArticleId><ArticleId IdType="pubmed">26305788</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimaldi P, Saleem KS, Tsao D, Neuron. 90, 1325&#x2013;1342 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573145</ArticleId><ArticleId IdType="pubmed">27263973</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashita Y, Nature. 335, 817&#x2013;820 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3185711</ArticleId></ArticleIdList></Reference><Reference><Citation>Ison MJ, Quian Quiroga R., Fried I, Neuron. 87, 220&#x2013;230 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4509714</ArticleId><ArticleId IdType="pubmed">26139375</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashita Y, Nat. Rev. Neurosci. 20, 577&#x2013;592 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31485007</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura K et al., Science. 357, 687&#x2013;692 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28818944</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohayon S, Tsao DY, J. Neurosci. Methods. 204, 389&#x2013;397 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8204678</ArticleId><ArticleId IdType="pubmed">22192950</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Huang XF, Toga AW, (2000).</Citation></Reference><Reference><Citation>Willenbockel V et al., Behav. Res. Methods. 42, 671&#x2013;684 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20805589</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao DY, Freiwald WA, Tootell RBH, Livingstone MS, Science. 311, 670&#x2013;674 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678572</ArticleId><ArticleId IdType="pubmed">16456083</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolls ET, Critchley HD, Browning AS, Inoue K, Exp. Brain Res. 170, 74&#x2013;87 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16328289</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehaqani M-RA et al., J. Neurophysiol. 116, 587&#x2013;601 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4982903</ArticleId><ArticleId IdType="pubmed">27169503</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyers EM, Front. Neuroinformatics. 7, 8 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3660664</ArticleId><ArticleId IdType="pubmed">23734125</ArticleId></ArticleIdList></Reference><Reference><Citation>Naka KI, Rushton WA, The Journal of physiology. 185, 536&#x2013;555 (1966).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1395833</ArticleId><ArticleId IdType="pubmed">5918058</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34180956</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.</ArticleTitle><Pagination><StartPage>961</StartPage><EndPage>971</EndPage><MedlinePgn>961-971</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.1858</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Tau positron emission tomography (PET) tracers have proven useful for the differential diagnosis of dementia, but their utility for predicting cognitive change is unclear.</AbstractText><AbstractText Label="OBJECTIVE">To examine the prognostic accuracy of baseline fluorine 18 (18F)-flortaucipir and [18F]RO948 (tau) PET in individuals across the Alzheimer disease (AD) clinical spectrum and to perform a head-to-head comparison against established magnetic resonance imaging (MRI) and amyloid PET markers.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This prognostic study collected data from 8 cohorts in South Korea, Sweden, and the US from June 1, 2014, to February 28, 2021, with a mean (SD) follow-up of 1.9&#x2009;(0.8) years. A total of 1431 participants were recruited from memory clinics, clinical trials, or cohort studies; 673 were cognitively unimpaired (CU group; 253 [37.6%] positive for amyloid-&#x3b2; [A&#x3b2;]), 443 had mild cognitive impairment (MCI group; 271 [61.2%] positive for A&#x3b2;), and 315 had a clinical diagnosis of AD dementia (315 [100%] positive for A&#x3b2;).</AbstractText><AbstractText Label="EXPOSURES">[18F]Flortaucipir PET in the discovery cohort (n&#x2009;=&#x2009;1135) or [18F]RO948 PET in the replication cohort (n&#x2009;=&#x2009;296), T1-weighted MRI (n = 1431), and amyloid PET (n&#x2009;=&#x2009;1329) at baseline and repeated Mini-Mental State Examination (MMSE) evaluation.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Baseline [18F]flortaucipir/[18F]RO948 PET retention within a temporal region of interest, MRI-based AD-signature cortical thickness, and amyloid PET Centiloids were used to predict changes in MMSE using linear mixed-effects models adjusted for age, sex, education, and cohort. Mediation/interaction analyses tested whether associations between baseline tau PET and cognitive change were mediated by baseline MRI measures and whether age, sex, and APOE genotype modified these associations.</AbstractText><AbstractText Label="RESULTS">Among 1431 participants, the mean (SD) age was 71.2&#x2009;(8.8) years; 751 (52.5%) were male. Findings for [18F]flortaucipir PET predicted longitudinal changes in MMSE, and effect sizes were stronger than for AD-signature cortical thickness and amyloid PET across all participants (R2, 0.35 [tau PET] vs 0.24 [MRI] vs 0.17 [amyloid PET]; P &lt; .001, bootstrapped for difference) in the A&#x3b2;-positive MCI group (R2, 0.25 [tau PET] vs 0.15 [MRI] vs 0.07 [amyloid PET]; P&#x2009;&lt;&#x2009;.001, bootstrapped for difference) and in the A&#x3b2;-positive CU group (R2, 0.16 [tau PET] vs 0.08 [MRI] vs 0.08 [amyloid PET]; P&#x2009;&lt;&#x2009;.001, bootstrapped for difference). These findings were replicated in the [18F]RO948 PET cohort. MRI mediated the association between [18F]flortaucipir PET and MMSE in the groups with AD dementia (33.4% [95% CI, 15.5%-60.0%] of the total effect) and A&#x3b2;-positive MCI (13.6% [95% CI, 0.0%-28.0%] of the total effect), but not the A&#x3b2;-positive CU group (3.7% [95% CI, -17.5% to 39.0%]; P&#x2009;=&#x2009;.71). Age (t&#x2009;=&#x2009;-2.28; P&#x2009;=&#x2009;.02), but not sex (t&#x2009;=&#x2009;0.92; P&#x2009;=&#x2009;.36) or APOE genotype (t&#x2009;=&#x2009;1.06; P&#x2009;=&#x2009;.29) modified the association between baseline [18F]flortaucipir PET and cognitive change, such that older individuals showed faster cognitive decline at similar tau PET levels.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The findings of this prognostic study suggest that tau PET is a promising tool for predicting cognitive change that is superior to amyloid PET and MRI and may support the prognostic process in preclinical and prodromal stages of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattsson-Carlgren</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groot</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leuzy</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strandberg</LastName><ForeName>Olof</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmqvist</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Tomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Radiation Physics, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf6;gi</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Physiology and Nuclear Medicine, Sk&#xe5;ne University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stormrud</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Young Hoon</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jae Yong</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Applied Radiological Imaging, Korea Institute Radiological and Medical Sciences, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boxer</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorno-Tempini</LastName><ForeName>Maria L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soleimani-Meigooni</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iaccarino</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Joie</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lawrence Berkeley National Laboratory, Berkeley, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borroni</LastName><ForeName>Edilio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontecorvo</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devous</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><Suffix>Sr</Suffix><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Lawrence Berkeley National Laboratory, Berkeley, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helen Wills Neuroscience Institute, University of California, Berkeley.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyoo</LastName><ForeName>Chul Hyoung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Memory and Aging Center, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Biomedical Imaging, University of California, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Associate Editor, JAMA Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>J09QS3Z3WB</RegistryNumber><NameOfSubstance UI="C000591008">7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>AJR Am J Roentgenol. 2022 May;218(5):924. doi: 10.2214/AJR.21.26836.</RefSource><PMID Version="1">35234499</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002243" MajorTopicYN="N">Carbolines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Boxer reported receiving research support from the National Institutes of Health (NIH), the Tau Research Consortium, the Association for Frontotemporal Degeneration, the Bluefield Project to Cure Frontotemporal Dementia, Avid Radiopharmaceuticals, Eisai Inc, Biogen Inc, and Roche and serving as a consultant for Applied Genetic Technologies Corporation, Alector, Inc, Arkuda Therapeutics, Arvinas, Inc, Bioage, Ionis Pharmaceuticals, Inc, H Lundbeck A/S, Passage Bio, Inc, Samumed, Ono Pharmaceutical Co, Ltd, Sangamo Therapeutics, Inc, Stealth BioTherapeutics Inc, Third Rock Ventures, Transposon Therapeutics, Inc, UCB, and Wave Life Sciences. Dr Pontecorvo reported being a minor stockholder in Eli Lilly and Company. Dr Devous reported being a minor stockholder in Eli Lilly and Company. Dr Rabinovici reported receiving research support from the NIH, Alzheimer&#x2019;s Association, American College of Radiology, Avid Radiopharmaceuticals, GE Healthcare, and Life Molecular Imaging and receiving consulting fees from AXON Neuroscience, Eisai Inc, GE Healthcare, Johnson &amp; Johnson, and Merck &amp; Co, Inc, in the past 2 years. Dr Hansson reported acquiring research support (for the institution) from Avid Radiopharmaceuticals, Biogen Inc, Eli Lilly and Company, Eisai Inc, GE Healthcare, Pfizer Inc, and Roche and receiving consultancy/speaker fees from AC Immune, ALZpath, Biogen Inc, Cerveau Technologies, and Roche in the past 2 years. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>28</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34180956</ArticleId><ArticleId IdType="pmc">PMC8240013</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.1858</ArticleId><ArticleId IdType="pii">2781465</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gill TM. The central role of prognosis in clinical decision making. JAMA. 2012;307(2):199-200. doi:10.1001/jama.2011.1992</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2011.1992</ArticleId><ArticleId IdType="pmc">PMC3273781</ArticleId><ArticleId IdType="pubmed">22235093</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, De Strooper B, Kivipelto M, et al. . Alzheimer&#x2019;s disease. Lancet. 2021;397(10284):1577-1590. doi:10.1016/S0140-6736(20)32205-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32205-4</ArticleId><ArticleId IdType="pmc">PMC8354300</ArticleId><ArticleId IdType="pubmed">33667416</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, et al. . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-381. doi:10.1097/NEN.0b013e31825018f7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer&#x2019;s disease. Neuron. 2014;82(4):756-771. doi:10.1016/j.neuron.2014.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.05.004</ArticleId><ArticleId IdType="pmc">PMC4135182</ArticleId><ArticleId IdType="pubmed">24853936</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Chiotis K, Lemoine L, et al. . Tau PET imaging in neurodegenerative tauopathies&#x2014;still a challenge. Mol Psychiatry. 2019;24(8):1112-1134. doi:10.1038/s41380-018-0342-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0342-8</ArticleId><ArticleId IdType="pmc">PMC6756230</ArticleId><ArticleId IdType="pubmed">30635637</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Pontecorvo MJ, Devous MD Sr, et al. ; A16 Study Investigators . Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77(7):829-839. doi:10.1001/jamaneurol.2020.0528</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0528</ArticleId><ArticleId IdType="pmc">PMC7186920</ArticleId><ArticleId IdType="pubmed">32338734</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Lundt ES, Albertson SM, et al. . Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 2020;16(3):561-571. doi:10.1016/j.jalz.2019.09.079</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.09.079</ArticleId><ArticleId IdType="pmc">PMC7067654</ArticleId><ArticleId IdType="pubmed">31784374</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino L, La Joie R, Edwards L, et al. . Spatial relationships between molecular pathology and neurodegeneration in the Alzheimer&#x2019;s disease continuum. Cereb Cortex. 2021;31(1):1-14. doi:10.1093/cercor/bhaa184</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhaa184</ArticleId><ArticleId IdType="pmc">PMC7727356</ArticleId><ArticleId IdType="pubmed">32808011</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Schonhaut DR, Sch&#xf6;ll M, et al. . Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer&#x2019;s disease. Brain. 2016;139(pt 5):1551-1567. doi:10.1093/brain/aww027</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww027</ArticleId><ArticleId IdType="pmc">PMC5006248</ArticleId><ArticleId IdType="pubmed">26962052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sintini I, Graff-Radford J, Senjem ML, et al. . Longitudinal neuroimaging biomarkers differ across Alzheimer&#x2019;s disease phenotypes. Brain. 2020;143(7):2281-2294. doi:10.1093/brain/awaa155</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa155</ArticleId><ArticleId IdType="pmc">PMC7363492</ArticleId><ArticleId IdType="pubmed">32572464</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison TM, Du R, Klencklen G, Baker SL, Jagust WJ. Distinct effects of beta-amyloid and tau on cortical thickness in cognitively healthy older adults. Alzheimers Dement. 2020. doi:10.1002/alz.12249</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12249</ArticleId><ArticleId IdType="pmc">PMC8203764</ArticleId><ArticleId IdType="pubmed">33325068</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Smith R, Ohlsson T, et al. . Associations between tau, A&#x3b2;, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92(6):e601-e612. doi:10.1212/WNL.0000000000006875</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006875</ArticleId><ArticleId IdType="pmc">PMC6382060</ArticleId><ArticleId IdType="pubmed">30626656</ArticleId></ArticleIdList></Reference><Reference><Citation>Bejanin A, Schonhaut DR, La Joie R, et al. . Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer&#x2019;s disease. Brain. 2017;140(12):3286-3300. doi:10.1093/brain/awx243</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx243</ArticleId><ArticleId IdType="pmc">PMC5841139</ArticleId><ArticleId IdType="pubmed">29053874</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, et al. . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110-119. doi:10.1002/ana.24546</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24546</ArticleId><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;ll M, Lockhart SN, Schonhaut DR, et al. . PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971-982. doi:10.1016/j.neuron.2016.01.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.01.028</ArticleId><ArticleId IdType="pmc">PMC4779187</ArticleId><ArticleId IdType="pubmed">26938442</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Smith R, Ossenkoppele R, et al. . Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 2020;77(8):955-965. doi:10.1001/jamaneurol.2020.0989</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0989</ArticleId><ArticleId IdType="pmc">PMC7215644</ArticleId><ArticleId IdType="pubmed">32391858</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Rabinovici GD, Smith R, et al. . Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320(11):1151-1162. doi:10.1001/jama.2018.12917</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.12917</ArticleId><ArticleId IdType="pmc">PMC6233630</ArticleId><ArticleId IdType="pubmed">30326496</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Botha H, et al. . The bivariate distribution of amyloid-&#x3b2; and tau: relationship with established neurocognitive clinical syndromes. Brain. 2019;142(10):3230-3242. doi:10.1093/brain/awz268</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz268</ArticleId><ArticleId IdType="pmc">PMC6763736</ArticleId><ArticleId IdType="pubmed">31501889</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal TA, Therriault J, Benedet AL, et al. . 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143(9):2818-2830. doi:10.1093/brain/awaa180</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa180</ArticleId><ArticleId IdType="pubmed">32671408</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Lee HS, et al. . Progressive tau accumulation in Alzheimer disease: 2-year follow-up study. J Nucl Med. 2019;60(11):1611-1621. doi:10.2967/jnumed.118.221697</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.118.221697</ArticleId><ArticleId IdType="pmc">PMC6836867</ArticleId><ArticleId IdType="pubmed">30926651</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Korman D, Baker SL, Landau SM, Jagust WJ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Longitudinal cognitive and biomarker measurements support a unidirectional pathway in Alzheimer&#x2019;s disease pathophysiology. Biol Psychiatry. 2021;89(8):786-794. doi:10.1016/j.biopsych.2020.06.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2020.06.029</ArticleId><ArticleId IdType="pmc">PMC9682985</ArticleId><ArticleId IdType="pubmed">32919611</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Devous MD, Kennedy I, et al. . A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer&#x2019;s disease dementia. Brain. 2019;142(6):1723-1735. doi:10.1093/brain/awz090</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz090</ArticleId><ArticleId IdType="pmc">PMC6536847</ArticleId><ArticleId IdType="pubmed">31009046</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Mormino EC, Schultz AP, et al. . The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019;85(2):181-193. doi:10.1002/ana.25395</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25395</ArticleId><ArticleId IdType="pmc">PMC6402593</ArticleId><ArticleId IdType="pubmed">30549303</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. . Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76(8):915-924. doi:10.1001/jamaneurol.2019.1424</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1424</ArticleId><ArticleId IdType="pmc">PMC6547132</ArticleId><ArticleId IdType="pubmed">31157827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu M, Pontecorvo MJ, Devous MD Sr, et al. ; AVID Collaborators . Aggregated tau measured by visual interpretation of flortaucipir positron emission tomography and the associated risk of clinical progression of mild cognitive impairment and Alzheimer disease: results from 2 phase III clinical trials. JAMA Neurol. 2021;78(4):445-453. doi:10.1001/jamaneurol.2020.5505</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.5505</ArticleId><ArticleId IdType="pmc">PMC7885097</ArticleId><ArticleId IdType="pubmed">33587110</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Therneau TM, et al. . Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA. 2019;321(23):2316-2325. doi:10.1001/jama.2019.7437</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.7437</ArticleId><ArticleId IdType="pmc">PMC6582267</ArticleId><ArticleId IdType="pubmed">31211344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Leuzy A, Cho H, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative; PREVENT-AD research group . The impact of demographic, clinical, genetic, and imaging variables on tau PET status. Published online November 19, 2020. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-020-05099-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-05099-w</ArticleId><ArticleId IdType="pmc">PMC8131404</ArticleId><ArticleId IdType="pubmed">33215319</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Lyoo CH, Jester-Broms J, et al. . Assessment of demographic, genetic, and imaging variables associated with brain resilience and cognitive resilience to pathological tau in patients with Alzheimer disease. JAMA Neurol. 2020;77(5):632-642. doi:10.1001/jamaneurol.2019.5154</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.5154</ArticleId><ArticleId IdType="pmc">PMC7042808</ArticleId><ArticleId IdType="pubmed">32091549</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Lyoo CH, Sudre CH, et al. . Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer&#x2019;s disease. Alzheimers Dement. 2020;16(2):335-344. doi:10.1016/j.jalz.2019.08.201</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.08.201</ArticleId><ArticleId IdType="pmc">PMC7012375</ArticleId><ArticleId IdType="pubmed">31672482</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, et al. . Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. 2016;87(4):375-383. doi:10.1212/WNL.0000000000002892</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002892</ArticleId><ArticleId IdType="pubmed">27358341</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Visani AV, Baker SL, et al. . Prospective longitudinal atrophy in Alzheimer&#x2019;s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12(524):eaau5732. doi:10.1126/scitranslmed.aau5732</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau5732</ArticleId><ArticleId IdType="pmc">PMC7035952</ArticleId><ArticleId IdType="pubmed">31894103</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP. Introduction to special issue: overview of Alzheimer&#x2019;s Disease Neuroimaging Initiative. Alzheimers Dement. 2015;11(7):730-733. doi:10.1016/j.jalz.2015.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.05.007</ArticleId><ArticleId IdType="pmc">PMC5536175</ArticleId><ArticleId IdType="pubmed">26194308</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, et al. . Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341-355. doi:10.1016/S0896-6273(02)00569-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00569-X</ArticleId><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A. 2000;97(20):11050-11055. doi:10.1073/pnas.200033797</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.200033797</ArticleId><ArticleId IdType="pmc">PMC27146</ArticleId><ArticleId IdType="pubmed">10984517</ArticleId></ArticleIdList></Reference><Reference><Citation>Maass A, Landau S, Baker SL, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer&#x2019;s disease. Neuroimage. 2017;157:448-463. doi:10.1016/j.neuroimage.2017.05.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.05.058</ArticleId><ArticleId IdType="pmc">PMC5814575</ArticleId><ArticleId IdType="pubmed">28587897</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgeat P, Dor&#xe9; V, Fripp J, et al. ; AIBL research group . Implementing the Centiloid transformation for 11C-PiB and &#x3b2;-amyloid 18F-PET tracers using CapAIBL. Neuroimage. 2018;183:387-393. doi:10.1016/j.neuroimage.2018.08.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2018.08.044</ArticleId><ArticleId IdType="pubmed">30130643</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Koeppe RA, Price JC, et al. . The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1-15.e1, 4. doi:10.1016/j.jalz.2014.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.07.003</ArticleId><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Defining imaging biomarker cut points for brain aging and Alzheimer&#x2019;s disease. Alzheimers Dement. 2017;13(3):205-216. doi:10.1016/j.jalz.2016.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.08.005</ArticleId><ArticleId IdType="pmc">PMC5344738</ArticleId><ArticleId IdType="pubmed">27697430</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, et al. . In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80(2):247-258. doi:10.1002/ana.24711</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24711</ArticleId><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanhaute H, Ceccarini J, Michiels L, et al. . In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment. Neurology. 2020;95(5):e545-e553. doi:10.1212/WNL.0000000000009818</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009818</ArticleId><ArticleId IdType="pubmed">32493717</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanseeuw BJ, Betensky RA, Schultz AP, et al. . Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann Neurol. 2017;81(4):583-596. doi:10.1002/ana.24910</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24910</ArticleId><ArticleId IdType="pmc">PMC5404378</ArticleId><ArticleId IdType="pubmed">28253546</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Lo AC, Duggan Evans C, et al. . Donanemab in early Alzheimer&#x2019;s disease. N Engl J Med. 2021;384(18):1691-1704. doi:10.1056/NEJMoa2100708</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100708</ArticleId><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer&#x2019;s disease. Neuron. 2013;80(6):1347-1358. doi:10.1016/j.neuron.2013.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.003</ArticleId><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609-622. doi:10.1016/S1474-4422(13)70090-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70090-5</ArticleId><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Menkes-Caspi N, Yamin HG, Kellner V, Spires-Jones TL, Cohen D, Stern EA. Pathological tau disrupts ongoing network activity. Neuron. 2015;85(5):959-966. doi:10.1016/j.neuron.2015.01.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.01.025</ArticleId><ArticleId IdType="pubmed">25704951</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. ; Amyloid Biomarker Study Group . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-1938. doi:10.1001/jama.2015.4668</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.4668</ArticleId><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Schwarz CG, et al. . Longitudinal tau PET in ageing and Alzheimer&#x2019;s disease. Brain. 2018;141(5):1517-1528. doi:10.1093/brain/awy059</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy059</ArticleId><ArticleId IdType="pmc">PMC5917767</ArticleId><ArticleId IdType="pubmed">29538647</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubal DB. Sex difference in Alzheimer&#x2019;s disease: an updated, balanced and emerging perspective on differing vulnerabilities. Handb Clin Neurol. 2020;175:261-273. doi:10.1016/B978-0-444-64123-6.00018-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-64123-6.00018-7</ArticleId><ArticleId IdType="pubmed">33008530</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Strandberg O, Mattsson-Carlgren N, et al. . The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain. 2020;143(12):3805-3815. doi:10.1093/brain/awaa327</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa327</ArticleId><ArticleId IdType="pmc">PMC7805812</ArticleId><ArticleId IdType="pubmed">33439987</ArticleId></ArticleIdList></Reference><Reference><Citation>Emrani S, Arain HA, DeMarshall C, Nuriel T. APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer&#x2019;s disease: a systematic review. Alzheimers Res Ther. 2020;12(1):141. doi:10.1186/s13195-020-00712-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00712-4</ArticleId><ArticleId IdType="pmc">PMC7643479</ArticleId><ArticleId IdType="pubmed">33148345</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Scott MR, Jacobs HIL, et al. . Sex mediates relationships between regional tau pathology and cognitive decline. Ann Neurol. 2020;88(5):921-932. doi:10.1002/ana.25878</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25878</ArticleId><ArticleId IdType="pmc">PMC7581543</ArticleId><ArticleId IdType="pubmed">32799367</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Sch&#xf6;ll M, Leuzy A, et al. . Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948. Eur J Nucl Med Mol Imaging. 2020;47(2):342-354. doi:10.1007/s00259-019-04496-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-019-04496-0</ArticleId><ArticleId IdType="pmc">PMC6974501</ArticleId><ArticleId IdType="pubmed">31612245</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34187891</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>118</Volume><Issue>27</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Acute <i>Trem2</i> reduction triggers increased microglial phagocytosis, slowing amyloid deposition in mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e2100356118</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2100356118</ELocationID><Abstract><AbstractText>Heterozygous genetic variants within the <i>TREM2</i> gene show a strong association with increased Alzheimer's disease (AD) risk. Amyloid beta-depositing mouse models haploinsufficient or null for <i>Trem2</i> have identified important relationships among TREM2, microglia, and AD pathology; however, results are challenging to interpret in the context of varying microglial phenotypes and disease progression. We hypothesized that acute <i>Trem2</i> reduction may alter amyloid pathology and microglial responses independent of genetic <i>Trem2</i> deletion in mouse models. We developed antisense oligonucleotides (ASOs) that potently but transiently lower <i>Trem2</i> messenger RNA throughout the brain and administered them to APP/PS1 mice at varying stages of plaque pathology. Late-stage ASO-mediated <i>Trem2</i> knockdown significantly reduced plaque deposition and attenuated microglial association around plaque deposits when evaluated 1 mo after ASO injection. Changes in microglial gene signatures 1 wk after ASO administration and phagocytosis measured in ASO-treated cells together indicate that microglia may be activated with short-term <i>Trem2</i> reduction. These results suggest a time- and/or dose-dependent role for TREM2 in mediating plaque deposition and microglial responses in which loss of TREM2 function may be beneficial for microglial activation and plaque removal in an acute context.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schoch</LastName><ForeName>Kathleen M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0001-6710-5147</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110; miller.t@wustl.edu kmschoch@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezerskiy</LastName><ForeName>Lubov A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-1869-0658</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morhaus</LastName><ForeName>Michaela M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bannon</LastName><ForeName>Riley N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauerbeck</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shabsovich</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafar-Nejad</LastName><ForeName>Paymaan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 92010.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigo</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ionis Pharmaceuticals, Carlsbad, CA 92010.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-3424-5511</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO 63110; miller.t@wustl.edu kmschoch@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS078398</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR027552</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="Y">Phagocytosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Trem2</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">antisense oligonucleotide</Keyword><Keyword MajorTopicYN="N">microglia</Keyword></KeywordList><CoiStatement>Competing interest statement: P.J.-N. and F.R. are paid employees of Ionis Pharmaceuticals. Washington University in St. Louis has an existing licensing agreement with Ionis Pharmaceuticals for use of antisense oligonucleotides in these studies. T.M.M. is a consultant for Ionis Pharmaceuticals.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>30</Day><Hour>5</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34187891</ArticleId><ArticleId IdType="pmc">PMC8271763</ArticleId><ArticleId IdType="doi">10.1073/pnas.2100356118</ArticleId><ArticleId IdType="pii">2100356118</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman R. J.et al. .; Dominantly Inherited Alzheimer Network , Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N. Engl. J. Med. 367, 795&#x2013;804 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C. R. Jr, et al. ., Tracking pathophysiological processes in Alzheimer&#x2019;s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207&#x2013;216 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Calsolaro V., Edison P., Neuroinflammation in Alzheimer&#x2019;s disease: Current evidence and future directions. Alzheimers Dement. 12, 719&#x2013;732 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27179961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail R., et al. ., The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer&#x2019;s disease: A longitudinal PET study. J. Neuroinflammation 17, 151 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7203856</ArticleId><ArticleId IdType="pubmed">32375809</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinney J. W., et al. ., Inflammation as a central mechanism in Alzheimer&#x2019;s disease. Alzheimers Dement. (N. Y.) 4, 575&#x2013;590 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6214864</ArticleId><ArticleId IdType="pubmed">30406177</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijen J., Sleegers K., Understanding Alzheimer disease at the interface between genetics and transcriptomics. Trends Genet. 34, 434&#x2013;447 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29573818</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R.et al. .; Alzheimer Genetic Analysis Group , TREM2 variants in Alzheimer&#x2019;s disease. N. Engl. J. Med. 368, 117&#x2013;127 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T., et al. ., Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N. Engl. J. Med. 368, 107&#x2013;116 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull I. R., et al. ., Cutting edge: TREM-2 attenuates macrophage activation. J. Immunol. 177, 3520&#x2013;3524 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A., Weiner A., Amit I., The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell 181, 1207&#x2013;1217 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32531244</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H., et al. ., A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S., et al. ., The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566&#x2013;581.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay T. R., et al. ., TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J. Exp. Med. 212, 287&#x2013;295 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich J. D., et al. ., Altered microglial response to A&#x3b2; plaques in APPPS1-21 mice heterozygous for TREM2. Mol. Neurodegener. 9, 20 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., et al. ., TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P., et al. ., TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 92, 252&#x2013;264 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27710785</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C., Yuan P., Schain A., Grutzendler J., Microglia constitute a barrier that prevents neurotoxic protofibrillar A&#x3b2;42 hotspots around plaques. Nat. Commun. 6, 6176 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., et al. ., TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 213, 667&#x2013;675 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns C. E. G., et al. ., TREM2 function impedes tau seeding in neuritic plaques. Nat. Neurosci. 22, 1217&#x2013;1222 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6660358</ArticleId><ArticleId IdType="pubmed">31235932</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay T. R., et al. ., Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer&#x2019;s disease. J. Neurosci. 37, 637&#x2013;647 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S., et al. ., Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat. Neurosci. 22, 191&#x2013;204 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng L., et al. ., Microglial Trem2 induces synaptic impairment at early stage and prevents amyloidosis at late stage in APP/PS1 mice. FASEB J. 33, 10425&#x2013;10442 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31219699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawabori M., et al. ., Triggering receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia and exacerbates ischemic damage in experimental stroke. J. Neurosci. 35, 3384&#x2013;3396 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339351</ArticleId><ArticleId IdType="pubmed">25716838</ArticleId></ArticleIdList></Reference><Reference><Citation>Saber M., Kokiko-Cochran O., Puntambekar S. S., Lathia J. D., Lamb B. T., Triggering receptor expressed on myeloid cells 2 deficiency alters acute macrophage distribution and improves recovery after traumatic brain injury. J. Neurotrauma 34, 423&#x2013;435 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">26976047</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantoni C., et al. ., TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathol. 129, 429&#x2013;447 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4667728</ArticleId><ArticleId IdType="pubmed">25631124</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayed F. A., et al. ., Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy. Proc. Natl. Acad. Sci. U.S.A. 115, 10172&#x2013;10177 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6176614</ArticleId><ArticleId IdType="pubmed">30232263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze M., et al. ., Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. J. Clin. Invest. 130, 4954&#x2013;4968 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456230</ArticleId><ArticleId IdType="pubmed">32544086</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns C. E. G., et al. ., TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc. Natl. Acad. Sci. U.S.A. 114, 11524&#x2013;11529 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="pubmed">29073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Bemiller S. M., et al. ., TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol. Neurodegener. 12, 74 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5644120</ArticleId><ArticleId IdType="pubmed">29037207</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M., et al. ., Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 24, 516&#x2013;524 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17029828</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J. L., et al. ., Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13, 159&#x2013;170 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamphuis W., et al. ., GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One 7, e42823 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418292</ArticleId><ArticleId IdType="pubmed">22912745</ArticleId></ArticleIdList></Reference><Reference><Citation>Raha A. A., et al. ., Neuroprotective effect of TREM-2 in aging and Alzheimer&#x2019;s disease model. J. Alzheimers Dis. 55, 199&#x2013;217 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27662313</ArticleId></ArticleIdList></Reference><Reference><Citation>Matarin M., et al. ., A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep. 10, 633&#x2013;644 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25620700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue L. F., et al. ., TREM2 protein expression changes correlate with Alzheimer&#x2019;s disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Pathol. 25, 469&#x2013;480 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4427527</ArticleId><ArticleId IdType="pubmed">25186950</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez S. E., et al. ., Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer&#x2019;s disease. Neurobiol. Aging 54, 133&#x2013;143 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6344038</ArticleId><ArticleId IdType="pubmed">28365005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L., et al. ., Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer&#x2019;s disease brains. Mol. Neurodegener. 11, 72 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5124229</ArticleId><ArticleId IdType="pubmed">27887626</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., et al. ., TREM2 is a receptor for &#x3b2;-amyloid that mediates microglial function. Neuron 97, 1023&#x2013;1031.e7 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="pubmed">29518356</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurt M. A., Davies D. C., Kidd M., Duff K., Howlett D. R., Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiol. Dis. 14, 89&#x2013;97 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">13678670</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez M., Mor&#xe1;n M. A., Ferrer I., Avila J., G&#xf3;mez-Ramos P., Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic mice and Alzheimer disease. Acta Neuropathol. 116, 409&#x2013;418 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18679696</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J., Park S., Lee H., Kim Y., Thioflavin-positive tau aggregates complicating quantification of amyloid plaques in the brain of 5XFAD transgenic mouse model. Sci. Rep. 11, 1617 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7810901</ArticleId><ArticleId IdType="pubmed">33452414</ArticleId></ArticleIdList></Reference><Reference><Citation>Meilandt W. J., et al. ., Trem2 deletion reduces late-stage amyloid plaque accumulation, elevates the A&#x3b2;42:A&#x3b2;40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP Alzheimer&#x2019;s mouse model. J. Neurosci. 40, 1956&#x2013;1974 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7046459</ArticleId><ArticleId IdType="pubmed">31980586</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher K. I., Wyss-Coray T., Microglial dysfunction in brain aging and Alzheimer&#x2019;s disease. Biochem. Pharmacol. 88, 594&#x2013;604 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972294</ArticleId><ArticleId IdType="pubmed">24445162</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K., et al. ., Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol. Med. 12, e11227 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136959</ArticleId><ArticleId IdType="pubmed">32154671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., et al. ., Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer&#x2019;s disease model. J. Exp. Med. 217, e20200785 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478730</ArticleId><ArticleId IdType="pubmed">32579671</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S. S., et al. ., Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. J. Exp. Med. 215, 2235&#x2013;2245 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6122978</ArticleId><ArticleId IdType="pubmed">30082275</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean H. B., Roberson E. D., Song Y., Neurodegenerative disease-associated variants in TREM2 destabilize the apical ligand-binding region of the immunoglobulin domain. Front. Neurol. 10, 1252 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985895</ArticleId><ArticleId IdType="pubmed">32021611</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober D. L., et al. ., Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. eLife 5, e20391 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5173322</ArticleId><ArticleId IdType="pubmed">27995897</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W., et al. ., Alzheimer&#x2019;s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimers Dement. 13, 381&#x2013;387 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299056</ArticleId><ArticleId IdType="pubmed">27520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J. L., et al. ., Co-expression of multiple transgenes in mouse CNS: A comparison of strategies. Biomol. Eng. 17, 157&#x2013;165 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Tanila H., Puoliv&#xe4;li J., Kadish I., van Groen T., Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol. Dis. 14, 318&#x2013;327 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14678749</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts T. C., Langer R., Wood M. J. A., Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 19, 673&#x2013;694 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7419031</ArticleId><ArticleId IdType="pubmed">32782413</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos S. L., Miller T. M., Direct intraventricular delivery of drugs to the rodent central nervous system. J. Vis. Exp. e50326 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679837</ArticleId><ArticleId IdType="pubmed">23712122</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin K. B. J., Paxinos G., Paxinos and Franklin&#x2019;s The Mouse Brain in Stereotaxic Coordinates (Academic Press, an imprint of Elsevier, Amsterdam, ed. 4, 2013), pp. 1&#x2013;360.</Citation></Reference><Reference><Citation>Schildge S., Bohrer C., Beck K., Schachtrup C., Isolation and culture of mouse cortical astrocytes. J. Vis. Exp. 50079 10.3791/50079 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/50079</ArticleId><ArticleId IdType="pmc">PMC3582677</ArticleId><ArticleId IdType="pubmed">23380713</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34233201</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4186</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>04</Day></PubDate></JournalIssue><Title>Structure (London, England : 1993)</Title><ISOAbbreviation>Structure</ISOAbbreviation></Journal><ArticleTitle>Selection and structural characterization of anti-TREM2 scFvs that reduce levels of shed ectodomain.</ArticleTitle><Pagination><StartPage>1241</StartPage><EndPage>1252.e5</EndPage><MedlinePgn>1241-1252.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.str.2021.06.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-2126(21)00214-8</ELocationID><Abstract><AbstractText>Mutations in TREM2, a receptor expressed by microglia in the brain, are associated with an increased risk of neurodegeneration, including Alzheimer's disease. Numerous studies support a role for TREM2 in sensing damaging stimuli and triggering signaling cascades necessary for neuroprotection. Despite its significant role, ligands and regulators of TREM2 activation, and the mechanisms governing TREM2-dependent responses and its cleavage from the membrane, remain poorly characterized. Here, we present phage display generated antibody single-chain variable fragments (scFvs) to human TREM2 immunoglobulin-like domain. Co-crystal structures revealed the binding of two scFvs to an epitope on the TREM2 domain distal to the putative ligand-binding site. Enhanced functional activity was observed for oligomeric scFv species, which inhibited the production of soluble TREM2 in a HEK293 cell model. We hope that detailed characterization of their epitopes and properties will facilitate the use of these renewable binders as structural and functional biology tools for TREM2 research.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Szykowska</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Eisai Inc., 35 Cambridgepark Drive, Cambridge, MA 02140, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Thomas B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Alzheimer's Research UK Oxford Drug Discovery Institute, NDM Research Building, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7FZ, UK; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preger</LastName><ForeName>Charlotta</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Structural Genomics Consortium (SGC), Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, 171 76 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Viva Biotech Ltd., 334 Aidisheng Road, Zhangjiang High-Tech Park, Shanghai 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Dongming</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Viva Biotech Ltd., 334 Aidisheng Road, Zhangjiang High-Tech Park, Shanghai 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukhopadhyay</LastName><ForeName>Shubhashish M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wigren</LastName><ForeName>Edvard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Structural Genomics Consortium (SGC), Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, 171 76 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neame</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Eisai Ltd., Mosquito Way, Hatfield AL10 9SN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xe4;slund</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Structural Genomics Consortium (SGC), Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, 171 76 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Persson</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Science for Life Laboratory, Drug Discovery and Development &amp; School of Engineering Sciences in Chemistry, Biotechnology and Health, Royal Institute of Technology (KTH), Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atkinson</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Eisai Ltd., Mosquito Way, Hatfield AL10 9SN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Daniel</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Alzheimer's Research UK Oxford Drug Discovery Institute, NDM Research Building, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7FZ, UK; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Alzheimer's Research UK Oxford Drug Discovery Institute, NDM Research Building, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7FZ, UK; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Eisai Inc., 35 Cambridgepark Drive, Cambridge, MA 02140, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>John B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Alzheimer's Research UK Oxford Drug Discovery Institute, NDM Research Building, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7FZ, UK; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK. Electronic address: john.davis@cmd.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgess-Brown</LastName><ForeName>Nicola A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK. Electronic address: nicola.burgess-brown@cmd.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bullock</LastName><ForeName>Alex N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK. Electronic address: alex.bullock@cmd.ox.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>106169/ZZ14/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Structure</MedlineTA><NlmUniqueID>101087697</NlmUniqueID><ISSNLinking>0969-2126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057127">Single-Chain Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Structure. 2021 Nov 4;29(11):1215-1216. doi: 10.1016/j.str.2021.10.009.</RefSource><PMID Version="1">34739822</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057127" MajorTopicYN="N">Single-Chain Antibodies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">X-ray crystallography</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">single-chain variable fragments</Keyword></KeywordList><CoiStatement>Declaration of interests Y.C., S.J.N., P.J.A., and J.W. are employees of Eisai Ltd., and Eisai Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>7</Day><Hour>20</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34233201</ArticleId><ArticleId IdType="pmc">PMC8575122</ArticleId><ArticleId IdType="doi">10.1016/j.str.2021.06.010</ArticleId><ArticleId IdType="pii">S0969-2126(21)00214-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aricescu A.R., Lu W., Jones E.Y. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr. D. Biol. Crystallogr. 2006;62:1243&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pubmed">17001101</ArticleId></ArticleIdList></Reference><Reference><Citation>Berner D.K., Wessolowski L., Armbrust F., Schneppenheim J., Schlepckow K., Koudelka T., Scharfenberg F., Lucius R., Tholey A., Kleinberger G. Meprin &#x3b2; cleaves TREM2 and controls its phagocytic activity on macrophages. FASEB J. 2020;34:6675&#x2013;6687.</Citation><ArticleIdList><ArticleId IdType="pubmed">32237095</ArticleId></ArticleIdList></Reference><Reference><Citation>Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007;8:57&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">17180163</ArticleId></ArticleIdList></Reference><Reference><Citation>Bricogne G., Blanc E., Brandl M., Flensburg C., Keller P., Paciorek W., Roversi P., Sharff A., Smart O.S., Vonrhein C. Phasing Ltd; 2016. BUSTER Version X.Y.Z. Cambridge, United Kingdom Glob.</Citation></Reference><Reference><Citation>Cheng Q., Danao J., Talreja S., Wen P., Yin J., Sun N., Li C.M., Chui D., Tran D., Koirala S. TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer&#x2019;s disease variant Trem2R47Hon murine myeloid cell function. J.&#xa0;Biol. Chem. 2018;293:12620&#x2013;12633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093249</ArticleId><ArticleId IdType="pubmed">29599291</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellwanger D.C., Wang S., Brioschi S., Shao Z., Green L., Case R., Yoo D., Weishuhn D., Rathanaswami P., Bradley J. Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. 2021;118 e2017742118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7826333</ArticleId><ArticleId IdType="pubmed">33446504</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P., Lohkamp B., Scott W.G., Cowtan K. Features and development of coot. Acta Crystallogr. D Biol. Crystallogr. 2010;75:861&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans P. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 2006;62:72&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369096</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairhead M., Preger C., Wigren E., Strain-Damerell C., Ossipova E., Ye M., Makola M., Burgess-Brown N.A., Persson H., von Delft F. Strategies to improve scFvs as crystallization chaperones suggested by analysis of a complex with the human PHD-bromodomain SP140. bioRxiv. 2019:767376. doi: 10.1101/767376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/767376</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassler M., Rappaport M.S., Cu&#xf1;o C.B., George J. Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer&#x2019;s disease models. J.&#xa0;Neuroinflammation. 2021;18:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7796541</ArticleId><ArticleId IdType="pubmed">33422057</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard T.D., Huang C.C., Meng E.C., Pettersen E.F., Couch G.S., Morris J.H., Ferrin T.E. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 2018;27:14&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5734306</ArticleId><ArticleId IdType="pubmed">28710774</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S.K., Younkin S. TREM2 variants in Alzheimer&#x2019;s disease. N.&#xa0;Engl. J. Med. 2013;368:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibach M., Mathews M., Linnartz-Gerlach B., Theil S., Kumar S., Feederle R., Br&#xfc;stle O., Neumann H., Walter J. A reporter cell system for the triggering receptor expressed on myeloid cells 2 reveals differential effects of disease-associated variants on receptor signaling and activation by antibodies against the stalk region. Glia. 2021;69:1126&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">33314333</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay T.R., Hirsch A.M., Broihier M.L., Miller C.M., Neilson L.E., Ransohoff R.M., Lamb B.T., Landreth G.E. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer&#x2019;s disease. J.&#xa0;Neurosci. 2017;37:637&#x2013;647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T., Tan L., Chen Q., Tan M.S., Zhou J.S., Zhu X.C., Lu H., Wang H.F., Zhang Y.D., Yu J.T. A rare coding variant in TREM2 increases risk for Alzheimer&#x2019;s disease in Han Chinese. Neurobiol. Aging. 2016;42:217.e1&#x2013;217.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">27067662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S.C., Benitez B.A., Karch C.M., Cooper B., Skorupa T., Carrell D., Norton J.B., Hsu S., Harari O., Cai Y. Coding variants in TREM2 increase risk for Alzheimer&#x2019;s disease. Hum. Mol. Genet. 2014;23:5838&#x2013;5846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4189899</ArticleId><ArticleId IdType="pubmed">24899047</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P.V., Snaedal J., Bjornsson S., Huttenlocher J., Levey A.I., Lah J.J. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N.&#xa0;Engl. J. Med. 2013;368:107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabsch W., T. B.A., K. D., A. K.P., K. D., S. M., G. R.R.B., P. E., S. F., K. W. XDS. Acta Crystallogr. D Biol. Crystallogr. 2010;66:125&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815665</ArticleId><ArticleId IdType="pubmed">20124692</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T.K., David E., Baruch K., Lara-Astaiso D., Toth B. A unique microglia type associated with restricting development of Alzheimer&#x2019;s disease. Cell. 2017;169:1276&#x2013;1290.e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober D.L., Alexander-Brett J.M., Karch C.M., Cruchaga C., Colonna M., Holtzman M.J., Brett T.J. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. eLife. 2016;5:e20391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5173322</ArticleId><ArticleId IdType="pubmed">27995897</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi H., Kiyama H. Microglial TREM2/DAP12 signaling: a double-edged sword in neural diseases. Front. Cell. Neurosci. 2018;12:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6087757</ArticleId><ArticleId IdType="pubmed">30127720</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortt A.A., Dolezal O., Power B.E., Hudson P.J. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng. 2001;18:95&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">11566601</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S., Madore C., Cialic R., Baufeld C., Calcagno N., El Fatimy R., Beckers L., O&#x2019;Loughlin E., Xu Y., Fanek Z. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566&#x2013;581.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J.C., Ibrahim-Verbaas C.A., Harold D., Naj A.C., Sims R., Bellenguez C., Jun G., DeStefano A.L., Bis J.C., Beecham G.W. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet. 2013;45:1452&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefranc M.-P., Pommi&#xe9; C., Ruiz M., Giudicelli V., Foulquier E., Truong L., Thouvenin-Contet V., Lefranc G. IMGT unique numbering for immunoglobulin and T&#xa0;cell receptor variable domains and Ig superfamily V-like domains. Dev. Comp. Immunol. 2003;27:55&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">12477501</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebschner D., Afonine P.V., Baker M.L., Bunkoczi G., Chen V.B., Croll T.I., Hintze B., Hung L.W., Jain S., McCoy A.J. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 2019;75:861&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778852</ArticleId><ArticleId IdType="pubmed">31588918</ArticleId></ArticleIdList></Reference><Reference><Citation>Long J.M., Holtzman D.M. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179:312&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent A.A., Lin K., van Lengerich B., Lianoglou S., Przybyla L., Davis S.S., Llapashtica C., Wang J., Kim D.J., Xia D. TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron. 2020;105:837&#x2013;854.e9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31902528</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J., Mandelin J., Kiialainen A., B&#xf6;hling T., Prudlo J., Hakola P., Haltia M., Konttinen Y.T., Peltonen L. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J.&#xa0;Exp. Med. 2003;198:669&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2194176</ArticleId><ArticleId IdType="pubmed">12925681</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S., Arzberger T., Brendel M., Kleinberger G., Deussing M., Focke C., Nuscher B., Xiong M., Ghasemigharagoz A., Katzmarski N. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat. Neurosci. 2019;22:191&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L., Buonsanti C., Cella M., Tassi I., Schmidt R.E., Fenoglio C., Rinker J.2nd, Naismith R.T., Panina-Bordignon P., Passini N. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain. 2008;131:3081&#x2013;3091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577803</ArticleId><ArticleId IdType="pubmed">18790823</ArticleId></ArticleIdList></Reference><Reference><Citation>Preger C., Wigren E., Ossipova E., Marks C., Lengqvist J., Hofstr&#xf6;m C., Andersson O., Jakobsson P.-J., Gr&#xe4;slund S., Persson H. Generation and validation of recombinant antibodies to study human aminoacyl-tRNA synthetases. J.&#xa0;Biol. Chem. 2020;295:13981&#x2013;13993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7549041</ArticleId><ArticleId IdType="pubmed">32817337</ArticleId></ArticleIdList></Reference><Reference><Citation>Price B.R., Sudduth T.L., Weekman E.M., Johnson S., Hawthorne D., Woolums A., Wilcock D.M. Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition. J.&#xa0;Neuroinflammation. 2020;17:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427742</ArticleId><ArticleId IdType="pubmed">32795308</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauchmann B.S., Schneider-Axmann T., Alexopoulos P., Perneczky R. CSF soluble TREM2 as a measure of immune response along the Alzheimer&#x2019;s disease continuum. Neurobiol. Aging. 2019;74:182&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331262</ArticleId><ArticleId IdType="pubmed">30458365</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe4;ll A., Walle M., Wingren C., M&#xfc;ller S., Nyman T., Vala A., Ohlin M., Borrebaeck C.A.K., Persson H. Generation and analyses of human synthetic antibody libraries and their application for protein microarrays. Protein Eng. Des. Sel. 2016;29:427&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">27590051</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K., Kleinberger G., Fukumori A., Feederle R., Lichtenthaler S.F., Steiner H., Haass C. An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol. Med. 2017;9:1356&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623859</ArticleId><ArticleId IdType="pubmed">28855300</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlepckow K., Monroe K.M., Kleinberger G., Cantuti-Castelvetri L., Parhizkar S., Xia D., Willem M., Werner G., Pettkus N., Brunner B. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol. Med. 2020;12:e11227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136959</ArticleId><ArticleId IdType="pubmed">32154671</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Holtzman D.M. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat. Rev. Immunol. 2018;18:759&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425488</ArticleId><ArticleId IdType="pubmed">30140051</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R., van der Lee S.J., Naj A.C., Bellenguez C.C., Badarinarayan N., Jakobsdottir J., Kunkle B.W., Boland A., Raybould R., Bis J.C. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer&#x2019;s disease. Nat. Genet. 2017;49:1373&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W., Hooli B., Mullin K., Jin S.C., Cella M., Ulland T.K., Wang Y., Tanzi R.E., Colonna M. Alzheimer&#x2019;s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimer&#x2019;s Dement. 2017;13:381&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299056</ArticleId><ArticleId IdType="pubmed">27520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Strain-Damerell C., Mahajan P., Gileadi O., Burgess-Brown N.A. In: Structural Genomics: General Applications. Chen Y.W., editor. Humana Press); 2014. Medium-throughput production of recombinant human proteins: ligation-independent cloning; pp. 55&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">24203324</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M., Caballero M.&#xc1;.A., Kleinberger G., Bateman R.J., Fagan A.M., Morris J.C., Levin J., Danek A., Ewers M., Haass C. Early changes in CSF sTREM2 in dominantly inherited Alzheimer&#x2019;s disease occur after amyloid deposition and neuronal injury. Sci. Transl. Med. 2016;8:34&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5385711</ArticleId><ArticleId IdType="pubmed">27974666</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudom A., Talreja S., Danao J., Bragg E., Kegel R., Min X., Marcora E., Thibault S., Bradley J., Wood S. Molecular basis for the loss-of-function effects of the Alzheimer&#x2019;s disease-associated R47H variant of the immune receptor TREM2. 2018;293:12634&#x2013;12646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093241</ArticleId><ArticleId IdType="pubmed">29794134</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton P., Sevalle J., Deery M.J., Fraser G., Zhou Y., St&#xe5;hl S., Franssen E.H., Dodd R.B., Qamar S., Gomez Perez-Nievas B. TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer&#x2019;s disease-associated H157Y variant. EMBO Mol. Med. 2017;9:e201707673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623839</ArticleId><ArticleId IdType="pubmed">28855301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland T.K., Colonna M. TREM2&#x2014;a key player in microglial biology and Alzheimer disease. Nat. Rev. Neurol. 2018;14:667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">30266932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland T.K., Song W.M., Huang S.C.-C.C., Ulrich J.D., Sergushichev A., Beatty W.L., Loboda A.A., Zhou Y., Cairns N.J., Kambal A. TREM2 maintains microglial metabolic fitness in Alzheimer&#x2019;s disease. Cell. 2017;170:649&#x2013;663.e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich J.D., Holtzman D.M. Elucidating the role of TREM2 in Alzheimer&#x2019;s disease. Neuron. 2017;94:237&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">28426958</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonrhein C., Flensburg C., Keller P., Sharff A., Smart O., Paciorek W., Womack T., Bricogne G. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D Biol. Crystallogr. 2011;67:293&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3069744</ArticleId><ArticleId IdType="pubmed">21460447</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonrhein C., Tickle I.J., Flensburg C., Keller P., Paciorek W., Sharff A., Bricogne G. Advances in automated data analysis and processing within autoPROC, combined with improved characterisation, mitigation and visualisation of the anisotropy of diffraction limits using STARANISO. Acta Crystallogr. A. 2018;74:a360.</Citation></Reference><Reference><Citation>Wang S., Mustafa M., Yuede C.M., Salazar S.V., Kong P., Long H., Ward M., Siddiqui O., Paul R., Gilfillan S. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer&#x2019;s disease model. J.&#xa0;Exp. Med. 2020;217:e20200785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478730</ArticleId><ArticleId IdType="pubmed">32579671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Cella M., Mallinson K., Ulrich J.D., Young K.L., Robinette M.L., Gilfillan S., Krishnan G.M., Sudhakar S., Zinselmeyer B.H. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell. 2015;160:1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Winter G. Xia2: an expert system for macromolecular crystallography data reduction. J.&#xa0;Appl. Crystallogr. 2010;43:186&#x2013;190.</Citation></Reference><Reference><Citation>Winter G., Waterman D.G., Parkhurst J.M., Brewster A.S., Gildea R.J., Gerstel M., Fuentes-Montero L., Vollmar M., Michels-Clark T., Young I.D. DIALS: implementation and evaluation of a new integration package. Acta Crystallogr. D Struct. Biol. 2018;74:85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5947772</ArticleId><ArticleId IdType="pubmed">29533234</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunderlich P., Glebov K., Kemmerling N., Tien N.T., Neumann H., Walter J. Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and &#x3b3;-secretase-dependent intramembranous cleavage. J.&#xa0;Biol. Chem. 2013;288:33027&#x2013;33036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829152</ArticleId><ArticleId IdType="pubmed">24078628</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh F.L., Wang Y., Tom I., Gonzalez L.C., Sheng M. TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron. 2016;91:328&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">27477018</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P., Condello C., Keene C.D., Wang Y., Bird T.D., Paul S.M., Luo W., Colonna M., Baddeley D., Grutzendler J. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;92:252&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">27710785</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Wang N., Raab R.W., McKown R.L., Irwin J.A., Kwon I., van Kuppevelt T.H., Laurie G.W. Targeting of heparanase-modified syndecan-1 by prosecretory mitogen lacritin requires conserved core GAGAL plus heparan and chondroitin sulfate as a novel hybrid binding site that enhances selectivity. J.&#xa0;Biol. Chem. 2013;288:12090&#x2013;12101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636894</ArticleId><ArticleId IdType="pubmed">23504321</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Wu X., Li X., Jiang L.L., Gui X., Liu Y., Sun Y., Zhu B., Pi&#xf1;a-Crespo J.C., Zhang M. TREM2 is a receptor for &#x3b2;-amyloid that mediates microglial function. Neuron. 2018;97:1023&#x2013;1031.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5889092</ArticleId><ArticleId IdType="pubmed">29518356</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L., Xu Y., Zhuo R., Wang T., Wang K., Huang R., Wang D., Gao Y., Zhu Y., Sheng X. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer&#x2019;s disease model. Nat. Commun. 2019;10:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6433910</ArticleId><ArticleId IdType="pubmed">30911003</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann I., Egloff P., Hutter C.A.J., Kuhn B.T., Br&#xe4;uer P., Newstead S., Dawson R.J.P., Geertsma E.R., Seeger M.A. Generation of synthetic nanobodies against delicate proteins. Nat. Protoc. 2020;15:1707&#x2013;1741.</Citation><ArticleIdList><ArticleId IdType="pubmed">32269381</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34233180</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Microglia enable mature perineuronal nets disassembly upon anesthetic ketamine exposure or 60-Hz light entrainment in the healthy brain.</ArticleTitle><Pagination><StartPage>109313</StartPage><MedlinePgn>109313</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2021.109313</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(21)00689-6</ELocationID><Abstract><AbstractText>Perineuronal nets (PNNs), components of the extracellular matrix, preferentially coat parvalbumin-positive interneurons and constrain critical-period plasticity in the adult cerebral cortex. Current strategies to remove PNN are long-lasting, invasive, and trigger neuropsychiatric symptoms. Here, we apply repeated anesthetic ketamine as a method with minimal behavioral effect. We find that this paradigm strongly reduces PNN coating in the healthy adult brain and promotes juvenile-like plasticity. Microglia are critically involved in PNN loss because they engage with parvalbumin-positive neurons in their defined cortical layer. We identify external 60-Hz light-flickering entrainment to recapitulate microglia-mediated PNN removal. Importantly, 40-Hz frequency, which is known to remove amyloid plaques, does not induce PNN loss, suggesting microglia might functionally tune to distinct brain frequencies. Thus, our 60-Hz light-entrainment strategy provides an alternative form of PNN intervention in the healthy adult brain.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Venturino</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Science and Technology (IST) Austria, Am Campus 1, 3400 Klosterneuburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>Rouven</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Science and Technology (IST) Austria, Am Campus 1, 3400 Klosterneuburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jes&#xfa;s-Cort&#xe9;s</LastName><ForeName>H&#xe9;ctor</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maes</LastName><ForeName>Margaret E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Institute of Science and Technology (IST) Austria, Am Campus 1, 3400 Klosterneuburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagy</LastName><ForeName>B&#xe1;lint</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Science and Technology (IST) Austria, Am Campus 1, 3400 Klosterneuburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reilly-And&#xfa;jar</LastName><ForeName>Francis</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Science and Technology (IST) Austria, Am Campus 1, 3400 Klosterneuburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cubero</LastName><ForeName>Ryan John A</ForeName><Initials>RJA</Initials><AffiliationInfo><Affiliation>Institute of Science and Technology (IST) Austria, Am Campus 1, 3400 Klosterneuburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoot Uiterkamp</LastName><ForeName>Florianne E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>Institute of Science and Technology (IST) Austria, Am Campus 1, 3400 Klosterneuburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bear</LastName><ForeName>Mark F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siegert</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Science and Technology (IST) Austria, Am Campus 1, 3400 Klosterneuburg, Austria. Electronic address: sandra.siegert@ist.ac.at.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>715571</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant><Grant><GrantID>R01 EY023037</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY029245</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000777">Anesthetics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010320">Parvalbumins</NameOfSubstance></Chemical><Chemical><RegistryNumber>690G0D6V8H</RegistryNumber><NameOfSubstance UI="D007649">Ketamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000777" MajorTopicYN="N">Anesthetics</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007649" MajorTopicYN="N">Ketamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008027" MajorTopicYN="Y">Light</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010320" MajorTopicYN="N">Parvalbumins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010775" MajorTopicYN="N">Photic Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">60-Hz</Keyword><Keyword MajorTopicYN="N">anesthesia</Keyword><Keyword MajorTopicYN="N">ketamine</Keyword><Keyword MajorTopicYN="N">light entrainment</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">ocular dominance plasticity</Keyword><Keyword MajorTopicYN="N">perineuronal net</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests. A.V. and S.S. disclose an international patent application (PCT/EP2020/079365).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>7</Day><Hour>20</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34233180</ArticleId><ArticleId IdType="mid">NIHMS1715352</ArticleId><ArticleId IdType="pmc">PMC8284881</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.109313</ArticleId><ArticleId IdType="pii">S2211-1247(21)00689-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahnaou A, Huysmans H, Biermans R, Manyakov NV, and Drinkenburg WHIM (2017). Ketamine: differential neurophysiological dynamics in functional networks in the rat brain. Transl. Psychiatry.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5639243</ArticleId><ArticleId IdType="pubmed">28926001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates D, M&#xe4;chler M, Bolker B, and Walker S (2015). Fitting Linear Mixed-Effects Models Using lme4 | Bates | Journal of Statistical Software. J. Stat. Softw.</Citation></Reference><Reference><Citation>Bauer J, Sminia T, Wouterlood FG, and Dijkstra CD (1994). Phagocytic activity of macrophages and microglial cells during the course of acute and chronic relapsing experimental autoimmune encephalomyelitis. J. Neurosci. Res.</Citation><ArticleIdList><ArticleId IdType="pubmed">7932870</ArticleId></ArticleIdList></Reference><Reference><Citation>Beroun A, Mitra S, Michaluk P, Pijet B, Stefaniuk M, and Kaczmarek L (2019). MMPs in learning and memory and neuropsychiatric disorders. Cell. Mol. Life Sci.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6647627</ArticleId><ArticleId IdType="pubmed">31172215</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, and Calhoun ME (2008). Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J. Neurosci. 28, 4283&#x2013;4292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown EN, Purdon PL, and Van Dort CJ (2011). General Anesthesia and Altered States of Arousal: A Systems Neuroscience Analysis. Annu. Rev. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390788</ArticleId><ArticleId IdType="pubmed">21513454</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardin JA, Carl&#xe9;n M, Meletis K, Knoblich U, Zhang F, Deisseroth K, Tsai LH, and Moore CI (2009). Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3655711</ArticleId><ArticleId IdType="pubmed">19396156</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrier N, and Kabbaj M (2013). Sex differences in the antidepressant-like effects of ketamine. Neuropharmacology.</Citation><ArticleIdList><ArticleId IdType="pubmed">23337256</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro-Zaballa S, Cavelli ML, Gonzalez J, Nardi AE, Machado S, Scorza C, and Torterolo P (2019). EEG 40 Hz coherence decreases in REM sleep and ketamine model of psychosis. Front. Psychiatry.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6345101</ArticleId><ArticleId IdType="pubmed">30705645</ArticleId></ArticleIdList></Reference><Reference><Citation>Celio MR, and Blumcke I (1994). Perineuronal nets - a specialized form of extracellular matrix in the adult nervous system. Brain Res. Rev.</Citation><ArticleIdList><ArticleId IdType="pubmed">8167657</ArticleId></ArticleIdList></Reference><Reference><Citation>Crapser JD, Spangenberg EE, Barahona RA, Arreola MA, Hohsfield LA, and Green KN (2020). Microglia facilitate loss of perineuronal nets in the Alzheimer&#x2019;s disease brain. EBioMedicine.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7399129</ArticleId><ArticleId IdType="pubmed">32745992</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagher NN, Najafi AR, Kayala KMN, Elmore MRP, White TE, Medeiros R, West BL, and Green KN (2015). Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. J. Neuroinflammation.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4522109</ArticleId><ArticleId IdType="pubmed">26232154</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, and Gan WB (2005). ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8, 752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Dityatev A, Schachner M, and Sonderegger P (2010). The dual role of the extracellular matrix in synaptic plasticity and homeostasis. Nat. Rev. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pubmed">20944663</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragulescu AA (2014). Read, write, format Excel 2007 (xlsx) files. R Guid.</Citation></Reference><Reference><Citation>Dziembowska M, Milek J, Janusz A, Rejmak E, Romanowska E, Gorkiewicz T, Tiron A, Bramham CR, and Kaczmarek L (2012). Activity-dependent local translation of matrix metalloproteinase-9. J. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621441</ArticleId><ArticleId IdType="pubmed">23077039</ArticleId></ArticleIdList></Reference><Reference><Citation>Fawcett JW, Oohashi T, and Pizzorusso T (2019). The roles of perineuronal nets and the perinodal extracellular matrix in neuronal function. Nat. Rev. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pubmed">31263252</ArticleId></ArticleIdList></Reference><Reference><Citation>Fields RD (2011). Nonsynaptic and nonvesicular ATP release from neurons and relevance to neuron-glia signaling. Semin. Cell Dev. Biol.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163842</ArticleId><ArticleId IdType="pubmed">21320624</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong M, Mitchell DE, Duffy KR, and Bear MF (2016). Rapid recovery from the effects of early monocular deprivation is enabled by temporary inactivation of the retinas. Proc. Natl. Acad. Sci.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5150384</ArticleId><ArticleId IdType="pubmed">27856748</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenkel MY, and Bear MF (2004). How monocular deprivation shifts ocular dominance in visual cortex of young mice. Neuron.</Citation><ArticleIdList><ArticleId IdType="pubmed">15603735</ArticleId></ArticleIdList></Reference><Reference><Citation>Fries P, Reynolds JH, Rorie AE, and Desimone R (2001). Modulation of oscillatory neuronal synchronization by selective visual attention. Science (80-. ).</Citation><ArticleIdList><ArticleId IdType="pubmed">11222864</ArticleId></ArticleIdList></Reference><Reference><Citation>Fries P, Nikoli&#x107; D, and Singer W (2007). The gamma cycle. Trends Neurosci.</Citation><ArticleIdList><ArticleId IdType="pubmed">17555828</ArticleId></ArticleIdList></Reference><Reference><Citation>Frischknecht R, and Gundelfinger ED (2012). The brain&#x2019;s extracellular matrix and its role in synaptic plasticity. Adv. Exp. Med. Biol.</Citation><ArticleIdList><ArticleId IdType="pubmed">22351055</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon JA, and Stryker MP (1996). Experience-dependent plasticity of binocular responses in the primary visual cortex of the mouse. J. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579137</ArticleId><ArticleId IdType="pubmed">8627365</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray CM, K&#xf6;nig P, Engel AK, and Singer W (1989). Oscillatory responses in cat visual cortex exhibit inter-columnar synchronization which reflects global stimulus properties. Nature.</Citation><ArticleIdList><ArticleId IdType="pubmed">2922061</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, and Winberg JO (2011). Regulation of matrix metalloproteinase activity in health and disease. FEBS J.</Citation><ArticleIdList><ArticleId IdType="pubmed">21087458</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;rtig W, Brauer K, and Br&#xfc;ckner G (1992). Wisteria floribunda agglutinin-labelled nets surround parvalbumin-containing neurons. Neuroreport.</Citation><ArticleIdList><ArticleId IdType="pubmed">1421090</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser MJ, Isbrandt D, and Roeper J (2017). Disturbances of novel object exploration and recognition in a chronic ketamine mouse model of schizophrenia. Behav. Brain Res.</Citation><ArticleIdList><ArticleId IdType="pubmed">28634108</ArticleId></ArticleIdList></Reference><Reference><Citation>Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, and Julius D (2006). The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pubmed">17115040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensch TK (2005). Critical period plasticity in local cortical circuits. Nat. Rev. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pubmed">16261181</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert JM, Frehel D, Vallee E, Kieffer G, Gouy D, Berger Y, Necciari J, Defreyn G, and Maffrand JP (1993). Clopidogrel, A Novel Antiplatelet and Antithrombotic Agent. Cardiovasc. Drug Rev.</Citation></Reference><Reference><Citation>Herrmann CS (2001). Human EEG responses to 1&#x2013;100 Hz flicker: Resonance phenomena in visual cortex and their potential correlation to cognitive phenomena. Exp. Brain Res.</Citation><ArticleIdList><ArticleId IdType="pubmed">11355381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohlbaum K, Bert B, Dietze S, Palme R, Fink H, and Th&#xf6;ne-Reineke C (2018). Impact of repeated anesthesia with ketamine and xylazine on the well-being of C57BL/6JRj mice. PLoS One.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6145541</ArticleId><ArticleId IdType="pubmed">30231081</ArticleId></ArticleIdList></Reference><Reference><Citation>Hothorn T, Bretz F, and Westfall P (2008). Simultaneous inference in general parametric models. Biometrical J.</Citation><ArticleIdList><ArticleId IdType="pubmed">18481363</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, et al. (2016). Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5656389</ArticleId><ArticleId IdType="pubmed">27929004</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaczmarek L (2016). Mmp-9 in control of synaptic plasticity: a subjective account. Opera Medica Physiol.</Citation></Reference><Reference><Citation>Kaplan ES, Cooke SF, Komorowski RW, Chubykin AA, Thomazeau A, Khibnik LA, Gavornik JP, and Bear MF (2016). Contrasting roles for parvalbumin-expressing inhibitory neurons in two forms of adult visual cortical plasticity. Elife.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786407</ArticleId><ArticleId IdType="pubmed">26943618</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik R, Lipachev N, Matuszko G, Kochneva A, Dvoeglazova A, Becker A, Paveliev M, and Dityatev A (2020). Fine structure analysis of perineuronal nets in the ketamine model of schizophrenia. Eur. J. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pubmed">32510674</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly EA, Russo AS, Jackson CD, Lamantia CEL, and Majewska AK (2015). Proteolytic regulation of synaptic plasticity in the mouse primary visual cortex: Analysis of matrix metalloproteinase 9 deficient mice. Front. Cell. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4585116</ArticleId><ArticleId IdType="pubmed">26441540</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettenmann H, Hanisch UK, Noda M, and Verkhratsky A (2011). Physiology of Microglia. Physiol. Rev. 91, 461&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">21527731</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettenmann H, Kirchhoff F, and Verkhratsky A (2013). Microglia: New Roles for the Synaptic Stripper. Neuron 77, 10&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">23312512</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlman SJ, Olivas ND, Tring E, Ikrar T, Xu X, and Trachtenberg JT (2013). A disinhibitory microcircuit initiates critical-period plasticity in the visual cortex. Nature.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3962838</ArticleId><ArticleId IdType="pubmed">23975100</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavender E, Hirasawa-Fujita M, and Domino EF (2020). Ketamine&#x2019;s dose related multiple mechanisms of actions: Dissociative anesthetic to rapid antidepressant. Behav. Brain Res.</Citation><ArticleIdList><ArticleId IdType="pubmed">32437885</ArticleId></ArticleIdList></Reference><Reference><Citation>Lensj&#xf8; KK, Lepper&#xf8;d ME, Dick G, Hafting T, and Fyhn M (2017). Removal of perineuronal nets unlocks juvenile plasticity through network mechanisms of decreased inhibition and increased gamma activity. J. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6596863</ArticleId><ArticleId IdType="pubmed">28039374</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, and Vlisides PE (2016). Ketamine: 50 Years of Modulating the Mind. Front. Hum. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5126726</ArticleId><ArticleId IdType="pubmed">27965560</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Given KS, Dickson EL, Owens GP, Macklin WB, and Bennett JL (2019). Concentration-dependent effects of CSF1R inhibitors on oligodendrocyte progenitor cells ex vivo and in vivo. Exp. Neurol.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6615458</ArticleId><ArticleId IdType="pubmed">31029597</ArticleId></ArticleIdList></Reference><Reference><Citation>Malla N, Berg E, Uhlin-Hansen L, and Winberg JO (2008). Interaction of pro-matrix metalloproteinase-9/proteoglycan heteromer with gelatin and collagen. J. Biol. Chem.</Citation><ArticleIdList><ArticleId IdType="pubmed">18359769</ArticleId></ArticleIdList></Reference><Reference><Citation>Matuszko G, Curreli S, Kaushik R, Becker A, and Dityatev A (2017). Extracellular matrix alterations in the ketamine model of schizophrenia. Neuroscience.</Citation><ArticleIdList><ArticleId IdType="pubmed">28323012</ArticleId></ArticleIdList></Reference><Reference><Citation>Murase S, Lantz CL, and Quinlan EM (2017). Light reintroduction after dark exposure reactivates plasticity in adults via perisynaptic activation of MMP-9. Elife.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5630258</ArticleId><ArticleId IdType="pubmed">28875930</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen PT, Dorman LC, Pan S, Vainchtein ID, Han RT, Nakao-Inoue H, Taloma SE, Barron JJ, Molofsky AB, Kheirbek MA, et al. (2020). Microglial Remodeling of the Extracellular Matrix Promotes Synapse Plasticity. Cell.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497728</ArticleId><ArticleId IdType="pubmed">32615087</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, and Helmchen F (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science (80-. ). 308, 1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L, et al. (2011). Synaptic Pruning by Microglia Is Necessary for Normal Brain Development. Science (80-. ). 333, 1456&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR, Lafaille JJ, Hempstead BL, Littman DR, and Gan WB (2013). Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155, 1596&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033691</ArticleId><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Picard N, Takesian AE, Fagiolini M, and Hensch TK (2019). NMDA 2A receptors in parvalbumin cells mediate sex-specific rapid ketamine response on cortical activity. Mol. Psychiatry.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6756203</ArticleId><ArticleId IdType="pubmed">30696941</ArticleId></ArticleIdList></Reference><Reference><Citation>Pielecka-Fortuna J, Kalogeraki E, Fortuna MG, and L&#xf6;wel S (2015). Optimal level activity of matrix metalloproteinases is critical for adult visual plasticity in the healthy and stroke-affected brain. Elife.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718812</ArticleId><ArticleId IdType="pubmed">26609811</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinault D (2008). N-Methyl d-Aspartate Receptor Antagonists Ketamine and MK-801 Induce Wake-Related Aberrant &#x3b3; Oscillations in the Rat Neocortex. Biol. Psychiatry.</Citation><ArticleIdList><ArticleId IdType="pubmed">18022604</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzorusso T, Medini P, Berardi N, Chierzi S, Fawcett JW, and Maffei L (2002). Reactivation of ocular dominance plasticity in the adult visual cortex. Science (80-. ).</Citation><ArticleIdList><ArticleId IdType="pubmed">12424383</ArticleId></ArticleIdList></Reference><Reference><Citation>Rager G (1998). The response of cat visual cortex to flicker stimuli of variable frequency. Eur. J. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pubmed">9751156</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhard SM, Razak K, and Ethell IM (2015). A delicate balance: Role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders. Front. Cell. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4518323</ArticleId><ArticleId IdType="pubmed">26283917</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato M, and Stryker MP (2008). Distinctive features of adult ocular dominance plasticity. J. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851628</ArticleId><ArticleId IdType="pubmed">18842887</ArticleId></ArticleIdList></Reference><Reference><Citation>Savi P, Labouret C, Delesque N, Guette F, J. ,L, and Herbert J (2001). P2Y12, a new platelet ADP receptor, target of clopidogrel. Biochem. Biophys. Res. Commun. 283, 379&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">11327712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawtell NB, Frenkel MY, Philpot BD, Nakazawa K, Tonegawa S, and Bear MF (2003). NMDA receptor-dependent ocular dominance plasticity in adult visual cortex. Neuron.</Citation><ArticleIdList><ArticleId IdType="pubmed">12818182</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, and Stevens B (2012). Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner. Neuron 74, 691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, Inbar BP, Corcoran CM, Lieberman JA, Moore H, et al. (2013). Imaging Patients with Psychosis and a Mouse Model Establishes a Spreading Pattern of Hippocampal Dysfunction and Implicates Glutamate as a Driver. Neuron.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3966570</ArticleId><ArticleId IdType="pubmed">23583108</ArticleId></ArticleIdList></Reference><Reference><Citation>Sipe GO, Lowery RL, Tremblay M, Kelly EA, Lamantia CE, and Majewska AK (2016). Microglial P2Y12 is necessary for synaptic plasticity in mouse visual cortex. Nat. Commun.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4786684</ArticleId><ArticleId IdType="pubmed">26948129</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohal VS, Zhang F, Yizhar O, and Deisseroth K (2009). Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969859</ArticleId><ArticleId IdType="pubmed">19396159</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg E, Severson PL, Hohsfield LA, Crapser J, Zhang J, Burton EA, Zhang Y, Spevak W, Lin J, Phan NY, et al. (2019). Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer&#x2019;s disease model. Nat. Commun.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6704256</ArticleId><ArticleId IdType="pubmed">31434879</ArticleId></ArticleIdList></Reference><Reference><Citation>Spolidoro M, Putignano E, Munaf C, Maffei L, and Pizzorusso T (2012). Inhibition of matrix metalloproteinases prevents the potentiation of nondeprived-eye responses after monocular deprivation in juvenile rats. Cereb. Cortex.</Citation><ArticleIdList><ArticleId IdType="pubmed">21685398</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewari BP, Chaunsali L, Campbell SL, Patel DC, Goode AE, and Sontheimer H (2018). Perineuronal nets decrease membrane capacitance of peritumoral fast spiking interneurons in a model of epilepsy. Nat. Commun.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6226462</ArticleId><ArticleId IdType="pubmed">30413686</ArticleId></ArticleIdList></Reference><Reference><Citation>Thelen C, Sens J, Mauch J, Pandit R, and Pitychoutis PM (2016). Repeated ketamine treatment induces sex-specific behavioral and neurochemical effects in mice. Behav. Brain Res.</Citation><ArticleIdList><ArticleId IdType="pubmed">27343934</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay M&#x11a;, Lowery RL, and Majewska AK (2010). Microglial interactions with synapses are modulated by visual experience. PLoS Biol.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2970556</ArticleId><ArticleId IdType="pubmed">21072242</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukamoto A, Serizawa K, Sato R, Yamazaki J, and Inomata T (2015). Vital signs monitoring during injectable andn inhalant anesthesia in mice. Exp. Anim.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329516</ArticleId><ArticleId IdType="pubmed">25312399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueno H, Suemitsu S, Murakami S, Kitamura N, Wani K, Okamoto M, Matsumoto Y, and Ishihara T (2017a). Region-specific impairments in parvalbumin interneurons in social isolation-reared mice. Neuroscience.</Citation><ArticleIdList><ArticleId IdType="pubmed">28723388</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueno H, Suemitsu S, Okamoto M, Matsumoto Y, and Ishihara T (2017b). Sensory experience-dependent formation of perineuronal nets and expression of Cat-315 immunoreactive components in the mouse somatosensory cortex. Neuroscience.</Citation><ArticleIdList><ArticleId IdType="pubmed">28495333</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueno H, Suemitsu S, Murakami S, Kitamura N, Wani K, Matsumoto Y, Aoki S, Okamoto M, and Ishihara T (2018). Hyaluronic acid is present on specific perineuronal nets in the mouse cerebral cortex. Brain Res.</Citation><ArticleIdList><ArticleId IdType="pubmed">30099038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueno H, Suemitsu S, Murakami S, Kitamura N, Wani K, Matsumoto Y, Okamoto M, and Ishihara T (2019). Layer-specific expression of extracellular matrix molecules in the mouse somatosensory and piriform cortices. IBRO Reports.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6293036</ArticleId><ArticleId IdType="pubmed">30582064</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vivo L, Landi S, Panniello M, Baroncelli L, Chierzi S, Mariotti L, Spolidoro M, Pizzorusso T, Maffei L, and Ratto GM (2013). Extracellular matrix inhibits structural and functional plasticity of dendritic spines in the adult visual cortex. Nat. Commun.</Citation><ArticleIdList><ArticleId IdType="pubmed">23403561</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen TH, Binder DK, Ethell IM, and Razak KA (2018). The Perineuronal &#x2018;Safety&#x2019; Net? Perineuronal Net Abnormalities in Neurological Disorders. Front. Mol. Neurosci.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6085424</ArticleId><ArticleId IdType="pubmed">30123106</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham H (2016). ggplot2 Elegant Graphics for Data Analysis (Use R!). Springer.</Citation></Reference><Reference><Citation>Winberg JO, Berg E, Kolset SO, and Uhlin-Hansen L (2003). Calcium-induced activation and truncation of promatrix metalloproteinase-9 linked to the core protein of chondroitin sulfate proteoglycans. Eur. J. Biochem.</Citation><ArticleIdList><ArticleId IdType="pubmed">14511382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf SA, Boddeke HWGM, and Kettenmann H (2017). Microglia in Physiology and Disease. Annu. Rev. Physiol. 79, 619&#x2013;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">27959620</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Q, and Miao Q. long (2013). Experience-dependent development of perineuronal nets and chondroitin sulfate proteoglycan receptors in mouse visual cortex. Matrix Biol.</Citation><ArticleIdList><ArticleId IdType="pubmed">23597636</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Lauver DA, Wang H, Sun D, Hollenberg PF, Chen YE, Osawa Y, and Eitzman DT (2016). Significant improvement of antithrombotic responses to clopidogrel by use of a novel conjugate as revealed in an arterial model of thrombosiss. J. Pharmacol. Exp. Ther.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5034710</ArticleId><ArticleId IdType="pubmed">27511819</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Fujita Y, and Hashimoto K (2018). Lack of metabolism in (R)-ketamine&#x2019;s antidepressant actions in a chronic social defeat stress model. Sci. Rep.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5838158</ArticleId><ArticleId IdType="pubmed">29507385</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34233165</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>184</Volume><Issue>15</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>GABA-receptive microglia selectively sculpt developing inhibitory circuits.</ArticleTitle><Pagination><StartPage>4048</StartPage><EndPage>4063.e32</EndPage><MedlinePgn>4048-4063.e32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2021.06.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(21)00753-4</ELocationID><Abstract><AbstractText>Microglia, the resident immune cells of the brain, have emerged as crucial regulators of synaptic refinement and brain wiring. However, whether the remodeling of distinct synapse types during development is mediated by specialized microglia is unknown. Here, we show that GABA-receptive microglia selectively interact with inhibitory cortical synapses during a critical window of mouse postnatal development. GABA initiates a transcriptional synapse remodeling program within these specialized microglia, which in turn sculpt inhibitory connectivity without impacting excitatory synapses. Ablation of GABA<sub>B</sub> receptors within microglia impairs this process and leads to behavioral abnormalities. These findings demonstrate that brain wiring relies on the selective communication between matched neuronal and glial cell types.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Favuzzi</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Shuhan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saldi</LastName><ForeName>Giuseppe A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Biology, New York University, New York, NY 10003, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binan</LastName><ForeName>Lo&#xef;c</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Leena A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Otero</LastName><ForeName>Marian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Yuqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeine</LastName><ForeName>Ayman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sefah</LastName><ForeName>Adwoa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>New York University Abu Dhabi, Abu Dhabi, UAE.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khlestova</LastName><ForeName>Elizaveta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farhi</LastName><ForeName>Samouil L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonneau</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biology, New York University, New York, NY 10003, USA; Center for Computational Biology, Flatiron Institute, New York, NY 10010, USA; Center for Data Science, New York University, New York, NY 10011, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Datta</LastName><ForeName>Sandeep Robert</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevens</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Boston Children's Hospital, F.M. Kirby Neurobiology Center, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fishell</LastName><ForeName>Gord</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address: gordon_fishell@hms.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 NS074972</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS072030</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH071679</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 MH121289</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UG3 MH120096</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 MH071679</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS081297</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010320">Parvalbumins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018080">Receptors, GABA-B</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2021 Sep;22(9):517. doi: 10.1038/s41583-021-00504-1.</RefSource><PMID Version="1">34312535</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Cell. 2021 Oct 28;184(22):5686. doi: 10.1016/j.cell.2021.10.009.</RefSource><PMID Version="1">34715023</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009433" MajorTopicYN="N">Neural Inhibition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010320" MajorTopicYN="N">Parvalbumins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018080" MajorTopicYN="N">Receptors, GABA-B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cerebral cortex</Keyword><Keyword MajorTopicYN="N">development</Keyword><Keyword MajorTopicYN="N">glia-neuron interactions</Keyword><Keyword MajorTopicYN="N">inhibitory synapses</Keyword><Keyword MajorTopicYN="N">interneurons</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neurodevelopmental disorders</Keyword></KeywordList><CoiStatement>Declaration of interests B.S. serves on the SAB and is a minor shareholder of Annexon. G.F. is a founder of Regel. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>7</Day><Hour>20</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34233165</ArticleId><ArticleId IdType="mid">NIHMS1716062</ArticleId><ArticleId IdType="pmc">PMC9122259</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.06.018</ArticleId><ArticleId IdType="pii">S0092-8674(21)00753-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (APA Publishing; ).</Citation></Reference><Reference><Citation>Amezquita RA, Lun ATL, Becht E, Carey VJ, Carpp LN, Geistlinger L, Marini F, Rue-Albrecht K, Risso D, Soneson C, et al. (2020). Orchestrating single-cell analysis with Bioconductor. Nat. Methods 17, 137&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7358058</ArticleId><ArticleId IdType="pubmed">31792435</ArticleId></ArticleIdList></Reference><Reference><Citation>Amir AD, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, Shenfeld DK, Krishnaswamy S, Nolan GP, and Pe&#x2019;er D. (2013). viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat. Biotechnol 31, 545&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076922</ArticleId><ArticleId IdType="pubmed">23685480</ArticleId></ArticleIdList></Reference><Reference><Citation>Badimon A, Strasburger HJ, Ayata P, Chen X, Nair A, Ikegami A, Hwang P, Chan AT, Graves SM, Uweru JO, et al. (2020). Negativefeedback control of neuronal activity by microglia. Nature 586, 417&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577179</ArticleId><ArticleId IdType="pubmed">32999463</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlen CJ, Friedman BA, Dejanovic B, and Sheng M. (2019). Microglia in Brain Development, Homeostasis, and Neurodegeneration. Annu. Rev. Genet 53, 263&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">31518519</ArticleId></ArticleIdList></Reference><Reference><Citation>Botto M, Dell&#x2019;Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, and Walport MJ (1998). HomozygousC1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet 19, 56&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">9590289</ArticleId></ArticleIdList></Reference><Reference><Citation>Braat S, and Kooy RF (2015).TheGABAA ReceptorasaTherapeuticTarget for Neurodevelopmental Disorders. Neuron 86, 1119&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">26050032</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J, Spielmann M, Qiu X, Huang X, Ibrahim DM, Hill AJ, Zhang F, Mundlos S, Christiansen L, Steemers FJ, et al. (2019). The single-cell transcriptional landscape of mammalian organogenesis. Nature 566, 496&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6434952</ArticleId><ArticleId IdType="pubmed">30787437</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellot G, and Cherubini E. (2013). Functional role ofambientGABA in refining neuronal circuits early in postnatal development. Front. Neural Circuits 7,136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3741556</ArticleId><ArticleId IdType="pubmed">23964205</ArticleId></ArticleIdList></Reference><Reference><Citation>Charrin S, Jouannet S, Boucheix C, and Rubinstein E. (2014). Tetraspanins at a glance. J. Cell Sci 127, 3641&#x2013;3648.</Citation><ArticleIdList><ArticleId IdType="pubmed">25128561</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheadle L, Rivera SA, Phelps JS, Ennis KA, Stevens B, Burkly LC, Lee WA, and Greenberg ME (2020). Sensory Experience Engages Microglia to Shape Neural Connectivity through a Non-Phagocytic Mechanism. Neuron 108, 451&#x2013;468.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7666095</ArticleId><ArticleId IdType="pubmed">32931754</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Jalabi W, Hu W, Park H-J, Gale JT, Kidd GJ, Bernatowicz R, Gossman ZC, Chen JT, Dutta R, and Trapp BD (2014). Microglial displacement of inhibitory synapses provides neuroprotection in the adult brain. Nat. Commun 5, 4486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4109015</ArticleId><ArticleId IdType="pubmed">25047355</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JA, Pe&#xf1;agarikano O, Belgard TG, Swarup V, and Geschwind DH (2015a). The emerging picture of autism spectrum disorder: genetics and pathology. Annu. Rev. Pathol 10, 111&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">25621659</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KH, Boettiger AN, Moffitt JR, Wang S, and Zhuang X. (2015b). RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. Science 348, aaa6090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4662681</ArticleId><ArticleId IdType="pubmed">25858977</ArticleId></ArticleIdList></Reference><Reference><Citation>Crapser JD., Ochaba J, Soni N, Reidling JC, Thompson L,M, and Green KN (2020). Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington&#x2019;s disease. Brain 143, 266&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6935750</ArticleId><ArticleId IdType="pubmed">31848580</ArticleId></ArticleIdList></Reference><Reference><Citation>Csardi G, and Nepusz T. (2006). The igraph software package for complex network research. InterJournal Complex Syst. 1695, 1&#x2013;9.</Citation></Reference><Reference><Citation>Cser&#xe9;p C, P&#xf3;sfai B, L&#xe9;n&#xe1;rt N, Fekete R, L&#xe1;szl&#xf3; ZI, Lele Z, Orsolits B, Moln&#xe1;r G, Heindl S, Schwarcz AD, et al. (2020). Microglia monitorand protect neuronal function through specialized somatic purinergic junctions. Science 367, 528&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">31831638</ArticleId></ArticleIdList></Reference><Reference><Citation>Cubillo A, Halari R, Smith A, Taylor E, and Rubia K. (2012). A review of fronto-striatal and fronto-cortical brain abnormalities in children and adults with Attention Deficit Hyperactivity Disorder (ADHD) and new evidence for dysfunction in adults with ADHD during motivation and attention. Cortex 48, 194&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">21575934</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, and Amit I. (2018). Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. Cell 173, 1073&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">29775591</ArticleId></ArticleIdList></Reference><Reference><Citation>Doolen S, Cook J, Riedl M, Kitto K, Kohsaka S, Honda CN, Fairbanks CA, Taylor BK, and Vulchanova L. (2017). Complement 3a receptor in dorsal horn microglia mediates pronociceptive neuropeptide signaling. Glia 65, 1976&#x2013;1989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5747931</ArticleId><ArticleId IdType="pubmed">28850719</ArticleId></ArticleIdList></Reference><Reference><Citation>Edden RAE, Crocetti D, Zhu H, Gilbert DL, and Mostofsky SH (2012). Reduced GABA concentration in attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 69, 750&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3970207</ArticleId><ArticleId IdType="pubmed">22752239</ArticleId></ArticleIdList></Reference><Reference><Citation>Emanuel G, and Babcock H. (2020). ZhuangLab/MERlin: MERlin v0.1.6 (Zenodo; ).</Citation></Reference><Reference><Citation>Favuzzi E, and Rico B. (2018). Molecular diversity underlying cortical excitatory and inhibitory synapse development. Curr. Opin. Neurobiol 53, 8&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">29704699</ArticleId></ArticleIdList></Reference><Reference><Citation>Favuzzi E, Marques-Smith A, Deogracias R, Winterflood CM, S&#xe1;nchez-Aguilera A, Mantoan L, Maeso P, Fernandes C, Ewers H, and Rico B. (2017). Activity-Dependent Gating of Parvalbumin Interneuron Function by the Perineuronal Net Protein Brevican. Neuron 95, 639&#x2013;655.e10.</Citation><ArticleIdList><ArticleId IdType="pubmed">28712654</ArticleId></ArticleIdList></Reference><Reference><Citation>Favuzzi E, Deogracias R, Marques-Smith A, Maeso P, Jezequel J, Exposito-Alonso D, Balia M, Kroon T, Hinojosa AJ, F Maraver E, and Rico B. (2019). Distinct molecular programs regulate synapse specificity in cortical inhibitory circuits. Science 363, 413&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">30679375</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipello F, Morini R, Corradini I, Zerbi V, Canzi A, Michalski B, Erreni M, Markicevic M, Starvaggi-Cucuzza C, Otero K, et al. (2018). The Microglial Innate Immune Receptor TREM2 Is Required for Synapse Elimination and Normal Brain Connectivity. Immunity 48, 979&#x2013;991.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29752066</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontainhas AM, Wang M, Liang KJ, Chen S, Mettu P, Damani M, Fariss RN, Li W, and Wong WT (2011). Microglial morphology and dynamic behavior is regulated by ionotropic glutamatergic and GABAergic neurotransmission. PLoS ONE 6, e15973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026789</ArticleId><ArticleId IdType="pubmed">21283568</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiarsa J-L, and Porcher C. (2013). Emerging neurotrophic role of GABAB receptors in neuronal circuit development. Front. Cell. Neurosci 7, 206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824957</ArticleId><ArticleId IdType="pubmed">24282395</ArticleId></ArticleIdList></Reference><Reference><Citation>Gehman LT, Stoilov P, Maguire J, Damianov A, Lin C-H, Shiue L, Ares M Jr., Mody I, and Black DL (2011). The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain. Nat. Genet 43,706&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125461</ArticleId><ArticleId IdType="pubmed">21623373</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert DL, Isaacs KM, Augusta M, Macneil LK, and Mostofsky SH (2011). Motor cortex inhibition: a marker of ADHD behavior and motor development in children. Neurology 76, 615&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053341</ArticleId><ArticleId IdType="pubmed">21321335</ArticleId></ArticleIdList></Reference><Reference><Citation>Haller C, Casanova E, Muller M, Vacher C-M, Vigot R, Doll T, Barbieri S, Gassmann M, and Bettler B. (2004). Floxed allele for conditional inactivation of the GABAB(1) gene. Genesis 40, 125&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">15493018</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond TR, Dufort C, Dissing-Olesen L, Giera S, Young A, Wysoker A, Walker AJ, Gergits F, Segel M, Nemesh J, et al. (2019). Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. Immunity 50,253&#x2013;271.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6655561</ArticleId><ArticleId IdType="pubmed">30471926</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones KA, Borowsky B,Tamm JA, Craig DA, Durkin MM, Dai M, Yao W-J, Johnson M, Gunwaldsen C, Huang L-Y, et al. (1998). GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 396, 674&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">9872315</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser T, and Feng G. (2019). Tmem119-EGFP and Tmem119-CreERT2 Transgenic Mice for Labeling and Manipulating Microglia. eNeuro 6, ENEURO.0448&#x2013;18.2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6712208</ArticleId><ArticleId IdType="pubmed">31371457</ArticleId></ArticleIdList></Reference><Reference><Citation>Katayama H, Yamamoto A, Mizushima N, Yoshimori T, and Miyawaki A. (2008). GFP-like proteins stably accumulate in lysosomes. Cell Struct. Funct 33, 1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">18256512</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. (2017).A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 769, 1276&#x2013;1290.e17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O&#x2019;Loughlin E, Xu Y, Fanek Z, et al. (2017). The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566&#x2013;581.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn SA, van Landeghem FKH, Zacharias R, F&#xe4;rber K, Rappert A, Pavlovic S, Hoffmann A, Nolte C, and Kettenmann H. (2004). Microglia express GABA(B) receptors to modulate interleukin release. Mol. Cell. Neurosci 25, 312&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">15019947</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Cheng Z, Zhou L, Darmanis S, Neff NF, Okamoto J, Gulati G, Bennett ML, Sun LO, Clarke LE, et al. (2019). Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA Sequencing. Neuron 707, 207&#x2013;223.e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336504</ArticleId><ArticleId IdType="pubmed">30606613</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YU, Ying Y, Li Y, Eyo UB, Chen T, Zheng J, Umpierre AD, Zhu J, Bosco DB, Dong H, and Wu LJ (2019). Neuronal network activity controls microglial process surveillance in awake mice via norepinephrine signaling. Nat. Neurosci 22, 1771&#x2013;1781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858573</ArticleId><ArticleId IdType="pubmed">31636449</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y-J, Spangenberg E, Tang B, Holmes TC, Green KN, and Xu X. (2021). Microglia elimination increases neural circuit connectivity and activity in adult mouse cortex. J. Neurosci 47, 1274&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7888230</ArticleId><ArticleId IdType="pubmed">33380470</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang H-Y, Shang Y, Oldham MC, Martens LH, Gao F, et al. (2016). Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Cell 765, 921&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860138</ArticleId><ArticleId IdType="pubmed">27114033</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun AT, Bach K, and Marioni JC (2016a). Pooling across cells to normalize single-cell RNA sequencing data with many zero counts. Genome Biol. 77,75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4848819</ArticleId><ArticleId IdType="pubmed">27122128</ArticleId></ArticleIdList></Reference><Reference><Citation>Lun ATL, McCarthy DJ, and Marioni JC (2016b). A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res. 5,2122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5112579</ArticleId><ArticleId IdType="pubmed">27909575</ArticleId></ArticleIdList></Reference><Reference><Citation>Madisen L, Mao T, Koch H, Zhuo JM, Berenyi A, Fujisawa S, Hsu Y-WA, Garcia AJ 3rd, Gu X, Zanella S, et al. (2012). A toolbox of Cre-dependent optogenetic transgenic mice for light-induced activation and silencing. Nat. Neurosci 75, 793&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3337962</ArticleId><ArticleId IdType="pubmed">22446880</ArticleId></ArticleIdList></Reference><Reference><Citation>Madry C, and Attwell D. (2015). Receptors, ion channels, and signaling mechanisms underlying microglial dynamics. J. Biol. Chem 290, 12443&#x2013;12450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4432265</ArticleId><ArticleId IdType="pubmed">25855789</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowitz JE, Gillis WF, Beron CC, Neufeld SQ, Robertson K, Bhagat ND, Peterson RE, Peterson E, Hyun M, Linderman SW, et al. (2018). The Striatum Organizes 3D Behavior via Moment-to-Moment Action Selection. Cell 774, 44&#x2013;58.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6026065</ArticleId><ArticleId IdType="pubmed">29779950</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Sankowski R, Staszewski O, Bottcher C, Amann L, Sagar, Scheiwe C, Nessler S, Kunz P, van Loo G, et al. (2019). Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature 566, 388&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">30760929</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcovitch-Natan O, Winter DR, Giladi A, Vargas Aguilar S, Spinrad A, Sarrazin S, Ben-Yehuda H, David E, Zelada Gonzalez F, Perrin P, et al. (2016). Microglia development follows a stepwise program to regulate brain homeostasis. Science 353, aad8670.</Citation><ArticleIdList><ArticleId IdType="pubmed">27338705</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy DJ, Campbell KR, Lun ATL, and Wills QF (2017). Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics 33, 1179&#x2013;1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5408845</ArticleId><ArticleId IdType="pubmed">28088763</ArticleId></ArticleIdList></Reference><Reference><Citation>Mederos S, and Perea G. (2019). GABAergic-astrocyte signaling: A refinement of inhibitory brain networks. Glia 67, 1842&#x2013;1851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772151</ArticleId><ArticleId IdType="pubmed">31145508</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffitt JR, Bambah-Mukku D, Eichhorn SW, Vaughn E, Shekhar K, Perez JD, Rubinstein ND, Hao J, Regev A, Dulac C, and Zhuang X. (2018). Molecular, spatial, and functional single-cell profiling of the hypothalamic preoptic region. Science 362, eaau5324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482113</ArticleId><ArticleId IdType="pubmed">30385464</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai J, Rajbhandari AK, Gangwani MR, Hachisuka A, Coppola G, Masmanidis SC, Fanselow MS, and Khakh BS (2019). Hyperactivity with Disrupted Attention by Activation of an Astrocyte Synaptogenic Cue. Cell 177, 1280&#x2013;1292.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6526045</ArticleId><ArticleId IdType="pubmed">31031006</ArticleId></ArticleIdList></Reference><Reference><Citation>Neniskyte U, and Gross CT (2017). Errant gardeners: glial-cell-dependent synaptic pruning and neurodevelopmental disorders. Nat. Rev. Neurosci 18, 658&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">28931944</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen PT, Dorman LC, Pan Vainchtein ID, Han RT, Nakao-Inoue H, Taloma SE, Barron JJ, Molofsky AB, Kheirbek MA., et al. (2020). Microglial Remodeling of the Extracellular Matrix Promotes Synapse Plasticity. Cell 182, 388&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497728</ArticleId><ArticleId IdType="pubmed">32615087</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh WC, Lutzu S, Castillo PE, and Kwon H-B (2016). De novo synaptogenesis induced by GABA in the developing mouse cortex. Science 353, 1037&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5104171</ArticleId><ArticleId IdType="pubmed">27516412</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L, et al. (2011). Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Parslow A, Cardona A, and Bryson-Richardson RJ (2014). Sample Drift Correction Following 4D Confocal Time-lapse Imaging. J. Vis. Exp (86), 51086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4166950</ArticleId><ArticleId IdType="pubmed">24747942</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto JGA, Jones DG, and Murphy KM (2013). Comparing development of synaptic proteins in rat visual, somatosensory, and frontal cortex. Front. Neural Circuits 7, 97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664769</ArticleId><ArticleId IdType="pubmed">23754984</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock JM, and Kettenmann H. (2007). Neurotransmitter receptors on microglia. Trends Neurosci. 30, 527&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">17904651</ArticleId></ArticleIdList></Reference><Reference><Citation>Pola&#x144;ski K, Young MD, Miao Z, Meyer KB, Teichmann SA, and Park J-E (2020). BBKNN: fast batch alignment of single cell transcriptomes. Bioinformatics 36, 964&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9883685</ArticleId><ArticleId IdType="pubmed">31400197</ArticleId></ArticleIdList></Reference><Reference><Citation>Racine RJ (1972). Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol 32, 281&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">4110397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff RM, and Perry VH (2009). Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol 27, 119&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">19302036</ArticleId></ArticleIdList></Reference><Reference><Citation>Satija R, Farrell JA, Gennert D, Schier AF, and Regev A. (2015). Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol 33, 495&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4430369</ArticleId><ArticleId IdType="pubmed">25867923</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A, Macosko EZ, Wysoker A, Goldman M, Krienen FM, de Rivera H, Bien E, Baum M, Bortolin L, Wang S, et al. (2018). Molecular Diversity and Specializations among the Cells of the Adult Mouse Brain. Cell 174, 1015&#x2013;1030.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447408</ArticleId><ArticleId IdType="pubmed">30096299</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, and Stevens B. (2012). Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Rasband WS, and Eliceiri KW (2012). NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinoda H, Ma Y, Nakashima R, Sakurai K, Matsuda T, and Nagai T. (2018a). Acid-Tolerant Monomeric GFP from Olindias formosa. Cell Chem. Biol 25, 330&#x2013;338.e7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29290624</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinoda H, Shannon M, and Nagai T. (2018b). Fluorescent Proteins for Investigating Biological Events in Acidic Environments. Int. J. Mol. Sci 19, 1548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6032295</ArticleId><ArticleId IdType="pubmed">29789517</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohal VS, and Rubenstein JLR (2019). Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders. Mol. Psychiatry 24, 1248&#x2013;1257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742424</ArticleId><ArticleId IdType="pubmed">31089192</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg E, Severson PL, Hohsfield LA, Crapser J, Zhang J, Burton EA, Zhang Y, Spevak W, Lin J, Phan NY, et al. (2019). Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer&#x2019;s disease model. Nat. Commun 10, 3758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6704256</ArticleId><ArticleId IdType="pubmed">31434879</ArticleId></ArticleIdList></Reference><Reference><Citation>Squarzoni P, Oller G, Hoeffel G, Pont-Lezica L, Rostaing P, Low D, Bessis A, Ginhoux F, and Garel S. (2014). Microglia modulate wiring of the embryonic forebrain. Cell Rep. 8, 1271&#x2013;1279.</Citation><ArticleIdList><ArticleId IdType="pubmed">25159150</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark C, Breitkreutz B-J, Reguly T, Boucher L, Breitkreutz A, and Tyers M. (2006). BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 34, D535&#x2013;D539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347471</ArticleId><ArticleId IdType="pubmed">16381927</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, et al. (2007). The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Stowell RD, Sipe GO, Dawes RP, Batchelor HN, Lordy KA, Whitelaw BS, Stoessel MB, Bidlack JM, Brown E, Sur M, and Majewska AK (2019). Noradrenergic signaling in the wakeful state inhibits microglial surveillance and synaptic plasticity in the mouse visual cortex. Nat. Neurosci 22, 1782&#x2013;1792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6875777</ArticleId><ArticleId IdType="pubmed">31636451</ArticleId></ArticleIdList></Reference><Reference><Citation>The UniProt Consortium (2017). UniProt: the universal protein knowledgebase. Nucleic Acids Res. 45 (D1), D158&#x2013;D169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210571</ArticleId><ArticleId IdType="pubmed">27899622</ArticleId></ArticleIdList></Reference><Reference><Citation>Thion MS, Ginhoux F, and Garel S. (2018). Microglia and early brain development: An intimate journey. Science 362, 185&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">30309946</ArticleId></ArticleIdList></Reference><Reference><Citation>Thion MS, Mosser C-A, Ferezou I, Grisel P, Baptista S, Low D, Ginhoux F, Garel S, and Audinat E. (2019). Biphasic Impact of Prenatal Inflammation and Macrophage Depletion on the Wiring of Neocortical Inhibitory Circuits. Cell Rep. 28, 1119&#x2013;1126.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6685496</ArticleId><ArticleId IdType="pubmed">31365857</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting JT, Lee BR, Chong P, Soler-Llavina G, Cobbs C, Koch C, Zeng H, and Lein E. (2018). Preparation of Acute Brain Slices Using an Optimized N-Methyl-D-glucamine Protective Recovery Method. J. Vis. Exp (132), 53825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5931343</ArticleId><ArticleId IdType="pubmed">29553547</ArticleId></ArticleIdList></Reference><Reference><Citation>Tj&#xe4;rnberg A, Mahmood O, Jackson CA, Saldi G-A, Cho K, Christiaen LA, and Bonneau RA (2020). Optimal tuning of weighted kNN- and diffusion-based methods for denoising single cell genomics data. bioRxiv. 10.1101/2020.02.28.970202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.02.28.970202</ArticleId><ArticleId IdType="pmc">PMC7817019</ArticleId><ArticleId IdType="pubmed">33411784</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hove H, Martens L, Scheyltjens I, De Vlaminck K, Pombo Antunes AR, De Prijck S, Vandamme N, De Schepper S, Van Isterdael G, Scott CL, et al. (2019). A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat. Neurosci 22, 1021&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pubmed">31061494</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogels TP, and Abbott LF (2009). Gating multiple signals through detailed balance of excitation and inhibition in spiking networks. Nat. Neurosci 12, 483&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693069</ArticleId><ArticleId IdType="pubmed">19305402</ArticleId></ArticleIdList></Reference><Reference><Citation>von Ehr A, Attaai A, Neidert N, Potru PS, Ru&#xdf; T, Z&#xf6;ller T, and Spittau B. (2020). Inhibition of Microglial TGF&#x3b2; Signaling Increases Expression of Mrc1. Front. Cell. Neurosci 14, 66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7137652</ArticleId><ArticleId IdType="pubmed">32296307</ArticleId></ArticleIdList></Reference><Reference><Citation>Vormstein-Schneider D, Lin JD, Pelkey KA, Chittajallu R, Guo B, Arias-Garcia MA, Allaway K, Sakopoulos S, Schneider G, Stevenson O, et al. (2020). Viral manipulation of functionally distinct interneurons in mice, non-human primates and humans. Nat. Neurosci 23, 1629&#x2013;1636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8015416</ArticleId><ArticleId IdType="pubmed">32807948</ArticleId></ArticleIdList></Reference><Reference><Citation>Wamsley B, Jaglin XH, Favuzzi E, Quattrocolo G, Nigro MJ, Yusuf N, Khodadadi-Jamayran A, Rudy B, and Fishell G. (2018). Rbfox1 Mediates Cell-type-Specific Splicing in Cortical Interneurons. Neuron 100, 846&#x2013;859.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6541232</ArticleId><ArticleId IdType="pubmed">30318414</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang DD, and Kriegstein AR (2009). Defining the role of GABA in cortical development. J. Physiol 587, 1873&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689328</ArticleId><ArticleId IdType="pubmed">19153158</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilton DK, Dissing-Olesen L, and Stevens B. (2019). Neuron-Glia Signaling in Synapse Elimination. Annu. Rev. Neurosci 42, 107&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">31283900</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiltschko AB, Johnson MJ, Iurilli G, Peterson RE, Katon JM, Pashkovski SL, Abraira VE, Adams RP, and Datta SR (2015). Mapping Sub-Second Structure in Mouse Behavior. Neuron 88, 1121&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4708087</ArticleId><ArticleId IdType="pubmed">26687221</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf FA, Angerer P, and Theis FJ (2018). SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802054</ArticleId><ArticleId IdType="pubmed">29409532</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Fu Y, Knott G, Lu J, Di Cristo G, and Huang ZJ (2012). GABA signaling promotes synapse elimination and axon pruning in developing cortical inhibitory interneurons. J. Neurosci 32, 331&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742883</ArticleId><ArticleId IdType="pubmed">22219294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer H, Riese S, and Regnier-Vigouroux A. (2003). Functional characterization of mannose receptor expressed by immunocompetent mouse microglia. Glia 42, 89&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">12594740</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34228117</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>APOE &#x3b5;4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome-Implications for Clinical Trials and Treatments for All.</ArticleTitle><Pagination><StartPage>913</StartPage><EndPage>915</EndPage><MedlinePgn>913-915</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.1649</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lemere</LastName><ForeName>Cynthia A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Neurol. 2021 Aug 1;78(8):937-947. doi: 10.1001/jamaneurol.2021.1893.</RefSource><PMID Version="1">34228042</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="Y">Down Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>6</Day><Hour>13</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34228117</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.1649</ArticleId><ArticleId IdType="pii">2781527</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34228042</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Apolipoprotein E &#x25b;4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome.</ArticleTitle><Pagination><StartPage>937</StartPage><EndPage>947</EndPage><MedlinePgn>937-947</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.1893</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Alzheimer disease (AD) is the leading cause of death in individuals with Down syndrome (DS). Previous studies have suggested that the APOE &#x25b;4 allele plays a role in the risk and age at onset of dementia in DS; however, data on in vivo biomarkers remain scarce.</AbstractText><AbstractText Label="OBJECTIVE">To investigate the association of the APOE &#x25b;4 allele with clinical and multimodal biomarkers of AD in adults with DS.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This dual-center cohort study recruited adults with DS in Barcelona, Spain, and in Cambridge, UK, between June 1, 2009, and February 28, 2020. Included individuals had been genotyped for APOE and had at least 1 clinical or AD biomarker measurement; 2 individuals were excluded because of the absence of trisomy 21. Participants were either APOE &#x25b;4 allele carriers or noncarriers.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Participants underwent a neurological and neuropsychological assessment. A subset of participants had biomarker measurements: A&#x3b2;1-42, A&#x3b2;1-40, phosphorylated tau 181 (pTau181) and neurofilament light chain (NfL) in cerebrospinal fluid (CSF), pTau181, and NfL in plasma; amyloid positron emission tomography (PET); fluorine 18-labeled-fluorodeoxyglucose PET; and/or magnetic resonance imaging. Age at symptom onset was compared between APOE &#x25b;4 allele carriers and noncarriers, and within-group local regression models were used to compare the association of biomarkers with age. Voxelwise analyses were performed to assess topographical differences in gray matter metabolism and volume.</AbstractText><AbstractText Label="RESULTS">Of the 464 adults with DS included in the study, 97 (20.9%) were APOE &#x25b;4 allele carriers and 367 (79.1%) were noncarriers. No differences between the 2 groups were found by age (median [interquartile range], 45.9 [36.4-50.2] years vs 43.7 [34.9-50.2] years; P&#x2009;=&#x2009;.56) or sex (51 male carriers [52.6%] vs 199 male noncarriers [54.2%]). APOE &#x25b;4 allele carriers compared with noncarriers presented with AD symptoms at a younger age (mean [SD] age, 50.7 [4.4] years vs 52.7 [5.8] years; P&#x2009;=&#x2009;.02) and showed earlier cognitive decline. Locally estimated scatterplot smoothing curves further showed between-group differences in biomarker trajectories with age as reflected by nonoverlapping CIs. Specifically, carriers showed lower levels of the CSF A&#x3b2;1-42 to A&#x3b2;1-40 ratio until age 40 years, earlier increases in amyloid PET and plasma pTau181, and earlier loss of cortical metabolism and hippocampal volume. No differences were found in NfL biomarkers or CSF total tau and pTau181. Voxelwise analyses showed lower metabolism in subcortical and parieto-occipital structures and lower medial temporal volume in APOE &#x25b;4 allele carriers.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this study, the APOE &#x25b;4 allele was associated with earlier clinical and biomarker changes of AD in DS. These results provide insights into the mechanisms by which APOE increases the risk of AD, emphasizing the importance of APOE genotype for future clinical trials in DS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bejanin</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iulita</LastName><ForeName>Maria Florencia</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilaplana</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmona-Iragui</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona Down Medical Center, Fundaci&#xf3; Catalana S&#xed;ndrome de Down, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benejam</LastName><ForeName>Bessy</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Barcelona Down Medical Center, Fundaci&#xf3; Catalana S&#xed;ndrome de Down, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Videla</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona Down Medical Center, Fundaci&#xf3; Catalana S&#xed;ndrome de Down, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barroeta</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altuna</LastName><ForeName>Miren</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pegueroles</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montal</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valldeneu</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gim&#xe9;nez</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Multidisciplinary Sleep Unit, Respiratory Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Ortiz</LastName><ForeName>Sof&#xed;a</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hospital del Mar, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz</LastName><ForeName>Laia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padilla</LastName><ForeName>Concepci&#xf3;n</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aranha</LastName><ForeName>Mateus Rozalem</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estell&#xe9;s</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ill&#xe1;n-Gala</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belbin</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camacho</LastName><ForeName>Valle</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Liam Reese</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Cambridge Intellectual and Developmental Disabilities Research Group, Department of Psychiatry, University of Cambridge, Douglas House, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Annus</LastName><ForeName>Tiina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cambridge Intellectual and Developmental Disabilities Research Group, Department of Psychiatry, University of Cambridge, Douglas House, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osorio</LastName><ForeName>Ricardo S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Healthy Brain Aging and Sleep Center, Department of Psychiatry, New York University Grossman School of Medicine, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Videla</LastName><ForeName>Sebasti&#xe1;n</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Research Support Unit, Bellvitge Biomedical Research Institute Department of Clinical Pharmacology, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Le Laboratoire de Biochimie et Prot&#xe9;omique Clinique, Universit&#xe9; Montpellier, Centre Hospitalier Universitaire Montpellier, Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Cambridge Intellectual and Developmental Disabilities Research Group, Department of Psychiatry, University of Cambridge, Douglas House, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;nldal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at University College London (UCL), London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;nldal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcolea</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarimon</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaman</LastName><ForeName>Shahid H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Cambridge Intellectual and Developmental Disabilities Research Group, Department of Psychiatry, University of Cambridge, Douglas House, Cambridge, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cambridgeshire and Peterborough National Health Service (NHS) Foundation Trust, Fulbourn Hospital, Elizabeth House, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blesa</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona Down Medical Center, Fundaci&#xf3; Catalana S&#xed;ndrome de Down, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066512</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000612345">ApoE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2021 Aug 1;78(8):913-915. doi: 10.1001/jamaneurol.2021.1649.</RefSource><PMID Version="1">34228117</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Carmona-Iragui reported receiving grant GBHI_ALZ-18-543740 from the Alzheimer's Association and Global Brain Health Institute Project and grant Project No. 1913 Cycle 2019B from the J&#xe9;r&#xf4;me Lejeune Foundation outside the submitted work. Dr Belbin reported receiving personal fees from ADx NeuroSciences outside the submitted work. Dr Annus reported being a current employee at Johnson &amp; Johnson. Dr Lehmann reported receiving personal fees for service on the scientific advisory boards of Roche Diagnostics and Fujirebio. Dr Holland reported receiving grants from the Medical Research Council UK and Alzheimer's Research UK during the conduct of the study as well as nonfinancial support from the Down Syndrome Association UK outside the submitted work. Dr Zetterberg reported receiving personal fees for service on the scientific advisory boards of Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx; receiving personal fees for giving lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen; and being the cofounder of Brain Biomarker Solutions in Gothenburg AB (part of the GU Ventures Incubator Program) outside the submitted work. Dr Blennow reported serving as a consultant at advisory boards or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Eli Lilly and Company, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers as well as being the cofounder of Brain Biomarker Solutions in Gothenburg AB (part of the GU Ventures Incubator Program) outside the submitted work. Dr Alcolea reported receiving personal fees for advisory board services and/or speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmac&#xe9;utica SL, and Esteve Pharmaceuticals SA outside the submitted work as well as holding a patent for WO2019175379 A1 markers of synaptopathy in neurodegenerative disease (licensed to ADx). Dr Zaman reported receiving nonfinancial support from the National Institute for Health Research (NIHR) Cambridge Dementia Biomedical Research Unit and personal fees for a short-term advisory role from Lundbeck outside the submitted work. Dr Fortea reported receiving personal fees for service on the advisory boards or adjudication committees of AC Immune, Novartis, Lundbeck, Roche Diagnostics, and Merck outside the submitted work; receiving conference fees from Esteve, Novo Nordisk, Roche Diagnostics, Fujirebio, and Biogen; and holding a patent for markers of synaptopathy in neurodegenerative disease (licensed EP18382175.0). No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>6</Day><Hour>13</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34228042</ArticleId><ArticleId IdType="pmc">PMC8261691</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.1893</ArticleId><ArticleId IdType="pii">2781524</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hithersay R, Startin CM, Hamburg S, et al. . Association of dementia with mortality among adults with Down syndrome older than 35 years. JAMA Neurol. 2019;76(2):152-160. doi:10.1001/jamaneurol.2018.3616</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.3616</ArticleId><ArticleId IdType="pmc">PMC6439956</ArticleId><ArticleId IdType="pubmed">30452522</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortea J, Vilaplana E, Carmona-Iragui M, et al. . Clinical and biomarker changes of Alzheimer&#x2019;s disease in adults with Down syndrome: a cross-sectional study. Lancet. 2020;395(10242):1988-1997. doi:10.1016/S0140-6736(20)30689-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30689-9</ArticleId><ArticleId IdType="pmc">PMC7322523</ArticleId><ArticleId IdType="pubmed">32593336</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261(5123):921-923. doi:10.1126/science.8346443</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, et al. . Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(5):1977-1981. doi:10.1073/pnas.90.5.1977</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.5.1977</ArticleId><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, et al. . APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122-131. doi:10.1002/ana.21843</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21843</ArticleId><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, et al. . Preclinical evidence of Alzheimer&#x2019;s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334(12):752-758. doi:10.1056/NEJM199603213341202</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199603213341202</ArticleId><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra S, Blazey TM, Holtzman DM, et al. . Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE &#x3b5;4 genotype. Brain. 2018;141(6):1828-1839. doi:10.1093/brain/awy103</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy103</ArticleId><ArticleId IdType="pmc">PMC5972633</ArticleId><ArticleId IdType="pubmed">29672664</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasher VP, Sajith SG, Rees SD, et al. . Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer&#x2019;s disease and mortality in persons with Down syndrome. Int J Geriatr Psychiatry. 2008;23(11):1134-1140. doi:10.1002/gps.2039</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.2039</ArticleId><ArticleId IdType="pmc">PMC2714805</ArticleId><ArticleId IdType="pubmed">18464295</ArticleId></ArticleIdList></Reference><Reference><Citation>Schupf N, Kapell D, Lee JH, et al. . Onset of dementia is associated with apolipoprotein E epsilon4 in Down&#x2019;s syndrome. Ann Neurol. 1996;40(5):799-801. doi:10.1002/ana.410400518</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410400518</ArticleId><ArticleId IdType="pubmed">8957023</ArticleId></ArticleIdList></Reference><Reference><Citation>Deb S, Braganza J, Norton N, et al. . APOE epsilon 4 influences the manifestation of Alzheimer&#x2019;s disease in adults with Down&#x2019;s syndrome. Br J Psychiatry. 2000;176:468-472. doi:10.1192/bjp.176.5.468</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.176.5.468</ArticleId><ArticleId IdType="pubmed">10912224</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppus AM, Evenhuis HM, Verberne GJ, et al. . The impact of apolipoprotein E on dementia in persons with Down&#x2019;s syndrome. Neurobiol Aging. 2008;29(6):828-835. doi:10.1016/j.neurobiolaging.2006.12.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2006.12.013</ArticleId><ArticleId IdType="pubmed">17250929</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, West HL, Rebeck GW, et al. . Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci U S A. 1995;92(8):3586-3590. doi:10.1073/pnas.92.8.3586</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.8.3586</ArticleId><ArticleId IdType="pmc">PMC42212</ArticleId><ArticleId IdType="pubmed">7724603</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539-547. doi:10.1212/WNL.0000000000002923</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002923</ArticleId><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="pubmed">27371494</ArticleId></ArticleIdList></Reference><Reference><Citation>Annus T, Wilson LR, Hong YT, et al. . The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement. 2016;12(5):538-545. doi:10.1016/j.jalz.2015.07.490</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.07.490</ArticleId><ArticleId IdType="pmc">PMC4867786</ArticleId><ArticleId IdType="pubmed">26362596</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteba-Castillo S, Dalmau-Bueno A, Ribas-Vidal N, Vil&#xe0;-Alsina M, Novell-Alsina R, Garc&#xed;a-Alba J. Adaptation and validation of CAMDEX-DS (Cambridge Examination for Mental Disorders of Older People with Down&#x2019;s Syndrome and others with intellectual disabilities) in Spanish population with intellectual disabilities [in Spanish]. Rev Neurol. 2013;57(8):337-346.</Citation><ArticleIdList><ArticleId IdType="pubmed">24081888</ArticleId></ArticleIdList></Reference><Reference><Citation>Benejam B, Fortea J, Molina-L&#xf3;pez R, Videla S. Patterns of performance on the modified Cued Recall Test in Spanish adults with Down syndrome with and without dementia. Am J Intellect Dev Disabil. 2015;120(6):481-489. doi:10.1352/1944-7558-120.6.481</Citation><ArticleIdList><ArticleId IdType="doi">10.1352/1944-7558-120.6.481</ArticleId><ArticleId IdType="pubmed">26505869</ArticleId></ArticleIdList></Reference><Reference><Citation>Benejam B, Videla L, Vilaplana E, et al. . Diagnosis of prodromal and Alzheimer&#x2019;s disease dementia in adults with Down syndrome using neuropsychological tests. Alzheimers Dement (Amst). 2020;12(1):e12047. doi:10.1002/dad2.12047</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12047</ArticleId><ArticleId IdType="pmc">PMC7322242</ArticleId><ArticleId IdType="pubmed">32613076</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortea J, Carmona-Iragui M, Benejam B, et al. . Plasma and CSF biomarkers for the diagnosis of Alzheimer&#x2019;s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 2018;17(10):860-869. doi:10.1016/S1474-4422(18)30285-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30285-0</ArticleId><ArticleId IdType="pubmed">30172624</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona-Iragui M, Santos T, Videla S, et al. . Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer&#x2019;s disease in subjects with Down syndrome. J Alzheimers Dis. 2017;55(4):1489-1496. doi:10.3233/JAD-160827</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160827</ArticleId><ArticleId IdType="pubmed">27858714</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Pascoal TA, Ashton NJ, et al. . Blood phosphorylated tau 181 as a biomarker for Alzheimer&#x2019;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-433. doi:10.1016/S1474-4422(20)30071-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30071-5</ArticleId><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcolea D, Clarim&#xf3;n J, Carmona-Iragui M, et al. . The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: a data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement (N Y). 2019;5:597-609. doi:10.1016/j.trci.2019.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2019.09.005</ArticleId><ArticleId IdType="pmc">PMC6804606</ArticleId><ArticleId IdType="pubmed">31650016</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578-586. doi:10.1002/ana.23650</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23650</ArticleId><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207-1218. doi:10.1016/j.neurobiolaging.2009.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.07.002</ArticleId><ArticleId IdType="pmc">PMC2891865</ArticleId><ArticleId IdType="pubmed">19660834</ArticleId></ArticleIdList></Reference><Reference><Citation>Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage. 2011;54(3):2033-2044. doi:10.1016/j.neuroimage.2010.09.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2010.09.025</ArticleId><ArticleId IdType="pmc">PMC3065962</ArticleId><ArticleId IdType="pubmed">20851191</ArticleId></ArticleIdList></Reference><Reference><Citation>Handen BL, Cohen AD, Channamalappa U, et al. . Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimers Dement. 2012;8(6):496-501. doi:10.1016/j.jalz.2011.09.229</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.09.229</ArticleId><ArticleId IdType="pmc">PMC3532743</ArticleId><ArticleId IdType="pubmed">23102120</ArticleId></ArticleIdList></Reference><Reference><Citation>Zammit MD, Laymon CM, Betthauser TJ, et al. . Amyloid accumulation in Down syndrome measured with amyloid load. Alzheimers Dement (Amst). 2020;12(1):e12020. doi:10.1002/dad2.12020</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12020</ArticleId><ArticleId IdType="pmc">PMC7233422</ArticleId><ArticleId IdType="pubmed">32435686</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Koeppe RA, Price JC, et al. . The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1-15.e1, 4. doi:10.1016/j.jalz.2014.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.07.003</ArticleId><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor P, Roe CM, Villegas A, et al. . Apolipoprotein epsilon4 modifies Alzheimer&#x2019;s disease onset in an E280A PS1 kindred. Ann Neurol. 2003;54(2):163-169. doi:10.1002/ana.10636</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10636</ArticleId><ArticleId IdType="pubmed">12891668</ArticleId></ArticleIdList></Reference><Reference><Citation>Firth NC, Startin CM, Hithersay R, et al. ; LonDownS Consortium . Aging related cognitive changes associated with Alzheimer&#x2019;s disease in Down syndrome. Ann Clin Transl Neurol. 2018;5(6):741-751. doi:10.1002/acn3.571</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.571</ArticleId><ArticleId IdType="pmc">PMC5989753</ArticleId><ArticleId IdType="pubmed">29928657</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai F, Kammann E, Rebeck GW, Anderson A, Chen Y, Nixon RA. APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome. Neurology. 1999;53(2):331-336. doi:10.1212/WNL.53.2.331</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.53.2.331</ArticleId><ArticleId IdType="pubmed">10430422</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol. 2010;67(3):308-316. doi:10.1002/ana.21953</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21953</ArticleId><ArticleId IdType="pmc">PMC2886799</ArticleId><ArticleId IdType="pubmed">20373342</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek MS, Cho H, Lee HS, Lee JH, Ryu YH, Lyoo CH. Effect of APOE &#x3b5;4 genotype on amyloid-&#x3b2; and tau accumulation in Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2020;12(1):140. doi:10.1186/s13195-020-00710-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00710-6</ArticleId><ArticleId IdType="pmc">PMC7603688</ArticleId><ArticleId IdType="pubmed">33129364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. ; Amyloid Biomarker Study Group . Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-1938. doi:10.1001/jama.2015.4668</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.4668</ArticleId><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxtoby NP, Young AL, Cash DM, et al. . Data-driven models of dominantly-inherited Alzheimer&#x2019;s disease progression. Brain. 2018;141(5):1529-1544. doi:10.1093/brain/awy050</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy050</ArticleId><ArticleId IdType="pmc">PMC5920320</ArticleId><ArticleId IdType="pubmed">29579160</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Hassenstab J, Cruchaga C, et al. ; Dominantly Inherited Alzheimer Network . BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer&#x2019;s disease. Brain. 2016;139(pt 10):2766-2777. doi:10.1093/brain/aww200</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww200</ArticleId><ArticleId IdType="pmc">PMC5815565</ArticleId><ArticleId IdType="pubmed">27521573</ArticleId></ArticleIdList></Reference><Reference><Citation>Henson RL, Doran E, Christian BT, et al. . Cerebrospinal fluid biomarkers of Alzheimer&#x2019;s disease in a cohort of adults with Down syndrome. Alzheimers Dement (Amst). 2020;12(1):e12057. doi:10.1002/dad2.12057</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12057</ArticleId><ArticleId IdType="pmc">PMC7346867</ArticleId><ArticleId IdType="pubmed">32671183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. 1996;3(1):16-32. doi:10.1006/nbdi.1996.0003</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.1996.0003</ArticleId><ArticleId IdType="pubmed">9173910</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley RF, Mormino EC, Chhatwal J, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiol Aging. 2019;78:178-185. doi:10.1016/j.neurobiolaging.2019.02.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.02.019</ArticleId><ArticleId IdType="pmc">PMC6545139</ArticleId><ArticleId IdType="pubmed">30947113</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohman TJ, Dumitrescu L, Barnes LL, et al. ; Alzheimer&#x2019;s Disease Genetics Consortium and the Alzheimer&#x2019;s Disease Neuroimaging Initiative . Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of tau. JAMA Neurol. 2018;75(8):989-998. doi:10.1001/jamaneurol.2018.0821</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0821</ArticleId><ArticleId IdType="pmc">PMC6142927</ArticleId><ArticleId IdType="pubmed">29801024</ArticleId></ArticleIdList></Reference><Reference><Citation>La Joie R, Visani AV, Lesman-Segev OH, et al. . Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET. Neurology. 2021;96(5):e650-e661. doi:10.1212/WNL.0000000000011270</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011270</ArticleId><ArticleId IdType="pmc">PMC7884991</ArticleId><ArticleId IdType="pubmed">33262228</ArticleId></ArticleIdList></Reference><Reference><Citation>Emrani S, Arain HA, DeMarshall C, Nuriel T. APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer&#x2019;s disease: a systematic review. Alzheimers Res Ther. 2020;12(1):141. doi:10.1186/s13195-020-00712-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00712-4</ArticleId><ArticleId IdType="pmc">PMC7643479</ArticleId><ArticleId IdType="pubmed">33148345</ArticleId></ArticleIdList></Reference><Reference><Citation>El Haj M, Antoine P, Amouyel P, et al. . Apolipoprotein E (APOE) &#x3b5;4 and episodic memory decline in Alzheimer&#x2019;s disease: a review. Ageing Res Rev. 2016;27:15-22. doi:10.1016/j.arr.2016.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2016.02.002</ArticleId><ArticleId IdType="pmc">PMC5114144</ArticleId><ArticleId IdType="pubmed">26876367</ArticleId></ArticleIdList></Reference><Reference><Citation>Strydom A, Coppus A, Blesa R, et al. . Alzheimer&#x2019;s disease in Down syndrome: an overlooked population for prevention trials. Alzheimers Dement (N Y). 2018;4:703-713. doi:10.1016/j.trci.2018.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2018.10.006</ArticleId><ArticleId IdType="pmc">PMC6296162</ArticleId><ArticleId IdType="pubmed">30581976</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD, McDade E, Christian B, et al. . Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer&#x2019;s disease from late-onset amyloid deposition. Alzheimers Dement. 2018;14(6):743-750. doi:10.1016/j.jalz.2018.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.01.002</ArticleId><ArticleId IdType="pmc">PMC5994364</ArticleId><ArticleId IdType="pubmed">29477284</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinohara M, Fujioka S, Murray ME, et al. . Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer&#x2019;s disease. Brain. 2014;137(pt 5):1533-1549. doi:10.1093/brain/awu046</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu046</ArticleId><ArticleId IdType="pmc">PMC3999719</ArticleId><ArticleId IdType="pubmed">24625695</ArticleId></ArticleIdList></Reference><Reference><Citation>Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer&#x2019;s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541(1):163-166. doi:10.1016/0006-8993(91)91092-F</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(91)91092-F</ArticleId><ArticleId IdType="pubmed">2029618</ArticleId></ArticleIdList></Reference><Reference><Citation>Therriault J, Benedet AL, Pascoal TA, et al. . Association of apolipoprotein E &#x3b5;4 with medial temporal tau independent of amyloid-&#x3b2;. JAMA Neurol. 2020;77(4):470-479. doi:10.1001/jamaneurol.2019.4421</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.4421</ArticleId><ArticleId IdType="pmc">PMC6990684</ArticleId><ArticleId IdType="pubmed">31860000</ArticleId></ArticleIdList></Reference><Reference><Citation>Day RJ, McCarty KL, Ockerse KE, Head E, Rohn TT. Proteolytic cleavage of apolipoprotein E in the Down syndrome brain. Aging Dis. 2016;7(3):267-277. doi:10.14336/AD.2015.1020</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2015.1020</ArticleId><ArticleId IdType="pmc">PMC4898923</ArticleId><ArticleId IdType="pubmed">27330841</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34168338</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>A large-scale nanoscopy and biochemistry analysis of postsynaptic dendritic spines.</ArticleTitle><Pagination><StartPage>1151</StartPage><EndPage>1162</EndPage><MedlinePgn>1151-1162</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-021-00874-w</ELocationID><Abstract><AbstractText>Dendritic spines, the postsynaptic compartments of excitatory neurotransmission, have different shapes classified from 'stubby' to 'mushroom-like'. Whereas mushroom spines are essential for adult brain function, stubby spines disappear during brain maturation. It is still unclear whether and how they differ in protein composition. To address this, we combined electron microscopy and quantitative biochemistry with super-resolution microscopy to annotate more than 47,000 spines for more than 100 synaptic targets. Surprisingly, mushroom and stubby spines have similar average protein copy numbers and topologies. However, an analysis of the correlation of each protein to the postsynaptic density mass, used as a marker of synaptic strength, showed substantially more significant results for the mushroom spines. Secretion and trafficking proteins correlated particularly poorly to the strength of stubby spines. This suggests that stubby spines are less likely to adequately respond to dynamic changes in synaptic transmission than mushroom spines, which possibly explains their loss during brain maturation.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Helm</LastName><ForeName>Martin S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-6217-911X</Identifier><AffiliationInfo><Affiliation>International Max-Planck Research School Molecular Biology, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>G&#xf6;ttingen Graduate Center for Neurosciences Biophysics, and Molecular Biosciences, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for Neuro- and Sensory Physiology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dankovich</LastName><ForeName>Tal M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0003-4757-9462</Identifier><AffiliationInfo><Affiliation>G&#xf6;ttingen Graduate Center for Neurosciences Biophysics, and Molecular Biosciences, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for Neuro- and Sensory Physiology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Max-Planck Research School Neuroscience, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandad</LastName><ForeName>Sunit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department for Neuro- and Sensory Physiology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rammner</LastName><ForeName>Burkhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department for Neuro- and Sensory Physiology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xe4;hne</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>G&#xf6;ttingen Graduate Center for Neurosciences Biophysics, and Molecular Biosciences, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for Neuro- and Sensory Physiology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Max-Planck Research School Neuroscience, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salimi</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department for Neuro- and Sensory Physiology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koerbs</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department for Neuro- and Sensory Physiology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leibrandt</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Data Analytics and Machine Learning Group, Department of Informatics, Technical University of Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urlaub</LastName><ForeName>Henning</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioanalytical Mass Spectrometry Group, Max-Planck Institute of Biophysical Chemistry, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schikorski</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Universidad Central del Caribe, Bayamon, Puerto Rico, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzoli</LastName><ForeName>Silvio O</ForeName><Initials>SO</Initials><Identifier Source="ORCID">0000-0002-1667-7839</Identifier><AffiliationInfo><Affiliation>Department for Neuro- and Sensory Physiology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany. srizzol@gwdg.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biostructural Imaging of Neurodegeneration, BIN, G&#xf6;ttingen, Germany. srizzol@gwdg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R15 NS095318</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057907" MajorTopicYN="N">Post-Synaptic Density</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34168338</ArticleId><ArticleId IdType="doi">10.1038/s41593-021-00874-w</ArticleId><ArticleId IdType="pii">10.1038/s41593-021-00874-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Humeau, Y. &amp; Choquet, D. The next generation of approaches to investigate the link between synaptic plasticity and learning. Nat. Neurosci. 22, 1536&#x2013;1543 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31477899</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0480-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourne, J. N. &amp; Harris, K. M. Balancing structure and function at hippocampal dendritic spines. Annu. Rev. Neurosci. 31, 47&#x2013;67 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18284372</ArticleId><ArticleId IdType="pmc">2561948</ArticleId><ArticleId IdType="doi">10.1146/annurev.neuro.31.060407.125646</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest, M. P., Parnell, E. &amp; Penzes, P. Dendritic structural plasticity and neuropsychiatric disease. Nat. Rev. Neurosci. 19, 215&#x2013;234 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29545546</ArticleId><ArticleId IdType="pmc">6442683</ArticleId><ArticleId IdType="doi">10.1038/nrn.2018.16</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry, K. P. &amp; Nedivi, E. Spine dynamics: are they all the same? Neuron 96, 43&#x2013;55 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28957675</ArticleId><ArticleId IdType="pmc">5661952</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.08.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris, K. M., Jensen, F. E. &amp; Tsao, B. Three-dimensional structure of dendritic spines and synapses in rat hippocampus (CA1) at postnatal day 15 and adult ages: implications for the maturation of synaptic physiology and long-term potentiation. J. Neurosci. 12, 2685&#x2013;2705 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1613552</ArticleId><ArticleId IdType="pmc">6575840</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.12-07-02685.1992</ArticleId></ArticleIdList></Reference><Reference><Citation>Spacek, J. &amp; Harris, K. M. Three-dimensional organization of smooth endoplasmic reticulum in hippocampal CA1 dendrites and dendritic spines of the immature and mature rat. J. Neurosci. 17, 190&#x2013;203 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">8987748</ArticleId><ArticleId IdType="pmc">6793680</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.17-01-00190.1997</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf8;nnesen, J., Katona, G., R&#xf3;zsa, B. &amp; N&#xe4;gerl, U. V. Spine neck plasticity regulates compartmentalization of synapses. Nat. Neurosci. 17, 678&#x2013;685 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24657968</ArticleId><ArticleId IdType="doi">10.1038/nn.3682</ArticleId></ArticleIdList></Reference><Reference><Citation>Araya, R. Input transformation by dendritic spines of pyramidal neurons. Front. Neuroanat. https://doi.org/10.3389/fnana.2014.00141 (2014).</Citation></Reference><Reference><Citation>Nakahata, Y. &amp; Yasuda, R. Plasticity of spine structure: local signaling, translation and cytoskeletal reorganization. Front. Synaptic Neurosci. 10, 29 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30210329</ArticleId><ArticleId IdType="pmc">6123351</ArticleId><ArticleId IdType="doi">10.3389/fnsyn.2018.00029</ArticleId></ArticleIdList></Reference><Reference><Citation>Biederer, T., Kaeser, P. S. &amp; Blanpied, T. A. Transcellular nanoalignment of synaptic function. Neuron 96, 680&#x2013;696 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29096080</ArticleId><ArticleId IdType="pmc">5777221</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2017.10.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarchi, T., Buonarati, O. R. &amp; Hell, J. W. Postsynaptic localization and regulation of AMPA receptors and Cav1.2 by &#x3b2;2 adrenergic receptor/PKA and Ca<sup>2+</sup>/CaMKII signaling. EMBO J. 37, e99771 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30249603</ArticleId><ArticleId IdType="pmc">6187224</ArticleId><ArticleId IdType="doi">10.15252/embj.201899771</ArticleId></ArticleIdList></Reference><Reference><Citation>Papa, M., Bundman, M. C., Greenberger, V. &amp; Segal, M. Morphological analysis of dendritic spine development in primary cultures of hippocampal neurons. J. Neurosci. 15, 1&#x2013;11 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7823120</ArticleId><ArticleId IdType="pmc">6578316</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.15-01-00001.1995</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaech, S. &amp; Banker, G. Culturing hippocampal neurons. Nat. Protoc. 1, 2406&#x2013;2415 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17406484</ArticleId><ArticleId IdType="doi">10.1038/nprot.2006.356</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter, K. N. et al. Glyoxal as an alternative fixative to formaldehyde in immunostaining and super&#x2010;resolution microscopy. EMBO J. https://doi.org/10.15252/embj.201695709 (2017).</Citation></Reference><Reference><Citation>Hruska, M., Henderson, N., Le Marchand, S. J., Jafri, H. &amp; Dalva, M. B. Synaptic nanomodules underlie the organization and plasticity of spine synapses. Nat. Neurosci. https://doi.org/10.1038/s41593-018-0138-9 (2018).</Citation></Reference><Reference><Citation>Ikeda, K. &amp; Bekkers, J. M. Counting the number of releasable synaptic vesicles in a presynaptic terminal. Proc. Natl Acad. Sci. USA 106, 2945&#x2013;2950 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19202060</ArticleId><ArticleId IdType="pmc">2650301</ArticleId><ArticleId IdType="doi">10.1073/pnas.0811017106</ArticleId></ArticleIdList></Reference><Reference><Citation>Schanzenb&#xe4;cher, C. T., Sambandan, S., Langer, J. D. &amp; Schuman, E. M. Nascent proteome remodeling following homeostatic scaling at hippocampal synapses. Neuron 92, 358&#x2013;371 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27764671</ArticleId><ArticleId IdType="pmc">5078608</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2016.09.058</ArticleId></ArticleIdList></Reference><Reference><Citation>Schanzenb&#xe4;cher, C. T., Langer, J. D. &amp; Schuman, E. M. Time- and polarity-dependent proteomic changes associated with homeostatic scaling at central synapses. eLife 7, e33322 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29447110</ArticleId><ArticleId IdType="pmc">5814146</ArticleId><ArticleId IdType="doi">10.7554/eLife.33322</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziv, N. E. &amp; Brenner, N. Synaptic tenacity or lack thereof: spontaneous remodeling of synapses. Trends Neurosci. 41, 89&#x2013;99 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29275902</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2017.12.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban, N. T., Willig, K. I., Hell, S. W. &amp; N&#xe4;gerl, U. V. STED nanoscopy of actin dynamics in synapses deep inside living brain slices. Biophys. J. 101, 1277&#x2013;1284 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21889466</ArticleId><ArticleId IdType="pmc">3164186</ArticleId><ArticleId IdType="doi">10.1016/j.bpj.2011.07.027</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;gerl, U. V., Willig, K. I., Hein, B., Hell, S. W. &amp; Bonhoeffer, T. Live-cell imaging of dendritic spines by STED microscopy. Proc. Natl Acad. Sci. USA 105, 18982&#x2013;18987 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19028874</ArticleId><ArticleId IdType="pmc">2585941</ArticleId><ArticleId IdType="doi">10.1073/pnas.0810028105</ArticleId></ArticleIdList></Reference><Reference><Citation>Willig, K. I. et al. Nanoscopy of filamentous actin in cortical dendrites of a living mouse. Biophys. J. 106, L01&#x2013;L03 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24411266</ArticleId><ArticleId IdType="pmc">3907229</ArticleId><ArticleId IdType="doi">10.1016/j.bpj.2013.11.1119</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegner, W. et al. In vivo mouse and live cell STED microscopy of neuronal actin plasticity using far-red emitting fluorescent proteins. Sci. Rep. 7, 11781 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28924236</ArticleId><ArticleId IdType="pmc">5603588</ArticleId><ArticleId IdType="doi">10.1038/s41598-017-11827-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegner, W., Mott, A. C., Grant, S. G. N., Steffens, H. &amp; Willig, K. I. In vivo STED microscopy visualizes PSD95 sub-structures and morphological changes over several hours in the mouse visual cortex. Sci. Rep. 8, 219 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29317733</ArticleId><ArticleId IdType="pmc">5760696</ArticleId><ArticleId IdType="doi">10.1038/s41598-017-18640-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrigiano, G. G., Leslie, K. R., Desai, N. S., Rutherford, L. C. &amp; Nelson, S. B. Activity-dependent scaling of quantal amplitude in neocortical neurons. Nature 391, 892&#x2013;896 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9495341</ArticleId><ArticleId IdType="doi">10.1038/36103</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallimore, A. R., Kim, T., Tanaka-Yamamoto, K. &amp; De Schutter, E. Switching on depression and potentiation in the cerebellum. Cell Rep. 22, 722&#x2013;733 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29346769</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2017.12.084</ArticleId></ArticleIdList></Reference><Reference><Citation>Freer, R. et al. Supersaturated proteins are enriched at synapses and underlie cell and tissue vulnerability in Alzheimer&#x2019;s disease. Heliyon https://doi.org/10.1016/j.heliyon.2019.e02589 (2019).</Citation></Reference><Reference><Citation>Wilhelm, B. G. et al. Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. Science 344, 1023&#x2013;1028 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24876496</ArticleId><ArticleId IdType="doi">10.1126/science.1252884</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhausen, T., Owen, D. &amp; Harrison, S. C. Molecular structure, function, and dynamics of clathrin-mediated membrane traffic. Cold Spring Harb. Perspect. Biol. 6, a016725 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24789820</ArticleId><ArticleId IdType="pmc">3996469</ArticleId><ArticleId IdType="doi">10.1101/cshperspect.a016725</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon, H. T. &amp; Boucrot, E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat. Rev. Mol. Cell Biol. 12, 517&#x2013;533 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21779028</ArticleId><ArticleId IdType="doi">10.1038/nrm3151</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearse, B. M. &amp; Crowther, R. A. Structure and assembly of coated vesicles. Annu. Rev. Biophys. Biophys. Chem. 16, 49&#x2013;68 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">2885011</ArticleId><ArticleId IdType="doi">10.1146/annurev.bb.16.060187.000405</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanpied, T. A., Scott, D. B. &amp; Ehlers, M. D. Dynamics and regulation of clathrin coats at specialized endocytic zones of dendrites and spines. Neuron 36, 435&#x2013;449 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12408846</ArticleId><ArticleId IdType="doi">10.1016/S0896-6273(02)00979-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteves da Silva, M. et al. Positioning of AMPA receptor-containing endosomes regulates synapse architecture. Cell Rep. 13, 933&#x2013;943 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26565907</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2015.09.062</ArticleId></ArticleIdList></Reference><Reference><Citation>Shnyrova, A. V. et al. Geometric catalysis of membrane fission driven by flexible dynamin rings. Science 339, 1433&#x2013;1436 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23520112</ArticleId><ArticleId IdType="pmc">3980720</ArticleId><ArticleId IdType="doi">10.1126/science.1233920</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, K. et al. Time-resolved imaging reveals heterogeneous landscapes of nanomolar Ca<sup>2+</sup> in neurons and astroglia. Neuron 88, 277&#x2013;288 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26494277</ArticleId><ArticleId IdType="pmc">4622934</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2015.09.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Higley, M. J. &amp; Sabatini, B. L. Calcium signaling in dendritic spines. Cold Spring Harb. Perspect. Biol. 4, a005686 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22338091</ArticleId><ArticleId IdType="pmc">3312680</ArticleId><ArticleId IdType="doi">10.1101/cshperspect.a005686</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, B. J. et al. Calreticulin, a calcium-binding molecular chaperone, is required for stress response and fertility in Caenorhabditis elegans. Mol. Biol. Cell 12, 2835&#x2013;2845 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11553721</ArticleId><ArticleId IdType="pmc">59717</ArticleId><ArticleId IdType="doi">10.1091/mbc.12.9.2835</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura, K. et al. Functional specialization of calreticulin domains. J. Cell Biol. 154, 961&#x2013;972 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11524434</ArticleId><ArticleId IdType="pmc">2196195</ArticleId><ArticleId IdType="doi">10.1083/jcb.200102073</ArticleId></ArticleIdList></Reference><Reference><Citation>Solovyova, N., Veselovsky, N., Toescu, E. C. &amp; Verkhratsky, A. Ca<sup>2+</sup> dynamics in the lumen of the endoplasmic reticulum in sensory neurons: direct visualization of Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release triggered by physiological Ca<sup>2+</sup> entry. EMBO J. 21, 622&#x2013;630 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11847110</ArticleId><ArticleId IdType="pmc">125857</ArticleId><ArticleId IdType="doi">10.1093/emboj/21.4.622</ArticleId></ArticleIdList></Reference><Reference><Citation>Biever, A., Donlin-Asp, P. G. &amp; Schuman, E. M. Local translation in neuronal processes. Curr. Opin. Neurobiol. 57, 141&#x2013;148 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30861464</ArticleId><ArticleId IdType="doi">10.1016/j.conb.2019.02.008</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rrbaum, A. R., Kochen, L., Langer, J. D. &amp; Schuman, E. M. Local and global influences on protein turnover in neurons and glia. eLife 7, e34202 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29914620</ArticleId><ArticleId IdType="pmc">6008053</ArticleId><ArticleId IdType="doi">10.7554/eLife.34202</ArticleId></ArticleIdList></Reference><Reference><Citation>Riba, A. et al. Protein synthesis rates and ribosome occupancies reveal determinants of translation elongation rates. Proc. Natl Acad. Sci. USA 116, 15023&#x2013;15032 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31292258</ArticleId><ArticleId IdType="pmc">6660795</ArticleId><ArticleId IdType="doi">10.1073/pnas.1817299116</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberghina, F. A. M., Sturani, E. &amp; Gohlke, J. R. Levels and rates of synthesis of ribosomal ribonucleic acid, transfer ribonucleic acid, and protein in Neurospora crassa in different steady states of growth. J. Biol. Chem. 250, 4381&#x2013;4388 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">124730</ArticleId><ArticleId IdType="doi">10.1016/S0021-9258(19)41313-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Forchhammer, J. &amp; Lindahl, L. Growth rate of polypeptide chains as a function of the cell growth rate in a mutant of Escherichia coli 15. J. Mol. Biol. 55, 563&#x2013;568 (1971).</Citation><ArticleIdList><ArticleId IdType="pubmed">4927947</ArticleId><ArticleId IdType="doi">10.1016/0022-2836(71)90337-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, S. et al. Disruption of dendritic translation of CaMKII&#x3b1; impairs stabilization of synaptic plasticity and memory consolidation. Neuron 36, 507&#x2013;519 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12408852</ArticleId><ArticleId IdType="doi">10.1016/S0896-6273(02)00978-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter, K. N. et al. Comparative synaptosome imaging: a semi-quantitative method to obtain copy numbers for synaptic and neuronal proteins. Sci. Rep. 8, 14838 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30287847</ArticleId><ArticleId IdType="pmc">6172260</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-33130-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, F. et al. Architecture of the mouse brain synaptome. Neuron 99, 781&#x2013;799.e10 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30078578</ArticleId><ArticleId IdType="pmc">6117470</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2018.07.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciryam, P., Tartaglia, G. G., Morimoto, R. I., Dobson, C. M. &amp; Vendruscolo, M. Widespread aggregation and neurodegenerative diseases are associated with supersaturated proteins. Cell Rep. 5, 781&#x2013;790 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24183671</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2013.09.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornasiero, E. F. et al. Precisely measured protein lifetimes in the mouse brain reveal differences across tissues and subcellular fractions. Nat. Commun. 9, 4230 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30315172</ArticleId><ArticleId IdType="pmc">6185916</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-06519-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandad, S. et al. The codon sequences predict protein lifetimes and other parameters of the protein life cycle in the mouse brain. Sci. Rep. 8, 16913 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30443017</ArticleId><ArticleId IdType="pmc">6237891</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-35277-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrigiano, G. G. The self-tuning neuron: synaptic scaling of excitatory synapses. Cell 135, 422&#x2013;435 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18984155</ArticleId><ArticleId IdType="pmc">2834419</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2008.10.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda, T. &amp; Cepko, C. L. Controlled expression of transgenes introduced by in vivo electroporation. Proc. Natl Acad. Sci. USA 104, 1027&#x2013;1032 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17209010</ArticleId><ArticleId IdType="pmc">1764220</ArticleId><ArticleId IdType="doi">10.1073/pnas.0610155104</ArticleId></ArticleIdList></Reference><Reference><Citation>Schikorski, T. &amp; Stevens, C. F. Quantitative ultrastructural analysis of hippocampal excitatory synapses. J. Neurosci. 17, 5858&#x2013;5867 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9221783</ArticleId><ArticleId IdType="pmc">6573206</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.17-15-05858.1997</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins, M. O. et al. Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. J. Neurochem. 97, 16&#x2013;23 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16635246</ArticleId><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03507.x</ArticleId></ArticleIdList></Reference><Reference><Citation>De Chaumont, F. et al. Icy: an open bioimage informatics platform for extended reproducible research. Nat. Methods 9, 690&#x2013;696 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22743774</ArticleId><ArticleId IdType="doi">10.1038/nmeth.2075</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivo-Marin, J. C. Extraction of spots in biological images using multiscale products. Pattern Recognit. 35, 1989&#x2013;1996 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0031-3203(01)00127-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart, D. M. G. in Numerical Taxonomy (ed. Cole, A. J.) 282&#x2013;311 (Academic Press, 1969).</Citation></Reference><Reference><Citation>Witkin, A. Scale-space filtering: a new approach to multi-scale description. In Proc. ICASSP &#x2019;84. IEEE International Conference on Acoustics, Speech, and Signal Processing 9 150&#x2013;153 (Institute of Electrical and Electronics Engineers, 1983).</Citation></Reference><Reference><Citation>Leung, Yee, Zhang, Jiang-She &amp; Xu, Zong-Ben Clustering by scale-space filtering. IEEE Trans. Pattern Anal. Mach. Intell. 22, 1396&#x2013;1410 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/34.895974</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibrandt, R. &amp; G&#xfc;nnemann, S. Gauss Shift: Density Attractor Clustering Faster than Mean Shift. In Proc. ECML-PKDD 2020: The European Conference on Machine Learning and Principles and Practice of Knowledge Discovery in Databases (ECML-PKDD) 14&#x2013;18 (2020).</Citation></Reference><Reference><Citation>Fukunaga, K. &amp; Hostetler, L. The estimation of the gradient of a density function, with applications in pattern recognition. IEEE Trans. Inf. Theory 21, 32&#x2013;40 (1975).</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TIT.1975.1055330</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, P. K. et al. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76&#x2013;85 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">3843705</ArticleId><ArticleId IdType="doi">10.1016/0003-2697(85)90442-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwanh&#xe4;usser, B. et al. Global quantification of mammalian gene expression control. Nature 473, 337&#x2013;342 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21593866</ArticleId><ArticleId IdType="doi">10.1038/nature10098</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahn, R., Schiebler, W., Ouimet, C. &amp; Greengard, P. A 38,000-dalton membrane protein (p38) present in synaptic vesicles. Proc. Natl Acad. Sci. USA 82, 4137&#x2013;4141 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">3923488</ArticleId><ArticleId IdType="pmc">397950</ArticleId><ArticleId IdType="doi">10.1073/pnas.82.12.4137</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohil, A. B., Robertson, B. W. &amp; Cheney, R. E. Myosin-X is a molecular motor that functions in filopodia formation. Proc. Natl Acad. Sci. USA 103, 12411&#x2013;12416 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16894163</ArticleId><ArticleId IdType="pmc">1567893</ArticleId><ArticleId IdType="doi">10.1073/pnas.0602443103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, L. S. &amp; Studzinski, G. P. Correlation between cell enlargement and nucleic acid and protein content of hela cells in unbalanced growth produced by inhibitors of DNA synthesis. J. Cell. Physiol. 69, 331&#x2013;339 (1967).</Citation><ArticleIdList><ArticleId IdType="pubmed">4230858</ArticleId><ArticleId IdType="doi">10.1002/jcp.1040690309</ArticleId></ArticleIdList></Reference><Reference><Citation>Krombach, F. et al. Cell size of alveolar macrophages: an interspecies comparison. Environ. Health Perspect. 105, 1261&#x2013;1263 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9400735</ArticleId><ArticleId IdType="pmc">1470168</ArticleId></ArticleIdList></Reference><Reference><Citation>Luby-Phelps, K. Cytoarchitecture and physical properties of cytoplasm: volume, viscosity, diffusion, intracellular surface area. Int. Rev. Cytol. 192, 189&#x2013;221 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10553280</ArticleId><ArticleId IdType="doi">10.1016/S0074-7696(08)60527-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Puck, T. T., Marcus, P. I. &amp; Cieciura, S. J. Clonal growth of mammalian cells in vitro; growth characteristics of colonies from single HeLa cells with and without a feeder layer. J. Exp. Med. 103, 273&#x2013;283 (1956).</Citation><ArticleIdList><ArticleId IdType="pubmed">13286432</ArticleId><ArticleId IdType="pmc">2136583</ArticleId><ArticleId IdType="doi">10.1084/jem.103.2.273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, L. et al. Intracellular water-specific MR of microbead-adherent cells: the HeLa cell intracellular water exchange lifetime. NMR Biomed. 21, 159&#x2013;164 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17461436</ArticleId><ArticleId IdType="pmc">2700831</ArticleId><ArticleId IdType="doi">10.1002/nbm.1173</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips, R., Kodev, J., Therio, J. &amp; Garcia, H. Physical Biology of the Cell (Garland Science, 2008).</Citation></Reference><Reference><Citation>Zou, M., Holloway, M., Carr, N. &amp; Ju, T. Topology-constrained surface reconstruction from cross-sections. ACM Trans. Graph. https://doi.org/10.1145/2766976 (2015).</Citation></Reference><Reference><Citation>Roy, A., Kucukural, A. &amp; Zhang, Y. I-TASSER: A unified platform for automated protein structure and function prediction. Nat. Protoc. https://doi.org/10.1038/nprot.2010.5 (2010).</Citation></Reference><Reference><Citation>Zhang, Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics https://doi.org/10.1186/1471-2105-9-40 (2008).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34233951</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>601</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Genome-encoded cytoplasmic double-stranded RNAs, found in <i>C9ORF72</i> ALS-FTD brain, propagate neuronal loss.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eaaz4699</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.aaz4699</ELocationID><Abstract><AbstractText>Triggers of innate immune signaling in the CNS of patients with amyotrophic lateral sclerosis and frontotemporal degeneration (ALS/FTD) remain elusive. We report the presence of cytoplasmic double-stranded RNA (cdsRNA), an established trigger of innate immunity, in ALS-FTD brains carrying <i>C9ORF72</i> intronic hexanucleotide expansions that included genomically encoded expansions of the G<sub>4</sub>C<sub>2</sub> repeat sequences. The presence of cdsRNA in human brains was coincident with cytoplasmic TAR DNA binding protein 43 (TDP-43) inclusions, a pathologic hallmark of ALS/FTD. Introducing cdsRNA into cultured human neural cells induced type I interferon (IFN-I) signaling and death that was rescued by FDA-approved JAK inhibitors. In mice, genomically encoded dsRNAs expressed exclusively in a neuronal class induced IFN-I and death in connected neurons non-cell-autonomously. Our findings establish that genomically encoded cdsRNAs trigger sterile, viral-mimetic IFN-I induction and propagated death within neural circuits and may drive neuroinflammation and neurodegeneration in patients with ALS/FTD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Steven</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2708-5791</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahin</LastName><ForeName>Asli</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4706-3071</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schrank</LastName><ForeName>Benjamin R</ForeName><Initials>BR</Initials><Identifier Source="ORCID">0000-0001-8138-4250</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Lawati</LastName><ForeName>Hawra</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5228-1025</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costantino</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-8807-2305</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benz</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fard</LastName><ForeName>Darian</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4413-1833</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albers</LastName><ForeName>Alefiya D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0003-2660-6927</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, Endicott College, Beverly, MA 01915, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Luxiang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Alexis C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0003-3522-623X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Kyle</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6246-9520</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratti</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9321-7908</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7075-1681</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-3940-9861</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talkowski</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2889-0992</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorger</LastName><ForeName>Peter K</ForeName><Initials>PK</Initials><Identifier Source="ORCID">0000-0002-3364-1838</Identifier><AffiliationInfo><Affiliation>Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><Identifier Source="ORCID">0000-0002-7959-9401</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albers</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><Identifier Source="ORCID">0000-0001-7855-3455</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02129, USA. albers.mark@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG058063</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 OD006662</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS094861</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG058063</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 GM107618</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012330">RNA, Double-Stranded</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="Y">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012330" MajorTopicYN="N">RNA, Double-Stranded</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>8</Day><Hour>5</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34233951</ArticleId><ArticleId IdType="mid">NIHMS1768798</ArticleId><ArticleId IdType="pmc">PMC8779652</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aaz4699</ArticleId><ArticleId IdType="pii">13/601/eaaz4699</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA, Gene regulation and DNA damage in the ageing human brain. Nature 429, 883&#x2013;891 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruch K, Deczkowska A, David E, Castellano JM, Miller O, Kertser A, Berkutzki T, Barnett-Itzhaki Z, Bezalel D, Wyss-Coray T, Amit I, Schwartz M, Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346, 89&#x2013;93 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869326</ArticleId><ArticleId IdType="pubmed">25147279</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu JH, Zhang H, Wagey R, Krieger C, Pelech SL, Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. Journal of Neurochemistry 85, 432&#x2013;442 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12675919</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Rourke JG, Bogdanik L, Yanez A, Lall D, Wolf AJ, Muhammad AK, Ho R, Carmona S, Vit JP, Zarrow J, Kim KJ, Bell S, Harms MB, Miller TM, Dangler CA, Underhill DM, Goodridge HS, Lutz CM, Baloh RH, C9orf72 is required for proper macrophage and microglial function in mice. Science 351, 1324&#x2013;1329 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JM, Minter MR, Newman AG, Zhang M, Adlard PA, Crack PJ, Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease. Neurobiology of aging 35, 1012&#x2013;1023 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24262201</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Yang B, Zhang D, Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model. Glia 59, 946&#x2013;958 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077460</ArticleId><ArticleId IdType="pubmed">21446050</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Baglio F, Agostini S, Cabinio M, Lagana MM, Hernis A, Margaritella N, Guerini FR, Zanzottera M, Nemni R, Clerici M, Relationship between herpes simplex virus-1-specific antibody titers and cortical brain damage in Alzheimer's disease and amnestic mild cognitive impairment. Frontiers in aging neuroscience 6, 285 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197651</ArticleId><ArticleId IdType="pubmed">25360113</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckham JD, Pastula DM, Massey A, Tyler KL, Zika Virus as an Emerging Global Pathogen: Neurological Complications of Zika Virus. JAMA neurology 73, 875&#x2013;879 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5087605</ArticleId><ArticleId IdType="pubmed">27183312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Beck J, Rohrer JD, Lashley T, Mok K, Shakespeare T, Yeatman T, Warrington EK, Schott JM, Fox NC, Rossor MN, Hardy J, Collinge J, Revesz T, Mead S, Warren JD, Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain : a journal of neurology 135, 736&#x2013;750 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286330</ArticleId><ArticleId IdType="pubmed">22366791</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Bieniek KF, Zhang YJ, Jansen-West K, Ash PE, Caulfield T, Daughrity L, Dunmore JH, Castanedes-Casey M, Chew J, Cosio DM, van Blitterswijk M, Lee WC, Rademakers R, Boylan KB, Dickson DW, Petrucelli L, Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol 126, 829&#x2013;844 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830741</ArticleId><ArticleId IdType="pubmed">24129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, Jiang J, Watt AT, Chun S, Katz M, Qiu J, Sun Y, Ling SC, Zhu Q, Polymenidou M, Drenner K, Artates JW, McAlonis-Downes M, Markmiller S, Hutt KR, Pizzo DP, Cady J, Harms MB, Baloh RH, Vandenberg SR, Yeo GW, Fu XD, Bennett CF, Cleveland DW, Ravits J, Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proceedings of the National Academy of Sciences of the United States of America 110, E4530&#x2013;4539 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung DW, Basler CF, Amarasinghe GK, Molecular mechanisms of viral inhibitors of RIG-I-like receptors. Trends Microbiol 20, 139&#x2013;146 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299846</ArticleId><ArticleId IdType="pubmed">22325030</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonin M, Oberstrass J, Lukacs N, Ewert K, Oesterschulze E, Kassing R, Nellen W, Determination of preferential binding sites for anti-dsRNA antibodies on double-stranded RNA by scanning force microscopy. RNA 6, 563&#x2013;570 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1369937</ArticleId><ArticleId IdType="pubmed">10786847</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldi TK, Ash PE, Wilson G, Gonzales P, Garrido&#x2013;Lecca A, Roberts CM, Dostal V. Gendron TF, Stein LD, Blumenthal T, Petrucelli L, Link CD, TDP&#x2013;1, the Caenorhabditis elegans ortholog of TDP&#x2013;43, limits the accumulation of double&#x2013;stranded RNA. 33, 2947&#x2013;2966 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282642</ArticleId><ArticleId IdType="pubmed">25391662</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo CB, Erlandsen H, Mouser DJ, Feinstein AG, Robinson VL, May ER, Cole JL, Structural Basis of Protein Kinase R Autophosphorylation. Biochemistry 58, 2967&#x2013;2977 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6615999</ArticleId><ArticleId IdType="pubmed">31246429</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Belzil VV, Batra R, Ross CA, Gendron TF, Pregent LJ, Murray ME, Overstreet KK, Piazza-Johnston AE, Desaro P, Bieniek KF, DeTure M, Lee WC, Biendarra SM, Davis MD, Baker MC, Perkerson RB, van Blitterswijk M, Stetler CT, Rademakers R, Link CD, Dickson DW, Boylan KB, Li H, Petrucelli L, Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat Neurosci 18, 1175&#x2013;1182 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4830686</ArticleId><ArticleId IdType="pubmed">26192745</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A, Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637064</ArticleId><ArticleId IdType="pubmed">23586463</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YH, Choi SH, D'Avanzo C, Hebisch M, Sliwinski C, Bylykbashi E, Washicosky KJ, Klee JB, Brustle O, Tanzi RE, Kim DY, A 3D human neural cell culture system for modeling Alzheimer's disease. Nature protocols 10, 985&#x2013;1006 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4499058</ArticleId><ArticleId IdType="pubmed">26068894</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y, Subramanian K, Berberich MJ, Rodriguez S, Latorre IJ, Luria CM, Everley R, Albers MW, Mitchison TJ, Sorger PK, A dynamic view of the proteomic landscape during differentiation of ReNcell VM cells, an immortalized human neural progenitor line. Sci Data 6, 190016 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380223</ArticleId><ArticleId IdType="pubmed">30778261</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohal VS, Zhang F, Yizhar O, Deisseroth K, Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459, 698&#x2013;702 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969859</ArticleId><ArticleId IdType="pubmed">19396159</ArticleId></ArticleIdList></Reference><Reference><Citation>Shykind BM, Rohani SC, O'Donnell S, Nemes A, Mendelsohn M, Sun Y, Axel R, Barnea G, Gene switching and the stability of odorant receptor gene choice. Cell 117, 801&#x2013;815 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15186780</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogos JA, Osborne J, Nemes A, Mendelsohn M, Axel R, Genetic ablation and restoration of the olfactory topographic map. Cell 103, 609&#x2013;620 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11106731</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanscom C, Talkowski M, Design of large-insert jumping libraries for structural variant detection using illumina sequencing. Current protocols in human genetics / editorial board, Jonathan L. Haines &#x2026; [et al.] 80, 7 22 21&#x2013;29 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4009510</ArticleId><ArticleId IdType="pubmed">24789519</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Schrank BR, Rodriguez S, Benz EG, Moulia TW, Rickenbacher GT, Gomez AC, Levites Y, Edwards SR, Golde TE, Hyman BT, Barnea G, Albers MW, Abeta alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo. Nat Commun 3, 1009 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529477</ArticleId><ArticleId IdType="pubmed">22910355</ArticleId></ArticleIdList></Reference><Reference><Citation>Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O, The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. The Journal of neuroscience : the official journal of the Society for Neuroscience 30, 16091&#x2013;16101 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3075577</ArticleId><ArticleId IdType="pubmed">21123556</ArticleId></ArticleIdList></Reference><Reference><Citation>Gantier MP, Williams BR, The response of mammalian cells to double-stranded RNA. Cytokine Growth Factor Rev 18, 363&#x2013;371 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2084215</ArticleId><ArticleId IdType="pubmed">17698400</ArticleId></ArticleIdList></Reference><Reference><Citation>Melton LM, Keith AB, Davis S, Oakley AE, Edwardson JA, Morris CM, Chronic glial activation, neurodegeneration, and APP immunoreactive deposits following acute administration of double-stranded RNA. Glia 44, 1&#x2013;12 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12951652</ArticleId></ArticleIdList></Reference><Reference><Citation>Nallagatla SR, Toroney R, Bevilacqua PC, Regulation of innate immunity through RNA structure and the protein kinase PKR. Current opinion in structural biology 21, 119&#x2013;127 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3075410</ArticleId><ArticleId IdType="pubmed">21145228</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B, Peisley A, Richards C, Yao H, Zeng X, Lin C, Chu F, Walz T, Hur S, Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5. Cell 152, 276&#x2013;289 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23273991</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi O, Akira S, Pattern recognition receptors and inflammation. Cell 140, 805&#x2013;820 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20303872</ArticleId></ArticleIdList></Reference><Reference><Citation>Brubaker SW, Gauthier AE, Mills EW, Ingolia NT, Kagan JC, A Bicistronic MAVS Transcript Highlights a Class of Truncated Variants in Antiviral Immunity. Cell 156, 800&#x2013;811 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959641</ArticleId><ArticleId IdType="pubmed">24529381</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanier C, Zemirli N, Portier A, Garcin D, Bidere N, Vazquez A, Arnoult D, MAVS ubiquitination by the E3 ligase TRIM25 and degradation by the proteasome is involved in type I interferon production after activation of the antiviral RIG-I-like receptors. BMC biology 10, 44 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372421</ArticleId><ArticleId IdType="pubmed">22626058</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialas AR, Presumey J, Das A, Poel C. E. v. d., Lapchak PH, Mesin L, Victora G, Tsokos GC, Mawrin C, Herbst R, Carroll MC, Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature, (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28614301</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C, Zhu F, Cho YY, Tang F, Zykova T, Ma WY, Bode AM, Dong Z, Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol Cell 23, 121&#x2013;132 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2227311</ArticleId><ArticleId IdType="pubmed">16818236</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Guo L, Gonzales PK, Gendron TF, Wu Y, Jansen-West K, O'Raw AD, Pickles SR, Prudencio M, Carlomagno Y, Gachechiladze MA, Ludwig C, Tian R, Chew J, DeTure M, Lin WL, Tong J, Daughrity LM, Yue M, Song Y, Andersen JW, Castanedes-Casey M, Kurti A, Datta A, Antognetti G, McCampbell A, Rademakers R, Oskarsson B, Dickson DW, Kampmann M, Ward ME, Fryer JD, Link CD, Shorter J, Petrucelli L, Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science 363, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524780</ArticleId><ArticleId IdType="pubmed">30765536</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C, Petrucelli L, Genetic Convergence Brings Clarity to the Enigmatic Red Line in ALS. Neuron 101, 1057&#x2013;1069 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30897357</ArticleId></ArticleIdList></Reference><Reference><Citation>Hautbergue GM, Castelli LM, Ferraiuolo L, Sanchez-Martinez A, Cooper-Knock J, Higginbottom A, Lin YH, Bauer CS, Dodd JE, Myszczynska MA, Alam SM, Garneret P, Chandran JS, Karyka E, Stopford MJ, Smith EF, Kirby J, Meyer K, Kaspar BK, Isaacs AM, El-Khamisy SF, De Vos KJ, Ning K, Azzouz M, Whitworth AJ, Shaw PJ, SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits. Nature communications 8, 16063 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5504286</ArticleId><ArticleId IdType="pubmed">28677678</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, Gupta S, Thomas MA, Hong I, Chiu SL, Huganir RL, Ostrow LW, Matunis MJ, Wang J, Sattler R, Lloyd TE, Rothstein JD, The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56&#x2013;61 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Taylor JP, Lost in Transportation: Nucleocytoplasmic Transport Defects in ALS and Other Neurodegenerative Diseases. Neuron 96, 285&#x2013;297 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5678982</ArticleId><ArticleId IdType="pubmed">29024655</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KM, Glineburg MR, Kearse MG, Flores BN, Linsalata AE, Fedak SJ, Goldstrohm AC, Barmada SJ, Todd PK, RAN translation at C9orf72-associated repeat expansions is selectively enhanced by the integrated stress response. Nat Commun 8, 2005 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5722904</ArticleId><ArticleId IdType="pubmed">29222490</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldi TK, Gonzales PK, LaRocca TJ, Link CD, Neurodegeneration, Heterochromatin, and Double-Stranded RNA. Journal of Experimental Neuroscience 13, 1179069519830697 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6376497</ArticleId><ArticleId IdType="pubmed">30792577</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam OH, Rozhkov NV, Shaw R, Kim D, Hubbard I, Fennessey S, Propp N, Consortium NA, Fagegaltier D, Harris BT, Ostrow LW, Phatnani H, Ravits J, Dubnau J, Gale Hammell M, Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia. Cell Rep 29, 1164&#x2013;1177 e1165 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6866666</ArticleId><ArticleId IdType="pubmed">31665631</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TA, Smith BRC, Tate MD, Belz GT, Barrios MH, Elgass KD, Weisman AS, Baker PJ, Preston SP, Whitehead L, Garnham A, Lundie RJ, Smyth GK, Pellegrini M, O'Keeffe M, Wicks IP, Masters SL, Hunter CP, Pang KC, SIDT2 Transports Extracellular dsRNA into the Cytoplasm for Innate Immune Recognition. Immunity 47, 498&#x2013;509 e496 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5679266</ArticleId><ArticleId IdType="pubmed">28916264</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X, Chen J, Xu H, Liu S, Jiang QX, Halfmann R, Chen ZJ, Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation. Cell 156, 1207&#x2013;1222 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4034535</ArticleId><ArticleId IdType="pubmed">24630723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ, MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 146, 448&#x2013;461 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3179916</ArticleId><ArticleId IdType="pubmed">21782231</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodato MA, Rodin RE, Bohrson CL, Coulter ME, Barton AR, Kwon M, Sherman MA, Vitzthum CM, Luquette LJ, Yandava C, Yang P, Chittenden TW, Hatem NE, Ryu SC, Woodworth MB, Park PJ, Walsh CA, Aging and neurodegeneration are associated with increased mutations in single human neurons. Science, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5831169</ArticleId><ArticleId IdType="pubmed">29217584</ArticleId></ArticleIdList></Reference><Reference><Citation>Eimer WA, Vijaya Kumar DK, Navalpur Shanmugam NK, Rodriguez AS, Mitchell T, Washicosky KJ, Gyorgy B, Breakefield XO, Tanzi RE, Moir RD, Alzheimer's Disease-Associated beta-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection. Neuron 99, 56&#x2013;63 e53 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6075814</ArticleId><ArticleId IdType="pubmed">30001512</ArticleId></ArticleIdList></Reference><Reference><Citation>Readhead B, Haure-Mirande J-V, Funk CC, Richards MA, Shannon P, Haroutunian V, Sano M, Liang WS, Beckmann ND, Price ND, Reiman EM, Schadt EE, Ehrlich ME, Gandy S, Dudley JT, Multiscale Analysis of Independent Alzheimer&#x2019;s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6551233</ArticleId><ArticleId IdType="pubmed">29937276</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H, Calis JJA, Wu X, Sun T, Yu Y, Sarbanes SL, Dao Thi VL, Shilvock AR, Hoffmann HH, Rosenberg BR, Rice CM, Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown. Cell, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5831367</ArticleId><ArticleId IdType="pubmed">29395325</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Suzuki N, Wang JY, Moccia R, Mordes DA, Stewart MH, Suzuki-Uematsu S, Ghosh S, Singh A, Merkle FT, Koszka K, Li QZ, Zon L, Rossi DJ, Trowbridge JJ, Notarangelo LD, Eggan K, Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med 8, 347ra393 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, Jiang J, Gendron TF, McAlonis-Downes M, Jiang L, Taylor A, Diaz Garcia S, Ghosh Dastidar S, Rodriguez MJ, King P, Zhang Y, La Spada AR, Xu H, Petrucelli L, Ravits J, Da Cruz S, Lagier-Tourenne C, Cleveland DW, Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nat Neurosci 23, 615&#x2013;624 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384305</ArticleId><ArticleId IdType="pubmed">32284607</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack CR, Petersen RC, Dickson DW, Staging TDP-43 pathology in Alzheimer's disease. Acta neuropathologica 127, 441&#x2013;450 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944799</ArticleId><ArticleId IdType="pubmed">24240737</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, Petrucelli L, Senjem ML, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Jack CR Jr., Parisi JE, Petersen RC, Dickson DW, TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta neuropathologica 127, 811&#x2013;824 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172544</ArticleId><ArticleId IdType="pubmed">24659241</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez S, Sickles HM, Deleonardis C, Alcaraz A, Gridley T, Lin DM, Notch2 is required for maintaining sustentacular cell function in the adult mouse main olfactory epithelium. Dev Biol 314, 40&#x2013;58 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2374763</ArticleId><ArticleId IdType="pubmed">18155189</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L, Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28, 511&#x2013;515 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146043</ArticleId><ArticleId IdType="pubmed">20436464</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, McDermott MG, Monteiro CD, Gundersen GW, Ma'ayan A, Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 44, W90&#x2013;97 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987924</ArticleId><ArticleId IdType="pubmed">27141961</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai L, Barnea G, A critical period defined by axon-targeting mechanisms in the murine olfactory bulb. Science 344, 197&#x2013;200 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104295</ArticleId><ArticleId IdType="pubmed">24723611</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D'Avanzo C, Chen H, Hooli B, Asselin C, Muffat J, Klee JB, Zhang C, Wainger BJ, Peitz M, Kovacs DM, Woolf CJ, Wagner SL, Tanzi RE, Kim DY, A three-dimensional human neural cell culture model of Alzheimer's disease. Nature, (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366007</ArticleId><ArticleId IdType="pubmed">25307057</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34239129</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders.</ArticleTitle><Pagination><StartPage>1302</StartPage><EndPage>1312</EndPage><MedlinePgn>1302-1312</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-021-00886-6</ELocationID><Abstract><AbstractText>Understanding the tissue-specific genetic controls of protein levels is essential to uncover mechanisms of post-transcriptional gene regulation. In this study, we generated a genomic atlas of protein levels in three tissues relevant to neurological disorders (brain, cerebrospinal fluid and plasma) by profiling thousands of proteins from participants with and without Alzheimer's disease. We identified 274, 127 and 32 protein quantitative trait loci (pQTLs) for cerebrospinal fluid, plasma and brain, respectively. cis-pQTLs were more likely to be tissue shared, but trans-pQTLs tended to be tissue specific. Between 48.0% and 76.6% of pQTLs did not co-localize with expression, splicing, DNA methylation or histone acetylation QTLs. Using Mendelian randomization, we nominated proteins implicated in neurological diseases, including Alzheimer's disease, Parkinson's disease and stroke. This first multi-tissue study will be instrumental to map signals from genome-wide association studies onto functional genes, to discover pathways and to identify drug targets for neurological diseases.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chengran</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4577-5590</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farias</LastName><ForeName>Fabiana H G</ForeName><Initials>FHG</Initials><Identifier Source="ORCID">0000-0002-5215-7304</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibanez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suhy</LastName><ForeName>Adam</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1282-6339</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadler</LastName><ForeName>Brooke</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-3268-3809</Identifier><AffiliationInfo><Affiliation>Pediatrics Hematology/Oncology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Maria Victoria</ForeName><Initials>MV</Initials><Identifier Source="ORCID">0000-0002-9669-5147</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fengxian</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7677-5406</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradley</LastName><ForeName>Joseph L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eiffert</LastName><ForeName>Brett</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahena</LastName><ForeName>Jorge A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budde</LastName><ForeName>John P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0001-7778-7276</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zeran</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-7434-6499</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dube</LastName><ForeName>Umber</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-9324-1927</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Yun Ju</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihindukulasuriya</LastName><ForeName>Kathie A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0001-9372-3758</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-3443-7716</Identifier><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benitez</LastName><ForeName>Bruno A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0002-2699-3878</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhinn</LastName><ForeName>Herve</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics, Alector, Inc., South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harari</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-2635-6975</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0276-2899</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA. ccruchaga@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO, USA. ccruchaga@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA. ccruchaga@wustl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA. ccruchaga@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG064877</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057777</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053303</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS118146</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058922</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG058501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="N">Plasma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="Y">Quantitative Trait Loci</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34239129</ArticleId><ArticleId IdType="mid">NIHMS1711548</ArticleId><ArticleId IdType="pmc">PMC8521603</ArticleId><ArticleId IdType="doi">10.1038/s41593-021-00886-6</ArticleId><ArticleId IdType="pii">10.1038/s41593-021-00886-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altshuler D, Daly MJ &amp; Lander ES Genetic Mapping in Human Disease. Science 322, 881&#x2013;888 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694957</ArticleId><ArticleId IdType="pubmed">18988837</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris AP et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nature Genetics 44, 981&#x2013;990 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3442244</ArticleId><ArticleId IdType="pubmed">22885922</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nature Genetics 51, 414 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Claussnitzer M. et al. A brief history of human disease genetics. Nature 577, 179&#x2013;189 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405896</ArticleId><ArticleId IdType="pubmed">31915397</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguet F. et al. The GTEx Consortium atlas of genetic regulatory effects across human tissues. bioRxiv 787903 (2019) doi:10.1101/787903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/787903</ArticleId><ArticleId IdType="pmc">PMC7737656</ArticleId><ArticleId IdType="pubmed">32913098</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wijst MGP et al. Single-cell eQTLGen Consortium: a personalized understanding of disease. arXiv:1909.12550 [q-bio] (2019).</Citation></Reference><Reference><Citation>Aguet F. et al. Genetic effects on gene expression across human tissues. Nature 550, 204&#x2013;213 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5776756</ArticleId><ArticleId IdType="pubmed">29022597</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamazon ER, Zwinderman AH, Cox NJ, Denys D. &amp; Derks EM Multi-tissue transcriptome analyses identify genetic mechanisms underlying neuropsychiatric traits. Nature Genetics 1 (2019) doi:10.1038/s41588-019-0409-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0409-8</ArticleId><ArticleId IdType="pmc">PMC6590703</ArticleId><ArticleId IdType="pubmed">31086352</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xf5;sa U. et al. Unraveling the polygenic architecture of complex traits using blood eQTL metaanalysis. bioRxiv 447367 (2018) doi:10.1101/447367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/447367</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun BB et al. Genomic atlas of the human plasma proteome. Nature 558, 73&#x2013;79 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697541</ArticleId><ArticleId IdType="pubmed">29875488</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhre K. et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nature Communications 8, 14357 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333359</ArticleId><ArticleId IdType="pubmed">28240269</ArticleId></ArticleIdList></Reference><Reference><Citation>Folkersen L. et al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLOS Genetics 13, e1006706 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5393901</ArticleId><ArticleId IdType="pubmed">28369058</ArticleId></ArticleIdList></Reference><Reference><Citation>Deming Y. et al. Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits. Scientific Reports 6, 18092 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4698720</ArticleId><ArticleId IdType="pubmed">36647296</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasayama D. et al. Genome-wide quantitative trait loci mapping of the human cerebrospinal fluid proteome. Hum Mol Genet 26, 44&#x2013;51 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28031287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JSK et al. Genome-Wide Association Study of CSF Levels of 59 Alzheimer&#x2019;s Disease Candidate Proteins: Significant Associations with Proteins Involved in Amyloid Processing and Inflammation. PLOS Genetics 10, e1004758 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4207667</ArticleId><ArticleId IdType="pubmed">25340798</ArticleId></ArticleIdList></Reference><Reference><Citation>Robins C. et al. Genetic control of the human brain proteome. bioRxiv 816652 (2019) doi:10.1101/816652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/816652</ArticleId><ArticleId IdType="pmc">PMC8008492</ArticleId><ArticleId IdType="pubmed">33571421</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold L. et al. Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery. PLOS ONE 5, e15004 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000457</ArticleId><ArticleId IdType="pubmed">21165148</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddick PCG et al. A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimer&#x2019;s Disease Brains. J. Alzheimers Dis. 56, 1037&#x2013;1054 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5667357</ArticleId><ArticleId IdType="pubmed">28106546</ArticleId></ArticleIdList></Reference><Reference><Citation>Marek K. et al. The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology 95, 629&#x2013;635 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9014725</ArticleId><ArticleId IdType="pubmed">21930184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovestone S. et al. AddNeuroMed&#x2014;The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer&#x2019;s Disease. Annals of the New York Academy of Sciences 1180, 36&#x2013;46 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19906259</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamat MA et al. PhenoScanner V2: an expanded tool for searching human genotype&#x2013;phenotype associations. Bioinformatics (2019) doi:10.1093/bioinformatics/btz469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz469</ArticleId><ArticleId IdType="pmc">PMC6853652</ArticleId><ArticleId IdType="pubmed">31233103</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaratnam S, Khoo AKL &amp; Basic D. Rapidly progressive Alzheimer&#x2019;s disease and elevated 14&#x2013;3-3 proteins in cerebrospinal fluid. Age Ageing 37, 467&#x2013;469 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18460497</ArticleId></ArticleIdList></Reference><Reference><Citation>Foote M. &amp; Zhou Y. 14&#x2013;3-3 proteins in neurological disorders. Int J Biochem Mol Biol 3, 152&#x2013;164 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388734</ArticleId><ArticleId IdType="pubmed">22773956</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez L. et al. Overlap in the Genetic Architecture of Stroke Risk, Early Neurological Changes, and Cardiovascular Risk Factors. Stroke 50, 1339&#x2013;1345 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6538457</ArticleId><ArticleId IdType="pubmed">31084338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourdusamy A. et al. Identification of cis-regulatory variation influencing protein abundance levels in human plasma. Hum Mol Genet 21, 3719&#x2013;3726 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6446535</ArticleId><ArticleId IdType="pubmed">22595970</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker RL et al. Genetic Control of Expression and Splicing in Developing Human Brain Informs Disease Mechanisms. Cell 179, 750&#x2013;771.e22 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8963725</ArticleId><ArticleId IdType="pubmed">31626773</ArticleId></ArticleIdList></Reference><Reference><Citation>Orozco LD et al. Integration of eQTL and a Single-Cell Atlas in the Human Eye Identifies Causal Genes for Age-Related Macular Degeneration. Cell Reports 30, 1246&#x2013;1259.e6 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31995762</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbut SM, Wang G, Carbonetto P. &amp; Stephens M. Flexible statistical methods for estimating and testing effects in genomic studies with multiple conditions. Nature Genetics 51, 187&#x2013;195 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309609</ArticleId><ArticleId IdType="pubmed">30478440</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillary RF et al. Genome and epigenome wide studies of neurological protein biomarkers in the Lothian Birth Cohort 1936. Nat Commun 10, 3160&#x2013;3160 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6639385</ArticleId><ArticleId IdType="pubmed">31320639</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhre K, McCarthy MI &amp; Schwenk JM Genetics meets proteomics: perspectives for large population-based studies. Nature Reviews Genetics 1&#x2013;19 (2020) doi:10.1038/s41576-020-0268-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-020-0268-2</ArticleId><ArticleId IdType="pubmed">32860016</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao C. et al. Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nature Communications 9, 3268 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093935</ArticleId><ArticleId IdType="pubmed">30111768</ArticleId></ArticleIdList></Reference><Reference><Citation>Par&#xe9; G. et al. Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet. 4, e1000118 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2432033</ArticleId><ArticleId IdType="pubmed">18604267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndungu A, Payne A, Torres JM, Bunt M. van de &amp; McCarthy MIA Multi-tissue Transcriptome Analysis of Human Metabolites Guides Interpretability of Associations Based on Multi-SNP Models for Gene Expression. The American Journal of Human Genetics 0, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7010967</ArticleId><ArticleId IdType="pubmed">31978332</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C. et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer&#x2019;s disease. Hum Mol Genet 21, 4558&#x2013;4571 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3459471</ArticleId><ArticleId IdType="pubmed">22821396</ArticleId></ArticleIdList></Reference><Reference><Citation>Kibinge NK, Relton CL, Gaunt TR &amp; Richardson TG Characterizing the Causal Pathway for Genetic Variants Associated with Neurological Phenotypes Using Human Brain-Derived Proteome Data. Am J Hum Genet 106, 885&#x2013;892 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273531</ArticleId><ArticleId IdType="pubmed">32413284</ArticleId></ArticleIdList></Reference><Reference><Citation>Del-Aguila JL et al. A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimer&#x2019;s Research &amp; Therapy 11, 71 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6689177</ArticleId><ArticleId IdType="pubmed">31399126</ArticleId></ArticleIdList></Reference><Reference><Citation>Alector Inc. First in Human Study for Safety and Tolerability of AL003. - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03822208.</Citation></Reference><Reference><Citation>Nalls MA et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. The Lancet Neurology 18, 1091&#x2013;1102 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422160</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bethea JW Clinical Anesthesia, 6th Edition. Anesthesiology 112, 767&#x2013;768 (2010).</Citation></Reference><Reference><Citation>Camerino GM et al. Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options. Scientific Reports 9, 3185 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6395744</ArticleId><ArticleId IdType="pubmed">30816241</ArticleId></ArticleIdList></Reference><Reference><Citation>Savitz SI et al. The novel beta-blocker, carvedilol, provides neuroprotection in transient focal stroke. J Cereb Blood Flow Metab 20, 1197&#x2013;1204 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10950380</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson MR et al. The support of human genetic evidence for approved drug indications. Nature Genetics 47, 856&#x2013;860 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26121088</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliano Taliun SA et al. Exploring and visualizing large-scale genetic associations by using PheWeb. Nature Genetics 52, 550&#x2013;552 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7754083</ArticleId><ArticleId IdType="pubmed">32504056</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemani G. et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife 7, e34408 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5976434</ArticleId><ArticleId IdType="pubmed">29846171</ArticleId></ArticleIdList></Reference><Reference><Citation>Del-Aguila JL et al. Assessment of the Genetic Architecture of Alzheimer&#x2019;s Disease Risk in Rate of Memory Decline. J. Alzheimers Dis. 62, 745&#x2013;756 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5989565</ArticleId><ArticleId IdType="pubmed">29480181</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K. et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer&#x2019;s disease. Nature Neuroscience 20, 1052&#x2013;1061 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759334</ArticleId><ArticleId IdType="pubmed">28628103</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W. et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics 48, 1043&#x2013;1048 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R. et al. Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol 13, 686&#x2013;699 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112126</ArticleId><ArticleId IdType="pubmed">24943344</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik R. et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nature Genetics 50, 524 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5968830</ArticleId><ArticleId IdType="pubmed">29531354</ArticleId></ArticleIdList></Reference><Reference><Citation>Demenais F. et al. Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. Nat Genet 50, 42&#x2013;53 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901974</ArticleId><ArticleId IdType="pubmed">29273806</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H. VennDiagram: Generate High-Resolution Venn and Euler Plots. (2018).</Citation></Reference><Reference><Citation>Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412&#x2013;2414 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology 41, 479&#x2013;486 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian ZS Diagnosis of Alzheimer&#x2019;s disease. Arch. Neurol. 42, 1097&#x2013;1105 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">2864910</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattlecker M. et al. Alzheimer&#x2019;s disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement 10, 724&#x2013;734 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24768341</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams SA et al. Plasma protein patterns as comprehensive indicators of health. Nature Medicine 1&#x2013;7 (2019) doi:10.1038/s41591-019-0665-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0665-2</ArticleId><ArticleId IdType="pmc">PMC6922049</ArticleId><ArticleId IdType="pubmed">31792462</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber W. et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Meth 12, 115&#x2013;121 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4509590</ArticleId><ArticleId IdType="pubmed">25633503</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium UniProt. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res 47, D506&#x2013;D515 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323992</ArticleId><ArticleId IdType="pubmed">30395287</ArticleId></ArticleIdList></Reference><Reference><Citation>Howie BN, Donnelly P. &amp; Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2689936</ArticleId><ArticleId IdType="pubmed">19543373</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. GigaScience 4, 7 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4342193</ArticleId><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruim RJ et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26, 2336&#x2013;2337 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935401</ArticleId><ArticleId IdType="pubmed">20634204</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y. &amp; Abecasis GR METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190&#x2013;2191 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M. &amp; Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38, e164&#x2013;e164 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham H. ggplot2: Elegant Graphics for Data Analysis. (Springer-Verlag, 2009). doi:10.1007/978-0-387-98141-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-0-387-98141-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Iotchkova V. et al. GARFIELD classifies disease-relevant genomic features through integration of functional annotations with association signals. Nature Genetics 51, 343 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6908448</ArticleId><ArticleId IdType="pubmed">30692680</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso N. et al. Integrating Gene Expression with Summary Association Statistics to Identify Genes Associated with 30 Complex Traits. The American Journal of Human Genetics 100, 473&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5339290</ArticleId><ArticleId IdType="pubmed">28238358</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Z, Gu L, Eils R, Schlesner M. &amp; Brors B. circlize Implements and enhances circular visualization in R. Bioinformatics 30, 2811&#x2013;2812 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24930139</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace C. Statistical Testing of Shared Genetic Control for Potentially Related Traits. Genetic Epidemiology 37, 802&#x2013;813 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4158901</ArticleId><ArticleId IdType="pubmed">24227294</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C. et al. Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. PLOS Genetics 10, e1004383 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng B. et al. An xQTL map integrates the genetic architecture of the human brain&#x2019;s transcriptome and epigenome. Nat. Neurosci. 20, 1418&#x2013;1426 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785926</ArticleId><ArticleId IdType="pubmed">28869584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H. et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Ongen H, Buil A, Brown AA, Dermitzakis ET &amp; Delaneau O. Fast and efficient QTL mapper for thousands of molecular phenotypes. Bioinformatics 32, 1479&#x2013;1485 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4866519</ArticleId><ArticleId IdType="pubmed">26708335</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart DS et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34, D668&#x2013;D672 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347430</ArticleId><ArticleId IdType="pubmed">16381955</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34239132</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1143</StartPage><EndPage>1155</EndPage><MedlinePgn>1143-1155</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-021-00894-z</ELocationID><Abstract><AbstractText>The gene-regulatory landscape of the brain is highly dynamic in health and disease, coordinating a menagerie of biological processes across distinct cell types. Here, we present a multi-omic single-nucleus study of 191,890 nuclei in late-stage Alzheimer's disease (AD), accessible through our web portal, profiling chromatin accessibility and gene expression in the same biological samples and uncovering vast cellular heterogeneity. We identified cell-type-specific, disease-associated candidate cis-regulatory elements and their candidate target genes, including an oligodendrocyte-associated regulatory module containing links to APOE and CLU. We describe cis-regulatory relationships in specific cell types at a subset of AD risk loci defined by genome-wide association studies, demonstrating the utility of this multi-omic single-nucleus approach. Trajectory analysis of glial populations identified disease-relevant transcription factors, such as SREBF1, and their regulatory targets. Finally, we introduce single-nucleus consensus weighted gene coexpression analysis, a coexpression network analysis strategy robust to sparse single-cell data, and perform a systems-level analysis of the AD transcriptome.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Morabito</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7768-4856</Identifier><AffiliationInfo><Affiliation>Mathematical, Computational and Systems Biology (MCSB) Program, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders (MIND), University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Miyoshi</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8151-0560</Identifier><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders (MIND), University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Michael</LastName><ForeName>Neethu</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders (MIND), University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahin</LastName><ForeName>Saba</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders (MIND), University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martini</LastName><ForeName>Alessandra Cadete</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Justine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leavy</LastName><ForeName>Kelsey</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez-Rosendahl</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swarup</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-3762-2746</Identifier><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders (MIND), University of California, Irvine, CA, USA. vswarup@uci.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, CA, USA. vswarup@uci.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG071683</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG071683</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002843">Chromatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497387">SREBF1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051780">Sterol Regulatory Element Binding Protein 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002843" MajorTopicYN="N">Chromatin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012045" MajorTopicYN="Y">Regulatory Sequences, Nucleic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051780" MajorTopicYN="N">Sterol Regulatory Element Binding Protein 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34239132</ArticleId><ArticleId IdType="mid">NIHMS1755678</ArticleId><ArticleId IdType="pmc">PMC8766217</ArticleId><ArticleId IdType="doi">10.1038/s41588-021-00894-z</ArticleId><ArticleId IdType="pii">10.1038/s41588-021-00894-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lake BB et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. Science (80-.). 352, 1586&#x2013;1590 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5038589</ArticleId><ArticleId IdType="pubmed">27339989</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasic B et al. Adult mouse cortical cell taxonomy revealed by single cell transcriptomics. Nat. Neurosci 19, 335&#x2013;346 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4985242</ArticleId><ArticleId IdType="pubmed">26727548</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel A et al. Molecular Architecture of the Mouse Nervous System. Cell 174, 999&#x2013;1014.e22 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6086934</ArticleId><ArticleId IdType="pubmed">30096314</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodge RD et al. Conserved cell types with divergent features in human versus mouse cortex. Nature 573, 61&#x2013;68 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919571</ArticleId><ArticleId IdType="pubmed">31435019</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med 26, 131&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci 22, 2087&#x2013;2097 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng K et al. Molecular characterization of selectively vulnerable neurons in Alzheimer&#x2019;s disease. Nat. Neurosci 24, 276&#x2013;287 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854528</ArticleId><ArticleId IdType="pubmed">33432193</ArticleId></ArticleIdList></Reference><Reference><Citation>Del-Aguila JL et al. A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimers. Res. Ther 1&#x2013;16 (2019). doi:10.1101/593756</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/593756</ArticleId><ArticleId IdType="pmc">PMC6689177</ArticleId><ArticleId IdType="pubmed">31399126</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat. Genet 51, 404&#x2013;413 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet 51, 414&#x2013;430 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer&#x2019;s disease. Nat. Genet 41, 192&#x2013;198 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873177</ArticleId><ArticleId IdType="pubmed">19136949</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat. Genet 41, 1088&#x2013;1093 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat. Genet 43, 429&#x2013;436 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibar DP et al. Novel genetic loci associated with hippocampal volume. Nat. Commun 8, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5253632</ArticleId><ArticleId IdType="pubmed">28098162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet 45, 1452&#x2013;1458 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Nott A et al. Brain cell type&#x2013;specific enhancer&#x2013;promoter interactome maps and disease-risk association. Science (80-.) 366, 1134&#x2013;1139 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7028213</ArticleId><ArticleId IdType="pubmed">31727856</ArticleId></ArticleIdList></Reference><Reference><Citation>Buenrostro JD et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature 523, 486&#x2013;490 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4685948</ArticleId><ArticleId IdType="pubmed">26083756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat. Biotechnol 36, 70&#x2013;80 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5951394</ArticleId><ArticleId IdType="pubmed">29227469</ArticleId></ArticleIdList></Reference><Reference><Citation>Corces MR et al. Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Nat. Genet 52, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7606627</ArticleId><ArticleId IdType="pubmed">33106633</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghverdi L, Lun ATL, Morgan MD &amp; Marioni JC Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. Nat. Biotechnol 36, 421&#x2013;427 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6152897</ArticleId><ArticleId IdType="pubmed">29608177</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch JD et al. Single-Cell Multi-omic Integration Compares and Contrasts Features of Brain Cell Identity. Cell 177, 1873&#x2013;1887.e17 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6716797</ArticleId><ArticleId IdType="pubmed">31178122</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes L, Healy J &amp; Melville J UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. arxiv (2018).</Citation></Reference><Reference><Citation>Traag VA, Waltman L &amp; van Eck NJ From Louvain to Leiden: guaranteeing well-connected communities. Sci. Rep 9, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6435756</ArticleId><ArticleId IdType="pubmed">30914743</ArticleId></ArticleIdList></Reference><Reference><Citation>Schep AN, Wu B, Buenrostro JD &amp; Greenleaf WJ ChromVAR: Inferring transcription-factor-associated accessibility from single-cell epigenomic data. Nat. Methods 14, 975&#x2013;978 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623146</ArticleId><ArticleId IdType="pubmed">28825706</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature 566, 388&#x2013;392 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30760929</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888&#x2013;1902.e21 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E &amp; Satija R Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N et al. Disease-associated astrocytes in Alzheimer&#x2019;s disease and aging. Nat. Neurosci 1&#x2013;6 (2020). doi:10.1038/s41593-020-0624-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-0624-8</ArticleId><ArticleId IdType="pmc">PMC9262034</ArticleId><ArticleId IdType="pubmed">32341542</ArticleId></ArticleIdList></Reference><Reference><Citation>Pliner HA et al. Cicero Predicts cis-Regulatory DNA Interactions from Single-Cell Chromatin Accessibility Data. Mol. Cell 71, 858&#x2013;871.e8 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6582963</ArticleId><ArticleId IdType="pubmed">30078726</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh JI, Kawana N &amp; Yamamoto Y Pathway Analysis of ChIP-Seq-Based NRF1 Target Genes Suggests a Logical Hypothesis of their Involvement in the pathogenesis of Neurodegenerative Diseases. Gene Regul. Syst. Bio 2013, 139&#x2013;152 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3825669</ArticleId><ArticleId IdType="pubmed">24250222</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapnell C et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol 32, 381&#x2013;386 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4122333</ArticleId><ArticleId IdType="pubmed">24658644</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature 566, 496&#x2013;502 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6434952</ArticleId><ArticleId IdType="pubmed">30787437</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X et al. Reversed graph embedding resolves complex single-cell trajectories. Nat. Methods 14, 979&#x2013;982 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5764547</ArticleId><ArticleId IdType="pubmed">28825705</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra R &amp; Maclean AL RVAgene : Generative modeling of gene expression time series data. bioRxiv 1&#x2013;17 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8504625</ArticleId><ArticleId IdType="pubmed">33974008</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques S et al. Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. Science (80-.) 352, 1326&#x2013;1329 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5221728</ArticleId><ArticleId IdType="pubmed">27284195</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;kel S et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature 566, 543&#x2013;547 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6544546</ArticleId><ArticleId IdType="pubmed">30747918</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimano H &amp; Sato R SREBP-regulated lipid metabolism: Convergent physiology-divergent pathophysiology. Nat. Rev. Endocrinol 13, 710&#x2013;730 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28849786</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed A, Viveiros A, Williams K &amp; De Chaves EP A&#x3b2; inhibits SREBP-2 activation through Akt inhibition. J. Lipid Res 59, 1&#x2013;13 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748492</ArticleId><ArticleId IdType="pubmed">29122977</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugacheva EM et al. CTCF mediates chromatin looping via N-terminal domain-dependent cohesin retention. Proc. Natl. Acad. Sci. U. S. A 117, 2020&#x2013;2031 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6995019</ArticleId><ArticleId IdType="pubmed">31937660</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Yu NK &amp; Kaang BK CTCF as a multifunctional protein in genome regulation and gene expression. Exp. Mol. Med 47, e166 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4491725</ArticleId><ArticleId IdType="pubmed">26045254</ArticleId></ArticleIdList></Reference><Reference><Citation>Finucane HK et al. Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. Nat. Genet 50, 621&#x2013;629 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5896795</ArticleId><ArticleId IdType="pubmed">29632380</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R et al. Frontotemporal dementia and its subtypes: A genome-wide association study. Lancet Neurol. 13, 686&#x2013;699 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112126</ArticleId><ArticleId IdType="pubmed">24943344</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J et al. Genome-wide association study identifies MAPT locus influencing human plasma tau levels. Neurology 88, 669&#x2013;676 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5317386</ArticleId><ArticleId IdType="pubmed">28100725</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi&#xf1;as AF et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat. Genet 50, 381&#x2013;389 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5918692</ArticleId><ArticleId IdType="pubmed">29483656</ArticleId></ArticleIdList></Reference><Reference><Citation>Andlauer TFM et al. Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Sci. Adv 2, 1&#x2013;12 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4928990</ArticleId><ArticleId IdType="pubmed">27386562</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet 47, 979&#x2013;986 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4881818</ArticleId><ArticleId IdType="pubmed">26192919</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood AR et al. Defining the role of common variation in the genomic and biological architecture of adult human height. Nat. Genet 46, 1173&#x2013;1186 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4250049</ArticleId><ArticleId IdType="pubmed">25282103</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ et al. Discovery and refinement of loci associated with lipid levels. Nat. Genet 45, 1274&#x2013;1285 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838666</ArticleId><ArticleId IdType="pubmed">24097068</ArticleId></ArticleIdList></Reference><Reference><Citation>Cusanovich DA, Hill AJ, Disteche CM, Trapnell C &amp; Shendure J A Single-Cell Atlas of In&amp;nbsp;Vivo Mammalian Chromatin Accessibility. Cell 174, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6158300</ArticleId><ArticleId IdType="pubmed">30078704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulirsch JC et al. Interrogation of human hematopoiesis at single-cell and single-variant resolution. Nat. Genet 51, 683&#x2013;693 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6441389</ArticleId><ArticleId IdType="pubmed">30858613</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P &amp; Horvath S WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics 9, (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B &amp; Horvath S A general framework for weighted gene co-expression network analysis. Stat. Appl. Genet. Mol. Biol 4, (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16646834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell 153, 707&#x2013;720 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>Rexach JE et al. Tau Pathology Drives Dementia Risk-Associated Gene Networks toward Chronic Inflammatory States and Immunosuppression. Cell Rep. 33, 108398 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7842189</ArticleId><ArticleId IdType="pubmed">33207193</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafavi S et al. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#x2019;s disease. Nat. Neurosci 21, 811&#x2013;819 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>Morabito S, Miyoshi E, Michael N &amp; Swarup V Integrative genomics approach identifies conserved transcriptomic networks in Alzheimer&#x2019;s disease. Hum. Mol. Genet 00, 1&#x2013;21 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566321</ArticleId><ArticleId IdType="pubmed">32803238</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V et al. Identification of Conserved Proteomic Networks in Neurodegenerative Dementia. Cell Rep. 31, 107807 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221021</ArticleId><ArticleId IdType="pubmed">32579933</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V et al. Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nat. Med 25, 152&#x2013;164 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6602064</ArticleId><ArticleId IdType="pubmed">30510257</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen M et al. Conserved brain myelination networks are altered in Alzheimer&#x2019;s and other neurodegenerative diseases. Alzheimer&#x2019;s Dement. 14, 352&#x2013;366 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866744</ArticleId><ArticleId IdType="pubmed">29107053</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YE, Pan L, Zuo Y, Li X &amp; Hong W Detecting Activated Cell Populations Using Single-Cell RNA-Seq. Neuron 96, 313&#x2013;329.e6 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29024657</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Methods only references</Title><Reference><Citation>Sun Y, Ip P &amp; Chakrabartty A Simple elimination of background fluorescence in formalin-fixed human brain tissue for immunofluorescence microscopy. J. Vis. Exp 2017, 1&#x2013;6 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5614400</ArticleId><ArticleId IdType="pubmed">28892031</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, Srivastava A, Lareau C &amp; Satija R Multimodal single-cell chromatin analysis with Signac. bioRxiv 2020.11.09.373613 (2020).</Citation></Reference><Reference><Citation>Granja JM et al. ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis. Nat. Genet 53, 403&#x2013;411 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8012210</ArticleId><ArticleId IdType="pubmed">33633365</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Z, Eils R &amp; Schlesner M Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847&#x2013;2849 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27207943</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A et al. JASPAR 2018: Update of the open-access database of transcription factor binding profiles and its web framework. Nucleic Acids Res. 46, D260&#x2013;D266 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753243</ArticleId><ArticleId IdType="pubmed">29140473</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaujoux R &amp; Seoighe C A flexible R package for nonnegative matrix factorization. BMC Bioinformatics 11, (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912887</ArticleId><ArticleId IdType="pubmed">20598126</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuleshov MV et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90&#x2013;W97 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987924</ArticleId><ArticleId IdType="pubmed">27141961</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen EY et al. Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637064</ArticleId><ArticleId IdType="pubmed">23586463</ArticleId></ArticleIdList></Reference><Reference><Citation>Lage K et al. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat. Biotechnol 25, 309&#x2013;316 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17344885</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark C BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 34, D535&#x2013;D539 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347471</ArticleId><ArticleId IdType="pubmed">16381927</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607&#x2013;D613 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Morabito S &amp; Swamp Lab. swaruplabUCI/Single-nuclei-epigenomic-and-transcriptomic-landscape-in-Alzheimer-disease: publication. (2021). doi:10.5281/zenodo.4681643</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.4681643</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34262178</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>595</Volume><Issue>7869</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Astrocytic interleukin-3 programs microglia and limits Alzheimer's disease.</ArticleTitle><Pagination><StartPage>701</StartPage><EndPage>706</EndPage><MedlinePgn>701-706</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-021-03734-6</ELocationID><Abstract><AbstractText>Communication within the glial cell ecosystem is essential for neuronal and brain health<sup>1-3</sup>. The influence of glial cells on the accumulation and clearance of &#x3b2;-amyloid (A&#x3b2;) and neurofibrillary tau in the brains of individuals with Alzheimer's disease (AD) is poorly understood, despite growing awareness that these are therapeutically important interactions<sup>4,5</sup>. Here we show, in humans and mice, that astrocyte-sourced interleukin-3 (IL-3) programs microglia to ameliorate the pathology of AD. Upon recognition of A&#x3b2; deposits, microglia increase their expression of IL-3R&#x3b1;-the specific receptor for IL-3 (also known as CD123)-making them responsive to IL-3. Astrocytes constitutively produce IL-3, which elicits transcriptional, morphological, and functional programming of microglia to endow them with an acute immune response program, enhanced motility, and the capacity to cluster and clear aggregates of A&#x3b2; and tau. These changes restrict AD pathology and cognitive decline. Our findings identify IL-3 as a key mediator of astrocyte-microglia cross-talk and a node for therapeutic intervention in AD.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McAlpine</LastName><ForeName>Cameron S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Institute and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Friedman Brain Institute and Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griciuc</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Eunhee</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Se Hoon</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwamoto</LastName><ForeName>Yoshiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiss</LastName><ForeName>M&#xe1;t&#xe9; G</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0002-9215-8328</Identifier><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christie</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Center for Genomic Medicine, Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinegoni</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9818-3639</Identifier><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poller</LastName><ForeName>Wolfram C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Institute and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mindur</LastName><ForeName>John E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0002-2212-3904</Identifier><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Christopher T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Shun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janssen</LastName><ForeName>Henrike</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Lai Ping</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Downey</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Sumnima</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anzai</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7474-1309</Identifier><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahles</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jorfi</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4724-6190</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feruglio</LastName><ForeName>Paolo Fumene</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadreyev</LastName><ForeName>Ruslan I</ForeName><Initials>RI</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weissleder</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0828-4143</Identifier><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleinstiver</LastName><ForeName>Benjamin P</ForeName><Initials>BP</Initials><Identifier Source="ORCID">0000-0002-5469-0655</Identifier><AffiliationInfo><Affiliation>Center for Genomic Medicine, Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahrendorf</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4021-1887</Identifier><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-7032-1454</Identifier><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA. rtanzi@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swirski</LastName><ForeName>Filip K</ForeName><Initials>FK</Initials><Identifier Source="ORCID">0000-0002-3163-9152</Identifier><AffiliationInfo><Affiliation>Center for Systems Biology and Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. filip.swirski@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Research Institute and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. filip.swirski@mssm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R00 HL151750</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 CA218870</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 GM139598</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HL131478</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA158534</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 HL135752</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 HL151750</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 HL139598</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL158534</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R13 CA135752</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 HL147364</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HL142494</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508596">IL3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007377">Interleukin-3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2021 Sep;17(9):525. doi: 10.1038/s41582-021-00546-0.</RefSource><PMID Version="1">34321636</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007377" MajorTopicYN="N">Interleukin-3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. C.S.M., F.K.S., and R.E.T. are inventors on a patent application filed by Mass General Brigham that describes targeting IL-3 signaling in Alzheimer&#x2019;s disease (invention record no. 2020-568). B.P.K. is an inventor on patent applications filed by Mass General Brigham that describe genome engineering technologies and methods, is an advisor to Acrigen Biosciences, and consults for Avectas Inc. and ElevateBio.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34262178</ArticleId><ArticleId IdType="mid">NIHMS1783128</ArticleId><ArticleId IdType="pmc">PMC8934148</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03734-6</ArticleId><ArticleId IdType="pii">10.1038/s41586-021-03734-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Linnerbauer M, Wheeler MA &amp; Quintana FJ Astrocyte Crosstalk in CNS Inflammation. Neuron 1&#x2013;15 (2020) doi:10.1016/j.neuron.2020.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.012</ArticleId><ArticleId IdType="pmc">PMC7704785</ArticleId><ArticleId IdType="pubmed">32898475</ArticleId></ArticleIdList></Reference><Reference><Citation>Vainchtein ID &amp; Molofsky AV Astrocytes and Microglia: In Sickness and in Health. Trends Neurosci. 43, 144&#x2013;154 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7472912</ArticleId><ArticleId IdType="pubmed">32044129</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani G &amp; Schwartz M Immunological Features of Non-neuronal Brain Cells: Implications for Alzheimer&#x2019;s Disease Immunotherapy. Trends in Immunology (2020) doi:10.1016/j.it.2020.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2020.07.005</ArticleId><ArticleId IdType="pubmed">32800704</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhoury M Microglia and astrocytes in Alzheimer&#x2019;s disease: implications for therapy. Curr. Neuropharmacol (2017) doi:10.2174/1570159x15666170720095240.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159x15666170720095240</ArticleId><ArticleId IdType="pmc">PMC5997862</ArticleId><ArticleId IdType="pubmed">28730967</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JM &amp; Holtzman DM Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell (2019) doi:10.1016/j.cell.2019.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.09.001</ArticleId><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber GF et al. Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science (80-. ). 347, 1260&#x2013;1265 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4376966</ArticleId><ArticleId IdType="pubmed">25766237</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams GT, Smith CA, Spooncer E, Dexter TM &amp; Taylor DR Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature (1990) doi:10.1038/343076a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/343076a0</ArticleId><ArticleId IdType="pubmed">1688645</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy AJ et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J. Clin. Invest 121, 4138&#x2013;4149 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3195472</ArticleId><ArticleId IdType="pubmed">21968112</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins CS et al. Extramedullary hematopoiesis generates Ly-6C high monocytes that infiltrate atherosclerotic lesions. Circulation 125, 364&#x2013;374 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3263762</ArticleId><ArticleId IdType="pubmed">22144566</ArticleId></ArticleIdList></Reference><Reference><Citation>Yvan-Charvet L et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science (80-. ). 328, 1689&#x2013;1693 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032591</ArticleId><ArticleId IdType="pubmed">20488992</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzai A et al. Self-reactive CD4+ IL-3+ T cells amplify autoimmune inflammation in myocarditis by inciting monocyte chemotaxis. J. Exp. Med 216, 369&#x2013;383 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6363430</ArticleId><ArticleId IdType="pubmed">30670465</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofstetter HH et al. The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL/6 mice. J. Neuroimmunol (2005) doi:10.1016/j.jneuroim.2005.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2005.09.004</ArticleId><ArticleId IdType="pubmed">16257061</ArticleId></ArticleIdList></Reference><Reference><Citation>Renner K et al. IL-3 promotes the development of experimental autoimmune encephalitis. JCI Insight (2016) doi:10.1172/jci.insight.87157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.87157</ArticleId><ArticleId IdType="pmc">PMC5053150</ArticleId><ArticleId IdType="pubmed">27734026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravetti MG &amp; Moscato P Identification of a 5-protein biomarker molecular signature for predicting Alzheimer&#x2019;s disease. PLoS One (2008) doi:10.1371/journal.pone.0003111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003111</ArticleId><ArticleId IdType="pmc">PMC2518833</ArticleId><ArticleId IdType="pubmed">18769539</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S et al. Classification and prediction of clinical Alzheimer&#x2019;s diagnosis based on plasma signaling proteins. Nat. Med (2007) doi:10.1038/nm1653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1653</ArticleId><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>Britschgi M et al. Modeling of pathological traits in Alzheimer&#x2019;s disease based on systemic extracellular signaling proteome. Mol. Cell. Proteomics 10, 1&#x2013;11 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3205866</ArticleId><ArticleId IdType="pubmed">21742799</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares HD et al. Plasma biomarkers associated with the apolipoprotein E genotype and alzheimer disease. Arch. Neurol 69, 1310&#x2013;1317 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683865</ArticleId><ArticleId IdType="pubmed">22801723</ArticleId></ArticleIdList></Reference><Reference><Citation>Huberman M et al. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J. Neuroimmunol (1994) doi:10.1016/0165-5728(94)90108-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5728(94)90108-2</ArticleId><ArticleId IdType="pubmed">8034754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiddle SJ et al. Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden. PLoS One (2012) doi:10.1371/journal.pone.0044260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044260</ArticleId><ArticleId IdType="pmc">PMC3454385</ArticleId><ArticleId IdType="pubmed">23028511</ArticleId></ArticleIdList></Reference><Reference><Citation>Frei K, Bodmer S, Schwerdel C &amp; Fontana A Astrocytes of the brain synthesize interleukin 3-like factors. J. Immunol (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">3934273</ArticleId></ArticleIdList></Reference><Reference><Citation>Frei K, Bodmer S, Schwerdel C &amp; Fontana A Astrocyte-derived interleukin 3 as a growth factor for microglia cells and peritoneal macrophages. J. Immunol (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3491140</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano A, Otth C, B. Maccioni R. &amp; I. Concha I IL-3 Control Tau Modifications and Protects Cortical Neurons from Neurodegeneration. Curr. Alzheimer Res (2010) doi:10.2174/156720510793499011.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720510793499011</ArticleId><ArticleId IdType="pubmed">20964623</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano A, Otth C, Mujica L, Concha II &amp; Maccioni RB Interleukin-3 prevents neuronal death induced by amyloid peptide. BMC Neurosci. (2007) doi:10.1186/1471-2202-8-82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-8-82</ArticleId><ArticleId IdType="pmc">PMC2089076</ArticleId><ArticleId IdType="pubmed">17915029</ArticleId></ArticleIdList></Reference><Reference><Citation>Herisson F et al. Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration. Nat. Neurosci (2018) doi:10.1038/s41593-018-0213-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0213-2</ArticleId><ArticleId IdType="pmc">PMC6148759</ArticleId><ArticleId IdType="pubmed">30150661</ArticleId></ArticleIdList></Reference><Reference><Citation>Gate D et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer&#x2019;s disease. Nature (2020) doi:10.1038/s41586-019-1895-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1895-7</ArticleId><ArticleId IdType="pmc">PMC7445078</ArticleId><ArticleId IdType="pubmed">31915375</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenaro E et al. Neutrophils promote Alzheimer&#x2019;s disease-like pathology and cognitive decline via LFA-1 integrin. Nat. Med (2015) doi:10.1038/nm.3913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3913</ArticleId><ArticleId IdType="pubmed">26214837</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasciuto E et al. Microglia Require CD4 T Cells to Complete the Fetal-to-Adult Transition. Cell 182, 625&#x2013;640.e24 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427333</ArticleId><ArticleId IdType="pubmed">32702313</ArticleId></ArticleIdList></Reference><Reference><Citation>Khakh BS &amp; Deneen B The Emerging Nature of Astrocyte Diversity. Annual Review of Neuroscience (2019) doi:10.1146/annurev-neuro-070918-050443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-070918-050443</ArticleId><ArticleId IdType="pubmed">31283899</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature (2017) doi:10.1038/nature21029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Komuczki J et al. Fate-Mapping of GM-CSF Expression Identifies a Discrete Subset of Inflammation-Driving T Helper Cells Regulated by Cytokines IL-23 and IL-1&#x3b2;. Immunity (2019) doi:10.1016/j.immuni.2019.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.04.006</ArticleId><ArticleId IdType="pubmed">31079916</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler MA et al. Environmental Control of Astrocyte Pathogenic Activities in CNS Inflammation. Cell (2019) doi:10.1016/j.cell.2018.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.12.012</ArticleId><ArticleId IdType="pmc">PMC6440749</ArticleId><ArticleId IdType="pubmed">30661753</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med 26, 131&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A et al. TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer&#x2019;s Disease. Neuron 103, 820&#x2013;835.e7 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6728215</ArticleId><ArticleId IdType="pubmed">31301936</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med (2016) doi:10.1084/jem.20151948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151948</ArticleId><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat. Neurosci (2019) doi:10.1038/s41593-018-0296-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0296-9</ArticleId><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer&#x2019;s disease mouse models. J. Exp. Med (2015) doi:10.1084/jem.20142322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20142322</ArticleId><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell (2015) doi:10.1016/j.cell.2015.01.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.049</ArticleId><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T et al. Variant of TREM2 Associated with the Risk of Alzheimer&#x2019;s Disease . N. Engl. J. Med (2013) doi:10.1056/nejmoa1211103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M et al. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer&#x2019;s disease. Sci. Transl. Med (2019) doi:10.1126/scitranslmed.aav6221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aav6221</ArticleId><ArticleId IdType="pmc">PMC7050285</ArticleId><ArticleId IdType="pubmed">31462511</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H et al. Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature (2019) doi:10.1038/s41586-019-1195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1195-2</ArticleId><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki Y, Zhao N, Caulfield TR, Liu CC &amp; Bu G Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nature Reviews Neurology (2019) doi:10.1038/s41582-019-0228-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0228-7</ArticleId><ArticleId IdType="pmc">PMC7055192</ArticleId><ArticleId IdType="pubmed">31367008</ArticleId></ArticleIdList></Reference><Reference><Citation>Lively S &amp; Schlichter LC The microglial activation state regulates migration and roles of matrix-dissolving enzymes for invasion. J. Neuroinflammation (2013) doi:10.1186/1742-2094-10-75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-10-75</ArticleId><ArticleId IdType="pmc">PMC3693964</ArticleId><ArticleId IdType="pubmed">23786632</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH et al. A three-dimensional human neural cell culture model of Alzheimer&#x2019;s disease. Nature 515, 274&#x2013;278 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366007</ArticleId><ArticleId IdType="pubmed">25307057</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J et al. A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer&#x2019;s disease. Nat. Neurosci 21, 941&#x2013;951 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800152</ArticleId><ArticleId IdType="pubmed">29950669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Lee JW, Nam H, Yu SW &amp; Yu SW Cx3cr1 CreERT2-driven Atg7 deletion in adult mice induces intestinal adhesion. Mol. Brain (2020) doi:10.1186/s13041-020-00630-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-020-00630-4</ArticleId><ArticleId IdType="pmc">PMC7281947</ArticleId><ArticleId IdType="pubmed">32513210</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao XF et al. Targeting microglia using Cx3cr1-Cre lines: Revisiting the specificity. eNeuro (2019) doi:10.1523/ENEURO.0114-19.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0114-19.2019</ArticleId><ArticleId IdType="pmc">PMC6620394</ArticleId><ArticleId IdType="pubmed">31201215</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association. Alzheimer&#x2019;s Association 2020 Facts and Figures Report. Alzheimer&#x2019;s Assoc. 1 (2020).</Citation></Reference><Reference><Citation>Oakley H et al. Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: Potential factors in amyloid plaque formation. J. Neurosci (2006) doi:10.1523/JNEURoSCI.1202-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEURoSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzai A et al. Self-reactive CD4+ IL-3+ T cells amplify autoimmune inflammation in myocarditis by inciting monocyte chemotaxis. J. Exp. Med 216, 369&#x2013;383 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6363430</ArticleId><ArticleId IdType="pubmed">30670465</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber GF et al. Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science (80-. ). 347, 1260&#x2013;1265 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4376966</ArticleId><ArticleId IdType="pubmed">25766237</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR et al. Cutting Edge: TREM-2 Attenuates Macrophage Activation. J. Immunol (2006) doi:10.4049/jimmunol.177.6.3520.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.6.3520</ArticleId><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Doench JG et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol (2016) doi:10.1038/nbt.3437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3437</ArticleId><ArticleId IdType="pmc">PMC4744125</ArticleId><ArticleId IdType="pubmed">26780180</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae S, Park J &amp; Kim JS Cas-OFFinder: A fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics (2014) doi:10.1093/bioinformatics/btu048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu048</ArticleId><ArticleId IdType="pmc">PMC4016707</ArticleId><ArticleId IdType="pubmed">24463181</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiau T et al. Inference of CRISPR Edits from Sanger Trace Data. bioRxiv (2018) doi:10.1101/251082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/251082</ArticleId><ArticleId IdType="pubmed">35119294</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinstiver BP et al. Engineered CRISPR&#x2013;Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat. Biotechnol (2019) doi:10.1038/s41587-018-0011-0-0011-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-018-0011-0-0011-0</ArticleId><ArticleId IdType="pmc">PMC6401248</ArticleId><ArticleId IdType="pubmed">30742127</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohland N &amp; Reich D Cost-effective, high-throughput DNA sequencing libraries for multiplexed target capture. Genome Res. (2012) doi:10.1101/gr.128124.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.128124.111</ArticleId><ArticleId IdType="pmc">PMC3337438</ArticleId><ArticleId IdType="pubmed">22267522</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins CS et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat. Med (2013) doi:10.1038/nm.3258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3258</ArticleId><ArticleId IdType="pmc">PMC3769444</ArticleId><ArticleId IdType="pubmed">23933982</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL &amp; Miller TM Direct intraventricular delivery of drugs to the rodent central nervous system. J. Vis. Exp (2013) doi:10.3791/50326.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/50326</ArticleId><ArticleId IdType="pmc">PMC3679837</ArticleId><ArticleId IdType="pubmed">23712122</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A et al. TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer&#x2019;s Disease. Neuron 103, 820&#x2013;835.e7 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6728215</ArticleId><ArticleId IdType="pubmed">31301936</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH et al. A three-dimensional human neural cell culture model of Alzheimer&#x2019;s disease. Nature 515, 274&#x2013;278 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366007</ArticleId><ArticleId IdType="pubmed">25307057</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J et al. A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer&#x2019;s disease. Nat. Neurosci 21, 941&#x2013;951 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800152</ArticleId><ArticleId IdType="pubmed">29950669</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A et al. Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol. Neurodegener (2018) doi:10.1186/s13024-018-0297-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0297-x</ArticleId><ArticleId IdType="pmc">PMC6303871</ArticleId><ArticleId IdType="pubmed">30577865</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A et al. Alzheimer&#x2019;s disease risk gene cd33 inhibits microglial uptake of amyloid beta. Neuron 78, 631&#x2013;643 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraeuter AK, Guest PC &amp; Sarnyai Z The Y-Maze for Assessment of Spatial Working and Reference Memory in Mice. in Methods in Molecular Biology (2019). doi:10.1007/978-1-4939-8994-2_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-8994-2_10</ArticleId><ArticleId IdType="pubmed">30535688</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorhees CV &amp; Williams MT Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat. Protoc (2006) doi:10.1038/nprot.2006.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.116</ArticleId><ArticleId IdType="pmc">PMC2895266</ArticleId><ArticleId IdType="pubmed">17406317</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34262030</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>14</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome.</ArticleTitle><Pagination><StartPage>4304</StartPage><MedlinePgn>4304</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4304</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-021-24319-x</ELocationID><Abstract><AbstractText>Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73-0.87] and 0.92 [95% CI 0.89-0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2568-5478</Identifier><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain. alleo@santpau.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. alleo@santpau.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3930-4354</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;ndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pegueroles</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karikari</LastName><ForeName>Thomas K</ForeName><Initials>TK</Initials><Identifier Source="ORCID">0000-0003-1422-4358</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;ndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmona-Iragui</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona Down Medical Center, Fundaci&#xf3; Catalana S&#xed;ndrome de Down, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashton</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;ndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montal</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barroeta</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lantero-Rodr&#xed;guez</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7426-678X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;ndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Videla</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona Down Medical Center, Fundaci&#xf3; Catalana S&#xed;ndrome de Down, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altuna</LastName><ForeName>Miren</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9709-5314</Identifier><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benejam</LastName><ForeName>Bessy</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona Down Medical Center, Fundaci&#xf3; Catalana S&#xed;ndrome de Down, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Barcelona Down Medical Center, Fundaci&#xf3; Catalana S&#xed;ndrome de Down, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valldeneu</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garz&#xf3;n</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bejanin</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9958-0951</Identifier><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iulita</LastName><ForeName>Maria Florencia</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camacho</LastName><ForeName>Valle</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-0748-0847</Identifier><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medrano-Martorell</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6586-7284</Identifier><AffiliationInfo><Affiliation>Hospital del Mar-Universitat Aut&#xf2;noma Barcelona (UAB), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belbin</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-6109-6371</Identifier><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarimon</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Institute for Neurosciences of Montpellier, Universit&#xe9; de Montpellier, Centre Hospitalier Universitaire de Montpellier, INSERM, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcolea</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3819-3245</Identifier><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blesa</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-1890-4193</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;ndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain. jfortea@santpau.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. jfortea@santpau.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona Down Medical Center, Fundaci&#xf3; Catalana S&#xed;ndrome de Down, Barcelona, Spain. jfortea@santpau.cat.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/S005145/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R21 AG056974</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056850</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061566</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Dr. Lle&#xf3; has served as a consultant or at advisory boards for Fujirebio-Europe, Roche, Biogen and Nutricia. In addition, Dr. Lle&#xf3; has a patent WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease issued. Dr. Zetterberg has served as a consultant or at advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Dr. Alcolea has served as a consultant or at advisory boards for Krka Farmac&#xe9;utica S.L., Fujirebio-Europe, Roche Diagnostics and Nutricia. In addition, Dr. Alcolea has a patent WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease issued. Dr. Blennow has served as a consultant or at advisory boards for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Dr. Fortea has served as a consultant or at advisory boards for AC Immune, Novartis, and Merck. In addition, Dr. Fortea has a patent WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease issued. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>15</Day><Hour>5</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34262030</ArticleId><ArticleId IdType="pmc">PMC8280160</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-24319-x</ArticleId><ArticleId IdType="pii">10.1038/s41467-021-24319-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ballard C, Mobley W, Hardy J, Williams G, Corbett A. Dementia in Down&#x2019;s syndrome. Lancet Neurol. 2016;15:622&#x2013;636. doi: 10.1016/S1474-4422(16)00063-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00063-6</ArticleId><ArticleId IdType="pubmed">27302127</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittles AH, Bower C, Hussain R, Glasson EJ. The four ages of Down syndrome. Eur. J. Public Health. 2007;17:221&#x2013;225. doi: 10.1093/eurpub/ckl103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurpub/ckl103</ArticleId><ArticleId IdType="pubmed">16857692</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarron M, et al. A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. J. Intellect. Disabil. Res. 2017;61:843&#x2013;852. doi: 10.1111/jir.12390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jir.12390</ArticleId><ArticleId IdType="pubmed">28664561</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortea J, et al. Clinical and biomarker changes of Alzheimer&#x2019;s disease in adults with Down syndrome: a cross-sectional study. Lancet. 2020;395:1988&#x2013;1997. doi: 10.1016/S0140-6736(20)30689-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30689-9</ArticleId><ArticleId IdType="pmc">PMC7322523</ArticleId><ArticleId IdType="pubmed">32593336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hithersay R, et al. Association of dementia with mortality among adults with Down syndrome older than 35 years. JAMA Neurol. 2019;76:152&#x2013;160. doi: 10.1001/jamaneurol.2018.3616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.3616</ArticleId><ArticleId IdType="pmc">PMC6439956</ArticleId><ArticleId IdType="pubmed">30452522</ArticleId></ArticleIdList></Reference><Reference><Citation>Startin CM, et al. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer&#x2019;s disease. Alzheimers Res. Ther. 2019;11:26. doi: 10.1186/s13195-019-0477-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0477-0</ArticleId><ArticleId IdType="pmc">PMC6429702</ArticleId><ArticleId IdType="pubmed">30902060</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortea J, et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer&#x2019;s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 2018;17:860&#x2013;869. doi: 10.1016/S1474-4422(18)30285-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30285-0</ArticleId><ArticleId IdType="pubmed">30172624</ArticleId></ArticleIdList></Reference><Reference><Citation>Henson RL, et al. Cerebrospinal fluid biomarkers of Alzheimer&#x2019;s disease in a cohort of adults with Down syndrome. Alzheimers Dement. (Amst.) 2020;12:e12057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7346867</ArticleId><ArticleId IdType="pubmed">32671183</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Burnham SC. Blood-based molecular biomarkers for Alzheimer&#x2019;s disease. Mol. Brain. 2019;12:26. doi: 10.1186/s13041-019-0448-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-019-0448-1</ArticleId><ArticleId IdType="pmc">PMC6437931</ArticleId><ArticleId IdType="pubmed">30922367</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 2018;14:577&#x2013;589. doi: 10.1038/s41582-018-0058-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovod V, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13:841&#x2013;849. doi: 10.1016/j.jalz.2017.06.2266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.06.2266</ArticleId><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, et al. High performance plasma amyloid-beta biomarkers for Alzheimer&#x2019;s disease. Nature. 2018;554:249&#x2013;254. doi: 10.1038/nature25456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25456</ArticleId><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, et al. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647&#x2013;e1659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="pubmed">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer&#x2019;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422&#x2013;433. doi: 10.1016/S1474-4422(20)30071-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30071-5</ArticleId><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen, E. H. et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat. Med. 26, 387&#x2013;397 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, et al. Plasma p-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat. Med. 2020;26:379&#x2013;386. doi: 10.1038/s41591-020-0755-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0755-1</ArticleId><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, et al. Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14:989&#x2013;997. doi: 10.1016/j.jalz.2018.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.013</ArticleId><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772&#x2013;781. doi: 10.1001/jama.2020.12134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lantero Rodriguez J, et al. Plasma p-tau181 accurately predicts Alzheimer&#x2019;s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020;140:267&#x2013;278. doi: 10.1007/s00401-020-02195-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02195-x</ArticleId><ArticleId IdType="pmc">PMC7423866</ArticleId><ArticleId IdType="pubmed">32720099</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatebe H, et al. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer&#x2019;s disease and Down syndrome. Mol. Neurodegener. 2017;12:63. doi: 10.1186/s13024-017-0206-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0206-8</ArticleId><ArticleId IdType="pmc">PMC5582385</ArticleId><ArticleId IdType="pubmed">28866979</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor, A. et al. Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer&#x2019;s disease: a longitudinal cohort study. Mol. Psychiatry Jul 14. 10.1038/s41380-020-0838-x (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612227</ArticleId><ArticleId IdType="pubmed">32665603</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, et al. Advancing research diagnostic criteria for Alzheimer&#x2019;s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614&#x2013;629. doi: 10.1016/S1474-4422(14)70090-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70090-0</ArticleId><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer&#x2019;s disease. Sci. Transl. Med. 2014;6:226ra230. doi: 10.1126/scitranslmed.3007901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007901</ArticleId><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="pubmed">24598588</ArticleId></ArticleIdList></Reference><Reference><Citation>Lle&#xf3; A, et al. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer&#x2019;s disease continuum in the BIOMARKAPD study. Alzheimers Dement. 2019;15:742&#x2013;753. doi: 10.1016/j.jalz.2019.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.01.015</ArticleId><ArticleId IdType="pubmed">30967340</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N. Engl. J. Med. 2012;367:795&#x2013;804. doi: 10.1056/NEJMoa1202753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Illan-Gala I, et al. Challenges associated with biomarker-based classification systems for Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;10:346&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6114028</ArticleId><ArticleId IdType="pubmed">30175226</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings D, et al. Age dependence of brain beta-amyloid deposition in Down syndrome: an [18F]florbetaben PET study. Neurology. 2015;84:500&#x2013;507. doi: 10.1212/WNL.0000000000001212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001212</ArticleId><ArticleId IdType="pubmed">25568295</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcolea D, et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: a data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement. 2019;5:597&#x2013;609. doi: 10.1016/j.trci.2019.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2019.09.005</ArticleId><ArticleId IdType="pmc">PMC6804606</ArticleId><ArticleId IdType="pubmed">31650016</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcolea D, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer&#x2019;s disease on Lumipulse. Ann. Clin. Transl. Neurol. 2019;6:1815&#x2013;1824. doi: 10.1002/acn3.50873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.50873</ArticleId><ArticleId IdType="pmc">PMC6764494</ArticleId><ArticleId IdType="pubmed">31464088</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34253922</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Single-cell profiling of CNS border compartment leukocytes reveals that B cells and their progenitors reside in non-diseased meninges.</ArticleTitle><Pagination><StartPage>1225</StartPage><EndPage>1234</EndPage><MedlinePgn>1225-1234</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-021-00880-y</ELocationID><Abstract><AbstractText>The CNS is ensheathed by the meninges and cerebrospinal fluid, and recent findings suggest that these CNS-associated border tissues have complex immunological functions. Unlike myeloid lineage cells, lymphocytes in border compartments have yet to be thoroughly characterized. Based on single-cell transcriptomics, we here identified a highly location-specific composition and expression profile of tissue-resident leukocytes in CNS parenchyma, pia-enriched subdural meninges, dura mater, choroid plexus and cerebrospinal fluid. The dura layer of the meninges contained a large population of B cells under homeostatic conditions in mice and rats. Murine dura B cells exhibited slow turnover and long-term tissue residency, and they matured in experimental neuroinflammation. The dura also contained B lineage progenitors at the pro-B cell stage typically not found outside of bone marrow, without direct influx from the periphery or the skull bone marrow. This identified the dura as an unexpected site of B cell residence and potentially of development in both homeostasis and neuroinflammation.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Schafflick</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University Hospital M&#xfc;nster, Medical Faculty, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wolbert</LastName><ForeName>Jolien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University Hospital M&#xfc;nster, Medical Faculty, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Heming</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9568-2790</Identifier><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University Hospital M&#xfc;nster, Medical Faculty, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6642-7774</Identifier><AffiliationInfo><Affiliation>Institute of Neuropathology, University Hospital M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartlehnert</LastName><ForeName>Maike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University Hospital M&#xfc;nster, Medical Faculty, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf6;rsch</LastName><ForeName>Anna-Lena</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University Hospital M&#xfc;nster, Medical Faculty, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricci</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3051-8113</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;n-Salamanca</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Area of Cell and Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaolin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University Hospital M&#xfc;nster, Medical Faculty, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>I-Na</ForeName><Initials>IN</Initials><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University Hospital M&#xfc;nster, Medical Faculty, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pawlak</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minnerup</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University Hospital M&#xfc;nster, Medical Faculty, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strecker</LastName><ForeName>Jan-Kolja</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University Hospital M&#xfc;nster, Medical Faculty, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seidenbecher</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Physiology I, Westf&#xe4;lische Wilhelms-University M&#xfc;nster, Medical Faculty, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meuth</LastName><ForeName>Sven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University Hospital M&#xfc;nster, Medical Faculty, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidalgo</LastName><ForeName>Andres</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5513-555X</Identifier><AffiliationInfo><Affiliation>Area of Cell and Developmental Biology, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liesz</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiendl</LastName><ForeName>Heinz</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-4310-3432</Identifier><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University Hospital M&#xfc;nster, Medical Faculty, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer Zu Horste</LastName><ForeName>Gerd</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4341-4719</Identifier><AffiliationInfo><Affiliation>Department of Neurology with Institute of Translational Neurology, University Hospital M&#xfc;nster, Medical Faculty, M&#xfc;nster, Germany. gerd.meyerzuhoerste@ukmuenster.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008578" MajorTopicYN="N">Meninges</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054448" MajorTopicYN="N">Precursor Cells, B-Lymphoid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34253922</ArticleId><ArticleId IdType="doi">10.1038/s41593-021-00880-y</ArticleId><ArticleId IdType="pii">10.1038/s41593-021-00880-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Engelhardt, B., Vajkoczy, P. &amp; Weller, R. O. The movers and shapers in immune privilege of the CNS. Nat. Immunol. 18, 123&#x2013;131 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28092374</ArticleId><ArticleId IdType="doi">10.1038/ni.3666</ArticleId></ArticleIdList></Reference><Reference><Citation>Aspelund, A. et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212, 991&#x2013;999 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26077718</ArticleId><ArticleId IdType="pmc">4493418</ArticleId><ArticleId IdType="doi">10.1084/jem.20142290</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337&#x2013;341 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26030524</ArticleId><ArticleId IdType="pmc">4506234</ArticleId><ArticleId IdType="doi">10.1038/nature14432</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau, A. et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat. Neurosci. 21, 1380&#x2013;1391 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30224810</ArticleId><ArticleId IdType="pmc">6214619</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0227-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivisakk, P. et al. Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann. Neurol. 65, 457&#x2013;469 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">18496841</ArticleId><ArticleId IdType="pmc">3305810</ArticleId><ArticleId IdType="doi">10.1002/ana.21379</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinnery, H. R., Ruitenberg, M. J. &amp; McMenamin, P. G. Novel characterization of monocyte-derived cell populations in the meninges and choroid plexus and their rates of replenishment in bone marrow chimeric mice. J. Neuropathol. Exp. Neurol. 69, 896&#x2013;909 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20720507</ArticleId><ArticleId IdType="doi">10.1097/NEN.0b013e3181edbc1a</ArticleId></ArticleIdList></Reference><Reference><Citation>Mundt, S. et al. Conventional DCs sample and present myelin antigens in the healthy CNS and allow parenchymal T cell entry to initiate neuroinflammation. Sci. Immunol. 4, eaau8380 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30679199</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.aau8380</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hove, H. et al. A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat. Neurosci. 22, 1021&#x2013;1035 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31061494</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0393-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Jord&#xe3;o, M. J. C. et al. Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science 363, eaat7554 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30679343</ArticleId><ArticleId IdType="doi">10.1126/science.aat7554</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinert, E. M. et al. Quantifying memory CD8 T cells reveals regionalization of immunosurveillance. Cell 161, 737&#x2013;749 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25957682</ArticleId><ArticleId IdType="pmc">4426972</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2015.03.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafflick, D. et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat. Commun. 11, 247 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31937773</ArticleId><ArticleId IdType="pmc">6959356</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-14118-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayed, B. A., Christy, A. L., Walker, M. E. &amp; Brown, M. A. Meningeal mast cells affect early T cell central nervous system infiltration and blood-brain barrier integrity through TNF: a role for neutrophil recruitment? J. Immunol. 184, 6891&#x2013;6900 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20488789</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1000126</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawant, K. V. et al. Chemokine CXCL1 mediated neutrophil recruitment: role of glycosaminoglycan interactions. Sci. Rep. 6, 33123 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27625115</ArticleId><ArticleId IdType="pmc">5021969</ArticleId><ArticleId IdType="doi">10.1038/srep33123</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell, O. W. et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134, 2755&#x2013;2771 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21840891</ArticleId><ArticleId IdType="doi">10.1093/brain/awr182</ArticleId></ArticleIdList></Reference><Reference><Citation>Pr&#xf6;bstel, A.-K. et al. Gut microbiota&#x2013;specific IgA<sup>+</sup> B cells traffic to the CNS in active multiple sclerosis. Sci. Immunol. 5, eabc7191 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33219152</ArticleId><ArticleId IdType="pmc">8043673</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.abc7191</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick, Z. et al. Gut-educated IgA plasma cells defend the meningeal venous sinuses. Nature 587, 472&#x2013;476 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33149302</ArticleId><ArticleId IdType="pmc">7748383</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2886-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker Harp, C. R. et al. Neutrophils promote VLA-4-dependent B cell antigen presentation and accumulation within the meninges during neuroinflammation. Proc. Natl Acad. Sci. USA 116, 24221&#x2013;24230 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31699814</ArticleId><ArticleId IdType="pmc">6883802</ArticleId><ArticleId IdType="doi">10.1073/pnas.1909098116</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke, G., Steinhauser, G., Gr&#xfc;n, J. &amp; Berek, C. In silico subtraction approach reveals a close lineage relationship between follicular dendritic cells and BP3(hi) stromal cells isolated from SCID mice. Eur. J. Immunol. 40, 2165&#x2013;2173 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20518031</ArticleId><ArticleId IdType="doi">10.1002/eji.200940202</ArticleId></ArticleIdList></Reference><Reference><Citation>Heming, M. et al. Neurological manifestations of COVID-19 feature T cell exhaustion and dedifferentiated monocytes in cerebrospinal fluid. Immunity 54, 164&#x2013;175.e6 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33382973</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2020.12.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaffer, S., Maul-Pavicic, A., Voll, R. E. &amp; Chevalier, N. Optimized isolation of renal plasma cells for flow cytometric analysis. J. Immunol. Methods 474, 112628 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31254500</ArticleId><ArticleId IdType="doi">10.1016/j.jim.2019.06.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnarfi, N. et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J. Exp. Med. 210, 2921&#x2013;2937 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24323356</ArticleId><ArticleId IdType="pmc">3865476</ArticleId><ArticleId IdType="doi">10.1084/jem.20130699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunis, G. et al. IFN-&#x3b3;-dependent activation of the brain&#x2019;s choroid plexus for CNS immune surveillance and repair. Brain 136, 3427&#x2013;3440 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24088808</ArticleId><ArticleId IdType="doi">10.1093/brain/awt259</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau, A., Filiano, A. J. &amp; Kipnis, J. Meningeal whole mount preparation and characterization of neural cells by flow cytometry. Curr. Protoc. Immunol. 121, e50 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30008983</ArticleId><ArticleId IdType="pmc">6040815</ArticleId><ArticleId IdType="doi">10.1002/cpim.50</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn, J. H. et al. Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid. Nature 572, 62&#x2013;66 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31341278</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1419-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabula Muris Consortium et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. Nature 562, 367&#x2013;372 (2018).</Citation></Reference><Reference><Citation>Han, X. et al. Mapping the mouse cell atlas by Microwell-seq. Cell 172, 1091&#x2013;1107.e17 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29474909</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2018.02.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendall, S. C. et al. Single-cell trajectory detection uncovers progression and regulatory coordination in human B cell development. Cell 157, 714&#x2013;725 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24766814</ArticleId><ArticleId IdType="pmc">4045247</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2014.04.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Mombaerts, P. et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869&#x2013;877 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1547488</ArticleId><ArticleId IdType="doi">10.1016/0092-8674(92)90030-G</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura, D., Roes, J., K&#xfc;hn, R. &amp; Rajewsky, K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin &#x3bc; chain gene. Nature 350, 423&#x2013;426 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1901381</ArticleId><ArticleId IdType="doi">10.1038/350423a0</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright, D. E., Wagers, A. J., Gulati, A. P., Johnson, F. L. &amp; Weissman, I. L. Physiological migration of hematopoietic stem and progenitor cells. Science 294, 1933&#x2013;1936 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11729320</ArticleId><ArticleId IdType="doi">10.1126/science.1064081</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai, R. et al. Panoptic imaging of transparent mice reveals whole-body neuronal projections and skull&#x2013;meninges connections. Nat. Neurosci. 22, 317&#x2013;327 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30598527</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0301-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Herisson, F. et al. Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration. Nat. Neurosci. 21, 1209&#x2013;1217 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30150661</ArticleId><ArticleId IdType="pmc">6148759</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0213-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao, H. et al. Leukaemia hijacks a neural mechanism to invade the central nervous system. Nature 560, 55&#x2013;60 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30022166</ArticleId><ArticleId IdType="doi">10.1038/s41586-018-0342-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth, T. L. et al. Transcranial amelioration of inflammation and cell death after brain injury. Nature 505, 223&#x2013;228 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24317693</ArticleId><ArticleId IdType="doi">10.1038/nature12808</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;neboom, A. et al. A network of trans-cortical capillaries as mainstay for blood circulation in long bones. Nat. Metab. 1, 236&#x2013;250 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31620676</ArticleId><ArticleId IdType="pmc">6795552</ArticleId><ArticleId IdType="doi">10.1038/s42255-018-0016-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Korin, B. et al. High-dimensional, single-cell characterization of the brain&#x2019;s immune compartment. Nat. Neurosci. 20, 1300&#x2013;1309 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28758994</ArticleId><ArticleId IdType="doi">10.1038/nn.4610</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepok, S. et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128, 1667&#x2013;1676 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15800022</ArticleId><ArticleId IdType="doi">10.1093/brain/awh486</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado-Santos, J. et al. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8<sup>+</sup> T lymphocytes and B cells. Brain 141, 2066&#x2013;2082 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29873694</ArticleId><ArticleId IdType="pmc">6022681</ArticleId><ArticleId IdType="doi">10.1093/brain/awy151</ArticleId></ArticleIdList></Reference><Reference><Citation>Magliozzi, R. et al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann. Neurol. 68, 477&#x2013;493 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20976767</ArticleId><ArticleId IdType="doi">10.1002/ana.22230</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh-Takayama, N. et al. Bacteria-induced group 2 innate lymphoid cells in the stomach provide immune protection through induction of IgA. Immunity 52, 635&#x2013;649.e4 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32240600</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2020.03.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegg, C. C., He, C., Stroink, A. R., Kattner, K. A. &amp; Wang, C. X. Technique for collection of cerebrospinal fluid from the cisterna magna in rat. J. Neurosci. Methods 187, 8&#x2013;12 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20005255</ArticleId><ArticleId IdType="doi">10.1016/j.jneumeth.2009.12.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowyer, J. F. et al. A visual description of the dissection of the cerebral surface vasculature and associated meninges and the choroid plexus from rat brain. J. Vis. Exp. 14, e4285 (2012).</Citation></Reference><Reference><Citation>Korn, T. et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 13, 423&#x2013;431 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17384649</ArticleId><ArticleId IdType="pmc">3427780</ArticleId><ArticleId IdType="doi">10.1038/nm1564</ArticleId></ArticleIdList></Reference><Reference><Citation>Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. &amp; Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495&#x2013;502 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25867923</ArticleId><ArticleId IdType="pmc">4430369</ArticleId><ArticleId IdType="doi">10.1038/nbt.3192</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafemeister, C. &amp; Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 296 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31870423</ArticleId><ArticleId IdType="pmc">6927181</ArticleId><ArticleId IdType="doi">10.1186/s13059-019-1874-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289&#x2013;1296 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31740819</ArticleId><ArticleId IdType="pmc">6884693</ArticleId><ArticleId IdType="doi">10.1038/s41592-019-0619-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, H., Zhou, Y., Fei, L., Chen, H. &amp; Guo, G. scMCA: a tool to define mouse cell types based on single-cell digital expression. Methods Mol. Biol. 1935, 91&#x2013;96 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30758821</ArticleId><ArticleId IdType="doi">10.1007/978-1-4939-9057-3_6</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90&#x2013;W97 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27141961</ArticleId><ArticleId IdType="pmc">4987924</ArticleId><ArticleId IdType="doi">10.1093/nar/gkw377</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14, 128 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23586463</ArticleId><ArticleId IdType="pmc">3637064</ArticleId><ArticleId IdType="doi">10.1186/1471-2105-14-128</ArticleId></ArticleIdList></Reference><Reference><Citation>Borcherding, N., Bormann, N. L. &amp; Kraus, G. scRepertoire: an R-based toolkit for single-cell immune receptor analysis. F1000Res. 9, 47 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32789006</ArticleId><ArticleId IdType="pmc">7400693</ArticleId><ArticleId IdType="doi">10.12688/f1000research.22139.2</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillje, R., Pelicci, P. G. &amp; Luzi, L. Cerebro: interactive visualization of scRNA-seq data. Bioinformatics 36, 2311&#x2013;2313 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31764967</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btz877</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34617884</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-084X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2021</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>eLife</Title><ISOAbbreviation>Elife</ISOAbbreviation></Journal><ArticleTitle>NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e72034</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7554/eLife.72034</ELocationID><Abstract><AbstractText>Apolipoprotein E4 (ApoE4) is the most important and prevalent risk factor for late-onset Alzheimer's disease (AD). The isoelectric point of ApoE4 matches the pH of the early endosome (EE), causing its delayed dissociation from ApoE receptors and hence impaired endolysosomal trafficking, disruption of synaptic homeostasis, and reduced amyloid clearance. We have shown that enhancing endosomal acidification by inhibiting the EE-specific sodium-hydrogen exchanger 6 (NHE6) restores vesicular trafficking and normalizes synaptic homeostasis. Remarkably and unexpectedly, loss of NHE6 (encoded by the gene <i>Slc9a6</i>) in mice effectively suppressed amyloid deposition even in the absence of ApoE4, suggesting that accelerated acidification of EEs caused by the absence of NHE6 occludes the effect of ApoE on amyloid plaque formation. NHE6 suppression or inhibition may thus be a universal, ApoE-independent approach to prevent amyloid buildup in the brain. These findings suggest a novel therapeutic approach for the prevention of AD by which partial NHE6 inhibition reverses the ApoE4-induced endolysosomal trafficking defect and reduces plaque load.</AbstractText><CopyrightInformation>&#xa9; 2021, Pohlkamp et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Pohlkamp</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3923-1917</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Neurodegeneration Research, Dallas, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Xian</LastName><ForeName>Xunde</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Neurodegeneration Research, Dallas, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiovascular Sciences and Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wong</LastName><ForeName>Connie H</ForeName><Initials>CH</Initials><Identifier Source="ORCID">0000-0002-6452-7966</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Neurodegeneration Research, Dallas, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durakoglugil</LastName><ForeName>Murat S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0003-4483-8166</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Neurodegeneration Research, Dallas, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werthmann</LastName><ForeName>Gordon Chandler</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Neurodegeneration Research, Dallas, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, Riken Center for Brain Science, Wako, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evers</LastName><ForeName>Bret M</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0000-0001-5686-0315</Identifier><AffiliationInfo><Affiliation>Center for Translational Neurodegeneration Research, Dallas, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials><Suffix>3rd</Suffix><Identifier Source="ORCID">0000-0002-3870-2804</Identifier><AffiliationInfo><Affiliation>Pathology, University of Texas Southwestern Medical Center, Dallas, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Connor</LastName><ForeName>Jade</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Neurodegeneration Research, Dallas, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammer</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herz</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8506-3400</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Translational Neurodegeneration Research, Dallas, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS093382</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL063762</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS108115</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG053391</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD021684</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG067708</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 HL063762</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Elife</MedlineTA><NlmUniqueID>101579614</NlmUniqueID><ISSNLinking>2050-084X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026503">Low Density Lipoprotein Receptor-Related Protein-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486645">Lrp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C503961">NHE6 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017923">Sodium-Hydrogen Exchangers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026503" MajorTopicYN="N">Low Density Lipoprotein Receptor-Related Protein-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017923" MajorTopicYN="N">Sodium-Hydrogen Exchangers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's</Keyword><Keyword MajorTopicYN="N">ApoE</Keyword><Keyword MajorTopicYN="N">NHE6</Keyword><Keyword MajorTopicYN="N">endosome</Keyword><Keyword MajorTopicYN="N">mouse</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neuroscience</Keyword><Keyword MajorTopicYN="N">trafficking</Keyword></KeywordList><CoiStatement>TP, CW, MD, GW, TS, BE, CW, JC, RH No competing interests declared, XX, JH Inventor of Patent: https://patents.google.com/patent/US20110136832A1/en</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>7</Day><Hour>12</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34617884</ArticleId><ArticleId IdType="pmc">PMC8547963</ArticleId><ArticleId IdType="doi">10.7554/eLife.72034</ArticleId><ArticleId IdType="pii">72034</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arboleda-Velasquez JF, Lopera F, O&#x2019;Hare M, Delgado-Tirado S, Marino C, Chmielewska N, Saez-Torres KL, Amarnani D, Schultz AP, Sperling RA, Leyton-Cifuentes D, Chen K, Baena A, Aguillon D, Rios-Romenets S, Giraldo M, Guzm&#xe1;n-V&#xe9;lez E, Norton DJ, Pardilla-Delgado E, Artola A, Sanchez JS, Acosta-Uribe J, Lalli M, Kosik KS, Huentelman MJ, Zetterberg H, Blennow K, Reiman RA, Luo J, Chen Y, Thiyyagura P, Su Y, Jun GR, Naymik M, Gai X, Bootwalla M, Ji J, Shen L, Miller JB, Kim LA, Tariot PN, Johnson KA, Reiman EM, Quiroz YT. Resistance to autosomal dominant Alzheimer&#x2019;s disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine. 2019;25:1680&#x2013;1683. doi: 10.1038/s41591-019-0611-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0611-3</ArticleId><ArticleId IdType="pmc">PMC6898984</ArticleId><ArticleId IdType="pubmed">31686034</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu SK, Goldstein JL, Anderson GW, Brown MS. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. PNAS. 1976;73:3178&#x2013;3182. doi: 10.1073/pnas.73.9.3178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.73.9.3178</ArticleId><ArticleId IdType="pmc">PMC430973</ArticleId><ArticleId IdType="pubmed">184464</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U, Weeber EJ, Durudas A, Qiu S, Masiulis I, Sweatt JD, Li W-P, Adelmann G, Frotscher M, Hammer RE, Herz J. Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2. Neuron. 2005;47:567&#x2013;579. doi: 10.1016/j.neuron.2005.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.07.007</ArticleId><ArticleId IdType="pubmed">16102539</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, Karran E, De Strooper B. The toxic A&#x3b2; oligomer and Alzheimer&#x2019;s disease: an emperor in need of clothes. Nature Neuroscience. 2012;15:349&#x2013;357. doi: 10.1038/nn.3028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3028</ArticleId><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Braybrooke JP, Spink KG, Thacker J, Hickson ID. The RAD51 family member, RAD51L3, is a DNA-stimulated ATPase that forms a complex with XRCC2. The Journal of Biological Chemistry. 2000;275:29100&#x2013;29106. doi: 10.1074/jbc.M002075200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M002075200</ArticleId><ArticleId IdType="pubmed">10871607</ArticleId></ArticleIdList></Reference><Reference><Citation>Brich J, Shie F-S, Howell BW, Li R, Tus K, Wakeland EK, Jin L-W, Mumby M, Churchill G, Herz J, Cooper JA. Genetic modulation of tau phosphorylation in the mouse. The Journal of Neuroscience. 2003;23:187&#x2013;192. doi: 10.1523/JNEUROSCI.23-01-00187.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-01-00187.2003</ArticleId><ArticleId IdType="pmc">PMC6742161</ArticleId><ArticleId IdType="pubmed">12514215</ArticleId></ArticleIdList></Reference><Reference><Citation>Caporaso GL, Takei K, Gandy SE, Matteoli M, Mundigl O, Greengard P, De Camilli P. Morphologic and biochemical analysis of the intracellular trafficking of the Alzheimer beta/A4 amyloid precursor protein. The Journal of Neuroscience. 1994;14:3122&#x2013;3138. doi: 10.1523/JNEUROSCI.14-05-03122.1994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.14-05-03122.1994</ArticleId><ArticleId IdType="pmc">PMC6577440</ArticleId><ArticleId IdType="pubmed">8182461</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey JR, Grinstein S, Orlowski J. Sensors and regulators of intracellular pH. Nature Reviews. Molecular Cell Biology. 2010;11:50&#x2013;61. doi: 10.1038/nrm2820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2820</ArticleId><ArticleId IdType="pubmed">19997129</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer&#x2019;s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. The American Journal of Pathology. 2000;157:277&#x2013;286. doi: 10.1016/s0002-9440(10)64538-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9440(10)64538-5</ArticleId><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Beffert U, Ertunc M, Tang TS, Kavalali ET, Bezprozvanny I, Herz J. Reelin modulates NMDA receptor activity in cortical neurons. The Journal of Neuroscience. 2005;25:8209&#x2013;8216. doi: 10.1523/JNEUROSCI.1951-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1951-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725528</ArticleId><ArticleId IdType="pubmed">16148228</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Durakoglugil MS, Xian X, Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. PNAS. 2010;107:12011&#x2013;12016. doi: 10.1073/pnas.0914984107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0914984107</ArticleId><ArticleId IdType="pmc">PMC2900641</ArticleId><ArticleId IdType="pubmed">20547867</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Rimmler JB, Locke PA, Conneally PM, Schmader KE. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genetics. 1994;7:180&#x2013;184. doi: 10.1038/ng0694-180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0694-180</ArticleId><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis CG, Goldstein JL, S&#xfc;dhof TC, Anderson RG, Russell DW, Brown MS. Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. Nature. 1987;326:760&#x2013;765. doi: 10.1038/326760a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/326760a0</ArticleId><ArticleId IdType="pubmed">3494949</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bouteiller O, Merck E, Hasan UA, Hubac S, Benguigui B, Trinchieri G, Bates EEM, Caux C. Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. The Journal of Biological Chemistry. 2005;280:38133&#x2013;38145. doi: 10.1074/jbc.M507163200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M507163200</ArticleId><ArticleId IdType="pubmed">16144834</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane EC, Ilie AE, Sizdahkhani S, Das Gupta M, Orlowski J, McKinney RA. Enhanced recruitment of endosomal Na+/H+ exchanger NHE6 into Dendritic spines of hippocampal pyramidal neurons during NMDA receptor-dependent long-term potentiation. The Journal of Neuroscience. 2013;33:595&#x2013;610. doi: 10.1523/JNEUROSCI.2583-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2583-12.2013</ArticleId><ArticleId IdType="pmc">PMC6704919</ArticleId><ArticleId IdType="pubmed">23303939</ArticleId></ArticleIdList></Reference><Reference><Citation>Durakoglugil MS, Chen Y, White CL, Kavalali ET, Herz J. Reelin signaling antagonizes beta-amyloid at the synapse. PNAS. 2009;106:15938&#x2013;15943. doi: 10.1073/pnas.0908176106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908176106</ArticleId><ArticleId IdType="pmc">PMC2747222</ArticleId><ArticleId IdType="pubmed">19805234</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Arcangelo G, Nakajima K, Miyata T, Ogawa M, Mikoshiba K, Curran T. Reelin is a secreted glycoprotein recognized by the CR-50 monoclonal antibody. The Journal of Neuroscience. 1997;17:23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793694</ArticleId><ArticleId IdType="pubmed">8987733</ArticleId></ArticleIdList></Reference><Reference><Citation>Eto M, Watanabe K, Ishii K. A rapid flat gel isoelectric focusing method for the determination of apolipoprotein E phenotypes and its application. Clinica Chimica Acta; International Journal of Clinical Chemistry. 1985;149:21&#x2013;28. doi: 10.1016/0009-8981(85)90269-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0009-8981(85)90269-4</ArticleId><ArticleId IdType="pubmed">4028432</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer&#x2019;s disease. Neurobiology of Disease. 2002;9:305&#x2013;318. doi: 10.1006/nbdi.2002.0483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2002.0483</ArticleId><ArticleId IdType="pubmed">11950276</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Monreal M, S&#xe1;nchez-Castillo C, Esteban JA. APPL1 gates long-term potentiation through its plekstrin homology domain. Journal of Cell Science. 2016;129:2793&#x2013;2803. doi: 10.1242/jcs.183475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.183475</ArticleId><ArticleId IdType="pubmed">27257087</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer AH, Jacobson KA, Rose J, Zeller R. Hematoxylin and eosin staining of tissue and cell sections. Cold Spring Harbor Protocols. 2008;2008:prot4986. doi: 10.1101/pdb.prot4986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/pdb.prot4986</ArticleId><ArticleId IdType="pubmed">21356829</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus. 2019;5:4&#x2013;10. doi: 10.1177/0961203396005001031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203396005001031</ArticleId><ArticleId IdType="pubmed">8803903</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S, Casey AE, Sargeant TJ, M&#xe4;kinen V-P. Genetic variation within endolysosomal system is associated with late-onset Alzheimer&#x2019;s disease. Brain. 2018;141:2711&#x2013;2720. doi: 10.1093/brain/awy197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy197</ArticleId><ArticleId IdType="pubmed">30124770</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao AYL, Ilie A, Chang PKY, Orlowski J, McKinney RA. A Christianson syndrome-linked deletion mutation (&#x394;287ES288) in SLC9A6 impairs hippocampal neuronal plasticity. Neurobiology of Disease. 2019;130:104490. doi: 10.1016/j.nbd.2019.104490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104490</ArticleId><ArticleId IdType="pubmed">31175985</ArticleId></ArticleIdList></Reference><Reference><Citation>Guntern R, Bouras C, Hof PR, Vallet PG. An improved thioflavine S method for staining neurofibrillary tangles and senile plaques in Alzheimer&#x2019;s disease. Experientia. 1992;48:8&#x2013;10. doi: 10.1007/BF01923594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01923594</ArticleId><ArticleId IdType="pubmed">1371102</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harbor Perspectives in Medicine. 2012;2:a006270. doi: 10.1101/cshperspect.a006270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006270</ArticleId><ArticleId IdType="pmc">PMC3331683</ArticleId><ArticleId IdType="pubmed">22553493</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Developmental Biology. 2002;244:305&#x2013;318. doi: 10.1006/dbio.2002.0597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/dbio.2002.0597</ArticleId><ArticleId IdType="pubmed">11944939</ArticleId></ArticleIdList></Reference><Reference><Citation>Heeren J, Weber W, Beisiegel U. tracellular processing of endocytosed triglyceride-rich lipoproteins comprises both recycling and degradation. Journal of Cell Science. 1999;112:349&#x2013;359. doi: 10.1242/jcs.112.3.349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.112.3.349</ArticleId><ArticleId IdType="pubmed">9885288</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiesberger T, Trommsdorff M, Howell BW, Goffinet A, Mumby MC, Cooper JA, Herz J. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron. 1999;24:481&#x2013;489. doi: 10.1016/S0896-6273(00)80861-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80861-2</ArticleId><ArticleId IdType="pubmed">10571241</ArticleId></ArticleIdList></Reference><Reference><Citation>Hook VYH, Toneff T, Aaron W, Yasothornsrikul S, Bundey R, Reisine T. Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta-secretase activity in chromaffin vesicles. Journal of Neurochemistry. 2002;81:237&#x2013;256. doi: 10.1046/j.1471-4159.2002.00794.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.00794.x</ArticleId><ArticleId IdType="pubmed">12064471</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102. doi: 10.1126/science.274.5284.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5284.99</ArticleId><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh T-PV, Davis AA, Ulrich JD, Holtzman DM. Apolipoprotein E and Alzheimer&#x2019;s disease: the influence of apolipoprotein E on amyloid-&#x3b2; and other amyloidogenic proteins. Journal of Lipid Research. 2017;58:824&#x2013;836. doi: 10.1194/jlr.R075481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R075481</ArticleId><ArticleId IdType="pmc">PMC5408619</ArticleId><ArticleId IdType="pubmed">28246336</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilie A, Gao AYL, Boucher A, Park J, Berghuis AM, Hoffer MJV, Hilhorst-Hofstee Y, McKinney RA, Orlowski J. A potential gain-of-function variant of SLC9A6 leads to endosomal alkalinization and neuronal atrophy associated with Christianson Syndrome. Neurobiology of Disease. 2019;121:187&#x2013;204. doi: 10.1016/j.nbd.2018.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.10.002</ArticleId><ArticleId IdType="pubmed">30296617</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilie A, Boucher A, Park J, Berghuis AM, McKinney RA, Orlowski J. Assorted dysfunctions of endosomal alkali cation/proton exchanger SLC9A6 variants linked to Christianson syndrome. The Journal of Biological Chemistry. 2020;295:7075&#x2013;7095. doi: 10.1074/jbc.RA120.012614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA120.012614</ArticleId><ArticleId IdType="pmc">PMC7242699</ArticleId><ArticleId IdType="pubmed">32277048</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovic M, Sharma M, Rahajeng J, Caplan S. The early endosome: a busy sorting station for proteins at the crossroads. Histology and Histopathology. 2010;25:99&#x2013;112. doi: 10.14670/HH-25.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.14670/HH-25.99</ArticleId><ArticleId IdType="pmc">PMC2810677</ArticleId><ArticleId IdType="pubmed">19924646</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Amieva H, Petersen RC, Ch&#xe9;telat G, Holtzman DM, Hyman BT, Nixon RA, Jones DT. Alzheimer disease. Nature Reviews. Disease Primers. 2021;7:33. doi: 10.1038/s41572-021-00269-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-021-00269-y</ArticleId><ArticleId IdType="pmc">PMC8574196</ArticleId><ArticleId IdType="pubmed">33986301</ArticleId></ArticleIdList></Reference><Reference><Citation>Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, Sullivan PM, Maeda N. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. The Journal of Clinical Investigation. 1999;103:1579&#x2013;1586. doi: 10.1172/JCI6172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI6172</ArticleId><ArticleId IdType="pmc">PMC408371</ArticleId><ArticleId IdType="pubmed">10359567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, Bellenguez C, Frizatti A, Chouraki V, Martin ER, Sleegers K, Badarinarayan N, Jakobsdottir J, Hamilton-Nelson KL, Moreno-Grau S, Olaso R, Raybould R, Chen Y, Kuzma AB, Hiltunen M, Morgan T, Ahmad S, Vardarajan BN, Epelbaum J, Hoffmann P, Boada M, Beecham GW, Garnier J-G, Harold D, Fitzpatrick AL, Valladares O, Moutet M-L, Gerrish A, Smith AV, Qu L, Bacq D, Denning N, Jian X, Zhao Y, Del Zompo M, Fox NC, Choi S-H, Mateo I, Hughes JT, Adams HH, Malamon J, Sanchez-Garcia F, Patel Y, Brody JA, Dombroski BA, Naranjo MCD, Daniilidou M, Eiriksdottir G, Mukherjee S, Wallon D, Uphill J, Aspelund T, Cantwell LB, Garzia F, Galimberti D, Hofer E, Butkiewicz M, Fin B, Scarpini E, Sarnowski C, Bush WS, Meslage S, Kornhuber J, White CC, Song Y, Barber RC, Engelborghs S, Sordon S, Voijnovic D, Adams PM, Vandenberghe R, Mayhaus M, Cupples LA, Albert MS, De Deyn PP, Gu W, Himali JJ, Beekly D, Squassina A, Hartmann AM, Orellana A, Blacker D, Rodriguez-Rodriguez E, Lovestone S, Garcia ME, Doody RS, Munoz-Fernadez C, Sussams R, Lin H, Fairchild TJ, Benito YA, Holmes C, Karamuji&#x107;-&#x10c;omi&#x107; H, Frosch MP, Thonberg H, Maier W, Roshchupkin G, Ghetti B, Giedraitis V, Kawalia A, Li S, Huebinger RM, Kilander L, Moebus S, Hern&#xe1;ndez I, Kamboh MI, Brundin R, Turton J, Yang Q, Katz MJ, Concari L, Lord J, Beiser AS, Keene CD, Helisalmi S, Kloszewska I, Kukull WA, Koivisto AM, Lynch A, Tarraga L, Larson EB, Haapasalo A, Lawlor B, Mosley TH, Lipton RB, Solfrizzi V, Gill M, Longstreth WT, Jr, Montine TJ, Frisardi V, Diez-Fairen M, Rivadeneira F, Petersen RC, Deramecourt V, Alvarez I, Salani F, Ciaramella A, Boerwinkle E, Reiman EM, Fievet N, Rotter JI, Reisch JS, Hanon O, Cupidi C, Andre Uitterlinden AG, Royall DR, Dufouil C, Maletta RG, de Rojas I, Sano M, Brice A, Cecchetti R, George-Hyslop PS, Ritchie K, Tsolaki M, Tsuang DW, Dubois B, Craig D, Wu C-K, Soininen H, Avramidou D, Albin RL, Fratiglioni L, Germanou A, Apostolova LG, Keller L, Koutroumani M, Arnold SE, Panza F, Gkatzima O, Asthana S, Hannequin D, Whitehead P, Atwood CS, Caffarra P, Hampel H, Quintela I, Carracedo &#xc1;, Lannfelt L, Rubinsztein DC, Barnes LL, Pasquier F, Fr&#xf6;lich L, Barral S, McGuinness B, Beach TG, Johnston JA, Becker JT, Passmore P, Bigio EH, Schott JM, Bird TD, Warren JD, Boeve BF, Lupton MK, Bowen JD, Proitsi P, Boxer A, Powell JF, Burke JR, Kauwe JSK, Burns JM, Mancuso M, Buxbaum JD, Bonuccelli U, Cairns NJ, McQuillin A, Cao C, Livingston G, Carlson CS, Bass NJ, Carlsson CM, Hardy J, Carney RM, Bras J, Carrasquillo MM, Guerreiro R, Allen M, Chui HC, Fisher E, Masullo C, Crocco EA, DeCarli C, Bisceglio G, Dick M, Ma L, Duara R, Graff-Radford NR, Evans DA, Hodges A, Faber KM, Scherer M, Fallon KB, Riemenschneider M, Fardo DW, Heun R, Farlow MR, K&#xf6;lsch H, Ferris S, Leber M, Foroud TM, Heuser I, Galasko DR, Giegling I, Gearing M, H&#xfc;ll M, Geschwind DH, Gilbert JR, Morris J, Green RC, Mayo K, Growdon JH, Feulner T, Hamilton RL, Harrell LE, Drichel D, Honig LS, Cushion TD, Huentelman MJ, Hollingworth P, Hulette CM, Hyman BT, Marshall R, Jarvik GP, Meggy A, Abner E, Menzies GE, Jin L-W, Leonenko G, Real LM, Jun GR, Baldwin CT, Grozeva D, Karydas A, Russo G, Kaye JA, Kim R, Jessen F, Kowall NW, Vellas B, Kramer JH, Vardy E, LaFerla FM, J&#xf6;ckel K-H, Lah JJ, Dichgans M, Leverenz JB, Mann D, Levey AI, Pickering-Brown S, Lieberman AP, Klopp N, Lunetta KL, Wichmann H-E, Lyketsos CG, Morgan K, Marson DC, Brown K, Martiniuk F, Medway C, Mash DC, N&#xf6;then MM, Masliah E, Hooper NM, McCormick WC, Daniele A, McCurry SM, Bayer A, McDavid AN, Gallacher J, McKee AC, van den Bussche H, Mesulam M, Brayne C, Miller BL, Riedel-Heller S, Miller CA, Miller JW, Al-Chalabi A, Morris JC, Shaw CE, Myers AJ, Wiltfang J, O&#x2019;Bryant S, Olichney JM, Alvarez V, Parisi JE, Singleton AB, Paulson HL, Collinge J, Perry WR, Mead S, Peskind E, Cribbs DH, Rossor M, Pierce A, Ryan NS, Poon WW, Nacmias B, Potter H, Sorbi S, Quinn JF, Sacchinelli E, Raj A, Spalletta G, Raskind M, Caltagirone C, Boss&#xf9; P, Orfei MD, Reisberg B, Clarke R, Reitz C, Smith AD, Ringman JM, Warden D, Roberson ED, Wilcock G, Rogaeva E, Bruni AC, Rosen HJ, Gallo M, Rosenberg RN, Ben-Shlomo Y, Sager MA, Mecocci P, Saykin AJ, Pastor P, Cuccaro ML, Vance JM, Schneider JA, Schneider LS, Slifer S, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Swerdlow RH, Tang M, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Wilhelmsen KC, Williamson J, Wingo TS, Woltjer RL, Wright CB, Yu C-E, Yu L, Saba Y, Pilotto A, Bullido MJ, Peters O, Crane PK, Bennett D, Bosco P, Coto E, Boccardi V, De Jager PL, Lleo A, Warner N, Lopez OL, Ingelsson M, Deloukas P, Cruchaga C, Graff C, Gwilliam R, Fornage M, Goate AM, Sanchez-Juan P, Kehoe PG, Amin N, Ertekin-Taner N, Berr C, Debette S, Love S, Launer LJ, Younkin SG, Dartigues J-F, Corcoran C, Ikram MA, Dickson DW, Nicolas G, Campion D, Tschanz J, Schmidt H, Hakonarson H, Clarimon J, Munger R, Schmidt R, Farrer LA, Van Broeckhoven C, C O&#x2019;Donovan M, DeStefano AL, Jones L, Haines JL, Deleuze J-F, Owen MJ, Gudnason V, Mayeux R, Escott-Price V, Psaty BM, Ramirez A, Wang L-S, Ruiz A, van Duijn CM, Holmans PA, Seshadri S, Williams J, Amouyel P, Schellenberg GD, Lambert J-C, Pericak-Vance MA, Alzheimer Disease Genetics Consortium (ADGC) European Alzheimer&#x2019;s Disease Initiative (EADI) Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE) Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer&#x2019;s Disease Consortium (GERAD/PERADES) Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nature Genetics. 2019;51:414&#x2013;430. doi: 10.1038/s41588-019-0358-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. Journal of Immunology. 2011;186:4794&#x2013;4804. doi: 10.4049/jimmunol.1000702.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1000702</ArticleId><ArticleId IdType="pubmed">21398612</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane-Donovan C, Philips GT, Herz J. More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration. Neuron. 2014;83:771&#x2013;787. doi: 10.1016/j.neuron.2014.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.08.005</ArticleId><ArticleId IdType="pmc">PMC4240629</ArticleId><ArticleId IdType="pubmed">25144875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane-Donovan C, Philips GT, Wasser CR, Durakoglugil MS, Masiulis I, Upadhaya A, Pohlkamp T, Coskun C, Kotti T, Steller L, Hammer RE, Frotscher M, Bock HH, Herz J. Reelin protects against amyloid &#x3b2; toxicity in vivo. Science Signaling. 2015;8:ra67. doi: 10.1126/scisignal.aaa6674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.aaa6674</ArticleId><ArticleId IdType="pmc">PMC4652952</ArticleId><ArticleId IdType="pubmed">26152694</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane-Donovan C, Herz J. ApoE, ApoE Receptors, and the Synapse in Alzheimer&#x2019;s Disease. Trends in Endocrinology and Metabolism. 2017;28:273&#x2013;284. doi: 10.1016/j.tem.2016.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2016.12.001</ArticleId><ArticleId IdType="pmc">PMC5366078</ArticleId><ArticleId IdType="pubmed">28057414</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EC, Yu D, Martinez de Velasco J, Tessarollo L, Swing DA, Court DL, Jenkins NA, Copeland NG. A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics. 2001;73:56&#x2013;65. doi: 10.1006/geno.2000.6451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/geno.2000.6451</ArticleId><ArticleId IdType="pubmed">11352566</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee U, Choi C, Ryu SH, Park D, Lee SE, Kim K, Kim Y, Chang S. SCAMP5 plays a critical role in axonal trafficking and synaptic localization of NHE6 to adjust quantal size at glutamatergic synapses. PNAS. 2020;118:e2011371118. doi: 10.1073/pnas.2011371118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2011371118</ArticleId><ArticleId IdType="pmc">PMC7812776</ArticleId><ArticleId IdType="pubmed">33372133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee U, Ryu SH, Chang S. SCAMP5 mediates activity-dependent enhancement of NHE6 recruitment to synaptic vesicles during synaptic plasticity. Molecular Brain. 2021;14:47. doi: 10.1186/s13041-021-00763-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-021-00763-0</ArticleId><ArticleId IdType="pmc">PMC7934559</ArticleId><ArticleId IdType="pubmed">33663553</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao F, Zhang TJ, Jiang H, Lefton KB, Robinson GO, Vassar R, Sullivan PM, Holtzman DM. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathologica Communications. 2015;3:70. doi: 10.1186/s40478-015-0250-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0250-y</ArticleId><ArticleId IdType="pmc">PMC4641345</ArticleId><ArticleId IdType="pubmed">26556230</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucien F, Pelletier PP, Lavoie RR, Lacroix JM, Roy S, Parent JL, Arsenault D, Harper K, Dubois CM. Hypoxia-induced mobilization of NHE6 to the plasma membrane triggers endosome hyperacidification and chemoresistance. Nature Communications. 2017;8:15884. doi: 10.1038/ncomms15884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15884</ArticleId><ArticleId IdType="pmc">PMC5482059</ArticleId><ArticleId IdType="pubmed">28635961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Ouyang Q, Werthmann GC, Thompson HM, Morrow EM. Live-cell Microscopy and Fluorescence-based Measurement of Luminal pH in Intracellular Organelles. Frontiers in Cell and Developmental Biology. 2017;5:71. doi: 10.3389/fcell.2017.00071.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2017.00071</ArticleId><ArticleId IdType="pmc">PMC5566985</ArticleId><ArticleId IdType="pubmed">28871281</ArticleId></ArticleIdList></Reference><Reference><Citation>Madisen L, Zwingman TA, Sunkin SM, Oh SW, Zariwala HA, Gu H, Ng LL, Palmiter RD, Hawrylycz MJ, Jones AR, Lein ES, Zeng H. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nature Neuroscience. 2010;13:133&#x2013;140. doi: 10.1038/nn.2467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2467</ArticleId><ArticleId IdType="pmc">PMC2840225</ArticleId><ArticleId IdType="pubmed">20023653</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer&#x2019;s disease. Nature. 2008;451:720&#x2013;724. doi: 10.1038/nature06616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06616</ArticleId><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Minett T, Classey J, Matthews FE, Fahrenhold M, Taga M, Brayne C, Ince PG, Nicoll JAR, Boche D, MRC CFAS Microglial immunophenotype in dementia with Alzheimer&#x2019;s pathology. Journal of Neuroinflammation. 2016;13:135. doi: 10.1186/s12974-016-0601-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0601-z</ArticleId><ArticleId IdType="pmc">PMC4890505</ArticleId><ArticleId IdType="pubmed">27256292</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrow JA, Hatters DM, Lu B, Hochtl P, Oberg KA, Rupp B, Weisgraber KH. Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. The Journal of Biological Chemistry. 2002;277:50380&#x2013;50385. doi: 10.1074/jbc.M204898200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M204898200</ArticleId><ArticleId IdType="pubmed">12393895</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura N, Tanaka S, Teko Y, Mitsui K, Kanazawa H. Four Na+/H+ exchanger isoforms are distributed to Golgi and post-Golgi compartments and are involved in organelle pH regulation. The Journal of Biological Chemistry. 2005;280:1561&#x2013;1572. doi: 10.1074/jbc.M410041200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M410041200</ArticleId><ArticleId IdType="pubmed">15522866</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslavsky N, Caplan S. The enigmatic endosome - sorting the ins and outs of endocytic trafficking. Journal of Cell Science. 2018;131:jcs216499. doi: 10.1242/jcs.216499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.216499</ArticleId><ArticleId IdType="pmc">PMC6051342</ArticleId><ArticleId IdType="pubmed">29980602</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer&#x2019;s disease: inseparable partners in a multifactorial disease. FASEB Journal. 2017;31:2729&#x2013;2743. doi: 10.1096/fj.201700359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201700359</ArticleId><ArticleId IdType="pmc">PMC6137496</ArticleId><ArticleId IdType="pubmed">28663518</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuriel T, Peng KY, Ashok A, Dillman AA, Figueroa HY, Apuzzo J, Ambat J, Levy E, Cookson MR, Mathews PM, Duff KE. The Endosomal-Lysosomal Pathway Is Dysregulated by APOE4 Expression in Vivo. Frontiers in Neuroscience. 2017;11:702. doi: 10.3389/fnins.2017.00702.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00702</ArticleId><ArticleId IdType="pmc">PMC5733017</ArticleId><ArticleId IdType="pubmed">29311783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohgaki R, Matsushita M, Kanazawa H, Ogihara S, Hoekstra D, van Ijzendoorn SCD. The Na+/H+ exchanger NHE6 in the endosomal recycling system is involved in the development of apical bile canalicular surface domains in HepG2 cells. Molecular Biology of the Cell. 2010;21:1293&#x2013;1304. doi: 10.1091/mbc.E09-09-0767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E09-09-0767</ArticleId><ArticleId IdType="pmc">PMC2847532</ArticleId><ArticleId IdType="pubmed">20130086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ordovas JM, Litwack-Klein L, Wilson PW, Schaefer MM, Schaefer EJ. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. Journal of Lipid Research. 1987;28:371&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">3585172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouimet M, Barrett TJ, Fisher EA. HDL and Reverse Cholesterol Transport. Circulation Research. 2019;124:1505&#x2013;1518. doi: 10.1161/CIRCRESAHA.119.312617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.119.312617</ArticleId><ArticleId IdType="pmc">PMC6813799</ArticleId><ArticleId IdType="pubmed">31071007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang Q, Lizarraga SB, Schmidt M, Yang U, Gong J, Ellisor D, Kauer JA, Morrow EM. Christianson syndrome protein NHE6 modulates TrkB endosomal signaling required for neuronal circuit development. Neuron. 2013;80:97&#x2013;112. doi: 10.1016/j.neuron.2013.07.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.043</ArticleId><ArticleId IdType="pmc">PMC3830955</ArticleId><ArticleId IdType="pubmed">24035762</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza F, Solfrizzi V, Torres F, Mastroianni F, Colacicco AM, Basile AM, Capurso C, D&#x2019;Introno A, Del Parigi A, Capurso A. Apolipoprotein E in Southern Italy: protective effect of epsilon 2 allele in early- and late-onset sporadic Alzheimer&#x2019;s disease. Neuroscience Letters. 2000;292:79&#x2013;82. doi: 10.1016/s0304-3940(00)01447-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0304-3940(00)01447-6</ArticleId><ArticleId IdType="pubmed">10998553</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, M&#xfc;ller SA, Colombo A, Monasor LS, Tahirovic S, Herms J, Willem M, Pettkus N, Butovsky O, Bartenstein P, Edbauer D, Rominger A, Ert&#xfc;rk A, Grathwohl SA, Neher JJ, Holtzman DM, Meyer-Luehmann M, Haass C. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nature Neuroscience. 2019;22:191&#x2013;204. doi: 10.1038/s41593-018-0296-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0296-9</ArticleId><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Pensalfini A, Kim S, Subbanna S, Bleiwas C, Goulbourne CN, Stavrides PH, Jiang Y, Lee J-H, Darji S, Pawlik M, Huo C, Peddy J, Berg MJ, Smiley JF, Basavarajappa BS, Nixon RA. Endosomal Dysfunction Induced by Directly Overactivating Rab5 Recapitulates Prodromal and Neurodegenerative Features of Alzheimer&#x2019;s Disease. Cell Reports. 2020;33:108420. doi: 10.1016/j.celrep.2020.108420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108420</ArticleId><ArticleId IdType="pmc">PMC7714675</ArticleId><ArticleId IdType="pubmed">33238112</ArticleId></ArticleIdList></Reference><Reference><Citation>Petitjean H, Fatima T, Mouchbahani-Constance S, Davidova A, Ferland CE, Orlowski J, Sharif-Naeini R. Loss of SLC9A6/NHE6 impairs nociception in a mouse model of Christianson syndrome. Pain. 2020;161:2619&#x2013;2628. doi: 10.1097/j.pain.0000000000001961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000001961</ArticleId><ArticleId IdType="pmc">PMC7566297</ArticleId><ArticleId IdType="pubmed">32569089</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohlkamp T, Wasser CR, Herz J. Functional Roles of the Interaction of APP and Lipoprotein Receptors. Frontiers in Molecular Neuroscience. 2017;10:54. doi: 10.3389/fnmol.2017.00054.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00054</ArticleId><ArticleId IdType="pmc">PMC5331069</ArticleId><ArticleId IdType="pubmed">28298885</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad H, Rao R. The Na+/H+ exchanger NHE6 modulates endosomal pH to control processing of amyloid precursor protein in a cell culture model of Alzheimer disease. The Journal of Biological Chemistry. 2015;290:5311&#x2013;5327. doi: 10.1074/jbc.M114.602219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.602219</ArticleId><ArticleId IdType="pmc">PMC4342450</ArticleId><ArticleId IdType="pubmed">25561733</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad H, Rao R. Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH. PNAS. 2018;115:E6640&#x2013;E6649. doi: 10.1073/pnas.1801612115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1801612115</ArticleId><ArticleId IdType="pmc">PMC6048470</ArticleId><ArticleId IdType="pubmed">29946028</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawat V, Wang S, Sima J, Bar R, Liraz O, Gundimeda U, Parekh T, Chan J, Johansson JO, Tang C, Chui HC, Harrington MG, Michaelson DM, Yassine HN. ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes. The Journal of Neuroscience. 2019;39:9611&#x2013;9622. doi: 10.1523/JNEUROSCI.1400-19.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1400-19.2019</ArticleId><ArticleId IdType="pmc">PMC6880458</ArticleId><ArticleId IdType="pubmed">31641056</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, Chen Y, Su Y, Myers AJ, Hardy J, Paul Vonsattel J, Younkin SG, Bennett DA, De Jager PL, Larson EB, Crane PK, Keene CD, Kamboh MI, Kofler JK, Duque L, Gilbert JR, Gwirtsman HE, Buxbaum JD, Dickson DW, Frosch MP, Ghetti BF, Lunetta KL, Wang L-S, Hyman BT, Kukull WA, Foroud T, Haines JL, Mayeux RP, Pericak-Vance MA, Schneider JA, Trojanowski JQ, Farrer LA, Schellenberg GD, Beecham GW, Montine TJ, Jun GR, Alzheimer&#x2019;s Disease Genetics Consortium Exceptionally low likelihood of Alzheimer&#x2019;s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nature Communications. 2020;11:667. doi: 10.1038/s41467-019-14279-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-14279-8</ArticleId><ArticleId IdType="pmc">PMC6997393</ArticleId><ArticleId IdType="pubmed">32015339</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. Journal of Neuropathology and Experimental Neurology. 1994;53:429&#x2013;437. doi: 10.1097/00005072-199409000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199409000-00002</ArticleId><ArticleId IdType="pubmed">8083686</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudenko G, Henry L, Henderson K, Ichtchenko K, Brown MS, Goldstein JL, Deisenhofer J. Structure of the LDL receptor extracellular domain at endosomal pH. Science. 2002;298:2353&#x2013;2358. doi: 10.1126/science.1078124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1078124</ArticleId><ArticleId IdType="pubmed">12459547</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC. Single App knock-in mouse models of Alzheimer&#x2019;s disease. Nature Neuroscience. 2014;17:661&#x2013;663. doi: 10.1038/nn.3697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3697</ArticleId><ArticleId IdType="pubmed">24728269</ArticleId></ArticleIdList></Reference><Reference><Citation>Sando SB, Melquist S, Cannon A, Hutton ML, Sletvold O, Saltvedt I, White LR, Lydersen S, Aasly JO. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer&#x2019;s disease; a case control study from central Norway. BMC Neurology. 2008;8:9. doi: 10.1186/1471-2377-8-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-8-9</ArticleId><ArticleId IdType="pmc">PMC2375917</ArticleId><ArticleId IdType="pubmed">18416843</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarlus H, Heneka MT. Microglia in Alzheimer&#x2019;s disease. The Journal of Clinical Investigation. 2017;127:3240&#x2013;3249. doi: 10.1172/JCI90606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI90606</ArticleId><ArticleId IdType="pmc">PMC5669553</ArticleId><ArticleId IdType="pubmed">28862638</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid SL. Reciprocal regulation of signaling and endocytosis: Implications for the evolving cancer cell. The Journal of Cell Biology. 2017;216:2623&#x2013;2632. doi: 10.1083/jcb.201705017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201705017</ArticleId><ArticleId IdType="pmc">PMC5584184</ArticleId><ArticleId IdType="pubmed">28674108</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Muzikansky A, G&#xf3;mez-Isla T, Growdon JH, Betensky RA, Frosch MP, Hyman BT. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. Journal of Neuropathology and Experimental Neurology. 2013;72:462&#x2013;471. doi: 10.1097/NEN.0b013e3182933788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3182933788</ArticleId><ArticleId IdType="pmc">PMC3661683</ArticleId><ArticleId IdType="pubmed">23656989</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussi&#xe8;re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O&#x2019;Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature. 2016;537:50&#x2013;56. doi: 10.1038/nature19323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19323</ArticleId><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Andhey PS, Ising C, Wang K, Snipes LL, Boyer K, Lawson S, Yamada K, Qin W, Manis M, Serrano JR, Benitez BA, Schmidt RE, Artyomov M, Ulrich JD, Holtzman DM. Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms. Neuron. 2021;109:2413&#x2013;2426. doi: 10.1016/j.neuron.2021.05.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.05.034</ArticleId><ArticleId IdType="pmc">PMC8349883</ArticleId><ArticleId IdType="pubmed">34157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Tosaki A, Kaneko K, Hisano T, Sakurai T, Nukina N. Crystal structure of an active form of BACE1, an enzyme responsible for amyloid beta protein production. Molecular and Cellular Biology. 2008;28:3663&#x2013;3671. doi: 10.1128/MCB.02185-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.02185-07</ArticleId><ArticleId IdType="pmc">PMC2423307</ArticleId><ArticleId IdType="pubmed">18378702</ArticleId></ArticleIdList></Reference><Reference><Citation>Shore VG, Shore B. Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components. Biochemistry. 1973;12:502&#x2013;507. doi: 10.1021/bi00727a022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00727a022</ArticleId><ArticleId IdType="pubmed">4345806</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinclair RA, Burns J, Dunnill MS. Immunoperoxidase staining of formalin-fixed, paraffin-embedded, human renal biopsies with a comparison of the peroxidase-antiperoxidase (PAP) and indirect methods. Journal of Clinical Pathology. 1981;34:859&#x2013;865. doi: 10.1136/jcp.34.8.859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jcp.34.8.859</ArticleId><ArticleId IdType="pmc">PMC493958</ArticleId><ArticleId IdType="pubmed">7024314</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Simoes-Spassov S, Mayeux R, Petsko GA. Endosomal Traffic Jams Represent a Pathogenic Hub and Therapeutic Target in Alzheimer&#x2019;s Disease. Trends in Neurosciences. 2017;40:592&#x2013;602. doi: 10.1016/j.tins.2017.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2017.08.003</ArticleId><ArticleId IdType="pmc">PMC5654621</ArticleId><ArticleId IdType="pubmed">28962801</ArticleId></ArticleIdList></Reference><Reference><Citation>Stawicki TM, Owens KN, Linbo T, Reinhart KE, Rubel EW, Raible DW. The zebrafish merovingian mutant reveals a role for pH regulation in hair cell toxicity and function. Disease Models &amp; Mechanisms. 2014;7:847&#x2013;856. doi: 10.1242/dmm.016576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.016576</ArticleId><ArticleId IdType="pmc">PMC4073274</ArticleId><ArticleId IdType="pubmed">24973752</ArticleId></ArticleIdList></Reference><Reference><Citation>Str&#xf8;mme P, Dobrenis K, Sillitoe RV, Gulinello M, Ali NF, Davidson C, Micsenyi MC, Stephney G, Ellevog L, Klungland A, Walkley SU. X-linked Angelman-like syndrome caused by Slc9a6 knockout in mice exhibits evidence of endosomal-lysosomal dysfunction. Brain. 2011;134:3369&#x2013;3383. doi: 10.1093/brain/awr250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr250</ArticleId><ArticleId IdType="pmc">PMC3212719</ArticleId><ArticleId IdType="pubmed">21964919</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. The Journal of Biological Chemistry. 1997;272:17972&#x2013;17980. doi: 10.1074/jbc.272.29.17972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.29.17972</ArticleId><ArticleId IdType="pubmed">9218423</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallquist MD, Soriano P. Epiblast-restricted Cre expression in MORE mice: a tool to distinguish embryonic vs. extra-embryonic gene function. Genesis. 2000;26:113&#x2013;115. doi: 10.1002/(sici)1526-968x(200002)26:2&lt;113::aid-gene3&gt;3.0.co;2-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1526-968x(200002)26:2&lt;113::aid-gene3&gt;3.0.co;2-2</ArticleId><ArticleId IdType="pubmed">10686601</ArticleId></ArticleIdList></Reference><Reference><Citation>Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, Hammer RE, Richardson JA, Herz J. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell. 1999;97:689&#x2013;701. doi: 10.1016/S0092-8674(00)80782-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80782-5</ArticleId><ArticleId IdType="pubmed">10380922</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Acker ZP, Bretou M, Annaert W. Endo-lysosomal dysregulations and late-onset Alzheimer&#x2019;s disease: impact of genetic risk factors. Molecular Neurodegeneration. 2019;14:20. doi: 10.1186/s13024-019-0323-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0323-7</ArticleId><ArticleId IdType="pmc">PMC6547588</ArticleId><ArticleId IdType="pubmed">31159836</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741. doi: 10.1126/science.286.5440.735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.286.5440.735</ArticleId><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheijen J, Sleegers K. Understanding Alzheimer Disease at the Interface between Genetics and Transcriptomics. Trends in Genetics. 2018;34:434&#x2013;447. doi: 10.1016/j.tig.2018.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2018.02.007</ArticleId><ArticleId IdType="pubmed">29573818</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle S.E, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. The Journal of Biological Chemistry. 2004;279:40987&#x2013;40993. doi: 10.1074/jbc.M407963200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M407963200</ArticleId><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle S.E, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. The Journal of Biological Chemistry. 2005;280:43236&#x2013;43242. doi: 10.1074/jbc.M508780200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508780200</ArticleId><ArticleId IdType="pubmed">16207708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. The Journal of Clinical Investigation. 2008;118:671&#x2013;682. doi: 10.1172/JCI33622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI33622</ArticleId><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Jing T, Wang X, Yao D. Beta-secretase/BACE1 promotes APP endocytosis and processing in the endosomes and on cell membrane. Neuroscience Letters. 2018;685:63&#x2013;67. doi: 10.1016/j.neulet.2018.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2018.08.016</ArticleId><ArticleId IdType="pubmed">30120949</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnick GR, Mayfield C, Albers JJ, Hazzard WR. Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3. Clinical Chemistry. 1979;25:279&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">215348</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeber EJ, Beffert U, Jones C, Christian JM, Forster E, Sweatt JD, Herz J. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. The Journal of Biological Chemistry. 2002;277:39944&#x2013;39952. doi: 10.1074/jbc.M205147200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M205147200</ArticleId><ArticleId IdType="pubmed">12167620</ArticleId></ArticleIdList></Reference><Reference><Citation>West HL, Rebeck GW, Hyman BT. Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease. Neuroscience Letters. 1994;175:46&#x2013;48. doi: 10.1016/0304-3940(94)91074-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(94)91074-x</ArticleId><ArticleId IdType="pubmed">7970208</ArticleId></ArticleIdList></Reference><Reference><Citation>Wintersteiner O, Abramson HA. The isoelectric point of insulin: Electrical properties of adsorbed and crystalline insulin. The Journal of Biological Chemistry. 1933;99:741&#x2013;753.</Citation></Reference><Reference><Citation>Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus. 2006;15:268&#x2013;275. doi: 10.1191/0961203306lu2299oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203306lu2299oa</ArticleId><ArticleId IdType="pubmed">16761500</ArticleId></ArticleIdList></Reference><Reference><Citation>Xian X, Pohlkamp T, Durakoglugil MS, Wong CH, Beck JK, Lane-Donovan C, Plattner F, Herz J. Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer&#x2019;s disease. eLife. 2018;7:e40048. doi: 10.7554/eLife.40048.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.40048</ArticleId><ArticleId IdType="pmc">PMC6261251</ArticleId><ArticleId IdType="pubmed">30375977</ArticleId></ArticleIdList></Reference><Reference><Citation>Xinhan L, Matsushita M, Numaza M, Taguchi A, Mitsui K, Kanazawa H. Na + /H + exchanger isoform 6 (NHE6/SLC9A6) is involved in clathrin-dependent endocytosis of transferrin. American Journal of Physiology-Cell Physiology. 2011;301:C1431&#x2013;C1444. doi: 10.1152/ajpcell.00154.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00154.2011</ArticleId><ArticleId IdType="pubmed">21881004</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M, Ouyang Q, Gong J, Pescosolido MF, Pruett BS, Mishra S, Schmidt M, Jones RN, Gamsiz Uzun ED, Lizarraga SB, Morrow EM. Mixed Neurodevelopmental and Neurodegenerative Pathology in Nhe6-Null Mouse Model of Christianson Syndrome. ENeuro. 2017;4:ENEURO.0388-17.2017. doi: 10.1523/ENEURO.0388-17.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0388-17.2017</ArticleId><ArticleId IdType="pmc">PMC5771691</ArticleId><ArticleId IdType="pubmed">29349289</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T, Chen HC, Guigard E, Kay CM, Ryan RO. Molecular studies of pH-dependent ligand interactions with the low-density lipoprotein receptor. Biochemistry. 2008;47:11647&#x2013;11652. doi: 10.1021/bi801117t.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi801117t</ArticleId><ArticleId IdType="pmc">PMC2630525</ArticleId><ArticleId IdType="pubmed">18847225</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nature Reviews. Neurology. 2019;15:501&#x2013;518. doi: 10.1038/s41582-019-0228-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0228-7</ArticleId><ArticleId IdType="pmc">PMC7055192</ArticleId><ArticleId IdType="pubmed">31367008</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Kozicky L, Saferali A, Fung S-Y, Afacan N, Cai B, Falsafi R, Gill E, Liu M, Kollmann TR, Hancock REW, Sly LM, Turvey SE. Endosomal pH modulation by peptide-gold nanoparticle hybrids enables potent anti-inflammatory activity in phagocytic immune cells. Biomaterials. 2016;111:90&#x2013;102. doi: 10.1016/j.biomaterials.2016.09.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2016.09.032</ArticleId><ArticleId IdType="pubmed">27728817</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanuck SF. Microglial Phagocytosis of Neurons: Diminishing Neuronal Loss in Traumatic, Infectious, Inflammatory, and Autoimmune CNS Disorders. Frontiers in Psychiatry. 2019;10:712. doi: 10.3389/fpsyt.2019.00712.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2019.00712</ArticleId><ArticleId IdType="pmc">PMC6786049</ArticleId><ArticleId IdType="pubmed">31632307</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, Liddelow SA, Zhang C, Daneman R, Maniatis T, Barres BA, Wu JQ. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. The Journal of Neuroscience. 2014;34:11929&#x2013;11947. doi: 10.1523/JNEUROSCI.1860-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1860-14.2014</ArticleId><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, Wang D, Gao Y, Zhu Y, Sheng X, Chen K, Wang N, Zhu L, Can D, Marten Y, Shinohara M, Liu C-C, Du D, Sun H, Wen L, Xu H, Bu G, Chen X-F. Author Correction: Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer&#x2019;s disease model. Nature Communications. 2019;10:2923. doi: 10.1038/s41467-019-10950-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10950-2</ArticleId><ArticleId IdType="pmc">PMC6606585</ArticleId><ArticleId IdType="pubmed">31266955</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler-Waldkirch S, Meyer-Luehmann M. The Role of Glial Cells and Synapse Loss in Mouse Models of Alzheimer&#x2019;s Disease. Frontiers in Cellular Neuroscience. 2018;12:473. doi: 10.3389/fncel.2018.00473.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00473</ArticleId><ArticleId IdType="pmc">PMC6297249</ArticleId><ArticleId IdType="pubmed">30618627</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34279580</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Young-Onset Dementia-New Insights for an Underappreciated Problem.</ArticleTitle><Pagination><StartPage>1055</StartPage><EndPage>1056</EndPage><MedlinePgn>1055-1056</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.1760</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Neurol. 2021 Sep 1;78(9):1080-1090. doi: 10.1001/jamaneurol.2021.2161.</RefSource><PMID Version="1">34279544</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>19</Day><Hour>12</Hour><Minute>56</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34279580</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.1760</ArticleId><ArticleId IdType="pii">2781921</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34279544</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>1080</StartPage><EndPage>1090</EndPage><MedlinePgn>1080-1090</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.2161</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Reliable prevalence estimates are lacking for young-onset dementia (YOD), in which symptoms of dementia start before the age of 65 years. Such estimates are needed for policy makers to organize appropriate health care.</AbstractText><AbstractText Label="OBJECTIVE">To determine the global prevalence of YOD.</AbstractText><AbstractText Label="DATA SOURCES">The PubMed, Embase, CINAHL, and PsycInfo databases were systematically searched for population-based studies on the prevalence of YOD published between January 1, 1990, and March 31, 2020.</AbstractText><AbstractText Label="STUDY SELECTION">Studies containing data on the prevalence of dementia in individuals younger than 65 years were screened by 2 researchers for inclusion in a systematic review and meta-analysis.</AbstractText><AbstractText Label="DATA EXTRACTION AND SYNTHESIS">Prevalence estimates on 5-year age bands, from 30 to 34 years to 60 to 64 years, were extracted. Random-effects meta-analyses were conducted to pool prevalence estimates. Results were age standardized for the World Standard Population. Heterogeneity was assessed by subgroup analyses for sex, dementia subtype, study design, and economic status based on the World Bank classification and by meta-regression.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Prevalence estimates of YOD for 5-year age bands.</AbstractText><AbstractText Label="RESULTS">A total of 95 unique studies were included in this systematic review, of which 74 with 2 760 379 unique patients were also included in 5-year age band meta-analyses. Studies were mostly conducted in Europe and in older groups in Asia, North America, and Oceania. Age-standardized prevalence estimates increased from 1.1 per 100&#x202f;000 population in the group aged 30 to 34 years to 77.4 per 100&#x202f;000 population in the group aged 60 to 64 years. This gives an overall global age-standardized prevalence of 119.0 per 100&#x202f;000 population in the age range of 30 to 64 years, corresponding to 3.9 million people aged 30 to 64 years living with YOD in the world. Subgroup analyses showed prevalence between men and women to be similar (crude estimates for men, 216.5 per 100 000 population; for women, 293.1 per 100 000 population), whereas prevalence was lower in high-income countries (crude estimate, 663.9 per 100 000 population) compared with upper-middle-income (crude estimate, 1873.6 per 100 000 population) and lower-middle-income (crude estimate, 764.2 per 100 000 population) countries. Meta-regression showed that age range (P &lt; .001), sample size (P &lt; .001), and study methodology (P = .02) significantly influenced heterogeneity between studies.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This systematic review and meta-analysis found an age-standardized prevalence of YOD of 119.0 per 100&#x202f;000 population, although estimates of the prevalence in low-income countries and younger age ranges remain scarce. These results should help policy makers organize sufficient health care for this subgroup of individuals with dementia.</AbstractText><AbstractText Label="STUDY REGISTRATION">PROSPERO CRD42019119288.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hendriks</LastName><ForeName>Stevie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peetoom</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakker</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Primary and Community Care, Radboud University Medical Center, Radboud, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Groenhuysen, Center for Specialized Geriatric Care, Roosendaal, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radboudumc Alzheimer Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC (University Medical Center), Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papma</LastName><ForeName>Janne M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koopmans</LastName><ForeName>Raymond</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Primary and Community Care, Radboud University Medical Center, Radboud, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radboudumc Alzheimer Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhey</LastName><ForeName>Frans R J</ForeName><Initials>FRJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Vugt</LastName><ForeName>Marjolein</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;hler</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Young-Onset Dementia Epidemiology Study Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Withall</LastName><ForeName>Adrienne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Faculty of Medicine, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parlevliet</LastName><ForeName>Juliette L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uysal-Bozkir</LastName><ForeName>&#xd6;zg&#xfc;l</ForeName><Initials>&#xd6;</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Section of Geriatric Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibson</LastName><ForeName>Roger C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Community Health and Psychiatry, University of the West Indies, Kingston, Jamaica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neita</LastName><ForeName>Susanne M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Community Health and Psychiatry, University of the West Indies, Kingston, Jamaica.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Thomas Rune</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Psychology, Faculty of Social Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salem</LastName><ForeName>Lise C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Psychology, Faculty of Social Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Brain Repair and Rehabilitation, Institute for Neuroscience and Psychology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Marcos Antonio</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Federal University of Santa Catarina, Florian&#xf3;polis, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dominguez</LastName><ForeName>Jacqueline C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>St Luke's Medical Center, Quezon City, Metro Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Guzman</LastName><ForeName>Ma Fe</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>St Luke's Medical Center, Quezon City, Metro Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egeberg</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radford</LastName><ForeName>Kylie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broe</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramaniam</LastName><ForeName>Mythily</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Division, Institute of Mental Health Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdin</LastName><ForeName>Edimansyah</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Research Division, Institute of Mental Health Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruni</LastName><ForeName>Amalia C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Regional Neurogenetic Centre, Azienda Sanitaria Provinciale Catanzaro, Lamezia Terme, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Lorenzo</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Regional Neurogenetic Centre, Azienda Sanitaria Provinciale Catanzaro, Lamezia Terme, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Western Australian Centre for Health and Aging, University of Western Australia, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flicker</LastName><ForeName>Leon</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Western Australian Centre for Health and Aging, University of Western Australia, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mol</LastName><ForeName>Merel O</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basta</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University Hospital of Heraklion, University of Crete, Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Doris</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Nethersole School of Nursing, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masika</LastName><ForeName>Golden</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>The Nethersole School of Nursing, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Maria S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Occupational Medicine and Public Health, The Faroese Hospital System, T&#xf3;rshavn, Faroe Islands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruano</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>EPIUnit-Instituto de Saude Publica, University of Porto, Porto, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2021 Sep 1;78(9):1055-1056. doi: 10.1001/jamaneurol.2021.1760.</RefSource><PMID Version="1">34279580</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Int J Public Health. 2022 Nov 03;67:1605099. doi: 10.3389/ijph.2022.1605099.</RefSource><PMID Version="1">36405531</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="Y">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Mrs Hendriks reported receiving grants from Gieskes-Strijbis Foundation, Alzheimer Netherlands, and Dutch Young-Onset Dementia Knowledge Centre during the conduct of the study. Dr Peetoom reported receiving grants from Gieskes-Strijbis fonds/Gieskes-Strijbis fund, Alzheimer Netherlands, and Kenniscentrum Dementie op Jonge Leeftijd/Knowledge Center Young-Onset Dementia during the conduct of the study. Dr Bakker reported receiving grants from Gieskes Strijbis, Alzheimer Netherlands, and Kenniscentrum Dementie op Jonge Leeftijd during the conduct of the study. Dr van der Flier reported receiving grants from ZonMW, NWO, CVON, Alzheimer Netherlands, Gieskes-Strijbisfonds, Combinostics, Fujifilm, Roche, AVID, Health&#x2013;Holland, Topsector Life Sciences &amp; Health, EU-JPND, Stichting Dioraphte, Stichting Equilibrio, Pasman Stichting, Biogen, Life-MI, Philips, Novartis NL, Neurocast, and ADX-Neuroscience outside the submitted work; has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, and WebMD Neurology (Medscape); is a consultant for Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc; served on the advisory board for Biogen MA Inc.; is associate editor at Alzheimer&#x2019;s Research &amp; Therapy; and all funding is paid to her institution. Dr de Vugt reported receiving grants from Alzheimer Netherlands, Gieskes Strijbes Fund, and Dutch Knowledge Center Young Onset Dementia during the conduct of the study. Dr Parlevliet reported coauthorship of the Cross-Cultural Dementia screening test. Dr Radford reported receiving grants from Australian National Health and Medical Research Council 510347 &amp; 1103312 and RW &amp; JG Fellowship in Aboriginal Health &amp; Ageing during the conduct of the study. Dr Broe reported receiving grants from Australian National Health and Medical Research Council Chief Investigator B during the conduct of the study. Dr Smith reported receiving grants from Australian National Health Medical Research Council during the conduct of the study. Dr Subramaniam reported receiving grants from Ministry of Health Singapore and Temasek Foundation during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>19</Day><Hour>12</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34279544</ArticleId><ArticleId IdType="pmc">PMC8290331</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.2161</ArticleId><ArticleId IdType="pii">2781919</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koopmans R, Rosness T. Young onset dementia&#x2014;what does the name imply? Int Psychogeriatr. 2014;26(12):1931-1933. doi:10.1017/S1041610214001574</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610214001574</ArticleId><ArticleId IdType="pubmed">25382199</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferies K, Agrawal N. Early-onset dementia. Adv Psychiatr Treatment. 2009;15(5):380-388. doi:10.1192/apt.bp.107.004572</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/apt.bp.107.004572</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vliet D, de Vugt ME, Bakker C, Koopmans RTCM, Verhey FRJ. Impact of early onset dementia on caregivers: a review. Int J Geriatr Psychiatry. 2010;25(11):1091-1100. doi:10.1002/gps.2439</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.2439</ArticleId><ArticleId IdType="pubmed">20957692</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF. The accurate diagnosis of early-onset dementia. Int J Psychiatry Med. 2006;36(4):401-412. doi:10.2190/Q6J4-R143-P630-KW41</Citation><ArticleIdList><ArticleId IdType="doi">10.2190/Q6J4-R143-P630-KW41</ArticleId><ArticleId IdType="pubmed">17407994</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vliet D, de Vugt ME, Bakker C, et al. . Time to diagnosis in young-onset dementia as compared with late-onset dementia. Psychol Med. 2013;43(2):423-432. doi:10.1017/S0033291712001122</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291712001122</ArticleId><ArticleId IdType="pubmed">22640548</ArticleId></ArticleIdList></Reference><Reference><Citation>Draper B, Cations M, White F, et al. . Time to diagnosis in young-onset dementia and its determinants: the INSPIRED study. Int J Geriatr Psychiatry. 2016;31(11):1217-1224. doi:10.1002/gps.4430</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.4430</ArticleId><ArticleId IdType="pubmed">26807846</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63-75.e2. doi:10.1016/j.jalz.2012.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.11.007</ArticleId><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols E, Szoeke CEI, Vollset SE, et al. ; GBD 2016 Dementia Collaborators . Global, regional, and national burden of Alzheimer&#x2019;s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88-106. doi:10.1016/S1474-4422(18)30403-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30403-4</ArticleId><ArticleId IdType="pmc">PMC6291454</ArticleId><ArticleId IdType="pubmed">30497964</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol. 2010;9(8):793-806. doi:10.1016/S1474-4422(10)70159-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70159-9</ArticleId><ArticleId IdType="pmc">PMC2947856</ArticleId><ArticleId IdType="pubmed">20650401</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey RJ, Skelton-Robinson M, Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry. 2003;74(9):1206-1209. doi:10.1136/jnnp.74.9.1206</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.74.9.1206</ArticleId><ArticleId IdType="pmc">PMC1738690</ArticleId><ArticleId IdType="pubmed">12933919</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikejima C, Yasuno F, Mizukami K, Sasaki M, Tanimukai S, Asada T. Prevalence and causes of early-onset dementia in Japan: a population-based study. Stroke. 2009;40(8):2709-2714. doi:10.1161/STROKEAHA.108.542308</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.108.542308</ArticleId><ArticleId IdType="pubmed">19478230</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MA, Bickel H, Prince M, et al. . Estimating the burden of early onset dementia: systematic review of disease prevalence. Eur J Neurol. 2014;21(4):563-569. doi:10.1111/ene.12325</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12325</ArticleId><ArticleId IdType="pubmed">24418291</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira RT, Caixeta L, Machado S, et al. . Epidemiology of early-onset dementia: a review of the literature. Clin Pract Epidemiol Ment Health. 2013;9:88-95. doi:10.2174/1745017901309010088</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1745017901309010088</ArticleId><ArticleId IdType="pmc">PMC3715758</ArticleId><ArticleId IdType="pubmed">23878613</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X-C, Tan L, Wang H-F, et al. . Rate of early onset Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Ann Transl Med. 2015;3(3):38. doi:10.3978/j.issn.2305-5839.2015.01.19</Citation><ArticleIdList><ArticleId IdType="doi">10.3978/j.issn.2305-5839.2015.01.19</ArticleId><ArticleId IdType="pmc">PMC4356853</ArticleId><ArticleId IdType="pubmed">25815299</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, et al. . Meta-analysis of observational studies in epidemiology: a proposal for reporting: Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012. doi:10.1001/jama.283.15.2008</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.15.2008</ArticleId><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174. doi:10.2307/2529310</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2529310</ArticleId><ArticleId IdType="pubmed">843571</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy D, Brooks P, Woolf A, et al. . Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65(9):934-939. doi:10.1016/j.jclinepi.2011.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2011.11.014</ArticleId><ArticleId IdType="pubmed">22742910</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W.Conducting meta-analyses in R with the metafor package. J Stat Software. 2010;36(3):1-48. doi:10.18637/jss.v036.i03 doi:10.18637/jss.v036.i03</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v036.i03</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age standardization of rates: a new WHO standard. GPE Discussion Paper Series No. 31. World Health Organization; 2001;9(10). Accessed May 21, 2020. https://www.who.int/healthinfo/paper31.pdf</Citation></Reference><Reference><Citation>Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected US population. Healthy People 2000 Stat Notes.2001;(20):1-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11503781</ArticleId></ArticleIdList></Reference><Reference><Citation>Commission E.Revision of the European Standard Population&#x2014;Report of Eurostat's Task Force 2013 edition. November 7, 2013. Accessed May 21, 2020. https://ec.europa.eu/eurostat/web/products-manuals-and-guidelines/-/KS-RA-13-028</Citation></Reference><Reference><Citation>World Bank . World Bank Country and Lending Groups 2020. 2019. Accessed March 6, 2020. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups</Citation></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. doi:10.1016/0197-2456(86)90046-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocca WA, Bonaiuto S, Lippi A, et al. . Prevalence of clinically diagnosed Alzheimer&#x2019;s disease and other dementing disorders: a door-to-door survey in Appignano, Macerata Province, Italy. Neurology. 1990;40(4):626-631. doi:10.1212/WNL.40.4.626</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.40.4.626</ArticleId><ArticleId IdType="pubmed">2320236</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard CM, Kokmen E, Offord K, Kurland LT. Is the prevalence of dementia changing? Neurology. 1991;41(12):1911-1914. doi:10.1212/WNL.41.12.1911</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.41.12.1911</ArticleId><ArticleId IdType="pubmed">1745347</ArticleId></ArticleIdList></Reference><Reference><Citation>Phanthumchinda K, Jitapunkul S, Sitthi-Amorn C, Bunnag SC. Prevalence of dementia in an urban slum population in Thailand: validity of screening methods. Int J Geriatr Psychiatry. 1991;6(9):639-46. doi:10.1002/gps.930060905</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.930060905</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachman DL, Wolf PA, Linn R, et al. . Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham study. Neurology. 1992;42(1):115-119. doi:10.1212/WNL.42.1.115</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.42.1.115</ArticleId><ArticleId IdType="pubmed">1734291</ArticleId></ArticleIdList></Reference><Reference><Citation>Corso EA, Campo G, Triglio A, Napoli A, Reggio A, Lanaia F. Prevalence of moderate and severe Alzheimer dementia and multi-infarct dementia in the population of southeastern Sicily. Ital J Neurol Sci. 1992;13(3):215-219. doi:10.1007/BF02224392</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02224392</ArticleId><ArticleId IdType="pubmed">1624277</ArticleId></ArticleIdList></Reference><Reference><Citation>Coria F, Gomez de Caso JA, Minguez L, Rodriguez-Artalejo F, Claveria LE. Prevalence of age-associated memory impairment and dementia in a rural community. J Neurol Neurosurg Psychiatry. 1993;56(9):973-976. doi:10.1136/jnnp.56.9.973</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.56.9.973</ArticleId><ArticleId IdType="pmc">PMC489731</ArticleId><ArticleId IdType="pubmed">8410037</ArticleId></ArticleIdList></Reference><Reference><Citation>Newens AJ, Forster DP, Kay DW, Kirkup W, Bates D, Edwardson J. Clinically diagnosed presenile dementia of the Alzheimer type in the Northern Health Region: ascertainment, prevalence, incidence and survival. Psychol Med. 1993;23(3):631-644. doi:10.1017/S0033291700025411</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291700025411</ArticleId><ArticleId IdType="pubmed">8234570</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HC, Chou P, Lin KN, et al. . Assessing cognitive abilities and dementia in a predominantly illiterate population of older individuals in Kinmen. Psychol Med. 1994;24(3):763-770. doi:10.1017/S0033291700027914</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291700027914</ArticleId><ArticleId IdType="pubmed">7991758</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HC, Lin KN, Teng EL, et al. . Prevalence and subtypes of dementia in Taiwan: a community survey of 5297 individuals. J Am Geriatr Soc. 1995;43(2):144-149. doi:10.1111/j.1532-5415.1995.tb06379.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.1995.tb06379.x</ArticleId><ArticleId IdType="pubmed">7836638</ArticleId></ArticleIdList></Reference><Reference><Citation>Ott A, Breteler MM, van Harskamp F, et al. . Prevalence of Alzheimer&#x2019;s disease and vascular dementia: association with education: the Rotterdam study. BMJ. 1995;310(6985):970-973. doi:10.1136/bmj.310.6985.970</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.310.6985.970</ArticleId><ArticleId IdType="pmc">PMC2549358</ArticleId><ArticleId IdType="pubmed">7728032</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaji S, Promodu K, Abraham T, Roy KJ, Verghese A. An epidemiological study of dementia in a rural community in Kerala, India. Br J Psychiatry. 1996;168(6):745-749. doi:10.1192/bjp.168.6.745</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.168.6.745</ArticleId><ArticleId IdType="pubmed">8773818</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins P, Annegers JF, Doody RS, Cooke N, Aday L, Vernon SW. Incidence and prevalence of dementia in a multiethnic cohort of municipal retirees. Neurology. 1997;49(1):44-50. doi:10.1212/WNL.49.1.44</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.49.1.44</ArticleId><ArticleId IdType="pubmed">9222168</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra V, Ganguli M, Pandav R, Johnston J, Belle S, DeKosky ST. Prevalence of Alzheimer&#x2019;s disease and other dementias in rural India: the Indo-US study. Neurology. 1998;51(4):1000-1008. doi:10.1212/WNL.51.4.1000</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.51.4.1000</ArticleId><ArticleId IdType="pubmed">9781520</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrag A, Farwiz HM, Khedr EH, Mahfouz RM, Omran SM. Prevalence of Alzheimer&#x2019;s disease and other dementing disorders: Assiut&#x2013;Upper Egypt study. Dement Geriatr Cogn Disord. 1998;9(6):323-328. doi:10.1159/000017084</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000017084</ArticleId><ArticleId IdType="pubmed">9769445</ArticleId></ArticleIdList></Reference><Reference><Citation>Freyne A, Kidd N, Lawlor BA. Early onset dementia: a catchment area study of prevalence and clinical characteristics. Ir J Psychol Med. 1998;15(3):87-90. doi:10.1017/S0790966700003748</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0790966700003748</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Urakami K, Adachi Y, Wakutani Y, et al. . Epidemiologic and genetic studies of dementia of the Alzheimer type in Japan. Dement Geriatr Cogn Disord. 1998;9(5):294-298. doi:10.1159/000017074</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000017074</ArticleId><ArticleId IdType="pubmed">9701681</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N, Blennow K, Sj&#xf6;din C, Winblad B, Sv&#xe4;rdsudd K. Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden: the Pite&#xe5; Dementia Project. Neuroepidemiology. 1999;18(3):144-155. doi:10.1159/000026206</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000026206</ArticleId><ArticleId IdType="pubmed">10202268</ArticleId></ArticleIdList></Reference><Reference><Citation>Campion D, Dumanchin C, Hannequin D, et al. . Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65(3):664-670. doi:10.1086/302553</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/302553</ArticleId><ArticleId IdType="pmc">PMC1377972</ArticleId><ArticleId IdType="pubmed">10441572</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatada K, Okazaki Y, Yoshitake K, Takada K, Nakane Y. Further evidence of westernization of dementia prevalence in Nagasaki, Japan, and family recognition. Int Psychogeriatr. 1999;11(2):123-138. doi:10.1017/S1041610299005682</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610299005682</ArticleId><ArticleId IdType="pubmed">11475427</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wu S, Cheng X, et al. . Prevalence of Alzheimer&#x2019;s disease and other dementing disorders in an urban community of Beijing, China. Neuroepidemiology. 2000;19(4):194-200. doi:10.1159/000026255</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000026255</ArticleId><ArticleId IdType="pubmed">10859498</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowirrat A, Treves TA, Friedland RP, Korczyn AD. Prevalence of Alzheimer&#x2019;s type dementia in an elderly Arab population. Eur J Neurol. 2001;8(2):119-123. doi:10.1046/j.1468-1331.2001.00183.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1468-1331.2001.00183.x</ArticleId><ArticleId IdType="pubmed">11284991</ArticleId></ArticleIdList></Reference><Reference><Citation>Jitapunkul S, Kunanusont C, Phoolcharoen W, Suriyawongpaisal P. Prevalence estimation of dementia among Thai elderly: a national survey. J Med Assoc Thai. 2001;84(4):461-467.</Citation><ArticleIdList><ArticleId IdType="pubmed">11460954</ArticleId></ArticleIdList></Reference><Reference><Citation>Vas CJ, Pinto C, Panikker D, et al. . Prevalence of dementia in an urban Indian population. Int Psychogeriatr. 2001;13(4):439-450. doi:10.1017/S1041610201007852</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610201007852</ArticleId><ArticleId IdType="pubmed">12003250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58(11):1615-1621. doi:10.1212/WNL.58.11.1615</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.11.1615</ArticleId><ArticleId IdType="pubmed">12058088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibach B, Koch H, Koller M, Wolfersdorf M; Workgroup for Geriatric Psychiatry of the Psychiatric State Hospitals of Germany; Workgroup for Clinical Research of the Psychiatric State Hospitals of Germany . Hospital admission circumstances and prevalence of frontotemporal lobar degeneration: a multicenter psychiatric state hospital study in Germany. Dement Geriatr Cogn Disord. 2003;16(4):253-264. doi:10.1159/000072810</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000072810</ArticleId><ArticleId IdType="pubmed">14512721</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosso SM, Donker Kaat L, Baks T, et al. . Frontotemporal dementia in the Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain. 2003;126(pt 9):2016-2022. doi:10.1093/brain/awg204</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awg204</ArticleId><ArticleId IdType="pubmed">12876142</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ronchi D, Berardi D, Menchetti M, et al. . Occurrence of cognitive impairment and dementia after the age of 60: a population-based study from Northern Italy. Dement Geriatr Cogn Disord. 2005;19(2-3):97-105. doi:10.1159/000082660</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000082660</ArticleId><ArticleId IdType="pubmed">15591799</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZX, Zahner GEP, Rom&#xe1;n GC, et al. . Dementia subtypes in China: prevalence in Beijing, Xian, Shanghai, and Chengdu. Arch Neurol. 2005;62(3):447-453. doi:10.1001/archneur.62.3.447</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.3.447</ArticleId><ArticleId IdType="pubmed">15767510</ArticleId></ArticleIdList></Reference><Reference><Citation>Das SK, Biswas A, Roy T, et al. . A random sample survey for prevalence of major neurological disorders in Kolkata. Indian J Med Res. 2006;124(2):163-172.</Citation><ArticleIdList><ArticleId IdType="pubmed">17015930</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou DF, Wu CS, Qi H, et al. . Prevalence of dementia in rural China: impact of age, gender and education. Acta Neurol Scand. 2006;114(4):273-280. doi:10.1111/j.1600-0404.2006.00641.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2006.00641.x</ArticleId><ArticleId IdType="pubmed">16942548</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens PJ, Fransoo R, Burland E, Burchill C, Prior HJ, Ekuma O; Need to Know Team . Prevalence of mental illness and its impact on the use of home care and nursing homes: a population-based study of older adults in Manitoba. Can J Psychiatry. 2007;52(9):581-590. doi:10.1177/070674370705200906</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/070674370705200906</ArticleId><ArticleId IdType="pubmed">17953162</ArticleId></ArticleIdList></Reference><Reference><Citation>Molero AE, Pino-Ram&#xed;rez G, Maestre GE. High prevalence of dementia in a Caribbean population. Neuroepidemiology. 2007;29(1-2):107-112. doi:10.1159/000109824</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000109824</ArticleId><ArticleId IdType="pubmed">17940342</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee TK, Mukherjee CS, Dutt A, Shekhar A, Hazra A. Cognitive dysfunction in an urban Indian population: some observations. Neuroepidemiology. 2008;31(2):109-114. doi:10.1159/000146252</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000146252</ArticleId><ArticleId IdType="pubmed">18753798</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottino CMC, Azevedo D Jr, Tatsch M, et al. . Estimate of dementia prevalence in a community sample from S&#xe3;o Paulo, Brazil. Dement Geriatr Cogn Disord. 2008;26(4):291-299. doi:10.1159/000161053</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000161053</ArticleId><ArticleId IdType="pubmed">18843181</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina S, Razdan S, Pandita KK, Raina S. Prevalence of dementia among Kashmiri migrants. Ann Indian Acad Neurol. 2008;11(2):106-108. doi:10.4103/0972-2327.41878</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0972-2327.41878</ArticleId><ArticleId IdType="pmc">PMC2771955</ArticleId><ArticleId IdType="pubmed">19893648</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahadevan S, Saw SM, Gao W, et al. . Ethnic differences in Singapore&#x2019;s dementia prevalence: the Stroke, Parkinson&#x2019;s Disease, Epilepsy, and Dementia in Singapore study. J Am Geriatr Soc. 2008;56(11):2061-2068. doi:10.1111/j.1532-5415.2008.01992.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2008.01992.x</ArticleId><ArticleId IdType="pubmed">19016940</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith K, Flicker L, Lautenschlager NT, et al. . High prevalence of dementia and cognitive impairment in indigenous Australians. Neurology. 2008;71(19):1470-1473. doi:10.1212/01.wnl.0000320508.11013.4f</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000320508.11013.4f</ArticleId><ArticleId IdType="pubmed">18799785</ArticleId></ArticleIdList></Reference><Reference><Citation>Wangtongkum S, Sucharitkul P, Silprasert N, Inthrachak R. Prevalence of dementia among population age over 45 years in Chiang Mai, Thailand. J Med Assoc Thai. 2008;91(11):1685-1690.</Citation><ArticleIdList><ArticleId IdType="pubmed">19127790</ArticleId></ArticleIdList></Reference><Reference><Citation>Arslanta&#x15f; D, Ozbabalik D, Metinta&#x15f; S, et al. . Prevalence of dementia and associated risk factors in Middle Anatolia, Turkey. J Clin Neurosci. 2009;16(11):1455-1459. doi:10.1016/j.jocn.2009.03.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2009.03.033</ArticleId><ArticleId IdType="pubmed">19748273</ArticleId></ArticleIdList></Reference><Reference><Citation>Spada RS, Stella G, Calabrese S, et al. . Prevalence of dementia in mountainous village of Sicily. J Neurol Sci. 2009;283(1-2):62-65. doi:10.1016/j.jns.2009.02.311</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2009.02.311</ArticleId><ArticleId IdType="pubmed">19264327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler U, Doblhammer G. Prevalence and incidence of dementia in Germany&#x2014;a study based on data from the public sick funds in 2002. Article in German. Gesundheitswesen. 2009;71(5):281-290. doi:10.1055/s-0028-1119384</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0028-1119384</ArticleId><ArticleId IdType="pubmed">19288422</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathuranath PS, Cherian PJ, Mathew R, et al. . Dementia in Kerala, South India: prevalence and influence of age, education and gender. Int J Geriatr Psychiatry. 2010;25(3):290-297. doi:10.1002/gps.2338</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.2338</ArticleId><ArticleId IdType="pmc">PMC4367932</ArticleId><ArticleId IdType="pubmed">19621355</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng TP, Leong T, Chiam PC, Kua EH. Ethnic variations in dementia: the contributions of cardiovascular, psychosocial and neuropsychological factors. Dement Geriatr Cogn Disord. 2010;29(2):131-138. doi:10.1159/000275668</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000275668</ArticleId><ArticleId IdType="pubmed">20145399</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes B, Silva RD, Cruz VT, Roriz JM, Pais J, Silva MC. Prevalence and pattern of cognitive impairment in rural and urban populations from Northern Portugal. BMC Neurol. 2010;10:42. doi:10.1186/1471-2377-10-42</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-10-42</ArticleId><ArticleId IdType="pmc">PMC2905352</ArticleId><ArticleId IdType="pubmed">20540726</ArticleId></ArticleIdList></Reference><Reference><Citation>Phung TK, Waltoft BL, Kessing LV, Mortensen PB, Waldemar G. Time trend in diagnosing dementia in secondary care. Dement Geriatr Cogn Disord. 2010;29(2):146-153. doi:10.1159/000269933</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000269933</ArticleId><ArticleId IdType="pubmed">20150733</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina SK, Razdan S, Pandita KK. Prevalence of dementia in ethnic Dogra population of Jammu district, North India: a comparison survey. Neurol Asia. 2010;15(1):65-69.</Citation></Reference><Reference><Citation>Winblad I, Viramo P, Remes A, Manninen M, Jokelainen J.. Prevalence of dementia&#x2014;a rising challenge among ageing populations. Eur Geriatr Med. 2010;1(6):330-333. doi:10.1016/j.eurger.2010.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eurger.2010.10.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Adelman S, Blanchard M, Rait G, Leavey G, Livingston G. Prevalence of dementia in African-Caribbean compared with UK-born White older people: two-stage cross-sectional study. Br J Psychiatry. 2011;199(2):119-125. doi:10.1192/bjp.bp.110.086405</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.bp.110.086405</ArticleId><ArticleId IdType="pubmed">21653946</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Alberici A, Grassi M, et al. . Prevalence and demographic features of early-onset neurodegenerative dementia in Brescia County, Italy. Alzheimer Dis Assoc Disord. 2011;25(4):341-344. doi:10.1097/WAD.0b013e3182147f80</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e3182147f80</ArticleId><ArticleId IdType="pubmed">21399481</ArticleId></ArticleIdList></Reference><Reference><Citation>Huriletemuer H, Wen S, Zhang C, et al. . An epidemiological study of Alzheimer&#x2019;s disease in elderly Mongolian and Han populations living in rural areas of Inner Mongolia. Aging Clin Exp Res. 2011;23(5-6):470-475. doi:10.1007/BF03325243</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03325243</ArticleId><ArticleId IdType="pubmed">22526079</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen TR, Vogel A, Phung TK, Gade A, Waldemar G. Over- and under-diagnosis of dementia in ethnic minorities: a nationwide register-based study. Int J Geriatr Psychiatry. 2011;26(11):1128-1135.</Citation><ArticleIdList><ArticleId IdType="pubmed">21194100</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi L, Frangipane F, Smirne N, et al. . Epidemiology and genetics of frontotemporal dementia: a door-to-door survey in southern Italy. Neurobiol Aging. 2012;33(12):2948.e1-2948.e10. doi:10.1016/j.neurobiolaging.2012.06.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.06.017</ArticleId><ArticleId IdType="pmc">PMC5019339</ArticleId><ArticleId IdType="pubmed">22819134</ArticleId></ArticleIdList></Reference><Reference><Citation>El Tallawy HN, Farghly WMA, Shehata GA, et al. . Prevalence of dementia in Al Kharga District, New Valley Governorate, Egypt. Neuroepidemiology. 2012;38(3):130-137. doi:10.1159/000335655</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000335655</ArticleId><ArticleId IdType="pubmed">22433971</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilberti N, Turla M, Alberici A, et al. . Prevalence of frontotemporal lobar degeneration in an isolated population: the Vallecamonica study. Neurol Sci. 2012;33(4):899-904. doi:10.1007/s10072-011-0865-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-011-0865-0</ArticleId><ArticleId IdType="pubmed">22127750</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes MA, Ferrioli E, Nakano EY, Litvoc J, Bottino CM. High prevalence of dementia in a community-based survey of older people from Brazil: association with intellectual activity rather than education. J Alzheimers Dis. 2012;32(2):307-316. doi:10.3233/JAD-2012-120847</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-120847</ArticleId><ArticleId IdType="pubmed">22785401</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada-Isoe K, Ito S, Adachi T, et al. . Epidemiological survey of frontotemporal lobar degeneration in Tottori prefecture, Japan. Dement Geriatr Cogn Dis Extra. 2012;2(1):381-386. doi:10.1159/000342972</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000342972</ArticleId><ArticleId IdType="pmc">PMC3529564</ArticleId><ArticleId IdType="pubmed">23300493</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeda ER, Haan MN, Kanaya AM, Yaffe K, Neuhaus J. Type 2 diabetes and 10-year risk of dementia and cognitive impairment among older Mexican Americans. Diabetes Care. 2013;36(9):2600-2606. doi:10.2337/dc12-2158</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc12-2158</ArticleId><ArticleId IdType="pmc">PMC3747945</ArticleId><ArticleId IdType="pubmed">23514732</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstr&#xf6;m P, Nordstr&#xf6;m A, Eriksson M, Wahlund LO, Gustafson Y. Risk factors in late adolescence for young-onset dementia in men: a nationwide cohort study. JAMA Intern Med. 2013;173(17):1612-1618. doi:10.1001/jamainternmed.2013.9079</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2013.9079</ArticleId><ArticleId IdType="pubmed">23939347</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina SK, Raina S, Chander V, Grover A, Singh S, Bhardwaj A. Identifying risk for dementia across populations: a study on the prevalence of dementia in tribal elderly population of Himalayan region in Northern India. Ann Indian Acad Neurol. 2013;16(4):640-644. doi:10.4103/0972-2327.120494</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0972-2327.120494</ArticleId><ArticleId IdType="pmc">PMC3841618</ArticleId><ArticleId IdType="pubmed">24339597</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartoloni L, Blatt G, Insua I, et al. . A population-based study of cognitive impairment in socially vulnerable adults in Argentina: the Matanza Riachuelo study preliminary results. Dement Neuropsychol. 2014;8(4):339-344. doi:10.1590/S1980-57642014DN84000006</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1980-57642014DN84000006</ArticleId><ArticleId IdType="pmc">PMC5619181</ArticleId><ArticleId IdType="pubmed">29213923</ArticleId></ArticleIdList></Reference><Reference><Citation>Bawih Inu P, Othman Z, Drahman I.. Dementia among Elderly Melanau: a community survey of an indigenous people in East Malaysia. Int Med J. 2014;21(5):468-471.</Citation></Reference><Reference><Citation>Ding D, Zhao Q, Guo Q, et al. . The Shanghai Aging Study: study design, baseline characteristics, and prevalence of dementia. Neuroepidemiology. 2014;43(2):114-122. doi:10.1159/000366163</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000366163</ArticleId><ArticleId IdType="pubmed">25376362</ArticleId></ArticleIdList></Reference><Reference><Citation>El Tallawy HN, Farghly WM, Badry R, et al. . Prevalence of dementia in Al-Quseir city, Red Sea Governorate, Egypt. Clin Interv Aging. 2014;9:9-14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3862590</ArticleId><ArticleId IdType="pubmed">24353410</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SQ, Guthridge SL, Eswara Aratchige P, et al. . Dementia prevalence and incidence among the indigenous and non-indigenous populations of the Northern Territory. Med J Aust. 2014;200(8):465-469. doi:10.5694/mja13.11052</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja13.11052</ArticleId><ArticleId IdType="pubmed">24794609</ArticleId></ArticleIdList></Reference><Reference><Citation>Momtaz YA, Hamid TA, Ibrahim R. Gastritis may boost odds of dementia. Am J Alzheimers Dis Other Demen. 2014;29(5):452-456. doi:10.1177/1533317513518654</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533317513518654</ArticleId><ArticleId IdType="pmc">PMC10852707</ArticleId><ArticleId IdType="pubmed">24408749</ArticleId></ArticleIdList></Reference><Reference><Citation>Neita SM, Abel WD, Eldemire-Shearer D, James K, Gibson RC. The prevalence and associated demographic factors of dementia from a cross-sectional community survey in Kingston, Jamaica. Int J Geriatr Psychiatry. 2014;29(1):103-105. doi:10.1002/gps.3982</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.3982</ArticleId><ArticleId IdType="pubmed">23637080</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg J, &#xc5;berg MA, Schi&#xf6;ler L, et al. . Cardiovascular and cognitive fitness at age 18 and risk of early-onset dementia. Brain. 2014;137(pt 5):1514-1523. doi:10.1093/brain/awu041</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu041</ArticleId><ArticleId IdType="pubmed">24604561</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer K, Kabir ZN, Ahmed T, et al. . Prevalence of dementia and factors associated with dementia in rural Bangladesh: data from a cross-sectional, population-based study. Int Psychogeriatr. 2014;26(11):1905-1915. doi:10.1017/S1041610214001392</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610214001392</ArticleId><ArticleId IdType="pubmed">25033341</ArticleId></ArticleIdList></Reference><Reference><Citation>Raina SK, Raina S, Chander V, Grover A, Singh S, Bhardwaj A. Is dementia differentially distributed? a study on the prevalence of dementia in migrant, urban, rural, and tribal elderly population of Himalayan region in northern India. N Am J Med Sci. 2014;6(4):172-177. doi:10.4103/1947-2714.131243</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1947-2714.131243</ArticleId><ArticleId IdType="pmc">PMC4024584</ArticleId><ArticleId IdType="pubmed">24843850</ArticleId></ArticleIdList></Reference><Reference><Citation>Withall A, Draper B, Seeher K, Brodaty H. The prevalence and causes of younger onset dementia in Eastern Sydney, Australia. Int Psychogeriatr. 2014;26(12):1955-1965. doi:10.1017/S1041610214001835</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610214001835</ArticleId><ArticleId IdType="pubmed">25307142</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath CA, Mercer SW, Guthrie B. Vascular comorbidities in younger people with dementia: a cross-sectional population-based study of 616&#x2009;245 middle-aged people in Scotland. J Neurol Neurosurg Psychiatry. 2015;86(9):959-964. doi:10.1136/jnnp-2014-309033</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-309033</ArticleId><ArticleId IdType="pubmed">25406350</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y, Shi Z, Zhang Y, et al. . Prevalence of dementia and main subtypes in rural northern China. Dement Geriatr Cogn Disord. 2015;39(5-6):294-302. doi:10.1159/000375366</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000375366</ArticleId><ArticleId IdType="pmc">PMC4993106</ArticleId><ArticleId IdType="pubmed">25792116</ArticleId></ArticleIdList></Reference><Reference><Citation>Luukkainen L, Bloigu R, Moilanen V, Remes AM. Epidemiology of frontotemporal lobar degeneration in northern Finland. Dement Geriatr Cogn Dis Extra. 2015;5(3):435-441. doi:10.1159/000440858</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000440858</ArticleId><ArticleId IdType="pmc">PMC4677706</ArticleId><ArticleId IdType="pubmed">26675285</ArticleId></ArticleIdList></Reference><Reference><Citation>Radford K, Mack HA, Draper B, et al. . Prevalence of dementia in urban and regional Aboriginal Australians. Alzheimers Dement. 2015;11(3):271-279. doi:10.1016/j.jalz.2014.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.03.007</ArticleId><ArticleId IdType="pubmed">24985534</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramaniam M, Chong SA, Vaingankar JA, et al. . Prevalence of dementia in people aged 60 years and above: results from the WiSE Study. J Alzheimers Dis. 2015;45(4):1127-1138. doi:10.3233/JAD-142769</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-142769</ArticleId><ArticleId IdType="pubmed">25672767</ArticleId></ArticleIdList></Reference><Reference><Citation>C&#xe9;sar KG, Brucki SM, Takada LT, et al. . Prevalence of cognitive impairment without dementia and dementia in Trememb&#xe9;, Brazil. Alzheimer Dis Assoc Disord. 2016;30(3):264-271. doi:10.1097/WAD.0000000000000122</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0000000000000122</ArticleId><ArticleId IdType="pubmed">26629676</ArticleId></ArticleIdList></Reference><Reference><Citation>Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Patients with rosacea have increased risk of dementia. Ann Neurol. 2016;79(6):921-928. doi:10.1002/ana.24645</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24645</ArticleId><ArticleId IdType="pubmed">27121663</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Shang Y, Luo Y, et al. . Lower prevalence of Alzheimer&#x2019;s disease among Tibetans: association with religious and genetic factors. J Alzheimers Dis. 2016;50(3):659-667. doi:10.3233/JAD-150697</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150697</ArticleId><ArticleId IdType="pubmed">26757186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosteniuk JG, Morgan DG, O&#x2019;Connell ME, et al. . Simultaneous temporal trends in dementia incidence and prevalence, 2005-2013: a population-based retrospective cohort study in Saskatchewan, Canada. Int Psychogeriatr. 2016;28(10):1643-1658. doi:10.1017/S1041610216000818</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610216000818</ArticleId><ArticleId IdType="pubmed">27352934</ArticleId></ArticleIdList></Reference><Reference><Citation>Parlevliet JL, Uysal-Bozkir &#xd6;, Goudsmit M, et al. . Prevalence of mild cognitive impairment and dementia in older non-western immigrants in the Netherlands: a cross-sectional study. Int J Geriatr Psychiatry. 2016;31(9):1040-1049. doi:10.1002/gps.4417</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.4417</ArticleId><ArticleId IdType="pubmed">26799690</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharifi F, Fakhrzadeh H, Varmaghani M, et al. . Prevalence of dementia and associated factors among older adults in Iran: National Elderly Health Survey (NEHS). Arch Iran Med. 2016;19(12):838-844.</Citation><ArticleIdList><ArticleId IdType="pubmed">27998158</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong SL, Gilmour H, Ramage-Morin PL. Alzheimer&#x2019;s disease and other dementias in Canada. Health Rep. 2016;27(5):11-16.</Citation><ArticleIdList><ArticleId IdType="pubmed">27192206</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue W, Wang XD, Shi Z, et al. . The prevalence of dementia with Lewy bodies in a rural area of China. Parkinsonism Relat Disord. 2016;29:72-77. doi:10.1016/j.parkreldis.2016.05.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2016.05.022</ArticleId><ArticleId IdType="pubmed">27264344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi-Abhari S, Guzman-Castillo M, Bandosz P, et al. . Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study. BMJ. 2017;358:j2856. doi:10.1136/bmj.j2856</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.j2856</ArticleId><ArticleId IdType="pmc">PMC5497174</ArticleId><ArticleId IdType="pubmed">28679494</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee TK, Dutta S, Das S, et al. . Epidemiology of dementia and its burden in the city of Kolkata, India. Int J Geriatr Psychiatry. 2017;32(6):605-614. doi:10.1002/gps.4499</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.4499</ArticleId><ArticleId IdType="pubmed">27251089</ArticleId></ArticleIdList></Reference><Reference><Citation>Basta M, Simos P, Bertsias A, et al. . Association between insomnia symptoms and cognitive impairment in the Cretan Aging Cohort. Eur Geriatr Med. 2018;9(5):697-706. doi:10.1007/s41999-018-0086-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41999-018-0086-7</ArticleId><ArticleId IdType="pubmed">34654220</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez J, Fe de Guzman M, Reandelar M, Thi Phung TK. Prevalence of dementia and associated risk factors: a population-based study in the Philippines. J Alzheimers Dis. 2018;63(3):1065-1073. doi:10.3233/JAD-180095</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180095</ArticleId><ArticleId IdType="pubmed">29710725</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodesh A. Prevalence and comorbidities of dementia in Israel: a nationally representative cohort study. Int Psychogeriatr. 2018;1-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">30318021</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurl S, Laukkanen JA, Lonnroos E, Remes AM, Soininen H. Cardiorespiratory fitness and risk of dementia: a prospective population-based cohort study. Age Ageing. 2018;47(4):611-614. doi:10.1093/ageing/afy060</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afy060</ArticleId><ArticleId IdType="pubmed">29718064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvello-Alme M, Br&#xe5;then G, White LR, Sando SB. The prevalence and subtypes of young onset dementia in central Norway: a population-based study. J Alzheimers Dis. 2019;69(2):479-487. doi:10.3233/JAD-181223</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-181223</ArticleId><ArticleId IdType="pmc">PMC6598022</ArticleId><ArticleId IdType="pubmed">31006688</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MS, Restorff M, St&#xf3;r&#xe1; T, Waldemar G, Joensen S. Trend in the incidence and prevalence of dementia in the Faroe Islands. J Alzheimers Dis. 2019;71(3):969-978. doi:10.3233/JAD-190341</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-190341</ArticleId><ArticleId IdType="pmc">PMC6839477</ArticleId><ArticleId IdType="pubmed">31450498</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruano L, Ara&#xfa;jo N, Branco M, et al. . Prevalence and causes of cognitive impairment and dementia in a population-based cohort from northern Portugal. Am J Alzheimers Dis Other Demen. 2019;34(1):49-56. doi:10.1177/1533317518813550</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533317518813550</ArticleId><ArticleId IdType="pmc">PMC10852416</ArticleId><ArticleId IdType="pubmed">30514090</ArticleId></ArticleIdList></Reference><Reference><Citation>Masika GM, Yu DSF, Li PWC. Accuracy of the Montreal Cognitive Assessment in detecting mild cognitive impairment and dementia in the rural African population. Arch Clin Neuropsychol. 2021;36(3):371-380. doi:10.1093/arclin/acz086</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/arclin/acz086</ArticleId><ArticleId IdType="pubmed">31942599</ArticleId></ArticleIdList></Reference><Reference><Citation>United Nations, Department of Economic and Social Affairs, Population Dynamics.  (2019). World Population Prospects 2019. 2019. Accessed September 2, 2020. https://population.un.org/wpp/DataQuery/</Citation></Reference><Reference><Citation>Prince MJ, Bryce R, Ferri CP. World Alzheimer Report 2011: The Benefits of Early Diagnosis and Intervention. Alzheimer&#x2019;s Disease International; 2011.</Citation></Reference><Reference><Citation>Johnson JK, Diehl J, Mendez MF, et al. . Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol. 2005;62(6):925-930. doi:10.1001/archneur.62.6.925</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.6.925</ArticleId><ArticleId IdType="pubmed">15956163</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol. 2005;4(11):771-780. doi:10.1016/S1474-4422(05)70223-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(05)70223-4</ArticleId><ArticleId IdType="pubmed">16239184</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer&#x2019;s disease&#x2014;lessons from pathology. BMC Med. 2014;12(1):206. doi:10.1186/s12916-014-0206-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-014-0206-2</ArticleId><ArticleId IdType="pmc">PMC4226890</ArticleId><ArticleId IdType="pubmed">25385447</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiest KM, Jett&#xe9; N, Roberts JI, et al. . The prevalence and incidence of dementia: a systematic review and meta-analysis. Can J Neurol Sci. 2016;43(suppl 1)(suppl 1):S3-S50. doi:10.1017/cjn.2016.18</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cjn.2016.18</ArticleId><ArticleId IdType="pubmed">27307127</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xfc;cker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I2 in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008;8(1):79. doi:10.1186/1471-2288-8-79</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-8-79</ArticleId><ArticleId IdType="pmc">PMC2648991</ArticleId><ArticleId IdType="pubmed">19036172</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson T, Ly A, Schnier C, et al. ; UK Biobank Neurodegenerative Outcomes Group and Dementias Platform UK . Identifying dementia cases with routinely collected health data: a systematic review. Alzheimers Dement. 2018;14(8):1038-1051. doi:10.1016/j.jalz.2018.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.016</ArticleId><ArticleId IdType="pmc">PMC6105076</ArticleId><ArticleId IdType="pubmed">29621480</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero JP, Benito-Le&#xf3;n J, Mitchell AJ, Trincado R, Bermejo-Pareja F. Under reporting of dementia deaths on death certificates using data from a population-based study (NEDICES). J Alzheimers Dis. 2014;39(4):741-748. doi:10.3233/JAD-131622</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-131622</ArticleId><ArticleId IdType="pubmed">24254704</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen LC, Ersb&#xf8;ll AK. When the entire population is the sample: strengths and limitations in register-based epidemiology. Eur J Epidemiol. 2014;29(8):551-558. doi:10.1007/s10654-013-9873-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-013-9873-0</ArticleId><ArticleId IdType="pubmed">24407880</ArticleId></ArticleIdList></Reference><Reference><Citation>World Bank . Why use GNI per capita to classify economies into income groupings? 2020. Accessed May 25, 2020. https://datahelpdesk.worldbank.org/knowledgebase/articles/378831-why-use-gni-per-capita-to-classify-economies-into</Citation></Reference><Reference><Citation>Schwarzer G, Chemaitelly H, Abu-Raddad LJ, R&#xfc;cker G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods. 2019;10(3):476-483. doi:10.1002/jrsm.1348</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1348</ArticleId><ArticleId IdType="pmc">PMC6767151</ArticleId><ArticleId IdType="pubmed">30945438</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34289368</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>20</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer's disease and frontotemporal dementia.</ArticleTitle><Pagination><StartPage>109419</StartPage><MedlinePgn>109419</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2021.109419</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(21)00832-9</ELocationID><Abstract><AbstractText>Aging, pathological tau oligomers (TauO), and chronic inflammation in the brain play a central role in tauopathies, including Alzheimer's disease (AD) and frontotemporal dementia (FTD). However, the underlying mechanism of TauO-induced aging-related neuroinflammation remains unclear. Here, we show that TauO-associated astrocytes display a senescence-like phenotype in the brains of patients with AD and FTD. TauO exposure triggers astrocyte senescence through high mobility group box 1 (HMGB1) release and inflammatory senescence-associated secretory phenotype (SASP), which mediates paracrine senescence in adjacent cells. HMGB1 release inhibition using ethyl pyruvate (EP) and glycyrrhizic acid (GA) prevents TauO-induced senescence through inhibition of p38-mitogen-activated protein kinase (MAPK) and nuclear factor &#x3ba;B (NF-&#x3ba;B)-the essential signaling pathways for SASP development. Despite the developed tauopathy in 12-month-old hTau mice, EP+GA treatment significantly decreases TauO and senescent cell loads in the brain, reduces neuroinflammation, and thus ameliorates cognitive functions. Collectively, TauO-induced HMGB1 release promotes cellular senescence and neuropathology, which could represent an important common pathomechanism in tauopathies including AD and FTD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gaikwad</LastName><ForeName>Sagar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puangmalai</LastName><ForeName>Nicha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bittar</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montalbano</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAllen</LastName><ForeName>Salome</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatt</LastName><ForeName>Nemil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonawane</LastName><ForeName>Minal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sengupta</LastName><ForeName>Urmi</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kayed</LastName><ForeName>Rakez</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA; Departments of Neurology, Neuroscience, and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555, USA. Electronic address: rakayed@utmb.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AG067952</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG055771</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054025</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG060718</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG060718</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS094557</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011773">Pyruvates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>03O98E01OB</RegistryNumber><NameOfSubstance UI="C046522">ethyl pyruvate</NameOfSubstance></Chemical><Chemical><RegistryNumber>6FO62043WK</RegistryNumber><NameOfSubstance UI="D019695">Glycyrrhizic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016922" MajorTopicYN="Y">Cellular Senescence</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019695" MajorTopicYN="N">Glycyrrhizic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024243" MajorTopicYN="N">HMGB1 Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011773" MajorTopicYN="N">Pyruvates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HMGB1</Keyword><Keyword MajorTopicYN="N">SASP</Keyword><Keyword MajorTopicYN="N">aging</Keyword><Keyword MajorTopicYN="N">astrocytes</Keyword><Keyword MajorTopicYN="N">cognitive functions</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">senescence</Keyword><Keyword MajorTopicYN="N">tau oligomers</Keyword><Keyword MajorTopicYN="N">tauopathies</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>21</Day><Hour>20</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34289368</ArticleId><ArticleId IdType="mid">NIHMS1726841</ArticleId><ArticleId IdType="pmc">PMC8341760</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.109419</ArticleId><ArticleId IdType="pii">S2211-1247(21)00832-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, Athineos D, Kang TW, Lasitschka F, Andrulis M, et al. (2013). A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol 15, 978&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3732483</ArticleId><ArticleId IdType="pubmed">23770676</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, and Davies P (2003). Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem 86, 582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859672</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, and Blennow K (2001). Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol 58, 373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ar&#xe9;lin K, Kinoshita A, Whelan CM, Irizarry MC, Rebeck GW, Strickland DK, and Hyman BT (2002). LRP and senile plaques in Alzheimer&#x2019;s disease: colocalization with apolipoprotein E and with activated astrocytes. Brain Res. Mol. Brain Res 104, 38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">12117549</ArticleId></ArticleIdList></Reference><Reference><Citation>Aucott H, Lundberg J, Salo H, Klevenvall L, Damberg P, Ottosson L, Andersson U, Holmin S, and Erlandsson Harris H (2018). Neuroinflammation in Response to Intracerebral Injections of Different HMGB1 Redox Isoforms. J Innate Immun 10, 215&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6050639</ArticleId><ArticleId IdType="pubmed">29478057</ArticleId></ArticleIdList></Reference><Reference><Citation>Basisty N, Kale A, Jeon OH, Kuehnemann C, Payne T, Rao C, Holtz A, Shah S, Sharma V, Ferrucci L, et al. (2020). A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biol. 18, e3000599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6964821</ArticleId><ArticleId IdType="pubmed">31945054</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett-Guerrero E, Swaminathan M, Grigore AM, Roach GW, Aberle LG, Johnston JM, and Fink MP (2009). A phase II multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth 23, 324&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">18835526</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat R, Crowe EP, Bitto A, Moh M, Katsetos CD, Garcia FU, Johnson FB, Trojanowski JQ, Sell C, and Torres C (2012). Astrocyte senescence as a component of Alzheimer&#x2019;s disease. PLoS ONE 7, e45069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3440417</ArticleId><ArticleId IdType="pubmed">22984612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitto A, Sell C, Crowe E, Lorenzini A, Malaguti M, Hrelia S, and Torres C (2010). Stress-induced senescence in human and rodent astrocytes. Exp. Cell Res 316, 2961&#x2013;2968.</Citation><ArticleIdList><ArticleId IdType="pubmed">20620137</ArticleId></ArticleIdList></Reference><Reference><Citation>Boisvert MM, Erikson GA, Shokhirev MN, and Allen NJ (2018). The Aging Astrocyte Transcriptome from Multiple Regions of the Mouse Brain. Cell Rep. 22, 269&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783200</ArticleId><ArticleId IdType="pubmed">29298427</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussian TJ, Aziz A, Meyer CF, Swenson BL, van Deursen JM, and Baker DJ (2018). Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 562, 578&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206507</ArticleId><ArticleId IdType="pubmed">30232451</ArticleId></ArticleIdList></Reference><Reference><Citation>Calogero S, Grassi F, Aguzzi A, Voigtl&#xe4;nder T, Ferrier P, Ferrari S, and Bianchi ME (1999). The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet 22, 276&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391216</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Guan B, Wang B, Pu H, Bai X, Chen X, Liu J, Li C, Qiu J, Yang D, et al. (2019). Glycyrrhizin Prevents Hemorrhagic Transformation and Improves Neurological Outcome in Ischemic Stroke with Delayed Thrombolysis Through Targeting Peroxynitrite-Mediated HMGB1 Signaling. Transl. Stroke Res 11, 967&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">31872339</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin SS, and Goldman JE (1996). Glial inclusions in CNS degenerative diseases. J. Neuropathol. Exp. Neurol 55, 499&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">8627339</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinta SJ, Woods G, Demaria M, Rane A, Zou Y, McQuade A, Rajagopalan S, Limbad C, Madden DT, Campisi J, and Andersen JK (2018). Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and Contributes to Neuropathology Linked to Parkinson&#x2019;s Disease. Cell Rep. 22, 930&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5806534</ArticleId><ArticleId IdType="pubmed">29386135</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun H, Im H, Kang YJ, Kim Y, Shin JH, Won W, Lim J, Ju Y, Park YM, Kim S, et al. (2020). Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer&#x2019;s disease via H2O2&#x2212; production. Nat. Neurosci 23, 1555&#x2013;1566.</Citation><ArticleIdList><ArticleId IdType="pubmed">33199896</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke LE, Liddelow SA, Chakraborty C, M&#xfc;nch AE, Heiman M, and Barres BA (2018). Normal aging induces A1-like astrocyte reactivity. Proc. Natl. Acad. Sci. USA 115, E1896&#x2013;E1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5828643</ArticleId><ArticleId IdType="pubmed">29437957</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J, and Torres C (2019). Astrocyte senescence: Evidence and significance. Aging Cell 18, e12937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6516680</ArticleId><ArticleId IdType="pubmed">30815970</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos AR, Kawahara M, Malhotra GK, Schaum N, Huang J, Ved U, Beausejour CM, Coppe JP, Rodier F, and Campisi J (2013). p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes. J. Cell Biol 201, 613&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653366</ArticleId><ArticleId IdType="pubmed">23649808</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, et al. (2013). A phase 3 trial of semagacestat for treatment of Alzheimer&#x2019;s disease. N. Engl. J. Med 369, 341&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pubmed">23883379</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Farlow M, and Aisen PS; Alzheimer&#x2019;s Disease Cooperative Study Data Analysis and Publication Committee (2014). Phase 3 trials of solanezumab and bapineuzumab for Alzheimer&#x2019;s disease. N. Engl. J. Med 370, 1460.</Citation><ArticleIdList><ArticleId IdType="pubmed">24716687</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhoury M (2018). Microglia and Astrocytes in Alzheimer&#x2019;s Disease: Implications for Therapy. Curr. Neuropharmacol. 16, 508&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5997862</ArticleId><ArticleId IdType="pubmed">28730967</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmer KM, Ghag G, Puangmalai N, Montalbano M, Bhatt N, and Kayed R (2020). P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer&#x2019;s disease. Acta Neuropathol. Commun 8, 132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418370</ArticleId><ArticleId IdType="pubmed">32778161</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink MP (2007). Ethyl pyruvate: a novel anti-inflammatory agent. J. Intern. Med 261, 349&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17391109</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonken LK, Frank MG, Kitt MM, D&#x2019;Angelo HM, Norden DM, Weber MD, Barrientos RM, Godbout JP, Watkins LR, and Maier SF (2016). The Alarmin HMGB1 Mediates Age-Induced Neuroinflammatory Priming. J. Neurosci 36, 7946&#x2013;7956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4961779</ArticleId><ArticleId IdType="pubmed">27466339</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Lal D, Zhang B, Dabir DV, Swanson E, Lee VM, and Trojanowski JQ (2005). Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. J. Neurosci 25, 3539&#x2013;3550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725385</ArticleId><ArticleId IdType="pubmed">15814784</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund A, Patil CK, and Campisi J (2011). p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J. 30, 1536&#x2013;1548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102277</ArticleId><ArticleId IdType="pubmed">21399611</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita K, Motoki K, Tagawa K, Chen X, Hama H, Nakajima K, Homma H, Tamura T, Watanabe H, Katsuno M, et al. (2016). HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer&#x2019;s disease. Sci. Rep 6, 31895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4997258</ArticleId><ArticleId IdType="pubmed">27557632</ArticleId></ArticleIdList></Reference><Reference><Citation>Funayama A, Shishido T, Netsu S, Narumi T, Kadowaki S, Takahashi H, Miyamoto T, Watanabe T, Woo CH, Abe J, et al. (2013). Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure. Cardiovasc. Res 99, 657&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746952</ArticleId><ArticleId IdType="pubmed">23708738</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerson J, Castillo-Carranza DL, Sengupta U, Bodani R, Prough DS, DeWitt DS, Hawkins BE, and Kayed R (2016). Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice. J. Neurotrauma 33, 2034&#x2013;2043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5116695</ArticleId><ArticleId IdType="pubmed">26729399</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerson JE, Sengupta U, and Kayed R (2017). Tau Oligomers as Pathogenic Seeds: Preparation and Propagation In Vitro and In Vivo. Methods Mol. Biol 1523, 141&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">27975249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghag G, Bhatt N, Cantu DV, Guerrero-Munoz MJ, Ellsworth A, Sengupta U, and Kayed R (2018). Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross-seeding behavior. Protein Sci 27, 1901&#x2013;1909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6201727</ArticleId><ArticleId IdType="pubmed">30125425</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Schneider LS, and Koo EH (2011). Anti-a&#x3b2; therapeutics in Alzheimer&#x2019;s disease: the need for a paradigm shift. Neuron 69, 203&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058906</ArticleId><ArticleId IdType="pubmed">21262461</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Tortosa E, Baradaran-Heravi Y, Gonzalez Alvarez V, Sainz MJ, Prieto-Jurczynska C, Guerrero-Lopez R, Aguero Rabes P, Van Broeckhoven C, van der Zee J, Rabano Gutierrez A, et al. (2019). Presence of tau astrogliopathy in frontotemporal dementia caused by a novel Grn nonsense (Trp2*) mutation. Neurobiol. Aging 76, 214.e211&#x2013;214.e215.</Citation><ArticleIdList><ArticleId IdType="pubmed">30545478</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Reyes RE, Nava-Mesa MO, Vargas-S&#xe1;nchez K, Ariza-Salamanca D, and Mora-Mur&#xf1;oz L (2017). Involvement of Astrocytes in Alzheimer&#x2019;s Disease from a Neuroinflammatory and Oxidative Stress Perspective. Front. Mol. Neurosci 10, 427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5742194</ArticleId><ArticleId IdType="pubmed">29311817</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman-Martinez L, Maccioni RB, Andrade V, Navarrete LP, Pastor MG, and Ramos-Escobar N (2019). Neuroinflammation as a Common Feature of Neurodegenerative Disorders. Front. Pharmacol 10, 1008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6751310</ArticleId><ArticleId IdType="pubmed">31572186</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Zhang T, Liu H, Mi Y, and Gou X (2020). Astrocyte Senescence and Alzheimer&#x2019;s Disease: A Review. Front. Aging Neurosci 12, 148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7297132</ArticleId><ArticleId IdType="pubmed">32581763</ArticleId></ArticleIdList></Reference><Reference><Citation>Heithoff BP, George KK, Phares AN, Zuidhoek IA, Munoz-Ballester C, and Robel S (2021). Astrocytes are necessary for blood-brain barrier maintenance in the adult mouse brain. Glia 69, 436&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736206</ArticleId><ArticleId IdType="pubmed">32955153</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou S, Zhang T, Li Y, Guo F, and Jin X (2017). Glycyrrhizic Acid Prevents Diabetic Nephropathy by Activating AMPK/SIRT1/PGC-1&#x3b1; Signaling in db/db Mice. J. Diabetes Res 2017, 2865912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5697128</ArticleId><ArticleId IdType="pubmed">29238727</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT (2014). Tau propagation, different tau phenotypes, and prion-like properties of tau. Neuron 82, 1189&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">24945760</ArticleId></ArticleIdList></Reference><Reference><Citation>Iram T, Trudler D, Kain D, Kanner S, Galron R, Vassar R, Barzilai A, Blinder P, Fishelson Z, and Frenkel D (2016). Astrocytes from old Alzheimer&#x2019;s disease mice are impaired in A&#x3b2; uptake and in neuroprotection. Neurobiol. Dis 96, 84&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">27544484</ArticleId></ArticleIdList></Reference><Reference><Citation>Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, Schwartz S, Albasset S, McManus RM, Tejera D, et al. (2019). NLRP3 inflammasome activation drives tau pathology. Nature 575, 669&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7324015</ArticleId><ArticleId IdType="pubmed">31748742</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasa H, Han J, and Ishikawa F (2003). Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway. Genes Cells 8, 131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">12581156</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon OH, Kim C, Laberge RM, Demaria M, Rathod S, Vasserot AP, Chung JW, Kim DH, Poon Y, David N, et al. (2017). Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat. Med 23, 775&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785239</ArticleId><ArticleId IdType="pubmed">28436958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DE, and Davalos AR (2019). Alarmin Detection in Senescent Cells. Methods Mol. Biol 1896, 71&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">30474841</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YM, Park EJ, Kim JH, Park SW, Kim HJ, and Chang KC (2016). Ethyl pyruvate inhibits the acetylation and release of HMGB1 via effects on SIRT1/STAT signaling in LPS-activated RAW264.7 cells and peritoneal macrophages. Int. Immunopharmacol. 41, 98&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">27865166</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG (2020). Astroglia and Tau: New Perspectives. Front. Aging Neurosci. 12, 96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7160822</ArticleId><ArticleId IdType="pubmed">32327993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H, Cairns NJ, Crary JF, Duyckaerts C, Ghetti B, et al. (2016). Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 131, 87&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879001</ArticleId><ArticleId IdType="pubmed">26659578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Lee VM, and Trojanowski JQ (2017a). Protein astrogliopathies in human neurodegenerative diseases and aging. Brain Pathol. 27, 675&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5578412</ArticleId><ArticleId IdType="pubmed">28805003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Xie SX, Lee EB, Robinson JL, Caswell C, Irwin DJ, Toledo JB, Johnson VE, Smith DH, Alafuzoff I, et al. (2017b). Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG). J. Neuropathol. Exp. Neurol 76, 605&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251511</ArticleId><ArticleId IdType="pubmed">28591867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon YJ, Son DH, Chung TH, and Lee YJ (2020).A Review of the Pharmacological Efficacy and Safety of Licorice Root from Corroborative Clinical Trial Findings. J. Med. Food 23, 12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">31874059</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, and Kayed R (2010). Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49, 10039&#x2013;10041.</Citation><ArticleIdList><ArticleId IdType="pubmed">21047142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, and Kayed R (2012). Identification of oligomers at early stages of tau aggregation in Alzheimer&#x2019;s disease. FASEB J. 26, 1946&#x2013;1959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046102</ArticleId><ArticleId IdType="pubmed">22253473</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Lee JH, Lee HY, and Min KJ (2019). Sirtuin signaling in cellular senescence and aging. BMB Rep. 52, 24&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6386230</ArticleId><ArticleId IdType="pubmed">30526767</ArticleId></ArticleIdList></Reference><Reference><Citation>Limbad C, Oron TR, Alimirah F, Davalos AR, Tracy TE, Gan L, Desprez PY, and Campisi J (2020). Astrocyte senescence promotes glutamate toxicity in cortical neurons. PLoS ONE 15, e0227887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6964973</ArticleId><ArticleId IdType="pubmed">31945125</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotze MT, and Tracey KJ (2005). High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol 5, 331&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">15803152</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly PT, Cai F, and Song W (2011). Detection of neuritic plaques in Alzheimer&#x2019;s disease mouse model. J. Vis. Exp 53, 2831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197440</ArticleId><ArticleId IdType="pubmed">21841757</ArticleId></ArticleIdList></Reference><Reference><Citation>Lye JJ, Latorre E, Lee BP, Bandinelli S, Holley JE, Gutowski NJ, Ferrucci L, and Harries LW (2019). Astrocyte senescence may drive alterations in GFAP&#x3b1;, CDKN2A p14ARF, and TAU3 transcript expression and contribute to cognitive decline. Geroscience 41, 561&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6885035</ArticleId><ArticleId IdType="pubmed">31654269</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, and Takashima A (2006). Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer&#x2019;s disease. Neurosci. Res 54, 197&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">16406150</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy KD, and deVellis J (1980). Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J. Cell Biol 85, 890&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2111442</ArticleId><ArticleId IdType="pubmed">6248568</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon R, Behnia F, Polettini J, Saade GR, Campisi J, and Velarde M (2016). Placental membrane aging and HMGB1 signaling associated with human parturition. Aging (Albany NY) 8, 216&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4789578</ArticleId><ArticleId IdType="pubmed">26851389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ming GL, and Song H (2011). Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 70, 687&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3106107</ArticleId><ArticleId IdType="pubmed">21609825</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, Agresti A, Trisciuoglio L, Musco G, and Bianchi ME (2007). Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem. Biol 14, 431&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">17462578</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalbano M, McAllen S, Puangmalai N, Sengupta U, Bhatt N, Johnson OD, Kharas MG, and Kayed R (2020). RNA-binding proteins Musashi and tau soluble aggregates initiate nuclear dysfunction. Nat. Commun 11, 4305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7453003</ArticleId><ArticleId IdType="pubmed">32855391</ArticleId></ArticleIdList></Reference><Reference><Citation>Morsch R, Simon W, and Coleman PD (1999). Neurons may live for decades with neurofibrillary tangles. J. Neuropathol. Exp. Neurol 58, 188&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">10029101</ArticleId></ArticleIdList></Reference><Reference><Citation>Musi N, Valentine JM, Sickora KR, Baeuerle E, Thompson CS, Shen Q, and Orr ME (2018). Tau protein aggregation is associated with cellular senescence in the brain. Aging Cell 17, e12840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6260915</ArticleId><ArticleId IdType="pubmed">30126037</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicaise AM, Wagstaff LJ, Willis CM, Paisie C, Chandok H, Robson P, Fossati V, Williams A, and Crocker SJ (2019). Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis. Proc. Natl. Acad. Sci. USA 116, 9030&#x2013;9039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6500153</ArticleId><ArticleId IdType="pubmed">30910981</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilson AN, English KC, Gerson JE, Barton Whittle T, Nicolas Crain C, Xue J, Sengupta U, Castillo-Carranza DL, Zhang W, Gupta P, and Kayed R (2017). Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases. J. Alzheimers Dis 55, 1083&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5147514</ArticleId><ArticleId IdType="pubmed">27716675</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan A, De Paula Franca Resende, E., Petersen C, Neylan K, Spina S, Huang E, Seeley W, Miller Z, and Grinberg LT. (2019). Astrocytic Tau Deposition Is Frequent in Typical and Atypical Alzheimer Disease Presentations. J. Neuropathol. Exp. Neurol 78, 1112&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7967845</ArticleId><ArticleId IdType="pubmed">31626288</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Halbgebauer S, Anderl-Straub S, Steinacker P, Huss AM, Neugebauer H, von Arnim CAF, Diehl-Schmid J, Grimmer T, Kornhuber J, et al. (2019). Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer&#x2019;s Disease and Correlates with Cognitive Impairment. J. Alzheimers Dis 67, 481&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">30594925</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogrodnik M, Salmonowicz H, Jurk D, and Passos JF (2019). Expansion and Cell-Cycle Arrest: Common Denominators of Cellular Senescence.Trends Biochem. Sci 44, 996&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">31345557</ArticleId></ArticleIdList></Reference><Reference><Citation>Paudel YN, Shaikh MF, Chakraborti A, Kumari Y, Aledo-Serrano A, Aleksovska K, Alvim MKM, and Othman I (2018). HMGB1: A Common Biomarker and Potential Target for TBI, Neuroinflammation, Epilepsy, and Cognitive Dysfunction. Front. Neurosci 12, 628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6142787</ArticleId><ArticleId IdType="pubmed">30271319</ArticleId></ArticleIdList></Reference><Reference><Citation>Paudel YN, Angelopoulou E, Piperi C, Othman I, Aamir K, and Shaikh MF (2020). Impact of HMGB1, RAGE, and TLR4 in Alzheimer&#x2019;s Disease (AD): From Risk Factors to Therapeutic Targeting. Cells 9, 383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7072620</ArticleId><ArticleId IdType="pubmed">32046119</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Nievas BG, and Serrano-Pozo A (2018). Deciphering the Astrocyte Reaction in Alzheimer&#x2019;s Disease. Front. Aging Neurosci 10, 114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5996928</ArticleId><ArticleId IdType="pubmed">29922147</ArticleId></ArticleIdList></Reference><Reference><Citation>Pern&#xe8;gre C, Duquette A, and Leclerc N (2019). Tau Secretion: Good and Bad for Neurons. Front. Neurosci 13, 649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6606725</ArticleId><ArticleId IdType="pubmed">31293374</ArticleId></ArticleIdList></Reference><Reference><Citation>Piacentini R, Li Puma DD, Mainardi M, Lazzarino G, Tavazzi B, Arancio O, and Grassi C (2017). Reduced gliotransmitter release from astrocytes mediates tau-induced synaptic dysfunction in cultured hippocampal neurons. Glia 65, 1302&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5520670</ArticleId><ArticleId IdType="pubmed">28519902</ArticleId></ArticleIdList></Reference><Reference><Citation>Polydoro M, Acker CM, Duff K, Castillo PE, and Davies P (2009). Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J. Neurosci 29, 10741&#x2013;10749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760256</ArticleId><ArticleId IdType="pubmed">19710325</ArticleId></ArticleIdList></Reference><Reference><Citation>Puangmalai N, Bhatt N, Montalbano M, Sengupta U, Gaikwad S, Ventura F, McAllen S, Ellsworth A, Garcia S, and Kayed R (2020). Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer&#x2019;s disease, progressive supranuclear palsy and dementia with Lewy bodies. Cell Death Dis. 11, 314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198578</ArticleId><ArticleId IdType="pubmed">32366836</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE, Leshuk C, Hernandez I, Wegmann S, Hyman BT, et al. (2020). LRP1 is a master regulator of tau uptake and spread. Nature 580, 381&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7687380</ArticleId><ArticleId IdType="pubmed">32296178</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid MJ, Beltran-Lobo P, Johnson L, Perez-Nievas BG, and Noble W (2020). Astrocytes in Tauopathies. Front. Neurol 11, 572850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7542303</ArticleId><ArticleId IdType="pubmed">33071951</ArticleId></ArticleIdList></Reference><Reference><Citation>Richetin K, Steullet P, Pachoud M, Perbet R, Parietti E, Maheswaran M, Eddarkaoui S, B&#xe9;gard S, Pythoud C, Rey M, et al. (2020). Tau accumulation in astrocytes of the dentate gyrus induces neuronal dysfunction and memory deficits in Alzheimer&#x2019;s disease. Nat. Neurosci 23, 1567&#x2013;1579.</Citation><ArticleIdList><ArticleId IdType="pubmed">33169029</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen A, Ojala J, Kaarniranta K, Haapasalo A, Hiltunen M, and Soininen H (2011). Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. Eur. J. Neurosci 34, 3&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">21649759</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen A, Kauppinen A, and Kaarniranta K (2012). Emerging role of NF-&#x3ba;B signaling in the induction of senescence-associated secretory phenotype (SASP). Cell. Signal 24, 835&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pubmed">22182507</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh A, Brace CS, Rensing N, Cliften P, Wozniak DF, Herzog ED, Yamada KA, and Imai S (2013). Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab. 18, 416&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3794712</ArticleId><ArticleId IdType="pubmed">24011076</ArticleId></ArticleIdList></Reference><Reference><Citation>Schildge S, Bohrer C, Beck K, and Schachtrup C (2013). Isolation and culture of mouse cortical astrocytes. J. Vis. Exp 71, 50079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3582677</ArticleId><ArticleId IdType="pubmed">23380713</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta U, Portelius E, Hansson O, Farmer K, Castillo-Carranza D, Woltjer R, Zetterberg H, Galasko D, Blennow K, and Kayed R (2017). Tau oligomers in cerebrospinal fluid in Alzheimer&#x2019;s disease. Ann. Clin. Transl. Neurol 4, 226&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5376754</ArticleId><ArticleId IdType="pubmed">28382304</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafiei SS, Guerrero-Mu&#xf1;oz MJ, and Castillo-Carranza DL (2017). Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage. Front. Aging Neurosci 9, 83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5378766</ArticleId><ArticleId IdType="pubmed">28420982</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen H, Hu X, Liu C, Wang S, Zhang W, Gao H, Stetler RA, Gao Y, and Chen J (2010). Ethyl pyruvate protects against hypoxic-ischemic brain injury via anti-cell death and anti-inflammatory mechanisms. Neurobiol. Dis 37, 711&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824008</ArticleId><ArticleId IdType="pubmed">20026271</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Chen H, Dai J, Wan Z, Xiong P, Xu Y, Han Z, Chai W, Gong F, and Zheng F (2018). Glycyrrhizin Protects Mice Against Experimental Autoimmune Encephalomyelitis by Inhibiting High-Mobility Group Box 1 (HMGB1) Expression and Neuronal HMGB1 Release. Front. Immunol 9, 1518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6036111</ArticleId><ArticleId IdType="pubmed">30013568</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q, Cao Y, Xiong W, Ke X, Zhang J, Xia Y, and Liu D (2020). Glycyrrhizic acid exerts protective effects against hypoxia/reoxygenation-induced human coronary artery endothelial cell damage by regulating mitochondria. Exp. Ther. Med 20, 335&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271712</ArticleId><ArticleId IdType="pubmed">32509013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, Czura CJ, Fink MP, and Tracey KJ (2002). Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. USA 99, 12351&#x2013;12356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129448</ArticleId><ArticleId IdType="pubmed">12209006</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasile F, Dossi E, and Rouach N (2017). Human astrocytes: structure and functions in the healthy brain. Brain Struct. Funct 222, 2017&#x2013;2029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5504258</ArticleId><ArticleId IdType="pubmed">28280934</ArticleId></ArticleIdList></Reference><Reference><Citation>Victorelli S, Lagnado A, Halim J, Moore W, Talbot D, Barrett K, Chapman J, Birch J, Ogrodnik M, Meves A, et al. (2019). Senescent human melanocytes drive skin ageing via paracrine telomere dysfunction. EMBO J. 38, e101982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6885734</ArticleId><ArticleId IdType="pubmed">31633821</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Li W, Goldstein R, Tracey KJ, and Sama AE (2007). HMGB1 as a potential therapeutic target. Novartis Found. Symp 280, 73&#x2013;85, discussion 85&#x2013;91, 160&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">17380789</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M, Pirtskhalava T, Farr JN, Weigand BM, Palmer AK, Weivoda MM, Inman CL, Ogrodnik MB, Hachfeld CM, Fraser DG, et al. (2018). Senolytics improve physical function and increase lifespan in old age. Nat. Med 24, 1246&#x2013;1256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6082705</ArticleId><ArticleId IdType="pubmed">29988130</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandarashvili L, Sahu D, Lee K, Lee YS, Singh P, Rajarathnam K, and Iwahara J (2013). Real-time kinetics of high-mobility group box 1 (HMGB1) oxidation in extracellular fluids studied by in situ protein NMR spectroscopy. J. Biol. Chem 288, 11621&#x2013;11627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636853</ArticleId><ArticleId IdType="pubmed">23447529</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MS, Li G, et al. (2016). Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron 89, 37&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Kishimoto Y, Grammatikakis I, Gottimukkala K, Cutler RG, Zhang S, Abdelmohsen K, Bohr VA, Misra Sen J, Gorospe M, and Mattson MP (2019a). Senolytic therapy alleviates A&#x3b2;-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer&#x2019;s disease model. Nat. Neurosci 22, 719&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6605052</ArticleId><ArticleId IdType="pubmed">30936558</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Guan XW, Gribben JG, Liu FT, and Jia L (2019b). Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma. Cell Death Dis. 10, 330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6465275</ArticleId><ArticleId IdType="pubmed">30988279</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao F, Fang Y, Deng S, Li X, Zhou Y, Gong Y, Zhu H, and Wang W (2017). Glycyrrhizin Protects Rats from Sepsis by Blocking HMGB1 Signaling. BioMed Res. Int. 2017, 9719647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5412259</ArticleId><ArticleId IdType="pubmed">28484719</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Wu H, and Tang XQ (2021). Tau internalization: A complex step in tau propagation. Ageing Res. Rev 67, 101272.</Citation><ArticleIdList><ArticleId IdType="pubmed">33571704</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34312508</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2157-846X</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature biomedical engineering</Title><ISOAbbreviation>Nat Biomed Eng</ISOAbbreviation></Journal><ArticleTitle>Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer's disease alleviates amyloid-related pathologies in mice.</ArticleTitle><Pagination><StartPage>168</StartPage><EndPage>180</EndPage><MedlinePgn>168-180</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41551-021-00759-0</ELocationID><Abstract><AbstractText>The pathology of familial Alzheimer's disease, which is caused by dominant mutations in the gene that encodes amyloid-beta precursor protein (APP) and in those that encode presenilin 1 and presenilin 2, is characterized by extracellular amyloid plaques and intracellular neurofibrillary tangles in multiple brain regions. Here we show that the brain-wide selective disruption of a mutated APP allele in transgenic mouse models carrying the human APP Swedish mutation alleviates amyloid-beta-associated pathologies for at least six months after a single intrahippocampal administration of an adeno-associated virus that encodes both Cas9 and a single-guide RNA that targets the mutation. We also show that the deposition of amyloid-beta, as well as microgliosis, neurite dystrophy and the impairment of cognitive performance, can all be ameliorated when the CRISPR-Cas9 construct is delivered intravenously via a modified adeno-associated virus that can cross the blood-brain barrier. Brain-wide disease-modifying genome editing could represent a viable strategy for the treatment of familial Alzheimer's disease and other monogenic diseases that affect multiple brain regions.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Duan</LastName><ForeName>Yangyang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0823-6574</Identifier><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, Center for Stem Cell Research, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ye</LastName><ForeName>Tao</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8075-7323</Identifier><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, Center for Stem Cell Research, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, HKUST Shenzhen Research Institute, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chinese Academy of Sciences Key Laboratory of Brain Connectome and Manipulation, Shenzhen Key Laboratory of Translational Research for Brain Diseases, The Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yuewen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, Center for Stem Cell Research, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, HKUST Shenzhen Research Institute, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chinese Academy of Sciences Key Laboratory of Brain Connectome and Manipulation, Shenzhen Key Laboratory of Translational Research for Brain Diseases, The Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miranda</LastName><ForeName>Abigail</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, Center for Stem Cell Research, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiaopu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, Center for Stem Cell Research, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lok</LastName><ForeName>Ka-Chun</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, Center for Stem Cell Research, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, Center for Stem Cell Research, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, HKUST Shenzhen Research Institute, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chinese Academy of Sciences Key Laboratory of Brain Connectome and Manipulation, Shenzhen Key Laboratory of Translational Research for Brain Diseases, The Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Amy K Y</ForeName><Initials>AKY</Initials><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, Center for Stem Cell Research, The Hong Kong University of Science and Technology, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, HKUST Shenzhen Research Institute, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gradinaru</LastName><ForeName>Viviana</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5868-348X</Identifier><AffiliationInfo><Affiliation>Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ip</LastName><ForeName>Nancy Y</ForeName><Initials>NY</Initials><Identifier Source="ORCID">0000-0002-2763-8907</Identifier><AffiliationInfo><Affiliation>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, Center for Stem Cell Research, The Hong Kong University of Science and Technology, Hong Kong, China. boip@ust.hk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China. boip@ust.hk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, HKUST Shenzhen Research Institute, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen, China. boip@ust.hk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Biomed Eng</MedlineTA><NlmUniqueID>101696896</NlmUniqueID><ISSNLinking>2157-846X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064113" MajorTopicYN="N">CRISPR-Cas Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>27</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34312508</ArticleId><ArticleId IdType="doi">10.1038/s41551-021-00759-0</ArticleId><ArticleId IdType="pii">10.1038/s41551-021-00759-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cai, Y., An, S. S. &amp; Kim, S. Mutations in presenilin 2 and its implications in Alzheimer&#x2019;s disease and other dementia-associated disorders. Clin. Interv. Aging 10, 1163&#x2013;1172 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26203236</ArticleId><ArticleId IdType="pmc">4507455</ArticleId></ArticleIdList></Reference><Reference><Citation>Campion, D. et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 65, 664&#x2013;670 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10441572</ArticleId><ArticleId IdType="pmc">1377972</ArticleId><ArticleId IdType="doi">10.1086/302553</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacace, R., Sleegers, K. &amp; Van Broeckhoven, C. Molecular genetics of early-onset Alzheimer&#x2019;s disease revisited. Alzheimers Dement. 12, 733&#x2013;748 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27016693</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2016.01.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper, P. S. The epidemiology of Huntington&#x2019;s disease. Hum. Genet. 89, 365&#x2013;376 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1535611</ArticleId><ArticleId IdType="doi">10.1007/BF00194305</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio, A. et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41, 118&#x2013;130 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23860588</ArticleId><ArticleId IdType="doi">10.1159/000351153</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe, D. J. &amp; Hardy, J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol. Med. 8, 595&#x2013;608 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27025652</ArticleId><ArticleId IdType="pmc">4888851</ArticleId><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran, F. A. et al. Genome engineering using the CRISPR&#x2013;Cas9 system. Nat. Protoc. 8, 2281&#x2013;2308 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24157548</ArticleId><ArticleId IdType="pmc">3969860</ArticleId><ArticleId IdType="doi">10.1038/nprot.2013.143</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo, A., Frosch, M. P., Masliah, E. &amp; Hyman, B. T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22229116</ArticleId><ArticleId IdType="pmc">3234452</ArticleId><ArticleId IdType="doi">10.1101/cshperspect.a006189</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak, H. &amp; Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18, 351&#x2013;357 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId><ArticleId IdType="doi">10.1016/S0197-4580(97)00056-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S. &amp; Simonato, M. Gene therapy tools for brain diseases. Front. Pharmacol. 10, 724 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31312139</ArticleId><ArticleId IdType="pmc">6613496</ArticleId><ArticleId IdType="doi">10.3389/fphar.2019.00724</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172&#x2013;1179 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28671695</ArticleId><ArticleId IdType="pmc">5529245</ArticleId><ArticleId IdType="doi">10.1038/nn.4593</ArticleId></ArticleIdList></Reference><Reference><Citation>Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204&#x2013;209 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26829320</ArticleId><ArticleId IdType="pmc">5088052</ArticleId><ArticleId IdType="doi">10.1038/nbt.3440</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedbrook, C. N., Deverman, B. E. &amp; Gradinaru, V. Viral strategies for targeting the central and peripheral nervous systems. Annu. Rev. Neurosci. 41, 323&#x2013;348 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29709207</ArticleId><ArticleId IdType="doi">10.1146/annurev-neuro-080317-062048</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng, J. et al. TRIM9-mediated resolution of neuroinflammation confers neuroprotection upon ischemic stroke in mice. Cell Rep. 27, 549&#x2013;560.e6 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30970257</ArticleId><ArticleId IdType="pmc">6485958</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2018.12.055</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortiz-Virumbrales, M. et al. CRISPR/Cas9-correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer&#x2019;s PSEN2 <sup>N141I</sup> neurons. Acta Neuropathol. Commun. 5, 77 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29078805</ArticleId><ArticleId IdType="pmc">5660456</ArticleId><ArticleId IdType="doi">10.1186/s40478-017-0475-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyorgy, B. et al. CRISPR/Cas9 mediated disruption of the Swedish APP allele as a therapeutic approach for early-onset Alzheimer&#x2019;s disease. Mol. Ther. Nucleic Acids 11, 429&#x2013;440 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29858078</ArticleId><ArticleId IdType="pmc">5992788</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2018.03.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434&#x2013;443 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32461654</ArticleId><ArticleId IdType="pmc">7334197</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2308-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, B. et al. &#x3b3;-Secretase gene mutations in familial acne inversa. Science 330, 1065 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20929727</ArticleId><ArticleId IdType="doi">10.1126/science.1196284</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullan, M. et al. A pathogenic mutation for probable Alzheimer&#x2019;s disease in the APP gene at the N-terminus of &#x3b2;-amyloid. Nat. Genet. 1, 345&#x2013;347 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1302033</ArticleId><ArticleId IdType="doi">10.1038/ng0892-345</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron, M. et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc. Natl Acad. Sci. USA 91, 11993&#x2013;11997 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7991571</ArticleId><ArticleId IdType="pmc">45362</ArticleId><ArticleId IdType="doi">10.1073/pnas.91.25.11993</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston, J. A. et al. Increased &#x3b2;-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer&#x2019;s disease APP670/671 mutation. FEBS Lett. 354, 274&#x2013;278 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7957938</ArticleId><ArticleId IdType="doi">10.1016/0014-5793(94)01137-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedenheft, B. et al. RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions. Proc. Natl Acad. Sci. USA 108, 10092&#x2013;10097 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21536913</ArticleId><ArticleId IdType="pmc">3121849</ArticleId><ArticleId IdType="doi">10.1073/pnas.1102716108</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, X. et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. Nature 553, 217&#x2013;221 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29258297</ArticleId><ArticleId IdType="doi">10.1038/nature25164</ArticleId></ArticleIdList></Reference><Reference><Citation>Mashiko, D. et al. Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA. Sci. Rep. 3, 3355 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24284873</ArticleId><ArticleId IdType="pmc">3842082</ArticleId><ArticleId IdType="doi">10.1038/srep03355</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929&#x2013;11947 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25186741</ArticleId><ArticleId IdType="pmc">4152602</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1860-14.2014</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley, H. et al. Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17021169</ArticleId><ArticleId IdType="pmc">6674618</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura, R. &amp; Ohno, M. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol. Dis. 33, 229&#x2013;235 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19026746</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2008.10.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao, C. Y., Mirra, S. S., Sait, H. B., Sacktor, T. C. &amp; Sigurdsson, E. M. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced A&#x3b2; and tau pathology in transgenic mouse models of Alzheimer&#x2019;s disease. Acta Neuropathol. 122, 285&#x2013;292 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21630115</ArticleId><ArticleId IdType="pmc">3437675</ArticleId><ArticleId IdType="doi">10.1007/s00401-011-0843-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowrishankar, S. et al. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer&#x2019;s disease amyloid plaques. Proc. Natl Acad. Sci. USA 112, E3699&#x2013;E3708 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26124111</ArticleId><ArticleId IdType="pmc">4507205</ArticleId><ArticleId IdType="doi">10.1073/pnas.1510329112</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharoar, M. G., Hu, X., Ma, X. M., Zhu, X. &amp; Yan, R. Sequential formation of different layers of dystrophic neurites in Alzheimer&#x2019;s brains. Mol. Psychiatry 24, 1369&#x2013;1382 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30899091</ArticleId><ArticleId IdType="pmc">7204504</ArticleId><ArticleId IdType="doi">10.1038/s41380-019-0396-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones, T. L. &amp; Hyman, B. T. The intersection of amyloid beta and tau at synapses in Alzheimer&#x2019;s disease. Neuron 82, 756&#x2013;771 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24853936</ArticleId><ArticleId IdType="pmc">4135182</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodhouse, A., West, A. K., Chuckowree, J. A., Vickers, J. C. &amp; Dickson, T. C. Does &#x3b2;-amyloid plaque formation cause structural injury to neuronal processes? Neurotox. Res. 7, 5&#x2013;15 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15639794</ArticleId><ArticleId IdType="doi">10.1007/BF03033772</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky, J. L. et al. Mutant presenilins specifically elevate the levels of the 42 residue &#x3b2;-amyloid peptide in vivo: evidence for augmentation of a 42-specific &#x3b3; secretase. Hum. Mol. Genet. 13, 159&#x2013;170 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddh019</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza, M. et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 24, 516&#x2013;524 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17029828</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2006.08.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu, A. K. et al. IL-33 ameliorates Alzheimer&#x2019;s disease-like pathology and cognitive decline. Proc. Natl Acad. Sci. USA 113, E2705&#x2013;E2713 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27091974</ArticleId><ArticleId IdType="pmc">4868478</ArticleId><ArticleId IdType="doi">10.1073/pnas.1604032113</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde, R., Kim, H. D., Maxwell, J. A. &amp; Fukuchi, K. Exploratory activity and spatial learning in 12-month-old APP<sub>695</sub>SWE/co+PS1/&#x394;E9 mice with amyloid plaques. Neurosci. Lett. 390, 87&#x2013;92 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16169151</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2005.08.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, J. H. et al. Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons. Mol. Brain 7, 17 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24618276</ArticleId><ArticleId IdType="pmc">3975461</ArticleId><ArticleId IdType="doi">10.1186/1756-6606-7-17</ArticleId></ArticleIdList></Reference><Reference><Citation>Patricio, M. I., Barnard, A. R., Orlans, H. O., McClements, M. E. &amp; MacLaren, R. E. Inclusion of the woodchuck hepatitis virus posttranscriptional regulatory element enhances AAV2-driven transduction of mouse and human retina. Mol. Ther. Nucleic Acids 6, 198&#x2013;208 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28325286</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2016.12.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. A. &amp; Wirths, O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal A&#x3b2; aggregation in the 5XFAD mouse model of Alzheimer&#x2019;s disease. Neurobiol. Aging 33, 196.e29&#x2013;40 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.05.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Tible, M. et al. PKR knockout in the 5xFAD model of Alzheimer&#x2019;s disease reveals beneficial effects on spatial memory and brain lesions. Aging Cell 18, e12887 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30821420</ArticleId><ArticleId IdType="pmc">6516179</ArticleId><ArticleId IdType="doi">10.1111/acel.12887</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186&#x2013;191 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25830891</ArticleId><ArticleId IdType="pmc">4393360</ArticleId><ArticleId IdType="doi">10.1038/nature14299</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts, M., Theuns, J. &amp; Van Broeckhoven, C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutat. 33, 1340&#x2013;1344 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22581678</ArticleId><ArticleId IdType="pmc">3465795</ArticleId><ArticleId IdType="doi">10.1002/humu.22117</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinstiver, B. P. et al. Broadening the targeting range of Staphylococcus aureus CRISPR&#x2013;Cas9 by modifying PAM recognition. Nat. Biotechnol. 33, 1293&#x2013;1298 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26524662</ArticleId><ArticleId IdType="pmc">4689141</ArticleId><ArticleId IdType="doi">10.1038/nbt.3404</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata, K. et al. Generation of App knock-in mice reveals deletion mutations protective against Alzheimer&#x2019;s disease-like pathology. Nat. Commun. 9, 1800 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29728560</ArticleId><ArticleId IdType="pmc">5935712</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-04238-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, H. et al. In vivo neuronal gene editing via CRISPR&#x2013;Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer&#x2019;s disease. Nat. Neurosci. 22, 524&#x2013;528 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30858603</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0352-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Filser, S. et al. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions. Biol. Psychiatry 77, 729&#x2013;739 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25599931</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2014.10.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou-Yang, M.-H. et al. Axonal organization defects in the hippocampus of adult conditional BACE1 knockout mice. Sci. Transl. Med. 10, eaao5620 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30232227</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aao5620</ArticleId></ArticleIdList></Reference><Reference><Citation>Blume, T. et al. BACE1 inhibitor MK-8931 alters formation but not stability of dendritic spines. Front. Aging Neurosci. 10, 229 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30093858</ArticleId><ArticleId IdType="pmc">6070607</ArticleId><ArticleId IdType="doi">10.3389/fnagi.2018.00229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindra Kumar, S. et al. Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types. Nat. Methods 17, 541&#x2013;550 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32313222</ArticleId><ArticleId IdType="doi">10.1038/s41592-020-0799-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Flytzanis, N. C. et al. Broad gene expression throughout the mouse and marmoset brain after intravenous delivery of engineered AAV capsids. Preprint at bioRxiv https://doi.org/10.1101/2020.06.16.152975 (2020).</Citation></Reference><Reference><Citation>Bloch, D. B. et al. Sp110 localizes to the PML-Sp100 nuclear body and may function as a nuclear hormone receptor transcriptional coactivator. Mol. Cell. Biol. 20, 6138&#x2013;6146 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10913195</ArticleId><ArticleId IdType="pmc">86089</ArticleId><ArticleId IdType="doi">10.1128/MCB.20.16.6138-6146.2000</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo, W. &amp; Zhang, J. T. Human ABCG2: structure, function, and its role in multidrug resistance. Int J. Biochem Mol. Biol. 3, 1&#x2013;27 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22509477</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang, Z. et al. The pseudokinase CaMKv is required for the activity-dependent maintenance of dendritic spines. Nat. Commun. 7, 13282 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27796283</ArticleId><ArticleId IdType="pmc">5095516</ArticleId><ArticleId IdType="doi">10.1038/ncomms13282</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, J. et al. CRISPR/Cas9 editing of APP C-terminus attenuates &#x3b2;-cleavage and promotes &#x3b1;-cleavage. Nat. Commun. 10, 53 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30604771</ArticleId><ArticleId IdType="pmc">6318289</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-07971-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Hocquemiller, M., Giersch, L., Audrain, M., Parker, S. &amp; Cartier, N. Adeno-associated virus-based gene therapy for CNS diseases. Hum. Gene Ther. 27, 478&#x2013;496 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27267688</ArticleId><ArticleId IdType="pmc">4960479</ArticleId><ArticleId IdType="doi">10.1089/hum.2016.087</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudry, E. &amp; Vandenberghe, L. H. Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101, 839&#x2013;862 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30844402</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2019.02.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Challis, R. C. et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat. Protoc. 14, 379&#x2013;414 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30626963</ArticleId><ArticleId IdType="doi">10.1038/s41596-018-0097-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Keane, T. M. et al. Mouse genomic variation and its effect on phenotypes and gene regulation. Nature 477, 289&#x2013;294 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21921910</ArticleId><ArticleId IdType="pmc">3276836</ArticleId><ArticleId IdType="doi">10.1038/nature10413</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojtowicz, J. M. &amp; Kee, N. BrdU assay for neurogenesis in rodents. Nat. Protoc. 1, 1399&#x2013;1405 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17406427</ArticleId><ArticleId IdType="doi">10.1038/nprot.2006.224</ArticleId></ArticleIdList></Reference><Reference><Citation>Styren, S. D., Hamilton, R. L., Styren, G. C. &amp; Klunk, W. E. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer&#x2019;s disease pathology. J. Histochem. Cytochem. 48, 1223&#x2013;1232 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10950879</ArticleId><ArticleId IdType="doi">10.1177/002215540004800906</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo, J. et al. Activity-dependent p25 generation regulates synaptic plasticity and A&#x3b2;-induced cognitive impairment. Cell 157, 486&#x2013;498 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24725413</ArticleId><ArticleId IdType="pmc">4327772</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2014.01.065</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, K. et al. Replenishment of microRNA-188-5p restores the synaptic and cognitive deficits in 5XFAD mouse model of Alzheimer&#x2019;s disease. Sci. Rep. 6, 34433 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27708404</ArticleId><ArticleId IdType="pmc">5052619</ArticleId><ArticleId IdType="doi">10.1038/srep34433</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi, L. &amp; Ohno, M. Mitochondrial dysfunction and accumulation of the &#x3b2;-secretase-cleaved C-terminal fragment of APP in Alzheimer&#x2019;s disease transgenic mice. Neurobiol. Dis. 45, 417&#x2013;424 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21933711</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2011.09.001</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34314093</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Aducanumab: Appropriate use recommendations.</ArticleTitle><Pagination><StartPage>531</StartPage><EndPage>533</EndPage><MedlinePgn>531-533</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12444</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas, Nevada, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Butler Hospital and Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 AG071476</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS093334</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072980</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 GM109025</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053798</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 AG068053</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016433">News</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>105J35OE21</RegistryNumber><NameOfSubstance UI="C000600266">aducanumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARIA</Keyword><Keyword MajorTopicYN="N">Aduhelm</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">MRI</Keyword><Keyword MajorTopicYN="N">aducanumab</Keyword><Keyword MajorTopicYN="N">amyloid imaging</Keyword><Keyword MajorTopicYN="N">appropriate use</Keyword><Keyword MajorTopicYN="N">titration</Keyword></KeywordList><CoiStatement>J.C. has provided consultation to Acadia, Alkahest, AriBio, Avanir, Axsome, Behren Therapeutics, Biogen, Cassava, Cerecin, Cerevel, Cortexyme, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, Grifols, Janssen, Jazz, Karuna, LSP, Merck, Novo Nordisk, Otsuka, ReMYND, Resverlogix, Roche, Signant Health, Sunovion, Suven, United Neuroscience, and Unlearn AI pharmaceutical and assessment companies. J.C. owns the copyright of the Neuropsychiatric Inventory. S.S. was a site PI and co&#x2010;chair of the investigator steering committee for the ENGAGE trial and he receives research support and consultancy fees from Lilly, Biogen, Avid, Eisai, Genentech, and Roche.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>27</Day><Hour>12</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34314093</ArticleId><ArticleId IdType="mid">NIHMS1736525</ArticleId><ArticleId IdType="pmc">PMC8792094</ArticleId><ArticleId IdType="doi">10.1002/alz.12444</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cummings J, Aisen P, Apostolova LG, et&#xa0;al. Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis. 2021. In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8835345</ArticleId><ArticleId IdType="pubmed">34585212</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration . Early Alzheimer's Disease: Developing Drugs for Treatment Guidance for Industry. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER; ). February 2018.</Citation></Reference><Reference><Citation>
U.S. Food &amp; Drug Administration Drugs@FDA: FDA&#x2010;Approved Drugs. Aducanumab
. 2021. Reference ID 4822820 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=761178
</Citation></Reference><Reference><Citation>Babulal GM, Quiroz YT, Albensi BC, et&#xa0;al. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: update and areas of immediate need. Alzheimers Dement. 2019;15:292&#x2010;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6368893</ArticleId><ArticleId IdType="pubmed">30555031</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34233151</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>16</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Early-life inflammation promotes depressive symptoms in adolescence via microglial engulfment of dendritic spines.</ArticleTitle><Pagination><StartPage>2573</StartPage><EndPage>2589.e9</EndPage><MedlinePgn>2573-2589.e9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2021.06.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(21)00427-X</ELocationID><Abstract><AbstractText>Early-life inflammation increases the risk for depression in later life. Here, we demonstrate how early-life inflammation causes adolescent depressive-like symptoms: by altering the long-term neuronal spine engulfment capacity of microglia. For mice exposed to lipopolysaccharide (LPS)-induced inflammation via the Toll-like receptor 4/NF-&#x3ba;B signaling pathway at postnatal day (P) 14, ongoing longitudinal imaging of the living brain revealed that later stress (delivered during adolescence on P45) increases the extent of microglial engulfment around anterior cingulate cortex (ACC) glutamatergic neuronal (ACC<sup>Glu</sup>) spines. When the ACC microglia of LPS-treated mice were deleted or chemically inhibited, the mice did not exhibit depressive-like behaviors during adolescence. Moreover, we show that the fractalkine receptor CX3CR1 mediates stress-induced engulfment of ACC<sup>Glu</sup> neuronal spines. Together, our findings establish that early-life inflammation causes dysregulation of microglial engulfment capacity, which encodes long-lasting maladaptation of ACC<sup>Glu</sup> neurons to stress, thus promoting development of depression-like symptoms during adolescence.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of USTC, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Changmao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of USTC, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>An</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiology, School of Basic Medical Sciences, Anhui Medical University, Hefei 230022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shan</LastName><ForeName>Qinghong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of USTC, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of USTC, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Chunhui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of USTC, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Xiaoqi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of USTC, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Mingjun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of USTC, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farzinpour</LastName><ForeName>Zahra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of USTC, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of USTC, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of USTC, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jiang-Ning</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of USTC, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xiaoyuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of USTC, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Liecheng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Physiology, School of Basic Medical Sciences, Anhui Medical University, Hefei 230022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Physiology, School of Basic Medical Sciences, Anhui Medical University, Hefei 230022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Changjian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, the First Affiliated Hospital of Wannan Medical College, Wuhu 241002, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Stroke Center &amp; Department of Neurology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Yu-Qiang</ForeName><Initials>YQ</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, and Department of Laboratory Animal Science, Fudan University, Shanghai 200032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of USTC, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China. Electronic address: jinyan@ustc.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Key Laboratory of Animal Models and Human Disease Mechanisms, and Laboratory of Learning and Memory, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China. Electronic address: lxu@vip.163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of USTC, Hefei National Laboratory for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, China. Electronic address: zhizhang@ustc.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2021 Aug 18;109(16):2503-2505. doi: 10.1016/j.neuron.2021.07.023.</RefSource><PMID Version="1">34411536</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACC</Keyword><Keyword MajorTopicYN="N">calcium imaging</Keyword><Keyword MajorTopicYN="N">chemogenetics</Keyword><Keyword MajorTopicYN="N">dendritic spines</Keyword><Keyword MajorTopicYN="N">depressive symptoms</Keyword><Keyword MajorTopicYN="N">early-life inflammation</Keyword><Keyword MajorTopicYN="N">microglial engulfment</Keyword><Keyword MajorTopicYN="N">neuronal activity</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>7</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34233151</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2021.06.012</ArticleId><ArticleId IdType="pii">S0896-6273(21)00427-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34333238</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up.</ArticleTitle><Pagination><StartPage>103512</StartPage><MedlinePgn>103512</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">103512</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2021.103512</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(21)00305-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neurologic manifestations are well-recognized features of coronavirus disease 2019 (COVID-19). However, the longitudinal association of biomarkers reflecting CNS impact and neurological symptoms is not known. We sought to determine whether plasma biomarkers of CNS injury were associated with neurologic sequelae after COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with confirmed acute COVID-19 were studied prospectively. Neurological symptoms were recorded during the acute phase of the disease and at six months follow-up, and blood samples were collected longitudinally. Healthy age-matched individuals were included as controls. We analysed plasma concentrations of neurofilament light-chain (NfL), glial fibrillary acidic protein (GFAp), and growth differentiation factor 15 (GDF-15).</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">One hundred patients with mild (n&#xa0;=&#xa0;24), moderate (n&#xa0;=&#xa0;28), and severe (n&#xa0;=&#xa0;48) COVID-19 were followed for a median (IQR) of 225 (187-262) days. In the acute phase, patients with severe COVID-19 had higher concentrations of NfL than all other groups (all p &lt; 0&#xb7;001), and higher GFAp than controls (p &lt; 0&#xb7;001). GFAp was also significantly increased in moderate disease (p &lt; 0&#xb7;05) compared with controls. NfL (r&#xa0;=&#xa0;0&#xb7;53, p &lt; 0&#xb7;001) and GFAp (r&#xa0;=&#xa0;0&#xb7;39, p &lt; 0&#xb7;001) correlated with GDF-15 during the acute phase. After six months, NfL and GFAp concentrations had normalized, with no persisting group differences. Despite this, 50 patients reported persistent neurological symptoms, most commonly fatigue (n&#xa0;=&#xa0;40), "brain-fog" (n&#xa0;=&#xa0;29), and changes in cognition (n&#xa0;=&#xa0;25). We found no correlation between persistent neurological symptoms and CNS injury biomarkers in the acute phase.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">The normalization of CNS injury biomarkers in all individuals, regardless of previous disease severity or persisting neurological symptoms, indicates that post COVID-19 neurological sequelae are not accompanied by ongoing CNS injury.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">The Swedish State Support for Clinical Research, SciLifeLab Sweden, and the Knut and Alice Wallenberg Foundation have provided funding for this project.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kanberg</LastName><ForeName>Nelly</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Infectious Diseases, Region V&#xe4;stra G&#xf6;taland, Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: nelly.kanberg@gu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simr&#xe9;n</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience &amp; Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ed&#xe9;n</LastName><ForeName>Arvid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Infectious Diseases, Region V&#xe4;stra G&#xf6;taland, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>Lars-Magnus</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Infectious Diseases, Region V&#xe4;stra G&#xf6;taland, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Staffan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashton</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience &amp; Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, UK; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundvall</LastName><ForeName>P&#xe4;r-Daniel</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Research, Education, Development and Innovation, Primary Health Care, Region V&#xe4;stra G&#xf6;taland, Sweden; General Practice/Family Medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nellg&#xe5;rd</LastName><ForeName>Bengt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive care, Institution of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience &amp; Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience &amp; Physiology, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gissl&#xe9;n</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Infectious Diseases, Region V&#xe4;stra G&#xf6;taland, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CNS</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">GDF-15</Keyword><Keyword MajorTopicYN="N">GFAp</Keyword><Keyword MajorTopicYN="N">NfL</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest KB has served as a consultant, on advisory boards, or on data monitoring committees for Abcam, Axon, Biogen, Julius Clinical, Lilly, MagQu, Merck, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions (BBS) in Gothenburg, Sweden, a part of the GU Ventures Incubator Program (externally submitted work). HZ has served on scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics; and CogRx; has lectured at symposia sponsored by Fujirebio, Alzecure, and Biogen; and is a co-founder of Brain Biomarker Solutions (BBS) in Gothenburg, Sweden, part of the GU Ventures Incubator Program (external submitted work). MG has received research grants from Gilead Sciences and Janssen-Cilag, and honoraria from Amgen, Biogen, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Janssen-Cilag, MSD, Novocure, and Novo Nordic as a speaker or scientific advisor. All other authors report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>1</Day><Hour>20</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34333238</ArticleId><ArticleId IdType="pmc">PMC8320425</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2021.103512</ArticleId><ArticleId IdType="pii">S2352-3964(21)00305-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon T. Neurological infection with SARS-CoV-2 &#x2014; the story so far. Nat Rev Neurol. 2021;17(2):65&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7789883</ArticleId><ArticleId IdType="pubmed">33414554</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L., Jin H., Wang M. Neurologic manifestations of hospitalized patients with Coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker A., Anson M., Harky A. Neurological manifestations of COVID-19: a systematic review and current update. Acta Neurol Scand. 2020;142(1):14&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273036</ArticleId><ArticleId IdType="pubmed">32412088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellul M.A., Benjamin L., Singh B. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Liotta E.M., Batra A., Clark J.R. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol. 2020;7(11):2221&#x2013;2230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7664279</ArticleId><ArticleId IdType="pubmed">33016619</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon P.J., Panczykowski D.M., Yue J.K. Measurement of the glial fibrillary acidic protein and its breakdown products GFAP-BDP biomarker for the detection of traumatic brain injury compared to computed tomography and magnetic resonance imaging. J Neurotrauma. 2015;32(8):527&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394160</ArticleId><ArticleId IdType="pubmed">25264814</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H., Blennow K. Fluid biomarkers for mild traumatic brain injury and related conditions. Nat Rev Neurol. 2016;12(10):563&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">27632903</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg N., Ashton N.J., Andersson L.M. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology. 2020;95(12):e1754&#x2013;e17e9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32546655</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter R., Hert L., De Marchis G.M. Serum neurofilament light chain levels in the intensive care unit: comparison between severely ill patients with and without Coronavirus disease. Ann Neurol. 2019;89(3):610&#x2013;616. 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">33377539</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper J., Stukas S., Hoiland R.L. Quantification of neurological blood-based biomarkers in critically ill patients with Coronavirus disease 2019. Crit Care Explor. 2020;2(10):e0238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7535554</ArticleId><ArticleId IdType="pubmed">33063038</ArticleId></ArticleIdList></Reference><Reference><Citation>Myhre P.L., Prebensen C., Strand H. Growth differentiation factor 15 provides prognostic information superior to established cardiovascular and inflammatory biomarkers in unselected patients hospitalized with COVID-19. Circulation. 2020;142(22):2128&#x2013;2137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7688084</ArticleId><ArticleId IdType="pubmed">33058695</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Miners S., Kehoe P.G., Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimers Res Ther. 2020;12(1):170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7772800</ArticleId><ArticleId IdType="pubmed">33380345</ArticleId></ArticleIdList></Reference><Reference><Citation>A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192&#x2013;e1e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Bes&#xe8;r A., Sorjonen K., Wahlberg K., Peterson U., Nygren A., Asberg M. Construction and evaluation of a self rating scale for stress-induced exhaustion disorder, the Karolinska exhaustion disorder scale. Scand J Psychol. 2014;55(1):72&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4235404</ArticleId><ArticleId IdType="pubmed">24236500</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz A., Marklund E., Andersson M. Upper respiratory tract levels of severe acute respiratory syndrome Coronavirus 2 RNA and duration of viral RNA shedding do not differ between patients with mild and severe/critical Coronavirus disease 2019. J Infect Dis. 2021;223(1):15&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665561</ArticleId><ArticleId IdType="pubmed">33020822</ArticleId></ArticleIdList></Reference><Reference><Citation>Gissl&#xe9;n M., Price R.W., Andreasson U. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739412</ArticleId><ArticleId IdType="pubmed">26870824</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B., Lautner R., Andreasson U. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Coll A.P., Chen M., Taskar P. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7234839</ArticleId><ArticleId IdType="pubmed">31875646</ArticleId></ArticleIdList></Reference><Reference><Citation>Virhammar J., Kumlien E., F&#xe4;llmar D. Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. Neurology. 2020;95(10):445&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538220</ArticleId><ArticleId IdType="pubmed">32586897</ArticleId></ArticleIdList></Reference><Reference><Citation>Virhammar J., N&#xe4;&#xe4;s A., F&#xe4;llmar D. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. Eur J Neurol. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8518988</ArticleId><ArticleId IdType="pubmed">33369818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A., Masciocchi S., Volonghi I. SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses. Clin Infect Dis. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799260</ArticleId><ArticleId IdType="pubmed">33395482</ArticleId></ArticleIdList></Reference><Reference><Citation>Ed&#xe9;n A., Kanberg N., Gostner J. CSF biomarkers in patients with COVID-19 and neurologic symptoms: a case series. Neurology. 2021;96(2):e294&#x2013;e300.</Citation><ArticleIdList><ArticleId IdType="pubmed">33004602</ArticleId></ArticleIdList></Reference><Reference><Citation>Studahl M., Rosengren L., G&#xfc;nther G., Hagberg L. Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction. J Neurol. 2000;247(8):636&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">11041333</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J. Long covid: WHO calls on countries to offer patients more rehabilitation. BMJ. 2021;372:n405.</Citation><ArticleIdList><ArticleId IdType="pubmed">33568362</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Geddes J.R., Husain M., Luciano S., Harrison P.J. 6-month neurological and psychiatric outcomes in 236&#x2009;379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M., Teunissen C.E., Otto M. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L., Al-Faraj A., Ayub N. Electroencephalographic abnormalities are common in COVID-19 and are associated with outcomes. Ann Neurol. 2021;89(5):872&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8104061</ArticleId><ArticleId IdType="pubmed">33704826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton N.J., Janelidze S., Al Khleifat A. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12(1):3400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185001</ArticleId><ArticleId IdType="pubmed">34099648</ArticleId></ArticleIdList></Reference><Reference><Citation>Appleton R.T., Kinsella J., Quasim T. The incidence of intensive care unit-acquired weakness syndromes: a systematic review. J Intensive Care Soc. 2015;16(2):126&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5606476</ArticleId><ArticleId IdType="pubmed">28979394</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann P., De Simoni D., Kaider A. Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barr&#xe9; syndrome. J Neuroinflamm. 2020;17(1):86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7079539</ArticleId><ArticleId IdType="pubmed">32183837</ArticleId></ArticleIdList></Reference><Reference><Citation>Millere E., Rots D., Simr&#xe9;n J. Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. Eur J Neurol. 2021;28(3):974&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pubmed">33340200</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34333531</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2158-3188</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>Translational psychiatry</Title><ISOAbbreviation>Transl Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Herpes simplex virus, early neuroimaging markers and incidence of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>414</StartPage><MedlinePgn>414</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">414</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41398-021-01532-2</ELocationID><Abstract><AbstractText>While previous studies suggest the implication of herpes simplex virus (HSV) in the onset of Alzheimer's disease (AD), no study has investigated its association with early neuroimaging markers of AD. In the Three-City and the AMI cohorts, the associations between HSV infection and (i) hippocampal volume (n&#x2009;=&#x2009;349), (ii) white matter alterations in the parahippocampal cingulum and fornix using diffusion tensor imaging (n&#x2009;=&#x2009;260), and (iii) incidence of AD (n&#x2009;=&#x2009;1599) were assessed according to APOE4 status. Regardless of APOE4 status, infected subjects presented (i) significantly more microstructural alterations of the parahippocampal cingulum and fornix, (ii) lower hippocampal volumes only when their anti-HSV IgG level was in the highest tercile-reflecting possibly more frequent reactivations of the virus (p&#x2009;=&#x2009;0.03 for subjects with a high anti-HSV IgG level while there was no association for all infected subjects, p&#x2009;=&#x2009;0.19), and (iii) had no increased risk of developing AD. Nevertheless, among APOE4 carriers, infected subjects presented lower hippocampal volumes, although not significant (p&#x2009;=&#x2009;0.09), and a two or three times higher risk of developing AD (adjusted Hazard ratio (aHR)&#x2009;=&#x2009;2.72 [1.07-6.91] p&#x2009;=&#x2009;0.04 for infected subjects and aHR&#x2009;=&#x2009;3.87 [1.45-10.28] p&#x2009;=&#x2009;0.007 for infected subjects with an anti-HSV IgG level in the highest tercile) while no association was found among APOE4 noncarriers. Our findings support an association between HSV infection and AD and a potential interaction between HSV status and APOE4. This reinforces the need to further investigate the infectious hypothesis of AD, especially the associated susceptibility factors and the possibility of preventive treatments.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Linard</LastName><ForeName>Morgane</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5179-4678</Identifier><AffiliationInfo><Affiliation>University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F-33000, Bordeaux, France. morgane.linard@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baillet</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F-33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Letenneur</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F-33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garrigue</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University of Bordeaux, CNRS-UMR 5234 and CHU Bordeaux, Virology Department, F-33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catheline</LastName><ForeName>Gwena&#xeb;lle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>EPHE, PSL Research University, Neuroimaging and Daily Life Laboratory, F-33000, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Bordeaux, CNRS, UMR 5287, Institute of Integrative and Cognitive Neuroscience of Aquitaine, F-33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dartigues</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F-33000, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bordeaux University Hospital, Memory Consultation, CMRR, Bordeaux, F-33076, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peres</LastName><ForeName>Karine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F-33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helmer</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5169-7421</Identifier><AffiliationInfo><Affiliation>University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F-33000, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Epidemiological Research Unit, INSERM CIC1401, F-33000, Bordeaux, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AAP 2016</GrantID><Agency>Fondation Plan Alzheimer</Agency><Country/></Grant><Grant><GrantID>AAP 2016</GrantID><Agency>Fondation Plan Alzheimer</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Psychiatry</MedlineTA><NlmUniqueID>101562664</NlmUniqueID><ISSNLinking>2158-3188</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="N">Diffusion Tensor Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006561" MajorTopicYN="Y">Herpes Simplex</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018139" MajorTopicYN="N">Simplexvirus</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>1</Day><Hour>21</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34333531</ArticleId><ArticleId IdType="pmc">PMC8325675</ArticleId><ArticleId IdType="doi">10.1038/s41398-021-01532-2</ArticleId><ArticleId IdType="pii">10.1038/s41398-021-01532-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;16. doi: 10.1016/S1474-4422(12)70291-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison JR, Bhatia S, Tan ZX, Mirza-Davies A, Benkert H, Tax C, et al. Imaging Alzheimer&#x2019;s genetic risk using diffusion MRI: a systematic review. NeuroImage: Clin. 2020;27:102359. doi: 10.1016/j.nicl.2020.102359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2020.102359</ArticleId><ArticleId IdType="pmc">PMC7399253</ArticleId><ArticleId IdType="pubmed">32758801</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K. Fractional anisotropy of the fornix and hippocampal atrophy in Alzheimer&#x2019;s disease. Front Aging Neurosci. 2014;6:316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4230048</ArticleId><ArticleId IdType="pubmed">25431558</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe1;rquez F, Yassa MA. Neuroimaging biomarkers for Alzheimer&#x2019;s disease. Mol Neurodegener. 2019;14:21. doi: 10.1186/s13024-019-0325-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0325-5</ArticleId><ArticleId IdType="pmc">PMC6555939</ArticleId><ArticleId IdType="pubmed">31174557</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Xu Y, Zhu B, Kantarci K. The role of diffusion tensor imaging in detecting microstructural changes in prodromal Alzheimer&#x2019;s disease. CNS Neurosci Ther. 2014;20:3&#x2013;9. doi: 10.1111/cns.12166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12166</ArticleId><ArticleId IdType="pmc">PMC5846708</ArticleId><ArticleId IdType="pubmed">24330534</ArticleId></ArticleIdList></Reference><Reference><Citation>Moir RD, Lathe R, Tanzi RE. The antimicrobial protection hypothesis of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14:1602&#x2013;14. doi: 10.1016/j.jalz.2018.06.3040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.06.3040</ArticleId><ArticleId IdType="pubmed">30314800</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF. Corroboration of a major role for herpes simplex virus type 1 in Alzheimer&#x2019;s disease. Front Aging Neurosci. 2018;10:324. doi: 10.3389/fnagi.2018.00324.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00324</ArticleId><ArticleId IdType="pmc">PMC6202583</ArticleId><ArticleId IdType="pubmed">30405395</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, et al. Microbes and Alzheimer&#x2019;s disease. J Alzheimer&#x2019;s Dis. 2016;51:979&#x2013;84. doi: 10.3233/JAD-160152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160152</ArticleId><ArticleId IdType="pmc">PMC5457904</ArticleId><ArticleId IdType="pubmed">26967229</ArticleId></ArticleIdList></Reference><Reference><Citation>Steel AJ, Eslick GD. Herpes viruses increase the risk of Alzheimer&#x2019;s disease: a meta-analysis. J Alzheimer&#x2019;s Dis. 2015;47:351&#x2013;64. doi: 10.3233/JAD-140822.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-140822</ArticleId><ArticleId IdType="pubmed">26401558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball MJ. Limbic predilection in Alzheimer dementia: is reactivated herpesvirus involved? Can J Neurol Sci. 1982;9:303&#x2013;6. doi: 10.1017/S0317167100044115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0317167100044115</ArticleId><ArticleId IdType="pubmed">7116237</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Alzheimer&#x2019;s pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathologica. 2011;121:589&#x2013;95. doi: 10.1007/s00401-011-0825-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0825-z</ArticleId><ArticleId IdType="pubmed">21516512</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellon M, Nicot C. Telomere dynamics in immune senescence and exhaustion triggered by chronic viral infection. Viruses. 2017;9:289. doi: 10.3390/v9100289.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v9100289</ArticleId><ArticleId IdType="pmc">PMC5691640</ArticleId><ArticleId IdType="pubmed">28981470</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol. 2017;8:1960. doi: 10.3389/fimmu.2017.01960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01960</ArticleId><ArticleId IdType="pmc">PMC5767595</ArticleId><ArticleId IdType="pubmed">29375577</ArticleId></ArticleIdList></Reference><Reference><Citation>Stowe RP, Peek MK, Cutchin MP, Goodwin JS. Reactivation of herpes simplex virus type 1 is associated with cytomegalovirus and age. J Med Virol. 2012;84:1797&#x2013;802. doi: 10.1002/jmv.23397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23397</ArticleId><ArticleId IdType="pmc">PMC3463941</ArticleId><ArticleId IdType="pubmed">22997083</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter CJ. Alzheimer&#x2019;s disease plaques and tangles: cemeteries of a Pyrrhic victory of the immune defence network against herpes simplex infection at the expense of complement and inflammation-mediated neuronal destruction. Neurochemistry Int. 2011;58:301&#x2013;20. doi: 10.1016/j.neuint.2010.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2010.12.003</ArticleId><ArticleId IdType="pubmed">21167244</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris SA, Harris EA. Molecular mechanisms for herpes simplex virus type 1 pathogenesis in Alzheimer&#x2019;s disease. Front Aging Neurosc. 2018;10:48. 10.3389/fnagi.2018.00048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5845560</ArticleId><ArticleId IdType="pubmed">29559905</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgade K, Dupuis G, Frost EH, F&#xfc;l&#xf6;p T. Anti- J. Alzheimers Dis. 2016;54:859&#x2013;78. doi: 10.3233/JAD-160517.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160517</ArticleId><ArticleId IdType="pubmed">27392871</ArticleId></ArticleIdList></Reference><Reference><Citation>Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, et al. The Alzheimer&#x2019;s disease-associated amyloid &#x3b2;-protein is an antimicrobial peptide. PLoS ONE. 2010;5:e9505. doi: 10.1371/journal.pone.0009505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009505</ArticleId><ArticleId IdType="pmc">PMC2831066</ArticleId><ArticleId IdType="pubmed">20209079</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter C. Alzheimer&#x2019;s disease: APP, gamma secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and their relationships with herpes simplex, C. pneumoniae, other suspect pathogens, and the immune system. Int J Alzheimers Dis. 2011;2011:34. 10.4061/2011/501862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3255168</ArticleId><ArticleId IdType="pubmed">22254144</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter CJ. Interactions between the products of the Herpes simplex genome and Alzheimer&#x2019;s disease susceptibility genes: Relevance to pathological-signalling cascades. Neurochemistry Int. 2008;52:920&#x2013;34. doi: 10.1016/j.neuint.2007.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2007.11.003</ArticleId><ArticleId IdType="pubmed">18164103</ArticleId></ArticleIdList></Reference><Reference><Citation>Looker K, Garnett G. A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect. 2005;81:103&#x2013;7. doi: 10.1136/sti.2004.012039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/sti.2004.012039</ArticleId><ArticleId IdType="pmc">PMC1764655</ArticleId><ArticleId IdType="pubmed">15800084</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren-Gash C, Forbes HJ, Williamson E, Breuer J, Hayward AC, Mavrodaris A, et al. Human herpesvirus infections and dementia or mild cognitive impairment: a systematic review and meta-analysis. Sci Rep. 2019;9:4743. 10.1038/s41598-019-41218-w.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426940</ArticleId><ArticleId IdType="pubmed">30894595</ArticleId></ArticleIdList></Reference><Reference><Citation>Agostini S, Mancuso R, Baglio F, Cabinio M, Hernis A, Costa AS, et al. High avidity HSV-1 antibodies correlate with absence of amnestic Mild Cognitive Impairment conversion to Alzheimer&#x2019;s disease. Brain, Behav, Immun. 2016;58:254&#x2013;60. doi: 10.1016/j.bbi.2016.07.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2016.07.153</ArticleId><ArticleId IdType="pubmed">27470229</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Baglio F, Cabinio M, Calabrese E, Hernis A, Nemni R, et al. Titers of herpes simplex virus type 1 antibodies positively correlate with grey matter volumes in Alzheimer&#x2019;s disease. J Alzheimer&#x2019;s Dis. 2014;38:5&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">24072067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Baglio F, Agostini S, Agostini MC, Lagan&#xe0; MM, Hernis A, et al. Relationship between herpes simplex virus-1-specific antibody titers and cortical brain damage in Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. Front Aging Neurosci. 2014;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197651</ArticleId><ArticleId IdType="pubmed">25360113</ArticleId></ArticleIdList></Reference><Reference><Citation>Linard M, Letenneur L, Garrigue I, Doize A, Dartigues JF, Helmer C. Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 2020;16:200&#x2013;8. doi: 10.1002/alz.12008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12008</ArticleId><ArticleId IdType="pubmed">31914220</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;r&#xe8;s K, Matharan F, Allard M, Amieva H, Baldi I, Barberger-Gateau P, et al. Health and aging in elderly farmers: the AMI cohort. BMC Public Health. 2012;12:558. doi: 10.1186/1471-2458-12-558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-12-558</ArticleId><ArticleId IdType="pmc">PMC3413609</ArticleId><ArticleId IdType="pubmed">22839764</ArticleId></ArticleIdList></Reference><Reference><Citation>The 3C Study Group. Vascular factors and risk of dementia: design of the three-city study and baseline characteristics of the study population. Neuroepidemiology. 2003;22:316&#x2013;25. doi: 10.1159/000072920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000072920</ArticleId><ArticleId IdType="pubmed">14598854</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington DC: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage. 2011;56:907&#x2013;22. doi: 10.1016/j.neuroimage.2011.02.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2011.02.046</ArticleId><ArticleId IdType="pmc">PMC3417233</ArticleId><ArticleId IdType="pubmed">21352927</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage. 2006;31:1487&#x2013;505. doi: 10.1016/j.neuroimage.2006.02.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.02.024</ArticleId><ArticleId IdType="pubmed">16624579</ArticleId></ArticleIdList></Reference><Reference><Citation>Commenges D, Letenneur L, Joly P, Alioum A, Dartigues J-F. Modelling age-specific risk: application to dementia. Stat Med. 1998;17:1973&#x2013;88. doi: 10.1002/(SICI)1097-0258(19980915)17:17&lt;1973::AID-SIM892&gt;3.0.CO;2-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(19980915)17:17&lt;1973::AID-SIM892&gt;3.0.CO;2-5</ArticleId><ArticleId IdType="pubmed">9777690</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad KM, Watson AMM, Dickerson FB, Yolken RH, Nimgaonkar VL. Exposure to herpes simplex virus type 1 and cognitive impairments in individuals with schizophrenia. Schizophr Bull. 2012;38:1137&#x2013;48. doi: 10.1093/schbul/sbs046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/schbul/sbs046</ArticleId><ArticleId IdType="pmc">PMC3494052</ArticleId><ArticleId IdType="pubmed">22490995</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitford TJ, Wood SJ, Yung A, Cocchi L, Berger G, Shenton ME, et al. Structural abnormalities in the cuneus associated with Herpes Simplex Virus (type 1) infection in people at ultra high risk of developing psychosis. Schizophr Res. 2012;135:175&#x2013;80. doi: 10.1016/j.schres.2011.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2011.11.003</ArticleId><ArticleId IdType="pmc">PMC3405258</ArticleId><ArticleId IdType="pubmed">22244184</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad KM, Eack SM, Goradia D, Pancholi KM, Keshavan MS, Yolken RH, et al. Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study. Am J Psychiatry. 2011;168:822&#x2013;30. doi: 10.1176/appi.ajp.2011.10101423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2011.10101423</ArticleId><ArticleId IdType="pmc">PMC4209378</ArticleId><ArticleId IdType="pubmed">21632649</ArticleId></ArticleIdList></Reference><Reference><Citation>Grydeland H, Walhovd KB, Westlye LT, Due-T&#xf8;nnessen P, Ormaasen V, Sundseth &#xd8;, et al. Amnesia following herpes simplex encephalitis: diffusion-tensor imaging uncovers reduced integrity of normal-appearing white matter. Radiology. 2010;257:774&#x2013;81. doi: 10.1148/radiol.10100179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.10100179</ArticleId><ArticleId IdType="pubmed">20935078</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler-Kingshott CAM, Cercignani M. About axial and radial diffusivities. Magn Reson Med. 2009;61:1255&#x2013;60. doi: 10.1002/mrm.21965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrm.21965</ArticleId><ArticleId IdType="pubmed">19253405</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S-K, Sun SW, Ramsbottom MJ, Chang C, Russell J, Cross AH. Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. NeuroImage. 2002;17:1429&#x2013;36. doi: 10.1006/nimg.2002.1267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nimg.2002.1267</ArticleId><ArticleId IdType="pubmed">12414282</ArticleId></ArticleIdList></Reference><Reference><Citation>Mott KR, Zandian M, Allen SJ, Ghiasi H. Role of interleukin-2 and herpes simplex virus 1 in central nervous system demyelination in mice. J Virol. 2013;87:12102&#x2013;9. doi: 10.1128/JVI.02241-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02241-13</ArticleId><ArticleId IdType="pmc">PMC3807926</ArticleId><ArticleId IdType="pubmed">23986600</ArticleId></ArticleIdList></Reference><Reference><Citation>Osorio Y, La Point SF, Nusinowitz S, Hofman FM, Ghiasi H. CD8+-dependent CNS demyelination following ocular infection of mice with a recombinant HSV-1 expressing murine IL-2. Exp Neurol. 2005;193:1&#x2013;18. doi: 10.1016/j.expneurol.2004.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2004.12.004</ArticleId><ArticleId IdType="pubmed">15817260</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;vheim H, Norman T, Weidung B, Olsson J, Josefsson M, Adolfsson R, et al. Herpes simplex virus, APOE &#x25b;4, and cognitive decline in old age: results from the Betula Cohort Study. J Alzheimer&#x2019;s Dis. 2019;67:211&#x2013;20. doi: 10.3233/JAD-171162.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-171162</ArticleId><ArticleId IdType="pubmed">30636735</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;vheim H, Gilthorpe J, Adolfsson R, Nilsson L-G, Elgh F. Reactivated herpes simplex infection increases the risk of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 2015;11:593&#x2013;9. doi: 10.1016/j.jalz.2014.04.522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.04.522</ArticleId><ArticleId IdType="pubmed">25043910</ArticleId></ArticleIdList></Reference><Reference><Citation>Letenneur L, P&#xe9;r&#xe8;s K, Fleury H, Garrigue I, Barberger-Gateau P, Helmer C, et al. Seropositivity to herpes simplex virus antibodies and risk of Alzheimer&#x2019;s Disease: a population-based cohort study. PLoS ONE. 2008;3:e3637. doi: 10.1371/journal.pone.0003637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003637</ArticleId><ArticleId IdType="pmc">PMC2572852</ArticleId><ArticleId IdType="pubmed">18982063</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams OA, An Y, Beason-Held L, Huo Y, Ferrucci L, Landman BA, et al. Vascular burden and APOE &#x3b5;4 are associated with white matter microstructural decline in cognitively normal older adults. NeuroImage. 2019;188:572&#x2013;83. doi: 10.1016/j.neuroimage.2018.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2018.12.009</ArticleId><ArticleId IdType="pmc">PMC6601608</ArticleId><ArticleId IdType="pubmed">30557663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopatko Lindman K, Weidung B, Olsson J, Josefsson M, Kok E, Johansson A, et al. A genetic signature including apolipoprotein E&#x3b5;4 potentiates the risk of herpes simplex-associated Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement: Transl Res Clin Interventions. 2019;5:697&#x2013;704. doi: 10.1016/j.trci.2019.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2019.09.014</ArticleId><ArticleId IdType="pmc">PMC6944738</ArticleId><ArticleId IdType="pubmed">31921962</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U. HSV-1 in brain and risk of Alzheimer&#x2019;s disease. Lancet. 1998;351:1330&#x2013;31. doi: 10.1016/S0140-6736(05)79057-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)79057-7</ArticleId><ArticleId IdType="pubmed">9643802</ArticleId></ArticleIdList></Reference><Reference><Citation>Itabashi S, Arai H, Matsui T, Higuchi S, Sasaki H. Herpes simplex virus and risk of Alzheimer&#x2019;s disease. Lancet. 1997;349:1102. doi: 10.1016/S0140-6736(05)62325-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)62325-2</ArticleId><ArticleId IdType="pubmed">9107270</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA. Herpes simplex virus type 1 in brain and risk of Alzheimer&#x2019;s disease. Lancet. 1997;349:241&#x2013;4. doi: 10.1016/S0140-6736(96)10149-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)10149-5</ArticleId><ArticleId IdType="pubmed">9014911</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W-R, Shang D, Wilcock GK, Itzhaki RF. Alzheimer&#x2019;s disease, herpes simplex virus type 1, cold sores and apolipoprotein E4. Portland Press Limited; 1995.</Citation><ArticleIdList><ArticleId IdType="pubmed">8654779</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgos JS, Ramirez C, Sastre I, Valdivieso F. Effect of apolipoprotein E on the cerebral load of latent herpes simplex virus type 1 DNA. J Virol. 2006;80:5383&#x2013;7. doi: 10.1128/JVI.00006-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00006-06</ArticleId><ArticleId IdType="pmc">PMC1472141</ArticleId><ArticleId IdType="pubmed">16699018</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgos JS, Ramirez C, Sastre I, Bullido MJ, Valdivieso F. ApoE4 is more efficient than E3 in brain access by herpes simplex virus type. Genet Nerv Syst Dis. 2003;14:3&#x2013;1827.</Citation><ArticleIdList><ArticleId IdType="pubmed">14534428</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman-Sanchez F, Valdivieso F, Burgos JS. Aging- J Alzheimer&#x2019;s Dis. 2012;30:779&#x2013;90. doi: 10.3233/JAD-2012-120070.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-120070</ArticleId><ArticleId IdType="pubmed">22466000</ArticleId></ArticleIdList></Reference><Reference><Citation>Urosevic N, Martins RN. Infection and Alzheimer&#x2019;s disease: the APOE &#x3b5;4 connection and lipid metabolism. J. Alzheimer&#x2019;s Dis. 2008;13:421&#x2013;35. doi: 10.3233/JAD-2008-13407.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2008-13407</ArticleId><ArticleId IdType="pubmed">18487850</ArticleId></ArticleIdList></Reference><Reference><Citation>Koelle DM, Magaret A, Warren T, Schellenberg GD, Wald A. APOE genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding. Sexually Transmitted Infect. 2010;86:202&#x2013;6. doi: 10.1136/sti.2009.039735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/sti.2009.039735</ArticleId><ArticleId IdType="pmc">PMC2881187</ArticleId><ArticleId IdType="pubmed">20410080</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF, Wozniak MA. Herpes simplex virus type 1 in Alzheimer&#x2019;s disease: the enemy within. J Alzheimers Dis. 2008;13:393&#x2013;405. doi: 10.3233/JAD-2008-13405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2008-13405</ArticleId><ArticleId IdType="pubmed">18487848</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34379124</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>02</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Longitudinal Association of Total Tau Concentrations and Physical Activity With Cognitive Decline in a Population Sample.</ArticleTitle><Pagination><StartPage>e2120398</StartPage><MedlinePgn>e2120398</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2120398</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2021.20398</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Tau is a brain protein located in neurons and develops abnormally in individuals with Alzheimer disease. New technology is convenient for measuring blood total tau concentrations and provides a unique and increased opportunity for early intervention to slow cognitive decline.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate the association of physical activity and total tau concentrations with cognitive decline at baseline and over time.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The Chicago Health and Aging Project is a population-based cohort study conducted in 4 Chicago communities. Data collection occurred in 3-year cycles between 1993 and 2012. Participants completed in-home interviews. Clinical evaluations, which included blood samples, were performed with a stratified random sample of 1159 participants. Statistical analyses were conducted from October 30, 2020, to May 25, 2021.</AbstractText><AbstractText Label="EXPOSURES">Physical activity and total serum tau concentrations. Data on physical activity were obtained through self-report items, and a sum of minutes per week was calculated. Little physical activity was defined as no participation in a minimum of 4 of the items on the physical activity measure. Medium activity was defined as participating in less than 150 minutes of physical activity per week, and high activity was defined as participating in 150 minutes or more of physical activity per week.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The main outcome for this study is global cognitive function, measured through a battery of cognitive tests. The study hypothesis was developed after data were collected.</AbstractText><AbstractText Label="RESULTS">Of the 1159 participants in the study, 728 were women (63%), and 696 were African American (60%); the mean (SD) age was 77.4 (6.0) years, and the mean (SD) educational level was 12.6 (3.5) years. Participants with high total tau concentrations with medium physical activity had a 58% slower rate of cognitive decline (estimate, -0.028 standard deviation unit [SDU] per year [95% CI, -0.057 to 0.002 SDU per year]; difference, 0.038 SDU per year [95% CI, 0.011-0.065 SDU per year]), and those with high physical activity had a 41% slower rate of cognitive decline (estimate, -0.038 SDU per year [95% CI, -0.068 to -0.009 SDU per year]; difference, 0.027 SDU per year [95% CI, -0.002 to 0.056 SDU per year]), compared with those with little physical activity. Among participants with low total tau concentrations, medium physical activity was associated with a 2% slower rate of cognitive decline (estimate, -0.050 SDU per year [95% CI, -0.069 to -0.031 SDU per year]; difference, 0.001 SDU per year [95% CI, -0.019 to 0.021 SDU per year]), and high physical activity was associated with a 27% slower rate of cognitive decline (estimate, -0.037 SDU per year [95% CI, -0.055 to -0.019 SDU per year]; difference, 0.014 SDU per year [95% CI, -0.007 to 0.034 SDU per year]), compared with little physical activity. Individual tests of cognitive function showed similar results.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study suggests that, among participants with both high and low total tau concentrations, physical activity was associated with slower cognitive decline. Results support the potential utility of blood biomarkers in measuring the benefits associated with health behaviors and may contribute to specifying target populations or informing interventions for trials that focus on improving physical activity behavior. Future work should examine the association of total tau concentrations with other health behaviors and physical activity types.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Pankaja</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Rush Institute for Healthy Aging, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Denis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Rush Institute for Healthy Aging, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhana</LastName><ForeName>Klodian</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Rush Institute for Healthy Aging, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Neelum T</ForeName><Initials>NT</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAninch</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Rush Institute for Healthy Aging, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajan</LastName><ForeName>Kumar B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Rush Institute for Healthy Aging, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of California at Davis, Davis.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG051635</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG058679</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG073627</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057532</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002641" MajorTopicYN="N" Type="Geographic">Chicago</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Evans reported receiving grants from the National Institutes of Health during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>11</Day><Hour>12</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34379124</ArticleId><ArticleId IdType="pmc">PMC8358733</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.20398</ArticleId><ArticleId IdType="pii">2782979</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010;7(8):656-664. doi:10.2174/156720510793611592</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720510793611592</ArticleId><ArticleId IdType="pmc">PMC3090074</ArticleId><ArticleId IdType="pubmed">20678074</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nat Rev Neurosci. 2007;8(9):663-672. doi:10.1038/nrn2194</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2194</ArticleId><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Llorens F, Villar-Piqu&#xe9; A, Candelise N, Ferrer I, Zerr I. Tau protein as a biological fluid biomarker in neurodegenerative dementias. In: Sibat HF, ed. Cognitive Disorders. IntechOpen; 2019. doi:10.5772/intechopen.73528</Citation><ArticleIdList><ArticleId IdType="doi">10.5772/intechopen.73528</ArticleId></ArticleIdList></Reference><Reference><Citation>Quanterix. Tau. Accessed January 6, 2021. https://www.quanterix.com/simoa-assay-kits/tau/#:~:text=The%20Simoa%E2%84%A2%20Human%20Total,assay%20recognizes%20all%20tau%20isoforms</Citation></Reference><Reference><Citation>Rajan KB, Aggarwal NT, McAninch EA, et al. . Remote blood biomarkers of longitudinal cognitive outcomes in a population study. Ann Neurol. 2020;88(6):1065-1076. doi:10.1002/ana.25874</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25874</ArticleId><ArticleId IdType="pmc">PMC9186023</ArticleId><ArticleId IdType="pubmed">32799383</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Hagen CE, Wennberg AMV, et al. . Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic Study on Aging. JAMA Neurol. 2017;74(9):1073-1080. doi:10.1001/jamaneurol.2017.1359</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1359</ArticleId><ArticleId IdType="pmc">PMC5710182</ArticleId><ArticleId IdType="pubmed">28692710</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H. Blood-based biomarkers for Alzheimer&#x2019;s disease&#x2014;an update. J Neurosci Methods. 2019;319:2-6. doi:10.1016/j.jneumeth.2018.10.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2018.10.025</ArticleId><ArticleId IdType="pubmed">30352211</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Lautner R, Andreasson U, et al. . CSF and blood biomarkers for the diagnosis of Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673-684. doi:10.1016/S1474-4422(16)00070-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00070-3</ArticleId><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lu X, Zhang L, et al. . Potential value of plasma amyloid-&#x3b2;, total tau, and neurofilament light for identification of early Alzheimer&#x2019;s disease. ACS Chem Neurosci. 2019;10(8):3479-3485. doi:10.1021/acschemneuro.9b00095</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.9b00095</ArticleId><ArticleId IdType="pubmed">31145586</ArticleId></ArticleIdList></Reference><Reference><Citation>Pase MP, Beiser AS, Himali JJ, et al. . Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol. 2019;76(5):598-606. doi:10.1001/jamaneurol.2018.4666</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.4666</ArticleId><ArticleId IdType="pmc">PMC6515589</ArticleId><ArticleId IdType="pubmed">30830207</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajan KB, Wilson RS, Weuve J, Barnes LL, Evans DA. Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. Neurology. 2015;85(10):898-904. doi:10.1212/WNL.0000000000001774</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001774</ArticleId><ArticleId IdType="pmc">PMC4560057</ArticleId><ArticleId IdType="pubmed">26109713</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. . Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging&#x2013;Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280-292. doi:10.1016/j.jalz.2011.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.003</ArticleId><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin JS, Klein H, Kirn DR, et al. . Associations of physical activity and &#x3b2;-amyloid with longitudinal cognition and neurodegeneration in clinically normal older adults. JAMA Neurol. 2019;76(10):1203-1210. doi:10.1001/jamaneurol.2019.1879</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1879</ArticleId><ArticleId IdType="pmc">PMC6635892</ArticleId><ArticleId IdType="pubmed">31312836</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolland Y, Abellan van Kan G, Vellas B. Physical activity and Alzheimer&#x2019;s disease: from prevention to therapeutic perspectives. J Am Med Dir Assoc. 2008;9(6):390-405. doi:10.1016/j.jamda.2008.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2008.02.007</ArticleId><ArticleId IdType="pubmed">18585641</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofi F, Valecchi D, Bacci D, et al. . Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med. 2011;269(1):107-117. doi:10.1111/j.1365-2796.2010.02281.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2010.02281.x</ArticleId><ArticleId IdType="pubmed">20831630</ArticleId></ArticleIdList></Reference><Reference><Citation>Cass SP. Alzheimer&#x2019;s disease and exercise: a literature review. Curr Sports Med Rep. 2017;16(1):19-22. doi:10.1249/JSR.0000000000000332</Citation><ArticleIdList><ArticleId IdType="doi">10.1249/JSR.0000000000000332</ArticleId><ArticleId IdType="pubmed">28067736</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan ZS, Spartano NL, Beiser AS, et al. . Physical activity, brain volume, and dementia risk: the Framingham Study. J Gerontol A Biol Sci Med Sci. 2017;72(6):789-795. doi:10.1093/gerona/glw130</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glw130</ArticleId><ArticleId IdType="pmc">PMC6075525</ArticleId><ArticleId IdType="pubmed">27422439</ArticleId></ArticleIdList></Reference><Reference><Citation>Okonkwo OC, Schultz SA, Oh JM, et al. . Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology. 2014;83(19):1753-1760. doi:10.1212/WNL.0000000000000964</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000964</ArticleId><ArticleId IdType="pmc">PMC4239838</ArticleId><ArticleId IdType="pubmed">25298312</ArticleId></ArticleIdList></Reference><Reference><Citation>US Census Bureau . 1990 Census of population: general population characteristics: United States. US Government Printing Office; 1992.</Citation></Reference><Reference><Citation>Bienias JL, Beckett LA, Bennett DA, Wilson RS, Evans DA. Design of the Chicago Health and Aging Project (CHAP). J Alzheimers Dis. 2003;5(5):349-355. doi:10.3233/JAD-2003-5501</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2003-5501</ArticleId><ArticleId IdType="pubmed">14646025</ArticleId></ArticleIdList></Reference><Reference><Citation>McPhillips JB, Pellettera KM, Barrett-Connor E, Wingard DL, Criqui MH. Exercise patterns in a population of older adults. Am J Prev Med. 1989;5(2):65-72. doi:10.1016/S0749-3797(18)31107-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0749-3797(18)31107-3</ArticleId><ArticleId IdType="pubmed">2730794</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturman MT, Morris MC, Mendes de Leon CF, Bienias JL, Wilson RS, Evans DA. Physical activity, cognitive activity, and cognitive decline in a biracial community population. Arch Neurol. 2005;62(11):1750-1754. doi:10.1001/archneur.62.11.1750</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.11.1750</ArticleId><ArticleId IdType="pubmed">16286550</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith A.Symbol Digit Modalities Test Manual. Western Psychological Services; 1982.</Citation></Reference><Reference><Citation>Scherr PA, Albert MS, Funkenstein HH, et al. . Correlates of cognitive function in an elderly community population. Am J Epidemiol. 1988;128(5):1084-1101. doi:10.1093/oxfordjournals.aje.a115051</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a115051</ArticleId><ArticleId IdType="pubmed">3189282</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, Jones K, Savage CR, et al. . Predictors of cognitive change in older persons: MacArthur studies of successful aging. Psychol Aging. 1995;10(4):578-589. doi:10.1037/0882-7974.10.4.578</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0882-7974.10.4.578</ArticleId><ArticleId IdType="pubmed">8749585</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Bennett DA, Bienias JL, Mendes de Leon CF, Morris MC, Evans DA. Cognitive activity and cognitive decline in a biracial community population. Neurology. 2003;61(6):812-816. doi:10.1212/01.WNL.0000083989.44027.05</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000083989.44027.05</ArticleId><ArticleId IdType="pubmed">14504326</ArticleId></ArticleIdList></Reference><Reference><Citation>Piercy KL, Troiano RP, Ballard RM, et al. . The Physical Activity Guidelines for Americans. JAMA. 2018;320(19):2020-2028. doi:10.1001/jama.2018.14854</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.14854</ArticleId><ArticleId IdType="pmc">PMC9582631</ArticleId><ArticleId IdType="pubmed">30418471</ArticleId></ArticleIdList></Reference><Reference><Citation>Olanrewaju O, Stockwell S, Stubbs B, Smith L. Sedentary behaviours, cognitive function, and possible mechanisms in older adults: a systematic review. Aging Clin Exp Res. 2020;32(6):969-984. doi:10.1007/s40520-019-01457-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40520-019-01457-3</ArticleId><ArticleId IdType="pubmed">32026419</ArticleId></ArticleIdList></Reference><Reference><Citation>Law LL, Rol RN, Schultz SA, et al. . Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer&#x2019;s disease. Alzheimers Dement (Amst). 2018;10:188-195. doi:10.1016/j.dadm.2018.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2018.01.001</ArticleId><ArticleId IdType="pmc">PMC5842318</ArticleId><ArticleId IdType="pubmed">29527551</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen CS, Bahl JM, &#xd8;stergaard LB, et al. . Exercise as a potential modulator of inflammation in patients with Alzheimer&#x2019;s disease measured in cerebrospinal fluid and plasma. Exp Gerontol. 2019;121:91-98. doi:10.1016/j.exger.2019.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2019.04.003</ArticleId><ArticleId IdType="pubmed">30980923</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang KY, Mintun MA, Fagan AM, et al. . Exercise and Alzheimer&#x2019;s disease biomarkers in cognitively normal older adults. Ann Neurol. 2010;68(3):311-318. doi:10.1002/ana.22096</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22096</ArticleId><ArticleId IdType="pmc">PMC2936720</ArticleId><ArticleId IdType="pubmed">20818789</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallis JF, Saelens BE. Assessment of physical activity by self-report: status, limitations, and future directions. Res Q Exerc Sport. 2000;71(suppl 2):1-14. doi:10.1080/02701367.2000.11082780</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02701367.2000.11082780</ArticleId><ArticleId IdType="pubmed">25680007</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickman AM, Manly JJ, Honig LS, et al. . Plasma p-tau181, p-tau217, and other blood-based Alzheimer&#x2019;s disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. Published online February 13, 2021. doi:10.1002/alz.12301</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12301</ArticleId><ArticleId IdType="pmc">PMC8451860</ArticleId><ArticleId IdType="pubmed">33580742</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34380771</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>606</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>11</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>The <i>Uppsala APP</i> deletion causes early onset autosomal dominant Alzheimer's disease by altering APP processing and increasing amyloid &#x3b2; fibril formation.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">eabc6184</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abc6184</ELocationID><Abstract><AbstractText>Point mutations in the amyloid precursor protein gene (<i>APP</i>) cause familial Alzheimer's disease (AD) by increasing generation or altering conformation of amyloid &#x3b2; (A&#x3b2;). Here, we describe the <i>Uppsala APP</i> mutation (&#x394;690-695), the first reported deletion causing autosomal dominant AD. Affected individuals have an age at symptom onset in their early forties and suffer from a rapidly progressing disease course. Symptoms and biomarkers are typical of AD, with the exception of normal cerebrospinal fluid (CSF) A&#x3b2;42 and only slightly pathological amyloid-positron emission tomography signals. Mass spectrometry and Western blot analyses of patient CSF and media from experimental cell cultures indicate that the <i>Uppsala APP</i> mutation alters APP processing by increasing &#x3b2;-secretase cleavage and affecting &#x3b1;-secretase cleavage. Furthermore, in vitro aggregation studies and analyses of patient brain tissue samples indicate that the longer form of mutated A&#x3b2;, A&#x3b2;Upp1-42<sub>&#x394;19-24</sub>, accelerates the formation of fibrils with unique polymorphs and their deposition into amyloid plaques in the affected brain.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pagnon de la Vega</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1845-9138</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giedraitis</LastName><ForeName>Vilmantas</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-3423-2021</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michno</LastName><ForeName>Wojciech</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-3096-3604</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, University of Gothenburg, 43180 Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Physiology and Pharmacology, University College London, WC1E 6BT London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilander</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;ner</LastName><ForeName>G&#xf6;khan</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5875-5815</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) and Neuroproteomics, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zielinski</LastName><ForeName>Mara</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7443-917X</Identifier><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7) and JuStruct, J&#xfc;lich Center for Structural Biology, Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf6;wenmark</LastName><ForeName>Malin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brundin</LastName><ForeName>RoseMarie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danfors</LastName><ForeName>Torsten</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2454-5086</Identifier><AffiliationInfo><Affiliation>Department of Surgical Sciences, Radiology, Uppsala University, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf6;derberg</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>BioArctic AB, 11251 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alafuzoff</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Immunology, Genetics and Pathology, Clinical and Experimental Pathology, Uppsala University, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Lars N G</ForeName><Initials>LNG</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Oslo and Oslo University Hospital, 0316 Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erlandsson</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7292-1608</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willbold</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0065-7366</Identifier><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7) and JuStruct, J&#xfc;lich Center for Structural Biology, Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut f&#xfc;r Physikalische Biologie, Heinrich-Heine-Universit&#xe4;t D&#xfc;sseldorf, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology, State University, 141701 Dolgoprudny, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0003-3414-307X</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) and Neuroproteomics, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schr&#xf6;der</LastName><ForeName>Gunnar F</ForeName><Initials>GF</Initials><Identifier Source="ORCID">0000-0003-1803-5431</Identifier><AffiliationInfo><Affiliation>Institute of Biological Information Processing, Structural Biochemistry (IBI-7) and JuStruct, J&#xfc;lich Center for Structural Biology, Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Physics Department, Heinrich-Heine-Universit&#xe4;t D&#xfc;sseldorf, 40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanrieder</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6059-198X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, University of Gothenburg, 43180 Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Queen Square Institute of Neurology, University College London, WC1N 3BG London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lichtenthaler</LastName><ForeName>Stefan F</ForeName><Initials>SF</Initials><Identifier Source="ORCID">0000-0003-2211-2575</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) and Neuroproteomics, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lannfelt</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sehlin</LastName><ForeName>Dag</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9430-3859</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, 75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingelsson</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5466-8370</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, 75185 Uppsala, Sweden. martin.ingelsson@pubcare.uu.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Sci Transl Med. 2022 Jan 12;14(627):eabn9847. doi: 10.1126/scitranslmed.abn9847.</RefSource><PMID Version="1">35020408</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>12</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34380771</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abc6184</ArticleId><ArticleId IdType="pii">13/606/eabc6184</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34446931</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Microglial activation and tau propagate jointly across Braak stages.</ArticleTitle><Pagination><StartPage>1592</StartPage><EndPage>1599</EndPage><MedlinePgn>1592-1599</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41591-021-01456-w</ELocationID><Abstract><AbstractText>Compelling experimental evidence suggests that microglial activation is involved in the spread of tau tangles over the neocortex in Alzheimer's disease (AD). We tested the hypothesis that the spatial propagation of microglial activation and tau accumulation colocalize in a Braak-like pattern in the living human brain. We studied 130 individuals across the aging and AD clinical spectrum with positron emission tomography brain imaging for microglial activation ([<sup>11</sup>C]PBR28), amyloid-&#x3b2; (A&#x3b2;) ([<sup>18</sup>F]AZD4694) and tau ([<sup>18</sup>F]MK-6240) pathologies. We further assessed microglial triggering receptor expressed on myeloid cells 2 (TREM2) cerebrospinal fluid (CSF) concentrations and brain gene expression patterns. We found that [<sup>11</sup>C]PBR28 correlated with CSF soluble TREM2 and showed regional distribution resembling TREM2 gene expression. Network analysis revealed that microglial activation and tau correlated hierarchically with each other following Braak-like stages. Regression analysis revealed that the longitudinal tau propagation pathways depended on the baseline microglia network rather than the tau network circuits. The co-occurrence of A&#x3b2;, tau and microglia abnormalities was the strongest predictor of cognitive impairment in our study population. Our findings support a model where an interaction between A&#x3b2; and activated microglia sets the pace for tau spread across Braak stages.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pascoal</LastName><ForeName>Tharick A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0001-9057-8014</Identifier><AffiliationInfo><Affiliation>Departments of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. PASCOAL@pitt.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. PASCOAL@pitt.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest-de-l'&#xce;le-de-Montr&#xe9;al, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada. PASCOAL@pitt.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada. PASCOAL@pitt.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benedet</LastName><ForeName>Andrea L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0001-8219-1741</Identifier><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest-de-l'&#xce;le-de-Montr&#xe9;al, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashton</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley, NHS Foundation, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Min Su</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0003-0745-6222</Identifier><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest-de-l'&#xce;le-de-Montr&#xe9;al, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Therriault</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7826-4781</Identifier><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest-de-l'&#xce;le-de-Montr&#xe9;al, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chamoun</LastName><ForeName>Mira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest-de-l'&#xce;le-de-Montr&#xe9;al, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savard</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest-de-l'&#xce;le-de-Montr&#xe9;al, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lussier</LastName><ForeName>Firoza Z</ForeName><Initials>FZ</Initials><Identifier Source="ORCID">0000-0002-6877-4825</Identifier><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest-de-l'&#xce;le-de-Montr&#xe9;al, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tissot</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2711-3833</Identifier><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest-de-l'&#xce;le-de-Montr&#xe9;al, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karikari</LastName><ForeName>Thomas K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ottoy</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Molecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LC Campbell Cognitive Neurology Unit, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathotaarachchi</LastName><ForeName>Sulantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest-de-l'&#xce;le-de-Montr&#xe9;al, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevenson</LastName><ForeName>Jenna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest-de-l'&#xce;le-de-Montr&#xe9;al, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massarweh</LastName><ForeName>Gassan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xf6;ll</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Radiology Weill Medical Center Brain Health Imaging Institute, Cornell University, Ithaca, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soucy</LastName><ForeName>Jean-Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edison</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Brain Sciences, Imperial College London, Hammersmith Hospital Campus, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest-de-l'&#xce;le-de-Montr&#xe9;al, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosa-Neto</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9116-1376</Identifier><AffiliationInfo><Affiliation>Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre int&#xe9;gr&#xe9; universitaire de sant&#xe9; et de services sociaux (CIUSSS) de l'Ouest-de-l'&#xce;le-de-Montr&#xe9;al, and Departments of Neurology, Neurosurgery, Psychiatry, Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada. pedro.rosa@mcgill.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada. pedro.rosa@mcgill.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP-11-51-31</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>FRN 152985</GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Med. 2021 Nov;27(11):2048-2049. doi: 10.1038/s41591-021-01568-3.</RefSource><PMID Version="1">34654920</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>49</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34446931</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01456-w</ArticleId><ArticleId IdType="pii">10.1038/s41591-021-01456-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ising, C. et al. NLRP3 inflammasome activation drives tau pathology. Nature 575, 669&#x2013;673 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31748742</ArticleId><ArticleId IdType="pmc">7324015</ArticleId><ArticleId IdType="doi">10.1038/s41586-019-1769-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter, M. W. &amp; Stevens, B. Microglia emerge as central players in brain disease. Nat. Med. 23, 1018&#x2013;1027 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28886007</ArticleId><ArticleId IdType="doi">10.1038/nm.4397</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheffield, L. G., Marquis, J. G. &amp; Berman, N. E. Regional distribution of cortical microglia parallels that of neurofibrillary tangles in Alzheimer&#x2019;s disease. Neurosci. Lett. 285, 165&#x2013;168 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10806312</ArticleId><ArticleId IdType="doi">10.1016/S0304-3940(00)01037-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo, A. et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer&#x2019;s disease. Am. J. Pathol. 179, 1373&#x2013;1384 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21777559</ArticleId><ArticleId IdType="pmc">3157187</ArticleId><ArticleId IdType="doi">10.1016/j.ajpath.2011.05.047</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopp, S. C. et al. The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer&#x2019;s disease. J. Neuroinflammation 15, 269 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30227881</ArticleId><ArticleId IdType="pmc">6145371</ArticleId><ArticleId IdType="doi">10.1186/s12974-018-1309-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak, H. &amp; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId><ArticleId IdType="doi">10.1007/BF00308809</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak, H. &amp; Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18, 351&#x2013;357 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId><ArticleId IdType="doi">10.1016/S0197-4580(97)00056-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson, P. T. et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71, 362&#x2013;381 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22487856</ArticleId><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack, C. R. Jr. et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207&#x2013;216 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23332364</ArticleId><ArticleId IdType="pmc">3622225</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal, D. R., R&#xfc;b, U., Orantes, M. &amp; Braak, H. Phases of A&#x3b2;-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791&#x2013;1800 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId><ArticleId IdType="doi">10.1212/WNL.58.12.1791</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani, M. et al. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer&#x2019;s disease. Brain 141, 2740&#x2013;2754 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30052812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisl, W. C. et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer&#x2019;s disease. Brain 136, 2228&#x2013;2238 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23775979</ArticleId><ArticleId IdType="pmc">3692038</ArticleId><ArticleId IdType="doi">10.1093/brain/awt145</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal, T. A. et al. A&#x3b2;-induced vulnerability propagates via the brain&#x2019;s default mode network. Nat. Commun. 10, 2353 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31164641</ArticleId><ArticleId IdType="pmc">6547716</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-10217-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen, D. R. et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J. Cereb. Blood Flow Metab. 32, 1&#x2013;5 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22008728</ArticleId><ArticleId IdType="doi">10.1038/jcbfm.2011.147</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt, S. et al. PTSD is associated with neuroimmune suppression: evidence from PET imaging and postmortem transcriptomic studies. Nat. Commun. 11, 2360 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32398677</ArticleId><ArticleId IdType="pmc">7217830</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-15930-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisl, W. C. et al. PET imaging of neuroinflammation in neurological disorders. Lancet Neurol. 19, 940&#x2013;950 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33098803</ArticleId><ArticleId IdType="pmc">7912433</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(20)30346-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal, T. A. et al. In vivo quantification of neurofibrillary tangles with [<sup>18</sup>F]MK-6240. Alzheimers Res. Ther. 10, 74 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30064520</ArticleId><ArticleId IdType="pmc">6069775</ArticleId><ArticleId IdType="doi">10.1186/s13195-018-0402-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal, T. A. et al. <sup>18</sup>F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain 143, 2818&#x2013;2830 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32671408</ArticleId><ArticleId IdType="doi">10.1093/brain/awaa180</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom, P. et al. Neuroinflammation&#x2014;an early event in both the history and pathogenesis of Alzheimer&#x2019;s disease. Neurodegener. Dis. 7, 38&#x2013;41 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20160456</ArticleId><ArticleId IdType="doi">10.1159/000283480</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze, M., Leyns, C. E. G. &amp; Holtzman, D. M. New insights into the role of TREM2 in Alzheimer&#x2019;s disease. Mol. Neurodegener. 13, 66 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30572908</ArticleId><ArticleId IdType="pmc">6302500</ArticleId><ArticleId IdType="doi">10.1186/s13024-018-0298-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisl, W. C. et al. <sup>11</sup>C-PBR28 binding to translocator protein increases with progression of Alzheimer&#x2019;s disease. Neurobiol. Aging 44, 53&#x2013;61 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27318133</ArticleId><ArticleId IdType="pmc">4939713</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.04.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou, J. et al. Microglial activation, but not tau pathology, is independently associated with amyloid positivity and memory impairment. Neurobiol. Aging 85, 11&#x2013;21 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31698286</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.09.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawrylycz, M. J. et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 489, 391&#x2013;399 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22996553</ArticleId><ArticleId IdType="pmc">4243026</ArticleId><ArticleId IdType="doi">10.1038/nature11405</ArticleId></ArticleIdList></Reference><Reference><Citation>Brendel, M. et al. Increase of TREM2 during aging of an Alzheimer&#x2019;s disease mouse model is paralleled by microglial activation and amyloidosis. Front. Aging Neurosci. 9, 8 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28197095</ArticleId><ArticleId IdType="pmc">5282474</ArticleId><ArticleId IdType="doi">10.3389/fnagi.2017.00008</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio, L. et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 131, 925&#x2013;933 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26754641</ArticleId><ArticleId IdType="pmc">4867123</ArticleId><ArticleId IdType="doi">10.1007/s00401-016-1533-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Heslegrave, A. et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer&#x2019;s disease. Mol. Neurodegener. 11, 3 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26754172</ArticleId><ArticleId IdType="pmc">4709982</ArticleId><ArticleId IdType="doi">10.1186/s13024-016-0071-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, T. et al. Silencing of TREM2 exacerbates tau pathology, neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice. Neurobiol. Aging 36, 3176&#x2013;3186 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26364736</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.08.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantarella, G. et al. Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer&#x2019;s disease. Brain 138, 203&#x2013;216 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25472798</ArticleId><ArticleId IdType="doi">10.1093/brain/awu318</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, K. et al. CXCL1 contributes to &#x3b2;-amyloid-induced transendothelial migration of monocytes in Alzheimer&#x2019;s disease. PLoS ONE 8, e72744 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23967336</ArticleId><ArticleId IdType="pmc">3743906</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0072744</ArticleId></ArticleIdList></Reference><Reference><Citation>Bol&#xf3;s, M. et al. Absence of CX3CR1 impairs the internalization of Tau by microglia. Mol. Neurodegener. 12, 59 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28810892</ArticleId><ArticleId IdType="pmc">5558740</ArticleId><ArticleId IdType="doi">10.1186/s13024-017-0200-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekert, J. O., Gould, R. L., Reynolds, G. &amp; Howard, R. J. TNF alpha inhibitors in Alzheimer&#x2019;s disease: a systematic review. Int. J. Geriatr. Psychiatry 33, 688&#x2013;694 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29516540</ArticleId><ArticleId IdType="doi">10.1002/gps.4871</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurent, C., Bu&#xe9;e, L. &amp; Blum, D. Tau and neuroinflammation: what impact for Alzheimer&#x2019;s disease and tauopathies? Biomed. J. 41, 21&#x2013;33 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29673549</ArticleId><ArticleId IdType="pmc">6138617</ArticleId><ArticleId IdType="doi">10.1016/j.bj.2018.01.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Faura, J. et al. CCL23: a chemokine associated with progression from mild cognitive impairment to Alzheimer&#x2019;s disease. J. Alzheimers Dis. 73, 1585&#x2013;1595 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31958084</ArticleId><ArticleId IdType="pmc">8010612</ArticleId><ArticleId IdType="doi">10.3233/JAD-190753</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan, R. S. et al. Stromelysin-2 (MMP10) moderates inflammation by controlling macrophage activation. J. Immunol. 197, 899&#x2013;909 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27316687</ArticleId><ArticleId IdType="doi">10.4049/jimmunol.1600502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y., Anoopkumar-Dukie, S. &amp; Davey, A. K. SIRT1 and SIRT2 modulators: potential anti-inflammatory treatment for depression? Biomolecules 11, 353 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33669121</ArticleId><ArticleId IdType="pmc">7996578</ArticleId><ArticleId IdType="doi">10.3390/biom11030353</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X.-X., Tan, M.-S., Yu, J.-T. &amp; Tan, L. Matrix metalloproteinases and their multiple roles in Alzheimer&#x2019;s disease. Biomed Res. Int. 2014, 908636 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25050378</ArticleId><ArticleId IdType="pmc">4094696</ArticleId></ArticleIdList></Reference><Reference><Citation>Willette, A. A. et al. Interleukin-8 and interleukin-10, brain volume and microstructure, and the influence of calorie restriction in old rhesus macaques. Age (Dordr.) 35, 2215&#x2013;2227 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-013-9518-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez, J. A. et al. Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Front. Biosci. 13, 2916&#x2013;2921 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17981764</ArticleId><ArticleId IdType="doi">10.2741/2896</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak, H., Thal, D. R., Ghebremedhin, E. &amp; Del Tredici, K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960&#x2013;969 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId><ArticleId IdType="doi">10.1097/NEN.0b013e318232a379</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettenmann, H., Hanisch, U.-K., Noda, M. &amp; Verkhratsky, A. Physiology of microglia. Physiol. Rev. 91, 461&#x2013;553 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21527731</ArticleId><ArticleId IdType="doi">10.1152/physrev.00011.2010</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos, S. L. et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med. 9, eaag0481 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28123067</ArticleId><ArticleId IdType="pmc">5792300</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.aag0481</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda, S. et al. Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer&#x2019;s disease mouse model and human patients. Ann. Neurol. 80, 355&#x2013;367 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27351289</ArticleId><ArticleId IdType="pmc">5016222</ArticleId><ArticleId IdType="doi">10.1002/ana.24716</ArticleId></ArticleIdList></Reference><Reference><Citation>Saman, S. et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 287, 3842&#x2013;3849 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22057275</ArticleId><ArticleId IdType="doi">10.1074/jbc.M111.277061</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiandaca, M. S. et al. Identification of preclinical Alzheimer&#x2019;s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimers Dement. 11, 600&#x2013;607.e1 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25130657</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2014.06.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh, D. M. &amp; Selkoe, D. J. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat. Rev. Neurosci. 17, 251&#x2013;260 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26988744</ArticleId><ArticleId IdType="pmc">6701169</ArticleId><ArticleId IdType="doi">10.1038/nrn.2016.13</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez, J. S. et al. The cortical origin and initial spread of medial temporal tauopathy in Alzheimer&#x2019;s disease assessed with positron emission tomography. Sci. Transl. Med. 13, eabc0655 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33472953</ArticleId><ArticleId IdType="pmc">7978042</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abc0655</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Nievas, B. G. et al. Dissecting phenotypic traits linked to human resilience to Alzheimer&#x2019;s pathology. Brain 136, 2510&#x2013;2526 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23824488</ArticleId><ArticleId IdType="pmc">3722351</ArticleId><ArticleId IdType="doi">10.1093/brain/awt171</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack, C. R. Jr. et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539&#x2013;547 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27371494</ArticleId><ArticleId IdType="pmc">4970664</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000002923</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman, A. et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci. 22, 2087&#x2013;2097 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId><ArticleId IdType="doi">10.1038/s41593-019-0539-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Criscuolo, C. et al. Entorhinal cortex dysfunction can be rescued by inhibition of microglial RAGE in an Alzheimer&#x2019;s disease mouse model. Sci. Rep. 7, 42370 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28205565</ArticleId><ArticleId IdType="pmc">5304222</ArticleId><ArticleId IdType="doi">10.1038/srep42370</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison, P. et al. Microglia, amyloid, and cognition in Alzheimer&#x2019;s disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol. Dis. 32, 412&#x2013;419 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18786637</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2008.08.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann, S. et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47, 566&#x2013;581.e.9 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28930663</ArticleId><ArticleId IdType="pmc">5719893</ArticleId><ArticleId IdType="doi">10.1016/j.immuni.2017.08.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen, D. V., Hanson, J. E. &amp; Sheng, M. Microglia in Alzheimer&#x2019;s disease. J. Cell Biol. 217, 459&#x2013;472 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29196460</ArticleId><ArticleId IdType="pmc">5800817</ArticleId><ArticleId IdType="doi">10.1083/jcb.201709069</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyoo, C. H. et al. Cerebellum can serve as a pseudo-reference region in Alzheimer disease to detect neuroinflammation measured with PET radioligand binding to translocator protein. J. Nucl. Med. 56, 701&#x2013;706 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25766898</ArticleId><ArticleId IdType="doi">10.2967/jnumed.114.146027</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, D. et al. Soluble TREM2 changes during the clinical course of Alzheimer&#x2019;s disease: a meta-analysis. Neurosci. Lett. 686, 10&#x2013;16 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30171911</ArticleId><ArticleId IdType="doi">10.1016/j.neulet.2018.08.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Diedrichsen, J., Balsters, J. H., Flavell, J., Cussans, E. &amp; Ramnani, N. A probabilistic MR atlas of the human cerebellum. Neuroimage 46, 39&#x2013;46 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19457380</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2009.01.045</ArticleId></ArticleIdList></Reference><Reference><Citation>Therriault, J. et al. Determining amyloid-&#x3b2; positivity using <sup>18</sup>F-AZD4694 PET imaging. J. Nucl. Med. 62, 247&#x2013;252 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32737243</ArticleId><ArticleId IdType="doi">10.2967/jnumed.120.245209</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoal, T. A. et al. Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer&#x2019;s disease. Eur. J. Nucl. Med. Mol. Imaging 45, 1021&#x2013;1030 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29396637</ArticleId><ArticleId IdType="pmc">5915512</ArticleId><ArticleId IdType="doi">10.1007/s00259-018-3933-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, A. &amp; Tourville, J. 101 labeled brain images and a consistent human cortical labeling protocol. Front. Neurosci. 6, 171 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23227001</ArticleId><ArticleId IdType="pmc">3514540</ArticleId><ArticleId IdType="doi">10.3389/fnins.2012.00171</ArticleId></ArticleIdList></Reference><Reference><Citation>Gryglewski, G. et al. Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging. Neuroimage 176, 259&#x2013;267 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29723639</ArticleId><ArticleId IdType="doi">10.1016/j.neuroimage.2018.04.068</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen, C. S. et al. Exercise as a potential modulator of inflammation in patients with Alzheimer&#x2019;s disease measured in cerebrospinal fluid and plasma. Exp. Gerontol. 121, 91&#x2013;98 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30980923</ArticleId><ArticleId IdType="doi">10.1016/j.exger.2019.04.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer&#x2019;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422&#x2013;433 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32333900</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(20)30071-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathotaarachchi, S. et al. VoxelStats: a MATLAB package for multi-modal voxel-wise brain image analysis. Front. Neuroinform. 10, 20 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27378902</ArticleId><ArticleId IdType="pmc">4908129</ArticleId><ArticleId IdType="doi">10.3389/fninf.2016.00020</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34453888</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4164</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><Issue>20</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Molecular cell</Title><ISOAbbreviation>Mol Cell</ISOAbbreviation></Journal><ArticleTitle>Interaction of tau with HNRNPA2B1 and N<sup>6</sup>-methyladenosine RNA mediates the progression of tauopathy.</ArticleTitle><Pagination><StartPage>4209</StartPage><EndPage>4227.e12</EndPage><MedlinePgn>4209-4227.e12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molcel.2021.07.038</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1097-2765(21)00622-5</ELocationID><Abstract><AbstractText>The microtubule-associated protein tau oligomerizes, but the actions of oligomeric tau (oTau) are unknown. We have used Cry2-based optogenetics to induce tau oligomers (oTau-c). Optical induction of oTau-c elicits tau phosphorylation, aggregation, and a translational stress response that includes stress granules and reduced protein synthesis. Proteomic analysis identifies HNRNPA2B1 as a principle target of oTau-c. The association of HNRNPA2B1 with endogenous oTau was verified in neurons, animal models, and human Alzheimer brain tissues. Mechanistic studies demonstrate that HNRNPA2B1 functions as a linker, connecting oTau with N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) modified RNA transcripts. Knockdown of HNRNPA2B1 prevents oTau or oTau-c from associating with m<sup>6</sup>A or from reducing protein synthesis and reduces oTau-induced neurodegeneration. Levels of m<sup>6</sup>A and the m<sup>6</sup>A-oTau-HNRNPA2B1 complex are increased up to 5-fold in the brains of Alzheimer subjects and P301S tau mice. These results reveal a complex containing oTau, HNRNPA2B1, and m<sup>6</sup>A that contributes to the integrated stress response of oTau.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lulu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Network Systems Biology, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ash</LastName><ForeName>Peter E A</ForeName><Initials>PEA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Mamta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwan</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Network Systems Biology, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Vliet</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhuo</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Anna Lourdes</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boudeau</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maziuk</LastName><ForeName>Brandon F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Shuwen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Jaehyup</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Victor E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hovde</LastName><ForeName>Stacy</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abisambra</LastName><ForeName>Jose F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of Florida, Gainesville, FL 32611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Min-Hao</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanaan</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Translational Science and Molecular Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crary</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Pathology, Mount Sinai Medical Center, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, Boston University, Boston, MA 02459, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Ji-Xin</ForeName><Initials>JX</Initials><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, Boston University, Boston, MA 02459, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emili</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Network Systems Biology, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolozin</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA; Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA; Center for Neurophotonics, Boston University, Boston, MA 02215, USA; Center for Systems Neuroscience, Boston University, Boston, MA 02215, USA. Electronic address: bwolozin@bu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG072577</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD023663</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066511</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056318</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG050471</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089544</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061706</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG064932</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Cell</MedlineTA><NlmUniqueID>9802571</NlmUniqueID><ISSNLinking>1097-2765</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034481">Heterogeneous-Nuclear Ribonucleoprotein Group A-B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C439768">hnRNP A2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>CLE6G00625</RegistryNumber><NameOfSubstance UI="C010223">N-methyladenosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Mol Cell Biol. 2021 Oct;22(10):650. doi: 10.1038/s41580-021-00419-w.</RefSource><PMID Version="1">34480148</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034481" MajorTopicYN="N">Heterogeneous-Nuclear Ribonucleoprotein Group A-B</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008745" MajorTopicYN="N">Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012323" MajorTopicYN="Y">RNA Processing, Post-Transcriptional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">METTL3</Keyword><Keyword MajorTopicYN="N">RNA methylation</Keyword><Keyword MajorTopicYN="N">RNA translation</Keyword><Keyword MajorTopicYN="N">fibrils</Keyword><Keyword MajorTopicYN="N">lamin</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">nuclear envelope</Keyword><Keyword MajorTopicYN="N">stress granules</Keyword><Keyword MajorTopicYN="N">tau oligomerization</Keyword></KeywordList><CoiStatement>Declaration of interests B.W. is a co-founder and chief scientific officer of Aquinnah Pharmaceuticals Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>28</Day><Hour>20</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34453888</ArticleId><ArticleId IdType="mid">NIHMS1731762</ArticleId><ArticleId IdType="pmc">PMC8541906</ArticleId><ArticleId IdType="doi">10.1016/j.molcel.2021.07.038</ArticleId><ArticleId IdType="pii">S1097-2765(21)00622-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alarcon CR, Goodarzi H, Lee H, Liu X, Tavazoie S, and Tavazoie SF (2015). HNRNPA2B1 Is a Mediator of m(6)A-Dependent Nuclear RNA Processing Events. Cell 162, 1299&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4673968</ArticleId><ArticleId IdType="pubmed">26321680</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders M, Chelysheva I, Goebel I, Trenkner T, Zhou J, Mao Y, Verzini S, Qian SB, and Ignatova Z (2018). Dynamic m(6)A methylation facilitates mRNA triaging to stress granules. Life Sci Alliance 1, e201800113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6238392</ArticleId><ArticleId IdType="pubmed">30456371</ArticleId></ArticleIdList></Reference><Reference><Citation>Apicco DJ, Ash PEA, Maziuk B, LeBlang C, Medalla M, Al Abdullatif A, Ferragud A, Botelho E, Ballance HI, Dhawan U, et al. (2018). Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo. Nat Neurosci 21, 72&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5745051</ArticleId><ArticleId IdType="pubmed">29273772</ArticleId></ArticleIdList></Reference><Reference><Citation>Arguello AE, DeLiberto AN, and Kleiner RE (2017). RNA Chemical Proteomics Reveals the N(6)-Methyladenosine (m(6)A)-Regulated Protein-RNA Interactome. J Am Chem Soc 139, 17249&#x2013;17252.</Citation><ArticleIdList><ArticleId IdType="pubmed">29140688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PEA, Lei S, Shattuck J, Boudeau S, Carlomagno Y, Medalla M, Mashimo BL, Socorro G, Al-Mohanna LFA, Jiang L, et al. (2021). TIA1 potentiates tau phase separation and promotes generation of toxic oligomeric tau. Proc Natl Acad Sci U S A 118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7936275</ArticleId><ArticleId IdType="pubmed">33619090</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, et al. (2007). Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27, 3650&#x2013;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672413</ArticleId><ArticleId IdType="pubmed">17409229</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishof I, Dammer EB, Duong DM, Kundinger SR, Gearing M, Lah JJ, Levey AI, and Seyfried NT (2018). RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer&#x2019;s disease. J Biol Chem 293, 11047&#x2013;11066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052236</ArticleId><ArticleId IdType="pubmed">29802200</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauderlier A, Gilles M, Spolcova A, Caillierez R, Chwastyniak M, Kress M, Drobecq H, Bonnefoy E, Pinet F, Weil D, et al. (2018). Tau/DDX6 interaction increases microRNA activity. Biochim Biophys Acta Gene Regul Mech 1861, 762&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">29966762</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen XY, Zhang J, and Zhu JS (2019). The role of m(6)A RNA methylation in human cancer. Mol Cancer 18, 103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6540575</ArticleId><ArticleId IdType="pubmed">31142332</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs B, and Kanaan NM (2017). Exposure of the Amino Terminus of Tau Is a Pathological Event in Multiple Tauopathies. Am J Pathol 187, 1222&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818634</ArticleId><ArticleId IdType="pubmed">28413156</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook C, Carlomagno Y, Gendron TF, Dunmore J, Scheffel K, Stetler C, Davis M, Dickson D, Jarpe M, DeTure M, et al. (2014). Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet 23, 104&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857946</ArticleId><ArticleId IdType="pubmed">23962722</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornelison GL, Levy SA, Jenson T, and Frost B (2019). Tau-induced nuclear envelope invagination causes a toxic accumulation of mRNA in Drosophila. Aging Cell 18, e12847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6351838</ArticleId><ArticleId IdType="pubmed">30411463</ArticleId></ArticleIdList></Reference><Reference><Citation>Edupuganti RR, Geiger S, Lindeboom RGH, Shi H, Hsu PJ, Lu Z, Wang SY, Baltissen MPA, Jansen P, Rossa M, et al. (2017). N(6)-methyladenosine (m(6)A) recruits and repels proteins to regulate mRNA homeostasis. Nat Struct Mol Biol 24, 870&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5725193</ArticleId><ArticleId IdType="pubmed">28869609</ArticleId></ArticleIdList></Reference><Reference><Citation>Eftekharzadeh B, Daigle JG, Kapinos LE, Coyne A, Schiantarelli J, Carlomagno Y, Cook C, Miller SJ, Dujardin S, Amaral AS, et al. (2018). Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer&#x2019;s Disease. Neuron 99, 925&#x2013;940 e927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6240334</ArticleId><ArticleId IdType="pubmed">30189209</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans HT, Benetatos J, van Roijen M, Bodea LG, and Gotz J (2019). Decreased synthesis of ribosomal proteins in tauopathy revealed by non-canonical amino acid labelling. EMBO J 38, e101174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6600635</ArticleId><ArticleId IdType="pubmed">31268600</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, and van Duijn CM (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama 278, 1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Bardai FH, and Feany MB (2016). Lamin Dysfunction Mediates Neurodegeneration in Tauopathies. Curr Biol 26, 129&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713335</ArticleId><ArticleId IdType="pubmed">26725200</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JM, Whiten DR, Brown RA, Barros TP, Kumita JR, Yerbury JJ, Satapathy S, McDade K, Smith C, Luheshi LM, et al. (2017). Clusterin protects neurons against intracellular proteotoxicity. Acta Neuropathol Commun 5, 81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5678579</ArticleId><ArticleId IdType="pubmed">29115989</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman-Martinez L, Farias GA, and Maccioni RB (2013). Tau oligomers as potential targets for Alzheimer&#x2019;s diagnosis and novel drugs. Front Neurol 4, 167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3808896</ArticleId><ArticleId IdType="pubmed">24191153</ArticleId></ArticleIdList></Reference><Reference><Citation>Han M, Liu Z, Xu Y, Liu X, Wang D, Li F, Wang Y, and Bi J (2020). Abnormality of m6A mRNA Methylation Is Involved in Alzheimer&#x2019;s Disease. Front Neurosci 14, 98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7058666</ArticleId><ArticleId IdType="pubmed">32184705</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, et al. (2009). Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat Genet 41, 1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L, Ash PEA, Maziuk BF, Ballance HI, Boudeau S, Abdullatif AA, Orlando M, Petrucelli L, Ikezu T, and Wolozin B (2019). TIA1 regulates the generation and response to toxic tau oligomers. Acta Neuropathol 137, 259&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377165</ArticleId><ArticleId IdType="pubmed">30465259</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L, Zhao J, Cheng JX, and Wolozin B (2020). Tau Oligomers and Fibrils Exhibit Differential Patterns of Seeding and Association With RNA Binding Proteins. Front Neurol 11, 579434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7554625</ArticleId><ArticleId IdType="pubmed">33101187</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ECB, Dammer EB, Duong DM, Ping L, Zhou M, Yin L, Higginbotham LA, Guajardo A, White B, Troncoso JC, et al. (2020). Large-scale proteomic analysis of Alzheimer&#x2019;s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med 26, 769&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405761</ArticleId><ArticleId IdType="pubmed">32284590</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ECB, Dammer EB, Duong DM, Yin L, Thambisetty M, Troncoso JC, Lah JJ, Levey AI, and Seyfried NT (2018). Deep proteomic network analysis of Alzheimer&#x2019;s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease. Mol Neurodegener 13, 52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6172707</ArticleId><ArticleId IdType="pubmed">30286791</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gronka S, Wuu J, et al. (2010). Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68, 857&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanaan NM, Cox K, Alvarez VE, Stein TD, Poncil S, and McKee AC (2016). Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy. J Neuropathol Exp Neurol 75, 19&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4891281</ArticleId><ArticleId IdType="pubmed">26671985</ArticleId></ArticleIdList></Reference><Reference><Citation>Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, Totoki Y, Chiba K, Sato-Otsubo A, Nagae G, et al. (2015). Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 47, 1304&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pubmed">26437031</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, Maclea KS, Freibaum B, Li S, Molliex A, et al. (2013a). Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim NC, Tresse E, Kolaitis RM, Molliex A, Thomas RE, Alami NH, Wang B, Joshi A, Smith RB, Ritson GP, et al. (2013b). VCP Is Essential for Mitochondrial Quality Control by PINK1/Parkin and this Function Is Impaired by VCP Mutations. Neuron 78, 65&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683300</ArticleId><ArticleId IdType="pubmed">23498974</ArticleId></ArticleIdList></Reference><Reference><Citation>Koren SA, Hamm MJ, Meier SE, Weiss BE, Nation GK, Chishti EA, Arango JP, Chen J, Zhu H, Blalock EM, et al. (2019). Tau drives translational selectivity by interacting with ribosomal proteins. Acta Neuropathol 137, 571&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426815</ArticleId><ArticleId IdType="pubmed">30759285</ArticleId></ArticleIdList></Reference><Reference><Citation>Koss DJ, Jones G, Cranston A, Gardner H, Kanaan NM, and Platt B (2016). Soluble pre-fibrillar tau and beta-amyloid species emerge in early human Alzheimer&#x2019;s disease and track disease progression and cognitive decline. Acta Neuropathol 132, 875&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5106509</ArticleId><ArticleId IdType="pubmed">27770234</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamprecht R (2019). Regulation of signaling proteins in the brain by light. Prog Neurobiol 180, 101638.</Citation><ArticleIdList><ArticleId IdType="pubmed">31199959</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, and Kayed R (2011). Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener 6, 39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3224595</ArticleId><ArticleId IdType="pubmed">21645391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, and Strittmatter SM (2009). Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Dou X, Chen C, Chen C, Liu C, Xu MM, Zhao S, Shen B, Gao Y, Han D, et al. (2020a). N (6)-methyladenosine of chromosome-associated regulatory RNA regulates chromatin state and transcription. Science 367, 580&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7213019</ArticleId><ArticleId IdType="pubmed">31949099</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Sui D, Dexheimer T, Hovde S, Deng X, Wang KW, Lin HL, Chien HT, Kweon HK, Kuo NS, et al. (2020b). Hyperphosphorylation Renders Tau Prone to Aggregate and to Cause Cell Death. Mol Neurobiol 57, 4704&#x2013;4719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7530023</ArticleId><ArticleId IdType="pubmed">32780352</ArticleId></ArticleIdList></Reference><Reference><Citation>Maraldi NM (2018). The lamin code. Biosystems 164, 68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">28735035</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez FJ, Pratt GA, Van Nostrand EL, Batra R, Huelga SC, Kapeli K, Freese P, Chun SJ, Ling K, Gelboin-Burkhart C, et al. (2016). Protein-RNA Networks Regulated by Normal and ALS-Associated Mutant HNRNPA2B1 in the Nervous System. Neuron 92, 780&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5123850</ArticleId><ArticleId IdType="pubmed">27773581</ArticleId></ArticleIdList></Reference><Reference><Citation>Maziuk BF, Apicco DJ, Cruz AL, Jiang L, Ash PEA, da Rocha EL, Zhang C, Yu WH, Leszyk J, Abisambra JF, et al. (2018). RNA binding proteins co-localize with small tau inclusions in tauopathy. Acta Neuropathol Commun 6, 71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6069705</ArticleId><ArticleId IdType="pubmed">30068389</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan WA, Falcon B, Vaysburd M, Clift D, Oblak AL, Ghetti B, Goedert M, and James LC (2017). Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc Natl Acad Sci U S A 114, 574&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5255578</ArticleId><ArticleId IdType="pubmed">28049840</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier S, Bell M, Lyons DN, Rodriguez-Rivera J, Ingram A, Fontaine SN, Mechas E, Chen J, Wolozin B, LeVine H 3rd, et al. (2016). Pathological Tau Promotes Neuronal Damage by Impairing Ribosomal Function and Decreasing Protein Synthesis. J Neurosci 36, 1001&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4719006</ArticleId><ArticleId IdType="pubmed">26791227</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau K, Fleming A, Imarisio S, Lopez Ramirez A, Mercer JL, Jimenez-Sanchez M, Bento CF, Puri C, Zavodszky E, Siddiqi F, et al. (2014). PICALM modulates autophagy activity and tau accumulation. Nat Commun 5, 4998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4199285</ArticleId><ArticleId IdType="pubmed">25241929</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkus JL, Amato AA, Taylor JP, and Greenberg SA (2014). Abnormal distribution of heterogeneous nuclear ribonucleoproteins in sporadic inclusion body myositis. Neuromuscul Disord 24, 611&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">24857366</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi X, Pang Q, Wang J, Zhao Z, Wang O, Xu L, Mao J, Jiang Y, Li M, Xing X, et al. (2017). Familial Early-Onset Page&#x2019;s Disease of Bone Associated with a Novel hnRNPA2B1 Mutation. Calcif Tissue Int 101, 159&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">28389692</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE, Leshuk C, Hernandez I, Wegmann S, Hyman BT, et al. (2020). LRP1 is a master regulator of tau uptake and spread. Nature.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7687380</ArticleId><ArticleId IdType="pubmed">32296178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ries RJ, Zaccara S, Klein P, Olarerin-George A, Namkoong S, Pickering BF, Patil DP, Kwak H, Lee JH, and Jaffrey SR (2019). m(6)A enhances the phase separation potential of mRNA. Nature 571, 424&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6662915</ArticleId><ArticleId IdType="pubmed">31292544</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, and Smyth GK (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Z, Pathak D, Venkatesan K, Yoshii-Kitahara A, Muraoka S, Bhatt N, Yukawa-Takamatsu K, Hu J, Wang Y, Hersh S, et al. (2020). Alzheimer&#x2019;s disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain (in press).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7880668</ArticleId><ArticleId IdType="pubmed">33246331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, et al. (2014). Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, et al. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, and Van der Flier WM (2016). Alzheimer&#x2019;s disease. Lancet 388, 505&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">26921134</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin Y, Berry J, Pannucci N, Haataja MP, Toettcher JE, and Brangwynne CP (2017). Spatiotemporal Control of Intracellular Phase Transitions Using Light-Activated optoDroplets. Cell 168, 159&#x2013;171 e114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5562165</ArticleId><ArticleId IdType="pubmed">28041848</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva JM, Rodrigues S, Sampaio-Marques B, Gomes P, Neves-Carvalho A, Dioli C, Soares-Cunha C, Mazuik BF, Takashima A, Ludovico P, et al. (2019). Dysregulation of autophagy and stress granule-related proteins in stress-driven Tau pathology. Cell Death Differ 26, 1411&#x2013;1427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6748085</ArticleId><ArticleId IdType="pubmed">30442948</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Samimi H, Gamez M, Zare H, and Frost B (2018). Pathogenic tau-induced piRNA depletion promotes neuronal death through transposable element dysregulation in neurodegenerative tauopathies. Nat Neurosci 21, 1038&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6095477</ArticleId><ArticleId IdType="pubmed">30038280</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al. (2019). STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 47, D607&#x2013;D613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AD, Scaglione KM, Prensner J, Gillies AT, Chinnaiyan A, Paulson HL, Jinwal UK, Dickey CA, and Gestwicki JE (2012). Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. ACS Chem Biol 7, 1677&#x2013;1686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3477299</ArticleId><ArticleId IdType="pubmed">22769591</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong J, Flavell RA, and Li HB (2018). RNA m(6)A modification and its function in diseases. Front Med 12, 481&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">30097961</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh ME, Dammer EB, Dai J, Duong DM, Lah JJ, Levey AI, Gearing M, Glass JD, and Seyfried NT (2018). A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med 10, 48&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760858</ArticleId><ArticleId IdType="pubmed">29191947</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderweyde T, Apicco DJ, Youmans-Kidder K, Ash PE, Cook C, Lummertz da Rocha E, Jansen-West K, Frame AA, Citro A, Leszyk JD, et al. (2016). Interaction of tau with the RNA-binding Protein TIA1 Regulates tau Pathophysiology and Toxicity. Cell reports 15, 1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325702</ArticleId><ArticleId IdType="pubmed">27160897</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderweyde T, Yu H, Varnum M, Liu-Yesucevitz L, Citro A, Ikezu T, Duff K, and Wolozin B (2012). Contrasting Pathology of Stress Granule Proteins TIA-1 and G3BP in Tauopathies. J Neurosci 32, 8270&#x2013;8283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3402380</ArticleId><ArticleId IdType="pubmed">22699908</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma M, Charles RCM, Chakrapani B, Coumar MS, Govindaraju G, Rajavelu A, Chavali S, and Dhayalan A (2017). PRMT7 Interacts with ASS1 and Citrullinemia Mutations Disrupt the Interaction. J Mol Biol 429, 2278&#x2013;2289.</Citation><ArticleIdList><ArticleId IdType="pubmed">28587924</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Joberty G, Buist A, Vanoosthuyse A, Stancu IC, Vasconcelos B, Pierrot N, Faelth-Savitski M, Kienlen-Campard P, Octave JN, et al. (2017). Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo. Acta Neuropathol 133, 731&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5390007</ArticleId><ArticleId IdType="pubmed">28083634</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Williams D, Muller I, Lemieux M, Dukart R, Maia IBL, Wang H, Woerman AL, and Schmitt-Ulms G (2019). Tau interactome analyses in CRISPR-Cas9 engineered neuronal cells reveal ATPase-dependent binding of wild-type but not P301L Tau to non-muscle myosins. Sci Rep 9, 16238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6838314</ArticleId><ArticleId IdType="pubmed">31700063</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, and Mandelkow E (2016). Tau in physiology and pathology. Nat Rev Neurosci 17, 5&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26631930</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, Cheng R, Lee JH, Bird TD, Bennett DA, Diaz-Arrastia R, et al. (2011). Genome-wide association of familial late-onset Alzheimer&#x2019;s disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet 7, e1001308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3040659</ArticleId><ArticleId IdType="pubmed">21379329</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaccara S, Ries RJ, and Jaffrey SR (2019). Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol 20, 608&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">31520073</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, Coyne AN, Ruan K, Grima JC, Bowen KE, Wadhwa H, Yang P, Rigo F, et al. (2018). Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell 173, 958&#x2013;971 e917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, et al. (2015). The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Vigers M, McCarty J, Rauch JN, Fredrickson GH, Wilson MZ, Shea JE, Han S, and Kosik KS (2020). The proline-rich domain promotes Tau liquid-liquid phase separation in cells. J Cell Biol 219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7594490</ArticleId><ArticleId IdType="pubmed">32997736</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Hayashi I, Wong J, Tugusheva K, Renger JJ, and Zerbinatti C (2014). Intracellular clusterin interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated protein Tau in Alzheimer&#x2019;s disease. PLoS One 9, e103187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4106906</ArticleId><ArticleId IdType="pubmed">25051234</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34459862</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Short and Long Sleep Duration With Amyloid-&#x3b2; Burden and Cognition in Aging.</ArticleTitle><Pagination><StartPage>1187</StartPage><EndPage>1196</EndPage><MedlinePgn>1187-1196</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.2876</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Disrupted sleep is common in aging and is associated with cognition. Age-related changes to sleep are associated with multiple causes, including early Alzheimer disease pathology (amyloid &#x3b2; [A&#x3b2;]), depression, and cardiovascular disease.</AbstractText><AbstractText Label="OBJECTIVE">To investigate the associations between self-reported sleep duration and brain A&#x3b2; burden as well as the demographic, cognitive, and lifestyle variables in adults with normal cognition.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cross-sectional study obtained data from participants in the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study, which is being conducted in 67 sites in the United States, Canada, Australia, and Japan. The sample for this analysis consisted of individuals aged 65 to 85 years who underwent an A&#x3b2; positron emission tomography (PET) scan, had complete apolipoprotein E (APOE) genotype data, and were identified as clinically normal (per a Clinical Dementia Rating score of 0) and cognitively unimpaired (per a Mini-Mental State Examination score of 25 to 30 and Logical Memory Delayed Recall test score of 6 to 18). Data were analyzed from April 3, 2020, to June 20, 2021.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The outcome was self-reported nightly sleep duration (grouped by short sleep duration: &#x2264;6 hours, normal sleep duration: 7-8 hours, and long sleep duration: &#x2265;9 hours) compared with demographic characteristics, A&#x3b2; burden (as measured with a fluorine 18-labeled-florbetapir PET scan), objective and subjective cognitive function measures, and lifestyle variables.</AbstractText><AbstractText Label="RESULTS">The 4417 participants in the study included 2618 women (59%) and had a mean (SD) age of 71.3 (4.7) years. Self-reported shorter sleep duration was linearly associated with higher A&#x3b2; burden (&#x3b2; [SE]&#x2009;=&#x2009;-0.01 [0.00]; P&#x2009;=&#x2009;.005), and short sleep duration was associated with reduced cognition that was mostly in memory domains. No difference in A&#x3b2; was found between long and normal sleep duration groups (&#x3b2; [SE]&#x2009;=&#x2009;0.00&#x2009;[0.01]; P&#x2009;=&#x2009;.99). However, compared with normal sleep duration, both short and long sleep durations were associated with higher body mass index (short vs normal sleep duration: &#x3b2; [SE]&#x2009;=&#x2009;0.48 [0.17], P&#x2009;=&#x2009;.01; long vs normal sleep duration: &#x3b2; [SE]&#x2009;=&#x2009;0.97 [0.31], P&#x2009;=&#x2009;.002), depressive symptoms (short vs normal sleep duration: &#x3b2; [SE]&#x2009;=&#x2009;0.31 [0.05], P&#x2009;&lt;&#x2009;.001; long vs normal sleep duration: &#x3b2; [SE]&#x2009;=&#x2009;0.39 [0.09], P&#x2009;&lt;&#x2009;.001), and daytime napping (short vs normal sleep duration: &#x3b2; [SE]&#x2009;=&#x2009;2.66 [0.77], P&#x2009;=&#x2009;.001; long vs normal sleep duration: &#x3b2; [SE]&#x2009;=&#x2009;3.62 [1.38], P&#x2009;=&#x2009;.01). Long sleep duration was associated with worse performance across multiple cognitive domains.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this cross-sectional study, both short and long sleep durations were associated with worse outcomes for older adults, such as greater A&#x3b2; burden, greater depressive symptoms, higher body mass index, and cognitive decline, emphasizing the importance of maintaining adequate sleep.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winer</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deters</LastName><ForeName>Kacie D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein-Piekarski</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sierra-Pacific Mental Illness Research, Education, and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poston</LastName><ForeName>Kathleen L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>Elizabeth C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 AG074625</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG063689</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Poston reported receiving grants from the National Institutes of Health (NIH) during the conduct of the study; grants from NIH and Michael J. Fox Foundation for Parkinson's Research outside the submitted work; and consulting fees from CuraSen Therapeutics Inc. Dr Mormino reported receiving grants from NIH, personal fees from Roche and Lilly during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>30</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34459862</ArticleId><ArticleId IdType="pmc">PMC8406215</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.2876</ArticleId><ArticleId IdType="pii">2783664</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mander BA, Winer JR, Walker MP. Sleep and human aging. Neuron. 2017;94(1):19-36. doi:10.1016/j.neuron.2017.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.02.004</ArticleId><ArticleId IdType="pmc">PMC5810920</ArticleId><ArticleId IdType="pubmed">28384471</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep. 2004;27(7):1255-1273. doi:10.1093/sleep/27.7.1255</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/27.7.1255</ArticleId><ArticleId IdType="pubmed">15586779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kocevska D, Lysen TS, Dotinga A, et al. . Sleep characteristics across the lifespan in 1.1&#x2009;million people from the Netherlands, United Kingdom and United States: a systematic review and meta-analysis. Nat Hum Behav. 2021;5(1):113-122. doi:10.1038/s41562-020-00965-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41562-020-00965-x</ArticleId><ArticleId IdType="pubmed">33199855</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. Dialogues Clin Neurosci. 2008;10(4):473-481. doi:10.31887/DCNS.2008.10.4/plfranzen</Citation><ArticleIdList><ArticleId IdType="doi">10.31887/DCNS.2008.10.4/plfranzen</ArticleId><ArticleId IdType="pmc">PMC3108260</ArticleId><ArticleId IdType="pubmed">19170404</ArticleId></ArticleIdList></Reference><Reference><Citation>Potvin O, Lorrain D, Belleville G, Grenier S, Pr&#xe9;ville M. Subjective sleep characteristics associated with anxiety and depression in older adults: a population-based study. Int J Geriatr Psychiatry. 2014;29(12):1262-1270. doi:10.1002/gps.4106</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.4106</ArticleId><ArticleId IdType="pubmed">24733621</ArticleId></ArticleIdList></Reference><Reference><Citation>Devore EE, Grodstein F, Duffy JF, Stampfer MJ, Czeisler CA, Schernhammer ES. Sleep duration in midlife and later life in relation to cognition. J Am Geriatr Soc. 2014;62(6):1073-1081. doi:10.1111/jgs.12790</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.12790</ArticleId><ArticleId IdType="pmc">PMC4188530</ArticleId><ArticleId IdType="pubmed">24786726</ArticleId></ArticleIdList></Reference><Reference><Citation>Virta JJ, Heikkil&#xe4; K, Perola M, et al. . Midlife sleep characteristics associated with late life cognitive function. Sleep. 2013;36(10):1533-1541, 1541A. doi:10.5665/sleep.3052</Citation><ArticleIdList><ArticleId IdType="doi">10.5665/sleep.3052</ArticleId><ArticleId IdType="pmc">PMC3773203</ArticleId><ArticleId IdType="pubmed">24082313</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim ASP, Yu L, Kowgier M, Schneider JA, Buchman AS, Bennett DA. Modification of the relationship of the apolipoprotein E &#x3b5;4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol. 2013;70(12):1544-1551. doi:10.1001/jamaneurol.2013.4215</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.4215</ArticleId><ArticleId IdType="pmc">PMC3859706</ArticleId><ArticleId IdType="pubmed">24145819</ArticleId></ArticleIdList></Reference><Reference><Citation>Lysen TS, Luik AI, Ikram MK, Tiemeier H, Ikram MA. Actigraphy-estimated sleep and 24-hour activity rhythms and the risk of dementia. Alzheimers Dement. 2020;16(9):1259-1267. doi:10.1002/alz.12122</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12122</ArticleId><ArticleId IdType="pmc">PMC7984295</ArticleId><ArticleId IdType="pubmed">32558256</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappuccio FP, Cooper D, D&#x2019;Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J. 2011;32(12):1484-1492. doi:10.1093/eurheartj/ehr007</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehr007</ArticleId><ArticleId IdType="pubmed">21300732</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappuccio FP, D&#x2019;Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2010;33(2):414-420. doi:10.2337/dc09-1124</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc09-1124</ArticleId><ArticleId IdType="pmc">PMC2809295</ArticleId><ArticleId IdType="pubmed">19910503</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirshkowitz M, Whiton K, Albert SM, et al. . National Sleep Foundation&#x2019;s updated sleep duration recommendations: final report. Sleep Health. 2015;1(4):233-243. doi:10.1016/j.sleh.2015.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleh.2015.10.004</ArticleId><ArticleId IdType="pubmed">29073398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo JC, Groeger JA, Cheng GH, Dijk D-J, Chee MWL. Self-reported sleep duration and cognitive performance in older adults: a systematic review and meta-analysis. Sleep Med. 2016;17:87-98. doi:10.1016/j.sleep.2015.08.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2015.08.021</ArticleId><ArticleId IdType="pubmed">26847980</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Liang L, Zheng F, Shi L, Zhong B, Xie W. Association between sleep duration and cognitive decline. JAMA Netw Open. 2020;3(9):e2013573. doi:10.1001/jamanetworkopen.2020.13573</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.13573</ArticleId><ArticleId IdType="pmc">PMC7506513</ArticleId><ArticleId IdType="pubmed">32955572</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP, Gamaldo AA, An Y, et al. . Self-reported sleep and &#x3b2;-amyloid deposition in community-dwelling older adults. JAMA Neurol. 2013;70(12):1537-1543. doi:10.1001/jamaneurol.2013.4258</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.4258</ArticleId><ArticleId IdType="pmc">PMC3918480</ArticleId><ArticleId IdType="pubmed">24145859</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . NIA-AA research framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W. Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci. 2018;19(11):687-700. doi:10.1038/s41583-018-0067-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-018-0067-3</ArticleId><ArticleId IdType="pmc">PMC7032048</ArticleId><ArticleId IdType="pubmed">30266970</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. . The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13. doi:10.1126/scitranslmed.3007941</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007941</ArticleId><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Donohue MC, Raman R, et al. ; A4 Study Team . Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol. 2020;77(6):735-745. doi:10.1001/jamaneurol.2020.0387</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0387</ArticleId><ArticleId IdType="pmc">PMC7136861</ArticleId><ArticleId IdType="pubmed">32250387</ArticleId></ArticleIdList></Reference><Reference><Citation>Deters KD, Napolioni V, Sperling RA, et al. . Amyloid PET imaging in self-identified non-Hispanic Black participants of the anti-amyloid in asymptomatic Alzheimer&#x2019;s disease (A4) study. Neurology. 2021;96(11):e1491-e1500. doi:10.1212/WNL.0000000000011599</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011599</ArticleId><ArticleId IdType="pmc">PMC8032379</ArticleId><ArticleId IdType="pubmed">33568538</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingsbury JH, Buxton OM, Emmons KM. Sleep and its relationship to racial and ethnic disparities in cardiovascular disease. Curr Cardiovasc Risk Rep. 2013;7(5). doi:10.1007/s12170-013-0330-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12170-013-0330-0</ArticleId><ArticleId IdType="pmc">PMC3824366</ArticleId><ArticleId IdType="pubmed">24244756</ArticleId></ArticleIdList></Reference><Reference><Citation>Carnethon MR, De Chavez PJ, Zee PC, et al. . Disparities in sleep characteristics by race/ethnicity in a population-based sample: Chicago Area Sleep Study. Sleep Med. 2016;18:50-55. doi:10.1016/j.sleep.2015.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2015.07.005</ArticleId><ArticleId IdType="pmc">PMC4728038</ArticleId><ArticleId IdType="pubmed">26459680</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Salmon DP, et al. ; Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Alzheimer&#x2019;s Disease Cooperative Study . The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961-970. doi:10.1001/jamaneurol.2014.803</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.803</ArticleId><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="pubmed">24886908</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Papp KV, Rentz DM, et al. . Early and late change on the preclinical Alzheimer&#x2019;s cognitive composite in clinically normal older individuals with elevated amyloid &#x3b2;. Alzheimers Dement. 2017;13(9):1004-1012. doi:10.1016/j.jalz.2017.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.01.018</ArticleId><ArticleId IdType="pmc">PMC5573651</ArticleId><ArticleId IdType="pubmed">28253478</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Sanders AE, Hall C, Lipton RB. Free and cued selective reminding identifies very mild dementia in primary care. Alzheimer Dis Assoc Disord. 2010;24(3):284-290. doi:10.1097/WAD.0b013e3181cfc78b</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e3181cfc78b</ArticleId><ArticleId IdType="pmc">PMC2929322</ArticleId><ArticleId IdType="pubmed">20683186</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariglio RE, Donohue MC, Marshall GA, et al. ; Alzheimer&#x2019;s Disease Cooperative Study . Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer&#x2019;s Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol. 2015;72(4):446-454. doi:10.1001/jamaneurol.2014.3375</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.3375</ArticleId><ArticleId IdType="pmc">PMC4397164</ArticleId><ArticleId IdType="pubmed">25706191</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronholm E, Sallinen M, Suutama T, Sulkava R, Era P, Partonen T. Self-reported sleep duration and cognitive functioning in the general population. J Sleep Res. 2009;18(4):436-446. doi:10.1111/j.1365-2869.2009.00765.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2869.2009.00765.x</ArticleId><ArticleId IdType="pubmed">19732318</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp KV, Rentz DM, Mormino EC, et al. . Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology. 2017;88(15):1431-1438. doi:10.1212/WNL.0000000000003812</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003812</ArticleId><ArticleId IdType="pmc">PMC5386436</ArticleId><ArticleId IdType="pubmed">28283594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J-E, Lim MM, Bateman RJ, et al. . Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005-1007. doi:10.1126/science.1180962</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1180962</ArticleId><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JH, Huang Y, Bero AW, et al. . Disruption of the sleep-wake cycle and diurnal fluctuation of &#x3b2;-amyloid in mice with Alzheimer&#x2019;s disease pathology. Sci Transl Med. 2012;4(150):150ra122. doi:10.1126/scitranslmed.3004291</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3004291</ArticleId><ArticleId IdType="pmc">PMC3654377</ArticleId><ArticleId IdType="pubmed">22956200</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, Hicks TJ, McLeland JS, et al. . Effect of sleep on overnight cerebrospinal fluid amyloid &#x3b2; kinetics. Ann Neurol. 2018;83(1):197-204. doi:10.1002/ana.25117</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25117</ArticleId><ArticleId IdType="pmc">PMC5876097</ArticleId><ArticleId IdType="pubmed">29220873</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L, Kang H, Xu Q, et al. . Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377. doi:10.1126/science.1241224</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1241224</ArticleId><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Hablitz LM, Pl&#xe1; V, Giannetto M, et al. . Circadian control of brain glymphatic and lymphatic fluid flow. Nat Commun. 2020;11(1):4411. doi:10.1038/s41467-020-18115-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18115-2</ArticleId><ArticleId IdType="pmc">PMC7468152</ArticleId><ArticleId IdType="pubmed">32879313</ArticleId></ArticleIdList></Reference><Reference><Citation>Fultz NE, Bonmassar G, Setsompop K, et al. . Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep. Science. 2019;366(6465):628-631. doi:10.1126/science.aax5440</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aax5440</ArticleId><ArticleId IdType="pmc">PMC7309589</ArticleId><ArticleId IdType="pubmed">31672896</ArticleId></ArticleIdList></Reference><Reference><Citation>Branger P, Arenaza-Urquijo EM, Tomadesso C, et al. . Relationships between sleep quality and brain volume, metabolism, and amyloid deposition in late adulthood. Neurobiol Aging. 2016;41:107-114. doi:10.1016/j.neurobiolaging.2016.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.02.009</ArticleId><ArticleId IdType="pubmed">27103523</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprecher KE, Koscik RL, Carlsson CM, et al. . Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology. 2017;89(5):445-453. doi:10.1212/WNL.0000000000004171</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004171</ArticleId><ArticleId IdType="pmc">PMC5539733</ArticleId><ArticleId IdType="pubmed">28679595</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YE-S, McLeland JS, Toedebusch CD, et al. . Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013;70(5):587-593. doi:10.1001/jamaneurol.2013.2334</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.2334</ArticleId><ArticleId IdType="pmc">PMC3676720</ArticleId><ArticleId IdType="pubmed">23479184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettore E, Bakardjian H, Sol&#xe9; M, et al. . Relationships between objectives sleep parameters and brain amyloid load in subjects at risk for Alzheimer&#x2019;s disease: the INSIGHT-preAD Study. Sleep. 2019;42(9):zsz137. doi:10.1093/sleep/zsz137</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/zsz137</ArticleId><ArticleId IdType="pubmed">31267124</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Marks SM, Vogel JW, et al. . &#x3b2;-amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. Nat Neurosci. 2015;18(7):1051-1057. doi:10.1038/nn.4035</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4035</ArticleId><ArticleId IdType="pmc">PMC4482795</ArticleId><ArticleId IdType="pubmed">26030850</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga AW, Wohlleber ME, Gim&#xe9;nez S, et al. . Reduced slow-wave sleep is associated with high cerebrospinal fluid A&#x3b2;42 levels in cognitively normal elderly. Sleep. 2016;39(11):2041-2048. doi:10.5665/sleep.6240</Citation><ArticleIdList><ArticleId IdType="doi">10.5665/sleep.6240</ArticleId><ArticleId IdType="pmc">PMC5070758</ArticleId><ArticleId IdType="pubmed">27568802</ArticleId></ArticleIdList></Reference><Reference><Citation>Winer JR, Mander BA, Kumar S, et al. . Sleep disturbance forecasts &#x3b2;-amyloid accumulation across subsequent years. Curr Biol. 2020;30(21):4291-4298.e3. doi:10.1016/j.cub.2020.08.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7642104</ArticleId><ArticleId IdType="pubmed">32888482</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Winer JR, Jagust WJ, Walker MP. Sleep: a novel mechanistic pathway, biomarker, and treatment target in the pathology of Alzheimer&#x2019;s disease? Trends Neurosci. 2016;39(8):552-566. doi:10.1016/j.tins.2016.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2016.05.002</ArticleId><ArticleId IdType="pmc">PMC4967375</ArticleId><ArticleId IdType="pubmed">27325209</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Holtzman DM. Bidirectional relationship between sleep and Alzheimer&#x2019;s disease: role of amyloid, tau, and other factors. Neuropsychopharmacology. 2020;45(1):104-120. doi:10.1038/s41386-019-0478-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41386-019-0478-5</ArticleId><ArticleId IdType="pmc">PMC6879647</ArticleId><ArticleId IdType="pubmed">31408876</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandner MA, Drummond SPA. Who are the long sleepers? Towards an understanding of the mortality relationship. Sleep Med Rev. 2007;11(5):341-360. doi:10.1016/j.smrv.2007.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smrv.2007.03.010</ArticleId><ArticleId IdType="pmc">PMC3755488</ArticleId><ArticleId IdType="pubmed">17625932</ArticleId></ArticleIdList></Reference><Reference><Citation>Benito-Le&#xf3;n J, Louis ED, Bermejo-Pareja F. Cognitive decline in short and long sleepers: a prospective population-based study (NEDICES). J Psychiatr Res. 2013;47(12):1998-2003. doi:10.1016/j.jpsychires.2013.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2013.09.007</ArticleId><ArticleId IdType="pmc">PMC3839098</ArticleId><ArticleId IdType="pubmed">24094933</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Falvey CM, Hoang T. Connections between sleep and cognition in older adults. Lancet Neurol. 2014;13(10):1017-1028. doi:10.1016/S1474-4422(14)70172-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70172-3</ArticleId><ArticleId IdType="pubmed">25231524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemos R, Duro D, Sim&#xf5;es MR, Santana I. The free and cued selective reminding test distinguishes frontotemporal dementia from Alzheimer&#x2019;s disease. Arch Clin Neuropsychol. 2014;29(7):670-679. doi:10.1093/arclin/acu031</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/arclin/acu031</ArticleId><ArticleId IdType="pmc">PMC4263917</ArticleId><ArticleId IdType="pubmed">25062746</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolazzo J, Xu K, Lavale A, et al. . Sleep symptomatology is associated with greater subjective cognitive concerns: findings from the community-based Healthy Brain Project. Sleep. 2021;zsab097. doi:10.1093/sleep/zsab097</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/zsab097</ArticleId><ArticleId IdType="pmc">PMC8436141</ArticleId><ArticleId IdType="pubmed">33838045</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng Y, Wainwright NWJ, Cappuccio FP, et al. . Self-reported sleep patterns in a British population cohort. Sleep Med. 2014;15(3):295-302. doi:10.1016/j.sleep.2013.10.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC3988958</ArticleId><ArticleId IdType="pubmed">24503473</ArticleId></ArticleIdList></Reference><Reference><Citation>George KM, Peterson RL, Gilsanz P, et al. . Racial/ethnic differences in sleep quality among older adults: Kaiser Healthy Aging and Diverse Life Experiences (KHANDLE) study. Ethn Dis. 2020;30(3):469-478. doi:10.18865/ed.30.3.469</Citation><ArticleIdList><ArticleId IdType="doi">10.18865/ed.30.3.469</ArticleId><ArticleId IdType="pmc">PMC7360172</ArticleId><ArticleId IdType="pubmed">32742152</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandner MA, Williams NJ, Knutson KL, Roberts D, Jean-Louis G. Sleep disparity, race/ethnicity, and socioeconomic position. Sleep Med. 2016;18:7-18. doi:10.1016/j.sleep.2015.01.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2015.01.020</ArticleId><ArticleId IdType="pmc">PMC4631795</ArticleId><ArticleId IdType="pubmed">26431755</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamatakis KA, Kaplan GA, Roberts RE. Short sleep duration across income, education, and race/ethnic groups: population prevalence and growing disparities during 34 years of follow-up. Ann Epidemiol. 2007;17(12):948-955. doi:10.1016/j.annepidem.2007.07.096</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annepidem.2007.07.096</ArticleId><ArticleId IdType="pmc">PMC2140008</ArticleId><ArticleId IdType="pubmed">17855122</ArticleId></ArticleIdList></Reference><Reference><Citation>Whinnery J, Jackson N, Rattanaumpawan P, Grandner MA. Short and long sleep duration associated with race/ethnicity, sociodemographics, and socioeconomic position. Sleep. 2014;37(3):601-611. doi:10.5665/sleep.3508</Citation><ArticleIdList><ArticleId IdType="doi">10.5665/sleep.3508</ArticleId><ArticleId IdType="pmc">PMC3920327</ArticleId><ArticleId IdType="pubmed">24587584</ArticleId></ArticleIdList></Reference><Reference><Citation>Slopen N, Williams DR. Discrimination, other psychosocial stressors, and self-reported sleep duration and difficulties. Sleep. 2014;37(1):147-156. doi:10.5665/sleep.3326</Citation><ArticleIdList><ArticleId IdType="doi">10.5665/sleep.3326</ArticleId><ArticleId IdType="pmc">PMC3865350</ArticleId><ArticleId IdType="pubmed">24381373</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas KS, Bardwell WA, Ancoli-Israel S, Dimsdale JE. The toll of ethnic discrimination on sleep architecture and fatigue. Health Psychol. 2006;25(5):635-642. doi:10.1037/0278-6133.25.5.635</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0278-6133.25.5.635</ArticleId><ArticleId IdType="pubmed">17014281</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty DL, Hall MH, Kamarck TA, et al. . Unfair treatment is associated with poor sleep in African American and Caucasian adults: Pittsburgh SleepSCORE project. Health Psychol. 2011;30(3):351-359. doi:10.1037/a0022976</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/a0022976</ArticleId><ArticleId IdType="pmc">PMC3131074</ArticleId><ArticleId IdType="pubmed">21553979</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman NG, Izci-Balserak B, Schopfer E, et al. . Sleep duration versus sleep insufficiency as predictors of cardiometabolic health outcomes. Sleep Med. 2012;13(10):1261-1270. doi:10.1016/j.sleep.2012.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2012.08.005</ArticleId><ArticleId IdType="pmc">PMC3527631</ArticleId><ArticleId IdType="pubmed">23141932</ArticleId></ArticleIdList></Reference><Reference><Citation>Knutson KL. Sleep duration and cardiometabolic risk: a review of the epidemiologic evidence. Best Pract Res Clin Endocrinol Metab. 2010;24(5):731-743. doi:10.1016/j.beem.2010.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2010.07.001</ArticleId><ArticleId IdType="pmc">PMC3011978</ArticleId><ArticleId IdType="pubmed">21112022</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu DC, Mormino EC, Schultz AP, et al. ; Harvard Aging Brain Study . Lower late-life body-mass index is associated with higher cortical amyloid burden in clinically normal elderly. J Alzheimers Dis. 2016;53(3):1097-1105. doi:10.3233/JAD-150987</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150987</ArticleId><ArticleId IdType="pmc">PMC4976009</ArticleId><ArticleId IdType="pubmed">27340843</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng Y, Redline S, Stone KL, Ancoli-Israel S, Yaffe K. Objective napping, cognitive decline, and risk of cognitive impairment in older men. Alzheimers Dement. 2019;15(8):1039-1047. doi:10.1016/j.jalz.2019.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.04.009</ArticleId><ArticleId IdType="pmc">PMC6699896</ArticleId><ArticleId IdType="pubmed">31227429</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Laffan AM, Harrison SL, et al. . Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA. 2011;306(6):613-619. doi:10.1001/jama.2011.1115</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2011.1115</ArticleId><ArticleId IdType="pmc">PMC3600944</ArticleId><ArticleId IdType="pubmed">21828324</ArticleId></ArticleIdList></Reference><Reference><Citation>Osorio RS, Gumb T, Pirraglia E, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Sleep-disordered breathing advances cognitive decline in the elderly. Neurology. 2015;84(19):1964-1971. doi:10.1212/WNL.0000000000001566</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001566</ArticleId><ArticleId IdType="pmc">PMC4433459</ArticleId><ArticleId IdType="pubmed">25878183</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju Y-ES, Finn MB, Sutphen CL, et al. . Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluid. Ann Neurol. 2016;80(1):154-159. doi:10.1002/ana.24672</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24672</ArticleId><ArticleId IdType="pmc">PMC5120585</ArticleId><ArticleId IdType="pubmed">27129429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma RA, Varga AW, Bubu OM, et al. . Obstructive sleep apnea severity affects amyloid burden in cognitively normal elderly. A longitudinal study. Am J Respir Crit Care Med. 2018;197(7):933-943. doi:10.1164/rccm.201704-0704OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201704-0704OC</ArticleId><ArticleId IdType="pmc">PMC6020410</ArticleId><ArticleId IdType="pubmed">29125327</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9; C, Rehel S, Kuhn E, et al. ; Medit-Ageing Research Group . Association of sleep-disordered breathing with Alzheimer disease biomarkers in community-dwelling older adults: a secondary analysis of a randomized clinical trial. JAMA Neurol. 2020;77(6):716-724. doi:10.1001/jamaneurol.2020.0311</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0311</ArticleId><ArticleId IdType="pmc">PMC7091393</ArticleId><ArticleId IdType="pubmed">32202593</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubu OM, Pirraglia E, Andrade AG, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Obstructive sleep apnea and longitudinal Alzheimer&#x2019;s disease biomarker changes. Sleep. 2019;42(6):zsz048. doi:10.1093/sleep/zsz048</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/zsz048</ArticleId><ArticleId IdType="pmc">PMC6765111</ArticleId><ArticleId IdType="pubmed">30794315</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte RLM, Mendes BA, Oliveira-E-S&#xe1; TS, Magalh&#xe3;es-da-Silveira FJ, Gozal D. Perception of sleep duration in adult patients with suspected obstructive sleep apnea. PLoS One. 2020;15(8):e0238083. doi:10.1371/journal.pone.0238083</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0238083</ArticleId><ArticleId IdType="pmc">PMC7451567</ArticleId><ArticleId IdType="pubmed">32853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauderdale DS, Knutson KL, Yan LL, Liu K, Rathouz PJ. Self-reported and measured sleep duration: how similar are they? Epidemiology. 2008;19(6):838-845. doi:10.1097/EDE.0b013e318187a7b0</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e318187a7b0</ArticleId><ArticleId IdType="pmc">PMC2785092</ArticleId><ArticleId IdType="pubmed">18854708</ArticleId></ArticleIdList></Reference><Reference><Citation>Landry GJ, Best JR, Liu-Ambrose T. Measuring sleep quality in older adults: a comparison using subjective and objective methods. Front Aging Neurosci. 2015;7:166. doi:10.3389/fnagi.2015.00166</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2015.00166</ArticleId><ArticleId IdType="pmc">PMC4561455</ArticleId><ArticleId IdType="pubmed">26441633</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews KA, Patel SR, Pantesco EJ, et al. . Similarities and differences in estimates of sleep duration by polysomnography, actigraphy, diary, and self-reported habitual sleep in a community sample. Sleep Health. 2018;4(1):96-103. doi:10.1016/j.sleh.2017.10.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleh.2017.10.011</ArticleId><ArticleId IdType="pmc">PMC5771411</ArticleId><ArticleId IdType="pubmed">29332687</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan KA, Hardas PP, Redline S, Zeitzer JM; Sleep Heart Health Study Research Group . Correlates of sleep quality in midlife and beyond: a machine learning analysis. Sleep Med. 2017;34:162-167. doi:10.1016/j.sleep.2017.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2017.03.004</ArticleId><ArticleId IdType="pmc">PMC5456454</ArticleId><ArticleId IdType="pubmed">28522086</ArticleId></ArticleIdList></Reference><Reference><Citation>Buysse DJ. Sleep health: can we define it? Does it matter? Sleep. 2014;37(1):9-17. doi:10.5665/sleep.3298</Citation><ArticleIdList><ArticleId IdType="doi">10.5665/sleep.3298</ArticleId><ArticleId IdType="pmc">PMC3902880</ArticleId><ArticleId IdType="pubmed">24470692</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34469725</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Long-term depression links amyloid-&#x3b2; to the pathological hyperphosphorylation of tau.</ArticleTitle><Pagination><StartPage>109638</StartPage><MedlinePgn>109638</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">109638</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2021.109638</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(21)01081-0</ELocationID><Abstract><AbstractText>In Alzheimer's disease, soluble oligomers of the amyloid-&#x3b2; peptide (A&#x3b2;<sub>o</sub>) trigger a cascade of events that includes abnormal hyperphosphorylation of the protein tau, which is essential for pathogenesis. However, the mechanistic link between these two key pathological proteins remains unclear. Using hippocampal slices, we show here that an A&#x3b2;<sub>o</sub>-mediated increase in glutamate release probability causes enhancement of synaptically evoked N-methyl-d-aspartate subtype glutamate receptor (NMDAR)-dependent long-term depression (LTD). We also find that elevated glutamate release probability is required for A&#x3b2;<sub>o</sub>-induced pathological hyperphosphorylation of tau, which is likewise NMDAR dependent. Finally, we show that chronic, repeated chemical or optogenetic induction of NMDAR-dependent LTD alone is sufficient to cause tau hyperphosphorylation without A&#x3b2;<sub>o</sub>. Together, these results support a possible causal chain in which A&#x3b2;<sub>o</sub> increases glutamate release probability, thus leading to enhanced LTD induction, which in turn drives hyperphosphorylation of tau. Our data identify a mechanistic pathway linking the two critical pathogenic proteins of&#xa0;AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Henry B C</ForeName><Initials>HBC</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emptage</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK. Electronic address: nigel.emptage@pharm.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeans</LastName><ForeName>Alexander F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK. Electronic address: alexander.jeans@pharm.ox.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BB/J018724/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0501572</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0802812</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558298">Mapt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489131">Mapt protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="N">Excitatory Postsynaptic Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036881" MajorTopicYN="Y">Long-Term Synaptic Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyloid-&#x3b2;</Keyword><Keyword MajorTopicYN="N">long-term depression</Keyword><Keyword MajorTopicYN="N">neurotransmitter release</Keyword><Keyword MajorTopicYN="N">phosphorylation</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>1</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34469725</ArticleId><ArticleId IdType="pmc">PMC8424646</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.109638</ArticleId><ArticleId IdType="pii">S2211-1247(21)01081-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association 2020 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2020;16:391&#x2013;460.</Citation></Reference><Reference><Citation>Arnth-Jensen N., Jabaudon D., Scanziani M. Cooperation between independent hippocampal synapses is controlled by glutamate uptake. Nat. Neurosci. 2002;5:325&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">11896395</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibow S., Ozenne V., Biernat J., Blackledge M., Mandelkow E., Zweckstetter M. Structural impact of proline-directed pseudophosphorylation at AT8, AT100, and PHF1 epitopes on 441-residue tau. J.&#xa0;Am. Chem. Soc. 2011;133:15842&#x2013;15845.</Citation><ArticleIdList><ArticleId IdType="pubmed">21910444</ArticleId></ArticleIdList></Reference><Reference><Citation>Billingsley M.L., Kincaid R.L. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem. J. 1997;323:577&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1218358</ArticleId><ArticleId IdType="pubmed">9169588</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak E., Braak H., Mandelkow E.M. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. 1994;87:554&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">7522386</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley C.A., Peineau S., Taghibiglou C., Nicolas C.S., Whitcomb D.J., Bortolotto Z.A., Kaang B.K., Cho K., Wang Y.T., Collingridge G.L. A pivotal role of GSK-3 in synaptic plasticity. Front. Mol. Neurosci. 2012;5:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3279748</ArticleId><ArticleId IdType="pubmed">22363262</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramblett G.T., Goedert M., Jakes R., Merrick S.E., Trojanowski J.Q., Lee V.M. Abnormal tau phosphorylation at Ser396 in Alzheimer&#x2019;s disease recapitulates development and contributes to reduced microtubule binding. Neuron. 1993;10:1089&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">8318230</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito-Moreira J., Paula-Lima A.C., Bomfim T.R., Oliveira F.B., Sep&#xfa;lveda F.J., De Mello F.G., Aguayo L.G., Panizzutti R., Ferreira S.T. A&#x3b2; oligomers induce glutamate release from hippocampal neurons. Curr. Alzheimer Res. 2011;8:552&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">21244351</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche M.A., Konnerth A. Impairments of neural circuit function in Alzheimer&#x2019;s disease. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2016;371:20150429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4938029</ArticleId><ArticleId IdType="pubmed">27377723</ArticleId></ArticleIdList></Reference><Reference><Citation>Butner K.A., Kirschner M.W. Tau protein binds to microtubules through a flexible array of distributed weak sites. J.&#xa0;Cell Biol. 1991;115:717&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289193</ArticleId><ArticleId IdType="pubmed">1918161</ArticleId></ArticleIdList></Reference><Reference><Citation>Chromy B.A., Nowak R.J., Lambert M.P., Viola K.L., Chang L., Velasco P.T., Jones B.W., Fernandez S.J., Lacor P.N., Horowitz P. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry. 2003;42:12749&#x2013;12760.</Citation><ArticleIdList><ArticleId IdType="pubmed">14596589</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Xiong Z., Chen P., Wei J., Chen S., Yan Z. &#x3b2;-amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3. Neurobiol. Aging. 2014;35:449&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7034321</ArticleId><ArticleId IdType="pubmed">24094580</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolev I., Fogel H., Milshtein H., Berdichevsky Y., Lipstein N., Brose N., Gazit N., Slutsky I. Spike bursts increase amyloid-&#x3b2; 40/42 ratio by inducing a presenilin-1 conformational change. Nat. Neurosci. 2013;16:587&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">23563578</ArticleId></ArticleIdList></Reference><Reference><Citation>Drubin D.G., Kirschner M.W. Tau protein function in living cells. J.&#xa0;Cell Biol. 1986;103:2739&#x2013;2746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2114585</ArticleId><ArticleId IdType="pubmed">3098742</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutar P., Potier B. Susceptibility to A&#x3b2;o and TBOA of LTD and Extrasynaptic NMDAR-Dependent Tonic Current in the Aged Rat Hippocampus. Neurochem. Res. 2019;44:692&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">30426348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira S.T., Lourenco M.V., Oliveira M.M., De Felice F.G. Soluble amyloid-&#x3b2; oligomers as synaptotoxins leading to cognitive impairment in Alzheimer&#x2019;s disease. Front. Cell. Neurosci. 2015;9:191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4443025</ArticleId><ArticleId IdType="pubmed">26074767</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster W.J., Taylor H.B.C., Padamsey Z., Jeans A.F., Galione A., Emptage N.J. Hippocampal mGluR1-dependent long-term potentiation requires NAADP-mediated acidic store Ca2+ signaling. Sci. Signal. 2018;11:eaat9093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6679716</ArticleId><ArticleId IdType="pubmed">30482851</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Jakes R., Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci. Lett. 1995;189:167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogolla N., Galimberti I., DePaola V., Caroni P. Preparation of organotypic hippocampal slice cultures for long-term live imaging. Nat. Protoc. 2006;1:1165&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406399</ArticleId></ArticleIdList></Reference><Reference><Citation>Griebel G., Stemmelin J., Lopez-Grancha M., Boulay D., Boquet G., Slowinski F., Pichat P., Beesk&#xe9; S., Tanaka S., Mori A. The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer&#x2019;s disease in rodents. Sci. Rep. 2019;9:18045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6888874</ArticleId><ArticleId IdType="pubmed">31792284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J.A., Higgins G.A. Alzheimer&#x2019;s disease: the amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Wei M., Wu Y., Qin H., Li W., Ma X., Cheng J., Ren J., Shen Y., Chen Z. Amyloid &#x3b2; oligomers suppress excitatory transmitter release via presynaptic depletion of phosphatidylinositol-4,5-bisphosphate. Nat. Commun. 2019;10:1193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416269</ArticleId><ArticleId IdType="pubmed">30867420</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer&#x2019;s disease. J.&#xa0;Neurochem. 2008;104:1433&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073119</ArticleId><ArticleId IdType="pubmed">18088381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H., Boehm J., Sato C., Iwatsubo T., Tomita T., Sisodia S., Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu S., Begum A.N., Jones M.R., Oh M.S., Beech W.K., Beech B.H., Yang F., Chen P., Ubeda O.J., Kim P.C. GSK3 inhibitors show benefits in an Alzheimer&#x2019;s disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol. Dis. 2009;33:193&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4313761</ArticleId><ArticleId IdType="pubmed">19038340</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., W&#xf6;lfing H., Chieng B.C., Christie M.J., Napier I.A. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer&#x2019;s disease mouse models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeans A., Padamsey Z., Taylor H., Weglinski C., Collins H., Bannerman D., Foster W.J., Klein W.L., van den Maagdenberg A., Emptage N. Partial Suppression of Cav2.1 Function Prevents Synaptic and Behavioral Impairments in Alzheimer&#x2019;s Disease Models. SSRN. 2020 doi: 10.2139/ssrn.3701260.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3701260</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeganathan S., Hascher A., Chinnathambi S., Biernat J., Mandelkow E.M., Mandelkow E. Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau&#xa0;and generates a pathological (MC-1) conformation. J.&#xa0;Biol. Chem. 2008;283:32066&#x2013;32076.</Citation><ArticleIdList><ArticleId IdType="pubmed">18725412</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo J., Whitcomb D.J., Olsen K.M., Kerrigan T.L., Lo S.C., Bru-Mercier G., Dickinson B., Scullion S., Sheng M., Collingridge G., Cho K. A&#x3b2;(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3&#x3b2;. Nat. Neurosci. 2011;14:545&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">21441921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabogo D., Rauw G., Amritraj A., Baker G., Kar S. &#xdf;-amyloid-related peptides potentiate K+-evoked glutamate release from adult rat hippocampal slices. Neurobiol. Aging. 2010;31:1164&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">18819729</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavalali E.T., Jorgensen E.M. Visualizing presynaptic function. Nat. Neurosci. 2014;17:10&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">24369372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp N., Bashir Z.I. Long-term depression: a cascade of induction and expression mechanisms. Prog. Neurobiol. 2001;65:339&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">11527572</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T., Whitcomb D.J., Jo J., Regan P., Piers T., Heo S., Brown C., Hashikawa T., Murayama M., Seok H. Microtubule-associated protein tau is essential for long-term depression in the hippocampus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2013;369:20130144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843876</ArticleId><ArticleId IdType="pubmed">24298146</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein W.L. Abeta toxicity in Alzheimer&#x2019;s disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 2002;41:345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopeikina K.J., Hyman B.T., Spires-Jones T.L. Soluble forms of tau are toxic in Alzheimer&#x2019;s disease. Transl. Neurosci. 2012;3:223&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3460520</ArticleId><ArticleId IdType="pubmed">23029602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauretti E., Dincer O., Pratic&#xf2; D. Glycogen synthase kinase-3 signaling in Alzheimer&#x2019;s disease. Biochim. Biophys. Acta Mol. Cell Res. 2020;1867:118664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7047718</ArticleId><ArticleId IdType="pubmed">32006534</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G., Neve R.L., Kosik K.S. The microtubule binding domain of tau protein. Neuron. 1989;2:1615&#x2013;1624.</Citation><ArticleIdList><ArticleId IdType="pubmed">2516729</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.K., Kameyama K., Huganir R.L., Bear M.F. NMDA induces long-term synaptic depression and dephosphorylation of the GluR1 subunit of AMPA receptors in hippocampus. Neuron. 1998;21:1151&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856470</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Hong S., Shepardson N.E., Walsh D.M., Shankar G.M., Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62:788&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Jin M., Koeglsperger T., Shepardson N.E., Shankar G.M., Selkoe D.J. Soluble A&#x3b2; oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J.&#xa0;Neurosci. 2011;31:6627&#x2013;6638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F., Iqbal K., Grundke-Iqbal I., Gong C.X. Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett. 2002;530:209&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">12387894</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozovaya N.A., Kopanitsa M.V., Boychuk Y.A., Krishtal O.A. Enhancement of glutamate release uncovers spillover-mediated transmission by N-methyl-D-aspartate receptors in the rat hippocampus. Neuroscience. 1999;91:1321&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391439</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;scher C., Malenka R.C. NMDA receptor-dependent long-term potentiation and long-term depression (LTP/LTD) Cold Spring Harb. Perspect. Biol. 2012;4:a005710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367554</ArticleId><ArticleId IdType="pubmed">22510460</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow E.M., Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med. 2012;2:a006247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385935</ArticleId><ArticleId IdType="pubmed">22762014</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondrag&#xf3;n-Rodr&#xed;guez S., Trillaud-Doppia E., Dudilot A., Bourgeois C., Lauzon M., Leclerc N., Boehm J. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. J.&#xa0;Biol. Chem. 2012;287:32040&#x2013;32053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3442535</ArticleId><ArticleId IdType="pubmed">22833681</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondrag&#xf3;n-Rodr&#xed;guez S., Perry G., Luna-Mu&#xf1;oz J., Acevedo-Aquino M.C., Williams S. Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer&#x2019;s disease and Down syndrome. Neuropathol. Appl. Neurobiol. 2014;40:121&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">24033439</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Garcia J.A., Luna-Medina R., Alonso-Gil S., Sanz-Sancristobal M., Palomo V., Gil C., Santos A., Martinez A., Perez-Castillo A. Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in&#xa0;vitro and in&#xa0;vivo. ACS Chem. Neurosci. 2012;3:963&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3503340</ArticleId><ArticleId IdType="pubmed">23173075</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L., Selkoe D.J. Neurotoxicity of amyloid &#x3b2;-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2012;2:a006338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Neddens J., Temmel M., Flunkert S., Kerschbaumer B., Hoeller C., Loeffler T., Niederkofler V., Daum G., Attems J., Hutter-Paier B. Phosphorylation of different tau sites during progression of Alzheimer&#x2019;s disease. Acta Neuropathol. Commun. 2018;6:52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027763</ArticleId><ArticleId IdType="pubmed">29958544</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmrich V., Grimm C., Draguhn A., Barghorn S., Lehmann A., Schoemaker H., Hillen H., Gross G., Ebert U., Bruehl C. Amyloid &#x3b2; oligomers (A &#x3b2;(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J.&#xa0;Neurosci. 2008;28:788&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671006</ArticleId><ArticleId IdType="pubmed">18216187</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr M.E., Sullivan A.C., Frost B. A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies. Trends Pharmacol. Sci. 2017;38:637&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5476494</ArticleId><ArticleId IdType="pubmed">28455089</ArticleId></ArticleIdList></Reference><Reference><Citation>Papouin T., Oliet S.H. Organization, control and function of extrasynaptic NMDA receptors. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2014;369:20130601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4173287</ArticleId><ArticleId IdType="pubmed">25225095</ArticleId></ArticleIdList></Reference><Reference><Citation>Papouin T., Lad&#xe9;p&#xea;che L., Ruel J., Sacchi S., Labasque M., Hanini M., Groc L., Pollegioni L., Mothet J.-P., Oliet S.H. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell. 2012;150:633&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">22863013</ArticleId></ArticleIdList></Reference><Reference><Citation>Penn A.C., Zhang C.L., Georges F., Royer L., Breillat C., Hosy E., Petersen J.D., Humeau Y., Choquet D. Hippocampal LTP and contextual learning require surface diffusion of AMPA receptors. Nature. 2017;549:384&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5683353</ArticleId><ArticleId IdType="pubmed">28902836</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickett E.K., Herrmann A.G., McQueen J., Abt K., Dando O., Tulloch J., Jain P., Dunnett S., Sohrabi S., Fjeldstad M.P. Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of Alzheimer&#x2019;s Disease. Cell Rep. 2019;29:3592&#x2013;3604.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6915767</ArticleId><ArticleId IdType="pubmed">31825838</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport M., Dawson H.N., Binder L.I., Vitek M.P., Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA. 2002;99:6364&#x2013;6369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122954</ArticleId><ArticleId IdType="pubmed">11959919</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan P., Piers T., Yi J.-H., Kim D.-H., Huh S., Park S.J., Ryu J.H., Whitcomb D.J., Cho K. Tau phosphorylation at serine 396 residue is required for hippocampal LTD. J.&#xa0;Neurosci. 2015;35:4804&#x2013;4812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4389589</ArticleId><ArticleId IdType="pubmed">25810511</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth R.H., Cudmore R.H., Tan H.L., Hong I., Zhang Y., Huganir R.L. Cortical Synaptic AMPA Receptor Plasticity during Motor Learning. Neuron. 2020;105:895&#x2013;908.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7060107</ArticleId><ArticleId IdType="pubmed">31901303</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell C.L., Semerdjieva S., Empson R.M., Austen B.M., Beesley P.W., Alifragis P. Amyloid-&#x3b2; acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2. PLoS ONE. 2012;7:e43201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3419646</ArticleId><ArticleId IdType="pubmed">22905234</ArticleId></ArticleIdList></Reference><Reference><Citation>Seren&#xf3; L., Coma M., Rodr&#xed;guez M., S&#xe1;nchez-Ferrer P., S&#xe1;nchez M.B., Gich I., Agull&#xf3; J.M., P&#xe9;rez M., Avila J., Guardia-Laguarta C. A novel GSK-3beta inhibitor reduces Alzheimer&#x2019;s pathology and rescues neuronal loss in&#xa0;vivo. Neurobiol. Dis. 2009;35:359&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">19523516</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat. Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shipton O.A., Leitz J.R., Dworzak J., Acton C.E., Tunbridge E.M., Denk F., Dawson H.N., Vitek M.P., Wade-Martins R., Paulsen O., Vargas-Caballero M. Tau protein is required for amyloid beta-induced impairment of hippocampal long-term potentiation. J.&#xa0;Neurosci. 2011;31:1688&#x2013;1692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836238</ArticleId><ArticleId IdType="pubmed">21289177</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S.A., Duff K. Linking Abeta and tau in late-onset Alzheimer&#x2019;s disease: a dual pathway hypothesis. Neuron. 2008;60:534&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692134</ArticleId><ArticleId IdType="pubmed">19038212</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones T.L., Hyman B.T. The intersection of amyloid beta and tau at synapses in Alzheimer&#x2019;s disease. Neuron. 2014;82:756&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135182</ArticleId><ArticleId IdType="pubmed">24853936</ArticleId></ArticleIdList></Reference><Reference><Citation>Styr B., Slutsky I. Imbalance between firing homeostasis and synaptic plasticity drives early-phase Alzheimer&#x2019;s disease. Nat. Neurosci. 2018;21:463&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6533171</ArticleId><ArticleId IdType="pubmed">29403035</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson E., Breckenridge L., McMahon L., Som S., McConnell I., Bloom G.S. Extracellular Tau Oligomers Induce Invasion of Endogenous Tau into the Somatodendritic Compartment and Axonal Transport Dysfunction. J.&#xa0;Alzheimers Dis. 2017;58:803&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5581403</ArticleId><ArticleId IdType="pubmed">28482642</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer&#x2019;s disease. J.&#xa0;Alzheimers Dis. 2006;9(Suppl 3):309&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914869</ArticleId></ArticleIdList></Reference><Reference><Citation>Talantova M., Sanz-Blasco S., Zhang X., Xia P., Akhtar M.W., Okamoto S., Dziewczapolski G., Nakamura T., Cao G., Pratt A.E. A&#x3b2; induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl. Acad. Sci. USA. 2013;110:E2518&#x2013;E2527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3704025</ArticleId><ArticleId IdType="pubmed">23776240</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong R., Emptage N.J., Padamsey Z. A two-compartment model of synaptic computation and plasticity. Mol. Brain. 2020;13:79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7238589</ArticleId><ArticleId IdType="pubmed">32434549</ArticleId></ArticleIdList></Reference><Reference><Citation>Velasco P.T., Heffern M.C., Sebollela A., Popova I.A., Lacor P.N., Lee K.B., Sun X., Tiano B.N., Viola K.L., Eckermann A.L. Synapse-binding subpopulations of A&#x3b2; oligomers sensitive to peptide assembly blockers and scFv antibodies. ACS Chem. Neurosci. 2012;3:972&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3503444</ArticleId><ArticleId IdType="pubmed">23173076</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in&#xa0;vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.Z., Wu Q., Smith A., Grundke-Iqbal I., Iqbal K. Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its&#xa0;biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett. 1998;436:28&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">9771888</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi J.H., Baek S.J., Heo S., Park H.J., Kwon H., Lee S., Jung J., Park S.J., Kim B.C., Lee Y.C. Direct pharmacological Akt activation rescues Alzheimer&#x2019;s disease like memory impairments and aberrant synaptic plasticity. Neuropharmacology. 2018;128:282&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">29079294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakharenko S.S., Zablow L., Siegelbaum S.A. Visualization of changes in presynaptic function during long-term synaptic plasticity. Nat. Neurosci. 2001;4:711&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">11426227</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H., Luedtke J., Kumar Y., Biernat J., Dawson H., Mandelkow E., Mandelkow E.M. Amyloid-&#x3b2; oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J. 2013;32:2920&#x2013;2937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831312</ArticleId><ArticleId IdType="pubmed">24065130</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34473944</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>21</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>03</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Stem cell-derived neurons reflect features of protein networks, neuropathology, and cognitive outcome of their aged human donors.</ArticleTitle><Pagination><StartPage>3402</StartPage><EndPage>3420.e9</EndPage><MedlinePgn>3402-3420.e9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2021.08.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(21)00578-X</ELocationID><Abstract><AbstractText>We have generated a controlled and manipulable resource that captures genetic risk for Alzheimer's disease: iPSC lines from 53 individuals coupled with RNA and proteomic profiling of both iPSC-derived neurons and brain tissue of the same individuals. Data collected for each person include genome sequencing, longitudinal cognitive scores, and quantitative neuropathology. The utility of this resource is exemplified here by analyses of neurons derived from these lines, revealing significant associations between specific A&#x3b2; and tau species and the levels of plaque and tangle deposition in the brain and, more importantly, with the trajectory of cognitive decline. Proteins and networks are identified that are associated with AD phenotypes in iPSC neurons, and relevant associations are validated in brain. The data presented establish this iPSC collection as a resource for investigating person-specific processes in the brain that can aid in identifying and validating molecular pathways underlying AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lagomarsino</LastName><ForeName>Valentina N</ForeName><Initials>VN</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearse</LastName><ForeName>Richard V</ForeName><Initials>RV</Initials><Suffix>2nd</Suffix><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Yi-Chen</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Marty A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinton</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paull</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>New York Stem Cell Foundation Research Institute, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felsky</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry and Institute of Medical Science, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tasaki</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaiteri</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology and the Taub Institute for the Study of Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muratore</LastName><ForeName>Christina R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benoit</LastName><ForeName>Courtney R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Vicky</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fancher</LastName><ForeName>Seeley B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merchant</LastName><ForeName>Julie P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duong</LastName><ForeName>Duc M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Emory School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Hector</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>New York Stem Cell Foundation Research Institute, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>New York Stem Cell Foundation Research Institute, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bah</LastName><ForeName>Fatmata</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vicent</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stricker</LastName><ForeName>Jonathan M S</ForeName><Initials>JMS</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jishu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dammer</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Emory School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chibnik</LastName><ForeName>Lori B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>Vilas</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology and the Taub Institute for the Study of Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seyfried</LastName><ForeName>Nicholas T</ForeName><Initials>NT</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Emory School of Medicine, Atlanta, GA, USA; Department of Neurology, Emory School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Center for Translational and Computational Neuroimmunology, Department of Neurology and the Taub Institute for the Study of Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noggle</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>New York Stem Cell Foundation Research Institute, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young-Pearse</LastName><ForeName>Tracy L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA. Electronic address: tpearse@bwh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG056011</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007753</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS117446</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057457</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061798</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG061356</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG030146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046170</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG055909</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061894</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG072572</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH118576</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS117446</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG036836</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s</Keyword><Keyword MajorTopicYN="N">A&#x3b2;</Keyword><Keyword MajorTopicYN="N">LOAD</Keyword><Keyword MajorTopicYN="N">MAPT</Keyword><Keyword MajorTopicYN="N">PP1</Keyword><Keyword MajorTopicYN="N">PRS</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">iPSC</Keyword><Keyword MajorTopicYN="N">neuron</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>Declaration of interests D.J.S. is a director and consultant for Prothena Biosciences.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>2</Day><Hour>20</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34473944</ArticleId><ArticleId IdType="mid">NIHMS1738198</ArticleId><ArticleId IdType="pmc">PMC8571042</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2021.08.003</ArticleId><ArticleId IdType="pii">S0896-6273(21)00578-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>ABUD EM, RAMIREZ RN, MARTINEZ ES, HEALY LM, NGUYEN CHH, NEWMAN SA, YEROMIN AV, SCARFONE VM, MARSH SE, FIMBRES C, CARAWAY CA, FOTE GM, MADANY AM, AGRAWAL A, KAYED R, GYLYS KH, CAHALAN MD, CUMMINGS BJ, ANTEL JP, MORTAZAVI A, CARSON MJ, POON WW &amp; BLURTON-JONES M 2017. iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases. Neuron, 94, 278&#x2013;293 e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference><Reference><Citation>AGGARWAL NT, WILSON RS, BECK TL, BIENIAS JL &amp; BENNETT DA 2005. Mild cognitive impairment in different functional domains and incident Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry, 76, 1479&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739422</ArticleId><ArticleId IdType="pubmed">16227534</ArticleId></ArticleIdList></Reference><Reference><Citation>BARNES LL, NELSON JK &amp; REUTER-LORENZ PA 2001. Object-based attention and object working memory: overlapping processes revealed by selective interference effects in humans. Prog Brain Res, 134, 471&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">11702562</ArticleId></ArticleIdList></Reference><Reference><Citation>BARNES LL, SCHNEIDER JA, BOYLE PA, BIENIAS JL &amp; BENNETT DA 2006. Memory complaints are related to Alzheimer disease pathology in older persons. Neurology, 67, 1581&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740723</ArticleId><ArticleId IdType="pubmed">17101887</ArticleId></ArticleIdList></Reference><Reference><Citation>BENNETT DA, BUCHMAN AS, BOYLE PA, BARNES LL, WILSON RS &amp; SCHNEIDER JA 2018. Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis, 64, S161&#x2013;S189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>BENNETT DA, SCHNEIDER JA, ARVANITAKIS Z &amp; WILSON RS 2012a. Overview and findings from the religious orders study. Curr Alzheimer Res, 9, 628&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>BENNETT DA, SCHNEIDER JA, BUCHMAN AS, BARNES LL, BOYLE PA &amp; WILSON RS 2012b. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res, 9, 646&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>BENNETT DA, SCHNEIDER JA, WILSON RS, BIENIAS JL &amp; ARNOLD SE 2004. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol, 61, 378&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>BENNETT DA, SCHNEIDER JA, WILSON RS, BIENIAS JL &amp; ARNOLD SE 2005. Education modifies the association of amyloid but not tangles with cognitive function. Neurology, 65, 953&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16186546</ArticleId></ArticleIdList></Reference><Reference><Citation>BENTAHIR M, NYABI O, VERHAMME J, TOLIA A, HORRE K, WILTFANG J, ESSELMANN H &amp; DE STROOPER B 2006. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem, 96, 732&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>BERECZKI E, FRANCIS PT, HOWLETT D, PEREIRA JB, HOGLUND K, BOGSTEDT A, CEDAZO-MINGUEZ A, BAEK JH, HORTOBAGYI T, ATTEMS J, BALLARD C &amp; AARSLAND D 2016. Synaptic proteins predict cognitive decline in Alzheimer&#x2019;s disease and Lewy body dementia. Aizheimers Dement, 12, 1149&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pubmed">27224930</ArticleId></ArticleIdList></Reference><Reference><Citation>BERTRAM L, LILL CM &amp; TANZI RE 2010. The genetics of Alzheimer disease: back to the future. Neuron, 68, 270&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">20955934</ArticleId></ArticleIdList></Reference><Reference><Citation>BRAY NL, PIMENTEL H, MELSTED P &amp; PACHTER L 2016. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 34, 525&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27043002</ArticleId></ArticleIdList></Reference><Reference><Citation>CANALS I, GINISTY A, QUIST E, TIMMERMAN R, FRITZE J, MISKINYTE G, MONNI E, HANSEN MG, HIDALGO I, BRYDER D, BENGZON J &amp; AHLENIUS H 2018. Rapid and efficient induction of functional astrocytes from human pluripotent stem cells. Nat Methods, 15, 693&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">30127505</ArticleId></ArticleIdList></Reference><Reference><Citation>CANCHI S, RAAO B, MASLIAH D, ROSENTHAL SB, SASIK R, FISCH KM, DE JAGER PL, BENNETT DA &amp; RISSMAN RA 2019. Integrating Gene and Protein Expression Reveals Perturbed Functional Networks in Alzheimer&#x2019;s Disease. Cell Rep, 28, 1103&#x2013;1116 e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7503200</ArticleId><ArticleId IdType="pubmed">31340147</ArticleId></ArticleIdList></Reference><Reference><Citation>CHALFANT CE, KISHIKAWA K, MUMBY MC, KAMIBAYASHI C, BIELAWSKA A &amp; HANNUN YA 1999. Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J Biol Chem, 274, 20313&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10400653</ArticleId></ArticleIdList></Reference><Reference><Citation>DOBROWSKY RT &amp; HANNUN YA 1992. Ceramide stimulates a cytosolic protein phosphatase. J Biol Chem, 267, 5048&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">1312082</ArticleId></ArticleIdList></Reference><Reference><Citation>DUDBRIDGE F 2013. Power and predictive accuracy of polygenic risk scores. PLoS Genet, 9, e1003348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605113</ArticleId><ArticleId IdType="pubmed">23555274</ArticleId></ArticleIdList></Reference><Reference><Citation>DUJARDIN S, COMMINS C, LATHUILIERE A, BEEREPOOT P, FERNANDES AR, KAMATH TV, DE LOS SANTOS MB, KLICKSTEIN N, CORJUC DL, CORJUC BT, DOOLEY PM, VIODE A, OAKLEY DH, MOORE BD, MULLIN K, JEAN-GILLES D, CLARK R, ATCHISON K, MOORE R, CHIBNIK LB, TANZI RE, FROSCH MP, SERRANO-POZO A, ELWOOD F, STEEN JA, KENNEDY ME &amp; HYMAN BT 2020. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer&#x2019;s disease. Nat Med, 26, 1256&#x2013;1263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603860</ArticleId><ArticleId IdType="pubmed">32572268</ArticleId></ArticleIdList></Reference><Reference><Citation>FELSKY D, PATRICK E, SCHNEIDER JA, MOSTAFAVI S, GAITERI C, PATSOPOULOS N, BENNETT DA &amp; DE JAGER PL 2018. Polygenic analysis of inflammatory disease variants and effects on microglia in the aging brain. Mol Neurodegener, 13, 38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6057096</ArticleId><ArticleId IdType="pubmed">30041668</ArticleId></ArticleIdList></Reference><Reference><Citation>FELSKY D, ROOSTAEI T, NHO K, RISACHER SL, BRADSHAW EM, PETYUK V, SCHNEIDER JA, SAYKIN A, BENNETT DA &amp; DE JAGER PL 2019. Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. Nat Commun, 10, 409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6345810</ArticleId><ArticleId IdType="pubmed">30679421</ArticleId></ArticleIdList></Reference><Reference><Citation>GARCIA-ESPARCIA P, SIDERIS-LAMPRETSAS G, HERNANDEZ-ORTEGA K, GRAU-RIVERA O, SKLAVIADIS T, GELPI E &amp; FERRER I 2017. Altered mechanisms of protein synthesis in frontal cortex in Alzheimer disease and a mouse model. Am J Neurodegener Dis, 6, 15&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5498849</ArticleId><ArticleId IdType="pubmed">28695061</ArticleId></ArticleIdList></Reference><Reference><Citation>GOTZ J, CHEN F, VAN DORPE J &amp; NITSCH RM 2001. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science, 293, 1491&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>HO SM, HARTLEY BJ, TCW J, BEAUMONT M, STAFFORD K, SLESINGER PA &amp; BRENNAND KJ 2016. Rapid Ngn2-induction of excitatory neurons from hiPSC-derived neural progenitor cells. Methods, 101, 113&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860098</ArticleId><ArticleId IdType="pubmed">26626326</ArticleId></ArticleIdList></Reference><Reference><Citation>HSIEH YC, GUO C, YALAMANCHILI HK, ABREHA M, AL-OURAN R, LI Y, DAMMER EB, LAH JJ, LEVEY AI, BENNETT DA, DE JAGER PL, SEYFRIED NT, LIU Z &amp; SHULMAN JM 2019. Tau-Mediated Disruption of the Spliceosome Triggers Cryptic RNA Splicing and Neurodegeneration in Alzheimer&#x2019;s Disease. Cell Rep, 29, 301&#x2013;316 e10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919331</ArticleId><ArticleId IdType="pubmed">31597093</ArticleId></ArticleIdList></Reference><Reference><Citation>HUNG COY &amp; LIVESEY FJ 2018. Altered gamma-Secretase Processing of APP Disrupts Lysosome and Autophagosome Function in Monogenic Alzheimer&#x2019;s Disease. Cell Rep, 25, 3647&#x2013;3660 e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6315085</ArticleId><ArticleId IdType="pubmed">30590039</ArticleId></ArticleIdList></Reference><Reference><Citation>ISRAEL MA, YUAN SH, BARDY C, REYNA SM, MU Y, HERRERA C, HEFFERAN MP, VAN GORP S, NAZOR KL, BOSCOLO FS, CARSON CT, LAURENT LC, MARSALA M, GAGE FH, REMES AM, KOO EH &amp; GOLDSTEIN LS 2012. Probing sporadic and familial Alzheimer&#x2019;s disease using induced pluripotent stem cells. Nature, 482, 216&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>JANSEN IE, SAVAGE JE, WATANABE K, BRYOIS J, WILLIAMS DM, STEINBERG S, SEALOCK J, KARLSSON IK, HAGG S, ATHANASIU L, VOYLE N, PROITSI P, WITOELAR A, STRINGER S, AARSLAND D, ALMDAHL IS, ANDERSEN F, BERGH S, BETTELLA F, BJORNSSON S, BRAEKHUS A, BRATHEN G, DE LEEUW C, DESIKAN RS, DJUROVIC S, DUMITRESCU L, FLADBY T, HOHMAN TJ, JONSSON PV, KIDDLE SJ, RONGVE A, SALTVEDT I, SANDO SB, SELBAEK G, SHOAI M, SKENE NG, SNAEDAL J, STORDAL E, ULSTEIN ID, WANG Y, WHITE LR, HARDY J, HJERLING-LEFFLER J, SULLIVAN PF, VAN DER FLIER WM, DOBSON R, DAVIS LK, STEFANSSON H, STEFANSSON K, PEDERSEN NL, RIPKE S, ANDREASSEN OA &amp; POSTHUMA D 2019. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat Genet, 51, 404&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>JIN M, SHEPARDSON N, YANG T, CHEN G, WALSH D &amp; SELKOE DJ 2011. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A, 108, 5819&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>JOHNSON ECB, DAMMER EB, DUONG DM, PING L, ZHOU M, YIN L, HIGGINBOTHAM LA, GUAJARDO A, WHITE B, TRONCOSO JC, THAMBISETTY M, MONTINE TJ, LEE EB, TROJANOWSKI JQ, BEACH TG, REIMAN EM, HAROUTUNIAN V, WANG M, SCHADT E, ZHANG B, DICKSON DW, ERTEKIN-TANER N, GOLDE TE, PETYUK VA, DE JAGER PL, BENNETT DA, WINGO TS, RANGARAJU S, HAJJAR I, SHULMAN JM, LAH JJ, LEVEY AI &amp; SEYFRIED NT 2020. Large-scale proteomic analysis of Alzheimer&#x2019;s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405761</ArticleId><ArticleId IdType="pubmed">32284590</ArticleId></ArticleIdList></Reference><Reference><Citation>KANG HM, SUBRAMANIAM M, TARG S, NGUYEN M, MALISKOVA L, MCCARTHY E, WAN E, WONG S, BYRNES L, LANATA CM, GATE RE, MOSTAFAVI S, MARSON A, ZAITLEN N, CRISWELL LA &amp; YE CJ 2018. Multiplexed droplet single-cell RNA-sequencing using natural genetic variation. Nat Biotechnol, 36, 89&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5784859</ArticleId><ArticleId IdType="pubmed">29227470</ArticleId></ArticleIdList></Reference><Reference><Citation>KNOBLOCH M, FARINELLI M, KONIETZKO U, NITSCH RM &amp; MANSUY IM 2007. Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci, 27, 7648&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672892</ArticleId><ArticleId IdType="pubmed">17634359</ArticleId></ArticleIdList></Reference><Reference><Citation>KONDO T, ASAI M, TSUKITA K, KUTOKU Y, OHSAWA Y, SUNADA Y, IMAMURA K, EGAWA N, YAHATA N, OKITA K, TAKAHASHI K, ASAKA I, AOI T, WATANABE A, WATANABE K, KADOYA C, NAKANO R, WATANABE D, MARUYAMA K, HORI O, HIBINO S, CHOSHI T, NAKAHATA T, HIOKI H, KANEKO T, NAITOH M, YOSHIKAWA K, YAMAWAKI S, SUZUKI S, HATA R, UENO S, SEKI T, KOBAYASHI K, TODA T, MURAKAMI K, IRIE K, KLEIN WL, MORI H, ASADA T, TAKAHASHI R, IWATA N, YAMANAKA S &amp; INOUE H 2013. Modeling Alzheimer&#x2019;s disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell, 12, 487&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">23434393</ArticleId></ArticleIdList></Reference><Reference><Citation>KUNKLE BW, GRENIER-BOLEY B, SIMS R, BIS JC, DAMOTTE V, NAJ AC, BOLAND A, VRONSKAYA M, VAN DER LEE SJ, AMLIE-WOLF A, BELLENGUEZ C, FRIZATTI A, CHOURAKI V, MARTIN ER, SLEEGERS K, BADARINARAYAN N, JAKOBSDOTTIR J, HAMILTON-NELSON KL, MORENO-GRAU S, OLASO R, RAYBOULD R, CHEN Y, KUZMA AB, HILTUNEN M, MORGAN T, AHMAD S, VARDARAJAN BN, EPELBAUM J, HOFFMANN P, BOADA M, BEECHAM GW, GARNIER JG, HAROLD D, FITZPATRICK AL, VALLADARES O, MOUTET ML, GERRISH A, SMITH AV, QU L, BACQ D, DENNING N, JIAN X, ZHAO Y, DEL ZOMPO M, FOX NC, CHOI SH, MATEO I, HUGHES JT, ADAMS HH, MALAMON J, SANCHEZ-GARCIA F, PATEL Y, BRODY JA, DOMBROSKI BA, NARANJO MCD, DANIILIDOU M, EIRIKSDOTTIR G, MUKHERJEE S, WALLON D, UPHILL J, ASPELUND T, CANTWELL LB, GARZIA F, GALIMBERTI D, HOFER E, BUTKIEWICZ M, FIN B, SCARPINI E, SARNOWSKI C, BUSH WS, MESLAGE S, KORNHUBER J, WHITE CC, SONG Y, BARBER RC, ENGELBORGHS S, SORDON S, VOIJNOVIC D, ADAMS PM, VANDENBERGHE R, MAYHAUS M, CUPPLES LA, ALBERT MS, DE DEYN PP, GU W, HIMALI JJ, BEEKLY D, SQUASSINA A, HARTMANN AM, ORELLANA A, BLACKER D, RODRIGUEZ-RODRIGUEZ E, LOVESTONE S, GARCIA ME, DOODY RS, MUNOZ-FERNADEZ C, SUSSAMS R, LIN H, FAIRCHILD TJ, BENITO YA, et al. 2019. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet, 51, 414&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>KWART D, GREGG A, SCHECKEL C, MURPHY EA, PAQUET D, DUFFIELD M, FAK J, OLSEN O, DARNELL RB &amp; TESSIER-LAVIGNE M 2019. A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP beta-CTFs, Not Abeta. Neuron, 104, 256&#x2013;270 e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">31416668</ArticleId></ArticleIdList></Reference><Reference><Citation>LAMBERT JC, IBRAHIM-VERBAAS CA, HAROLD D, NAJ AC, SIMS R, BELLENGUEZ C, DESTAFANO AL, BIS JC, BEECHAM GW, GRENIER-BOLEY B, RUSSO G, THORTON-WELLS TA, JONES N, SMITH AV, CHOURAKI V, THOMAS C, IKRAM MA, ZELENIKA D, VARDARAJAN BN, KAMATANI Y, LIN CF, GERRISH A, SCHMIDT H, KUNKLE B, DUNSTAN ML, RUIZ A, BIHOREAU MT, CHOI SH, REITZ C, PASQUIER F, CRUCHAGA C, CRAIG D, AMIN N, BERR C, LOPEZ OL, DE JAGER PL, DERAMECOURT V, JOHNSTON JA, EVANS D, LOVESTONE S, LETENNEUR L, MORON FJ, RUBINSZTEIN DC, EIRIKSDOTTIR G, SLEEGERS K, GOATE AM, FIEVET N, HUENTELMAN MW, GILL M, BROWN K, KAMBOH MI, KELLER L, BARBERGER-GATEAU P, MCGUINESS B, LARSON EB, GREEN R, MYERS AJ, DUFOUIL C, TODD S, WALLON D, LOVE S, ROGAEVA E, GALLACHER J, ST GEORGE-HYSLOP P, CLARIMON J, LLEO A, BAYER A, TSUANG DW, YU L, TSOLAKI M, BOSSU P, SPALLETTA G, PROITSI P, COLLINGE J, SORBI S, SANCHEZ-GARCIA F, FOX NC, HARDY J, DENIZ NARANJO MC, BOSCO P, CLARKE R, BRAYNE C, GALIMBERTI D, MANCUSO M, MATTHEWS F, EUROPEAN ALZHEIMER&#x2019;S DISEASE, I., GENETIC, ENVIRONMENTAL RISK IN ALZHEIMER&#x2019;S, D., ALZHEIMER&#x2019;S DISEASE GENETIC, C., COHORTS FOR, H., AGING RESEARCH IN GENOMIC, E., MOEBUS S, MECOCCI P, DEL ZOMPO M, MAIER W, HAMPEL H, PILOTTO A, BULLIDO M, PANZA F, CAFFARRA P, et al. 2013. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet, 45, 1452&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>LIU L, LAURO BM, WOLFE MS &amp; SELKOE DJ 2021. Hydrophilic loop 1 of Presenilin-1 and the APP GxxxG transmembrane motif regulate gamma-secretase function in generating Alzheimer-causing Abeta peptides. J Biol Chem, 100393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7961089</ArticleId><ArticleId IdType="pubmed">33571524</ArticleId></ArticleIdList></Reference><Reference><Citation>MCQUADE A, COBURN M, TU CH, HASSELMANN J, DAVTYAN H &amp; BLURTON-JONES M 2018. Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol Neurodegener, 13, 67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6303871</ArticleId><ArticleId IdType="pubmed">30577865</ArticleId></ArticleIdList></Reference><Reference><Citation>MOORE S, EVANS LD, ANDERSSON T, PORTELIUS E, SMITH J, DIAS TB, SAURAT N, MCGLADE A, KIRWAN P, BLENNOW K, HARDY J, ZETTERBERG H &amp; LIVESEY FJ 2015. APP metabolism regulates tau proteostasis in human cerebral cortex neurons. Cell Rep, 11, 689&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4431668</ArticleId><ArticleId IdType="pubmed">25921538</ArticleId></ArticleIdList></Reference><Reference><Citation>MOOTHA VK, LINDGREN CM, ERIKSSON KF, SUBRAMANIAN A, SIHAG S, LEHAR J, PUIGSERVER P, CARLSSON E, RIDDERSTRALE M, LAURILA E, HOUSTIS N, DALY MJ, PATTERSON N, MESIROV JP, GOLUB TR, TAMAYO P, SPIEGELMAN B, LANDER ES, HIRSCHHORN JN, ALTSHULER D &amp; GROOP LC 2003. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet, 34, 267&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">12808457</ArticleId></ArticleIdList></Reference><Reference><Citation>MOSTAFAVI S, GAITERI C, SULLIVAN SE, WHITE CC, TASAKI S, XU J, TAGA M, KLEIN HU, PATRICK E, KOMASHKO V, MCCABE C, SMITH R, BRADSHAW EM, ROOT DE, REGEV A, YU L, CHIBNIK LB, SCHNEIDER JA, YOUNG-PEARSE TL, BENNETT DA &amp; DE JAGER PL 2018. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer&#x2019;s disease. Nat Neurosci, 21, 811&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6599633</ArticleId><ArticleId IdType="pubmed">29802388</ArticleId></ArticleIdList></Reference><Reference><Citation>MURATORE CR, RICE HC, SRIKANTH P, CALLAHAN DG, SHIN T, BENJAMIN L, WALSH DM, SELKOE DJ &amp; YOUNG-PEARSE TL 2014. The familial Alzheimer&#x2019;s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum Mol Genet, 23, 3523&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049307</ArticleId><ArticleId IdType="pubmed">24524897</ArticleId></ArticleIdList></Reference><Reference><Citation>MURATORE CR, ZHOU C, LIAO M, FERNANDEZ MA, TAYLOR WM, LAGOMARSINO VN, PEARSE RV 2ND, RICE HC, NEGRI JM, HE A, SRIKANTH P, CALLAHAN DG, SHIN T, ZHOU M, BENNETT DA, NOGGLE S, LOVE JC, SELKOE DJ &amp; YOUNG-PEARSE TL 2017. Cell-type Dependent Alzheimer&#x2019;s Disease Phenotypes: Probing the Biology of Selective Neuronal Vulnerability. Stem Cell Reports, 9, 1868&#x2013;1884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785690</ArticleId><ArticleId IdType="pubmed">29153990</ArticleId></ArticleIdList></Reference><Reference><Citation>NEGRI J, MENON V &amp; YOUNG-PEARSE TL 2020. Assessment of Spontaneous Neuronal Activity In Vitro Using Multi-Well Multi-Electrode Arrays: Implications for Assay Development. eNeuro, 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6984810</ArticleId><ArticleId IdType="pubmed">31896559</ArticleId></ArticleIdList></Reference><Reference><Citation>NEHME R, ZUCCARO E, GHOSH SD, LI C, SHERWOOD JL, PIETILAINEN O, BARRETT LE, LIMONE F, WORRINGER KA, KOMMINENI S, ZANG Y, CACCHIARELLI D, MEISSNER A, ADOLFSSON R, HAGGARTY S, MADISON J, MULLER M, ARLOTTA P, FU Z, FENG G &amp; EGGAN K 2018. Combining NGN2 Programming with Developmental Patterning Generates Human Excitatory Neurons with NMDAR-Mediated Synaptic Transmission. Cell Rep, 23, 2509&#x2013;2523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6003669</ArticleId><ArticleId IdType="pubmed">29791859</ArticleId></ArticleIdList></Reference><Reference><Citation>NG B, WHITE CC, KLEIN HU, SIEBERTS SK, MCCABE C, PATRICK E, XU J, YU L, GAITERI C, BENNETT DA, MOSTAFAVI S &amp; DE JAGER PL 2017. An xQTL map integrates the genetic architecture of the human brain&#x2019;s transcriptome and epigenome. Nat Neurosci, 20, 1418&#x2013;1426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785926</ArticleId><ArticleId IdType="pubmed">28869584</ArticleId></ArticleIdList></Reference><Reference><Citation>ODDO S, BILLINGS L, KESSLAK JP, CRIBBS DH &amp; LAFERLA FM 2004. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 43, 321&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>PANG ZP, YANG N, VIERBUCHEN T, OSTERMEIER A, FUENTES DR, YANG TQ, CITRI A, SEBASTIANO V, MARRO S, SUDHOF TC &amp; WERNIG M 2011. Induction of human neuronal cells by defined transcription factors. Nature, 476, 220&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3159048</ArticleId><ArticleId IdType="pubmed">21617644</ArticleId></ArticleIdList></Reference><Reference><Citation>PAULL D, SEVILLA A, ZHOU H, HAHN AK, KIM H, NAPOLITANO C, TSANKOV A, SHANG L, KRUMHOLZ K, JAGADEESAN P, WOODARD CM, SUN B, VILBOUX T, ZIMMER M, FORERO E, MOROZIEWICZ DN, MARTINEZ H, MALICDAN MC, WEISS KA, VENSAND LB, DUSENBERRY CR, POLUS H, SY KT, KAHLER DJ, GAHL WA, SOLOMON SL, CHANG S, MEISSNER A, EGGAN K &amp; NOGGLE SA Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. Nat Methods.</Citation><ArticleIdList><ArticleId IdType="pubmed">26237226</ArticleId></ArticleIdList></Reference><Reference><Citation>PAULL D, SEVILLA A, ZHOU H, HAHN AK, KIM H, NAPOLITANO C, TSANKOV A, SHANG L, KRUMHOLZ K, JAGADEESAN P, WOODARD CM, SUN B, VILBOUX T, ZIMMER M, FORERO E, MOROZIEWICZ DN, MARTINEZ H, MALICDAN MC, WEISS KA, VENSAND LB, DUSENBERRY CR, POLUS H, SY KT, KAHLER DJ, GAHL WA, SOLOMON SL, CHANG S, MEISSNER A, EGGAN K &amp; NOGGLE SA 2015. Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. Nat Methods, 12, 885&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">26237226</ArticleId></ArticleIdList></Reference><Reference><Citation>PIMENTEL H, BRAY NL, PUENTE S, MELSTED P &amp; PACHTER L 2017. Differential analysis of RNA-seq incorporating quantification uncertainty. Nat Methods, 14, 687&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">28581496</ArticleId></ArticleIdList></Reference><Reference><Citation>SCHEUNER D, ECKMAN C, JENSEN M, SONG X, CITRON M, SUZUKI N, BIRD TD, HARDY J, HUTTON M, KUKULL W, LARSON E, LEVY-LAHAD E, VIITANEN M, PESKIND E, POORKAJ P, SCHELLENBERG G, TANZI R, WASCO W, LANNFELT L, SELKOE D &amp; YOUNKIN S 1996. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nat Med, 2, 864&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>SELKOE DJ &amp; HARDY J 2016. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol Med, 8, 595&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>SEYFRIED NT, DAMMER EB, SWARUP V, NANDAKUMAR D, DUONG DM, YIN L, DENG Q, NGUYEN T, HALES CM, WINGO T, GLASS J, GEARING M, THAMBISETTY M, TRONCOSO JC, GESCHWIND DH, LAH JJ &amp; LEVEY AI 2017. A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer&#x2019;s Disease. Cell Syst, 4, 60&#x2013;72 e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5269514</ArticleId><ArticleId IdType="pubmed">27989508</ArticleId></ArticleIdList></Reference><Reference><Citation>SHI Y, KIRWAN P, SMITH J, MACLEAN G, ORKIN SH &amp; LIVESEY FJ 2012. A human stem cell model of early Alzheimer&#x2019;s disease pathology in Down syndrome. Sci Transl Med, 4, 124ra29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129935</ArticleId><ArticleId IdType="pubmed">22344463</ArticleId></ArticleIdList></Reference><Reference><Citation>SPROUL AA, JACOB S, PRE D, KIM SH, NESTOR MW, NAVARRO-SOBRINO M, SANTA-MARIA I, ZIMMER M, AUBRY S, STEELE JW, KAHLER DJ, DRANOVSKY A, ARANCIO O, CRARY JF, GANDY S &amp; NOGGLE SA 2014. Characterization and molecular profiling of PSEN1 familial Alzheimer&#x2019;s disease iPSC-derived neural progenitors. PLoS ONE, 9, e84547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3885572</ArticleId><ArticleId IdType="pubmed">24416243</ArticleId></ArticleIdList></Reference><Reference><Citation>SRIKANTH P, LAGOMARSINO VN, PEARSE RV 2ND, LIAO M, GHOSH S, NEHME R, SEYFRIED N, EGGAN K &amp; YOUNG-PEARSE TL 2018. Convergence of independent DISC1 mutations on impaired neurite growth via decreased UNC5D expression. Transl Psychiatry, 8, 245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6224395</ArticleId><ArticleId IdType="pubmed">30410030</ArticleId></ArticleIdList></Reference><Reference><Citation>SUBRAMANIAN A, TAMAYO P, MOOTHA VK, MUKHERJEE S, EBERT BL, GILLETTE MA, PAULOVICH A, POMEROY SL, GOLUB TR, LANDER ES &amp; MESIROV JP 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 102, 15545&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>TASAKI S, GAITERI C, MOSTAFAVI S, YU L, WANG Y, DE JAGER PL &amp; BENNETT DA 2018. Multi-omic Directed Networks Describe Features of Gene Regulation in Aged Brains and Expand the Set of Genes Driving Cognitive Decline. Front Genet, 9, 294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6095043</ArticleId><ArticleId IdType="pubmed">30140277</ArticleId></ArticleIdList></Reference><Reference><Citation>TERRY RD, MASLIAH E, SALMON DP, BUTTERS N, DETERESA R, HILL R, HANSEN LA &amp; KATZMAN R 1991. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol, 30, 572&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>VAN ACKER ZP, BRETOU M &amp; ANNAERT W 2019. Endo-lysosomal dysregulations and late-onset Alzheimer&#x2019;s disease: impact of genetic risk factors. Mol Neurodegener, 14, 20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547588</ArticleId><ArticleId IdType="pubmed">31159836</ArticleId></ArticleIdList></Reference><Reference><Citation>WANG C, NAJM R, XU Q, JEONG DE, WALKER D, BALESTRA ME, YOON SY, YUAN H, LI G, MILLER ZA, MILLER BL, MALLOY MJ &amp; HUANG Y 2018. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med, 24, 647&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948154</ArticleId><ArticleId IdType="pubmed">29632371</ArticleId></ArticleIdList></Reference><Reference><Citation>WANG C, XIONG M, GRATUZE M, BAO X, SHI Y, ANDHEY PS, MANIS M, SCHROEDER C, YIN Z, MADORE C, BUTOVSKY O, ARTYOMOV M, ULRICH JD &amp; HOLTZMAN DM 2021. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron, 109, 1657&#x2013;1674 e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8141024</ArticleId><ArticleId IdType="pubmed">33831349</ArticleId></ArticleIdList></Reference><Reference><Citation>WILSON RS, BECK TL, BIENIAS JL &amp; BENNETT DA 2007. Terminal cognitive decline: accelerated loss of cognition in the last years of life. Psychosom Med, 69, 131&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17327212</ArticleId></ArticleIdList></Reference><Reference><Citation>WILSON RS, FLEISCHMAN DA, MYERS RA, BENNETT DA, BIENIAS JL, GILLEY DW &amp; EVANS DA 2004. Premorbid proneness to distress and episodic memory impairment in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry, 75, 191&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738931</ArticleId><ArticleId IdType="pubmed">14742585</ArticleId></ArticleIdList></Reference><Reference><Citation>WOLFF RA, DOBROWSKY RT, BIELAWSKA A, OBEID LM &amp; HANNUN YA 1994. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. J Biol Chem, 269, 19605&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8034729</ArticleId></ArticleIdList></Reference><Reference><Citation>ZHANG B, GAITERI C, BODEA LG, WANG Z, MCELWEE J, PODTELEZHNIKOV AA, ZHANG C, XIE T, TRAN L, DOBRIN R, FLUDER E, CLURMAN B, MELQUIST S, NARAYANAN M, SUVER C, SHAH H, MAHAJAN M, GILLIS T, MYSORE J, MACDONALD ME, LAMB JR, BENNETT DA, MOLONY C, STONE DJ, GUDNASON V, MYERS AJ, SCHADT EE, NEUMANN H, ZHU J &amp; EMILSSON V 2013a. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer&#x2019;s disease. Cell, 153, 707&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677161</ArticleId><ArticleId IdType="pubmed">23622250</ArticleId></ArticleIdList></Reference><Reference><Citation>ZHANG Y, PAK C, HAN Y, AHLENIUS H, ZHANG Z, CHANDA S, MARRO S, PATZKE C, ACUNA C, COVY J, XU W, YANG N, DANKO T, CHEN L, WERNIG M &amp; SUDHOF TC 2013b. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron, 78, 785&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3751803</ArticleId><ArticleId IdType="pubmed">23764284</ArticleId></ArticleIdList></Reference><Reference><Citation>ZHAO J, FU Y, YAMAZAKI Y, REN Y, DAVIS MD, LIU CC, LU W, WANG X, CHEN K, CHERUKURI Y, JIA L, MARTENS YA, JOB L, SHUE F, NGUYEN TT, YOUNKIN SG, GRAFF-RADFORD NR, WSZOLEK ZK, BRAFMAN DA, ASMANN YW, ERTEKIN-TANER N, KANEKIYO T &amp; BU G 2020. APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer&#x2019;s disease patient iPSC-derived cerebral organoids. Nat Commun, 11, 5540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7608683</ArticleId><ArticleId IdType="pubmed">33139712</ArticleId></ArticleIdList></Reference><Reference><Citation>ZHOU H, MARTINEZ H, SUN B, LI A, ZIMMER M, KATSANIS N, DAVIS EE, KURTZBERG J, LIPNICK S, NOGGLE S, RAO M &amp; CHANG S 2015. Rapid and Efficient Generation of Transgene-Free iPSC from a Small Volume of Cryopreserved Blood. Stem Cell Rev, 11, 652&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4493720</ArticleId><ArticleId IdType="pubmed">25951995</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34493870</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1276</StartPage><EndPage>1282</EndPage><MedlinePgn>1276-1282</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-021-00921-z</ELocationID><Abstract><AbstractText>Late-onset Alzheimer's disease is a prevalent age-related polygenic disease that accounts for 50-70% of dementia cases. Currently, only a fraction of the genetic variants underlying Alzheimer's disease have been identified. Here we show that increased sample sizes allowed identification of seven previously unidentified genetic loci contributing to Alzheimer's disease. This study highlights microglia, immune cells and protein catabolism as relevant to late-onset Alzheimer's disease, while identifying and prioritizing previously unidentified genes of potential interest. We anticipate that these results can be included in larger meta-analyses of Alzheimer's disease to identify further genetic variants that contribute to Alzheimer's pathology.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wightman</LastName><ForeName>Douglas P</ForeName><Initials>DP</Initials><Identifier Source="ORCID">0000-0003-3377-4806</Identifier><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Iris E</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savage</LastName><ForeName>Jeanne E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0002-2034-8341</Identifier><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shadrin</LastName><ForeName>Alexey A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-7467-250X</Identifier><AffiliationInfo><Affiliation>NORMENT Centre, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahrami</LastName><ForeName>Shahram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NORMENT Centre, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rongve</LastName><ForeName>Arvid</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0476-4134</Identifier><AffiliationInfo><Affiliation>Department of Research and Innovation, Helse Fonna, Haugesund Hospital, Haugesund, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Bergen, Institute of Clinical Medicine (K1), Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf8;rte</LastName><ForeName>Sigrid</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9540-3256</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Communication Unit for Musculoskeletal Health (FORMI), Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winsvold</LastName><ForeName>Bendik S</ForeName><Initials>BS</Initials><Identifier Source="ORCID">0000-0003-4171-8919</Identifier><AffiliationInfo><Affiliation>K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drange</LastName><ForeName>Ole Kristian</ForeName><Initials>OK</Initials><AffiliationInfo><Affiliation>Department of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Mental Health Care, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinsen</LastName><ForeName>Amy E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skogholt</LastName><ForeName>Anne Heidi</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willer</LastName><ForeName>Cristen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5645-4966</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Br&#xe5;then</LastName><ForeName>Geir</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3224-7983</Identifier><AffiliationInfo><Affiliation>Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatrics, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosnes</LastName><ForeName>Ingunn</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Hospital Namsos, Nord-Tr&#xf8;ndelag Health Trust, Namsos, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Jonas Bille</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fritsche</LastName><ForeName>Lars G</ForeName><Initials>LG</Initials><Identifier Source="ORCID">0000-0002-2110-1690</Identifier><AffiliationInfo><Affiliation>Center for Statistical Genetics, Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Laurent F</ForeName><Initials>LF</Initials><Identifier Source="ORCID">0000-0003-0548-2486</Identifier><AffiliationInfo><Affiliation>K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Linda M</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0002-8448-983X</Identifier><AffiliationInfo><Affiliation>Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabrielsen</LastName><ForeName>Maiken E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnsen</LastName><ForeName>Marianne Bakke</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Communication Unit for Musculoskeletal Health (FORMI), Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meisingset</LastName><ForeName>Tore Wergeland</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-7719-0859</Identifier><AffiliationInfo><Affiliation>Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proitsi</LastName><ForeName>Petroula</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2553-6974</Identifier><AffiliationInfo><Affiliation>Institute of Psychiatry Psychology and Neurosciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodges</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5565-6678</Identifier><AffiliationInfo><Affiliation>Institute of Psychiatry Psychology and Neurosciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobson</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4224-9245</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research UK London, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velayudhan</LastName><ForeName>Latha</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7712-930X</Identifier><AffiliationInfo><Affiliation>Institute of Psychiatry Psychology and Neurosciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heilbron</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>23andMe Inc., Sunnyvale, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auton</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>23andMe Inc., Sunnyvale, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>23andMe Research Team</CollectiveName></Author><Author ValidYN="Y"><LastName>Sealock</LastName><ForeName>Julia M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-9346-3498</Identifier><AffiliationInfo><Affiliation>Division of Genetic Medicine, Department of Medicine Vanderbilt University Medical Center Nashville, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Lea K</ForeName><Initials>LK</Initials><Identifier Source="ORCID">0000-0001-5143-2282</Identifier><AffiliationInfo><Affiliation>Division of Genetic Medicine, Department of Medicine Vanderbilt University Medical Center Nashville, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Nancy L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Chandra A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0001-6502-7173</Identifier><AffiliationInfo><Affiliation>Department of Psychology, University of California-Riverside, Riverside, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlsson</LastName><ForeName>Ida K</ForeName><Initials>IK</Initials><AffiliationInfo><Affiliation>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Gerontology and Aging Research Network - J&#xf6;nk&#xf6;ping (ARN-J), School of Health and Welfare, J&#xf6;nk&#xf6;ping University, J&#xf6;nk&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magnusson</LastName><ForeName>Sigurdur</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6669-3071</Identifier><AffiliationInfo><Affiliation>deCODE Genetics/Amgen, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefansson</LastName><ForeName>Hreinn</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9331-6666</Identifier><AffiliationInfo><Affiliation>deCODE Genetics/Amgen, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thordardottir</LastName><ForeName>Steinunn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Landspitali University Hospital, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonsson</LastName><ForeName>Palmi V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Landspitali University Hospital, Reykjavik, Iceland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Iceland, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snaedal</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Landspitali University Hospital, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zettergren</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7182-8417</Identifier><AffiliationInfo><Affiliation>Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, Centre for Ageing and Health (AGECAP) at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skoog</LastName><ForeName>Ingmar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, Centre for Ageing and Health (AGECAP) at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Region V&#xe4;stra G&#xf6;taland, Sahlgrenska University Hospital, Psychiatry, Cognition and Old Age Psychiatry Clinic, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>Silke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, Centre for Ageing and Health (AGECAP) at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Region V&#xe4;stra G&#xf6;taland, Sahlgrenska University Hospital, Psychiatry, Cognition and Old Age Psychiatry Clinic, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waern</LastName><ForeName>Margda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, Centre for Ageing and Health (AGECAP) at the University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Region V&#xe4;stra G&#xf6;taland, Sahlgrenska University Hospital, Psychosis Clinic, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stordal</LastName><ForeName>Eystein</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2443-7923</Identifier><AffiliationInfo><Affiliation>Department of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Hospital Namsos, Nord-Tr&#xf8;ndelag Health Trust, Namsos, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hveem</LastName><ForeName>Kristian</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HUNT Research Center, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwart</LastName><ForeName>John-Anker</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0001-5721-0154</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Athanasiu</LastName><ForeName>Lavinia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NORMENT Centre, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selnes</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saltvedt</LastName><ForeName>Ingvild</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-7897-9808</Identifier><AffiliationInfo><Affiliation>Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatrics, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sando</LastName><ForeName>Sigrid B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ulstein</LastName><ForeName>Ingun</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djurovic</LastName><ForeName>Srdjan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8140-8061</Identifier><AffiliationInfo><Affiliation>Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fladby</LastName><ForeName>Tormod</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9984-9797</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aarsland</LastName><ForeName>Dag</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry Psychology and Neurosciences, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selb&#xe6;k</LastName><ForeName>Geir</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6511-8219</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, T&#xf8;nsberg, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ripke</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3622-835X</Identifier><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charit&#xe9;-Universit&#xe4;tsmedizin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stefansson</LastName><ForeName>Kari</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-1676-864X</Identifier><AffiliationInfo><Affiliation>deCODE Genetics/Amgen, Reykjavik, Iceland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials><Identifier Source="ORCID">0000-0002-4461-3568</Identifier><AffiliationInfo><Affiliation>NORMENT Centre, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Posthuma</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7582-2365</Identifier><AffiliationInfo><Affiliation>Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU Amsterdam, Amsterdam, the Netherlands. d.posthuma@vu.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry and Pediatric Psychology, Section Complex Trait Genetics, Amsterdam Neuroscience, Vrije Universiteit Medical Center, Amsterdam University Medical Center, Amsterdam, the Netherlands. d.posthuma@vu.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS017950</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054076</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_PC_17214</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG072122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG028555</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017561</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG060470</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>082604/2/07/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 HD103537</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL105756</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>503480</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG066546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2021 Nov;17(11):659. doi: 10.1038/s41582-021-00575-9.</RefSource><PMID Version="1">34599319</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Genet. 2021 Dec;53(12):1722. doi: 10.1038/s41588-021-00977-x.</RefSource><PMID Version="1">34773122</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Genet. 2022 Jul;54(7):1062. doi: 10.1038/s41588-022-01126-8.</RefSource><PMID Version="1">35726068</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020412" MajorTopicYN="N">Multifactorial Inheritance</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests Statement. All other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Agee</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aslibekyan</LastName><ForeName>Stella</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Babalola</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Robert K</ForeName><Initials>RK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bielenberg</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bryc</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bullis</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cameron</LastName><ForeName>Briana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coker</LastName><ForeName>Daniella</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Partida</LastName><ForeName>Gabriel Cuellar</ForeName><Initials>GC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dhamija</LastName><ForeName>Devika</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Das</LastName><ForeName>Sayantan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elson</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Filshtein</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletez-Brant</LastName><ForeName>Kipper</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fontanillas</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freyman</LastName><ForeName>Will</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gandhi</LastName><ForeName>Pooja M</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hicks</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinds</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huber</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jewett</LastName><ForeName>Ethan M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yunxuan</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kleinman</LastName><ForeName>Aaron</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kukar</LastName><ForeName>Katelyn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Keng-Han</ForeName><Initials>KH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lowe</LastName><ForeName>Maya</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luff</LastName><ForeName>Marie K</ForeName><Initials>MK</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCreight</LastName><ForeName>Jey C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Matthew H</ForeName><Initials>MH</Initials></Investigator><Investigator ValidYN="Y"><LastName>McManus</LastName><ForeName>Kimberly F</ForeName><Initials>KF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Micheletti</LastName><ForeName>Steven J</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moreno</LastName><ForeName>Meghan E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mountain</LastName><ForeName>Joanna L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mozaffari</LastName><ForeName>Sahar V</ForeName><Initials>SV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nandakumar</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noblin</LastName><ForeName>Elizabeth S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Connell</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrakovitz</LastName><ForeName>Aaron A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poznik</LastName><ForeName>G David</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schumacher</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shastri</LastName><ForeName>Anjali J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shelton</LastName><ForeName>Janie F</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shi</LastName><ForeName>Jingchunzi</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shringarpure</LastName><ForeName>Suyash</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tian</LastName><ForeName>Chao</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tran</LastName><ForeName>Vinh</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tung</LastName><ForeName>Joyce Y</ForeName><Initials>JY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weldon</LastName><ForeName>Catherine H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilton</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34493870</ArticleId><ArticleId IdType="mid">NIHMS1871222</ArticleId><ArticleId IdType="pmc">PMC10243600</ArticleId><ArticleId IdType="doi">10.1038/s41588-021-00921-z</ArticleId><ArticleId IdType="pii">10.1038/s41588-021-00921-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bacigalupo I.et al. A Systematic Review and Meta-Analysis on the Prevalence of Dementia in Europe: Estimates from the Highest-Quality Studies Adopting the DSM IV Diagnostic Criteria. J. Alzheimers. Dis 66, 1471&#x2013;1481 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6294583</ArticleId><ArticleId IdType="pubmed">30412486</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B.et al. Defeating Alzheimer&#x2019;s disease and other dementias: a priority for European science and society. Lancet. Neurol 15, 455&#x2013;532 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26987701</ArticleId></ArticleIdList></Reference><Reference><Citation>DeTure MA &amp; Dickson DW The neuropathological diagnosis of Alzheimer&#x2019;s disease. Mol. Neurodegener 14, 32 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6679484</ArticleId><ArticleId IdType="pubmed">31375134</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M.et al. Heritability for Alzheimer&#x2019;s disease: the study of dementia in Swedish twins. J. Gerontol. A. Biol. Sci. Med. Sci 52, M117&#x2013;25 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9060980</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M.et al. Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry 63, 168&#x2013;174 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q.et al. Risk prediction of late-onset Alzheimer&#x2019;s disease implies an oligogenic architecture. Nat. Commun 11, 4799 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7511365</ArticleId><ArticleId IdType="pubmed">32968074</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D.et al. The genetic architecture of human complex phenotypes is modulated by linkage disequilibrium and heterozygosity. Genetics 217, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8045737</ArticleId><ArticleId IdType="pubmed">33789345</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat. Genet 51, 404&#x2013;413 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan BK et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet 47, 291&#x2013;295 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4495769</ArticleId><ArticleId IdType="pubmed">25642630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J-C et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat. Genet 45, 1452&#x2013;1458 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bakker PIW et al. Practical aspects of imputation-driven meta-analysis of genome-wide association studies. Hum. Mol. Genet 17, R122&#x2013;R128 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782358</ArticleId><ArticleId IdType="pubmed">18852200</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan B.et al. An atlas of genetic correlations across human diseases and traits. Nat. Genet 47, 1236&#x2013;1241 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4797329</ArticleId><ArticleId IdType="pubmed">26414676</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J.et al. LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. Bioinformatics 33, 272&#x2013;279 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5542030</ArticleId><ArticleId IdType="pubmed">27663502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet 51, 414&#x2013;430 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw CA, Mooij JM, Heskes T.&amp; Posthuma D.MAGMA: Generalized Gene-Set Analysis of GWAS Data. PLOS Comput. Biol 11, e1004219 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4401657</ArticleId><ArticleId IdType="pubmed">25885710</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K, Umi&#x107;evi&#x107; Mirkov M, de Leeuw CA, van den Heuvel MP &amp; Posthuma D.Genetic mapping of cell type specificity for complex traits. Nat. Commun 10, 3222 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6642112</ArticleId><ArticleId IdType="pubmed">31324783</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart DS et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074&#x2013;D1082 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753335</ArticleId><ArticleId IdType="pubmed">29126136</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambartolomei C.et al. Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. PLOS Genet. 10, e1004383 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022491</ArticleId><ArticleId IdType="pubmed">24830394</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamilov R.&amp; Aneskievich BJ TNIP1 in Autoimmune Diseases: Regulation of Toll-like Receptor Signaling. J. Immunol. Res 2018, 3491269 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6192141</ArticleId><ArticleId IdType="pubmed">30402506</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho CE et al. A modular analysis of microglia gene expression, insights into the aged phenotype. BMC Genomics 20, 164 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6396472</ArticleId><ArticleId IdType="pubmed">30819113</ArticleId></ArticleIdList></Reference><Reference><Citation>Nho K.et al. Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer&#x2019;s disease. BMC Med. Genomics 10, 29 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5461522</ArticleId><ArticleId IdType="pubmed">28589856</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.et al. Systematic Analysis and Biomarker Study for Alzheimer&#x2019;s Disease. Sci. Rep 8, 17394 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6255913</ArticleId><ArticleId IdType="pubmed">30478411</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques-Coelho D.et al. Differential transcript usage unravels gene expression alterations in Alzheimer&#x2019;s disease human brains. npj Aging Mech. Dis 7, 2 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7782705</ArticleId><ArticleId IdType="pubmed">33398016</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M.et al. A transcriptomic atlas of aged human microglia. Nat. Commun 9, 539 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5803269</ArticleId><ArticleId IdType="pubmed">29416036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE et al. The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci 16, 1896&#x2013;1905 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam KN et al. Effect of high fat diet on phenotype, brain transcriptome and lipidome in Alzheimer&#x2019;s model mice. Sci. Rep 7, 4307 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5487356</ArticleId><ArticleId IdType="pubmed">28655926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ol&#xe1;h J.et al. Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alpha-synuclein. J. Biol. Chem 286, 34088&#x2013; 34100 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190826</ArticleId><ArticleId IdType="pubmed">21832049</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F.et al. Distinct roles for BAI1 and TIM-4 in the engulfment of dying neurons by microglia. Nat. Commun 5, 4046 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24898390</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciani M, Benussi L, Bonvicini C.&amp; Ghidoni R.Genome Wide Association Study and Next Generation Sequencing: A Glimmer of Light Toward New Possible Horizons in Frontotemporal Dementia Research. Front. Neurosci 13, 506 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6532367</ArticleId><ArticleId IdType="pubmed">31156380</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z.et al. The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathol. 139, 45&#x2013;61 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942643</ArticleId><ArticleId IdType="pubmed">31456032</ArticleId></ArticleIdList></Reference><Reference><Citation>Prodan CI et al. Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease. Neurology 76, 247&#x2013;252 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034392</ArticleId><ArticleId IdType="pubmed">21242492</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaves CV &amp; Rohrer JD An update on genetic frontotemporal dementia. J. Neurol 266, 2075&#x2013;2086 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6647117</ArticleId><ArticleId IdType="pubmed">31119452</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.et al. Leukocyte immunoglobulin-like receptors in human diseases: an overview of their distribution, function, and potential application for immunotherapies. J. Leukoc. Biol 102, 351&#x2013;360 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5505746</ArticleId><ArticleId IdType="pubmed">28351852</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q.et al. Inhibiting amyloid-&#x3b2; cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design. Nat. Chem 10, 1213&#x2013;1221 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250578</ArticleId><ArticleId IdType="pubmed">30297750</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JZ, Erlich Y.&amp; Pickrell JK Case-control association mapping by proxy using family history of disease. Nat. Genet 49, 325&#x2013;331 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28092683</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwabe T, Srinivasan K.&amp; Rhinn H.Shifting paradigms: The central role of microglia in Alzheimer&#x2019;s disease. Neurobiol. Dis 143, 104962 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32535152</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao DW, O&#x2019;Connor LJ, Price AL &amp; Gusev A.Quantifying genetic effects on disease mediated by assayed gene expression levels. Nat. Genet 52, 626&#x2013;633 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7276299</ArticleId><ArticleId IdType="pubmed">32424349</ArticleId></ArticleIdList></Reference><Reference><Citation>Corces MR et al. Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Nat. Genet 52, 1158&#x2013;1168 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7606627</ArticleId><ArticleId IdType="pubmed">33106633</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler TW et al. Quality control and conduct of genome-wide association meta-analyses. Nat. Protoc 9, 1192&#x2013;1212 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4083217</ArticleId><ArticleId IdType="pubmed">24762786</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn RM, Haussler D.&amp; Kent WJ The UCSC genome browser and associated tools. Brief. Bioinform 14, 144&#x2013;161 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3603215</ArticleId><ArticleId IdType="pubmed">22908213</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionita-Laza I, Lee S, Makarov V, Buxbaum JD &amp; Lin X.Sequence Kernel Association Tests for the Combined Effect of Rare and Common Variants. Am. J. Hum. Genet 92, 841&#x2013;853 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675243</ArticleId><ArticleId IdType="pubmed">23684009</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K, Taskesen E, van Bochoven A.&amp; Posthuma D.Functional mapping and annotation of genetic associations with FUMA. Nat. Commun 8, 1826 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5705698</ArticleId><ArticleId IdType="pubmed">29184056</ArticleId></ArticleIdList></Reference><Reference><Citation>Auton A.et al. A global reference for human genetic variation. Nature 526, 68&#x2013;74 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow C.et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Med. 12, e1001779 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P-P, Xie Y, Meng X-Y &amp; Kang J-S History and progress of hypotheses and clinical trials for Alzheimer&#x2019;s disease. Signal Transduct. Target. Ther 4, 29 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6799833</ArticleId><ArticleId IdType="pubmed">31637009</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni RE et al. GWAS on family history of Alzheimer&#x2019;s disease. Transl. Psychiatry 8, 99 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5959890</ArticleId><ArticleId IdType="pubmed">29777097</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS et al. Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score. PLOS Med. 14, e1002258 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360219</ArticleId><ArticleId IdType="pubmed">28323831</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G.et al. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol. Psychiatry 21, 108&#x2013;117 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4573764</ArticleId><ArticleId IdType="pubmed">25778476</ArticleId></ArticleIdList></Reference><Reference><Citation>de Rojas I.et al. Common variants in Alzheimer's disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores. medRxiv 19012021 (2020) doi:10.1101/19012021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/19012021</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartzentruber J.et al. Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer&#x2019;s disease risk genes. Nat. Genet 53, 392&#x2013;402 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610386</ArticleId><ArticleId IdType="pubmed">33589840</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruim RJ et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26, 2336&#x2013;2337 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935401</ArticleId><ArticleId IdType="pubmed">20634204</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A.et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417&#x2013;425 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707969</ArticleId><ArticleId IdType="pubmed">26771021</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw CA, Stringer S, Dekkers IA, Heskes T.&amp; Posthuma D.Conditional and interaction gene-set analysis reveals novel functional pathways for blood pressure. Nat. Commun 9, 3768 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6138636</ArticleId><ArticleId IdType="pubmed">30218068</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodge RD et al. Conserved cell types with divergent features in human versus mouse cortex. Nature 573, 61&#x2013;68 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919571</ArticleId><ArticleId IdType="pubmed">31435019</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N.et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat. Methods 14, 955&#x2013;958 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623139</ArticleId><ArticleId IdType="pubmed">28846088</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong S.et al. A single-cell RNA-seq survey of the developmental landscape of the human prefrontal cortex. Nature 555, 524&#x2013;528 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29539641</ArticleId></ArticleIdList></Reference><Reference><Citation>Darmanis S.et al. A survey of human brain transcriptome diversity at the single cell level. Proc. Natl. Acad. Sci. U. S. A 112, 7285&#x2013;7290 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4466750</ArticleId><ArticleId IdType="pubmed">26060301</ArticleId></ArticleIdList></Reference><Reference><Citation>Enge M.et al. Single-Cell Analysis of Human Pancreas Reveals Transcriptional Signatures of Aging and Somatic Mutation Patterns. Cell 171, 321&#x2013;330.e14 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6047899</ArticleId><ArticleId IdType="pubmed">28965763</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochgerner H.et al. STRT-seq-2i: dual-index 5&#x2019; single cell and nucleus RNA-seq on an addressable microwell array. Sci. Rep 7, 16327 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5703850</ArticleId><ArticleId IdType="pubmed">29180631</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X.et al. Mapping the Mouse Cell Atlas by Microwell-Seq. Cell 172, 1091&#x2013;1107.e17 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29474909</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng GXY et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun 8, 14049 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5241818</ArticleId><ArticleId IdType="pubmed">28091601</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D.et al. Comprehensive functional genomic resource and integrative model for the human brain. Science 362, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6413328</ArticleId><ArticleId IdType="pubmed">30545857</ArticleId></ArticleIdList></Reference><Reference><Citation>Alasoo K.et al. Shared genetic effects on chromatin and gene expression indicate a role for enhancer priming in immune response. Nat. Genet 50, 424&#x2013;431 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548559</ArticleId><ArticleId IdType="pubmed">29379200</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L.et al. Genetic Drivers of Epigenetic and Transcriptional Variation in Human Immune Cells. Cell 167, 1398&#x2013;1414.e24 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5119954</ArticleId><ArticleId IdType="pubmed">27863251</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe AE et al. Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis. Nat. Neurosci 21, 1117&#x2013;1125 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6438700</ArticleId><ArticleId IdType="pubmed">30050107</ArticleId></ArticleIdList></Reference><Reference><Citation>Momozawa Y.et al. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nat. Commun 9, 2427 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6013502</ArticleId><ArticleId IdType="pubmed">29930244</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfax BP et al. Genetics of gene expression in primary immune cells identifies cell type&#x2013;specific master regulators and roles of HLA alleles. Nat. Genet 44, 502&#x2013;510 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437404</ArticleId><ArticleId IdType="pubmed">22446964</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfax BP et al. Innate Immune Activity Conditions the Effect of Regulatory Variants upon Monocyte Gene Expression. Science (80-. ) 343, 1246949 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4064786</ArticleId><ArticleId IdType="pubmed">24604202</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez-Arcelus M.et al. Passive and active DNA methylation and the interplay with genetic variation in gene regulation. Elife 2, e00523 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3673336</ArticleId><ArticleId IdType="pubmed">23755361</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasela S.et al. Pathogenic implications for autoimmune mechanisms derived by comparative eQTL analysis of CD4+ versus CD8+ T cells. PLOS Genet. 13, e1006643 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5352142</ArticleId><ArticleId IdType="pubmed">28248954</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepik K.et al. C-reactive protein upregulates the whole blood expression of CD59 - an integrative analysis. PLOS Comput. Biol 13, e1005766 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5609773</ArticleId><ArticleId IdType="pubmed">28922377</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranbhai V.et al. Genomic modulators of gene expression in human neutrophils. Nat. Commun 6, 7545 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4507005</ArticleId><ArticleId IdType="pubmed">26151758</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe9;d&#xe9;lec Y.et al. Genetic Ancestry and Natural Selection Drive Population Differences in Immune Responses to Pathogens. Cell 167, 657&#x2013;669.e21 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27768889</ArticleId></ArticleIdList></Reference><Reference><Citation>Quach H.et al. Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations. Cell 167, 643&#x2013;656.e17 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5075285</ArticleId><ArticleId IdType="pubmed">27768888</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartzentruber J.et al. Molecular and functional variation in iPSC-derived sensory neurons. Nat. Genet 50, 54&#x2013;61 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5742539</ArticleId><ArticleId IdType="pubmed">29229984</ArticleId></ArticleIdList></Reference><Reference><Citation>Buil A.et al. Gene-gene and gene-environment interactions detected by transcriptome sequence analysis in twins. Nat. Genet 47, 88&#x2013;91 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643454</ArticleId><ArticleId IdType="pubmed">25436857</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xf5;sa U.et al. Unraveling the polygenic architecture of complex traits using blood eQTL metaanalysis. bioRxiv 447367 (2018) doi:10.1101/447367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/447367</ArticleId></ArticleIdList></Reference><Reference><Citation>Westra H-J et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet 45, 1238&#x2013;1243 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3991562</ArticleId><ArticleId IdType="pubmed">24013639</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhernakova DV et al. Identification of context-dependent expression quantitative trait loci in whole blood. Nat. Genet 49, 139&#x2013;145 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27918533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng B.et al. An xQTL map integrates the genetic architecture of the human brain&#x2019;s transcriptome and epigenome. Nat. Neurosci 20, 1418&#x2013;1426 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785926</ArticleId><ArticleId IdType="pubmed">28869584</ArticleId></ArticleIdList></Reference><Reference><Citation>Fromer M.et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat. Neurosci 19, 1442&#x2013;1453 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5083142</ArticleId><ArticleId IdType="pubmed">27668389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy A.et al. Genetic variability in the regulation of gene expression in ten regions of the human brain. Nat. Neurosci 17, 1418&#x2013;1428 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4208299</ArticleId><ArticleId IdType="pubmed">25174004</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace C.Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. PLOS Genet. 16, e1008720 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7192519</ArticleId><ArticleId IdType="pubmed">32310995</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerimov N.et al. eQTL Catalogue: a compendium of uniformly processed human gene expression and splicing QTLs. bioRxiv 2020.01.29.924266 (2020) doi:10.1101/2020.01.29.924266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.01.29.924266</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AMH et al. A map of transcriptional heterogeneity and regulatory variation in human microglia. bioRxiv 2019.12.20.874099 (2019) doi:10.1101/2019.12.20.874099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2019.12.20.874099</ArticleId><ArticleId IdType="pmc">PMC7610960</ArticleId><ArticleId IdType="pubmed">34083789</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Sarkar A, Carbonetto P.&amp; Stephens M.A simple new approach to variable selection in regression, with application to genetic fine mapping. J. R. Stat. Soc. Ser. B (Statistical Methodol n/a, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10201948</ArticleId><ArticleId IdType="pubmed">37220626</ArticleId></ArticleIdList></Reference><Reference><Citation>Benner C.et al. Prospects of Fine-Mapping Trait-Associated Genomic Regions by Using Summary Statistics from Genome-wide Association Studies. Am. J. Hum. Genet 101, 539&#x2013;551 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5630179</ArticleId><ArticleId IdType="pubmed">28942963</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; (2017).</Citation></Reference><Reference><Citation>Kundaje A.et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317&#x2013;330 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530010</ArticleId><ArticleId IdType="pubmed">25693563</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence M.et al. Software for Computing and Annotating Genomic Ranges. PLOS Comput. Biol 9, e1003118 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3738458</ArticleId><ArticleId IdType="pubmed">23950696</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Li M.&amp; Hakonarson H.ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164&#x2013;e164 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938201</ArticleId><ArticleId IdType="pubmed">20601685</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Leary NA et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic Acids Res. 44, D733&#x2013;D745 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702849</ArticleId><ArticleId IdType="pubmed">26553804</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham Hadley. ggplot2: Elegant Graphics for Data Analysis. (Springer-Verlag New York, 2016).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34499725</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>326</Volume><Issue>16</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.</ArticleTitle><Pagination><StartPage>1627</StartPage><EndPage>1629</EndPage><MedlinePgn>1627-1629</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2021.15286</ELocationID><Abstract><AbstractText>This study evaluates whether patients enrolled in trials of aducanumab, EMERGE and ENGAGE, were representative of patients with dementia enrolled in Medicare by estimating the proportions of Medicare beneficiaries with Alzheimer disease (AD) or mild cognitive impairment (MCI) who would have been excluded from these trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Timothy S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayanian</LastName><ForeName>John Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Editor, JAMA Health Forum.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souza</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landon</LastName><ForeName>Bruce E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG032952</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>105J35OE21</RegistryNumber><NameOfSubstance UI="C000600266">aducanumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jamainternmed.2021.4607</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jama.2021.3854</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jama.2021.11768</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000075203" MajorTopicYN="N">Contraindications, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057239" MajorTopicYN="Y">Early Termination of Clinical Trials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007345" MajorTopicYN="N">Insurance Claim Review</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Anderson reported receiving grants from the National Institute on Aging (NIA) during the conduct of the study and personal fees from Alosa Health and grants from the American College of Cardiology and Boston Claude D. Pepper Older Americans Independence Center outside the submitted work. Dr Ayanian reported receiving grants from the NIA during the conduct of the study and grants from the National Library of Medicine, Michigan Department of Health and Human Services, and Merck Foundation; personal fees from The JAMA Network, the <i>New England Journal of Medicine</i>, Harvard University, University of Massachusetts Medical School, and University of Chicago; and nonfinancial support from the National Academy of Medicine, the National Institutes of Health, and AcademyHealth outside the submitted work. Dr Landon reported receiving grants from the NIA during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>9</Day><Hour>17</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34499725</ArticleId><ArticleId IdType="pmc">PMC8430904</ArticleId><ArticleId IdType="doi">10.1001/jama.2021.15286</ArticleId><ArticleId IdType="pii">2784225</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alexander GC, Emerson S, Kesselheim AS. Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA. 2021;325(17):1717-1718. doi:10.1001/jama.2021.3854</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3854</ArticleId><ArticleId IdType="pubmed">33783469</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Medicare &amp; Medicaid Services . Chronic Conditions Data Warehouse. Accessed July 10, 2021. https://www2.ccwdata.org/web/guest/condition-categories</Citation></Reference><Reference><Citation>ClinicalTrials.gov . 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer&#x2019;s Disease (EMERGE). Accessed July 10, 2021. https://clinicaltrials.gov/ct2/show/NCT02484547</Citation></Reference><Reference><Citation>ClinicalTrials.gov . 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer&#x2019;s Disease (ENGAGE). Accessed July 10, 2021. https://clinicaltrials.gov/ct2/show/NCT02477800</Citation></Reference><Reference><Citation>US Food and Drug Administration. Aducanumab (marketed as Aduhelm) information. Accessed July 14, 2021. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aducanumab-marketed-aduhelm-information</Citation></Reference><Reference><Citation>Lee E, Gatz M, Tseng C, et al. . Evaluation of Medicare claims data as a tool to identify dementia. J Alzheimers Dis. 2019;67(2):769-778. doi:10.3233/JAD-181005</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-181005</ArticleId><ArticleId IdType="pmc">PMC7164318</ArticleId><ArticleId IdType="pubmed">30689589</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34505023</PMID><DateRevised><Year>2024</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-5370</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>EClinicalMedicine</Title><ISOAbbreviation>EClinicalMedicine</ISOAbbreviation></Journal><ArticleTitle>High cerebrospinal amyloid-&#x3b2; 42 is associated with normal cognition in individuals with brain amyloidosis.</ArticleTitle><Pagination><StartPage>100988</StartPage><MedlinePgn>100988</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100988</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eclinm.2021.100988</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Brain amyloidosis does not invariably predict dementia. We hypothesized that high soluble 42-amino acid &#x3b2; amyloid (A&#x3b2;42) peptide levels are associated with normal cognition and hippocampal volume despite increasing brain amyloidosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This cross-sectional study of 598 amyloid-positive participants in the Alzheimer's Disease Neuroimaging Initiative cohort examined whether levels of soluble A&#x3b2;42 are higher in amyloid-positive normal cognition (NC) individuals compared to mild cognitive impairment (MCI) and Alzheimer's disease (AD) and whether this relationship applies to neuropsychological assessments and hippocampal volume measured within the same year. All subjects were evaluated between June 2010 and February 2019. Brain amyloid positivity was defined as positron emission tomography-based standard uptake value ratio (SUVR) &#x2265;1.08 for <sup>[18]</sup> F-florbetaben or 1.11 for <sup>[18]</sup>F-florbetapir, with higher SUVR indicating more brain amyloidosis. Analyses were adjusted for age, sex, education, <i>APOE4, p</i>-tau, <i>t</i>-tau, and centiloids levels.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Higher soluble A&#x3b2;42 levels were observed in NC (864.00 pg/ml) than in MCI (768.60 pg/ml) or AD (617.46 pg/ml), with the relationship between NC, MCI, and AD maintained across all amyloid tertiles. In adjusted analysis, there was a larger absolute effect size of soluble A&#x3b2;42 than SUVR for NC (0.82&#xa0;vs. 0.40) and MCI (0.60&#xa0;vs. 0.26) versus AD. Each standard deviation increase in A&#x3b2;42 was associated with greater odds of NC than AD (adjusted odds ratio, 6.26; <i>p</i>&#xa0;&lt;&#xa0;0.001) or MCI (1.42; <i>p</i>&#xa0;=&#xa0;0.006). Higher soluble A&#x3b2;42 levels were also associated with better neuropsychological function and larger hippocampal volume.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Normal cognition and hippocampal volume are associated with preservation of high soluble A&#x3b2;42 levels despite increasing brain amyloidosis.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Please refer to the Funding section at the end of the article.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sturchio</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>James J. and Joan A. Gardner Family Center for Parkinson's disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Neuro Svenningsson, Karolinska Institute, 171 76 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dwivedi</LastName><ForeName>Alok K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Division of Biostatistics &amp; Epidemiology, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Christina B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malm</LastName><ForeName>Tarja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsili</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>James J. and Joan A. Gardner Family Center for Parkinson's disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>James J. and Joan A. Gardner Family Center for Parkinson's disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahajan</LastName><ForeName>Abhimanyu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>James J. and Joan A. Gardner Family Center for Parkinson's disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Emily J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>James J. and Joan A. Gardner Family Center for Parkinson's disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andaloussi</LastName><ForeName>Samir El</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poston</LastName><ForeName>Kathleen L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manfredsson</LastName><ForeName>Fredric P</ForeName><Initials>FP</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Barrow Neurological Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>University of Southern California Keck School of Medicine, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezzat</LastName><ForeName>Kariem</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espay</LastName><ForeName>Alberto J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>James J. and Joan A. Gardner Family Center for Parkinson's disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG012435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066530</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EClinicalMedicine</MedlineTA><NlmUniqueID>101733727</NlmUniqueID><ISSNLinking>2589-5370</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Atrophy</Keyword><Keyword MajorTopicYN="N">Hippocampus</Keyword><Keyword MajorTopicYN="N">&#x392;-amyloid</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>10</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34505023</ArticleId><ArticleId IdType="pmc">PMC8413261</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2021.100988</ArticleId><ArticleId IdType="pii">S2589-5370(21)00268-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D.J., Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8:595&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Malmberg M., Malm T., Gustafsson O. Disentangling the amyloid pathways: a mechanistic approach to etiology. Front Neurosci. 2020;14:256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186396</ArticleId><ArticleId IdType="pubmed">32372895</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagase T., Iwaya K., Iwaki Y. Insulin-derived amyloidosis and poor glycemic control: a case series. Am J Med. 2014;127:450&#x2013;454. May.</Citation><ArticleIdList><ArticleId IdType="pubmed">24462809</ArticleId></ArticleIdList></Reference><Reference><Citation>Navalkar A., Ghosh S., Pandey S., Paul A., Datta D., Maji S.K. Prion-like p53 amyloids in cancer. Biochemistry. 2020;59:146&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">31603660</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent S.A., Spires-Jones T.L., Durrant C.S. The physiological roles of tau and A&#x3b2;: implications for Alzheimer's disease pathology and therapeutics. Acta Neuropathol. 2020;140:417&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7498448</ArticleId><ArticleId IdType="pubmed">32728795</ArticleId></ArticleIdList></Reference><Reference><Citation>McDade E., Wang G., Gordon B.A. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018;91:e1295&#x2013;e1306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6177272</ArticleId><ArticleId IdType="pubmed">30217935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G., La Joie R., Villain N. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin. 2013;2:356&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777672</ArticleId><ArticleId IdType="pubmed">24179789</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal H., Dickson D., Fuld P. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology. 1988;38:1682&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pubmed">3185902</ArticleId></ArticleIdList></Reference><Reference><Citation>Polvikoski T., Sulkava R., Myllykangas L. Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. Neurology. 2001;56:1690&#x2013;1696.</Citation><ArticleIdList><ArticleId IdType="pubmed">11425935</ArticleId></ArticleIdList></Reference><Reference><Citation>Panza F., Lozupone M., Seripa D., Imbimbo B.P. Amyloid-&#x3b2; immunotherapy for alzheimer disease: is it now a long shot? Ann Neurol. 2019;85:303&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">30635926</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C.R., Bennett D.A., Blennow K. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C.R., Therneau T.M., Weigand S.D. Prevalence of biologically vs clinically defined alzheimer spectrum entities using the national institute on aging-Alzheimer's association research framework. JAMA Neurol. 2019;76:1174&#x2013;1183. [published online ahead of print, 2019 Jul 15]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632154</ArticleId><ArticleId IdType="pubmed">31305929</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A.M., Mintun M.A., Mach R.H. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N., Insel P.S., Donohue M. Independent information from cerebrospinal fluid amyloid-&#x3b2; and florbetapir imaging in Alzheimer's disease. Brain. 2015;138:772&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339769</ArticleId><ArticleId IdType="pubmed">25541191</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito J.R., May P.C., O'Dell M.A. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwan M.D., Rinne J.O., Hasselbalch S.G. Use of amyloid PET-to determine cutpoints for CSF markers: a multicenter study. Neurology. 2016;86:50&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731290</ArticleId><ArticleId IdType="pubmed">26468410</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane P.K., Carle A., Gibbons L.E. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Brain Imaging Behav. 2012;6:502&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806057</ArticleId><ArticleId IdType="pubmed">22782295</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons L.E., Carle A.C., Mackin R.S. A composite score for executive functioning, validated in Alzheimer's disease neuroimaging initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6:517&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684181</ArticleId><ArticleId IdType="pubmed">22644789</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwivedi A.K., Mallawaarachchi I., Alvarado L.A. Analysis of small sample size studies using nonparametric bootstrap test with pooled resampling method. Stat Med. 2017;36:2187&#x2013;2205.</Citation><ArticleIdList><ArticleId IdType="pubmed">28276584</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau S.M., Lu M., Joshi A.D. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of &#x3b2;-amyloid. Ann Neurol. 2013;74:826&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo J.A., Lim J.H., Sul A.R., Lee M., Youn Y.C., Kim H.J. Cerebrospinal fluid &#x3b2;-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease&#x2013;systematic review and meta-analysis. PLoS ONE. 2015;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339391</ArticleId><ArticleId IdType="pubmed">25710596</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Toledano M.A., Shelanski M.L. Neurogenic effect of beta-amyloid peptide in the development of neural stem cells. J Neurosci. 2004;24:5439&#x2013;5444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729298</ArticleId><ArticleId IdType="pubmed">15190117</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D., Privitera L., Fa' M. Endogenous amyloid-&#x3b2; is necessary for hippocampal synaptic plasticity and memory. Ann Neurol. 2011;69:819&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4071456</ArticleId><ArticleId IdType="pubmed">21472769</ArticleId></ArticleIdList></Reference><Reference><Citation>Stomrud E., Minthon L., Zetterberg H., Blennow K., Hansson O. Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: a prospective 9-year study. Alzheimers Dement. 2015;1:403&#x2013;411. (Amst)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879483</ArticleId><ArticleId IdType="pubmed">27239521</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman R.J., Xiong C., Benzinger T.L. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795&#x2013;804. [published correction appears in N Engl J Med. 2012 Aug 23;367(8):780]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C.R., Knopman D.S., Jagust W.J. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E., H&#xf6;ltt&#xe4; M., Soininen H. Altered cerebrospinal fluid levels of amyloid &#x3b2; and amyloid precursor-like protein 1 peptides in Down's syndrome. Neuromolecular Med. 2014;16:510&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">24740518</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman R.J., Siemers E.R., Mawuenyega K.G. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009;66:48&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730994</ArticleId><ArticleId IdType="pubmed">19360898</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan M.F., Kost J., Voss T. Randomized trial of verubecestat for prodromal Alzheimer's disease. N Engl J Med. 2019;380:1408&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776078</ArticleId><ArticleId IdType="pubmed">30970186</ArticleId></ArticleIdList></Reference><Reference><Citation>Espay A.J., Sturchio A., Schneider L.S., Ezzat K. Soluble amyloid-&#x3b2; consumption in Alzheimer's disease. J Alzheimers Dis. 2021;82 doi: 10.3233/JAD-210415.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-210415</ArticleId><ArticleId IdType="pubmed">34151810</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34504028</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>18</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET.</ArticleTitle><Pagination><StartPage>e1823</StartPage><EndPage>e1834</EndPage><MedlinePgn>e1823-e1834</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000012775</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">To predict when cognitively normal individuals with brain amyloidosis will develop symptoms of Alzheimer disease (AD).</AbstractText><AbstractText Label="METHODS">Brain amyloid burden was measured by amyloid PET with Pittsburgh compound B. The mean cortical standardized uptake value ratio (SUVR) was transformed into a timescale with the use of longitudinal data.</AbstractText><AbstractText Label="RESULTS">Amyloid accumulation was evaluated in 236 individuals who underwent &gt;1 amyloid PET scan. The average age was 66.5 &#xb1; 9.2 years, and 12 individuals (5%) had cognitive impairment at their baseline amyloid PET scan. A tipping point in amyloid accumulation was identified at a low level of amyloid burden (SUVR 1.2), after which nearly all individuals accumulated amyloid at a relatively consistent rate until reaching a high level of amyloid burden (SUVR 3.0). The average time between levels of amyloid burden was used to estimate the age at which an individual reached SUVR 1.2. Longitudinal clinical diagnoses for 180 individuals were aligned by the estimated age at SUVR 1.2. In the 22 individuals who progressed from cognitively normal to a typical AD dementia syndrome, the estimated age at which an individual reached SUVR 1.2 predicted the age at symptom onset (<i>R</i> <sup>2</sup> = 0.54, <i>p</i> &lt; 0.0001, root mean square error [RMSE] 4.5 years); the model was more accurate after exclusion of 3 likely misdiagnoses (<i>R</i> <sup>2</sup> = 0.84, <i>p</i> &lt; 0.0001, RMSE 2.8 years).</AbstractText><AbstractText Label="CONCLUSION">The age at symptom onset in sporadic AD is strongly correlated with the age at which an individual reaches a tipping point in amyloid accumulation.</AbstractText><CopyrightInformation>&#xa9; 2021 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schindler</LastName><ForeName>Suzanne E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0002-1680-1465</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., Y.L., V.D.B., A.M.F., D.M.H., R.J.B., J.C.M.), Knight Alzheimer Disease Research Center (S.E.S., V.D.B., B.A.G., T.L.S.B., G.W., D.C., A.M.F., D.M.H., R.J.B., J.C.M., C.X.), Division of Biostatistics (Y.L., G.W., D.C., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (A.M.F., D.M.H., R.J.B.), Washington University School of Medicine, St. Louis, MO; and Department of Neurology and Psychiatry (W.E.K.), University of Pittsburgh, PA. schindler.s.e@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., Y.L., V.D.B., A.M.F., D.M.H., R.J.B., J.C.M.), Knight Alzheimer Disease Research Center (S.E.S., V.D.B., B.A.G., T.L.S.B., G.W., D.C., A.M.F., D.M.H., R.J.B., J.C.M., C.X.), Division of Biostatistics (Y.L., G.W., D.C., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (A.M.F., D.M.H., R.J.B.), Washington University School of Medicine, St. Louis, MO; and Department of Neurology and Psychiatry (W.E.K.), University of Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia D</ForeName><Initials>VD</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., Y.L., V.D.B., A.M.F., D.M.H., R.J.B., J.C.M.), Knight Alzheimer Disease Research Center (S.E.S., V.D.B., B.A.G., T.L.S.B., G.W., D.C., A.M.F., D.M.H., R.J.B., J.C.M., C.X.), Division of Biostatistics (Y.L., G.W., D.C., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (A.M.F., D.M.H., R.J.B.), Washington University School of Medicine, St. Louis, MO; and Department of Neurology and Psychiatry (W.E.K.), University of Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., Y.L., V.D.B., A.M.F., D.M.H., R.J.B., J.C.M.), Knight Alzheimer Disease Research Center (S.E.S., V.D.B., B.A.G., T.L.S.B., G.W., D.C., A.M.F., D.M.H., R.J.B., J.C.M., C.X.), Division of Biostatistics (Y.L., G.W., D.C., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (A.M.F., D.M.H., R.J.B.), Washington University School of Medicine, St. Louis, MO; and Department of Neurology and Psychiatry (W.E.K.), University of Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TLS</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., Y.L., V.D.B., A.M.F., D.M.H., R.J.B., J.C.M.), Knight Alzheimer Disease Research Center (S.E.S., V.D.B., B.A.G., T.L.S.B., G.W., D.C., A.M.F., D.M.H., R.J.B., J.C.M., C.X.), Division of Biostatistics (Y.L., G.W., D.C., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (A.M.F., D.M.H., R.J.B.), Washington University School of Medicine, St. Louis, MO; and Department of Neurology and Psychiatry (W.E.K.), University of Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guoqiao</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., Y.L., V.D.B., A.M.F., D.M.H., R.J.B., J.C.M.), Knight Alzheimer Disease Research Center (S.E.S., V.D.B., B.A.G., T.L.S.B., G.W., D.C., A.M.F., D.M.H., R.J.B., J.C.M., C.X.), Division of Biostatistics (Y.L., G.W., D.C., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (A.M.F., D.M.H., R.J.B.), Washington University School of Medicine, St. Louis, MO; and Department of Neurology and Psychiatry (W.E.K.), University of Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coble</LastName><ForeName>Dean</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7551-3132</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., Y.L., V.D.B., A.M.F., D.M.H., R.J.B., J.C.M.), Knight Alzheimer Disease Research Center (S.E.S., V.D.B., B.A.G., T.L.S.B., G.W., D.C., A.M.F., D.M.H., R.J.B., J.C.M., C.X.), Division of Biostatistics (Y.L., G.W., D.C., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (A.M.F., D.M.H., R.J.B.), Washington University School of Medicine, St. Louis, MO; and Department of Neurology and Psychiatry (W.E.K.), University of Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., Y.L., V.D.B., A.M.F., D.M.H., R.J.B., J.C.M.), Knight Alzheimer Disease Research Center (S.E.S., V.D.B., B.A.G., T.L.S.B., G.W., D.C., A.M.F., D.M.H., R.J.B., J.C.M., C.X.), Division of Biostatistics (Y.L., G.W., D.C., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (A.M.F., D.M.H., R.J.B.), Washington University School of Medicine, St. Louis, MO; and Department of Neurology and Psychiatry (W.E.K.), University of Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., Y.L., V.D.B., A.M.F., D.M.H., R.J.B., J.C.M.), Knight Alzheimer Disease Research Center (S.E.S., V.D.B., B.A.G., T.L.S.B., G.W., D.C., A.M.F., D.M.H., R.J.B., J.C.M., C.X.), Division of Biostatistics (Y.L., G.W., D.C., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (A.M.F., D.M.H., R.J.B.), Washington University School of Medicine, St. Louis, MO; and Department of Neurology and Psychiatry (W.E.K.), University of Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-3400-0856</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., Y.L., V.D.B., A.M.F., D.M.H., R.J.B., J.C.M.), Knight Alzheimer Disease Research Center (S.E.S., V.D.B., B.A.G., T.L.S.B., G.W., D.C., A.M.F., D.M.H., R.J.B., J.C.M., C.X.), Division of Biostatistics (Y.L., G.W., D.C., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (A.M.F., D.M.H., R.J.B.), Washington University School of Medicine, St. Louis, MO; and Department of Neurology and Psychiatry (W.E.K.), University of Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-7729-1702</Identifier><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., Y.L., V.D.B., A.M.F., D.M.H., R.J.B., J.C.M.), Knight Alzheimer Disease Research Center (S.E.S., V.D.B., B.A.G., T.L.S.B., G.W., D.C., A.M.F., D.M.H., R.J.B., J.C.M., C.X.), Division of Biostatistics (Y.L., G.W., D.C., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (A.M.F., D.M.H., R.J.B.), Washington University School of Medicine, St. Louis, MO; and Department of Neurology and Psychiatry (W.E.K.), University of Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., Y.L., V.D.B., A.M.F., D.M.H., R.J.B., J.C.M.), Knight Alzheimer Disease Research Center (S.E.S., V.D.B., B.A.G., T.L.S.B., G.W., D.C., A.M.F., D.M.H., R.J.B., J.C.M., C.X.), Division of Biostatistics (Y.L., G.W., D.C., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (A.M.F., D.M.H., R.J.B.), Washington University School of Medicine, St. Louis, MO; and Department of Neurology and Psychiatry (W.E.K.), University of Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Neurology (S.E.S., Y.L., V.D.B., A.M.F., D.M.H., R.J.B., J.C.M.), Knight Alzheimer Disease Research Center (S.E.S., V.D.B., B.A.G., T.L.S.B., G.W., D.C., A.M.F., D.M.H., R.J.B., J.C.M., C.X.), Division of Biostatistics (Y.L., G.W., D.C., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (A.M.F., D.M.H., R.J.B.), Washington University School of Medicine, St. Louis, MO; and Department of Neurology and Psychiatry (W.E.K.), University of Pittsburgh, PA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG050921</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG053474</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025350</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG053426</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD025214</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="Y">Amyloidosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>10</Day><Hour>5</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34504028</ArticleId><ArticleId IdType="pmc">PMC8610624</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000012775</ArticleId><ArticleId IdType="pii">WNL.0000000000012775</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. . Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. . Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Lansbury PT Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem. 1997;66:385-407.</Citation><ArticleIdList><ArticleId IdType="pubmed">9242912</ArticleId></ArticleIdList></Reference><Reference><Citation>Morel B, Conejero-Lara F. Early mechanisms of amyloid fibril nucleation in model and disease-related proteins. Biochim Biophys Acta Proteins Proteom. 2019;1867(11):140264.</Citation><ArticleIdList><ArticleId IdType="pubmed">31437584</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava AK, Pittman JM, Zerweck J, et al. . &#x3b2;-Amyloid aggregation and heterogeneous nucleation. Protein Sci. 2019;28(9):1567-1581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6699094</ArticleId><ArticleId IdType="pubmed">31276610</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Lesnick TG, et al. . Brain beta-amyloid load approaches a plateau. Neurology. 2013;80(10):890-896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653215</ArticleId><ArticleId IdType="pubmed">23446680</ArticleId></ArticleIdList></Reference><Reference><Citation>Budgeon CA, Murray K, Turlach BA, et al. . Constructing longitudinal disease progression curves using sparse, short-term individual data with an application to Alzheimer's disease. Stat Med. 2017;36(17):2720-2734.</Citation><ArticleIdList><ArticleId IdType="pubmed">28444781</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM; Alzheimer's Disease Neuroimaging Initiative. Temporal dynamics of beta-amyloid accumulation in aging and Alzheimer disease. Neurology. 2021;96(9):e1347&#x2013;e1357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055327</ArticleId><ArticleId IdType="pubmed">33408147</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor P, Roe CM, Villegas A, et al. . Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol. 2003;54(2):163-169.</Citation><ArticleIdList><ArticleId IdType="pubmed">12891668</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW Jr, Miller JP, Baty J, Morris JC. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol. 1993;50(4):349-358.</Citation><ArticleIdList><ArticleId IdType="pubmed">8460956</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, et al. . The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease centers. Alzheimer Dis Assoc Disord. 2006;20(4):210-216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, Miller JP, et al. . Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58(3):397-405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255443</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology. 2006;67(3):467-473.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894109</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Blennow K, Froelich L, et al. . Harmonized diagnostic criteria for Alzheimer's disease: recommendations. J Intern Med. 2014;275(3):204-213.</Citation><ArticleIdList><ArticleId IdType="pubmed">24605805</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. . Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55(3):306-319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Blazey TM, Snyder AZ, et al. . Partial volume correction in quantitative amyloid imaging. NeuroImage. 2015;107:55-64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300252</ArticleId><ArticleId IdType="pubmed">25485714</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39(5):904-911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, McCue L, Jasielec MS, et al. . Imaging and cerebrospinal fluid biomarkers in early preclinical Alzheimer disease. Ann Neurol. 2016;80(3):379-387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016232</ArticleId><ArticleId IdType="pubmed">27398953</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Flores S, Wang G, et al. . Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alzheimers Dement (Amst). 2019;11:180-190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6389727</ArticleId><ArticleId IdType="pubmed">30847382</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Dukart J, Brendel M, et al. . Rate of beta-amyloid accumulation varies with baseline amyloid burden: implications for anti-amyloid drug trials. Alzheimers Dement. 2018;14(11):1387-1396.</Citation><ArticleIdList><ArticleId IdType="pubmed">30420035</ArticleId></ArticleIdList></Reference><Reference><Citation>Koscik RL, Betthauser TJ, Jonaitis EM, et al. . Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimers Dement. 2020;12(1):e12007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7085284</ArticleId><ArticleId IdType="pubmed">32211502</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgel M, An Y, Zhou Y, et al. . Individual estimates of age at detectable amyloid onset for risk factor assessment. Alzheimers Dement. 2016;12(4):373-379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4841700</ArticleId><ArticleId IdType="pubmed">26588863</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrell ME, Jiang S, Schultz AP, et al. . Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation. Neurology. 2021;96(4):e619-e631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7905788</ArticleId><ArticleId IdType="pubmed">33199430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussy A, Snider BJ, Coble D, et al. . Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. Neurobiol Aging. 2019;75:42-50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6385602</ArticleId><ArticleId IdType="pubmed">30530186</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra S, Blazey TM, Holtzman DM, et al. . Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE epsilon4 genotype. Brain. 2018;141(6):1828-1839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5972633</ArticleId><ArticleId IdType="pubmed">29672664</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Pike KE, Chetelat G, et al. . Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69(1):181-192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045039</ArticleId><ArticleId IdType="pubmed">21280088</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Liu X, et al. . Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging. 2013;34(1):1-12.</Citation><ArticleIdList><ArticleId IdType="pubmed">22633529</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Wiste HJ, Weigand SD, et al. . Age, sex, and APOE epsilon4 effects on memory, brain structure, and beta-amyloid across the adult life span. JAMA Neurol. 2015;72(5):511-519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428984</ArticleId><ArticleId IdType="pubmed">25775353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, Campbell EM, Yu Z, et al. . Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories. Neurobiol Aging. 2020;94:111-120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7483397</ArticleId><ArticleId IdType="pubmed">32603776</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlassenko AG, Mintun MA, Xiong C, et al. . Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol. 2011;70(5):857-861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243969</ArticleId><ArticleId IdType="pubmed">22162065</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimmer T, Tholen S, Yousefi BH, et al. . Progression of cerebral amyloid load is associated with the apolipoprotein E epsilon4 genotype in Alzheimer's disease. Biol Psychiatry. 2010;68(10):879-884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045041</ArticleId><ArticleId IdType="pubmed">20598287</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Bilgel M, Moghekar A, et al. . Changes in Abeta biomarkers and associations with APOE genotype in 2 longitudinal cohorts. Neurobiol Aging. 2015;36(8):2333-2339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084914</ArticleId><ArticleId IdType="pubmed">26004017</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Mormino EC, Alzheimer's Disease Neuroimaging Initiative. APOE genotype and early beta-amyloid accumulation in older adults without dementia. Neurology. 2017;89(10):1028-1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5589795</ArticleId><ArticleId IdType="pubmed">28794245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryman DC, Acosta-Baena N, Aisen PS, et al. . Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253-260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117367</ArticleId><ArticleId IdType="pubmed">24928124</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim YS, Roe CM, Buckles VD, Morris JC. Clinicopathologic study of Alzheimer's disease: Alzheimer mimics. J Alzheimers Dis. 2013;35(4):799-811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3725959</ArticleId><ArticleId IdType="pubmed">23481687</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. . Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939-1949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517678</ArticleId><ArticleId IdType="pubmed">25988463</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012;11(11):1006-1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507991</ArticleId><ArticleId IdType="pubmed">23079557</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and 'wingmen. Nat Neurosci. 2015;18(6):800-806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4445458</ArticleId><ArticleId IdType="pubmed">26007213</ArticleId></ArticleIdList></Reference><Reference><Citation>Arboleda-Velasquez JF, Lopera F, O'Hare M, et al. . Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25(11):1680-1683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6898984</ArticleId><ArticleId IdType="pubmed">31686034</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Ances BM, Head D, et al. . Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain. 2018;141(11):3233-3248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6202574</ArticleId><ArticleId IdType="pubmed">30304397</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Grant EA, et al. . Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66(12):1469-1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Flores S, Hornbeck RC, et al. . Utilizing the centiloid scale in cross-sectional and longitudinal PiB PET studies. Neuroimage Clin. 2018;19:406-416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6051499</ArticleId><ArticleId IdType="pubmed">30035025</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Benzinger TL, Berry S, et al. . The DIAN-TU Next Generation Alzheimer's Prevention Trial: adaptive design and disease progression model. Alzheimers Dement. 2017;13(1):8-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5218895</ArticleId><ArticleId IdType="pubmed">27583651</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34524859</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>611</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Wolframin-1-expressing neurons in the entorhinal cortex propagate tau to CA1 neurons and impair hippocampal memory in mice.</ArticleTitle><Pagination><StartPage>eabe8455</StartPage><MedlinePgn>eabe8455</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abe8455</ELocationID><Abstract><AbstractText>Abnormally phosphorylated tau, an early neuropathologic marker of Alzheimer&#x2019;s disease (AD), first occurs in the brain&#x2019;s entorhinal cortex layer II (ECII) and then spreads to the CA1 field of the hippocampus. Animal models of tau propagation aiming to recapitulate this phenomenon mostly show tau transfer from ECII stellate neurons to the dentate gyrus, but tau pathology in the dentate gyrus does not appear until advanced stages of AD. Wolframin-1&#x2013;expressing (Wfs1<sup>+</sup>) pyramidal neurons have been shown functionally to modulate hippocampal CA1 neurons in mice. Here, we report that Wfs1<sup>+</sup> pyramidal neurons are conserved in the ECII of postmortem human brain tissue and that Wfs1 colocalized with abnormally phosphorylated tau in brains from individuals with early AD. Wfs1<sup>+</sup> neuron&#x2013;specific expression of human P301L mutant tau in mouse ECII resulted in transfer of tau to hippocampal CA1 pyramidal neurons, suggesting spread of tau pathology as observed in the early Braak stages of AD. In mice expressing human mutant tau specifically in the ECII brain region, electrophysiological recordings of CA1 pyramidal neurons showed reduced excitability. Multielectrode array recordings of optogenetically stimulated Wfs1<sup>+</sup> ECII axons resulted in reduced CA1 neuronal firing. Chemogenetic activation of CA1 pyramidal neurons showed a reduction in c-fos<sup>+</sup> cells in the CA1. Last, a fear conditioning task revealed deficits in trace and contextual memory in mice overexpressing human mutant tau in the ECII. This work demonstrates tau transfer from the ECII to CA1 in mouse brain and provides an early Braak stage preclinical model of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delpech</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0003-2674-1598</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Bordeaux, INRAE, Bordeaux INP, NutriNeuro, UMR 1286, F-33000 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathak</LastName><ForeName>Dhruba</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varghese</LastName><ForeName>Merina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1517-3903</Identifier><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience, Friedman Brain Institute, and Ronald C. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalavai</LastName><ForeName>Srinidhi Venkatesan</ForeName><Initials>SV</Initials><Identifier Source="ORCID">0000-0003-1888-0520</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hays</LastName><ForeName>Emma C</ForeName><Initials>EC</Initials><Identifier Source="ORCID">0000-0002-5526-2732</Identifier><AffiliationInfo><Affiliation>Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hof</LastName><ForeName>Patrick R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0002-3208-1154</Identifier><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience, Friedman Brain Institute, and Ronald C. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>W Evan</ForeName><Initials>WE</Initials><Identifier Source="ORCID">0000-0002-6247-6595</Identifier><AffiliationInfo><Affiliation>Computational Biomedicine, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikezu</LastName><ForeName>Seiko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medalla</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4890-2532</Identifier><AffiliationInfo><Affiliation>Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Systems Neuroscience, Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luebke</LastName><ForeName>Jennifer I</ForeName><Initials>JI</Initials><Identifier Source="ORCID">0000-0003-1399-6073</Identifier><AffiliationInfo><Affiliation>Anatomy and Neurobiology, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Systems Neuroscience, Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikezu</LastName><ForeName>Tsuneya</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3979-8596</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Systems Neuroscience, Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 AG054199</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG067763</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG066429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054672</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG072719</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="Y">Entorhinal Cortex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="Y">Hippocampus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> T.I. consults for Takeda Pharmaceuticals. J.I.L. has consulted for the Allen Institute for Brain Science. P.R.H. consults for the Journal of Comparative Neurology. All other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>15</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34524859</ArticleId><ArticleId IdType="mid">NIHMS1769104</ArticleId><ArticleId IdType="pmc">PMC8763211</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abe8455</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Braak E, Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL, Alzheimer&#x2019;s disease: Cell-specific pathology isolates the hippocampal formation. Science 225, 1168&#x2013;1170 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K, Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 112, 389&#x2013;404 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Beall MJ, Lewis DA, Heterogeneity of layer II neurons in human entorhinal cortex. J. Comp. Neurol. 321, 241&#x2013;266 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1500542</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohara S, Gianatti M, Itou K, Berndtsson CH, Doan TP, Kitanishi T, Mizuseki K, Iijima T, Tsutsui KI, Witter MP, Entorhinal layer II calbindin-expressing neurons originate widespread telencephalic and intrinsic projections. Front. Syst. Neurosci. 13, 54 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6803526</ArticleId><ArticleId IdType="pubmed">31680885</ArticleId></ArticleIdList></Reference><Reference><Citation>Witter MP, Doan TP, Jacobsen B, Nilssen ES, Ohara S, Architecture of the entorhinal cortex a review of entorhinal anatomy in rodents with some comparative notes. Front. Syst. Neurosci. 11, 46 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5488372</ArticleId><ArticleId IdType="pubmed">28701931</ArticleId></ArticleIdList></Reference><Reference><Citation>Naumann RK, Ray S, Prokop S, Las L, Heppner FL, Brecht M, Conserved size and periodicity of pyramidal patches in layer 2 of medial/caudal entorhinal cortex. J. Comp. Neurol. 524, 783&#x2013;806 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014138</ArticleId><ArticleId IdType="pubmed">26223342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura T, Pignatelli M, Suh J, Kohara K, Yoshiki A, Abe K, Tonegawa S, Island cells control temporal association memory. Science 343, 896&#x2013;901 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5572219</ArticleId><ArticleId IdType="pubmed">24457215</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Koyama A, Maeda S, Ho K, Devidze N, Dubal DB, Yu GQ, Masliah E, Mucke L, Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLOS ONE 7, e45881 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3454317</ArticleId><ArticleId IdType="pubmed">23029293</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K, Trans-synaptic spread of tau pathology in vivo. PLOS ONE 7, e31302 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT, Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 73, 685&#x2013;697 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, Wolozin B, Butovsky O, K&#xfc;gler S, Ikezu T, Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 18, 1584&#x2013;1593 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694577</ArticleId><ArticleId IdType="pubmed">26436904</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Wegmann S, Dujardin S, Commins C, Schiantarelli J, Klickstein N, Kamath TV, Carlson GA, Nelken I, Hyman BT, Tau impairs neural circuits, dominating amyloid-&#x3b2; effects, in Alzheimer models in vivo. Nat. Neurosci. 22, 57&#x2013;64 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6560629</ArticleId><ArticleId IdType="pubmed">30559471</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth BL, DREADDs for neuroscientists. Neuron 89, 683&#x2013;694 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4759656</ArticleId><ArticleId IdType="pubmed">26889809</ArticleId></ArticleIdList></Reference><Reference><Citation>Tulving E, Episodic memory: From mind to brain. Annu. Rev. Psychol. 53, 1&#x2013;25 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11752477</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichenbaum H, A cortical-hippocampal system for declarative memory. Nat. Rev. Neurosci. 1, 41&#x2013;50 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11252767</ArticleId></ArticleIdList></Reference><Reference><Citation>Hales JB, Schlesiger MI, Leutgeb JK, Squire LR, Leutgeb S, Clark RE, Medial entorhinal cortex lesions only partially disrupt hippocampal place cells and hippocampus-dependent place memory. Cell Rep. 9, 893&#x2013;901 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4294707</ArticleId><ArticleId IdType="pubmed">25437546</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh J, Rivest AJ, Nakashiba T, Tominaga T, Tonegawa S, Entorhinal cortex layer III input to the hippocampus is crucial for temporal association memory. Science 334, 1415&#x2013;1420 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22052975</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankland PW, Bontempi B, The organization of recent and remote memories. Nat. Rev. Neurosci. 6, 119&#x2013;130 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15685217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartsch T, Dohring J, Rohr A, Jansen O, Deuschl G, CA1 neurons in the human hippocampus are critical for autobiographical memory, mental time travel, and autonoetic consciousness. Proc. Natl. Acad. Sci. U.S.A. 108, 17562&#x2013;17567 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198338</ArticleId><ArticleId IdType="pubmed">21987814</ArticleId></ArticleIdList></Reference><Reference><Citation>Soltesz I, Losonczy A, CA1 pyramidal cell diversity enabling parallel information processing in the hippocampus. Nat. Neurosci. 21, 484&#x2013;493 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909691</ArticleId><ArticleId IdType="pubmed">29593317</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowski MM, Ronnqvist KC, Tsanov M, Vann SD, Wright NF, Erichsen JT, Aggleton JP, O&#x2019;Mara SM, The anterior thalamus provides a subcortical circuit supporting memory and spatial navigation. Front. Syst. Neurosci. 7, 45 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3757326</ArticleId><ArticleId IdType="pubmed">24009563</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Trecidi K, Neuroanatomy and pathology of sporadic Alzheimer&#x2019;s disease. Adv. Anat. Embryol. Cell Biol. 215, 1&#x2013;162 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25920101</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, Lee JH, Ryu YH, Lee MS, Lyoo CH, In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann. Neurol. 80, 247&#x2013;258 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27323247</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Alzheimer&#x2019;s disease affects limbic nuclei of the thalamus. Acta Neuropathol. 81, 261&#x2013;268 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1711755</ArticleId></ArticleIdList></Reference><Reference><Citation>Rub U, Stratmann K, Heinsen H, Turco DD, Ghebremedhin E, Seidel K, den Dunnen W, Korf H-W, Hierarchical distribution of the tau cytoskeletal pathology in the thalamus of Alzheimer&#x2019;s disease patients. J. Alzheimers Dis. 49, 905&#x2013;915 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26519431</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs EC, Neitz A, Pinna R, Melzer S, Caputi A, Monyer H, Local and distant input controlling excitation in layer II of the medial entorhinal cortex. Neuron 89, 194&#x2013;208 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4712190</ArticleId><ArticleId IdType="pubmed">26711115</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakst I, Amaral DG, The distribution of acetylcholinesterase in the hippocampal formation of the monkey. J. Comp. Neurol. 225, 344&#x2013;371 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6725649</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S, Naumann R, Burgalossi A, Tang Q, Schmidt H, Brecht M, Grid-layout and theta-modulation of layer 2 pyramidal neurons in medial entorhinal cortex. Science 343, 891&#x2013;896 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24457213</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland DC, Obenhaus HA, Skyt&#xf8;en ER, Zhang Q, Kentros CG, Moser EI, Moser M-B, Functional properties of stellate cells in medial entorhinal cortex layer II. eLife 7, e36664 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6140717</ArticleId><ArticleId IdType="pubmed">30215597</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, Rodriguez GA, Herman M, Emrani S, Nahmani E, Barrett G, Figueroa HY, Goldberg E, Hussaini SA, Duff KE, Tau pathology induces excitatory neuron loss, grid cell dysfunction, and spatial memory deficits reminiscent of early Alzheimer&#x2019;s disease. Neuron 93, 533&#x2013;541.e5 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363269</ArticleId><ArticleId IdType="pubmed">28111080</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak E, Braak H, Alzheimer&#x2019;s disease: Transiently developing dendritic changes in pyramidal cells of sector CA1 of the Ammon&#x2019;s horn. Acta Neuropathol. 93, 323&#x2013;325 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9113196</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovett-Barron M, Kaifosh P, Kheirbek MA, Danielson N, Zaremba JD, Reardon TR, Turi GF, Hen R, Zemelman BV, Losonczy A, Dendritic inhibition in the hippocampus supports fear learning. Science 343, 857&#x2013;863 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4018419</ArticleId><ArticleId IdType="pubmed">24558155</ArticleId></ArticleIdList></Reference><Reference><Citation>Beam CR, Kaneshiro C, Jang JY, Reynolds CA, Pedersen NL, Gatz M, Differences between women and men in incidence rates of dementia and Alzheimer&#x2019;s disease. J. Alzheimers Dis. 64, 1077&#x2013;1083 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6226313</ArticleId><ArticleId IdType="pubmed">30010124</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH, Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476&#x2013;481 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, van Slegtenhorst M, Gwinn-Hardy K, Murphy MP, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M, Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25, 402&#x2013;405 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Z, Pathak D, Venkatesan Kalavai S, Yoshii-Kitahara A, Muraoka S, Bhatt N, Takamatsu-Yukawa K, Hu J, Wang Y, Hersh S, Ericsson M, Gorantla S, Gendelman HE, Kayed R, Ikezu S, Luebke JI, Ikezu T, Alzheimer&#x2019;s disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain 144, 288&#x2013;309 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7880668</ArticleId><ArticleId IdType="pubmed">33246331</ArticleId></ArticleIdList></Reference><Reference><Citation>Clayton K, Delpech JC, Herron S, Iwahara N, Ericsson M, Saito T, Saido TC, Ikezu S, Ikezu T, Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model. Mol. Neurodegener 16, 18 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7986521</ArticleId><ArticleId IdType="pubmed">33752701</ArticleId></ArticleIdList></Reference><Reference><Citation>You Y, Botros MB, Enoo AAV, Bockmiller A, Herron S, Delpech JC, Ikezu T, Cre-inducible adeno associated virus-mediated expression of P301L mutant Tau causes motor deficits and neuronal degeneration in the substantia nigra. Neuroscience 422, 65&#x2013;74 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6898791</ArticleId><ArticleId IdType="pubmed">31689387</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway EM, Luo L, Monosynaptic circuit tracing with glycoprotein-deleted rabies viruses. J. Neurosci. 35, 8979&#x2013;8985 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469731</ArticleId><ArticleId IdType="pubmed">26085623</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Schultz C, Sassin I, Ghebremedhin E, del Tredici K, Braak E, Braak H, Sequence of Abeta-protein deposition in the human medial temporal lobe. J. Neuropathol. Exp. Neurol. 59, 733&#x2013;748 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10952063</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussi&#xe8;re T, Friend PD, Sadeghi N, Wicinski B, Lin GI, Bouras C, Giannakopoulos P, Robakis NK, Morrison JH, Perl DP, Hof PR, Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer&#x2019;s disease. Neuroscience 112, 75&#x2013;91 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12044473</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A, Fiji: An open-source platform for biological-image analysis. Nat. Methods 9, 676&#x2013;682 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunkin SM, Ng L, Lau C, Dolbeare T, Gilbert TL, Thompson CL, Hawrylycz M, Dang C, Allen Brain Atlas: An integrated spatio-temporal portal for exploring the central nervous system. Nucleic Acids Res. 41, D996&#x2013;D1008 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531093</ArticleId><ArticleId IdType="pubmed">23193282</ArticleId></ArticleIdList></Reference><Reference><Citation>Medalla M, Gilman JP, Wang JY, Luebke JI, Strength and diversity of inhibitory signaling differentiates primate anterior cingulate from lateral prefrontal cortex. J. Neurosci. 37, 4717&#x2013;4734 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5426565</ArticleId><ArticleId IdType="pubmed">28381592</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Rasband WS, Eliceiri KW, NIH Image to ImageJ: 25 Years of image analysis. Nat. Methods 9, 671&#x2013;675 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Medalla M, Barbas H, Synapses with inhibitory neurons differentiate anterior cingulate from dorsolateral prefrontal pathways associated with cognitive control. Neuron 61, 609&#x2013;620 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804928</ArticleId><ArticleId IdType="pubmed">19249280</ArticleId></ArticleIdList></Reference><Reference><Citation>Medalla M, Barbas H, Anterior cingulate synapses in prefrontal areas 10 and 46 suggest differential influence in cognitive control. J. Neurosci. 30, 16068&#x2013;16081 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064955</ArticleId><ArticleId IdType="pubmed">21123554</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A, Palay SL, Webster HD, The fine structure of the nervous system: The neurons and supporting cells. Ann. Neurol. 4, 588&#x2013;588 (1978).</Citation></Reference><Reference><Citation>Papouin T, Haydon PG, Obtaining acute brain slices. Bio Protoc. 8, e2699 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856250</ArticleId><ArticleId IdType="pubmed">29552595</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34542571</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Head-to-Head Comparison of 8 Plasma Amyloid-&#x3b2; 42/40 Assays in Alzheimer Disease.</ArticleTitle><Pagination><StartPage>1375</StartPage><EndPage>1382</EndPage><MedlinePgn>1375-1382</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.3180</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Blood-based tests for brain amyloid-&#x3b2; (A&#x3b2;) pathology are needed for widespread implementation of Alzheimer disease (AD) biomarkers in clinical care and to facilitate patient screening and monitoring of treatment responses in clinical trials.</AbstractText><AbstractText Label="OBJECTIVE">To compare the performance of plasma A&#x3b2;42/40 measured using 8 different A&#x3b2; assays when detecting abnormal brain A&#x3b2; status in patients with early AD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This study included 182 cognitively unimpaired participants and 104 patients with mild cognitive impairment from the BioFINDER cohort who were enrolled at 3 different hospitals in Sweden and underwent A&#x3b2; positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) and plasma collection from 2010 to 2014. Plasma A&#x3b2;42/40 was measured using an immunoprecipitation-coupled mass spectrometry developed at Washington University (IP-MS-WashU), antibody-free liquid chromatography MS developed by Araclon (LC-MS-Arc), and immunoassays from Roche Diagnostics (IA-Elc); Euroimmun (IA-EI); and Amsterdam University Medical Center, ADx Neurosciences, and Quanterix (IA-N4PE). Plasma A&#x3b2;42/40 was also measured using an IP-MS-based method from Shimadzu in 200 participants (IP-MS-Shim) and an IP-MS-based method from the University of Gothenburg (IP-MS-UGOT) and another immunoassay from Quanterix (IA-Quan) among 227 participants. For validation, 122 participants (51 cognitively normal, 51 with mild cognitive impairment, and 20 with AD dementia) were included from the Alzheimer Disease Neuroimaging Initiative who underwent A&#x3b2;-PET and plasma A&#x3b2; assessments using IP-MS-WashU, IP-MS-Shim, IP-MS-UGOT, IA-Elc, IA-N4PE, and IA-Quan assays.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Discriminative accuracy of plasma A&#x3b2;42/40 quantified using 8 different assays for abnormal CSF A&#x3b2;42/40 and A&#x3b2;-PET status.</AbstractText><AbstractText Label="RESULTS">A total of 408 participants were included in this study. In the BioFINDER cohort, the mean (SD) age was 71.6 (5.6) years and 49.3% of the cohort were women. When identifying participants with abnormal CSF A&#x3b2;42/40 in the whole cohort, plasma IP-MS-WashU A&#x3b2;42/40 showed significantly higher accuracy (area under the receiver operating characteristic curve [AUC], 0.86; 95% CI, 0.81-0.90) than LC-MS-Arc A&#x3b2;42/40, IA-Elc A&#x3b2;42/40, IA-EI A&#x3b2;42/40, and IA-N4PE A&#x3b2;42/40 (AUC range, 0.69-0.78; P&#x2009;&lt;&#x2009;.05). Plasma IP-MS-WashU A&#x3b2;42/40 performed significantly better than IP-MS-UGOT A&#x3b2;42/40 and IA-Quan A&#x3b2;42/40 (AUC, 0.84 vs 0.68 and 0.64, respectively; P&#x2009;&lt;&#x2009;.001), while there was no difference in the AUCs between IP-MS-WashU A&#x3b2;42/40 and IP-MS-Shim A&#x3b2;42/40 (0.87 vs 0.83; P&#x2009;=&#x2009;.16) in the 2 subcohorts where these biomarkers were available. The results were similar when using A&#x3b2;-PET as outcome. Plasma IPMS-WashU A&#x3b2;42/40 and IPMS-Shim A&#x3b2;42/40 showed highest coefficients for correlations with CSF A&#x3b2;42/40 (r range, 0.56-0.65). The BioFINDER results were replicated in the Alzheimer Disease Neuroimaging Initiative cohort (mean [SD] age, 72.4 [5.4] years; 43.4% women), where the IP-MS-WashU assay performed significantly better than the IP-MS-UGOT, IA-Elc, IA-N4PE, and IA-Quan assays but not the IP-MS-Shim assay.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The results from 2 independent cohorts indicate that certain MS-based methods performed better than most of the immunoassays for plasma A&#x3b2;42/40 when detecting brain A&#x3b2; pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Janelidze</LastName><ForeName>Shorena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience &amp; Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, University College London Institute of Neurology, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>United Kingdom Dementia Research Institute at University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allu&#xe9;</LastName><ForeName>Jos&#xe9; Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Mass Spectrometry Laboratory, Araclon Biotech, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarasa</LastName><ForeName>Leticia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Mass Spectrometry Laboratory, Araclon Biotech, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eichenlaub</LastName><ForeName>Udo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Roche Diagnostics, Penzberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bittner</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ovod</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verberk</LastName><ForeName>Inge M W</ForeName><Initials>IMW</Initials><AffiliationInfo><Affiliation>Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toba</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Akinori</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience &amp; Physiology, the Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#xf6;, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 AG061900</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061900</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2023 Apr 1;80(4):422. doi: 10.1001/jamaneurol.2022.5184.</RefSource><PMID Version="1">36648932</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Teunissen reports nonfinancial support from Quanterix during the conduct of the study; has a patent pending for glial fibrillary acidic protein as a biomarker; serves as an editorial board member of <i>Alzheimer Research and Therapy</i>, Medidact Neurologie, Springer, and <i>Neurology: Neuroimmunology &amp; Neuroinflammation</i>; serves as an editor of Neuromethods Book Series, Springer; and reports grants from Roche Diagnostics, nonfinancial support from ADx Neurosciences and Eli Lilly, and compensation from ACImmune, Axon Neurosciences, Biogen, Brainstorm Cell Therapeutics, Celgene, Denali Therapeutics, EIP Pharma, Eisai, PeopleBio, Toyama Pharmaceutical Association, and Vivoryon Therapeutics outside the submitted work. Dr Zetterberg reports personal fees from Alector, AlzeCure Pharma, AZTherapies, Biogen, Biosplice Therapeutics, Cellectricon, Cognition Therapeutics, Denali Therapeutics, Eisai, Fujirebio Diagnostics, NervGen, Pinteon Therapeutics, Red Abbey Labs, Roche Diagnostics, Siemens Healthineers, and Wave Life Sciences outside the submitted work; and is a cofounder of Brain Biomarker Solutions in Gothenburg AB. Drs Allu&#xe9; and Sarasa report a patent pending for EP2020382352 and are employed at Araclon Biotech. Dr Eichenlaub is employed at Roche Diagnostics. Dr Bittner is employed at F. Hoffmann-La Roche, has a patent pending for blood-based biomarkers, and owns stock from F. Hoffmann-LaRoche. Mr Ovod has submitted the US provisional patent application &#x201c;Plasma Based Methods for Detecting CNS Amyloid Deposition&#x201d; as a coinventor and may receive royalty income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. Dr Toba reports grants from Amedisys during the conduct of the study. Dr Nakamura reports grants from Amedisys during the conduct of the study. Dr Bateman reports consulting for Eisai and Janssen; personal fees from ACImmune, Amgen, C2N Diagnostics, and Pfizer; grants from AbbVie, Avid Radiopharmaceuticals, Biogen, Centene, Eisai, Eli Lilly, F. Hoffmann-LaRoche, Genentech, Janssen Pharmaceuticals, and United Neuroscience outside the submitted work; he is a member of the DIAN-TU Pharma Consortium (Eli Lilly and Company/Avid Radiopharmaceuticals, Hoffmann-La Roche/Genentech, Biogen, Eisai, Janssen, and United Neuroscience), the NFL Consortium (AbbVie, Biogen, Roche, BMS), and Tau SIK Consortium (AbbVie, Avid Radiopharmaceuticals, Biogen, Eli Lilly); has a patent for a plasma amyloid-beta test licensed to C2N Diagnostics; and cofounded C2N Diagnostics; in addition, Washington University and Dr. Bateman have equity ownership interest in C2N Diagnostics and receive royalty income based on blood plasma assay technology licensed by Washington University to C2N Diagnostics; Washington University and Dr Bateman have submitted the US provisional patent application &#x201c;Plasma Based Methods for Detecting CNS Amyloid Deposition.&#x201d; Dr Blennow reports personal fees from Abcam, Axon, Biogen, the Japanese Organization for Medical Device Development, Julius Clinical, Eli Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, Shimadzu, and Siemens Healthineers and grants from the Swedish Research Council during the conduct of the study as well as research funding from Biogen, Eisai, and Roche Diagnostics and nonfinancial support from AC Immune and Eli Lilly outside the submitted work; and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program. Dr Hansson reports research support paid to his institution from Avid Radiopharmaceuticals, Biogen, Eisai, Eli Lilly, General Electric Healthcare, Pfizer, and Roche Diagnostics and has received personal fees from AC Immune, Alzpath, Biogen, Cerveau, and Roche Diagnostics. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>20</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34542571</ArticleId><ArticleId IdType="pmc">PMC8453354</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.3180</ArticleId><ArticleId IdType="pii">2784411</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954-963. doi:10.1038/s41591-021-01382-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01382-x</ArticleId><ArticleId IdType="pubmed">34083813</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Lautner R, Andreasson U, et al. . CSF and blood biomarkers for the diagnosis of Alzheimer&#x2019;s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673-684. doi:10.1016/S1474-4422(16)00070-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00070-3</ArticleId><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Palmqvist S, et al. . Plasma &#x3b2;-amyloid in Alzheimer&#x2019;s disease and vascular disease. Sci Rep. 2016;6:26801. doi:10.1038/srep26801</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep26801</ArticleId><ArticleId IdType="pmc">PMC4886210</ArticleId><ArticleId IdType="pubmed">27241045</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura A, Kaneko N, Villemagne VL, et al. . High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer&#x2019;s disease. Nature. 2018;554(7691):249-254. doi:10.1038/nature25456</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25456</ArticleId><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovod V, Ramsey KN, Mawuenyega KG, et al. . Amyloid &#x3b2; concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841-849. doi:10.1016/j.jalz.2017.06.2266</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.06.2266</ArticleId><ArticleId IdType="pmc">PMC5567785</ArticleId><ArticleId IdType="pubmed">28734653</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Bollinger JG, Ovod V, et al. . High-precision plasma &#x3b2;-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647-e1659. doi:10.1212/WNL.0000000000008081</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008081</ArticleId><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="pubmed">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Stomrud E, et al. . Performance of fully automated plasma assays as screening tests for Alzheimer disease-related &#x3b2;-amyloid status. JAMA Neurol. 2019;76(9):1060-1069. doi:10.1001/jamaneurol.2019.1632</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1632</ArticleId><ArticleId IdType="pmc">PMC6593637</ArticleId><ArticleId IdType="pubmed">31233127</ArticleId></ArticleIdList></Reference><Reference><Citation>Verberk IMW, Slot RE, Verfaillie SCJ, et al. . Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol. 2018;84(5):648-658. doi:10.1002/ana.25334</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25334</ArticleId><ArticleId IdType="pmc">PMC6282982</ArticleId><ArticleId IdType="pubmed">30196548</ArticleId></ArticleIdList></Reference><Reference><Citation>ADNI . Alzheimer&#x2019;s Disease Neuroimaging Initiative. Accessed June 25, 2021. http://adni.loni.usc.edu/</Citation></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, et al. . Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772-781. doi:10.1001/jama.2020.12134</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12134</ArticleId><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, Verberk IMW, Vanbrabant J, et al. . Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer&#x2019;s disease. Sci Rep. 2021;11(1):9736. doi:10.1038/s41598-021-89004-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-89004-x</ArticleId><ArticleId IdType="pmc">PMC8102604</ArticleId><ArticleId IdType="pubmed">33958661</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Palmqvist S, Leuzy A, et al. . Detecting amyloid positivity in early Alzheimer&#x2019;s disease using combinations of plasma A&#x3b2;42/40 and p-tau. Alzheimers Dement. Published online June 20, 2020. doi:10.1002/alz.12395</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12395</ArticleId><ArticleId IdType="pubmed">34151519</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Zetterberg H, Blennow K, et al. . Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid &#x3b2;-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71(10):1282-1289. doi:10.1001/jamaneurol.2014.1358</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1358</ArticleId><ArticleId IdType="pubmed">25155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Lu M, Joshi AD, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Comparing positron emission tomography imaging and cerebrospinal fluid measurements of &#x3b2;-amyloid. Ann Neurol. 2013;74(6):826-836. doi:10.1002/ana.23908</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23908</ArticleId><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578-586. doi:10.1002/ana.23650</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23650</ArticleId><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Minta K, Brinkmalm G, Janelidze S, et al. . Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. Alzheimers Res Ther. 2020;12(1):19. doi:10.1186/s13195-020-00585-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00585-7</ArticleId><ArticleId IdType="pmc">PMC7020540</ArticleId><ArticleId IdType="pubmed">32054532</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Berron D, Smith R, et al. . Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 2021;78(2):149-156. doi:10.1001/jamaneurol.2020.4201</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4201</ArticleId><ArticleId IdType="pmc">PMC7653537</ArticleId><ArticleId IdType="pubmed">33165506</ArticleId></ArticleIdList></Reference><Reference><Citation>Neubert H, Shuford CM, Olah TV, et al. . Protein biomarker quantification by immunoaffinity liquid chromatography-tandem mass spectrometry: current state and future vision. Clin Chem. 2020;66(2):282-301. doi:10.1093/clinchem/hvz022</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinchem/hvz022</ArticleId><ArticleId IdType="pubmed">32040572</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Seibyl J, Stomrud E, et al. ; Swedish BioFINDER study group; Alzheimer&#x2019;s Disease Neuroimaging Initiative . CSF biomarkers of Alzheimer&#x2019;s disease concord with amyloid-&#x3b2; PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470-1481. doi:10.1016/j.jalz.2018.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.01.010</ArticleId><ArticleId IdType="pmc">PMC6119541</ArticleId><ArticleId IdType="pubmed">29499171</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34550726</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>612</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>22</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline.</ArticleTitle><Pagination><StartPage>eabj2511</StartPage><MedlinePgn>eabj2511</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abj2511</ELocationID><Abstract><AbstractText>Several autopsy studies recognize the locus coeruleus (LC) as the initial site of hyperphosphorylated TAU aggregation, and as the number of LC neurons harboring TAU increases, TAU pathology emerges throughout the cortex. By conjointly using dedicated MRI measures of LC integrity and TAU and amyloid PET imaging, we aimed to address the question whether in vivo LC measures relate to initial cortical patterns of Alzheimer&#x2019;s disease (AD) fibrillar proteinopathies or cognitive dysfunction in 174 cognitively unimpaired and impaired older individuals with longitudinal cognitive measures. To guide our interpretations, we verified these associations in autopsy data from 1524 Religious Orders Study and Rush Memory and Aging Project and 2145 National Alzheimer&#x2019;s Coordinating Center cases providing three different LC measures (pigmentation, tangle density, and neuronal density), Braak staging, &#x3b2;-amyloid, and longitudinal cognitive measures. Lower LC integrity was associated with elevated TAU deposition in the entorhinal cortex among unimpaired individuals consistent with postmortem correlations between LC tangle density and successive Braak staging. LC pigmentation ratings correlated with LC neuronal density but not with LC tangle density and were particularly worse at advanced Braak stages. In the context of elevated &#x3b2;-amyloid, lower LC integrity and greater cortical tangle density were associated with greater TAU burden beyond the medial temporal lobe and retrospective memory decline. These findings support neuropathologic data in which early LC TAU accumulation relates to disease progression and identify LC integrity as a promising indicator of initial AD-related processes and subtle changes in cognitive trajectories of preclinical AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Heidi I L</ForeName><Initials>HIL</Initials><Identifier Source="ORCID">0000-0001-7620-3822</Identifier><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, 6200 MD Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>John A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0001-7435-1338</Identifier><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwong</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engels-Dom&#xed;nguez</LastName><ForeName>Nina</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-9871-6829</Identifier><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, 6200 MD Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prokopiou</LastName><ForeName>Prokopis C</ForeName><Initials>PC</Initials><Identifier Source="ORCID">0000-0002-5444-8359</Identifier><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papp</LastName><ForeName>Kathryn V</ForeName><Initials>KV</Initials><Identifier Source="ORCID">0000-0003-1687-4370</Identifier><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Properzi</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7855-2372</Identifier><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampton</LastName><ForeName>Olivia L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>d'Oleire Uquillas</LastName><ForeName>Federico</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9078-9452</Identifier><AffiliationInfo><Affiliation>Princeton Neuroscience Institute, Princeton University, Princeton, NJ 08544, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Justin S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0003-4421-3078</Identifier><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-6318-9213</Identifier><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Fakhri</LastName><ForeName>Georges</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Normandin</LastName><ForeName>Marc D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0003-1645-523X</Identifier><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0003-3689-554X</Identifier><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0003-1535-6133</Identifier><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0002-5916-6043</Identifier><AffiliationInfo><Affiliation>Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG050436</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047266</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG052414</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072977</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR023043</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG046396</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG053760</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 EB022544</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062428</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032984</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR021110</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG035982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR019307</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072980</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD018035</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG049638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD010364</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062715</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 EB013180</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG062559</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR023401</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008125" MajorTopicYN="N">Locus Coeruleus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069338" MajorTopicYN="N">Neuropathology</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests. HIJ received funding from the European Union&#x2019;s Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie Grant agreement [IF-2015-GF, 706714]. KVP has served as a paid consultant for Biogen. DMR has done consulting for Eli Lilly, Biogen Idec and Digital Cognition Technologys and served on the Scientific Advisory Board for Neurotrack. KAJ has served as paid consultant for Janssen, Novartis, Biogen, Roche, Lundberg, and Abbvie. He is a site co-investigator for Lilly/Avid and Janssen, and receives research support for clinical trials from Eisai, Lilly, and Cerveau. RAS has served as a paid consultant for Ionis, Shionogi, Biogen, Genentech, Oligomerix, Cytox, Acumen, JOMDD, Renew, Neuraly, AC Immune, Alnylam, Janssen, Neurocentria, Prothena, Eisai, Takeda and Roche and receives research support for clinical trials from Eisai, Eli Lilly, NIA and Alzheimer&#x2019;s Association. DAB was on a DSMB for AbbVie, an adjudication committee for Takeda, a SBIR consultant for Origent, and he has funding from Neurovision to perform eye amyloid imaging. JCP also holds an adjunct professor position at the University of Pittsburgh. These relationships are not related to the content in the manuscript. All other authors report no relevant conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>22</Day><Hour>17</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34550726</ArticleId><ArticleId IdType="mid">NIHMS1755941</ArticleId><ArticleId IdType="pmc">PMC8641759</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abj2511</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Braak H, Braak E, Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K, Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70, 960&#x2013;969 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG, Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71, 362&#x2013;381 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, The pathological process underlying Alzheimer&#x2019;s disease in individuals under thirty. Acta neuropathologica 121, 171&#x2013;181 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21170538</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenberg AJ, Nguy AK, Theofilas P, Dunlop S, Suemoto CK, Di Lorenzo Alho AT, Leite RP, Diehl Rodriguez R, Mejia MB, Rub U, Farfel JM, de Lucena Ferretti-Rebustini RE, Nascimento CF, Nitrini R, Pasquallucci CA, Jacob-Filho W, Miller B, Seeley WW, Heinsen H, Grinberg LT, Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer&#x2019;s disease. Neuropathol Appl Neurobiol 43, 393&#x2013;408 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642282</ArticleId><ArticleId IdType="pubmed">28117917</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Nag S, Boyle PA, Hizel LP, Yu L, Buchman AS, Schneider JA, Bennett DA, Neural reserve, neuronal density in the locus ceruleus, and cognitive decline. Neurology 80, 1202&#x2013;1208 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691778</ArticleId><ArticleId IdType="pubmed">23486878</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilas P, Ehrenberg AJ, Dunlop S, Di Lorenzo Alho AT, Nguy A, Leite RE, Rodriguez RD, Mejia MB, Suemoto CK, Ferretti-Rebustini RE, Polichiso L, Nascimento CF, Seeley WW, Nitrini R, Pasqualucci CA, Jacob Filho W, Rueb U, Neuhaus J, Heinsen H, Grinberg LT, Locus coeruleus volume and cell population changes during Alzheimer&#x2019;s disease progression: A stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimers Dement 13, 236&#x2013;246 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5298942</ArticleId><ArticleId IdType="pubmed">27513978</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML, Vasdev N, Dickerson BC, Gomperts SN, Growdon JH, Johnson KA, Frosch MP, Hyman BT, Gomez-Isla T, Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78, 787&#x2013;800 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900162</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucca FA, Segura-Aguilar J, Ferrari E, Munoz P, Paris I, Sulzer D, Sarna T, Casella L, Zecca L, Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson&#x2019;s disease. Prog Neurobiol 155, 96&#x2013;119 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826627</ArticleId><ArticleId IdType="pubmed">26455458</ArticleId></ArticleIdList></Reference><Reference><Citation>Betts MJ, Kirilina E, Otaduy MCG, Ivanov D, Acosta-Cabronero J, Callaghan MF, Lambert C, Cardenas-Blanco A, Pine K, Passamonti L, Loane C, Keuken MC, Trujillo P, Lusebrink F, Mattern H, Liu KY, Priovoulos N, Fliessbach K, Dahl MJ, Maass A, Madelung CF, Meder D, Ehrenberg AJ, Speck O, Weiskopf N, Dolan R, Inglis B, Tosun D, Morawski M, Zucca FA, Siebner HR, Mather M, Uludag K, Heinsen H, Poser BA, Howard R, Zecca L, Rowe JB, Grinberg LT, Jacobs HIL, Duzel E, Hammerer D, Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain 142, 2558&#x2013;2571 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6736046</ArticleId><ArticleId IdType="pubmed">31327002</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren NI, Taheri S, Vazey EM, Morgan PS, Granholm AC, Aston-Jones GS, Eckert MA, Histologic validation of locus coeruleus MRI contrast in post-mortem tissue. NeuroImage 113, 235&#x2013;245 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4649944</ArticleId><ArticleId IdType="pubmed">25791783</ArticleId></ArticleIdList></Reference><Reference><Citation>Vila M, Neuromelanin, aging, and neuronal vulnerability in Parkinson&#x2019;s disease. Mov Disord 34, 1440&#x2013;1451 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7079126</ArticleId><ArticleId IdType="pubmed">31251435</ArticleId></ArticleIdList></Reference><Reference><Citation>Priovoulos N, van Boxel SCJ, Jacobs HIL, Poser BA, Uludag K, Verhey FRJ, Ivanov D, Unraveling the contributions to the neuromelanin-MRI contrast. Brain structure &amp; function 225, 2757&#x2013;2774 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674382</ArticleId><ArticleId IdType="pubmed">33090274</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata E, Sasaki M, Tohyama K, Kanbara Y, Otsuka K, Ehara S, Sakai A, Age-related changes in locus ceruleus on neuromelanin magnetic resonance imaging at 3 Tesla. Magn Reson Med Sci 5, 197&#x2013;200 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17332710</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu KY, Acosta-Cabronero J, Cardenas-Blanco A, Loane C, Berry AJ, Betts MJ, Kievit RA, Henson RN, Duzel E, Cam CAN, Howard R, Hammerer D, In vivo visualization of age-related differences in the locus coeruleus. Neurobiol Aging 74, 101&#x2013;111 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6338679</ArticleId><ArticleId IdType="pubmed">30447418</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammerer D, Callaghan MF, Hopkins A, Kosciessa J, Betts M, Cardenas-Blanco A, Kanowski M, Weiskopf N, Dayan P, Dolan RJ, Duzel E, Locus coeruleus integrity in old age is selectively related to memories linked with salient negative events. Proceedings of the National Academy of Sciences of the United States of America 115, 2228&#x2013;2233 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5834676</ArticleId><ArticleId IdType="pubmed">29440429</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Yates PO, Lipoprotein pigments--their relationship to ageing in the human nervous system. I. The lipofuscin content of nerve cells. Brain 97, 481&#x2013;488 (1974).</Citation><ArticleIdList><ArticleId IdType="pubmed">4423477</ArticleId></ArticleIdList></Reference><Reference><Citation>Manaye KF, McIntire DD, Mann DM, German DC, Locus coeruleus cell loss in the aging human brain: a non-random process. The Journal of comparative neurology 358, 79&#x2013;87 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7560278</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucca FA, Bellei C, Giannelli S, Terreni MR, Gallorini M, Rizzio E, Pezzoli G, Albertini A, Zecca L, Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. J Neural Transm (Vienna) 113, 757&#x2013;767 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16755380</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohm TG, Busch C, Bohl J, Unbiased estimation of neuronal numbers in the human nucleus coeruleus during aging. Neurobiol Aging 18, 393&#x2013;399 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9330970</ArticleId></ArticleIdList></Reference><Reference><Citation>Mouton PR, Pakkenberg B, Gundersen HJ, Price DL, Absolute number and size of pigmented locus coeruleus neurons in young and aged individuals. J Chem Neuroanat 7, 185&#x2013;190 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7848573</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA, Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis 64, S161&#x2013;S189 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Besser LM, Kukull WA, Teylan MA, Bigio EH, Cairns NJ, Kofler JK, Montine TJ, Schneider JA, Nelson PT, The Revised National Alzheimer&#x2019;s Coordinating Center&#x2019;s Neuropathology Form-Available Data and New Analyses. J Neuropathol Exp Neurol 77, 717&#x2013;726 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6044344</ArticleId><ArticleId IdType="pubmed">29945202</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CM, Jacobs HIL, Marquie M, Becker JA, Andrea NV, Jin DS, Schultz AP, Frosch MP, Gomez-Isla T, Sperling RA, Johnson KA, 18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. J Alzheimers Dis 62, 1691&#x2013;1702 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5957532</ArticleId><ArticleId IdType="pubmed">29614677</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Mormino EC, Schultz AP, Betensky RA, Papp KV, Amariglio RE, Hanseeuw BJ, Buckley R, Chhatwal J, Hedden T, Marshall GA, Quiroz YT, Donovan NJ, Jackson J, Gatchel JR, Rabin JS, Jacobs H, Yang HS, Properzi M, Kirn DR, Rentz DM, Johnson KA, The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol 85, 181&#x2013;193 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402593</ArticleId><ArticleId IdType="pubmed">30549303</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp K, Marshall G, Albers M, Mauro S, Pepin L, Alverio J, Judge K, Philiossaint M, Shoup T, Yokell D, Dickerson B, Gomez-Isla T, Hyman B, Vasdev N, Sperling R, Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79, 110&#x2013;119 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4738026</ArticleId><ArticleId IdType="pubmed">26505746</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, The preclinical phase of the pathological process underlying sporadic Alzheimer&#x2019;s disease. Brain 138, 2814&#x2013;2833 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26283673</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe T, Tan Z, Wang X, Martinez-Hernandez A, Frahm J, Magnetic resonance imaging of noradrenergic neurons. Brain structure &amp; function 224, 1609&#x2013;1625 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6509075</ArticleId><ArticleId IdType="pubmed">30903359</ArticleId></ArticleIdList></Reference><Reference><Citation>Sara SJ, The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 10, 211&#x2013;223 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19190638</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemon N, Aydin-Abidin S, Funke K, Manahan-Vaughan D, Locus coeruleus activation facilitates memory encoding and induces hippocampal LTD that depends on beta-adrenergic receptor activation. Cereb Cortex 19, 2827&#x2013;2837 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774396</ArticleId><ArticleId IdType="pubmed">19435710</ArticleId></ArticleIdList></Reference><Reference><Citation>Devauges V, Sara SJ, Memory retrieval enhancement by locus coeruleus stimulation: evidence for mediation by beta-receptors. Behav Brain Res 43, 93&#x2013;97 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1650233</ArticleId></ArticleIdList></Reference><Reference><Citation>Sara SJ, Devauges V, Priming stimulation of locus coeruleus facilitates memory retrieval in the rat. Brain Res 438, 299&#x2013;303 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3345434</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Boyle PA, Segawa E, Leurgans S, Schneider JA, Wilson RS, Bennett DA, Residual decline in cognition after adjustment for common neuropathologic conditions. Neuropsychology 29, 335&#x2013;343 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4420708</ArticleId><ArticleId IdType="pubmed">25495832</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT, Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 73, 685&#x2013;697 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs HIL, Hedden T, Schultz AP, Sepulcre J, Perea RD, Amariglio RE, Papp KV, Rentz DM, Sperling RA, Johnson KA, Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci 21, 424&#x2013;431 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5857215</ArticleId><ArticleId IdType="pubmed">29403032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Torraville SE, Mukherjee B, Walling SG, Martin GM, Harley CW, Yuan Q, An experimental model of Braak&#x2019;s pretangle proposal for the origin of Alzheimer&#x2019;s disease: the role of locus coeruleus in early symptom development. Alzheimers Res Ther 11, 59 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6607586</ArticleId><ArticleId IdType="pubmed">31266535</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, McBride JD, Guo JL, Zhang B, Trojanowski JQ, Lee VM, Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC&#x2019;s afferent and efferent connections. Acta Neuropathol 130, 349&#x2013;362 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545685</ArticleId><ArticleId IdType="pubmed">26150341</ArticleId></ArticleIdList></Reference><Reference><Citation>Rorabaugh JM, Chalermpalanupap T, Botz-Zapp CA, Fu VM, Lembeck NA, Cohen RM, Weinshenker D, Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer&#x2019;s disease. Brain 140, 3023&#x2013;3038 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841201</ArticleId><ArticleId IdType="pubmed">29053824</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbi V, Floriou-Servou A, Markicevic M, Vermeiren Y, Sturman O, Privitera M, von Ziegler L, Ferrari KD, Weber B, De Deyn PP, Wenderoth N, Bohacek J, Rapid Reconfiguration of the Functional Connectome after Chemogenetic Locus Coeruleus Activation. Neuron 103, 702&#x2013;718 e705 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31227310</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalermpalanupap T, Schroeder JP, Rorabaugh JM, Liles LC, Lah JJ, Levey AI, Weinshenker D, Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice. J Neurosci 38, 74&#x2013;92 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5761438</ArticleId><ArticleId IdType="pubmed">29133432</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, Jardanhazi-Kurutz D, Walter J, Kirchhoff F, Hanisch UK, Kummer MP, Locus ceruleus controls Alzheimer&#x2019;s disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A 107, 6058&#x2013;6063 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851853</ArticleId><ArticleId IdType="pubmed">20231476</ArticleId></ArticleIdList></Reference><Reference><Citation>Minneman KP, Dibner MD, Wolfe BB, Molinoff PB, beta1- and beta2-Adrenergic receptors in rat cerebral cortex are independently regulated. Science 204, 866&#x2013;868 (1979).</Citation><ArticleIdList><ArticleId IdType="pubmed">35829</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Zhang D, Yang T, Koeglsperger T, Fu H, Selkoe DJ, Environmental novelty activates beta2-adrenergic signaling to prevent the impairment of hippocampal LTP by Abeta oligomers. Neuron 77, 929&#x2013;941 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3596823</ArticleId><ArticleId IdType="pubmed">23473322</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Gannon M, Chen Y, Yan S, Zhang S, Feng W, Tao J, Sha B, Liu Z, Saito T, Saido T, Keene CD, Jiao K, Roberson ED, Xu H, Wang Q, beta-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3beta/tau cascade. Sci Transl Med 12, eaay6931 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7891768</ArticleId><ArticleId IdType="pubmed">31941827</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs HIL, Riphagen JM, Ramakers I, Verhey FRJ, Alzheimer&#x2019;s disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms. Mol Psychiatry 26, 897&#x2013;906 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">31138892</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK, Del Tredici K, Thomas TL, Braak H, Diamond MI, Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer&#x2019;s disease and PART. Acta Neuropathol 136, 57&#x2013;67 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015098</ArticleId><ArticleId IdType="pubmed">29752551</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinsen H, Grinberg LT, On the origin of tau seeding activity in Alzheimer&#x2019;s disease. Acta Neuropathol 136, 815&#x2013;817 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508082</ArticleId><ArticleId IdType="pubmed">30039213</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, Spreading of Tau Pathology in Sporadic Alzheimer&#x2019;s Disease Along Cortico-cortical Top-Down Connections. Cereb Cortex 28, 3372&#x2013;3384 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6095209</ArticleId><ArticleId IdType="pubmed">29982389</ArticleId></ArticleIdList></Reference><Reference><Citation>Reznikoff GA, Manaker S, Rhodes CH, Winokur A, Rainbow TC, Localization and quantification of beta-adrenergic receptors in human brain. Neurology 36, 1067&#x2013;1073 (1986).</Citation><ArticleIdList><ArticleId IdType="pubmed">3016604</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Neuroplasticity failure in Alzheimer&#x2019;s disease: bridging the gap between plaques and tangles. Neuron 24, 521&#x2013;529 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10595506</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagley A, LaPoint M, Huijbers W, Hedden T, McLaren DG, Chatwal JP, Papp KV, Amariglio RE, Blacker D, Rentz DM, Johnson KA, Sperling RA, Schultz AP, Harvard Aging Brain Study: Dataset and accessibility. NeuroImage 144, 255&#x2013;258 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4592689</ArticleId><ArticleId IdType="pubmed">25843019</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43, 2412&#x2013;2414 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh J, Yesavage J, in Clinical Gerontology: A Guide to Assessment and Intervention, Brink TL, Ed. (Haworth Press, New York, 1986), pp. 165&#x2013;173.</Citation></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS, Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res 9, 646&#x2013;663 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS, Overview and findings from the religious orders study. Curr Alzheimer Res 9, 628&#x2013;645 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Aggarwal NT, Arvanitakis Z, Shah RC, Kelly JF, Fox JH, Cochran EJ, Arends D, Treinkman AD, Wilson RS, Decision rules guiding the clinical diagnosis of Alzheimer&#x2019;s disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology 27, 169&#x2013;176 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17035694</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J, Natural history of mild cognitive impairment in older persons. Neurology 59, 198&#x2013;205 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12136057</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA, Centers N. I. A. A. s. D., The National Alzheimer&#x2019;s Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord 21, 249&#x2013;258 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17804958</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA, The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 20, 210&#x2013;216 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford NR, Chui H, Cummings J, DeCarli C, Foster NL, Galasko D, Peskind E, Dietrich W, Beekly DL, Kukull WA, Morris JC, The Alzheimer&#x2019;s Disease Centers&#x2019; Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord 23, 91&#x2013;101 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743984</ArticleId><ArticleId IdType="pubmed">19474567</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Fischl B, Sereno MI, Cortical surface-based analysis. I. Segmentation and surface reconstruction. NeuroImage 9, 179&#x2013;194 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">9931268</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ, et al., Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(&#x2212;)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10, 740&#x2013;747 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2384545</ArticleId></ArticleIdList></Reference><Reference><Citation>Greve DN, Svarer C, Fisher PM, Feng L, Hansen AE, Baare W, Rosen B, Fischl B, Knudsen GM, Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. NeuroImage 92, 225&#x2013;236 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4008670</ArticleId><ArticleId IdType="pubmed">24361666</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs HIL, Augustinack JC, Schultz AP, Hanseeuw BJ, Locascio J, Amariglio RE, Papp KV, Rentz DM, Sperling RA, Johnson KA, The presubiculum links incipient amyloid and tau pathology to memory function in older persons. Neurology 94, e1916&#x2013;e1928 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7274925</ArticleId><ArticleId IdType="pubmed">32273431</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez JS, Becker JA, Jacobs HIL, Hanseeuw BJ, Jiang S, Schultz AP, Properzi MJ, Katz SR, Beiser A, Satizabal CL, O&#x2019;Donnell A, DeCarli C, Killiany R, El Fakhri G, Normandin MD, Gomez-Isla T, Quiroz YT, Rentz DM, Sperling RA, Seshadri S, Augustinack J, Price JC, Johnson KA, The cortical origin and initial spread of medial temporal tauopathy in Alzheimer&#x2019;s disease assessed with positron emission tomography. Sci Transl Med 13, eabc0655, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7978042</ArticleId><ArticleId IdType="pubmed">33472953</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Lorenzo D, Longo-Dos Santos C, Ewenczyk C, Leu-Semenescu S, Gallea C, Quattrocchi G, Pita Lobo P, Poupon C, Benali H, Arnulf I, Vidailhet M, Lehericy S, The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson&#x2019;s disease. Brain 136, 2120&#x2013;2129 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692035</ArticleId><ArticleId IdType="pubmed">23801736</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein A, Andersson J, Ardekani BA, Ashburner J, Avants B, Chiang MC, Christensen GE, Collins DL, Gee J, Hellier P, Song JH, Jenkinson M, Lepage C, Rueckert D, Thompson P, Vercauteren T, Woods RP, Mann JJ, Parsey RV, Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration. NeuroImage 46, 786&#x2013;802 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747506</ArticleId><ArticleId IdType="pubmed">19195496</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS, Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66, 1837&#x2013;1844 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE, Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 61, 378&#x2013;384 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Nag S, Shulman JM, Lim AS, VanderHorst VG, Leurgans SE, Schneider JA, Bennett DA, Locus coeruleus neuron density and parkinsonism in older adults without Parkinson&#x2019;s disease. Mov Disord 27, 1625&#x2013;1631 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628555</ArticleId><ArticleId IdType="pubmed">23038629</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H, Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791&#x2013;1800 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L, The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology 41, 479&#x2013;486 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT, National Institute on A, Alzheimer&#x2019;s A, National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta neuropathologica 123, 1&#x2013;11 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Lutz MW, Wilson RS, Burns DK, Roses AD, Saunders AM, Gaiteri C, De Jager PL, Barnes LL, Bennett DA, TOMM40&#x2019;523 variant and cognitive decline in older persons with APOE epsilon3/3 genotype. Neurology 88, 661&#x2013;668 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5317377</ArticleId><ArticleId IdType="pubmed">28108637</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC, Optimizing the preclinical Alzheimer&#x2019;s cognitive composite with semantic processing: The PACC5. Alzheimers Dement (N Y) 3, 668&#x2013;677 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5726754</ArticleId><ArticleId IdType="pubmed">29264389</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS, Alzheimer&#x2019;s Disease Neuroimaging I, Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA 317, 2305&#x2013;2316 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736301</ArticleId><ArticleId IdType="pubmed">28609533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Boyle PA, Yu L, Barnes LL, Schneider JA, Bennett DA, Life-span cognitive activity, neuropathologic burden, and cognitive aging. Neurology 81, 314&#x2013;321 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772831</ArticleId><ArticleId IdType="pubmed">23825173</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Boyle PA, Yu L, Barnes LL, Sytsma J, Buchman AS, Bennett DA, Schneider JA, Temporal course and pathologic basis of unawareness of memory loss in dementia. Neurology 85, 984&#x2013;991 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4567465</ArticleId><ArticleId IdType="pubmed">26311746</ArticleId></ArticleIdList></Reference><Reference><Citation>Agresti A, An Introduction to Categorical Data Analysis. (Wiley-Interscience, Hoboken, New Jersey, 2007), vol. 2nd Edition.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34550630</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>An ultra-sensitive immunoassay detects and quantifies soluble A&#x3b2; oligomers in human plasma.</ArticleTitle><Pagination><StartPage>1186</StartPage><EndPage>1202</EndPage><MedlinePgn>1186-1202</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12457</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Evidence strongly suggests that soluble oligomers of amyloid beta protein (oA&#x3b2;) help initiate the pathogenic cascade of Alzheimer's disease (AD). To date, there have been no validated assays specific for detecting and quantifying oA&#x3b2; in human blood.</AbstractText><AbstractText Label="METHODS">We developed an ultrasensitive oA&#x3b2; immunoassay using a novel capture antibody (71A1) with N-terminal antibody 3D6 for detection that specifically quantifies soluble oA&#x3b2; in the human brain, cerebrospinal fluid (CSF), and plasma.</AbstractText><AbstractText Label="RESULTS">Two new antibodies (71A1; 1G5) are oA&#x3b2;-selective, label A&#x3b2; plaques in non-fixed AD brain sections, and potently neutralize the synaptotoxicity of AD brain-derived oA&#x3b2;. The 71A1/3D6 assay showed excellent dilution linearity in CSF and plasma without matrix effects, good spike recovery, and specific immunodepletion.</AbstractText><AbstractText Label="DISCUSSION">We have created a sensitive, high throughput, and inexpensive method to quantify synaptotoxic oA&#x3b2; in human plasma for analyzing large cohorts of aged and AD subjects to assess the dynamics of this key pathogenic species and response to therapy.</AbstractText><CopyrightInformation>&#xa9; 2021 the Alzheimer's Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4604-4629</Identifier><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, Massachusetts, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwak</LastName><ForeName>Hyunchang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, Massachusetts, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawton</LastName><ForeName>Trebor L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Abyssinia Biologics, LLC, 23 Cedar Point Rd, Durham, New Hampshire, 03824, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Shan-Xue</ForeName><Initials>SX</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, Massachusetts, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meunier</LastName><ForeName>Angela L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, Massachusetts, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dang</LastName><ForeName>Yifan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, Massachusetts, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostaszewski</LastName><ForeName>Beth</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, Massachusetts, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pietras</LastName><ForeName>Alison C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, Massachusetts, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, Massachusetts, 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, Massachusetts, 02115, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R25 NS065743</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG063046</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">amyloid beta protein</Keyword><Keyword MajorTopicYN="N">oligomeric amyloid beta</Keyword><Keyword MajorTopicYN="N">plasma biomarkers</Keyword></KeywordList><CoiStatement><b>Conflicts of interest:</b> T.L.L is the technical founder of Abyssinia Biologics, LLC and is responsible for the original immunogen design and production of monoclonal antibodies 71A1 and 1G5. D.J.S. is a director and consultant of Prothena Biosciences. T.L.L and D.J.S. are planning a patent application on uses of anti-oligomeric amyloid &#x3b2; monoclonal antibodies for Alzheimer&#x2019;s disease and related diseases. All other authors have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>22</Day><Hour>12</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34550630</ArticleId><ArticleId IdType="mid">NIHMS1733041</ArticleId><ArticleId IdType="pmc">PMC8938295</ArticleId><ArticleId IdType="doi">10.1002/alz.12457</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M et al. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998; 95: 6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M et al. A&#x3b2; oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer&#x2019;s disease. Journal of Neuroscience 2007; 27: 796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 2009; 106: 4012&#x2013;4017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Sondag CM, Dhawan G, Combs CK. Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. Journal of neuroinflammation 2009; 6: 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2632990</ArticleId><ArticleId IdType="pubmed">19123954</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan G, Floden AM, Combs CK. Amyloid-&#x3b2; oligomers stimulate microglia through a tyrosine kinase dependent mechanism. Neurobiology of aging 2012; 33: 2247&#x2013;2261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3294077</ArticleId><ArticleId IdType="pubmed">22133278</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Rajsombath MM, Weikop P, Selkoe DJ. Enriched environment enhances &#x3b2;-adrenergic signaling to prevent microglia inflammation by amyloid-&#x3b2;. EMBO molecular medicine 2018; 10: e8931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6127891</ArticleId><ArticleId IdType="pubmed">30093491</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer&#x2019;s disease. Am J Pathol 1999; 155: 853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer&#x2019;s disease. Ann Neurol 1999; 46: 860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Zott B, Simon MM, Hong W, Unger F, Chen-Engerer HJ, Frosch MP et al. A vicious cycle of &#x3b2; amyloid-dependent neuronal hyperactivation. Science 2019; 365: 559&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6690382</ArticleId><ArticleId IdType="pubmed">31395777</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong W, Wang Z, Liu W, O&#x2019;Malley TT, Jin M, Willem M et al. Diffusible, highly bioactive oligomers represent a critical minority of soluble A&#x3b2; in Alzheimer&#x2019;s disease brain. Acta Neuropathol 2018; 136: 19&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6647843</ArticleId><ArticleId IdType="pubmed">29687257</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009; 62: 788&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Liu L, Dang Y, Ostaszewski BL, Selkoe DJ. Decoding the synaptic dysfunction of bioactive human AD brain soluble A&#x3b2; to inspire novel therapeutic avenues for Alzheimer&#x2019;s disease. Acta Neuropathol Commun 2018; 6: 121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6225562</ArticleId><ArticleId IdType="pubmed">30409172</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I et al. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM et al. Amyloid-&#x3b2; oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 2013; 73: 104&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3563737</ArticleId><ArticleId IdType="pubmed">23225543</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CW, Quaranta V, Glenner GG. Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proc Natl Acad Sci U S A 1985; 82: 8729&#x2013;8732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC391510</ArticleId><ArticleId IdType="pubmed">2934737</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Abraham CR, Podlisny MB, Duffy LK. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer&#x2019;s disease. J Neurochem 1986; 46: 1820&#x2013;1834.</Citation><ArticleIdList><ArticleId IdType="pubmed">3517233</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J et al. Vaccination with soluble A&#x3b2; oligomers generates toxicity-neutralizing antibodies. Journal of neurochemistry 2001; 79: 595&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701763</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci U S A 2002; 99: 1485&#x2013;1490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122217</ArticleId><ArticleId IdType="pubmed">11818542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN et al. Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 2007; 100: 23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17116235</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Nuallain B, Klyubin I, Mc Donald JM, Foster JS, Welzel A, Barry A et al. A monoclonal antibody against synthetic A&#x3b2; dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting A&#x3b2;. Journal of neurochemistry 2011; 119: 189&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174526</ArticleId><ArticleId IdType="pubmed">21781116</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgado I, Wieligmann K, Bereza M, R&#xf6;nicke R, Meinhardt K, Annamalai K et al. Molecular basis of &#x3b2;-amyloid oligomer recognition with a conformational antibody fragment. Proceedings of the National Academy of Sciences 2012; 109: 12503&#x2013;12508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3412029</ArticleId><ArticleId IdType="pubmed">22814377</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage MJ, Kalinina J, Wolfe A, Tugusheva K, Korn R, Cash-Mason T et al. A sensitive a&#x3b2; oligomer assay discriminates Alzheimer&#x2019;s and aged control cerebrospinal fluid. Journal of Neuroscience 2014; 34: 2884&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608513</ArticleId><ArticleId IdType="pubmed">24553930</ArticleId></ArticleIdList></Reference><Reference><Citation>Phay M, Welzel AT, Williams AD, McWilliams-Koeppen HP, Blinder V, O&#x2019;Malley TT et al. IgG Conformer&#x2019;s Binding to Amyloidogenic Aggregates. PLoS One 2015; 10: e0137344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4569075</ArticleId><ArticleId IdType="pubmed">26367058</ArticleId></ArticleIdList></Reference><Reference><Citation>Mably AJ, Liu W, Mc Donald JM, Dodart JC, Bard F, Lemere CA et al. Anti-A&#x3b2; antibodies incapable of reducing cerebral A&#x3b2; oligomers fail to attenuate spatial reference memory deficits in J20 mice. Neurobiol Dis 2015; 82: 372&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641028</ArticleId><ArticleId IdType="pubmed">26215784</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami K, Tokuda M, Suzuki T, Irie Y, Hanaki M, Izuo N et al. Monoclonal antibody with conformational specificity for a toxic conformer of amyloid &#x3b2;42 and its application toward the Alzheimer&#x2019;s disease diagnosis. Sci Rep 2016; 6: 29038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4931470</ArticleId><ArticleId IdType="pubmed">27374357</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochiishi T, Itakura A, Liu L, Akatsu H, Kohno H, Nishimura M et al. Immunohistochemical detection of the delayed formation of nonfibrillar large amyloid-&#x3b2; aggregates. Genes Cells 2016; 21: 200&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">26805741</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs E, Silverman JM, Zhao B, Peng X, Wang J, Wellington CL et al. A rationally designed humanized antibody selective for amyloid beta oligomers in Alzheimer&#x2019;s disease. Scientific reports 2019; 9: 1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6614461</ArticleId><ArticleId IdType="pubmed">31285517</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T,T O&#x2019;Malley T, Kanmert D, Jerecic J, Zieske LR, Zetterberg H et al. A highly sensitive novel immunoassay specifically detects low levels of soluble A&#x3b2; oligomers in human cerebrospinal fluid. Alzheimer&#x2019;s research &amp; therapy 2015; 7: 1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369838</ArticleId><ArticleId IdType="pubmed">25802556</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Dang Y, Ostaszewski B, Mengel D, Steffen V, Rabe C et al. Target engagement in an Alzheimer trial: Crenezumab lowers amyloid &#x3b2; oligomers in cerebrospinal fluid. Annals of neurology 2019; 86: 215&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6771589</ArticleId><ArticleId IdType="pubmed">31168802</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Stern A, Dang Y, Ostaszewski B, Chhatwal JP, Selkoe DJ. Predicting development of AD clinical symptoms and their progression through a collection of novel plasma A&#x3b2; immunoassays: Biomarkers (non-neuroimaging): Blood based biomarkers. Alzheimer&#x2019;s &amp; Dementia 2020; 16: e043670.</Citation></Reference><Reference><Citation>Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor&#xe9; V et al. High performance plasma amyloid-&#x3b2; biomarkers for Alzheimer&#x2019;s disease. Nature 2018; 554: 249&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">29420472</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA et al. High-precision plasma &#x3b2;-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 2019; 93: e1647&#x2013;e1659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946467</ArticleId><ArticleId IdType="pubmed">31371569</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Mengel D, Keshavan A, Rissman RA, Billinton A, Perkinton M et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s &amp; Dementia 2019; 15: 487&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6476313</ArticleId><ArticleId IdType="pubmed">30419228</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhatwal JP, Schultz AP, Dang Y, Ostaszewski B, Liu L, Yang H-S et al. Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. Nature Communications 2020; 11: 6024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7695712</ArticleId><ArticleId IdType="pubmed">33247134</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ et al. Plasma phospho-tau181 increases with Alzheimer&#x2019;s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement 2018; 14: 989&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097897</ArticleId><ArticleId IdType="pubmed">29626426</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer&#x2019;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. The Lancet Neurology 2020; 19: 422&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer&#x2019;s disease. Nat Commun 2020; 11: 1683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125218</ArticleId><ArticleId IdType="pubmed">32246036</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR, Bateman RJ, Hirtz C, Marin P, Becher F, Sato C et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer&#x2019;s disease and PET amyloid-positive patient identification. Alzheimers Res Ther 2020; 12: 26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7079453</ArticleId><ArticleId IdType="pubmed">32183883</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat Med 2020; 26: 387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. Jama 2020; 324: 772&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388060</ArticleId><ArticleId IdType="pubmed">32722745</ArticleId></ArticleIdList></Reference><Reference><Citation>Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE et al. Plasma P-tau181 in Alzheimer&#x2019;s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer&#x2019;s dementia. Nat Med 2020; 26: 379&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">32123385</ArticleId></ArticleIdList></Reference><Reference><Citation>van Helmond Z, Heesom K, Love S. Characterisation of two antibodies to oligomeric Abeta and their use in ELISAs on human brain tissue homogenates. J Neurosci Methods 2009; 176: 206&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">18824027</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE et al. Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci 2010; 30: 14411&#x2013;14419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987723</ArticleId><ArticleId IdType="pubmed">20980598</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008; 30: 58&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS et al. Prevalence of mild cognitive impairment is higher in men: The Mayo Clinic Study of Aging. Neurology 2010; 75: 889&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938972</ArticleId><ArticleId IdType="pubmed">20820000</ArticleId></ArticleIdList></Reference><Reference><Citation>St Sauver JL, Grossardt BR, Yawn BP, Melton LJ III, Pankratz JJ, Brue SM et al. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. International journal of epidemiology 2012; 41: 1614&#x2013;1624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535751</ArticleId><ArticleId IdType="pubmed">23159830</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmalm G, Hong W, Wang Z, Liu W, O&#x2019;Malley TT, Sun X et al. Identification of neurotoxic cross-linked amyloid-&#x3b2; dimers in the Alzheimer&#x2019;s brain. Brain 2019; 142: 1441&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487330</ArticleId><ArticleId IdType="pubmed">31032851</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Ding L, Rovere M, Wolfe MS, Selkoe DJ. A cellular complex of BACE1 and &#x3b3;-secretase sequentially generates A&#x3b2; from its full-length precursor. Journal of Cell Biology 2019; 218: 644&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6363461</ArticleId><ArticleId IdType="pubmed">30626721</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Lauro BM, Wolfe MS, Selkoe DJ. Hydrophilic loop 1 of Presenilin-1 and the APP GxxxG transmembrane motif regulate &#x3b3;-secretase function in generating Alzheimer-causing A&#x3b2; peptides. Journal of Biological Chemistry 2021; 100393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7961089</ArticleId><ArticleId IdType="pubmed">33571524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, O&#x2019;Nuallain B, Hong W, Boyd J, Lagomarsino VN, O&#x2019;Malley TT et al. An in vitro paradigm to assess potential anti-A&#x3b2; antibodies for Alzheimer&#x2019;s disease. Nature communications 2018; 9: 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6041266</ArticleId><ArticleId IdType="pubmed">29992960</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Li S, Xu H, Walsh DM, Selkoe DJ. Large soluble oligomers of amyloid &#x3b2;-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. Journal of Neuroscience 2017; 37: 152&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5214627</ArticleId><ArticleId IdType="pubmed">28053038</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble A&#x3b2; oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. Journal of Neuroscience 2011; 31: 6627&#x2013;6638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang MJ, Yi S, Han J-y, Park SY, Jang J-W, Chun IK et al. Oligomeric forms of amyloid-&#x3b2; protein in plasma as a potential blood-based biomarker for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s research &amp; therapy 2017; 9: 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5732503</ArticleId><ArticleId IdType="pubmed">29246249</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng X, Li T, Wang X, Lv X, Sun Z, Zhang J et al. Association between increased levels of amyloid-&#x3b2; oligomers in plasma and episodic memory loss in Alzheimer&#x2019;s disease. Alzheimer&#x2019;s research &amp; therapy 2019; 11: 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6814096</ArticleId><ArticleId IdType="pubmed">31651358</ArticleId></ArticleIdList></Reference><Reference><Citation>Youn YC, Lee BS, Kim GJ, Ryu JS, Lim K, Lee R et al. Blood amyloid-&#x3b2; oligomerization as a biomarker of Alzheimer&#x2019;s disease: A blinded validation study. Journal of Alzheimer&#x2019;s Disease 2020; 1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32310175</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34555357</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>184</Volume><Issue>20</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes.</ArticleTitle><Pagination><StartPage>5089</StartPage><EndPage>5106.e21</EndPage><MedlinePgn>5089-5106.e21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2021.09.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(21)01054-0</ELocationID><Abstract><AbstractText>Microglia are the CNS resident immune cells that react to misfolded proteins through pattern recognition receptor ligation and activation of inflammatory pathways. Here, we studied how microglia handle and cope with &#x3b1;-synuclein (&#x3b1;-syn) fibrils and their clearance. We found that microglia exposed to &#x3b1;-syn establish a cellular network through the formation of F-actin-dependent intercellular connections, which transfer &#x3b1;-syn from overloaded microglia to neighboring naive microglia where the &#x3b1;-syn cargo got rapidly and effectively degraded. Lowering the &#x3b1;-syn burden attenuated the inflammatory profile of microglia and improved their survival. This degradation strategy was compromised in cells carrying the LRRK2 G2019S mutation. We confirmed the intercellular transfer of &#x3b1;-syn assemblies in microglia using organotypic slice cultures, 2-photon microscopy, and neuropathology of patients. Together, these data identify a mechanism by which microglia create an "on-demand" functional network in order to improve pathogenic &#x3b1;-syn clearance.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scheiblich</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, 53127 Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dansokho</LastName><ForeName>Cira</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, 53127 Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercan</LastName><ForeName>Dilek</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, 53127 Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Susanne V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University of Bonn Medical Center, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bousset</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institut Fran&#xe7;ois Jacob, MIRCen, CEA and Laboratory of Neurodegenerative Diseases, CNRS, 92265 Fontenay-aux-Roses, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wischhof</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eikens</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, 53127 Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odainic</LastName><ForeName>Alexandru</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University of Bonn Medical Center, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spitzer</LastName><ForeName>Jasper</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Innate Immunity, University of Bonn Medical Center, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griep</LastName><ForeName>Angelika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bano</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latz</LastName><ForeName>Eicke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany; Institute of Innate Immunity, University of Bonn Medical Center, 53127 Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melki</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institut Fran&#xe7;ois Jacob, MIRCen, CEA and Laboratory of Neurodegenerative Diseases, CNRS, 92265 Fontenay-aux-Roses, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn Medical Center, 53127 Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany; Divison of Infectious Diseases and Immunology, University of Massachusetts Medical School, 01605 Worcester, MA, USA. Electronic address: michael.heneka@ukbonn.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG059752</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000199">Actins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000720047">Tunneling Nanotubes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071158">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2021 Sep 30;184(20):5082-5084. doi: 10.1016/j.cell.2021.08.033.</RefSource><PMID Version="1">34597598</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2021 Oct 20;109(20):3228-3230. doi: 10.1016/j.neuron.2021.10.008.</RefSource><PMID Version="1">34672979</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021961" MajorTopicYN="N">Cell Membrane Structures</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003599" MajorTopicYN="N">Cytoskeleton</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071158" MajorTopicYN="N">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043942" MajorTopicYN="N">Nanotubes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="Y">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LRRK2</Keyword><Keyword MajorTopicYN="N">alpha-synuclein</Keyword><Keyword MajorTopicYN="N">cell-to-cell transfer</Keyword><Keyword MajorTopicYN="N">clearance</Keyword><Keyword MajorTopicYN="N">degradation</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">synucleinopathies</Keyword><Keyword MajorTopicYN="N">tunneling nanotubes</Keyword></KeywordList><CoiStatement>Declaration of interests Michael T. Heneka serves as an advisory board member at IFM Therapeutics, Alector and Tiaki. He received honoraria for oral presentations from Novartis, Roche, and Biogen. The other authors declare that there is no conflict of interest with regard to the experimental part of this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>23</Day><Hour>20</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34555357</ArticleId><ArticleId IdType="pmc">PMC8527836</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2021.09.007</ArticleId><ArticleId IdType="pii">S0092-8674(21)01054-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abounit S., Bousset L., Loria F., Zhu S., de Chaumont F., Pieri L., Olivo-Marin J.C., Melki R., Zurzolo C. Tunneling nanotubes spread fibrillar &#x3b1;-synuclein by intercellular trafficking of lysosomes. EMBO J. 2016;35:2120&#x2013;2138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5048354</ArticleId><ArticleId IdType="pubmed">27550960</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad T., Mukherjee S., Pattnaik B., Kumar M., Singh S., Kumar M., Rehman R., Tiwari B.K., Jha K.A., Barhanpurkar A.P. Miro1 regulates intercellular mitochondrial transport &amp; enhances mesenchymal stem cell rescue efficacy. EMBO J. 2014;33:994&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4193933</ArticleId><ArticleId IdType="pubmed">24431222</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarcon-Martinez L., Villafranca-Baughman D., Quintero H., Kacerovsky J.B., Dotigny F., Murai K.K., Prat A., Drapeau P., Di Polo A. Interpericyte tunnelling nanotubes regulate neurovascular coupling. Nature. 2020;585:91&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">32788726</ArticleId></ArticleIdList></Reference><Reference><Citation>Amano M., Nakayama M., Kaibuchi K. Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken) 2010;67:545&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038199</ArticleId><ArticleId IdType="pubmed">20803696</ArticleId></ArticleIdList></Reference><Reference><Citation>Arkwright P.D., Luchetti F., Tour J., Roberts C., Ayub R., Morales A.P., Rodr&#xed;guez J.J., Gilmore A., Canonico B., Papa S., Esposti M.D. Fas stimulation of T lymphocytes promotes rapid intercellular exchange of death signals via membrane nanotubes. Cell Res. 2010;20:72&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822704</ArticleId><ArticleId IdType="pubmed">19770844</ArticleId></ArticleIdList></Reference><Reference><Citation>Barcia C., Ros C.M., Annese V., Carrillo-de Sauvage M.A., Ros-Bernal F., G&#xf3;mez A., Yuste J.E., Campuzano C.M., de Pablos V., Fernandez-Villalba E., Herrero M.T. ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in&#xa0;vivo. Sci. Rep. 2012;2:809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3492875</ArticleId><ArticleId IdType="pubmed">23139861</ArticleId></ArticleIdList></Reference><Reference><Citation>Billingsley K.J., Barbosa I.A., Bandr&#xe9;s-Ciga S., Quinn J.P., Bubb V.J., Deshpande C., Botia J.A., Reynolds R.H., Zhang D., Simpson M.A., International Parkinson&#x2019;s Disease Genomics Consortium (IPDGC) Mitochondria function associated genes contribute to Parkinson&#x2019;s Disease risk and later age at onset. NPJ Parkinsons Dis. 2019;5:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6531455</ArticleId><ArticleId IdType="pubmed">31123700</ArticleId></ArticleIdList></Reference><Reference><Citation>Blesa J., Przedborski S. Parkinson&#x2019;s disease: animal models and dopaminergic cell vulnerability. Front. Neuroanat. 2014;8:155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266040</ArticleId><ArticleId IdType="pubmed">25565980</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousset L., Pieri L., Ruiz-Arlandis G., Gath J., Jensen P.H., Habenstein B., Madiona K., Olieric V., B&#xf6;ckmann A., Meier B.H., Melki R. Structural and functional characterization of two alpha-synuclein strains. Nat. Commun. 2013;4:2575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826637</ArticleId><ArticleId IdType="pubmed">24108358</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P., Li J.-Y., Holton J.L., Lindvall O., Revesz T. Research in motion: the enigma of Parkinson&#x2019;s disease pathology spread. Nat. Rev. Neurosci. 2008;9:741&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">18769444</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukoreshtliev N.V., Wang X., Hodneland E., Gurke S., Barroso J.F.V., Gerdes H.-H. Selective block of tunneling nanotube (TNT) formation inhibits intercellular organelle transfer between PC12 cells. FEBS Lett. 2009;583:1481&#x2013;1488.</Citation><ArticleIdList><ArticleId IdType="pubmed">19345217</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho Y.M., Kim J.H., Kim M., Park S.J., Koh S.H., Ahn H.S., Kang G.H., Lee J.-B., Park K.S., Lee H.K. Mesenchymal stem cells transfer mitochondria to the cells with virtually no mitochondrial function but not with pathogenic mtDNA mutations. PLoS ONE. 2012;7:e32778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3295770</ArticleId><ArticleId IdType="pubmed">22412925</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi I., Zhang Y., Seegobin S.P., Pruvost M., Wang Q., Purtell K., Zhang B., Yue Z. Microglia clear neuron-released &#x3b1;-synuclein via selective autophagy and prevent neurodegeneration. Nat. Commun. 2020;11:1386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7069981</ArticleId><ArticleId IdType="pubmed">32170061</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M., Butovsky O. Microglia Function in the Central Nervous System During Health and Neurodegeneration. Annu. Rev. Immunol. 2017;35:441&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8167938</ArticleId><ArticleId IdType="pubmed">28226226</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft C.L., Noble W. Preparation of organotypic brain slice cultures for the study of Alzheimer&#x2019;s disease. F1000Res. 2018;7:592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964634</ArticleId><ArticleId IdType="pubmed">29904599</ArticleId></ArticleIdList></Reference><Reference><Citation>Croisier E., Moran L.B., Dexter D.T., Pearce R.K.B., Graeber M.B. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J.&#xa0;Neuroinflammation. 2005;2:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1177985</ArticleId><ArticleId IdType="pubmed">15935098</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant &#x3b1;-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292&#x2013;1295.</Citation><ArticleIdList><ArticleId IdType="pubmed">15333840</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis C.H., Kim K.-Y., Bushong E.A., Mills E.A., Boassa D., Shih T., Kinebuchi M., Phan S., Zhou Y., Bihlmeyer N.A. Transcellular degradation of axonal mitochondria. Proc. Natl. Acad. Sci. USA. 2014;111:9633&#x2013;9638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4084443</ArticleId><ArticleId IdType="pubmed">24979790</ArticleId></ArticleIdList></Reference><Reference><Citation>Desplats P., Lee H.-J., Bae E.-J., Patrick C., Rockenstein E., Crews L., Spencer B., Masliah E., Lee S.-J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. USA. 2009;106:13010&#x2013;13015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722313</ArticleId><ArticleId IdType="pubmed">19651612</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieriks B.V., Park T.I.-H., Fourie C., Faull R.L.M., Dragunow M., Curtis M.A. &#x3b1;-synuclein transfer through tunneling nanotubes occurs in SH-SY5Y cells and primary brain pericytes from Parkinson&#x2019;s disease patients. Sci. Rep. 2017;7:42984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5322400</ArticleId><ArticleId IdType="pubmed">28230073</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilsizoglu Senol A., Pepe A., Grudina C., Sassoon N., Reiko U., Bousset L., Melki R., Piel J., Gugger M., Zurzolo C. Effect of tolytoxin on tunneling nanotube formation and function. Sci. Rep. 2019;9:5741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450976</ArticleId><ArticleId IdType="pubmed">30952909</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupont M., Souriant S., Lugo-Villarino G., Maridonneau-Parini I., V&#xe9;rollet C. Tunneling Nanotubes: Intimate Communication between Myeloid Cells. Front. Immunol. 2018;9:43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5788888</ArticleId><ArticleId IdType="pubmed">29422895</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Agnaf O.M.A., Salem S.A., Paleologou K.E., Cooper L.J., Fullwood N.J., Gibson M.J., Curran M.D., Court J.A., Mann D.M.A., Ikeda S. &#x3b1;-synuclein implicated in Parkinson&#x2019;s disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003;17:1945&#x2013;1947.</Citation><ArticleIdList><ArticleId IdType="pubmed">14519670</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmanouilidou E., Melachroinou K., Roumeliotis T., Garbis S.D., Ntzouni M., Margaritis L.H., Stefanis L., Vekrellis K. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J.&#xa0;Neurosci. 2010;30:6838&#x2013;6851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842464</ArticleId><ArticleId IdType="pubmed">20484626</ArticleId></ArticleIdList></Reference><Reference><Citation>Eugen&#xed;n E.A., Eckardt D., Theis M., Willecke K., Bennett M.V.L., Saez J.C. Microglia at brain stab wounds express connexin 43 and in&#xa0;vitro form functional gap junctions after treatment with interferon-gamma and tumor necrosis factor-alpha. Proc. Natl. Acad. Sci. USA. 2001;98:4190&#x2013;4195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC31201</ArticleId><ArticleId IdType="pubmed">11259646</ArticleId></ArticleIdList></Reference><Reference><Citation>Flavin W.P., Bousset L., Green Z.C., Chu Y., Skarpathiotis S., Chaney M.J., Kordower J.H., Melki R., Campbell E.M. Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins. Acta Neuropathol. 2017;134:629&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">28527044</ArticleId></ArticleIdList></Reference><Reference><Citation>Freundt E.C., Maynard N., Clancy E.K., Roy S., Bousset L., Sourigues Y., Covert M., Melki R., Kirkegaard K., Brahic M. Neuron-to-neuron transmission of &#x3b1;-synuclein fibrils through axonal transport. Ann. Neurol. 2012;72:517&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490229</ArticleId><ArticleId IdType="pubmed">23109146</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentry E.G., Henderson B.W., Arrant A.E., Gearing M., Feng Y., Riddle N.C., Herskowitz J.H. Rho Kinase Inhibition as a Therapeutic for&#xa0;Progressive Supranuclear Palsy and Corticobasal Degeneration. J.&#xa0;Neurosci. 2016;36:1316&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4728727</ArticleId><ArticleId IdType="pubmed">26818518</ArticleId></ArticleIdList></Reference><Reference><Citation>George S., Rey N.L., Tyson T., Esquibel C., Meyerdirk L., Schulz E., Pierce S., Burmeister A.R., Madaj Z., Steiner J.A. Microglia affect &#x3b1;-synuclein cell-to-cell transfer in a mouse model of Parkinson&#x2019;s disease. Mol. Neurodegener. 2019;14:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697982</ArticleId><ArticleId IdType="pubmed">31419995</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R.B., Brooks D.J. In&#xa0;vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson&#x2019;s disease. Neurobiol. Dis. 2006;21:404&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">16182554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghee M., Melki R., Michot N., Mallet J. PA700, the regulatory complex of the 26S proteasome, interferes with &#x3b1;-synuclein assembly. FEBS J. 2005;272:4023&#x2013;4033.</Citation><ArticleIdList><ArticleId IdType="pubmed">16098186</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D., Baker T.J. Characterization of ameboid microglia isolated from developing mammalian brain. J.&#xa0;Neurosci. 1986;6:2163&#x2013;2178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568755</ArticleId><ArticleId IdType="pubmed">3018187</ArticleId></ArticleIdList></Reference><Reference><Citation>Grozdanov V., Bousset L., Hoffmeister M., Bliederhaeuser C., Meier C., Madiona K., Pieri L., Kiechle M., McLean P.J., Kassubek J. Increased Immune Activation by Pathologic &#x3b1;-Synuclein in Parkinson&#x2019;s Disease. Ann. Neurol. 2019;86:593&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">31343083</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C., Angot E., Bergstr&#xf6;m A.-L., Steiner J.A., Pieri L., Paul G., Outeiro T.F., Melki R., Kallunki P., Fog K. &#x3b1;-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J.&#xa0;Clin. Invest. 2011;121:715&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026723</ArticleId><ArticleId IdType="pubmed">21245577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa K., Esposito E., Wang X., Terasaki Y., Liu Y., Xing C., Ji X., Lo E.H. Transfer of mitochondria from astrocytes to neurons after stroke. Nature. 2016;535:551&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968589</ArticleId><ArticleId IdType="pubmed">27466127</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefendehl J.K., Milford D., Eicke D., Wegenast-Braun B.M., Calhoun M.E., Grathwohl S.A., Jucker M., Liebig C. Repeatable target localization for long-term in&#xa0;vivo imaging of mice with 2-photon microscopy. J.&#xa0;Neurosci. Methods. 2012;205:357&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">22093765</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka M.T., Kummer M.P., Latz E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 2014;14:463&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pubmed">24962261</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetz C., Papa F.R. The Unfolded Protein Response and Cell Fate Control. Mol. Cell. 2018;69:169&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">29107536</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat A., Bonhoeffer T., Chow D.K., Chuckowree J., De Paola V., Hofer S.B., H&#xfc;bener M., Keck T., Knott G., Lee W.-C.A. Long-term, high-resolution imaging in the mouse neocortex through a chronic cranial window. Nat. Protoc. 2009;4:1128&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072839</ArticleId><ArticleId IdType="pubmed">19617885</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C.-H., Shaltouki A., Gonzalez A.E., Bettencourt da Cruz A., Burbulla L.F., St Lawrence E., Sch&#xfc;le B., Krainc D., Palmer T.D., Wang X. Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson&#x2019;s Disease. Cell Stem Cell. 2016;19:709&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5135570</ArticleId><ArticleId IdType="pubmed">27618216</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu D., Niu J.Y., Xiong J., Nie S.K., Zeng F., Zhang Z.H. LRRK2 G2019S Mutation Inhibits Degradation of &#x3b1;-Synuclein in an In&#xa0;Vitro Model of Parkinson&#x2019;s Disease. Curr. Med. Sci. 2018;38:1012&#x2013;1017.</Citation><ArticleIdList><ArticleId IdType="pubmed">30536063</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam M.N., Das S.R., Emin M.T., Wei M., Sun L., Westphalen K., Rowlands D.J., Quadri S.K., Bhattacharya S., Bhattacharya J. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat. Med. 2012;18:759&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3727429</ArticleId><ArticleId IdType="pubmed">22504485</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamentsky L., Jones T.R., Fraser A., Bray M.-A., Logan D.J., Madden K.L., Ljosa V., Rueden C., Eliceiri K.W., Carpenter A.E. Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. Bioinformatics. 2011;27:1179&#x2013;1180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072555</ArticleId><ArticleId IdType="pubmed">21349861</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller K.E., Bradley J.M., Sun Y.Y., Yang Y.-F., Acott T.S. Tunneling Nanotubes are Novel Cellular Structures That Communicate Signals Between Trabecular Meshwork Cells. Invest. Ophthalmol. Vis. Sci. 2017;58:5298&#x2013;5307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5656416</ArticleId><ArticleId IdType="pubmed">29049733</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecours C., Bordeleau M., Cantin L., Parent M., Paolo T.D., Tremblay M.-&#xc8;. Microglial Implication in Parkinson&#x2019;s Disease: Loss of Beneficial Physiological Roles or Gain of Inflammatory Functions? Front. Cell. Neurosci. 2018;12:282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6125334</ArticleId><ArticleId IdType="pubmed">30214398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.-J., Suk J.-E., Bae E.-J., Lee S.-J. Clearance and deposition of extracellular &#x3b1;-synuclein aggregates in microglia. Biochem. Biophys. Res. Commun. 2008;372:423&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">18492487</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.-J., Suk J.-E., Patrick C., Bae E.-J., Cho J.-H., Rho S., Hwang D., Masliah E., Lee S.-J. Direct transfer of &#x3b1;-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J.&#xa0;Biol. Chem. 2010;285:9262&#x2013;9272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838344</ArticleId><ArticleId IdType="pubmed">20071342</ArticleId></ArticleIdList></Reference><Reference><Citation>Maekawa M., Ishizaki T., Boku S., Watanabe N., Fujita A., Iwamatsu A., Obinata T., Ohashi K., Mizuno K., Narumiya S. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science. 1999;285:895&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">10436159</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda-Suzukake M., Nonaka T., Hosokawa M., Oikawa T., Arai T., Akiyama H., Mann D.M.A., Hasegawa M. Prion-like spreading of pathological &#x3b1;-synuclein in brain. Brain. 2013;136:1128&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613715</ArticleId><ArticleId IdType="pubmed">23466394</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson&#x2019;s and Alzheimer&#x2019;s disease brains. Neurology. 1988;38:1285&#x2013;1291.</Citation><ArticleIdList><ArticleId IdType="pubmed">3399080</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollenhauer B., Locascio J.J., Schulz-Schaeffer W., Sixel-D&#xf6;ring F., Trenkwalder C., Schlossmacher M.G. &#x3b1;-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10:230&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">21317042</ArticleId></ArticleIdList></Reference><Reference><Citation>Okafo G., Prevedel L., Eugenin E. Tunneling nanotubes (TNT) mediate long-range gap junctional communication: Implications for HIV cell to cell spread. Sci. Rep. 2017;7:16660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5709493</ArticleId><ArticleId IdType="pubmed">29192225</ArticleId></ArticleIdList></Reference><Reference><Citation>Onfelt B., Nedvetzki S., Benninger R.K.P., Purbhoo M.A., Sowinski S., Hume A.N., Seabra M.C., Neil M.A.A., French P.M.W., Davis D.M. Structurally distinct membrane nanotubes between human macrophages support long-distance vesicular traffic or surfing of bacteria. J.&#xa0;Immunol. 2006;177:8476&#x2013;8483.</Citation><ArticleIdList><ArticleId IdType="pubmed">17142745</ArticleId></ArticleIdList></Reference><Reference><Citation>Panasiuk M., Rych&#x142;owski M., Derewo&#x144;ko N., Bie&#x144;kowska-Szewczyk K. Tunneling Nanotubes as a Novel Route of Cell-to-Cell Spread of Herpesviruses. J.&#xa0;Virol. 2018;92 e00090&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5923070</ArticleId><ArticleId IdType="pubmed">29491165</ArticleId></ArticleIdList></Reference><Reference><Citation>Peelaerts W., Bousset L., Van der Perren A., Moskalyuk A., Pulizzi R., Giugliano M., Van den Haute C., Melki R., Baekelandt V. &#x3b1;-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522:340&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">26061766</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez A.-M., Nakhle J., Griessinger E., Vignais M.-L. Intercellular mitochondria trafficking highlighting the dual role of mesenchymal stem cells as both sensors and rescuers of tissue injury. Cell Cycle. 2018;17:712&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5969546</ArticleId><ArticleId IdType="pubmed">29582715</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostami J., Holmqvist S., Lindstr&#xf6;m V., Sigvardson J., Westermark G.T., Ingelsson M., Bergstr&#xf6;m J., Roybon L., Erlandsson A. Human Astrocytes Transfer Aggregated Alpha-Synuclein via Tunneling Nanotubes. J.&#xa0;Neurosci. 2017;37:11835&#x2013;11853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719970</ArticleId><ArticleId IdType="pubmed">29089438</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostami J., Mothes T., Kolahdouzan M., Eriksson O., Moslem M., Bergstr&#xf6;m J., Ingelsson M., O&#x2019;Callaghan P., Healy L.M., Falk A., Erlandsson A. Crosstalk between astrocytes and microglia results in increased degradation of &#x3b1;-synuclein and amyloid-&#x3b2; aggregates. J.&#xa0;Neuroinflammation. 2021;18:124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8173980</ArticleId><ArticleId IdType="pubmed">34082772</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusinova I., Forster S., Yu S., Kannan A., Masse M., Cumming H., Chapman R., Hertzog P.J. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 2013;41:D1040&#x2013;D1046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531205</ArticleId><ArticleId IdType="pubmed">23203888</ArticleId></ArticleIdList></Reference><Reference><Citation>Saal K.-A., Galter D., Roeber S., B&#xe4;hr M., T&#xf6;nges L., Lingor P. Altered Expression of Growth Associated Protein-43 and Rho Kinase in Human Patients with Parkinson&#x2019;s Disease. Brain Pathol. 2017;27:13&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029215</ArticleId><ArticleId IdType="pubmed">26748453</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S., Dammer E.B., Malovic E., Olsen A.L., Raza S.A., Gao T., Xiao H., Oliver D.L., Duong D., Joers V. Molecular Signatures of Neuroinflammation Induced by &#x3b1;Synuclein Aggregates in Microglial Cells. Front. Immunol. 2020;11:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7006296</ArticleId><ArticleId IdType="pubmed">32082315</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheiblich H., Bousset L., Schwartz S., Griep A., Latz E., Melki R., Heneka M.T. Microglial NLRP3 inflammasome activation upon TLR2 and TLR5 ligation by distinct &#x3b1;-synuclein assemblies. J.&#xa0;Immunol. 2021 doi: 10.4049/jimmunol.2100035.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2100035</ArticleId><ArticleId IdType="pmc">PMC8490941</ArticleId><ArticleId IdType="pubmed">34507948</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellgren C.M., Sheridan S.D., Gracias J., Xuan D., Fu T., Perlis R.H. Patient-specific models of microglia-mediated engulfment of synapses and neural progenitors. Mol. Psychiatry. 2017;22:170&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5285468</ArticleId><ArticleId IdType="pubmed">27956744</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahmoradian S.H., Lewis A.J., Genoud C., Hench J., Moors T.E., Navarro P.P., Casta&#xf1;o-D&#xed;ez D., Schweighauser G., Graff-Meyer A., Goldie K.N. Lewy pathology in Parkinson&#x2019;s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 2019;22:1099&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">31235907</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Wu X., Surma M., Vemula S., Zhang L., Yang Y., Kapur R., Wei L. Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment. Cell Death Dis. 2013;4:e483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3734810</ArticleId><ArticleId IdType="pubmed">23392171</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisakhtnezhad S., Khosravi L. Emerging physiological and pathological implications of tunneling nanotubes formation between cells. Eur. J. Cell Biol. 2015;94:429&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">26164368</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder H., Mensah K., Theisler C., Lee J., Matouschek A., Wolozin B. Aggregated and monomeric &#x3b1;-synuclein bind to the S6&#xa2; proteasomal protein and inhibit proteasomal function. J.&#xa0;Biol. Chem. 2003;278:11753&#x2013;11759.</Citation><ArticleIdList><ArticleId IdType="pubmed">12551928</ArticleId></ArticleIdList></Reference><Reference><Citation>Spees J.L., Olson S.D., Whitney M.J., Prockop D.J. Mitochondrial transfer between cells can rescue aerobic respiration. Proc. Natl. Acad. Sci. USA. 2006;103:1283&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1345715</ArticleId><ArticleId IdType="pubmed">16432190</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M.G., Schmidt M.L., Lee V.M.-Y., Trojanowski J.Q., Jakes R., Goedert M. &#x3b1;-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatenhorst L., Eckermann K., Dambeck V., Fonseca-Ornelas L., Walle H., Lopes da Fonseca T., Koch J.C., Becker S., T&#xf6;nges L., B&#xe4;hr M. Fasudil attenuates aggregation of &#x3b1;-synuclein in models of Parkinson&#x2019;s disease. Acta Neuropathol. Commun. 2016;4:39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4840958</ArticleId><ArticleId IdType="pubmed">27101974</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf6;nges L., Frank T., Tatenhorst L., Saal K.A., Koch J.C., Szego E.M., B&#xe4;hr M., Weishaupt J.H., Lingor P. Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson&#x2019;s disease. Brain. 2012;135:3355&#x2013;3370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501973</ArticleId><ArticleId IdType="pubmed">23087045</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf6;nges L., G&#xfc;nther R., Suhr M., Jansen J., Balck A., Saal K.-A., Barski E., Nientied T., G&#xf6;tz A.A., Koch J.-C. Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia. 2014;62:217&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">24311453</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallings R.L., Tansey M.G. LRRK2 regulation of immune-pathways and inflammatory disease. Biochem. Soc. Trans. 2019;47:1581&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6925522</ArticleId><ArticleId IdType="pubmed">31769472</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb P.H., Zhen W., Poon A.W., Conway K.A., Lansbury P.T., Jr. NACP, a protein implicated in Alzheimer&#x2019;s disease and learning, is natively unfolded. Biochemistry. 1996;35:13709&#x2013;13715.</Citation><ArticleIdList><ArticleId IdType="pubmed">8901511</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34586832</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>613</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle><i>APOE3</i>-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia.</ArticleTitle><Pagination><StartPage>eabc9375</StartPage><MedlinePgn>eabc9375</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abc9375</ELocationID><Abstract><AbstractText>Apolipoprotein E (<i>APOE</i>) genetic variants have been shown to modify Alzheimer&#x2019;s disease (AD) risk. We previously identified an <i>APOE3</i> variant (<i>APOE</i>3-V236E), named <i>APOE3</i>-Jacksonville (<i>APOE3</i>-Jac), associated with healthy brain aging and reduced risk for AD and dementia with Lewy bodies (DLB). Herein, we resolved the functional mechanism by which APOE3-Jac reduces APOE aggregation and enhances its lipidation in human brains, as well as in cellular and biochemical assays. Compared to APOE3, expression of APOE3-Jac in astrocytes increases several classes of lipids in the brain including phosphatidylserine, phosphatidylethanolamine, phosphatidic acid, and sulfatide, critical for synaptic functions. Mice expressing APOE3-Jac have reduced amyloid pathology, plaque-associated immune responses, and neuritic dystrophy. The V236E substitution is also sufficient to reduce the aggregation of APOE4, whose gene allele is a major genetic risk factor for AD and DLB. These findings suggest that targeting APOE aggregation might be an effective strategy for treating a subgroup of individuals with AD and DLB.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chen</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0001-7203-3926</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0001-7379-2545</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xia</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-3531-0861</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Na</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8648-9422</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heckman</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shue</LastName><ForeName>Francis</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-1659-1952</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martens</LastName><ForeName>Yuka</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5194-4269</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yonghe</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raulin</LastName><ForeName>Ana-Caroline</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0001-5044-9197</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Cassandra L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doss</LastName><ForeName>Sydney V</ForeName><Initials>SV</Initials><Identifier Source="ORCID">0000-0002-3427-4654</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jing</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4520-6307</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wren</LastName><ForeName>Melissa C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-9359-4941</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Yingxue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikezu</LastName><ForeName>Tadafumi C</ForeName><Initials>TC</Initials><Identifier Source="ORCID">0000-0002-3511-6009</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Wenyan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caulfield</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1055-3069</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trottier</LastName><ForeName>Zachary A</ForeName><Initials>ZA</Initials><Identifier Source="ORCID">0000-0003-0040-4294</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yixing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linares</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurti</LastName><ForeName>Aishe</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asmann</LastName><ForeName>Yan W</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wszolek</LastName><ForeName>Zbigniew K</ForeName><Initials>ZK</Initials><Identifier Source="ORCID">0000-0001-5487-1053</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Glenn E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-4286-0589</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Val J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0001-7916-622X</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferman</LastName><ForeName>Tanis J</ForeName><Initials>TJ</Initials><Identifier Source="ORCID">0000-0001-8377-6194</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><Identifier Source="ORCID">0000-0002-4153-8187</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><Identifier Source="ORCID">0000-0002-8178-6601</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0002-7818-3105</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fryer</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Scottsdale, AZ 85259, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Barshop Institute for Longevity and Aging Studies, San Antonio, TX 78229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Xianlin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Barshop Institute for Longevity and Aging Studies, San Antonio, TX 78229, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frieden</LastName><ForeName>Carl</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4471-2427</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biophysics, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Owen A</ForeName><Initials>OA</Initials><Identifier Source="ORCID">0000-0003-4813-756X</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Genomics, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3491-1016</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078086</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS074969</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021010</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG062110</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS072187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG027924</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057181</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS100620</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS076471</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015866</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS110435</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG052409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062677</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG046205</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG069701</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG061872</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000612345">ApoE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34586832</ArticleId><ArticleId IdType="mid">NIHMS1767924</ArticleId><ArticleId IdType="pmc">PMC8824726</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abc9375</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bertram L, Tanzi RE, Thirty years of Alzheimer&#x2019;s disease genetics: the implications of systematic meta-analyses. Nature reviews. Neuroscience 9, 768&#x2013;778 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18802446</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y, Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer&#x2019;s disease. Mol Neurodegener 15, 40 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364557</ArticleId><ArticleId IdType="pubmed">32677986</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, et al., A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature 488, 96&#x2013;99 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LS, Naj AC, Graham RR, Crane PK, Kunkle BW, et al., Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol 72, 209&#x2013;216 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324097</ArticleId><ArticleId IdType="pubmed">25531812</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science 261, 921&#x2013;923 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Trojanowski JQ, Weintraub D, Chen-Plotkin AS, Irwin DJ, Rick J, Schellenberg GD, Watson GS, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Quinn JF, Chung KA, Yearout D, Mata IF, Wan JY, Edwards KL, Montine TJ, Zabetian CP, APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 70, 223&#x2013;228 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580799</ArticleId><ArticleId IdType="pubmed">23407718</ArticleId></ArticleIdList></Reference><Reference><Citation>Schachter F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, Lesueur-Ginot L, Cohen D, Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 6, 29&#x2013;32 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8136829</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Shue F, Zhao N, Shinohara M, Bu G, APOE2: protective mechanism and therapeutic implications for Alzheimer&#x2019;s disease. Mol Neurodegener 15, 63 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7640652</ArticleId><ArticleId IdType="pubmed">33148290</ArticleId></ArticleIdList></Reference><Reference><Citation>Arboleda-Velasquez JF, Lopera F, O&#x2019;Hare M, Delgado-Tirado S, Marino C, Chmielewska N, Saez-Torres KL, Amarnani D, Schultz AP, Sperling RA, Leyton-Cifuentes D, Chen K, Baena A, Aguillon D, Rios-Romenets S, Giraldo M, Guzman-Velez E, Norton DJ, Pardilla-Delgado E, Artola A, Sanchez JS, Acosta-Uribe J, Lalli M, Kosik KS, Huentelman MJ, Zetterberg H, Blennow K, Reiman RA, Luo J, Chen Y, Thiyyagura P, Su Y, Jun GR, Naymik M, Gai X, Bootwalla M, Ji J, Shen L, Miller JB, Kim LA, Tariot PN, Johnson KA, Reiman EM, Quiroz YT, Resistance to autosomal dominant Alzheimer&#x2019;s disease in an APOE3 Christchurch homozygote: a case report. Nat Med 25, 1680&#x2013;1683 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6898984</ArticleId><ArticleId IdType="pubmed">31686034</ArticleId></ArticleIdList></Reference><Reference><Citation>Medway CW, Abdul-Hay S, Mims T, Ma L, Bisceglio G, Zou F, Pankratz S, Sando SB, Aasly JO, Barcikowska M, Siuda J, Wszolek ZK, Ross OA, Carrasquillo M, Dickson DW, Graff-Radford N, Petersen RC, Ertekin-Taner N, Morgan K, Bu G, Younkin SG, ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer&#x2019;s disease. Mol Neurodegener 9, 11 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3995879</ArticleId><ArticleId IdType="pubmed">24607147</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr., Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, Lowe VJ, Senjem ML, Gunter JL, Preboske GM, Pankratz VS, Vemuri P, Petersen RC, Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol 13, 997&#x2013;1005 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4324499</ArticleId><ArticleId IdType="pubmed">25201514</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, Donaghy P, Morris C, Taylor JP, Thomas A, Attems J, McKeith I, Dementia with Lewy bodies: an update and outlook. Mol Neurodegener 14, 5 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6341685</ArticleId><ArticleId IdType="pubmed">30665447</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Yee A, Brewer HB Jr., Das S, Potter H, Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372, 92&#x2013;94 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7969426</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, Wisniewski T, Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A 103, 18787&#x2013;18792 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1654132</ArticleId><ArticleId IdType="pubmed">17116874</ArticleId></ArticleIdList></Reference><Reference><Citation>Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K, Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer&#x2019;s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541, 163&#x2013;166 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2029618</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatters DM, Peters-Libeu CA, Weisgraber KH, Apolipoprotein E structure: insights into function. Trends Biochem Sci 31, 445&#x2013;454 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16820298</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund-Katz S, Phillips MC, High density lipoprotein structure-function and role in reverse cholesterol transport. Subcell Biochem 51, 183&#x2013;227 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3215094</ArticleId><ArticleId IdType="pubmed">20213545</ArticleId></ArticleIdList></Reference><Reference><Citation>Choy N, Raussens V, Narayanaswami V, Inter-molecular coiled-coil formation in human apolipoprotein E C-terminal domain. J Mol Biol 334, 527&#x2013;539 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14623192</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji ZS, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW, Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem 268, 10160&#x2013;10167 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">7683668</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito H, Dhanasekaran P, Nguyen D, Baldwin F, Weisgraber KH, Wehrli S, Phillips MC, Lund-Katz S, Characterization of the heparin binding sites in human apolipoprotein E. J Biol Chem 278, 14782&#x2013;14787 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12588864</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu G, Apolipoprotein E and its receptors in Alzheimer&#x2019;s disease: pathways, pathogenesis and therapy. Nature reviews. Neuroscience 10, 333&#x2013;344 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908393</ArticleId><ArticleId IdType="pubmed">19339974</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J, Liu CC, Chen XF, Zhang YW, Xu H, Bu G, Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Abeta metabolism in apoE4-targeted replacement mice. Mol Neurodegener 10, 6 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4356137</ArticleId><ArticleId IdType="pubmed">25871773</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM, Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 17, 263&#x2013;264 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Ulland TK, Mahan TE, Nystrom S, Nilsson KP, Song WM, Zhou Y, Reinartz M, Choi S, Jiang H, Stewart FR, Anderson E, Wang Y, Colonna M, Holtzman DM, ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med 215, 1047&#x2013;1058 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5881464</ArticleId><ArticleId IdType="pubmed">29483128</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, Itzkovitz S, Colonna M, Schwartz M, Amit I, A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290 e1217 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Betensky RA, Frosch MP, Hyman BT, Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease. Am J Pathol 186, 375&#x2013;384 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4729270</ArticleId><ArticleId IdType="pubmed">26687817</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Kanekiyo T, Xu H, Bu G, Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9, 106&#x2013;118 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Garai K, Frieden C, The association-dissociation behavior of the ApoE proteins: kinetic and equilibrium studies. Biochemistry 49, 9533&#x2013;9541 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038193</ArticleId><ArticleId IdType="pubmed">20923231</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou CY, Lin YL, Huang YC, Sheu SY, Lin TH, Tsay HJ, Chang GG, Shiao MS, Structural variation in human apolipoprotein E3 and E4: secondary structure, tertiary structure, and size distribution. Biophys J 88, 455&#x2013;466 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1305022</ArticleId><ArticleId IdType="pubmed">15475580</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C, Unfolding the role of protein misfolding in neurodegenerative diseases. Nature reviews. Neuroscience 4, 49&#x2013;60 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12511861</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA, Poirier MA, Protein aggregation and neurodegenerative disease. Nat Med 10 Suppl, S10&#x2013;17 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15272267</ArticleId></ArticleIdList></Reference><Reference><Citation>DeTure MA, Dickson DW, The neuropathological diagnosis of Alzheimer&#x2019;s disease. Mol Neurodegener 14, 32 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6679484</ArticleId><ArticleId IdType="pubmed">31375134</ArticleId></ArticleIdList></Reference><Reference><Citation>Twohig D, Nielsen HM, &#x3b1;-synuclein in the pathophysiology of Alzheimer&#x2019;s disease. Mol Neurodegener 14, 23 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6558879</ArticleId><ArticleId IdType="pubmed">31186026</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D, Diamond MI, Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A 110, E3138&#x2013;3147 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Zhao N, Yamaguchi Y, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G, Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-beta clearance and aggregation in Alzheimer&#x2019;s disease. Sci Transl Med 8, 332ra344 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5512541</ArticleId><ArticleId IdType="pubmed">27030596</ArticleId></ArticleIdList></Reference><Reference><Citation>Frieden C, Garai K, Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer&#x2019;s disease. Proc Natl Acad Sci U S A 109, 8913&#x2013;8918 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3384159</ArticleId><ArticleId IdType="pubmed">22615372</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paolo G, Kim TW, Linking lipids to Alzheimer&#x2019;s disease: cholesterol and beyond. Nat Rev Neurosci 12, 284&#x2013;296 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321383</ArticleId><ArticleId IdType="pubmed">21448224</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HY, Huang BX, Spector AA, Phosphatidylserine in the brain: metabolism and function. Prog Lipid Res 56, 1&#x2013;18 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4258547</ArticleId><ArticleId IdType="pubmed">24992464</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckhardt M, The role and metabolism of sulfatide in the nervous system. Mol Neurobiol 37, 93&#x2013;103 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18465098</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao YC, Ho PC, Tu YK, Jou IM, Tsai KJ, Lipids and Alzheimer&#x2019;s Disease. Int J Mol Sci 21, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073164</ArticleId><ArticleId IdType="pubmed">32098382</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Cheng H, Fryer JD, Fagan AM, Holtzman DM, Novel role for apolipoprotein E in the central nervous system. Modulation of sulfatide content. J Biol Chem 278, 8043&#x2013;8051 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12501252</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H, Zhou Y, Holtzman DM, Han X, Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer&#x2019;s disease. Neurobiol Aging 31, 1188&#x2013;1196 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873070</ArticleId><ArticleId IdType="pubmed">18762354</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefterov I, Wolfe CM, Fitz NF, Nam KN, Letronne F, Biedrzycki RJ, Kofler J, Han X, Wang J, Schug J, Koldamova R, APOE2 orchestrated differences in transcriptomic and lipidomic profiles of postmortem AD brain. Alzheimers Res Ther 11, 113 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6937981</ArticleId><ArticleId IdType="pubmed">31888770</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM, Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 118, 671&#x2013;682 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE, ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335, 1503&#x2013;1506 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651582</ArticleId><ArticleId IdType="pubmed">22323736</ArticleId></ArticleIdList></Reference><Reference><Citation>Garai K, Baban B, Frieden C, Dissociation of apolipoprotein E oligomers to monomer is required for high-affinity binding to phospholipid vesicles. Biochemistry 50, 2550&#x2013;2558 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3088999</ArticleId><ArticleId IdType="pubmed">21322570</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, Bu G, ApoE4 Accelerates Early Seeding of Amyloid Pathology. Neuron 96, 1024&#x2013;1032 e1023 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948105</ArticleId><ArticleId IdType="pubmed">29216449</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R, APOE and dementia - resequencing and genotyping in 105,597 individuals. Alzheimers Dement 16, 1624&#x2013;1637 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7984319</ArticleId><ArticleId IdType="pubmed">32808727</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski SA, Rawal B, Parisi JE, Petersen RC, Kantarci K, Ross OA, Duara R, Knopman DS, Jack CR Jr., Dickson DW, Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer&#x2019;s disease spectrum. Brain 138, 1370&#x2013;1381 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407190</ArticleId><ArticleId IdType="pubmed">25805643</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr., Wiste HJ, Weigand SD, Knopman DS, Lowe V, Vemuri P, Mielke MM, Jones DT, Senjem ML, Gunter JL, Gregg BE, Pankratz VS, Petersen RC, Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 81, 1732&#x2013;1740 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821718</ArticleId><ArticleId IdType="pubmed">24132377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan S, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Asztalos BF, Bittman R, Rothblat GH, A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol. J Lipid Res 52, 2332&#x2013;2340 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220299</ArticleId><ArticleId IdType="pubmed">21957199</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34585210</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2426-0266</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>The journal of prevention of Alzheimer's disease</Title><ISOAbbreviation>J Prev Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Editorial: Consequences of the FDA Decision on Aducanumab for Patient Care and Research.</ArticleTitle><Pagination><StartPage>393</StartPage><EndPage>395</EndPage><MedlinePgn>393-395</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14283/jpad.2021.43</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doody</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Rachelle Doody, F. Hoffmann-La Roche Ltd, Basel, Switzerland, rachelle.doody@roche.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Prev Alzheimers Dis</MedlineTA><NlmUniqueID>101638820</NlmUniqueID><ISSNLinking>2274-5807</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>105J35OE21</RegistryNumber><NameOfSubstance UI="C000600266">aducanumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005791" MajorTopicYN="Y">Patient Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012106" MajorTopicYN="Y">Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="Y">United States Food and Drug Administration</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>7</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34585210</ArticleId><ArticleId IdType="doi">10.14283/jpad.2021.43</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34588692</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>598</Volume><Issue>7880</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Structure-based classification of tauopathies.</ArticleTitle><Pagination><StartPage>359</StartPage><EndPage>363</EndPage><MedlinePgn>359-363</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-021-03911-7</ELocationID><Abstract><AbstractText>The ordered assembly of tau protein into filaments characterizes several neurodegenerative diseases, which are called tauopathies. It was previously reported that, by cryo-electron microscopy, the structures of tau filaments from Alzheimer's disease<sup>1,2</sup>,&#xfeff;&#xa0;Pick's disease<sup>3</sup>, chronic traumatic encephalopathy<sup>4</sup> and corticobasal degeneration<sup>5</sup> are distinct. Here we show that the structures of tau filaments from progressive supranuclear palsy (PSP) define a new three-layered fold. Moreover, the structures of tau filaments from globular glial tauopathy are similar to those from PSP. The tau filament fold of argyrophilic grain disease (AGD) differs, instead resembling the four-layered fold of corticobasal degeneration. The AGD fold is also observed in ageing-related tau astrogliopathy. Tau protofilament structures from inherited cases of mutations at positions +3 or +16 in intron 10 of MAPT (the&#xa0;microtubule-associated protein tau&#xa0;gene) are also identical to those from AGD, suggesting that relative overproduction of four-repeat tau can give rise to the AGD fold. Finally, the structures of tau filaments from cases of familial British dementia and familial Danish dementia are the same as those from cases of Alzheimer's disease and primary age-related tauopathy. These findings suggest a hierarchical classification of tauopathies on the basis of their filament folds, which complements clinical diagnosis and neuropathology and also allows the identification of new entities-as we show for a case diagnosed as PSP, but with filament structures that are intermediate between those of globular glial tauopathy and PSP.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Shi</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-1579-7561</Identifier><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Wenjuan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murzin</LastName><ForeName>Alexey G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falcon</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotecha</LastName><ForeName>Abhay</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4480-5439</Identifier><AffiliationInfo><Affiliation>Thermo Fisher Scientific, Eindhoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Beers</LastName><ForeName>Mike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Thermo Fisher Scientific, Eindhoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarutani</LastName><ForeName>Airi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kametani</LastName><ForeName>Fuyuki</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9125-7001</Identifier><AffiliationInfo><Affiliation>Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garringer</LastName><ForeName>Holly J</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0002-1899-7676</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallinan</LastName><ForeName>Grace I</ForeName><Initials>GI</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lashley</LastName><ForeName>Tammaryn</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease and Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murayama</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, University of Osaka, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Hidetomo</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-8490-3877</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakita</LastName><ForeName>Akiyoshi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-8828-8085</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0003-2208-7728</Identifier><AffiliationInfo><Affiliation>Clinical Sciences Building, University of Manchester, Salford Royal Foundation Trust, Salford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mann</LastName><ForeName>David M A</ForeName><Initials>DMA</Initials><AffiliationInfo><Affiliation>Clinical Sciences Building, University of Manchester, Salford Royal Foundation Trust, Salford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Gabor G</ForeName><Initials>GG</Initials><Identifier Source="ORCID">0000-0003-3841-5511</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology and Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revesz</LastName><ForeName>Tamas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease and Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1842-8019</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Masato</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7415-8159</Identifier><AffiliationInfo><Affiliation>Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goedert</LastName><ForeName>Michel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5214-7886</Identifier><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK. mg@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheres</LastName><ForeName>Sjors H W</ForeName><Initials>SHW</Initials><Identifier Source="ORCID">0000-0002-0462-6540</Identifier><AffiliationInfo><Affiliation>MRC Laboratory of Molecular Biology, Cambridge, UK. scheres@mrc-lmb.cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_U105192716</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_U105184291</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RF1 AG071177</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG072976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS110437</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_UP_A025_1013</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2021 Oct;598(7880):264-265. doi: 10.1038/d41586-021-02611-6.</RefSource><PMID Version="1">34588645</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="Y">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007438" MajorTopicYN="N">Introns</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="Y">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>
<b>Competing interests.</b> The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34588692</ArticleId><ArticleId IdType="mid">EMS136339</ArticleId><ArticleId IdType="pmc">PMC7611841</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03911-7</ArticleId><ArticleId IdType="pii">10.1038/s41586-021-03911-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fitzpatrick AWP, et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature. 2017;547:185&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Tau filaments from multiple cases of sporadic and inherited Alzheimer&#x2019;s disease adopt a common fold. Acta Neuropathol. 126:699&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6208733</ArticleId><ArticleId IdType="pubmed">30276465</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Structures of filaments from Pick&#x2019;s disease reveal a novel tau protein fold. Nature. 2018;561:137&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204212</ArticleId><ArticleId IdType="pubmed">30158706</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B, et al. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature. 2019;568:420&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472968</ArticleId><ArticleId IdType="pubmed">30894745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, et al. Novel tau filament fold in corticobasal degeneration. Nature. 2020;580:283&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7148158</ArticleId><ArticleId IdType="pubmed">32050258</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer&#x2019;s disease. Neuron. 1989;3:519&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">2484340</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghetti B, et al. Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: A chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol. 2015;41:24&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4329416</ArticleId><ArticleId IdType="pubmed">25556536</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease with PET ligand APN-1607. Acta Neuropathol. 2021;141:697&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043864</ArticleId><ArticleId IdType="pubmed">33723967</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brainstem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">14107684</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DR, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson&#x2019;s syndrome and PSP-parkinsonism. Brain. 2005;128:1247&#x2013;1258.</Citation><ArticleIdList><ArticleId IdType="pubmed">15788542</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger GU, et al. Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society criteria. Mov Disord. 2017;32:853&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5516529</ArticleId><ArticleId IdType="pubmed">28467028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020;140:99&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7360645</ArticleId><ArticleId IdType="pubmed">32383020</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82:1271&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina JA, et al. Primary progressive aphasia with glial cytoplasmic inclusions. Eur Neurol. 1998;40:71&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">9693235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, et al. Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: An emerging group of 4-repeat tauopathies. Acta Neuropathol. 2011;122:415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">21773886</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z, et al. Globular glial tauopathies (GGT): Consensus recommendations. Acta Neuropathol. 2013;126:537&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3914659</ArticleId><ArticleId IdType="pubmed">23995422</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CN, et al. Temporal variant frontotemporal dementia is associated with globular glial tauopathy. Cogn Behav Neurol. 2015;28:92&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4478068</ArticleId><ArticleId IdType="pubmed">26102999</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka H, et al. Globular glial tauopathy Type II: Clinicopathological study of two autopsy cases. Neuropathology. 2019;39:111&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">30646429</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu YJ, et al. Sporadic, four-repeat tauopathy with frontotemporal lobar degeneration, Parkinsonism, and motor neuron disease: a distinct clinicopathological and biochemical disease entity. Acta Neuropathol. 2010;120:21&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">20140439</ArticleId></ArticleIdList></Reference><Reference><Citation>Miki Y, Mori F, Hori E, Kaimori M, Wakabayashi K. Hippocampal sclerosis with four repeat tau-positive round inclusions in the dentate gyrus: a new type of four-repeat tauopathy. Acta Neuropathol. 2009;117:713&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">19360425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, et al. Tauopathy with hippocampal 4-repeat tau immunoreactive spherical inclusions: a report of three cases. Brain Pathol. 2018;28:274&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5484758</ArticleId><ArticleId IdType="pubmed">28019685</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrego-&#xc9;cija S, et al. Tauopathy with hippocampal 4-repeat tau immunoreactive spherical inclusions in a patient with PSP. Brain Pathol. 2018;28:284&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8028502</ArticleId><ArticleId IdType="pubmed">29516660</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakane T, et al. Single-particle cryo-EM at atomic resolution. Nature. 2020;587:152&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611073</ArticleId><ArticleId IdType="pubmed">33087931</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Argyrophilic grains: Characteristic pathology of cerebral cortex in cases of adult-onset dementia without Alzheimer changes. Neurosci Lett. 1987;76:124&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">2438598</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Cortical and subcortical argyrophilic grains characterize a disease associated with adult-onset dementia. Neuropathol Appl Neurobiol. 1989;15:13&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">2471109</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolnay M, Clavaguera F. Argyrophilic grain disease: A late-onset dementia with distinctive features among tauopathies. Neuropathology. 2004;24:269&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">15641585</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito Y, et al. Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol. 2004;63:911&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">15453090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Santpere G, Van Leeuwen FW. Argyrophilic grain disease. Brain. 2008;131:1416&#x2013;1432.</Citation><ArticleIdList><ArticleId IdType="pubmed">18234698</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, et al. Aging-related tau astrogliopathy (ARTAG): Harmonized evaluation strategy. Acta Neuropathol. 2016;131:87&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879001</ArticleId><ArticleId IdType="pubmed">26659578</ArticleId></ArticleIdList></Reference><Reference><Citation>Klotz S, et al. Multiple system aging-related tau astrogliopathy with complex proteinopathy in an oligosymptomatic octogenarian. Neuropathology. 2021;41:72&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7984345</ArticleId><ArticleId IdType="pubmed">33263220</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Familial multiple system tauopathy with presenile dementia: A disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci USA. 1997;94:4113&#x2013;4118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20577</ArticleId><ArticleId IdType="pubmed">9108114</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, et al. Association of missense and 5&#x2019;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA. 1998;95:7737&#x2013;7741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22742</ArticleId><ArticleId IdType="pubmed">9636220</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest SL, et al. Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain. 2018;141:521&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5888940</ArticleId><ArticleId IdType="pubmed">29253099</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol. 2004;55:72&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">14705114</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi-Watanabe S, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 2016;131:267&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4713716</ArticleId><ArticleId IdType="pubmed">26538150</ArticleId></ArticleIdList></Reference><Reference><Citation>Miki T, et al. Factors associated with development and distribution of granular/fuzzy astrocytes in neurodegenerative diseases. Brain Pathol. 2020;30:811&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383906</ArticleId><ArticleId IdType="pubmed">32293067</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R, et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature. 1999;399:776&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391242</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal R, et al. A decamer duplication in the 3&#x2019; region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci USA. 2000;97:4920&#x2013;4925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18333</ArticleId><ArticleId IdType="pubmed">10781099</ArticleId></ArticleIdList></Reference><Reference><Citation>Holton JL, et al. Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia. Am J Pathol. 2001;158:515&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850296</ArticleId><ArticleId IdType="pubmed">11159188</ArticleId></ArticleIdList></Reference><Reference><Citation>Holton JL, et al. Familial Danish dementia: A novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. J Neuropathol Exp Neurol. 2002;61:254&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">11895040</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan A, et al. Extensive deamidation at asparagine residue 279 accounts for weak immunoreactivity of tau with RD4 antibody in Alzheimer&#x2019;s disease brain. Acta Neuropathol Commun. 2013;1:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893535</ArticleId><ArticleId IdType="pubmed">24252707</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, et al. PART is part of Alzheimer disease. Acta Neuropathol. 2015;129:749&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4405349</ArticleId><ArticleId IdType="pubmed">25628035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallihan GI, et al. Structure of tau filaments in prion protein amyloidoses. Acta Neuropathol. 2021;142:227&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270882</ArticleId><ArticleId IdType="pubmed">34128081</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, et al. Comparison of common and disease-specific post-translational modifications of pathological tau associated with a wide range of tauopathies. Front Neurosci. 14:581936</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7672045</ArticleId><ArticleId IdType="pubmed">33250706</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinberg LT, et al. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta Neuropathol. 2013;125:581&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692283</ArticleId><ArticleId IdType="pubmed">23371364</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, et al. MAPT S305I mutation: implications for argyrophilic grain disease. Acta Neuropathol. 2008;116:103&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">18066559</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;nnb&#xe4;ck A, et al. Neuropathological characterization of two siblings carrying the MAPT S305S mutation demonstrates features resembling argyrophilic grain disease. Acta Neuropathol. 2014;127:297&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">24337498</ArticleId></ArticleIdList></Reference><Reference><Citation>Varani L, et al. Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. Proc Natl Acad Sci USA. 1999;96:8229&#x2013;8234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22217</ArticleId><ArticleId IdType="pubmed">10393977</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43:815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugiani O, et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol. 1999;58:667&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">10374757</ArticleId></ArticleIdList></Reference><Reference><Citation>Llad&#xf3; A, et al. A novel MAPT mutation (P301T) associated with familial frontotemporal dementia. Eur J Neurol. 2007;14:e9&#x2013;e10.</Citation><ArticleIdList><ArticleId IdType="pubmed">17662000</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nature Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002;22:9340&#x2013;9351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlin DG, Dickson DW, Josephs KA, Litvan I. Progressive supranuclear palsy and corticobasal degeneration. Adv Exp Med Biol. 2021;1281:151&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">33433875</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, et al. Atypical progressive supranuclear palsy with corticospinal tract degeneration. J Neuropathol Exp Neurol. 2006;65:396&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">16691120</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA. 2013;110:9535&#x2013;9540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans W, et al. The tau H2haplotype is almost exclusively Caucasian in origin. Neurosci Lett. 2004;369:183&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">15464261</ArticleId></ArticleIdList></Reference><Reference><Citation>Farlow JL, et al. Whole-exome sequencing in familial Parkinson&#x2019;s disease. JAMA Neurol. 2016;73:68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4946647</ArticleId><ArticleId IdType="pubmed">26595808</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S, et al. The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain. 2008;131:72&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702832</ArticleId><ArticleId IdType="pubmed">18065436</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E, Ohm T, Bohl J. Silver impregnation of Alzheimer&#x2019;s neurofibrillary changes counterstained for basophilic material and lipofuscin pigment. Stain Technol. 1988;69:197&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">2464205</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H, et al. Electron-event representation data enable efficient cryoEM file storage with full preservation of spatial and temporal resolution. IUCrJ. 2020;7:860&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7467176</ArticleId><ArticleId IdType="pubmed">32939278</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, et al. A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis. IUCrJ. 2020;6:5&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327179</ArticleId><ArticleId IdType="pubmed">30713699</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohou A, Grigorieff N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J Struct Biol. 192:216&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6760662</ArticleId><ArticleId IdType="pubmed">26278980</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, Scheres SHW. Helical reconstruction in RELION. J Struct Biol. 2017;198:163&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5479445</ArticleId><ArticleId IdType="pubmed">28193500</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife. 2018;7:e42166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner T, et al. SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. Communications Biology. 2019;2:218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6584505</ArticleId><ArticleId IdType="pubmed">31240256</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SHW. Amyloid structure determination in RELION-3.1. Acta Cryst. 2020;D76:94&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008511</ArticleId><ArticleId IdType="pubmed">32038040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov J, et al. Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. IUCrJ. 2020;7:253&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055373</ArticleId><ArticleId IdType="pubmed">32148853</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, et al. High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy. 2013;135:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3834153</ArticleId><ArticleId IdType="pubmed">23872039</ArticleId></ArticleIdList></Reference><Reference><Citation>Casa&#xf1;al A, et al. Current developments in Coot for macromolecular model building of Electron Cryo-microscopy and Crystallographic Data. Protein Science. 2020;29:1069&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096722</ArticleId><ArticleId IdType="pubmed">31730249</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams CJ, et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Science. 2018;27:293&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5734394</ArticleId><ArticleId IdType="pubmed">29067766</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A, et al. Tools for macromolecular model building and refinement into electron cryo-microscopy reconstructions. Acta Cryst. 2015;D71:136&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4304694</ArticleId><ArticleId IdType="pubmed">25615868</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonine PV, et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Cryst. 2018;D74:531&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6096492</ArticleId><ArticleId IdType="pubmed">29872004</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 2021;30:70&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737788</ArticleId><ArticleId IdType="pubmed">32881101</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34616039</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>599</Volume><Issue>7883</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Neurotoxic reactive astrocytes induce cell death via saturated lipids.</ArticleTitle><Pagination><StartPage>102</StartPage><EndPage>107</EndPage><MedlinePgn>102-107</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-021-03960-y</ELocationID><Abstract><AbstractText>Astrocytes regulate the response of the central nervous system to disease and injury and have been hypothesized to actively kill neurons in neurodegenerative disease<sup>1-6</sup>. Here we report an approach to isolate one component of the long-sought astrocyte-derived toxic factor<sup>5,6</sup>. Notably, instead of a protein, saturated lipids contained in APOE and APOJ lipoparticles mediate astrocyte-induced toxicity. Eliminating the formation of long-chain saturated lipids by astrocyte-specific knockout of the saturated lipid synthesis enzyme ELOVL1 mitigates astrocyte-mediated toxicity in vitro as well as in a model of acute axonal injury in vivo. These results suggest a mechanism by which astrocytes kill cells in the central nervous system.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guttenplan</LastName><ForeName>Kevin A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0003-4242-4349</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Weigel</LastName><ForeName>Maya K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Prakash</LastName><ForeName>Priya</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2193-9669</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wijewardhane</LastName><ForeName>Prageeth R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0002-9781-3053</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasel</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-4378-3685</Identifier><AffiliationInfo><Affiliation>Neuroscience Institute, NYU School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rufen-Blanchette</LastName><ForeName>Uriel</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Neuroscience Institute, NYU School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;nch</LastName><ForeName>Alexandra E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0002-9609-3277</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blum</LastName><ForeName>Jacob A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fine</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neal</LastName><ForeName>Mikaela C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruce</LastName><ForeName>Kimberley D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitler</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0001-8603-1526</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chopra</LastName><ForeName>Gaurav</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0942-7898</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Purdue Institute for Drug Discovery, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Purdue Center for Cancer Research, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Purdue Institute of Inflammation, Immunology and Infectious Disease, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liddelow</LastName><ForeName>Shane A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-0840-1437</Identifier><AffiliationInfo><Affiliation>Neuroscience Institute, NYU School of Medicine, New York, NY, USA. shane.liddelow@nyulangone.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience and Physiology, NYU School of Medicine, New York, NY, USA. shane.liddelow@nyulangone.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, NYU School of Medicine, New York, NY, USA. shane.liddelow@nyulangone.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Parekh Center for Interdisciplinary Neurology, NYU Grossman School of Medicine, New York, NY, USA. shane.liddelow@nyulangone.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barres</LastName><ForeName>Ben A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS069375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR027425</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG061549</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002529</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA023168</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA124435</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017077">Culture Media, Conditioned</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000630958">Elovl1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.1.-</RegistryNumber><NameOfSubstance UI="D000081031">Fatty Acid Elongases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017077" MajorTopicYN="N">Culture Media, Conditioned</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081031" MajorTopicYN="N">Fatty Acid Elongases</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055786" MajorTopicYN="N">Gene Knockout Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009498" MajorTopicYN="N">Neurotoxins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34616039</ArticleId><ArticleId IdType="mid">NIHMS2072349</ArticleId><ArticleId IdType="pmc">PMC12054010</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03960-y</ArticleId><ArticleId IdType="pii">10.1038/s41586-021-03960-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liddelow SA &amp; Barres BA Reactive Astrocytes: Production, Function, and Therapeutic Potential. Immunity 46, 957&#x2013;967 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28636962</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481&#x2013;487 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan KA et al. Neurotoxic Reactive Astrocytes Drive Neuronal Death after Retinal Injury. Cell Reports 31, 107776 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091906</ArticleId><ArticleId IdType="pubmed">32579912</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttenplan KA et al. Knockout of reactive astrocyte activating factors slows disease progression in an ALS mouse model. Nat Commun 11, 3753 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385161</ArticleId><ArticleId IdType="pubmed">32719333</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M. et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nature neuroscience 10, 615&#x2013;22 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgio F, Carrasco MA, Siao MC, Maniatis T &amp; Eggan K Non&#x2013;cell autonomous effect of glia on motor neurons in an embryonic stem cell&#x2013;based ALS model. Nature neuroscience 10, 608&#x2013;614 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3139463</ArticleId><ArticleId IdType="pubmed">17435754</ArticleId></ArticleIdList></Reference><Reference><Citation>Barres B, Schmid R, Sendnter M &amp; Raff M Multiple extracellular signals are required for long-term oligodendrocyte survival. Development (Cambridge, England) 118, 283&#x2013;95 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8375338</ArticleId></ArticleIdList></Reference><Reference><Citation>Banker GA &amp; Cowan WM Rat hippocampal neurons in dispersed cell culture. Brain Res 126, 397&#x2013;425 (1977).</Citation><ArticleIdList><ArticleId IdType="pubmed">861729</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukdereli H. et al. Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC. Proceedings of the National Academy of Sciences 108, E440&#x2013;E449 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156217</ArticleId><ArticleId IdType="pubmed">21788491</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi F. et al. Reactive astrocytes secrete lcn2 to promote neuron death. P Natl Acad Sci Usa 110, 4069&#x2013;74 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593910</ArticleId><ArticleId IdType="pubmed">23431168</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A. et al. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (&#x2212;/&#x2212;), and human apoE transgenic mice. The Journal of biological chemistry 274, 30001&#x2013;7 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10514484</ArticleId></ArticleIdList></Reference><Reference><Citation>FOLCH J, LEES M &amp; STANLEY GHS A simple method for the isolation and purification of total lipides from animal tissues. J Biological Chem 226, 497&#x2013;509 (1957).</Citation><ArticleIdList><ArticleId IdType="pubmed">13428781</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL, Phillips MC &amp; Lund-Katz S The conformation of apolipoprotein A-I in discoidal and spherical recombinant high density lipoprotein particles. 13C NMR studies of lysine ionization behavior. J Biological Chem 267, 25830&#x2013;8 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1464597</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos R, Brendza R &amp; Heuser J Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11578777</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha DA et al. Death Protein 5 and p53-Upregulated Modulator of Apoptosis Mediate the Endoplasmic Reticulum Stress-Mitochondrial Dialog Triggering Lipotoxic Rodent and Human -Cell Apoptosis. Diabetes 61, 2763&#x2013;2775 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3478544</ArticleId><ArticleId IdType="pubmed">22773666</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccolis M. et al. Probing the Global Cellular Responses to Lipotoxicity Caused by Saturated Fatty Acids. Mol Cell (2019) doi:10.1016/j.molcel.2019.01.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2019.01.036</ArticleId><ArticleId IdType="pmc">PMC7696670</ArticleId><ArticleId IdType="pubmed">30846318</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanning S. et al. Lipidomic Analysis of &#x3b1;-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. Mol Cell (2018) doi:10.1016/j.molcel.2018.11.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.11.028</ArticleId><ArticleId IdType="pmc">PMC6408259</ArticleId><ArticleId IdType="pubmed">30527540</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. The Journal of neuroscience : the official journal of the Society for Neuroscience 34, 11929&#x2013;47 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P. et al. Palmitic acid triggers cell apoptosis in RGC-5 retinal ganglion cells through the Akt/FoxO1 signaling pathway. Metab Brain Dis 32, 453&#x2013;460 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27928692</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterling JK et al. GLP-1 Receptor Agonist NLY01 Reduces Retinal Inflammation and Neuron Death Secondary to Ocular Hypertension. Cell Reports 33, 108271 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7660987</ArticleId><ArticleId IdType="pubmed">33147455</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou MS et al. Neuron-Astrocyte Metabolic Coupling Protects against Activity-Induced Fatty Acid Toxicity. Cell (2019) doi:10.1016/j.cell.2019.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.04.001</ArticleId><ArticleId IdType="pubmed">31130380</ArticleId></ArticleIdList></Reference><Reference><Citation>Legleiter J, DeMattos R &amp; Holtzman D In situ AFM studies of astrocyte-secreted apolipoprotein E-and J-containing lipoproteins. (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15313642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra V. et al. Systematic elucidation of neuron-astrocyte interaction in models of amyotrophic lateral sclerosis using multi-modal integrated bioinformatics workflow. Nat Commun 11, 5579 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7642391</ArticleId><ArticleId IdType="pubmed">33149111</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovi&#x10d;i&#x107; A &amp; Gitler AD Distinct repertoires of microRNAs present in mouse astrocytes compared to astrocyte-secreted exosomes. Plos One 12, e0171418 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5289606</ArticleId><ArticleId IdType="pubmed">28152040</ArticleId></ArticleIdList></Reference><Reference><Citation>Oishi Y. et al. SREBP1 Contributes to Resolution of Pro-inflammatory TLR4 Signaling by Reprogramming Fatty Acid Metabolism. Cell Metab 25, 412&#x2013;427 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5568699</ArticleId><ArticleId IdType="pubmed">28041958</ArticleId></ArticleIdList></Reference><Reference><Citation>Wurfel MM, Kunitake ST, Lichenstein H, Kane JP &amp; Wright SD Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Medicine 180, 1025&#x2013;1035 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2191628</ArticleId><ArticleId IdType="pubmed">8064223</ArticleId></ArticleIdList></Reference><Reference><Citation>Nugent AA et al. TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge. Neuron (2019) doi:10.1016/j.neuron.2019.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.12.007</ArticleId><ArticleId IdType="pubmed">31902528</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>METHODS REFERENCES:</Title><Reference><Citation>Foo LC et al. Development of a Method for the Purification and Culture of Rodent Astrocytes. Neuron 71, 799&#x2013;811 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3172573</ArticleId><ArticleId IdType="pubmed">21903074</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugas JC &amp; Emery B Purification of Oligodendrocyte Precursor Cells from Rat Cortices by Immunopanning. Cold Spring Harbor Protocols 2013, pdb.prot070862 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23906908</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullian EM, Sapperstein SK, Christopherson KS &amp; Barres BA Control of Synapse Number by Glia. Science 291, 657&#x2013;661 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11158678</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedrick VE, LaLand MN, Nakayasu ES &amp; Paul LN Digestion, Purification, and Enrichment of Protein Samples for Mass Spectrometry. Curr Protoc Chem Biology 7, 201&#x2013;222 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26331527</ArticleId></ArticleIdList></Reference><Reference><Citation>Barabas AJ, Aryal UK &amp; Gaskill BN Proteome characterization of used nesting material and potential protein sources from group housed male mice, Mus musculus. Sci Rep-uk 9, 17524 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6879570</ArticleId><ArticleId IdType="pubmed">31772257</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy DJ, Chen Y &amp; Smyth GK Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res 40, 4288&#x2013;4297 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378882</ArticleId><ArticleId IdType="pubmed">22287627</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ &amp; Smyth GK edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139&#x2013;140 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Bligh EG &amp; Dyer WJ A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION. Can J Biochem Phys 37, 911&#x2013;917 (1959).</Citation><ArticleIdList><ArticleId IdType="pubmed">13671378</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Ferreira CR, Virequ AA &amp; Cooks RG Multiple reaction monitoring profiling (MRM profiling): Small molecule exploratory analysis guided by chemical functionality. Chem Phys Lipids 235, 105048 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33561466</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias JE &amp; Gygi SP Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 4, 207&#x2013;214 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17327847</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34806027</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2662-8465</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature aging</Title><ISOAbbreviation>Nat Aging</ISOAbbreviation></Journal><ArticleTitle>Dissociable effects of <i>APOE</i>-&#x3b5;4 and &#x3b2;-amyloid pathology on visual working memory.</ArticleTitle><Pagination><StartPage>1002</StartPage><EndPage>1009</EndPage><MedlinePgn>1002-1009</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s43587-021-00117-4</ELocationID><Abstract><AbstractText>Although <i>APOE</i>-&#x3b5;4 carriers are at significantly higher risk of developing Alzheimer's disease than non-carriers<sup>1</sup>, controversial evidence suggests that <i>APOE</i>-&#x3b5;4 might confer some advantages, explaining the survival of this gene (antagonistic pleiotropy)<sup>2,3</sup>. In a population-based cohort born in one week in 1946 (assessed aged 69-71), we assessed differential effects of <i>APOE</i>-&#x3b5;4 and &#x3b2;-amyloid pathology (quantified using <sup>18</sup>F-Florbetapir-PET) on visual working memory (object-location binding). In 398 cognitively normal participants, <i>APOE</i>-&#x3b5;4 and &#x3b2;-amyloid had opposing effects on object identification, predicting better and poorer recall respectively. &#x3b5;4-carriers also recalled locations more precisely, with a greater advantage at higher &#x3b2;-amyloid burden. These results provide evidence of superior visual working memory in &#x3b5;4-carriers, showing that some benefits of this genotype are demonstrable in older age, even in the preclinical stages of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Kirsty</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholas</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pertzov</LastName><ForeName>Yoni</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Psychology, The Hebrew University of Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grogan</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Husain</LastName><ForeName>Masud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Psychology, University of Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavisic</LastName><ForeName>Ivanna M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Sarah-Naomi</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keshavan</LastName><ForeName>Ashvini</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keuss</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchanan</LastName><ForeName>Sarah M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray-Smith</LastName><ForeName>Heidi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cash</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malone</LastName><ForeName>Ian B</ForeName><Initials>IB</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudre</LastName><ForeName>Carole H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coath</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henley</LastName><ForeName>Susie M D</ForeName><Initials>SMD</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at UCL, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schott</LastName><ForeName>Jonathan M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crutch</LastName><ForeName>Sebastian J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>EP-W-17-011</GrantID><Acronym>EPA</Acronym><Agency>EPA</Agency><Country>United States</Country></Grant><Grant><GrantID>206330/Z/17/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12019/06</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_00019/3</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>CSUB19166</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12019/3</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12019/08</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>200109</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>PG/17/90/33415</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Aging</MedlineTA><NlmUniqueID>101773306</NlmUniqueID><ISSNLinking>2662-8465</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing Interests Statement All authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>22</Day><Hour>7</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34806027</ArticleId><ArticleId IdType="mid">EMS136366</ArticleId><ArticleId IdType="pmc">PMC7612005</ArticleId><ArticleId IdType="doi">10.1038/s43587-021-00117-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726719</ArticleId><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CJ, Ashford JW, Perfetti TA. Putative Survival Advantages in Young Apolipoprotein &#x3b5;4 Carriers are Associated with Increased Neural Stress. J Alzheimer&#x2019;s Dis. 2019;68:885&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6484250</ArticleId><ArticleId IdType="pubmed">30814349</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuminello ER, Duke Han S. The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations. Int J Alzheimers Dis. 2011;2011:726197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056453</ArticleId><ArticleId IdType="pubmed">21423560</ArticleId></ArticleIdList></Reference><Reference><Citation>Safieh M, Korczyn AD, Michaelson DM. ApoE4: an emerging therapeutic target for Alzheimer&#x2019;s disease. BMC Med. 2019;17:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6425600</ArticleId><ArticleId IdType="pubmed">30890171</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, et al. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, et al. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker JE, et al. Cognitive impairment and decline in cognitively normal older adults with high amyloid-&#x3b2;: A meta-analysis. Alzheimer&#x2019;s Dement Diagnosis, Assess Dis Monit. 2017;6:108&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5315443</ArticleId><ArticleId IdType="pubmed">28239636</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Abdalla N. Estimation of lifetime risks of Alzheimer&#x2019;s disease dementia using biomarkers for preclinical disease. Alzheimer&#x2019;s Dement. 2018;14:981&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097953</ArticleId><ArticleId IdType="pubmed">29802030</ArticleId></ArticleIdList></Reference><Reference><Citation>Byars SG, Voskarides K. Antagonistic Pleiotropy in Human Disease. Journal of Molecular Evolution. 2020;88:12&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">31863128</ArticleId></ArticleIdList></Reference><Reference><Citation>Jasienska G, et al. Apolipoprotein E (ApoE) polymorphism is related to differences in potential fertility in women: A case of antagonistic pleiotropy? Proc R Soc B Biol Sci. 2015;282</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4345437</ArticleId><ArticleId IdType="pubmed">25673673</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke Han S, Bondi MW. Revision of the apolipoprotein E compensatory mechanism recruitment hypothesis. Alzheimer&#x2019;s Dement. 2008;4:251&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631975</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusted JM, et al. APOE e4 polymorphism in young adults is associated with improved attention and indexed by distinct neural signatures. Neuroimage. 2013;65:364&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">23063453</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donoghue MC, Murphy SE, Zamboni G, Nobre AC, Mackay CE. APOE genotype and cognition in healthy individuals at risk of Alzheimer&#x2019;s disease: A review. Cortex. 2018;104:103&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">29800787</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacono D, Feltis GC. Impact of Apolipoprotein E gene polymorphism during normal and pathological conditions of the brain across the lifespan. Aging. 2019;11:787&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6366964</ArticleId><ArticleId IdType="pubmed">30677746</ArticleId></ArticleIdList></Reference><Reference><Citation>Zink N, Bensmann W, Arning L, Beste C, Stock AK. Apolipoprotein E4 is associated with better cognitive control allocation in healthy young adults. Neuroimage. 2019;185:274&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">30342978</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchant NL, King SL, Tabet N, Rusted JM. Positive Effects of Cholinergic Stimulation Favor Young APOE e4 Carriers. Neuropsychopharmacology. 2010;35:1090&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055410</ArticleId><ArticleId IdType="pubmed">20072115</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Souza H, et al. Differential Associations of Apolipoprotein E &#x3b5;4 Genotype With Attentional Abilities Across the Life Span of Individuals With Down Syndrome. JAMA Netw Open. 2020;3:e2018221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7522696</ArticleId><ArticleId IdType="pubmed">32986108</ArticleId></ArticleIdList></Reference><Reference><Citation>Austad SN, Hoffman JM. Is antagonistic pleiotropy ubiquitous in aging biology? Evol Med Public Heal. 2018:287&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6276058</ArticleId><ArticleId IdType="pubmed">30524730</ArticleId></ArticleIdList></Reference><Reference><Citation>Abondio P, et al. The genetic variability of APOE in different human populations and its implications for longevity. Genes. 2019;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6471373</ArticleId><ArticleId IdType="pubmed">30884759</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichlen DA, Alexander GE. Exercise, APOE genotype, and the evolution of the human lifespan. Trends Neurosci. 2014;37:247&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066890</ArticleId><ArticleId IdType="pubmed">24690272</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissberger GH, Nation DA, Nguyen CP, Bondi MW, Han SD. Metaanalysis of cognitive ability differences by apolipoprotein e genotype in young humans. Neurosci Biobehav Rev. 2018;94:49&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6231411</ArticleId><ArticleId IdType="pubmed">30125600</ArticleId></ArticleIdList></Reference><Reference><Citation>Pertzov Y, Dong MY, Peich M-C, Husain M. Forgetting what was where: the fragility of object-location binding. PLoS One. 2012;7:e48214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3485137</ArticleId><ArticleId IdType="pubmed">23118956</ArticleId></ArticleIdList></Reference><Reference><Citation>Zokaei N, et al. Sex and APOE: A memory advantage in male APOE &#x3b5;4 carriers in midlife. Cortex. 2017;88:98&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333781</ArticleId><ArticleId IdType="pubmed">28086184</ArticleId></ArticleIdList></Reference><Reference><Citation>Zokaei N, et al. Dissociable effects of the apolipoprotein-E (APOE) gene on short- and long-term memories. Neurobiol Aging. 2019;73:115&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6261846</ArticleId><ArticleId IdType="pubmed">30342272</ArticleId></ArticleIdList></Reference><Reference><Citation>Zokaei N, et al. Short-term memory advantage for brief durations in human APOE &#xa3;4 carriers. Sci Rep. 2020;10:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289888</ArticleId><ArticleId IdType="pubmed">32528115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma WJ, Husain M, Bays PM. Changing concepts of working memory. Nat Neurosci. 2014;17:347&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159388</ArticleId><ArticleId IdType="pubmed">24569831</ArticleId></ArticleIdList></Reference><Reference><Citation>Zokaei N, Burnett Heyes S, Gorgoraptis N, Budhdeo S, Husain M. Working memory recall precision is a more sensitive index than span. J Neuropsychol. 2015;9:319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">25208525</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane CA, et al. Study protocol: Insight 46 - a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurol. 2017;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5395844</ArticleId><ArticleId IdType="pubmed">28420323</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuh D, et al. The MRC National Survey of Health and Development reaches age 70: maintaining participation at older ages in a birth cohort study. Eur J Epidemiol. 2016;31:1135&#x2013;1147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5206260</ArticleId><ArticleId IdType="pubmed">27995394</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting. JAMA Neurol. 2018;75:970&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6142936</ArticleId><ArticleId IdType="pubmed">29710225</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern S, et al. Prevalence of preclinical Alzheimer disease: Comparison of current classification systems. Neurology. 2018;90:e1682&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5952969</ArticleId><ArticleId IdType="pubmed">29653987</ArticleId></ArticleIdList></Reference><Reference><Citation>Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol. 2015;11:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">25686760</ArticleId></ArticleIdList></Reference><Reference><Citation>Pertzov Y, Heider M, Liang Y, Husain M. Effects of healthy ageing on precision and binding of object location in visual short term memory. Psychol Aging. 2015;30:26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4360752</ArticleId><ArticleId IdType="pubmed">25528066</ArticleId></ArticleIdList></Reference><Reference><Citation>Grogan JP, et al. A new toolbox to distinguish the sources of spatial memory error. J Vis. 2020;20:1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7726590</ArticleId><ArticleId IdType="pubmed">33289797</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Battista AM, Heinsinger NM, Rebeck GW. Alzheimer&#x2019;s Disease Genetic Risk Factor APOE-&#x3b5;4 Also Affects Normal Brain Function. Curr Alzheimer Res. 2016;13:1200&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839141</ArticleId><ArticleId IdType="pubmed">27033053</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheller E, et al. APOE moderates compensatory recruitment of neuronal resources during working memory processing in healthy older adults. Neurobiol Aging. 2017;56:127&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">28528773</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawle MJ, et al. Apolipoprotein-E (Apoe) &#x3b5;4 and cognitive decline over the adult life course. Transl Psychiatry. 2018;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802532</ArticleId><ArticleId IdType="pubmed">29317609</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvato G. Does apolipoprotein e genotype influence cognition in middle-aged individuals? Curr Opin Neurol. 2015;28:612&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">26402402</ArticleId></ArticleIdList></Reference><Reference><Citation>Small BJ, Rosnick CB, Fratiglioni L, B&#xe4;ckman L. Apolipoprotein E and cognitive performance: A meta-analysis. Psychol Aging. 2004;19:592&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15584785</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermunt L, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer&#x2019;s disease in relation to age, sex, and APOE genotype. Alzheimer&#x2019;s Dement. 2019;15:888&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6646097</ArticleId><ArticleId IdType="pubmed">31164314</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, et al. A&#x3b2;-related memory decline in APOE &#x3b5;4 noncarriers: Implications for Alzheimer disease. Neurology. 2016;86:1635&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">27029632</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, et al. Visual short-term memory binding deficit in familial Alzheimer&#x2019;s disease. Cortex. 2016;78:150&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4865502</ArticleId><ArticleId IdType="pubmed">27085491</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu K, et al. Cognition at age 70: Life course predictors and associations with brain pathologies. Neurology. 2019;93</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6937487</ArticleId><ArticleId IdType="pubmed">31666352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu K, et al. Increased variability in reaction time is associated with amyloid beta pathology at age 70. Alzheimer&#x2019;s Dement Diagnosis Assess Dis Monit. 2020;12:e12076</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7416668</ArticleId><ArticleId IdType="pubmed">32789161</ArticleId></ArticleIdList></Reference><Reference><Citation>James S-N, et al. Using a birth cohort to study brain health and preclinical dementia: Recruitment and participation rates in Insight 46. BMC Res Notes. 2018;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6293512</ArticleId><ArticleId IdType="pubmed">30545411</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396:413&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane CA, et al. Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. Lancet Neurol. 2019;18:942&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6744368</ArticleId><ArticleId IdType="pubmed">31444142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu K, et al. Visuomotor integration deficits are common to both familial and sporadic preclinical Alzheimer&#x2019;s disease. Brain Commun. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7882207</ArticleId><ArticleId IdType="pubmed">33615219</ArticleId></ArticleIdList></Reference><Reference><Citation>Pertzov Y, et al. Binding deficits in memory following medial temporal lobe damage in patients with voltage-gated potassium channel complex antibody-associated limbic encephalitis. Brain. 2013;136:2474&#x2013;2485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3722347</ArticleId><ArticleId IdType="pubmed">23757763</ArticleId></ArticleIdList></Reference><Reference><Citation>Grogan JP. johnPGrogan/MemToolbox2D: Updated release. Zenodo. 2020 doi: 10.5281/zenodo.3752705.</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.3752705</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker TD, et al. Hippocampal subfield volumes and pre-clinical Alzheimer&#x2019;s disease in 408 cognitively normal adults born in 1946. PLoS One. 2019;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6797197</ArticleId><ArticleId IdType="pubmed">31622410</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, et al. Bayesian Model Selection for Pathological Neuroimaging Data Applied to White Matter Lesion Segmentation. IEEE Trans Med Imaging. 2015;34:2079&#x2013;2102.</Citation><ArticleIdList><ArticleId IdType="pubmed">25850086</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso J, et al. STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. Med Image Anal. 2013;17:671&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">23510558</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone IB, et al. Accurate automatic estimation of total intracranial volume: a nuisance variable with less nuisance. Neuroimage. 2015;104:366&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4265726</ArticleId><ArticleId IdType="pubmed">25255942</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards M, Sacker A. Lifetime Antecedents of Cognitive Reserve. J Clin Exp Neuropsychol. 2003;25:614&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">12815499</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards M, et al. Identifying the lifetime cognitive and socioeconomic antecedents of cognitive state: seven decades of follow-up in a British birth cohort study. BMJ Open. 2019;9:e024404</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6502022</ArticleId><ArticleId IdType="pubmed">31023749</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt. 2014;34:502&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">24697967</ArticleId></ArticleIdList></Reference><Reference><Citation>Althouse AD. Adjust for Multiple Comparisons? It&#x2019;s Not That Simple. Ann Thorac Surg. 2016;101:1644&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pubmed">27106412</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34644146</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>615</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>13</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases.</ArticleTitle><Pagination><StartPage>eabe5640</StartPage><MedlinePgn>eabe5640</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abe5640</ELocationID><Abstract><AbstractText>2-Deoxy-2-[<sup>18</sup>F]fluoro-d-glucose positron emission tomography (FDG-PET) is widely used to study cerebral glucose metabolism. Here, we investigated whether the FDG-PET signal is directly influenced by microglial glucose uptake in mouse models and patients with neurodegenerative diseases. Using a recently developed approach for cell sorting after FDG injection, we found that, at cellular resolution, microglia displayed higher glucose uptake than neurons and astrocytes. Alterations in microglial glucose uptake were responsible for both the FDG-PET signal decrease in <i>Trem2</i>-deficient mice and the FDG-PET signal increase in mouse models for amyloidosis. Thus, opposite microglial activation states determine the differential FDG uptake. Consistently, 12 patients with Alzheimer&#x2019;s disease and 21 patients with four-repeat tauopathies also exhibited a positive association between glucose uptake and microglial activity as determined by <sup>18</sup>F-GE-180 18-kDa translocator protein PET (TSPO-PET) in preserved brain regions, indicating that the cerebral glucose uptake in humans is also strongly influenced by microglial activity. Our findings suggest that microglia activation states are responsible for FDG-PET signal alterations in patients with neurodegenerative diseases and mouse models for amyloidosis. Microglial activation states should therefore be considered when performing FDG-PET.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Xianyuan</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-8125-9027</Identifier><AffiliationInfo><Affiliation>Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CAS Key Laboratory of Brain Connectome and Manipulation, Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, 518055 Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wind</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiedemann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blume</LastName><ForeName>Tanja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briel</LastName><ForeName>Nils</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4349-3277</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-University M&#xfc;nchen, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beyer</LastName><ForeName>Leonie</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7358-4495</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biechele</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckenweber</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zatcepin</LastName><ForeName>Artem</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0224-088X</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lammich</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribicic</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1683-9842</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahirovic</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4403-9559</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willem</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8829-3802</Identifier><AffiliationInfo><Affiliation>Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deussing</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palleis</LastName><ForeName>Carla</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4331-8145</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rauchmann</LastName><ForeName>Boris-Stephan</ForeName><Initials>BS</Initials><Identifier Source="ORCID">0000-0003-4547-6240</Identifier><AffiliationInfo><Affiliation>Department of Radiology, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gildehaus</LastName><ForeName>Franz-Josef</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindner</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spitz</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Biochemistry and Molecular Biology, University of Augsburg, 86159 Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franzmeier</LastName><ForeName>Nicolai</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9736-2283</Identifier><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research (ISD), University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumann</LastName><ForeName>Karlheinz</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Roche, Pharma Research and Early Development, NORD DTA/Neuroscience Discovery, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rominger</LastName><ForeName>Axel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1954-736X</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University of Bern, Inselspital, CH-3010 Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartenstein</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziegler</LastName><ForeName>Sibylle</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drzezga</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, 5091 Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Bonn-Cologne, 53127 Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuroscience and Medicine (INM-2), Molecular Organization of the Brain, Forschungszentrum J&#xfc;lich, 52425 J&#xfc;lich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Respondek</LastName><ForeName>Gesine</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, 30625 Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buerger</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Stroke and Dementia Research (ISD), University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perneczky</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1981-7435</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College, London SW7 2AZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5092-4306</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xf6;glinger</LastName><ForeName>G&#xfc;nter U</ForeName><Initials>GU</Initials><Identifier Source="ORCID">0000-0001-7587-6187</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, 30625 Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Technical University Munich, 81675 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herms</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Neuropathology and Prion Research, Ludwig-Maximilians-University M&#xfc;nchen, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4869-1627</Identifier><AffiliationInfo><Affiliation>Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9247-2843</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Sci Transl Med. 2022 Aug 24;14(659):eabn5104. doi: 10.1126/scitranslmed.abn5104.</RefSource><PMID Version="1">36001676</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Sci Transl Med. 2022 Aug 24;14(659):eabm8302. doi: 10.1126/scitranslmed.abm8302.</RefSource><PMID Version="1">36001681</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="Y">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>13</Day><Hour>17</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34644146</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abe5640</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34648304</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>374</Volume><Issue>6569</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>CD4<sup>+</sup> T cells contribute to neurodegeneration in Lewy body dementia.</ArticleTitle><Pagination><StartPage>868</StartPage><EndPage>874</EndPage><MedlinePgn>868-874</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.abf7266</ELocationID><Abstract><AbstractText>Recent studies indicate that the adaptive immune system plays a role in Lewy body dementia (LBD). However, the mechanism regulating T cell brain homing in LBD is unknown. Here, we observed T cells adjacent to Lewy bodies and dopaminergic neurons in postmortem LBD brains. Single-cell RNA sequencing of cerebrospinal fluid (CSF) identified up-regulated expression of <i>C-X-C motif chemokine receptor 4</i> (<i>CXCR4</i>) in CD4<sup>+</sup> T cells in LBD. CSF protein levels of the CXCR4 ligand, C-X-C motif chemokine ligand 12 (CXCL12), were associated with neuroaxonal damage in LBD. Furthermore, we observed clonal expansion and up-regulated <i>interleukin 17A</i> expression by CD4<sup>+</sup> T cells stimulated with a phosphorylated &#x3b1;-synuclein epitope. Thus, CXCR4-CXCL12 signaling may represent a mechanistic target for inhibiting pathological interleukin-17&#x2013;producing T cell trafficking in LBD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gate</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0481-9657</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tapp</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7900-5645</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leventhal</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-6371-9464</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahid</LastName><ForeName>Marian</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8515-3238</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nonninger</LastName><ForeName>Tim J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Andrew C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-6756-4746</Identifier><AffiliationInfo><Affiliation>Department of Bioengineering, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strempfl</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>QPS Austria GmbH, Parkring 12, 8074 Grambach, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unger</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-8677-0983</Identifier><AffiliationInfo><Affiliation>Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fehlmann</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1967-2918</Identifier><AffiliationInfo><Affiliation>Chair for Clinical Bioinformatics, Saarland University, Saarbrucken, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Hamilton</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8192-7593</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Channappa</LastName><ForeName>Divya</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Victor W</ForeName><Initials>VW</Initials><Identifier Source="ORCID">0000-0003-1198-9240</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chair for Clinical Bioinformatics, Saarland University, Saarbrucken, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aigner</LastName><ForeName>Ludwig</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0001-6195-3241</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Mark M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0001-6868-657X</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poston</LastName><ForeName>Kathleen L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0003-3424-7143</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5893-0831</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG045034</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG065156</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI057229</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS062684</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG047366</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS112458</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG055255</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS115114</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066515</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 NS112458</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515255">CXCL12 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2021 Dec;17(12):726. doi: 10.1038/s41582-021-00590-w.</RefSource><PMID Version="1">34754098</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Science. 2021 Nov 12;374(6569):823-824. doi: 10.1126/science.abm4739.</RefSource><PMID Version="1">34762456</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2022 Feb;37(2):268. doi: 10.1002/mds.28881.</RefSource><PMID Version="1">34859506</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002555" MajorTopicYN="N">Cerebrospinal Fluid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054377" MajorTopicYN="N">Chemokine CXCL12</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008578" MajorTopicYN="N">Meninges</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="Y">Nerve Degeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019718" MajorTopicYN="N">Receptors, CXCR4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058504" MajorTopicYN="N">Th17 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> K.L.P. has stock options and has received paid consulting fees from CuraSen Therapeutics, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>14</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34648304</ArticleId><ArticleId IdType="mid">NIHMS1780000</ArticleId><ArticleId IdType="pmc">PMC9122025</ArticleId><ArticleId IdType="doi">10.1126/science.abf7266</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Armstrong MJ, Okun MS, Diagnosis and Treatment of Parkinson Disease: A Review. JAMA 323, 548&#x2013;560 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32044947</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker Z, Possin KL, Boeve BF, Aarsland D, Lewy body dementias. Lancet 386, 1683&#x2013;1697 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792067</ArticleId><ArticleId IdType="pubmed">26595642</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M. et al., Neuroinflammation is associated with infiltration of T cells in Lewy body disease and alpha-synuclein transgenic models. J Neuroinflammation 17, 214 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7368752</ArticleId><ArticleId IdType="pubmed">32680537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindestam Arlehamn CS et al., alpha-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson&#x2019;s disease. Nat Commun 11, 1875 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7171193</ArticleId><ArticleId IdType="pubmed">32313102</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulzer D. et al., T cells from patients with Parkinson&#x2019;s disease recognize alpha-synuclein peptides. Nature 546, 656&#x2013;661 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5626019</ArticleId><ArticleId IdType="pubmed">28636593</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer A. et al., Th17 Lymphocytes Induce Neuronal Cell Death in a Human iPSC-Based Model of Parkinson&#x2019;s Disease. Cell Stem Cell 23, 123&#x2013;131 e126 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29979986</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannarkat GT, Boss JM, Tansey MG, The role of innate and adaptive immunity in Parkinson&#x2019;s disease. J Parkinsons Dis 3, 493&#x2013;514 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4102262</ArticleId><ArticleId IdType="pubmed">24275605</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders JA et al., CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson&#x2019;s disease. J Neuroimmune Pharmacol 7, 927&#x2013;938 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515774</ArticleId><ArticleId IdType="pubmed">23054369</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens CH et al., Reduced T helper and B lymphocytes in Parkinson&#x2019;s disease. J Neuroimmunol 252, 95&#x2013;99 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22910543</ArticleId></ArticleIdList></Reference><Reference><Citation>Brochard V. et al., Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119, 182&#x2013;192 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2613467</ArticleId><ArticleId IdType="pubmed">19104149</ArticleId></ArticleIdList></Reference><Reference><Citation>Cebrian C. et al., MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun 5, 3633 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4024461</ArticleId><ArticleId IdType="pubmed">24736453</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms AS et al., MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J Neurosci 33, 9592&#x2013;9600 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3903980</ArticleId><ArticleId IdType="pubmed">23739956</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Huang Y, Cao BB, Qiu YH, Peng YP, Th17 Cells Induce Dopaminergic Neuronal Death via LFA-1/ICAM-1 Interaction in a Mouse Model of Parkinson&#x2019;s Disease. Mol Neurobiol 54, 7762&#x2013;7776 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27844285</ArticleId></ArticleIdList></Reference><Reference><Citation>Singhania A. et al., The TCR repertoire of alpha-synuclein-specific T cells in Parkinson&#x2019;s disease is surprisingly diverse. Sci Rep 11, 302 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7801678</ArticleId><ArticleId IdType="pubmed">33432042</ArticleId></ArticleIdList></Reference><Reference><Citation>Gate D. et al., Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer&#x2019;s disease. Nature 577, 399&#x2013;404 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445078</ArticleId><ArticleId IdType="pubmed">31915375</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H. et al., Methods to investigate intrathecal adaptive immunity in neurodegeneration. Mol Neurodegener 16, 3 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7824942</ArticleId><ArticleId IdType="pubmed">33482851</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggi L. et al., CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur J Immunol 40, 2174&#x2013;2181 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20486123</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong KL et al., Killer-like receptors and GPR56 progressive expression defines cytokine production of human CD4(+) memory T cells. Nat Commun 10, 2263 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6531457</ArticleId><ArticleId IdType="pubmed">31118448</ArticleId></ArticleIdList></Reference><Reference><Citation>McCandless EE, Wang Q, Woerner BM, Harper JM, Klein RS, CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis. J Immunol 177, 8053&#x2013;8064 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17114479</ArticleId></ArticleIdList></Reference><Reference><Citation>Colin-York H. et al., Cytoskeletal Control of Antigen-Dependent T Cell Activation. Cell Rep 26, 3369&#x2013;3379 e3365 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426652</ArticleId><ArticleId IdType="pubmed">30893608</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinman L, A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13, 139&#x2013;145 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17290272</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell DJ, Kim CH, Butcher EC, Chemokines in the systemic organization of immunity. Immunol Rev 195, 58&#x2013;71 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12969310</ArticleId></ArticleIdList></Reference><Reference><Citation>Tischner D. et al., Single-cell profiling reveals GPCR heterogeneity and functional patterning during neuroinflammation. JCI Insight 2, (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5543912</ArticleId><ArticleId IdType="pubmed">28768912</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki Y. et al., Efficient inhibition of SDF-1alpha-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists. Cancer Sci 100, 778&#x2013;781 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11159168</ArticleId><ArticleId IdType="pubmed">19245436</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T. et al., The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob Agents Chemother 53, 2940&#x2013;2948 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704660</ArticleId><ArticleId IdType="pubmed">19451305</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone ND et al., Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother 51, 2351&#x2013;2358 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1913234</ArticleId><ArticleId IdType="pubmed">17452489</ArticleId></ArticleIdList></Reference><Reference><Citation>Donzella GA et al., AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4, 72&#x2013;77 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9427609</ArticleId></ArticleIdList></Reference><Reference><Citation>Nervi B. et al., Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113, 6206&#x2013;6214 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2699239</ArticleId><ArticleId IdType="pubmed">19050309</ArticleId></ArticleIdList></Reference><Reference><Citation>Domanska UM et al., CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia 14, 709&#x2013;718 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431178</ArticleId><ArticleId IdType="pubmed">22952424</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamamura H. et al., T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 550, 79&#x2013;83 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12935890</ArticleId></ArticleIdList></Reference><Reference><Citation>Reboldi A. et al., C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 10, 514&#x2013;523 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19305396</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Ke KF, Liu Z, Qiu YH, Peng YP, Th17 cell-mediated neuroinflammation is involved in neurodegeneration of abeta1&#x2013;42-induced Alzheimer&#x2019;s disease model rats. PLoS One 8, e75786 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790825</ArticleId><ArticleId IdType="pubmed">24124514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kebir H. et al., Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13, 1173&#x2013;1175 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5114125</ArticleId><ArticleId IdType="pubmed">17828272</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I. et al., Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 18, 467&#x2013;486 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12722160</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG et al., Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 89, 88&#x2013;100 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5496518</ArticleId><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvan I. et al., Diagnostic criteria for mild cognitive impairment in Parkinson&#x2019;s disease: Movement Disorder Society Task Force guidelines. Mov Disord 27, 349&#x2013;356 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3641655</ArticleId><ArticleId IdType="pubmed">22275317</ArticleId></ArticleIdList></Reference><Reference><Citation>Emre M. et al., Clinical diagnostic criteria for dementia associated with Parkinson&#x2019;s disease. Mov Disord 22, 1689&#x2013;1707; quiz 1837 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17542011</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E. et al., Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68, 568&#x2013;578 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12111846</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabl R. et al., Early start of progressive motor deficits in Line 61 alpha-synuclein transgenic mice. BMC Neurosci 18, 22 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5282838</ArticleId><ArticleId IdType="pubmed">28143405</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34554184</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>326</Volume><Issue>14</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.</ArticleTitle><Pagination><StartPage>1367</StartPage><EndPage>1368</EndPage><MedlinePgn>1367-1368</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2021.14861</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Emanuel</LastName><ForeName>Ezekiel J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>105J35OE21</RegistryNumber><NameOfSubstance UI="C000600266">aducanumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="Y">Drug Approval</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34554184</ArticleId><ArticleId IdType="doi">10.1001/jama.2021.14861</ArticleId><ArticleId IdType="pii">2784584</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34254981</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6114</ISSN><JournalIssue CitedMedium="Internet"><Volume>181</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA internal medicine</Title><ISOAbbreviation>JAMA Intern Med</ISOAbbreviation></Journal><ArticleTitle>Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway: The Need for Reforms.</ArticleTitle><Pagination><StartPage>1275</StartPage><EndPage>1276</EndPage><MedlinePgn>1275-1276</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamainternmed.2021.4604</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gyawali</LastName><ForeName>Bishal</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Departments of Oncology and Public Health Sciences, Queen's University, Kingston, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Joseph S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Section of General Medicine and the National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kesselheim</LastName><ForeName>Aaron S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Program On Regulation, Therapeutics and Law (PORTAL), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Intern Med</MedlineTA><NlmUniqueID>101589534</NlmUniqueID><ISSNLinking>2168-6106</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054316">Biomarkers, Pharmacological</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015507">Drugs, Investigational</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2021 Oct 1;181(10):1281. doi: 10.1001/jamainternmed.2021.4622.</RefSource><PMID Version="1">34254991</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054316" MajorTopicYN="N">Biomarkers, Pharmacological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="Y">Drug Approval</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004341" MajorTopicYN="Y">Drug Evaluation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004335" MajorTopicYN="Y">Drug and Narcotic Control</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015507" MajorTopicYN="N">Drugs, Investigational</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008495" MajorTopicYN="N">Medical Oncology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020380" MajorTopicYN="N">Needs Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="Y">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>13</Day><Hour>12</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34254981</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2021.4604</ArticleId><ArticleId IdType="pii">2782120</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34669475</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>43</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Microglia become hypofunctional and release metalloproteases and tau seeds when phagocytosing live neurons with P301S tau aggregates.</ArticleTitle><Pagination><StartPage>eabg4980</StartPage><MedlinePgn>eabg4980</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabg4980</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abg4980</ELocationID><Abstract><AbstractText>The microtubule-associated protein tau aggregates in multiple neurodegenerative diseases, causing inflammation and changing the inflammatory signature of microglia by unknown mechanisms. We have shown that microglia phagocytose live neurons containing tau aggregates cultured from P301S tau mice due to neuronal tau aggregate-induced exposure of the &#x201c;eat me&#x201d; signal phosphatidylserine. Here, we show that after phagocytosing tau aggregate-bearing neurons, microglia become hypophagocytic while releasing seed-competent insoluble tau aggregates. These microglia express a senescence-like phenotype, demonstrated by acidic &#x3b2;-galactosidase activity, secretion of paracrine senescence-associated cytokines, and maturation of matrix remodeling enzymes, results that are corroborated in P301S mouse brains and ex vivo brain slices. In particular, the nuclear factor &#x3ba;B&#x2013;dependent activation of matrix metalloprotease 3 (MMP3/stromelysin1) was replicated in brains from patients with tauopathy. These data show that microglia that have been activated to ingest live tau aggregates-bearing neurons behave hormetically, becoming hypofunctional while acting as vectors of tau aggregate spreading.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brelstaff</LastName><ForeName>Jack H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0003-4772-8018</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Clifford Allbutt Building, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4284-0174</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Clifford Allbutt Building, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsinelos</LastName><ForeName>Taxiarchis</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6951-3216</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Clifford Allbutt Building, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute Cambridge, Island Research Building, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEwan</LastName><ForeName>William A</ForeName><Initials>WA</Initials><Identifier Source="ORCID">0000-0002-4408-0407</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Clifford Allbutt Building, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute Cambridge, Island Research Building, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tolkovsky</LastName><ForeName>Aviva M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-1951-3175</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Clifford Allbutt Building, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spillantini</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0000-0002-8544-7332</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Clifford Allbutt Building, University of Cambridge, Cambridge CB2 0AH, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NC/L000741/1</GrantID><Acronym>NC3RS_</Acronym><Agency>National Centre for the Replacement, Refinement and Reduction of Animals in Research</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG010133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>20</Day><Hour>17</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34669475</ArticleId><ArticleId IdType="pmc">PMC8528424</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abg4980</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Spillantini M. G., Goedert M., Tau pathology and neurodegeneration. Lancet Neurol. 12, 609&#x2013;622 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilalta A., Brown G. C., Neurophagy, the phagocytosis of live neurons and synapses by glia, contributes to brain development and disease. FEBS J. 285, 3566&#x2013;3575 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29125686</ArticleId></ArticleIdList></Reference><Reference><Citation>Pampuscenko K., Morkuniene R., Sneideris T., Smirnovas V., Budvytyte R., Valincius G., Brown G. C., Borutaite V., Extracellular tau induces microglial phagocytosis of living neurons in cell cultures. J. Neurochem. 154, 316&#x2013;329 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31834946</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda A., Shinozaki Y., Kashiwagi K., Ohno N., Eto K., Wake H., Nabekura J., Koizumi S., Microglia mediate non-cell-autonomous cell death of retinal ganglion cells. Glia 66, 2366&#x2013;2384 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30375063</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott-Hewitt N., Perrucci F., Morini R., Erreni M., Mahoney M., Witkowska A., Carey A., Faggiani E., Schuetz L. T., Mason S., Tamborini M., Bizzotto M., Passoni L., Filipello F., Jahn R., Stevens B., Matteoli M., Local externalization of phosphatidylserine mediates developmental synaptic pruning by microglia. EMBO J. 39, e105380 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7429741</ArticleId><ArticleId IdType="pubmed">32657463</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S., Beja-Glasser V. F., Nfonoyim B. M., Frouin A., Li S., Ramakrishnan S., Merry K. M., Shi Q., Rosenthal A., Barres B. A., Lemere C. A., Selkoe D. J., Stevens B., Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712&#x2013;716 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094372</ArticleId><ArticleId IdType="pubmed">27033548</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho K., Faivre E., Pietrowski M. J., Marques X., Gomez-Murcia V., Deleau A., Huin V., Hansen J. N., Kozlov S., Danis C., Temido-Ferreira M., Coelho J. E., M&#xe9;riaux C., Eddarkaoui S., Gras S. L., Dumoulin M., Cellai L.; NeuroCEB Brain Bank, Landrieu I., Chern Y., Hamdane M., Bu&#xe9;e L., Boutillier A.-L., Levi S., Halle A., Lopes L. V., Blum D., Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor. Brain 142, 3636&#x2013;3654 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6821333</ArticleId><ArticleId IdType="pubmed">31599329</ArticleId></ArticleIdList></Reference><Reference><Citation>Brelstaff J., Tolkovsky A. M., Ghetti B., Goedert M., Spillantini M. G., Living neurons with tau filaments aberrantly expose phosphatidylserine and are phagocytosed by microglia. Cell Rep. 24, 1939&#x2013;1948.e4 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6161320</ArticleId><ArticleId IdType="pubmed">30134156</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry R. D., Masliah E., Salmon D. P., Butters N., De Teresa R., Hill R., Hansen L. A., Katzman R., Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: Synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572&#x2013;580 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellucci A., Westwood A. J., Ingram E., Casamenti F., Goedert M., Spillantini M. G., Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am. J. Pathol. 165, 1643&#x2013;1652 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618683</ArticleId><ArticleId IdType="pubmed">15509534</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres S. H. W., Zhang W., Falcon B., Goedert M., Cryo-EM structures of tau filaments. Curr. Opin. Struct. Biol. 64, 17&#x2013;25 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32603876</ArticleId></ArticleIdList></Reference><Reference><Citation>Akatsu H., Fraser G., Crowther R. A., Frank S., Hench J., Probst A., Winkler D. T., Reichwald J., Staufenbiel M., Ghetti B., Goedert M., Tolnay M., Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. U.S.A. 110, 9535&#x2013;9540 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel J. W., Iturria-Medina Y., Strandberg O. T., Smith R., Levitis E., Evans A. C., Hansson O.; Alzheimer&#x2019;s Disease Neuroimaging Initiative; Swedish BioFinder Study , Spread of pathological tau proteins through communicating neurons in human Alzheimer&#x2019;s disease. Nat. Commun. 11, 2612 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251068</ArticleId><ArticleId IdType="pubmed">32457389</ArticleId></ArticleIdList></Reference><Reference><Citation>Maphis N., Xu G., Kokiko-Cochran O. N., Jiang S., Cardona A., Ransohoff R. M., Lamb B. T., Bhaskar K., Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain 138, 1738&#x2013;1755 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4542622</ArticleId><ArticleId IdType="pubmed">25833819</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai H., Ikezu S., Tsunoda S., Medalla M., Luebke J., Haydar T., Wolozin B., Butovsky O., K&#xfc;gler S., Ikezu T., Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 18, 1584&#x2013;1593 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694577</ArticleId><ArticleId IdType="pubmed">26436904</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellone M., Kestoras D., Andrews M. R., Dassie E., Crowther R. A., Stokin G. B., Tinsley J., Horne G., Goedert M., Tolkovsky A. M., Spillantini M. G., Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: A system for screening drugs against tauopathies. J. Neurosci. 33, 18175&#x2013;18189 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3828468</ArticleId><ArticleId IdType="pubmed">24227726</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B., Ingram E., Takao M., Smith M. J., Jakes R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P. C., Atzori C., Migheli A., Crowther R. A., Ghetti B., Spillantini M. G., Goedert M., Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22, 9340&#x2013;9351 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Brelstaff J., Ossola B., Neher J. J., Klingstedt T., Nilsson K. P. R., Goedert M., Spillantini M. G., Tolkovsky A. M., The fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice. Front. Neurosci. 9, 184 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4448042</ArticleId><ArticleId IdType="pubmed">26074756</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu G., Gonzales V., Borchelt D. R., Rapid detection of protein aggregates in the brains of Alzheimer patients and transgenic mouse models of amyloidosis. Alzheimer Dis. Assoc. Disord. 16, 191&#x2013;195 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12218651</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan W. A., Falcon B., Vaysburd M., Clift D., Oblak A. L., Ghetti B., Goedert M., James L. C., Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc. Natl. Acad. Sci. U.S.A. 114, 574&#x2013;579 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5255578</ArticleId><ArticleId IdType="pubmed">28049840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha G. A., Bowser R., Kazam I. G., Davies P., Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J. Neurosci. Res. 48, 128&#x2013;132 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Brelstaff J., Spillantini M. G., Tolkovsky A. M., pFTAA: A high affinity oligothiophene probe that detects filamentous tau in vivo and in cultured neurons. Neural Regen. Res. 10, 1746&#x2013;1747 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4705778</ArticleId><ArticleId IdType="pubmed">26807101</ArticleId></ArticleIdList></Reference><Reference><Citation>Krabbe G., Halle A., Matyash V., Rinnenthal J. L., Eom G. D., Bernhardt U., Miller K. R., Prokop S., Kettenmann H., Heppner F. L., Functional impairment of microglia coincides with &#x3b2;-amyloid deposition in mice with Alzheimer-like pathology. PLOS ONE 8, e60921 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3620049</ArticleId><ArticleId IdType="pubmed">23577177</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussian T. J., Aziz A., Meyer C. F., Swenson B. L., van Deursen J. M., Baker D. J., Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 562, 578&#x2013;582 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206507</ArticleId><ArticleId IdType="pubmed">30232451</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit W. J., Braak H., Xue Q. S., Bechmann I., Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer&#x2019;s disease. Acta Neuropathol. 118, 475&#x2013;485 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737117</ArticleId><ArticleId IdType="pubmed">19513731</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoshiba K., Tsuji T., Kameyama S., Itoh M., Semba S., Yamaguchi K., Nakamura H., Senescence-associated secretory phenotype in a mouse model of bleomycin-induced lung injury. Exp. Toxicol. Pathol. 65, 1053&#x2013;1062 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23688655</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Gable A. L., Lyon D., Junge A., Wyder S., Huerta-Cepas J., Simonovic M., Doncheva N. T., Morris J. H., Bork P., Jensen L. J., Mering C., STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47 ( D1), D607&#x2013;D613 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Byun H. O., Lee Y. K., Kim J. M., Yoon G., From cell senescence to age-related diseases: Differential mechanisms of action of senescence-associated secretory phenotypes. BMB Rep. 48, 549&#x2013;558 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4911181</ArticleId><ArticleId IdType="pubmed">26129674</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S., Bay-Jensen A. C., Karsdal M. A., Siebuhr A. S., Zheng Q., Maksymowych W. P., Christiansen T. G., Henriksen K., The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases. BMC Musculoskelet. Disord. 15, 93 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003863</ArticleId><ArticleId IdType="pubmed">24641725</ArticleId></ArticleIdList></Reference><Reference><Citation>Dranse H. J., Muruganandan S., Fawcett J. P., Sinal C. J., Adipocyte-secreted chemerin is processed to a variety of isoforms and influences MMP3 and chemokine secretion through an NFkB-dependent mechanism. Mol. Cell. Endocrinol. 436, 114&#x2013;129 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27461525</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuleshov M. V., Jones M. R., Rouillard A. D., Fernandez N. F., Duan Q., Wang Z., Koplev S., Jenkins S. L., Jagodnik K. M., Lachmann A., Mc Dermott M. G., Monteiro C. D., Gundersen G. W., Ma&#x2019;ayan A., Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44( W1), W90&#x2013;W97 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987924</ArticleId><ArticleId IdType="pubmed">27141961</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori N., Yamada Y., Ikeda S., Yamasaki Y., Tsukasaki K., Tanaka Y., Tomonaga M., Yamamoto N., Fujii M., Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100, 1828&#x2013;1834 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12176906</ArticleId></ArticleIdList></Reference><Reference><Citation>Podle&#x15b;ny-Drabiniok A., Marcora E., Goate A. M., Microglial phagocytosis: A disease-associated process emerging from Alzheimer&#x2019;s disease genetics. Trends Neurosci. 43, 965&#x2013;979 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9080913</ArticleId><ArticleId IdType="pubmed">33127097</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopp S. C., Lin Y., Oakley D., Roe A. D., DeVos S. L., Hanlon D., Hyman B. T., The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer&#x2019;s disease. J. Neuroinflammation 15, 269 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6145371</ArticleId><ArticleId IdType="pubmed">30227881</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Del Tredici K., Spreading of tau pathology in sporadic Alzheimer&#x2019;s disease along cortico-cortical top-down connections. Cereb. Cortex 28, 3372&#x2013;3384 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6095209</ArticleId><ArticleId IdType="pubmed">29982389</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A., Polydoro M., Su&#xe1;rez-Calvet M., William C., Adamowicz D. H., Kopeikina K. J., Pitstick R., Sahara N., Ashe K. H., Carlson G. A., Spires-Jones T. L., Hyman B. T., Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron 73, 685&#x2013;697 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Bol&#xf3;s M., Llorens-Mart&#xed;n M., Jurado-Arjona J., Hern&#xe1;ndez F., R&#xe1;bano A., Avila J., Direct evidence of internalization of tau by microglia in vitro and in vivo. J. Alzheimers Dis. 50, 77&#x2013;87 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26638867</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I., L&#xf3;pez-Gonz&#xe1;lez I., Carmona M., Arregui L., Dalf&#xf3; E., Torrej&#xf3;n-Escribano B., Diehl R., Kovacs G. G., Glial and neuronal tau pathology in tauopathies: Characterization of disease-specific phenotypes and tau pathology progression. J. Neuropathol. Exp. Neurol. 73, 81&#x2013;97 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24335532</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W., Liu W., Hu X., Hanna M., Caravaca A., Paul S. M., Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci. Rep. 5, 11161 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4460904</ArticleId><ArticleId IdType="pubmed">26057852</ArticleId></ArticleIdList></Reference><Reference><Citation>Neniskyte U., Neher J. J., Brown G. C., Neuronal death induced by nanomolar amyloid &#x3b2; is mediated by primary phagocytosis of neurons by microglia. J. Biol. Chem. 286, 39904&#x2013;39913 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220594</ArticleId><ArticleId IdType="pubmed">21903584</ArticleId></ArticleIdList></Reference><Reference><Citation>Neher J. J., Neniskyte U., Zhao J. W., Bal-Price A., Tolkovsky A. M., Brown G. C., Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death. J. Immunol. 186, 4973&#x2013;4983 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21402900</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan X. D., Zhu Y. G., Lin N., Zhang J., Ye Q. Y., Huang H. P., Chen X. C., Microglial phagocytosis induced by fibrillar &#x3b2;-amyloid is attenuated by oligomeric &#x3b2;-amyloid: Implications for Alzheimer&#x2019;s disease. Mol. Neurodegener. 6, 45 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149591</ArticleId><ArticleId IdType="pubmed">21718498</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellwig S., Masuch A., Nestel S., Katzmarski N., Meyer-Luehmann M., Biber K., Forebrain microglia from wild-type but not adult 5xFAD mice prevent amyloid-&#x3b2; plaque formation in organotypic hippocampal slice cultures. Sci. Rep. 5, 14624 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586757</ArticleId><ArticleId IdType="pubmed">26416689</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue L. F., Walker D. G., Rogers J., Modeling microglial activation in Alzheimer&#x2019;s disease with human postmortem microglial cultures. Neurobiol. Aging 22, 945&#x2013;956 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11755003</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Condello C., Schain A., Harb R., Grutzendler J., CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-&#x3b2; phagocytosis. J. Neurosci. 30, 17091&#x2013;17101 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077120</ArticleId><ArticleId IdType="pubmed">21159979</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit W. J., Khoshbouei H., Bechmann I., Dystrophic microglia in late-onset Alzheimer&#x2019;s disease. Glia 68, 845&#x2013;854 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31922322</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit W. J., Sammons N. W., Kuhns A. J., Sparks D. L., Dystrophic microglia in the aging human brain. Glia 45, 208&#x2013;212 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14730714</ArticleId></ArticleIdList></Reference><Reference><Citation>Njie E. G., Boelen E., Stassen F. R., Steinbusch H. W. M., Borchelt D. R., Streit W. J., Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol. Aging 33, 195.e1&#x2013;195.e12 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4162517</ArticleId><ArticleId IdType="pubmed">20580465</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaerzadeh F., Phan L., Miller D., Dacquel M., Hachmeister W., Hansen C., Bechtle A., Tu D., Martcheva M., Foster T. C., Kumar A., Streit W. J., Khoshbouei H., Microglia senescence occurs in both substantia nigra and ventral tegmental area. Glia 68, 2228&#x2013;2245 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8356201</ArticleId><ArticleId IdType="pubmed">32275335</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Shani S., Tahiri H., Ortiz C., Gu M., Lavoie J. C., Croteau S., Hardy P., Extracellular microparticles exacerbate oxidative damage to retinal pigment epithelial cells. Exp. Cell Res. 390, 111957 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32173468</ArticleId></ArticleIdList></Reference><Reference><Citation>Rexach J. E., Polioudakis D., Yin A., Swarup V., Chang T. S., Nguyen T., Sarkar A., Chen L., Huang J., Lin L. C., Seeley W., Trojanowski J. Q., Malhotra D., Geschwind D. H., Tau pathology drives dementia risk-associated gene networks toward chronic inflammatory states and immunosuppression. Cell Rep. 33, 108398 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7842189</ArticleId><ArticleId IdType="pubmed">33207193</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y., Asahina M., Hattori T., Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer&#x2019;s disease brain. Acta Neuropathol. 99, 91&#x2013;95 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10672313</ArticleId></ArticleIdList></Reference><Reference><Citation>Horstmann S., Budig L., Gardner H., Koziol J., Deuschle M., Schilling C., Wagner S., Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer&#x2019;s disease. Int. Psychogeriatr. 22, 966&#x2013;972 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20561382</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchavanakit N., Saengtong W., Manokawinchoke J., Pavasant P., TNF-&#x3b1; stimulates MMP-3 production via PGE2 signalling through the NF-kB and p38 MAPK pathway in a murine cementoblast cell line. Arch. Oral Biol. 60, 1066&#x2013;1074 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25956994</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur U., Banerjee P., Bir A., Sinha M., Biswas A., Chakrabarti S., Reactive oxygen species, redox signaling and neuroinflammation in Alzheimer&#x2019; disease: The NFkappaB connection. Curr. Top. Med. Chem. 15, 446&#x2013;457 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25620241</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hove I., Lefevere E., De Groef L., Sergeys J., Salinas-Navarro M., Libert C., Vandenbroucke R., Moons L., MMP-3 deficiency alleviates endotoxin-induced acute inflammation in the posterior eye segment. Int. J. Mol. Sci. 17, 1825 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5133826</ArticleId><ArticleId IdType="pubmed">27809288</ArticleId></ArticleIdList></Reference><Reference><Citation>VanSaun M., Humburg B. C., Arnett M. G., Pence M., Werle M. J., Activation of matrix metalloproteinase-3 is altered at the frog neuromuscular junction following changes in synaptic activity. Dev. Neurobiol. 67, 1488&#x2013;1497 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17525979</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiera G., Nowak D., van Hove I., Dziegiel P., Moons L., Mozrzymas J. W., Mechanisms of NMDA receptor- and voltage-gated L-type calcium channel-dependent hippocampal LTP critically rely on proteolysis that is mediated by distinct metalloproteinases. J. Neurosci. 37, 1240&#x2013;1256 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6596865</ArticleId><ArticleId IdType="pubmed">28069922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting J. T., Lee B. R., Chong P., Soler-Llavina G., Cobbs C., Koch C., Zeng H., Lein E., Preparation of acute brain slices using an optimized N-methyl-D-glucamine protective recovery method. J. Vis. Exp. 2018, 53825 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5931343</ArticleId><ArticleId IdType="pubmed">29553547</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedregosa F., Varoquaux G., Gramfort A., Michel V., Thirion B., Grisel O., Blondel M., Prettenhofer P., Weiss R., Dubourg V., Vanderplas J., Passos A., Cournapeau D., Brucher M., Perrot M., Duchesnay &#xc9;., Scikit-learn: Machine learning in python. J. Mach. Learn. Res. 12, 28255&#x2013;22830 (2011).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34667166</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Highly efficient intercellular spreading of protein misfolding mediated by viral ligand-receptor interactions.</ArticleTitle><Pagination><StartPage>5739</StartPage><MedlinePgn>5739</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5739</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-021-25855-2</ELocationID><Abstract><AbstractText>Protein aggregates associated with neurodegenerative diseases have the ability to transmit to unaffected cells, thereby templating their own aberrant conformation onto soluble homotypic proteins. Proteopathic seeds can be released into the extracellular space, secreted in association with extracellular vesicles (EV) or exchanged by direct cell-to-cell contact. The extent to which each of these pathways contribute to the prion-like spreading of protein misfolding is unclear. Exchange of cellular cargo by both direct cell contact or via EV depends on receptor-ligand interactions. We hypothesized that enabling these interactions through viral ligands enhances intercellular proteopathic seed transmission. Using different cellular models propagating prions or pathogenic Tau aggregates, we demonstrate that vesicular stomatitis virus glycoprotein and SARS-CoV-2 spike S increase aggregate induction by cell contact or ligand-decorated EV. Thus, receptor-ligand interactions are important determinants of intercellular aggregate dissemination. Our data raise the possibility that viral infections contribute to proteopathic seed spreading by facilitating intercellular cargo transfer.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases Bonn (DZNE), Venusberg Campus 1/ 99, 53127, Bonn, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Federal Institute for Risk Assessment (BfR), German Centre for the Protection of Laboratory Animals (Bf3R), Max-Dohrn-Stra&#xdf;e 8-10, 10589, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hossinger</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases Bonn (DZNE), Venusberg Campus 1/ 99, 53127, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heum&#xfc;ller</LastName><ForeName>Stefanie-Elisabeth</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases Bonn (DZNE), Venusberg Campus 1/ 99, 53127, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornberger</LastName><ForeName>Annika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases Bonn (DZNE), Venusberg Campus 1/ 99, 53127, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buravlova</LastName><ForeName>Oleksandra</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases Bonn (DZNE), Venusberg Campus 1/ 99, 53127, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konstantoulea</LastName><ForeName>Katerina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0960-6274</Identifier><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0003-3414-307X</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroproteomics, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paulsen</LastName><ForeName>Lydia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases Bonn (DZNE), Venusberg Campus 1/ 99, 53127, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schymkowitz</LastName><ForeName>Joost</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>VIB Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lichtenthaler</LastName><ForeName>Stefan F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroproteomics, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, University Hospital T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Neuropathology of Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denner</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases Bonn (DZNE), Venusberg Campus 1/ 99, 53127, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vorberg</LastName><ForeName>Ina M</ForeName><Initials>IM</Initials><Identifier Source="ORCID">0000-0003-0583-4015</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases Bonn (DZNE), Venusberg Campus 1/ 99, 53127, Bonn, Germany. ina.vorberg@dzne.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheinische Friedrich-Wilhelms-Universit&#xe4;t Bonn, Venusberg Campus 1, 53127, Bonn, Germany. ina.vorberg@dzne.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C028391">G protein, vesicular stomatitis virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067128" MajorTopicYN="N">Extracellular Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069416" MajorTopicYN="N">Intravital Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34667166</ArticleId><ArticleId IdType="pmc">PMC8526834</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-25855-2</ArticleId><ArticleId IdType="pii">10.1038/s41467-021-25855-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jucker M, Walker LC. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat. Neurosci. 2018;21:1341&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375686</ArticleId><ArticleId IdType="pubmed">30258241</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl Acad. Sci. USA. 1986;83:4044&#x2013;4048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323662</ArticleId><ArticleId IdType="pubmed">2424016</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer&#x2019;s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys. Res Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG. Tauopathies. Handb. Clin. Neurol. 2017;145:355&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">28987182</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216:136&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">6801762</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases. Nature. 2016;539:217&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">27830781</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Lansbury PT., Jr. Seeding &#x201c;one-dimensional crystallization&#x201d; of amyloid: a pathogenic mechanism in Alzheimer&#x2019;s disease and scrapie? Cell. 1993;73:1055&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">8513491</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzinger E, et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington&#x2019;s disease pathology. Proc. Natl Acad. Sci. USA. 1999;96:4604&#x2013;4609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16379</ArticleId><ArticleId IdType="pubmed">10200309</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunello C. A., Merezhko M., Uronen R. L., &amp; Huttunen H. J. Mechanisms of secretion and spreading of pathological tau protein. Cell Mol Life Sci.77, 1721&#x2013;1744 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190606</ArticleId><ArticleId IdType="pubmed">31667556</ArticleId></ArticleIdList></Reference><Reference><Citation>Victoria GS, Zurzolo C. The spread of prion-like proteins by lysosomes and tunneling nanotubes: Implications for neurodegenerative diseases. J. Cell Biol. 2017;216:2633&#x2013;2644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5584166</ArticleId><ArticleId IdType="pubmed">28724527</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostami J, et al. Human astrocytes transfer aggregated alpha-synuclein via tunneling aanotubes. J. Neurosci. 2017;37:11835&#x2013;11853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719970</ArticleId><ArticleId IdType="pubmed">29089438</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardivel M, et al. Tunneling nanotube (TNT)-mediated neuron-to neuron transfer of pathological Tau protein assemblies. Acta Neuropathol. Commun. 2016;4:117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5096005</ArticleId><ArticleId IdType="pubmed">27809932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YJ, Lee SJ. Are exosomes the vehicle for protein aggregate propagation in neurodegenerative diseases? Acta Neuropathol. Commun. 2017;5:64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5576311</ArticleId><ArticleId IdType="pubmed">28851422</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl PD, Raposo G. Extracellular vesicles: exosomes and microvesicles, integrators of homeostasis. Physiol. (Bethesda) 2019;34:169&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">30968753</ArticleId></ArticleIdList></Reference><Reference><Citation>Thery C, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles. 2018;7:1535750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6322352</ArticleId><ArticleId IdType="pubmed">30637094</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, et al. Alzheimer&#x2019;s disease beta-amyloid peptides are released in association with exosomes. Proc. Natl Acad. Sci. USA. 2006;103:11172&#x2013;11177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544060</ArticleId><ArticleId IdType="pubmed">16837572</ArticleId></ArticleIdList></Reference><Reference><Citation>Saman S, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 2012;287:3842&#x2013;3849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3281682</ArticleId><ArticleId IdType="pubmed">22057275</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. The release and trans-synaptic transmission of Tau via exosomes. Mol. Neurodegener. 2017;12:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5237256</ArticleId><ArticleId IdType="pubmed">28086931</ArticleId></ArticleIdList></Reference><Reference><Citation>Fevrier B, et al. Cells release prions in association with exosomes. Proc. Natl Acad. Sci. USA. 2004;101:9683&#x2013;9688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC470735</ArticleId><ArticleId IdType="pubmed">15210972</ArticleId></ArticleIdList></Reference><Reference><Citation>Vella LJ, et al. Packaging of prions into exosomes is associated with a novel pathway of PrP processing. J. Pathol. 2007;211:582&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">17334982</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejlerskov P, et al. Tubulin polymerization-promoting protein (TPPP/p25alpha) promotes unconventional secretion of alpha-synuclein through exophagy by impairing autophagosome-lysosome fusion. J. Biol. Chem. 2013;288:17313&#x2013;17335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682534</ArticleId><ArticleId IdType="pubmed">23629650</ArticleId></ArticleIdList></Reference><Reference><Citation>Chivet M, et al. Exosomes secreted by cortical neurons upon glutamatergic synapse activation specifically interact with neurons. J. Extracell. Vesicles. 2014;3:24722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4232649</ArticleId><ArticleId IdType="pubmed">25398455</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu M, Martin-Jaular L, Lavieu G, Thery C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 2019;21:9&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">30602770</ArticleId></ArticleIdList></Reference><Reference><Citation>Prada I. &amp; Meldolesi J. Binding and fusion of extracellular vesicles to the plasma membrane of their cell targets. Int J Mol Sci.17, 1296 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5000693</ArticleId><ArticleId IdType="pubmed">27517914</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelshtein D, Werman A, Novick D, Barak S, Rubinstein M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc. Natl Acad. Sci. USA. 2013;110:7306&#x2013;7311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3645523</ArticleId><ArticleId IdType="pubmed">23589850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim IS, et al. Mechanism of membrane fusion induced by vesicular stomatitis virus G protein. Proc. Natl Acad. Sci. USA. 2017;114:E28&#x2013;E36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5224367</ArticleId><ArticleId IdType="pubmed">27974607</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer C, et al. Pseudotyping exosomes for enhanced protein delivery in mammalian cells. Int J. Nanomed. 2017;12:3153&#x2013;3170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5402897</ArticleId><ArticleId IdType="pubmed">28458537</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangeot PE, et al. Protein transfer into human cells by VSV-G-induced nanovesicles. Mol. Ther. 2011;19:1656&#x2013;1666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3182355</ArticleId><ArticleId IdType="pubmed">21750535</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickner R. B. Yeast and Fungal Prions. Cold Spring Harb Perspect Biol.8, a023531(2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5008071</ArticleId><ArticleId IdType="pubmed">27481532</ArticleId></ArticleIdList></Reference><Reference><Citation>Ter-Avanesyan MD, Dagkesamanskaya AR, Kushnirov VV, Smirnov VN. The SUP35 omnipotent suppressor gene is involved in the maintenance of the non-Mendelian determinant [psi+] in the yeast Saccharomyces cerevisiae. Genetics. 1994;137:671&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1206026</ArticleId><ArticleId IdType="pubmed">8088512</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer C, et al. The yeast Sup35NM domain propagates as a prion in mammalian cells. Proc. Natl Acad. Sci. USA. 2009;106:462&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626725</ArticleId><ArticleId IdType="pubmed">19114662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann JP, et al. Cell-to-cell propagation of infectious cytosolic protein aggregates. Proc. Natl Acad. Sci. USA. 2013;110:5951&#x2013;5956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625284</ArticleId><ArticleId IdType="pubmed">23509289</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Hossinger A., Hofmann J. P., Denner P., Vorberg I. M. Horizontal transmission of cytosolic sup35 prions by extracellular vesicles. MBio.7, e00915&#x2013;e00916 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958257</ArticleId><ArticleId IdType="pubmed">27406566</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Hossinger A, Gobbels S, Vorberg IM. Prions on the run: How extracellular vesicles serve as delivery vehicles for self-templating protein aggregates. Prion. 2017;11:98&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5399892</ArticleId><ArticleId IdType="pubmed">28402718</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanifer ML, Cureton DK, Whelan SP. A recombinant vesicular stomatitis virus bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that restores fusion. J. Virol. 2011;85:8105&#x2013;8115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3147994</ArticleId><ArticleId IdType="pubmed">21680501</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Belouzard S, Whittaker GR. Molecular architecture of the bipartite fusion loops of vesicular stomatitis virus glycoprotein G, a class III viral fusion protein. J. Biol. Chem. 2008;283:6418&#x2013;6427.</Citation><ArticleIdList><ArticleId IdType="pubmed">18165228</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolic J, Belot L, Raux H, Legrand P, Gaudin Y. A AA. Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein. Nat. Commun. 2018;9:1029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5847621</ArticleId><ArticleId IdType="pubmed">29531262</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche S, Gaudin Y. Characterization of the equilibrium between the native and fusion-inactive conformation of rabies virus glycoprotein indicates that the fusion complex is made of several trimers. Virology. 2002;297:128&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">12083843</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy L. A., Pink R. C., &amp; Carter D. R. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles.3, eCollection (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4122821</ArticleId><ArticleId IdType="pubmed">25143819</ArticleId></ArticleIdList></Reference><Reference><Citation>Cureton DK, Massol RH, Saffarian S, Kirchhausen TL, Whelan SP. Vesicular stomatitis virus enters cells through vesicles incompletely coated with clathrin that depend upon actin for internalization. PLoS Pathog. 2009;5:e1000394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667253</ArticleId><ArticleId IdType="pubmed">19390604</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannsdottir HK, Mancini R, Kartenbeck J, Amato L, Helenius A. Host cell factors and functions involved in vesicular stomatitis virus entry. J. Virol. 2009;83:440&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2612308</ArticleId><ArticleId IdType="pubmed">18971266</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Yau VK, Briggs BJ, Whittaker GR. Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells. Virology. 2005;338:53&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">15936793</ArticleId></ArticleIdList></Reference><Reference><Citation>Chazal N, Singer G, Aiken C, Hammarskjold ML, Rekosh D. Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J. Virol. 2001;75:4014&#x2013;4018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114896</ArticleId><ArticleId IdType="pubmed">11264394</ArticleId></ArticleIdList></Reference><Reference><Citation>Macia E, Ehrlich M, Massol R, Boucrot E, Brunner C. Kirchhausen T. Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell. 2006;10:839&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pubmed">16740485</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredericksen BL, Whitt MA. Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness. Virology. 1998;240:349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">9454708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 2020;11:1620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7100515</ArticleId><ArticleId IdType="pubmed">32221306</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders DW, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82:1271&#x2013;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorberg I. M. All the same? the secret life of prion strains within their target cells. Viruses.11, 334 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6520713</ArticleId><ArticleId IdType="pubmed">30970585</ArticleId></ArticleIdList></Reference><Reference><Citation>Alais S, et al. Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles. Biol. Cell/ auspices Eur. Cell Biol. Organ. 2008;100:603&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">18422484</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf H, et al. Modulation of glycosaminoglycans affects PrPSc metabolism but does not block PrPSc uptake. J. Virol. 2015;89:9853&#x2013;9864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4577896</ArticleId><ArticleId IdType="pubmed">26202247</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahal SP, et al. Prion strain discrimination in cell culture: the cell panel assay. Proc. Natl Acad. Sci. USA. 2007;104:20908&#x2013;20913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2409240</ArticleId><ArticleId IdType="pubmed">18077360</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell.181, 271&#x2013;280.e8(2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsinelos T, et al. Unconventional Secretion Mediates the Trans-cellular Spreading of Tau. Cell Rep. 2018;23:2039&#x2013;2055.</Citation><ArticleIdList><ArticleId IdType="pubmed">29768203</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl Acad. Sci. USA. 2013;110:E3138&#x2013;E3147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch JN, et al. LRP1 is a master regulator of tau uptake and spread. Nature. 2020;580:381&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7687380</ArticleId><ArticleId IdType="pubmed">32296178</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattei V, et al. Paracrine diffusion of PrP(C) and propagation of prion infectivity by plasma membrane-derived microvesicles. PLoS One. 2009;4:e5057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659799</ArticleId><ArticleId IdType="pubmed">19337375</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi P, et al. Microglia convert aggregated amyloid-beta into neurotoxic forms through the shedding of microvesicles. Cell Death Differ. 2014;21:582&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3950321</ArticleId><ArticleId IdType="pubmed">24336048</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford K. H. D., et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses.12, 513 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7291041</ArticleId><ArticleId IdType="pubmed">32384820</ArticleId></ArticleIdList></Reference><Reference><Citation>Itzhaki RF, Golde TE, Heneka MT, Readhead B. Do infections have a role in the pathogenesis of Alzheimer disease? Nat. Rev. Neurol. 2020;16:193&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">32152461</ArticleId></ArticleIdList></Reference><Reference><Citation>Readhead B, et al. Multiscale analysis of Independent Alzheimer&#x2019;s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron. 2018;99:64&#x2013;82 e67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6551233</ArticleId><ArticleId IdType="pubmed">29937276</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Sicurella M, Agostini S, Marconi P, Clerici M. Herpes simplex virus type 1 and Alzheimer&#x2019;s disease: link and potential impact on treatment. Expert Rev. Anti Infect. Ther. 2019;17:715&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">31414935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hategan A, Masliah E, Nath AHIV. and Alzheimer&#x2019;s disease: complex interactions of HIV-Tat with amyloid beta peptide and Tau protein. J. Neurovirol. 2019;25:648&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9056081</ArticleId><ArticleId IdType="pubmed">31016584</ArticleId></ArticleIdList></Reference><Reference><Citation>Lannuzel A, et al. Human immunodeficiency virus type 1 and its coat protein gp120 induce apoptosis and activate JNK and ERK mitogen-activated protein kinases in human neurons. Ann. Neurol. 1997;42:847&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pubmed">9403476</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, et al. Human endogenous retrovirus-K contributes to motor neuron disease. Sci. Transl. Med. 2015;7:307ra153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6344353</ArticleId><ArticleId IdType="pubmed">26424568</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodidela S., et al. Extracellular vesicles: a possible link between HIV and Alzheimer&#x2019;s disease-like pathology in HIV subjects? Cells.8, 968 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6769601</ArticleId><ArticleId IdType="pubmed">31450610</ArticleId></ArticleIdList></Reference><Reference><Citation>Leblanc P, et al. Retrovirus infection strongly enhances scrapie infectivity release in cell culture. EMBO J. 2006;25:2674&#x2013;2685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1500854</ArticleId><ArticleId IdType="pubmed">16724107</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian J, et al. Cell-based quantification of chronic wasting disease prions. J. Virol. 2010;84:8322&#x2013;8326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2916541</ArticleId><ArticleId IdType="pubmed">20519392</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, et al. Persistent retroviral infection with MoMuLV influences neuropathological signature and phenotype of prion disease. Acta Neuropathol. 2012;124:111&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">22271154</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dongen HM, Masoumi N, Witwer KW, Pegtel DM. Extracellular Vesicles Exploit Viral Entry Routes for Cargo Delivery. Microbiol Mol. Biol. Rev. 2016;80:369&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867369</ArticleId><ArticleId IdType="pubmed">26935137</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaillant A. HBsAg, subviral particles, and their clearance in establishing a functional cure of chronic hepatitis B virus infection. ACS Infect Dis.7, 1351&#x2013;1368 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33302622</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z, et al. A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature. 2013;496:367&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631468</ArticleId><ArticleId IdType="pubmed">23542590</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallhov H, et al. Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro. J. Immunol. 2011;186:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">21106852</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattentau Q. Avoiding the void: cell-to-cell spread of human viruses. Nat. Rev. Microbiol. 2008;6:815&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pubmed">18923409</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherer NM, et al. Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission. Nat. Cell Biol. 2007;9:310&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2628976</ArticleId><ArticleId IdType="pubmed">17293854</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020;12:69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271826</ArticleId><ArticleId IdType="pubmed">32498691</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodnar B, Patel K, Ho W, Luo JJ, Hu W. Cellular mechanisms underlying neurological/neuropsychiatric manifestations of COVID-19. J. Med Virol. 2021;93:1983&#x2013;1998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7897247</ArticleId><ArticleId IdType="pubmed">33300152</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang RD, et al. Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2. Cell. 2020;182:50&#x2013;58 e58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241398</ArticleId><ArticleId IdType="pubmed">32516571</ArticleId></ArticleIdList></Reference><Reference><Citation>Golden J. W., et al. Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight.5, e142032. (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566707</ArticleId><ArticleId IdType="pubmed">32841215</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E., et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med.218, e20202135 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles V. G., et al. Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med.383, 590&#x2013;592 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriguchi T, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J. Infect. Dis. 2020;94:55&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195378</ArticleId><ArticleId IdType="pubmed">32251791</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J., et al. Olfactory transmucosal SARS-CoV-2 invasion as port of 1 Central Nervous System entry in COVID-19 patients. Nat Neurosci. 24, 168&#x2013;175 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Butowt R, Meunier N, Bryche B, von Bartheld CS. The olfactory nerve is not a likely route to brain infection in COVID-19: a critical review of data from humans and animal models. Acta Neuropathol. 2021;141:809&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8075028</ArticleId><ArticleId IdType="pubmed">33903954</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman AL, et al. Tau prions from Alzheimer&#x2019;s disease and chronic traumatic encephalopathy patients propagate in cultured cells. Proc. Natl Acad. Sci. USA. 2016;113:E8187&#x2013;E8196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5167200</ArticleId><ArticleId IdType="pubmed">27911827</ArticleId></ArticleIdList></Reference><Reference><Citation>Follenzi A, Naldini L. HIV-based vectors. Preparation and use. Methods Mol. Med. 2002;69:259&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">11987783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertmer A, et al. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. J. Biol. Chem. 2004;279:41918&#x2013;41927.</Citation><ArticleIdList><ArticleId IdType="pubmed">15247213</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer C, et al. Prion protein/protein interactions: fusion with yeast Sup35p-NM modulates cytosolic PrP aggregation in mammalian cells. FASEB J. 2008;22:762&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928365</ArticleId></ArticleIdList></Reference><Reference><Citation>Taraboulos A, Serban D, Prusiner SB. Scrapie prion proteins accumulate in the cytoplasm of persistently infected cultured cells. J. Cell Biol. 1990;110:2117&#x2013;2132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2116143</ArticleId><ArticleId IdType="pubmed">1693623</ArticleId></ArticleIdList></Reference><Reference><Citation>Karapetyan YE, et al. Prion strain discrimination based on rapid in vivo amplification and analysis by the cell panel assay. PLoS One. 2009;4:e5730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2684634</ArticleId><ArticleId IdType="pubmed">19478942</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34686344</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Tau reduction affects excitatory and inhibitory neurons differently, reduces excitation/inhibition ratios, and counteracts network hypersynchrony.</ArticleTitle><Pagination><StartPage>109855</StartPage><MedlinePgn>109855</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2021.109855</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(21)01322-X</ELocationID><Abstract><AbstractText>The protein tau has been implicated in many brain disorders. In animal models, tau reduction suppresses epileptogenesis of diverse causes and ameliorates synaptic and behavioral abnormalities in various conditions associated with excessive excitation-inhibition (E/I) ratios. However, the underlying mechanisms are unknown. Global genetic ablation of tau in mice reduces the action potential (AP) firing and E/I ratio of pyramidal cells in acute cortical slices without affecting the excitability of these cells. Tau ablation reduces the excitatory inputs to inhibitory neurons, increases the excitability of these cells, and structurally alters their axon initial segments (AISs). In primary neuronal cultures subjected to prolonged overstimulation, tau ablation diminishes the homeostatic response of AISs in inhibitory neurons, promotes inhibition, and suppresses hypersynchrony. Together, these differential alterations in excitatory and inhibitory neurons help explain how tau reduction prevents network hypersynchrony and counteracts brain disorders causing abnormally increased E/I ratios.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Che-Wei</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Mark D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Xinxing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qiu</ForeName><Initials>GQ</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158, USA; Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, CA 94158, USA. Electronic address: lennart.mucke@gladstone.ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH115679</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558298">Mapt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019706" MajorTopicYN="Y">Excitatory Postsynaptic Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053444" MajorTopicYN="Y">Inhibitory Postsynaptic Potentials</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007395" MajorTopicYN="N">Interneurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057507" MajorTopicYN="N">Mice, 129 Strain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009433" MajorTopicYN="Y">Neural Inhibition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017966" MajorTopicYN="N">Pyramidal Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013003" MajorTopicYN="N">Somatosensory Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">axon initial segment</Keyword><Keyword MajorTopicYN="N">epilepsy</Keyword><Keyword MajorTopicYN="N">excitation-inhibition balance</Keyword><Keyword MajorTopicYN="N">hypersynchrony</Keyword><Keyword MajorTopicYN="N">interneurons</Keyword><Keyword MajorTopicYN="N">intrinsic excitability</Keyword><Keyword MajorTopicYN="N">neuronal plasticity</Keyword><Keyword MajorTopicYN="N">pyramidal cells</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>Declaration of interests L.M. has received research funding from Cure Network Dolby Acceleration Partners (CNDAP) and has served on CNDAP&#x2019;s board of managers. He has also served on the scientific advisory boards of Arvinas, Biogen, and Dolby Family Ventures and has consulted for Eisai and Sangamo Therapeutics. L.M. is a coinventor on patents held by the Gladstone Institutes that focus on tau reduction as a strategy to block neural network dysfunction.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34686344</ArticleId><ArticleId IdType="mid">NIHMS1749763</ArticleId><ArticleId IdType="pmc">PMC8648275</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.109855</ArticleId><ArticleId IdType="pii">S2211-1247(21)01322-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bender KJ, and Trussell LO (2012). The physiology of the axon initial segment. Annu. Rev. Neurosci 35, 249&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">22443507</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi M, Gladbach A, van Eersel J, Ittner A, Przybyla M, van Hummel A, Chua SW, van der Hoven J, Lee WS, M&#xfc;ller J, et al. (2017). Tau exacerbates excitotoxic brain damage in an animal model of stroke. Nat. Commun 8, 473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5589746</ArticleId><ArticleId IdType="pubmed">28883427</ArticleId></ArticleIdList></Reference><Reference><Citation>Black BJ, Atmaramani R, and Pancrazio JJ (2017). Spontaneous and evoked activity from murine ventral horn cultures on microelectrode arrays. Front. Cell. Neurosci 11, 304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5626830</ArticleId><ArticleId IdType="pubmed">29033792</ArticleId></ArticleIdList></Reference><Reference><Citation>Booker SA, Sim&#xf5;es de Oliveira L, Anstey NJ, Kozic Z, Dando OR, Jackson AD, Baxter PS, Isom LL, Sherman DL, Hardingham GE, et al. (2020). Input-output relationship of CA1 pyramidal neurons reveals intact homeostatic mechanisms in a mouse model of fragile x syndrome. Cell Rep. 32, 107988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7435362</ArticleId><ArticleId IdType="pubmed">32783927</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Wegmann S, Dujardin S, Commins C, Schiantarelli J, Klickstein N, Kamath TV, Carlson GA, Nelken I, and Hyman BT (2019). Tau impairs neural circuits, dominating amyloid-&#x3b2; effects, in Alzheimer models in vivo. Nat. Neurosci 22, 57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6560629</ArticleId><ArticleId IdType="pubmed">30559471</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CW, Shao E, and Mucke L (2021). Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies. Science 371, eabb8255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8118650</ArticleId><ArticleId IdType="pubmed">33632820</ArticleId></ArticleIdList></Reference><Reference><Citation>Crimins JL, Rocher AB, and Luebke JI (2012). Electrophysiological changes precede morphological changes to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy. Acta Neuropathol. 124, 777&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3509230</ArticleId><ArticleId IdType="pubmed">22976049</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, Chen G, Shen T, Tran H, Nichols B, et al. (2017). Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med 9, 1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792300</ArticleId><ArticleId IdType="pubmed">28123067</ArticleId></ArticleIdList></Reference><Reference><Citation>Duman RS, Sanacora G, and Krystal JH (2019). Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron 102, 75&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450409</ArticleId><ArticleId IdType="pubmed">30946828</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans MD, Sammons RP, Lebron S, Dumitrescu AS, Watkins TB, Uebele VN, Renger JJ, and Grubb MS (2013). Calcineurin signaling mediates activity-dependent relocation of the axon initial segment. J. Neurosci 33, 6950&#x2013;6963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3743026</ArticleId><ArticleId IdType="pubmed">23595753</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans MD, Dumitrescu AS, Kruijssen DLH, Taylor SE, and Grubb MS (2015). Rapid modulation of axon initial segment length influences repetitive spike firing. Cell Rep. 13, 1233&#x2013;1245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646840</ArticleId><ArticleId IdType="pubmed">26526995</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xe9;al A, Fassier C, Le Bras B, Bullier E, De Gois S, Hazan J, Hoogenraad CC, and Couraud F (2016). Cooperative interactions between 480 kDa ankyrin-G and EB proteins assemble the axon initial segment. J. Neurosci 36, 4421&#x2013;4433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6601828</ArticleId><ArticleId IdType="pubmed">27098687</ArticleId></ArticleIdList></Reference><Reference><Citation>Frega M, Linda K, Keller JM, G&#xfc;m&#xfc;&#x15f;-Akay G, Mossink B, van Rhijn JR, Negwer M, Klein Gunnewiek T, Foreman K, Kompier N, et al. (2019). Neuronal network dysfunction in a model for Kleefstra syndrome mediated by enhanced NMDAR signaling. Nat. Commun 10, 4928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6821803</ArticleId><ArticleId IdType="pubmed">31666522</ArticleId></ArticleIdList></Reference><Reference><Citation>Frere S, and Slutsky I (2018). Alzheimer&#x2019;s disease: From firing instability to homeostasis network collapse. Neuron 97, 32&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">29301104</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Cabrero AM, Guerrero-L&#xf3;pez R, Gir&#xe1;ldez BG, Llorens-Mart&#xed;n M, Avila J, Serratosa JM, and S&#xe1;nchez MP (2013). Hyperexcitability and epileptic seizures in a model of frontotemporal dementia. Neurobiol. Dis 58, 200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">23774255</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheyara AL, Ponnusamy R, Djukic B, Craft RJ, Ho K, Guo W, Finucane MM, Sanchez PE, and Mucke L (2014). Tau reduction prevents disease in a mouse model of Dravet syndrome. Ann. Neurol 76, 443&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338764</ArticleId><ArticleId IdType="pubmed">25042160</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, and Spillantini MG (2019). Ordered assembly of tau protein and neurodegeneration. In Tau Biology. Advances in Experimental Medicine and Biology, Takashima A, Wolozin B, and Buee L, eds. (Springer; ).</Citation><ArticleIdList><ArticleId IdType="pubmed">32096024</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg EM, and Coulter DA (2013). Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction. Nat. Rev. Neurosci 14, 337&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3982383</ArticleId><ArticleId IdType="pubmed">23595016</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouwens NW, Sorensen SA, Berg J, Lee C, Jarsky T, Ting J, Sunkin SM, Feng D, Anastassiou CA, Barkan E, et al. (2019). Classification of electrophysiological and morphological neuron types in the mouse visual cortex. Nat. Neurosci 22, 1182&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8078853</ArticleId><ArticleId IdType="pubmed">31209381</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouwens NW, Sorensen SA, Baftizadeh F, Budzillo A, Lee BR, Jarsky T, Alfiler L, Baker K, Barkan E, Berry K, et al. (2020). Integrated morpho-electric and transcriptomic classification of cortical GABAergic cells. Cell 183, 935&#x2013;953.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781065</ArticleId><ArticleId IdType="pubmed">33186530</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubb MS, and Burrone J (2010). Activity-dependent relocation of the axon initial segment fine-tunes neuronal excitability. Nature 465, 1070&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196626</ArticleId><ArticleId IdType="pubmed">20543823</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubb MS, Shu Y, Kuba H, Rasband MN, Wimmer VC, and Bender KJ (2011). Short- and long-term plasticity at the axon initial segment. J. Neurosci 31, 16049&#x2013;16055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3232445</ArticleId><ArticleId IdType="pubmed">22072655</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman SJ, Schl&#xf6;gl A, and Schmidt-Hieber C (2014). Stimfit: quantifying electrophysiological data with Python. Front. Neuroinform 8, 16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3931263</ArticleId><ArticleId IdType="pubmed">24600389</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatch RJ, Wei Y, Xia D, and G&#xf6;tz J (2017). Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment. Acta Neuropathol. 133, 717&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389999</ArticleId><ArticleId IdType="pubmed">28091722</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth JK, Bomben VC, Reed JG, Inoue T, Younkin L, Younkin SG, Pautler RG, Botas J, and Noebels JL (2013). Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J. Neurosci 33, 1651&#x2013;1659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711605</ArticleId><ArticleId IdType="pubmed">23345237</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, W&#xf6;lfing H, Chieng BC, Christie MJ, Napier IA, et al. (2010). Dendritic function of tau mediates amyloid-&#x3b2; toxicity in Alzheimer&#x2019;s disease mouse models. Cell 142, 387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanner AM (2016). Management of psychiatric and neurological comorbidities in epilepsy. Nat. Rev. Neurol 12, 106&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">26782334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuba H, Oichi Y, and Ohmori H (2010). Presynaptic activity regulates Na(+) channel distribution at the axon initial segment. Nature 465, 1075&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pubmed">20543825</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam AD, Sarkis RA, Pellerin KR, Jing J, Dworetzky BA, Hoch DB, Jacobs CS, Lee JW, Weisholtz DS, Zepeda R, et al. (2020). Association of epileptiform abnormalities and seizures in Alzheimer disease. Neurology 95, e2259&#x2013;e2270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7713786</ArticleId><ArticleId IdType="pubmed">32764101</ArticleId></ArticleIdList></Reference><Reference><Citation>Leterrier C, Vacher H, Fache MP, d&#x2019;Ortoli SA, Castets F, Autillo-Touati A, and Dargent B (2011). End-binding proteins EB3 and EB1 link microtubules to ankyrin G in the axon initial segment. Proc. Natl. Acad. Sci. USA 108, 8826&#x2013;8831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102358</ArticleId><ArticleId IdType="pubmed">21551097</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Cui D, Jiruska P, Fox JE, Yao X, and Jefferys JG (2007). Synchronization measurement of multiple neuronal populations. J. Neurophysiol 98, 3341&#x2013;3348.</Citation><ArticleIdList><ArticleId IdType="pubmed">17913983</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda S, Djukic B, Taneja P, Yu GQ, Lo I, Davis A, Craft R, Guo W, Wang X, Kim D, et al. (2016). Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. EMBO Rep. 17, 530&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818780</ArticleId><ArticleId IdType="pubmed">26931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Marvin JS, Shimoda Y, Magloire V, Leite M, Kawashima T, Jensen TP, Kolb I, Knott EL, Novak O, Podgorski K, et al. (2019). A genetically encoded fluorescent sensor for in vivo imaging of GABA. Nat. Methods 16, 763&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">31308547</ArticleId></ArticleIdList></Reference><Reference><Citation>Menkes-Caspi N, Yamin HG, Kellner V, Spires-Jones TL, Cohen D, and Stern EA (2015). Pathological tau disrupts ongoing network activity. Neuron 85, 959&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">25704951</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J, Wang QW, Kim Y, Yu DX, Pham S, Yang B, Zheng Y, Diffenderfer KE, Zhang J, Soltani S, et al.; Pharmacogenomics of Bipolar Disorder Study (2015). Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature 527, 95&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4742055</ArticleId><ArticleId IdType="pubmed">26524527</ArticleId></ArticleIdList></Reference><Reference><Citation>Naka A, and Adesnik H (2016). Inhibitory circuits in cortical layer 5. Front. Neural Circuits 10, 35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4859073</ArticleId><ArticleId IdType="pubmed">27199675</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, and Mucke L (2016). Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat. Rev. Neurosci 17, 777&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8162106</ArticleId><ArticleId IdType="pubmed">27829687</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan-Vazquez A, Wefelmeyer W, Gonzalez Sabater V, Neves G, and Burrone J (2020). Activity-dependent plasticity of axo-axonic synapses at the axon initial segment. Neuron 106, 265&#x2013;276.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7181187</ArticleId><ArticleId IdType="pubmed">32109363</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel TP, Ventre SC, and Meaney DF (2012). Dynamic changes in neural circuit topology following mild mechanical injury in vitro. Ann. Biomed. Eng 40, 23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5553048</ArticleId><ArticleId IdType="pubmed">21994056</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack PO, Guillemain I, Hu E, Deransart C, Depaulis A, and Charpier S (2007). Deep layer somatosensory cortical neurons initiate spike-and-wave discharges in a genetic model of absence seizures. J. Neurosci 27, 6590&#x2013;6599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672429</ArticleId><ArticleId IdType="pubmed">17567820</ArticleId></ArticleIdList></Reference><Reference><Citation>Polepalli JS, Wu H, Goswami D, Halpern CH, S&#xfc;dhof TC, and Malenka RC (2017). Modulation of excitation on parvalbumin interneurons by neuroligin-3 regulates the hippocampal network. Nat. Neurosci 20, 219&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5272845</ArticleId><ArticleId IdType="pubmed">28067903</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakhade SN, and Jensen FE (2009). Epileptogenesis in the immature brain: emerging mechanisms. Nat. Rev. Neurol 5, 380&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822660</ArticleId><ArticleId IdType="pubmed">19578345</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu G-Q, and Mucke L (2007). Reducing endogenous tau ameliorates amyloid &#x3b2;-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science 316, 750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu G-Q, et al. (2011). Amyloid-&#x3b2;/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer&#x2019;s disease. J. Neurosci 31, 700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="pubmed">21228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu G-Q, Palop JJ, and Mucke L (2012). Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer&#x2019;s disease model. Proc. Natl. Acad. Sci. USA 109, E2895&#x2013;E2903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3479491</ArticleId><ArticleId IdType="pubmed">22869752</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders A, Macosko EZ, Wysoker A, Goldman M, Krienen FM, de Rivera H, Bien E, Baum M, Bortolin L, Wang S, et al. (2018). Molecular diversity and specializations among the cells of the adult mouse brain. Cell 174, 1015&#x2013;1030.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447408</ArticleId><ArticleId IdType="pubmed">30096299</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayas CL, Tortosa E, Bollati F, Ram&#xed;rez-R&#xed;os S, Arnal I, and Avila J (2015). Tau regulates the localization and function of End-binding proteins 1 and 3 in developing neuronal cells. J. Neurochem 133, 653&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">25761518</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimojo M, Takuwa H, Takado Y, Tokunaga M, Tsukamoto S, Minatohara K, Ono M, Seki C, Maeda J, Urushihata T, et al. (2020). Selective disruption of inhibitory synapses leading to neuronal hyperexcitability at an early stage of tau pathogenesis in a mouse model. J. Neurosci 40, 3491&#x2013;3501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7178904</ArticleId><ArticleId IdType="pubmed">32265258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohal VS, and Rubenstein JLR (2019). Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders. Mol. Psychiatry 24, 1248&#x2013;1257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742424</ArticleId><ArticleId IdType="pubmed">31089192</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn PD, Huang CT, Yan R, Fan L, Tracy TE, Camargo CM, Montgomery KM, Arhar T, Mok SA, Freilich R, et al. (2019). Pathogenic tau impairs axon initial segment plasticity and excitability homeostasis. Neuron 104, 458&#x2013;470.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6880876</ArticleId><ArticleId IdType="pubmed">31542321</ArticleId></ArticleIdList></Reference><Reference><Citation>Staley K (2015). Molecular mechanisms of epilepsy. Nat. Neurosci 18, 367&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4409128</ArticleId><ArticleId IdType="pubmed">25710839</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai C, Abe Y, Westenbroek RE, Scheuer T, and Catterall WA (2014). Impaired excitability of somatostatin- and parvalbumin-expressing cortical interneurons in a mouse model of Dravet syndrome. Proc. Natl. Acad. Sci. USA 111, E3139&#x2013;E3148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4121787</ArticleId><ArticleId IdType="pubmed">25024183</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai C, Chang CW, Yu GQ, Lopez I, Yu X, Wang X, Guo W, and Mucke L (2020). Tau reduction prevents key features of autism in mouse models. Neuron 106, 421&#x2013;437.e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7210056</ArticleId><ArticleId IdType="pubmed">32126198</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuchman R, Cuccaro M, and Alessandri M (2010). Autism and epilepsy: historical perspective. Brain Dev. 32, 709&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">20510557</ArticleId></ArticleIdList></Reference><Reference><Citation>Tukker AM, Bouwman LMS, van Kleef RGDM, Hendriks HS, Legler J, and Westerink RHS (2020). Perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) acutely affect human &#x3b1;1-&#x3b2;2&#x3b3;2L GABAA receptor and spontaneous neuronal network function in vitro. Sci. Rep 10, 5311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7093421</ArticleId><ArticleId IdType="pubmed">32210279</ArticleId></ArticleIdList></Reference><Reference><Citation>VandeVrede L, Boxer AL, and Polydoro M (2020). Targeting tau: Clinical trials and novel therapeutic approaches. Neurosci. Lett 731, 134919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212860</ArticleId><ArticleId IdType="pubmed">32380145</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, et al. (2012). Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149, 708&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Ranasinghe KG, Beagle AJ, Mizuiri D, Honma SM, Dowling AF, Darwish SM, Van Berlo V, Barnes DE, Mantle M, et al. (2016). Incidence and impact of subclinical epileptiform activity in Alzheimer&#x2019;s disease. Ann. Neurol 80, 858&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5177487</ArticleId><ArticleId IdType="pubmed">27696483</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler JM, McMillan PJ, Hawk M, Iba M, Robinson L, Xu GJ, Dombroski BA, Jeong D, Dichter MA, Juul H, et al. (2015). High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration. Acta Neuropathol. Commun 3, 33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4453289</ArticleId><ArticleId IdType="pubmed">26041339</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamuro K, Bicks LK, Leventhal MB, Kato D, Im S, Flanigan ME, Garkun Y, Norman KJ, Caro K, Sadahiro M, et al. (2020). A prefrontal-paraventricular thalamus circuit requires juvenile social experience to regulate adult sociability in mice. Nat. Neurosci 23, 1240&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7898783</ArticleId><ArticleId IdType="pubmed">32868932</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. (2014). An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci 34, 11929&#x2013;11947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MS, Li G, et al. (2016). Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89, 37&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Li HL, Tian N, Liu F, Wang L, Yin Y, Yue L, Ma L, Wan Y, and Wang JZ (2020). Interneuron accumulation of phosphorylated tau impairs adult hippocampal neurogenesis by suppressing GABAergic transmission. Cell Stem Cell 26, 331&#x2013;345.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">31978364</ArticleId></ArticleIdList></Reference><Reference><Citation>Zott B, Simon MM, Hong W, Unger F, Chen-Engerer HJ, Frosch MP, Sakmann B, Walsh DM, and Konnerth A (2019).A vicious cycle of &#x3b2; amyloid-dependent neuronal hyperactivation. Science 365, 559&#x2013;565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6690382</ArticleId><ArticleId IdType="pubmed">31395777</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34694957</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1748-2631</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International journal of qualitative studies on health and well-being</Title><ISOAbbreviation>Int J Qual Stud Health Well-being</ISOAbbreviation></Journal><ArticleTitle>The impact of dance activities on the health of persons with Parkinson's disease in Sweden.</ArticleTitle><Pagination><StartPage>1992842</StartPage><MedlinePgn>1992842</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1992842</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/17482631.2021.1992842</ELocationID><Abstract><AbstractText><b>Purpose:</b> Parkinson's disease (PD) is associated with motor and non-motor symptoms that negatively influence the person's quality of life. To reduce illness and increase quality of life, alternative treatments of PD such as dance might be experienced as beneficial. The aim of this study was to explore experiences of how a dance program in Sweden influences perceived physical, social, and emotional wellbeing in persons with PD.<b>Method:</b> A qualitative method with semi-structured interviews and content analysis was used, and 10 participants with variations in age, gender, and how long they had been diagnosed with the disease were interviewed.<b>Results:</b> The results showed that dancing was experienced as improving health, which implied feeling both calmed and excited, getting better sleep, and being able to move with more focus and freedom. The dance program was experienced as a social context through the importance of community, feelings of togetherness, and being able to compare oneself with others. Experiences of self-support included experiencing increased self-esteem and joy, but also a sense of being confirmed and having structure, which gave meaning to everyday life.<b>Conclusions:</b> To reduce illness and increase quality of life in persons with PD, it is important to investigate alternative treatment methods, and this study shows the importance of participating in a dance program in Sweden for the life situation and health of people with PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gyrling</LastName><ForeName>Therese</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>School of Health and Welfare, Halmstad University, Halmstad, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ljunggren</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Health and Welfare, Halmstad University, Halmstad, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karlsson</LastName><ForeName>Staffan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6624-9963</Identifier><AffiliationInfo><Affiliation>School of Health and Welfare, Halmstad University, Halmstad, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Science, Kristianstad University, Kristianstad, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Qual Stud Health Well-being</MedlineTA><NlmUniqueID>101256506</NlmUniqueID><ISSNLinking>1748-2623</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005610" MajorTopicYN="N">Freedom</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dance</Keyword><Keyword MajorTopicYN="N">health</Keyword><Keyword MajorTopicYN="N">parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">qualitative study</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>25</Day><Hour>17</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34694957</ArticleId><ArticleId IdType="pmc">PMC8547839</ArticleId><ArticleId IdType="doi">10.1080/17482631.2021.1992842</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Apeldorf, W. J., &amp; Alexopoulos, G. S. (2003). Late life mood disorders. Principles of geriatric medicine and gerontology (5th ed.). McGraw-Hill.</Citation></Reference><Reference><Citation>Barker, P. J., &amp; Buchanan-Barker, P. (2005). The tidal model- a guide for mental health professionals. Routledge.</Citation></Reference><Reference><Citation>Barker, P. J. (2002). Doing what needs to be done: A respectful response to burnard and grant. Journal of Psychiatric and Mental Health Nursing, 9 2 , 232&#x2013;10 10.1046/j.1365-2850.2002.00004.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2850.2002.00004.x</ArticleId><ArticleId IdType="pubmed">11966996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bath, P. A., &amp; Gardiner, A. (2005). Social engagement and health and social care use and medication use among older people. European Journal of Ageing, 2(1), 56&#x2013;63. 10.1007/s10433-005-0022-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10433-005-0022-9</ArticleId><ArticleId IdType="pmc">PMC5547669</ArticleId><ArticleId IdType="pubmed">28794717</ArticleId></ArticleIdList></Reference><Reference><Citation>Bek, J., Arakaki, A. I., Lawrence, A., Sullivan, M., Ganapathy, G., &amp; Poliakoff, E. (2020). Dance and Parkinson&#x2019;s: A review and exploration of the role of cognitive representations of action. Neuroscience and Biobehavioral Reviews, 109, 16&#x2013;28. 10.1016/j.neubiorev.2019.12.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2019.12.023</ArticleId><ArticleId IdType="pubmed">31846651</ArticleId></ArticleIdList></Reference><Reference><Citation>Bognar, S., DeFaria, A. M., O&#x2019;Dwyer, C., Pankiw, E., Simic Bogler, J., Teixeria, S., Nyhof-Young, J., &amp; Evans, C. (2017). More than just dancing: Experiences of people with parkinson&#x2019;sdisease in a therapeutic dance program. Disability and Rehabilitation, 39(11), 1073&#x2013;1078. 10.1080/09638288.2016.1175037</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09638288.2016.1175037</ArticleId><ArticleId IdType="pubmed">27216230</ArticleId></ArticleIdList></Reference><Reference><Citation>Carapellotti A M, Stevenson R, Doumas M and Bayer A. (2020). The efficacy of dance for improving motor impairments, non-motor symptoms, and quality of life in Parkinson&#x2019;s disease: A systematic review and meta-analysis. PLoS ONE, 15(8), e0236820 doi: 10.1371/journal.pone.0236820</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0236820</ArticleId><ArticleId IdType="pmc">PMC7406058</ArticleId><ArticleId IdType="pubmed">32756578</ArticleId></ArticleIdList></Reference><Reference><Citation>Carod-Artal, F. J., Ziomkowski, S., Mour&#xe3;o Mesquita, H., &amp; Mart&#xed;nez-Martin, P. (2008). Anxiety and depression: Main determinants of health-related quality of life in brazilian patients with parkinson&#x2019;s disease. Parkinsonism &amp; Related Disorders, 14(2), 102&#x2013;108. 10.1016/j.parkreldis.2007.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2007.06.011</ArticleId><ArticleId IdType="pubmed">17719828</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke, C. E. (2007). Parkinson&#x2019;s disease. BMJ: British Medical Journal, 335(7617), 441&#x2013;445. 10.1136/bmj.39289.437454.AD</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39289.437454.AD</ArticleId><ArticleId IdType="pmc">PMC1962892</ArticleId><ArticleId IdType="pubmed">17762036</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtin, E., &amp; Knapp, M. (2017). Social isolation, loneliness and health in old age: A scoping review. Health &amp; Social Care in the Community, 25(3), 799&#x2013;812. 10.1111/hsc.12311</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hsc.12311</ArticleId><ArticleId IdType="pubmed">26712585</ArticleId></ArticleIdList></Reference><Reference><Citation>Danielsson, E. (2017). Kvalitativ forskningsintervju. In Henricson M. (Ed.), Vetenskaplig teori och metod: Fr&#xe5;n id&#xe9; till examination inom omv&#xe5;rdnad (2nd ed., pp. 143&#x2013;154). Studentlitteratur.</Citation></Reference><Reference><Citation>Duncan, R. P., &amp; Earhart, G. M. (2011). Measuring participation in individuals with Parkinson disease: Relationships with disease severity, quality of life, and mobility. Disability and Rehabilitation, 33(15&#x2013;16), 1440&#x2013;1446. 10.3109/09638288.2010.533245</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/09638288.2010.533245</ArticleId><ArticleId IdType="pubmed">21091047</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox, K. (1999). The influence of physical activity on mental well-being. Public Health Nutrition, 2(3a), 411&#x2013;418. 10.1017/S1368980099000567</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1368980099000567</ArticleId><ArticleId IdType="pubmed">10610081</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenklach, A. (2016). Management of depression in Parkinson&#x2019;s disease. American Journal of Psychiatry Residents&#x2018; Journal, 11(4), 8&#x2013;11. 10.1176/appi.ajp-rj.2016.110405</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp-rj.2016.110405</ArticleId></ArticleIdList></Reference><Reference><Citation>Graneheim, U., &amp; Lundman, B. (2004). Qualitative content analysis in nursing research: Concepts, procedures and measures to achieve trustworthiness. Nurse Education Today, 24(2), 105&#x2013;112. 10.1016/j.nedt.2003.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nedt.2003.10.001</ArticleId><ArticleId IdType="pubmed">14769454</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackney, M. E., &amp; Bennett, C. (2014). Dance therapy for individuals with Parkinson&#x2019;s disease: Improving quality of life. Research and Reviews in Parkinsonism, (2014(4), 17&#x2013;25. 10.2147/JPRLS.S40042</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JPRLS.S40042</ArticleId></ArticleIdList></Reference><Reference><Citation>Hackney, M. E., &amp; Earhart, G. M. (2009). Health related quality of life and alternative forms of exercise in Parkinson&#x2019;s disease. Parkinsonism &amp; Related Disorders, 15(9), 644&#x2013;648. 10.1016/j.parkreldis.2009.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2009.03.003</ArticleId><ArticleId IdType="pmc">PMC2783812</ArticleId><ArticleId IdType="pubmed">19329350</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto, H., Takabatake, S., Miyaguchi, H., Nakanishi, H., &amp; Naitou, Y. (2015). Effects of dance on motor functions, cognitive functions, and mental symptoms of Parkinson&#x2019;s disease: A quasi-randomized pilot trial. Complementary Therapies in Medicine, 23(2), 210&#x2010;219. 10.1016/j.ctim.2015.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctim.2015.01.010</ArticleId><ArticleId IdType="pubmed">25847558</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiberger, L., Maurer, C., Amtage, F., Mendez-Balbuena, I., Schulte-M&#xf6;nting, J., Hepp- Reymond, M. C., &amp; Kristeva, R. (2011). Impact of a weekly dance class on the functional mobility and on the quality of life of individuals with Parkinson&#x2019;s disease. Frontiers in Aging Neuroscience, 3, 1&#x2013;15. 10.3389/fnagi.2011.00014</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2011.00014</ArticleId><ArticleId IdType="pmc">PMC3189543</ArticleId><ArticleId IdType="pubmed">22013420</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes, W. M., &amp; Hackney, M. E. (2017). Adapted tango for adults with Parkinson&#x2019;s disease: A qualitative study. Adapted Physical Activity Quarterly, 34(3), 256&#x2013;275. 10.1123/apaq.2015-0113</Citation><ArticleIdList><ArticleId IdType="doi">10.1123/apaq.2015-0113</ArticleId><ArticleId IdType="pubmed">28727513</ArticleId></ArticleIdList></Reference><Reference><Citation>Houston, S., &amp; McGill, A. (2013). A mixed-methods study into ballet for people living with Parkinson&#x2019;s. Arts &amp; Health, 5(2), 103&#x2013;119. 10.1080/17533015.2012.745580</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17533015.2012.745580</ArticleId><ArticleId IdType="pmc">PMC3687249</ArticleId><ArticleId IdType="pubmed">23805165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang, M., &amp; Ellis-Hill, C. (2015). How do people live life successfully with Parkinson&#x2019;s disease? Journal of Clinical Nursing, 24(15&#x2013;16), 2314&#x2013;2322. 10.1111/jocn.12819</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocn.12819</ArticleId><ArticleId IdType="pubmed">25939827</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiepe, M., St&#xf6;ckigt, B., &amp; Keil, T. (2012). Effects of dance therapy and ballroom dances on physical and mental illnesses: A systematic review. The Arts in Psychotherapy, 39(5), 404&#x2013;411. 10.1016/j.aip.2012.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aip.2012.06.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjellstr&#xf6;m, S. (2017). Forskningsetik. In M. Henricson. In Vetenskaplig teori och metod fr&#xe5;n id&#xe9; till examination inom omv&#xe5;rdnad (2nd ed., pp. 69&#x2013;92). Studentlitteratur.</Citation></Reference><Reference><Citation>Lee, J., Choi, M., &amp; Yoo, Y. (2017). A meta-analysis of nonpharmacological interventions for people with Parkinson&#x2019;s disease. Clinical Nursing Research, 26(5), 608. 10.1177/1054773816655091</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1054773816655091</ArticleId><ArticleId IdType="pubmed">27318243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis, C., Annett, L. E., Davenport, S., Hall, A. A., &amp; Lovatt, P. (2016). Mood changes following social dance sessions in people with Parkinson&#xb4;s disease. Journal of Health Psychology, 21(4), 483&#x2013;492. 10.1177/1359105314529681</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1359105314529681</ArticleId><ArticleId IdType="pubmed">24752558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundman, B., &amp; H&#xe4;llgren-Graneheim, U. H. (2012). Kvalitativ inneh&#xe5;llsanalys. In Gransk&#xe4;r M. &amp; H&#xf6;glund-Nielsen B. (Eds.), Till&#xe4;mpad kvalitativ forskning inom h&#xe4;lso- och sjukv&#xe5;rd (2. ed., pp. 187&#x2013;201). Studentlitteratur.</Citation></Reference><Reference><Citation>McKee, K. E., &amp; Hackney, M. E. (2013). The effects of adapted tango on spatial cognition and disease severity in Parkinson&#x2019;s disease. Journal of Motor Behavior, 45(6), 519&#x2013;529. 10.1080/00222895.2013.834288</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00222895.2013.834288</ArticleId><ArticleId IdType="pmc">PMC3864026</ArticleId><ArticleId IdType="pubmed">24116748</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeely, M. E., Duncan, R. P., &amp; Earhart, G. M. (2015). Impacts of dance on non-motor symtoms, participation, and quality of life in Parkinson disease and healthy older adults. Maturitas, 82(4), 336&#x2013;341. 10.1016/j.maturitas.2015.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.maturitas.2015.08.002</ArticleId><ArticleId IdType="pmc">PMC4648639</ArticleId><ArticleId IdType="pubmed">26318265</ArticleId></ArticleIdList></Reference><Reference><Citation>Murrock, C. J., &amp; Graor, C. H. (2016). Depression, social isolation, and the lived experience of dancing disadvantaged adults. Archives of Psychiatric Nursing, 30(1), 27&#x2013;34. 10.1016/j.apnu.2015.10.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apnu.2015.10.010</ArticleId><ArticleId IdType="pubmed">26804498</ArticleId></ArticleIdList></Reference><Reference><Citation>National Board of Health and Welfare . (2016). Nationella riktlinjer f&#xf6;r v&#xe5;rd vid multipel skleros och Parkinsons sjukdom &#x2013; St&#xf6;d f&#xf6;r styrning och ledning (National guidelines for care in multiple sclerosis and Parkinson&#x2019;s disease - Support for management and guidance).</Citation></Reference><Reference><Citation>Nicoletti, A., Mostile, G., Stocchi, F., Abbruzzese, G., Ceravolo, R., Cortelli, P., D&#x2019;Amelio, M., De Pandis, M., Fabbrini, G., Pacchetti, C., Pezzoli, G., Tessitore, A., Canesi, M., Zappia, M., &amp; De Castro, F. (2017). Factors influencing psychological well-being in patients with Parkinson&#x2019;s disease. PLoS ONE, 12(12), e0189682. 10.1371/journal.pone.0189682</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0189682</ArticleId><ArticleId IdType="pmc">PMC5731732</ArticleId><ArticleId IdType="pubmed">29244834</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donahue, W. T., &amp; Cummings, N. A. (2011). Evidenced-based adjunctive treatments. Elsevier Academic Press.</Citation></Reference><Reference><Citation>Ossowska, K., &amp; Lorenc-Koci, E. (2013). Review: Depression in Parkinson&#x2019;s disease. Pharmacological Reports, 65(6), 1545&#x2013;1557. 10.1016/S1734-1140(13)71516-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1734-1140(13)71516-0</ArticleId><ArticleId IdType="pubmed">24553003</ArticleId></ArticleIdList></Reference><Reference><Citation>Papapetropoulos, S., Ellul, J., Argyriou, A. A., Chroni, E., &amp; Lekka, N. P. (2006). The effect of depression on motor function and disease severity of Parkinson&#x2019;s disease. Clinical Neurology And Neurosurgery, 108(5), 465&#x2013;469. 10.1016/j.clineuro.2005.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2005.08.002</ArticleId><ArticleId IdType="pubmed">16150537</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasco, J., Williams, L., Jacka, F., Henry, M., Coulson, C., Brennan, S., Leslie, E., Nicholson, G., Kotowicz, M., &amp; Berk, M. (2011). Habitual physical activity and the risk for depressive and anxiety disorders among older men and women. International Psychogeriatrics, 23(2), 292&#x2013;298. 10.1017/S1041610210001833</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1041610210001833</ArticleId><ArticleId IdType="pubmed">20863424</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieto, L., Norris, M. L., &amp; Columna, L. (2021). &#x201c;Keep moving&#x201d;: Experiences of people with Parkinson&#x2019;s and their care partners in a dance class. Adapted Physical Activity Quarterly, 38(2), 307&#x2013;328. 10.1123/apaq.2019-0125</Citation><ArticleIdList><ArticleId IdType="doi">10.1123/apaq.2019-0125</ArticleId><ArticleId IdType="pubmed">33596544</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha, P. A., Slade, S. C., McClelland, J., &amp; Morris, M. E. (2017). Dance is more than therapy: Qualitative analysis on therapeutic dancing classes for Parkinson&#x2019;s. Complementary Therapies in Medicine, 34, 1&#x2013;9. 10.1016/j.ctim.2017.07.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctim.2017.07.006</ArticleId><ArticleId IdType="pubmed">28917359</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan, R. M., &amp; Deci, E. L. (2001). On happiness and human potentials: A review of research on hedonic and eudaimonic well-being. Annual Review of Psychology, 52(1), 141. 10.1146/annurev.psych.52.1.141</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.psych.52.1.141</ArticleId><ArticleId IdType="pubmed">11148302</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz, R., &amp; Pell, M. D. (2017). When emotion and expression diverge: The social costs of Parkinson&#x2019;s disease. Journal of Clinical and Experimental Neuropsychology, 39(3), 211&#x2013;230. 10.1080/13803395.2016.1216090</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13803395.2016.1216090</ArticleId><ArticleId IdType="pubmed">27548715</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp, K., &amp; Hewitt, J. (2014). Dance as an intervention for people with Parkinson&#x2019;s disease: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 47, 445&#x2013;456. 10.1016/j.neubiorev.2014.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2014.09.009</ArticleId><ArticleId IdType="pubmed">25268548</ArticleId></ArticleIdList></Reference><Reference><Citation>Str&#xf6;hle, A. (2009). Physical activity, exercise, depression and anxiety disorders. Journal of Neural Transmission, 116(6), 777. 10.1007/s00702-008-0092-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-008-0092-x</ArticleId><ArticleId IdType="pubmed">18726137</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;umec, R., Filip, P., Sheardov&#xe1;, K., &amp; Bare&#x161;, M. (2015). Psychological benefits of nonpharmacological methods aimed for improving balance in Parkinson&#x2019;s disease: A systematic review. Behavioural Neurology, (2015, 620674. https://ezproxy.bib.hh.se/docview/1710260906?accountid=11261</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4508472</ArticleId><ArticleId IdType="pubmed">26236107</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura, M. I., Barnes, D. E., Ross, J. M., Lanni, K. E., Sigvardt, K. A., &amp; Disbrow, E. A. (2016). A pilot study to evaluate multidimensional effects of dance for people with Parkinson&#x2019;s disease. Contemporary Clinical Trials, 51, 50&#x2013;55. 10.1016/j.cct.2016.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cct.2016.10.001</ArticleId><ArticleId IdType="pmc">PMC5108673</ArticleId><ArticleId IdType="pubmed">27765693</ArticleId></ArticleIdList></Reference><Reference><Citation>Westheimer, O., McRae, C., Henchcliffe, C., Fesharaki, A., Glazman, S., Ene, H., &amp; Bodis- Wollner, I. (2015). Dance for PD: A preliminary investigation of effects on motor function and quality of life among persons with Parkinson&#x2019;s disease (PD). Journal of Neural Transmission, 122(9), 1263&#x2013;1270. 10.1007/s00702-015-1380-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-015-1380-x</ArticleId><ArticleId IdType="pubmed">25836752</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO) . (1948). Constitution of WHO: Principles.</Citation></Reference><Reference><Citation>Zhang Q, Hu J, Wei L, Jia Y and Jin Y. (2019). Effects of dance therapy on cognitive and mood symptoms in people with Parkinson's disease: A systematic review and meta-analysis. Complementary Therapies in Clinical Practice, 36 12&#x2013;17. 10.1016/j.ctcp.2019.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctcp.2019.04.005</ArticleId><ArticleId IdType="pubmed">31383428</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34694344</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Long-term Risk of Parkinson Disease Following Influenza and Other Infections.</ArticleTitle><Pagination><StartPage>1461</StartPage><EndPage>1470</EndPage><MedlinePgn>1461-1470</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.3895</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Influenza has been associated with the risk of developing Parkinson disease, but the association is controversial.</AbstractText><AbstractText Label="OBJECTIVE">To examine whether prior influenza and other infections are associated with Parkinson disease more than 10 years after infection.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This case-control study used data from 1977 to 2016 from the Danish National Patient Registry. All individuals with Parkinson disease, excluding those with drug-induced parkinsonism, were included and matched to 5 population controls on sex, age, and date of Parkinson diagnosis. Data were analyzed from December 2019 to September 2021.</AbstractText><AbstractText Label="EXPOSURES">Infections were ascertained between 1977 and 2016 and categorized by time from infection to Parkinson disease diagnosis. To increase specificity of influenza diagnoses, influenza exposure was restricted to months of peak influenza activity.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Parkinson disease diagnoses were identified between January 1, 2000, and December 31, 2016. Crude and adjusted odds ratios (ORs) and 95% CIs were calculated by conditional logistic regression overall and stratified by time between infection and Parkinson disease (5 years or less, more than 5 to 10 years, more than 10 years).</AbstractText><AbstractText Label="RESULTS">Of 61&#x202f;626 included individuals, 23&#x202f;826 (38.7%) were female, and 53&#x202f;202 (86.3%) were older than 60 years. A total of 10&#x202f;271 individuals with Parkinson disease and 51&#x202f;355 controls were identified. Influenza diagnosed at any time during a calendar year was associated with Parkinson disease more than 10 years later (OR, 1.73; 95% CI, 1.11-2.71). When influenza exposure was restricted to months of highest influenza activity, an elevated OR with a wider confidence interval was found (OR, 1.52; 95% CI, 0.80-2.89). There was no evidence of an association with any type of infection more than 10 years prior to Parkinson disease (OR, 1.04; 95% CI, 0.98-1.10). Several specific infections yielded increased odds of Parkinson disease within 5 years of infection, but results were null when exposure occurred more than 10 years prior.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this case-control study, influenza was associated with diagnoses of Parkinson disease more than 10 years after infection. These observational data suggest a link between influenza and Parkinson disease but do not demonstrate causality. While other infections were associated with Parkinson disease diagnoses soon after infection, null associations after more than 10 years suggest these shorter-term associations are not causal.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cocoros</LastName><ForeName>Noelle M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svensson</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Danish Clinical Quality Program, National Clinical Registries, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sz&#xe9;pligeti</LastName><ForeName>Szimonetta Komj&#xe1;thine</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vestergaard</LastName><ForeName>S&#xf8;ren Viborg</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szentk&#xfa;ti</LastName><ForeName>P&#xe9;ter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomsen</LastName><ForeName>Reimar W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borghammer</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine and PET, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;rensen</LastName><ForeName>Henrik Toft</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Excellence Research Center, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Victor W</ForeName><Initials>VW</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Population Health, Stanford University, Stanford, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG059307</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Svensson has received funding from the Augustinus Foundation. Dr Vestergaard has received grants from Lundbeck Foundation and Augustinus Foundation. Dr Henderson has received grants from the National Institutes of Health and personal fees from the National Institutes of Health, Canadian Consortium on Neurodegeneration in Aging, and Aarhus University. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34694344</ArticleId><ArticleId IdType="pmc">PMC8546623</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.3895</ArticleId><ArticleId IdType="pii">2785029</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Postuma RB, Berg D, Stern M, et al. . MDS clinical diagnostic criteria for Parkinson&#x2019;s disease. Mov Disord. 2015;30(12):1591-1601. doi:10.1002/mds.26424</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26424</ArticleId><ArticleId IdType="pubmed">26474316</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson&#x2019;s disease: a review of the evidence. Eur J Epidemiol. 2011;26(suppl 1):S1-S58. doi:10.1007/s10654-011-9581-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-011-9581-6</ArticleId><ArticleId IdType="pubmed">21626386</ArticleId></ArticleIdList></Reference><Reference><Citation>Tysnes OB, Storstein A. Epidemiology of Parkinson&#x2019;s disease. J Neural Transm (Vienna). 2017;124(8):901-905. doi:10.1007/s00702-017-1686-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-017-1686-y</ArticleId><ArticleId IdType="pubmed">28150045</ArticleId></ArticleIdList></Reference><Reference><Citation>Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson&#x2019;s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583-1590. doi:10.1002/mds.25945</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25945</ArticleId><ArticleId IdType="pubmed">24976103</ArticleId></ArticleIdList></Reference><Reference><Citation>Vestergaard SV, Rasmussen TB, Stallknecht S, et al. . Occurrence, mortality and cost of brain disorders in Denmark: a population-based cohort study. BMJ Open. 2020;10(11):e037564. doi:10.1136/bmjopen-2020-037564</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-037564</ArticleId><ArticleId IdType="pmc">PMC7674107</ArticleId><ArticleId IdType="pubmed">33208323</ArticleId></ArticleIdList></Reference><Reference><Citation>von Campenhausen S, Bornschein B, Wick R, et al. . Prevalence and incidence of Parkinson&#x2019;s disease in Europe. Eur Neuropsychopharmacol. 2005;15(4):473-490. doi:10.1016/j.euroneuro.2005.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2005.04.007</ArticleId><ArticleId IdType="pubmed">15963700</ArticleId></ArticleIdList></Reference><Reference><Citation>Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Time trends in the incidence of Parkinson disease. JAMA Neurol. 2016;73(8):981-989. doi:10.1001/jamaneurol.2016.0947</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.0947</ArticleId><ArticleId IdType="pmc">PMC5004732</ArticleId><ArticleId IdType="pubmed">27323276</ArticleId></ArticleIdList></Reference><Reference><Citation>Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol. 2010;67(7):798-801. doi:10.1001/archneurol.2010.135</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.135</ArticleId><ArticleId IdType="pubmed">20625084</ArticleId></ArticleIdList></Reference><Reference><Citation>Limphaibool N, Iwanowski P, Holstad MJV, Kobylarek D, Kozubski W. Infectious etiologies of parkinsonism: pathomechanisms and clinical implications. Front Neurol. 2019;10:652. doi:10.3389/fneur.2019.00652</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00652</ArticleId><ArticleId IdType="pmc">PMC6593078</ArticleId><ArticleId IdType="pubmed">31275235</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen LK, Dowd E, McKernan DP. A role for viral infections in Parkinson&#x2019;s etiology? Neuronal Signal. 2018;2(2):NS20170166. doi:10.1042/NS20170166</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/NS20170166</ArticleId><ArticleId IdType="pmc">PMC7373231</ArticleId><ArticleId IdType="pubmed">32714585</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore G. Influenza and Parkinson&#x2019;s disease. Public Health Rep. 1977;92(1):79-80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1431968</ArticleId><ArticleId IdType="pubmed">834846</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry J, Smeyne RJ, Jang H, Miller B, Okun MS. Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries. Parkinsonism Relat Disord. 2010;16(9):566-571. doi:10.1016/j.parkreldis.2010.06.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2010.06.012</ArticleId><ArticleId IdType="pmc">PMC4684089</ArticleId><ArticleId IdType="pubmed">20650672</ArticleId></ArticleIdList></Reference><Reference><Citation>Poskanzer DC, Schwab RS. Cohort analysis of Parkinson&#x2019;s syndrome: evidence for a single etiology related to subclinical infection about 1920. J Chronic Dis. 1963;16(9):961-973. doi:10.1016/0021-9681(63)90098-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(63)90098-5</ArticleId><ArticleId IdType="pubmed">14066517</ArticleId></ArticleIdList></Reference><Reference><Citation>Dourmashkin RR. What caused the 1918-30 epidemic of encephalitis lethargica? J R Soc Med. 1997;90(9):515-520. doi:10.1177/014107689709000916</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/014107689709000916</ArticleId><ArticleId IdType="pmc">PMC1296535</ArticleId><ArticleId IdType="pubmed">9370993</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond M, Bechter K, M&#xfc;ller N, Tebartz van Elst L, Meier U-C. A role for pathogen risk factors and autoimmunity in encephalitis lethargica? Prog Neuropsychopharmacol Biol Psychiatry. 2021;109:110276. doi:10.1016/j.pnpbp.2021.110276</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2021.110276</ArticleId><ArticleId IdType="pubmed">33549696</ArticleId></ArticleIdList></Reference><Reference><Citation>Estupinan D, Nathoo S, Okun MS. The demise of Poskanzer and Schwab&#x2019;s influenza theory on the pathogenesis of Parkinson&#x2019;s disease. Parkinsons Dis. 2013;2013:167843. doi:10.1155/2013/167843</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/167843</ArticleId><ArticleId IdType="pmc">PMC3693163</ArticleId><ArticleId IdType="pubmed">23853734</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeyne RJ, Noyce AJ, Byrne M, Savica R, Marras C. Infection and risk of Parkinson&#x2019;s disease. J Parkinsons Dis. 2021;11(1):31-43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7990414</ArticleId><ArticleId IdType="pubmed">33361610</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Schmidt SAJ, Adelborg K, et al. . The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563-591. doi:10.2147/CLEP.S179083</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S179083</ArticleId><ArticleId IdType="pmc">PMC6634267</ArticleId><ArticleId IdType="pubmed">31372058</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Pedersen L, S&#xf8;rensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541-549. doi:10.1007/s10654-014-9930-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-014-9930-3</ArticleId><ArticleId IdType="pubmed">24965263</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, S&#xf8;rensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449-490. doi:10.2147/CLEP.S91125</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S91125</ArticleId><ArticleId IdType="pmc">PMC4655913</ArticleId><ArticleId IdType="pubmed">26604824</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesdottir SA, Horv&#xe1;th-Puh&#xf3; E, Ehrenstein V, Schmidt M, Pedersen L, S&#xf8;rensen HT. Existing data sources for clinical epidemiology: the Danish National Database of Reimbursed Prescriptions. Clin Epidemiol. 2012;4:303-313. doi:10.2147/CLEP.S37587</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S37587</ArticleId><ArticleId IdType="pmc">PMC3508607</ArticleId><ArticleId IdType="pubmed">23204870</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H-S, Lobbestael E, Vermeire S, Sabino J, Cleynen I. Inflammatory bowel disease and Parkinson&#x2019;s disease: common pathophysiological links. Gut. 2021;70(2):408-417.</Citation><ArticleIdList><ArticleId IdType="pubmed">33067333</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs BM, Belete D, Bestwick J, et al. . Parkinson&#x2019;s disease determinants, prediction and gene-environment interactions in the UK Biobank. J Neurol Neurosurg Psychiatry. 2020;91(10):1046-1054. doi:10.1136/jnnp-2020-323646</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323646</ArticleId><ArticleId IdType="pmc">PMC7509524</ArticleId><ArticleId IdType="pubmed">32934108</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Li W, Liu G, Shen X, Tang Y. Association between cigarette smoking and Parkinson&#x2019;s disease: a meta-analysis. Arch Gerontol Geriatr. 2015;61(3):510-516. doi:10.1016/j.archger.2015.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archger.2015.08.004</ArticleId><ArticleId IdType="pubmed">26272284</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritz B, Ascherio A, Checkoway H, et al. . Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol. 2007;64(7):990-997. doi:10.1001/archneur.64.7.990</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.7.990</ArticleId><ArticleId IdType="pubmed">17620489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferini-Strambi L, Oertel W, Dauvilliers Y, et al. . Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case-control study. J Neurol. 2014;261(6):1112-1118. doi:10.1007/s00415-014-7317-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-014-7317-8</ArticleId><ArticleId IdType="pubmed">24687894</ArticleId></ArticleIdList></Reference><Reference><Citation>Su CM, Kung CT, Chen FC, et al. . Manifestations and outcomes of patients with Parkinson&#x2019;s disease and serious infection in the emergency department. Biomed Res Int. 2018;2018:6014896. doi:10.1155/2018/6014896</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/6014896</ArticleId><ArticleId IdType="pmc">PMC6207881</ArticleId><ArticleId IdType="pubmed">30417011</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerlach OH, Winogrodzka A, Weber WE. Clinical problems in the hospitalized Parkinson&#x2019;s disease patient: systematic review. Mov Disord. 2011;26(2):197-208. doi:10.1002/mds.23449</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23449</ArticleId><ArticleId IdType="pmc">PMC3130138</ArticleId><ArticleId IdType="pubmed">21284037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg D. The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care. 2013;19(10)(suppl):s191-s196.</Citation><ArticleIdList><ArticleId IdType="pubmed">24495240</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers MA, Fries BE, Kaufman SR, Mody L, McMahon LF Jr, Saint S. Mobility and other predictors of hospitalization for urinary tract infection: a retrospective cohort study. BMC Geriatr. 2008;8:31. doi:10.1186/1471-2318-8-31</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2318-8-31</ArticleId><ArticleId IdType="pmc">PMC2605742</ArticleId><ArticleId IdType="pubmed">19032784</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan A, Balakrishnan P, Patel A, et al. . Epidemiology of inpatient stay in Parkinson&#x2019;s disease in the United States: insights from the Nationwide Inpatient Sample. J Clin Neurosci. 2016;31:162-165. doi:10.1016/j.jocn.2016.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2016.03.005</ArticleId><ArticleId IdType="pubmed">27242063</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Ramirez D, Velazquez-Avila ES, Almaraz-Espinoza A, et al. . Lower urinary tract and gastrointestinal dysfunction are common in early Parkinson&#x2019;s disease. Parkinsons Dis. 2020;2020:1694547. doi:10.1155/2020/1694547</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/1694547</ArticleId><ArticleId IdType="pmc">PMC7586173</ArticleId><ArticleId IdType="pubmed">33123339</ArticleId></ArticleIdList></Reference><Reference><Citation>Fereshtehnejad S-M, Yao C, Pelletier A, Montplaisir JY, Gagnon J-F, Postuma RB. Evolution of prodromal Parkinson&#x2019;s disease and dementia with Lewy bodies: a prospective study. Brain. 2019;142(7):2051-2067. doi:10.1093/brain/awz111</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz111</ArticleId><ArticleId IdType="pubmed">31111143</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Gao HM, Hong JS. Parkinson&#x2019;s disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect. 2003;111(8):1065-1073. doi:10.1289/ehp.6361</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/ehp.6361</ArticleId><ArticleId IdType="pmc">PMC1241555</ArticleId><ArticleId IdType="pubmed">12826478</ArticleId></ArticleIdList></Reference><Reference><Citation>Marras C, Lang AE, Austin PC, Lau C, Urbach DR. Appendectomy in mid and later life and risk of Parkinson&#x2019;s disease: a population-based study. Mov Disord. 2016;31(8):1243-1247. doi:10.1002/mds.26670</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26670</ArticleId><ArticleId IdType="pubmed">27241338</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson E, Horv&#xe1;th-Puh&#xf3; E, Stokholm MG, S&#xf8;rensen HT, Henderson VW, Borghammer P. Appendectomy and risk of Parkinson&#x2019;s disease: a nationwide cohort study with more than 10 years of follow-up. Mov Disord. 2016;31(12):1918-1922. doi:10.1002/mds.26761</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26761</ArticleId><ArticleId IdType="pubmed">27621223</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizuka M, Shibuya N, Takagi K, et al. . Appendectomy does not increase the risk of future emergence of Parkinson&#x2019;s disease: a meta-analysis. Am Surg. Published online January 30, 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">33522253</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Liu X, Tan C, et al. . Bacterial, viral, and fungal infection-related risk of Parkinson&#x2019;s disease: meta-analysis of cohort and case-control studies. Brain Behav. 2020;10(3):e01549. doi:10.1002/brb3.1549</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.1549</ArticleId><ArticleId IdType="pmc">PMC7066372</ArticleId><ArticleId IdType="pubmed">32017453</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng L, Shen L, Ji HF. Impact of infection on risk of Parkinson&#x2019;s disease: a quantitative assessment of case-control and cohort studies. J Neurovirol. 2019;25(2):221-228. doi:10.1007/s13365-018-0707-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-018-0707-4</ArticleId><ArticleId IdType="pubmed">30632012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijarnpreecha K, Chesdachai S, Jaruvongvanich V, Ungprasert P. Hepatitis C virus infection and risk of Parkinson&#x2019;s disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30(1):9-13. doi:10.1097/MEG.0000000000000991</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000991</ArticleId><ArticleId IdType="pubmed">29049127</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurizi CP. Influenza caused epidemic encephalitis (encephalitis lethargica): the circumstantial evidence and a challenge to the nonbelievers. Med Hypotheses. 2010;74(5):798-801. doi:10.1016/j.mehy.2009.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2009.12.012</ArticleId><ArticleId IdType="pubmed">20060230</ArticleId></ArticleIdList></Reference><Reference><Citation>Toovey S, Jick SS, Meier CR. Parkinson&#x2019;s disease or Parkinson symptoms following seasonal influenza. Influenza Other Respir Viruses. 2011;5(5):328-333. doi:10.1111/j.1750-2659.2011.00232.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-2659.2011.00232.x</ArticleId><ArticleId IdType="pmc">PMC4942044</ArticleId><ArticleId IdType="pubmed">21668692</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris MA, Tsui JK, Marion SA, Shen H, Teschke K. Association of Parkinson&#x2019;s disease with infections and occupational exposure to possible vectors. Mov Disord. 2012;27(9):1111-1117. doi:10.1002/mds.25077</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25077</ArticleId><ArticleId IdType="pubmed">22753266</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlajinac H, Dzoljic E, Maksimovic J, Marinkovic J, Sipetic S, Kostic V. Infections as a risk factor for Parkinson&#x2019;s disease: a case-control study. Int J Neurosci. 2013;123(5):329-332. doi:10.3109/00207454.2012.760560</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00207454.2012.760560</ArticleId><ArticleId IdType="pubmed">23270425</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattock C, Marmot M, Stern G. Could Parkinson&#x2019;s disease follow intra-uterine influenza?: a speculative hypothesis. J Neurol Neurosurg Psychiatry. 1988;51(6):753-756. doi:10.1136/jnnp.51.6.753</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.51.6.753</ArticleId><ArticleId IdType="pmc">PMC1033143</ArticleId><ArticleId IdType="pubmed">3404182</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebmeier KP, Calder SA, Besson JA. Psychiatric aspects of Parkinson&#x2019;s disease. BMJ. 1989;299(6700):683. doi:10.1136/bmj.299.6700.683</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.299.6700.683</ArticleId><ArticleId IdType="pmc">PMC1837575</ArticleId><ArticleId IdType="pubmed">2508869</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Chen H, Fang F, Tillander A, Wirdefeldt K. Early-life factors and risk of Parkinson&#x2019;s disease: a register-based cohort study. PLoS One. 2016;11(4):e0152841. doi:10.1371/journal.pone.0152841</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0152841</ArticleId><ArticleId IdType="pmc">PMC4833308</ArticleId><ArticleId IdType="pubmed">27082111</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma RB, Wolfson C, Rajput A, et al. . Is there seasonal variation in risk of Parkinson&#x2019;s disease? Mov Disord. 2007;22(8):1097-1101. doi:10.1002/mds.21272</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21272</ArticleId><ArticleId IdType="pubmed">17486603</ArticleId></ArticleIdList></Reference><Reference><Citation>Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020;87:34-39. doi:10.1016/j.bbi.2020.04.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.04.027</ArticleId><ArticleId IdType="pmc">PMC7152874</ArticleId><ArticleId IdType="pubmed">32298803</ArticleId></ArticleIdList></Reference><Reference><Citation>Christiansen CF, Heide-J&#xf8;rgensen U, Rasmussen TB, et al. . Renin-angiotensin system blockers and adverse outcomes of influenza and pneumonia: a Danish cohort study. J Am Heart Assoc. 2020;9(19):e017297. doi:10.1161/JAHA.120.017297</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.017297</ArticleId><ArticleId IdType="pmc">PMC7792378</ArticleId><ArticleId IdType="pubmed">32998607</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34699252</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1937-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>706</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>Science signaling</Title><ISOAbbreviation>Sci Signal</ISOAbbreviation></Journal><ArticleTitle>Activation of PPAR&#x3b1; enhances astroglial uptake and degradation of &#x3b2;-amyloid.</ArticleTitle><Pagination><StartPage>eabg4747</StartPage><MedlinePgn>eabg4747</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scisignal.abg4747</ELocationID><Abstract><AbstractText>Astrocytes are a type of glial cell that are activated in the brain tissue of patients with Alzheimer&#x2019;s disease to induce the accumulation of amyloid (A&#x3b2;). We previously found that a combination of low-dose gemfibrozil (GFB; a drug approved to treat high cholesterol) and retinoic acid (RA; a vitamin A derivative) induces lysosomal bio-genesis through peroxisome proliferator&#x2013;activated receptor &#x3b1; (PPAR&#x3b1;)&#x2013;mediated transcription of the gene encoding transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy. Here, we found that the same combination (GFB-RA) enhanced the uptake of A&#x3b2; from the extracellular space and its subsequent degradation in astrocytes through a PPAR&#x3b1;-dependent pathway. GFB-RA stimulated the abundance of both low-density lipoprotein receptor (LDLR) and TFEB in astrocytes through PPAR&#x3b1;. LDLR was critical for A&#x3b2; uptake, whereas TFEB was critical for its degradation. GFB-RA treatment also increased autophagic flux and lysosomal activity in astrocytes. Consistent with these effects and in a manner dependent on astroglial PPAR&#x3b1;, oral administration of GFB-RA switched astroglial activation to a neuroprotective state, lowered A&#x3b2; burden in the brain, and improved spatial learning and memory in the 5XFAD mouse model of Alzheimer&#x2019;s disease. These findings uncover a new function of PPAR&#x3b1; in stimulating astroglial uptake and degradation of A&#x3b2; and suggest possible repurposing of GFB-RA combination therapy for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raha</LastName><ForeName>Sumita</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6480-7266</Identifier><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Arunava</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8471-8161</Identifier><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dutta</LastName><ForeName>Debashis</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0086-3581</Identifier><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Dhruv R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-5438-1051</Identifier><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pahan</LastName><ForeName>Kalipada</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-6048-9598</Identifier><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IK6 BX004982</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG050431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Signal</MedlineTA><NlmUniqueID>101465400</NlmUniqueID><ISSNLinking>1945-0877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047493">PPAR alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047493" MajorTopicYN="Y">PPAR alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests</b>: KP and AG are inventors on patent application (20200297657) held/submitted by Rush University Medical Center that covers the stimulation of astroglial plaque clearance. The other authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>17</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34699252</ArticleId><ArticleId IdType="mid">NIHMS1766094</ArticleId><ArticleId IdType="pmc">PMC8793854</ArticleId><ArticleId IdType="doi">10.1126/scisignal.abg4747</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK, Co-occurrence of Alzheimer&#x2019;s disease ss-amyloid and tau pathologies at synapses. Neurobiol Aging 31, 1145&#x2013;1152; published online EpubJul (S0197&#x2013;4580(08)00277&#x2013;7 [pii] 10.1016/j.neurobiolaging.2008.07.021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.07.021</ArticleId><ArticleId IdType="pmc">PMC2909664</ArticleId><ArticleId IdType="pubmed">18771816</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Chen L, Lee DH, Yu LC, Zhang Y, The role of intracellular amyloid beta in Alzheimer&#x2019;s disease. Prog Neurobiol 83, 131&#x2013;139 (2007); published online EpubOct (S0301&#x2013;0082(07)00157&#x2013;8 [pii] 10.1016/j.pneurobio.2007.08.002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2007.08.002</ArticleId><ArticleId IdType="pubmed">17889422</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Teplow DB, Selkoe DJ, Generation of amyloid beta protein from its precursor is sequence specific. Neuron 14, 661&#x2013;670 (1995); published online EpubMar (0896&#x2013;6273(95)90323&#x2013;2 [pii]).</Citation><ArticleIdList><ArticleId IdType="pubmed">7695913</ArticleId></ArticleIdList></Reference><Reference><Citation>Okochi M, Eimer S, Bottcher A, Baumeister R, Romig H, Walter J, Capell A, Steiner H, Haass C, A loss of function mutant of the presenilin homologue SEL-12 undergoes aberrant endoproteolysis in Caenorhabditis elegans and increases abeta 42 generation in human cells. J Biol Chem 275, 40925&#x2013;40932 (2000); published online EpubDec 29 (10.1074/jbc.M005254200M005254200 [pii]).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M005254200M005254200</ArticleId><ArticleId IdType="pubmed">11013240</ArticleId></ArticleIdList></Reference><Reference><Citation>Capell A, Steiner H, Willem M, Kaiser H, Meyer C, Walter J, Lammich S, Multhaup G, Haass C, Maturation and pro-peptide cleavage of beta-secretase. J Biol Chem 275, 30849&#x2013;30854 (2000); published online EpubOct 6 (10.1074/jbc.M003202200M003202200 [pii]).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M003202200M003202200</ArticleId><ArticleId IdType="pubmed">10801872</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Zhang YW, Xu H, Thinakaran G, Pathological and physiological functions of presenilins. Mol Neurodegener 1, 4 (2006)1750&#x2013;1326-1&#x2013;4 [pii] 10.1186/1750-1326-1-4).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-1-4</ArticleId><ArticleId IdType="pmc">PMC1513131</ArticleId><ArticleId IdType="pubmed">16930451</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Thinakaran G, Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. Neurology 66, S69&#x2013;73 (2006); published online EpubJan 24 (66/1_suppl_1/S69 [pii] 10.1212/01.wnl.0000192107.17175.39).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000192107.17175.39</ArticleId><ArticleId IdType="pubmed">16432149</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci 120, 4081&#x2013;4091 (2007); published online EpubDec 1 (120/23/4081 [pii] 10.1242/jcs.019265).</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.019265</ArticleId><ArticleId IdType="pubmed">18032783</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L, Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer&#x2019;s disease. Neuron 51, 703&#x2013;714 (2006); published online EpubSep 21 (S0896&#x2013;6273(06)00597&#x2013;6 [pii] 10.1016/j.neuron.2006.07.027).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.07.027</ArticleId><ArticleId IdType="pubmed">16982417</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Sheng R, Qin Z, The lysosome and neurodegenerative diseases. Acta Biochim Biophys Sin (Shanghai) 41, 437&#x2013;445 (2009); published online EpubJun (</Citation><ArticleIdList><ArticleId IdType="pubmed">19499146</ArticleId></ArticleIdList></Reference><Reference><Citation>Ditaranto K, Tekirian TL, Yang AJ, Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer&#x2019;s disease. Neurobiol Dis 8, 19&#x2013;31 (2001); published online EpubFeb (10.1006/nbdi.2000.0364S0969-9961(00)90364-4 [pii]).</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2000.0364S0969-9961(00)90364-4</ArticleId><ArticleId IdType="pubmed">11162237</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Jana M, Modi K, Gonzalez FJ, Sims KB, Berry-Kravis E, Pahan K, Activation of peroxisome proliferator-activated receptor alpha induces lysosomal biogenesis in brain cells: implications for lysosomal storage disorders. J Biol Chem 290, 10309&#x2013;10324 (2015); published online EpubApr 17 (M114.610659 [pii] 10.1074/jbc.M114.610659).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.610659</ArticleId><ArticleId IdType="pmc">PMC4400343</ArticleId><ArticleId IdType="pubmed">25750174</ArticleId></ArticleIdList></Reference><Reference><Citation>van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM, Heparan sulphate proteoglycans in Alzheimer&#x2019;s disease and amyloid-related disorders. Lancet Neurol 2, 482&#x2013;492 (2003); published online EpubAug (S1474442203004848 [pii]).</Citation><ArticleIdList><ArticleId IdType="pubmed">12878436</ArticleId></ArticleIdList></Reference><Reference><Citation>Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM, Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Abeta uptake and degradation by astrocytes. J Biol Chem 287, 13959&#x2013;13971 (2012); published online EpubApr 20 (10.1074/jbc.M111.288746).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.288746</ArticleId><ArticleId IdType="pmc">PMC3340151</ArticleId><ArticleId IdType="pubmed">22383525</ArticleId></ArticleIdList></Reference><Reference><Citation>Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM, Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Abeta uptake and degradation by astrocytes. J Biol Chem 287, 13959&#x2013;13971; published online EpubApr 20 (M111.288746 [pii] 10.1074/jbc.M111.288746).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.288746</ArticleId><ArticleId IdType="pmc">PMC3340151</ArticleId><ArticleId IdType="pubmed">22383525</ArticleId></ArticleIdList></Reference><Reference><Citation>Basak JM, Kim J, Pyatkivskyy Y, Wildsmith KR, Jiang H, Parsadanian M, Patterson BW, Bateman RJ, Holtzman DM, Measurement of apolipoprotein E and amyloid beta clearance rates in the mouse brain using bolus stable isotope labeling. Mol Neurodegener 7, 14 (2012)#N/A [pii] 10.1186/1750-1326-7-14).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-14</ArticleId><ArticleId IdType="pmc">PMC3405485</ArticleId><ArticleId IdType="pubmed">22512932</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey KL, Paulus GLC, Wang L, Balce DR, Luo JW, Bergman P, Ferder IC, Kong L, Renaud N, Singh S, Kost-Alimova M, Nyfeler B, Lassen KG, Virgin HW, Xavier RJ, TFEB Transcriptional Responses Reveal Negative Feedback by BHLHE40 and BHLHE41. Cell Rep 33, 108371 (2020); published online EpubNov 10 (10.1016/j.celrep.2020.108371).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108371</ArticleId><ArticleId IdType="pmc">PMC7686957</ArticleId><ArticleId IdType="pubmed">33176151</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R, Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 10129&#x2013;10140 (2006); published online EpubOct 4 (10.1523/JNEUROSCI.1202-06.2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Modi KK, Roy A, Brahmachari S, Rangasamy SB, Pahan K, Cinnamon and Its Metabolite Sodium Benzoate Attenuate the Activation of p21rac and Protect Memory and Learning in an Animal Model of Alzheimer&#x2019;s Disease. PLoS One 10, e0130398 (2015)10.1371/journal.pone.0130398).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0130398</ArticleId><ArticleId IdType="pmc">PMC4478015</ArticleId><ArticleId IdType="pubmed">26102198</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangasamy SB, Corbett GT, Roy A, Modi KK, Bennett DA, Mufson EJ, Ghosh S, Pahan K, Intranasal Delivery of NEMO-Binding Domain Peptide Prevents Memory Loss in a Mouse Model of Alzheimer&#x2019;s Disease. J Alzheimers Dis 47, 385&#x2013;402 (2015)JAD150040 [pii] 10.3233/JAD-150040).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150040</ArticleId><ArticleId IdType="pmc">PMC4582676</ArticleId><ArticleId IdType="pubmed">26401561</ArticleId></ArticleIdList></Reference><Reference><Citation>Escartin C, Galea E, Lakatos A, O&#x2019;Callaghan JP, Petzold GC, Serrano-Pozo A, Steinhauser C, Volterra A, Carmignoto G, Agarwal A, Allen NJ, Araque A, Barbeito L, Barzilai A, Bergles DE, Bonvento G, Butt AM, Chen WT, Cohen-Salmon M, Cunningham C, Deneen B, De Strooper B, Diaz-Castro B, Farina C, Freeman M, Gallo V, Goldman JE, Goldman SA, Gotz M, Gutierrez A, Haydon PG, Heiland DH, Hol EM, Holt MG, Iino M, Kastanenka KV, Kettenmann H, Khakh BS, Koizumi S, Lee CJ, Liddelow SA, MacVicar BA, Magistretti P, Messing A, Mishra A, Molofsky AV, Murai KK, Norris CM, Okada S, Oliet SHR, Oliveira JF, Panatier A, Parpura V, Pekna M, Pekny M, Pellerin L, Perea G, Perez-Nievas BG, Pfrieger FW, Poskanzer KE, Quintana FJ, Ransohoff RM, Riquelme-Perez M, Robel S, Rose CR, Rothstein JD, Rouach N, Rowitch DH, Semyanov A, Sirko S, Sontheimer H, Swanson RA, Vitorica J, Wanner IB, Wood LB, Wu J, Zheng B, Zimmer ER, Zorec R, Sofroniew MV, Verkhratsky A, Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci 24, 312&#x2013;325 (2021); published online EpubMar (10.1038/s41593-020-00783-4).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00783-4</ArticleId><ArticleId IdType="pmc">PMC8007081</ArticleId><ArticleId IdType="pubmed">33589835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K, Kleinman HK, Lee HJ, Pahan K, Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders. Orphanet J Rare Dis 12, 113 (2017); published online EpubJun 17 (10.1186/s13023-017-0663-8).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-017-0663-8</ArticleId><ArticleId IdType="pmc">PMC5474050</ArticleId><ArticleId IdType="pubmed">28623936</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy A, Pahan K, Gemfibrozil, stretching arms beyond lipid lowering. Immunopharmacol Immunotoxicol 31, 339&#x2013;351 (2009)10.1080/08923970902785253).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08923970902785253</ArticleId><ArticleId IdType="pmc">PMC2772998</ArticleId><ArticleId IdType="pubmed">19694602</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Q, Yan P, Ma X, Liu H, Perez R, Zhu A, Gonzales E, Burchett JM, Schuler DR, Cirrito JR, Diwan A, Lee JM, Enhancing astrocytic lysosome biogenesis facilitates Abeta clearance and attenuates amyloid plaque pathogenesis. J Neurosci 34, 9607&#x2013;9620; published online EpubJul 16 (34/29/9607 [pii] 10.1523/JNEUROSCI.3788-13.2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3788-13.2014</ArticleId><ArticleId IdType="pmc">PMC4099542</ArticleId><ArticleId IdType="pubmed">25031402</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Q, Yan P, Ma X, Liu H, Perez R, Zhu A, Gonzales E, Tripoli DL, Czerniewski L, Ballabio A, Cirrito JR, Diwan A, Lee JM, Neuronal-Targeted TFEB Accelerates Lysosomal Degradation of APP, Reducing Abeta Generation and Amyloid Plaque Pathogenesis. J Neurosci 35, 12137&#x2013;12151; published online EpubSep 2 (35/35/12137 [pii] 10.1523/JNEUROSCI.0705-15.2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0705-15.2015</ArticleId><ArticleId IdType="pmc">PMC4556784</ArticleId><ArticleId IdType="pubmed">26338325</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasgupta S, Roy A, Jana M, Hartley DM, Pahan K, Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Mol Pharmacol 72, 934&#x2013;946 (2007); published online EpubOct (mol.106.033787 [pii] 10.1124/mol.106.033787).</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.106.033787</ArticleId><ArticleId IdType="pubmed">17625103</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy A, Jana M, Corbett GT, Ramaswamy S, Kordower JH, Gonzalez FJ, Pahan K, Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-activated receptor alpha. Cell Rep 4, 724&#x2013;737 (2013); published online EpubAug 29 (S2211&#x2013;1247(13)00390&#x2013;2 [pii] 10.1016/j.celrep.2013.07.028).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.07.028</ArticleId><ArticleId IdType="pmc">PMC3804033</ArticleId><ArticleId IdType="pubmed">23972989</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy A, Jana M, Kundu M, Corbett GT, Rangaswamy SB, Mishra RK, Luan CH, Gonzalez FJ, Pahan K, HMG-CoA Reductase Inhibitors Bind to PPARalpha to Upregulate Neurotrophin Expression in the Brain and Improve Memory in Mice. Cell Metab 22, 253&#x2013;265 (2015); published online EpubAug 4 (S1550&#x2013;4131(15)00265-X [pii] 10.1016/j.cmet.2015.05.022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2015.05.022</ArticleId><ArticleId IdType="pmc">PMC4526399</ArticleId><ArticleId IdType="pubmed">26118928</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy A, Kundu M, Jana M, Mishra RK, Yung Y, Luan CH, Gonzalez FJ, Pahan K, Identification and characterization of PPARalpha ligands in the hippocampus. Nat Chem Biol 12, 1075&#x2013;1083 (2016); published online EpubOct 17 (nchembio.2204 [pii] 10.1038/nchembio.2204).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.2204</ArticleId><ArticleId IdType="pmc">PMC5110367</ArticleId><ArticleId IdType="pubmed">27748752</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM, Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 64, 632&#x2013;644 (2009); published online EpubDec 10 (S0896&#x2013;6273(09)00896&#x2013;4 [pii] 10.1016/j.neuron.2009.11.013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.11.013</ArticleId><ArticleId IdType="pmc">PMC2787195</ArticleId><ArticleId IdType="pubmed">20005821</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM, Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Abeta clearance in a mouse model of beta-amyloidosis. Proc Natl Acad Sci U S A 109, 15502&#x2013;15507; published online EpubSep 18 (1206446109 [pii] 10.1073/pnas.1206446109).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206446109</ArticleId><ArticleId IdType="pmc">PMC3458349</ArticleId><ArticleId IdType="pubmed">22927427</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsouri L, Georgopoulos S, Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer&#x2019;s disease mouse model. PLoS One 6, e21880 10.1371/journal.pone.0021880PONE-D-11-05741 [pii]).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021880PONE-D-11-05741</ArticleId><ArticleId IdType="pmc">PMC3130747</ArticleId><ArticleId IdType="pubmed">21755005</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahr BA, Abai B, Gall CM, Vanderklish PW, Hoffman KB, Lynch G, Induction of beta-amyloid-containing polypeptides in hippocampus: evidence for a concomitant loss of synaptic proteins and interactions with an excitotoxin. Exp Neurol 129, 81&#x2013;94 (1994); published online EpubSep (S0014&#x2013;4886(84)71149&#x2013;6 [pii] 10.1006/exnr.1994.1149).</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1994.1149</ArticleId><ArticleId IdType="pubmed">7925845</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Yang DS, Autophagy and neuronal cell death in neurological disorders. Cold Spring Harb Perspect Biol 4, cshperspect.a008839 [pii] 10.1101/cshperspect.a008839).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a008839</ArticleId><ArticleId IdType="pmc">PMC3475163</ArticleId><ArticleId IdType="pubmed">22983160</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanida I, Ueno T, Kominami E, Human light chain 3/MAP1LC3B is cleaved at its carboxyl-terminal Met121 to expose Gly120 for lipidation and targeting to autophagosomal membranes. J Biol Chem 279, 47704&#x2013;47710 (2004); published online EpubNov 12 (10.1074/jbc.M407016200M407016200 [pii]).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M407016200M407016200</ArticleId><ArticleId IdType="pubmed">15355958</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanida I, Ueno T, Kominami E, LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol 36, 2503&#x2013;2518 (2004); published online EpubDec (10.1016/j.biocel.2004.05.009S1357272504002110 [pii]).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2004.05.009S1357272504002110</ArticleId><ArticleId IdType="pmc">PMC7129593</ArticleId><ArticleId IdType="pubmed">15325588</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherz-Shouval R, Elazar Z, ROS, mitochondria and the regulation of autophagy. Trends Cell Biol 17, 422&#x2013;427 (2007); published online EpubSep (S0962&#x2013;8924(07)00168&#x2013;7 [pii] 10.1016/j.tcb.2007.07.009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2007.07.009</ArticleId><ArticleId IdType="pubmed">17804237</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z, Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 26, 1749&#x2013;1760 (2007); published online EpubApr 4 (7601623 [pii] 10.1038/sj.emboj.7601623).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601623</ArticleId><ArticleId IdType="pmc">PMC1847657</ArticleId><ArticleId IdType="pubmed">17347651</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanida I, Yamaji T, Ueno T, Ishiura S, Kominami E, Hanada K, Consideration about negative controls for LC3 and expression vectors for four colored fluorescent protein-LC3 negative controls. Autophagy 4, 131&#x2013;134 (2008); published online EpubJan (5233 [pii]).</Citation><ArticleIdList><ArticleId IdType="pubmed">18000393</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N, Yoshimori T, How to interpret LC3 immunoblotting. Autophagy 3, 542&#x2013;545 (2007); published online EpubNov-Dec (4600 [pii]).</Citation><ArticleIdList><ArticleId IdType="pubmed">17611390</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanida I, Ueno T, Kominami E, LC3 and Autophagy. Methods Mol Biol 445, 77&#x2013;88 (2008)10.1007/978-1-59745-157-4_4).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-59745-157-4_4</ArticleId><ArticleId IdType="pubmed">18425443</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuma A, Matsui M, Mizushima N, LC3, an autophagosome marker, can be incorporated into protein aggregates independent of autophagy: caution in the interpretation of LC3 localization. Autophagy 3, 323&#x2013;328 (2007); published online EpubJul-Aug (4012 [pii]).</Citation><ArticleIdList><ArticleId IdType="pubmed">17387262</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett GT, Gonzalez FJ, Pahan K, Activation of peroxisome proliferator-activated receptor alpha stimulates ADAM10-mediated proteolysis of APP. Proc Natl Acad Sci U S A 112, 8445&#x2013;8450 (2015); published online EpubJul 7 (1504890112 [pii] 10.1073/pnas.1504890112).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1504890112</ArticleId><ArticleId IdType="pmc">PMC4500265</ArticleId><ArticleId IdType="pubmed">26080426</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmachari S, Pahan K, Sodium benzoate, a food additive and a metabolite of cinnamon, modifies T cells at multiple steps and inhibits adoptive transfer of experimental allergic encephalomyelitis. J Immunol 179, 275&#x2013;283 (2007); published online EpubJul 1 (179/1/275 [pii]).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1976122</ArticleId><ArticleId IdType="pubmed">17579047</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha RN, Pahan K, Differential regulation of Mn-superoxide dismutase in neurons and astroglia by HIV-1 gp120: Implications for HIV-associated dementia. Free Radic Biol Med 42, 1866&#x2013;1878 (2007); published online EpubJun 15 (S0891&#x2013;5849(07)00217&#x2013;1 [pii] 10.1016/j.freeradbiomed.2007.03.022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2007.03.022</ArticleId><ArticleId IdType="pmc">PMC1955471</ArticleId><ArticleId IdType="pubmed">17512466</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, Baker TJ, Characterization of ameboid microglia isolated from developing mammalian brain. J Neurosci 6, 2163&#x2013;2178 (1986); published online EpubAug (</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568755</ArticleId><ArticleId IdType="pubmed">3018187</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmachari S, Fung YK, Pahan K, Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. J Neurosci 26, 4930&#x2013;4939 (2006); published online EpubMay 3 (26/18/4930 [pii] 10.1523/JNEUROSCI.5480-05.2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5480-05.2006</ArticleId><ArticleId IdType="pmc">PMC1963412</ArticleId><ArticleId IdType="pubmed">16672668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jana M, Jana A, Pal U, Pahan K, A simplified method for isolating highly purified neurons, oligodendrocytes, astrocytes, and microglia from the same human fetal brain tissue. Neurochem Res 32, 2015&#x2013;2022 (2007); published online EpubDec (10.1007/s11064-007-9340-y).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-007-9340-y</ArticleId><ArticleId IdType="pmc">PMC2085356</ArticleId><ArticleId IdType="pubmed">17447141</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundu M, Roy A, Pahan K, Selective neutralization of IL-12 p40 monomer induces death in prostate cancer cells via IL-12-IFN-gamma. Proc Natl Acad Sci U S A 114, 11482&#x2013;11487 (2017); published online EpubOct 24 (10.1073/pnas.1705536114).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1705536114</ArticleId><ArticleId IdType="pmc">PMC5664500</ArticleId><ArticleId IdType="pubmed">29073075</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondal S, Kundu M, Jana M, Roy A, Rangasamy SB, Modi KK, Wallace J, Albalawi YA, Balabanov R, Pahan K, IL-12 p40 monomer is different from other IL-12 family members to selectively inhibit IL-12Rbeta1 internalization and suppress EAE. Proc Natl Acad Sci U S A 117, 21557&#x2013;21567 (2020); published online EpubSep 1 (10.1073/pnas.2000653117).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2000653117</ArticleId><ArticleId IdType="pmc">PMC7474649</ArticleId><ArticleId IdType="pubmed">32817415</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett GT, Roy A, Pahan K, Gemfibrozil, a Lipid-Lowering Drug, Upregulates IL-1 Receptor Antagonist in Mouse Cortical Neurons: Implications for Neuronal Self-Defense. J Immunol 189, 1002&#x2013;1013; published online EpubJul 15 (jimmunol.1102624 [pii] 10.4049/jimmunol.1102624).</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1102624</ArticleId><ArticleId IdType="pmc">PMC3523125</ArticleId><ArticleId IdType="pubmed">22706077</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha RN, Liu X, Pahan K, Up-regulation of BDNF in astrocytes by TNF-alpha: a case for the neuroprotective role of cytokine. J Neuroimmune Pharmacol 1, 212&#x2013;222 (2006); published online EpubSep (10.1007/s11481-006-9020-8).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-006-9020-8</ArticleId><ArticleId IdType="pmc">PMC2131740</ArticleId><ArticleId IdType="pubmed">18040799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond JS, Barrett AJ, Degradation of fructose-1,6-bisphosphate aldolase by cathepsin B. Biochem J 189, 17&#x2013;25 (1980); published online EpubJul 1 (</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1161913</ArticleId><ArticleId IdType="pubmed">7458901</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett AJ, Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates. Biochem J 187, 909&#x2013;912 (1980); published online EpubJun 1 (</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1162479</ArticleId><ArticleId IdType="pubmed">6897924</ArticleId></ArticleIdList></Reference><Reference><Citation>Khasnavis S, Pahan K, Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson&#x2019;s disease. J Neuroimmune Pharmacol 9, 569&#x2013;581 (2014); published online EpubSep (10.1007/s11481-014-9552-2).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-014-9552-2</ArticleId><ArticleId IdType="pmc">PMC4167597</ArticleId><ArticleId IdType="pubmed">24946862</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Pahan K, Gemfibrozil, a Lipid-Lowering Drug, Lowers Amyloid Plaque Pathology and Enhances Memory in a Mouse Model of Alzheimer&#x2019;s Disease via Peroxisome Proliferator-Activated Receptor alpha. J Alzheimers Dis Rep 3, 149&#x2013;168 (2019); published online EpubMay 18 (10.3233/ADR-190104).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/ADR-190104</ArticleId><ArticleId IdType="pmc">PMC6597963</ArticleId><ArticleId IdType="pubmed">31259309</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett GT, Roy A, Pahan K, Sodium phenylbutyrate enhances astrocytic neurotrophin synthesis via protein kinase C (PKC)-mediated activation of cAMP-response element-binding protein (CREB): implications for Alzheimer disease therapy. J Biol Chem 288, 8299&#x2013;8312 (2013); published online EpubMar 22 (M112.426536 [pii] 10.1074/jbc.M112.426536).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.426536</ArticleId><ArticleId IdType="pmc">PMC3605648</ArticleId><ArticleId IdType="pubmed">23404502</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel D, Roy A, Kundu M, Jana M, Luan CH, Gonzalez FJ, Pahan K, Aspirin binds to PPAR&#x3b1; to stimulate hippocampal plasticity and protect memory. Proc Natl Acad Sci U S A 115, E7408&#x2013;E7417 (2018); published online Epub07 (10.1073/pnas.1802021115).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1802021115</ArticleId><ArticleId IdType="pmc">PMC6077698</ArticleId><ArticleId IdType="pubmed">30012602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansuy IM, Mayford M, Jacob B, Kandel ER, Bach ME, Restricted and regulated overexpression reveals calcineurin as a key component in the transition from short-term to long-term memory. Cell 92, 39&#x2013;49 (1998); published online EpubJan (10.1016/s0092-8674(00)80897-1).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(00)80897-1</ArticleId><ArticleId IdType="pubmed">9489698</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeano P, Martino Adami PV, Do Carmo S, Blanco E, Rotondaro C, Capani F, Castano EM, Cuello AC, Morelli L, Longitudinal analysis of the behavioral phenotype in a novel transgenic rat model of early stages of Alzheimer&#x2019;s disease. Front Behav Neurosci 8, 321 (2014)10.3389/fnbeh.2014.00321).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnbeh.2014.00321</ArticleId><ArticleId IdType="pmc">PMC4165352</ArticleId><ArticleId IdType="pubmed">25278855</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Liang Z, Blanchard J, Dai CL, Sun S, Lee MH, Grundke-Iqbal I, Iqbal K, Liu F, Gong CX, A non-transgenic mouse model (icv-STZ mouse) of Alzheimer&#x2019;s disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol 47, 711&#x2013;725 (2013); published online EpubApr (10.1007/s12035-012-8375-5).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8375-5</ArticleId><ArticleId IdType="pmc">PMC3582864</ArticleId><ArticleId IdType="pubmed">23150171</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34675436</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>The SARS-CoV-2 main protease M<sup>pro</sup> causes microvascular brain pathology by cleaving NEMO in brain endothelial cells.</ArticleTitle><Pagination><StartPage>1522</StartPage><EndPage>1533</EndPage><MedlinePgn>1522-1533</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-021-00926-1</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) can damage cerebral small vessels and cause neurological symptoms. Here we describe structural changes in cerebral small vessels of patients with COVID-19 and elucidate potential mechanisms underlying the vascular pathology. In brains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected individuals and animal models, we found an increased number of empty basement membrane tubes, so-called string vessels representing remnants of lost capillaries. We obtained evidence that brain endothelial cells are infected and that the main protease of SARS-CoV-2 (M<sup>pro</sup>) cleaves NEMO, the essential modulator of nuclear factor-&#x3ba;B. By ablating NEMO, M<sup>pro</sup> induces the death of human brain endothelial cells and the occurrence of string vessels in mice. Deletion of receptor-interacting protein kinase (RIPK) 3, a mediator of regulated cell death, blocks the vessel rarefaction and disruption of the blood-brain barrier due to NEMO ablation. Importantly, a pharmacological inhibitor of RIPK signaling prevented the M<sup>pro</sup>-induced microvascular pathology. Our data suggest RIPK as a potential therapeutic target to treat the neuropathology of COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wenzel</LastName><ForeName>Jan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6313-2439</Identifier><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Research Centre for Cardiovascular Research), Hamburg-L&#xfc;beck-Kiel and Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lampe</LastName><ForeName>Josephine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Research Centre for Cardiovascular Research), Hamburg-L&#xfc;beck-Kiel and Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>M&#xfc;ller-Fielitz</LastName><ForeName>Helge</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2815-4426</Identifier><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuster</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zille</LastName><ForeName>Marietta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0609-8956</Identifier><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Research Centre for Cardiovascular Research), Hamburg-L&#xfc;beck-Kiel and Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krohn</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5345-9048</Identifier><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Research Centre for Cardiovascular Research), Hamburg-L&#xfc;beck-Kiel and Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;rbelin</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5435-7182</Identifier><AffiliationInfo><Affiliation>Department of Oncology, Hematology &amp; Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Linlin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), partner site Hamburg-L&#xfc;beck-Borstel-Riems, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;zorhan</LastName><ForeName>&#xdc;mit</ForeName><Initials>&#xdc;</Initials><Identifier Source="ORCID">0000-0002-7661-2818</Identifier><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Research Centre for Cardiovascular Research), Hamburg-L&#xfc;beck-Kiel and Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neve</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Julian U G</ForeName><Initials>JUG</Initials><AffiliationInfo><Affiliation>DZHK (German Research Centre for Cardiovascular Research), Hamburg-L&#xfc;beck-Kiel and Frankfurt, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Cardiovascular Regeneration, Cardiopulmonary Institute (CPI), University Frankfurt, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bojkova</LastName><ForeName>Denisa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Medical Virology, University Frankfurt, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shumliakivska</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Cardiovascular Regeneration, Cardiopulmonary Institute (CPI), University Frankfurt, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2886-7373</Identifier><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xe4;hnrich</LastName><ForeName>Anke</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Experimental Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Cardiogenetics, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ott</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Experimental Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Cardiogenetics, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sencio</LastName><ForeName>Valentin</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-6379-4317</Identifier><AffiliationInfo><Affiliation>Centre d'Infection et d'Immunit&#xe9; de Lille, Inserm U1019, CNRS UMR 9017, University of Lille, CHU Lille, Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robil</LastName><ForeName>Cyril</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3607-244X</Identifier><AffiliationInfo><Affiliation>Centre d'Infection et d'Immunit&#xe9; de Lille, Inserm U1019, CNRS UMR 9017, University of Lille, CHU Lille, Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfefferle</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7489-6557</Identifier><AffiliationInfo><Affiliation>Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauve</LastName><ForeName>Florent</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille Neuroscience &amp; Cognition, UMR-S 1172, DISTALZ, EGID, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Co&#xea;lho</LastName><ForeName>Caio Fernando Ferreira</ForeName><Initials>CFF</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille Neuroscience &amp; Cognition, UMR-S 1172, DISTALZ, EGID, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franz</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7523-6622</Identifier><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Campus Institute for Dynamics of Biological Networks, University of G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Max Planck Institute for Experimental Medicine, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spiecker</LastName><ForeName>Frauke</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lembrich</LastName><ForeName>Beate</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binder</LastName><ForeName>Sonja</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feller</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Research Centre for Cardiovascular Research), Hamburg-L&#xfc;beck-Kiel and Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xf6;nig</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Airway Research Center North, Member of the German Center for Lung Research (DZL), L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Anatomy, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busch</LastName><ForeName>Hauke</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Experimental Dermatology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Cardiogenetics, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collin</LastName><ForeName>Ludovic</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villase&#xf1;or</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf6;hren</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-0532-5133</Identifier><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altmeppen</LastName><ForeName>Hermann C</ForeName><Initials>HC</Initials><Identifier Source="ORCID">0000-0001-9439-6533</Identifier><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasparakis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9870-0966</Identifier><AffiliationInfo><Affiliation>Institute for Genetics, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimmeler</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>DZHK (German Research Centre for Cardiovascular Research), Hamburg-L&#xfc;beck-Kiel and Frankfurt, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Cardiovascular Regeneration, Cardiopulmonary Institute (CPI), University Frankfurt, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cinatl</LastName><ForeName>Jindrich</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Medical Virology, University Frankfurt, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xfc;schel</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Legal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zelic</LastName><ForeName>Matija</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rare and Neurologic Diseases Research, Sanofi, Framingham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ofengeim</LastName><ForeName>Dimitry</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Rare and Neurologic Diseases Research, Sanofi, Framingham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stadelmann</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trottein</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Centre d'Infection et d'Immunit&#xe9; de Lille, Inserm U1019, CNRS UMR 9017, University of Lille, CHU Lille, Institut Pasteur de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nogueiras</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9976-9930</Identifier><AffiliationInfo><Affiliation>Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigaci&#xf3;n Sanitaria, Santiago de Compostela, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilgenfeld</LastName><ForeName>Rolf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Molecular Medicine, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), partner site Hamburg-L&#xfc;beck-Borstel-Riems, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glatzel</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7720-8817</Identifier><AffiliationInfo><Affiliation>Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prevot</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-7185-3615</Identifier><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Lille Neuroscience &amp; Cognition, UMR-S 1172, DISTALZ, EGID, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwaninger</LastName><ForeName>Markus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4510-9718</Identifier><AffiliationInfo><Affiliation>Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism (CBBM), University of L&#xfc;beck, L&#xfc;beck, Germany. markus.schwaninger@uni-luebeck.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZHK (German Research Centre for Cardiovascular Research), Hamburg-L&#xfc;beck-Kiel and Frankfurt, Germany. markus.schwaninger@uni-luebeck.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>810331</GrantID><Acronym>ERC_</Acronym><Agency>European Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C514981">NEMO protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086782">Coronavirus 3C Proteases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086782" MajorTopicYN="N">Coronavirus 3C Proteases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008647" MajorTopicYN="N">Mesocricetus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055806" MajorTopicYN="N">Microvessels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>L.C. and R.V. are under paid employment by Hoffman La Roche. M. Zelic and D.O. are under paid employment by Sanofi. M.K. worked as a part-time consultant of Immungenetics AG. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34675436</ArticleId><ArticleId IdType="mid">EMS133510</ArticleId><ArticleId IdType="pmc">PMC8553622</ArticleId><ArticleId IdType="doi">10.1038/s41593-021-00926-1</ArticleId><ArticleId IdType="pii">10.1038/s41593-021-00926-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Helms J, et al. Neurologic features in severe SARS-CoV-2 infection. N. Engl. J. Med. 2020;382:2268&#x2013;2270. doi: 10.1056/NEJMc2008597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2008597</ArticleId><ArticleId IdType="pmc">PMC7179967</ArticleId><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson RW, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020;143:3104&#x2013;3120. doi: 10.1093/brain/awaa240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa240</ArticleId><ArticleId IdType="pmc">PMC7454352</ArticleId><ArticleId IdType="pubmed">32637987</ArticleId></ArticleIdList></Reference><Reference><Citation>Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the nervous system. Cell. 2020;183:16&#x2013;27. doi: 10.1016/j.cell.2020.08.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.028</ArticleId><ArticleId IdType="pmc">PMC7437501</ArticleId><ArticleId IdType="pubmed">32882182</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Paniz-Mondolfi A, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) J. Med. Virol. 2020;92:699&#x2013;702. doi: 10.1002/jmv.25915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25915</ArticleId><ArticleId IdType="pmc">PMC7264598</ArticleId><ArticleId IdType="pubmed">32314810</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles VG, et al. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. 2020;383:590&#x2013;592. doi: 10.1056/NEJMc2011400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2011400</ArticleId><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson MI, et al. SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus. Wellcome Open Res. 2020;5:181. doi: 10.12688/wellcomeopenres.16002.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.16002.2</ArticleId><ArticleId IdType="pmc">PMC7689603</ArticleId><ArticleId IdType="pubmed">33283055</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri L, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020;370:856&#x2013;860. doi: 10.1126/science.abd2985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd2985</ArticleId><ArticleId IdType="pmc">PMC7857391</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 2021;24:168&#x2013;175. doi: 10.1038/s41593-020-00758-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00758-5</ArticleId><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med. 2021;218:e20202135. doi: 10.1084/jem.20202135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202135</ArticleId><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N. Engl. J. Med. 2020;383:120&#x2013;128. doi: 10.1056/NEJMoa2015432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417&#x2013;1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Radmanesh A, et al. COVID-19-associated diffuse leukoencephalopathy and microhemorrhages. Radiology. 2020;297:E223&#x2013;E227. doi: 10.1148/radiol.2020202040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2020202040</ArticleId><ArticleId IdType="pmc">PMC7507998</ArticleId><ArticleId IdType="pubmed">32437314</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte G, et al. COVID-19-associated PRES-like encephalopathy with perivascular gadolinium enhancement. AJNR Am. J. Neuroradiol. 2020;41:2206&#x2013;2208. doi: 10.3174/ajnr.A6762.</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A6762</ArticleId><ArticleId IdType="pmc">PMC7963244</ArticleId><ArticleId IdType="pubmed">32816769</ArticleId></ArticleIdList></Reference><Reference><Citation>Conklin J, et al. Susceptibility-weighted imaging reveals cerebral microvascular injury in severe COVID-19. J. Neurol. Sci. 2021;421:117308. doi: 10.1016/j.jns.2021.117308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117308</ArticleId><ArticleId IdType="pmc">PMC7832284</ArticleId><ArticleId IdType="pubmed">33497950</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaunmuktane Z, et al. Microvascular injury and hypoxic damage: emerging neuropathological signatures in COVID-19. Acta Neuropathol. 2020;140:397&#x2013;400. doi: 10.1007/s00401-020-02190-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02190-2</ArticleId><ArticleId IdType="pmc">PMC7340758</ArticleId><ArticleId IdType="pubmed">32638079</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichard RR, et al. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol. 2020;140:1&#x2013;6. doi: 10.1007/s00401-020-02166-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02166-2</ArticleId><ArticleId IdType="pmc">PMC7245994</ArticleId><ArticleId IdType="pubmed">32449057</ArticleId></ArticleIdList></Reference><Reference><Citation>Koralnik IJ, Tyler KL. COVID-19: a global threat to the nervous system. Ann. Neurol. 2020;88:1&#x2013;11. doi: 10.1002/ana.25807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25807</ArticleId><ArticleId IdType="pmc">PMC7300753</ArticleId><ArticleId IdType="pubmed">32506549</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J, et al. Neuropathology of patients with COVID-19 in Germany: a postmortem case series. Lancet Neurol. 2020;19:919&#x2013;929. doi: 10.1016/S1474-4422(20)30308-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30308-2</ArticleId><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science. 2020;368:409&#x2013;412. doi: 10.1126/science.abb3405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3405</ArticleId><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev. Immunol. 2014;32:461&#x2013;488. doi: 10.1146/annurev-immunol-032713-120156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032713-120156</ArticleId><ArticleId IdType="pubmed">24655297</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondylis V, Kumari S, Vlantis K, Pasparakis M. The interplay of IKK, NF-&#x3ba;B and RIPK1 signaling in the regulation of cell death, tissue homeostasis and inflammation. Immunol. Rev. 2017;277:113&#x2013;127. doi: 10.1111/imr.12550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12550</ArticleId><ArticleId IdType="pubmed">28462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown WR. A review of string vessels or collapsed, empty basement membrane tubes. J. Alzheimers Dis. 2010;21:725&#x2013;739. doi: 10.3233/JAD-2010-100219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-100219</ArticleId><ArticleId IdType="pmc">PMC3081641</ArticleId><ArticleId IdType="pubmed">20634580</ArticleId></ArticleIdList></Reference><Reference><Citation>Shilts J, Crozier TWM, Greenwood EJD, Lehner PJ, Wright GJ. No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor. Sci. Rep. 2021;11:413. doi: 10.1038/s41598-020-80464-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80464-1</ArticleId><ArticleId IdType="pmc">PMC7801465</ArticleId><ArticleId IdType="pubmed">33432067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203:631&#x2013;637. doi: 10.1002/path.1570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1570</ArticleId><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;280. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct. Target Ther. 2020;5:283. doi: 10.1038/s41392-020-00426-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00426-x</ArticleId><ArticleId IdType="pmc">PMC7714896</ArticleId><ArticleId IdType="pubmed">33277466</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB, et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat. Biotechnol. 2018;36:70&#x2013;80. doi: 10.1038/nbt.4038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.4038</ArticleId><ArticleId IdType="pmc">PMC5951394</ArticleId><ArticleId IdType="pubmed">29227469</ArticleId></ArticleIdList></Reference><Reference><Citation>He, L. et al. Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2&#x2014;implications for microvascular inflammation and hypercoagulopathy in COVID-19. Preprint at bioRxiv10.1101/2020.05.11.088500 (2020).</Citation></Reference><Reference><Citation>Kaneko N, et al. Flow-mediated susceptibility and molecular response of cerebral endothelia to SARS-CoV-2 infection. Stroke. 2021;52:260&#x2013;270. doi: 10.1161/STROKEAHA.120.032764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.120.032764</ArticleId><ArticleId IdType="pmc">PMC7769899</ArticleId><ArticleId IdType="pubmed">33161843</ArticleId></ArticleIdList></Reference><Reference><Citation>McCracken IR, et al. Lack of evidence of angiotensin-converting enzyme 2 expression and replicative infection by SARS-CoV-2 in human endothelial cells. Circulation. 2021;143:865&#x2013;868. doi: 10.1161/CIRCULATIONAHA.120.052824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.052824</ArticleId><ArticleId IdType="pmc">PMC7899720</ArticleId><ArticleId IdType="pubmed">33405941</ArticleId></ArticleIdList></Reference><Reference><Citation>Conde JN, Schutt WR, Gorbunova EE, Mackow ER. Recombinant ACE2 expression is required for SARS-CoV-2 to infect primary human endothelial cells and induce inflammatory and procoagulative responses. mBio. 2020;11:e03185&#x2013;03120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7751258</ArticleId><ArticleId IdType="pubmed">33310781</ArticleId></ArticleIdList></Reference><Reference><Citation>Krichel B, Falke S, Hilgenfeld R, Redecke L, Uetrecht C. Processing of the SARS-CoV pp1a/ab nsp7-10 region. Biochem. J. 2020;477:1009&#x2013;1019. doi: 10.1042/BCJ20200029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20200029</ArticleId><ArticleId IdType="pmc">PMC7078746</ArticleId><ArticleId IdType="pubmed">32083638</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718&#x2013;724. doi: 10.1126/science.abc6027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon DE, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459&#x2013;468. doi: 10.1038/s41586-020-2286-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2286-9</ArticleId><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rbelin J, et al. A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases. EMBO Mol. Med. 2016;8:609&#x2013;625. doi: 10.15252/emmm.201506078.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201506078</ArticleId><ArticleId IdType="pmc">PMC4888852</ArticleId><ArticleId IdType="pubmed">27137490</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridder DA, et al. Brain endothelial TAK1 and NEMO safeguard the neurovascular unit. J. Exp. Med. 2015;212:1529&#x2013;1549. doi: 10.1084/jem.20150165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20150165</ArticleId><ArticleId IdType="pmc">PMC4577837</ArticleId><ArticleId IdType="pubmed">26347470</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothhammer V, et al. Microglial control of astrocytes in response to microbial metabolites. Nature. 2018;557:724&#x2013;728. doi: 10.1038/s41586-018-0119-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0119-x</ArticleId><ArticleId IdType="pmc">PMC6422159</ArticleId><ArticleId IdType="pubmed">29769726</ArticleId></ArticleIdList></Reference><Reference><Citation>Welz PS, et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature. 2011;477:330&#x2013;334. doi: 10.1038/nature10273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10273</ArticleId><ArticleId IdType="pubmed">21804564</ArticleId></ArticleIdList></Reference><Reference><Citation>Mifflin L, Ofengeim D, Yuan J. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat. Rev. Drug Discov. 2020;19:553&#x2013;571. doi: 10.1038/s41573-020-0071-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0071-y</ArticleId><ArticleId IdType="pmc">PMC7362612</ArticleId><ArticleId IdType="pubmed">32669658</ArticleId></ArticleIdList></Reference><Reference><Citation>Villase&#xf1;or R, et al. Trafficking of endogenous immunoglobulins by endothelial cells at the blood&#x2013;brain barrier. Sci. Rep. 2016;6:25658. doi: 10.1038/srep25658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep25658</ArticleId><ArticleId IdType="pmc">PMC4858719</ArticleId><ArticleId IdType="pubmed">27149947</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens S, Hofmans S, Declercq W, Augustyns K, Vandenabeele P. Inhibitors targeting RIPK1/RIPK3: old and new drugs. Trends Pharmacol. Sci. 2020;41:209&#x2013;224. doi: 10.1016/j.tips.2020.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2020.01.002</ArticleId><ArticleId IdType="pubmed">32035657</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarcon-Martinez L, et al. Interpericyte tunnelling nanotubes regulate neurovascular coupling. Nature. 2020;585:91&#x2013;95. doi: 10.1038/s41586-020-2589-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2589-x</ArticleId><ArticleId IdType="pubmed">32788726</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, X. et al. Reduction of neuronal activity mediated by blood-vessel regression in the brain. Preprint at bioRxiv10.1101/2020.09.15.262782 (2020).</Citation></Reference><Reference><Citation>Colmenero I, et al. SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases. Br. J. Dermatol. 2020;183:729&#x2013;737. doi: 10.1111/bjd.19327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.19327</ArticleId><ArticleId IdType="pmc">PMC7323219</ArticleId><ArticleId IdType="pubmed">32562567</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung ML, et al. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin&#x2013;angiotensin system. Cell. 2021;184:2212&#x2013;2228. doi: 10.1016/j.cell.2021.02.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.053</ArticleId><ArticleId IdType="pmc">PMC7923941</ArticleId><ArticleId IdType="pubmed">33713620</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly JL, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020;370:861&#x2013;865. doi: 10.1126/science.abd3072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd3072</ArticleId><ArticleId IdType="pmc">PMC7612957</ArticleId><ArticleId IdType="pubmed">33082294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, et al. A systemic and molecular study of subcellular localization of SARS-CoV-2 proteins. Signal Transduct. Target. Ther. 2020;5:269. doi: 10.1038/s41392-020-00372-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00372-8</ArticleId><ArticleId IdType="pmc">PMC7670843</ArticleId><ArticleId IdType="pubmed">33203855</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto S. Nuclear initiated NF-&#x3ba;B signaling: NEMO and ATM take center stage. Cell Res. 2011;21:116&#x2013;130. doi: 10.1038/cr.2010.179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2010.179</ArticleId><ArticleId IdType="pmc">PMC3193401</ArticleId><ArticleId IdType="pubmed">21187855</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam PS, et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. 2020;369:1210&#x2013;1220. doi: 10.1126/science.abc6261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6261</ArticleId><ArticleId IdType="pmc">PMC7665312</ArticleId><ArticleId IdType="pubmed">32788292</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, et al. Porcine epidemic diarrhea virus 3C-like protease regulates its interferon antagonism by cleaving NEMO. J. Virol. 2016;90:2090&#x2013;2101. doi: 10.1128/JVI.02514-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02514-15</ArticleId><ArticleId IdType="pmc">PMC4733996</ArticleId><ArticleId IdType="pubmed">26656704</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, et al. Porcine deltacoronavirus nsp5 inhibits interferon-beta production through the cleavage of NEMO. Virology. 2017;502:33&#x2013;38. doi: 10.1016/j.virol.2016.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.12.005</ArticleId><ArticleId IdType="pmc">PMC7111669</ArticleId><ArticleId IdType="pubmed">27984784</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, et al. Feline infectious peritonitis virus Nsp5 inhibits type I interferon production by cleaving NEMO at multiple sites. Viruses. 2019;12:43. doi: 10.3390/v12010043.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12010043</ArticleId><ArticleId IdType="pmc">PMC7019732</ArticleId><ArticleId IdType="pubmed">31905881</ArticleId></ArticleIdList></Reference><Reference><Citation>Gareus R, et al. Endothelial cell-specific NF-&#x3ba;B inhibition protects mice from atherosclerosis. Cell Metab. 2008;8:372&#x2013;383. doi: 10.1016/j.cmet.2008.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2008.08.016</ArticleId><ArticleId IdType="pubmed">19046569</ArticleId></ArticleIdList></Reference><Reference><Citation>van Loo G, et al. Inhibition of transcription factor NF-kB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat. Immunol. 2006;7:954&#x2013;961. doi: 10.1038/ni1372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1372</ArticleId><ArticleId IdType="pubmed">16892069</ArticleId></ArticleIdList></Reference><Reference><Citation>Meuwissen ME, Mancini GM. Neurological findings in incontinentia pigmenti; a review. Eur. J. Med. Genet. 2012;55:323&#x2013;331. doi: 10.1016/j.ejmg.2012.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmg.2012.04.007</ArticleId><ArticleId IdType="pubmed">22564885</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg N, et al. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology. 2020;95:e1754&#x2013;e1759. doi: 10.1212/WNL.0000000000010111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010111</ArticleId><ArticleId IdType="pubmed">32546655</ArticleId></ArticleIdList></Reference><Reference><Citation>Senatorov VV, Jr., et al. Blood&#x2013;brain barrier dysfunction in aging induces hyperactivation of TGF&#x3b2; signaling and chronic yet reversible neural dysfunction. Sci. Transl. Med. 2019;11:eaaw8283. doi: 10.1126/scitranslmed.aaw8283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaw8283</ArticleId><ArticleId IdType="pubmed">31801886</ArticleId></ArticleIdList></Reference><Reference><Citation>Nampoothiri, S. et al. The hypothalamus as a hub for SARS-CoV-2 brain infection and pathogenesis. Preprint at bioRxiv10.1101/2020.06.08.139329 (2020).</Citation></Reference><Reference><Citation>Schmidt-Supprian M, et al. NEMO/IKK&#x3b3;-deficient mice model incontinentia pigmenti. Mol. Cell. 2000;5:981&#x2013;992. doi: 10.1016/S1097-2765(00)80263-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1097-2765(00)80263-4</ArticleId><ArticleId IdType="pubmed">10911992</ArticleId></ArticleIdList></Reference><Reference><Citation>Luedde T, et al. Deletion of NEMO/IKK&#x3b3; in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2007;11:119&#x2013;132. doi: 10.1016/j.ccr.2006.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2006.12.016</ArticleId><ArticleId IdType="pubmed">17292824</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridder DA, et al. TAK1 in brain endothelial cells mediates fever and lethargy. J. Exp. Med. 2011;208:2615&#x2013;2623. doi: 10.1084/jem.20110398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20110398</ArticleId><ArticleId IdType="pmc">PMC3244031</ArticleId><ArticleId IdType="pubmed">22143887</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton K, Sun X, Dixit VM. Kinase RIP3 is dispensable for normal NF-&#x3ba;Bs, signaling by the B cell and T cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol. Cell. Biol. 2004;24:1464&#x2013;1469. doi: 10.1128/MCB.24.4.1464-1469.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.24.4.1464-1469.2004</ArticleId><ArticleId IdType="pmc">PMC344190</ArticleId><ArticleId IdType="pubmed">14749364</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelic M, et al. RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosis. Cell Rep. 2021;35:109112. doi: 10.1016/j.celrep.2021.109112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109112</ArticleId><ArticleId IdType="pmc">PMC8917516</ArticleId><ArticleId IdType="pubmed">33979622</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, et al. RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer. Cancer Cell. 2018;34:757&#x2013;774. doi: 10.1016/j.ccell.2018.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2018.10.006</ArticleId><ArticleId IdType="pmc">PMC6836726</ArticleId><ArticleId IdType="pubmed">30423296</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin JY, et al. Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS ONE. 2010;5:e10611. doi: 10.1371/journal.pone.0010611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010611</ArticleId><ArticleId IdType="pmc">PMC2868906</ArticleId><ArticleId IdType="pubmed">20485554</ArticleId></ArticleIdList></Reference><Reference><Citation>Dogbevia GK, et al. Gene therapy decreases seizures in a model of incontinentia pigmenti. Ann. Neurol. 2017;82:93&#x2013;104. doi: 10.1002/ana.24981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24981</ArticleId><ArticleId IdType="pubmed">28628231</ArticleId></ArticleIdList></Reference><Reference><Citation>Korte J, Mienert J, Hennigs JK, Korbelin J. Inactivation of adeno-associated viral vectors by oxidant-based disinfectants. Hum. Gene Ther. 2021;32:771&#x2013;781. doi: 10.1089/hum.2020.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2020.120</ArticleId><ArticleId IdType="pubmed">33023320</ArticleId></ArticleIdList></Reference><Reference><Citation>Dogbevia G, Grasshoff H, Othman A, Penno A, Schwaninger M. Brain endothelial specific gene therapy improves experimental Sandhoff disease. J. Cereb. Blood Flow Metab. 2020;40:1338&#x2013;1350. doi: 10.1177/0271678X19865917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X19865917</ArticleId><ArticleId IdType="pmc">PMC7238384</ArticleId><ArticleId IdType="pubmed">31357902</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojkova D, et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature. 2020;583:469&#x2013;472. doi: 10.1038/s41586-020-2332-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2332-7</ArticleId><ArticleId IdType="pmc">PMC7616921</ArticleId><ArticleId IdType="pubmed">32408336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoehl S, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N. Engl. J. Med. 2020;382:1278&#x2013;1280. doi: 10.1056/NEJMc2001899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2001899</ArticleId><ArticleId IdType="pmc">PMC7121749</ArticleId><ArticleId IdType="pubmed">32069388</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfefferle, S. et al. Complete genome sequence of a SARS-CoV-2 strain isolated in northern Germany. Microbiol. Resour. Announc.9, e00520-20 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272567</ArticleId><ArticleId IdType="pubmed">32499358</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan HC, Fu GK, Fodor SP. Expression profiling. Combinatorial labeling of single cells for gene expression cytometry. Science. 2015;347:1258367. doi: 10.1126/science.1258367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1258367</ArticleId><ArticleId IdType="pubmed">25657253</ArticleId></ArticleIdList></Reference><Reference><Citation>Munawar A, et al. Elapid snake venom analyses show the specificity of the peptide composition at the level of genera Naja and Notechis. Toxins. 2014;6:850&#x2013;868. doi: 10.3390/toxins6030850.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/toxins6030850</ArticleId><ArticleId IdType="pmc">PMC3968365</ArticleId><ArticleId IdType="pubmed">24590383</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008;26:1367&#x2013;1372. doi: 10.1038/nbt.1511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1511</ArticleId><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan C, et al. OMERO: flexible, model-driven data management for experimental biology. Nat. Methods. 2012;9:245&#x2013;253. doi: 10.1038/nmeth.1896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1896</ArticleId><ArticleId IdType="pmc">PMC3437820</ArticleId><ArticleId IdType="pubmed">22373911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chozinski TJ, et al. Expansion microscopy with conventional antibodies and fluorescent proteins. Nat. Methods. 2016;13:485&#x2013;488. doi: 10.1038/nmeth.3833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3833</ArticleId><ArticleId IdType="pmc">PMC4929147</ArticleId><ArticleId IdType="pubmed">27064647</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaehtgens P. Flow of blood through narrow capillaries: rheological mechanisms determining capillary hematocrit and apparent viscosity. Biorheology. 1980;17:183&#x2013;189. doi: 10.3233/BIR-1980-171-220.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/BIR-1980-171-220</ArticleId><ArticleId IdType="pubmed">7407348</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunziker O, Abdel&#x2019;Al S, Schulz U. The aging human cerebral cortex: a stereological characterization of changes in the capillary net. J. Gerontol. 1979;34:345&#x2013;350. doi: 10.1093/geronj/34.3.345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geronj/34.3.345</ArticleId><ArticleId IdType="pubmed">429767</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, et al. Cerebral angiogenesis ameliorates pathological disorders in Nemo-deficient mice with small-vessel disease. J. Cereb. Blood Flow Metab. 2021;41:219&#x2013;235. doi: 10.1177/0271678X20910522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0271678X20910522</ArticleId><ArticleId IdType="pmc">PMC8369998</ArticleId><ArticleId IdType="pubmed">32151223</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34706971</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>20</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Trends in Mortality From Parkinson Disease in the United States, 1999-2019.</ArticleTitle><Pagination><StartPage>e1986</StartPage><EndPage>e1993</EndPage><MedlinePgn>e1986-e1993</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000012826</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">The mortality from Parkinson disease (PD) and its long-term trends in the United States in recent decades remains unknown. This study aimed to describe the trends in PD mortality in the United States from 1999 to 2019.</AbstractText><AbstractText Label="METHODS">We used data from the National Vital Statistics System, a nationwide, population-based death registry, to determine national trends in PD mortality, overall and by age, sex, race/ethnicity, urban-rural classification, and geographic location. Analyses focused on the data from 479,059 deaths due to PD from 1999 to 2019. Joinpoint regression was performed to examine temporal trends in age-adjusted death rates.</AbstractText><AbstractText Label="RESULTS">The age-adjusted mortality from PD increased from 5.4 (95% confidence interval [CI] 5.3-5.5) per 100,000 population in 1999 to 8.8 (95% CI, 8.7-8.9) per 100,000 population in 2019, with an average annual percent change of 2.4% (95% CI, 1.8%-3.0%). From 1999 to 2019, PD mortality increased significantly across all age groups, both sexes, various racial/ethnic groups, and different urban-rural classifications. The US states and District of Columbia with reported death rates all experienced an increase in PD mortality. Significant differences by sex and race/ethnicity were noted. Age-adjusted PD mortality rates were twice as high in men as in women and were greater in White individuals than those from other racial/ethnic groups.</AbstractText><AbstractText Label="DISCUSSION">From 1999 to 2019, the mortality from PD in the United States has increased significantly. The increase was regardless of age, sex, race/ethnicity, urban-rural classification, and geographic location. A comprehensive evaluation of long-term trends in PD mortality is important for health care priority setting.</AbstractText><CopyrightInformation>&#xa9; 2021 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rong</LastName><ForeName>Shuang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition and Food Hygiene (S.R., B.L., J.L.), School of Public Health, Medical College, Wuhan University of Science and Technology, China; and Department of Epidemiology (S.R., G.X., B.L., Y.S., L.G.S., R.B.W., W.B.), College of Public Health, University of Iowa, Iowa City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Guifeng</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition and Food Hygiene (S.R., B.L., J.L.), School of Public Health, Medical College, Wuhan University of Science and Technology, China; and Department of Epidemiology (S.R., G.X., B.L., Y.S., L.G.S., R.B.W., W.B.), College of Public Health, University of Iowa, Iowa City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Buyun</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition and Food Hygiene (S.R., B.L., J.L.), School of Public Health, Medical College, Wuhan University of Science and Technology, China; and Department of Epidemiology (S.R., G.X., B.L., Y.S., L.G.S., R.B.W., W.B.), College of Public Health, University of Iowa, Iowa City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yangbo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition and Food Hygiene (S.R., B.L., J.L.), School of Public Health, Medical College, Wuhan University of Science and Technology, China; and Department of Epidemiology (S.R., G.X., B.L., Y.S., L.G.S., R.B.W., W.B.), College of Public Health, University of Iowa, Iowa City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snetselaar</LastName><ForeName>Linda G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition and Food Hygiene (S.R., B.L., J.L.), School of Public Health, Medical College, Wuhan University of Science and Technology, China; and Department of Epidemiology (S.R., G.X., B.L., Y.S., L.G.S., R.B.W., W.B.), College of Public Health, University of Iowa, Iowa City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition and Food Hygiene (S.R., B.L., J.L.), School of Public Health, Medical College, Wuhan University of Science and Technology, China; and Department of Epidemiology (S.R., G.X., B.L., Y.S., L.G.S., R.B.W., W.B.), College of Public Health, University of Iowa, Iowa City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Benchao</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition and Food Hygiene (S.R., B.L., J.L.), School of Public Health, Medical College, Wuhan University of Science and Technology, China; and Department of Epidemiology (S.R., G.X., B.L., Y.S., L.G.S., R.B.W., W.B.), College of Public Health, University of Iowa, Iowa City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Jingling</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Nutrition and Food Hygiene (S.R., B.L., J.L.), School of Public Health, Medical College, Wuhan University of Science and Technology, China; and Department of Epidemiology (S.R., G.X., B.L., Y.S., L.G.S., R.B.W., W.B.), College of Public Health, University of Iowa, Iowa City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-7301-5786</Identifier><AffiliationInfo><Affiliation>From the Department of Nutrition and Food Hygiene (S.R., B.L., J.L.), School of Public Health, Medical College, Wuhan University of Science and Technology, China; and Department of Epidemiology (S.R., G.X., B.L., Y.S., L.G.S., R.B.W., W.B.), College of Public Health, University of Iowa, Iowa City. drwbao@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnicity</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005843" MajorTopicYN="N">Geography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="Y">Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044469" MajorTopicYN="N">Racial Groups</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012424" MajorTopicYN="N">Rural Population</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014505" MajorTopicYN="N">Urban Population</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>28</Day><Hour>5</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34706971</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000012826</ArticleId><ArticleId IdType="pii">WNL.0000000000012826</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34714685</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>44</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>29</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>eabh1448</StartPage><MedlinePgn>eabh1448</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabh1448</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abh1448</ELocationID><Abstract><AbstractText>Both the replication of protein aggregates and their spreading throughout the brain are implicated in the progression of Alzheimer&#x2019;s disease (AD). However, the rates of these processes are unknown and the identity of the rate-determining process in humans has therefore remained elusive. By bringing together chemical kinetics with measurements of tau seeds and aggregates across brain regions, we can quantify their replication rate in human brains. Notably, we obtain comparable rates in several different datasets, with five different methods of tau quantification, from postmortem seed amplification assays to tau PET studies in living individuals. Our results suggest that from Braak stage III onward, local replication, rather than spreading between brain regions, is the main process controlling the overall rate of accumulation of tau in neocortical regions. The number of seeds doubles only every &#x223c;5 years. Thus, limiting local replication likely constitutes the most promising strategy to control tau accumulation during AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meisl</LastName><ForeName>Georg</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-6562-7715</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidari</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-4777-5239</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Biomedical Campus, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allinson</LastName><ForeName>Kieren</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-3468-2110</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Biomedical Campus, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rittman</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1063-6937</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Biomedical Campus, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeVos</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0003-0921-1763</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, MassGeneral Institute for Neuro-degenerative Disease, Massachusetts General Hospital, Charlestown, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Denali Therapeutics Inc., South San Francisco, CA 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Justin S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0003-4421-3078</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, MassGeneral Institute for Neuro-degenerative Disease, Massachusetts General Hospital, Charlestown, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Catherine K</ForeName><Initials>CK</Initials><Identifier Source="ORCID">0000-0003-4726-636X</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duff</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials><Identifier Source="ORCID">0000-0002-6177-868X</Identifier><AffiliationInfo><Affiliation>Dementia Research Institute, University College London, London W1T 7NF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0002-5916-6043</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, MassGeneral Institute for Neuro-degenerative Disease, Massachusetts General Hospital, Charlestown, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>James B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0001-7216-8679</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Cambridge, Biomedical Campus, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Council Cognition and Brain Sciences Unit, Cambridge CB2 7EF, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cambridge University Hospitals NHS Trust, Cambridge CB2 0SZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><Identifier Source="ORCID">0000-0002-7959-9401</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Harvard Medical School, MassGeneral Institute for Neuro-degenerative Disease, Massachusetts General Hospital, Charlestown, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knowles</LastName><ForeName>Tuomas P J</ForeName><Initials>TPJ</Initials><Identifier Source="ORCID">0000-0002-7879-0140</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cavendish Laboratory, University of Cambridge, 19 JJ Thomson Avenue, Cambridge CB3 0HE, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klenerman</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7116-6954</Identifier><AffiliationInfo><Affiliation>Yusuf Hamied Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Cambridge, Cambridge CB2 0XY, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/M009041/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059789</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG056151</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG063521</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>17</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34714685</ArticleId><ArticleId IdType="pmc">PMC8555892</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abh1448</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chiti F., Dobson C. M., Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333&#x2013;366 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles T. P. J., Vendruscolo M., Dobson C. M., The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15, 384&#x2013;396 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24854788</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A., Frosch M. P., Masliah E., Hyman B. T., Neuropathological alterations in alzheimer disease. Cold Spring Harb. Perspect. Med. 1, a006189 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett R. E., De Vos S. L., Dujardin S., Corjuc B., Gor R., Gonzalez J., Roe A. D., Frosch M. P., Pitstick R., Carlson G. A., Hyman B. T., Enhanced tau aggregation in the presence of amyloid &#x3b2;. Am. J. Pathol. 187, 1601&#x2013;1612 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5500829</ArticleId><ArticleId IdType="pubmed">28500862</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M., Guo J. L., McBride J. D., Zhang B., Trojanowski J. Q., Lee V. M.-Y., Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of alzheimer&#x2019;s-like tauopathy. J. Neurosci. 33, 1024&#x2013;1037 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F., Bolmont T., Anthony Crowther R., Abramowski D., Frank S., Probst A., Fraser G., Stalder A. K., Beibel M., Staufenbiel M., Jucker M., Goedert M., Tolnay M., Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909&#x2013;913 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F., Akatsu H., Fraser G., Anthony Crowther R., Frank S., Hench J., Probst A., Winkler D. T., Reichwald J., Staufenbiel M., Ghetti B., Goedert M., Tolnay M., Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. U.S.A. 110, 9535&#x2013;9540 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Drouet V., Wu J. W., Witter M. P., Small S. A., Clelland C., Duff K., Trans-synaptic spread of tau pathology in vivo. PLOS ONE 7, e31302 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Dujardin S., Commins C., Lathuiliere A., Beerepoot P., Fernandes A. R., Kamath T. V., De Los Santos M. B., Klickstein N., Corjuc D. L., Corjuc B. T., Dooley P. M., Viode A., Oakley D. H., Moore B. D., Mullin K., Jean-Gilles D., Clark R., Atchison K., Moore R., Chibnik L. B., Tanzi R. E., Frosch M. P., Serrano-Pozo A., Elwood F., Steen J. A., Kennedy M. E., Hyman B. T., Tau molecular diversity contributes to clinical heterogeneity in alzheimer&#x2019;s disease. Nat. Med. 26, 1256&#x2013;1263 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603860</ArticleId><ArticleId IdType="pubmed">32572268</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H., Abid Hussaini S., Wegmann S., Profaci C., Daniels J. D., Herman M., Emrani S., Figueroa H. Y., Hyman B. T., Davies P., Duff K. E., 3d visualization of the temporal and spatial spread of tau pathology reveals extensive sites of tau accumulation associated with neuronal loss and recognition memory deficit in aged tau transgenic mice. PLOS ONE 11, e0159463 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4965059</ArticleId><ArticleId IdType="pubmed">27466814</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S., Maury E. A., Kirk M. J., Saqran L., Roe A., De Vos S. L., Nicholls S., Fan Z., Takeda S., Cagsal-Getkin O., William C. M., Spires-Jones T. L., Pitstick R., Carlson G. A., Pooler A. M., Hyman B. T., Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO J. 34, 3028&#x2013;3041 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4687785</ArticleId><ArticleId IdType="pubmed">26538322</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A., Polydoro M., Su&#xe1;rez-Calvet M., William C., Adamowicz D. H., Kopeikina K. J., Pitstick R., Sahara N., Ashe K. H., Carlson G. A., Spires-Jones T. L., Hyman B. T., Propagation of tau pathology in a model of early alzheimer&#x2019;s disease. Neuron 73, 685&#x2013;697 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Thal D. R., Ghebremedhin E., Tredici K. D., Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960&#x2013;969 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cope T. E., Rittman T., Borchert R. J., Jones P. S., Vatansever D., Allinson K., Passamonti L., Rodriguez P. V., Bevan-Jones W. R., O&#x2019;Brien J. T., Rowe J. B., Tau burden and the functional connectome in Alzheimer&#x2019;s disease and progressive supranuclear palsy. Brain 141, 550&#x2013;567 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837359</ArticleId><ArticleId IdType="pubmed">29293892</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher R. A., The wave of advance of advantageous genes. Ann. Eugenics 7, 353&#x2013;369 (1937).</Citation></Reference><Reference><Citation>Cohen S. I. A., Rajah L., Yoon C. H., Buell A. K., White D. A., Sperling R. A., Vendruscolo M., Terentjev E. M., Dobson C. M., Weitz D. A., Knowles T. P. J., Spatial propagation of protein polymerization. Phys. Rev. Lett. 112, 098101 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24655282</ArticleId></ArticleIdList></Reference><Reference><Citation>Weickenmeier J., Kuhl E., Goriely A., Multiphysics of prionlike diseases: Progression and atrophy. Phys. Rev. Lett. 121, 158101 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30362787</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos S. L., Corjuc B. T., Oakley D. H., Nobuhara C. K., Bannon R. N., Chase A., Commins C., Gonzalez J. A., Dooley P. M., Frosch M. P., Hyman B. T., Synaptic tau seeding precedes tau pathology in human Alzheimer&#x2019;s disease brain. Front. Neurosci. 12, 267 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5928393</ArticleId><ArticleId IdType="pubmed">29740275</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman J. L., Vaquer-Alicea J., White C. L., Cairns N. J., Nelson P. T., Diamond M. I., Widespread tau seeding activity at early braak stages. Acta Neuropathol. 133, 91&#x2013;100 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833300</ArticleId><ArticleId IdType="pubmed">27878366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman S. K., Tredici K. D., Thomas T. L., Braak H., Diamond M. I., Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer&#x2019;s disease and part. Acta Neuropathol. 136, 57&#x2013;67 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015098</ArticleId><ArticleId IdType="pubmed">29752551</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T., Hollister R., West H., Mui S., Growdon J. H., Petersen R. C., Parisi J. E., Hyman B. T., Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019;s disease. Ann. Neurol. 41, 17&#x2013;24 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian J., Hyman B. T., Betensky R. A., Neurofibrillary tangle stage and the rate of progression of Alzheimer symptoms: Modeling using an autopsy cohort and application to clinical trial design. JAMA Neurol. 74, 540&#x2013;548 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5547572</ArticleId><ArticleId IdType="pubmed">28288263</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez J. S., Becker J. A., Jacobs H. I. L., Hanseeuw B. J., Jiang S., Schultz A. P., Properzi M. J., Katz S. R., Beiser A., Satizabal C. L., O&#x2019;Donnell A., De Carli C., Killiany R., Fakhri G. E., Normandin M. D., G&#xf3;mez-Isla T., Quiroz Y. T., Rentz D. M., Sperling R. A., Seshadri S., Augustinack J., Price J. C., Johnson K. A., The cortical origin and initial spread of medial temporal tauopathy in Alzheimer&#x2019;s disease assessed with positron emission tomography. Sci. Transl. Med. 13, eabc0655 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7978042</ArticleId><ArticleId IdType="pubmed">33472953</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes B. B., Furman J. L., Mahan T. E., Yamasaki T. R., Mirbaha H., Eades W. C., Belaygorod L., Cairns N. J., Holtzman D. M., Diamond M. I., Proteopathic tau seeding predicts tauopathy in vivo. Proc. Natl. Acad. Sci. U.S.A. 111, E4376&#x2013;E4385 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205609</ArticleId><ArticleId IdType="pubmed">25261551</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles T. P. J., Waudby C. A., Devlin G. L., Cohen S. I. A., Aguzzi A., Vendruscolo M., Terentjev E. M., Welland M. E., Dobson C. M., An analytical solution to the kinetics of breakable filament assembly. Science 326, 1533&#x2013;1537 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">20007899</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisl G., Kurt T., Condado-Morales I., Bett C., Sorce S., Nuvolone M., Michaels T. C. T., Heinzer D., Avar M., Cohen S. I. A., Hornemann S., Aguzzi A., Dobson C. M., Sigurdson C. J., Knowles T. P. J., Scaling analysis reveals the mechanism and rates of prion replication in vivo. Nat. Struct. Mol. Biol. 28, 365&#x2013;372 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8922999</ArticleId><ArticleId IdType="pubmed">33767451</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundel F., Hong L., Falcon B., McEwan W. A., Michaels T. C. T., Meisl G., Esteras N., Abramov A. Y., Knowles T. J. P., Goedert M., Klenerman D., Measurement of tau filament fragmentation provides insights into prion-like spreading. ACS Chem. Neurosci. 9, 1276&#x2013;1282 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6014609</ArticleId><ArticleId IdType="pubmed">29590529</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegmann S., Eftekharzadeh B., Tepper K., Zoltowska K. M., Bennett R. E., Dujardin S., Laskowski P. R., Kenzie D. M., Kamath T., Commins C., Vanderburg C., Roe A. D., Fan Z., Molliex A. M., Hernandez-Vega A., Muller D., Hyman A. A., Mandelkow E., Taylor J. P., Hyman B. T., Tau protein liquid&#x2013;liquid phase separation can initiate tau aggregation. EMBO J. 37, e98049 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5881631</ArticleId><ArticleId IdType="pubmed">29472250</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans L. D., Wassmer T., Fraser G., Smith J., Perkinton M., Billinton A., Livesey F. J., Extracellular monomeric and aggregated tau efficiently enter human neurons through overlapping but distinct pathways. Cell Rep. 22, 3612&#x2013;3624 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5896171</ArticleId><ArticleId IdType="pubmed">29590627</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan W. A., Falcon B., Vaysburd M., Clift D., Oblak A. L., Ghetti B., Goedert M., James L. C., Cytosolic fc receptor trim21 inhibits seeded tau aggregation. Proc. Natl. Acad. Sci. U.S.A. 114, 574&#x2013;579 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5255578</ArticleId><ArticleId IdType="pubmed">28049840</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z., Cooper J., Murray T. K., Garn K., Naughton E. M., Clarke H., Parhizkar S., Ward M. A., Cavallini A., Jackson S., Bose S., Clavaguera F., Tolnay M., Lavenir I., Goedert M., Hutton M. L., O&#x2019;Neill M. J., A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: The pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 127, 667&#x2013;683 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4252866</ArticleId><ArticleId IdType="pubmed">24531916</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzmeier N., Neitzel J., Rubinski A., Smith R., Strandberg O., Ossenkoppele R., Hansson O., Ewers M.; Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) , Functional brain architecture is associated with the rate of tau accumulation in Alzheimer&#x2019;s disease. Nat. Commun. 11, 347 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6969065</ArticleId><ArticleId IdType="pubmed">31953405</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoyagi A., Condello C., St&#xf6;hr J., Yue W., Rivera B. M., Lee J. C., Woerman A. L., Halliday G., van Duinen S., Ingelsson M., Lannfelt L., Graff C., Bird T. D., Dirk Keene C., Seeley W. W., De Grado W. F., Prusiner S. B., A&#x3b2; and tau prion-like activities decline with longevity in the Alzheimer&#x2019;s disease human brain. Sci. Transl. Med. 11, eaat8462 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6640844</ArticleId><ArticleId IdType="pubmed">31043574</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell J. L., Martin P., Graff-Radford J., Machulda M. M., Senjem M. L., Schwarz C. G., Weigand S. D., Spychalla A. J., Drubach D. A., Jack C. R. Jr., Lowe V. J., Josephs K. A., The role of age on tau pet uptake and gray matter atrophy in atypical Alzheimer&#x2019;s disease. Alzheimers Dement. 15, 675&#x2013;685 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6511453</ArticleId><ArticleId IdType="pubmed">30853465</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittington A., Sharp D. J., Gunn R. N., Spatiotemporal distribution of &#x3b2;-amyloid in Alzheimer disease is the result of heterogeneous regional carrying capacities. J. Nucl. Med. 59, 822&#x2013;827 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932528</ArticleId><ArticleId IdType="pubmed">29146694</ArticleId></ArticleIdList></Reference><Reference><Citation>G. Meisl, A. J. Dear, T. C. T. Michaels, T. P. J. Knowles, Mechanism, scaling and rates of protein aggregation from in vivo measurements. arXiv:2008.09699 [physics.bio-ph] (21 August 2020).</Citation></Reference><Reference><Citation>Hanseeuw B. J., Betensky R. A., Jacobs H. I. L., Schultz A. P., Sepulcre J., Alex Becker J., Cosio D. M. O., Farrell M., Quiroz Y. T., Mormino E. C., Buckley R. F., Papp K. V., Amariglio R. A., Dewachter I., Ivanoiu A., Huijbers W., Hedden T., Marshall G. A., Chhatwal J. P., Rentz D. M., Sperling R. A., Johnson K., Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study. JAMA Neurol. 76, 915&#x2013;924 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6547132</ArticleId><ArticleId IdType="pubmed">31157827</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang J. C., Meisl G., Thackray A. M., Hong L., Ponjavic A., Knowles T. P. J., Bujdoso R., Klenerman D., Direct observation of murine prion protein replication in vitro. J. Am. Chem. Soc. 140, 14789&#x2013;14798 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6225343</ArticleId><ArticleId IdType="pubmed">30351023</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisl G., Yang X., Dobson C. M., Linse S., Knowles T. P. J., Modulation of electrostatic interactions to reveal a reaction network unifying the aggregation behaviour of the a&#x3b2;42 peptide and its variants. Chem. Sci. 8, 4352&#x2013;4362 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5580342</ArticleId><ArticleId IdType="pubmed">28979758</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson S. J., Kerridge C., Cooper J., Cavallini A., Falcon B., Cella C. V., Landi A., Szekeres P. G., Murray T. K., Ahmed Z., Goedert M., Hutton M., O&#x2019;Neill M. J., Bose S., Short fibrils constitute the major species of seed-competent tau in the brains of mice transgenic for human p301s tau. J. Neurosci. 36, 762&#x2013;772 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4719013</ArticleId><ArticleId IdType="pubmed">26791207</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick A. W. P., Falcon B., He S., Murzin A. G., Murshudov G., Garringer H. J., Anthony Crowther R., Ghetti B., Goedert M., Scheres S. H. W., Cryo-em structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547, 185&#x2013;190 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34719765</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>143</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Genome-wide association study and functional validation implicates JADE1 in tauopathy.</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>53</EndPage><MedlinePgn>33-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-021-02379-z</ELocationID><Abstract><AbstractText>Primary age-related tauopathy (PART) is a neurodegenerative pathology with features distinct from but also overlapping with Alzheimer disease (AD). While both exhibit Alzheimer-type temporal lobe neurofibrillary degeneration alongside amnestic cognitive impairment, PART develops independently of amyloid-&#x3b2; (A&#x3b2;) plaques. The pathogenesis of PART is not known, but evidence&#xa0;suggests an&#xa0;association with genes that promote tau pathology and others that protect from A&#x3b2; toxicity. Here, we performed a genetic association study in an autopsy cohort of individuals with PART (n&#x2009;=&#x2009;647) using Braak neurofibrillary tangle stage as a quantitative trait. We found some significant associations with candidate loci associated with AD (SLC24A4, MS4A6A, HS3ST1) and progressive supranuclear palsy (MAPT and EIF2AK3). Genome-wide association analysis revealed a novel significant association with a single nucleotide polymorphism on chromosome 4 (rs56405341) in a locus containing three genes, including JADE1 which was significantly upregulated in tangle-bearing neurons by single-soma RNA-seq. Immunohistochemical studies using antisera targeting JADE1 protein revealed localization within tau aggregates in autopsy brains with four microtubule-binding domain repeats (4R) isoforms and mixed 3R/4R, but not with 3R exclusively. Co-immunoprecipitation in post-mortem human PART brain tissue revealed a specific binding of JADE1 protein to four repeat tau lacking N-terminal inserts (0N4R). Finally, knockdown of the Drosophila JADE1 homolog rhinoceros (rno) enhanced tau-induced toxicity and apoptosis in vivo in a humanized 0N4R mutant tau knock-in model, as quantified by rough eye phenotype and terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) in the fly brain. Together, these findings indicate that PART has a genetic architecture that partially overlaps with AD and other tauopathies and suggests a novel role for JADE1 as a modifier of neurofibrillary degeneration.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Farrell</LastName><ForeName>Kurt</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Neuropathology Brain Bank and Research CoRE, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>SoongHo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, Neuropathology Brain Bank and Research CoRE, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, Neuropathology Brain Bank and Research CoRE, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iida</LastName><ForeName>Megan A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Pathology, Neuropathology Brain Bank and Research CoRE, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Elias M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Cell Systems and Anatomy, Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, the Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otero-Garcia</LastName><ForeName>Marcos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Division of Neuropathology, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Jamie M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Timothy E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Pathology and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renton</LastName><ForeName>Alan E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Shea J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fulton-Howard</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Humphrey</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vialle</LastName><ForeName>Ricardo A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowles</LastName><ForeName>Kathryn R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Paiva Lopes</LastName><ForeName>Katia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitney</LastName><ForeName>Kristen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pathology, Neuropathology Brain Bank and Research CoRE, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dangoor</LastName><ForeName>Diana K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Pathology, Neuropathology Brain Bank and Research CoRE, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Hadley</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology, Neuropathology Brain Bank and Research CoRE, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcora</LastName><ForeName>Edoardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hefti</LastName><ForeName>Marco M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casella</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Neuropathology Brain Bank and Research CoRE, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sissoko</LastName><ForeName>Cheick T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Pathology, Neuropathology Brain Bank and Research CoRE, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapoor</LastName><ForeName>Manav</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novikova</LastName><ForeName>Gloriia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Udine</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Garrett</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Weijing</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Palo Alto, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhangale</LastName><ForeName>Tushar</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Genentech, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunkapiller</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Genentech, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayalon</LastName><ForeName>Gai</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neumora Therapeutics, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Robert R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Maze Therapeutics, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cherry</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), VA Medical Center, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortes</LastName><ForeName>Etty P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Department of Pathology, Neuropathology Brain Bank and Research CoRE, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borukov</LastName><ForeName>Valeriy Y</ForeName><Initials>VY</Initials><AffiliationInfo><Affiliation>Department of Pathology, Neuropathology Brain Bank and Research CoRE, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>Ann C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), VA Medical Center, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Thor D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), VA Medical Center, Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vonsattel</LastName><ForeName>Jean-Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Department of Neurology, and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teich</LastName><ForeName>Andy F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Department of Neurology, and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine (Neuropathology) and Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine (Neuropathology) and Neurology, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pathology, Division of Neuropathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Neurology and Pathology, Harvard Medical School and Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology and Pathology, Harvard Medical School and Massachusetts General Hospital, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attems</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flanagan</LastName><ForeName>Margaret E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), Northwestern Cognitive Neurology and Alzheimer Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qinwen</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), Northwestern Cognitive Neurology and Alzheimer Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mesulam</LastName><ForeName>M-Marsel</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), Northwestern Cognitive Neurology and Alzheimer Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), Northwestern Cognitive Neurology and Alzheimer Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woltjer</LastName><ForeName>Randy L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Pathology, Oregon Health Sciences University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Thao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Oregon Health Sciences University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kofler</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Departments of Pathology (Neuropathology) and Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departments of Pathology (Neuropathology) and Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purohit</LastName><ForeName>Dushyant P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Pathology, Neuropathology Brain Bank and Research CoRE, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Alzheimer's Disease Research Center, James J. Peters VA Medical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haroutunian</LastName><ForeName>Vahram</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Alzheimer's Disease Research Center, James J. Peters VA Medical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hof</LastName><ForeName>Patrick R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandy</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Alzheimer's Disease Research Center, James J. Peters VA Medical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Center for Cognitive Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Alzheimer's Disease Research Center, James J. Peters VA Medical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Department of Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Wayne</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Department of Epidemiology, Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawas</LastName><ForeName>Claudia H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corrada</LastName><ForeName>Mar&#xed;a M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Department of Epidemiology, Institute for Memory Impairments and Neurological Disorders, UC Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rissman</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurosciences University of California and the Veterans Affairs San Diego Healthcare System, La Jolla, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metcalf</LastName><ForeName>Jeff</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences University of California and the Veterans Affairs San Diego Healthcare System, La Jolla, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shuldberg</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurosciences University of California and the Veterans Affairs San Diego Healthcare System, La Jolla, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salehi</LastName><ForeName>Bahar</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurosciences University of California and the Veterans Affairs San Diego Healthcare System, La Jolla, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Peter T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology) and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolk</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Corey T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, University of f Medicine, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latimer</LastName><ForeName>Caitlin S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, University of f Medicine, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, University of f Medicine, Seattle, WA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Palo Alto, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Gabor G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Laboratory Medicine Program, Krembil Brain Institute, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Disease and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lutz</LastName><ForeName>Mirjam I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Institute of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Danube Hospital, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrin</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Department of Neurology, Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>College of Medicine and Health, University of Exeter, Exeter, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franklin</LastName><ForeName>Erin E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Department of Pathology and Immunology, Department of Neurology, Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Herbert T</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Departments of Medicine, Pathology, and Pharmacology, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raj</LastName><ForeName>Towfique</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cobos</LastName><ForeName>Inma</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University, Palo Alto, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Bess</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cell Systems and Anatomy, Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, the Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White Iii</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Pathology (Neuropathology), University of Texas Southwestern Medical School, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crary</LastName><ForeName>John F</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0002-0556-293X</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Neuropathology Brain Bank and Research CoRE, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA. john.crary@mountsinai.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nash Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. john.crary@mountsinai.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA. john.crary@mountsinai.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG000538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG070109</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054008</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG065463</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L016451/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072946</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066518</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021055</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA079830</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066511</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG059848</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG062348</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>75N95019C00049</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072980</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062429</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD026880</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS115266</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS109284</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG066152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066462</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS086736</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066530</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0400074</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS095252</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG066597</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001414</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072977</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 OD030463</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG062418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG060961</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS072026</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066468</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG058635</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG066567</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS095252</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG056098</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS055077</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072979</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C469360">JADE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018398" MajorTopicYN="N">Homeodomain Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of interest</b> JFC, DWD, MF, PRH, GGK, EBL, PTN, JQT, are editorial board members and JA is editor in chief of Acta Neuropathologica, but were not involved in the editorial handling of this article. JH, TB, are employees of Genentech (a subsidiary of Roche) and hold stocks/stock options in FH-LR Ltd. AG is on the Scientific advisory board for Genentech and consultant for AbbVie. All other authors declare no relevant conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34719765</ArticleId><ArticleId IdType="mid">NIHMS1770049</ArticleId><ArticleId IdType="pmc">PMC8786260</ArticleId><ArticleId IdType="doi">10.1007/s00401-021-02379-z</ArticleId><ArticleId IdType="pii">10.1007/s00401-021-02379-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abner EL, Neltner JH, Jicha GA, Patel E, Anderson SL, Wilcock DM et al. (2018) Diffuse amyloid-beta plaques, neurofibrillary tangles, and the impact of APOE in elderly persons&#x2019; brains lacking neuritic amyloid plaques. J Alzh Dis 64:1307&#x2013;1324. 10.3233/Jad-180514</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/Jad-180514</ArticleId><ArticleId IdType="pmc">PMC6537103</ArticleId><ArticleId IdType="pubmed">30040735</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldridge GM, Podrebarac DM, Greenough WT, Weiler IJ (2008) The use of total protein stains as loading controls: an alternative to high-abundance single-protein controls in semi-quantitative immunoblotting. J Neurosci Methods 172:250&#x2013;254. 10.1016/j.jneumeth.2008.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2008.05.003</ArticleId><ArticleId IdType="pmc">PMC2567873</ArticleId><ArticleId IdType="pubmed">18571732</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT (2010) Data quality control in genetic case-control association studies. Nat Protoc 5:1564&#x2013;1573. 10.1038/nprot.2010.116</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2010.116</ArticleId><ArticleId IdType="pmc">PMC3025522</ArticleId><ArticleId IdType="pubmed">21085122</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews SJ, Fulton-Howard B, Goate A (2020) Interpretation of risk loci from genome-wide association studies of Alzheimer&#x2019;s disease. Lancet Neurol 19:326&#x2013;335. 10.1016/S1474-4422(19)30435-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30435-1</ArticleId><ArticleId IdType="pmc">PMC8176461</ArticleId><ArticleId IdType="pubmed">31986256</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer&#x2019;s disease. Acta Neuropathol 103:26&#x2013;35. 10.1007/s004010100423</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010100423</ArticleId><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ et al. (2014) Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer&#x2019;s disease and related dementias. Plos Genet. 10.1371/journal.pgen.1004606</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004606</ArticleId><ArticleId IdType="pmc">PMC4154667</ArticleId><ArticleId IdType="pubmed">25188341</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell WR, An Y, Kageyama Y, English C, Rudow GL, Pletnikova O et al. (2019) Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer&#x2019;s disease. Alzheimers Dement 15:8&#x2013;16. 10.1016/j.jalz.2018.07.215</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.07.215</ArticleId><ArticleId IdType="pmc">PMC6542566</ArticleId><ArticleId IdType="pubmed">30465754</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC et al. (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66:1837&#x2013;1844. 10.1212/01.wnl.0000219668.47116.e6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000219668.47116.e6</ArticleId><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Besser LM, Crary JF, Mock C, Kukull WA (2017) Comparison of symptomatic and asymptomatic persons with primary age-related tauopathy. Neurology 89:1707&#x2013;1715. 10.1212/WNL.0000000000004521</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004521</ArticleId><ArticleId IdType="pmc">PMC5644462</ArticleId><ArticleId IdType="pubmed">28916532</ArticleId></ArticleIdList></Reference><Reference><Citation>Besser LM, Mock C, Teylan MA, Hassenstab J, Kukull WA, Crary JF (2019) Differences in cognitive impairment in primary age-related tauopathy versus alzheimer disease. J Neuropath Exp Neur 78:219&#x2013;228. 10.1093/jnen/nly132</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nly132</ArticleId><ArticleId IdType="pmc">PMC6380319</ArticleId><ArticleId IdType="pubmed">30715383</ArticleId></ArticleIdList></Reference><Reference><Citation>Boettger LM, Handsaker RE, Zody MC, McCarroll SA (2012) Structural haplotypes and recent evolution of the human 17q21.31 region. Nat Genet 44:881&#x2013;882. 10.1038/ng.2334</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2334</ArticleId><ArticleId IdType="pmc">PMC4020351</ArticleId><ArticleId IdType="pubmed">22751096</ArticleId></ArticleIdList></Reference><Reference><Citation>Boone DK, Weisz HA, Bi M, Falduto MT, Torres KEO, Willey HE et al. (2017) Evidence linking microRNA suppression of essential prosurvival genes with hippocampal cell death after traumatic brain injury. Sci Rep 7:6645. 10.1038/s41598-017-06341-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-06341-6</ArticleId><ArticleId IdType="pmc">PMC5532254</ArticleId><ArticleId IdType="pubmed">28751711</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgal L, Habbig S, Hatzold J, Liebau MC, Dafinger C, Sacarea I et al. (2012) The ciliary protein nephrocystin-4 translocates the canonical Wnt regulator Jade-1 to the nucleus to negatively regulate beta-catenin signaling. J Biol Chem 287:25370&#x2013;25380. 10.1074/jbc.M112.385658</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.385658</ArticleId><ArticleId IdType="pmc">PMC3408186</ArticleId><ArticleId IdType="pubmed">22654112</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak E, Braak H, Mandelkow EM (1994) A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 87:554&#x2013;567. 10.1007/BF00293315</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00293315</ArticleId><ArticleId IdType="pubmed">7522386</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1995) Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol Aging 16:271&#x2013;278. 10.1016/0197-4580(95)00021-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(95)00021-6</ArticleId><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K (2014) Are cases with tau pathology occurring in the absence of A beta deposits part of the AD-related pathological process? Acta Neuropathol 128:767&#x2013;772. 10.1007/s00401-014-1356-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1356-1</ArticleId><ArticleId IdType="pubmed">25359108</ArticleId></ArticleIdList></Reference><Reference><Citation>Broce I, Karch CM, Wen N, Fan CC, Wang YP, Tan CH et al. (2018) Immune-related genetic enrichment in frontotemporal dementia: an analysis of genome-wide association studies. Plos Med. 10.1371/journal.pmed.1002487</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002487</ArticleId><ArticleId IdType="pmc">PMC5760014</ArticleId><ArticleId IdType="pubmed">29315334</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JA, Chen Z, Won H, Huang AY, Lowe JK, Wojta K et al. (2018) Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. Mol Neurodegener 13:41. 10.1186/s13024-018-0270-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0270-8</ArticleId><ArticleId IdType="pmc">PMC6083608</ArticleId><ArticleId IdType="pubmed">30089514</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitalia VC, Foy RL, Bachschmid MM, Zeng L, Panchenko MV, Zhou MI et al. (2008) Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat Cell Biol 10:1208&#x2013;1216. 10.1038/ncb1781</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1781</ArticleId><ArticleId IdType="pmc">PMC2830866</ArticleId><ArticleId IdType="pubmed">18806787</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke L, Fairley S, Zheng-Bradley XQ, Streeter I, Perry E, Lowy E et al. (2017) The international genome sample resource (IGSR): a worldwide collection of genome variation incorporating the 1000 genomes project data. Nucleic Acids Res 45:D854&#x2013;D859. 10.1093/nar/gkw829</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw829</ArticleId><ArticleId IdType="pmc">PMC5210610</ArticleId><ArticleId IdType="pubmed">27638885</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs B, Kanaan NM (2017) Exposure of the amino terminus of tau is a pathological event in multiple tauopathies. Am J Pathol 187:1222&#x2013;1229. 10.1016/j.ajpath.2017.01.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2017.01.019</ArticleId><ArticleId IdType="pmc">PMC5818634</ArticleId><ArticleId IdType="pubmed">28413156</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon EE, Sigurdsson EM (2018) Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol 14:399&#x2013;415. 10.1038/s41582-018-0013-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0013-z</ArticleId><ArticleId IdType="pmc">PMC6463489</ArticleId><ArticleId IdType="pubmed">29895964</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I et al. (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128:755&#x2013;766. 10.1007/s00401-014-1349-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1349-0</ArticleId><ArticleId IdType="pmc">PMC4257842</ArticleId><ArticleId IdType="pubmed">25348064</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A et al. (2016) Next-generation genotype imputation service and methods. Nat Genet 48:1284&#x2013;1287. 10.1038/ng.3656</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3656</ArticleId><ArticleId IdType="pmc">PMC5157836</ArticleId><ArticleId IdType="pubmed">27571263</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, Ma Y, McCabe C, Xu J, Vardarajan BN, Felsky D et al. (2018) A multi-omic atlas of the human frontal cortex for aging and Alzheimer&#x2019;s disease research. Sci Data 5:180142. 10.1038/sdata.2018.142</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2018.142</ArticleId><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Derisbourg M, Leghay C, Chiappetta G, Fernandez-Gomez FJ, Laurent C, Demeyer D et al. (2015) Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci Rep-Uk. 10.1038/srep09659</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep09659</ArticleId><ArticleId IdType="pmc">PMC4431475</ArticleId><ArticleId IdType="pubmed">25974414</ArticleId></ArticleIdList></Reference><Reference><Citation>Dregni AJ, Mandala VS, Wu H, Elkins MR, Wang HK, Hung I et al. (2019) In vitro 0N4R tau fibrils contain a monomorphic beta-sheet core enclosed by dynamically heterogeneous fuzzy coat segments. Proc Natl Acad Sci U S A 116:16357&#x2013;16366. 10.1073/pnas.1906839116</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1906839116</ArticleId><ArticleId IdType="pmc">PMC6697781</ArticleId><ArticleId IdType="pubmed">31358628</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Braak H, Brion JP, Buee L, Del Tredici K, Goedert M et al. (2015) PART is part of Alzheimer disease. Acta Neuropathol 129:749&#x2013;756. 10.1007/s00401-015-1390-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1390-7</ArticleId><ArticleId IdType="pmc">PMC4405349</ArticleId><ArticleId IdType="pubmed">25628035</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou AG, Goate AM (2017) Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol Neurodegener 12:43. 10.1186/s13024-017-0184-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0184-x</ArticleId><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Farfel JM, Yu L, De Jager PL, Schneider JA, Bennett DA (2016) Association of APOE with tau-tangle pathology with and without beta-amyloid. Neurobiol Aging 37:19&#x2013;25. 10.1016/j.neurobiolaging.2015.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.09.011</ArticleId><ArticleId IdType="pmc">PMC4716785</ArticleId><ArticleId IdType="pubmed">26481403</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK et al. (2015) MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol 16:278. 10.1186/s13059-015-0844-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-015-0844-5</ArticleId><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ et al. (2017) Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease. Nature 547:185&#x2013;190. 10.1038/nature23002</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23002</ArticleId><ArticleId IdType="pmc">PMC5552202</ArticleId><ArticleId IdType="pubmed">28678775</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Robins LN, Helzer JE (1983) The mini-mental state examination. Arch Gen Psychiatry 40:812.</Citation><ArticleIdList><ArticleId IdType="pubmed">6860082</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Ollesch J, Wille H, Diamond MI (2009) Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem 284:3546&#x2013;3551. 10.1074/jbc.M805627200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M805627200</ArticleId><ArticleId IdType="pmc">PMC2635036</ArticleId><ArticleId IdType="pubmed">19010781</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoglinger GU, Melhem NM, Dickson DW, Sleiman PMA, Wang LS, Klei L et al. (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43:699&#x2013;U125. 10.1038/ng.859</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.859</ArticleId><ArticleId IdType="pmc">PMC3125476</ArticleId><ArticleId IdType="pubmed">21685912</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Devos SL, Kfoury N, Li M, Jacks R, Yanamandra K et al. (2013) Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. P Natl Acad Sci USA 110:E3138&#x2013;E3147. 10.1073/pnas.1301440110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1301440110</ArticleId><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Prokopenko D, Dobricic V, Kilpert F, Bos I, Vos SJB et al. (2020) Genome-wide association study of Alzheimer&#x2019;s disease CSF biomarkers in the EMIF-AD multimodal biomarker discovery dataset. Trans Psychiatry 10:403. 10.1038/s41398-020-01074-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-020-01074-z</ArticleId><ArticleId IdType="pmc">PMC7680793</ArticleId><ArticleId IdType="pubmed">33223526</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H et al. (1998) Association of missense and 5&#x2019;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702&#x2013;705. 10.1038/31508</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/31508</ArticleId><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Iida MA, Farrell K, Walker JM, Richardson TE, Marx G, Bryce CH et al. (2021) Predictors of cognitive impairment in primary age-related tauopathy: an autopsy study. bioRxiv. 10.1101/2021.06.08.447553</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.08.447553</ArticleId><ArticleId IdType="pmc">PMC8340493</ArticleId><ArticleId IdType="pubmed">34353357</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Akiyama H, Arai T, Oda T, Kato M, Iseki E et al. (1999) Clinical aspects of &#x201c;senile dementia of the tangle type&#x201d; - A subset of dementia in the senium separable from late-onset Alzheimer&#x2019;s disease. Dement Geriatr Cogn 10:6&#x2013;11. 10.1159/000017091</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000017091</ArticleId><ArticleId IdType="pubmed">9844032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Akiyama H, Arai T, Sahara N, Mori H, Usami M et al. (1997) A subset of senile dementia with high incidence of the apolipoprotein E epsilon2 allele. Ann Neurol 41:693&#x2013;695. 10.1002/ana.410410522</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410522</ArticleId><ArticleId IdType="pubmed">9153535</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabbari E, Koga S, Valentino RR, Reynolds RH, Ferrari R, Tan MMX et al. (2021) Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurol 20:107&#x2013;116. 10.1016/S1474-4422(20)30394-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30394-X</ArticleId><ArticleId IdType="pmc">PMC7116626</ArticleId><ArticleId IdType="pubmed">33341150</ArticleId></ArticleIdList></Reference><Reference><Citation>Janocko NJ, Brodersen KA, Soto-Ortolaza AI, Ross OA, Lies-inger AM, Duara R et al. (2012) Neuropathologically defined subtypes of Alzheimer&#x2019;s disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol 124:681&#x2013;692. 10.1007/s00401-012-1044-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1044-y</ArticleId><ArticleId IdType="pmc">PMC3483034</ArticleId><ArticleId IdType="pubmed">22968369</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S et al. (2019) Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#x2019;s disease risk. Nat Genet 51:404&#x2013;413. 10.1038/s41588-018-0311-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0311-9</ArticleId><ArticleId IdType="pmc">PMC6836675</ArticleId><ArticleId IdType="pubmed">30617256</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Attems J (2007) Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. Acta Neuropathol 113:107&#x2013;117. 10.1007/s00401-006-0156-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0156-7</ArticleId><ArticleId IdType="pubmed">17089134</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert JC, Chung J, Naj AC et al. (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21:108&#x2013;117. 10.1038/mp.2015.23</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.23</ArticleId><ArticleId IdType="pmc">PMC4573764</ArticleId><ArticleId IdType="pubmed">25778476</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK et al. (2017) A unique microglia type associated with restricting development of alzheimer&#x2019;s disease. Cell 169(1276&#x2013;1290):e1217. 10.1016/j.cell.2017.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ et al. (2003) Neuropathology of cognitively normal elderly. J Neuropath Exp Neur 62:1087&#x2013;1095. 10.1093/jnen/62.11.1087</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/62.11.1087</ArticleId><ArticleId IdType="pubmed">14656067</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A et al. (2015) Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun. 10.1038/ncomms8247</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8247</ArticleId><ArticleId IdType="pmc">PMC4469997</ArticleId><ArticleId IdType="pubmed">26077951</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG (2015) Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol 41:3&#x2013;23. 10.1111/nan.12208</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12208</ArticleId><ArticleId IdType="pubmed">25495175</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H et al. (2016) Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol 131:87&#x2013;102. 10.1007/s00401-015-1509-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1509-x</ArticleId><ArticleId IdType="pmc">PMC4879001</ArticleId><ArticleId IdType="pubmed">26659578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC et al. (2019) Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet 51:414&#x2013;430. 10.1038/s41588-019-0358-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-019-0358-2</ArticleId><ArticleId IdType="pmc">PMC6463297</ArticleId><ArticleId IdType="pubmed">30820047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lafirdeen ASM, Cognat E, Sabia S, Hourregue C, Lilamand M, Dugravot A et al. (2019) Biomarker profiles of Alzheimer&#x2019;s disease and dynamic of the association between cerebrospinal fluid levels of beta-amyloid peptide and tau. PLoS ONE 14:e0217026. 10.1371/journal.pone.0217026</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0217026</ArticleId><ArticleId IdType="pmc">PMC6516653</ArticleId><ArticleId IdType="pubmed">31086391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C et al. (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#x2019;s disease. Nat Genet 45:1452&#x2013;1458. 10.1038/ng.2802</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2802</ArticleId><ArticleId IdType="pmc">PMC3896259</ArticleId><ArticleId IdType="pubmed">24162737</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson M, Duffy DL, Zhu G, Liu JZ, Macgregor S, McRae AF et al. (2011) GWAS findings for human iris patterns: associations with variants in genes that influence normal neuronal pattern development. Am J Hum Genet 89:334&#x2013;343. 10.1016/j.ajhg.2011.07.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2011.07.011</ArticleId><ArticleId IdType="pmc">PMC3155193</ArticleId><ArticleId IdType="pubmed">21835309</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Meilandt WJ, Xie L, Gandham VD, Ngu H, Barck KH et al. (2021) Trem2 restrains the enhancement of tau accumulation and neurodegeneration by beta-amyloid pathology. Neuron 109(1283&#x2013;1301):e1286. 10.1016/j.neuron.2021.02.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.02.010</ArticleId><ArticleId IdType="pubmed">33675684</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W (1999) The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Gene Dev 13:1822&#x2013;1833. 10.1101/gad.13.14.1822</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.13.14.1822</ArticleId><ArticleId IdType="pmc">PMC316884</ArticleId><ArticleId IdType="pubmed">10421634</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD et al. (2018) GWAS on family history of Alzheimer&#x2019;s disease. Transl Psychiatry 8:99. 10.1038/s41398-018-0150-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-018-0150-6</ArticleId><ArticleId IdType="pmc">PMC5959890</ArticleId><ArticleId IdType="pubmed">29777097</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C et al. (2013) Tau protein kinases: involvement in Alzheimer&#x2019;s disease. Ageing Res Rev 12:289&#x2013;309. 10.1016/j.arr.2012.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2012.06.003</ArticleId><ArticleId IdType="pubmed">22742992</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A et al. (2016) A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet 48:1279&#x2013;1283. 10.1038/ng.3643</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3643</ArticleId><ArticleId IdType="pmc">PMC5388176</ArticleId><ArticleId IdType="pubmed">27548312</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan CT, Lee EB, Jefferson-George K, Naj A, Van Deerlin VM, Trojanowski JQ et al. (2018) Alzheimer&#x2019;s genetic risk is reduced in primary age-related tauopathy: a potential model of resistance? Ann Clin Transl Neur 5:927&#x2013;934. 10.1002/acn3.581</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.581</ArticleId><ArticleId IdType="pmc">PMC6093846</ArticleId><ArticleId IdType="pubmed">30128317</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brown-lee LM et al. (1991) The consortium to establish a registry for Alzheimer&#x2019;s disease (CERAD). Part II standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology 41:479&#x2013;486</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell TW, Mufson EJ, Schneider JA, Cochran EJ, Nissanov J, Han LY et al. (2002) Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer&#x2019;s disease. Ann Neurol 51:182&#x2013;189. 10.1002/ana.10086</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10086</ArticleId><ArticleId IdType="pubmed">11835374</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43:2412&#x2013;2414</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungas D, Tractenberg R, Schneider JA, Crane PK, Bennett DA (2014) A 2-process model for neuropathology of Alzheimer&#x2019;s disease. Neurobiol Aging 35:301&#x2013;308. 10.1016/j.neurobiolaging.2013.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.08.007</ArticleId><ArticleId IdType="pmc">PMC3977862</ArticleId><ArticleId IdType="pubmed">24080173</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, Kaleem M, Marlowe L, Pittman AM, Lees AJ, Fung HC et al. (2005) The H1c haplotype at the MAPT locus is associated with Alzheimer&#x2019;s disease. Hum Mol Genet 14:2399&#x2013;2404. 10.1093/hmg/ddi241</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddi241</ArticleId><ArticleId IdType="pubmed">16000317</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, VatterBittner B, Braak H, Braak E, Yilmazer DM, Schultz C et al. (1997) Staging of Alzheimer-type pathology: an interrater-intrarater study. Dement Geriatr Cogn 8:248&#x2013;251. 10.1159/000106639</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000106639</ArticleId><ArticleId IdType="pubmed">9213071</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D et al. (2019) Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 18:1091&#x2013;1102. 10.1016/S1474-4422(19)30320-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30320-5</ArticleId><ArticleId IdType="pmc">PMC8422160</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Santacruz K et al. (2009) Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J Neuropathol Exp Neurol 68:774&#x2013;784. 10.1097/NEN.0b013e3181aacbe9</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181aacbe9</ArticleId><ArticleId IdType="pmc">PMC2725359</ArticleId><ArticleId IdType="pubmed">19535994</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al. (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362&#x2013;381. 10.1097/NEN.0b013e31825018f7</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS et al. (2007) Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles &#x201c;do count&#x201d; when staging disease severity. J Neuropathol Exp Neurol 66:1136&#x2013;1146. 10.1097/nen.0b013e31815c5efb</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31815c5efb</ArticleId><ArticleId IdType="pmc">PMC3034246</ArticleId><ArticleId IdType="pubmed">18090922</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak M, Jakes R, Edwards PC, Milstein C, Wischik CM (1991) Difference between the tau-protein of alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies-423 and antibodies-7.51. P Natl Acad Sci USA 88:5837&#x2013;5841. 10.1073/pnas.88.13.5837</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.13.5837</ArticleId><ArticleId IdType="pmc">PMC51973</ArticleId><ArticleId IdType="pubmed">1712107</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero-Garcia M, Xue Y-Q, Shakouri T, Deng Y, Morabito S, Allison T et al. (2020) Single-soma transcriptomics of tangle-bearing neurons in Alzheimer&#x2019;s disease reveals the signatures of tau-associated synaptic dysfunction. bioRxiv. 10.1101/2020.05.11.088591</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.11.088591</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagiotou OA, Ioannidis JPA, Project G-WS (2012) What should the genome-wide significance threshold be? Empirical replication of borderline genetic associations. Int J Epidemiol 41:273&#x2013;286. 10.1093/ije/dyr178</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyr178</ArticleId><ArticleId IdType="pubmed">22253303</ArticleId></ArticleIdList></Reference><Reference><Citation>Panchenko MV (2016) Structure, function and regulation of jade family PHD finger 1 (JADE1). Gene 589:1&#x2013;11. 10.1016/j.gene.2016.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2016.05.002</ArticleId><ArticleId IdType="pmc">PMC4903948</ArticleId><ArticleId IdType="pubmed">27155521</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38:904&#x2013;909. 10.1038/ng1847</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1847</ArticleId><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP et al. (2010) LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 26:2336&#x2013;2337. 10.1093/bioinformatics/btq419</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq419</ArticleId><ArticleId IdType="pmc">PMC2935401</ArticleId><ArticleId IdType="pubmed">20634204</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D et al. (2007) PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559&#x2013;575. 10.1086/519795</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/519795</ArticleId><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ et al. (2020) Exceptionally low likelihood of Alzheimer&#x2019;s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 10.1038/s41467-019-14279-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-14279-8</ArticleId><ArticleId IdType="pmc">PMC6997393</ArticleId><ArticleId IdType="pubmed">32015339</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Geser F, Corrada MM, Berlau DJ, Arnold SE, Lee VM et al. (2011) Neocortical and hippocampal amyloid-beta and tau measures associate with dementia in the oldest-old. Brain 134:3708&#x2013;3715. 10.1093/brain/awr308</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr308</ArticleId><ArticleId IdType="pmc">PMC3235569</ArticleId><ArticleId IdType="pubmed">22120149</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Contreras MY, Kouri N, Cook CN, Serie DJ, Heckman MG, Finch NA et al. (2018) Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Mol Neurodegener. 10.1186/s13024-018-0267-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0267-3</ArticleId><ArticleId IdType="pmc">PMC6038352</ArticleId><ArticleId IdType="pubmed">29986742</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Juan P, Moreno S, de Rojaso I, Hernandez I, Valero S, Alegret M et al. (2019) The MAPT H1 haplotype is a risk factor for Alzheimer&#x2019;s disease in APOE epsilon 4 non-carriers. Front Aging Neurosci. 10.3389/fnagi.2019.00327</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00327</ArticleId><ArticleId IdType="pmc">PMC6905227</ArticleId><ArticleId IdType="pubmed">31866851</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa-Maria I, Haggiagi A, Liu XM, Wasserscheid J, Nelson PT, Dewar K et al. (2012) The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol 124:693&#x2013;704. 10.1007/s00401-012-1017-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1017-1</ArticleId><ArticleId IdType="pmc">PMC3608475</ArticleId><ArticleId IdType="pubmed">22802095</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SH, Zhang W, Falcon B, Goedert M (2020) Cryo-EM structures of tau filaments. Curr Opin Struct Biol 64:17&#x2013;25. 10.1016/j.sbi.2020.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2020.05.011</ArticleId><ArticleId IdType="pubmed">32603876</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA (2009) The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 18:691&#x2013;701. 10.3233/Jad-2009-1227</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/Jad-2009-1227</ArticleId><ArticleId IdType="pmc">PMC2853869</ArticleId><ArticleId IdType="pubmed">19749406</ArticleId></ArticleIdList></Reference><Reference><Citation>Sealey MA, Vourkou E, Cowan CM, Bossing T, Quraishe S, Gram-menoudi S et al. (2017) Distinct phenotypes of three-repeat and four-repeat human tau in a transgenic model of tauopathy. Neurobiol Dis 105:74&#x2013;83. 10.1016/j.nbd.2017.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2017.05.003</ArticleId><ArticleId IdType="pubmed">28502805</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao LZ, Luo WJ et al. (2017) ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549:523&#x2013;524. 10.1038/nature24016</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24016</ArticleId><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieberts SK, Perumal TM, Carrasquillo MM, Allen M, Reddy JS, Hoffman GE et al. (2020) Large eQTL meta-analysis reveals differing patterns between cerebral cortical and cerebellar brain regions. Scient Data. 10.1038/s41597-020-00642-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-020-00642-8</ArticleId><ArticleId IdType="pmc">PMC7550587</ArticleId><ArticleId IdType="pubmed">33046718</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva MC, Ferguson FM, Cai Q, Donovan KA, Nandi G, Patnaik D et al. (2019) Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. Elife. 10.7554/eLife.45457</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.45457</ArticleId><ArticleId IdType="pmc">PMC6450673</ArticleId><ArticleId IdType="pubmed">30907729</ArticleId></ArticleIdList></Reference><Reference><Citation>Siriwardana NS, Meyer R, Havasi A, Dominguez I, Panchenko MV (2014) Cell cycle-dependent chromatin shuttling of HBO1-JADE1 histone acetyl transferase (HAT) complex. Cell Cycle 13:1885&#x2013;1901. 10.4161/cc.28759</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.28759</ArticleId><ArticleId IdType="pmc">PMC4111752</ArticleId><ArticleId IdType="pubmed">24739512</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith HL, Mallucci GR (2016) The unfolded protein response: mechanisms and therapy of neurodegeneration. Brain 139:2113&#x2013;2121. 10.1093/brain/aww101</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww101</ArticleId><ArticleId IdType="pmc">PMC4958893</ArticleId><ArticleId IdType="pubmed">27190028</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg KM, Antonacci F, Sudmant PH, Kidd JM, Campbell CD, Vives L et al. (2012) Structural diversity and African origin of the 17q21.31 inversion polymorphism. Nat Genet 44:872&#x2013;873. 10.1038/ng.2335</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2335</ArticleId><ArticleId IdType="pmc">PMC3408829</ArticleId><ArticleId IdType="pubmed">22751100</ArticleId></ArticleIdList></Reference><Reference><Citation>Strickland SL, Reddy JS, Allen M, N&#x2019;songo A, Burgess JD, Corda MM et al. (2020) MAPT haplotype-stratified GWAS reveals differential association for AD risk variants. Alzheimers Dement 16:983&#x2013;1002. 10.1002/alz.12099</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12099</ArticleId><ArticleId IdType="pmc">PMC7983911</ArticleId><ArticleId IdType="pubmed">32400971</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzbach LD, Xie SX, Naj AC, Albin R, Gilman S, Lee VMY et al. (2013) The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer&#x2019;s disease. Acta Neuropathol Com. 10.1186/2051-5960-1-31</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-1-31</ArticleId><ArticleId IdType="pmc">PMC3893579</ArticleId><ArticleId IdType="pubmed">24252572</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cauwenberghe C, Van Broeckhoven C, Sleegers K (2016) The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med 18:421&#x2013;430. 10.1038/gim.2015.117</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.117</ArticleId><ArticleId IdType="pmc">PMC4857183</ArticleId><ArticleId IdType="pubmed">26312828</ArticleId></ArticleIdList></Reference><Reference><Citation>Voas MG, Rebay I (2003) The novel plant homeodomain protein rhinoceros antagonizes Ras signaling in the Drosophila eye. Genetics 165:1993&#x2013;2006</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1462918</ArticleId><ArticleId IdType="pubmed">14704181</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker JM, Richardson TE, Farrell K, Iida MA, Foong C, Shang P et al. (2021) Early selective vulnerability of the CA2 hippocampal subfield in primary age-related tauopathy. J Neuropath Exp Neur 80:102&#x2013;111. 10.1093/jnen/nlaa153</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlaa153</ArticleId><ArticleId IdType="pmc">PMC8453611</ArticleId><ArticleId IdType="pubmed">33367843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesseling H, Mair W, Kumar M, Schlaffner CN, Tang S, Beerepoot P et al. (2020) Tau PTM profiles identify patient heterogeneity and stages of Alzheimer&#x2019;s disease. Cell 183(1699&#x2013;1713):e1613. 10.1016/j.cell.2020.10.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.029</ArticleId><ArticleId IdType="pmc">PMC8168922</ArticleId><ArticleId IdType="pubmed">33188775</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26:2190&#x2013;2191. 10.1093/bioinformatics/btq340</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq340</ArticleId><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M et al. (2001) Tauopathy in drosophila: neurodegeneration without neurofibrillary tangles. Science 293:711&#x2013;714. 10.1126/science.1062382</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1062382</ArticleId><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada M (2003) Senile dementia of the neurofibrillary tangle type (tangle-only dementia): neuropathological criteria and clinical guidelines for diagnosis. Neuropathology 23:311&#x2013;317. 10.1046/j.1440-1789.2003.00522.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1789.2003.00522.x</ArticleId><ArticleId IdType="pubmed">14719548</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama JS, Karch CM, Fan CC, Bonham LW, Kouri N, Ross OA et al. (2017) Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathol 133:825&#x2013;837. 10.1007/s00401-017-1693-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1693-y</ArticleId><ArticleId IdType="pmc">PMC5429027</ArticleId><ArticleId IdType="pubmed">28271184</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, Chibnik LB, Srivastava GP, Pochet N, Yang J, Xu J et al. (2015) Association of Brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4, and BIN1 with pathological diagnosis of Alzheimer disease. JAMA Neurol 72:15&#x2013;24. 10.1001/jamaneurol.2014.3049</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.3049</ArticleId><ArticleId IdType="pmc">PMC4344367</ArticleId><ArticleId IdType="pubmed">25365775</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng LL, Bai M, Mittal AK, El-Jouni W, Zhou J, Cohen DM et al. (2013) Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell Carcinoma. Cancer Res 73:5371&#x2013;5380. 10.1158/0008-5472.Can-12-4707</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.Can-12-4707</ArticleId><ArticleId IdType="pmc">PMC3766477</ArticleId><ArticleId IdType="pubmed">23824745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou MI, Foy RL, Chitalia VC, Zhao J, Panchenko MV, Wang HM et al. (2005) Jade-1, a candidate renal tumor suppressor that promotes apoptosis. P Natl Acad Sci USA 102:11035&#x2013;11040. 10.1073/pnas.0500757102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0500757102</ArticleId><ArticleId IdType="pmc">PMC1182408</ArticleId><ArticleId IdType="pubmed">16046545</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou MI, Wang H, Ross JJ, Kuzmin I, Xu C, Cohen HT (2002) The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1. J Biol Chem 277:39887&#x2013;39898. 10.1074/jbc.M205040200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M205040200</ArticleId><ArticleId IdType="pubmed">12169691</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR et al. (2020) Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat Med 26:131&#x2013;142. 10.1038/s41591-019-0695-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0695-9</ArticleId><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34724033</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of White Matter Hyperintensities With Pathology and Progression of Parkinsonism in Aging.</ArticleTitle><Pagination><StartPage>1494</StartPage><EndPage>1502</EndPage><MedlinePgn>1494-1502</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.3996</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Progressive parkinsonism is common in older adults without a diagnosis of Parkinson disease and is associated with adverse health outcomes, but its pathologic basis is controversial.</AbstractText><AbstractText Label="OBJECTIVE">To examine if the burden of cerebral white matter hyperintensity (WMH), a common manifestation of cerebrovascular disease pathologies, is associated with the rate of progressive parkinsonism.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This community-based cohort study included participants recruited in 3 ongoing cohorts that began enrollment in 1994, 1997, and 2004. Prior to death, participants were observed for a mean of 7.5 years, with annual clinical assessments. From 4427 participants enrolled in the 3 cohorts, 2134 died. Postmortem autopsy was performed in 1725 decedents, and 598 also had ex vivo brain magnetic resonance imaging. Participants were excluded if they were missing any of the 9 postmortem pathology indices (n&#x2009;=&#x2009;22) or repeated parkinsonism assessment (n&#x2009;=&#x2009;41) or had received a clinical diagnosis of Parkinson disease at any point before or during the study (n&#x2009;=&#x2009;19). Data were analyzed from April 2020 to August 2021.</AbstractText><AbstractText Label="EXPOSURES">WMH burden was assessed using a modified Fazekas rating scale.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Parkinsonism was assessed annually using 26 items of a modified motor portion of the Unified Parkinson's Disease Rating Scale. A summary score was developed from the item scores, with higher scores indicating more severe parkinsonism.</AbstractText><AbstractText Label="RESULTS">Of 516 included decedents, 364 (70.5%) were female, and the mean (SD) age at death was 90.2 (6.4) years. Higher WMH was associated with faster progressive parkinsonism (estimate, 0.024; SE, 0.008; P&#x2009;=&#x2009;.002). The attenuation of this association was greater when controlling for indices of cerebrovascular disease pathologies than when controlling for neurodegenerative pathologies (cerebrovascular disease: estimate, 0.019; SE, 0.008; P&#x2009;=&#x2009;.02; neurodegenerative: estimate, 0.022; SE, 0.008; P&#x2009;=&#x2009;.003), but both remained significant.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this cohort study, higher levels of both WMH and indices of cerebrovascular disease pathologies in aging brains were associated with more rapid progressive parkinsonism. Further studies are needed to determine if in vivo brain imaging of older adults for evidence of WMH and aggressive medical treatment of vascular risk factors and diseases can reduce the occurrence or severity of late-life parkinsonism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oveisgharan</LastName><ForeName>Shahram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poole</LastName><ForeName>Victoria N</ForeName><Initials>VN</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diagnostic Radiology and Nuclear Medicine, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evia</LastName><ForeName>Arnold M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diagnostic Radiology and Nuclear Medicine, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arfanakis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diagnostic Radiology and Nuclear Medicine, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Illinois Institute of Technology, Chicago.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchman</LastName><ForeName>Aron S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG064044</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056405</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG047976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2022 May 1;79(5):531. doi: 10.1001/jamaneurol.2022.0536.</RefSource><PMID Version="1">35311952</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Drs Oveisgharan, Schneider, Arfanakis, and Buchman have received grants from the National Institutes of Health. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>1</Day><Hour>16</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34724033</ArticleId><ArticleId IdType="pmc">PMC8561430</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.3996</ArticleId><ArticleId IdType="pii">2785850</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Louis ED, Luchsinger JA, Tang MX, Mayeux R. Parkinsonian signs in older people: prevalence and associations with smoking and coffee. Neurology. 2003;61(1):24-28. doi:10.1212/01.WNL.0000072330.07328.D6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000072330.07328.D6</ArticleId><ArticleId IdType="pubmed">12847151</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahodwala N, Nwadiogbu C, Fitts W, Partridge H, Karlawish J. Parkinsonian signs are a risk factor for falls. Gait Posture. 2017;55:1-5. doi:10.1016/j.gaitpost.2017.03.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gaitpost.2017.03.039</ArticleId><ArticleId IdType="pmc">PMC5467529</ArticleId><ArticleId IdType="pubmed">28407503</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis ED, Tang MX, Schupf N. Mild parkinsonian signs are associated with increased risk of dementia in a prospective, population-based study of elders. Mov Disord. 2010;25(2):172-178. doi:10.1002/mds.22943</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22943</ArticleId><ArticleId IdType="pmc">PMC2831155</ArticleId><ArticleId IdType="pubmed">20077482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou G, Duan L, Sun F, Yan B, Ren S. Association between mild parkinsonian signs and mortality in an elderly male cohort in China. J Clin Neurosci. 2010;17(2):173-176. doi:10.1016/j.jocn.2009.07.102</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2009.07.102</ArticleId><ArticleId IdType="pubmed">20056423</ArticleId></ArticleIdList></Reference><Reference><Citation>Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson&#x2019;s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583-1590. doi:10.1002/mds.25945</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25945</ArticleId><ArticleId IdType="pubmed">24976103</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosso AL, Bohnen NI, Launer LJ, Aizenstein HJ, Yaffe K, Rosano C. Vascular and dopaminergic contributors to mild parkinsonian signs in older adults. Neurology. 2018;90(3):e223-e229. doi:10.1212/WNL.0000000000004842</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004842</ArticleId><ArticleId IdType="pmc">PMC5772161</ArticleId><ArticleId IdType="pubmed">29247072</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis ED, Brickman AM, DeCarli C, et al. . Quantitative brain measurements in community-dwelling elderly persons with mild parkinsonian signs. Arch Neurol. 2008;65(12):1649-1654. doi:10.1001/archneurol.2008.504</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2008.504</ArticleId><ArticleId IdType="pmc">PMC2676900</ArticleId><ArticleId IdType="pubmed">19064753</ArticleId></ArticleIdList></Reference><Reference><Citation>de Laat KF, van Norden AGW, Gons RAR, et al. . Cerebral white matter lesions and lacunar infarcts contribute to the presence of mild parkinsonian signs. Stroke. 2012;43(10):2574-2579. doi:10.1161/STROKEAHA.112.657130</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.112.657130</ArticleId><ArticleId IdType="pubmed">22858727</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatate J, Miwa K, Matsumoto M, et al. . Association between cerebral small vessel diseases and mild parkinsonian signs in the elderly with vascular risk factors. Parkinsonism Relat Disord. 2016;26:29-34. doi:10.1016/j.parkreldis.2016.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2016.02.011</ArticleId><ArticleId IdType="pubmed">26949060</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Leurgans SE, Nag S, Bennett DA, Schneider JA. Cerebrovascular disease pathology and parkinsonian signs in old age. Stroke. 2011;42(11):3183-3189. doi:10.1161/STROKEAHA.111.623462</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.111.623462</ArticleId><ArticleId IdType="pmc">PMC3202031</ArticleId><ArticleId IdType="pubmed">21885844</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Holst HM, van Uden IWM, Tuladhar AM, et al. . Cerebral small vessel disease and incident parkinsonism: the RUN DMC study. Neurology. 2015;85(18):1569-1577. doi:10.1212/WNL.0000000000002082</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002082</ArticleId><ArticleId IdType="pmc">PMC4642143</ArticleId><ArticleId IdType="pubmed">26446068</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Yu L, Oveisgharan S, Farfel JM, Schneider JA, Bennett DA. Person-specific contributions of brain pathologies to progressive parkinsonism in older adults. J Gerontol A Biol Sci Med Sci. 2021;76(4):615-621. doi:10.1093/gerona/glaa176</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glaa176</ArticleId><ArticleId IdType="pmc">PMC8240996</ArticleId><ArticleId IdType="pubmed">32720690</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Yu L, Wilson RS, et al. . Progressive parkinsonism in older adults is related to the burden of mixed brain pathologies. Neurology. 2019;92(16):e1821-e1830. doi:10.1212/WNL.0000000000007315</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007315</ArticleId><ArticleId IdType="pmc">PMC6550497</ArticleId><ArticleId IdType="pubmed">30894446</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious Orders Study and Rush Memory and Aging Project. J Alzheimers Dis. 2018;64(s1):S161-S189. doi:10.3233/JAD-179939</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-179939</ArticleId><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Shah RC, Aggarwal NT, Bennett DA, Schneider JA. The Minority Aging Research Study: ongoing efforts to obtain brain donation in African Americans without dementia. Curr Alzheimer Res. 2012;9(6):734-745. doi:10.2174/156720512801322627</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322627</ArticleId><ArticleId IdType="pmc">PMC3409294</ArticleId><ArticleId IdType="pubmed">22471868</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Shannon KM, Beckett LA, Wilson RS. Dimensionality of parkinsonian signs in aging and Alzheimer&#x2019;s disease. J Gerontol A Biol Sci Med Sci. 1999;54(4):M191-M196. doi:10.1093/gerona/54.4.M191</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/54.4.M191</ArticleId><ArticleId IdType="pubmed">10219010</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Shannon KM, Beckett LA, Goetz CG, Wilson RS. Metric properties of nurses&#x2019; ratings of parkinsonian signs with a modified Unified Parkinson&#x2019;s Disease Rating Scale. Neurology. 1997;49(6):1580-1587. doi:10.1212/WNL.49.6.1580</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.49.6.1580</ArticleId><ArticleId IdType="pubmed">9409350</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Schneider JA, Beckett LA, Evans DA, Bennett DA. Progression of gait disorder and rigidity and risk of death in older persons. Neurology. 2002;58(12):1815-1819. doi:10.1212/WNL.58.12.1815</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.12.1815</ArticleId><ArticleId IdType="pubmed">12084882</ArticleId></ArticleIdList></Reference><Reference><Citation>Oveisgharan S, Yu L, Bennett DA, Buchman AS. Incident mobility disability, parkinsonism, and mortality in community-dwelling older adults. PLoS One. 2021;16(2):e0246206. doi:10.1371/journal.pone.0246206</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246206</ArticleId><ArticleId IdType="pmc">PMC7857621</ArticleId><ArticleId IdType="pubmed">33534811</ArticleId></ArticleIdList></Reference><Reference><Citation>Arfanakis K, Evia AM, Leurgans SE, et al. . Neuropathologic correlates of white matter hyperintensities in a community-based cohort of older adults. J Alzheimers Dis. 2020;73(1):333-345. doi:10.3233/JAD-190687</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-190687</ArticleId><ArticleId IdType="pmc">PMC6996196</ArticleId><ArticleId IdType="pubmed">31771057</ArticleId></ArticleIdList></Reference><Reference><Citation>Oveisgharan S, Arvanitakis Z, Yu L, Farfel J, Schneider JA, Bennett DA. Sex differences in Alzheimer&#x2019;s disease and common neuropathologies of aging. Acta Neuropathol. 2018;136(6):887-900. doi:10.1007/s00401-018-1920-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1920-1</ArticleId><ArticleId IdType="pmc">PMC6279593</ArticleId><ArticleId IdType="pubmed">30334074</ArticleId></ArticleIdList></Reference><Reference><Citation>Oveisgharan S, Dawe RJ, Leurgans SE, et al. . Total daily physical activity, brain pathologies, and parkinsonism in older adults. PLoS One. 2020;15(4):e0232404. doi:10.1371/journal.pone.0232404</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0232404</ArticleId><ArticleId IdType="pmc">PMC7190120</ArticleId><ArticleId IdType="pubmed">32348372</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, et al. . Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503-1527. doi:10.1093/brain/awz099</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Oveisgharan S, Yu L, Dawe RJ, Bennett DA, Buchman AS. Total daily physical activity and the risk of parkinsonism in community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2020;75(4):702-711. doi:10.1093/gerona/glz111</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glz111</ArticleId><ArticleId IdType="pmc">PMC7328202</ArticleId><ArticleId IdType="pubmed">31046115</ArticleId></ArticleIdList></Reference><Reference><Citation>Medi-Span . Master drug data base documentation manual. Accessed October 1, 2021. https://www.wolterskluwer.com/en/solutions/medi-span</Citation></Reference><Reference><Citation>Buchman AS, Leurgans SE, Yu L, et al. . Incident parkinsonism in older adults without Parkinson disease. Neurology. 2016;87(10):1036-1044. doi:10.1212/WNL.0000000000003059</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003059</ArticleId><ArticleId IdType="pmc">PMC5027813</ArticleId><ArticleId IdType="pubmed">27488597</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Wilson RS, Shulman JM, Leurgans SE, Schneider JA, Bennett DA. Parkinsonism in older adults and its association with adverse health outcomes and neuropathology. J Gerontol A Biol Sci Med Sci. 2016;71(4):549-556. doi:10.1093/gerona/glv153</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glv153</ArticleId><ArticleId IdType="pmc">PMC5014188</ArticleId><ArticleId IdType="pubmed">26362440</ArticleId></ArticleIdList></Reference><Reference><Citation>Vizcarra JA, Lang AE, Sethi KD, Espay AJ. Vascular parkinsonism: deconstructing a syndrome. Mov Disord. 2015;30(7):886-894. doi:10.1002/mds.26263</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26263</ArticleId><ArticleId IdType="pmc">PMC4478160</ArticleId><ArticleId IdType="pubmed">25997420</ArticleId></ArticleIdList></Reference><Reference><Citation>Rektor I, Bohnen NI, Korczyn AD, et al. . An updated diagnostic approach to subtype definition of vascular parkinsonism&#x2014;recommendations from an expert working group. Parkinsonism Relat Disord. 2018;49:9-16. doi:10.1016/j.parkreldis.2017.12.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2017.12.030</ArticleId><ArticleId IdType="pmc">PMC5857227</ArticleId><ArticleId IdType="pubmed">29310988</ArticleId></ArticleIdList></Reference><Reference><Citation>Zijlmans JCM, Daniel SE, Hughes AJ, R&#xe9;v&#xe9;sz T, Lees AJ. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord. 2004;19(6):630-640. doi:10.1002/mds.20083</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20083</ArticleId><ArticleId IdType="pubmed">15197700</ArticleId></ArticleIdList></Reference><Reference><Citation>Deverdun J, Menjot de Champfleur S, Cabello-Aguilar S, et al. . Diffusion tensor imaging differentiates vascular parkinsonism from parkinsonian syndromes of degenerative origin in elderly subjects. Eur J Radiol. 2014;83(11):2074-2079. doi:10.1016/j.ejrad.2014.07.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejrad.2014.07.012</ArticleId><ArticleId IdType="pubmed">25154005</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Dawe RJ, Yu L, et al. . Brain pathology is related to total daily physical activity in older adults. Neurology. 2018;90(21):e1911-e1919. doi:10.1212/WNL.0000000000005552</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005552</ArticleId><ArticleId IdType="pmc">PMC5962918</ArticleId><ArticleId IdType="pubmed">29695600</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal P, Wang Y, Buchman AS, Holland TM, Bennett DA, Morris MC. Dietary antioxidants associated with slower progression of parkinsonian signs in older adults. Nutr Neurosci. Published online May 22, 2020. doi:10.1080/1028415X.2020.1769411</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1028415X.2020.1769411</ArticleId><ArticleId IdType="pmc">PMC7680274</ArticleId><ArticleId IdType="pubmed">32441566</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinetti ME, Han L, Lee DSH, et al. . Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014;174(4):588-595. doi:10.1001/jamainternmed.2013.14764</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2013.14764</ArticleId><ArticleId IdType="pmc">PMC4136657</ArticleId><ArticleId IdType="pubmed">24567036</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilmot KA, Khan A, Krishnan S, Eapen DJ, Sperling L. Statins in the elderly: a patient-focused approach. Clin Cardiol. 2015;38(1):56-61. doi:10.1002/clc.22338</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.22338</ArticleId><ArticleId IdType="pmc">PMC6711018</ArticleId><ArticleId IdType="pubmed">25336290</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34724534</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of Physical Activity, Including Amount and Maintenance, With All-Cause Mortality in Parkinson Disease.</ArticleTitle><Pagination><StartPage>1446</StartPage><EndPage>1453</EndPage><MedlinePgn>1446-1453</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.3926</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The protective effects of physical activity (PA) against Parkinson disease (PD) development have been suggested; however, the association of PA with mortality in PD has rarely been investigated.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate the association between PA and mortality in individuals with PD and determine how the amount and maintenance of PA are associated with mortality.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This nationwide population-based cohort study used Korean National Health Insurance System data. Participants were included from January 1, 2010, and December 31, 2013, and were followed up until December 31, 2017. Data were analyzed from September 2020 to March 2021. Individuals who were newly diagnosed with PD were selected using the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision code G20 and registration code V124 in the program for rare intractable diseases in 2010 through 2013. Individuals who underwent health checkups within 2 years before and after the PD diagnosis were enrolled. Those aged younger than 40 years or with missing data were excluded.</AbstractText><AbstractText Label="EXPOSURES">Physical activity levels were collected using self-reported questionnaires.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">All-cause mortality.</AbstractText><AbstractText Label="RESULTS">A total of 45&#x202f;923 individuals were identified; 10&#x202f;987 were enrolled, and 34 individuals younger than 40 years and 254 with missing data were excluded. A total of 10&#x202f;699 individuals with PD were included; 4925 (46%) were male and 5774 (54%) were female, and the mean (SD) age was 69.2 (8.8) years. During the 8-year follow-up period, there were 1823 deaths (17%). The mortality rate was lower among individuals who were physically active vs inactive at all PA intensities (vigorous: hazard ratio [HR], 0.80 [95% CI, 0.69-0.93]; moderate: HR, 0.66 [95% CI, 0.55-0.78]; light: HR, 0.81 [95% CI, 0.73-0.90]). There was a significant inverse dose-response association between the total amount of PA and mortality (HRs: vigorous, 0.80 [95% CI, 0.69-0.93]; moderate, 0.66 [95% CI, 0.55-0.78]; light, 0.81 [95% CI, 0.73-0.90]; P&#x2009;&lt;&#x2009;.001). Moreover, maintenance of PA was associated with the mortality rate. Individuals with PD who were physically active both before and after the PD diagnosis had the greatest reduction in mortality rate across all PA intensities (HRs: vigorous, 0.66 [95% CI, 0.50-0.88]; moderate, 0.49 [95% CI, 0.32-0.75]; light, 0.76 [95% CI, 0.66-0.89]). Individuals who started PA after receiving the PD diagnosis had a lower mortality rate than those who remained physically inactive (HRs: vigorous, 0.82 [95% CI, 0.70-0.97]; moderate, 0.69 [95% CI, 0.57-0.83]; light, 0.86 [95% CI, 0.78-0.98]).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This analysis found a dose-response association between PA and all-cause mortality in PD. Reverse causality may exist, and future prospective randomized clinical trials are warranted to determine the effect of PA on mortality in PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Seo Yeon</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine &amp; Rehabilitation, Korea University Guro Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>Jee Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, Bundang Jesaeng General Hospital, Gyeonggi-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Seung Nam</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine &amp; Rehabilitation, Korea University Guro Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Kyungdo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yong Wook</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2021 Dec 1;78(12):1443-1445. doi: 10.1001/jamaneurol.2021.3744.</RefSource><PMID Version="1">34724528</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Neurol. 2021 Dec 1;78(12):1443-1445. doi: 10.1001/jamaneurol.2021.3744.</RefSource><PMID Version="1">34724528</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Yoon reported grant funding from the National Research Foundation of Korea (funded by the Korean government) during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>1</Day><Hour>17</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34724534</ArticleId><ArticleId IdType="pmc">PMC8561431</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.3926</ArticleId><ArticleId IdType="pii">2785851</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nag N, Jelinek GA. A narrative review of lifestyle factors associated with Parkinson&#x2019;s disease risk and progression. Neurodegener Dis. 2019;19(2):51-59. doi:10.1159/000502292</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000502292</ArticleId><ArticleId IdType="pubmed">31487721</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, Blauwendraat C, Vallerga CL, et al. ; 23andMe Research Team; System Genomics of Parkinson&#x2019;s Disease Consortium; International Parkinson&#x2019;s Disease Genomics Consortium . Identification of novel risk loci, causal insights, and heritable risk for Parkinson&#x2019;s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091-1102. doi:10.1016/S1474-4422(19)30320-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30320-5</ArticleId><ArticleId IdType="pmc">PMC8422160</ArticleId><ArticleId IdType="pubmed">31701892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellou V, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis JP. Environmental risk factors and Parkinson&#x2019;s disease: an umbrella review of meta-analyses. Parkinsonism Relat Disord. 2016;23:1-9. doi:10.1016/j.parkreldis.2015.12.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2015.12.008</ArticleId><ArticleId IdType="pubmed">26739246</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez-Jim&#xe9;nez FJ, Alonso-Navarro H, Garc&#xed;a-Mart&#xed;n E, Ag&#xfa;ndez JAG. Alcohol consumption and risk for Parkinson&#x2019;s disease: a systematic review and meta-analysis. J Neurol. 2019;266(8):1821-1834. doi:10.1007/s00415-018-9032-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-9032-3</ArticleId><ArticleId IdType="pubmed">30155737</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettiol SS, Rose TC, Hughes CJ, Smith LA. Alcohol consumption and Parkinson&#x2019;s disease risk: a review of recent findings. J Parkinsons Dis. 2015;5(3):425-442. doi:10.3233/JPD-150533</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-150533</ArticleId><ArticleId IdType="pmc">PMC4923726</ArticleId><ArticleId IdType="pubmed">26406123</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X, Han D, Cheng Q, et al. . Association of levels of physical activity with risk of Parkinson disease: a systematic review and meta-analysis. JAMA Netw Open. 2018;1(5):e182421. doi:10.1001/jamanetworkopen.2018.2421</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2018.2421</ArticleId><ArticleId IdType="pmc">PMC6324511</ArticleId><ArticleId IdType="pubmed">30646166</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Li W, Liu G, Shen X, Tang Y. Association between cigarette smoking and Parkinson&#x2019;s disease: a meta-analysis. Arch Gerontol Geriatr. 2015;61(3):510-516. doi:10.1016/j.archger.2015.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.archger.2015.08.004</ArticleId><ArticleId IdType="pubmed">26272284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Takkouche B, Caama&#xf1;o-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson&#x2019;s disease. Ann Neurol. 2002;52(3):276-284. doi:10.1002/ana.10277</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10277</ArticleId><ArticleId IdType="pubmed">12205639</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Zhang SM, Schwarzschild MA, Hern&#xe1;n MA, Ascherio A. Physical activity and the risk of Parkinson disease. Neurology. 2005;64(4):664-669. doi:10.1212/01.WNL.0000151960.28687.93</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000151960.28687.93</ArticleId><ArticleId IdType="pubmed">15728289</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe4;&#xe4;ksj&#xe4;rvi K, Knekt P, M&#xe4;nnist&#xf6; S, et al. . Reduced risk of Parkinson&#x2019;s disease associated with lower body mass index and heavy leisure-time physical activity. Eur J Epidemiol. 2014;29(4):285-292. doi:10.1007/s10654-014-9887-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-014-9887-2</ArticleId><ArticleId IdType="pubmed">24633681</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasco AJ, Paffenbarger RS Jr, Gendre I, Wing AL. The role of physical exercise in the occurrence of Parkinson&#x2019;s disease. Arch Neurol. 1992;49(4):360-365. doi:10.1001/archneur.1992.00530280040020</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1992.00530280040020</ArticleId><ArticleId IdType="pubmed">1558515</ArticleId></ArticleIdList></Reference><Reference><Citation>Thacker EL, Chen H, Patel AV, et al. . Recreational physical activity and risk of Parkinson&#x2019;s disease. Mov Disord. 2008;23(1):69-74. doi:10.1002/mds.21772</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21772</ArticleId><ArticleId IdType="pmc">PMC2387117</ArticleId><ArticleId IdType="pubmed">17960818</ArticleId></ArticleIdList></Reference><Reference><Citation>LaHue SC, Comella CL, Tanner CM. The best medicine? the influence of physical activity and inactivity on Parkinson&#x2019;s disease. Mov Disord. 2016;31(10):1444-1454. doi:10.1002/mds.26728</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26728</ArticleId><ArticleId IdType="pmc">PMC9491025</ArticleId><ArticleId IdType="pubmed">27477046</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul KC, Chuang YH, Shih IF, et al. . The association between lifestyle factors and Parkinson&#x2019;s disease progression and mortality. Mov Disord. 2019;34(1):58-66. doi:10.1002/mds.27577</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27577</ArticleId><ArticleId IdType="pmc">PMC6544143</ArticleId><ArticleId IdType="pubmed">30653734</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan RP, Earhart GM. Randomized controlled trial of community-based dancing to modify disease progression in Parkinson disease. Neurorehabil Neural Repair. 2012;26(2):132-143. doi:10.1177/1545968311421614</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1545968311421614</ArticleId><ArticleId IdType="pubmed">21959675</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcos DM, Robichaud JA, David FJ, et al. . A two-year randomized controlled trial of progressive resistance exercise for Parkinson&#x2019;s disease. Mov Disord. 2013;28(9):1230-1240. doi:10.1002/mds.25380</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25380</ArticleId><ArticleId IdType="pmc">PMC3701730</ArticleId><ArticleId IdType="pubmed">23536417</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Harmer P, Fitzgerald K, et al. . Tai chi and postural stability in patients with Parkinson&#x2019;s disease. N Engl J Med. 2012;366(6):511-519. doi:10.1056/NEJMoa1107911</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1107911</ArticleId><ArticleId IdType="pmc">PMC3285459</ArticleId><ArticleId IdType="pubmed">22316445</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig CL, Marshall AL, Sj&#xf6;str&#xf6;m M, et al. . International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381-1395. doi:10.1249/01.MSS.0000078924.61453.FB</Citation><ArticleIdList><ArticleId IdType="doi">10.1249/01.MSS.0000078924.61453.FB</ArticleId><ArticleId IdType="pubmed">12900694</ArticleId></ArticleIdList></Reference><Reference><Citation>Pescatello LS, Riebe D, Thompson PD. ACSM's Guidelines for Exercise Testing and Prescription. Lippincott Williams &amp; Wilkins; 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">23851406</ArticleId></ArticleIdList></Reference><Reference><Citation>Ainsworth BE, Haskell WL, Herrmann SD, et al. . 2011 compendium of physical activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011;43(8):1575-1581. doi:10.1249/MSS.0b013e31821ece12</Citation><ArticleIdList><ArticleId IdType="doi">10.1249/MSS.0b013e31821ece12</ArticleId><ArticleId IdType="pubmed">21681120</ArticleId></ArticleIdList></Reference><Reference><Citation>Patki G, Lau YS. Impact of exercise on mitochondrial transcription factor expression and damage in the striatum of a chronic mouse model of Parkinson&#x2019;s disease. Neurosci Lett. 2011;505(3):268-272. doi:10.1016/j.neulet.2011.10.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2011.10.036</ArticleId><ArticleId IdType="pmc">PMC3227723</ArticleId><ArticleId IdType="pubmed">22040668</ArticleId></ArticleIdList></Reference><Reference><Citation>Galassetti PR, Nemet D, Pescatello A, Rose-Gottron C, Larson J, Cooper DM. Exercise, caloric restriction, and systemic oxidative stress. J Investig Med. 2006;54(2):67-75. doi:10.2310/6650.2005.05024</Citation><ArticleIdList><ArticleId IdType="doi">10.2310/6650.2005.05024</ArticleId><ArticleId IdType="pubmed">16472476</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsou YH, Shih CT, Ching CH, et al. . Treadmill exercise activates Nrf2 antioxidant system to protect the nigrostriatal dopaminergic neurons from MPP+ toxicity. Exp Neurol. 2015;263:50-62. doi:10.1016/j.expneurol.2014.09.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.09.021</ArticleId><ArticleId IdType="pubmed">25286336</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch MA, Iyer SS, Sanjak M. Exercise-induced neuroplasticity in human Parkinson&#x2019;s disease: what is the evidence telling us? Parkinsonism Relat Disord. 2016;22(suppl 1):S78-S81. doi:10.1016/j.parkreldis.2015.09.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2015.09.030</ArticleId><ArticleId IdType="pubmed">26439945</ArticleId></ArticleIdList></Reference><Reference><Citation>Prodoehl J, Rafferty MR, David FJ, et al. . Two-year exercise program improves physical function in Parkinson&#x2019;s disease: the PRET-PD randomized clinical trial. Neurorehabil Neural Repair. 2015;29(2):112-122. doi:10.1177/1545968314539732</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1545968314539732</ArticleId><ArticleId IdType="pmc">PMC4276552</ArticleId><ArticleId IdType="pubmed">24961994</ArticleId></ArticleIdList></Reference><Reference><Citation>David FJ, Robichaud JA, Leurgans SE, et al. . Exercise improves cognition in Parkinson&#x2019;s disease: the PRET-PD randomized, clinical trial. Mov Disord. 2015;30(12):1657-1663. doi:10.1002/mds.26291</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26291</ArticleId><ArticleId IdType="pmc">PMC4609235</ArticleId><ArticleId IdType="pubmed">26148003</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Kolk NM, de Vries NM, Kessels RPC, et al. . Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson&#x2019;s disease: a double-blind, randomised controlled trial. Lancet Neurol. 2019;18(11):998-1008. doi:10.1016/S1474-4422(19)30285-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30285-6</ArticleId><ArticleId IdType="pubmed">31521532</ArticleId></ArticleIdList></Reference><Reference><Citation>Park A, Zid D, Russell J, et al. . Effects of a formal exercise program on Parkinson&#x2019;s disease: a pilot study using a delayed start design. Parkinsonism Relat Disord. 2014;20(1):106-111. doi:10.1016/j.parkreldis.2013.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2013.10.003</ArticleId><ArticleId IdType="pmc">PMC4030674</ArticleId><ArticleId IdType="pubmed">24209458</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento CM, Ayan C, Cancela JM, Gobbi LT, Gobbi S, Stella F. Effect of a multimodal exercise program on sleep disturbances and instrumental activities of daily living performance on Parkinson&#x2019;s and Alzheimer&#x2019;s disease patients. Geriatr Gerontol Int. 2014;14(2):259-266. doi:10.1111/ggi.12082</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ggi.12082</ArticleId><ArticleId IdType="pubmed">23647635</ArticleId></ArticleIdList></Reference><Reference><Citation>Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep. 1985;100(2):126-131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1424733</ArticleId><ArticleId IdType="pubmed">3920711</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Brink CL, Picavet H, Van Den Bos GA, Giampaoli S, Nissinen A, Kromhout D. Duration and intensity of physical activity and disability among European elderly men. Disabil Rehabil. 2005;27(6):341-347. doi:10.1080/09638280400018452</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09638280400018452</ArticleId><ArticleId IdType="pubmed">16040534</ArticleId></ArticleIdList></Reference><Reference><Citation>Chave SP, Morris JN, Moss S, Semmence AM. Vigorous exercise in leisure time and the death rate: a study of male civil servants. J Epidemiol Community Health. 1978;32(4):239-243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1060957</ArticleId><ArticleId IdType="pubmed">744813</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenkman M, Moore CG, Kohrt WM, et al. . Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol. 2018;75(2):219-226. doi:10.1001/jamaneurol.2017.3517</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.3517</ArticleId><ArticleId IdType="pmc">PMC5838616</ArticleId><ArticleId IdType="pubmed">29228079</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano A, Canning CG, Hausdorff JM, Lord S, Rochester L. Falls in Parkinson&#x2019;s disease: a complex and evolving picture. Mov Disord. 2017;32(11):1524-1536. doi:10.1002/mds.27195</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27195</ArticleId><ArticleId IdType="pubmed">29067726</ArticleId></ArticleIdList></Reference><Reference><Citation>Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson&#x2019;s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583-1590. doi:10.1002/mds.25945</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25945</ArticleId><ArticleId IdType="pubmed">24976103</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantri S, Fullard ME, Duda JE, Morley JF. Physical activity in early Parkinson disease. J Parkinsons Dis. 2018;8(1):107-111. doi:10.3233/JPD-171218</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-171218</ArticleId><ArticleId IdType="pmc">PMC5836409</ArticleId><ArticleId IdType="pubmed">29480222</ArticleId></ArticleIdList></Reference><Reference><Citation>Amara AW, Chahine L, Seedorff N, Caspell-Garcia CJ, Coffey C, Simuni T; Parkinson&#x2019;s Progression Markers Initiative . Self-reported physical activity levels and clinical progression in early Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2019;61:118-125. doi:10.1016/j.parkreldis.2018.11.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2018.11.006</ArticleId><ArticleId IdType="pubmed">30554993</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Trolle Lagerros Y, Bellocco R, et al. . Physical activity and risk of Parkinson&#x2019;s disease in the Swedish National March Cohort. Brain. 2015;138(Pt 2):269-275. doi:10.1093/brain/awu323</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu323</ArticleId><ArticleId IdType="pubmed">25410713</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34731000</PMID><DateRevised><Year>2024</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>45</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>05</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>Deletion of <i>Abi3</i> gene locus exacerbates neuropathological features of Alzheimer's disease in a mouse model of A&#x3b2; amyloidosis.</ArticleTitle><Pagination><StartPage>eabe3954</StartPage><MedlinePgn>eabe3954</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabe3954</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abe3954</ELocationID><Abstract><AbstractText>Recently, large-scale human genetics studies identified a rare coding variant in the <i>ABI3</i> gene that is associated with an increased risk of Alzheimer&#x2019;s disease (AD). However, pathways by which ABI3 contributes to the pathogenesis of AD are unknown. To address this question, we determined whether loss of ABI3 function affects pathological features of AD in the 5XFAD mouse model. We demonstrate that the deletion of <i>Abi3</i> locus significantly increases amyloid &#x3b2; (A&#x3b2;) accumulation and decreases microglia clustering around the plaques. Furthermore, long-term potentiation is impaired in <i>5XFAD;Abi3</i> knockout (&#x201c;<i>Abi3<sup>&#x2212;/&#x2212;</sup></i>&#x201d;) mice. Moreover, we identified marked changes in the proportion of microglia subpopulations in <i>Abi3<sup>&#x2212;/&#x2212;</sup></i> mice using a single-cell RNA sequencing approach. Mechanistic studies demonstrate that <i>Abi3</i> knockdown in microglia impairs migration and phagocytosis. Together, our study provides the first in vivo functional evidence that loss of ABI3 function may increase the risk of developing AD by affecting A&#x3b2; accumulation and neuroinflammation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karahan</LastName><ForeName>Hande</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3192-7362</Identifier><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><Identifier Source="ORCID">0000-0002-2910-6533</Identifier><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Neuroscience Graduate Program, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Byungwook</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-8390-7713</Identifier><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabin</LastName><ForeName>Luke C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0001-6365-291X</Identifier><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Amin</LastName><ForeName>Md Mamun</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0003-4234-7152</Identifier><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wijeratne</LastName><ForeName>H R Sagara</ForeName><Initials>HRS</Initials><Identifier Source="ORCID">0000-0002-8209-5626</Identifier><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pennington</LastName><ForeName>Taylor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viana di Prisco</LastName><ForeName>Gonzalo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCord</LastName><ForeName>Brianne</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Peter Bor-Chian</ForeName><Initials>PB</Initials><Identifier Source="ORCID">0000-0002-8954-9045</Identifier><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Neuroscience Graduate Program, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuxin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9739-9860</Identifier><AffiliationInfo><Affiliation>Departments of Structural Biology and Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Junmin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0472-7648</Identifier><AffiliationInfo><Affiliation>Departments of Structural Biology and Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oblak</LastName><ForeName>Adrian L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0003-1210-8791</Identifier><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Neuroscience Graduate Program, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Shaoyou</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atwood</LastName><ForeName>Brady K</ForeName><Initials>BK</Initials><Identifier Source="ORCID">0000-0002-7441-2724</Identifier><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Neuroscience Graduate Program, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jungsu</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6931-8581</Identifier><AffiliationInfo><Affiliation>Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Neuroscience Graduate Program, Indiana University School of Medicine, Indianapolis, IN 46202, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG053242</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053500</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054102</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG050804</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>17</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34731000</ArticleId><ArticleId IdType="pmc">PMC8565913</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abe3954</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Long J. M., Holtzman D. M., Alzheimer disease: An update on pathobiology and treatment strategies. Cell 179, 312&#x2013;339 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778042</ArticleId><ArticleId IdType="pubmed">31564456</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T., Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? Nat. Med. 12, 1005&#x2013;1015 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Mhatre S. D., Tsai C. A., Rubin A. J., James M. L., Andreasson K. I., Microglial malfunction: The third rail in the development of Alzheimer&#x2019;s disease. Trends Neurosci. 38, 621&#x2013;636 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4670239</ArticleId><ArticleId IdType="pubmed">26442696</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthymiou A. G., Goate A. M., Late onset Alzheimer&#x2019;s disease genetics implicates microglial pathways in disease risk. Mol. Neurodegener. 12, 43 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446752</ArticleId><ArticleId IdType="pubmed">28549481</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O., Weiner H. L., Microglial signatures and their role in health and disease. Nat. Rev. Neurosci. 19, 622&#x2013;635 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255106</ArticleId><ArticleId IdType="pubmed">30206328</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotti A., Ransohoff R. M., Microglial physiology and pathophysiology: Insights from genome-wide transcriptional profiling. Immunity 44, 505&#x2013;515 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26982357</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanisch U. K., Kettenmann H., Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10, 1387&#x2013;1394 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17965659</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims R., van der Lee S. J., Naj A. C., Bellenguez C., Badarinarayan N., Jakobsdottir J., Kunkle B. W., Boland A., Raybould R., Bis J. C., Martin E. R., Grenier-Boley B., Heilmann-Heimbach S., Chouraki V., Kuzma A. B., Sleegers K., Vronskaya M., Ruiz A., Graham R. R., Olaso R., Hoffmann P., Grove M. L., Vardarajan B. N., Hiltunen M., Nothen M. M., White C. C., Hamilton-Nelson K. L., Epelbaum J., Maier W., Choi S. H., Beecham G. W., Dulary C., Herms S., Smith A. V., Funk C. C., Derbois C., Forstner A. J., Ahmad S., Li H., Bacq D., Harold D., Satizabal C. L., Valladares O., Squassina A., Thomas R., Brody J. A., Qu L., Sanchez-Juan P., Morgan T., Wolters F. J., Zhao Y., Garcia F. S., Denning N., Fornage M., Malamon J., Naranjo M. C. D., Majounie E., Mosley T. H., Dombroski B., Wallon D., Lupton M. K., Dupuis J., Whitehead P., Fratiglioni L., Medway C., Jian X., Mukherjee S., Keller L., Brown K., Lin H., Cantwell L. B., Panza F., McGuinness B., Moreno-Grau S., Burgess J. D., Solfrizzi V., Proitsi P., Adams H. H., Allen M., Seripa D., Pastor P., Cupples L. A., Price N. D., Hannequin D., Frank-Garcia A., Levy D., Chakrabarty P., Caffarra P., Giegling I., Beiser A. S., Giedraitis V., Hampel H., Garcia M. E., Wang X., Lannfelt L., Mecocci P., Eiriksdottir G., Crane P. K., Pasquier F., Boccardi V., Henandez I., Barber R. C., Scherer M., Tarraga L., Adams P. M., Leber M., Chen Y., Albert M. S., Riedel-Heller S., Emilsson V., Beekly D., Braae A., Schmidt R., Blacker D., Masullo C., Schmidt H., Doody R. S., Spalletta G., Longstreth W. T. Jr., Fairchild T. J., Bossu P., Lopez O. L., Frosch M. P., Sacchinelli E., Ghetti B., Yang Q., Huebinger R. M., Jessen F., Li S., Kamboh M. I., Morris J., Sotolongo-Grau O., Katz M. J., Corcoran C., Dunstan M., Braddel A., Thomas C., Meggy A., Marshall R., Gerrish A., Chapman J., Aguilar M., Taylor S., Hill M., Fairen M. D., Hodges A., Vellas B., Soininen H., Kloszewska I., Daniilidou M., Uphill J., Patel Y., Hughes J. T., Lord J., Turton J., Hartmann A. M., Cecchetti R., Fenoglio C., Serpente M., Arcaro M., Caltagirone C., Orfei M. D., Ciaramella A., Pichler S., Mayhaus M., Gu W., Lleo A., Fortea J., Blesa R., Barber I. S., Brookes K., Cupidi C., Maletta R. G., Carrell D., Sorbi S., Moebus S., Urbano M., Pilotto A., Kornhuber J., Bosco P., Todd S., Craig D., Johnston J., Gill M., Lawlor B., Lynch A., Fox N. C., Hardy J., Consortium A., Albin R. L., Apostolova L. G., Arnold S. E., Asthana S., Atwood C. S., Baldwin C. T., Barnes L. L., Barral S., Beach T. G., Becker J. T., Bigio E. H., Bird T. D., Boeve B. F., Bowen J. D., Boxer A., Burke J. R., Burns J. M., Buxbaum J. D., Cairns N. J., Cao C., Carlson C. S., Carlsson C. M., Carney R. M., Carrasquillo M. M., Carroll S. L., Diaz C. C., Chui H. C., Clark D. G., Cribbs D. H., Crocco E. A., DeCarli C., Dick M., Duara R., Evans D. A., Faber K. M., Fallon K. B., Fardo D. W., Farlow M. R., Ferris S., Foroud T. M., Galasko D. R., Gearing M., Geschwind D. H., Gilbert J. R., Graff-Radford N. R., Green R. C., Growdon J. H., Hamilton R. L., Harrell L. E., Honig L. S., Huentelman M. J., Hulette C. M., Hyman B. T., Jarvik G. P., Abner E., Jin L. W., Jun G., Karydas A., Kaye J. A., Kim R., Kowall N. W., Kramer J. H., LaFerla F. M., Lah J. J., Leverenz J. B., Levey A. I., Li G., Lieberman A. P., Lunetta K. L., Lyketsos C. G., Marson D. C., Martiniuk F., Mash D. C., Masliah E., McCormick W. C., McCurry S. M., McDavid A. N., McKee A. C., Mesulam M., Miller B. L., Miller C. A., Miller J. W., Morris J. C., Murrell J. R., Myers A. J., O'Bryant S., Olichney J. M., Pankratz V. S., Parisi J. E., Paulson H. L., Perry W., Peskind E., Pierce A., Poon W. W., Potter H., Quinn J. F., Raj A., Raskind M., Reisberg B., Reitz C., Ringman J. M., Roberson E. D., Rogaeva E., Rosen H. J., Rosenberg R. N., Sager M. A., Saykin A. J., Schneider J. A., Schneider L. S., Seeley W. W., Smith A. G., Sonnen J. A., Spina S., Stern R. A., Swerdlow R. H., Tanzi R. E., Thornton-Wells T. A., Trojanowski J. Q., Troncoso J. C., Van Deerlin V. M., Van Eldik L. J., Vinters H. V., Vonsattel J. P., Weintraub S., Welsh-Bohmer K. A., Wilhelmsen K. C., Williamson J., Wingo T. S., Woltjer R. L., Wright C. B., Yu C. E., Yu L., Garzia F., Golamaully F., Septier G., Engelborghs S., Vandenberghe R., De Deyn P. P., Fernadez C. M., Benito Y. A., Thonberg H., Forsell C., Lilius L., Kinhult-Stahlbom A., Kilander L., Brundin R., Concari L., Helisalmi S., Koivisto A. M., Haapasalo A., Dermecourt V., Fievet N., Hanon O., Dufouil C., Brice A., Ritchie K., Dubois B., Himali J. J., Keene C. D., Tschanz J., Fitzpatrick A. L., Kukull W. A., Norton M., Aspelund T., Larson E. B., Munger R., Rotter J. I., Lipton R. B., Bullido M. J., Hofman A., Montine T. J., Coto E., Boerwinkle E., Petersen R. C., Alvarez V., Rivadeneira F., Reiman E. M., Gallo M., O'Donnell C. J., Reisch J. S., Bruni A. C., Royall D. R., Dichgans M., Sano M., Galimberti D., George-Hyslop P. S., Scarpini E., Tsuang D. W., Mancuso M., Bonuccelli U., Winslow A. R., Daniele A., Wu C. K.; GERAD/PERADES, CHARGE, ADGC, EADI, Peters O., Nacmias B., Riemenschneider M., Heun R., Brayne C., Rubinsztein D. C., Bras J., Guerreiro R., Al-Chalabi A., Shaw C. E., Collinge J., Mann D., Tsolaki M., Clarimon J., Sussams R., Lovestone S., O'Donovan M. C., Owen M. J., Behrens T. W., Mead S., Goate A. M., Uitterlinden A. G., Holmes C., Cruchaga C., Ingelsson M., Bennett D. A., Powell J., Golde T. E., Graff C., De Jager P. L., Morgan K., Ertekin-Taner N., Combarros O., Psaty B. M., Passmore P., Younkin S. G., Berr C., Gudnason V., Rujescu D., Dickson D. W., Dartigues J. F., DeStefano A. L., Ortega-Cubero S., Hakonarson H., Campion D., Boada M., Kauwe J. K., Farrer L. A., Van Broeckhoven C., Ikram M. A., Jones L., Haines J. L., Tzourio C., Launer L. J., Escott-Price V., Mayeux R., Deleuze J. F., Amin N., Holmans P. A., Pericak-Vance M. A., Amouyel P., van Duijn C. M., Ramirez A., Wang L. S., Lambert J. C., Seshadri S., Williams J., Schellenberg G. D., Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat. Genet. 49, 1373&#x2013;1384 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669039</ArticleId><ArticleId IdType="pubmed">28714976</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway O. J., Carrasquillo M. M., Wang X., Bredenberg J. M., Reddy J. S., Strickland S. L., Younkin C. S., Burgess J. D., Allen M., Lincoln S. J., Nguyen T., Malphrus K. G., Soto A. I., Walton R. L., Boeve B. F., Petersen R. C., Lucas J. A., Ferman T. J., Cheshire W. P., van Gerpen J. A., Uitti R. J., Wszolek Z. K., Ross O. A., Dickson D. W., Graff-Radford N. R., Ertekin-Taner N., ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Mol. Neurodegener. 13, 53 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6190665</ArticleId><ArticleId IdType="pubmed">30326945</ArticleId></ArticleIdList></Reference><Reference><Citation>Olive C., Ibanez L., Farias F. H. G., Wang F., Budde J. P., Norton J. B., Gentsch J., Morris J. C., Li Z., Dube U., Del-Aguila J., Bergmann K., Bradley J., Benitez B. A., Harari O., Fagan A., Ances B., Cruchaga C., Fernandez M. V., Examination of the effect of rare variants in TREM2, ABI3, and PLCG2 in LOAD through multiple phenotypes. J. Alzheimers Dis. 77, 1469&#x2013;1482 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7927150</ArticleId><ArticleId IdType="pubmed">32894242</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh J. I., Kino Y., Yanaizu M., Tosaki Y., Sakai K., Ishida T., Saito Y., Microglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease. Intractable Rare Dis. Res. 6, 262&#x2013;268 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5735279</ArticleId><ArticleId IdType="pubmed">29259854</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekino S., Kashiwagi Y., Kanazawa H., Takada K., Baba T., Sato S., Inoue H., Kojima M., Tani K., The NESH/Abi-3-based WAVE2 complex is functionally distinct from the Abi-1-based WAVE2 complex. Cell Commun. Signal 13, 41 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4589964</ArticleId><ArticleId IdType="pubmed">26428302</ArticleId></ArticleIdList></Reference><Reference><Citation>Moraes L., Zanchin N. I. T., Cerutti J. M., ABI3, a component of the WAVE2 complex, is potentially regulated by PI3K/AKT pathway. Oncotarget 8, 67769&#x2013;67781 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5620210</ArticleId><ArticleId IdType="pubmed">28978070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K. S., Marcogliese P. C., Yang J., Callaghan S. M., Resende V., Abdel-Messih E., Marras C., Visanji N. P., Huang J., Schlossmacher M. G., Trinkle-Mulcahy L., Slack R. S., Lang A. E., Park D. S., Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 115, E5164&#x2013;E5173 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984500</ArticleId><ArticleId IdType="pubmed">29760073</ArticleId></ArticleIdList></Reference><Reference><Citation>Takenawa T., Miki H., WASP and WAVE family proteins: Key molecules for rapid rearrangement of cortical actin filaments and cell movement. J. Cell Sci. 114, 1801&#x2013;1809 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11329366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichigotani Y., Yokozaki S., Fukuda Y., Hamaguchi M., Matsuda S., Forced expression of NESH suppresses motility and metastatic dissemination of malignant cells. Cancer Res. 62, 2215&#x2013;2219 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11956071</ArticleId></ArticleIdList></Reference><Reference><Citation>Latini F. R., Hemerly J. P., Freitas B. C., Oler G., Riggins G. J., Cerutti J. M., ABI3 ectopic expression reduces in vitro and in vivo cell growth properties while inducing senescence. BMC Cancer 11, 11 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032749</ArticleId><ArticleId IdType="pubmed">21223585</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B., Wang X., Li Y., Chen P. C., Yu K., Dey K. K., Yarbro J. M., Han X., Lutz B. M., Rao S., Jiao Y., Sifford J. M., Han J., Wang M., Tan H., Shaw T. I., Cho J. H., Zhou S., Wang H., Niu M., Mancieri A., Messler K. A., Sun X., Wu Z., Pagala V., High A. A., Bi W., Zhang H., Chi H., Haroutunian V., Zhang B., Beach T. G., Yu G., Peng J., Deep multilayer brain proteomics identifies molecular networks in Alzheimer's disease progression. Neuron 105, 975&#x2013;991.e7 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7318843</ArticleId><ArticleId IdType="pubmed">31926610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L., Allen M., Sakae N., Ertekin-Taner N., Graff-Radford N. R., Dickson D. W., Younkin S. G., Sevlever D., Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's disease brains. Mol. Neurodegener. 11, 72 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5124229</ArticleId><ArticleId IdType="pubmed">27887626</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay T. R., Miller C. M., Cheng P. J., Graham L. C., Bemiller S., Broihier M. L., Xu G., Margevicius D., Karlo J. C., Sousa G. L., Cotleur A. C., Butovsky O., Bekris L., Staugaitis S. M., Leverenz J. B., Pimplikar S. W., Landreth G. E., Howell G. R., Ransohoff R. M., Lamb B. T., TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J. Exp. Med. 212, 287&#x2013;295 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4354365</ArticleId><ArticleId IdType="pubmed">25732305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich J. D., Finn M. B., Wang Y., Shen A., Mahan T. E., Jiang H., Stewart F. R., Piccio L., Colonna M., Holtzman D. M., Altered microglial response to A&#x3b2; plaques in APPPS1-21 mice heterozygous for TREM2. Mol. Neurodegener. 9, 20 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Cella M., Mallinson K., Ulrich J. D., Young K. L., Robinette M. L., Gilfillan S., Krishnan G. M., Sudhakar S., Zinselmeyer B. H., Holtzman D. M., Cirrito J. R., Colonna M., TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160, 1061&#x2013;1071 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Meilandt W. J., Ngu H., Gogineni A., Lalehzadeh G., Lee S. H., Srinivasan K., Imperio J., Wu T., Weber M., Kruse A. J., Stark K. L., Chan P., Kwong M., Modrusan Z., Friedman B. A., Elstrott J., Foreman O., Easton A., Sheng M., Hansen D. V., Trem2 deletion reduces late-stage amyloid plaque accumulation, elevates the A&#x3b2;42:A&#x3b2;40 ratio, and exacerbates axonal dystrophy and dendritic spine loss in the PS2APP Alzheimer's mouse model. J. Neurosci. 40, 1956&#x2013;1974 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7046459</ArticleId><ArticleId IdType="pubmed">31980586</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C. Y. D., Daggett A., Gu X., Jiang L. L., Langfelder P., Li X., Wang N., Zhao Y., Park C. S., Cooper Y., Ferando I., Mody I., Coppola G., Xu H., Yang X. W., Elevated TREM2 gene dosage reprograms microglia responsivity and ameliorates pathological phenotypes in Alzheimer's disease models. Neuron 97, 1032&#x2013;1048.e5 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927822</ArticleId><ArticleId IdType="pubmed">29518357</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadleir K. R., Eimer W. A., Cole S. L., Vassar R., A&#x3b2; reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level. Mol. Neurodegener. 10, 1 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297413</ArticleId><ArticleId IdType="pubmed">25567526</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J., Gao J., Kim J., Hong C., Kim J., Tontonoz P., The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Abeta amyloidosis. Sci. Transl. Med. 7, 314ra184 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153735</ArticleId><ArticleId IdType="pubmed">26582899</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard A. R., Soulet D., Gowing G., Julien J. P., Rivest S., Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49, 489&#x2013;502 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16476660</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman S., Izzy S., Sen P., Morsett L., El Khoury J., Microglia in neurodegeneration. Nat. Neurosci. 21, 1359&#x2013;1369 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817969</ArticleId><ArticleId IdType="pubmed">30258234</ArticleId></ArticleIdList></Reference><Reference><Citation>Preuss C., Pandey R., Piazza E., Fine A., Uyar A., Perumal T., Garceau D., Kotredes K. P., Williams H., Mangravite L. M., Lamb B. T., Oblak A. L., Howell G. R., Sasner M., Logsdon B. A., Carter G. W., A novel systems biology approach to evaluate mouse models of late-onset Alzheimer&#x2019;s disease. bioRxiv, 682856 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7656729</ArticleId><ArticleId IdType="pubmed">33172468</ArticleId></ArticleIdList></Reference><Reference><Citation>Harigaya Y., Shoji M., Nakamura T., Matsubara E., Hosoda K., Hirai S., Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease. Intern. Med. 34, 481&#x2013;484 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7549128</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedes J. R., Lao T., Cardoso A. L., El Khoury J., Roles of microglial and monocyte chemokines and their receptors in regulating Alzheimer's disease-associated Amyloid-&#x3b2; and Tau pathologies. Front. Neurol. 9, 549 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6104478</ArticleId><ArticleId IdType="pubmed">30158892</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L., Cassatella M. A., Szendrei G. I., Otvos L. Jr., Baron P., Villalba M., Ferrari D., Rossi F., Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 374, 647&#x2013;650 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7715705</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S. S., Ebbert M. T. W., Baker K. E., Cook C., Wang X., Sens J. P., Kocher J. P., Petrucelli L., Fryer J. D., Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. J. Exp. Med. 215, 2235&#x2013;2245 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6122978</ArticleId><ArticleId IdType="pubmed">30082275</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D. J., Alzheimer's disease is a synaptic failure. Science 298, 789&#x2013;791 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L., Selkoe D. J., Neurotoxicity of amyloid &#x3b2;-protein: Synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2, a006338 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385944</ArticleId><ArticleId IdType="pubmed">22762015</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T. K., David E., Baruch K., Lara-Astaiso D., Toth B., Itzkovitz S., Colonna M., Schwartz M., Amit I., A unique microglia type associated with restricting development of Alzheimer's disease. Cell 169, 1276&#x2013;1290.e17 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Song W. M., Andhey P. S., Swain A., Levy T., Miller K. R., Poliani P. L., Cominelli M., Grover S., Gilfillan S., Cella M., Ulland T. K., Zaitsev K., Miyashita A., Ikeuchi T., Sainouchi M., Kakita A., Bennett D. A., Schneider J. A., Nichols M. R., Beausoleil S. A., Ulrich J. D., Holtzman D. M., Artyomov M. N., Colonna M., Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nat. Med. 26, 131&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Philtjens S., Turnbull M. T., Thedy B. P., Moon Y., Kim J., Chemogenetic activation of astrocytes in the hippocampus and cortex changes the transcriptome of microglia and other cell types. bioRxiv, 2020.2004.2027.064881 (2020).</Citation></Reference><Reference><Citation>Wu Y. E., Pan L., Zuo Y., Li X., Hong W., Detecting activated cell populations using single-cell RNA-Seq. Neuron 96, 313&#x2013;329.e6 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29024657</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Cheng Z., Zhou L., Darmanis S., Neff N. F., Okamoto J., Gulati G., Bennett M. L., Sun L. O., Clarke L. E., Marschallinger J., Yu G., Quake S. R., Wyss-Coray T., Barres B. A., Developmental heterogeneity of microglia and brain myeloid cells revealed by deep single-cell RNA sequencing. Neuron 101, 207&#x2013;223.e10 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336504</ArticleId><ArticleId IdType="pubmed">30606613</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X., Wang R., Zhou Y., Fei L., Sun H., Lai S., Saadatpour A., Zhou Z., Chen H., Ye F., Huang D., Xu Y., Huang W., Jiang M., Jiang X., Mao J., Chen Y., Lu C., Xie J., Fang Q., Wang Y., Yue R., Li T., Huang H., Orkin S. H., Yuan G.-C., Chen M., Guo G., Mapping the mouse cell atlas by microwell-seq. Cell 172, 1091&#x2013;1107.e17 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29474909</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernier L. P., Bohlen C. J., York E. M., Choi H. B., Kamyabi A., Dissing-Olesen L., Hefendehl J. K., Collins H. Y., Stevens B., Barres B. A., MacVicar B. A., Nanoscale surveillance of the brain by microglia via cAMP-regulated filopodia. Cell Rep. 27, 2895&#x2013;2908.e4 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31167136</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura Y., Shibagaki K., Takata K., Tsuchiya D., Taniguchi T., Gebicke-Haerter P. J., Miki H., Takenawa T., Shimohama S., Involvement of wiskott-aldrich syndrome protein family verprolin-homologous protein (WAVE) and Rac1 in the phagocytosis of Amyloid-&#x3b2;(1&#x2013;42) in rat microglia. J. Pharmacol. Sci. 92, 115&#x2013;123 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12832839</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae J., Sung B. H., Cho I. H., Song W. K., F-actin-dependent regulation of NESH dynamics in rat hippocampal neurons. PLOS ONE 7, e34514 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319579</ArticleId><ArticleId IdType="pubmed">22496823</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P., Condello C., Keene C. D., Wang Y., Bird T. D., Paul S. M., Luo W., Colonna M., Baddeley D., Grutzendler J., TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 92, 252&#x2013;264 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27710785</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Ulland T. K., Ulrich J. D., Song W., Tzaferis J. A., Hole J. T., Yuan P., Mahan T. E., Shi Y., Gilfillan S., Cella M., Grutzendler J., DeMattos R. B., Cirrito J. R., Holtzman D. M., Colonna M., TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 213, 667&#x2013;675 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M., Kiyota T., Horiba M., Buescher J. L., Walsh S. M., Gendelman H. E., Ikezu T., Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am. J. Pathol. 170, 680&#x2013;692 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851864</ArticleId><ArticleId IdType="pubmed">17255335</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson L. N., Bales K. R., DiCarlo G., Gordon M. N., Morgan D., Paul S. M., Potter H., &#x3b1;-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 1444&#x2013;1451 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762932</ArticleId><ArticleId IdType="pubmed">11222634</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J. T., Leiter L. M., McPhee J., Cahill C. M., Zhan S. S., Potter H., Nilsson L. N., Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5&#x2032;-Untranslated region sequences. J. Biol. Chem. 274, 6421&#x2013;6431 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10037734</ArticleId></ArticleIdList></Reference><Reference><Citation>Alasmari F., Alshammari M. A., Alasmari A. F., Alanazi W. A., Alhazzani K., Neuroinflammatory cytokines induce amyloid beta neurotoxicity through modulating amyloid precursor protein levels/metabolism. Biomed. Res. Int. 2018, 1&#x2013;8 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6222241</ArticleId><ArticleId IdType="pubmed">30498753</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z. X., Tan L., Liu J., Yu J. T., The essential role of soluble A&#x3b2; oligomers in Alzheimer's disease. Mol. Neurobiol. 53, 1905&#x2013;1924 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">25833098</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierksma A., Lu A., Mancuso R., Fattorelli N., Thrupp N., Salta E., Zoco J., Blum D., Buee L., De Strooper B., Fiers M., Novel Alzheimer risk genes determine the microglia response to amyloid-beta but not to TAU pathology. EMBO Mol. Med. 12, e10606 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7059012</ArticleId><ArticleId IdType="pubmed">31951107</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S. S., Kurti A., Baker K. E., Liu C. C., Colonna M., Ulrich J. D., Holtzman D. M., Bu G., Fryer J. D., Behavioral and transcriptomic analysis of Trem2-null mice: Not all knockout mice are created equal. Hum. Mol. Genet. 27, 211&#x2013;223 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886290</ArticleId><ArticleId IdType="pubmed">29040522</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S. M., Mun B. R., Lee S. J., Joh Y., Lee H. Y., Ji K. Y., Choi H. R., Lee E. H., Kim E. M., Jang J. H., Song H. W., Mook-Jung I., Choi W. S., Kang H. S., TREM2 promotes A&#x3b2; phagocytosis by upregulating C/EBP&#x3b1;-dependent CD36 expression in microglia. Sci. Rep. 7, 11118 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5593901</ArticleId><ArticleId IdType="pubmed">28894284</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F., Snaidero N., Kleinberger G., Madore C., Daria A., Werner G., Krasemann S., Capell A., Tr&#xfc;mbach D., Wurst W., Brunner B., Bultmann S., Tahirovic S., Kerschensteiner M., Misgeld T., Butovsky O., Haass C., TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep. 18, 1186&#x2013;1198 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>Donzis E. J., Tronson N. C., Modulation of learning and memory by cytokines: Signaling mechanisms and long term consequences. Neurobiol. Learn. Mem. 115, 68&#x2013;77 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4250287</ArticleId><ArticleId IdType="pubmed">25151944</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Cui G., Zhu M., Kang X., Guo H., Neuroinflammation in Alzheimer's disease: Chemokines produced by astrocytes and chemokine receptors. Int. J. Clin. Exp. Pathol. 7, 8342&#x2013;8355 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4314046</ArticleId><ArticleId IdType="pubmed">25674199</ArticleId></ArticleIdList></Reference><Reference><Citation>Galimberti D., Schoonenboom N., Scheltens P., Fenoglio C., Bouwman F., Venturelli E., Guidi I., Blankenstein M. A., Bresolin N., Scarpini E., Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch. Neurol. 63, 538&#x2013;543 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16606766</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia M. Q., Bacskai B. J., Knowles R. B., Qin S. X., Hyman B. T., Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: In vitro ERK1/2 activation and role in Alzheimer's disease. J. Neuroimmunol. 108, 227&#x2013;235 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10900358</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathy D., Thirumangalakudi L., Grammas P., Expression of macrophage inflammatory protein 1-alpha is elevated in Alzheimer's vessels and is regulated by oxidative stress. J. Alzheimers Dis. 11, 447&#x2013;455 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17656823</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlkolinsk&#xfd; R., Siggins G. R., Campbell I. L., Krucker T., Acute exposure to CXC chemokine ligand 10, but not its chronic astroglial production, alters synaptic plasticity in mouse hippocampal slices. J. Neuroimmunol. 150, 37&#x2013;47 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15081247</ArticleId></ArticleIdList></Reference><Reference><Citation>Marciniak E., Faivre E., Dutar P., Alves Pires C., Demeyer D., Caillierez R., Laloux C., Bu&#xe9;e L., Blum D., Humez S., The chemokine MIP-1&#x3b1;/CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory. Sci. Rep. 5, 15862 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4625372</ArticleId><ArticleId IdType="pubmed">26511387</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae J., Sung B. H., Cho I. H., Kim S. M., Song W. K., NESH regulates dendritic spine morphology and synapse formation. PLOS ONE 7, e34677 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3317636</ArticleId><ArticleId IdType="pubmed">22485184</ArticleId></ArticleIdList></Reference><Reference><Citation>Kommaddi R. P., Das D., Karunakaran S., Nanguneri S., Bapat D., Ray A., Shaw E., Bennett D. A., Nair D., Ravindranath V., A&#x3b2; mediates F-actin disassembly in dendritic spines leading to cognitive deficits in Alzheimer's disease. J. Neurosci. 38, 1085&#x2013;1099 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5792472</ArticleId><ArticleId IdType="pubmed">29246925</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson M. R., Tipney H., Painter J. L., Shen J., Nicoletti P., Shen Y., Floratos A., Sham P. C., Li M. J., Wang J., Cardon L. R., Whittaker J. C., Sanseau P., The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856&#x2013;860 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26121088</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H., Cole S. L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R., Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J. Neurosci. 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Castellano J. M., Jiang H., Basak J. M., Parsadanian M., Pham V., Mason S. M., Paul S. M., Holtzman D. M., Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 64, 632&#x2013;644 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787195</ArticleId><ArticleId IdType="pubmed">20005821</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Jiang H., Park S., Eltorai A. E., Stewart F. R., Yoon H., Basak J. M., Finn M. B., Holtzman D. M., Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-&#x3b2; amyloidosis. J. Neurosci. 31, 18007&#x2013;18012 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257514</ArticleId><ArticleId IdType="pubmed">22159114</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B., Tinevez J. Y., White D. J., Hartenstein V., Eliceiri K., Tomancak P., Cardona A., Fiji: An open-source platform for biological-image analysis. Nat. Methods 9, 676&#x2013;682 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuin C., Goodman A., Chernyshev V., Kamentsky L., Cimini B. A., Karhohs K. W., Doan M., Ding L., Rafelski S. M., Thirstrup D., Wiegraebe W., Singh S., Becker T., Caicedo J. C., Carpenter A. E., CellProfiler 3.0: Next-generation image processing for biology. PLoS Biol. 16, e2005970 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029841</ArticleId><ArticleId IdType="pubmed">29969450</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine W. B., Jungbauer L., Yu C., LaDu M. J., Preparing synthetic A&#x3b2; in different aggregation states. Methods Mol. Biol. 670, 13&#x2013;32 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752843</ArticleId><ArticleId IdType="pubmed">20967580</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Li Y., Wu Z., Wang H., Tan H., Peng J., JUMP: A tag-based database search tool for peptide identification with high sensitivity and accuracy. Mol. Cell. Proteomics 13, 3663&#x2013;3673 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4256513</ArticleId><ArticleId IdType="pubmed">25202125</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates A. D., Achuthan P., Akanni W., Allen J., Allen J., Alvarez-Jarreta J., Amode M. R., Armean I. M., Azov A. G., Bennett R., Bhai J., Billis K., Boddu S., Marug&#xe1;n J. C., Cummins C., Davidson C., Dodiya K., Fatima R., Gall A., Giron C. G., Gil L., Grego T., Haggerty L., Haskell E., Hourlier T., Izuogu O. G., Janacek S. H., Juettemann T., Kay M., Lavidas I., Le T., Lemos D., Martinez J. G., Maurel T., McDowall M., McMahon A., Mohanan S., Moore B., Nuhn M., Oheh D. N., Parker A., Parton A., Patricio M., Sakthivel M. P., Abdul Salam A. I., Schmitt B. M., Schuilenburg H., Sheppard D., Sycheva M., Szuba M., Taylor K., Thormann A., Threadgold G., Vullo A., Walts B., Winterbottom A., Zadissa A., Chakiachvili M., Flint B., Frankish A., Hunt S. E., IIsley G., Kostadima M., Langridge N., Loveland J. E., Martin F. J., Morales J., Mudge J. M., Muffato M., Perry E., Ruffier M., Trevanion S. J., Cunningham F., Howe K. L., Zerbino D. R., Flicek P., Ensembl 2020. Nucleic Acids Res. 48, D682&#x2013;D688 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145704</ArticleId><ArticleId IdType="pubmed">31691826</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A., Davis C. A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T. R., STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders S., Pyl P. T., Huber W., HTSeq&#x2014;A Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166&#x2013;169 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287950</ArticleId><ArticleId IdType="pubmed">25260700</ArticleId></ArticleIdList></Reference><Reference><Citation>Satija R., Farrell J. A., Gennert D., Schier A. F., Regev A., Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495&#x2013;502 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4430369</ArticleId><ArticleId IdType="pubmed">25867923</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc7;avu&#x15f; I., Koo P. H., Teyler T. J., Inhibition of long-term potentiation development in rat hippocampal slice by &#x3b1;2-macroglobulin, an acute-phase protein in the brain. J. Neurosci. Res. 43, 282&#x2013;288 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8714517</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakharenko S. S., Zablow L., Siegelbaum S. A., Visualization of changes in presynaptic function during long-term synaptic plasticity. Nat. Neurosci. 4, 711&#x2013;717 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11426227</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34731016</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>618</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>03</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Restoring activity in the thalamic reticular nucleus improves sleep architecture and reduces A&#x3b2; accumulation in mice.</ArticleTitle><Pagination><StartPage>eabh4284</StartPage><MedlinePgn>eabh4284</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abh4284</ELocationID><Abstract><AbstractText>Sleep disruptions promote increases of amyloid &#x3b2; (A&#x3b2;) and tau in the brain and increase Alzheimer&#x2019;s disease (AD) risk, but the precise mechanisms that give rise to sleep disturbances have yet to be defined. The thalamic reticular nucleus (TRN) is essential for sleep maintenance and for the regulation of slow-wave sleep (SWS). We examined the TRN in transgenic mice that express mutant human amyloid precursor protein (APP) and found reduced neuronal activity, increased sleep fragmentation, and decreased SWS time as compared to nontransgenic littermates. Selective activation of the TRN using excitatory DREADDs restored sleep maintenance, increased time in SWS, and reduced amyloid plaque load in both hippocampus and cortex. Our findings suggest that the TRN may play a major role in symptoms associated with AD. Enhancing TRN activity might be a promising therapeutic strategy for AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jagirdar</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4706-7619</Identifier><AffiliationInfo><Affiliation>Memory and Brain Research Center, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Chia-Hsuan</ForeName><Initials>CH</Initials><Identifier Source="ORCID">0000-0002-0905-8917</Identifier><AffiliationInfo><Affiliation>Memory and Brain Research Center, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3073-0285</Identifier><AffiliationInfo><Affiliation>Memory and Brain Research Center, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corbett</LastName><ForeName>Brian F</ForeName><Initials>BF</Initials><Identifier Source="ORCID">0000-0003-3688-4859</Identifier><AffiliationInfo><Affiliation>Memory and Brain Research Center, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seibt</LastName><ForeName>Frederik M</ForeName><Initials>FM</Initials><Identifier Source="ORCID">0000-0003-0536-5212</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology and Anatomy, McGovern Medical School at UTHealth, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beierlein</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2210-3118</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology and Anatomy, McGovern Medical School at UTHealth, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chin</LastName><ForeName>Jeannie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9902-3744</Identifier><AffiliationInfo><Affiliation>Memory and Brain Research Center, Baylor College of Medicine, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 HD103555</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG065290</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS085171</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS007413</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Sci Transl Med. 2024 Feb 7;16(733):eado1402. doi: 10.1126/scitranslmed.ado1402.</RefSource><PMID Version="1">38324642</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>17</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34731016</ArticleId><ArticleId IdType="mid">NIHMS1788941</ArticleId><ArticleId IdType="pmc">PMC8985235</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abh4284</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mander BA, Local Sleep and Alzheimer's Disease Pathophysiology. Front Neurosci 14, 525970 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538792</ArticleId><ArticleId IdType="pubmed">33071726</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Winer JR, Jagust WJ, Walker MP, Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? Trends Neurosci 39, 552&#x2013;566 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4967375</ArticleId><ArticleId IdType="pubmed">27325209</ArticleId></ArticleIdList></Reference><Reference><Citation>Minakawa EN, Wada K, Nagai Y, Sleep Disturbance as a Potential Modifiable Risk Factor for Alzheimer's Disease. Int J Mol Sci 20, 803 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6412395</ArticleId><ArticleId IdType="pubmed">30781802</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprecher KE et al., High Resolution Topography of Age-Related Changes in Non-Rapid Eye Movement Sleep Electroencephalography. PLoS One 11, e0149770 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4764685</ArticleId><ArticleId IdType="pubmed">26901503</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga AW et al., Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid A&#x3b2;42 Levels in Cognitively Normal Elderly. Sleep 39, 2041&#x2013;2048 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070758</ArticleId><ArticleId IdType="pubmed">27568802</ArticleId></ArticleIdList></Reference><Reference><Citation>De Gennaro L et al., The Fall of Sleep K-Complex in Alzheimer Disease. Sci Rep 7, 39688 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5206737</ArticleId><ArticleId IdType="pubmed">28045040</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorgoni M et al., Parietal Fast Sleep Spindle Density Decrease in Alzheimer's Disease and Amnesic Mild Cognitive Impairment. Neural Plast 2016, 8376108 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4811201</ArticleId><ArticleId IdType="pubmed">27066274</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerberg CE et al., Concurrent impairments in sleep and memory in amnestic mild cognitive impairment. J Int Neuropsychol Soc 18, 490&#x2013;500 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468412</ArticleId><ArticleId IdType="pubmed">22300710</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YE, Lucey BP, Holtzman DM, Sleep and Alzheimer disease pathology--a bidirectional relationship. Nat Rev Neurol 10, 115&#x2013;119 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979317</ArticleId><ArticleId IdType="pubmed">24366271</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Holtzman DM, Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors. Neuropsychopharmacology 45, 104&#x2013;120 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6879647</ArticleId><ArticleId IdType="pubmed">31408876</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YE et al., Sleep quality and preclinical Alzheimer disease. JAMA Neurol 70, 587&#x2013;593 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3676720</ArticleId><ArticleId IdType="pubmed">23479184</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Winer JR, Walker MP, Sleep and Human Aging. Neuron 94, 19&#x2013;36 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5810920</ArticleId><ArticleId IdType="pubmed">28384471</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubu OM et al., Sleep, Cognitive impairment, and Alzheimer's disease: A Systematic Review and Meta-Analysis. Sleep 40, zsw032 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28364458</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE et al., Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326, 1005&#x2013;1007 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim AS, Kowgier M, Yu L, Buchman AS, Bennett DA, Sleep Fragmentation and the Risk of Incident Alzheimer's Disease and Cognitive Decline in Older Persons. Sleep 36, 1027&#x2013;1032 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3669060</ArticleId><ArticleId IdType="pubmed">23814339</ArticleId></ArticleIdList></Reference><Reference><Citation>Spira AP et al., Self-reported sleep and &#x3b2;-amyloid deposition in community-dwelling older adults. JAMA Neurol 70, 1537&#x2013;1543 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918480</ArticleId><ArticleId IdType="pubmed">24145859</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K et al., Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. Jama 306, 613&#x2013;619 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3600944</ArticleId><ArticleId IdType="pubmed">21828324</ArticleId></ArticleIdList></Reference><Reference><Citation>Holth JK et al., The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science 363, 880&#x2013;884 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6410369</ArticleId><ArticleId IdType="pubmed">30679382</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA, Disturbed sleep in preclinical cognitive impairment: cause and effect? Sleep 36, 1275&#x2013;1276 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3738034</ArticleId><ArticleId IdType="pubmed">23997358</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander BA et al., &#x3b2;-amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. Nat Neurosci 18, 1051&#x2013;1057 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4482795</ArticleId><ArticleId IdType="pubmed">26030850</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L et al., Sleep drives metabolite clearance from the adult brain. Science 342, 373&#x2013;377 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880190</ArticleId><ArticleId IdType="pubmed">24136970</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth&#xe9;lemy NR et al., Sleep Deprivation Affects Tau Phosphorylation in Human Cerebrospinal Fluid. Ann Neurol 87, 700&#x2013;709 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289061</ArticleId><ArticleId IdType="pubmed">32057125</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju YS et al., Slow wave sleep disruption increases cerebrospinal fluid amyloid-&#x3b2; levels. Brain 140, 2104&#x2013;2111 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790144</ArticleId><ArticleId IdType="pubmed">28899014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP et al., Effect of sleep on overnight cerebrospinal fluid amyloid &#x3b2; kinetics. Ann Neurol 83, 197&#x2013;204 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5876097</ArticleId><ArticleId IdType="pubmed">29220873</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP et al., Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease. Sci Transl Med 11, eaau6550 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6342564</ArticleId><ArticleId IdType="pubmed">30626715</ArticleId></ArticleIdList></Reference><Reference><Citation>Winer JR et al., Sleep as a Potential Biomarker of Tau and &#x3b2;-Amyloid Burden in the Human Brain. J Neurosci 39, 6315&#x2013;6324 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687908</ArticleId><ArticleId IdType="pubmed">31209175</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedergaard M, Goldman SA, Glymphatic failure as a final common pathway to dementia. Science 370, 50&#x2013;56 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8186542</ArticleId><ArticleId IdType="pubmed">33004510</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A et al., Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. J Clin Invest 127, 3210&#x2013;3219 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5669566</ArticleId><ArticleId IdType="pubmed">28862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan MJ et al., Effects of the dual orexin receptor antagonist DORA-22 on sleep in 5XFAD mice. Alzheimers Dement (N Y) 5, 70&#x2013;80 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6396100</ArticleId><ArticleId IdType="pubmed">30859123</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JH et al., Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease. J Exp Med 211, 2487&#x2013;2496 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4267230</ArticleId><ArticleId IdType="pubmed">25422493</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauvilliers YA, Lehmann S, Jaussent I, Gabelle A, Hypocretin and brain &#x3b2;-amyloid peptide interactions in cognitive disorders and narcolepsy. Front Aging Neurosci 6, 119 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4052448</ArticleId><ArticleId IdType="pubmed">24966833</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabelle A et al., Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. Neurobiol Aging 53, 59&#x2013;66 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28235679</ArticleId></ArticleIdList></Reference><Reference><Citation>Herring WJ et al., Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimers Dement 16, 541&#x2013;551 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7984350</ArticleId><ArticleId IdType="pubmed">31944580</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori C et al., Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol 71, 1498&#x2013;1505 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25322206</ArticleId></ArticleIdList></Reference><Reference><Citation>Steullet P et al., The thalamic reticular nucleus in schizophrenia and bipolar disorder: role of parvalbumin-expressing neuron networks and oxidative stress. Mol Psychiatry 23, 2057&#x2013;2065 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5972042</ArticleId><ArticleId IdType="pubmed">29180672</ArticleId></ArticleIdList></Reference><Reference><Citation>Young A, Wimmer RD, Implications for the thalamic reticular nucleus in impaired attention and sleep in schizophrenia. Schizophr Res 180, 44&#x2013;47 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27510855</ArticleId></ArticleIdList></Reference><Reference><Citation>Manoach DS, Stickgold R, Abnormal Sleep Spindles, Memory Consolidation, and Schizophrenia. Annu Rev Clin Psychol 15, 451&#x2013;479 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7307009</ArticleId><ArticleId IdType="pubmed">30786245</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagirdar R, Chin J, Corticothalamic network dysfunction and Alzheimer's disease. Brain Res 1702, 38&#x2013;45 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5854522</ArticleId><ArticleId IdType="pubmed">28919464</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis LD et al., Thalamic reticular nucleus induces fast and local modulation of arousal state. Elife 4, e08760 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4686423</ArticleId><ArticleId IdType="pubmed">26460547</ArticleId></ArticleIdList></Reference><Reference><Citation>Timofeev I, Contreras D, Steriade M, Synaptic responsiveness of cortical and thalamic neurones during various phases of slow sleep oscillation in cat. J Physiol 494 (Pt 1), 265&#x2013;278 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1160628</ArticleId><ArticleId IdType="pubmed">8814620</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogerson PM, Huguenard JR, Tapping the Brakes: Cellular and Synaptic Mechanisms that Regulate Thalamic Oscillations. Neuron 92, 687&#x2013;704 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5131525</ArticleId><ArticleId IdType="pubmed">27883901</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks GA, Roffwarg HP, Spontaneous activity in the thalamic reticular nucleus during the sleep/wake cycle of the freely-moving rat. Brain Res 623, 241&#x2013;248 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8221106</ArticleId></ArticleIdList></Reference><Reference><Citation>Destexhe A, Contreras D, Steriade M, Mechanisms underlying the synchronizing action of corticothalamic feedback through inhibition of thalamic relay cells. J Neurophysiol 79, 999&#x2013;1016 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9463458</ArticleId></ArticleIdList></Reference><Reference><Citation>Steriade M, Timofeev I, Neuronal plasticity in thalamocortical networks during sleep and waking oscillations. Neuron 37, 563&#x2013;576 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12597855</ArticleId></ArticleIdList></Reference><Reference><Citation>Halassa MM et al., State-dependent architecture of thalamic reticular subnetworks. Cell 158, 808&#x2013;821 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4205482</ArticleId><ArticleId IdType="pubmed">25126786</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimmer RD et al., Thalamic control of sensory selection in divided attention. Nature 526, 705&#x2013;709 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626291</ArticleId><ArticleId IdType="pubmed">26503050</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlonan K, Cavanaugh J, Wurtz RH, Attentional modulation of thalamic reticular neurons. J Neurosci 26, 4444&#x2013;4450 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674014</ArticleId><ArticleId IdType="pubmed">16624964</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy C, Olfactory and other sensory impairments in Alzheimer disease. Nat Rev Neurol 15, 11&#x2013;24 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30532084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucey BP, It's complicated: The relationship between sleep and Alzheimer's disease in humans. Neurobiol Dis 144, 105031 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484285</ArticleId><ArticleId IdType="pubmed">32738506</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C et al., Neurocognitive pattern analysis reveals classificatory hierarchy of attention deficits in schizophrenia. Schizophr Bull 40, 878&#x2013;885 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4059438</ArticleId><ArticleId IdType="pubmed">23934819</ArticleId></ArticleIdList></Reference><Reference><Citation>Luck SJ, Gold JM, The construct of attention in schizophrenia. Biol Psychiatry 64, 34&#x2013;39 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562029</ArticleId><ArticleId IdType="pubmed">18374901</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Winkelman JW, Clinical significance of sleep EEG abnormalities in chronic schizophrenia. Schizophr Res 82, 251&#x2013;260 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16377158</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauer CJ, Schreiber W, Pollm&#xe4;cher T, Holsboer F, Krieg JC, Sleep in schizophrenia: a polysomnographic study on drug-naive patients. Neuropsychopharmacology 16, 51&#x2013;60 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">8981388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazra A et al., Corticothalamic network dysfunction and behavioral deficits in a mouse model of Alzheimer's disease. Neurobiol Aging 44, 96&#x2013;107 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4943218</ArticleId><ArticleId IdType="pubmed">27318137</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L et al., High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20, 4050&#x2013;4058 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett BF et al., &#x394;FosB Regulates Gene Expression and Cognitive Dysfunction in a Mouse Model of Alzheimer's Disease. Cell Rep 20, 344&#x2013;355 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785235</ArticleId><ArticleId IdType="pubmed">28700937</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu CH et al., Early Seizure Activity Accelerates Depletion of Hippocampal Neural Stem Cells and Impairs Spatial Discrimination in an Alzheimer's Disease Model. Cell Rep 27, 3741&#x2013;3751 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697001</ArticleId><ArticleId IdType="pubmed">31242408</ArticleId></ArticleIdList></Reference><Reference><Citation>You JC et al., Epigenetic suppression of hippocampal calbindin-D28k by &#x394;FosB drives seizure-related cognitive deficits. Nat Med 23, 1377&#x2013;1383 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5747956</ArticleId><ArticleId IdType="pubmed">29035369</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW et al., Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat Neurosci 14, 750&#x2013;756 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Boespflug EL, Iliff JJ, The Emerging Relationship Between Interstitial Fluid-Cerebrospinal Fluid Exchange, Amyloid-&#x3b2;, and Sleep. Biol Psychiatry 83, 328&#x2013;336 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5767516</ArticleId><ArticleId IdType="pubmed">29279202</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR et al., Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48, 913&#x2013;922 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ et al., A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#x3b2;. Sci Transl Med 4, 147ra111 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hablitz LM et al., Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia. Sci Adv 5, eaav5447 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6392807</ArticleId><ArticleId IdType="pubmed">30820460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam K, Duffy &#xc1; M, Moretto J, LaFrancois JJ, Scharfman HE, Interictal spikes during sleep are an early defect in the Tg2576 mouse model of &#x3b2;-amyloid neuropathology. Sci Rep 6, 20119 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4730189</ArticleId><ArticleId IdType="pubmed">26818394</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent BA et al., Delayed daily activity and reduced NREM slow-wave power in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Neurobiol Aging 78, 74&#x2013;86 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30884411</ArticleId></ArticleIdList></Reference><Reference><Citation>Beenhakker MP, Huguenard JR, Neurons that fire together also conspire together: is normal sleep circuitry hijacked to generate epilepsy? Neuron 62, 612&#x2013;632 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748990</ArticleId><ArticleId IdType="pubmed">19524522</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs F, Usrey WM, Emerging views of corticothalamic function. Curr Opin Neurobiol 18, 403&#x2013;407 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626162</ArticleId><ArticleId IdType="pubmed">18805486</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldemar G et al., Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 14, e1&#x2013;26 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17222085</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander GM et al., Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63, 27&#x2013;39 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751885</ArticleId><ArticleId IdType="pubmed">19607790</ArticleId></ArticleIdList></Reference><Reference><Citation>Guettier JM et al., A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A 106, 19197&#x2013;19202 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2767362</ArticleId><ArticleId IdType="pubmed">19858481</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez LM et al., Thalamic reticular control of local sleep in mouse sensory cortex. Elife 7, e39111 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6342525</ArticleId><ArticleId IdType="pubmed">30583750</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinault D, The thalamic reticular nucleus: structure, function and concept. Brain Res Brain Res Rev 46, 1&#x2013;31 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15297152</ArticleId></ArticleIdList></Reference><Reference><Citation>Vantomme G, Osorio-Forero A, L&#xfc;thi A, Fernandez LMJ, Regulation of Local Sleep by the Thalamic Reticular Nucleus. Front Neurosci 13, 576 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6560175</ArticleId><ArticleId IdType="pubmed">31231186</ArticleId></ArticleIdList></Reference><Reference><Citation>Deboer T, Sleep homeostasis and the circadian clock: Do the circadian pacemaker and the sleep homeostat influence each other's functioning? Neurobiol Sleep Circadian Rhythms 5, 68&#x2013;77 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6584681</ArticleId><ArticleId IdType="pubmed">31236513</ArticleId></ArticleIdList></Reference><Reference><Citation>Winer JR et al., Sleep Disturbance Forecasts &#x3b2;-Amyloid Accumulation across Subsequent Years. Curr Biol, 4291&#x2013;4298 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7642104</ArticleId><ArticleId IdType="pubmed">32888482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen MK, Mestre H, Nedergaard M, The glymphatic pathway in neurological disorders. Lancet Neurol 17, 1016&#x2013;1024 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6261373</ArticleId><ArticleId IdType="pubmed">30353860</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh JH et al., Disruption of the sleep-wake cycle and diurnal fluctuation of &#x3b2;-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med 4, 150ra122 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654377</ArticleId><ArticleId IdType="pubmed">22956200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F et al., Alteration in sleep architecture and electroencephalogram as an early sign of Alzheimer's disease preceding the disease pathology and cognitive decline. Alzheimers Dement 15, 590&#x2013;597 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30819626</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz PN et al., Changes in the sleep and waking EEGs of nondemented and demented elderly subjects. J Am Geriatr Soc 30, 86&#x2013;93 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">7199061</ArticleId></ArticleIdList></Reference><Reference><Citation>Winer JR, Mander BA, Waking Up to the Importance of Sleep in the Pathogenesis of Alzheimer Disease. JAMA Neurol 75, 654&#x2013;656 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29532083</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Garcia RI et al., Two dynamically distinct circuits drive inhibition in the sensory thalamus. Nature 583, 813&#x2013;818 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7394732</ArticleId><ArticleId IdType="pubmed">32699410</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y et al., Distinct subnetworks of the thalamic reticular nucleus. Nature 583, 819&#x2013;824 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7394718</ArticleId><ArticleId IdType="pubmed">32699411</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemente-Perez A et al., Distinct Thalamic Reticular Cell Types Differentially Modulate Normal and Pathological Cortical Rhythms. Cell Rep 19, 2130&#x2013;2142 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5557038</ArticleId><ArticleId IdType="pubmed">28591583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting JT, Daigle TL, Chen Q, Feng G, Acute brain slice methods for adult and aging animals: application of targeted patch clamp analysis and optogenetics. Methods Mol Biol 1183, 221&#x2013;242 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4219416</ArticleId><ArticleId IdType="pubmed">25023312</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34757788</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>46</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>A brain proteomic signature of incipient Alzheimer's disease in young <i>APOE</i> &#x3b5;4 carriers identifies novel drug targets.</ArticleTitle><Pagination><StartPage>eabi8178</StartPage><MedlinePgn>eabi8178</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eabi8178</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.abi8178</ELocationID><Abstract><AbstractText>Aptamer-based proteomics revealed differentially abundant proteins in Alzheimer&#x2019;s disease (AD) brains in the Baltimore Longitudinal Study of Aging and Religious Orders Study (mean age, 89 &#xb1; 9 years). A subset of these proteins was also differentially abundant in the brains of young <i>APOE</i> &#x3b5;4 carriers relative to noncarriers (mean age, 39 &#xb1; 6 years). Several of these proteins represent targets of approved and experimental drugs for other indications and were validated using orthogonal methods in independent human brain tissue samples as well as in transgenic AD models. Using cell culture&#x2013;based phenotypic assays, we showed that drugs targeting the cytokine transducer STAT3 and the Src family tyrosine kinases, YES1 and FYN, rescued molecular phenotypes relevant to AD pathogenesis. Our findings may accelerate the development of effective interventions targeting the earliest molecular triggers of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Jackson A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-2231-2454</Identifier><AffiliationInfo><Affiliation>Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varma</LastName><ForeName>Vijay R</ForeName><Initials>VR</Initials><AffiliationInfo><Affiliation>Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Brain Aging and Behavior Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varma</LastName><ForeName>Sudhir</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4096-4782</Identifier><AffiliationInfo><Affiliation>HiThru Analytics, Laurel, MD 20707, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Candia</LastName><ForeName>Juli&#xe1;n</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5793-8989</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fantoni</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Research Core, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiwari</LastName><ForeName>Vinod</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-2341-0953</Identifier><AffiliationInfo><Affiliation>Section on DNA Repair, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anerillas</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4424-7913</Identifier><AffiliationInfo><Affiliation>Laboratory of Genetics and Genomics, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loeffler</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>QPS Austria GmbH, Parkring 12, 8074 Grambach, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilcher</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>QPS Austria GmbH, Parkring 12, 8074 Grambach, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moaddel</LastName><ForeName>Ruin</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6812-0127</Identifier><AffiliationInfo><Affiliation>Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khadeer</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovett</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Toshiko</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-4161-3829</Identifier><AffiliationInfo><Affiliation>Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pletnikova</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0003-3689-554X</Identifier><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Kaiwen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6050-8477</Identifier><AffiliationInfo><Affiliation>Departments of Structural Biology and Developmental Neurobiology, Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Mingming</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3666-4450</Identifier><AffiliationInfo><Affiliation>Departments of Structural Biology and Developmental Neurobiology, Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haroutunian</LastName><ForeName>Vahram</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5860-2512</Identifier><AffiliationInfo><Affiliation>Departments of Psychiatry and Neuroscience, The Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Illness Research, Education and Clinical Center (MIRECC), James J. Peters VA Medical Center, Bronx, NY 10468, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-9549-5653</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences and Department of Pharmacological Sciences, Mount Sinai Center for Transformative Disease Modeling, Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Junmin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0472-7648</Identifier><AffiliationInfo><Affiliation>Departments of Structural Biology and Developmental Neurobiology, Center for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croteau</LastName><ForeName>Deborah L</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0002-6094-4084</Identifier><AffiliationInfo><Affiliation>Section on DNA Repair, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resnick</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Brain Aging and Behavior Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorospe</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5439-3434</Identifier><AffiliationInfo><Affiliation>Laboratory of Genetics and Genomics, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohr</LastName><ForeName>Vilhelm A</ForeName><Initials>VA</Initials><Identifier Source="ORCID">0000-0003-4823-6429</Identifier><AffiliationInfo><Affiliation>Section on DNA Repair, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6273-1613</Identifier><AffiliationInfo><Affiliation>Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thambisetty</LastName><ForeName>Madhav</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2200-2299</Identifier><AffiliationInfo><Affiliation>Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG072975</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066507</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG046170</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG053987</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>10</Day><Hour>17</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34757788</ArticleId><ArticleId IdType="pmc">PMC8580310</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abi8178</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Farrer L. A., Cupples L. A., Haines J. L., Hyman B., Kukull W. A., Mayeux R., Myers R. H., Pericak-Vance M. A., Risch N., van Duijn C. M., Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349&#x2013;1356 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Neu S. C., Pa J., Kukull W., Beekly D., Kuzma A., Gangadharan P., Wang L.-S., Romero K., Arneric S. P., Redolfi A., Orlandi D., Frisoni G. B., Au R., Devine S., Auerbach S., Espinosa A., Boada M., Ruiz A., Johnson S. C., Koscik R., Wang J.-J., Hsu W.-C., Chen Y.-L., Toga A. W., Apolipoprotein E genotype and sex risk factors for Alzheimer disease: A meta-analysis. JAMA Neurol. 74, 1178&#x2013;1189 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759346</ArticleId><ArticleId IdType="pubmed">28846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E., Hannequin D., Wallon D., Sleegers K., Hiltunen M., Combarros O., Bullido M. J., Engelborghs S., De Deyn P., Berr C., Pasquier F., Dubois B., Tognoni G., Fi&#xe9;vet N., Brouwers N., Bettens K., Arosio B., Coto E., Del Zompo M., Mateo I., Epelbaum J., Frank-Garcia A., Helisalmi S., Porcellini E., Pilotto A., Forti P., Ferri R., Scarpini E., Siciliano G., Solfrizzi V., Sorbi S., Spalletta G., Valdivieso F., Veps&#xe4;l&#xe4;inen S., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Boss&#xf9; P., Hanon O., Piccardi P., Annoni G., Seripa D., Galimberti D., Licastro F., Soininen H., Dartigues J.-F., Kamboh M. I., Van Broeckhoven C., Lambert J. C., Amouyel P., Campion D., APOE and Alzheimer disease: A major gene with semi-dominant inheritance. Mol. Psychiatry 16, 903&#x2013;907 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Sando S. B., Melquist S., Cannon A., Hutton M. L., Sletvold O., Saltvedt I., White L. R., Lydersen S., Aasly J. O., APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer&#x2019;s disease: A case control study from central Norway. BMC Neurol. 8, 9 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2375917</ArticleId><ArticleId IdType="pubmed">18416843</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science 261, 921&#x2013;923 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen W. J., Ossenkoppele R., Knol D. L., Tijms B. M., Scheltens P., Verhey F. R. J., Visser P. J.; Amyloid Biomarker Study Group, Aalten P., Aarsland D., Alcolea D., Alexander M., Almdahl I. S., Arnold S. E., Baldeiras I., Barthel H., van Berckel B. N. M., Bibeau K., Blennow K., Brooks D. J., van Buchem M. A., Camus V., Cavedo E., Chen K., Chetelat G., Cohen A. D., Drzezga A., Engelborghs S., Fagan A. M., Fladby T., Fleisher A. S., van der Flier W. M., Ford L., F&#xf6;rster S., Fortea J., Foskett N., Frederiksen K. S., Freund-Levi Y., Frisoni G. B., Froelich L., Gabryelewicz T., Gill K. D., Gkatzima O., G&#xf3;mez-Tortosa E., Gordon M. F., Grimmer T., Hampel H., Hausner L., Hellwig S., Herukka S.-K., Hildebrandt H., Ishihara L., Ivanoiu A., Jagust W. J., Johannsen P., Kandimalla R., Kapaki E., Klimkowicz-Mrowiec A., Klunk W. E., K&#xf6;hler S., Koglin N., Kornhuber J., Kramberger M. G., Van Laere K., Landau S. M., Lee D. Y., de Leon M., Lisetti V., Lle&#xf3; A., Madsen K., Maier W., Marcusson J., Mattsson N., de Mendon&#xe7;a A., Meulenbroek O., Meyer P. T., Mintun M. A., Mok V., Molinuevo J. L., M&#xf8;llerg&#xe5;rd H. M., Morris J. C., Mroczko B., Van der Mussele S., Na D. L., Newberg A., Nordberg A., Nordlund A., Novak G. P., Paraskevas G. P., Parnetti L., Perera G., Peters O., Popp J., Prabhakar S., Rabinovici G. D., Ramakers I. H. G. B., Rami L., de Oliveira C. R., Rinne J. O., Rodrigue K. M., Rodr&#xed;guez-Rodr&#xed;guez E., Roe C. M., Rot U., Rowe C. C., R&#xfc;ther E., Sabri O., Sanchez-Juan P., Santana I., Sarazin M., Schr&#xf6;der J., Sch&#xfc;tte C., Seo S. W., Soetewey F., Soininen H., Spiru L., Struyfs H., Teunissen C. E., Tsolaki M., Vandenberghe R., Verbeek M. M., Villemagne V. L., Vos S. J. B., L. J. C. van Waalwijk van Doorn, Waldemar G., Wallin A., Wallin &#xc5;. K., Wiltfang J., Wolk D. A., Zboch M., Zetterberg H., Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA 313, 1924&#x2013;1938 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Pletnikova O., Kageyama Y., Rudow G., La Clair K. D., Albert M., Crain B. J., Tian J., Fowler D., Troncoso J. C., The spectrum of preclinical Alzheimer&#x2019;s disease pathology and its modulation by ApoE genotype. Neurobiol. Aging 71, 72&#x2013;80 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30099348</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman E. M., Chen K., Alexander G. E., Caselli R. J., Bandy D., Osborne D., Saunders A. M., Hardy J., Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer&#x2019;s dementia. Proc. Natl. Acad. Sci. U.S.A. 101, 284&#x2013;289 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P., Lerch J. P., Pruessner J. C., Taylor K. N., Rose A., Greenstein D., Clasen L., Evans A., Rapoport J. L., Giedd J. N., Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: An observational study. Lancet Neurol. 6, 494&#x2013;500 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17509484</ArticleId></ArticleIdList></Reference><Reference><Citation>Nao J., Sun H., Wang Q., Ma S., Zhang S., Dong X., Ma Y., Wang X., Zheng D., Adverse effects of the apolipoprotein E epsilon4 allele on episodic memory, task switching and gray matter volume in healthy young adults. Front. Hum. Neurosci. 11, 346 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5489690</ArticleId><ArticleId IdType="pubmed">28706481</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Zhao Y., Zhang B., Efficient test and visualization of multi-set intersections. Sci. Rep. 5, 16923 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4658477</ArticleId><ArticleId IdType="pubmed">26603754</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S., Caccamo A., Shepherd J. D., Murphy M. P., Golde T. E., Kayed R., Metherate R., Mattson M. P., Akbari Y., La Ferla F. M., Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409&#x2013;421 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kageyama Y., Saito A., Pletnikova O., Rudow G. L., Irie Y., An Y., Murakami K., Irie K., Resnick S. M., Fowler D. R., Martin L. J., Troncoso J. C., Amyloid &#x3b2; toxic conformer has dynamic localization in the human inferior parietal cortex in absence of amyloid plaques. Sci. Rep. 8, 16895 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6237870</ArticleId><ArticleId IdType="pubmed">30442978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra S. S., Heyman A., Keel D. M., Sumi S. M., Crain B. J., Brownlee L. M., Vogel F. S., Hughes J. P., van Belle G., Berg L., The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology 41, 479&#x2013;486 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B., Wang X., Li Y., Chen P.-C., Yu K., Dey K. K., Yarbro J. M., Han X., Lutz B. M., Rao S., Jiao Y., Sifford J. M., Han J., Wang M., Tan H., Shaw T. I., Cho J.-H., Zhou S., Wang H., Niu M., Mancieri A., Messler K. A., Sun X., Wu Z., Pagala V., High A. A., Bi W., Zhang H., Chi H., Haroutunian V., Zhang B., Beach T. G., Yu G., Peng J., Deep multilayer brain proteomics identifies molecular networks in Alzheimer&#x2019;s disease progression. Neuron 106, 700 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7322979</ArticleId><ArticleId IdType="pubmed">32437656</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H., Davila-Velderrain J., Peng Z., Gao F., Mohammadi S., Young J. Z., Menon M., He L., Abdurrob F., Jiang X., Martorell A. J., Ransohoff R. M., Hafler B. P., Bennett D. A., Kellis M., Tsai L.-H., Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H., Cole S. L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R., Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: Potential factors in amyloid plaque formation. J. Neurosci. 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Angelo A., Sobhani N., Chapman R., Bagby S., Bortoletti C., Traversini M., Ferrari K., Voltolini L., Darlow J., Roviello G., Focus on ROS1-positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, resistance mechanisms and the newer generation of targeted therapies. Cancers 12, 3293 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7694780</ArticleId><ArticleId IdType="pubmed">33172113</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA grants orphan drug designation for napabucasin. Oncol. Times 38, 25 (2016).</Citation></Reference><Reference><Citation>Rousselot P., Mollica L., Guilhot J., Guerci A., Nicolini F. E., Etienne G., Legros L., Charbonnier A., Coiteux V., Dartigeas C., Escoffre-Barbe M., Roy L., Cony-Makhoul P., Dubruille V., Gardembas M., Huguet F., R&#xe9;a D., Cayssials E., Guilhot F., Bergeron A., Molimard M., Mahon F.-X., Cayuela J.-M., Busque L., Bouchet S., Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br. J. Haematol. 194, 393&#x2013;402 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34195988</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong M., Jiang H., Serrano J. R., Gonzales E. R., Wang C., Gratuze M., Hoyle R., Bien-Ly N., Silverman A. P., Sullivan P. M., Watts R. J., Ulrich J. D., Zipfel G. J., Holtzman D. M., APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci. Transl. Med. 13, eabd7522 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8128342</ArticleId><ArticleId IdType="pubmed">33597265</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder A., de Wit J., Leucine-rich repeat-containing synaptic adhesion molecules as organizers of synaptic specificity and diversity. Exp. Mol. Med. 50, 1&#x2013;9 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5938020</ArticleId><ArticleId IdType="pubmed">29628503</ArticleId></ArticleIdList></Reference><Reference><Citation>Lincoln S., Allen M., Cox C. L., Walker L. P., Malphrus K., Qiu Y., Nguyen T., Rowley C., Kouri N., Crook J., Pankratz V. S., Younkin S., Younkin L., Carrasquillo M., Zou F., Abdul-Hay S. O., Springer W., Sando S. B., Aasly J. O., Barcikowska M., Wszolek Z. K., Lewis J. M., Dickson D., Graff-Radford N. R., Petersen R. C., Eckman E., Younkin S. G., Ertekin-Taner N., LRRTM3 interacts with APP and BACE1 and has variants associating with late-onset Alzheimer&#x2019;s disease (LOAD). PLOS ONE 8, e64164 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3672107</ArticleId><ArticleId IdType="pubmed">23750206</ArticleId></ArticleIdList></Reference><Reference><Citation>Majercak J., Ray W. J., Espeseth A., Simon A., Shi X.-P., Wolffe C., Getty K., Marine S., Stec E., Ferrer M., Strulovici B., Bartz S., Gates A., Xu M., Huang Q., Ma L., Shughrue P., Burchard J., Colussi D., Pietrak B., Kahana J., Beher D., Rosahl T., Shearman M., Hazuda D., Sachs A. B., Koblan K. S., Seabrook G. R., Stone D. J., LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U.S.A. 103, 17967&#x2013;17972 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1635650</ArticleId><ArticleId IdType="pubmed">17098871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim N.-Y., Cho M.-H., Won S.-H., Kang H.-J., Yoon S.-Y., Kim D.-H., Sorting nexin-4 regulates &#x3b2;-amyloid production by modulating &#x3b2;-site-activating cleavage enzyme-1. Alzheimers Res. Ther. 9, 4 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5251330</ArticleId><ArticleId IdType="pubmed">28109317</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh W. H., Chia P. Z. C., Hossain M. I., Gleeson P. A., GGA1 regulates signal-dependent sorting of BACE1 to recycling endosomes, which moderates A&#x3b2; production. Mol. Biol. Cell 29, 191&#x2013;208 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909931</ArticleId><ArticleId IdType="pubmed">29142073</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez L., Alvarez V., Gonz&#xe1;lez P., Gonz&#xe1;lez I., Alvarez R., Coto E., Variation in the LRP-associated protein gene (LRPAP1) is associated with late-onset Alzheimer disease. Am. J. Med. Genet. 105, 76&#x2013;78 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11425005</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Uden E., Mallory M., Veinbergs I., Alford M., Rockenstein E., Masliah E., Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J. Neurosci. 22, 9298&#x2013;9304 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758061</ArticleId><ArticleId IdType="pubmed">12417655</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C., Conrad C., Roszkowski K., Rogers R. S., Mayeux R., Effect of genetic variation in LRRTM3 on risk of Alzheimer disease. Arch. Neurol. 69, 894&#x2013;900 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391336</ArticleId><ArticleId IdType="pubmed">22393166</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey P., Pradhan S., Mittal B., LRP-associated protein gene (LRPAP1) and susceptibility to degenerative dementia. Genes Brain Behav. 7, 943&#x2013;950 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18721259</ArticleId></ArticleIdList></Reference><Reference><Citation>Anguita E., Villalobo A., Src-family tyrosine kinases and the Ca2+ signal. Biochim. Biophys. Acta Mol. Cell Res. 1864, 915&#x2013;932 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27818271</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchesi W., Mizuno K., Giese K. P., Novel insights into CaMKII function and regulation during memory formation. Brain Res. Bull. 85, 2&#x2013;8 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21070840</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajan M. P., Hansen B. C., Higgs M. G., Kahn C. R., Braun U., Leitges M., Park C. R., Diamond D. M., Farese R. V., Atypical PKC, PKClambda/iota, activates &#x3b2;secretase and increases Abeta1-40/42 and phospho-tau in mouse brain and isolated neuronal cells, and may link hyperinsulinemia and other aPKC activators to development of pathological and memory abnormalities in Alzheimer&#x2019;s disease. Neurobiol. Aging 61, 225&#x2013;237 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5705272</ArticleId><ArticleId IdType="pubmed">29032894</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund A., Patil C. K., Campisi J., p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J. 30, 1536&#x2013;1548 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102277</ArticleId><ArticleId IdType="pubmed">21399611</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun A., Liu M., Nguyen X. V., Bing G., P38 MAP kinase is activated at early stages in Alzheimer&#x2019;s disease brain. Exp. Neurol. 183, 394&#x2013;405 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14552880</ArticleId></ArticleIdList></Reference><Reference><Citation>Briner A., Gotz J., Polanco J. C., Fyn kinase controls tau aggregation in vivo. Cell Rep. 32, 108045 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32814048</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A., Giese K. P., Calcium/calmodulin-dependent kinase II and Alzheimer&#x2019;s disease. Mol. Brain 8, 78 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4657223</ArticleId><ArticleId IdType="pubmed">26603284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Addlagatta A., Lu J., Matthews B. W., Liu J. O., Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progression. Proc. Natl. Acad. Sci. U.S.A. 103, 18148&#x2013;18153 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838721</ArticleId><ArticleId IdType="pubmed">17114291</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Hu S., Zhou L., Ye L., Wang X., Ho J., Ho W., Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons. Glia 59, 58&#x2013;67 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082435</ArticleId><ArticleId IdType="pubmed">20878770</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurston T. L., Wandel M. P., von Muhlinen N., Foeglein A., Randow F., Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nature 482, 414&#x2013;418 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343631</ArticleId><ArticleId IdType="pubmed">22246324</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B., Noad J., McMahon H., Randow F., Goedert M., Galectin-8-mediated selective autophagy protects against seeded tau aggregation. J. Biol. Chem. 293, 2438&#x2013;2451 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818177</ArticleId><ArticleId IdType="pubmed">29282296</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S., Bhaskar K., Degradation and transmission of tau by autophagic-endolysosomal networks and potential therapeutic targets for tauopathy. Front. Mol. Neurosci. 13, 586731 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596180</ArticleId><ArticleId IdType="pubmed">33177989</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H., Kim W., Kim S. H., Kim K. T., VRK3-mediated nuclear localization of HSP70 prevents glutamate excitotoxicity-induced apoptosis and Abeta accumulation via enhancement of ERK phosphatase VHR activity. Sci. Rep. 6, 38452 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5150261</ArticleId><ArticleId IdType="pubmed">27941812</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuminello E. R., Han S. D., The apolipoprotein e antagonistic pleiotropy hypothesis: Review and recommendations. Int. J. Alzheimers Dis. 2011, 726197 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056453</ArticleId><ArticleId IdType="pubmed">21423560</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitek M. P., Brown C. M., Colton C. A., APOE genotype-specific differences in the innate immune response. Neurobiol. Aging 30, 1350&#x2013;1360 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782461</ArticleId><ArticleId IdType="pubmed">18155324</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett S., Courtiol A., Lummaa V., Moorad J., Stearns S., The transition to modernity and chronic disease: Mismatch and natural selection. Nat. Rev. Genet. 19, 419&#x2013;430 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29743650</ArticleId></ArticleIdList></Reference><Reference><Citation>Trumble B. C., Stieglitz J., Blackwell A. D., Allayee H., Beheim B., Finch C. E., Gurven M., Kaplan H., Apolipoprotein E4 is associated with improved cognitive function in Amazonian forager-horticulturalists with a high parasite burden. FASEB J. 31, 1508&#x2013;1515 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349792</ArticleId><ArticleId IdType="pubmed">28031319</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson E. C. B., Dammer E. B., Duong D. M., Ping L., Zhou M., Yin L., Higginbotham L. A., Guajardo A., White B., Troncoso J. C., Thambisetty M., Montine T. J., Lee E. B., Trojanowski J. Q., Beach T. G., Reiman E. M., Haroutunian V., Wang M., Schadt E., Zhang B., Dickson D. W., Ertekin-Taner N., Golde T. E., Petyuk V. A., De Jager P. L., Bennett D. A., Wingo T. S., Rangaraju S., Hajjar I., Shulman J. M., Lah J. J., Levey A. I., Seyfried N. T., Large-scale proteomic analysis of Alzheimer&#x2019;s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat. Med. 26, 769&#x2013;780 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405761</ArticleId><ArticleId IdType="pubmed">32284590</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C. H., Tworoger S. S., Stampfer M. J., Dillon S. T., Gu X., Sawyer S. J., Chan A. T., Libermann T. A., Eliassen A. H., Stability and reproducibility of proteomic profiles measured with an aptamer-based platform. Sci. Rep. 8, 8382 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5976624</ArticleId><ArticleId IdType="pubmed">29849057</ArticleId></ArticleIdList></Reference><Reference><Citation>Oveisgharan S., Arvanitakis Z., Yu L., Farfel J., Schneider J. A., Bennett D. A., Sex differences in Alzheimer&#x2019;s disease and common neuropathologies of aging. Acta Neuropathol. 136, 887&#x2013;900 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6279593</ArticleId><ArticleId IdType="pubmed">30334074</ArticleId></ArticleIdList></Reference><Reference><Citation>M. Pietzner, E. Wheeler, J. Carrasco-Zanini, N. D. Kerrison, E. Oerton, M. Koprulu, J. Luan, A. D. Hingorani, S. A. Williams, N. J. Wareham, C. Langenberg, Cross-platform proteomics to advance genetic prioritisation strategies. bioRxiv 2021.03.18.435919 [Preprint]. 19 March 2021; 10.1101/2021.03.18.435919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.18.435919</ArticleId></ArticleIdList></Reference><Reference><Citation>Billing A. M., Hamidane H. B., Bhagwat A. M., Cotton R. J., Dib S. S., Kumar P., Hayat S., Goswami N., Suhre K., Rafii A., Graumann J., Complementarity of SOMAscan to LC-MS/MS and RNA-seq for quantitative profiling of human embryonic and mesenchymal stem cells. J. Proteomics 150, 86&#x2013;97 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27613379</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci L., The Baltimore Longitudinal Study of Aging (BLSA): A 50-year-long journey and plans for the future. J. Gerontol. A Biol. Sci. Med. Sci. 63, 1416&#x2013;1419 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5004590</ArticleId><ArticleId IdType="pubmed">19126858</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien R. J., Resnick S. M., Zonderman A. B., Ferrucci L., Crain B. J., Pletnikova O., Rudow G., Iacono D., Riudavets M. A., Driscoll I., Price D. L., Martin L. J., Troncoso J. C., Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). J. Alzheimers Dis. 18, 665&#x2013;675 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978421</ArticleId><ArticleId IdType="pubmed">19661626</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Troncoso J. C., Zonderman A. B., Resnick S. M., Crain B., Pletnikova O., O&#x2019;Brien R. J., Effect of infarcts on dementia in the Baltimore Longitudinal Study of Aging. Ann. Neurol. 64, 168&#x2013;176 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694129</ArticleId><ArticleId IdType="pubmed">18496870</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas C., Gray S., Brookmeyer R., Fozard J., Zonderman A., Age-specific incidence rates of Alzheimer&#x2019;s disease: The Baltimore Longitudinal Study of Aging. Neurology 54, 2072&#x2013;2077 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10851365</ArticleId></ArticleIdList></Reference><Reference><Citation>APA, Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R (American Psychiatric Association, 1987).</Citation></Reference><Reference><Citation>McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M., Clinical diagnosis of Alzheimer&#x2019;s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology 34, 939&#x2013;944 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D. A., Buchman A. S., Boyle P. A., Barnes L. L., Wilson R. S., Schneider J. A., Religious orders study and rush memory and aging project. J. Alzheimers Dis. 64, S161&#x2013;S189 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider J. A., Wilson R. S., Cochran E. J., Bienias J. L., Arnold S. E., Evans D. A., Bennett D. A., Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology 60, 1082&#x2013;1088 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12682310</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D. A., Wilson R. S., Schneider J. A., Evans D. A., Aggarwal N. T., Arnold S. E., Cochran E. J., Berry-Kravis E., Bienias J. L., Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer&#x2019;s disease. Neurology 60, 246&#x2013;252 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12552039</ArticleId></ArticleIdList></Reference><Reference><Citation>Consensus recommendations for the postmortem diagnosis of Alzheimer&#x2019;s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer&#x2019;s Disease. Neurobiol. Aging 18, S1&#x2013;S2 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson J. E., Vernier D. T., Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31, 545&#x2013;548 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Huff F. J., Growdon J. H., Corkin S., Rosen T. J., Age at onset and rate of progression of Alzheimer&#x2019;s disease. J. Am. Geriatr. Soc. 35, 27&#x2013;30 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3794143</ArticleId></ArticleIdList></Reference><Reference><Citation>Candia J., Cheung F., Kotliarov Y., Fantoni G., Sellers B., Griesman T., Huang J., Stuccio S., Zingone A., Ryan B. M., Tsang J. S., Biancotto A., Assessment of variability in the SOMAscan assay. Sci. Rep. 7, 14248 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5660188</ArticleId><ArticleId IdType="pubmed">29079756</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold L., Ayers D., Bertino J., Bock C., Bock A., Brody E. N., Carter J., Dalby A. B., Eaton B. E., Fitzwater T., Flather D., Forbes A., Foreman T., Fowler C., Gawande B., Goss M., Gunn M., Gupta S., Halladay D., Heil J., Heilig J., Hicke B., Husar G., Janjic N., Jarvis T., Jennings S., Katilius E., Keeney T. R., Kim N., Koch T. H., Kraemer S., Kroiss L., Le N., Levine D., Lindsey W., Lollo B., Mayfield W., Mehan M., Mehler R., Nelson S. K., Nelson M., Nieuwlandt D., Nikrad M., Ochsner U., Ostroff R. M., Otis M., Parker T., Pietrasiewicz S., Resnicow D. I., Rohloff J., Sanders G., Sattin S., Schneider D., Singer B., Stanton M., Sterkel A., Stewart A., Stratford S., Vaught J. D., Vrkljan M., Walker J. J., Watrobka M., Waugh S., Weiss A., Wilcox S. K., Wolfson A., Wolk S. K., Zhang C., Zichi D., Aptamer-based multiplexed proteomic technology for biomarker discovery. PLOS ONE 5, e15004 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000457</ArticleId><ArticleId IdType="pubmed">21165148</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyslop N. P., White W. H., Estimating precision using duplicate measurements. J. Air Waste Manag. Assoc. 59, 1032&#x2013;1039 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19785269</ArticleId></ArticleIdList></Reference><Reference><Citation>Bland J. M., Altman D. G., Measurement error proportional to the mean. BMJ 313, 106 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2351517</ArticleId><ArticleId IdType="pubmed">8688716</ArticleId></ArticleIdList></Reference><Reference><Citation>R. Jones, B. Payne, Clinical Investigation and Statistics in Laboratory Medicine (ACB Venture Publications, 1997).</Citation></Reference><Reference><Citation>An Y., Varma V. R., Varma S., Casanova R., Dammer E., Pletnikova O., Chia C. W., Egan J. M., Ferrucci L., Troncoso J., Levey A. I., Lah J., Seyfried N. T., Legido-Quigley C., O&#x2019;Brien Madhav Thambisetty R., Evidence for brain glucose dysregulation in Alzheimer&#x2019;s disease. Alzheimers Dement. 14, 318&#x2013;329 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866736</ArticleId><ArticleId IdType="pubmed">29055815</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y., Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289&#x2013;300 (1995).</Citation></Reference><Reference><Citation>Subramanian A., Tamayo P., Mootha V. K., Mukherjee S., Ebert B. L., Gillette M. A., Paulovich A., Pomeroy S. L., Golub T. R., Lander E. S., Mesirov J. P., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545&#x2013;15550 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Gable A. L., Lyon D., Junge A., Wyder S., Huerta-Cepas J., Simonovic M., Doncheva N. T., Morris J. H., Bork P., Jensen L. J., von Mering C., STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607&#x2013;D613 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Varma V. R., Oommen A. M., Varma S., Casanova R., An Y., Andrews R. M., O&#x2019;Brien R., Pletnikova O., Troncoso J. C., Toledo J., Baillie R., Arnold M., Kastenmueller G., Nho K., Doraiswamy P. M., Saykin A. J., Kaddurah-Daouk R., Legido-Quigley C., Thambisetty M., Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLOS Med. 15, e1002482 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5784884</ArticleId><ArticleId IdType="pubmed">29370177</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts J. A., Oommen A. M., Varma S., Casanova R., An Y., Andrews R. M., O&#x2019;Brien R., Pletnikova O., Troncoso J. C., Toledo J., Baillie R., Arnold M., Kastenmueller G., Nho K., Doraiswamy P. M., Saykin A. J., Kaddurah-Daouk R., Legido-Quigley C., Thambisetty M., Blood metabolite signature of metabolic syndrome implicates alterations in amino acid metabolism: Findings from the Baltimore Longitudinal Study of Aging (BLSA) and the Tsuruoka Metabolomics Cohort Study (TMCS). Int. J. Mol. Sci. 21, e1002482 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7072861</ArticleId><ArticleId IdType="pubmed">32070008</ArticleId></ArticleIdList></Reference><Reference><Citation>A. A. Sergushichev, An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. bioRxiv 060012 [Preprint]. 20 June 2016; 10.1101/060012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/060012</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock E. M., Geddes J. W., Chen K. C., Porter N. M., Markesbery W. R., Landfield P. W., Incipient Alzheimer&#x2019;s disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. U.S.A. 101, 2173&#x2013;2178 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X., Huang L., Zheng Y., Song Y., Xu Q., Wang J., Si K., Duan S., Gong W., Ultrafast optical clearing method for three-dimensional imaging with cellular resolution. Proc. Natl. Acad. Sci. U.S.A. 116, 11480&#x2013;11489 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6561250</ArticleId><ArticleId IdType="pubmed">31101714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Beckmann N. D., Roussos P., Wang E., Zhou X., Wang Q., Ming C., Neff R., Ma W., Fullard J. F., Hauberg M. E., Bendl J., Peters M. A., Logsdon B., Wang P., Mahajan M., Mangravite L. M., Dammer E. B., Duong D. M., Lah J. J., Seyfried N. T., Levey A. I., Buxbaum J. D., Ehrlich M., Gandy S., Katsel P., Haroutunian V., Schadt E., Zhang B., The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer&#x2019;s disease. Sci. Data 5, 180185 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132187</ArticleId><ArticleId IdType="pubmed">30204156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie M. E., Phipson B., Wu D., Hu Y., Law C. W., Shi W., Smyth G. K., limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson M. D., Oshlack A., A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864565</ArticleId><ArticleId IdType="pubmed">20196867</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer L. A., Cupples L. A., Haines J. L., Hyman B., Kukull W. A., Mayeux R., Myers R. H., Pericak-Vance M. A., Risch N., van Duijn C. M., Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349&#x2013;1356 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Neu S. C., Pa J., Kukull W., Beekly D., Kuzma A., Gangadharan P., Wang L.-S., Romero K., Arneric S. P., Redolfi A., Orlandi D., Frisoni G. B., Au R., Devine S., Auerbach S., Espinosa A., Boada M., Ruiz A., Johnson S. C., Koscik R., Wang J.-J., Hsu W.-C., Chen Y.-L., Toga A. W., Apolipoprotein E genotype and sex risk factors for Alzheimer disease: A meta-analysis. JAMA Neurol. 74, 1178&#x2013;1189 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5759346</ArticleId><ArticleId IdType="pubmed">28846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Genin E., Hannequin D., Wallon D., Sleegers K., Hiltunen M., Combarros O., Bullido M. J., Engelborghs S., De Deyn P., Berr C., Pasquier F., Dubois B., Tognoni G., Fi&#xe9;vet N., Brouwers N., Bettens K., Arosio B., Coto E., Del Zompo M., Mateo I., Epelbaum J., Frank-Garcia A., Helisalmi S., Porcellini E., Pilotto A., Forti P., Ferri R., Scarpini E., Siciliano G., Solfrizzi V., Sorbi S., Spalletta G., Valdivieso F., Veps&#xe4;l&#xe4;inen S., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Boss&#xf9; P., Hanon O., Piccardi P., Annoni G., Seripa D., Galimberti D., Licastro F., Soininen H., Dartigues J.-F., Kamboh M. I., Van Broeckhoven C., Lambert J. C., Amouyel P., Campion D., APOE and Alzheimer disease: A major gene with semi-dominant inheritance. Mol. Psychiatry 16, 903&#x2013;907 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162068</ArticleId><ArticleId IdType="pubmed">21556001</ArticleId></ArticleIdList></Reference><Reference><Citation>Sando S. B., Melquist S., Cannon A., Hutton M. L., Sletvold O., Saltvedt I., White L. R., Lydersen S., Aasly J. O., APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer&#x2019;s disease: A case control study from central Norway. BMC Neurol. 8, 9 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2375917</ArticleId><ArticleId IdType="pubmed">18416843</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vanc M. A., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science 261, 921&#x2013;923 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen W. J., Ossenkoppele R., Knol D. L., Tijms B. M., Scheltens P., Verhey F. R. J., Visser P. J.; Amyloid Biomarker Study Group, Aalten P., Aarsland D., Alcolea D., Alexander M., Almdahl I. S., Arnold S. E., Baldeiras I., Barthel H., van Berckel B. N. M., Bibeau K., Blennow K., Brooks D. J., van Buchem M. A., Camus V., Cavedo E., Chen K., Chetelat G., Cohen A. D., Drzezga A., Engelborghs S., Fagan A. M., Fladby T., Fleisher A. S., van der Flier W. M., Ford L., F&#xf6;rster S., Fortea J., Foskett N., Frederiksen K. S., Freund-Levi Y., Frisoni G. B., Froelich L., Gabryelewicz T., Gill K. D., Gkatzima O., G&#xf3;mez-Tortosa E., Gordon M. F., Grimmer T., Hampel H., Hausner L., Hellwig S., Herukka S.-K., Hildebrandt H., Ishihara L., Ivanoiu A., Jagust W. J., Johannsen P., Kandimalla R., Kapaki E., Klimkowicz-Mrowiec A., Klunk W. E., K&#xf6;hler S., Koglin N., Kornhuber J., Kramberger M. G., Van Laere K., Landau S. M., Lee D. Y., de Leon M., Lisetti V., Lle&#xf3; A., Madsen K., Maier W., Marcusson J., Mattsson N., de Mendon&#xe7;a A., Meulenbroek O., Meyer P. T., Mintun M. A., Mok V., Molinuevo J. L., M&#xf8;llerg&#xe5;rd H. M., Morris J. C., Mroczko B., Van der Mussele S., Na D. L., Newberg A., Nordberg A., Nordlund A., Novak G. P., Paraskevas G. P., Parnetti L., Perera G., Peters O., Popp J., Prabhakar S., Rabinovici G. D., Ramakers I. H. G. B., Rami L., de Oliveira C. R., Rinne J. O., Rodrigue K. M., Rodr&#xed;guez-Rodr&#xed;guez E., Roe C. M., Rot U., Rowe C. C., R&#xfc;ther E., Sabri O., Sanchez-Juan P., Santana I., Sarazin M., Schr&#xf6;der J., Sch&#xfc;tte C., Seo S. W., Soetewey F., Soininen H., Spiru L., Struyfs H., Teunissen C. E., Tsolaki M., Vandenberghe R., Verbeek M. M., Villemagne V. L., Vos S. J. B., L. J. C. van Waalwijk van Doorn, Waldemar G., Wallin A., Wallin &#xc5;. K., Wiltfang J., Wolk D. A., Zboch M., Zetterberg H., Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA 313, 1924&#x2013;1938 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Pletnikova O., Kageyama Y., Rudow G., La Clair K. D., Albert M., Crain B. J., Tian J., Fowler D., Troncoso J. C., The spectrum of preclinical Alzheimer&#x2019;s disease pathology and its modulation by ApoE genotype. Neurobiol. Aging 71, 72&#x2013;80 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30099348</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman E. M., Chen K., Alexander G. E., Caselli R. J., Bandy D., Osborne D., Saunders A. M., Hardy J., Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer&#x2019;s dementia. Proc. Natl. Acad. Sci. U.S.A. 101, 284&#x2013;289 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P., Lerch J. P., Pruessner J. C., Taylor K. N., Rose A. B., Greenstein D., Clasen L., Evans A., Rapoport J. L., Giedd J. N., Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: An observational study. Lancet Neurol. 6, 494&#x2013;500 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17509484</ArticleId></ArticleIdList></Reference><Reference><Citation>Nao J., Sun H., Wang Q., Ma S., Zhang S., Dong X., Ma Y., Wang X., Zheng D., Adverse effects of the apolipoprotein E &#x3b5;4 allele on episodic memory, task switching and gray matter volume in healthy young adults. Front. Hum. Neurosci. 11, 346 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5489690</ArticleId><ArticleId IdType="pubmed">28706481</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Zhao Y., Zhang B., Efficient test and visualization of multi-set intersections. Sci. Rep. 5, 16923 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4658477</ArticleId><ArticleId IdType="pubmed">26603754</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S., Caccamo A., Shepherd J. D., Murphy M. P., Golde T. E., Kayed R., Metherate R., Mattson M. P., Akbari Y., La Ferla F. M., Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: Intracellular A&#x3b2; and synaptic dysfunction. Neuron 39, 409&#x2013;421 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kageyama Y., Saito A., Pletnikova O., Rudow G. L., Irie Y., An Y., Murakami K., Irie K., Resnick S. M., Fowler D. R., Martin L. J., Troncoso J. C., Amyloid &#x3b2; toxic conformer has dynamic localization in the human inferior parietal cortex in absence of amyloid plaques. Sci. Rep. 8, 16895 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6237870</ArticleId><ArticleId IdType="pubmed">30442978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra S. S., Heyman A., Keel D. M., Sumi S. M., Crain B. J., Brownlee L. M., Vogel F. S., Hughes J. P., van Belle G., Berg L., The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology 41, 479&#x2013;486 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B., Wang X., Li Y., Chen P.-C., Yu K., Dey K. K., Yarbro J. M., Han X., Lutz B. M., Rao S., Jiao Y., Sifford J. M., Han J., Wang M., Tan H., Shaw T. I., Cho J.-H., Zhou S., Wang H., Niu M., Mancieri A., Messler K. A., Sun X., Wu Z., Pagala V., High A. A., Bi W., Zhang H., Chi H., Haroutunian V., Zhang B., Beach T. G., Yu G., Peng J., Deep multilayer brain proteomics identifies molecular networks in Alzheimer&#x2019;s disease progression. Neuron 106, 700 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7322979</ArticleId><ArticleId IdType="pubmed">32437656</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H., Davila-Velderrain J., Peng Z., Gao F., Mohammadi S., Young J. Z., Menon M., He L., Abdurrob F., Jiang X., Martorell A. J., Ransohoff R. M., Hafler B. P., Bennett D. A., Kellis M., Tsai L.-H., Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H., Cole S. L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R., Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: Potential factors in amyloid plaque formation. J. Neurosci. 26, 10129&#x2013;10140 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Angelo A., Sobhani N., Chapman R., Bagby S., Bortoletti C., Traversini M., Ferrari K., Voltolini L., Darlow J., Roviello G., Focus on ROS1-positive non-small cell lung cancer (NSCLC): Crizotinib, resistance mechanisms and the newer generation of targeted therapies. Cancers 12, 3293 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7694780</ArticleId><ArticleId IdType="pubmed">33172113</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Grants , Orphan drug designation for napabucasin. Oncology Times 38, 25 (2016).</Citation></Reference><Reference><Citation>Rousselot P., Mollica L., Guilhot J., Guerci A., Nicolini F. E., Etienne G., Legros L., Charbonnier A., Coiteux V., Dartigeas C., Escoffre-Barbe M., Roy L., Cony-Makhoul P., Dubruille V., Gardembas M., Huguet F., R&#xe9;a D., Cayssials E., Guilhot F., Bergeron A., Molimard M., Mahon F.-X., Cayuela J.-M., Busque L., Bouchet S., Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br. J. Haematol. 194, 393&#x2013;402 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34195988</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong M., Jiang H., Serrano J. R., Gonzales E. R., Wang C., Gratuze M., Hoyle R., Bien-Ly N., Silverman A. P., Sullivan P. M., Watts R. J., Ulrich J. D., Zipfel G. J., Holtzman D. M., APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci. Transl. Med. 13, eabd7522 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8128342</ArticleId><ArticleId IdType="pubmed">33597265</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder A., de Wit J., Leucine-rich repeat-containing synaptic adhesion molecules as organizers of synaptic specificity and diversity. Exp. Mol. Med. 50, 10 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5938020</ArticleId><ArticleId IdType="pubmed">29628503</ArticleId></ArticleIdList></Reference><Reference><Citation>Lincoln S., Allen M., Cox C. L., Walker L. P., Malphrus K., Qiu Y., Nguyen T., Rowley C., Kouri N., Crook J., Pankratz V. S., Younkin S., Younkin L., Carrasquillo M., Zou F., Abdul-Hay S. O., Springer W., Sando S. B., Aasly J. O., Barcikowska M., Wszolek Z. K., Lewis J. M., Dickson D., Graff-Radford N. R., Petersen R. C., Eckman E., Younkin S. G., Ertekin-Taner N., LRRTM3 interacts with APP and BACE1 and has variants associating with late-onset Alzheimer&#x2019;s disease (LOAD). PLOS ONE 8, e64164 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3672107</ArticleId><ArticleId IdType="pubmed">23750206</ArticleId></ArticleIdList></Reference><Reference><Citation>Majercak J., Ray W. J., Espeseth A., Simon A., Shi X.-P., Wolffe C., Getty K., Marine S., Stec E., Ferrer M., Strulovici B., Bartz S., Gates A., Xu M., Huang Q., Ma L., Shughrue P., Burchard J., Colussi D., Pietrak B., Kahana J., Beher D., Rosahl T., Shearman M., Hazuda D., Sachs A. B., Koblan K. S., Seabrook G. R., Stone D. J., LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer&#x2019;s disease. Proc. Natl. Acad. Sci. U.S.A. 103, 17967&#x2013;17972 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1635650</ArticleId><ArticleId IdType="pubmed">17098871</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim N. Y., Cho M.-H., Won S.-H., Kang H.-J., Yoon S.-Y., Kim D.-H., Sorting nexin-4 regulates &#x3b2;-amyloid production by modulating &#x3b2;-site-activating cleavage enzyme-1. Alzheimers Res. Ther. 9, 4 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5251330</ArticleId><ArticleId IdType="pubmed">28109317</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh W. H., Chia P. Z. C., Hossain M. I., Gleeson P. A., GGA1 regulates signal-dependent sorting of BACE1 to recycling endosomes, which moderates Abeta production. Mol. Biol. Cell 29, 191&#x2013;208 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5909931</ArticleId><ArticleId IdType="pubmed">29142073</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez L., Alvarez V., Gonz&#xe1;lez P., Gonz&#xe1;lez I., Alvarez R., Coto E., Variation in the LRP-associated protein gene (LRPAP1) is associated with late-onset Alzheimer disease. Am. J. Med. Genet. 105, 76&#x2013;78 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11425005</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Uden E., Mallory M., Veinbergs I., Alford M., Rockenstein E., Masliah E., Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J. Neurosci. 22, 9298&#x2013;9304 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758061</ArticleId><ArticleId IdType="pubmed">12417655</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitz C., Conrad C., Roszkowski K., Rogers R. S., Mayeux R., Effect of genetic variation in LRRTM3 on risk of Alzheimer disease. Arch. Neurol. 69, 894&#x2013;900 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391336</ArticleId><ArticleId IdType="pubmed">22393166</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey P., Pradhan S., Mittal B., LRP-associated protein gene (LRPAP1) and susceptibility to degenerative dementia. Genes Brain Behav. 7, 943&#x2013;950 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18721259</ArticleId></ArticleIdList></Reference><Reference><Citation>Anguita E., Villalobo A., Src-family tyrosine kinases and the Ca(2+) signal. Biochim. Biophys. Acta Mol. Cell. Res. 1864, 915&#x2013;932 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27818271</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchesi W., Mizuno K., Giese K. P., Novel insights into CaMKII function and regulation during memory formation. Brain Res. Bull. 85, 2&#x2013;8 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21070840</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajan M. P., Hansen B. C., Higgs M. G., Kahn C. R., Braun U., Leitges M., Park C. R., Diamond D. M., Farese R. V., Atypical PKC, PKC&#x3bb;/&#x3b9;, activates &#x3b2;-secretase and increases A&#x3b2;1-40/42 and phospho-tau in mouse brain and isolated neuronal cells, and may link hyperinsulinemia and other aPKC activators to development of pathological and memory abnormalities in Alzheimer&#x2019;s disease. Neurobiol. Aging 61, 225&#x2013;237 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5705272</ArticleId><ArticleId IdType="pubmed">29032894</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund A., Patil C. K., Campisi J., p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J. 30, 1536&#x2013;1548 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102277</ArticleId><ArticleId IdType="pubmed">21399611</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun A., Liu M., Nguyen X. V., Bing G., P38 MAP kinase is activated at early stages in Alzheimer&#x2019;s disease brain. Exp. Neurol. 183, 394&#x2013;405 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14552880</ArticleId></ArticleIdList></Reference><Reference><Citation>Briner A., Gotz J., Polanco J. C., Fyn kinase controls tau aggregation in vivo. Cell Rep. 32, 108045 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32814048</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A., Giese K. P., Calcium/calmodulin-dependent kinase II and Alzheimer&#x2019;s disease. Mol. Brain 8, 78 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4657223</ArticleId><ArticleId IdType="pubmed">26603284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Addlagatta A., Lu J., Matthews B. W., Liu J. O., Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progression. Proc. Natl. Acad. Sci. U.S.A. 103, 18148&#x2013;18153 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838721</ArticleId><ArticleId IdType="pubmed">17114291</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Hu S., Zhou L., Ye L., Wang X., Ho J., Ho W., Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons. Glia 59, 58&#x2013;67 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082435</ArticleId><ArticleId IdType="pubmed">20878770</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurston T. L., Wandel M. P., von Muhlinen N., Foeglein A., Randow F., Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nature 482, 414&#x2013;418 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343631</ArticleId><ArticleId IdType="pubmed">22246324</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon B., Noad J., McMahon H., Randow F., Goedert M., Galectin-8-mediated selective autophagy protects against seeded tau aggregation. J. Biol. Chem. 293, 2438&#x2013;2451 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5818177</ArticleId><ArticleId IdType="pubmed">29282296</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S., Bhaskar K., Degradation and transmission of tau by autophagic-endolysosomal networks and potential therapeutic targets for tauopathy. Front. Mol. Neurosci. 13, 586731 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596180</ArticleId><ArticleId IdType="pubmed">33177989</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H., Kim W., Kim S. H., Kim K. T., VRK3-mediated nuclear localization of HSP70 prevents glutamate excitotoxicity-induced apoptosis and A&#x3b2; accumulation via enhancement of ERK phosphatase VHR activity. Sci. Rep. 6, 38452 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5150261</ArticleId><ArticleId IdType="pubmed">27941812</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuminello E. R., Han S. D., The apolipoprotein e antagonistic pleiotropy hypothesis: Review and recommendations. Int. J. Alzheimers Dis. 2011, 726197 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056453</ArticleId><ArticleId IdType="pubmed">21423560</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitek M. P., Brown C. M., Colton C. A., APOE genotype-specific differences in the innate immune response. Neurobiol. Aging 30, 1350&#x2013;1360 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782461</ArticleId><ArticleId IdType="pubmed">18155324</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett S., Courtiol A., Lummaa V., Moorad J., Stearns S., The transition to modernity and chronic disease: Mismatch and natural selection. Nat. Rev. Genet. 19, 419&#x2013;430 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29743650</ArticleId></ArticleIdList></Reference><Reference><Citation>Trumble B. C., Stieglitz J., Blackwell A. D., Allayee H., Beheim B., Finch C. E., Gurven M., Kaplan H., Apolipoprotein E4 is associated with improved cognitive function in Amazonian forager-horticulturalists with a high parasite burden. FASEB J. 31, 1508&#x2013;1515 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5349792</ArticleId><ArticleId IdType="pubmed">28031319</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson E. C. B., Dammer E. B., Duong D. M., Ping L., Zhou M., Yin L., Higginbotham L. A., Guajardo A., White B., Troncoso J. C., Thambisetty M., Montine T. J., Lee E. B., Trojanowski J. Q., Beach T. G., Reiman E. M., Haroutunian V., Wang M., Schadt E., Zhang B., Dickson D. W., Ertekin-Taner N., Golde T. E., Petyuk V. A., De Jager P. L., Bennett D. A., Wingo T. S., Rangaraju S., Hajjar I., Shulman J. M., Lah J. J., Levey A. I., Seyfried N. T., Large-scale proteomic analysis of Alzheimer&#x2019;s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat. Med. 26, 769&#x2013;780 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405761</ArticleId><ArticleId IdType="pubmed">32284590</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C. H., Tworoger S. S., Stampfer M. J., Dillon S. T., Gu X., Sawyer S. J., Chan A. T., Libermann T. A., Eliassen A. H., Stability and reproducibility of proteomic profiles measured with an aptamer-based platform. Sci. Rep. 8, 8382 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5976624</ArticleId><ArticleId IdType="pubmed">29849057</ArticleId></ArticleIdList></Reference><Reference><Citation>Oveisgharan S., Arvanitakis Z., Yu L., Farfel J., Schneider J. A., Bennett D. A., Sex differences in Alzheimer&#x2019;s disease and common neuropathologies of aging. Acta Neuropathol. 136, 887&#x2013;900 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6279593</ArticleId><ArticleId IdType="pubmed">30334074</ArticleId></ArticleIdList></Reference><Reference><Citation>M. Pietzner, E. Wheeler, J. Carrasco-Zanini, N. D. Kerrison, E. Oerton, M. Koprulu, J. Luan, A. D. Hingorani, S. A. Williams, N. J. Wareham, C. Langenberg, Cross-platform proteomics to advance genetic prioritisation strategies. bioRxiv 2021.03.18.435919 [Preprint]. 19 March 2021; 10.1101/2021.03.18.435919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.18.435919</ArticleId></ArticleIdList></Reference><Reference><Citation>Billing A. M., Hamidane H. B., Bhagwat A. M., Cotton R. J., Dib S. S., Kumar P., Hayat S., Goswami N., Suhre K., Rafii A., Graumann J., Complementarity of SOMAscan to LC-MS/MS and RNA-seq for quantitative profiling of human embryonic and mesenchymal stem cells. J. Proteomics 150, 86&#x2013;97 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27613379</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci L., The Baltimore Longitudinal Study of Aging (BLSA): A 50-year-long journey and plans for the future. J. Gerontol. A Biol. Sci. Med. Sci. 63, 1416&#x2013;1419 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5004590</ArticleId><ArticleId IdType="pubmed">19126858</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien R. J., Resnick S. M., Zonderman A. B., Ferrucci L., Crain B. J., Pletnikova O., Rudow G., Iacono D., Riudavets M. A., Driscoll I., Price D. L., Martin L. J., Troncoso J. C., Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). J. Alzheimers Dis. 18, 665&#x2013;675 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2978421</ArticleId><ArticleId IdType="pubmed">19661626</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239&#x2013;259 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Troncoso J. C., Zonderman A. B., Resnick S. M., Crain B., Pletnikova O., O&#x2019;Brien R. J., Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann. Neurol. 64, 168&#x2013;176 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694129</ArticleId><ArticleId IdType="pubmed">18496870</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas C., Gray S., Brookmeyer R., Fozard J., Zonderman A., Age-specific incidence rates of Alzheimer&#x2019;s disease: The Baltimore Longitudinal Study of Aging. Neurology 54, 2072&#x2013;2077 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10851365</ArticleId></ArticleIdList></Reference><Reference><Citation>APA, Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R (American Psychiatric Association, 1987).</Citation></Reference><Reference><Citation>McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M., Clinical diagnosis of Alzheimer&#x2019;s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s disease. Neurology 34, 939&#x2013;944 (1984).</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D. A., Buchman A. S., Boyle P. A., Barnes L. L., Wilson R. S., Schneider J. A., Religious orders study and rush memory and aging project. J. Alzheimers Dis. 64, S161&#x2013;S189 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380522</ArticleId><ArticleId IdType="pubmed">29865057</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider J. A., Wilson R. S., Cochran E. J., Bienias J. L., Arnold S. E., Evans D. A., Bennett D. A., Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology 60, 1082&#x2013;1088 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12682310</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D. A., Wilson R. S., Schneider J. A., Evans D. A., Aggarwal N. T., Arnold S. E., Cochran E. J., Berry-Kravis E., Bienias J. L., Apolipoprotein E &#x3b5;4 allele, AD pathology, and the clinical expression of Alzheimer&#x2019;s disease. Neurology 60, 246&#x2013;252 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12552039</ArticleId></ArticleIdList></Reference><Reference><Citation>Consensus recommendations for the postmortem diagnosis of Alzheimer&#x2019;s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer&#x2019;s disease. Neurobiology Aging 18, S1&#x2013;S2 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson J. E., Vernier D. T., Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31, 545&#x2013;548 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Huff F. J., Growdon J. H., Corkin S., Rosen T. J., Age at onset and rate of progression of Alzheimer&#x2019;s disease. J. Am. Geriatr. Soc. 35, 27&#x2013;30 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3794143</ArticleId></ArticleIdList></Reference><Reference><Citation>Candia J., Cheung F., Kotliarov Y., Fantoni G., Sellers B., Griesman T., Huang J., Stuccio S., Zingone A., Ryan B. M., Tsang J. S., Biancotto A., Assessment of variability in the SOMAscan assay. Sci. Rep. 7, 14248 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5660188</ArticleId><ArticleId IdType="pubmed">29079756</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold L., Ayers D., Bertino J., Bock C., Bock A., Brody E. N., Carter J., Dalby A. B., Eaton B. E., Fitzwater T., Flather D., Forbes A., Foreman T., Fowler C., Gawande B., Goss M., Gunn M., Gupta S., Halladay D., Heil J., Heilig J., Hicke B., Husar G., Janjic N., Jarvis T., Jennings S., Katilius E., Keeney T. R., Kim N., Koch T. H., Kraemer S., Kroiss L., Le N., Levine D., Lindsey W., Lollo B., Mayfield W., Mehan M., Mehler R., Nelson S. K., Nelson M., Nieuwlandt D., Nikrad M., Ochsner U., Ostroff R. M., Otis M., Parker T., Pietrasiewicz S., Resnicow D. I., Rohloff J., Sanders G., Sattin S., Schneider D., Singer B., Stanton M., Sterkel A., Stewart A., Stratford S., Vaught J. D., Vrkljan M., Walker J. J., Watrobka M., Waugh S., Weiss A., Wilcox S. K., Wolfson A., Wolk S. K., Zhang C., Zichi D., Aptamer-based multiplexed proteomic technology for biomarker discovery. PLOS ONE 5, e15004 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000457</ArticleId><ArticleId IdType="pubmed">21165148</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyslop N. P., White W. H., Estimating precision using duplicate measurements. J. Air Waste Manag. Assoc. 59, 1032&#x2013;1039 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19785269</ArticleId></ArticleIdList></Reference><Reference><Citation>Bland J. M., Altman D. G., Measurement error proportional to the mean. BMJ 313, 106 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2351517</ArticleId><ArticleId IdType="pubmed">8688716</ArticleId></ArticleIdList></Reference><Reference><Citation>R. Jones, B. Payne, Clinical Investigation and Statistics in Laboratory Medicine (ACB Venture Publications, 1997).</Citation></Reference><Reference><Citation>An Y., Varma V. R., Varma S., Casanova R., Dammer E., Pletnikova O., Chia C. W., Egan J. M., Ferrucci L., Troncoso J., Levey A. I., Lah J., Seyfried N. T., Legido-Quigley C., O&#x2019;Brien Madhav Thambisetty R., Evidence for brain glucose dysregulation in Alzheimer&#x2019;s disease. Alzheimers Dement. 14, 318&#x2013;329 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5866736</ArticleId><ArticleId IdType="pubmed">29055815</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y., Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289&#x2013;300 (1995).</Citation></Reference><Reference><Citation>Subramanian A., Tamayo P., Mootha V. K., Mukherjee S., Ebert B. L., Gillette M. A., Paulovich A., Pomeroy S. L., Golub T. R., Lander E. S., Mesirov J. P., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545&#x2013;15550 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Gable A. L., Lyon D., Junge A., Wyder S., Huerta-Cepas J., Simonovic M., Doncheva N. T., Morris J. H., Bork P., Jensen L. J., von Mering C., STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607&#x2013;D613 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Varma V. R., Oommen A. M., Varma S., Casanova R., An Y., Andrews R. M., O&#x2019;Brien R., Pletnikova O., Troncoso J. C., Toledo J., Baillie R., Arnold M., Kastenmueller G., Nho K., Doraiswamy P. M., Saykin A. J., Kaddurah-Daouk R., Legido-Quigley C., Thambisetty M., Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLOS Med. 15, e1002482 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5784884</ArticleId><ArticleId IdType="pubmed">29370177</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts J. A., Oommen A. M., Varma S., Casanova R., An Y., Andrews R. M., O&#x2019;Brien R., Pletnikova O., Troncoso J. C., Toledo J., Baillie R., Arnold M., Kastenmueller G., Nho K., Doraiswamy P. M., Saykin A. J., Kaddurah-Daouk R., Legido-Quigley C., Thambisetty M., Blood metabolite signature of metabolic syndrome implicates alterations in amino acid metabolism: Findings from the Baltimore Longitudinal Study of Aging (BLSA) and the Tsuruoka Metabolomics Cohort Study (TMCS). Int. J. Mol. Sci. 21, e1002482 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7072861</ArticleId><ArticleId IdType="pubmed">32070008</ArticleId></ArticleIdList></Reference><Reference><Citation>A. A. Sergushichev, An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. bioRxiv 060012 [Preprint]. 20 June 2016; 10.1101/060012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/060012</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock E. M., Geddes J. W., Chen K. C., Porter N. M., Markesbery W. R., Landfield P. W., Incipient Alzheimer&#x2019;s disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. U.S.A. 101, 2173&#x2013;2178 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X., Huang L., Zheng Y., Song Y., Xu Q., Wang J., Si K., Duan S., Gong W., Ultrafast optical clearing method for three-dimensional imaging with cellular resolution. Proc. Natl. Acad. Sci. U.S.A. 116, 11480&#x2013;11489 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6561250</ArticleId><ArticleId IdType="pubmed">31101714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Beckmann N. D., Roussos P., Wang E., Zhou X., Wang Q., Ming C., Neff R., Ma W., Fullard J. F., Hauberg M. E., Bendl J., Peters M. A., Logsdon B., Wang P., Mahajan M., Mangravite L. M., Dammer E. B., Duong D. M., Lah J. J., Seyfried N. T., Levey A. I., Buxbaum J. D., Ehrlich M., Gandy S., Katsel P., Haroutunian V., Schadt E., Zhang B., The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer&#x2019;s disease. Sci. Data 5, 180185 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132187</ArticleId><ArticleId IdType="pubmed">30204156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie M. E., Phipson B., Wu D., Hu Y., Law C. W., Shi W., Smyth G. K., limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson M. D., Oshlack A., A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864565</ArticleId><ArticleId IdType="pubmed">20196867</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabbouj S., Natunen T., Koivisto H., Jokivarsi K., Takalo M., Marttinen M., Wittrahm R., Kemppainen S., Naderi R., Posado-Fern&#xe1;ndez A., Ryh&#xe4;nen S., M&#xe4;kinen P., Paldanius K. M. A., Doria G., Poutiainen P., Flores O., Haapasalo A., Tanila H., Hiltunen M., Intranasal insulin activates Akt2 signaling pathway in the hippocampus of wild-type but not in APP/PS1 Alzheimer model mice. Neurobiol. Aging 75, 98&#x2013;108 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30554086</ArticleId></ArticleIdList></Reference><Reference><Citation>Su F., Shu H., Ye Q., Wang Z., Xie C., Yuan B., Zhang Z., Bai F., Brain insulin resistance deteriorates cognition by altering the topological features of brain networks. Neuroimage Clin. 13, 280&#x2013;287 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5192246</ArticleId><ArticleId IdType="pubmed">28050343</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabbouj S., Ryh&#xe4;nen S., Marttinen M., Wittrahm R., Takalo M., Kemppainen S., Martiskainen H., Tanila H., Haapasalo A., Hiltunen M., Natunen T., Altered insulin signaling in Alzheimer&#x2019;s disease brain&#x2014;Special emphasis on PI3K-Akt pathway. Front. Neurosci. 13, 629 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6591470</ArticleId><ArticleId IdType="pubmed">31275108</ArticleId></ArticleIdList></Reference><Reference><Citation>Awad S., Al-Haffar K. M. A., Marashly Q., Quijada P., Kunhi M., Al-Yacoub N., Wade F. S., Mohammed S. F., Al-Dayel F., Sutherland G., Assiri A., Sussman M., Bers D., Al-Habeeb W., Poizat C., Control of histone H3 phosphorylation by CaMKII&#x3b4; in response to haemodynamic cardiac stress. J. Pathol. 235, 606&#x2013;618 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383650</ArticleId><ArticleId IdType="pubmed">25421395</ArticleId></ArticleIdList></Reference><Reference><Citation>Sando R. III, Gounko N., Pieraut S., Liao L., Yates J. III, Maximov A., HDAC4 governs a transcriptional program essential for synaptic plasticity and memory. Cell 151, 821&#x2013;834 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3496186</ArticleId><ArticleId IdType="pubmed">23141539</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S. E., Liang K. C., Spatial learning alters hippocampal calcium/calmodulin-dependent protein kinase II activity in rats. Brain Res. 711, 234&#x2013;240 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8680867</ArticleId></ArticleIdList></Reference><Reference><Citation>Akita T., Aoto K., Kato M., Shiina M., Mutoh H., Nakashima M., Kuki I., Okazaki S., Magara S., Shiihara T., Yokochi K., Aiba K., Tohyama J., Ohba C., Miyatake S., Miyake N., Ogata K., Fukuda A., Matsumoto N., Saitsu H., De novo variants in CAMK2A and CAMK2B cause neurodevelopmental disorders. Ann. Clin. Transl. Neurol. 5, 280&#x2013;296 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5846454</ArticleId><ArticleId IdType="pubmed">29560374</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;ry S., van Woerden G. M., Besnard T., Onori M. P., Latypova X., Towne M. C., Cho M. T., Prescott T. E., Ploeg M. A., Sanders S., Stessman H. A. F., Pujol A., Distel B., Robak L. A., Bernstein J. A., Denomm&#xe9;-Pichon A.-S., Lesca G., Sellars E. A., Berg J., Carr&#xe9; W., Busk &#xd8;. L., van Bon B. W. M., Waugh J. L., Deardorff M., Hoganson G. E., Bosanko K. B., Johnson D. S., Dabir T., Holla &#xd8;. L., Sarkar A., Tveten K., de Bellescize J., Braathen G. J., Terhal P. A., Grange D. K., van Haeringen A., Lam C., Mirzaa G., Burton J., Bhoj E. J., Douglas J., Santani A. B., Nesbitt A. I., Helbig K. L., Andrews M. V., Begtrup A., Tang S., van Gassen K. L. I., Juusola J., Foss K., Enns G. M., Moog U., Hinderhofer K., Paramasivam N., Lincoln S., Kusako B. H., Lindenbaum P., Charpentier E., Nowak C. B., Cherot E., Simonet T., Ruivenkamp C. A. L., Hahn S., Brownstein C. A., Xia F., Schmitt S., Deb W., Bonneau D., Nizon M., Quinquis D., Chelly J., Rudolf G., Sanlaville D., Parent P., Gilbert-Dussardier B., Toutain A., Sutton V. R., Thies J., Peart-Vissers L. E. L. M., Boisseau P., Vincent M., Grabrucker A. M., Dubourg C.; Undiagnosed Diseases Network, Tan W.-H., Verbeek N. E., Granzow M., Santen G. W. E., Shendure J., Isidor B., Pasquier L., Redon R., Yang Y., State M. W., Kleefstra T., Cogn&#xe9; B.; GEM HUGO; Deciphering Developmental Disorders Study, Petrovski S., Retterer K., Eichler E. E., Rosenfeld J. A., Agrawal P. B., B&#xe9;zieau S., Odent S., Elgersma Y., Mercier S., De novo mutations in protein kinase genes CAMK2A and CAMK2B cause intellectual disability. Am. J. Hum. Genet. 101, 768&#x2013;788 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5673671</ArticleId><ArticleId IdType="pubmed">29100089</ArticleId></ArticleIdList></Reference><Reference><Citation>Federman N., de la Fuente V., Zalcman G., Corbi N., Onori A., Passananti C., Romano A., Nuclear factor&#x3ba;B-dependent histone acetylation is specifically involved in persistent forms of memory. J. Neurosci. 33, 7603&#x2013;7614 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6619586</ArticleId><ArticleId IdType="pubmed">23616565</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalcman G., Federman N., Romano A., CaMKII isoforms in learning and memory: Localization and function. Front. Mol. Neurosci. 11, 445 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6288437</ArticleId><ArticleId IdType="pubmed">30564099</ArticleId></ArticleIdList></Reference><Reference><Citation>Xuan W., Qu Q., Zheng B., Xiong S., Fan G. H., The chemotaxis of M1 and M2 macrophages is regulated by different chemokines. J. Leukoc. Biol. 97, 61&#x2013;69 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25359998</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y., Chen R., Wang X., Hu K., Huang L., Lu M., Hu Q., CCL19 and CCR7 expression, signaling pathways, and adjuvant functions in viral infection and prevention. Front. Cell Dev. Biol. 7, 212 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6781769</ArticleId><ArticleId IdType="pubmed">31632965</ArticleId></ArticleIdList></Reference><Reference><Citation>Raju R., Gadakh S., Gopal P., George B., Advani J., Soman S., Prasad T. S. K., Girijadevi R., Differential ligand-signaling network of CCL19/CCL21-CCR7 system. Database 2015, bav106 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4620938</ArticleId><ArticleId IdType="pubmed">26504105</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero C., Eisele P. S., Schaeuble K., Groettrup M., Legler D. F., Distinct motifs in the chemokine receptor CCR7 regulate signal transduction, receptor trafficking and chemotaxis. J. Cell Sci. 121, 2759&#x2013;2767 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18664492</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Page A., Bourgade K., Lamoureux J., Frost E., Pawelec G., Larbi A., Witkowski J. M., Dupuis G., F&#xfc;l&#xf6;p T., NK cells are activated in amnestic mild cognitive impairment but not in mild Alzheimer&#x2019;s disease patients. J. Alzheimers Dis. 46, 93&#x2013;107 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25720398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ber Y., Shiloh R., Gilad Y., Degani N., Bialik S., Kimchi A., DAPK2 is a novel regulator of mTORC1 activity and autophagy. Cell Death Differ. 22, 465&#x2013;475 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4326577</ArticleId><ArticleId IdType="pubmed">25361081</ArticleId></ArticleIdList></Reference><Reference><Citation>Geering B., Stoeckle C., Rozman S., Oberson K., Benarafa C., Simon H.-U., DAPK2 positively regulates motility of neutrophils and eosinophils in response to intermediary chemoattractants. J. Leukoc. Biol. 95, 293&#x2013;303 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24163421</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim N., Chen D., Zhou X. Z., Lee T. H., Death-associated protein kinase 1 phosphorylation in neuronal cell death and neurodegenerative disease. Int. J. Mol. Sci. 20, 3131 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6651373</ArticleId><ArticleId IdType="pubmed">31248062</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L. Z., Li B. Q., Jia J. P., DAPK1: A novel pathology and treatment target for Alzheimer&#x2019;s disease. Mol. Neurobiol. 56, 2838&#x2013;2844 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30062675</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmouni S., Cerignoli F., Alonso A., Tsutji T., Henkens R., Zhu C., Louis-dit-Sully C., Moutschen M., Jiang W., Mustelin T., Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat. Cell Biol. 8, 524&#x2013;531 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16604064</ArticleId></ArticleIdList></Reference><Reference><Citation>Amand M., Erpicum C., Bajou K., Cerignoli F., Blacher S., Martin M., Dequiedt F., Drion P., Singh P., Zurashvili T., Vandereyken M., Musumeci L., Mustelin T., Moutschen M., Gilles C., Noel A., Rahmouni S., DUSP3/VHR is a pro-angiogenic atypical dual-specificity phosphatase. Mol. Cancer 13, 108 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038117</ArticleId><ArticleId IdType="pubmed">24886454</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S. H., Markham J. A., Weiler I. J., Greenough W. T., Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome. Proc. Natl. Acad. Sci. U.S.A. 105, 4429&#x2013;4434 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2393788</ArticleId><ArticleId IdType="pubmed">18332424</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Zuo H., Wang D., Peng R., Song T., Wang S., Xu X., Gao Y., Li Y., Wang S., Wang L., Zhao L., Improvement of spatial memory disorder and hippocampal damage by exposure to electromagnetic fields in an Alzheimer&#x2019;s disease rat model. PLOS ONE 10, e0126963 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433192</ArticleId><ArticleId IdType="pubmed">25978363</ArticleId></ArticleIdList></Reference><Reference><Citation>Musumeci L., Kuijpers M. J., Gilio K., Hego A., Th&#xe9;&#xe2;tre E., Maurissen L., Vandereyken M., Diogo C. V., Lecut C., Guilmain W., Bobkova E. V., Eble J. A., Dahl R., Drion P., Rascon J., Mostofi Y., Yuan H., Sergienko E., Chung T. D. Y., Thiry M., Senis Y., Moutschen M., Mustelin T., Lancellotti P., Heemskerk J. W. M., Tautz L., Oury C., Rahmouni S., Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis. Circulation 131, 656&#x2013;668 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334727</ArticleId><ArticleId IdType="pubmed">25520375</ArticleId></ArticleIdList></Reference><Reference><Citation>West K. L., Kelliher J. L., Xu Z., An L., Reed M. R., Eoff R. L., Wang J., Huen M. S. Y., Leung J. W. C., LC8/DYNLL1 is a 53BP1 effector and regulates checkpoint activation. Nucleic Acids Res. 47, 6236&#x2013;6249 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6614850</ArticleId><ArticleId IdType="pubmed">30982887</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannibal L., Nitric oxide homeostasis in neurodegenerative diseases. Curr. Alzheimer Res. 13, 135&#x2013;149 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26391043</ArticleId></ArticleIdList></Reference><Reference><Citation>Mkaddem S. B., Murua A., Flament H., Titeca-Beauport D., Bounaix C., Danelli L., Launay P., Benhamou M., Blank U., Daugas E., Charles N., Monteiro R. C., Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation. Nat. Commun. 8, 246 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5557797</ArticleId><ArticleId IdType="pubmed">28811476</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard H. B., Targeting Fyn kinase in Alzheimer&#x2019;s disease. Biol. Psychiatry 83, 369&#x2013;376 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5729051</ArticleId><ArticleId IdType="pubmed">28709498</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman A. C., Salazar S. V., Haas L. T., Yang J., Kostylev M. A., Jeng A. T., Robinson S. A., Gunther E. C., van Dyck C. H., Nygaard H. B., Strittmatter S. M., Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann. Neurol. 77, 953&#x2013;971 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4447598</ArticleId><ArticleId IdType="pubmed">25707991</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Gotz J., Somatodendritic accumulation of Tau in Alzheimer&#x2019;s disease is promoted by Fyn-mediated local protein translation. EMBO J. 36, 3120&#x2013;3138 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666608</ArticleId><ArticleId IdType="pubmed">28864542</ArticleId></ArticleIdList></Reference><Reference><Citation>Blais K., Sethi J., Tabarean I. V., Gastrin-releasing peptide receptor mediates the excitation of preoptic GABAergic neurons by bombesin. Neurosci. Lett. 633, 262&#x2013;267 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5074900</ArticleId><ArticleId IdType="pubmed">27693662</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito E., Oka K., Etcheberrigaray R., Nelson T. J., Phie D. L. M., Tofel-Grehl B., Gibson G. E., Alkon D. L., Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 91, 534&#x2013;538 (1994).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42983</ArticleId><ArticleId IdType="pubmed">8290560</ArticleId></ArticleIdList></Reference><Reference><Citation>Moody T. W., Pert C. B., Rivier J., Brown M. R., Bomebesin: Specific binding to rat brain membranes. Proc. Natl. Acad. Sci. U.S.A. 75, 5372&#x2013;5376 (1978).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC392965</ArticleId><ArticleId IdType="pubmed">281686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayer A., Zarjou A., Agarwal A., Stocker R., Heme oxygenases in cardiovascular health and disease. Physiol. Rev. 96, 1449&#x2013;1508 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5504454</ArticleId><ArticleId IdType="pubmed">27604527</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing S., Shen D., Chen C., Wang J., Yu Z., Early induction of oxidative stress in a mouse model of Alzheimer&#x2019;s disease with heme oxygenase activity. Mol. Med. Rep. 10, 599&#x2013;604 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4094768</ArticleId><ArticleId IdType="pubmed">24858858</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal C., Daescu K., Fitzgerald K. E., Starokadomska A., Bezprozvanny I., Zhang L., Amyloid &#x3b2; perturbs elevated heme flux induced with neuronal development. Alzheimers Dement. 5, 27&#x2013;37 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6352316</ArticleId><ArticleId IdType="pubmed">30723777</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese V., Sultana R., Scapagnini G., Guagliano E., Sapienza M., Bella R., Kanski J., Pennisi G., Mancuso C., Stella A. M. G., Butterfield D. A., Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer&#x2019;s disease. Antioxid. Redox Signal. 8, 1975&#x2013;1986 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17034343</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiziane E., Telemann H., Krueger M., Adler J., Arnhold J., Alia A., Flemmig J., Free Heme and Amyloid-&#x3b2;: A fatal liaison in Alzheimer&#x2019;s disease. J. Alzheimers Dis. 61, 963&#x2013;984 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29332049</ArticleId></ArticleIdList></Reference><Reference><Citation>Atamna H., Frey W. H. II, A role for heme in Alzheimer&#x2019;s disease: Heme binds amyloid beta and has altered metabolism. Proc. Natl. Acad. Sci. U.S.A. 101, 11153&#x2013;11158 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC503755</ArticleId><ArticleId IdType="pubmed">15263070</ArticleId></ArticleIdList></Reference><Reference><Citation>Egli A., Santer D. M., O&#x2019;Shea D., Tyrrell D. L., Houghton M., The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg. Microbes Infect. 3, e51 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126180</ArticleId><ArticleId IdType="pubmed">26038748</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura A. L., Zupunski V., Troakes C., Kathe C., Fratta P., Howell M., Gallo J.-M., Hortob&#xe1;gyi T., Shaw C. E., Rogelj B., Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain 133, 1763&#x2013;1771 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J., Abudu Y. P., Claude-Taupin A., Gu Y., Kumar S., Choi S. W., Peters R., Mudd M. H., Allers L., Salemi M., Phinney B., Johansen T., Deretic V., Galectins control mTOR in response to endomembrane damage. Mol. Cell 70, 120&#x2013;135.e8 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911935</ArticleId><ArticleId IdType="pubmed">29625033</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S., The role of mTOR signaling in Alzheimer disease. Front. Biosci. (Schol. Ed.) 4, 941&#x2013;952 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4111148</ArticleId><ArticleId IdType="pubmed">22202101</ArticleId></ArticleIdList></Reference><Reference><Citation>Boza-Serrano A., Ruiz R., Sanchez-Varo R., Garc&#xed;a-Revilla J., Yang Y., Jimenez-Ferrer I., Paulus A., Wennstr&#xf6;m M., Vilalta A., Allendorf D., Davila J. C., Stegmayr J., Jim&#xe9;nez S., Roca-Ceballos M. A., Navarro-Garrido V., Swanberg M., Hsieh C. L., Real L. M., Englund E., Linse S., Leffler H., Nilsson U. J., Brown G. C., Gutierrez A., Vitorica J., Venero J. L., Deierborg T., Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer&#x2019;s disease. Acta Neuropathol. 138, 251&#x2013;273 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6660511</ArticleId><ArticleId IdType="pubmed">31006066</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Niu Y., Yue C. X., Fu S., Wang R. T., Increased ileal bile acid binding protein and galectin-9 are associated with mild cognitive impairment and Alzheimer&#x2019;s disease. J. Psychiatr. Res. 119, 102&#x2013;106 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31593867</ArticleId></ArticleIdList></Reference><Reference><Citation>Um J. W., Choi T.-Y., Kang H., Cho Y. S., Choii G., Uvarov P., Park D., Jeong D., Jeon S., Lee D., Kim H., Lee S.-H., Bae Y.-C., Choi S.-Y., Airaksinen M. S., Ko J., LRRTM3 regulates excitatory synapse development through alternative splicing and neurexin binding. Cell Rep. 14, 808&#x2013;822 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26776509</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnoder L., Hao W., Qin Y., Liu S., Tomic I., Liu X., Fassbender K., Liu Y., Deficiency of neuronal p38alpha MAPK attenuates amyloid pathology in Alzheimer disease mouse and cell models through facilitating lysosomal degradation of BACE1. J. Biol. Chem. 291, 2067&#x2013;2079 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4732195</ArticleId><ArticleId IdType="pubmed">26663083</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan T. K., Alkon D. L., An internally controlled peripheral biomarker for Alzheimer&#x2019;s disease: Erk1 and Erk2 responses to the inflammatory signal bradykinin. Proc. Natl. Acad. Sci. U.S.A. 103, 13203&#x2013;13207 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559777</ArticleId><ArticleId IdType="pubmed">16920798</ArticleId></ArticleIdList></Reference><Reference><Citation>Frottin F., Bienvenut W. V., Bignon J., Jacquet E., Jacome A. S. V., Van Dorsselaer A., Cianferani S., Carapito C., Meinnel T., Giglione C., MetAP1 and MetAP2 drive cell selectivity for a potent anti-cancer agent in synergy, by controlling glutathione redox state. Oncotarget 7, 63306&#x2013;63323 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325365</ArticleId><ArticleId IdType="pubmed">27542228</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Yu G., Chu H., Wang X., Xiong L., Cai G., Liu R., Gao H., Tao B., Li W., Li G., Liang J., Yang W., Macrophage-associated PGK1 phosphorylation promotes aerobic glycolysis and tumorigenesis. Mol. Cell 71, 201&#x2013;215.e7 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30029001</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietri M., Dakowski C., Hannaoui S., Alleaume-Butaux A., Hernandez-Rapp J., Ragagnin A., Mouillet-Richard S., Haik S., Bailly Y., Peyrin J.-M., Launay J.-M., Kellermann O., Schneider B., PDK1 decreases TACE-mediated alpha-secretase activity and promotes disease progression in prion and Alzheimer&#x2019;s diseases. Nat. Med. 19, 1124&#x2013;1131 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23955714</ArticleId></ArticleIdList></Reference><Reference><Citation>Manterola L., Hernando-Rodr&#xed;guez M., Ruiz A., Apraiz A., Arrizabalaga O., Vell&#xf3;n L., Alberdi E., Cavaliere F., Lacerda H. M., Jimenez S., Parada L. A., Matute C., Zugaza J. L., 1-42 &#x3b2;-amyloid peptide requires PDK1/nPKC/Rac 1 pathway to induce neuronal death. Transl. Psychiatry 3, e219 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3566727</ArticleId><ArticleId IdType="pubmed">23340502</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonell A., Llad&#xf3; A., S&#xe1;nchez-Valle R., Sanfeliu C., Casserras T., Rami L., Mu&#xf1;oz-Garc&#xed;a C., Dangla-Valls A., Balasa M., Boya P., Kalko S. G., Molinuevo J. L., Altered blood gene expression of tumor-related genes (PRKCB, BECN1, and CDKN2A) in Alzheimer&#x2019;s disease. Mol. Neurobiol. 53, 5902&#x2013;5911 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26510741</ArticleId></ArticleIdList></Reference><Reference><Citation>Gersch&#xfc;tz A., Heinsen H., Gr&#xfc;nblatt E., Wagner A. K., Bartl J., Meissner C., Fallgatter A. J., Al-Sarraj S., Troakes C., Ferrer I., Arzberger T., Deckert J., Riederer P., Fischer M., Tatschner T., Monoranu C. M., Neuron-specific alterations in signal transduction pathways associated with Alzheimer&#x2019;s disease. J. Alzheimers Dis. 40, 135&#x2013;142 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24334724</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J., Guo Q., Zhu H., Wooten M. W., Mattson M. P., Protein kinase C iota protects neural cells against apoptosis induced by amyloid &#x3b2;-peptide. Brain Res. Mol. Brain Res. 82, 107&#x2013;113 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11042363</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu L., Li G., Xia D., Hongdu B., Xu C., Lin X., Chen Y., PRKCI negatively regulates autophagy via PIK3CA/AKT-MTOR signaling. Biochem. Biophys. Res. Commun. 470, 306&#x2013;312 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26792725</ArticleId></ArticleIdList></Reference><Reference><Citation>Skanland S. S., Walchli S., Brech A., Sandvig K., SNX4 in complex with clathrin and dynein: Implications for endosome movement. PLOS ONE 4, e5935 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691479</ArticleId><ArticleId IdType="pubmed">19529763</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiba T., Yamada M., Aiso S., Targeting the JAK2/STAT3 axis in Alzheimer&#x2019;s disease. Expert Opin. Ther. Targets 13, 1155&#x2013;1167 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19663649</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichenbach N., Delekate A., Plescher M., Schmitt F., Krauss S., Blank N., Halle A., Petzold G. C., Inhibition of Stat3-mediated astrogliosis ameliorates pathology in an Alzheimer&#x2019;s disease model. EMBO Mol. Med. 11, e9665 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6365929</ArticleId><ArticleId IdType="pubmed">30617153</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceyzeriat K., Haim L. B., Denizot A., Pommier D., Matos M., Guillemaud O., Palomares M.-A., Abjean L., Petit F., Gipchtein P., Gaillard M.-C., Guillermier M., Bernier S., Gaudin M., Aur&#xe9;gan G., Jos&#xe9;phine C., D&#xe9;champs N., Veran J., Langlais V., Cambon K., Bemelmans A. P., Baijer J., Bonvento G., Dhenain M., Deleuze J.-F., Oliet S. H. R., Brouillet E., Hantraye P., Sauvage M.-A. C.-d., Olaso R., Panatier A., Escartin C., Modulation of astrocyte reactivity improves functional deficits in mouse models of Alzheimer&#x2019;s disease. Acta Neuropathol. Commun. 6, 104 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6190663</ArticleId><ArticleId IdType="pubmed">30322407</ArticleId></ArticleIdList></Reference><Reference><Citation>An X. Q., Xi W., Gu C. Y., Huang X., Complement protein C5a enhances the &#x3b2;-amyloid-induced neuro-inflammatory response in microglia in Alzheimer&#x2019;s disease. Med. Sci. 34 Focus issue F1, 116&#x2013;120 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30403186</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J. Y., Sun J., Ji C.-M., Shen L., Chen Z.-J., Xie P., Sun Y.-Z., Yu R.-T., Selective deletion of apolipoprotein E in astrocytes ameliorates the spatial learning and memory deficits in Alzheimer&#x2019;s disease (APP/PS1) mice by inhibiting TGF-&#x3b2;/Smad2/STAT3 signaling. Neurobiol. Aging 54, 112&#x2013;132 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28366226</ArticleId></ArticleIdList></Reference><Reference><Citation>Vannini A., Cramer P., Conservation between the RNA polymerase I, II, and III transcription initiation machineries. Mol. Cell 45, 439&#x2013;446 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22365827</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid S. J., van Roon-Mom W. M. C., Wood P. C., Rees M. I., Owen M. J., Faull R. L. M., Dragunow M., Snell R. G., TBP, a polyglutamine tract containing protein, accumulates in Alzheimer&#x2019;s disease. Brain Res. Mol. Brain Res. 125, 120&#x2013;128 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15193429</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotsantis P., Silva L. M., Irmscher S., Jones R. M., Folkes L., Gromak N., Petermann E., Increased global transcription activity as a mechanism of replication stress in cancer. Nat. Commun. 7, 13087 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062618</ArticleId><ArticleId IdType="pubmed">27725641</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadt I., Gunther A. K., Voss D., Schelhaas M., Knebel-Morsdorf D., TATA-binding protein and TBP-associated factors during herpes simplex virus type 1 infection: Localization at viral DNA replication sites. Virus Res. 115, 207&#x2013;213 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16271277</ArticleId></ArticleIdList></Reference><Reference><Citation>Pommier Y., Drugging topoisomerases: Lessons and challenges. ACS Chem. Biol. 8, 82&#x2013;95 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549721</ArticleId><ArticleId IdType="pubmed">23259582</ArticleId></ArticleIdList></Reference><Reference><Citation>Durand-Dubief M., Persson J., Norman U., Hartsuiker E., Ekwall K., Topoisomerase I regulates open chromatin and controls gene expression in vivo. EMBO J. 29, 2126&#x2013;2134 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905247</ArticleId><ArticleId IdType="pubmed">20526281</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling A. S., Jeong K. S., Kitada T., Grunstein M., Topoisomerase II binds nucleosome-free DNA and acts redundantly with topoisomerase I to enhance recruitment of RNA Pol II in budding yeast. Proc. Natl. Acad. Sci. U.S.A. 108, 12693&#x2013;12698 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3150916</ArticleId><ArticleId IdType="pubmed">21771901</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B., Hemberg M., Lewis J., Feany M. B., Tau promotes neurodegeneration through global chromatin relaxation. Nat. Neurosci. 17, 357&#x2013;366 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4012297</ArticleId><ArticleId IdType="pubmed">24464041</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuma A. A., Cavalcanti D. P., Maia M. C., de Souza W., Motta M. C., Effect of topoisomerase inhibitors and DNA-binding drugs on the cell proliferation and ultrastructure of Trypanosoma cruzi. Int. J. Antimicrob. Agents 37, 449&#x2013;456 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21292448</ArticleId></ArticleIdList></Reference><Reference><Citation>Yurov Y. B., Vorsanova S. G., Iourov I. Y., The DNA replication stress hypothesis of Alzheimer&#x2019;s disease. Sci. World J. 11, 2602&#x2013;2612 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254013</ArticleId><ArticleId IdType="pubmed">22262948</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M., Liu Y., Huang Y., Wang J., Yan J., Zhang L., Zhang C., Re-exploring the core genes and modules in the human frontal cortex during chronological aging: Insights from network-based analysis of transcriptomic studies. Aging 10, 2816&#x2013;2831 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6224233</ArticleId><ArticleId IdType="pubmed">30341976</ArticleId></ArticleIdList></Reference><Reference><Citation>Leduc V., Legault V., Dea D., Poirier J., Normalization of gene expression using SYBR green qPCR: A case for paraoxonase 1 and 2 in Alzheimer&#x2019;s disease brains. J. Neurosci. Methods 200, 14&#x2013;19 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21672555</ArticleId></ArticleIdList></Reference><Reference><Citation>You L., Shou J., Deng D., Jiang L., Jing Z., Yao J., Li H., Xie J., Wang Z., Pan Q., Pan H., Huang W., Han W., Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines. Oncotarget 6, 40268&#x2013;40282 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4741894</ArticleId><ArticleId IdType="pubmed">26384345</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteiro L. F., Ferruzo P. Y. M., Russo L. C., Farias J. O., Forti F. L., DUSP3/VHR: A druggable dual phosphatase for human diseases. Rev. Physiol. Biochem. Pharmacol. 176, 1&#x2013;35 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30069819</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel B., Kishor C., Houston T. A., Shatz-Azoulay H., Zick Y., Vinik Y., Blanchard H., Rational design and synthesis of methyl-&#x3b2;-d-galactomalonyl phenyl esters as potent galectin-8N antagonists. J. Med. Chem. 63, 11573&#x2013;11584 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32809817</ArticleId></ArticleIdList></Reference><Reference><Citation>Elola M. T., Ferragut F., Delgado V. M. C., Nugnes L. G., Gentilini L., Laderach D., Troncoso M. F., Compagno D., Wolfenstein-Todel C., Rabinovich G. A., Expression, localization and function of galectin-8, a tandem-repeat lectin, in human tumors. Histol. Istopathol. 29, 1093&#x2013;1105 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24696431</ArticleId></ArticleIdList></Reference><Reference><Citation>Compagno D., Gentilini L. D., Jaworski F. M., P&#xe9;rez I. G., Contrufo G., Laderach D. J., Glycans and galectins in prostate cancer biology, angiogenesis and metastasis. Glycobiology 24, 899&#x2013;906 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24939371</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinik Y., Shatz-Azoulay H., Hiram-Bab S., Kandel L., Gabet Y., Rivkin G., Zick Y., Ablation of the mammalian lectin galectin-8 induces bone defects in mice. FASEB J. 32, 2366&#x2013;2380 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29259034</ArticleId></ArticleIdList></Reference><Reference><Citation>Eshkar Sebban L., Ronen D., Levartovsky D., Elkayam O., Caspi D., Aamar S., Amital H., Rubinow A., Golan I., Naor D., Zick Y., Golan I., The involvement of CD44 and its novel ligand galectin-8 in apoptotic regulation of autoimmune inflammation. J. Immunol. 179, 1225&#x2013;1235 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17617615</ArticleId></ArticleIdList></Reference><Reference><Citation>Montero J. C., Seoane S., Ocana A., Pandiella A., Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: Possible combinations in solid tumors. Clin. Cancer Res. 17, 5546&#x2013;5552 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21670084</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard S. C., Lee H., Gaddy D. F., Klinz S. G., Paz N., Kalra A. V., Drummond D. C., Chan D. C., Bunn P. A., Fitzgerald J. B., Hendriks B. S., Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Anticancer Drugs 28, 1086&#x2013;1096 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28857767</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34807243</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.</ArticleTitle><Pagination><StartPage>13</StartPage><EndPage>21</EndPage><MedlinePgn>13-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.4161</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that occur with treatment with aducanumab, an amyloid-&#x3b2; (A&#x3b2;)-targeting monoclonal antibody, in patients with mild cognitive impairment due to Alzheimer disease or mild Alzheimer disease dementia.</AbstractText><AbstractText Label="OBJECTIVE">To describe the radiographic and clinical characteristics of ARIA that occurred in EMERGE and ENGAGE.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Secondary analysis of data from the EMERGE and ENGAGE trials, which were 2 double-blind, placebo-controlled, parallel-group, phase 3 randomized clinical trials that compared low-dose and high-dose aducanumab treatment with placebo among participants at 348 sites across 20 countries. Enrollment occurred from August 2015 to July 2018, and the trials were terminated early (March 21, 2019) based on a futility analysis. The combined studies consisted of a total of 3285 participants with Alzheimer disease who received 1 or more doses of placebo (n&#x2009;=&#x2009;1087) or aducanumab (n&#x2009;=&#x2009;2198; 2752 total person-years of exposure) during the placebo-controlled period. Primary data analyses were performed from November 2019 to July 2020, with additional analyses performed through July 2021.</AbstractText><AbstractText Label="INTERVENTIONS">Participants were randomly assigned 1:1:1 to high-dose or low-dose intravenous aducanumab or placebo once every 4 weeks. Dose titration was used as a risk-minimization strategy.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Brain magnetic resonance imaging was used to monitor patients for ARIA; associated symptoms were reported as adverse events.</AbstractText><AbstractText Label="RESULTS">Of 3285 included participants, the mean (SD) age was 70.4 (7.45) years; 1706 participants (52%) were female, 2661 (81%) had mild cognitive impairment due to Alzheimer disease, and 1777 (54%) used symptomatic medications for Alzheimer disease. A total of 764 participants from EMERGE and 709 participants from ENGAGE were categorized as withdrawn before study completion, most often owing to early termination of the study by the sponsor. Unless otherwise specified, all results represent analyses from the 10-mg/kg group. During the placebo-controlled period, 425 of 1029 patients (41.3%) experienced ARIA, with serious cases occurring in 14 patients (1.4%). ARIA-edema (ARIA-E) was the most common adverse event (362 of 1029 [35.2%]), and 263 initial events (72.7%) occurred within the first 8 doses of aducanumab; 94 participants (26.0%) with an event exhibited symptoms. Common associated symptoms among 103 patients with symptomatic ARIA-E or ARIA-H were headache (48 [46.6%]), confusion (15 [14.6%]), dizziness (11 [10.7%]), and nausea (8 [7.8%]). Incidence of ARIA-E was highest in aducanumab-treated participants who were apolipoprotein E &#x3b5;4 allele carriers. Most events (479 of 488 [98.2%]) among those with ARIA-E resolved radiographically; 404 of 488 (82.8%) resolved within 16 weeks. In the placebo group, 29 of 1076 participants (2.7%) had ARIA-E (apolipoprotein E &#x3b5;4 carriers: 16 of 742 [2.2%]; noncarriers, 13 of 334 [3.9%]). ARIA-microhemorrhage and ARIA-superficial siderosis occurred in 197 participants (19.1%) and 151 participants (14.7%), respectively.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this integrated safety data set from EMERGE and ENGAGE, the most common adverse event in the 10-mg/kg group was ARIA-E, which occurred in 362 of the 1029 patients (35.2%) in the 10-mg/kg group with at least 1 postbaseline MRI scan, with 94 patients (26.0%) experiencing associated symptoms. The most common associated symptom was headache.</AbstractText><AbstractText Label="TRIAL REGISTRATIONS">ClinicalTrials.gov Identifiers: NCT02484547, NCT02477800.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Warren Alpert Medical School, Brown University, Providence, Rhode Island.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chalkias</LastName><ForeName>Spyros</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barkhof</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institutes of Healthcare Engineering and Neurology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burkett</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barakos</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>California Pacific Medical Center, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioclinica, Newark, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purcell</LastName><ForeName>Derk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>California Pacific Medical Center, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioclinica, Newark, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suhy</LastName><ForeName>Joyce</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Bioclinica, Newark, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrestal</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umans</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guanfang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cytel Inc, Waltham, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singhal</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Budd Haeberlein</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smirnakis</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02477800</AccessionNumber><AccessionNumber>NCT02484547</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>105J35OE21</RegistryNumber><NameOfSubstance UI="C000600266">aducanumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Drs Burkett, Tian, Umans, Singhal, Budd Haeberlien, and Smirnakis and Ms Forrestal are shareholders of Biogen. Dr Salloway has received grants from Biogen, Eisai, Avid, and Lilly; personal fees from Biogen, Eisai, Avid, Lilly, Novartis, Genentech, and Roche; and nonfinancial support from Biogen, Avid, Novartis, and Roche; and was a site investigator and co-chair of the investigator steering committee for the ENGAGE study. Dr Barkhof has received grants from Roche and Biogen as well as personal fees from Bayer, Biogen, Roche, Novartis, IXICO, Combinostics, Janssen, and Merck; is supported by NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust; and is the founder and a stockholder of Queen Square Analytics. Dr Barakos has received speaker fees from Biogen. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>22</Day><Hour>12</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34807243</ArticleId><ArticleId IdType="pmc">PMC8609465</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.4161</ArticleId><ArticleId IdType="pii">2786606</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Black RS, Sperling RA, Safirstein B, et al. . A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2010;24(2):198-203. doi:10.1097/WAD.0b013e3181c53b00</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e3181c53b00</ArticleId><ArticleId IdType="pmc">PMC3715117</ArticleId><ArticleId IdType="pubmed">20505438</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson C, Siemers E, Hake A, et al. . Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer&#x2019;s disease. Alzheimers Dement (Amst). 2016;2:75-85. doi:10.1016/j.dadm.2016.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2016.02.004</ArticleId><ArticleId IdType="pmc">PMC4879647</ArticleId><ArticleId IdType="pubmed">27239538</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Gilman S, et al. ; Bapineuzumab 201 Clinical Trial Investigators . A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73(24):2061-2070. doi:10.1212/WNL.0b013e3181c67808</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c67808</ArticleId><ArticleId IdType="pmc">PMC2790221</ArticleId><ArticleId IdType="pubmed">19923550</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrero J, Williams L, Stella H, et al. . First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer&#x2019;s disease. Alzheimers Dement (N Y). 2016;2(3):169-176. doi:10.1016/j.trci.2016.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2016.06.002</ArticleId><ArticleId IdType="pmc">PMC5651340</ArticleId><ArticleId IdType="pubmed">29067304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S, Lasser RA, Dorflinger E, et al. ; Scarlet Road Investigators . A phase III randomized trial of gantenerumab in prodromal Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2017;9(1):95. doi:10.1186/s13195-017-0318-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0318-y</ArticleId><ArticleId IdType="pmc">PMC5723032</ArticleId><ArticleId IdType="pubmed">29221491</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR Jr, Black SE, et al. . Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer&#x2019;s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367-385. doi:10.1016/j.jalz.2011.05.2351</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.05.2351</ArticleId><ArticleId IdType="pmc">PMC3693547</ArticleId><ArticleId IdType="pubmed">21784348</ArticleId></ArticleIdList></Reference><Reference><Citation>Budd Haeberlein S, O&#x2019;Gorman J, Chiao P, et al. . Clinical development of aducanumab, an anti-a&#x3b2; human monoclonal antibody being investigated for the treatment of early Alzheimer&#x2019;s disease. J Prev Alzheimers Dis. 2017;4(4):255-263.</Citation><ArticleIdList><ArticleId IdType="pubmed">29181491</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Cohen S, van Dyck CH, et al. . ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90(21):e1889-e1897. doi:10.1212/WNL.0000000000005550</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005550</ArticleId><ArticleId IdType="pmc">PMC5962917</ArticleId><ArticleId IdType="pubmed">29695589</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Thomas RG, Farlow M, et al. ; Alzheimer&#x2019;s Disease Cooperative Study Steering Committee; Solanezumab Study Group . Phase 3 trials of solanezumab for mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med. 2014;370(4):311-321. doi:10.1056/NEJMoa1312889</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1312889</ArticleId><ArticleId IdType="pubmed">24450890</ArticleId></ArticleIdList></Reference><Reference><Citation>Barakos J, Sperling R, Salloway S, et al. . MR imaging features of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol. 2013;34(10):1958-1965. doi:10.3174/ajnr.A3500</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A3500</ArticleId><ArticleId IdType="pmc">PMC7965435</ArticleId><ArticleId IdType="pubmed">23578674</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrighi HM, Barakos J, Barkhof F, et al. . Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer&#x2019;s disease treated with bapineuzumab: a historical, prospective secondary analysis. J Neurol Neurosurg Psychiatry. 2016;87(1):106-112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4717448</ArticleId><ArticleId IdType="pubmed">25669746</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease&#x2014;one peptide, two pathways. Nat Rev Neurol. 2020;16(1):30-42. doi:10.1038/s41582-019-0281-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0281-2</ArticleId><ArticleId IdType="pmc">PMC7268202</ArticleId><ArticleId IdType="pubmed">31827267</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Salloway S, Brooks DJ, et al. . Amyloid-related imaging abnormalities in patients with Alzheimer&#x2019;s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11(3):241-249. doi:10.1016/S1474-4422(12)70015-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70015-7</ArticleId><ArticleId IdType="pmc">PMC4063417</ArticleId><ArticleId IdType="pubmed">22305802</ArticleId></ArticleIdList></Reference><Reference><Citation>Zago W, Schroeter S, Guido T, et al. . Vascular alterations in PDAPP mice after anti-A&#x3b2; immunotherapy: implications for amyloid-related imaging abnormalities. Alzheimers Dement. 2013;9(5)(suppl):S105-S115. doi:10.1016/j.jalz.2012.11.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.11.010</ArticleId><ArticleId IdType="pubmed">23583235</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussi&#xe8;re T, et al. . The antibody aducanumab reduces A&#x3b2; plaques in Alzheimer&#x2019;s disease. Nature. 2016;537(7618):50-56. doi:10.1038/nature19323</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature19323</ArticleId><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Budd Haeberlein S, Salloway S, Aisen P, et al. . Evaluation of aducanumab efficacy in early Alzheimer&#x2019;s disease. Paper presented at: 15th International Conference on Alzheimer's &amp; Parkinson's Diseases virtual conference; March 9-14, 2021.</Citation></Reference><Reference><Citation>Chalkias S, Mummery C, Salloway S, et al. . Evaluation of aducanumab safety in early Alzheimer&#x2019;s disease. Paper presented at: 15th International Conference on Alzheimer's &amp; Parkinson's Diseases virtual conference; March 9-14, 2021.</Citation></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. . The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):270-279. doi:10.1016/j.jalz.2011.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.008</ArticleId><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):263-269. doi:10.1016/j.jalz.2011.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ketter N, Brashear HR, Bogert J, et al. . Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer&#x2019;s disease patients. J Alzheimers Dis. 2017;57(2):557-573. doi:10.3233/JAD-160216</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160216</ArticleId><ArticleId IdType="pubmed">28269765</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Fox NC, et al. ; Bapineuzumab 301 and 302 Clinical Trial Investigators . Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med. 2014;370(4):322-333. doi:10.1056/NEJMoa1304839</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304839</ArticleId><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Linn J, Halpin A, Demaerel P, et al. . Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010;74(17):1346-1350. doi:10.1212/WNL.0b013e3181dad605</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181dad605</ArticleId><ArticleId IdType="pmc">PMC2875936</ArticleId><ArticleId IdType="pubmed">20421578</ArticleId></ArticleIdList></Reference><Reference><Citation>VandeVrede L, Gibbs DM, Koestler M, et al. . Symptomatic amyloid-related imaging abnormalities in an APOE &#x3b5;4/&#x3b5;4 patient treated with aducanumab. Alzheimers Dement (Amst). 2020;12(1):e12101. doi:10.1002/dad2.12101</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12101</ArticleId><ArticleId IdType="pmc">PMC7545921</ArticleId><ArticleId IdType="pubmed">33072846</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis. 2021;8(4):398-410. doi:10.14283/jpad.2021.41</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2021.41</ArticleId><ArticleId IdType="pmc">PMC8835345</ArticleId><ArticleId IdType="pubmed">34585212</ArticleId></ArticleIdList></Reference><Reference><Citation>A study to evaluate safety and tolerability of aducanumab in participants with Alzheimer's disease who had previously participated in the aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205. ClinicalTrials.gov identifier: NCT04241068. Updated September 5, 2021. Accessed September 5, 2021. https://clinicaltrials.gov/ct2/show/NCT04241068</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34811521</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Microglia contribute to the propagation of A&#x3b2; into unaffected brain tissue.</ArticleTitle><Pagination><StartPage>20</StartPage><EndPage>25</EndPage><MedlinePgn>20-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41593-021-00951-0</ELocationID><Abstract><AbstractText>Microglia appear activated in the vicinity of amyloid beta (A&#x3b2;) plaques, but whether microglia contribute to A&#x3b2; propagation into unaffected brain regions remains unknown. Using transplantation of wild-type (WT) neurons, we show that A&#x3b2; enters WT grafts, and that this is accompanied by microglia infiltration. Manipulation of microglia function reduced A&#x3b2; deposition within grafts. Furthermore, in vivo imaging identified microglia as carriers of A&#x3b2; pathology in previously unaffected tissue. Our data thus argue for a hitherto unexplored mechanism of A&#x3b2; propagation.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>d'Errico</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziegler-Waldkirch</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aires</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Biology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mez&#xf6;</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Biology, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erny</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6000-8838</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monasor</LastName><ForeName>Laura Sebastian</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liebscher</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5633-8981</Identifier><AffiliationInfo><Affiliation>Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Neuroimmunology, Klinikum der Universit&#xe4;t M&#xfc;nchen, Ludwig-Maximilians University Munich, Martinsried, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Center, Medical Faculty, Ludwig-Maximilians University Munich, Martinsried, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravi</LastName><ForeName>Vidhya M</ForeName><Initials>VM</Initials><Identifier Source="ORCID">0000-0003-0062-2099</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microenvironment and Immunology Research Laboratory, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroelectronic Systems, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational NeuroOncology Research Group, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joseph</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-6317-8736</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microenvironment and Immunology Research Laboratory, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational NeuroOncology Research Group, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnell</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microenvironment and Immunology Research Laboratory, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational NeuroOncology Research Group, Medical Center - University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kierdorf</LastName><ForeName>Katrin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-9272-4780</Identifier><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Basics in NeuroModulation (NeuroModulBasics), Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staszewski</LastName><ForeName>Ori</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahirovic</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4403-9559</Identifier><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prinz</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0349-1955</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Basics in NeuroModulation (NeuroModulBasics), Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer-Luehmann</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3661-2220</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical Center - University of Freiburg, Freiburg, Germany. melanie.meyer-luehmann@uniklinik-freiburg.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Freiburg, Freiburg, Germany. melanie.meyer-luehmann@uniklinik-freiburg.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Basics in NeuroModulation (NeuroModulBasics), Faculty of Medicine, University of Freiburg, Freiburg, Germany. melanie.meyer-luehmann@uniklinik-freiburg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2022 Jan;25(1):3-4. doi: 10.1038/s41593-021-00963-w.</RefSource><PMID Version="1">34815557</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurosci Bull. 2022 Oct;38(10):1274-1276. doi: 10.1007/s12264-022-00907-9.</RefSource><PMID Version="1">35729454</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34811521</ArticleId><ArticleId IdType="pmc">PMC8737330</ArticleId><ArticleId IdType="doi">10.1038/s41593-021-00951-0</ArticleId><ArticleId IdType="pii">10.1038/s41593-021-00951-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer&#x2019;s disease at 25 years. EMBO Mol. Med. 2016;8:595&#x2013;608. doi: 10.15252/emmm.201606210.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606210</ArticleId><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosna J, et al. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer&#x2019;s disease. Mol. Neurodegener. 2018;13:11. doi: 10.1186/s13024-018-0244-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0244-x</ArticleId><ArticleId IdType="pmc">PMC5831225</ArticleId><ArticleId IdType="pubmed">29490706</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg E, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer&#x2019;s disease model. Nat. Commun. 2019;10:3758. doi: 10.1038/s41467-019-11674-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11674-z</ArticleId><ArticleId IdType="pmc">PMC6704256</ArticleId><ArticleId IdType="pubmed">31434879</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg EE, et al. Eliminating microglia in Alzheimer&#x2019;s mice prevents neuronal loss without modulating amyloid-&#x3b2; pathology. Brain J. Neurol. 2016;139:1265&#x2013;1281. doi: 10.1093/brain/aww016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww016</ArticleId><ArticleId IdType="pmc">PMC5006229</ArticleId><ArticleId IdType="pubmed">26921617</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Rapid appearance and local toxicity of amyloid-&#x3b2; plaques in a mouse model of Alzheimer&#x2019;s disease. Nature. 2008;451:720&#x2013;724. doi: 10.1038/nature06616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06616</ArticleId><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz M, Jung S, Priller J. Microglia biology: one century of evolving concepts. Cell. 2019;179:292&#x2013;311. doi: 10.1016/j.cell.2019.08.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.08.053</ArticleId><ArticleId IdType="pubmed">31585077</ArticleId></ArticleIdList></Reference><Reference><Citation>Baik SH, Kang S, Son SM, Mook-Jung I. Microglia contributes to plaque growth by cell death due to uptake of amyloid &#x3b2; in the brain of Alzheimer&#x2019;s disease mouse model. Glia. 2016;64:2274&#x2013;2290. doi: 10.1002/glia.23074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23074</ArticleId><ArticleId IdType="pubmed">27658617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer&#x2019;s disease. J. Neurosci. 2011;31:11159&#x2013;11171. doi: 10.1523/JNEUROSCI.6209-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6209-10.2011</ArticleId><ArticleId IdType="pmc">PMC6623351</ArticleId><ArticleId IdType="pubmed">21813677</ArticleId></ArticleIdList></Reference><Reference><Citation>Venegas C, et al. Microglia-derived ASC specks cross-seed amyloid-&#x3b2; in Alzheimer&#x2019;s disease. Nature. 2017;552:355&#x2013;361. doi: 10.1038/nature25158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25158</ArticleId><ArticleId IdType="pubmed">29293211</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler-Waldkirch S, et al. Seed-induced A&#x3b2; deposition is modulated by microglia under environmental enrichment in a mouse model of Alzheimer&#x2019;s disease. EMBO J. 2018;37:167&#x2013;182. doi: 10.15252/embj.201797021.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201797021</ArticleId><ArticleId IdType="pmc">PMC5770788</ArticleId><ArticleId IdType="pubmed">29229786</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizkar S, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat. Neurosci. 2019;22:191&#x2013;204. doi: 10.1038/s41593-018-0296-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0296-9</ArticleId><ArticleId IdType="pmc">PMC6417433</ArticleId><ArticleId IdType="pubmed">30617257</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat. Rev. Neurosci. 2016;17:251&#x2013;260. doi: 10.1038/nrn.2016.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.13</ArticleId><ArticleId IdType="pmc">PMC6701169</ArticleId><ArticleId IdType="pubmed">26988744</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat. Neurosci. 2003;6:370&#x2013;377. doi: 10.1038/nn1022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1022</ArticleId><ArticleId IdType="pubmed">12598899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachhuber T, et al. Inhibition of amyloid-&#x3b2; plaque formation by &#x3b1;-synuclein. Nat. Med. 2015;21:802&#x2013;807. doi: 10.1038/nm.3885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3885</ArticleId><ArticleId IdType="pubmed">26099047</ArticleId></ArticleIdList></Reference><Reference><Citation>Espuny-Camacho I, et al. Hallmarks of Alzheimer&#x2019;s disease in stem-cell-derived human neurons transplanted into mouse brain. Neuron. 2017;93:1066&#x2013;1081.e8. doi: 10.1016/j.neuron.2017.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.02.001</ArticleId><ArticleId IdType="pubmed">28238547</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, et al. Novel Hexb-based tools for studying microglia in the CNS. Nat. Immunol. 2020;21:802&#x2013;815. doi: 10.1038/s41590-020-0707-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0707-4</ArticleId><ArticleId IdType="pubmed">32541832</ArticleId></ArticleIdList></Reference><Reference><Citation>Floden AM, Combs CK. Microglia demonstrate age-dependent interaction with amyloid-&#x3b2; fibrils. J. Alzheimers Dis. 2011;25:279&#x2013;293. doi: 10.3233/JAD-2011-101014.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-101014</ArticleId><ArticleId IdType="pmc">PMC3295838</ArticleId><ArticleId IdType="pubmed">21403390</ArticleId></ArticleIdList></Reference><Reference><Citation>Krabbe G, et al. Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS ONE. 2013;8:e60921. doi: 10.1371/journal.pone.0060921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0060921</ArticleId><ArticleId IdType="pmc">PMC3620049</ArticleId><ArticleId IdType="pubmed">23577177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastian Monasor L, et al. Fibrillar A&#x3b2; triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. eLife. 2020;9:e54083. doi: 10.7554/eLife.54083.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.54083</ArticleId><ArticleId IdType="pmc">PMC7279888</ArticleId><ArticleId IdType="pubmed">32510331</ArticleId></ArticleIdList></Reference><Reference><Citation>Daria A, et al. Young microglia restore amyloid plaque clearance of aged microglia. EMBO J. 2017;36:583&#x2013;603. doi: 10.15252/embj.201694591.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201694591</ArticleId><ArticleId IdType="pmc">PMC5331757</ArticleId><ArticleId IdType="pubmed">28007893</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Condello C, Schain A, Harb R, Grutzendler J. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-&#x3b2; phagocytosis. J. Neurosci. 2010;30:17091&#x2013;17101. doi: 10.1523/JNEUROSCI.4403-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4403-10.2010</ArticleId><ArticleId IdType="pmc">PMC3077120</ArticleId><ArticleId IdType="pubmed">21159979</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagemeyer N, et al. Transcriptome-based profiling of yolk sac-derived macrophages reveals a role for Irf8 in macrophage maturation. EMBO J. 2016;35:1730&#x2013;1744. doi: 10.15252/embj.201693801.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201693801</ArticleId><ArticleId IdType="pmc">PMC5010043</ArticleId><ArticleId IdType="pubmed">27412700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K, et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat. Neurosci. 2013;16:273&#x2013;280. doi: 10.1038/nn.3318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3318</ArticleId><ArticleId IdType="pubmed">23334579</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, et al. IRF8 is a transcriptional determinant for microglial motility. Purinergic Signal. 2014;10:515&#x2013;521. doi: 10.1007/s11302-014-9413-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-014-9413-8</ArticleId><ArticleId IdType="pmc">PMC4152453</ArticleId><ArticleId IdType="pubmed">24798612</ArticleId></ArticleIdList></Reference><Reference><Citation>Davalos D, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 2005;8:752&#x2013;758. doi: 10.1038/nn1472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1472</ArticleId><ArticleId IdType="pubmed">15895084</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314&#x2013;1318. doi: 10.1126/science.1110647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1110647</ArticleId><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G, et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41&#x2013;51. doi: 10.1016/S0896-6273(00)00084-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)00084-2</ArticleId><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, et al. Intraneuronal &#x3b2;-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer&#x2019;s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006;26:10129&#x2013;10140. doi: 10.1523/JNEUROSCI.1202-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1202-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S, et al. Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell Biol. 2000;20:4106&#x2013;4114. doi: 10.1128/MCB.20.11.4106-4114.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.20.11.4106-4114.2000</ArticleId><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15&#x2013;21. doi: 10.1093/bioinformatics/bts635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923&#x2013;930. doi: 10.1093/bioinformatics/btt656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt656</ArticleId><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R, et al. Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses. Nucleic Acids Res. 2015;43:e97. doi: 10.1093/nar/gkv412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv412</ArticleId><ArticleId IdType="pmc">PMC4551905</ArticleId><ArticleId IdType="pubmed">25925576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolde, R. pheatmap: Pretty heatmaps [Software] (2015).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34842295</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>17</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>Heterotypic Amyloid &#x3b2; interactions facilitate amyloid assembly and modify amyloid structure.</ArticleTitle><Pagination><StartPage>e108591</StartPage><MedlinePgn>e108591</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e108591</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.15252/embj.2021108591</ELocationID><Abstract><AbstractText>It is still unclear why pathological amyloid deposition initiates in specific brain regions or why some cells or tissues are more susceptible than others. Amyloid deposition is determined by the self-assembly of short protein segments called aggregation-prone regions (APRs) that favour cross-&#x3b2; structure. Here, we investigated whether A&#x3b2; amyloid assembly can be modified by heterotypic interactions between A&#x3b2; APRs and short homologous segments in otherwise unrelated human proteins. Mining existing proteomics data of A&#x3b2; plaques from AD patients revealed an enrichment in proteins that harbour such homologous sequences to the A&#x3b2; APRs, suggesting heterotypic amyloid interactions may occur in patients. We identified homologous APRs from such proteins and show that they can modify A&#x3b2; assembly kinetics, fibril morphology and deposition pattern in vitro. Moreover, we found three of these proteins upon transient expression in an A&#x3b2; reporter cell line promote A&#x3b2; amyloid aggregation. Strikingly, we did not find a bias towards heterotypic interactions in plaques from AD mouse models where A&#x3b2; self-aggregation is observed. Based on these data, we propose that heterotypic APR interactions may play a hitherto unrealized role in amyloid-deposition diseases.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Konstantoulea</LastName><ForeName>Katerina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-0960-6274</Identifier><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramakers</LastName><ForeName>Meine</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9417-4196</Identifier><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louros</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aubrey</LastName><ForeName>Liam D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>School of Biosciences, University of Kent, Canterbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houben</LastName><ForeName>Bert</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-6750-011X</Identifier><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michiels</LastName><ForeName>Emiel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vleeschouwer</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lampi</LastName><ForeName>Yulia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiro</LastName><ForeName>Lu&#xed;s F</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wit</LastName><ForeName>Joris</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>VIB Center for Brain &amp; Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Wei-Feng</ForeName><Initials>WF</Initials><Identifier Source="ORCID">0000-0002-6504-0404</Identifier><AffiliationInfo><Affiliation>School of Biosciences, University of Kent, Canterbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schymkowitz</LastName><ForeName>Joost</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2020-0168</Identifier><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9189-7399</Identifier><AffiliationInfo><Affiliation>Switch Laboratory, VIB-KU Leuven Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BB/S003312/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060066" MajorTopicYN="Y">Protein Interaction Maps</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyloid beta</Keyword><Keyword MajorTopicYN="N">heterotypic aggregation</Keyword><Keyword MajorTopicYN="N">toxicity</Keyword></KeywordList><CoiStatement>Joost Schymkowitz and Frederic Rousseau are the scientific founders of, and scientific consultants to, Aelin Therapeutics NV. The Switch Laboratory is engaged in a collaboration research agreement with Aelin Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>29</Day><Hour>9</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34842295</ArticleId><ArticleId IdType="pmc">PMC8762568</ArticleId><ArticleId IdType="doi">10.15252/embj.2021108591</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aoyagi A, Condello C, Stohr J, Yue W, Rivera BM, Lee JC, Woerman AL, Halliday G, van Duinen S, Ingelsson M et al (2019) Abeta and tau prion&#x2010;like activities decline with longevity in the Alzheimer's disease human brain. Sci Transl Med 11: eaat8462</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6640844</ArticleId><ArticleId IdType="pubmed">31043574</ArticleId></ArticleIdList></Reference><Reference><Citation>Arakhamia T, Lee CE, Carlomagno Y, Duong DM, Kundinger SR, Wang K, Williams D, DeTure M, Dickson DW, Cook CN et al (2020) Posttranslational modifications mediate the structural diversity of tauopathy strains. Cell 180: 633&#x2013;644.e612</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491959</ArticleId><ArticleId IdType="pubmed">32032505</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubrey LD, Blakeman BJF, Lutter L, Serpell CJ, Tuite MF, Serpell LC, Xue WF (2020) Quantification of amyloid fibril polymorphism by nano&#x2010;morphometry reveals the individuality of filament assembly. Commun Chem 3: 125</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9814634</ArticleId><ArticleId IdType="pubmed">36703355</ArticleId></ArticleIdList></Reference><Reference><Citation>Betti C, Vanhoutte I, Coutuer S, De Rycke RM, Mishev K, Vuylsteke M, Aesaert S, Rombaut D, Gallardo R, De Smet F et al (2016) Sequence&#x2010;specific protein aggregation generates defined protein knockdowns in plants. Plant Physiol 171: 773&#x2013;787</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4902617</ArticleId><ArticleId IdType="pubmed">27208282</ArticleId></ArticleIdList></Reference><Reference><Citation>Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pages F, Trajanoski Z, Galon J (2009) ClueGO: a Cytoscape plug&#x2010;in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25: 1091&#x2013;1093</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666812</ArticleId><ArticleId IdType="pubmed">19237447</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciantini M, Calloni G, Chiti F, Formigli L, Nosi D, Dobson CM, Stefani M (2004) Pre&#x2010;fibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem 279: 31374&#x2013;31382</Citation><ArticleIdList><ArticleId IdType="pubmed">15133040</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507&#x2013;511</Citation><ArticleIdList><ArticleId IdType="pubmed">11932737</ArticleId></ArticleIdList></Reference><Reference><Citation>Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, Evangelisti E, Relini A, Stefani M, Dobson CM, Cecchi C et al (2010) A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol 6: 140&#x2013;147</Citation><ArticleIdList><ArticleId IdType="pubmed">20081829</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang WP, Downs D, Huang XP, Da H, Fung KM, Tang J (2007) Amyloid&#x2010;beta reduction by memapsin 2 (beta&#x2010;secretase) immunization. FASEB J 21: 3184&#x2013;3196</Citation><ArticleIdList><ArticleId IdType="pubmed">17494994</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson CM (2017) Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem 86: 27&#x2013;68</Citation><ArticleIdList><ArticleId IdType="pubmed">28498720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciryam P, Kundra R, Morimoto RI, Dobson CM, Vendruscolo M (2015) Supersaturation is a major driving force for protein aggregation in neurodegenerative diseases. Trends Pharmacol Sci 36: 72&#x2013;77</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4643722</ArticleId><ArticleId IdType="pubmed">25636813</ArticleId></ArticleIdList></Reference><Reference><Citation>Colom&#x2010;Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Marti MJ, Clarimon J, Lleo A (2013) Confluence of alpha&#x2010;synuclein, tau, and beta&#x2010;amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol 72: 1203&#x2013;1212</Citation><ArticleIdList><ArticleId IdType="pubmed">24226269</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson CM (1999) Protein misfolding, evolution and disease. Trends Biochem Sci 24: 329&#x2013;332</Citation><ArticleIdList><ArticleId IdType="pubmed">10470028</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond E, Nayak S, Faustin A, Pires G, Hickman RA, Askenazi M, Cohen M, Haldiman T, Kim C, Han X et al (2017a) Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer's disease. Acta Neuropathol 133: 933&#x2013;954</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5503748</ArticleId><ArticleId IdType="pubmed">28258398</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond E, Nayak S, Faustin A, Pires G, Hickman RA, Askenazi M, Cohen M, Haldiman T, Kim C, Han X et al (2017b) Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer's disease. Acta Neuropathol 133: 933&#x2013;954</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5503748</ArticleId><ArticleId IdType="pubmed">28258398</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond E, Pires G, MacMurray C, Askenazi M, Nayak S, Bourdon M, Safar J, Ueberheide B, Wisniewski T (2020a) Phosphorylated tau interactome in the human Alzheimer's disease brain. Brain 143: 2803&#x2013;2817</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7526722</ArticleId><ArticleId IdType="pubmed">32812023</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond E, Pires G, MacMurray C, Askenazi M, Nayak S, Bourdon M, Safar J, Ueberheide B, Wisniewski T (2020b) Phosphorylated tau interactome in the human Alzheimer's disease brain. Brain 143: 2803&#x2013;2817</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7526722</ArticleId><ArticleId IdType="pubmed">32812023</ArticleId></ArticleIdList></Reference><Reference><Citation>Egelman EH (1986) An algorithm for straightening images of curved filamentous structures. Ultramicroscopy 19: 367&#x2013;373</Citation><ArticleIdList><ArticleId IdType="pubmed">3775966</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez&#x2010;Escamilla AM, Rousseau F, Schymkowitz J, Serrano L (2004a) Prediction of sequence&#x2010;dependent and mutational effects on the&#x2009;aggregation of peptides and proteins. Nat Biotechnol 22: 1302&#x2013;1306</Citation><ArticleIdList><ArticleId IdType="pubmed">15361882</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez&#x2010;Escamilla AM, Rousseau F, Schymkowitz J, Serrano L (2004b) Prediction of sequence&#x2010;dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 22: 1302&#x2013;1306</Citation><ArticleIdList><ArticleId IdType="pubmed">15361882</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez&#x2010;Irigoyen J, Zelaya MV, Tunon T, Santamaria E (2014a) Anatomo&#x2010;proteomic characterization of human basal ganglia: focus on striatum and globus pallidus. Mol Brain 7: 83</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4236423</ArticleId><ArticleId IdType="pubmed">25406675</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez&#x2010;Irigoyen J, Zelaya MV, Tunon T, Santamaria E (2014b) Anatomo&#x2010;proteomic characterization of human basal ganglia: focus on striatum and globus pallidus. Mol Brain 7: 83</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4236423</ArticleId><ArticleId IdType="pubmed">25406675</ArticleId></ArticleIdList></Reference><Reference><Citation>Flagmeier P, De S, Michaels TCT, Yang X, Dear AJ, Emanuelsson C, Vendruscolo M, Linse S, Klenerman D, Knowles TPJ et al (2020) Direct measurement of lipid membrane disruption connects kinetics and toxicity of Abeta42 aggregation. Nat Struct Mol Biol 27: 886&#x2013;891</Citation><ArticleIdList><ArticleId IdType="pubmed">32778821</ArticleId></ArticleIdList></Reference><Reference><Citation>Forner S, Baglietto&#x2010;Vargas D, Martini AC, Trujillo&#x2010;Estrada L, LaFerla FM (2017) Synaptic impairment in Alzheimer's disease: a dysregulated symphony. Trends Neurosci 40: 347&#x2013;357</Citation><ArticleIdList><ArticleId IdType="pubmed">28494972</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H, Hardy J, Duff KE (2018) Selective vulnerability in neurodegenerative diseases. Nat Neurosci 21: 1350&#x2013;1358</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6360529</ArticleId><ArticleId IdType="pubmed">30250262</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu L, Niu B, Zhu Z, Wu S, Li W (2012) CD&#x2010;HIT: accelerated for clustering the next&#x2010;generation sequencing data. Bioinformatics 28: 3150&#x2013;3152</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3516142</ArticleId><ArticleId IdType="pubmed">23060610</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Kaneko K, Matsumoto G, Kurosawa M, Nukina N (2009) Cross&#x2010;seeding fibrillation of Q/N&#x2010;rich proteins offers new pathomechanism of polyglutamine diseases. J Neurosci 29: 5153&#x2013;5162</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665470</ArticleId><ArticleId IdType="pubmed">19386911</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo R, Ramakers M, De Smet F, Claes F, Khodaparast L, Khodaparast L, Couceiro JR, Langenberg T, Siemons M, Nystr&#xf6;m S et al (2016) De novo design of a biologically active amyloid. Science 354: aah4949</Citation><ArticleIdList><ArticleId IdType="pubmed">27846578</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo R, Ranson NA, Radford SE (2020) Amyloid structures: much more than just a cross&#x2010;beta fold. Curr Opin Struct Biol 60: 7&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pubmed">31683043</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan L, Cookson MR, Petrucelli L, La Spada AR (2018) Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci 21: 1300&#x2013;1309</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278826</ArticleId><ArticleId IdType="pubmed">30258237</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesan A, Debulpaep M, Wilkinson H, Van Durme J, De Baets G, Jonckheere W, Ramakers M, Ivarsson Y, Zimmermann P, Van Eldere J et al (2015) Selectivity of aggregation&#x2010;determining interactions. J Mol Biol 427: 236&#x2013;247</Citation><ArticleIdList><ArticleId IdType="pubmed">25451783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesan A, Siekierska A, Beerten J, Brams M, Van Durme J, De Baets G, Van der Kant R, Gallardo R, Ramakers M, Langenberg T et al (2016) Structural hot spots for the solubility of globular proteins. Nat Commun 7: 10816</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4770091</ArticleId><ArticleId IdType="pubmed">26905391</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM&#x2010;Y (2003) Initiation and synergistic fibrillization of tau and alpha&#x2010;synuclein. Science 300: 636&#x2013;640</Citation><ArticleIdList><ArticleId IdType="pubmed">12714745</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Eisenberg DS, Crowther RA (2017) Propagation of tau aggregates and neurodegeneration. Annu Rev Neurosci 40: 189&#x2013;210</Citation><ArticleIdList><ArticleId IdType="pubmed">28772101</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldschmidt L, Teng PK, Riek R, Eisenberg D (2010) Identifying the amylome, proteins capable of forming amyloid&#x2010;like fibrils. Proc Natl Acad Sci USA 107: 3487&#x2013;3492</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840437</ArticleId><ArticleId IdType="pubmed">20133726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hipp MS, Kasturi P, Hartl FU (2019) The proteostasis network and its decline in ageing. Nat Rev Mol Cell Biol 20: 421&#x2013;435</Citation><ArticleIdList><ArticleId IdType="pubmed">30733602</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann JP, Denner P, Nussbaum&#x2010;Krammer C, Kuhn PH, Suhre MH, Scheibel T, Lichtenthaler SF, Schatzl HM, Bano D, Vorberg IM (2013) Cell&#x2010;to&#x2010;cell propagation of infectious cytosolic protein aggregates. Proc Natl Acad Sci U S A 110: 5951&#x2013;5956</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625284</ArticleId><ArticleId IdType="pubmed">23509289</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Kant R, Louros N, Schymkowitz J, Rousseau F (2021) A structural analysis of amyloid polymorphism in disease: clues for selective vulnerability? bioRxiv 10.1101/2021.03.01.433317 [PREPRINT]</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.01.433317</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman SK, Sanders DW, Thomas TL, Ruchinskas AJ, Vaquer&#x2010;Alicea J, Sharma AM, Miller TM, Diamond MI (2016) Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo . Neuron 92: 796&#x2013;812</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5392364</ArticleId><ArticleId IdType="pubmed">27974162</ArticleId></ArticleIdList></Reference><Reference><Citation>Kehrloesser S, Osterburg C, Tuppi M, Schafer B, Vousden KH, Dotsch V (2016) Intrinsic aggregation propensity of the p63 and p73 TI domains correlates with p53R175H interaction and suggests further significance of aggregation events in the p53 family. Cell Death Differ 23: 1952&#x2013;1960</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5136486</ArticleId><ArticleId IdType="pubmed">27447112</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantoulea K, Louros N, Rousseau F, Schymkowitz J (2021) Heterotypic interactions in amyloid function and disease. FEBS J 10.1111/febs.15719</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15719</ArticleId><ArticleId IdType="pubmed">33460517</ArticleId></ArticleIdList></Reference><Reference><Citation>Krebs MR, Morozova&#x2010;Roche LA, Daniel K, Robinson CV, Dobson CM (2004) Observation of sequence specificity in the seeding of protein amyloid fibrils. Protein Sci 13: 1933&#x2013;1938</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2279934</ArticleId><ArticleId IdType="pubmed">15215533</ArticleId></ArticleIdList></Reference><Reference><Citation>Labbadia J, Morimoto RI (2015) The biology of proteostasis in aging and disease. Annu Rev Biochem 84: 435&#x2013;464</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4539002</ArticleId><ArticleId IdType="pubmed">25784053</ArticleId></ArticleIdList></Reference><Reference><Citation>Landreh M, Sawaya MR, Hipp MS, Eisenberg DS, Wuthrich K, Hartl FU (2016) The formation, function and regulation of amyloids: insights from structural biology. J Intern Med 280: 164&#x2013;176</Citation><ArticleIdList><ArticleId IdType="pubmed">27237473</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez de la Paz M, Serrano L (2004) Sequence determinants of amyloid fibril formation. Proc Natl Acad Sci U S A 101: 87&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314143</ArticleId><ArticleId IdType="pubmed">14691246</ArticleId></ArticleIdList></Reference><Reference><Citation>Louros NN, Chrysina ED, Baltatzis GE, Patsouris ES, Hamodrakas SJ, Iconomidou VA (2016) A common 'aggregation&#x2010;prone' interface possibly participates in the self&#x2010;assembly of human zona pellucida proteins. FEBS Lett 590: 619&#x2013;630</Citation><ArticleIdList><ArticleId IdType="pubmed">26879157</ArticleId></ArticleIdList></Reference><Reference><Citation>Louros N, Konstantoulea K, De Vleeschouwer M, Ramakers M, Schymkowitz J, Rousseau F (2020) WALTZ&#x2010;DB 2.0: an updated database containing structural information of experimentally determined amyloid&#x2010;forming peptides. Nucleic Acids Res 48: D389&#x2013;D393</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6943037</ArticleId><ArticleId IdType="pubmed">31504823</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutter L, Serpell CJ, Tuite MF, Xue WF (2019) The molecular lifecycle of amyloid &#x2010; Mechanism of assembly, mesoscopic organisation, polymorphism, suprastructures, and biological consequences. Biochim Biophys Acta Proteins Proteom 1867: 140257</Citation><ArticleIdList><ArticleId IdType="pubmed">31352057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutter L, Serpell CJ, Tuite MF, Serpell LC, Xue WF (2020) Three&#x2010;dimensional reconstruction of individual helical nano&#x2010;filament structures from atomic force microscopy topographs. Biomol Concepts 11: 102&#x2013;115</Citation><ArticleIdList><ArticleId IdType="pubmed">32374275</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly H, Verma N, Sharma S, Kotiya D, Despa S, Abner EL, Nelson PT, Jicha GA, Wilcock DM, Goldstein LB et al (2021) The association of circulating amylin with &#x3b2;&#x2010;amyloid in familial Alzheimer's disease. Alzheimers Dement 7: e12130</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816817</ArticleId><ArticleId IdType="pubmed">33521236</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R (2006) Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res 31: 1153&#x2013;1162</Citation><ArticleIdList><ArticleId IdType="pubmed">16947080</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall KE, Vadukul DM, Dahal L, Theisen A, Fowler MW, Al&#x2010;Hilaly Y, Ford L, Kemenes G, Day IJ, Staras K et al (2016) A critical role for the self&#x2010;assembly of Amyloid&#x2010;beta1&#x2010;42 in neurodegeneration. Sci Rep 6: 30182</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4957119</ArticleId><ArticleId IdType="pubmed">27443509</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurer&#x2010;Stroh S, Debulpaep M, Kuemmerer N, de la Paz ML, Martins IC, Reumers J, Morris KL, Copland A, Serpell L, Serrano L et al (2010) Exploring the sequence determinants of amyloid structure using position&#x2010;specific scoring matrices. Nat Methods 7: 237&#x2013;242</Citation><ArticleIdList><ArticleId IdType="pubmed">20154676</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormack A, Keating DJ, Chegeni N, Colella A, Wang JJ, Chataway T (2019a) Abundance of synaptic vesicle&#x2010;related proteins in alpha&#x2010;synuclein&#x2010;containing protein inclusions suggests a targeted formation mechanism. Neurotox Res 35: 883&#x2013;897</Citation><ArticleIdList><ArticleId IdType="pubmed">30796693</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormack A, Keating DJ, Chegeni N, Colella A, Wang JJ, Chataway T (2019b) Abundance of synaptic vesicle&#x2010;related proteins in alpha&#x2010;synuclein&#x2010;containing protein inclusions suggests a targeted formation mechanism. Neurotox Res 35: 883&#x2013;897</Citation><ArticleIdList><ArticleId IdType="pubmed">30796693</ArticleId></ArticleIdList></Reference><Reference><Citation>Michiels E, Liu S, Gallardo R, Louros N, Mathelie&#x2010;Guinlet M, Dufrene Y, Schymkowitz J, Vorberg I, Rousseau F (2020a) Entropic bristles tune the seeding efficiency of prion&#x2010;nucleating fragments. Cell Rep 30: 2834&#x2013;2845.e2833</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7043027</ArticleId><ArticleId IdType="pubmed">32101755</ArticleId></ArticleIdList></Reference><Reference><Citation>Michiels E, Roose K, Gallardo R, Khodaparast L, Khodaparast L, van der Kant R, Siemons M, Houben B, Ramakers M, Wilkinson H et al (2020b) Reverse engineering synthetic antiviral amyloids. Nat Commun 11: 2832</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7275043</ArticleId><ArticleId IdType="pubmed">32504029</ArticleId></ArticleIdList></Reference><Reference><Citation>Muratore CR, Zhou C, Liao M, Fernandez MA, Taylor WM, Lagomarsino VN, Pearse RV 2nd, Rice HC, Negri JM, He A et al (2017) Cell&#x2010;type dependent Alzheimer's disease phenotypes: probing the biology of selective neuronal vulnerability. Stem Cell Reports 9: 1868&#x2013;1884</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785690</ArticleId><ArticleId IdType="pubmed">29153990</ArticleId></ArticleIdList></Reference><Reference><Citation>Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG, Vendruscolo M, Hayer&#x2010;Hartl M, Hartl FU, Vabulas RM (2011) Amyloid&#x2010;like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144: 67&#x2013;78</Citation><ArticleIdList><ArticleId IdType="pubmed">21215370</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Nuallain B, Shivaprasad S, Kheterpal I, Wetzel R (2005) Thermodynamics of A beta(1&#x2013;40) amyloid fibril elongation. Biochemistry 44: 12709&#x2013;12718</Citation><ArticleIdList><ArticleId IdType="pubmed">16171385</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Nuallain B, Williams AD, Westermark P, Wetzel R (2004) Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 279: 17490&#x2013;17499</Citation><ArticleIdList><ArticleId IdType="pubmed">14752113</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson ME, Paulsson JF, Schultz SW, Ingelsson M, Westermark P, Westermark GT (2015) In vivo seeding and cross&#x2010;seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. Am J Pathol 185: 834&#x2013;846</Citation><ArticleIdList><ArticleId IdType="pubmed">25700985</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Paz ML, Serrano L (2004) Sequence determinants of amyloid fibril formation. Proc Natl Acad Sci U S A 101: 87&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314143</ArticleId><ArticleId IdType="pubmed">14691246</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham CL, Shanmugam N, Strange M, O'Carroll A, Brown JW, Sierecki E, Gambin Y, Steain M, Sunde M (2019) Viral M45 and necroptosis&#x2010;associated proteins form heteromeric amyloid assemblies. EMBO Rep 20: e46518</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6362354</ArticleId><ArticleId IdType="pubmed">30498077</ArticleId></ArticleIdList></Reference><Reference><Citation>Riek R, Eisenberg DS (2016) The activities of amyloids from a structural perspective. Nature 539: 227&#x2013;235</Citation><ArticleIdList><ArticleId IdType="pubmed">27830791</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseau F, Schymkowitz JW, Wilkinson HR, Itzhaki LS (2001) Three&#x2010;dimensional domain swapping in p13suc1 occurs in the unfolded state and is controlled by conserved proline residues. Proc Natl Acad Sci U S A 98: 5596&#x2013;5601</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33258</ArticleId><ArticleId IdType="pubmed">11344301</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseau F, Schymkowitz J, Serrano L (2006a) Protein aggregation and amyloidosis: confusion of the kinds? Curr Opin Struct Biol 16: 118&#x2013;126</Citation><ArticleIdList><ArticleId IdType="pubmed">16434184</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseau F, Serrano L, Schymkowitz JW (2006b) How evolutionary pressure against protein aggregation shaped chaperone specificity. J Mol Biol 355: 1037&#x2013;1047</Citation><ArticleIdList><ArticleId IdType="pubmed">16359707</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson TR, Challis C, Jain N, Moiseyenko A, Ladinsky MS, Shastri GG, Thron T, Needham BD, Horvath I, Debelius JW et al (2020) A gut bacterial amyloid promotes alpha&#x2010;synuclein aggregation and motor impairment in mice. eLife 9: e53111</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7012599</ArticleId><ArticleId IdType="pubmed">32043464</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders D, Kaufman S, DeVos S, Sharma A, Mirbaha H, Li A, Barker S, Foley A, Thorpe J, Serpell L et al (2014) Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82: 1271&#x2013;1288</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="pubmed">24857020</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres SH, Zhang W, Falcon B, Goedert M (2020) Cryo&#x2010;EM structures of tau filaments. Curr Opin Struct Biol 64: 17&#x2013;25</Citation><ArticleIdList><ArticleId IdType="pubmed">32603876</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva MVF, Loures CMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MDG (2019) Alzheimer's disease: risk factors and potentially protective measures. J Biomed Sci 26: 33</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6507104</ArticleId><ArticleId IdType="pubmed">31072403</ArticleId></ArticleIdList></Reference><Reference><Citation>Supek F, Bosnjak M, Skunca N, Smuc T (2011) REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One 6: e21800</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138752</ArticleId><ArticleId IdType="pubmed">21789182</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartaglia GG, Pechmann S, Dobson CM, Vendruscolo M (2007) Life on the edge: a link between gene expression levels and aggregation rates of human proteins. Trends Biochem Sci 32: 204&#x2013;206</Citation><ArticleIdList><ArticleId IdType="pubmed">17419062</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Hardy J, Fischbeck KH (2002) Toxic proteins in neurodegenerative disease. Science 296: 1991&#x2013;1995</Citation><ArticleIdList><ArticleId IdType="pubmed">12065827</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng PK, Eisenberg D (2009) Short protein segments can drive a non&#x2010;fibrillizing protein into the amyloid state. Protein Eng Des Sel 22: 531&#x2013;536</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719503</ArticleId><ArticleId IdType="pubmed">19602569</ArticleId></ArticleIdList></Reference><Reference><Citation>Tessier PM, Lindquist S (2007) Prion recognition elements govern nucleation, strain specificity and species barriers. Nature 447: 556&#x2013;561</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2144736</ArticleId><ArticleId IdType="pubmed">17495929</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhl&#xe9;n M, Fagerberg L, Hallstr&#xf6;m BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson &#xc5;, Kampf C, Sj&#xf6;stedt E, Asplund A et al (2015) Proteomics. Tissue&#x2010;based map of the human proteome. Science 347: 1260419</Citation><ArticleIdList><ArticleId IdType="pubmed">25613900</ArticleId></ArticleIdList></Reference><Reference><Citation>UniProt Consortium (2008) The universal protein resource (UniProt). Nucleic Acids Res 36: D190&#x2013;D195</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2238893</ArticleId><ArticleId IdType="pubmed">18045787</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandersteen A, Masman MF, De Baets G, Jonckheere W, van der Werf K, Marrink SJ, Rozenski J, Benilova I, De Strooper B, Subramaniam V et al (2012) Molecular plasticity regulates oligomerization and cytotoxicity of the multipeptide&#x2010;length amyloid&#x2010;beta peptide pool. J Biol Chem 287: 36732&#x2013;36743</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3481277</ArticleId><ArticleId IdType="pubmed">22992745</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanik DL, Surewicz KA, Surewicz WK (2004) Molecular basis of barriers for interspecies transmissibility of mammalian prions. Mol Cell 14: 139&#x2013;145</Citation><ArticleIdList><ArticleId IdType="pubmed">15068810</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasconcelos B, Stancu I&#x2010;C, Buist A, Bird M, Wang P, Vanoosthuyse A, Van Kolen K, Verheyen AN, Kienlen&#x2010;Campard P, Octave J&#x2010;N et al (2016) Heterotypic seeding of Tau fibrillization by pre&#x2010;aggregated Abeta provides potent seeds for prion&#x2010;like seeding and propagation of Tau&#x2010;pathology in vivo . Acta Neuropathol 131: 549&#x2013;569</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4789256</ArticleId><ArticleId IdType="pubmed">26739002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura S, Zurdo J, Narayanan S, Parreno M, Mangues R, Reif B, Chiti F, Giannoni E, Dobson CM, Aviles FX et al (2004) Short amino acid stretches can mediate amyloid formation in globular proteins: the Src homology 3 (SH3) case. Proc Natl Acad Sci U S A 101: 7258&#x2013;7263</Citation><ArticleIdList><ArticleId IdType="pmc">PMC409906</ArticleId><ArticleId IdType="pubmed">15123800</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ (2016) A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci 17: 251&#x2013;260</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6701169</ArticleId><ArticleId IdType="pubmed">26988744</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Thulin E, Minogue AM, Gustavsson N, Pang E, Teplow DB, Linse S (2009) A facile method for expression and purification of the Alzheimer's disease&#x2010;associated amyloid beta&#x2010;peptide. FEBS J 276: 1266&#x2013;1281</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702495</ArticleId><ArticleId IdType="pubmed">19175671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Fersht AR (2015) Propagation of aggregated p53: Cross&#x2010;reaction and coaggregation vs. seeding. Proc Natl Acad Sci U S A 112: 2443&#x2013;2448</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4345553</ArticleId><ArticleId IdType="pubmed">25675527</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesseling H, Mair W, Kumar M, Schlaffner CN, Tang S, Beerepoot P, Fatou B, Guise AJ, Cheng L, Takeda S et al (2020) Tau PTM profiles identify patient heterogeneity and stages of Alzheimer's disease. Cell 183: 1699&#x2013;1713.e1613</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8168922</ArticleId><ArticleId IdType="pubmed">33188775</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermark GT, Westermark P (2010) Prion&#x2010;like aggregates: infectious agents in human disease. Trends Mol Med 16: 501&#x2013;507</Citation><ArticleIdList><ArticleId IdType="pubmed">20870462</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetzel R (2006) Kinetics and thermodynamics of amyloid fibril assembly. Acc Chem Res 39: 671&#x2013;679</Citation><ArticleIdList><ArticleId IdType="pubmed">16981684</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong F, Ge W, Ma C (2019a) Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer's disease. Alzheimers Dement 15: 429&#x2013;440</Citation><ArticleIdList><ArticleId IdType="pubmed">30502339</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong F, Ge W, Ma C (2019b) Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer's disease. Alzheimers Dement 15: 429&#x2013;440</Citation><ArticleIdList><ArticleId IdType="pubmed">30502339</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S, Cornelis A, Rozenski J, Zwolinska A, Marine J&#x2010;C et al (2011) Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 7: 285&#x2013;295</Citation><ArticleIdList><ArticleId IdType="pubmed">21445056</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue WF, Homans SW, Radford SE (2009) Amyloid fibril length distribution quantified by atomic force microscopy single&#x2010;particle image analysis. Protein Eng Des Sel 22: 489&#x2013;496</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719499</ArticleId><ArticleId IdType="pubmed">19581337</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan L&#x2010;M, Velkova A, Tatarek&#x2010;Nossol M, Andreetto E, Kapurniotu A (2007) IAPP mimic blocks Abeta cytotoxic self&#x2010;assembly: cross&#x2010;suppression of amyloid toxicity of Abeta and IAPP suggests a molecular link between Alzheimer's disease and type II diabetes. Angew Chem Int Ed Engl 46: 1246&#x2013;1252</Citation><ArticleIdList><ArticleId IdType="pubmed">17203498</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman M, Khan AN, Wahiduzzaman , Zakariya SM, Khan RH (2019) Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregation. Int J Biol Macromol 134: 1022&#x2013;1037</Citation><ArticleIdList><ArticleId IdType="pubmed">31128177</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Smith D, Leong BJ, Brannstrom K, Almqvist F, Chapman MR (2012) Promiscuous cross&#x2010;seeding between bacterial amyloids promotes interspecies biofilms. J Biol Chem 287: 35092&#x2013;35103</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3471717</ArticleId><ArticleId IdType="pubmed">22891247</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34851693</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>622</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>AD-linked R47H-<i>TREM2</i> mutation induces disease-enhancing microglial states via AKT hyperactivation.</ArticleTitle><Pagination><StartPage>eabe3947</StartPage><MedlinePgn>eabe3947</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abe3947</ELocationID><Abstract><AbstractText>The hemizygous R47H variant of triggering receptor expressed on myeloid cells 2 (<i>TREM2</i>), a microglia-specific gene in the brain, increases risk for late-onset Alzheimer&#x2019;s disease (AD). Using transcriptomic analysis of single nuclei from brain tissues of patients with AD carrying the R47H mutation or the common variant (CV)&#x2013;<i>TREM2</i>, we found that R47H-associated microglial subpopulations had enhanced inflammatory signatures reminiscent of previously identified disease-associated microglia (DAM) and hyperactivation of AKT, one of the signaling pathways downstream of TREM2. We established a tauopathy mouse model with heterozygous knock-in of the human <i>TREM2</i> with the R47H mutation or CV and found that R47H induced and exacerbated TAU-mediated spatial memory deficits in female mice. Single-cell transcriptomic analysis of microglia from these mice also revealed transcriptomic changes induced by R47H that had substantial overlaps with R47H microglia in human AD brains, including robust increases in proinflammatory cytokines, activation of AKT signaling, and elevation of a subset of DAM signatures. Pharmacological AKT inhibition with MK-2206 largely reversed the enhanced inflammatory signatures in primary R47H microglia treated with TAU fibrils. In R47H heterozygous tauopathy mice, MK-2206 treatment abolished a tauopathy-dependent microglial subcluster and rescued tauopathy-induced synapse loss. By uncovering disease-enhancing mechanisms of the R47H mutation conserved in human and mouse, our study supports inhibitors of AKT signaling as a microglial modulating strategy to treat AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sayed</LastName><ForeName>Faten A</ForeName><Initials>FA</Initials><Identifier Source="ORCID">0000-0003-3992-4668</Identifier><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kodama</LastName><ForeName>Lay</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-8419-8445</Identifier><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94107, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Scientist Training Program and Neuroscience Graduate Program, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Li</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1780-6919</Identifier><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carling</LastName><ForeName>Gillian K</ForeName><Initials>GK</Initials><Identifier Source="ORCID">0000-0002-1504-1716</Identifier><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Udeochu</LastName><ForeName>Joe C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-6526-335X</Identifier><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qingyun</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-3457-5967</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience and Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Man Ying</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horowitz</LastName><ForeName>Rose</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8177-941X</Identifier><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Pearly</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathys</LastName><ForeName>Hansruedi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5842-5245</Identifier><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Minghui</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9171-4962</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-7689-0941</Identifier><AffiliationInfo><Affiliation>Tri-Institutional Computational Biology and Medicine Program, Weill Cornell Medical College, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazutis</LastName><ForeName>Linas</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5552-6427</Identifier><AffiliationInfo><Affiliation>Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xueqiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xueting</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-6172-7148</Identifier><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fuying</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Neurology, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brendel</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3417-4597</Identifier><AffiliationInfo><Affiliation>Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Telpoukhovskaia</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5237-4042</Identifier><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tracy</LastName><ForeName>Tara E</ForeName><Initials>TE</Initials><Identifier Source="ORCID">0000-0003-3356-4091</Identifier><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-7658-954X</Identifier><AffiliationInfo><Affiliation>Chemical Biology Program, Weill Graduate School of Medical Sciences of Cornell University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yungui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yaqiao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9692-1290</Identifier><AffiliationInfo><Affiliation>Department of Computer Science, Hunter College, and The Graduate Center, The City University of New York, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Zuolin</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-5197-5874</Identifier><AffiliationInfo><Affiliation>Bradley Department of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, VA 24061, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Guoqiang</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-6743-7413</Identifier><AffiliationInfo><Affiliation>Bradley Department of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, VA 24061, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3122-0423</Identifier><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2105-1061</Identifier><AffiliationInfo><Affiliation>Departments of Psychiatry and Neurology, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-9459-9461</Identifier><AffiliationInfo><Affiliation>Department of Population Health Sciences, Weill Cornell Medical College, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeTure</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-4363-1262</Identifier><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-9549-5653</Identifier><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Lei</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9051-2111</Identifier><AffiliationInfo><Affiliation>Chemical Biology Program, Weill Graduate School of Medical Sciences of Cornell University, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trajnowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><Identifier Source="ORCID">0000-0002-9239-8794</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VMY</Initials><Identifier Source="ORCID">0000-0003-3536-6902</Identifier><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Shiaoching</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>Subhash C</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0001-8916-5677</Identifier><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Li</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4600-275X</Identifier><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94107, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/N026004/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1001253</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K01 AG057862</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG059319</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG051390</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/J004758/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG054214</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG064239</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG058505</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG072562</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L501542/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U54 NS100717</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/K01417X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 MH110504</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG054014</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007618</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG046170</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG057907</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-1307</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>202903/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>F30 AG062043</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG057555</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007175</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0901254</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> L.G. is founder of Aeton Therapeutics, Inc. S.C.S. is a consultant of Aeton Therapeutics, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>1</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34851693</ArticleId><ArticleId IdType="mid">NIHMS1824808</ArticleId><ArticleId IdType="pmc">PMC9345574</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abe3947</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J, Alzheimer Genetic Analysis G, TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med 368, 117&#x2013;127 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson K, TREM2 and neurodegenerative disease. N Engl J Med 369, 1568&#x2013;1569 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24131183</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, Fanek Z, Liu L, Chen Z, Rothstein JD, Ransohoff RM, Gygi SP, Antel JP, Weiner HL, Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci 17, 131&#x2013;143 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, El Khoury J, The microglial sensome revealed by direct RNA sequencing. Nature neuroscience 16, 1896&#x2013;1905 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840123</ArticleId><ArticleId IdType="pubmed">24162652</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M, Wang Y, TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci 17, 201&#x2013;207 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26911435</ArticleId></ArticleIdList></Reference><Reference><Citation>Deczkowska A, Weiner A, Amit I, The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway. Cell 181, 1207&#x2013;1217 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32531244</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, Loginicheva E, Gilfillan S, Cella M, Virgin HW, Unanue ER, Wang Y, Artyomov MN, Holtzman DM, Colonna M, TREM2 Maintains Microglial Metabolic Fitness in Alzheimer&#x2019;s Disease. Cell 170, 649&#x2013;663 e613 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573224</ArticleId><ArticleId IdType="pubmed">28802038</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M, TREM2 lipid sensing sustains the microglial response in an Alzheimer&#x2019;s disease model. Cell 160, 1061&#x2013;1071 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477963</ArticleId><ArticleId IdType="pubmed">25728668</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CD, Neumann H, Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201, 647&#x2013;657 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Q, Danao J, Talreja S, Wen P, Yin J, Sun N, Li CM, Chui D, Tran D, Koirala S, Chen H, Foltz IN, Wang S, Sambashivan S, TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer&#x2019;s disease variant Trem2(R47H) on murine myeloid cell function. J Biol Chem 293, 12620&#x2013;12633 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093249</ArticleId><ArticleId IdType="pubmed">29599291</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Jia L, Liu CC, Rong Z, Zhong L, Yang L, Chen XF, Fryer JD, Wang X, Zhang YW, Xu H, Bu G, TREM2 Promotes Microglial Survival by Activating Wnt/beta-Catenin Pathway. J Neurosci 37, 1772&#x2013;1784 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5320608</ArticleId><ArticleId IdType="pubmed">28077724</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE, A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109, 1144&#x2013;1156 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087597</ArticleId><ArticleId IdType="pubmed">19302484</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O&#x2019;Loughlin E, Xu Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, Conde-Sanroman P, Gacias M, Weng Z, Chen H, Tjon E, Mazaheri F, Hartmann K, Madi A, Ulrich JD, Glatzel M, Worthmann A, Heeren J, Budnik B, Lemere C, Ikezu T, Heppner FL, Litvak V, Holtzman DM, Lassmann H, Weiner HL, Ochando J, Haass C, Butovsky O, The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47, 566&#x2013;581 e569 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5719893</ArticleId><ArticleId IdType="pubmed">28930663</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, Itzkovitz S, Colonna M, Schwartz M, Amit I, A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell 169, 1276&#x2013;1290 e1217 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, Robinson GO, Anderson E, Colonna M, Holtzman DM, TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci USA 114, 11524&#x2013;11529 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663386</ArticleId><ArticleId IdType="pubmed">29073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayed FA, Telpoukhovskaia M, Kodama L, Li Y, Zhou Y, Le D, Hauduc A, Ludwig C, Gao F, Clelland C, Zhan L, Cooper YA, Davalos D, Akassoglou K, Coppola G, Gan L, Differential effects of partial and complete loss of TREM2 on microglial injury response and tauopathy. Proceedings of the National Academy of Sciences of the United States of America 115, 10172&#x2013;10177 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6176614</ArticleId><ArticleId IdType="pubmed">30232263</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM, Altered microglial response to Abeta plaques in APPPS1&#x2013;21 mice heterozygous for TREM2. Mol Neurodegener 9, 20 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="pubmed">24893973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, Cella M, Grutzendler J, DeMattos RB, Cirrito JR, Holtzman DM, Colonna M, TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213, 667&#x2013;675 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854736</ArticleId><ArticleId IdType="pubmed">27091843</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, Lamb BT, Landreth GE, Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer&#x2019;s Disease. J Neurosci 37, 637&#x2013;647 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5242410</ArticleId><ArticleId IdType="pubmed">28100745</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J, TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron 90, 724&#x2013;739 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4898967</ArticleId><ArticleId IdType="pubmed">27196974</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurrob F, Jiang X, Martorell AJ, Ransohoff RM, Hafler BP, Bennett DA, Kellis M, Tsai LH, Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan K, Friedman BA, Etxeberria A, Huntley MA, van der Brug MP, Foreman O, Paw JS, Modrusan Z, Beach TG, Serrano GE, Hansen DV, Alzheimer&#x2019;s Patient Microglia Exhibit Enhanced Aging and Unique Transcriptional Activation. Cell Rep 31, 107843 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7422733</ArticleId><ArticleId IdType="pubmed">32610143</ArticleId></ArticleIdList></Reference><Reference><Citation>Roussos P, Katsel P, Fam P, Tan W, Purohit DP, Haroutunian V, The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer&#x2019;s dementia. Alzheimers Dement 11, 1163&#x2013;1170 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4461564</ArticleId><ArticleId IdType="pubmed">25499537</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, Cella M, Ulland TK, Zaitsev K, Miyashita A, Ikeuchi T, Sainouchi M, Kakita A, Bennett DA, Schneider JA, Nichols MR, Beausoleil SA, Ulrich JD, Holtzman DM, Artyomov MN, Colonna M, Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nature medicine 26, 131&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, Colonna M, Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med 215, 745&#x2013;760 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839761</ArticleId><ArticleId IdType="pubmed">29321225</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratuze M, Leyns CE, Sauerbeck AD, St-Pierre MK, Xiong M, Kim N, Remolina Serrano J, Tremblay M, Kummer TT, Colonna M, Ulrich JD, Holtzman DM, Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. J Clin Invest, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456230</ArticleId><ArticleId IdType="pubmed">32544086</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubman A, Chew G, Ouyang JF, Sun G, Choo XY, McLean C, Simmons RK, Buckberry S, Vargas-Landin DB, Poppe D, Pflueger J, Lister R, Rackham OJL, Petretto E, Polo JM, A single-cell atlas of entorhinal cortex from individuals with Alzheimer&#x2019;s disease reveals cell-type-specific gene expression regulation. Nature neuroscience 22, 2087&#x2013;2097 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31768052</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N, Avraham-Davidi I, Basu A, Burks T, Shekhar K, Hofree M, Choudhury SR, Aguet F, Gelfand E, Ardlie K, Weitz DA, Rozenblatt-Rosen O, Zhang F, Regev A, Massively parallel single-nucleus RNA-seq with DroNc-seq. Nature methods 14, 955&#x2013;958 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623139</ArticleId><ArticleId IdType="pubmed">28846088</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis CS, Murrow LM, Gartner ZJ, DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst 8, 329&#x2013;337 e324 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6853612</ArticleId><ArticleId IdType="pubmed">30954475</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake BB, Chen S, Sos BC, Fan J, Kaeser GE, Yung YC, Duong TE, Gao D, Chun J, Kharchenko PV, Zhang K, Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. Nat Biotechnol 36, 70&#x2013;80 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5951394</ArticleId><ArticleId IdType="pubmed">29227469</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Liu S, Warrell J, Won H, Shi X, Navarro FCP, Clarke D, Gu M, Emani P, Yang YT, Xu M, Gandal MJ, Lou S, Zhang J, Park JJ, Yan C, Rhie SK, Manakongtreecheep K, Zhou H, Nathan A, Peters M, Mattei E, Fitzgerald D, Brunetti T, Moore J, Jiang Y, Girdhar K, Hoffman GE, Kalayci S, Gumus ZH, Crawford GE, Psych EC, Roussos P, Akbarian S, Jaffe AE, White KP, Weng Z, Sestan N, Geschwind DH, Knowles JA, Gerstein MB, Comprehensive functional genomic resource and integrative model for the human brain. Science 362, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6413328</ArticleId><ArticleId IdType="pubmed">30545857</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M, Menon V, Habib N, Taga MF, Ma Y, Yung CJ, Cimpean M, Khairallah A, Coronas-Samano G, Sankowski R, Gr&#xfc;n D, Kroshilina AA, Dionne D, Sarkis RA, Cosgrove GR, Helgager J, Golden JA, Pennell PB, Prinz M, Vonsattel JPG, Teich AF, Schneider JA, Bennett DA, Regev A, Elyaman W, Bradshaw EM, De Jager PL, Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer&#x2019;s disease. Nat Commun 11, 6129 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7704703</ArticleId><ArticleId IdType="pubmed">33257666</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, Modrusan Z, Larson JL, Kaminker JS, van der Brug MP, Hansen DV, Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer&#x2019;s Disease Not Evident in Mouse Models. Cell Rep 22, 832&#x2013;847 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29346778</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrupp N, Sala Frigerio C, Wolfs L, Skene NG, Fattorelli N, Poovathingal S, Fourne Y, Matthews PM, Theys T, Mancuso R, de Strooper B, Fiers M, Single-Nucleus RNA-Seq Is Not Suitable for Detection of Microglial Activation Genes in Humans. Cell Rep 32, 108189 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7527779</ArticleId><ArticleId IdType="pubmed">32997994</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT, Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer&#x2019;s disease. Ann Neurol 41, 17&#x2013;24 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, Morrison JH, Gold G, Hof PR, Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer&#x2019;s disease. Neurology 60, 1495&#x2013;1500 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM, Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337&#x2013;351 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver CL, Espinoza M, Kress Y, Davies P, Conformational change as one of the earliest alterations of tau in Alzheimer&#x2019;s disease. Neurobiol Aging 21, 719&#x2013;727 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11016541</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Cheng Z, Zhou L, Darmanis S, Neff NF, Okamoto J, Gulati G, Bennett ML, Sun LO, Clarke LE, Marschallinger J, Yu G, Quake SR, Wyss-Coray T, Barres BA, Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA Sequencing. Neuron 101, 207&#x2013;223.e210 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336504</ArticleId><ArticleId IdType="pubmed">30606613</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G, Krasemann S, Capell A, Tr&#xfc;mbach D, Wurst W, Brunner B, Bultmann S, Tahirovic S, Kerschensteiner M, Misgeld T, Butovsky O, Haass C, TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep 18, 1186&#x2013;1198 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494532</ArticleId><ArticleId IdType="pubmed">28483841</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao H, Coppola K, Schweig JE, Crawford F, Mullan M, Paris D, Distinct Signaling Pathways Regulate TREM2 Phagocytic and NF&#x3ba;B Antagonistic Activities. Front Cell Neurosci 13, 457 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6795686</ArticleId><ArticleId IdType="pubmed">31649511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, Tahirovic S, Lleo A, Alcolea D, Fortea J, Willem M, Lammich S, Molinuevo JL, Sanchez-Valle R, Antonell A, Ramirez A, Heneka MT, Sleegers K, van der Zee J, Martin JJ, Engelborghs S, Demirtas-Tatlidede A, Zetterberg H, Van Broeckhoven C, Gurvit H, Wyss-Coray T, Hardy J, Colonna M, Haass C, TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6, 243ra286 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24990881</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H, MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9, 1956&#x2013;1967 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20571069</ArticleId></ArticleIdList></Reference><Reference><Citation>Korvatska O, Kiianitsa K, Ratushny A, Matsushita M, Beeman N, Chien WM, Satoh JI, Dorschner MO, Keene CD, Bammler TK, Bird TD, Raskind WH, Triggering Receptor Expressed on Myeloid Cell 2 R47H Exacerbates Immune Response in Alzheimer&#x2019;s Disease Brain. Front Immunol 11, 559342 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7546799</ArticleId><ArticleId IdType="pubmed">33101276</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M, Menon V, Habib N, Taga MF, Ma Y, Yung CJ, Cimpean M, Khairallah A, Coronas-Samano G, Sankowski R, Grun D, Kroshilina AA, Dionne D, Sarkis RA, Cosgrove GR, Helgager J, Golden JA, Pennell PB, Prinz M, Vonsattel JPG, Teich AF, Schneider JA, Bennett DA, Regev A, Elyaman W, Bradshaw EM, De Jager PL, Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer&#x2019;s disease. Nat Commun 11, 6129 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7704703</ArticleId><ArticleId IdType="pubmed">33257666</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA, Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry 62, 685&#x2013;691 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15939846</ArticleId></ArticleIdList></Reference><Reference><Citation>Benke T, Delazer M, Sanin G, Schmidt H, Seiler S, Ransmayr G, Dal-Bianco P, Uran&#xfc;s M, Marksteiner J, Leblhuber F, Kapeller P, Bancher C, Schmidt R, Cognition, gender, and functional abilities in Alzheimer&#x2019;s disease: how are they related? J Alzheimers Dis 35, 247&#x2013;252 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23388173</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamberger D, Lavra&#x10d; N, Srivatsa S, Tanzi RE, Doraiswamy PM, Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer&#x2019;s disease. Sci Rep 7, 6763 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5533731</ArticleId><ArticleId IdType="pubmed">28755001</ArticleId></ArticleIdList></Reference><Reference><Citation>Koran MEI, Wagener M, Hohman TJ, Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging Behav 11, 205&#x2013;213 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4972701</ArticleId><ArticleId IdType="pubmed">26843008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanamsagar R, Bilbo SD, Environment matters: microglia function and dysfunction in a changing world. Curr Opin Neurobiol 47, 146&#x2013;155 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5732848</ArticleId><ArticleId IdType="pubmed">29096243</ArticleId></ArticleIdList></Reference><Reference><Citation>Villa A, Gelosa P, Castiglioni L, Cimino M, Rizzi N, Pepe G, Lolli F, Marcello E, Sironi L, Vegeto E, Maggi A, Sex-Specific Features of Microglia from Adult Mice. Cell Rep 23, 3501&#x2013;3511 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6024879</ArticleId><ArticleId IdType="pubmed">29924994</ArticleId></ArticleIdList></Reference><Reference><Citation>Guneykaya D, Ivanov A, Hernandez DP, Haage V, Wojtas B, Meyer N, Maricos M, Jordan P, Buonfiglioli A, Gielniewski B, Ochocka N, Comert C, Friedrich C, Artiles LS, Kaminska B, Mertins P, Beule D, Kettenmann H, Wolf SA, Transcriptional and Translational Differences of Microglia from Male and Female Brains. Cell Rep 24, 2773&#x2013;2783.e2776 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30184509</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM, Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama 278, 1349&#x2013;1356 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann A, Tian L, Henderson VW, Greicius MD, Alzheimer&#x2019;s Disease Neuroimaging Initiative Investigators, Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol 75, 563&#x2013;573 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117990</ArticleId><ArticleId IdType="pubmed">24623176</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, Mahley RW, Mucke L, Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci USA 95, 10914&#x2013;10919 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27995</ArticleId><ArticleId IdType="pubmed">9724804</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Manis M, Long J, Wang K, Sullivan PM, Remolina Serrano J, Hoyle R, Holtzman DM, Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J Exp Med 216, 2546&#x2013;2561 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829593</ArticleId><ArticleId IdType="pubmed">31601677</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, Gallardo G, Wang K, Roh J, Robinson G, Finn MB, Jiang H, Sullivan PM, Baufeld C, Wood MW, Sutphen C, McCue L, Xiong C, Del-Aguila JL, Morris JC, Cruchaga C, Alzheimer&#x2019;s Disease Neuroimaging I, Fagan AM, Miller BL, Boxer AL, Seeley WW, Butovsky O, Barres BA, Paul SM, Holtzman DM, ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523&#x2013;527 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodama L, Gan L, Do microglial sex differences contribute to sex differences in neurodegenerative diseases? Trends Mol Med, (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7338035</ArticleId><ArticleId IdType="pubmed">31171460</ArticleId></ArticleIdList></Reference><Reference><Citation>R. C. Team, R: A language and environment for statistical computing. R Foundation for Statistical Computing, (2017).</Citation></Reference><Reference><Citation>Wickham H, ggplot2 - Elegant Graphics for Data Analysis. (Springer, 2009).</Citation></Reference><Reference><Citation>Butler A, Hoffman P, Smibert P, Papalexi E, Satija R, Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6700744</ArticleId><ArticleId IdType="pubmed">29608179</ArticleId></ArticleIdList></Reference><Reference><Citation>Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK, Slichter CK, Miller HW, McElrath MJ, Prlic M, Linsley PS, Gottardo R, MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. Genome Biol 16, 278 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4676162</ArticleId><ArticleId IdType="pubmed">26653891</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102, 15545&#x2013;15550 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A, Subramanian A, Pinchback R, Thorvaldsd&#xf3;ttir H, Tamayo P, Mesirov JP, Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739&#x2013;1740 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3106198</ArticleId><ArticleId IdType="pubmed">21546393</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y, Controlling the false discovery rate - a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B-Statistical Methodology 57, 289&#x2013;300 (1995).</Citation></Reference><Reference><Citation>Lun ATL, Richard AC, Marioni JC, Testing for differential abundance in mass cytometry data. Nature methods 14, 707&#x2013;709 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6155493</ArticleId><ArticleId IdType="pubmed">28504682</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139&#x2013;140 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014)10.1186/s13059-014-0550-8).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Langfelder P, Horvath S, WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631488</ArticleId><ArticleId IdType="pubmed">19114008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O&#x2019;Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, Liddelow SA, Zhang C, Daneman R, Maniatis T, Barres BA, Wu JQ, An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34, 11929&#x2013;11947 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152602</ArticleId><ArticleId IdType="pubmed">25186741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G, Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature genetics 25, 25&#x2013;29 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3037419</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId></ArticleIdList></Reference><Reference><Citation>The Gene Ontology C, Expansion of the Gene Ontology knowledgebase and resources. Nucleic Acids Res 45, D331&#x2013;D338 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210579</ArticleId><ArticleId IdType="pubmed">27899567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Goto S, KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28, 27&#x2013;30 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102409</ArticleId><ArticleId IdType="pubmed">10592173</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T, Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research 13, 2498&#x2013;2504 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering C, The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 45, D362&#x2013;d368 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210637</ArticleId><ArticleId IdType="pubmed">27924014</ArticleId></ArticleIdList></Reference><Reference><Citation>Picelli S, Faridani OR, Bjorklund AK, Winberg G, Sagasser S, Sandberg R, Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc 9, 171&#x2013;181 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24385147</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmieder R, Edwards R, Quality control and preprocessing of metagenomic datasets. Bioinformatics 27, 863&#x2013;864 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3051327</ArticleId><ArticleId IdType="pubmed">21278185</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR, STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15&#x2013;21 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders S, Pyl PT, Huber W, HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166&#x2013;169 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4287950</ArticleId><ArticleId IdType="pubmed">25260700</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, Hao Y, Stoeckius M, Smibert P, Satija R, Comprehensive Integration of Single-Cell Data. Cell 177, 1888&#x2013;1902.e1821 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687398</ArticleId><ArticleId IdType="pubmed">31178118</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai H-F, Gajda J, Sloan TFW, Rares A &amp; Shen AQ, Usiigaci: Instance-aware cell tracking in stain-free phase contrast microscopy enabled by machine learning. SoftwareX 9, 230&#x2013;237 (2019).</Citation></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A, Fiji: an open-source platform for biological-image analysis. Nature methods 9, 676&#x2013;682 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Abadi M, Barham P, Chen J, Chen Z, Davis A, Dean J, Devin M, Ghemawat S, Irving G, Isard M, Kudlur M, Levenberg J, Monga R, Moore S, Murray DG, Steiner B, Tucker P, Vasudevan V, Warden P, Wicke M, Yu Y, and Zheng X, Google Brain, TensorFlow: A system for large-scale machine learning. USENIX Association 12th USENIX Symposium on Operating Systems Design and Implementation, (2016).</Citation></Reference><Reference><Citation>Chollet F, others, Keras: The Python Deep Learning library. Astrophysics Source Code Library; (2018), pp. ascl:1806.1022.</Citation></Reference><Reference><Citation>He K, Gkioxari G, Doll&#xe1;r P, Girshick R, Mask R-CNN. arXiv:1703.06870, (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29994331</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulla W, Mask R-CNN for object detection and instance segmentation on Keras and TensorFlow. GitHub repository, (2017).</Citation></Reference><Reference><Citation>Lombardot B, Manual drift correction ImageJ plugin. Fiji, (2016).</Citation></Reference><Reference><Citation>Young MD, Behjati S, SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data. Gigascience 9, (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7763177</ArticleId><ArticleId IdType="pubmed">33367645</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34851695</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>622</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>The CD22-IGF2R interaction is a therapeutic target for microglial lysosome dysfunction in Niemann-Pick type C.</ArticleTitle><Pagination><StartPage>eabg2919</StartPage><MedlinePgn>eabg2919</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.abg2919</ELocationID><Abstract><AbstractText>Lysosome dysfunction is a shared feature of rare lysosomal storage diseases and common age-related neurodegenerative diseases. Microglia, the brain-resident macrophages, are particularly vulnerable to lysosome dysfunction because of the phagocytic stress of clearing dying neurons, myelin, and debris. CD22 is a negative regulator of microglial homeostasis in the aging mouse brain, and soluble CD22 (sCD22) is increased in the cerebrospinal fluid of patients with Niemann-Pick type C disease (NPC). However, the role of CD22 in the human brain remains unknown. In contrast to previous findings in mice, here, we show that CD22 is expressed by oligodendrocytes in the human brain and binds to sialic acid&#x2013;dependent ligands on microglia. Using unbiased genetic and proteomic screens, we identify insulin-like growth factor 2 receptor (IGF2R) as the binding partner of sCD22 on human myeloid cells. Targeted truncation of IGF2R revealed that sCD22 docks near critical mannose 6-phosphate&#x2013;binding domains, where it disrupts lysosomal protein trafficking. Interfering with the sCD22-IGF2R interaction using CD22 blocking antibodies ameliorated lysosome dysfunction in human <i>NPC1</i> mutant induced pluripotent stem cell&#x2013;derived microglia-like cells without harming oligodendrocytes in vitro. These findings reinforce the differences between mouse and human microglia and provide a candidate microglia-directed immunotherapeutic to treat NPC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pluvinage</LastName><ForeName>John V</ForeName><Initials>JV</Initials><Identifier Source="ORCID">0000-0002-9607-2783</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jerry</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2971-4747</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claes</LastName><ForeName>Christel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flynn</LastName><ForeName>Ryan A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0001-5013-0442</Identifier><AffiliationInfo><Affiliation>Stem Cell Program, Children's Hospital Boston, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haney</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0001-7381-4054</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iram</LastName><ForeName>Tal</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Xiangling</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-3528-4037</Identifier><AffiliationInfo><Affiliation>Stanford Brain Organogenesis, Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindemann</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riley</LastName><ForeName>Nicholas M</ForeName><Initials>NM</Initials><Identifier Source="ORCID">0000-0002-1536-2966</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and ChEM-H, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Stanford University, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danhash</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0737-9311</Identifier><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chadarevian</LastName><ForeName>Jean Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tapp</LastName><ForeName>Emma</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7900-5645</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gate</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0481-9657</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondapavulur</LastName><ForeName>Sravani</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4412-5978</Identifier><AffiliationInfo><Affiliation>Medical Scientist Training Program, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cobos</LastName><ForeName>Inma</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chetty</LastName><ForeName>Sundari</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1940-9538</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pa&#x219;ca</LastName><ForeName>Anca M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-0445-9009</Identifier><AffiliationInfo><Affiliation>Division of Neonatology, Department of Pediatrics, Stanford University, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pa&#x219;ca</LastName><ForeName>Sergiu P</ForeName><Initials>SP</Initials><Identifier Source="ORCID">0000-0002-3216-3248</Identifier><AffiliationInfo><Affiliation>Stanford Brain Organogenesis, Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry-Kravis</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7099-1522</Identifier><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertozzi</LastName><ForeName>Carolyn R</ForeName><Initials>CR</Initials><Identifier Source="ORCID">0000-0003-4482-2754</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and ChEM-H, Stanford University, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Stanford University, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blurton-Jones</LastName><ForeName>Mathew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7770-7157</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5893-0831</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA 94304, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford, CA, 94305, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K00 CA212454</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000266</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG064897</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066519</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM058867</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 AG060638</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497867">CD22 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051918">Sialic Acid Binding Ig-like Lectin 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052556" MajorTopicYN="Y">Niemann-Pick Disease, Type C</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051918" MajorTopicYN="N">Sialic Acid Binding Ig-like Lectin 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> C.R.B. is a cofounder and Scientific Advisory Board member of Lycia Therapeutics, Palleon Pharmaceuticals, Enable Bioscience, InterVenn Bio, and Redwood Bioscience (a subsidiary of Catalent) and a member of the Board of Directors of Eli Lilly and Company. M.B.-J. is a cofounder of NovoGlia Inc. and coinventor of patent application WO/2018/160496, related to the differentiation of stem cells into microglia. T.W.-C., J.V.P., M.S.H., and C.R.B. are coinventors on a patent application related to the work in this paper (US16/956,339, &#x201c;Compositions and methods for treating age related disesases&#x201d;). T.W.-C. and J.V.P. are coinventors on a patent application related to the work in this paper (PCT/US21/32875, &#x201c;Compositions and methods for treating lysosomal storage disorders&#x201d;).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>1</Day><Hour>17</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34851695</ArticleId><ArticleId IdType="mid">NIHMS1797608</ArticleId><ArticleId IdType="pmc">PMC9067636</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abg2919</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>de Duve C, Pressman BC, Gianetto R, Wattiaux R, Appelmans F, Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem. J. 60, 604&#x2013;617 (1955).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1216159</ArticleId><ArticleId IdType="pubmed">13249955</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt FM, d&#x2019;Azzo A, Davidson BL, Neufeld EF, Tifft CJ, Lysosomal storage diseases. Nat. Rev. Dis. Primers. 4, 27 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30275469</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballabio A, Bonifacino JS, Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat. Rev. Mol. Cell Biol. 21, 101&#x2013;118 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31768005</ArticleId></ArticleIdList></Reference><Reference><Citation>Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R, Mutations in the glucocerebrosidase gene and Parkinson&#x2019;s disease in Ashkenazi Jews. N. Engl. J. Med. 351, 1972&#x2013;1977 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15525722</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy JV, Ganley IG, Pfeffer SR, Clues to neuro-degeneration in Niemann-Pick type C disease from global gene expression profiling. PLOS ONE 1, e19 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1762405</ArticleId><ArticleId IdType="pubmed">17183645</ArticleId></ArticleIdList></Reference><Reference><Citation>Cologna SM, Jiang X-S, Backlund PS, Cluzeau CVM, Dail MK, Yanjanin NM, Siebel S, Toth CL, Jun H-S, Wassif CA, Yergey AL, Porter FD, Quantitative proteomic analysis of Niemann-Pick disease, type C1 cerebellum identifies protein biomarkers and provides pathological insight. PLOS ONE 7, e47845 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483225</ArticleId><ArticleId IdType="pubmed">23144710</ArticleId></ArticleIdList></Reference><Reference><Citation>Malnar M, Hecimovic S, Mattsson N, Zetterberg H, Bidirectional links between Alzheimer&#x2019;s disease and Niemann-Pick type C disease. Neurobiol. Dis. 72(Pt. A), 37&#x2013;47 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24907492</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin L-W, Shie F-S, Maezawa I, Vincent I, Bird T, Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am. J. Pathol. 164, 975&#x2013;985 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1614713</ArticleId><ArticleId IdType="pubmed">14982851</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres S, Garc&#xed;a-Ruiz CM, Fernandez-Checa JC, Mitochondrial Cholesterol in Alzheimer&#x2019;s disease and Niemann-Pick type C disease. Front. Neurol 10, 1168 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6854033</ArticleId><ArticleId IdType="pubmed">31787922</ArticleId></ArticleIdList></Reference><Reference><Citation>Walterfang M, Fahey M, Desmond P, Wood A, Seal ML, Steward C, Adamson C, Kokkinos C, Fietz M, Velakoulis D, White and gray matter alterations in adults with Niemann-Pick disease type C: A cross-sectional study. Neurology 75, 49&#x2013;56 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20484681</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianconi SE, Hammond DI, Farhat NY, Dang Do A, Jenkins K, Cougnoux A, Martin K, Porter FD, Evaluation of age of death in Niemann-Pick disease, type C: Utility of disease support group websites to understand natural history. Mol. Genet. Metab. 126, 466&#x2013;469 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6535124</ArticleId><ArticleId IdType="pubmed">30850267</ArticleId></ArticleIdList></Reference><Reference><Citation>Cougnoux A, Drummond RA, Collar AL, Iben JR, Salman A, Westgarth H, Wassif CA, Cawley NX, Farhat NY, Ozato K, Lionakis MS, Porter FD, Microglia activation in Niemann&#x2013;Pick disease, type C1 is amendable to therapeutic intervention. Hum. Mol. Genet. 27, 2076&#x2013;2089 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5985727</ArticleId><ArticleId IdType="pubmed">29617956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavetsky L, Green KK, Boyle BR, Yousufzai FAK, Padron ZM, Melli SE, Kuhnel VL, Jackson HM, Blanco RE, Howell GR, Soto I, Increased interactions and engulfment of dendrites by microglia precede Purkinje cell degeneration in a mouse model of Niemann Pick Type-C. Sci. Rep. 9, 14722 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6788982</ArticleId><ArticleId IdType="pubmed">31605022</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaband&#xe9;-Rodr&#xed;guez E, P&#xe9;rez-Ca&#xf1;am&#xe1;s A, Soto-Huelin B, Mitroi DN, S&#xe1;nchez-Redondo S, Mart&#xed;nez-S&#xe1;ez E, Venero C, Peinado H, Ledesma MD, Lipid-induced lysosomal damage after demyelination corrupts microglia protective function in lysosomal storage disorders. EMBO J. 38, e99553 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331723</ArticleId><ArticleId IdType="pubmed">30530526</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo A, Dinkel L, M&#xfc;ller SA, Sebastian Monasor L, Schifferer M, Cantuti-Castelvetri L, K&#xf6;nig J, Vidatic L, Bremova-Ertl T, Lieberman AP, Hecimovic S, Simons M, Lichtenthaler SF, Strupp M, Schneider SA, Tahirovic S, Loss of NPC1 enhances phagocytic uptake and impairs lipid trafficking in microglia. Nat. Commun. 12, 1158 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7904859</ArticleId><ArticleId IdType="pubmed">33627648</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudry M, Yao Y, Simmons D, Liu J, Bi X, Postnatal development of inflammation in a murine model of Niemann-Pick type C disease: Immunohistochemical observations of microglia and astroglia. Exp. Neurol. 184, 887&#x2013;903 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14769381</ArticleId></ArticleIdList></Reference><Reference><Citation>Cologna SM, Cluzeau CVM, Yanjanin NM, Blank PS, Dail MK, Siebel S, Toth CL, Wassif CA, Lieberman AP, Porter FD, Human and mouse neuroinflammation markers in Niemann-Pick disease, type C1. J. Inherit. Metab. Dis. 37, 83&#x2013;92 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877698</ArticleId><ArticleId IdType="pubmed">23653225</ArticleId></ArticleIdList></Reference><Reference><Citation>Pluvinage JV, Haney MS, Smith BAH, Sun J, Iram T, Bonanno L, Li L, Lee DP, Morgens DW, Yang AC, Shuken SR, Gate D, Scott M, Khatri P, Luo J, Bertozzi CR, Bassik MC, Wyss-Coray T, CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. Nature 568, 187&#x2013;192 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6574119</ArticleId><ArticleId IdType="pubmed">30944478</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodge RD, Bakken TE, Miller JA, Smith KA, Barkan ER, Graybuck LT, Close JL, Long B, Johansen N, Penn O, Yao Z, Eggermont J, H&#xf6;llt T, Levi BP, Shehata SI, Aevermann B, Beller A, Bertagnolli D, Brouner K, Casper T, Cobbs C, Dalley R, Dee N, Ding S-L, Ellenbogen RG, Fong O, Garren E, Goldy J, Gwinn RP, Hirschstein D, Keene CD, Keshk M, Ko AL, Lathia K, Mahfouz A, Maltzer Z, McGraw M, Nguyen TN, Nyhus J, Ojemann JG, Oldre A, Parry S, Reynolds S, Rimorin C, Shapovalova NV, Somasundaram S, Szafer A, Thomsen ER, Tieu M, Quon G, Scheuermann RH, Yuste R, Sunkin SM, Lelieveldt B, Feng D, Ng L, Bernard A, Hawrylycz M, Phillips JW, Tasic B, Zeng H, Jones AR, Koch C, Lein ES, Conserved cell types with divergent features in human versus mouse cortex. Nature , 61&#x2013;68 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919571</ArticleId><ArticleId IdType="pubmed">31435019</ArticleId></ArticleIdList></Reference><Reference><Citation>Geirsdottir L, David E, Keren-Shaul H, Weiner A, Bohlen SC, Neuber J, Balic A, Giladi A, Sheban F, Dutertre C-A, Pfeifle C, Peri F, Raffo-Romero A, Vizioli J, Matiasek K, Scheiwe C, Meckel S, M&#xe4;tz-Rensing K, van der Meer F, Thormodsson FR, Stadelmann C, Zilkha N, Kimchi T, Ginhoux F, Ulitsky I, Erny D, Amit I, Prinz M, Cross-species single-cell analysis reveals divergence of the primate microglia program. Cell 179, 1609&#x2013;1622.e16 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31835035</ArticleId></ArticleIdList></Reference><Reference><Citation>Khrameeva E, Kurochkin I, Han D, Guijarro P, Kanton S, Santel M, Qian Z, Rong S, Mazin P, Sabirov M, Bulat M, Efimova O, Tkachev A, Guo S, Sherwood CC, Camp JG, P&#xe4;&#xe4;bo S, Treutlein B, Khaitovich P, Single-cell-resolution transcriptome map of human, chimpanzee, bonobo, and macaque brains. Genome Res. 30, 776&#x2013;789 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7263190</ArticleId><ArticleId IdType="pubmed">32424074</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y-N, Cai X, Zhou H-M, Jin W-D, Zhang M, Zhang Y, Du X-X, Chen Z-HK, Diagnostic and prognostic roles of soluble CD22 in patients with Gram-negative bacterial sepsis. Hepatobiliary Pancreat. Dis. Int. 14, 523&#x2013;529 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26459729</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita K, Margulies I, Onda M, Nagata S, Stetler-Stevenson M, Kreitman RJ, Soluble CD22 as a tumor marker for hairy cell leukemia. Blood 112, 2272&#x2013;2277 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2532804</ArticleId><ArticleId IdType="pubmed">18596230</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell LD, Sgroi D, Sjoberg ER, Stamenkovic I, Varki A, Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition. J. Biol. Chem. 268, 7019&#x2013;7027 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8463235</ArticleId></ArticleIdList></Reference><Reference><Citation>Ere&#xf1;o-Orbea J, Sicard T, Cui H, Mazhab-Jafari MT, Benlekbir S, Guarn&#xe9; A, Rubinstein JL, Julien J-P, Molecular basis of human CD22 function and therapeutic targeting. Nat. Commun. 8, 746 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5624926</ArticleId><ArticleId IdType="pubmed">28970495</ArticleId></ArticleIdList></Reference><Reference><Citation>Haney MS, Bohlen CJ, Morgens DW, Ousey JA, Barkal AA, Tsui CK, Ego BK, Levin R, Kamber RA, Collins H, Tucker A, Li A, Vorselen D, Labitigan L, Crane E, Boyle E, Jiang L, Chan J, Rincon E, Greenleaf WJ, Li B, Snyder MP, Weissman IL, Theriot JA, Collins SR, Barres BA, Bassik MC, Identification of phagocytosis regulators using magnetic genome-wide CRISPR screens. Nat. Genet. 50, 1716&#x2013;1727 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6719718</ArticleId><ArticleId IdType="pubmed">30397336</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgens DW, Deans RM, Li A, Bassik MC, Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes. Nat. Biotechnol. 34, 634&#x2013;636 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4900911</ArticleId><ArticleId IdType="pubmed">27159373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennet T, Chui D, Paulson JC, Marth JD, Immune regulation by the ST6Gal sialyltransferase. Proc. Natl. Acad. Sci. U.S.A. 95, 4504&#x2013;4509 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22519</ArticleId><ArticleId IdType="pubmed">9539767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramya TNC, Weerapana E, Liao L, Zeng Y, Tateno H, Liao L, Yates JR 3rd, Cravatt BF, Paulson JC, In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics. Mol. Cell. Proteomics 9, 1339&#x2013;1351 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2877991</ArticleId><ArticleId IdType="pubmed">20172905</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell LD, Jain RK, Matta KL, Sabesan S, Varki A, Characterization of sialyloligosaccharide binding by recombinant soluble and native cell-associated CD22. Evidence for a minimal structural recognition motif and the potential importance of multisite binding. J. Biol. Chem. 270, 7523&#x2013;7532 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7706299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornfeld S, Structure and function of the mannose 6-phosphate/insulin like growth factor II receptors. Annu. Rev. Biochem. 61, 307&#x2013;330 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1323236</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratantoni JC, Hall CW, Neufeld EF, Hurler and Hunter syndromes: Mutual correction of the defect in cultured fibroblasts. Science 162, 570&#x2013;572 (1968).</Citation><ArticleIdList><ArticleId IdType="pubmed">4236721</ArticleId></ArticleIdList></Reference><Reference><Citation>Vladutiu GD, Rattazzi MC, Excretion-reuptake route of beta-hexosaminidase in normal and I-cell disease cultured fibroblasts. J. Clin. Invest. 63, 595&#x2013;601 (1979).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC371993</ArticleId><ArticleId IdType="pubmed">438323</ArticleId></ArticleIdList></Reference><Reference><Citation>Neufeld EF, in Fabry Disease: Perspectives from 5 Years of FOS, Mehta A, Beck M, Sunder-Plassmann G, Eds. (Oxford PharmaGenesis, 2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21290683</ArticleId></ArticleIdList></Reference><Reference><Citation>Banik SM, Pedram K, Wisnovsky S, Ahn G, Riley NM, Bertozzi CR, Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291&#x2013;297 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727926</ArticleId><ArticleId IdType="pubmed">32728216</ArticleId></ArticleIdList></Reference><Reference><Citation>Amritraj A, Peake K, Kodam A, Salio C, Merighi A, Vance JE, Kar S, Increased activity and altered subcellular distribution of lysosomal enzymes determine neuronal vulnerability in Niemann-Pick type C1-deficient mice. Am. J. Pathol. 175, 2540&#x2013;2556 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789601</ArticleId><ArticleId IdType="pubmed">19893049</ArticleId></ArticleIdList></Reference><Reference><Citation>Cluzeau CVM, Watkins-Chow DE, Fu R, Borate B, Yanjanin N, Dail MK, Davidson CD, Walkley SU, Ory DS, Wassif CA, Pavan WJ, Porter FD, Microarray expression analysis and identification of serum biomarkers for Niemann-Pick disease, type C1. Hum. Mol. Genet. 21, 3632&#x2013;3646 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406758</ArticleId><ArticleId IdType="pubmed">22619379</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Ock J, Kim AK, Lee HW, Cho J-Y, Kim DR, Park J-Y, Suk K, Neurotoxicity of microglial cathepsin D revealed by secretome analysis. J. Neurochem. 103, 2640&#x2013;2650 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17953665</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Nixon RA, Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc. Natl. Acad. Sci. U.S.A. 87, 3861&#x2013;3865 (1990).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54003</ArticleId><ArticleId IdType="pubmed">1692625</ArticleId></ArticleIdList></Reference><Reference><Citation>Amritraj A, Wang Y, Revett TJ, Vergote D, Westaway D, Kar S, Role of cathepsin D in U18666A-induced neuronal cell death: Potential implication in Niemann-Pick type C disease pathogenesis. J. Biol. Chem. 288, 3136&#x2013;3152 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3561536</ArticleId><ArticleId IdType="pubmed">23250759</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleat DE, Wiseman JA, El-Banna M, Price SM, Verot L, Shen MM, Tint GS, Vanier MT, Walkley SU, Lobel P, Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport. Proc. Natl. Acad. Sci. U.S.A. 101, 5886&#x2013;5891 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395893</ArticleId><ArticleId IdType="pubmed">15071184</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler MBL, Kidmose RT, Szomek M, Thaysen K, Rawson S, Muench SP, W&#xfc;stner D, Pedersen BP, Structural insight into eukaryotic sterol transport through niemann-pick type C proteins. Cell 179, 485&#x2013;497.e18 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31543266</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian H, Wu X, Du X, Yao X, Zhao X, Lee J, Yang H, Yan N, Structural basis of Low-pH-Dependent lysosomal cholesterol egress by NPC1 and NPC2. Cell 182, 98&#x2013;111.e18 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32544384</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleat DE, Tannous A, Sohar I, Wiseman JA, Zheng H, Qian M, Zhao C, Xin W, Barone R, Sims KB, Moore DF, Lobel P, Proteomic Analysis of brain and cerebrospinal fluid from the three major forms of neuronal ceroid lipofuscinosis reveals potential biomarkers. J. Proteome Res. 16, 3787&#x2013;3804 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5860807</ArticleId><ArticleId IdType="pubmed">28792770</ArticleId></ArticleIdList></Reference><Reference><Citation>Willenborg M, Schmidt CK, Braun P, Landgrebe J, von Figura K, Saftig P, Eskelinen E-L, Mannose 6-phosphate receptors, Niemann-Pick C2 protein, and lysosomal cholesterol accumulation. J. Lipid Res. 46, 2559&#x2013;2569 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16177447</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths G, Hoflack B, Simons K, Mellman I, Kornfeld S, The mannose 6-phosphate receptor and the biogenesis of lysosomes. Cell 52, 329&#x2013;341 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">2964276</ArticleId></ArticleIdList></Reference><Reference><Citation>Waguri S, Dewitte F, Le Borgne R, Rouill&#xe9; Y, Uchiyama Y, Dubremetz J-F, Hoflack B, Visualization of TGN to endosome trafficking through fluorescently labeled MPR and AP-1 in living cells. Mol. Biol. Cell 14, 142&#x2013;155 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140234</ArticleId><ArticleId IdType="pubmed">12529433</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahms NM, Lobel P, Kornfeld S, Mannose 6-phosphate receptors and lysosomal enzyme targeting. J. Biol. Chem. 264, 12115&#x2013;12118 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2545698</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SX, Mallet WG, Huang AY, Maxfield FR, Endocytosed cation-independent mannose 6-phosphate receptor traffics via the endocytic recycling compartment en route to the trans-Golgi network and a subpopulation of late endosomes. Mol. Biol. Cell 15, 721&#x2013;733 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC329388</ArticleId><ArticleId IdType="pubmed">14595110</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub H, Abramovici A, Sandbank U, Booth AD, Pentchev PG, Sela B, Dysmyelination in NCTR-Balb/C mouse mutant with a lysosomal storage disorder. Morphological survey. Acta Neuropathol. 74, 374&#x2013;381 (1987).</Citation><ArticleIdList><ArticleId IdType="pubmed">3687389</ArticleId></ArticleIdList></Reference><Reference><Citation>Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ, Evolving therapy of adult acute lymphoblastic leukemia: State-of-the-art treatment and future directions. J. Hematol. Oncol. 13, 70 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7275444</ArticleId><ArticleId IdType="pubmed">32503572</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer SJ, Linder AT, Brandl C, Nitschke L, B cell siglecs-news on signaling and its interplay with ligand binding. Front. Immunol. 9, 2820 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6286995</ArticleId><ArticleId IdType="pubmed">30559744</ArticleId></ArticleIdList></Reference><Reference><Citation>Praggastis M, Tortelli B, Zhang J, Fujiwara H, Sidhu R, Chacko A, Chen Z, Chung C, Lieberman AP, Sikora J, Davidson C, Walkley SU, Pipalia NH, Maxfield FR, Schaffer JE, Ory DS, A murine Niemann-Pick C1 I1061T knock-in model recapitulates the pathological features of the most prevalent human disease allele. J. Neurosci. 35, 8091&#x2013;8106 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4444535</ArticleId><ArticleId IdType="pubmed">26019327</ArticleId></ArticleIdList></Reference><Reference><Citation>Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, Yeromin AV, Scarfone VM, Marsh SE, Fimbres C, Caraway CA, Fote GM, Madany AM, Agrawal A, Kayed R, Gylys KH, Cahalan MD, Cummings BJ, Antel JP, Mortazavi A, Carson MJ, Poon WW, Blurton-Jones M, iPSC-derived human microglia-like cells to study neurological diseases. Neuron 94, 278&#x2013;293.e9 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5482419</ArticleId><ArticleId IdType="pubmed">28426964</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade A, Coburn M, Tu CH, Hasselmann J, Davtyan H, Blurton-Jones M, Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol. Neurodegener. 13, 67 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6303871</ArticleId><ArticleId IdType="pubmed">30577865</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasselmann J, Coburn MA, England W, Figueroa Velez DX, Kiani Shabestari S, Tu CH, McQuade A, Kolahdouzan M, Echeverria K, Claes C, Nakayama T, Azevedo R, Coufal NG, Han CZ, Cummings BJ, Davtyan H, Glass CK, Healy LM, Gandhi SP, Spitale RC, Blurton-Jones M, Development of a chimeric model to study and manipulate human microglia in vivo. Neuron 103, 1016&#x2013;1033.e10 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7138101</ArticleId><ArticleId IdType="pubmed">31375314</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelsthorpe ME, Baumann N, Millard E, Gale SE, Langmade SJ, Schaffer JE, Ory DS, Niemann-Pick type C1 I1061T mutant encodes a functional protein that is selected for endoplasmic reticulum-associated degradation due to protein misfolding. J. Biol. Chem. 283, 8229&#x2013;8236 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276376</ArticleId><ArticleId IdType="pubmed">18216017</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu F, Liang Q, Abi-Mosleh L, Das A, De Brabander JK, Goldstein JL, Brown MS, Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection. eLife 4, e12177 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718804</ArticleId><ArticleId IdType="pubmed">26646182</ArticleId></ArticleIdList></Reference><Reference><Citation>Safaiyan S, Kannaiyan N, Snaidero N, Brioschi S, Biber K, Yona S, Edinger AL, Jung S, Rossner MJ, Simons M, Age-related myelin degradation burdens the clearance function of microglia during aging. Nat. Neurosci. 19, 995&#x2013;998 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116794</ArticleId><ArticleId IdType="pubmed">27294511</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, Menon M, He L, Abdurrob F, Jiang X, Martorell AJ, Ransohoff RM, Hafler BP, Bennett DA, Kellis M, Tsai L-H, Single-cell transcriptomic analysis of Alzheimer&#x2019;s disease. Nature 570, 332&#x2013;337 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6865822</ArticleId><ArticleId IdType="pubmed">31042697</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, Cella M, Ulland TK, Zaitsev K, Miyashita A, Ikeuchi T, Sainouchi M, Kakita A, Bennett DA, Schneider JA, Nichols MR, Beausoleil SA, Ulrich JD, Holtzman DM, Artyomov MN, Colonna M, Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer&#x2019;s disease. Nat. Med. 26, 131&#x2013;142 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980793</ArticleId><ArticleId IdType="pubmed">31932797</ArticleId></ArticleIdList></Reference><Reference><Citation>Olah M, Menon V, Habib N, Taga MF, Ma Y, Yung CJ, Cimpean M, Khairallah A, Coronas-Samano G, Sankowski R, Gr&#xfc;n D, Kroshilina AA, Dionne D, Sarkis RA, Cosgrove GR, Helgager J, Golden JA, Pennell PB, Prinz M, Vonsattel JPG, Teich AF, Schneider JA, Bennett DA, Regev A, Elyaman W, Bradshaw EM, De Jager PL, Single cell RNA sequencing of human microglia uncovers a subset associated with Alzheimer&#x2019;s disease. Nat. Commun. 11, 6129 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7704703</ArticleId><ArticleId IdType="pubmed">33257666</ArticleId></ArticleIdList></Reference><Reference><Citation>Cougnoux A, Drummond RA, Fellmeth M, Navid F, Collar AL, Iben J, Kulkarni AB, Pickel J, Schiffmann R, Wassif CA, Cawley NX, Lionakis MS, Porter FD, Unique molecular signature in mucolipidosis type IV microglia. J. Neuroinflammation 16, 276 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6935239</ArticleId><ArticleId IdType="pubmed">31883529</ArticleId></ArticleIdList></Reference><Reference><Citation>Douvaras P, Fossati V, Generation and isolation of oligodendrocyte progenitor cells from human pluripotent stem cells. Nat. Protoc. 10, 1143&#x2013;1154 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26134954</ArticleId></ArticleIdList></Reference><Reference><Citation>Peschl P, Schanda K, Zeka B, Given K, B&#xf6;hm D, Ruprecht K, Saiz A, Lutterotti A, Rost&#xe1;sy K, H&#xf6;ftberger R, Berger T, Macklin W, Lassmann H, Bradl M, Bennett JL, Reindl M, Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J. Neuroinflammation 14, 208 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657084</ArticleId><ArticleId IdType="pubmed">29070051</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerrits E, Heng Y, Boddeke EWGM, Eggen BJL, Transcriptional profiling of microglia; current state of the art and future perspectives. Glia 68, 740&#x2013;755 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7064956</ArticleId><ArticleId IdType="pubmed">31846124</ArticleId></ArticleIdList></Reference><Reference><Citation>Thrupp N, Sala Frigerio C, Wolfs L, Skene NG, Fattorelli N, Poovathingal S, Fourne Y, Matthews PM, Theys T, Mancuso R, de Strooper B, Fiers M, Single-nucleus RNA-Seq is not suitable for detection of microglial activation genes in humans. Cell Rep. 32, 108189 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7527779</ArticleId><ArticleId IdType="pubmed">32997994</ArticleId></ArticleIdList></Reference><Reference><Citation>Welch JD, Kozareva V, Ferreira A, Vanderburg C, Martin C, Macosko EZ, Single-cell multi-omic integration compares and contrasts features of brain cell identity. Cell 177, 1873&#x2013;1887.e17 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6716797</ArticleId><ArticleId IdType="pubmed">31178122</ArticleId></ArticleIdList></Reference><Reference><Citation>Heybrock S, Kanerva K, Meng Y, Ing C, Liang A, Xiong Z-J, Weng X, Ah Kim Y, Collins R, Trimble W, Pom&#xe8;s R, Priv&#xe9; GG, Annaert W, Schwake M, Heeren J, L&#xfc;llmann-Rauch R, Grinstein S, Ikonen E, Saftig P, Neculai D, Lysosomal integral membrane protein-2 (LIMP-2/SCARB2) is involved in lysosomal cholesterol export. Nat. Commun. 10, 3521 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6684646</ArticleId><ArticleId IdType="pubmed">31387993</ArticleId></ArticleIdList></Reference><Reference><Citation>Singhal A, Szente L, Hildreth JEK, Song B, Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann&#x2013;Pick C1 mutant cell via lysosome-associated membrane protein 1. Cell Death Dis. 9, 1019 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6170477</ArticleId><ArticleId IdType="pubmed">30282967</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Pfeffer SR, Lysosomal membrane glycoproteins bind cholesterol and contribute to lysosomal cholesterol export. eLife 5, e21635 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5068966</ArticleId><ArticleId IdType="pubmed">27664420</ArticleId></ArticleIdList></Reference><Reference><Citation>Twu Y-C, Lee T-S, Lin Y-L, Hsu S-M, Wang Y-H, Liao C-Y, Wang C-K, Liang Y-C, Liao Y-J, Niemann-Pick Type C2 protein mediates hepatic stellate cells activation by regulating free cholesterol accumulation. Int. J. Mol. Sci. 17, 1122 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4964497</ArticleId><ArticleId IdType="pubmed">27420058</ArticleId></ArticleIdList></Reference><Reference><Citation>Massa PT, Saha S, Wu C, Jarosinski KW, Expression and function of the protein tyrosine phosphatase SHP-1 in oligodendrocytes. Glia 29, 376&#x2013;385 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10652447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodachi T, Matsumoto S, Mizuguchi M, Osaka H, Kanai N, Nanba E, Ohno K, Yamagata T, Severe demyelination in a patient with a late infantile form of Niemann-Pick disease type C. Neuropathology 37, 426&#x2013;430 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28387450</ArticleId></ArticleIdList></Reference><Reference><Citation>Takikita S, Fukuda T, Mohri I, Yagi T, Suzuki K, Perturbed myelination process of premyelinating oligodendrocyte in Niemann-Pick type C mouse. J. Neuropathol. Exp. Neurol. 63, 660&#x2013;673 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15217094</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray TA, Cochran K, Kozlowski C, Wang J, Alexander G, Cady MA, Spencer WJ, Ruzycki PA, Clark BS, Laeremans A, He M-X, Wang X, Park E, Hao Y, Iannaccone A, Hu G, Fedrigo O, Skiba NP, Arshavsky VY, Kay JN, Comprehensive identification of mRNA isoforms reveals the diversity of neural cell-surface molecules with roles in retinal development and disease. Nat. Commun. 11, 3328 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7335077</ArticleId><ArticleId IdType="pubmed">32620864</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss K, Goebel C, Runz H, M&#xf6;bius W, Weiss S, Feussner I, Simons M, Schneider A, Exosome secretion ameliorates lysosomal storage of cholesterol in Niemann-Pick type C disease. J. Biol. Chem. 285, 26279&#x2013;26288 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924046</ArticleId><ArticleId IdType="pubmed">20554533</ArticleId></ArticleIdList></Reference><Reference><Citation>Hane M, Chen DY, Varki A, Human-specific microglial Siglec-11 transcript variant has the potential to affect polysialic acid-mediated brain functions at a distance. Glycobiology 31, 231&#x2013;242 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8022978</ArticleId><ArticleId IdType="pubmed">32845322</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DJ, Duka T, Stimpson CD, Schapiro SJ, Baze WB, McArthur MJ, Fobbs AJ, Sousa AMM, Sestan N, Wildman DE, Lipovich L, Kuzawa CW, Hof PR, Sherwood CC, Prolonged myelination in human neocortical evolution. Proc. Natl. Acad. Sci. U.S.A. 109, 16480&#x2013;16485 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3478650</ArticleId><ArticleId IdType="pubmed">23012402</ArticleId></ArticleIdList></Reference><Reference><Citation>Vite CH, Ding W, Bryan C, O&#x2019;Donnell P, Cullen K, Aleman D, Haskins ME, Van Winkle T, Clinical, electrophysiological, and serum biochemical measures of progressive neurological and hepatic dysfunction in feline Niemann-Pick type C disease. Pediatr. Res. 64, 544&#x2013;549 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3251164</ArticleId><ArticleId IdType="pubmed">18614965</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson CD, Gibson AL, Gu T, Baxter LL, Deverman BE, Beadle K, Incao AA, Rodriguez-Gil JL, Fujiwara H, Jiang X, Chandler RJ, Ory DS, Gradinaru V, Venditti CP, Pavan WJ, Improved systemic AAV gene therapy with a neurotrophic capsid in Niemann-Pick disease type C1 mice. Life Sci Alliance 4, e202101040 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380657</ArticleId><ArticleId IdType="pubmed">34407999</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson MC, Garver WS, Giugliani R, Imrie J, Jahnova H, Meaney FJ, Nadjar Y, Vanier MT, Moneuse P, Morand O, Rosenberg D, Schwierin B, H&#xe9;ron B, Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study. J. Inherit. Metab. Dis. 43, 1060&#x2013;1069 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7540716</ArticleId><ArticleId IdType="pubmed">32324281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkegaard T, Gray J, Priestman DA, Wallom K-L, Atkins J, Olsen OD, Klein A, Drndarski S, Petersen NHT, Ingemann L, Smith DA, Morris L, Born&#xe6;s C, J&#xf8;rgensen SH, Williams I, Hinsby A, Arenz C, Begley D, J&#xe4;&#xe4;ttel&#xe4; M, Platt FM, Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. Sci. Transl. Med. 8, 355ra118 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6821533</ArticleId><ArticleId IdType="pubmed">27605553</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam MS, Getz M, Haldar K, Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model. Sci. Transl. Med. 8, 326ra23 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26888431</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaya E, Smith DA, Smith C, Morris L, Bremova-Ertl T, Cortina-Borja M, Fineran P, Morten KJ, Poulton J, Boland B, Spencer J, Strupp M, Platt FM, Acetyl-Leucine slows disease progression in lysosomal storage disorders. bioRxiv 2020.05.20.105973 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7954382</ArticleId><ArticleId IdType="pubmed">33738443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ory DS, Ottinger EA, Farhat NY, King KA, Jiang X, Weissfeld L, Berry-Kravis E, Davidson CD, Bianconi S, Keener LA, Rao R, Soldatos A, Sidhu R, Walters KA, Xu X, Thurm A, Solomon B, Pavan WJ, Machielse BN, Kao M, Silber SA, McKew JC, Brewer CC, Vite CH, Walkley SU, Austin CP, Porter FD, Intrathecal 2-hydroxypropyl-&#x3b2;-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: A non-randomised, open-label, phase 1&#x2013;2 trial. Lancet 390, 1758&#x2013;1768 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6176479</ArticleId><ArticleId IdType="pubmed">28803710</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes MP, Smith DA, Morris L, Fletcher C, Colaco A, Huebecker M, Tordo J, Palomar N, Massaro G, Henckaerts E, Waddington SN, Platt FM, Rahim AA, AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann&#x2013;Pick type C1 disease. Hum. Mol. Genet. 27, 3079&#x2013;3098 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6097154</ArticleId><ArticleId IdType="pubmed">29878115</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes ME, Colombo G, Schulz R, Siegert S, Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges. Neurosci. Lett. 707, 134310 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6734419</ArticleId><ArticleId IdType="pubmed">31158432</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MSB, Li G, Duncan JA III, Cheshier SH, Shuer LM, Chang EF, Grant GA, Gephart MGH, Barres BA, Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89, 37&#x2013;53 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707064</ArticleId><ArticleId IdType="pubmed">26687838</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh KH, Stawski PS, Draycott AS, Udeshi ND, Lehrman EK, Wilton DK, Svinkina T, Deerinck TJ, Ellisman MH, Stevens B, Carr SA, Ting AY, Proteomic analysis of unbounded cellular compartments: Synaptic clefts. Cell 166, 1295&#x2013;1307.e21 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5167540</ArticleId><ArticleId IdType="pubmed">27565350</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung V, Udeshi ND, Lam SS, Loh KH, Cox KJ, Pedram K, Carr SA, Ting AY, Spatially resolved proteomic mapping in living cells with the engineered peroxidase APEX2. Nat. Protoc. 11, 456&#x2013;475 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4863649</ArticleId><ArticleId IdType="pubmed">26866790</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J, Mann M, MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367&#x2013;1372 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, Mann M, Cox J, The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731&#x2013;740 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27348712</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>